<SEC-DOCUMENT>0001193125-24-157500.txt : 20240607
<SEC-HEADER>0001193125-24-157500.hdr.sgml : 20240607
<ACCEPTANCE-DATETIME>20240607170200
ACCESSION NUMBER:		0001193125-24-157500
CONFORMED SUBMISSION TYPE:	S-1
PUBLIC DOCUMENT COUNT:		82
FILED AS OF DATE:		20240607
DATE AS OF CHANGE:		20240607

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			PLUS THERAPEUTICS, INC.
		CENTRAL INDEX KEY:			0001095981
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		ORGANIZATION NAME:           	08 Industrial Applications and Services
		IRS NUMBER:				330827593
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		S-1
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-280061
		FILM NUMBER:		241030507

	BUSINESS ADDRESS:	
		STREET 1:		4200 MARATHON BLVD.
		STREET 2:		SUITE 200
		CITY:			AUSTIN
		STATE:			TX
		ZIP:			78756
		BUSINESS PHONE:		737.255.7194

	MAIL ADDRESS:	
		STREET 1:		4200 MARATHON BLVD.
		STREET 2:		SUITE 200
		CITY:			AUSTIN
		STATE:			TX
		ZIP:			78756

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CYTORI THERAPEUTICS, INC.
		DATE OF NAME CHANGE:	20050712

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	MACROPORE INC
		DATE OF NAME CHANGE:	20010320
</SEC-HEADER>
<DOCUMENT>
<TYPE>S-1
<SEQUENCE>1
<FILENAME>d840996ds1.htm
<DESCRIPTION>S-1
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns:pstv="http://plus.com/20240331" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:deprecated="http://www.xbrl.org/2009/arcrole/deprecated" xmlns:country="http://xbrl.sec.gov/country/2023" xmlns:currency="http://xbrl.sec.gov/currency/2023" xmlns:exch="http://xbrl.sec.gov/exch/2023" xmlns:naics="http://xbrl.sec.gov/naics/2023" xmlns:sic="http://xbrl.sec.gov/sic/2023" xmlns:stpr="http://xbrl.sec.gov/stpr/2023" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:srt="http://fasb.org/srt/2023" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2022-02-16" xmlns:xbrll="http://www.xbrl.org/2003/linkbase" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns="http://www.w3.org/1999/xhtml">
<head>
<title>S-1</title>
<meta content="text/html; charset=UTF-8" http-equiv="Content-Type"/>
</head>
<body style="line-height:normal;background-color:white;"><div style="display: none"><ix:header><ix:hidden><ix:nonNumeric name="dei:AmendmentFlag" contextRef="P01_01_2024To03_31_2024" id="ixv-20278">false</ix:nonNumeric><ix:nonNumeric name="dei:EntityCentralIndexKey" contextRef="P01_01_2024To03_31_2024" id="ixv-20279">0001095981</ix:nonNumeric><ix:footnote id="FN_422111" xml:lang="en-US">Three month LIBOR rate with a floor of 1% plus 7.95%</ix:footnote><ix:footnote id="FN_422112" xml:lang="en-US">Monthly payment reflects principal and interest</ix:footnote></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="pstv-20240331.xsd"/></ix:references><ix:resources><xbrli:context id="PAsOn12_31_2023"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2024"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To03_31_2024"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To03_31_2023"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn04_20_2023"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-04-20</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P03_08_2024To03_08_2024"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-03-08</xbrli:startDate> <xbrli:endDate>2024-03-08</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_21_2023To04_21_2023"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-04-21</xbrli:startDate> <xbrli:endDate>2023-04-21</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_27_2023To04_27_2023"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-04-27</xbrli:startDate> <xbrli:endDate>2023-04-27</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_08_2024"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-03-08</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn04_30_2023"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-04-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn05_01_2023"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-05-01</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn04_04_2023"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-04-04</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2023"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapCashAndCashEquivalentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapCashAndCashEquivalentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_StockBasedCompensation2015EquityIncentivePlan1MemberusgaapPlanNameAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pstv:StockBasedCompensation2015EquityIncentivePlan1Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_StockBasedCompensation2020EquityIncentivePlanMemberusgaapPlanNameAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pstv:StockBasedCompensation2020EquityIncentivePlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_CommonClassBMemberusgaapStatementClassOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_RepresentativeSeriesUWarrantMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">pstv:RepresentativeSeriesUWarrantMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_TermLoanMemberusgaapDebtInstrumentAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pstv:TermLoanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_MaximumMembersrtRangeAxis_TermLoanMemberusgaapDebtInstrumentAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pstv:TermLoanMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_CharlottesvilleMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">pstv:CharlottesvilleMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_MinimumMembersrtRangeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_MaximumMembersrtRangeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_StateAndLocalJurisdictionMemberusgaapIncomeTaxAuthorityAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_SeriesUWarrantsMemberusgaapClassOfWarrantOrRightAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">pstv:SeriesUWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_SeriesUWarrantsMemberusgaapClassOfWarrantOrRightAxis_WarrantMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">pstv:SeriesUWarrantsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_NanoTxLicensesAgreementMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">pstv:NanoTxLicensesAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_AccountingStandardsUpdate201613MemberusgaapAdjustmentsForNewAccountingPronouncementsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201613Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_SeriesCConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis_TwoThousandEighteenRightsOfferingMemberusgaapClassOfWarrantOrRightAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">pstv:TwoThousandEighteenRightsOfferingMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pstv:SeriesCConvertiblePreferredStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_SeriesBConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis_TwoThousandEighteenRightsOfferingMemberusgaapClassOfWarrantOrRightAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">pstv:TwoThousandEighteenRightsOfferingMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pstv:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_PreClinicalResearchStudyObligationsMemberusgaapRecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis">pstv:PreClinicalResearchStudyObligationsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapCashAndCashEquivalentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapCashAndCashEquivalentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_TermLoanMemberusgaapDebtInstrumentAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pstv:TermLoanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis_LincolnParkCapitalFundLLCMemberdeiLegalEntityAxis_TwentyTwentyPurchaseAgreementMemberusgaapInvestmentTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">pstv:TwentyTwentyPurchaseAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis">pstv:LincolnParkCapitalFundLLCMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_GrantMembersrtProductOrServiceAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_OptionsMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">pstv:OptionsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_PreferredStockMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_WarrantMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_CanaccordGenuityLLCMemberdeiLegalEntityAxis_CommonStockMemberusgaapStatementEquityComponentsAxis_JanuaryTwoThousandAndTwentyTwoDistributionAgreementMemberusgaapInvestmentTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">pstv:JanuaryTwoThousandAndTwentyTwoDistributionAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis">pstv:CanaccordGenuityLLCMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis_LincolnParkCapitalFundLLCMemberdeiLegalEntityAxis_TwentyTwentyPurchaseAgreementMemberusgaapInvestmentTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">pstv:TwentyTwentyPurchaseAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis">pstv:LincolnParkCapitalFundLLCMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_TermLoanMemberusgaapDebtInstrumentAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pstv:TermLoanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_InProcessResearchAndDevelopmentMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_CancerPreventionAndResearchInstituteOfTexasContractMemberusgaapTypeOfArrangementAxis_GrantMembersrtProductOrServiceAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pstv:CancerPreventionAndResearchInstituteOfTexasContractMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_LoremVascularPteLtdMembersrtLitigationCaseAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">pstv:LoremVascularPteLtdMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_GrantMembersrtProductOrServiceAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_OptionsMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">pstv:OptionsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_PreferredStockMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_WarrantMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_TermLoanMemberusgaapDebtInstrumentAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pstv:TermLoanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_CommonClassAMemberusgaapStatementClassOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_SeriesUWarrantsMemberusgaapClassOfWarrantOrRightAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">pstv:SeriesUWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_MaximumMembersrtRangeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_StockBasedCompensation2020EquityIncentivePlanMemberusgaapPlanNameAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pstv:StockBasedCompensation2020EquityIncentivePlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis_LincolnParkCapitalFundLLCMemberdeiLegalEntityAxis_TwoThousandAndTwentyTwoPurchaseAgreementMemberusgaapInvestmentTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">pstv:TwoThousandAndTwentyTwoPurchaseAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis">pstv:LincolnParkCapitalFundLLCMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_CanaccordGenuityLLCMemberdeiLegalEntityAxis_CommonStockMemberusgaapStatementEquityComponentsAxis_JanuaryTwoThousandAndTwentyTwoDistributionAgreementMemberusgaapInvestmentTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">pstv:JanuaryTwoThousandAndTwentyTwoDistributionAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis">pstv:CanaccordGenuityLLCMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_AtTheMarketOfferingProgramMemberusgaapSubsidiarySaleOfStockAxis_CanaccordGenuityLLCMemberdeiLegalEntityAxis_CommonStockMemberusgaapStatementEquityComponentsAxis_SeptemberTwoThousandAndTwentyTwoDistributionAgreementMemberusgaapInvestmentTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">pstv:SeptemberTwoThousandAndTwentyTwoDistributionAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis">pstv:CanaccordGenuityLLCMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pstv:AtTheMarketOfferingProgramMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_CharlottesvilleMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">pstv:CharlottesvilleMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_CancerPreventionAndResearchInstituteOfTexasContractMemberusgaapTypeOfArrangementAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pstv:CancerPreventionAndResearchInstituteOfTexasContractMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_MinimumMembersrtRangeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_StateAndLocalJurisdictionMemberusgaapIncomeTaxAuthorityAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_PreferredStockMemberusgaapStatementEquityComponentsAxis_SeriesFPreferredStockMemberusgaapStatementClassOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesFPreferredStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_InProcessResearchAndDevelopmentMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_SeriesUWarrantsMemberusgaapClassOfWarrantOrRightAxis_WarrantMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">pstv:SeriesUWarrantsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_CancerPreventionAndResearchInstituteOfTexasContractMemberusgaapTypeOfArrangementAxis_GrantMembersrtProductOrServiceAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pstv:CancerPreventionAndResearchInstituteOfTexasContractMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis_MaximumMembersrtRangeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_TreasuryStockCommonMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_MaximumMembersrtRangeAxis_TermLoanMemberusgaapDebtInstrumentAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pstv:TermLoanMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_SeriesBConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis_TwoThousandEighteenRightsOfferingMemberusgaapClassOfWarrantOrRightAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">pstv:TwoThousandEighteenRightsOfferingMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pstv:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_SeriesCConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis_TwoThousandEighteenRightsOfferingMemberusgaapClassOfWarrantOrRightAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">pstv:TwoThousandEighteenRightsOfferingMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pstv:SeriesCConvertiblePreferredStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_PiramalPharmaSolutionsIncMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">pstv:PiramalPharmaSolutionsIncMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn04_30_2023_OutstandingWarrantsAndOptionsMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">pstv:OutstandingWarrantsAndOptionsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-04-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn04_30_2023_EquityIncentivePlansMemberusgaapPlanNameAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pstv:EquityIncentivePlansMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-04-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn05_01_2023_OutstandingWarrantsAndOptionsMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">pstv:OutstandingWarrantsAndOptionsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-05-01</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn05_01_2023_EquityIncentivePlansMemberusgaapPlanNameAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pstv:EquityIncentivePlansMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-05-01</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2023_CharlottesvilleMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">pstv:CharlottesvilleMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn07_01_2023_CharlottesvilleMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">pstv:CharlottesvilleMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-07-01</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P09_07_2023To09_07_2023_BioceptAgreementMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">pstv:BioceptAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-09-07</xbrli:startDate> <xbrli:endDate>2023-09-07</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_07_2023_BioceptAgreementMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">pstv:BioceptAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-09-07</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P10_01_2023To12_31_2023_BioceptAgreementMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">pstv:BioceptAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-10-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To01_31_2022_UTHSALicenseAgreementMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">pstv:UTHSALicenseAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-01-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P03_29_2020To03_29_2020_NanoTxLicensesAgreementMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">pstv:NanoTxLicensesAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-03-29</xbrli:startDate> <xbrli:endDate>2020-03-29</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P03_29_2020To03_29_2020_TermLoanMemberusgaapDebtInstrumentAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pstv:TermLoanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-03-29</xbrli:startDate> <xbrli:endDate>2020-03-29</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_29_2020_NanoTxLicensesAgreementMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">pstv:NanoTxLicensesAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-03-29</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P05_28_2015To05_29_2015_InterestRateFloorMemberusgaapDerivativeInstrumentRiskAxis_LiborMemberusgaapVariableRateAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateFloorMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">pstv:LiborMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2015-05-28</xbrli:startDate> <xbrli:endDate>2015-05-29</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P05_28_2015To05_29_2015_TermLoanMemberusgaapDebtInstrumentAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pstv:TermLoanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2015-05-28</xbrli:startDate> <xbrli:endDate>2015-05-29</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P05_28_2015To05_29_2015_LoanAndSecurityAgreementMemberusgaapFinancialInstrumentAxis_SaleOfJapaneseSubsidiaryAndCertainAssetsMemberusgaapDisposalGroupClassificationAxis_TermLoanMemberusgaapDebtInstrumentAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pstv:TermLoanMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">pstv:SaleOfJapaneseSubsidiaryAndCertainAssetsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">pstv:LoanAndSecurityAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2015-05-28</xbrli:startDate> <xbrli:endDate>2015-05-29</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn05_29_2015_TermLoanMemberusgaapDebtInstrumentAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pstv:TermLoanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2015-05-29</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn05_29_2015_MinimumMembersrtRangeAxis_TermLoanMemberusgaapDebtInstrumentAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pstv:TermLoanMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2015-05-29</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P09_19_2022To09_19_2022_CancerPreventionAndResearchInstituteOfTexasContractMemberusgaapTypeOfArrangementAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pstv:CancerPreventionAndResearchInstituteOfTexasContractMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-09-19</xbrli:startDate> <xbrli:endDate>2022-09-19</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_19_2022_CancerPreventionAndResearchInstituteOfTexasContractMemberusgaapTypeOfArrangementAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pstv:CancerPreventionAndResearchInstituteOfTexasContractMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-09-19</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P10_01_2022To12_31_2022_CancerPreventionAndResearchInstituteOfTexasContractMemberusgaapTypeOfArrangementAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pstv:CancerPreventionAndResearchInstituteOfTexasContractMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-10-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To03_31_2023_GrantMembersrtProductOrServiceAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To03_31_2023_OptionsMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">pstv:OptionsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To03_31_2023_PreferredStockMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To03_31_2023_WarrantMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To03_31_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To03_31_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_SeriesFPreferredStockMemberusgaapStatementClassOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesFPreferredStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To03_31_2023_SeriesFPreferredStockMemberusgaapStatementClassOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesFPreferredStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To03_31_2023_PreferredStockMemberusgaapStatementEquityComponentsAxis_SeriesFPreferredStockMemberusgaapStatementClassOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesFPreferredStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To03_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To03_31_2023_CancerPreventionAndResearchInstituteOfTexasContractMemberusgaapTypeOfArrangementAxis_GrantMembersrtProductOrServiceAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pstv:CancerPreventionAndResearchInstituteOfTexasContractMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To03_31_2023_CancerPreventionAndResearchInstituteOfTexasContractMemberusgaapTypeOfArrangementAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pstv:CancerPreventionAndResearchInstituteOfTexasContractMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To03_31_2023_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P03_03_2023To03_03_2023_SeriesFConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis_SubscriptionAgreementMemberusgaapSubsidiarySaleOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pstv:SeriesFConvertiblePreferredStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pstv:SubscriptionAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-03-03</xbrli:startDate> <xbrli:endDate>2023-03-03</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P03_03_2023To03_03_2023_SeriesFConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pstv:SeriesFConvertiblePreferredStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-03-03</xbrli:startDate> <xbrli:endDate>2023-03-03</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_03_2023_SeriesFConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pstv:SeriesFConvertiblePreferredStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-03-03</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_03_2023_SeriesFConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis_SubscriptionAgreementMemberusgaapSubsidiarySaleOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pstv:SeriesFConvertiblePreferredStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pstv:SubscriptionAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-03-03</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P05_16_2022To05_16_2022_CommonStockMemberusgaapStatementEquityComponentsAxis_LincolnParkCapitalFundLLCMemberdeiLegalEntityAxis_MinimumMembersrtRangeAxis_TwoThousandAndTwentyTwoPurchaseAgreementMemberusgaapInvestmentTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">pstv:TwoThousandAndTwentyTwoPurchaseAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis">pstv:LincolnParkCapitalFundLLCMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-05-16</xbrli:startDate> <xbrli:endDate>2022-05-16</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn05_16_2022_LincolnParkCapitalFundLLCMemberdeiLegalEntityAxis_MaximumMembersrtRangeAxis_TwoThousandAndTwentyTwoPurchaseAgreementMemberusgaapInvestmentTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">pstv:TwoThousandAndTwentyTwoPurchaseAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis">pstv:LincolnParkCapitalFundLLCMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-05-16</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn08_02_2022_CommonStockMemberusgaapStatementEquityComponentsAxis_LincolnParkCapitalFundLLCMemberdeiLegalEntityAxis_TwoThousandAndTwentyTwoPurchaseAgreementMemberusgaapInvestmentTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">pstv:TwoThousandAndTwentyTwoPurchaseAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis">pstv:LincolnParkCapitalFundLLCMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-08-02</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn07_14_2022_CommonStockMemberusgaapStatementEquityComponentsAxis_LincolnParkCapitalFundLLCMemberdeiLegalEntityAxis_TwoThousandAndTwentyTwoPurchaseAgreementMemberusgaapInvestmentTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">pstv:TwoThousandAndTwentyTwoPurchaseAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis">pstv:LincolnParkCapitalFundLLCMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-07-14</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P08_02_2022To08_02_2022_CommonStockMemberusgaapStatementEquityComponentsAxis_LincolnParkCapitalFundLLCMemberdeiLegalEntityAxis_TwoThousandAndTwentyTwoPurchaseAgreementMemberusgaapInvestmentTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">pstv:TwoThousandAndTwentyTwoPurchaseAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis">pstv:LincolnParkCapitalFundLLCMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-08-02</xbrli:startDate> <xbrli:endDate>2022-08-02</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn08_17_2022_CommonStockMemberusgaapStatementEquityComponentsAxis_LincolnParkCapitalFundLLCMemberdeiLegalEntityAxis_TwoThousandAndTwentyTwoPurchaseAgreementMemberusgaapInvestmentTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">pstv:TwoThousandAndTwentyTwoPurchaseAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis">pstv:LincolnParkCapitalFundLLCMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-08-17</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn08_17_2022_CommonStockMemberusgaapStatementEquityComponentsAxis_LincolnParkCapitalFundLLCMemberdeiLegalEntityAxis_MaximumMembersrtRangeAxis_TwoThousandAndTwentyTwoPurchaseAgreementMemberusgaapInvestmentTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">pstv:TwoThousandAndTwentyTwoPurchaseAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis">pstv:LincolnParkCapitalFundLLCMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-08-17</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P08_17_2022To12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis_LincolnParkCapitalFundLLCMemberdeiLegalEntityAxis_TwentyTwentyPurchaseAgreementMemberusgaapInvestmentTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">pstv:TwentyTwentyPurchaseAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis">pstv:LincolnParkCapitalFundLLCMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-08-17</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn08_18_2023_CommonStockMemberusgaapStatementEquityComponentsAxis_LincolnParkCapitalFundLLCMemberdeiLegalEntityAxis_MaximumMembersrtRangeAxis_TwoThousandAndTwentyTwoPurchaseAgreementMemberusgaapInvestmentTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">pstv:TwoThousandAndTwentyTwoPurchaseAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis">pstv:LincolnParkCapitalFundLLCMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-08-18</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P08_18_2023To12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis_LincolnParkCapitalFundLLCMemberdeiLegalEntityAxis_TwoThousandAndTwentyTwoPurchaseAgreementMemberusgaapInvestmentTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">pstv:TwoThousandAndTwentyTwoPurchaseAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis">pstv:LincolnParkCapitalFundLLCMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-08-18</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2020_CommonStockMemberusgaapStatementEquityComponentsAxis_LincolnParkCapitalFundLLCMemberdeiLegalEntityAxis_TwentyTwentyPurchaseAgreementMemberusgaapInvestmentTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">pstv:TwentyTwentyPurchaseAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis">pstv:LincolnParkCapitalFundLLCMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P08_17_2022To12_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis_LincolnParkCapitalFundLLCMemberdeiLegalEntityAxis_TwoThousandAndTwentyTwoPurchaseAgreementMemberusgaapInvestmentTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">pstv:TwoThousandAndTwentyTwoPurchaseAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis">pstv:LincolnParkCapitalFundLLCMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-08-17</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_14_2022To01_14_2022_AtTheMarketOfferingProgramMemberusgaapSubsidiarySaleOfStockAxis_CanaccordGenuityLLCMemberdeiLegalEntityAxis_CommonStockMemberusgaapStatementEquityComponentsAxis_JanuaryTwoThousandAndTwentyTwoDistributionAgreementMemberusgaapInvestmentTypeAxis_MaximumMembersrtRangeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">pstv:JanuaryTwoThousandAndTwentyTwoDistributionAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis">pstv:CanaccordGenuityLLCMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pstv:AtTheMarketOfferingProgramMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-14</xbrli:startDate> <xbrli:endDate>2022-01-14</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P09_09_2022To09_09_2022_AtTheMarketOfferingProgramMemberusgaapSubsidiarySaleOfStockAxis_CanaccordGenuityLLCMemberdeiLegalEntityAxis_CommonStockMemberusgaapStatementEquityComponentsAxis_MaximumMembersrtRangeAxis_SeptemberTwoThousandAndTwentyTwoDistributionAgreementMemberusgaapInvestmentTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">pstv:SeptemberTwoThousandAndTwentyTwoDistributionAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis">pstv:CanaccordGenuityLLCMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pstv:AtTheMarketOfferingProgramMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-09-09</xbrli:startDate> <xbrli:endDate>2022-09-09</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P09_09_2022To09_09_2022_AtTheMarketOfferingProgramMemberusgaapSubsidiarySaleOfStockAxis_CanaccordGenuityLLCMemberdeiLegalEntityAxis_SeptemberTwoThousandAndTwentyTwoDistributionAgreementMemberusgaapInvestmentTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">pstv:SeptemberTwoThousandAndTwentyTwoDistributionAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis">pstv:CanaccordGenuityLLCMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pstv:AtTheMarketOfferingProgramMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-09-09</xbrli:startDate> <xbrli:endDate>2022-09-09</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P09_09_2022To12_31_2022_AtTheMarketOfferingProgramMemberusgaapSubsidiarySaleOfStockAxis_CanaccordGenuityLLCMemberdeiLegalEntityAxis_CommonStockMemberusgaapStatementEquityComponentsAxis_SeptemberTwoThousandAndTwentyTwoDistributionAgreementMemberusgaapInvestmentTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">pstv:SeptemberTwoThousandAndTwentyTwoDistributionAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis">pstv:CanaccordGenuityLLCMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pstv:AtTheMarketOfferingProgramMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-09-09</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn10_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis_MaximumMembersrtRangeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-10-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To02_26_2024_CommonStockMemberusgaapStatementEquityComponentsAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-02-26</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn02_26_2024_CommonStockMemberusgaapStatementEquityComponentsAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-02-26</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2024_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapCashAndCashEquivalentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2024_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapCashAndCashEquivalentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2024_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_USTreasurySecuritiesMemberusgaapCashAndCashEquivalentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2024_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_USTreasurySecuritiesMemberusgaapCashAndCashEquivalentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2024_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2024_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2024_StockBasedCompensation2015EquityIncentivePlan1MemberusgaapPlanNameAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pstv:StockBasedCompensation2015EquityIncentivePlan1Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2024_StockBasedCompensation2020EquityIncentivePlanMemberusgaapPlanNameAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pstv:StockBasedCompensation2020EquityIncentivePlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2024_CommonClassBMemberusgaapStatementClassOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2024_RepresentativeSeriesUWarrantMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">pstv:RepresentativeSeriesUWarrantMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2024_MaximumMembersrtRangeAxis_TermLoanMemberusgaapDebtInstrumentAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pstv:TermLoanMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2024_CharlottesvilleMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">pstv:CharlottesvilleMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2024_SeriesUWarrantsMemberusgaapClassOfWarrantOrRightAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">pstv:SeriesUWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2024_SeriesUWarrantsMemberusgaapClassOfWarrantOrRightAxis_WarrantMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">pstv:SeriesUWarrantsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2024_TermLoanMemberusgaapDebtInstrumentAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pstv:TermLoanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2024_NanoTxLicensesAgreementMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">pstv:NanoTxLicensesAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2024_SeriesCConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis_TwoThousandEighteenRightsOfferingMemberusgaapClassOfWarrantOrRightAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">pstv:TwoThousandEighteenRightsOfferingMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pstv:SeriesCConvertiblePreferredStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2024_SeriesBConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis_TwoThousandEighteenRightsOfferingMemberusgaapClassOfWarrantOrRightAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">pstv:TwoThousandEighteenRightsOfferingMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pstv:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2024_PreClinicalResearchStudyObligationsMemberusgaapRecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis">pstv:PreClinicalResearchStudyObligationsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2024_CommonStockMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To03_31_2024_GrantMembersrtProductOrServiceAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To03_31_2024_OptionsMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">pstv:OptionsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To03_31_2024_PreferredStockMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To03_31_2024_WarrantMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To03_31_2024_TermLoanMemberusgaapDebtInstrumentAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pstv:TermLoanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To03_31_2024_SeriesUWarrantsMemberusgaapClassOfWarrantOrRightAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">pstv:SeriesUWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To03_31_2024_CommonClassAMemberusgaapStatementClassOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To03_31_2024_StockBasedCompensation2020EquityIncentivePlanMemberusgaapPlanNameAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pstv:StockBasedCompensation2020EquityIncentivePlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To03_31_2024_CommonStockMemberusgaapStatementEquityComponentsAxis_LincolnParkCapitalFundLLCMemberdeiLegalEntityAxis_TwoThousandAndTwentyTwoPurchaseAgreementMemberusgaapInvestmentTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">pstv:TwoThousandAndTwentyTwoPurchaseAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis">pstv:LincolnParkCapitalFundLLCMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To03_31_2024_BioceptAgreementMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">pstv:BioceptAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To03_31_2024_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To03_31_2024_CharlottesvilleMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">pstv:CharlottesvilleMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To03_31_2024_CancerPreventionAndResearchInstituteOfTexasContractMemberusgaapTypeOfArrangementAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pstv:CancerPreventionAndResearchInstituteOfTexasContractMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To03_31_2024_MinimumMembersrtRangeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To03_31_2024_MaximumMembersrtRangeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To03_31_2024_SeriesUWarrantsMemberusgaapClassOfWarrantOrRightAxis_WarrantMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">pstv:SeriesUWarrantsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To03_31_2024_CancerPreventionAndResearchInstituteOfTexasContractMemberusgaapTypeOfArrangementAxis_GrantMembersrtProductOrServiceAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pstv:CancerPreventionAndResearchInstituteOfTexasContractMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To03_31_2024_TreasuryStockCommonMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To03_31_2024_MaximumMembersrtRangeAxis_TermLoanMemberusgaapDebtInstrumentAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pstv:TermLoanMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To03_31_2024_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To03_31_2024_SeriesBConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis_TwoThousandEighteenRightsOfferingMemberusgaapClassOfWarrantOrRightAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">pstv:TwoThousandEighteenRightsOfferingMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pstv:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To03_31_2024_SeriesCConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis_TwoThousandEighteenRightsOfferingMemberusgaapClassOfWarrantOrRightAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">pstv:TwoThousandEighteenRightsOfferingMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pstv:SeriesCConvertiblePreferredStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To03_31_2024_CommonStockMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To03_31_2024_PiramalPharmaSolutionsIncMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">pstv:PiramalPharmaSolutionsIncMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To03_31_2024_BusinessContactMemberdeiEntityAddressesAddressTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:EntityAddressesAddressTypeAxis">dei:BusinessContactMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P06_28_2023To06_28_2023_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMemberusgaapVariableRateAxis_TermLoanMemberusgaapDebtInstrumentAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pstv:TermLoanMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-06-28</xbrli:startDate> <xbrli:endDate>2023-06-28</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_28_2023_TermLoanMemberusgaapDebtInstrumentAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pstv:TermLoanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-06-28</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P08_17_2022To03_31_2024_CommonStockMemberusgaapStatementEquityComponentsAxis_LincolnParkCapitalFundLLCMemberdeiLegalEntityAxis_TwentyTwentyPurchaseAgreementMemberusgaapInvestmentTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">pstv:TwentyTwentyPurchaseAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis">pstv:LincolnParkCapitalFundLLCMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-08-17</xbrli:startDate> <xbrli:endDate>2024-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P08_18_2023To03_31_2024_CommonStockMemberusgaapStatementEquityComponentsAxis_LincolnParkCapitalFundLLCMemberdeiLegalEntityAxis_TwoThousandAndTwentyTwoPurchaseAgreementMemberusgaapInvestmentTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">pstv:TwoThousandAndTwentyTwoPurchaseAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis">pstv:LincolnParkCapitalFundLLCMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-08-18</xbrli:startDate> <xbrli:endDate>2024-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_20_2023To04_20_2023_MinimumMembersrtRangeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-04-20</xbrli:startDate> <xbrli:endDate>2023-04-20</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_20_2023To04_20_2023_MaximumMembersrtRangeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-04-20</xbrli:startDate> <xbrli:endDate>2023-04-20</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn05_09_2024_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-05-09</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn05_09_2024_May2024PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pstv:May2024PrivatePlacementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-05-09</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P03_27_2020To03_28_2020_TermLoanMemberusgaapDebtInstrumentAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pstv:TermLoanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-03-27</xbrli:startDate> <xbrli:endDate>2020-03-28</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_08_2021To01_08_2021_PiramalPharmaSolutionsIncMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">pstv:PiramalPharmaSolutionsIncMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-08</xbrli:startDate> <xbrli:endDate>2021-01-08</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn01_14_2022_AtTheMarketOfferingProgramMemberusgaapSubsidiarySaleOfStockAxis_CanaccordGenuityLLCMemberdeiLegalEntityAxis_CommonStockMemberusgaapStatementEquityComponentsAxis_JanuaryTwoThousandAndTwentyTwoDistributionAgreementMemberusgaapInvestmentTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">pstv:JanuaryTwoThousandAndTwentyTwoDistributionAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis">pstv:CanaccordGenuityLLCMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pstv:AtTheMarketOfferingProgramMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-01-14</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P05_31_2024To05_31_2024_PershingCreditFacilityMemberusgaapCreditFacilityAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">pstv:PershingCreditFacilityMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-05-31</xbrli:startDate> <xbrli:endDate>2024-05-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn05_31_2024_PershingCreditFacilityMemberusgaapCreditFacilityAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">pstv:PershingCreditFacilityMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-05-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To09_30_2020_CommonStockMemberusgaapStatementEquityComponentsAxis_LincolnParkCapitalFundLLCMemberdeiLegalEntityAxis_TwentyTwentyPurchaseAgreementMemberusgaapInvestmentTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">pstv:TwentyTwentyPurchaseAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis">pstv:LincolnParkCapitalFundLLCMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P03_31_2022To03_31_2022_MedidataSolutionsIncMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_ServicesAgreementMemberusgaapTypeOfArrangementAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">pstv:MedidataSolutionsIncMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pstv:ServicesAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-03-31</xbrli:startDate> <xbrli:endDate>2022-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn05_05_2024_May2024PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pstv:May2024PrivatePlacementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-05-05</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P05_05_2024To05_05_2024_May2024PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pstv:May2024PrivatePlacementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-05-05</xbrli:startDate> <xbrli:endDate>2024-05-05</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P05_05_2024To05_05_2024_May2024PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_SeriesAWarrantMemberusgaapClassOfWarrantOrRightAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">pstv:SeriesAWarrantMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pstv:May2024PrivatePlacementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-05-05</xbrli:startDate> <xbrli:endDate>2024-05-05</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P05_05_2024To05_05_2024_May2024PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_SeriesBWarrantMemberusgaapClassOfWarrantOrRightAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">pstv:SeriesBWarrantMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pstv:May2024PrivatePlacementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-05-05</xbrli:startDate> <xbrli:endDate>2024-05-05</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P05_05_2024To05_05_2024_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-05-05</xbrli:startDate> <xbrli:endDate>2024-05-05</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P05_05_2024To05_05_2024_PreFundedWarrantMemberusgaapSubsidiarySaleOfStockAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pstv:PreFundedWarrantMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-05-05</xbrli:startDate> <xbrli:endDate>2024-05-05</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_26_2024To04_26_2024_BioceptAssetPurchaseMemberusgaapAssetAcquisitionAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">pstv:BioceptAssetPurchaseMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-04-26</xbrli:startDate> <xbrli:endDate>2024-04-26</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_ConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_ConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_TreasuryStockCommonMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_ConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2023_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2023_PreferredStockMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2023_ConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2024_TreasuryStockCommonMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2024_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2024_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2024_ConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:unit id="Unit_USD"> <xbrli:measure>iso4217:USD</xbrli:measure> </xbrli:unit><xbrli:unit id="Unit_shares"> <xbrli:measure>xbrli:shares</xbrli:measure> </xbrli:unit><xbrli:unit id="Unit_pure"> <xbrli:measure>xbrli:pure</xbrli:measure> </xbrli:unit><xbrli:unit id="Unit_Year"> <xbrli:measure>utr:Year</xbrli:measure> </xbrli:unit><xbrli:unit id="Unit_Month"> <xbrli:measure>utr:Month</xbrli:measure> </xbrli:unit><xbrli:unit id="Unit_USD_per_Share"> <xbrli:divide> <xbrli:unitNumerator> <xbrli:measure>iso4217:USD</xbrli:measure> </xbrli:unitNumerator> <xbrli:unitDenominator> <xbrli:measure>xbrli:shares</xbrli:measure> </xbrli:unitDenominator> </xbrli:divide> </xbrli:unit><xbrli:unit id="Unit_Votes"> <xbrli:measure>pstv:Votes</xbrli:measure> </xbrli:unit><xbrli:unit id="Unit_ReportableUnit"> <xbrli:measure>pstv:ReportableUnit</xbrli:measure> </xbrli:unit><xbrli:unit id="Unit_Segment"> <xbrli:measure>pstv:Segment</xbrli:measure> </xbrli:unit><ix:relationship fromRefs="Fact_116199642" toRefs="FN_422111"/><ix:relationship fromRefs="Fact_116199643" toRefs="FN_422112"/><ix:relationship fromRefs="Fact_116199647" toRefs="FN_422111"/><ix:relationship fromRefs="Fact_116199648" toRefs="FN_422112"/></ix:resources></ix:header></div><div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; letter-spacing: 0px; top: 0px;display:inline;">As filed with the Securities and Exchange Commission on June&#160;7, 2024 </div></div></div><div style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; letter-spacing: 0px; top: 0px;display:inline;">Registration No.&#160;333-&#8195;&#8195;&#8195; </div></div></div><div style="font-size: 4pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="font-size: 4pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="line-height: 1pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="line-height: 3pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 14pt; margin-top: 4pt; margin-bottom: 0pt;text-indent: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 14pt; letter-spacing: 0px; top: 0px;display:inline;">UNITED STATES </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 14pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 14pt; letter-spacing: 0px; top: 0px;display:inline;">SECURITIES AND EXCHANGE COMMISSION </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">WASHINGTON, D.C. 20549 </div></div></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="text-align: center;text-indent: 0px;"><div style="margin: 0pt auto 2pt; width: 21%; text-align: center; line-height: 6pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 14pt; margin-top: 6pt; margin-bottom: 0pt;text-indent: 0px;"><div style="font-weight:bold;display:inline;">FORM <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><ix:nonNumeric name="dei:DocumentType" contextRef="P01_01_2024To03_31_2024" id="ixv-22161">S-1</ix:nonNumeric></div> </div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 14pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 14pt; letter-spacing: 0px; top: 0px;display:inline;">REGISTRATION STATEMENT </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9.5pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">UNDER </div></div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9.5pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">THE SECURITIES ACT OF 1933 </div></div></div></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="text-align: center;text-indent: 0px;"><div style="margin: 0pt auto 2pt; width: 21%; text-align: center; line-height: 6pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 22pt; margin-top: 6pt; margin-bottom: 0pt;text-indent: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 22pt; letter-spacing: 0px; top: 0px;display:inline;"><ix:nonNumeric name="dei:EntityRegistrantName" contextRef="P01_01_2024To03_31_2024" id="ixv-22162">PLUS THERAPEUTICS, INC.</ix:nonNumeric> </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; letter-spacing: 0px; top: 0px;display:inline;">(Exact name of Registrant as specified in its charter) </div></div></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="text-align: center;text-indent: 0px;"><div style="margin: 0pt auto 2pt; width: 21%; text-align: center; line-height: 6pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 100%; font-family: Times New Roman; font-size: 7pt; border-collapse: collapse;text-indent: 0px;">
<tr>
<td style="width: 34%;"/>
<td style="vertical-align: bottom;"/>
<td style="width: 32%;"/>
<td style="width: 1%; vertical-align: bottom;"/>
<td style="width: 32%;"/></tr>
<tr style="font-family: Times New Roman; font-size: 8.5pt; page-break-inside: avoid;">
<td style="vertical-align: top;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" contextRef="P01_01_2024To03_31_2024" format="ixt-sec:stateprovnameen" id="ixv-22163">Delaware</ix:nonNumeric></div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonNumeric name="dei:EntityPrimarySicNumber" contextRef="P01_01_2024To03_31_2024" id="ixv-22164">2834</ix:nonNumeric></div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" contextRef="P01_01_2024To03_31_2024" id="ixv-22165">33-0827593</ix:nonNumeric></div></div></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 7pt; page-break-inside: avoid;">
<td style="vertical-align: top;text-align:center;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 7pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 7pt; letter-spacing: 0px; top: 0px;display:inline;">(State or other jurisdiction of</div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 7pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 7pt; letter-spacing: 0px; top: 0px;display:inline;">incorporation or organization)</div></div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;text-align:center;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 7pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 7pt; letter-spacing: 0px; top: 0px;display:inline;">(Primary Standard Industrial</div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 7pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 7pt; letter-spacing: 0px; top: 0px;display:inline;">Classification Code Number)</div></div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;text-align:center;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 7pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 7pt; letter-spacing: 0px; top: 0px;display:inline;">(I.R.S. Employer</div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 7pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 7pt; letter-spacing: 0px; top: 0px;display:inline;">Identification Number)</div></div></div></td></tr></table><div style="clear:both;max-height:0pt;text-indent: 0px;"></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; margin-top: 6pt; margin-bottom: 0pt;text-indent: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; letter-spacing: 0px; top: 0px;display:inline;"><ix:nonNumeric name="dei:EntityAddressAddressLine1" contextRef="P01_01_2024To03_31_2024" id="ixv-22166">4200 Marathon Blvd.</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressAddressLine2" contextRef="P01_01_2024To03_31_2024" id="ixv-22167">Suite 200</ix:nonNumeric> </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; letter-spacing: 0px; top: 0px;display:inline;"><ix:nonNumeric name="dei:EntityAddressCityOrTown" contextRef="P01_01_2024To03_31_2024" id="ixv-22168">Austin</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressStateOrProvince" contextRef="P01_01_2024To03_31_2024" format="ixt-sec:stateprovnameen" id="ixv-22169">Texas</ix:nonNumeric> <ix:nonNumeric name="dei:EntityAddressPostalZipCode" contextRef="P01_01_2024To03_31_2024" id="ixv-22170">78756</ix:nonNumeric> </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="font-weight:bold;display:inline;">(<ix:nonNumeric name="dei:CityAreaCode" contextRef="P01_01_2024To03_31_2024" id="ixv-22171">737</ix:nonNumeric>) <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><ix:nonNumeric name="dei:LocalPhoneNumber" contextRef="P01_01_2024To03_31_2024" id="ixv-22172">255-7194</ix:nonNumeric></div> </div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 7pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 7pt; letter-spacing: 0px; top: 0px;display:inline;">(Address, including zip code, and telephone number, including area code, of registrant&#8217;s principal executive offices) </div></div></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="text-align: center;text-indent: 0px;"><div style="margin: 0pt auto 2pt; width: 21%; text-align: center; line-height: 6pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; margin-top: 6pt; margin-bottom: 0pt;text-indent: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; letter-spacing: 0px; top: 0px;display:inline;"><ix:nonNumeric name="dei:ContactPersonnelName" contextRef="P01_01_2024To03_31_2024_BusinessContactMemberdeiEntityAddressesAddressTypeAxis" id="ixv-22173">Marc H. Hedrick, M.D.</ix:nonNumeric> </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; letter-spacing: 0px; top: 0px;display:inline;">President and Chief Executive Officer </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; letter-spacing: 0px; top: 0px;display:inline;">Plus Therapeutics, Inc. </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; letter-spacing: 0px; top: 0px;display:inline;"><ix:nonNumeric name="dei:EntityAddressAddressLine1" contextRef="P01_01_2024To03_31_2024_BusinessContactMemberdeiEntityAddressesAddressTypeAxis" id="ixv-22174">4200 Marathon Blvd.</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressAddressLine2" contextRef="P01_01_2024To03_31_2024_BusinessContactMemberdeiEntityAddressesAddressTypeAxis" id="ixv-22175">Suite 200</ix:nonNumeric> </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; letter-spacing: 0px; top: 0px;display:inline;"><ix:nonNumeric name="dei:EntityAddressCityOrTown" contextRef="P01_01_2024To03_31_2024_BusinessContactMemberdeiEntityAddressesAddressTypeAxis" id="ixv-22176">Austin</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressStateOrProvince" contextRef="P01_01_2024To03_31_2024_BusinessContactMemberdeiEntityAddressesAddressTypeAxis" format="ixt-sec:stateprovnameen" id="ixv-22177">Texas</ix:nonNumeric> <ix:nonNumeric name="dei:EntityAddressPostalZipCode" contextRef="P01_01_2024To03_31_2024_BusinessContactMemberdeiEntityAddressesAddressTypeAxis" id="ixv-22178">78756</ix:nonNumeric> </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="font-weight:bold;display:inline;">(<ix:nonNumeric name="dei:CityAreaCode" contextRef="P01_01_2024To03_31_2024_BusinessContactMemberdeiEntityAddressesAddressTypeAxis" id="ixv-22179">737</ix:nonNumeric>) <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><ix:nonNumeric name="dei:LocalPhoneNumber" contextRef="P01_01_2024To03_31_2024_BusinessContactMemberdeiEntityAddressesAddressTypeAxis" id="ixv-22180">255-7194</ix:nonNumeric></div> </div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 7pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 7pt; letter-spacing: 0px; top: 0px;display:inline;">(Name, address, including zip code, and telephone number, including area code, of agent for service) </div></div></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="text-align: center;text-indent: 0px;"><div style="margin: 0pt auto 2pt; width: 21%; text-align: center; line-height: 6pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; margin-top: 6pt; margin-bottom: 0pt;text-indent: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Copies to: </div></div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; margin-top: 6pt; margin-bottom: 0pt;text-indent: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; letter-spacing: 0px; top: 0px;display:inline;">Andrew L. Strong </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; letter-spacing: 0px; top: 0px;display:inline;">William I. Intner </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; letter-spacing: 0px; top: 0px;display:inline;">Hogan Lovells US LLP </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; letter-spacing: 0px; top: 0px;display:inline;">609 Main Street, Suite 4200 </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; letter-spacing: 0px; top: 0px;display:inline;">Houston, TX 77002 </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="font-weight:bold;display:inline;">(713) <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">632-1400</div> </div></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="text-align: center;text-indent: 0px;"><div style="margin: 0pt auto 2pt; width: 21%; text-align: center; line-height: 6pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div><div style="font-family: Times New Roman; font-size: 8.5pt; margin-top: 6pt; margin-bottom: 0pt;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Approximate Date of Commencement of Proposed Sale to the Public:</div></div> From time to time after the effective date of this registration statement. </div><div style="font-family: Times New Roman; font-size: 8.5pt; margin-top: 6pt; margin-bottom: 0pt;text-indent: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; letter-spacing: 0px; top: 0px;display:inline;">If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, check the following box:&#8194;&#9746; </div></div><div style="font-family: Times New Roman; font-size: 8.5pt; margin-top: 6pt; margin-bottom: 0pt;text-indent: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; letter-spacing: 0px; top: 0px;display:inline;">If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.&#8194;&#9744; </div></div><div style="font-family: Times New Roman; font-size: 8.5pt; margin-top: 6pt; margin-bottom: 0pt;text-indent: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; letter-spacing: 0px; top: 0px;display:inline;">If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.&#8194;&#9744; </div></div><div style="font-family: Times New Roman; font-size: 8.5pt; margin-top: 6pt; margin-bottom: 0pt;text-indent: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; letter-spacing: 0px; top: 0px;display:inline;">If this Form is a post-effective amendment filed pursuant to Rule&#160;462(d)&#160;under the&#160;Securities Act, check the following box and list the&#160;Securities Act&#160;registration statement number of the earlier effective registration statement for the same offering.&#8194;&#9744; </div></div><div style="font-family: Times New Roman; font-size: 8.5pt; margin-top: 6pt; margin-bottom: 0pt;text-indent: 0px;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">non-accelerated</div> filer, smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">12b-2</div> of the Exchange Act. </div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="text-align: center;text-indent: 0px;"><div style="margin: 0pt auto 2pt; width: 21%; text-align: center; line-height: 6pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 100%; font-family: Times New Roman; font-size: 8.5pt; border-collapse: collapse;text-indent: 0px;">
<tr>
<td style="width: 17%;"/>
<td style="width: 1%; vertical-align: bottom;"/>
<td style="width: 58%;"/>
<td style="width: 1%; vertical-align: bottom;"/>
<td style="width: 20%;"/>
<td style="width: 1%; vertical-align: bottom;"/>
<td style="width: 2%;"/></tr>
<tr style="font-family: Times New Roman; font-size: 8.5pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">Large&#160;accelerated&#160;filer</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#9744;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">Accelerated&#160;filer</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#9744;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 3pt;"/>
<td colspan="2" style="height: 3pt;"/>
<td colspan="2" style="height: 3pt;"/>
<td colspan="2" style="height: 3pt;"/></tr>
<tr style="font-family: Times New Roman; font-size: 8.5pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"></div><ix:nonNumeric name="dei:EntityFilerCategory" contextRef="P01_01_2024To03_31_2024" format="ixt-sec:entityfilercategoryen" id="ixv-229"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">Non-accelerated</div> filer</ix:nonNumeric></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#9746;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">Smaller&#160;reporting&#160;company</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><ix:nonNumeric name="dei:EntitySmallBusiness" contextRef="P01_01_2024To03_31_2024" format="ixt:fixed-true" id="ixv-22181">&#9746;</ix:nonNumeric></td></tr>
<tr style="font-size: 1pt;">
<td style="height: 3pt;"/>
<td colspan="2" style="height: 3pt;"/>
<td colspan="2" style="height: 3pt;"/>
<td colspan="2" style="height: 3pt;"/></tr>
<tr style="font-family: Times New Roman; font-size: 8.5pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">Emerging&#160;growth&#160;company</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><ix:nonNumeric name="dei:EntityEmergingGrowthCompany" contextRef="P01_01_2024To03_31_2024" format="ixt:fixed-false" id="ixv-22182">&#9744;</ix:nonNumeric></td></tr></table><div style="clear:both;max-height:0pt;text-indent: 0px;"></div><div style="font-family: Times New Roman; font-size: 8.5pt; margin-top: 6pt; margin-bottom: 0pt;text-indent: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; letter-spacing: 0px; top: 0px;display:inline;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;7(a)(2)(B) of the Securities Act.&#8194;&#9744; </div></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="text-align: center;text-indent: 0px;"><div style="margin: 0pt auto 2pt; width: 21%; text-align: center; line-height: 6pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; margin-top: 6pt; margin-bottom: 0pt;text-indent: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; letter-spacing: 0px; top: 0px;display:inline;">The registrant hereby amends this registration statement on such date or dates as may be necessary to delay its effective date until the registrant shall file a further amendment that specifically states that this registration statement shall thereafter become effective in accordance with Section&#160;8(a) of the Securities Act of 1933 or until the registration statement shall become effective on such date as the Securities and Exchange Commission, acting pursuant to said Section&#160;8(a), may determine. </div></div></div><div style="font-size: 4pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="font-size: 4pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="line-height: 1pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="line-height: 3pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div></div></div>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Arial Narrow"><span style="color:#ff4338"><span style="font-weight:bold">The information in this preliminary prospectus is not complete and may be changed. These securities may not be sold until the registration statement filed with the Securities and Exchange Commission is effective. This preliminary prospectus is not an offer to sell nor the solicitation of an offer to buy these securities in any jurisdiction where the offer or sale is not permitted. </span></span></p> <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><span style="color:#ff4338"><span style="font-weight:bold">SUBJECT TO COMPLETION DATED JUNE&#160;7, 2024 </span></span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">PRELIMINARY PROSPECTUS </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt;margin-bottom:0pt;text-align:center">


<img src="g840996g01a00.jpg" alt="LOGO"/>
 </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">Up to 10,774,596 Shares of Common Stock </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p><div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:12pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman">This prospectus relates to up to an aggregate of 10,774,596 shares of common stock, par value $0.001, of Plus Therapeutics, Inc., a Delaware corporation (&#8220;Plus Therapeutics,&#8221; &#8220;Plus,&#8221; &#8220;we,&#8221; &#8220;us&#8221; or &#8220;our&#8221;), which may be offered for sale from time to time by selling stockholders named herein. The shares of common stock covered in this prospectus consist of: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:9pt;text-align:left">up to 1,439,988 shares of common stock; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:9pt;text-align:left">up to 2,151,544<span style="font-weight:bold"> </span>shares of common stock issuable upon exercise of <span style="white-space:nowrap">pre-funded</span> warrants <span style="white-space:nowrap">(&#8220;Pre-Funded</span> Warrants&#8221;); </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:9pt;text-align:left">up to 3,591,532 shares of common stock issuable upon exercise of Series A common stock warrants (&#8220;Series A Common Stock Warrants&#8221;); and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:9pt;text-align:left">up to 3,591,532 shares of common stock issuable upon exercise of Series B common stock warrants (&#8220;Series B Common Stock Warrants&#8221;, and together with the Series A Common Stock Warrants, the &#8220;Common Warrants&#8221;). </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman">The shares of common stock being registered were issued pursuant to the Securities Purchase Agreement, dated May&#160;5, 2024 (the &#8220;Securities Purchase Agreement&#8221;), among us and certain accredited investors and Company insiders named therein (the &#8220;Purchasers,&#8221; or &#8220;selling stockholders&#8221;), which was subsequently amended by the First Amendment to Securities Purchase Agreement, dated May&#160;8, 2024 (the &#8220;Amendment to Securities Purchase Agreement&#8221;, and together with the &#8220;Securities Purchase Agreement&#8221;, the &#8220;Purchase Agreement&#8221;). </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman">We are registering the resale of the shares of common stock pursuant to the Registration Rights Agreement, dated May&#160;5, 2024 (the &#8220;Registration Rights Agreement&#8221;), that we entered into with the Purchasers in connection with the Purchase Agreement. See the section entitled &#8220;Selling Stockholders&#8221; for additional information regarding the Purchasers. Our registration of the resale of the shares of common stock covered by this prospectus does not mean that the&#160;selling stockholders will offer or sell all or any of the shares of common stock. The selling stockholders may offer, sell or distribute all or portion of their shares of common stock from time to time directly or indirectly through one or more underwriters, broker-dealers or agents, and in one or more public or private transactions. The shares of common stock may be sold in one or more transactions at fixed prices, at prevailing market prices at the time of the sale, at varying prices determined at the time of sale or at negotiated prices. These sales may be effected in transactions, which may involve crosses or block transactions. See the section entitled &#8220;<a href="#tx840996_18"><span style="text-decoration:underline">Plan of Distribution</span></a>&#8221; for more information. </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman">We are not selling any shares under this prospectus and will not receive any proceeds from the sale shares by the selling stockholders or their donees, pledgees, assignees, transferees or other <span style="white-space:nowrap"><span style="white-space:nowrap">successors-in-interest,</span></span> except with respect to amounts received by us upon exercise of the <span style="white-space:nowrap">Pre-Funded</span> Warrants, the Series A Common Stock Warrants and the Series B Common Stock Warrants (collectively, the &#8220;Warrants&#8221;), to the extent the Warrants are exercised for cash. We will bear all expenses of any offering of shares of the common stock, except that the selling stockholders will pay any applicable underwriting fees, discounts or commissions and transfer taxes. </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman">Our common stock is listed on The Nasdaq Capital Market under the trading symbol &#8220;PSTV.&#8221; On June&#160;6, 2024, the closing sale price of our Common Stock was $2.48 per share. </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p><div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:6pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman;font-weight:bold">Investing in our common stock involves a high degree of risk that are described in the section entitled &#8220;<a href="#tx840996_6">Risk Factors</a>&#8221; beginning on page 13 of this prospectus. You should also review carefully any risk factors included in any applicable prospectus supplement for a discussion of additional risks that you should consider before investing in our common stock. </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman;font-weight:bold">Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense. </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p><div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman;font-weight:bold;text-align:center">The date of this prospectus is&#8195;&#8195;&#8195;&#8195; , 2024. </p>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="toc">TABLE OF CONTENTS </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:95%"/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold"><a href="#tx840996_1">ABOUT THIS PROSPECTUS</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">ii</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold"><a href="#tx840996_2">CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">iii</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold"><a href="#tx840996_3">PROSPECTUS SUMMARY</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx840996_4"><span style="font-weight:bold">OUR COMPANY</span></a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx840996_5"><span style="font-weight:bold">THE OFFERING</span></a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">12</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold"><a href="#tx840996_6">RISK FACTORS</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">13</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold"><a href="#tx840996_7">USE OF PROCEEDS</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">45</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold"><a href="#tx840996_8">MARKET INFORMATION FOR COMMON STOCK</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">45</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold"><a href="#tx840996_9">DIVIDEND POLICY</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">46</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold"><a href="#tx840996_10">MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">46</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold"><a href="#tx840996_11">BUSINESS</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">58</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold"><a href="#tx840996_12">MANAGEMENT</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">64</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold"><a href="#tx840996_13">EXECUTIVE COMPENSATION</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">71</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold"><a href="#tx840996_14">CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">77</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold"><a href="#tx840996_15">SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">79</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold"><a href="#tx840996_16">DESCRIPTION OF SECURITIES</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">82</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold"><a href="#tx840996_17">SELLING STOCKHOLDERS</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">87</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold"><a href="#tx840996_18">PLAN OF DISTRIBUTION</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">93</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold"><a href="#tx840996_19">LEGAL MATTERS</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">96</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold"><a href="#tx840996_20">EXPERTS</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">96</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold"><a href="#tx840996_21">WHERE YOU CAN FIND ADDITIONAL INFORMATION</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">96</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx840996_22"><span style="font-weight:bold">REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING</span></a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">F-19</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
</table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p><div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">You should rely only on the information provided in this prospectus, as well as the information incorporated by reference to exhibits to the registration statement of which this prospectus forms a part and any applicable prospectus supplement or amendment. Neither we nor the selling stockholders have authorized anyone to provide you with different information. Neither we nor the selling stockholders are making an offer of these securities in any jurisdiction where the offer is not permitted. You should not assume that the information in this prospectus or any applicable prospectus supplement is accurate as of any date other than the date of the applicable document. Since the date of this prospectus and the documents filed as exhibits to the registration statement of which this prospectus forms a part, our business, financial condition, results of operations and prospects may have changed. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">i </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="tx840996_1">ABOUT THIS PROSPECTUS </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus relates to the resale by the selling stockholders identified in this prospectus under the section entitled &#8220;<a href="#tx840996_17"><span style="text-decoration:underline">Selling Stockholders</span></a>,&#8221; from time to time, of up to an aggregate up to 10,774,596 shares of our common stock, consisting of: (i) 1,439,988 are shares of common stock, (ii) 2,151,544 shares are issuable upon the exercise of <span style="white-space:nowrap">Pre-Funded</span> Warrants, (iii) 3,591,532 shares are issuable upon the exercise of Series A Common Stock Warrants, and (iv) 3,591,532 shares are issuable upon the exercise of Series B Common Stock Warrants. We are not selling any shares of common stock under this prospectus, and we will not receive any proceeds from the sale of shares of common stock offered hereby by the selling stockholders, although we may receive cash from the exercise of the Warrants. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">You should rely only on the information provided in this prospectus, including any information incorporated by reference. We have not authorized anyone to provide you with any other information and we take no responsibility for, and can provide no assurances as to the reliability of, any other information that others may give you. The information contained in this prospectus speaks only as of the date set forth on the cover page and may not reflect subsequent changes in our business, financial condition, results of operations and prospects. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are not, and the selling stockholders are not, making offers to sell these securities in any jurisdiction in which an offer or solicitation is not authorized or permitted or in which the person making such offer or solicitation is not qualified to do so or to any person to whom it is unlawful to make such an offer or solicitation. You should read this prospectus, including any information incorporated by reference, in its entirety before making an investment decision. You should also read and consider the information in the documents to which we have referred you in the sections entitled &#8220;<a href="#tx840996_21"><span style="text-decoration:underline">Where You Can Find Additional Information</span></a>&#8221; as well as any post-effective amendments to the registration statement of which this prospectus is a part, before you make any investment decision. To the extent there is a conflict between the information contained in this prospectus and any applicable prospectus supplement, including the information incorporated by reference, you should rely on the information in the applicable prospectus supplement. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">ii </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="tx840996_2">CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus contains &#8220;forward-looking statements&#8221; for purposes of the federal securities laws. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. Words such as &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;can,&#8221; &#8220;continue,&#8221; &#8220;could,&#8221; &#8220;designed,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;intend,&#8221; &#8220;likely,&#8221; &#8220;may,&#8221; &#8220;might,&#8221; &#8220;plan,&#8221; &#8220;possible,&#8221; &#8220;potential,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;seek,&#8221; &#8220;should,&#8221; &#8220;target,&#8221; &#8220;will&#8221; and &#8220;would,&#8221; as well as similar expressions which predict or indicate future events and trends or which do not relate to historical matters, are intended to identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. For example, we may use forward-looking statements when addressing topics such as: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:1%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our ability to enter into strategic arrangements and/or collaborations and to realize the potential benefits of such arrangements, including license agreements; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:1%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">U.S. Food and Drug Administration and European Medicines Agency approvals and interactions; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:1%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the timing or likelihood of regulatory filings and approvals; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:1%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the commercialization of our product candidates, if approved; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:1%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our ability to enroll patients in our clinical trials; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:1%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our ability and the potential to successfully manufacture and supply our product candidates for clinical trials and for commercial use, if approved; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:1%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our estimates regarding the potential market size and market opportunity for our product candidates, if approved; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:1%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our research and development efforts; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:1%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the timing of the initiation, progress, and expected results of our nonclinical studies, our <span style="white-space:nowrap">pre-clinical</span> and clinical trials, and our research and development programs; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:1%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our ability to advance product candidates into, and successfully complete, nonclinical studies and clinical trials; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:1%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">results from our <span style="white-space:nowrap">pre-clinical</span> and clinical studies and the implications of such results regarding the efficacy or safety of our product candidates; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:1%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the safety profile, pathways, and efficacy of our product candidates and formulations; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:1%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the anticipated advantages of our product candidates over other products available in the market and being developed; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:1%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the populations that will most benefit from our product candidates and indications that will be pursued with each product candidate; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:1%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the anticipated progress in our current and future clinical trials; plans and strategies to create novel technologies; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:1%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the scope of protection we are able to establish and maintain for intellectual property rights covering our technology platforms and product candidates, and the defense of such intellectual property rights; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:1%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">developments relating to our competitors and our industry, including competing product candidates and therapies; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:1%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">future development and/or expansion of our product candidates and therapies in our markets; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:1%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">sources of competition for any of our product candidates; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:1%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our ability to generate product or development revenue and the sources of such revenue; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:1%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our ability to effectively manage our gross profit margins; </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">iii </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:1%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our potential need for additional financing and the availability thereof; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:1%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our ability to continue as a going concern; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:1%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our ability to remain listed on the Nasdaq Capital Market (&#8220;Nasdaq&#8221;); </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:1%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our estimates regarding expenses, capital requirements, and needs for additional financing and our ability to obtain additional capital; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:1%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our ability to transfer the drug product manufacturing to a contract drug manufacturing organization; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:1%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the potential enhancement of our cash position through development, marketing, and licensing arrangements; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:1%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the implementation of our business model, strategic plans for our business, and product candidates; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:1%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our ability to contract with third-party suppliers and manufacturers and their ability to perform adequately; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:1%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">other factors detailed under the section entitled &#8220;<a href="#tx840996_6"><span style="text-decoration:underline">Risk Factors</span></a>&#8221; in this prospectus. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our business, financial condition and results of operations. Forward-looking statements are not guarantees of future performance, conditions or results, and are subject to risks, uncertainties and assumptions that are difficult to predict. Therefore, actual results may differ materially and adversely from those anticipated in any forward-looking statements. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this prospectus. While we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Important factors that could cause or contribute to such differences include, but are not limited to, those discussed under the &#8220;<a href="#tx840996_10"><span style="text-decoration:underline">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></a>&#8221; and &#8220;<a href="#tx840996_6"><span style="text-decoration:underline">Risk Factors</span></a>&#8221; sections of this prospectus, in our press releases and in our other filings with the U.S. Securities and Exchange Commission (&#8220;SEC&#8221;). Except as required by applicable law, we undertake no obligation to update or revise any forward-looking statements contained in this prospectus, whether as a result of new information, future events or otherwise. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">iv </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<div style="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="tx840996_3">PROSPECTUS SUMMARY </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">This summary highlights selected information from this prospectus and may not contain all of the information that is important to you in in making your investment decision. Before investing in our common stock, you should carefully read the entire prospectus, including our financial statements and the related notes included in this prospectus and the information set forth under the &#8220;<a href="#tx840996_6"><span style="text-decoration:underline">Risk Factors</span></a>&#8221; and &#8220;<span style="text-decoration:underline"><a href="#tx840996_10">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span>&#8221; sections of this prospectus. Also see the &#8220;<a href="#tx840996_21">Where You Can Find Additional Information</a>&#8221; section of this prospectus. </span></p> <p style="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="tx840996_4">Our Company </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Overview </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Plus Therapeutics is a U.S. pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (&#8220;CNS&#8221;) cancers. Our novel radioactive drug formulations and therapeutic candidates are designed to deliver safe and effective doses of radiation to tumors. To achieve this, we have developed innovative approaches to drug formulation, including encapsulating radionuclides such as rhenium isotopes with nanoliposomes and microspheres. Our formulations are intended to achieve elevated patient absorbed radiation doses and extend retention times such that the clearance of the isotope occurs after significant and essentially complete radiation decay, which will contribute and provide less normal tissue/organ exposure and improved safety margins. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our lead radiotherapeutic candidate, rhenium (<sup style="font-size:75%; vertical-align:top">186</sup>Re) obisbemeda, is designed specifically for CNS cancers including recurrent glioblastoma (&#8220;GBM&#8221;), leptomeningeal metastases (&#8220;LM&#8221;), and pediatric brain cancers (&#8220;PBC&#8221;) by direct localized delivery utilizing approved <span style="white-space:nowrap"><span style="white-space:nowrap">standard-of-care</span></span> tissue access such as with convection-enhanced delivery (&#8220;CED&#8221;) and intraventricular brain (Ommaya reservoir) catheters. Our acquired radiotherapeutic candidate, <span style="white-space:nowrap">Rhenium-188</span> NanoLiposome Biodegradable Alginate Microsphere (&#8220;<sup style="font-size:75%; vertical-align:top">188</sup><span style="white-space:nowrap">RNL-BAM&#8221;)</span> is designed to treat many solid organ cancers including primary and secondary liver cancers by intra-arterial injection. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have an established, good manufacturing practice validated research and development and manufacturing facility in San Antonio, Texas, tailored to produce Current Good Manufacturing Practice (&#8220;cGMP&#8221;) rhenium (<sup style="font-size:75%; vertical-align:top">186</sup>Re) obisbemeda. We have built a robust supply chain through strategic partnerships that enable the development, manufacturing and future potential commercialization of our products. Our current supply chain and key partners are positioned to supply cGMP rhenium (<sup style="font-size:75%; vertical-align:top">186</sup>Re) obisbemeda for ongoing and planned Phase 2 and Phase 3 clinical trials in patients with GBM, LM and PBC. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Pipeline </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our most advanced investigational drug, rhenium (<sup style="font-size:75%; vertical-align:top">186</sup>Re) obisbemeda, is a patented radiotherapy potentially useful for patients with CNS and other cancers. Preclinical study data describing the use of<sup style="font-size:75%; vertical-align:top"> </sup>rhenium (<sup style="font-size:75%; vertical-align:top">186</sup>Re) obisbemeda for several cancer targets have been published in peer-reviewed journals and reported at a variety of medical society peer-reviewed meetings. Besides GBM, LM and PBC, rhenium (<sup style="font-size:75%; vertical-align:top">186</sup>Re) obisbemeda has been reported to have potential applications for head and neck cancer, ovarian cancer, breast cancer and peritoneal metastases. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our rhenium (<sup style="font-size:75%; vertical-align:top">186</sup>Re) obisbemeda technology has been evaluated in preclinical studies for several cancer targets. We have an active $3.0&#160;million award from U.S. National Institutes of Health/National Cancer Institute, which is expected to provide financial support for the continued clinical development of rhenium (<sup style="font-size:75%; vertical-align:top">186</sup>Re) obisbemeda for recurrent GBM through the completion of a Phase 2 clinical trial, including enrollment of up to 55 patients. </p>
</div></div>

 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">1 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<div style="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On August&#160;29, 2022, we announced feedback from a Type C meeting with the FDA regarding Chemistry, Manufacturing and Controls (&#8220;CMC&#8221;) practices. The meeting focused on our cGMP clinical and commercial manufacturing process for our lead investigational targeted radiotherapeutic, BMEDA-chelated rhenium (<sup style="font-size:75%; vertical-align:top">186</sup>Re) obisbemeda, for recurrent GBM. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The FDA indicated agreement with our proposed application of cGMP guidance for radiotherapeutics, small molecule drug products and liposome drug products for our novel rhenium (<sup style="font-size:75%; vertical-align:top">186</sup>Re) obisbemeda in support of ongoing and future GBM clinical trials, manufacturing scale up, and commercialization. Alignment with the FDA includes support of our proposed controls and release strategy for new drug substance and new drug product. Because this product is identical for recurrent GBM, LM, and PBC, we believe alignment will be consistent for rhenium (<sup style="font-size:75%; vertical-align:top">186</sup>Re) obisbemeda used in other clinical development programs, including LM and PBC. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Rhenium (<sup style="font-size:75%; vertical-align:top">186</sup>Re) obisbemeda versus External Beam Radiation Therapy for Recurrent GBM </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Rhenium (<sup style="font-size:75%; vertical-align:top">186</sup>Re) obisbemeda is a novel injectable radiotherapy designed to deliver targeted, high dose radiation directly into GBM tumors in a safe, effective, and convenient manner that may ultimately prolong patient survival. Rhenium (<sup style="font-size:75%; vertical-align:top">186</sup>Re) obisbemeda is composed of the radionuclide <span style="white-space:nowrap">Rhenium-186</span> and a nanoliposomal carrier, and is infused in a highly targeted, controlled fashion, directly into the tumor via precision brain mapping and CED catheters. Potential benefits of rhenium (<sup style="font-size:75%; vertical-align:top">186</sup>Re) obisbemeda compared to standard external beam radiotherapy or external beam radiation therapy (&#8220;EBRT&#8221;) include: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">The rhenium (186Re) obisbemeda radiation dose delivered to patients may be up to 20 times greater than what is possible with commonly used EBRT, which, unlike EBRT and proton beam devices, spares normal tissue and the brain from radiation exposure. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Rhenium (186Re) obisbemeda can be visualized in real-time during administration, possibly giving clinicians better control of radiation dosing, distribution and retention. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Rhenium (186Re) obisbemeda potentially more effectively treats a bulk tumor and microscopic disease that has already invaded healthy tissue. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Rhenium (186Re) obisbemeda is infused directly into the targeted tumor by CED catheter insertion using MRI guided software to avoid critical patient neurological structures and neural pathways and also bypasses the blood brain barrier, which delivers the therapeutic product where it is needed. Importantly, it reduces radiation exposure to healthy cells, in contrast to EBRT, which passes through normal tissue to reach the tumor, continuing its path through the tumor, hence being less targeted and selective. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Rhenium (186Re) obisbemeda is given during a single, short, <span style="white-space:nowrap">in-patient</span> hospital visit, and is available in all hospitals with nuclear medicine and neurosurgery, while EBRT requires <span style="white-space:nowrap">out-patient</span> visits five days a week for approximately four to six weeks. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic"><span style="white-space:nowrap">ReSPECT-GBM</span> Trial for Recurrent GBM </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Recurrent GBM is the most common, complex, and aggressive primary brain cancer in adults. In the U.S., there are approximately 13,000 GBM cases diagnosed and approximately 10,000 patients succumb to the disease each year. The average length of overall survival (&#8220;OS&#8221;) for GBM patients is eight months, with a <span style="white-space:nowrap">one-year</span> survival rate of 40.8% and a five-year survival rate of only 6.8% and these estimates vary and are lower in some publications. GBM routinely presents with headaches, seizures, vision changes and other significant neurological complications, with a significant compromise in quality of life. Despite the best available medical treatments, the disease remains incurable. Even after efforts to manage the presenting signs and symptoms and completely resect the initial brain tumor, some microscopic disease almost always remains and tumor regrowth occurs within </p>
</div></div>

 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">2 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<div style="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
months. Approximately 90% or more of patients with primary GBM experience tumor recurrence. Complete surgical removal of GBM is usually not possible and GBM is often resistant or quickly develops resistance to most available current and investigational therapies. Even today, the treatment of GBM remains a significant challenge and it has been nearly a decade since the FDA approved a new therapy for this disease, and these more recent approvals have not improved GBM patients OS over past decades, and a significant unmet medical need persists. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For recurrent GBM, there are few currently approved treatments, which in the aggregate, provide only marginal survival benefit. Furthermore, these therapies are associated with significant side effects, which limit dosing and prolonged use. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">While EBRT has been shown to be safe and has temporary efficacy in many malignancies including GBM, typically at absorbed, fractionated radiation dose of ~30 Gray in GBM, this maximum possible administered dose is always limited by toxicity to the normal tissues surrounding the malignancy and because EBRT requires fractionation to manage toxicity and maximum EBRT limits are typically reached before long-term efficacy reached. Because of this limitation, EBRT cannot provide a cure or long term control of GBM and GBM always recurs within months after EBRT. In contrast, locally delivered and targeted radiopharmaceuticals that precisely deliver radiation in the form of beta particles such as <span style="white-space:nowrap">Iodine-131</span> for thyroid cancer, are known to be safe and effective and minimize exposure to normal cells and tissues especially with optimal administered dose and minimizing exposure to normal tissue. The locally delivered rhenium (<sup style="font-size:75%; vertical-align:top">186</sup>Re) obisbemeda is designed for and provides patient tolerability and safety. Though no rhenium (<sup style="font-size:75%; vertical-align:top">186</sup>Re) obisbemeda <span style="white-space:nowrap"><span style="white-space:nowrap">head-to-head</span></span> trial with chemo, immune, EBRT or systemic radiopharmaceutical products have been conducted, patient tolerability and safety considerations have been reported as expected. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Interim results from our ongoing Phase 1/2a <span style="white-space:nowrap">ReSPECT-GBM</span> trial (ClinicalTrials.gov NCT01906385) show that the beta particle energy from our lead investigational drug rhenium (<sup style="font-size:75%; vertical-align:top">186</sup>Re) obisbemeda has provided preliminary positive data and utility in treating GBM and potential other malignancies. More specifically, the preliminary data from our Phase 1/2a <span style="white-space:nowrap">ReSPECT-GBM</span> trial suggests that radiation, in the form of high energy beta particles or electrons, can be effective against GBM. Thus far, we have been able to deliver up to 740 Gy of absorbed radiation to tumor tissue in humans, without significant or dose limiting toxicities and with what we believe has the capability to go higher if required. In comparison, current EBRT protocols for recurrent GBM typically recommend a total maximum radiation dose of about <span style="white-space:nowrap">~30-35</span> Gray. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In September 2020, the FDA granted both Orphan Drug designation and Fast Track designations to rhenium (<sup style="font-size:75%; vertical-align:top">186</sup>Re) obisbemeda for the treatment of patients with GBM. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Rhenium (<sup style="font-size:75%; vertical-align:top">186</sup>Re) obisbemeda is under clinical investigation in a multicenter, sequential cohort, open-label, volume and dose escalation study of the safety, tolerability, and distribution of rhenium (<sup style="font-size:75%; vertical-align:top">186</sup>Re) obisbemeda given by CED catheters to patients with recurrent or progressive malignant glioma after standard surgical, radiation, and/or chemotherapy treatment (NCT01906385). The study uses a standard, modified 3x3 Fibonacci dose escalation, followed by a planned Phase 2 expansion trial at the maximum tolerated dose (&#8220;MTD&#8221;) / maximum feasible dose (&#8220;MFD&#8221;) or <span style="white-space:nowrap">non-dose</span> limiting toxicity (&#8220;DLT&#8221;) if MTD is not reached, to determine efficacy. The trial is funded through Phase 2 in large part by a National Institute of Health/National Cancer Institute (&#8220;NIH/NCI&#8221;) grant. These investigations have not reached DLT or MTD/MFD and the study is in its eighth dosing administration cohort. Due to the observation of a preliminary efficacy signal, we have initiated in parallel a Phase 2, <span style="white-space:nowrap">non-DLT</span> dose trial pursuant to the currently funded NIH/NCI grant. This trial will begin at the current <span style="white-space:nowrap">non-DLT</span> rhenium (<sup style="font-size:75%; vertical-align:top">186</sup>Re) obisbemeda dose and will expand exploring higher radiation doses in larger volumes to treat larger tumors. Additionally, two or more rhenium (<sup style="font-size:75%; vertical-align:top">186</sup>Re) obisbemeda administrations, if indicated, will be evaluated, and reviewed with the FDA, as well as expanded safety, imaging and efficacy data to support a planned future registrational trial. On September&#160;6, 2022, we announced a summary of our Type C clinical </p>
</div></div>

 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">3 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<div style="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
meeting with the FDA that focused on the <span style="white-space:nowrap">ReSPECT-GBM</span> trial. The FDA agreed with us that the <span style="white-space:nowrap">ReSPECT-GBM</span> clinical trial should proceed to the planned Phase 2. The key focus areas of clinical investigation of the Phase 2 trial will be (1)&#160;further dose exploration, including both increased dosing and multiple doses, and (2)&#160;collecting additional safety and efficacy data to inform the design of a future registrational trial. Because no DLT administered doses were observed, the FDA and we also agreed to continue to dose cohort eight. There was further agreement with the FDA that in a planned future registrational trial, overall survival should be used as the primary endpoint. We agreed with the FDA to hold future meeting(s) to consider the use of external data to augment the use of a control arm in the registrational trial. On January&#160;18, 2023, we announced that the first patient has been dosed in the <span style="white-space:nowrap">ReSPECT-GBM</span> Phase 2b dose expansion clinical trial evaluating rhenium obisbemeda for the treatment of recurrent GBM. The Phase 2b trial is expected to enroll up to 31 total patients with small- to <span style="white-space:nowrap">medium-sized</span> tumors and is targeted for full enrollment by the end of 2024. We currently have four clinical sites, with the plan to add additional sites to support the trial, and expect an initial data <span style="white-space:nowrap">read-out</span> by the end of 2024. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In June 2023, we presented data regarding the safety and feasibility results from our Phase 1/2 Clinical Trial of <sup style="font-size:75%; vertical-align:top">186</sup>RNL <span style="white-space:nowrap">(Rhenium-186</span> Nanoliposome) (<sup style="font-size:75%; vertical-align:top">186</sup>Re) Obisbemeda in Recurrent Glioma: The <span style="white-space:nowrap">ReSPECT-GBM</span> Trial at the Society of Nuclear Medicine&#160;&amp; Molecular Imaging Annual Meeting. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On November&#160;20, 2023, we announced positive data from the ongoing <span style="white-space:nowrap">ReSPECT-GBM</span> Phase 2 trial evaluating rhenium (<sup style="font-size:75%; vertical-align:top">186</sup>Re) obisbemeda, for the treatment of recurrent glioblastoma at the Society for NeuroOncology 28th Annual Meeting, which was held November <span style="white-space:nowrap">15-19,</span> 2023 in Vancouver, Canada. Key findings included: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Median overall survival (&#8220;mOS&#8221;) in 15 patients with recurrent glioblastoma (&#8220;rGBM&#8221;) from the Phase 2 study is 13 months, which is 63% better than current standard of care (bevacizumab monotherapy) of 8 months; 9 of the 15 patients remain alive. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Median progression free survival (&#8220;mPFS&#8221;) is 11 months, compared to SOC at 4 months. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Rhenium (186Re) obisbemeda continues to demonstrate a favorable safety profile, despite delivering up to 20x the dose of radiation (up to 740 Gy) typically delivered by EBRT for rGBM patients (up to 35 Gy). </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Imaging data presented by Andrew Brenner, MD, PhD is consistent with the efficacy signal of Rhenium (186Re) obisbemeda in rGBM. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On March&#160;31, 2022, we entered into a Sales Order (the &#8220;Sales Order&#8221;) with Medidata Solutions, Inc. (&#8220;Medidata&#8221;), pursuant to which Medidata built a Synthetic Control Arm<sup style="font-size:75%; vertical-align:top">&#174;</sup> platform that facilitates the use of historical clinical data to incorporate into our Phase 2 clinical trial of rhenium (<sup style="font-size:75%; vertical-align:top">186</sup>Re) obisbemeda in GBM. The Sales Order had a term of six (6)&#160;months. Work under this Sales Order has been completed. As part of this collaboration, we jointly submitted with Medidata a historical clinical trials control arm methodology abstract (&#8220;HCA&#8221;) to American Society of Clinical Oncology (&#8220;ASCO&#8221;) which was accepted for publication, further strengthening this collaboration and allowing applications to advance GBM development. We plan to use the HCA for breakthrough therapy designation and Phase 2 and/or a pivotal or registrational Phase 3 trial. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic"><span style="white-space:nowrap">ReSPECT-LM</span> Clinical Trial for LM </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">LM is a rare complication of cancer in which the disease spreads to the membranes (meninges) surrounding the brain and spinal cord. The incidence of LM is growing and occurs in approximately 5%, or more, of people with late-stage cancer, or 110,000 people in the U.S. each year. It is highly lethal with an average <span style="white-space:nowrap">one-year</span> survival of just 7%. All solid cancers, particularly breast, lung, GI, and melanoma, have the potential to spread to the leptomeninges. </p>
</div></div>

 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">4 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<div style="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The <span style="white-space:nowrap">ReSPECT-LM</span> Phase 1 clinical trial (ClinicalTrials.gov NCT05034497) was preceded with preclinical studies in which tolerance to doses of rhenium (<sup style="font-size:75%; vertical-align:top">186</sup>Re) obisbemeda as high as 1,075 Gy were shown in animal models with LM without significant observed toxicity. Furthermore, treatment led to a marked reduction in tumor burden in both C6 and <span style="white-space:nowrap">MDA-231</span> LM models. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Upon receiving acceptance of our Investigational New Drug application and Fast Track designation by the FDA for rhenium (<sup style="font-size:75%; vertical-align:top">186</sup>Re) obisbemeda for the treatment of LM in November 2021, we initiated the trial and began screening patients for the <span style="white-space:nowrap">ReSPECT-LM</span> Phase 1 clinical trial in Q4 2021. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The <span style="white-space:nowrap">ReSPECT-LM</span> is a multi-center, sequential cohort, open-label, dose escalation study evaluating the safety, tolerability, and efficacy of a single-dose application of rhenium (<sup style="font-size:75%; vertical-align:top">186</sup>Re) obisbemeda administered through intrathecal infusion to the ventricle of patients with LM after standard surgical, radiation, and/or chemotherapy treatment. The primary endpoint of the study is the incidence and severity of adverse events and dose limiting toxicities, together with determining the maximum tolerated and recommended Phase 2 dose. Full enrollment in the Phase 1 trial is expected by the end of 2024, with the plan to add additional clinical sites to support the trial. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On September&#160;19, 2022, we entered into a Cancer Research Grant Contract (the &#8220;CPRIT Contract&#8221;), effective as of August&#160;31, 2022, with Cancer Prevention and Research Institute of Texas (&#8220;CPRIT&#8221;), pursuant to which CPRIT will provide us a grant of up to $17.6&#160;million (the &#8220;CPRIT Grant&#8221;) over a three-year period to fund the continued development of rhenium (<sup style="font-size:75%; vertical-align:top">186</sup>Re) obisbemeda for the treatment of patients with LM through Phase 2 of the ReSPECT LM clinical trial. The CPRIT Grant is subject to customary CPRIT funding conditions, including, but not limited to, a matching fund requirement (one dollar from us for every two dollars awarded by CPRIT), revenue sharing obligations upon commercialization of rhenium (<sup style="font-size:75%; vertical-align:top">186</sup>Re) obisbemeda based on specific dollar thresholds until CPRIT receives the aggregate amount of 400% of the proceeds awarded under the CPRIT Grant, and certain reporting requirements. To date, we have received approximately $7&#160;million in milestone payments under the CPRIT Contract. We anticipate a continuing flow of milestone payments that throughout 2024 will include $6.9&#160;million upon the continued progression of the Phase 2 of the ReSPECT LM clinical trial. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Interim results showed that a single treatment with rhenium (<sup style="font-size:75%; vertical-align:top">186</sup>Re) obisbemeda resulted in a consistent decreased cerebrospinal fluid (&#8220;CSF&#8221;) tumor cell count/ml and was tolerated by all LM patients. Rhenium (<sup style="font-size:75%; vertical-align:top">186</sup>Re) obisbemeda is an outpatient administration and treatment and is easily and safely administered through a standard intraventricular catheter (Ommaya Reservoir), distributed promptly throughout the CSF, and with durable retention in the leptomeninges at least through day seven. All patients have shown well tolerated prompt and durable rhenium (<sup style="font-size:75%; vertical-align:top">186</sup>Re) obisbemeda distribution throughout the subarachnoid space. On March&#160;11, 2024, we announced we had completed Cohort 5 of the <span style="white-space:nowrap">ReSPECT-LM</span> Phase 1/2a dose escalation trial. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A total of 18 patients have received a single-dose of rhenium (186Re) obisbemeda in the <span style="white-space:nowrap">ReSPECT-LM</span> trial as of March&#160;31, 2024. There have been no dose limiting toxicities observed to date with administered radiation doses up to 66.14 millicuries in Cohort 5, a <span style="white-space:nowrap">ten-fold</span> increase over Cohort 1. We plan to initiate dosing in Cohort 6 in the second quarter of 2024, pending Data Safety Monitoring Board (DSMB) approval. In addition, five new clinical trial sites were added to this trial over the last year, bringing the total number of sites to seven. We are planning a new multiple dosing <span style="white-space:nowrap">ReSPECT-LM</span> clinical trial in late 2024 or early 2025. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On August&#160;10, 2023, we presented data from the <span style="white-space:nowrap">ReSPECT-LM</span> clinical trial of rhenium (<sup style="font-size:75%; vertical-align:top">186</sup>Re) obismeda at the Society for Neuro Oncology ASCO CNS Cancer Conference. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In November 2023, the FDA granted Orphan Drug designation to rhenium (<sup style="font-size:75%; vertical-align:top">186</sup>Re) obisbemeda for the treatment of patients with breast cancer with LM. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On December&#160;12, 2023, we announced our partnership with K2bio to implement novel analysis for CSF tumor and molecular biomarkers for CNS cancers. Initial clinical specimen processing and testing began in the first quarter 2024 in our ongoing Phase 1 <span style="white-space:nowrap">ReSPECT-LM</span> trial of rhenium (<sup style="font-size:75%; vertical-align:top">186</sup>Re) obisbemeda in patients with LM. </p>
</div></div>

 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">5 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<div style="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic"><span style="white-space:nowrap">ReSPECT-PBC</span> Clinical Trial for Pediatric Brain Cancer </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The average annual age adjusted mortality rate for children aged <span style="white-space:nowrap">0-14</span> for malignant brain (and other CNS) tumors is 0.71/100,000, making it the most common cause of death and cancer death in this age group. The 2021 World Health Organization Classification of CNS Tumors classifies gliomas, glioneuronal tumors, and neuronal tumors into six different families: (1)&#160;adult-type diffuse gliomas; (2)&#160;pediatric-type diffuse <span style="white-space:nowrap">low-grade</span> gliomas; (3)&#160;pediatric-type diffuse high-grade gliomas (&#8220;HGG&#8221;); (4) circumscribed astrocytic gliomas; (5)&#160;glioneuronal and neuronal tumors; and (6)&#160;ependymomas. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In August 2021, we announced plans for treating pediatric brain cancer at the 2021 American Association of Neurological Surgeons Annual Scientific Meeting. In July 2021, we reported that we had received FDA feedback pertaining to a pre-Investigational New Drug (&#8220;IND&#8221;) meeting briefing package in which the FDA stated that we are not required to perform any additional preclinical or toxicology studies. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Given the initial FDA feedback, receipt of adult GBM data and experience with rhenium (<sup style="font-size:75%; vertical-align:top">186</sup>Re) obisbemeda and <span style="white-space:nowrap">follow-up</span> communications with the FDA, we plan to submit a pediatric brain tumor IND to investigate the use of rhenium (<sup style="font-size:75%; vertical-align:top">186</sup>Re) obisbemeda in two pediatric brain cancers, high-grade glioma and ependymoma, by the third quarter of 2024. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pediatric high-grade gliomas can be found almost anywhere within the CNS; however, they are most commonly found within the supratentorium. The highest incidence of supratentorial, high-grade gliomas in pediatrics appears to occur in children aged 15 to 19 years, with a median age of approximately nine years. Overall, pediatric high-grade glioma confers a three-year progression free survival (&#8220;PFS&#8221;) of 11 &#177; 3% and three-year OS of 22% &#177;5%. <span style="white-space:nowrap">One-year</span> PFS is as low as 40% in recent trials. Ependymomas are slow-growing central nervous system tumors that involve the ventricular system. Diagnosis is based on MRI and biopsy and survival rate depends on tumor grade and how much of the tumor can be removed. Grade II pathology was associated with significantly improved OS compared to Grade III (anaplastic) pathology (five-year OS = 71 &#177; 5% vs. 57 &#177; 10%; p = 0.026). Gross total resection compared to subtotal resection was associated with significantly improved OS (five-year OS = 75 &#177; 5% vs. 54 &#177; 8%; p = 0.002). </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Overall, pediatric HGG and ependymoma are extremely <span style="white-space:nowrap"><span style="white-space:nowrap">difficult-to-treat</span></span> pediatric brain tumors, frequently aggressive, and in recurrent settings, carry an extremely poor prognosis. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic"><span style="white-space:nowrap">Rhenium-188</span> NanoLiposome Biodegradable Alginate Microsphere Technology </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In January 2022, we announced that we licensed Biodegradable Alginate Microsphere (&#8220;BAM&#8221;) patents and technology from The University of Texas Health Science Center at San Antonio (&#8220;UTHSA&#8221;) to expand our tumor targeting capabilities and precision radiotherapeutics pipeline. We intend to combine our Rhenium NanoLiposome technology with the BAM technology to create a novel radioembolization technology. Initially, we intend to utilize the <span style="white-space:nowrap">Rhenium-188</span> isotope, <sup style="font-size:75%; vertical-align:top">188</sup><span style="white-space:nowrap">RNL-BAM</span> for the intra-arterial embolization and local delivery of a high dose of targeted radiation for a variety of solid organ cancers such as hepatocellular cancer, hepatic metastases, pancreatic cancer and many others. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Preclinical data from an ex vivo embolization experiment in which <span style="white-space:nowrap">Technetium99m-BAM</span> was intra-arterially delivered to a bovine kidney perfusion model was presented at Society of Interventional Radiology Annual Scientific Meeting. The study concluded that the technology required for radiolabeling BAM could successfully deliver, embolize and retain radiation in the target organ. <sup style="font-size:75%; vertical-align:top">188</sup><span style="white-space:nowrap">RNL-BAM</span> is a preclinical investigational drug we intend to further develop and move into clinical trials. Specifically, in 2022 we transferred the <sup style="font-size:75%; vertical-align:top">188</sup><span style="white-space:nowrap">RNL-BAM</span> technology from UTHSA, and began planning to develop the drug product and complete early preclinical studies to support a future FDA IND submission. Our intended initial clinical target is liver cancer which is the sixth most common and third deadliest cancer worldwide. It is a rare disease with increasing U.S. annual incidence (42,000) and deaths (30,000). </p>
</div></div>

 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">6 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<div style="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Recent Developments </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" id="tx840996_24"><span style="font-style:italic">May 2024 PIPE Financing </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On May&#160;5, 2024, the Company entered into the Securities Purchase Agreement with the Purchasers, comprising of certain of the Company&#8217;s directors and executive officers (&#8220;Company Insiders&#8221;), for the sale and issuance by the Company of its securities (the &#8220;Initial Subscription&#8221;). On May&#160;8, 2024, the Company entered into a First Amendment to the Securities Purchase Agreement for the sale and issuance by the Company of additional securities to two of the Purchasers (the &#8220;Additional Subscription&#8221;, and together with the Initial Subscription, the &#8220;May 2024 PIPE Financing&#8221;). The Purchase Agreement, as amended, provides for the sale and issuance by the Company of an aggregate of 3,591,532 shares (the &#8220;Private Placement Shares&#8221;) of the Company&#8217;s common stock or, at the election of each Purchaser, <span style="white-space:nowrap">Pre-Funded</span> Warrants, exercisable immediately at an exercise price of $0.001 per share, with each Private Placement Share or <span style="white-space:nowrap">Pre-Funded</span> Warrant accompanied by (i)&#160;a Series A Common Stock Warrant to purchase one share of common stock, for an aggregate of 3,591,532 Series A Common Stock Warrants, and (ii)&#160;one Series B Common Stock Warrant to purchase one share of common stock, for an aggregate of 3,591,532 Series B Common Stock Warrants. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The combined purchase price for each Private Placement Share and <span style="white-space:nowrap">Pre-Funded</span> Warrant from the Initial Subscription was $2.022, and $2.158 from the Additional Subscription, in each case together with one accompanying Series A Common Stock Warrant and one accompanying Series B Common Stock Warrant, provided, that the Company Insiders participated in the Initial Subscription at an offering price of $2.04 per Private Placement Share and accompanying Series A Common Stock Warrant and Series B Common Stock Warrant. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The exercise price of each Series A Common Stock Warrant and Series B Common Stock Warrant from the Initial Subscription is $1.772 per share and $1.908 per share in the Additional Subscription, provided that the exercise price for the Series A Common Stock Warrants and Series B Common Stock Warrants issued to the Company Insiders is $1.79 per share. Subject to certain ownership limitations, the Series A Common Stock Warrants are exercisable until the five-year anniversary of issuance. Subject to certain ownership limitations, the Series B Common Stock Warrants are be exercisable until the <span style="white-space:nowrap">one-year</span> anniversary of the declaration of effectiveness of this prospectus. The <span style="white-space:nowrap">Pre-Funded</span> Warrant do not expire until exercised in full. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The May 2024 PIPE Financing closed on May&#160;9, 2024. The aggregate gross proceeds at the May 2024 PIPE Financing closing were approximately $7.25&#160;million, before deducting certain expenses payable by the Company, and excluding the proceeds, if any, from the exercise of the Series A Common Stock Warrant, the Series B Common Stock Warrant, and <span style="white-space:nowrap">Pre-Funded</span> Warrant. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Risk Factors </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our business is subject to numerous risks and uncertainties, including those highlighted in the &#8220;<a href="#tx840996_6"><span style="text-decoration:underline">Risk Factors</span></a>&#8221; section of this prospectus, that represent challenges that we face in connection with the successful implementation of our strategy and the growth of our business. In particular, the following considerations, among others, may offset our competitive strengths or have a negative effect on our business strategy, which could cause a decline in the price of our common stock and result in a loss of all or a portion of your investment: </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Risks Related to Our Financial Position and Capital Requirements </span></p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">We have incurred losses since inception, and we expect to incur significant net losses in the foreseeable future and we may never become profitable and our operating results have been and will likely continue to be volatile. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Uncertainties relating to our ability to fund our operations for at least the next 12 months raises substantial doubt about our ability to continue as a going concern. </p></td></tr></table>
</div></div>

 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">7 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<div style="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">We could be delisted from Nasdaq, which would seriously harm the liquidity of our stock and our ability to raise capital. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">We will need substantial additional funding to develop our product candidates and conduct our future operations and to repay our outstanding debt obligations. If we are unable to obtain the funds necessary to do so, we may be required to delay, scale back or eliminate our product development activities or may be unable to continue our business operations. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Borrowings under our line of credit have the effect of limiting our use of cash and marketable securities. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">We maintain our cash at financial institutions, often in balances that exceed federally insured limits. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Our ability to utilize our net operating loss carryforwards and certain other tax attributes may be limited. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Risks Related to Our Business and Industry </span></p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">If we fail to maintain proper and effective internal controls, our ability to produce accurate financial statements on a timely basis could be impaired. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Our future success is in large part dependent upon our ability to successfully develop our nanomedicine platform and commercialize rhenium (<sup style="font-size:75%; vertical-align:top">186</sup>Re) obisbemeda and <sup style="font-size:75%; vertical-align:top">188</sup><span style="white-space:nowrap">RNL-BAM</span> and any failure to do so could significantly harm our business and prospects. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">If we are unable to successfully partner with other companies to commercialize our product candidates, our business could materially suffer. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Our success depends in substantial part on our ability to obtain regulatory approvals for our rhenium (<sup style="font-size:75%; vertical-align:top">186</sup>Re) obisbemeda and <sup style="font-size:75%; vertical-align:top">188</sup><span style="white-space:nowrap">RNL-BAM</span> product candidates. However, we cannot be certain that we will receive regulatory approval for these product candidates or our other product candidates. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">If we or any party to a key collaboration, licensing, development, acquisition or similar arrangement fail to perform material obligations, or commit a breach, under such arrangement, or any arrangement is terminated for any reason, there could be an adverse effect on our business. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Our current business strategy is high-risk and may not be successful. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Reliance on government funding for our programs may impose requirements that limit our ability to take certain actions, and subject it to potential financial penalties, which could materially and adversely affect our business, financial condition and results of operations. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">If our competitors market or develop products that are marketed more effectively, approved more quickly than our product candidates, or demonstrated to be safer or more effective than our product candidates, our commercial opportunities could be reduced or eliminated. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Product development involves a lengthy and expensive process, with an uncertain outcome. We may incur additional costs or experience delays in completing, or ultimately be unable to complete, the development and commercialization of our product candidates. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="white-space:nowrap">Pre-clinical</span> studies and preliminary and interim data from clinical trials of our product candidates are not necessarily predictive of the results or success of ongoing or future clinical trials of our product candidates. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Because we have limited resources, we may decide to pursue a particular product candidate and fail to advance product candidates that later demonstrate a greater chance of clinical and commercial success. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Clinical trial results may fail to support approval of our product candidates. </p></td></tr></table>
</div></div>

 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">8 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<div style="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">If third parties with whom we engage are not able to successfully perform, we may not be able to successfully complete clinical development, obtain regulatory approval or commercialize our product candidates and our business could be substantially harmed. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">We may have difficulty enrolling, or fail to enroll patients in our clinical trials, which could delay or prevent clinical trials of our drug candidates. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">If a particular product candidate causes significant adverse events, then we may be unable to receive regulatory approval or market acceptance for such product candidate. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">If our product candidates and technologies receive regulatory approval but do not achieve broad market acceptance, especially by physicians, the revenue that we generate will be limited. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">All potential applications of our product candidates are investigational, which subjects us to development and marketing risks.<span style="font-weight:bold"><span style="font-style:italic"> </span></span> </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">We and our product candidates are subject to extensive regulation, and the requirements to obtain regulatory approvals in the United States and other jurisdictions can be costly, time-consuming, and unpredictable. If we or our partners are unable to obtain timely regulatory approval for our product candidates, our business may be substantially harmed. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">We will be subject to ongoing regulatory obligations and continued regulatory review, which may result in significant expense, and if we or our collaborators fail to comply with such requirements, regulatory agencies may take action against us or them, which could significantly harm our business. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Changing, new and/or emerging government regulations, including healthcare legislative reform measures, may adversely affect us. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Adequate coverage and reimbursement from third party payors may not be available for our products and we may be unable to successfully contract for coverage from pharmacy benefit managers and other organizations; conversely, to secure coverage from these organizations, we may be required to pay rebates or other discounts or other restrictions to reimbursement, either of which could diminish our sales or adversely affect our ability to sell our products profitably. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Some intellectual property that we have <span style="white-space:nowrap">in-licensed</span> has been discovered through government funded programs and thus may be subject to federal regulations such as <span style="white-space:nowrap">&#8220;march-in&#8221;</span> rights, certain reporting requirements and a preference for U.S.-based companies. Compliance with such regulations may limit our exclusive rights, and limit our ability to contract with <span style="white-space:nowrap">non-U.S.</span> manufacturers. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Orphan drug designation may not ensure that we will enjoy market exclusivity in a particular market, and if we fail to obtain or maintain orphan drug designation or other regulatory exclusivity for some of our product candidates, our competitive position could be harmed. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">If we experience an interruption in supply from a material sole source supplier, our business may be harmed. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">We may engage in strategic transactions that could impact our liquidity, increase our expenses, and present significant distractions to our management. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">We must maintain quality controls and compliance with manufacturing standards. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">If we are unable to identify, hire and/or retain key personnel, we may not be able to sustain or grow our business. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">We face potential product liability exposure, and if successful claims are brought against us, we may incur substantial liability if our insurance coverage for those claims is inadequate. </p></td></tr></table>
</div></div>

 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">9 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<div style="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">A failure to adequately protect private health information could result in severe harm to our reputation and subject us to significant liabilities, each of which could have a material adverse effect on our business. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">We and our collaborators must comply with environmental laws and regulations, including those pertaining to use of hazardous and biological materials in our business, and failure to comply with these laws and regulations could expose us to significant liabilities. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">If we are unable to successfully develop the CNside technology, or successfully utilize and fully integrate CNside into our operations, we may not generate revenues from or realize the anticipated benefits of CNside, within our expected timeline or at all, and our business may be harmed as a result. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Risks Related to Our Intellectual Property </span></p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Our success depends in part on our ability to protect our intellectual property. We may not be able to protect our trade secrets. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">We may be subject to claims that our employees have wrongfully used or disclosed alleged trade secrets of their former employers. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">We may incur substantial costs as a result of litigation or other proceedings relating to patent and other intellectual property rights, and we may be unable to protect our rights to our product candidates and technology. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">If we are sued for infringing intellectual property rights of third parties, it will be costly and time consuming, and an unfavorable outcome in that litigation would have a material adverse effect on our business. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Risks Related to the Securities Markets and an Investment in Our Common Stock </span></p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">We have been notified by Nasdaq of our failure to comply with certain continued listing requirements and, if we are unable to regain compliance with all applicable continued listing requirements and standards of Nasdaq, our common stock could be delisted from Nasdaq. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">We may issue additional shares of common stock or other equity securities without our stockholder approval, and holders of warrants and other securities convertible into shares of our common stock may choose to exercise their warrants and other securities requiring us to issue shares of common stock; all of these actions would dilute your ownership interest and may depress the market price of our common stock. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">The market price of our common stock may be volatile and fluctuate significantly, which could result in substantial losses for stockholders, and future sales of our common stock may depress our share price. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">We may be or become the target of securities litigation, which is costly and time-consuming to defend. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">We may issue debt and equity securities or securities convertible into equity securities, any of which may be senior to our common stock as to distributions and in liquidation, which could negatively affect the value of our common stock. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Our organizational documents contain anti-takeover provisions. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Company Information </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We were initially formed as a California general partnership in July 1996, and subsequently incorporated in the State of Delaware in May 1997. Our corporate offices are located at 4200 Marathon Blvd., Suite 200, Austin, </p>
</div></div>

 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">10 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<div style="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Texas 78756. Our telephone number is <span style="white-space:nowrap">(737)&#160;255-7194.&#160;We</span> maintain a website at www.plustherapeutics.com. The contents of our website are not part of this prospectus and the references in this prospectus to our website do not constitute incorporation by reference into this prospectus of the information contained therein. </p>
</div></div>

 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">11 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<div style="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="tx840996_5">The Offering </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="vertical-align:TOP">
<td style="width:38%"> <p style=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Issuer </p></td>
<td>Plus Therapeutics, Inc. </td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="vertical-align:TOP">
<td style="width:38%"> <p style=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Common stock Offered by the Selling Stockholders </p></td>
<td>10,774,596 shares of common stock </td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="vertical-align:TOP">
<td style="width:38%"> <p style=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Use of Proceeds </p></td>
<td>We will not receive any proceeds from the sale of the shares of common stock covered by this prospectus. </td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="vertical-align:TOP">
<td style="width:38%"> <p style=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Nasdaq Symbol </p></td>
<td>PSTV </td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="vertical-align:TOP">
<td style="width:38%"> <p style=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Offering Price </p></td>
<td>The selling stockholders will offer the shares of common stock offered by this prospectus at the prevailing market prices or at privately negotiated prices. </td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="vertical-align:TOP">
<td style="width:38%"> <p style=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Risk Factors </p></td>
<td>You should read the section entitled &#8220;<span style="text-decoration:underline"><span style="font-style:italic"><a href="#tx840996_6">Risk Factors</a></span></span>&#8221; of this prospectus for a discussion of factors to consider carefully before deciding to invest in shares of our common stock. </td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For additional information concerning the offering, see the section entitled &#8220;<span style="font-style:italic"><span style="text-decoration:underline"><a href="#tx840996_18">Plan of Distribution</a></span></span>&#8221; beginning on page&#160;92. </p>
</div></div>

 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">12 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="tx840996_6">RISK FACTORS </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Investing in our common stock involves a high degree of risk. You should carefully consider the risks described below as well as the other information in this prospectus, including our financial statements and the notes thereto, and &#8220;<span style="text-decoration:underline"><a href="#tx840996_10">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span>,&#8221; before deciding whether to invest in our common stock. The occurrence of any of the events or developments described below could adversely affect our business, results of operations, financial condition, reputation, and prospects. In such an event, the market price of our common stock could decline, and you may lose all or part of your investment. Additional risks and uncertainties not presently known to us or that we currently believe are not material may also impair our business, results of operations, financial condition, and prospects. </span></p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Risks Related to our Financial Position and Capital Requirements </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We have incurred losses since inception, we expect to incur significant net losses in the foreseeable future and we may never become profitable and our operating results have been and will likely continue to be volatile. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have generated negative cash flows from operations and have incurred net operating losses each year since we started business. For the year ended December&#160;31, 2023, and quarter ended March&#160;31, 2024, we incurred net losses of $13.3&#160;million and $3.3&#160;million, respectively, our net cash used in operating activities was $12.9&#160;million and $4.5&#160;million, respectively. As of March&#160;31, 2024, our accumulated deficit was approximately $483.8&#160;million. We expect to continue to incur net losses and negative cash flow from operating activities for at least the next twelve months. As our focus on development of nanomedicine and the development of therapeutic applications has increased, losses have resulted primarily from expenses associated with research and development and clinical trial-related activities, as well as general and administrative expenses. We expect to continue operating in a loss position and expect that recurring operating expenses will be at higher levels for the year ending December&#160;31, 2024, than the year ended December&#160;31, 2023, as we perform clinical trials and other development activities for our nanomedicine product candidates. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our ability to generate sufficient revenue from any of our products, product candidates or technologies to achieve profitability will depend on a number of factors including, but not limited to: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our ability to manufacture, test and validate our product candidates in compliance with applicable laws and as required for submission to applicable regulatory bodies, including manufacturing, testing and validation of our RNL candidates; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our or our partners&#8217; ability to successfully complete clinical trials of our product candidates; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our ability to obtain necessary regulatory approvals for our product candidates; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our or our partners&#8217; ability to negotiate and receive favorable reimbursement for our product candidates, including for our product candidates that have been granted or may be granted orphan drug status or otherwise command currently anticipated pricing levels; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our ability to negotiate favorable arrangements with third parties to help finance the development of, and market and distribute, our products and product candidates; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the degree to which our approved products are accepted in the marketplace. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Because of the numerous risks and uncertainties associated with our commercialization and product development efforts, we are unable to predict the extent of our future losses or when or if we will become profitable and it is possible we will never become profitable. If we do not generate significant sales from any of our product candidates that receive regulatory approval, there would be a material adverse effect on our business, results of operations, financial condition and prospects, which in turn could result in our inability to continue operations. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our prospects must be evaluated in light of the risks and difficulties frequently encountered by emerging companies and particularly by such companies in rapidly evolving and technologically advanced biotech, pharmaceutical and medical device fields. In addition, our budgeted expense levels are based in part on our </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">13 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
expectations concerning future research and development activities. We may be unable to reduce our expenditures in a timely manner to compensate for any unexpected events. Accordingly, unexpected events could have an immediate and material impact on our business and financial condition. From time to time, we have tried to update our investors&#8217; expectations as to our operating results. If we revise any timelines we may give with respect to our clinical trials, it could materially harm our reputation and the market&#8217;s perception of us and could cause our stock price to decline. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Uncertainties relating to our ability to fund our operations for at least the next 12 months raises substantial doubt about our ability to continue as a going concern. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of March&#160;31, 2024, we had an accumulated stockholders&#8217; deficit of approximately $483.8&#160;million, a working capital deficit of approximately $6.2&#160;million, and approximately $2.9&#160;million of cash and cash equivalents to fund our operations and capital requirements. We do not currently have sufficient available liquidity to fund our operations for at least the next 12 months. Consequently, absent further actions, these matters raise substantial doubt about our ability to continue as a going concern within one year after the date that the financial statements in this prospectus are issued. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have a history of generating losses and negative cash flows from operations. Our financial statements have been prepared under the assumption that we will continue as a going concern for the next twelve months. Our ability to continue as a going concern is dependent upon our ability to obtain additional debt, equity or other financing. Furthermore, we also could be required to seek funds through arrangements with collaborative partners or otherwise that may require us to relinquish rights to some of our intellectual property or product candidates or otherwise agree to terms unfavorable to us. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If we are unsuccessful in our efforts to raise any such additional capital, we would be required to take actions that could materially and adversely affect our business, including significant reductions in our research, development and administrative operations (including reduction of our employee base), possible surrender or other disposition of our rights to some technologies or product opportunities, delaying of our clinical trials or curtailing or ceasing operations. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We could be delisted from Nasdaq, which would seriously harm the liquidity of our stock and our ability to raise capital. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Nasdaq requires listing issuers to comply with certain standards in order to remain listed on its exchange. These requirements include, among other things, maintaining a closing bid price for our common stock of $1.00 per share (the &#8220;minimum bid price requirement&#8221;) and meeting one of the following three requirements: maintaining at least $2.5&#160;million in stockholders&#8217; equity; maintaining $35&#160;million of market value of listed securities; or having $500,000 in net income over the prior two years or two of the prior three years. In 2022, we received notice that because the closing bid price for our common stock had fallen below $1.00 per share for 30 consecutive business days, we no longer complied with the minimum bid price requirement. While we cured this deficiency in 2023 after effecting the Reverse Stock Split (as defined below), there is no assurance that we will be able to maintain compliance with this standard. As of December&#160;31, 2023, our stockholders&#8217; deficit was $1.3&#160;million. The market value of our listed securities was below $35&#160;million and we did not have net income in the last three years (the &#8220;Alternative Standards&#8221;). </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On March&#160;8, 2024, we received a letter (the &#8220;Notice&#8221;) from the Listing Qualifications staff of Nasdaq Capital Market (&#8220;Nasdaq Staff&#8221;), notifying us that we no longer complied with the requirement under Nasdaq Listing Rule 5550(b)(1) to maintain a minimum of $2.5&#160;million in stockholders&#8217; equity for continued listing on Nasdaq or the alternative requirements of having a market value of listed securities of $35&#160;million or net income from continuing operations of $500,000 in the most recently completed fiscal year or two of the last three most recently completed fiscal years (the &#8220;Alternative Standards&#8221;). The Notice states that our Annual Report on Form <span style="white-space:nowrap">10-K</span> for the fiscal year ended December&#160;31, 2023, disclosed stockholders&#8217; equity of ($1.3 million) as of December&#160;31, 2023, and that, as of March&#160;8, 2024, we did not meet the Alternative Standards. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">14 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On April&#160;22, 2024, we provided Nasdaq with our plan to achieve and sustain compliance with the stockholders&#8217; equity requirement and requested that Nasdaq grant us an extension of time until September&#160;4, 2024, to provide evidence of compliance with the stockholders&#8217; equity requirement. Consistent with that plan, in May 2024, we completed the May 2024 PIPE Financing, which resulted in our stockholders&#8217; equity being greater than $2.5&#160;million as of completion of the offering. Nasdaq has not yet responded to our plan, and there can be no assurance that Nasdaq will grant an extension or that we will be able to comply with the applicable listing standards of Nasdaq. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If, for any reason, Nasdaq were to delist our securities from trading on its exchange and we are unable to obtain listing on another reputable national securities exchange, a reduction in some or all of the following may occur, each of which could materially adversely affect our stockholders: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the liquidity and marketability of our common stock; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the market price of our common stock; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our ability to obtain financing for the continuation of our operations; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the number of institutional and general investors that will consider investing in our common stock; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the number of market makers in our common stock; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the availability of information concerning the trading prices and volume of our common stock; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the number of broker-dealers willing to execute trades in shares of our common stock. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, if we cease to be eligible to trade on Nasdaq, we may have to pursue trading on a less recognized or accepted market, such as the over the counter markets, our stock may be traded as a &#8220;penny stock,&#8221; which would make transactions in our stock more difficult and cumbersome, and we may be unable to access capital on favorable terms or at all, as companies trading on alternative markets may be viewed as less attractive investments with higher associated risks, such that existing or prospective institutional investors may be less interested in, or prohibited from, investing in our common stock. This may also cause the market price of our common stock to decline. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We will need substantial additional funding to develop our product candidates and conduct our future operations and to repay our outstanding debt obligations. If we are unable to obtain the funds necessary to do so, we may be required to delay, scale back or eliminate our product development activities or may be unable to continue our business operations. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have had, and we will continue to have, an ongoing need to raise additional cash from outside sources to continue funding our operations, including our continuing substantial research and development expenses and potential commercialization activities. We do not currently believe that our cash balance will be sufficient to fund the development and marketing efforts required to reach profitability without raising additional capital from accessible sources of financing in the near future. Our future capital requirements will depend on many factors, including: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our ability to raise capital to fund our operations on terms acceptable to us, or at all; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our perceived capital needs with respect to our development programs, and any delays in, adverse events and excessive costs of such programs beyond what we currently anticipate; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our ability to establish and maintain collaborative and other arrangements with third parties to assist in bringing our product candidates to market and the cost of such arrangements at the time; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">costs associated with operating at our San Antonio, Texas facility; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the cost of manufacturing our product candidates, including compliance with good manufacturing practices applicable to our product candidates; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">expenses related to the establishment of sales and marketing capabilities for product candidates awaiting approval or products that have been approved; </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">15 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">competing technological and market developments; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our ability to introduce and sell new products. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The amount and timing of our future funding requirements will depend on many factors, including the pace and results of its clinical development efforts. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have secured capital historically from grant revenue, collaboration proceeds, and debt and equity offerings. To obtain additional capital, we may pursue debt and/or equity offering programs, strategic corporate partnerships, state and federal development programs, licensing arrangements, and sales of assets or debt or equity securities. We cannot be certain that additional capital will be available on terms acceptable to us, or at all. If we are unsuccessful in our efforts to raise any such additional capital, we may be required to take actions that could materially and adversely harm our business, including a possible significant reduction in our research, development and administrative operations (including reduction of our employee base), the surrender of our rights to some technologies or product opportunities, delay of our clinical trials or regulatory and reimbursement efforts, or curtailment or cessation of operations. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Depending on the type and the terms of any financing we pursue, stockholders&#8217; rights and the value of their investment in our common stock could be reduced. A financing could involve one or more types of securities including common stock, convertible debt or warrants to acquire common stock. These securities could be issued at or below the then prevailing market price for our common stock. In addition, if we issue secured debt securities, the holders of the debt would have a claim to our assets that would be prior to the rights of stockholders until the debt is paid. Interest on these debt securities would increase costs and negatively impact operating results. If the issuance of new securities results in diminished rights to holders of our common stock, the market price of our common stock could be negatively impacted. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On August&#160;2, 2022, we entered into a purchase agreement (the &#8220;2022 Purchase Agreement&#8221;) and registration rights agreement pursuant to which Lincoln Park Capital Fund (&#8220;Lincoln Park&#8221;) committed to purchase up to $50.0&#160;million shares of our common stock. Under the terms and subject to the conditions of the 2022 Purchase Agreement, we have the right, but not the obligation, to sell to Lincoln Park, and Lincoln Park is obligated to purchase up to $50.0&#160;million shares of our common stock, provided that we cannot sell more than 57.5&#160;million shares pursuant to the 2022 Purchase Agreement. Sales of common stock by us are subject to certain limitations, and can occur from time to time, at our sole discretion, over the <span style="white-space:nowrap">36-month</span> period commencing on August&#160;17, 2022, subject to the satisfaction of certain conditions. As consideration for Lincoln Park&#8217;s irrevocable commitment to purchase shares of our common stock upon the terms of and subject to satisfaction of the conditions set forth in the Purchase Agreement, we paid $0.1&#160;million in cash as an Initial Commitment Fee and issued 492,698 Commitment Shares to Lincoln Park in consideration for its commitment to purchase shares of our common stock at our direction under the Purchase Agreement. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On August&#160;17, 2022, a registration statement (the &#8220;First Registration Statement&#8221;) was declared effective covering the resale of up to 9,500,000 shares of our common stock comprised of (i)&#160;the 492,698 Commitment Shares, and (ii)&#160;up to 9,007,302 shares that we reserved for issuance and sale to Lincoln Park under the Purchase Agreement. We cannot sell more shares under the 2022 Purchase Agreement without registering additional shares. We sold approximately 527,166 shares under the First Registration Statement. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On August&#160;18, 2023, a second registration statement (the &#8220;Second Registration Statement&#8221;) was declared effective covering the resale of up to an additional 1,500,000 shares of our common stock that we reserved for issuance and sale to Lincoln Park under the 2022 Purchase Agreement from time to time. We sold 150,000 shares under the Second Registration Statement. We cannot sell more shares pursuant to the 2022 Purchase Agreement than are registered under the Second Registration Statement without registering additional shares. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Even with the arrangements described above, we will need to complete additional financing transactions in order to continue operations. These arrangements may also not be sufficient in the near-term. Given, among other things, the current status of the capital markets and our recent stock price performance and financing strategies we may pursue may not be sufficient to fund our operations in the near term, there can be no assurances that we </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">16 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
will be able to secure additional financing, or if available, that it will be sufficient to meet our needs or be on favorable terms. Additionally, our cost of capital will depend upon numerous factors including, but not limited to, the strength of the financial markets, global market conditions, including inflationary pressures, interest rate fluctuations, our recovery and financial performance, the recovery and performance of our industry in general and the size, scope and timing of our financial needs. If we are unable to access current financings or secure future financings, including for any of the foregoing reasons, it will have a negative impact on our cash flows and our ability to meet our financial obligations. Failure to raise capital as and when needed, on favorable terms or at all, would have a significant negative impact on our financial condition and our ability to develop our product candidates. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Borrowings under our line of credit have the effect of limiting our use of cash and marketable securities. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have an existing margin loan facility under a line of credit (the &#8220;Pershing Credit Facility&#8221;) with Pershing LLC (&#8220;Pershing&#8221;), an affiliate of The Bank of New York Mellon Corporation. The available credit line limit under this facility fluctuates based on our request for extensions from time to time, subject to the value of the collateralized marketable securities we hold with Pershing, provided that the amount available to draw under the facility cannot exceed 91.5% of the value of the collateralized marketable securities deposited with Pershing. Depending on the value of the marketable securities we hold with Pershing, Pershing may require us from <span style="white-space:nowrap"><span style="white-space:nowrap">time-to-time</span></span> to deposit additional funds or marketable securities in order to restore the level of collateral to an acceptable level, and the amounts borrowed under the facility are due on demand. Volatility in the global markets could cause the interest rate to fluctuate from time to time increasing our costs, or could cause Pershing to terminate our ability to borrow funds. In addition, borrowings under the Pershing Credit Facility have the effect of limiting our use of cash and marketable securities. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We maintain our cash at financial institutions, often in balances that exceed federally insured limits. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Actual events involving limited liquidity, defaults, <span style="white-space:nowrap">non-performance</span> or other adverse developments that affect financial institutions, or other companies in the financial services industry or the financial services industry generally, or concerns or rumors about any events of these kinds or other similar risks, have in the past and may in the future lead to market-wide liquidity problems. The majority of our cash is held in accounts at U.S. banking institutions that we believe are of high quality. Cash held in depository accounts may exceed the $250,000 Federal Deposit Insurance Corporation (&#8220;FDIC&#8221;) insurance limits. If such banking institutions were to fail, we could lose all or a portion of those amounts held in excess of such insurance limitations. By way of example, the FDIC took control of Silicon Valley Bank (&#8220;SVB&#8221;) on March&#160;10, 2023. Similarly, on March&#160;12, 2023, Signature Bank and Silvergate Capital Corp. were each swept into receivership. Although depositors at SVB received access to their funds, uncertainty and liquidity concerns in the broader financial services industry remain. Inflation and rapid increases in interest rates have led to a decline in the trading value of previously issued government securities with interest rates below current market interest rates. The U.S. Department of Treasury, FDIC and Federal Reserve Board have announced a program to provide up to $25&#160;billion of loans to financial institutions secured by such government securities held by financial institutions to mitigate the risk of potential losses on the sale of such instruments. However, widespread demands for customer withdrawals or other needs of financial institutions for immediate liquidity may exceed the capacity of such program. There is no guarantee that the U.S. Department of Treasury, FDIC and Federal Reserve Board will provide access to uninsured funds in the future in the event of the closure of other banks or financial institutions in a timely fashion or at all. Additionally, in the future, our access to our cash in amounts adequate to finance our operations could be significantly impaired by the financial institutions with which we have arrangements directly facing liquidity constraints or failures. Any material loss that we may experience in the future could have a material adverse effect on our financial condition and could materially impact our ability to pay our operational expenses or make other payments. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Our ability to utilize our net operating loss carryforwards and certain other tax attributes may be limited. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We do not expect to make profits in the near future. Under Section&#160;382 of the Internal Revenue Code of 1986, as amended, if a corporation undergoes an &#8220;ownership change&#8221; (generally defined as a greater than 50% change, by </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">17 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
value, in its equity ownership over a three year period), the corporation&#8217;s ability to use its <span style="white-space:nowrap">pre-change</span> net operating loss carryforwards and other <span style="white-space:nowrap">pre-change</span> tax attributes to offset its post-change taxable income and taxes may be limited. We have undergone &#8220;ownership changes&#8221; as a result of shifts in stock ownership in the past, which significantly limited our ability to use net operating loss carryforwards and other <span style="white-space:nowrap">pre-change</span> tax attributes. Any additional ownership change within the definition of Section&#160;382 would further limit our ability to use net operating loss carryforwards and other tax attributes. This change may require us to pay federal income taxes in future years despite generating a loss for federal income tax purposes in prior years. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Risks Related to Our Business and Industry </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">If we fail to maintain proper and effective internal controls, our ability to produce accurate financial statements on a timely basis could be impaired. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are subject to the reporting requirements of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), the Sarbanes-Oxley Act and the rules and regulations of Nasdaq. The Sarbanes-Oxley Act requires, among other things, that we maintain effective disclosure controls and procedures and internal control over financial reporting. We must perform system and process evaluation and testing of our internal control over financial reporting to allow management to report on the effectiveness of our internal controls over financial reporting in our Form <span style="white-space:nowrap">10-K</span> and Form <span style="white-space:nowrap">10-Q,</span> as required by Section&#160;404 of the Sarbanes-Oxley Act. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">During the quarter ended June&#160;30, 2023, we recognized immaterial grant revenue related to reimbursable development costs incurred in the fourth quarter of 2022 and the first quarter of 2023 that were eligible for revenue recognition in those respective prior periods. These costs were eligible for reimbursement under our CPRIT Grant, but were not correctly recognized in prior period grant revenue due to management&#8217;s view that insufficient progress had been made in the ReSPECT <span style="white-space:nowrap">-LM</span> clinical trial, despite no performance specific milestones in the grant outside of a reasonableness test for reimbursement of expenses. Management has concluded that the correction to grant revenue in the prior periods did not cause a material misstatement of our financial statements. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As a result, we concluded that we did not have adequate controls to apply appropriate accounting principles to significant and unusual grant revenue transactions. Specifically, controls over identification of significant and/or unusual transactions requiring technical analysis were not operating effectively. Management evaluated the impact of this deficiency on our disclosure controls and procedures and concluded that the control deficiency represents a material weakness. A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of the Company&#8217;s annual or interim financial statements will not be prevented or detected on a timely basis. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Since the identification of the material weakness, we have taken steps to remediate the material weakness mentioned above, including strengthening our review process related to significant and unusual transactions, such as multiple level of review of categorization of the research and development expenses eligible for grant revenue and supporting evidence of such expenses. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the quarter ended March&#160;31, 2024, we completed the testing of the design and operating effectiveness of the controls over application of appropriate accounting principles to significant and unusual grant revenue transaction. While management determined that the controls are adequately designed and are operating effectively, and concluded that the material weakness identified in the Quarterly Report on Form <span style="white-space:nowrap">10-Q</span> for the quarter ended June&#160;30, 2023 had been remediated, there can be no certainty that the issue has been fully remediated or will not reoccur. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Furthermore, we may in the future discover additional weaknesses in our system of internal financial and accounting controls and procedures that could result in a material misstatement of our financial statements. Our internal control over financial reporting will not prevent or detect all errors and all fraud. A control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the control </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">18 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
system&#8217;s objectives will be met. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that misstatements due to error or fraud will not occur or that all control issues and instances of fraud will be detected. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If we are not able to comply with the requirements of Section&#160;404 of the Sarbanes-Oxley Act, or if we are unable to maintain proper and effective internal controls, we may not be able to produce timely and accurate financial statements. If that were to happen, the market price of our common stock could decline and we could be subject to sanctions or investigations by Nasdaq, the SEC or other regulatory authorities. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Our future success is in large part dependent upon our ability to successfully develop our nanomedicine platform and commercialize rhenium (<sup style="font-size:75%; vertical-align:top">186</sup>Re) obisbemeda and <sup style="font-size:75%; vertical-align:top">188</sup><span style="white-space:nowrap">RNL-BAM</span> and any failure to do so could significantly harm our business and prospects. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our ability to successfully develop and commercialize rhenium (<sup style="font-size:75%; vertical-align:top">186</sup>Re) obisbemeda and <sup style="font-size:75%; vertical-align:top">188</sup><span style="white-space:nowrap">RNL-BAM</span> is subject to a number of risks, including the following: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">we do not have substantive drug development, manufacturing, and commercialization experience, and thus we may be required to hire and rely on significant numbers of scientific, quality, regulatory and other technical personnel with the experience and expertise necessary to develop, manufacture, and commercialize our nanomedicine product candidates. We may be unable to identify, hire and retain personnel with the requisite experience to conduct the operations necessary to obtain regulatory approval and commercialize our RNL product candidates, in which case our business would be materially harmed; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">we intend to find a commercialization partner to share or assume responsibility for marketing, sales, and distribution activities and related costs and expenses for our RNL product candidates. There can be no assurance that we would obtain sufficient capital to fund the development, manufacturing, and commercialization of our nanomedicine program ourselves, or if we do obtain such capital, that our development, manufacturing, and commercialization efforts would be successful; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">to the extent that we incur unanticipated expenses in our business, are unable to timely obtain sufficient additional capital on terms acceptable to us (or at all) to fund this business, our ability to develop our RNL product candidates could be materially and adversely impacted. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">If we are unable to successfully partner with other companies to commercialize our product candidates, our business could materially suffer. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A key part of our business strategy is to leverage strategic partnerships and collaborations to commercialize our product candidates. We do not have the financial, human or other resources necessary to develop, commercialize, launch or sell our therapeutic offerings in all of the geographies that we are targeting, and thus it is important that we identify and partner with third parties who possess the necessary resources to bring our product candidates to market. We expect that any such partners will provide regulatory and reimbursement/pricing expertise, sales and marketing resources, and other expertise and resources vital to the success of our product offerings in their territories. We further expect, but cannot guarantee, that any such partnering arrangements will include upfront cash payments to us in return for the rights to develop, manufacture, and/or sell our product candidates in specified territories, as well as downstream revenue in the form of milestone payments and royalties. If we are unable to successfully partner with other companies to commercialize our product candidates, our business could materially suffer. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Our success depends in substantial part on our ability to obtain regulatory approvals for our RNL product candidates. However, we cannot be certain that we will receive regulatory approval for these product candidates or our other product candidates. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have a limited number of product candidates in development, and our business depends substantially on their successful development and commercialization. Our product candidates will require development, regulatory </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">19 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
review and approval in multiple jurisdictions, substantial investment, access to sufficient commercial manufacturing capacity and significant marketing efforts before we can generate any revenue from sales of our product candidates. The research, testing, manufacturing, labeling, approval, sale, marketing and distribution of products are subject to extensive regulation by the FDA and other regulatory authorities in the United States and other countries, whose regulations differ from country to country. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are not permitted to market our product candidates in the United States until we receive approval from the FDA, or in any foreign countries until we receive the requisite approval from the regulatory authorities of such countries (including centralized marketing authorization from EMA), and we may never receive such regulatory approvals. Obtaining regulatory approval for a product candidate is a lengthy, expensive and uncertain process, and may not be obtained. Any failure to obtain regulatory approval of any of our product candidates would limit our ability to generate future revenue (and any failure to obtain such approval for all of the indications and labeling claims we deem desirable could reduce our potential revenue), would potentially harm the development prospects of our product candidates and would have a material and adverse impact on our business. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Even if we successfully obtain regulatory approvals to market our product candidates, our revenue will be dependent, in part, on our ability to commercialize such products as well as the size of the markets in the territories for which we gain regulatory approval. If the markets for our product candidates are not as significant as we estimate, our business and prospects will be harmed. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If a product candidate is not approved in a timely fashion on commercially viable terms, or if development of any product candidate is terminated due to difficulties or delays encountered in the regulatory approval process, it could have a material adverse effect on our business, and we may become more dependent on the development of other proprietary products and/or our ability to successfully acquire other products and technologies. There can be no assurance that any product candidate will receive regulatory approval in a timely manner, or at all. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">If we or any party to a key collaboration, licensing, development, acquisition or similar arrangement fail to perform material obligations, or commit a breach, under such arrangement, or any arrangement is terminated for any reason, there could be an adverse effect on our business. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are currently party to certain licensing, collaboration and acquisition agreements under which we may make or receive future payments in the form of milestone payments, maintenance fees, royalties and/or minimum product purchases. Our collaborators may not devote the attention and resources to such efforts to be successful. The termination of a key collaboration agreement by one of our collaborators could materially impact our ability to enter into additional collaboration agreements with new collaborators on favorable terms. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On March&#160;29, 2020, we entered into an exclusive license agreement with NanoTx for the global rights to develop and commercialize NanoTx&#8217;s glioblastoma treatment, rhenium (<sup style="font-size:75%; vertical-align:top">186</sup>Re) obisbemeda. Under the license agreement with NanoTx, we are required to use commercial reasonable efforts to develop the rhenium (<sup style="font-size:75%; vertical-align:top">186</sup>Re) obisbemeda product candidate acquired under the license agreement. Further, we are subject to future milestone, <span style="white-space:nowrap">earn-out</span> and other payments to NanoTx all of which are tied to our commercialization and sale activities for product candidates. If we are unsuccessful in our efforts to develop these assets, or if NanoTx and we were to enter into a dispute over the terms of our agreement, then our business could be seriously harmed. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On December&#160;31, 2021, we entered into an exclusive license agreement with UT Health Science Center at San Antonio for the global rights to develop and commercialize <span style="white-space:nowrap">Rhenium-188</span> NanoLiposome biodegradable alginate microspheres (<sup style="font-size:75%; vertical-align:top">188</sup><span style="white-space:nowrap">RNL-BAM).</span> Under the license agreement with UTHSA, we are required to use commercial reasonable efforts to develop the <sup style="font-size:75%; vertical-align:top">188</sup><span style="white-space:nowrap">RNL-BAM</span> product candidate acquired under the license agreement. Further, we are subject to future milestone, <span style="white-space:nowrap">earn-out</span> and other payments to UTHSA all of which are tied to our commercialization and sale activities for product candidates. If we are unsuccessful in our efforts to develop these assets, or if UTHSA and we were to enter into a dispute over the terms of our agreement, then our business could be seriously harmed. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">20 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If we breach any of the agreements under which we license the use, development and commercialization rights to our product candidates or technology from third parties, we could lose license rights that are important to our business. Licensing of intellectual property is of critical importance to our business and involves complex legal, business and scientific issues. Disputes may arise between us and our licensors regarding intellectual property subject to a license agreement, including: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the scope of rights granted under the license agreement and other interpretation-related issues; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">whether and the extent to which our technology and processes infringe on intellectual property of the licensor that is not subject to the licensing agreement; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our right to sublicense patents and other intellectual property rights to third parties under collaborative development relationships; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our diligence obligations with respect to the use of the licensed technology in relation to our development and commercialization of our product candidates, and what activities satisfy those diligence obligations; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the ownership of inventions and <span style="white-space:nowrap">know-how</span> resulting from the joint creation or use of intellectual property by our licensors and us and our partners; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">whether and the extent to which inventors are able to contest the assignment of their rights to our licensors. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If disputes over intellectual property that we have licensed prevent or impair our ability to maintain our current licensing arrangements on acceptable terms or at all, we may be unable to successfully develop and commercialize the affected product candidates. In addition, if disputes arise as to ownership of licensed intellectual property, our ability to pursue or enforce the licensed patent rights may be jeopardized. If we or our licensors fail to adequately protect this intellectual property, our ability to commercialize our products could suffer. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Our current business strategy is high-risk and may not be successful. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our current business strategy is to aggressively develop our nanomedicine platforms, while simultaneously controlling expenses, which is a high-risk strategy for a number of reasons including the following: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">we do not have prior experience with obtaining regulatory, reimbursement, or other approvals for product candidates such as rhenium (<sup style="font-size:75%; vertical-align:top">186</sup>Re) obisbemeda and <sup style="font-size:75%; vertical-align:top">188</sup><span style="white-space:nowrap">RNL-BAM;</span> </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our nanomedicine product candidates, if commercialized, will compete against established competitive drugs that are marketed and sold by large companies with significant human, technical and financial resources; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">we are not experienced in acquiring and integrating new assets; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">there is an intense and rapidly evolving competitive landscape for our nanomedicine product candidates, including chemotherapies, targeted therapies and immuno-oncology therapies, and as such key assumptions regarding market entry, pricing, and revenue/unit share may not be realized; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our product candidates may never become commercially viable; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">we may not be able to prevent other companies from depriving us of market share and profit margins by selling products based on our intellectual property and developments. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Reliance on government funding for our programs may impose requirements that limit our ability to take certain actions, and subject it to potential financial penalties, which could materially and adversely affect our business, financial condition and results of operations. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A significant portion of our funding will come from grants received from CPRIT. The CPRIT Grant includes provisions that reflect the government&#8217;s substantial rights and remedies, many of which are not typically found in </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">21 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
commercial contracts, including powers of the government to potentially require repayment of all or a portion of the grant award proceeds, in certain cases with interest, in the event we violate certain covenants pertaining to various matters that include any potential relocation outside of the State of Texas. After the CPRIT Grant ends, we are not permitted to retain any unused grant award proceeds without CPRIT&#8217;s approval, but our obligation to pay CPRIT sales-based royalty, if and when commercialization is achieved, and other obligations, including our obligation to repay the disbursed grant proceeds under certain circumstances, to maintain certain records and documentation, to notify CPRIT of certain unexpected adverse events and our obligation to use reasonable efforts to ensure that any new or expanded preclinical testing, clinical trials, commercialization or manufacturing related to any aspect to our CPRIT project take place in Texas, survive the termination of the agreement. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our award from CPRIT requires us to pay CPRIT a portion of our revenues from sales of certain products by us, or received from our licensees or sublicensees, at tiered percentages of revenue in the <span style="white-space:nowrap">low-</span> to <span style="white-space:nowrap">mid-single</span> digits until the aggregate amount of such payments equals 400% of the grant award proceeds, and thereafter at a rate of 0.5% for as long as we maintain government exclusivity, subject to our right, under certain circumstances, to make a <span style="white-space:nowrap">one-time</span> payment in a specified amount to CPRIT to terminate such payment obligations. In addition, the grant contract also contains a provision that provides for repayment to CPRIT of some amount not to exceed the full amount of the grant proceeds under certain specified circumstances involving relocation of our principal place of business outside Texas. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The CPRIT Grant requires us, as a Texas-based company, to meet certain criteria, including among other things, that we maintain our headquarters in Texas and use certain vendors, consultants and employees that are located in Texas. If we fail to maintain compliance with any such requirements that may apply to us now or in the future, we may be subject to potential liability and to termination of our contracts, and potentially full repayment of the CPRIT Grant. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">If our competitors market or develop products that are marketed more effectively, approved more quickly than our product candidates, or demonstrated to be safer or more effective than our product candidates, our commercial opportunities could be reduced or eliminated. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The life science industry is characterized by rapidly advancing technologies, intense competition, and a strong emphasis on proprietary therapeutics. We face competition from a number of sources, some of which may target the same indications as our products or product candidates, including small and large, domestic and multinational, medical device, biotechnology and pharmaceutical companies, academic institutions, government agencies, and private and public research institutions. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Competitors may have greater experience in developing drugs, conducting clinical trials, obtaining regulatory clearances or approvals, manufacturing and commercialization. It is possible that competitors may obtain patent protection, approval, or clearance from the FDA or achieve commercialization earlier than we can, any of which could have a substantial negative effect on our business. Many of our potential competitors have substantially greater: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">capital resources; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">research and development resources and experience, including personnel and experience; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">product development, clinical trial and regulatory resources and experience; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">sales and marketing resources and experience; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">manufacturing and distribution resources and experience; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">name, brand and product recognition; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">resources, experience and expertise in prosecution and enforcement of intellectual property rights. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We expect that product candidates in our pipeline, if approved, to compete on the basis of, among other things, product efficacy and safety, time to market, price, coverage, and reimbursement by third-party payers, extent of </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">22 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
adverse side effects, and convenience of treatment procedures. One or more of our competitors may develop other products that compete with ours, obtain necessary approvals for such products from the FDA, EMA, Ministry of Health, Labour and Welfare or other agencies, if required, more rapidly than we do or develop alternative products or therapies that are safer, more effective and/or more cost effective than any products developed by us. The competition that we encounter with respect to any of our product candidates that receive the requisite regulatory approval and classification and are marketed may have an effect on our product prices, market share, and results of operations. We may not be able to differentiate any products that we are able to market from those of our competitors, successfully develop or introduce new products that are less costly or offer better results than those of our competitors, or offer purchasers of our products payment and other commercial terms as favorable as those offered by our competitors. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As a result of these factors, our competitors may obtain regulatory approval of their products more quickly than we are able to or may obtain patent protection or other intellectual property rights that limit or block us from developing or commercializing our product candidates. Our competitors may also develop products that are more effective, more useful, better tolerated, subject to fewer or less severe side effects, more widely prescribed or accepted, or less costly than ours and may also be more successful than we are in manufacturing and marketing their products. If we are unable to compete effectively with the marketed therapeutics of our competitors or if such competitors are successful in developing products that compete with any of our product candidates that are approved, our business, results of operations, financial condition, and prospects may be materially adversely affected. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Product development involves a lengthy and expensive process, with an uncertain outcome. We may incur additional costs or experience delays in completing, or ultimately be unable to complete, the development and commercialization of our product candidates. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Clinical testing of our product candidates is a long, expensive and uncertain process, and the failure or delay of a clinical trial can occur at any stage. Many factors, currently known and unknown, can adversely affect clinical trials and the ability to evaluate a product candidate&#8217;s efficacy. During the course of treatment, patients can die or suffer other adverse events for reasons that may or may not be related to the proposed product being tested. Even if initial results of preclinical and nonclinical studies or clinical trial results are promising, we may obtain different results in subsequent trials or studies that fail to show the desired levels of safety and efficacy, or we may not obtain applicable regulatory approval for a variety of other reasons. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Further, with respect to the conduct and results of clinical trials generally, in the United States, Europe, Japan, and other jurisdictions, the conduct and results of clinical trials can be delayed, limited, suspended, or otherwise adversely affected for many reasons, including, among others: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">delay or failure in reaching agreement with the FDA or other regulatory authorities outside of the United States on acceptable clinical trial design, or in obtaining authorization to commence a trial; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">delay or failure in reaching agreement on acceptable terms with prospective clinical research organizations (&#8220;CRO&#8221;), and clinical trial sites; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">delay or failure in obtaining approval of an IRB or ethics committees before a clinical trial can be initiated at a prospective trial site; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">withdrawal of clinical trial sites from our clinical trials, including as a result of changing standards of care or the ineligibility of a site to participate; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">clinical results may not meet prescribed endpoints for the studies, produce negative or inconclusive results, or otherwise not provide sufficient data to support the efficacy of our product candidates; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">clinical and nonclinical test results may reveal side effects, adverse events or unexpected safety issues associated with the use of our product candidates; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">emerging of dosing issues; </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">23 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">lack of adequate funding to continue the clinical trials, including the incurrence of unforeseen costs due to enrollment delays, requirements to conduct additional trials and studies, and increased expenses associated with the services of our CROs and other third parties; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">inability to design appropriate clinical trial protocols; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">slower than expected rates of subject recruitment and enrollment rates in clinical trials; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">clinical sites or investigators may deviate from trial protocol or fail to conduct the trial in accordance with applicable regulatory requirements, or drop out of a trial; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">regulatory review may not find a product safe or effective enough to merit either continued testing or final approval; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">regulatory authorities may require that we change our studies or conduct additional studies which may significantly delay or make continued pursuit of approval commercially unattractive; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">a regulatory agency may reject our trial data or disagree with our interpretations of either clinical trial data or applicable regulations; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the cost of clinical trials required for product approval may be greater than what we originally anticipate, and we may decide to not pursue regulatory approval for such a product; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">changes in the standard of care of the indication being studied; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">a regulatory agency may identify problems or other deficiencies in our existing manufacturing processes or facilities or the existing processes or facilities of our collaborators, our contract manufacturers, or our raw material suppliers; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">a regulatory agency may change its formal or informal approval requirements and policies, act contrary to previous guidance, adopt new regulations, or raise new issues or concerns late in the approval process; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">a regulatory agency may ask us to put a clinical study on hold pending additional safety data (and there can be no assurance that we will be able to satisfy the regulator agencies&#8217; requests in a timely manner, which can lead to significant uncertainty in the completion of a clinical study). </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We also face clinical trial-related risks with regard to our reliance on other third parties in the performance of many of the clinical trial functions, including CROs that help execute our clinical trials, the hospitals and clinics at which our trials are conducted, the clinical investigators at the trial sites, and other third-party service providers. Failure of any third-party service provider to adhere to applicable trial protocols, laws and regulations in the conduct of one of our clinical trials could adversely affect the conduct and results of such trial (including possible data integrity issues), which could seriously harm our business. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We, the FDA, other regulatory authorities outside the United States, or an IRB may suspend a clinical trial at any time for various reasons, including if it appears that the clinical trial is exposing participants to unacceptable health risks or if the FDA or one or more other regulatory authorities outside the United States find deficiencies in our IND or similar application outside the United States or the conduct of the trial. If we experience delays in the completion of, or the termination of, any clinical trial of any of our product candidates, the commercial prospects of such product candidate will be harmed, and our ability to generate product revenues from such product candidate will be delayed or inhibited. In addition, any delays in completing our clinical trials will increase our costs, slow down our product candidate development and approval process, and jeopardize our ability to commence product sales and generate revenues. Any of these occurrences may harm our business, financial condition, results of operations, cash flows and prospects significantly. In addition, many of the factors that cause, or lead to, a delay in the commencement or completion of clinical trials may also ultimately lead to the denial of regulatory approval of our product candidates. Further, regulatory authorities may disagree with our clinical trial design and our interpretation of data from clinical trials, or may change the requirements for approval even after they have reviewed and commented on the design for our clinical trials. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">24 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic"><span style="white-space:nowrap">Pre-clinical</span> studies and preliminary and interim data from clinical trials of our product candidates are not necessarily predictive of the results or success of ongoing or future clinical trials of our product candidates. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="white-space:nowrap">Pre-clinical</span> studies and any positive preliminary and interim data from our clinical trials of our product candidates may not necessarily be predictive of the results of ongoing or later clinical trials. A number of companies in the pharmaceutical and biotechnology industries, including us and many other companies with greater resources and experience than we, have suffered significant setbacks in clinical trials, even after seeing promising results in prior <span style="white-space:nowrap">pre-clinical</span> studies and clinical trials. Even if we are able to complete our planned clinical trials of our product candidates according to our current development timeline, initial positive results from <span style="white-space:nowrap">pre-clinical</span> studies and clinical trials of our product candidates may not be replicated in subsequent clinical trials. The design of our later stage clinical trials could differ in significant ways (e.g., inclusion and exclusion criteria, endpoints, statistical analysis plan) from our earlier stage clinical trials, which could cause the outcomes of the later stage trials to differ from those of our earlier stage clinical trials. If we fail to produce positive results in our planned clinical trials of any of our product candidates, the development timeline and regulatory approval and commercialization prospects for our product candidates, and, correspondingly, our business and financial prospects, could be materially adversely affected. If we fail to produce positive results in our planned clinical trials of any of our product candidates, the development timeline and regulatory approval and commercialization prospects for such product candidates, and, correspondingly, our business and financial prospects, could be materially adversely affected. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Because we have limited resources, we may decide to pursue a particular product candidate and fail to advance product candidates that later demonstrate a greater chance of clinical and commercial success. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are an early-stage company with limited resources and revenues. The product candidates we currently have under development will require significant development, <span style="white-space:nowrap">pre-clinical</span> and clinical testing and investment of significant funds before their commercialization. Because of this, we must make strategic decisions regarding resource allocations and which product candidates to pursue. There can be no assurance that we will be able to develop all potentially promising product candidates that we may identify. Based on preliminary results, we may choose to advance a particular product candidate that later fails to be successful, and simultaneously forgo or defer further investment in other product candidates that later are discovered to demonstrate greater promise in terms of clinical and commercial success. If we make resource allocation decisions that later are shown to be inaccurate, our business and prospects could be harmed. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Clinical trial results may fail to support approval of our product candidates. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Even if our clinical trials are successfully completed as planned, the results may not support approval of our product candidates under the laws and regulations of the FDA or other regulatory authorities outside the United States. The clinical trial process may fail to demonstrate that our product candidates are both safe and/or effective for their intended uses. <span style="white-space:nowrap">Pre-clinical</span> and clinical data and analyses are often able to be interpreted in different ways. Even if we view our results favorably, if a regulatory authority has a different view, we may still fail to obtain regulatory approval of our product candidates. This, in turn, would significantly adversely affect our business prospects. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">If third parties we engage are not able to successfully perform, we may not be able to successfully complete clinical development, obtain regulatory approval or commercialize our product candidates and our business could be substantially harmed. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We rely on third parties in the performance of many of the clinical trial functions, including CROs, which help execute our clinical trials, the hospitals and clinics at which our trials are conducted, the clinical investigators at the trial sites, and other third-party service providers. Failure of any third-party service provider to adhere to applicable trial protocols, laws and regulations in the conduct of one of our clinical trials could adversely affect the conduct and results of such trial (including possible data integrity issues), which could seriously harm our </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">25 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
business. As a result, results from our clinical trials may be delayed, which in turn would have a material adverse impact on our clinical trial plans and timelines and impair our ability to successfully complete clinical development, obtain regulatory approval, or commercialize our product candidates. This in turn would substantially harm our business and operations. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We also rely on third-party expertise to support us in this area. We have entered into contracts with third-party manufacturers to manufacture, supply, store and distribute supplies of our product candidates for our clinical trials. If any of our product candidates receives FDA approval, we expect to rely on third-party contractors to manufacture our drugs. We have no current plans to build internal manufacturing capacity for any product candidate, and we have no long-term supply arrangements. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our reliance on third-party manufacturers exposes us to potential risks, such as the following: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">we may be unable to contract with third-party manufacturers on acceptable terms, or at all, because the number of potential manufacturers is limited. Potential manufacturers of any product candidate that is approved will be subject to FDA compliance inspections and any new manufacturer would have to be qualified to produce our products; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our third-party manufacturers might be unable to formulate and manufacture our drugs in the volume and of the quality required to meet our clinical and commercial needs, if any; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our third-party manufacturers may not perform as agreed or may not remain in the contract manufacturing business for the time required to supply our clinical trials through completion or to successfully produce, store and distribute our commercial products, if approved; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">drug manufacturers are subject to ongoing periodic unannounced inspection by the FDA and other government agencies to ensure compliance with cGMP and other government regulations and corresponding foreign standards. We do not have control over third-party manufacturers&#8217; compliance with these regulations and standards, but we may ultimately be responsible for any of their failures; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">if any third-party manufacturer makes improvements in the manufacturing process for our products, we may not own, or may have to share, the intellectual property rights to such improvements; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">a third-party manufacturer may gain knowledge from working with us that could be used to supply one of our competitors with a product that competes with ours. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each of these risks could delay or have other adverse impacts on our clinical trials and the approval and commercialization of our product candidates, potentially resulting in higher costs, reduced revenues or both. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We may have difficulty enrolling, or fail to enroll patients, in our clinical trials, which could delay or prevent clinical trials of our drug candidates. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Identifying and enrolling patients to participate in clinical trials of our product candidates is essential to our success. The timing of our clinical trials depends in part on the rate at which we can recruit patients to participate in clinical trials of our product candidates, and we may experience delays in our clinical trials if we encounter difficulties in enrollment. The eligibility criteria of our planned clinical trials may further limit the available eligible trial participants as we require that patients have specific characteristics that we can measure or meet the criteria to assure their conditions are appropriate for inclusion in our clinical trials. We may not be able to identify, recruit and enroll a sufficient number of patients to complete our clinical trials in a timely manner because of the perceived risks and benefits of the drug candidate under study, the availability and efficacy of competing therapies and clinical trials, and the willingness of physicians to participate in our planned clinical trials. If patients are unwilling to participate in our clinical trials for any reason, the timeline for conducting trials and obtaining regulatory approval of our drug candidates may be delayed. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If we experience delays in the completion of, or termination of, any clinical trials of our drug candidates, the commercial prospects of our product candidates could be harmed, and our ability to generate product revenue </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">26 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
from any of these product candidates could be delayed or prevented. In addition, any delays in completing our clinical trials would likely increase our overall costs, impair product candidate development and jeopardize our ability to obtain regulatory approval relative to our current plans. Any of these occurrences may materially and adversely harm our business, financial condition, and prospects. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">If a particular product candidate causes significant adverse events, then we may be unable to receive regulatory approval or market acceptance for such product candidate. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may experience numerous unforeseen events during, or as a result of, the testing process that could delay or prevent commercialization of any of our product candidates, including the occurrence of significant adverse events in clinical trials. Such significant adverse events could lead to clinical trial challenges, such as difficulties in patient recruitment, retention, and adherence, potential product liability claims, and possible trial termination by us, regulatory authorities, and/or an IRB or ethics committees. These types of clinical trial challenges could delay or prevent regulatory approval of our product candidate. Significant adverse events may also lead regulatory authorities to require additional warnings on the label for such product, require us to conduct additional costly post-marketing studies, require us to develop a risk evaluation and mitigation strategy (&#8220;REMS&#8221;), among other possible requirements. If the product candidate has already been approved, such approval may be withdrawn. Any delay in, denial, or withdrawal of marketing approval for one of our product candidates will adversely affect our financial position. Even if our product candidates receive marketing approval, undesirable side effects may limit the product&#8217;s commercial viability. Patients may not wish to use our product, physicians may not prescribe our product, and our reputation may suffer. Any of these events may significantly harm our business and financial prospects. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">If our product candidates and technologies receive regulatory approval but do not achieve broad market acceptance, especially by physicians, the revenue that we generate will be limited. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The commercial success of any of our approved products or technologies will depend upon the acceptance of these products and technologies by physicians, patients and the medical community. The degree of market acceptance of these products and technologies will depend on a number of factors, including, among others: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">acceptance by physicians and patients of the product as a safe and effective treatment; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">any negative publicity or political action related to our or our competitors&#8217; products or technologies; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the relative convenience and ease of administration; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the prevalence and severity of adverse side effects; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">demonstration to authorities of the pharmacoeconomic benefits; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">demonstration to authorities of the improvement in burden of illness; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">limitations or warnings contained in a product&#8217;s approved labeling; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">payers&#8217; level of restrictions and/or barriers to coverage; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the clinical indications for which a product is approved; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">availability and perceived advantages of alternative treatments; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the effectiveness of our or future collaborators&#8217; sales, marketing and distribution strategies; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">pricing and cost effectiveness. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We expect physicians&#8217; inertia and skepticism to also be a significant barrier as we attempt to gain market penetration with our future products. We believe we will continue to need to finance lengthy and time-consuming clinical studies to provide evidence of the medical benefit of our products and resulting therapies in order to overcome this inertia and skepticism. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">27 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Overall, our efforts to educate the medical community on the benefits of any of our products or technologies for which we obtain marketing approval from the FDA or other regulatory authorities and gain broad market acceptance may require significant resources and may never be successful. If our products and technologies do not achieve an adequate level of acceptance by physicians, pharmacists and patients, we may not generate sufficient revenue from these products to become or remain profitable. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">All potential applications of our product candidates are investigational, which subjects us to development and marketing risks. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our product candidates are at various stages of development. Successful development and market acceptance of our products is subject to developmental risks, including risk of negative clinical data from current and anticipated trials, failure of inventive imagination, ineffectiveness, lack of safety, unreliability, manufacturing hurdles, failure to receive necessary regulatory clearances or approvals, high commercial cost, preclusion or obsolescence resulting from third parties&#8217; proprietary rights or superior or equivalent products, competition from copycat products and general economic conditions affecting purchasing patterns. There can be no assurance that we or our partners will successfully develop and commercialize our product candidates, or that our competitors will not develop competing technologies that are superior or less expensive. Failure to successfully develop and market our product candidates would have a substantial negative effect on our results of operations and financial condition. If we are unable to establish or sustain coverage and adequate reimbursement for any future product candidates from third-party payors, the adoption of those products and sales revenue will be adversely affected, which, in turn, could adversely affect the ability to market or sell those product candidates, if approved. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We and our product candidates are subject to extensive regulation, and the requirements to obtain regulatory approvals in the United States and other jurisdictions can be costly, time-consuming and unpredictable. If we or our partners are unable to obtain timely regulatory approval for our product candidates, our business may be substantially harmed. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The worldwide regulatory process for our nanomedicine drug candidates can be lengthy and expensive, with no guarantee of approval. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Before any new drugs may be introduced to the U.S. market, the manufacturer generally must obtain FDA approval through either an abbreviated new drug application (known as &#8216;ANDA&#8217;) process for generic drugs off patent that allow for bioequivalence to an existing reference listing drug (known as &#8216;RLD&#8217;) or the lengthier NDA process, which typically requires multiple successful and successive clinical trials to generate clinical data supportive of safety and efficacy along with extensive pharmacodynamic and pharmacokinetic preclinical testing to demonstrate safety. Our RNL product candidates are subject to the FDA&#8217;s 505(b)(1) NDA process. NDA drugs can take significant time due to the preclinical and clinical trial requirements. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There are numerous risks arising out of the regulation of our nanomedicine product candidates include the following: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">we can provide no assurances that our current and future oncology drugs will meet all of the stringent government regulation in the United States under the Federal Food, Drug and Cosmetic Act, and/or in international markets such as Europe, by the EMA under its Medicinal Products Directive; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our nanomedicine product candidates, if approved, will still be subject to post-market reporting requirements for instances where the drug may have caused or contributed to the death or serious injury, or serious adverse events; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">there are no assurances that our product candidates will not have safety or effectiveness problems occurring after the drugs reach the market; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">there are no assurances that regulatory authorities will not take steps to prevent or limit further marketing of the drug due to safety concerns; and </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">28 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">it is possible that the new legislation in our priority markets will yield additional regulatory requirements for therapeutic drugs for our nanomedicine product candidates. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We will be subject to ongoing regulatory obligations and continued regulatory review, which may result in significant expense, and if we or our collaborators fail to comply with such requirements, regulatory agencies may take action against us or them, which could significantly harm our business. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Approved drug products are subject to ongoing regulatory requirements and oversight, including requirements related to manufacturing, quality control, conduct of post-marketing studies, labeling, packaging, storage, distribution, safety surveillance, import, export, advertising, promotion, recordkeeping and reporting. Regulatory authorities subject a marketed product, its manufacturer, and the manufacturing facilities to continual review and periodic inspections. We, our collaborators, and our and their respective contractors, suppliers and vendors, will be subject to ongoing regulatory requirements, including complying with regulations and laws regarding advertising, promotion and sales of products (including applicable anti-kickback, fraud and abuse and other health care laws and regulations), required submissions of safety and other post-market information and reports, registration requirements, Clinical Good Manufacturing Practices regulations (including requirements relating to quality control and quality assurance, as well as the corresponding maintenance of records and documentation), and the requirements regarding the distribution of samples to physicians and recordkeeping requirements. Regulatory agencies may change existing requirements or adopt new requirements or policies. We, our collaborators, and our and their respective contractors, suppliers, and vendors, may be slow to adapt or may not be able to adapt to these changes or new requirements. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Failure to comply with regulatory requirements may result in any of the following: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">restrictions on the marketing of our product candidates or manufacturing processes; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">warning letters or untitled letters; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">withdrawal of the products from the market; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">voluntary or mandatory recall; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">fines; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">suspension or withdrawal of regulatory approvals; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">suspension or termination of any of our ongoing clinical trials; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">refusal to permit the import or export of our product candidates; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">refusal to approve pending applications or supplements to approved applications that we submit; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">product seizure; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">injunctions; or </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">imposition of civil or criminal penalties. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Changing, new and/or emerging government regulations, including healthcare legislative reform measures, may adversely affect us. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our nanoparticle and microparticle technologies and pipeline oncology products are being developed under existing government criteria, which are subject to change in the future. Clinical and/or <span style="white-space:nowrap">pre-clinical</span> criteria and cGMP manufacturing requirements may change and additional regulatory burdens may be imposed. Any regulatory review committees and advisory groups and any contemplated new guidelines may lengthen the regulatory review process, require us to perform additional studies, increase our development costs, lead to changes in regulatory positions and interpretations, delay or prevent approval and commercialization of our product candidates or lead to significant post-approval limitations or restrictions. As we advance our product candidates, we may be required to consult with these regulatory and advisory groups and comply with applicable </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">29 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
guidelines. If we fail to do so, we may be required to delay or discontinue development of our product candidates. Delay or failure to obtain, or unexpected costs in obtaining, the regulatory approval necessary to bring a product candidate to market could decrease our ability to generate sufficient revenue to maintain our business. Divergence in regulatory criteria for different regulatory agencies in international jurisdictions could result in the repeat of clinical studies and/or preclinical studies to satisfy local territory requirements, resulting in the repeating of studies and/or delays in the regulatory process. Some territories may require clinical data in their indigenous population, resulting in the repeat of clinical studies in whole or in part. Some territories may object to the formulation ingredients in the final finished product and may require reformulation to modify or remove objectionable components; resulting in delays in regulatory approvals. Such objectionable reformulations include, but are not limited to, human or animal components, Bovine Spongiform Encephalopathy and/or Transmissible Spongiform Encephalopathy risks, banned packaging components, prohibited chemicals, and banned substances. There can be no assurances that the FDA or foreign regulatory authorities will accept our <span style="white-space:nowrap">pre-clinical</span> and/or clinical data. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Anticipated or unanticipated changes in the way or manner in which the FDA or other regulators regulate products or classes and groups of products can delay, further burden, or alleviate regulatory pathways that were once available to other products. There are no guarantees that such changes in the FDA&#8217;s or other regulators&#8217; approach to the regulatory process will not deleteriously affect some or all of our product candidates or product applications. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the United States and in some other jurisdictions, there have been a number of legislative and regulatory changes and proposed changes regarding the health care system that could prevent or delay marketing approval of our drug candidates, restrict or regulate post-approval activities, or affect our ability to profitably sell any drug candidates for which we obtain marketing approval, if any. Further, any increased scrutiny of the FDA&#8217;s approval process for drugs and biological products may significantly delay or prevent marketing approval, as well as subject us to more stringent product labeling and post-marketing testing and other requirements. There also are a number of state and local legislative and regulatory efforts related to drug pricing, including drug price transparency laws that apply to pharmaceutical manufacturers, which may have an impact on our business. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, the Drug Supply Chain Security Act enacted in 2013 imposes obligations on manufacturers of pharmaceutical products related to product tracking and tracing. In December 2019, the Further Consolidated Appropriations Act for 2020 was signed into law (P.L. <span style="white-space:nowrap">116-94)</span> that includes a piece of bipartisan legislation called the Creating and Restoring Equal Access to Equivalent Samples Act of 2019 (the &#8220;CREATES Act&#8221;). The CREATES Act aims to address the concern articulated by both the FDA and others in the industry that some brand manufacturers have improperly restricted the distribution of their products, including by invoking the existence of a REMS for certain products, to deny generic and biosimilar product developers access to samples of brand products. The CREATES Act establishes a private cause of action that permits a generic or biosimilar product developer to sue the brand manufacturer to compel it to furnish the necessary samples on &#8220;commercially reasonable, market-based terms.&#8221; Whether and how generic and biosimilar product developments will use this new pathway, as well as the likely outcome of any legal challenges to provisions of the CREATES Act, remain highly uncertain and its potential effects on our future commercial products are unknown. Other legislative and regulatory proposals have been made to expand post-approval requirements and restrict sales and promotional activities for pharmaceutical products. We cannot be sure whether additional legislative changes will be enacted, or whether FDA regulations, guidance or interpretations will be changed, or what the impact of such changes on the marketing approvals, if any, of our drug candidates, may be or whether such changes will have any other impacts on our business. In addition, increased scrutiny by the U.S. Congress of the FDA&#8217;s approval process may significantly delay or prevent marketing approval, as well as subject us to more stringent product labeling and post-marketing conditions and other requirements. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the European Union, similar political, economic and regulatory developments may affect our ability to profitably commercialize our product candidates. In addition to continuing pressure on prices and cost containment measures, legislative developments at the European Union or E.U. member state level may result in significant additional requirements or obstacles that may increase our operating costs. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">30 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We expect that other legislative or healthcare reform measures that may be adopted in the future, may result in more rigorous coverage criteria, lower reimbursement, and additional downward pressure on the price that we will receive for any approved product. Any reduction in payments from Medicare or other government-funded programs may result in a similar reduction in payments from private payors. The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability, or commercialize our product candidates. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Adequate coverage and reimbursement from third party payors may not be available for our products and we may be unable to successfully contract for coverage from pharmacy benefit managers and other organizations; conversely, to secure coverage from these organizations, we may be required to pay rebates or other discounts or other restrictions to reimbursement, either of which could diminish our sales or adversely affect our ability to sell our products profitably. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In both U.S. and <span style="white-space:nowrap">non-U.S.</span> markets, our ability to successfully commercialize and achieve market acceptance of our products depends in significant part on adequate financial coverage and reimbursement from third party payors, including governmental payors (such as the Medicare and Medicaid programs in the U.S.), managed care organizations and private health insurers. Without third party payor reimbursement, patients may not be able to obtain or afford prescribed medications. In addition, reimbursement guidelines and incentives provided to prescribing physicians by third party payors may have a significant impact on the prescribing physicians&#8217; willingness and ability to prescribe our products. The demand for, and the profitability of, our products could be materially harmed if the state Medicaid programs, Medicare program, other healthcare programs in the U.S. or elsewhere, or third party commercial payors in the U.S. or elsewhere deny reimbursement for our products, limit the indications for which our products will be reimbursed, or provide reimbursement only on unfavorable terms. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As part of the overall trend toward cost containment, third party payors often require prior authorization for, and require reauthorization for continuation of, prescription products or impose step edits, which require prior use of another medication, usually a generic or preferred brand, prior to approving coverage for a new or more expensive product. Such restrictive conditions for reimbursement and an increase in reimbursement-related activities can extend the time required to fill prescriptions and may discourage patients from seeking treatment. We cannot predict actions that third party payors may take, or whether they will limit the access and level of reimbursement for our products or refuse to provide any approvals or coverage. From time to time, third party payors have refused to provide reimbursement for our products, and others may do so in the future. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Third party payors increasingly examine the cost-effectiveness of pharmaceutical products, in addition to their safety and efficacy, when making coverage and reimbursement decisions. We may need to conduct expensive pharmacoeconomic and/or clinical studies in order to demonstrate the cost-effectiveness of our products. If our competitors offer their products at prices that provide purportedly lower treatment costs than our products, or otherwise suggest that their products are safer, more effective or more cost-effective than our products, this may result in a greater level of access for their products relative to our products, which would reduce our sales and harm our results of operations. In some cases, for example, third party payors try to encourage the use of less expensive generic products through their prescription benefit coverage and reimbursement and <span style="white-space:nowrap">co-pay</span> policies. Because some of our products compete in a market with both branded and generic products, obtaining and maintaining access and reimbursement coverage for our products may be more challenging than for products that are new chemical entities for which no therapeutic alternatives exist. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Some intellectual property that we have <span style="white-space:nowrap">in-licensed</span> has been discovered through government funded programs and thus may be subject to federal regulations such as <span style="white-space:nowrap">&#8220;march-in&#8221;</span> rights, certain reporting requirements and a preference for U.S.-based companies. Compliance with such regulations may limit our exclusive rights and limit our ability to contract with <span style="white-space:nowrap">non-U.S.</span> manufacturers. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Some of the intellectual property rights we have licensed are generated through the use of U.S. government funding and are therefore subject to certain federal regulations. As a result, the U.S. government may have </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">31 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
certain rights to intellectual property embodied in our current or future product candidates pursuant to the Bayh-Dole Act of 1980, or Bayh-Dole Act, and implementing regulations. These U.S. government rights in certain inventions developed under a government-funded program include a <span style="white-space:nowrap">non-exclusive,</span> <span style="white-space:nowrap">non-transferable,</span> irrevocable worldwide license to use inventions for any governmental purpose. In addition, the U.S. government has the right to require us or our licensors to grant exclusive, partially exclusive, or <span style="white-space:nowrap">non-exclusive</span> licenses to any of these inventions to a third party if it determines that: (i)&#160;adequate steps have not been taken to commercialize the invention; (ii)&#160;government action is necessary to meet public health or safety needs; or (iii)&#160;government action is necessary to meet requirements for public use under federal regulations (also referred to as <span style="white-space:nowrap">&#8220;march-in</span> rights&#8221;). The U.S. government also has the right to take title to these inventions if we, or the applicable licensor, fail to disclose the invention to the government and fail to file an application to register the intellectual property within specified time limits. These time limits have recently been changed by regulation and may change in the future. Intellectual property generated under a government funded program is also subject to certain reporting requirements, compliance with which may require us or the applicable licensor to expend substantial resources. In addition, the U.S. government requires that any products embodying the subject invention or produced through the use of the subject invention be manufactured substantially in the United States. The manufacturing preference requirement can be waived if the owner of the intellectual property can show that reasonable but unsuccessful efforts have been made to grant licenses on similar terms to potential licensees that would be likely to manufacture substantially in the United States or that under the circumstances domestic manufacture is not commercially feasible. This preference for U.S. manufacturers may limit our ability to contract with <span style="white-space:nowrap">non-U.S.</span> product manufacturers for products covered by such intellectual property. To the extent any of our current or future intellectual property is generated through the use of U.S. government funding, the provisions of the Bayh-Dole Act may similarly apply. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Orphan drug designation may not ensure that we will enjoy market exclusivity in a particular market, and if we fail to obtain or maintain orphan drug designation or other regulatory exclusivity for some of our product candidates, our competitive position would be harmed. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A product candidate that receives orphan drug designation can benefit from potential commercial benefits following approval. Under the U.S. Orphan Drug Act, the FDA may designate a product candidate as an orphan drug if it is intended to treat a rare disease or condition, defined as affecting a patient population of fewer than 200,000 in the United States, or a patient population greater than 200,000 in the United States where there is no reasonable expectation that the cost of developing the drug will be recovered from sales in the United States. In the European Union, the EMA&#8217;s Committee for Orphan Medicinal Products, grants orphan drug designation to promote the development of products that are intended for the diagnosis, prevention or treatment of a life-threatening or chronically debilitating condition affecting not more than 10,000 persons in the European Union. Currently, this designation provides market exclusivity in the U.S. and the European Union for seven years and ten years, respectively, if a product is the first such product approved for such orphan indication. This market exclusivity does not, however, pertain to indications other than those for which the drug was specifically designated in the approval, nor does it prevent other types of drugs from receiving orphan designations or approvals in these same indications. Further, even after an orphan drug is approved, the FDA can subsequently approve a drug with similar chemical structure for the same condition if the FDA concludes that the new drug is clinically superior to the orphan product or a market shortage occurs. In the European Union, orphan exclusivity may be reduced to six years if the drug no longer satisfies the original designation criteria or can be lost altogether if the marketing authorization holder consents to a second orphan drug application or cannot supply enough drug, or when a second applicant demonstrates its drug is &#8220;clinically superior&#8221; to the original orphan drug. In September 2020, the FDA granted both Orphan Drug designation and Fast Track designation to rhenium (<sup style="font-size:75%; vertical-align:top">186</sup>Re) obisbemeda for the treatment of patients with GBM. In November 2021, the FDA granted Fast Track designation to rhenium (<sup style="font-size:75%; vertical-align:top">186</sup>Re) obisbemeda for the treatment of patients with LM. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">If we experience an interruption in supply from a material sole source supplier, our business may be harmed </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We acquire some of our components and other raw materials from sole source suppliers. If there is an interruption in supply of our raw materials from a sole source supplier, for any reason, there can be no assurance </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">32 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
that we will be able to obtain adequate quantities of the raw materials within a reasonable time or at commercially reasonable prices. Interruptions in supplies due to pricing, timing, availability, or other issues with our sole source suppliers could have a negative impact on our ability to manufacture products and product candidates, which in turn could adversely affect the development and commercialization of our nanomedicine product candidates and cause us to potentially breach our supply or other obligations under our agreements with certain other counterparties. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are dependent on sole source suppliers to manufacture the active pharmaceutical ingredients (&#8220;API&#8221;) and certain other components of our nanomedicine product candidates. There is no assurance that these sole source suppliers will enter into supply agreements with us to provide contractual assurance to us around supply and pricing. Regardless of whether a sole source supplier enters into a written supply arrangement with us, such supplier could still delay, suspend, or terminate supply of raw materials to us for a number of reasons, including manufacturing or quality issues, payment disputes with us, bankruptcy or insolvency, or other occurrences. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Manufacturing or quality assurance difficulties at our contractors and suppliers, the failure or refusal of a supplier or contract manufacturer to supply contracted quantities, or increases in demand on a supplier with constrained capacity could result in delays and disruptions in the manufacturing, distribution, and sale of our products and /or product candidates, leading to lost revenue or reduced market opportunities. Supply constraints may also lead to pauses, discontinuations, or other product availability issues in one or more markets, which could have a material adverse effect on our consolidated results of operations and cash flows. Further, cost inflation and global transportation and logistics challenges, as well as tight labor markets, have caused, and in the future may cause, delays in, and increase costs related to, distribution of our products, the construction or other acquisition of additional manufacturing capacity, procurement activity, and supplier or contract manufacturer arrangements. These disruptions and challenges could result from actual or perceived quality, oversight, or regulatory compliance problems; natural disasters (including increased instances or severity of natural disasters or other events that may be due to climate change), public health outbreaks, epidemics, or pandemics; periods of uneven economic growth or downturns; emergence or escalation of, and responses to international tension and conflicts; equipment, mechanical, data, or information technology system vulnerabilities, such as system inadequacies, inadequate controls or procedures, operating failures, unauthorized access, service interruptions or failures, security breaches, malicious intrusions, theft, exfiltration, ransomware or other cyber-attacks from a variety of sources; labor shortages; challenges and complexities in manufacturing new drug modalities; contractual disputes with our suppliers and contract manufacturers; vertical integration by competitors within our supply chain; or inability to obtain single-source or other raw or intermediate materials. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If a sole source supplier ceases supply of raw materials necessary, there is no guarantee that we will find an alternative supplier for the necessary raw materials on terms acceptable to us, or at all. Finding alternative suppliers if and as necessary due to geopolitical developments or otherwise may not be feasible or could take a significant amount of time and involve significant expense due to the nature of our products and product candidates. Further the qualification process for a new vendor could take months or years, and any such day in qualification could significantly harm our business. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We may engage in strategic transactions that could impact our liquidity, increase our expenses, and present significant distractions to our management. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">From time to time, we may consider strategic transactions, such as acquisitions of companies, asset purchases and <span style="white-space:nowrap">out-licensing</span> or <span style="white-space:nowrap">in-licensing</span> of products, product candidates or technologies. Growth of the nanomedicine business will require significant management time and attention. Further, the future growth of our business will depend in part on our ability to <span style="white-space:nowrap">in-license</span> or otherwise acquire the rights to additional product candidates or technologies. We cannot assure you that we will be able to <span style="white-space:nowrap">in-license</span> or acquire the rights to any product candidates or technologies from third parties on acceptable terms or at all. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Additional potential transactions that we may consider include a variety of different business arrangements, including spin-offs, strategic partnerships, joint ventures, restructurings, divestitures, business combinations and </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">33 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
investments. Any such transaction may require us to incur <span style="white-space:nowrap">non-recurring</span> or other charges, may increase our near and long-term expenditures and may pose significant integration challenges or disrupt our management or business, which could adversely affect our operations and financial results. For example, these transactions may entail numerous operational and financial risks, including: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">exposure to unknown liabilities; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">disruption of our business and diversion of our management&#8217;s time and attention in order to develop acquired products, product candidates or technologies; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">incurrence of substantial debt or dilutive issuances of equity securities to pay for acquisitions; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">higher than expected acquisition and integration costs; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">write-downs of assets or goodwill or impairment charges; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">increased amortization expenses; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">difficulty and cost in combining the operations and personnel of any acquired businesses with our operations and personnel; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">impairment of relationships with key suppliers or customers of any acquired businesses due to changes in management and ownership; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">inability to retain key employees of any acquired businesses. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The <span style="white-space:nowrap">in-licensing</span> and acquisition of these technologies is a competitive area, and a number of more established companies are also pursuing strategies to license or acquire product candidates or technologies that we may consider attractive. In addition, companies that perceive us to be a competitor may be unwilling to license rights to us. Furthermore, we may be unable to identify suitable product candidates or technologies within our area of focus. If we are unable to successfully obtain rights to suitable product candidates or technologies undertake or to successfully complete any additional transactions of the nature described above, our business, financial condition and prospects could suffer. In addition, even if we are able to successfully complete any additional transactions of the nature described above, any additional transactions that we do complete could have a material adverse effect on our business, results of operations, financial condition, and prospects. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We must maintain quality controls and compliance with manufacturing standards. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The manufacture of our product candidates is, and the manufacture of any future drug and/or cell-related therapeutic products would be, subject to periodic inspection by regulatory authorities and distribution partners. The manufacture of drug and device products for human use is subject to regulation and inspection from time to time by the FDA for compliance with the FDA&#8217;s cGMP, Quality System Regulations (&#8220;QSRs&#8221;), as well as equivalent requirements and inspections by state and <span style="white-space:nowrap">non-U.S.</span> regulatory authorities. There can be no assurance that the FDA or other authorities will not, during the course of an inspection of existing or new facilities, identify what they consider to be deficiencies in our compliance with QSRs or other requirements and request, or seek remedial action. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Failure to comply with such regulations or a potential delay in attaining compliance may adversely affect our manufacturing activities and could result in, among other things, injunctions, civil penalties, FDA refusal to grant <span style="white-space:nowrap">pre-</span> market approvals or clearances of future or pending product submissions, fines, recalls or seizures of products, total or partial suspensions of production and criminal prosecution. There can be no assurance that after such occurrences that we will be able to obtain additional necessary regulatory approvals or clearances on a timely basis, if at all. Delays in receipt of or failure to receive such approvals or clearances, or the loss of previously received approvals or clearances could have a substantial negative effect on our results of operations and financial condition. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">34 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">If we are unable to identify, hire and/or retain key personnel, we may not be able to sustain or grow our business. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We maintain a small executive team. Our ability to operate successfully and manage our potential future growth depends significantly upon our ability to attract, retain, and motivate highly skilled and qualified research, technical, clinical, regulatory, sales, marketing, managerial and financial personnel. We compete for talent with numerous companies, as well as universities and <span style="white-space:nowrap">non-profit</span> research organizations. In the future, we may hire a significant number of scientists, quality and regulatory personnel, and other technical staff with the requisite expertise to support and expand our nanomedicine business. The manufacturing of our oncology drug assets is a highly complex process that requires significant experience and <span style="white-space:nowrap">know-how.</span> If we are unable to attract personnel with the necessary skills and experience to reestablish and expand our nanomedicine business, which is currently conducted out of our San Antonio, Texas facility, our business could suffer. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our future success also depends on the personal efforts and abilities of the principal members of our senior management and scientific staff to provide strategic direction, manage our operations, and maintain a cohesive and stable environment. In particular, we are highly dependent on our executive officers, especially Marc Hedrick, M.D., our Chief Executive Officer. Given his leadership, extensive technical, scientific, and financial expertise and management and operational experience, if we were unable to retain the services of Dr.&#160;Hedrick for any reason, it would materially and adversely impact our business and operations. Further, the loss of services of Dr.&#160;Hedrick or any other executive officer could result in product development delays or the failure of our collaborations with current and future collaborators, which, in turn, may hurt our ability to develop and commercialize products and generate revenue. We do not maintain key man life insurance on the lives of any of the members of our senior management. The loss of key personnel for any reason or our inability to hire, retain, and motivate additional qualified personnel in the future could prevent us from sustaining or growing our business. The loss of services of any of our personnel, including Dr.&#160;Hedrick, particularly for an extended period, would likely result in product development delays or the failure of our collaborations with current and future collaborators, which, in turn, may impede or delay our ability to develop and commercialize products and generate revenue. In addition, it could also result in difficulty to obtain additional funding for our development of products and our future operations. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We face potential product liability exposure, and if successful claims are brought against us, we may incur substantial liability if our insurance coverage for those claims is inadequate. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The clinical use of our product candidates exposes us to the risk of product liability claims. This risk exists even if a product or product candidate is approved for commercial sale by applicable regulatory authorities and manufactured in facilities regulated by such authorities. Our product candidates are designed to affect important bodily functions and processes. Any side effects, manufacturing defects, misuse, or abuse associated with our product candidates could result in injury to a patient or even death. For example, rhenium (<sup style="font-size:75%; vertical-align:top">186</sup>Re) obisbemeda and <sup style="font-size:75%; vertical-align:top">188</sup><span style="white-space:nowrap">RNL-BAM</span> are cytotoxic, or toxic to living cells, and, if incorrectly or defectively manufactured or labeled, or incorrectly dosed or otherwise used in a manner not contemplated by its label, could result in patient harm and even death. In addition, a liability claim may be brought against us even if our product candidates merely appear to have caused an injury. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Product liability claims may be brought against us by consumers, health care providers, pharmaceutical companies or others selling or otherwise coming into contact with our products or product candidates, if approved, among others. If we cannot successfully defend ourselves against product liability claims, we will incur substantial liabilities. In addition, regardless of merit or eventual outcome, product liability claims may result in: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the inability to commercialize our product candidates; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">decreased demand for our product candidates, if approved; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">impairment of our business reputation; </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">35 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">product recall or withdrawal from the market; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">withdrawal of clinical trial participants; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">costs of related litigation; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">distraction of management&#8217;s attention from our primary business; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">substantial monetary awards to patients or other claimants; or </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">loss of revenue. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have obtained product liability insurance coverage for clinical trials with a $10&#160;million per occurrence and annual aggregate coverage limit. Our insurance coverage may not be sufficient to cover all of our product liability related expenses or losses and may not cover us for any expenses or losses we may suffer. Moreover, insurance coverage is becoming increasingly expensive, and, in the future, we may not be able to maintain insurance coverage at a reasonable cost, in sufficient amounts or upon adequate terms to protect us against losses due to product liability. If we determine that it is prudent to increase our product liability coverage, we may be unable to obtain this increased product liability insurance on commercially reasonable terms or at all. Large judgments have been awarded in class action or individual lawsuits based on drugs that had unanticipated side effects. A successful product liability claim or series of claims brought against us could cause our stock price to decline and, if judgments exceed our insurance coverage, could decrease our cash and have a material adverse effect on our business, results of operations, financial condition and prospects. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">A failure to adequately protect private health information could result in severe harm to our reputation and subject us to significant liabilities, each of which could have a material adverse effect on our business. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Throughout the clinical trial process, we may obtain the private health information of our trial subjects. There are a number of state, federal and international laws protecting the privacy and security of health information and personal data. The Healthcare Information Portability and Accountability Act (&#8220;HIPAA&#8221;) imposes privacy, security, breach reporting obligations, and mandatory contractual terms on covered entity health care providers, health plans, and health care clearinghouses, as well as their &#8220;business associates&#8221; &#8211; certain persons or covered entities that create, receive, maintain, or transmit protected health information in connection with providing a specified service or performing a function on behalf of a covered entity. We could potentially be subject to criminal penalties if we, our affiliates, or our agents knowingly use or disclose individually identifiable health information maintained by a HIPAA-covered entity in a manner that is not authorized or permitted by HIPAA. Most states have laws requiring notification of affected individuals and state regulators (breach notification laws) in the event of a breach of personal information, which is a broader class of information than the health information protected by HIPAA. Many state laws impose significant data security requirements, such as encryption or mandatory contractual terms to ensure ongoing protection of personal information. Additionally, in California, the California Consumer Privacy Act (&#8220;CCPA&#8221;) establishes certain requirements for data use and sharing transparency and creates new data privacy rights for California residents. The CCPA and its implementing regulations have already been amended multiple times since their enactment. In November 2020, California voters approved the California Privacy Rights Act (&#8220;CPRA&#8221;) ballot initiative which introduced significant amendments to the CCPA and established and funded a dedicated California privacy regulator, the California Privacy Protection Agency. The amendments introduced by the CPRA went into effect on January&#160;1, 2023. Failure to comply with the CCPA may result in, among other things, significant civil penalties and injunctive relief, or statutory or actual damages. In addition, California residents have the right to bring a private right of action in connection with certain types of incidents. These claims may result in significant liability and damages. Activities outside of the U.S. implicate local and national data protection standards, impose additional compliance requirements and generate additional risks of enforcement for <span style="white-space:nowrap">non-compliance.</span> The European Union&#8217;s General Data Protection Regulation, which imposes fines of up to EUR 20&#160;million or 4% of the annual global revenue of a noncompliant company, whichever is greater, Canada&#8217;s Personal Information Protection and Electronic Documents Act and other data protection, privacy and similar national, state/provincial and local laws </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">36 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
may also restrict the access, use and disclosure of patient health information abroad. We may be required to expend significant capital and other resources to ensure ongoing compliance with applicable privacy and data security laws, to protect against security breaches and hackers, or to alleviate problems caused by such breaches. Compliance with these laws is difficult, constantly evolving, time consuming, and requires a flexible privacy framework and substantial resources. Compliance efforts will likely be an increasing and substantial cost in the future. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We and our collaborators must comply with environmental laws and regulations, including those pertaining to use of hazardous and biological materials in our business, and failure to comply with these laws and regulations could expose us to significant liabilities. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We and our collaborators are subject to various federal, state, and local environmental laws, rules and regulations, including those relating to discharge of materials into the air, water and ground, those relating to manufacturing, storage, use, transportation and disposal of hazardous and biological materials, and those relating to the health and safety of employees with respect to laboratory activities required for the development of our products and activities. In particular, our nanomedicine products and processes involve the controlled storage, use and disposal of certain cytotoxic, or toxic to living cells, materials. Even if we and these suppliers and collaborators comply with the standards prescribed by law and regulation, the risk of accidental contamination or injury from hazardous materials, or other violations of applicable environmental laws, rules or regulations cannot be completely eliminated. In the event of any violation of such laws, rules or regulations, we could be held liable for any damages that result, and any liability could exceed the limits or fall outside the coverage of any insurance we may obtain and could exceed our financial resources. We may not be able to maintain insurance on acceptable terms, or at all. We may incur significant costs in complying with environmental laws, rules and regulations. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We recently acquired the CNSide diagnostic portfolio, and we may not be successful in our efforts to develop, fully utilize and monetize it. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In April 2024, we completed the acquisition of substantially all of the right, title and interest in CNside (&#8220;CNside&#8221;), a proprietary cell enumeration test designed to detect, quantify, and monitor tumor status in LM. We are currently evaluating and developing our business plan for developing the CNside diagnostic portfolio alongside our lead radiotherapeutic candidate, rhenium (<sup style="font-size:75%; vertical-align:top">186</sup>Re) obisbemeda, and seeking partnering opportunities for CNside but there can be no assurances that we will be able to develop the technology to allow for commercial applications, or successfully utilize and fully integrate CNside into our operations. We may not generate revenues from or realize the anticipated benefits of CNside within our expected timeline or at all. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Risks Related to Our Intellectual Property </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Our success depends in part on our ability to protect our intellectual property. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our success depends in part on our ability to obtain and maintain patent, trademark, and trade secret protection of our platform technology and current product candidates, including but not limited to our nanomedicine product candidates, including rhenium (<sup style="font-size:75%; vertical-align:top">186</sup>Re) obisbemeda and <sup style="font-size:75%; vertical-align:top">188</sup><span style="white-space:nowrap">RNL-BAM,</span> as well as successfully defending our intellectual property against third-party challenges. Our ability to stop unauthorized third parties from making, using, selling, offering to sell, or importing our platform technology and/or our product candidates is dependent upon the extent to which we have rights under valid and enforceable patents or trade secrets that cover these activities. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The degree of future protection for our proprietary rights is uncertain because legal means afford only limited protection and may not adequately protect our rights or permit us to gain or keep our competitive advantage. For example: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">we, NanoTx, or UTHSA, as the case may be, might not have been the first to file patent applications for the covered inventions; </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">37 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">it is possible that our pending patent applications will not result in issued patents; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">it is possible that there are dominating patents to our product candidates of which we are not aware; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">it is possible that there are prior public disclosures that could invalidate our patents, of which we are not aware; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">it is possible that others may circumvent our patents; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">it is possible that there are unpublished applications or patent applications maintained in secrecy that may later issue with claims covering our product candidates or technology similar to ours; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the claims of our patents or patent applications, if and when issued, may not cover our system or products, or our system or product candidates; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our owned or <span style="white-space:nowrap">in-licensed</span> issued patents may not provide us with any competitive advantages, or may be narrowed in scope, be held invalid or unenforceable as a result of legal administrative challenges by third parties; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">others may be able to make or use compounds that are the same or similar to the rhenium (<sup style="font-size:75%; vertical-align:top">186</sup>Re) obisbemeda or <span style="white-space:nowrap">188RNL-BAM</span> product candidates but that are not covered by the claims of our patents; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">we may not be able to detect infringement against our patents, which may be especially difficult for manufacturing processes or formulation patents, such as the patents/applications related to rhenium (<sup style="font-size:75%; vertical-align:top">186</sup>Re) obisbemeda or 188 <span style="white-space:nowrap">RNL-BAM;</span> </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the API used in rhenium (<sup style="font-size:75%; vertical-align:top">186</sup>Re) obisbemeda, <span style="white-space:nowrap">186-Re,</span> is routinely produced in nuclear reactors or at a particle accelerator and is commercially available as <span style="white-space:nowrap">186-Re</span> Sulfide for isotropic radiation synovectomy of medium sized joints and in developing countries as <span style="white-space:nowrap"><span style="white-space:nowrap">186-Re-HEDP</span></span> for bone pain palliation; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">we may not develop additional proprietary technologies for which we can obtain patent protection; or </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the patents of others may have an adverse effect on our business. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The patent positions of pharmaceutical, biopharmaceutical and medical device companies can be highly uncertain and involve complex legal and factual questions for which important legal principles remain unresolved. No consistent policy regarding the breadth of claims allowed in patents in these fields has emerged to date in the United States. There have been recent changes regarding how patent laws are interpreted, and both the USPTO and Congress have recently made significant changes to the patent system. There have been three U.S. Supreme Court decisions that now show a trend of the Supreme Court which is distinctly negative on patents. The trend of these decisions along with resulting changes in patentability requirements being implemented by the USPTO could make it increasingly difficult for us to obtain and maintain patents on our product candidates. We cannot accurately predict future changes in the interpretation of patent laws or changes to patent laws which might be enacted into law. Those changes may materially affect our patents, our ability to obtain patents and/or the patents and applications of our collaborators and licensors. The patent situation in these fields outside the United States is even more uncertain. Changes in either the patent laws or in interpretations of patent laws in the United States and other countries may diminish the value of our intellectual property or narrow the scope of our patent protection. Accordingly, we cannot predict the breadth of claims that may be allowed or enforced in the patents we own or to which we have a license or third-party patents. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Intellectual property law outside the United States is uncertain and in many countries is currently undergoing review and revisions. The laws of some countries do not protect our patent and other intellectual property rights to the same extent as United States laws. Third parties may attempt to oppose the issuance of patents to us in foreign countries by initiating opposition proceedings. Opposition proceedings against any of our patent filings in a foreign country could have an adverse effect on our corresponding patents that are issued or pending in the United States. It may be necessary or useful for us to participate in proceedings to determine the validity of our patents or our competitors&#8217; patents that have been issued in countries other than the United States. This could result in substantial costs, divert our efforts and attention from other aspects of our business, and could have a material adverse effect on our results of operations and financial condition. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">38 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Failure to obtain or maintain patent protection or protect trade secrets, for any reason (or third-party claims against our patents, trade secrets, or proprietary rights, or our involvement in disputes over our patents, trade secrets, or proprietary rights, including involvement in litigation), could have a substantial negative effect on our results of operations and financial condition. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We may not be able to protect our trade secrets. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may rely on trade secrets to protect our technology, especially with respect to the nanomedicine products, as well as in areas where we do not believe patent protection is appropriate or obtainable. Trade secrets are difficult to protect, and we have limited control over the protection of trade secrets used by our collaborators and suppliers. Although we use reasonable efforts to protect our trade secrets, our employees, consultants, contractors, outside scientific collaborators, and other advisors may unintentionally or willfully disclose our information to competitors. Enforcing a claim that a third party illegally obtained and is using any of our trade secrets is expensive and time consuming, and the outcome is unpredictable. In addition, state laws in the Unites States vary, and their courts as well as courts outside the United States are sometimes less willing to protect trade secrets. Moreover, our competitors may independently develop equivalent knowledge, methods, and <span style="white-space:nowrap">know-how.</span> If our confidential or proprietary information is divulged to or acquired by third parties, including our competitors, our competitive position in the marketplace will be harmed and our ability to successfully penetrate our target markets could be severely compromised. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We may be subject to claims that our employees have wrongfully used or disclosed alleged trade secrets of their former employers. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As is common in the device, biotechnology and pharmaceutical industries, we employ individuals who were previously employed at other device, biotechnology or pharmaceutical companies, including our competitors or potential competitors. Although no claims against us are currently pending, we may be subject to claims that these employees or we have inadvertently or otherwise used or disclosed trade secrets or other proprietary information of their former employers. Litigation may be necessary to defend against these claims. Even if we are successful in defending against these claims, litigation could result in substantial costs and be a distraction to management, which would adversely affect our financial condition. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We may incur substantial costs as a result of litigation or other proceedings relating to patent and other intellectual property rights, and we may be unable to protect our rights to our product candidates and technology. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Litigation may be necessary to enforce or confirm the ownership of any patents issued or licensed to us, or to determine the scope and validity of third-party proprietary rights, which would result in substantial costs to us and diversion of effort on our part. If our competitors claim technology also claimed by us and prepare and file patent applications in the United States, we may have to participate in interference proceedings declared by the USPTO or a foreign patent office to determine priority of invention, which could result in substantial costs to and diversion of effort, even if the eventual outcome is favorable to us. Any such litigation or interference proceeding, regardless of outcome, could be expensive and time-consuming. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Successful challenges to our patents through oppositions, reexamination proceedings or interference proceedings could result in a loss of patent rights in the relevant jurisdiction. If we are unsuccessful in actions we bring against the patents of other parties, and it is determined that we infringe the patents of third-parties, we may be subject to litigation, prevented from commercializing potential products in the relevant jurisdiction and/or may be required to obtain licenses to those patents or develop or obtain alternative technologies, any of which could harm our business. Furthermore, if such challenges to our patent rights are not resolved in our favor, we could be delayed or prevented from entering into new collaborations or from commercializing certain products, which could adversely affect our business and results of operations. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">39 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Competitors or third parties may infringe on or upon our patents. We may be required to file patent infringement claims, which can be expensive and time-consuming. In addition, in an infringement proceeding, a court may decide that a patent of ours is not valid or is unenforceable or that the third party&#8217;s technology does not in fact infringe upon our patents. An adverse determination of any litigation or defense proceedings could put one or more of our patents at risk of being invalidated or interpreted narrowly and could put our related pending patent applications at risk of not issuing. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Litigation may fail and, even if successful, may result in substantial costs and be a distraction to our management. We may not be able to prevent misappropriation of our proprietary rights, particularly in countries outside the United States where patent rights may be more difficult to enforce. Further, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential or sensitive information could be compromised by disclosure in the event of litigation. In addition, during the course of litigation there could be public announcements of the results of hearings, motions or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Some of our competitors may be able to sustain the costs of complex patent litigation more effectively than we can because they have substantially greater resources. In addition, any uncertainties resulting from the initiation and continuation of any litigation could have a material adverse effect on our ability to raise the funds necessary to continue our operations or otherwise have a material adverse effect on our business, results of operations, financial condition, and prospects. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">If we are sued for infringing intellectual property rights of third parties, it will be costly and time consuming, and an unfavorable outcome in that litigation would have a material adverse effect on our business. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our commercial success will also depend, in part, on our ability to avoid infringing on patents issued by others. There may be issued patents of third parties of which we are currently unaware, that are infringed or are alleged to be infringed by our product candidate or proprietary technologies. Because some patent applications in the United States may be maintained in secrecy until the patents are issued, patent applications in the United States and many foreign jurisdictions are typically not published until eighteen months after filing, and publications in the scientific literature often lag behind actual discoveries, we cannot be certain that others have not filed patent applications for technology covered by our owned and <span style="white-space:nowrap">in-licensed</span> issued patents or our pending applications, or that we or, if applicable, a licensor were the first to invent the technology. Our competitors may have filed, and may in the future file, patent applications covering our product candidates or technology similar to ours. Any such patent application may have priority over our patent applications or patents, which could further require us to obtain rights to issued patents covering such technologies. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may be exposed to, or threatened with, future litigation by third parties having patent or other intellectual property rights alleging that our product candidates and/or proprietary technologies infringe their intellectual property rights. These lawsuits are costly and could adversely affect our results of operations and divert the attention of managerial and technical personnel. There is a risk that a court would decide that we or our commercialization partners are infringing the third party&#8217;s patents and would order us or our partners to stop the activities covered by the patents. In addition, there is a risk that a court will order us or our partners to pay the other party damages for having violated the other party&#8217;s patents. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If a third-party&#8217;s patent were found to cover our product candidates, proprietary technologies or their uses, we could be enjoined by a court and required to pay damages and could be unable to commercialize our product candidates or use our proprietary technologies unless we or they obtained a license to the patent. A license may not be available to us on acceptable terms, if at all. In addition, during litigation, the patent holder could obtain a preliminary injunction or other equitable relief which could prohibit us from making, using or selling our product candidates, technologies or methods pending a trial on the merits, which could be years away. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">40 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Risks Related to the Securities Markets and an Investment in our Common Stock </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Our stockholders may experience substantial dilution in the value of their investment if we issue additional shares of our capital stock, including in connection with the sale or issuance of our common stock to Lincoln Park and the sale of the shares of common stock acquired by Lincoln Park and the sale of our common stock by Canaccord. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our certificate of incorporation, as amended (the &#8220;Charter&#8221;) allows us to issue up to 100,000,000 shares of our common stock and to issue and designate the rights of, without stockholder approval, up to 5,000,000 shares of preferred stock. To raise additional capital, we may in the future sell additional shares of our common stock or other securities convertible into or exchangeable for our common stock at prices that are lower than the prices paid by existing stockholders, and investors purchasing shares or other securities in the future could have rights superior to existing stockholders, which could result in substantial dilution to the interests of existing stockholders. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On August&#160;2, 2022, we entered into the 2022 Purchase Agreement with Lincoln Park, pursuant to which Lincoln Park committed to purchase up to $50.0&#160;million (the &#8220;Commitment Amount&#8221;) of our common stock, subject to certain limitations. As consideration for Lincoln Park&#8217;s irrevocable commitment to purchase shares of our common stock upon the terms of and subject to satisfaction of the conditions set forth in the 2022 Purchase Agreement, upon execution of the 2022 Purchase Agreement, we agreed to pay Lincoln Park an initial commitment fee equal to 1.5% of the Commitment Amount. The initial commitment fee was paid upon execution of the 2022 Purchase Agreement through the issuance of 492,698 shares of common stock and $0.1&#160;million in cash. An additional commitment fee equal to 2.5% of the remainder of the Commitment Amount will be paid if and when we sell over $25.0&#160;million of our common stock under the 2022 Purchase Agreement. The additional commitment fee may be paid in cash, common stock, or a combination of cash and common stock. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The remaining shares of our common stock that may be issued under the 2022 Purchase Agreement may be sold by us to Lincoln Park at our discretion from time to time over a <span style="white-space:nowrap">36-month</span> period commencing August&#160;17, 2022, subject to satisfaction of certain conditions. The purchase price for the shares that we may sell to Lincoln Park under the 2022 Purchase Agreement will fluctuate based on the price of our common stock. Depending on market liquidity at the time, sales of such shares may cause the trading price of our common stock to fall. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If and when we do sell shares to Lincoln Park, after Lincoln Park has acquired the shares, Lincoln Park may resell all or some of those shares at any time or from time to time in its discretion. Therefore, sales to Lincoln Park by us could result in substantial dilution to the interests of other holders of our common stock. Additionally, the sale of a substantial number of shares of our common stock to Lincoln Park, or the anticipation of such sales, could make it more difficult for us to sell equity or equity-related securities in the future at a time and at a price that we might otherwise wish to effect sale. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Future sales of our common stock may depress our share price. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&#160;31, 2023, we had issued 4,522,656 shares of our common stock, of which 4,444,097 shares were outstanding. Sales of a number of shares of common stock in the public market could cause the market price of our common stock to decline. We may also sell additional common stock or securities convertible into or exercisable or exchangeable for common stock in subsequent public or private offerings or other transactions, which may adversely affect the market price of our common stock. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">The market price of our common stock may be volatile and fluctuate significantly, which could result in substantial losses for stockholders. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The market price of our common stock has been, and may continue to be, subject to significant fluctuations. Among the factors that may cause the market price of our common stock to fluctuate are the risks described in this &#8220;Risk Factors&#8221; section and other factors, including: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">fluctuations in our operating results or the operating results of our competitors; </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">41 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the outcome of clinical trials involving the use of our product candidates, including our sponsored trials; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">changes in estimates of our financial results or recommendations by securities analysts; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">variance in our financial performance from the expectations of securities analysts; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">changes in the estimates of the future size and growth rate of our markets; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">changes in accounting principles or changes in interpretations of existing principles, which could affect our financial results; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">conditions and trends in the markets we currently serve or which we intend to target with our product candidates; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">changes in general economic, industry and market conditions; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">success of competitive products and services; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">changes in market valuations or earnings of our competitors; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">announcements of significant new products, contracts, acquisitions or strategic alliances by us or our competitors; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our continuing ability to list our securities on an established market or exchange; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the timing and outcome of regulatory reviews and approvals of our product candidates; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the commencement or outcome of litigation involving our company, our general industry or both; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">changes in our capital structure, such as future issuances of securities or the incurrence of additional debt; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">actual or expected sales of our common stock by the holders of our common stock; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the trading volume of our common stock. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, the financial markets may experience a loss of investor confidence or otherwise experience continued volatility and deterioration. A loss of investor confidence may result in extreme price and volume fluctuations in our common stock that are unrelated or disproportionate to the operating performance of our business, our financial condition or results of operations, which may materially harm the market price of our common stock and result in substantial losses for stockholders. Further, although our common stock is traded on the Nasdaq, there is currently a limited market for our common stock and an active market may never develop. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We may be or become the target of securities litigation, which is costly and time-consuming to defend. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the past, following periods of market volatility in the price of a company&#8217;s securities, the reporting of unfavorable news or continued decline in a company&#8217;s stock price, security holders have often instituted class action litigation. The market value of our securities has steadily declined over the past several years for a variety of reasons discussed elsewhere in this &#8220;Risk Factors&#8221; section, which heightens our litigation risk. If we face such litigation, we could incur substantial legal costs and our management&#8217;s attention could be diverted from the operation of our business, causing our business to suffer. Any adverse determination in any such litigation or any amounts paid to settle any such actual or threatened litigation could require that we make significant payments. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We may issue debt and equity securities or securities convertible into equity securities, any of which may be senior to our common stock as to distributions and in liquidation, which could negatively affect the value of our common stock. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the future, we may attempt to increase our capital resources by entering into debt or debt-like financing that is unsecured or secured by up to all of our assets, or by issuing additional debt or equity securities, which could include issuances of secured or unsecured commercial paper, medium-term notes, senior notes, subordinated </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">42 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
notes, guarantees, preferred stock, hybrid securities, or securities convertible into or exchangeable for equity securities. In the event of our liquidation, our lenders and holders of our debt and preferred securities would receive distributions of our available assets before distributions to the holders of our common stock. Because our decision to incur debt and issue securities in future offerings may be influenced by market conditions and other factors beyond our control, we cannot predict or estimate the amount, timing or nature of our future offerings or debt financings. Further, market conditions could require us to accept less favorable terms for the issuance of our securities in the future. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Our Charter documents contain anti-takeover provisions. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain provisions of our Charter and amended and restated bylaws (the &#8220;Bylaws&#8221;) could discourage, delay or prevent a merger, acquisition or other change of control that stockholders may consider favorable. These provisions could also prevent or frustrate attempts by our stockholders to replace or remove members of our Board of Directors (the &#8220;Board&#8221;). Stockholders who wish to participate in these transactions may not have the opportunity to do so. These provisions: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">authorize our Board to issue without stockholder approval up to 5,000,000 shares of preferred stock, the rights of which will be determined at the discretion of the Board; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">require that stockholder actions must be effected at a duly called stockholder meeting and cannot be taken by written consent; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">establish advance notice requirements for stockholder nominations to our Board or for stockholder proposals that can be acted on at stockholder meetings; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">limit who may call stockholder meetings. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are governed by the provisions of Section&#160;203 of the Delaware General Corporation Law (&#8220;DGCL&#8221;), which may, unless certain criteria are met, prohibit large stockholders, in particular those owning 15% or more of the voting rights on our common stock, from merging or combining with us for a prescribed period of time. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We presently do not intend to pay cash dividends on our common stock. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have never paid cash dividends in the past, and we currently anticipate that no cash dividends will be paid on the common stock in the foreseeable future. This could make an investment in our common stock inappropriate for some investors, and may serve to narrow our potential sources of additional capital. While our dividend policy will be based on the operating results and capital needs of the business, it is anticipated that all earnings, if any, will be retained to finance the future expansion of our business. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">If securities and/or industry analysts fail to continue publishing research about our business, if they change their recommendations adversely, or if our results of operations do not meet their expectations, our stock price and trading volume could decline. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The trading market for our common stock may be influenced by the research and reports that industry or securities analysts publish about us or our business. If one or more of these analysts cease coverage of our company or fail to publish reports on us regularly, we could lose visibility in the financial markets, which in turn could cause our stock price or trading volume to decline. In addition, it is likely that in some future period our operating results will be below the expectations of securities analysts or investors. If one or more of the analysts who cover us downgrade our stock, or if our results of operations do not meet their expectations, our stock price could decline. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">43 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We may issue additional shares of common stock or other equity securities without our stockholder approval, and holders of warrants and other securities convertible into shares of our common stock may choose to exercise their warrants and other securities requiring us to issue shares of common stock; all of these actions would dilute your ownership interest and may depress the market price of our common stock. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In May 2024, we entered into the Purchase Agreement with the selling stockholders, and issued and sold in the May 2024 PIPE Financing: (i)&#160;an aggregate of 3,591,532 shares of common stock (or in lieu of shares of common stock, <span style="white-space:nowrap">Pre-Funded</span> Warrants), and (ii)&#160;Warrants to purchase up to 7,183,064 shares of common stock. If these Warrants are exercised, it will result in significant dilution to our stockholders. In the alternative, these Warrants may not be exercised, in which event we are likely to seek alternative sources of financing to continue the clinical development of our product candidates. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, outstanding securities convertible into our shares of common stock may be exercised and restricted stock units may vest resulting in the issuance of additional shares of common stock, which will result in further dilution to our stockholders. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Significant additional capital may be needed in the future to continue our planned operations, including further development of our product candidates, preparing IND or equivalent filings, conducting preclinical studies and clinical trials, commercialization efforts, expanded research and development activities and costs associated with operating a public company. To raise capital, we may sell common stock, convertible securities or other equity securities in one or more transactions at prices and in a manner we determine from time to time. If we sell common stock, convertible securities or other equity securities, investors may be materially diluted by subsequent sales. Such sales may also result in material dilution to our existing stockholders, and new investors could gain rights, preferences and privileges senior to the holders of our shares of common stock. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may also issue additional shares of common stock or other equity securities of equal or senior rank in the future in connection with, among other things, future acquisitions or repayment of outstanding indebtedness, without stockholder approval, in a number of circumstances. The issuance of additional shares or other equity securities of equal or senior rank would have the following effects: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">existing stockholders&#8217; proportionate ownership interest in us will decrease; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the relative voting strength of each previously outstanding common stock may be diminished; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the market price of the common stock may decline. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">General Risk Factors </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Increased information technology security threats and more sophisticated and targeted computer crime could pose a risk to our systems, networks, and products. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Increased global information technology security threats and more sophisticated and targeted computer crime pose a risk to the security of our systems and networks and the confidentiality, availability and integrity of our data and communications. While we attempt to mitigate these risks by employing a number of measures, including employee refreshers, monitoring of our networks and systems, and maintenance of backup and protective systems, our systems, networks and products remain potentially vulnerable to advanced persistent threats. Depending on their nature and scope, such threats could potentially lead to the compromising of confidential information and communications, improper use of our systems and networks, manipulation and destruction of data, defective products, production downtimes and operational disruptions, which in turn could adversely affect our reputation, competitiveness and results of operations. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">44 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="tx840996_7">USE OF PROCEEDS </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We will not receive any proceeds from any sale of shares of our common stock by the selling stockholders or their permitted transferees. All proceeds from the sale of shares of common stock will be for the accounts of the selling stockholders or their permitted transferees. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We will receive approximately $12.0&#160;million from the exercise of all of the Common Warrants and <span style="white-space:nowrap">Pre-Funded</span> Warrants, assuming the exercise in full of all such warrants for cash. To the extent we receive proceeds from the cash exercise of the <span style="text-decoration:underline">Warrants</span>, we intend to use the proceeds for general corporate purposes. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our expected use of proceeds described above represents our current intentions based on our present plans and business condition. The amounts and timing of our actual expenditures will depend on numerous factors, including the time and cost necessary to conduct our planned clinical trials, the results of our planned clinical trials and other factors described in &#8220;<span style="text-decoration:underline"><a href="#tx840996_6">Risk Factors</a></span>&#8221; in this prospectus, as well as the amount of cash used in our operations and any unforeseen cash needs. </p> <p style="font-size:24pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="tx840996_8">MARKET INFORMATION FOR COMMON STOCK </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our common stock is listed on Nasdaq under the symbols &#8220;PSTV&#8221;. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of June&#160;7, 2024, there were outstanding 5,704,219 shares of our common stock, net of treasury shares, held of record by 4 holders. The actual number of stockholders of our common stock is greater than the number of record holders and includes stockholders whose common stock are held in street name by brokers and other nominees. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On June&#160;6, 2024, the closing sale price of our common stock was $2.48 per share. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">45 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="tx840996_9">DIVIDEND POLICY </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have never declared or paid any cash dividends on our capital stock. We currently intend to retain future earnings, if any, to finance the operation of our business and do not anticipate paying any cash dividends on our capital stock in the foreseeable future. Any future determination related to our dividend policy will be made at the discretion of our Board after considering our financial condition, results of operations, current and anticipated capital requirements, business prospects, and other factors our Board deems relevant, and subject to applicable laws and the restrictions contained in any future financing instruments. </p> <p style="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="tx840996_10">MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">You should read the following discussion and analysis of our financial condition and results of operations together with our audited and unaudited consolidated financial statements and related notes appearing elsewhere in this prospectus. This discussion contains forward-looking statements based upon current expectations that involve risks and uncertainties. Our actual results may differ materially from those anticipated in these forward-looking statements as a result of various factors, including those set forth under the sections titled &#8220;<span style="text-decoration:underline"><a href="#tx840996_2">Cautionary Note Regarding Forward-Looking Statements</a></span>&#8221; and &#8220;Risk Factors&#8221; or in other parts of this prospectus. Our historical results are not necessarily indicative of the results that may be expected for any period in the future. </span></p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Overview </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Plus Therapeutics is a U.S. pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for CNS cancers. Our novel radioactive drug formulations and therapeutic candidates are designed to deliver safe and effective doses of radiation to tumors. To achieve this, we have developed innovative approaches to drug formulation, including encapsulating radionuclides such as rhenium isotopes with nanoliposomes and microspheres. Our formulations are intended to achieve elevated patient absorbed radiation doses and extend retention times such that the clearance of the isotope occurs after significant and essentially complete radiation decay, which will contribute and provide less normal tissue/organ exposure and improved safety margins.</p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Traditional approaches to radiation therapy for cancer, such as external beam radiation, have many disadvantages including continuous treatment for four to six weeks (which is onerous for patients), that the radiation damages healthy cells and tissue, and that the amount of radiation delivered is very limited and, therefore, is frequently inadequate to fully destroy the cancer. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our targeted radiotherapeutic platform and unique investigational drugs have the potential to overcome these disadvantages by directing higher, more powerful radiation doses at the tumor&#8212;and only the tumor&#8212;potentially in a single treatment. By minimizing radiation exposure to healthy tissues while simultaneously maximizing locoregional delivery and, thereby, efficacy, we hope to reduce the radiation toxicity for patients, improving their quality of life and life expectancy. Our radiotherapeutic platform, combined with advances in surgery, nuclear medicine, interventional radiology, and radiation oncology, affords us the opportunity to target a broad variety of cancer types. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our lead radiotherapeutic candidate, rhenium (<sup style="font-size:75%; vertical-align:top">186</sup>Re) obisbemeda, is designed specifically for CNS cancers including GBM, LM, and PBC by direct localized delivery utilizing approved <span style="white-space:nowrap"><span style="white-space:nowrap">standard-of-care</span></span> tissue access such as with CED and intraventricular brain (Ommaya reservoir) catheters. Our acquired radiotherapeutic candidate, <sup style="font-size:75%; vertical-align:top">188</sup><span style="white-space:nowrap">RNL-BAM</span> is designed to treat many solid organ cancers including primary and secondary liver cancers by intra-arterial injection. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">46 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our headquarters and manufacturing facilities are in Texas and are in proximity to world-class cancer institutions and researchers. Our dedicated team of engineers, physicians, scientists, and other professionals are committed to advancing our targeted radiotherapeutic technology for the benefit of cancer patients and healthcare providers worldwide and our current pipeline is focused on treating rare and <span style="white-space:nowrap"><span style="white-space:nowrap">difficult-to-treat</span></span> cancers with significant unmet medical needs. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition to our headquarters in Austin, we have an established, good manufacturing practice validated research and development and manufacturing facility in San Antonio, Texas, tailored to produce cGMP rhenium (<sup style="font-size:75%; vertical-align:top">186</sup>Re) obisbemeda. We have built a robust supply chain through strategic partnerships that enable the development, manufacturing and future potential commercialization of our products. Our current supply chain and key partners are positioned to supply cGMP rhenium (<sup style="font-size:75%; vertical-align:top">186</sup>Re) obisbemeda for ongoing and planned Phase 2 and Phase 3 clinical trials in patients with GBM, LM and PBC. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Recent Developments </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Repayment of Oxford Term Loan and Use of Pershing Credit Facility </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On May&#160;29, 2015, we entered into a Loan and Security Agreement, that was subsequently amended, with Oxford Finance, LLC (&#8220;Oxford&#8221;) (the &#8220;Oxford Term Loan&#8221;). On June&#160;3, 2024, following the drawing of $3.3&#160;million on the Pershing Credit Facility on May&#160;31, 2024, we repaid the Oxford Term Loan in full, a payment amount that totaled approximately $3.3&#160;million, which included both the balance of outstanding principal and interest and the final payment fee due. The repayment in full of the Oxford Term Loan terminated Oxford&#8217;s security interest in our existing and after-acquired assets, as well as all other certain restrictions and covenants under the Oxford Term Loan. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our existing Pershing Credit Facility is a margin loan facility under a line of credit with Pershing, an affiliate of The Bank of New York Mellon Corporation. The available credit line limit under this facility fluctuates based on our request for extensions from time to time, subject to the value of the collateralized marketable securities we hold with Pershing, provided that the amount available to draw under the facility cannot exceed 91.5% of the value of the collateralized marketable securities deposited with Pershing. Depending on the value of the marketable securities we hold with Pershing, Pershing may require us from <span style="white-space:nowrap"><span style="white-space:nowrap">time-to-time</span></span> to deposit additional funds or marketable securities in order to restore the level of collateral to an acceptable level. The amounts borrowed under the Pershing Credit Facility are due on demand. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Borrowings under the Pershing Credit Facility bear interest at the target interest rate set by the Federal Open Market Committee, subject to a floor of 5.5%, plus a spread of 1.75% and applicable fees of 0.5%, subject to a maximum interest rate of the then applicable Prime Rate as published in The Wall Street Journal plus 3.0%. Interest payments thereunder are calculated on a monthly basis and, unless paid, are added to the outstanding balance under the Pershing Credit Facility. The proceeds under the Pershing Credit Facility are available for working capital needs and other general corporate purposes. Volatility in the global markets could cause the interest rate to fluctuate from time to time increasing our costs, or could cause Pershing to terminate our ability to borrow funds. In addition, borrowings under the Pershing Credit Facility have the effect of limiting our use of cash and marketable securities. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">May 2024 PIPE Financing </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In May 2024, we entered into the Purchase Agreement with the selling stockholders pursuant to which we agreed to sell and issue in a private placement pursuant to the exemption in Section&#160;4(a)(2) of the&#160;Securities Act&#160;for an aggregate of 10,774,596 shares of common stock for an aggregate purchase price of approximately $19.25&#160;million. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">47 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Biocept Asset Purchase </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On April&#160;26, 2024, we acquired from Biocept, for a total cash payment of $400,000, substantially all of the right, title and interest in CNside, including (i)&#160;intellectual property, (ii)&#160;inventory and raw materials, and (ii)&#160;data, information, results and reports pertaining to the completed and <span style="white-space:nowrap">on-going</span> clinical studies involving the use of the CNside test (including, but not limited to, the FOERSEE clinical study that was being conducted by Biocept), related to the development, making, selling, and exporting or importing of CNside, after having its bid accepted by the United States Bankruptcy Court for the District of Delaware. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are currently evaluating and developing our business plan for developing the CNside diagnostic portfolio alongside our lead radiotherapeutic candidate, rhenium (<sup style="font-size:75%; vertical-align:top">186</sup>Re) obisbemeda, and seeking partnering opportunities for CNside. In May 2024, we presented topline clinical trial data from the FORESEE trial, which met its primary endpoint of clinical utility for the CNside test in 40 patients with LM due to either breast or <span style="white-space:nowrap">non-small</span> cell lung cancer; a presentation of the full analysis is planned for the August&#160;8 through 10 SNO/ASCO Meeting in Denver, Colorado. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Department of Defense Grant </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On April&#160;22, 2024, we were selected by the Department of Defense (DoD) office of the Congressionally Directed Medical Research Programs (CDMRP) to receive a $3&#160;million fund for research and development purposes (&#8220;DoD Award&#8221;). Transfers of funds under the DoD Award are expected to commence in the third quarter of 2024, pending execution of formal agreements, in order to support the planned expansion of our clinical trial for pediatric brain cancer. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Financial Overview </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Operating Expenses </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Research and Development Expenses </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Research and development expenses consist of costs associated with the design, development, testing, and enhancement of our product candidates, payment of regulatory fees, laboratory supplies, <span style="white-space:nowrap">pre-clinical</span> studies, and clinical studies. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The successful development of our product candidates is highly uncertain. We plan to substantially increase our research and development expenses for the foreseeable future as we continue the development of our product candidates, conducts discovery and research activities for our preclinical programs. We cannot determine with certainty the timing of initiation, the duration or the completion costs of current or future preclinical studies and clinical trials of our product candidates due to the inherently unpredictable nature of preclinical and clinical development. Clinical and preclinical development timelines, the probability of success and development costs can differ materially from expectations. We anticipate that we will make determinations as to which product candidates to pursue and how much funding to direct to each product candidate on an ongoing basis in response to the results of ongoing and future preclinical studies and clinical trials, regulatory developments and our ongoing assessments as to each product candidate&#8217;s commercial potential. Our clinical development costs are expected to increase significantly as we commence clinical trials. We anticipate that our expenses will increase substantially, particularly due to the numerous risks and uncertainties associated with developing product candidates, including the uncertainty of: </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">the scope, rate of progress, and expenses of our ongoing research activities as well as any preclinical studies, clinical trials and other research and development activities; </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">establishing an appropriate safety profile with IND enabling studies; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">successful enrollment in and completion of clinical trials; </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">48 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">successful enrollment in and completion of clinical trials; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">whether our product candidates show safety and efficacy in our clinical trials; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">receipt of marketing approvals from applicable regulatory authorities; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">making arrangements with third-party manufacturers; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">obtaining and maintaining patent and trade secret protection and regulatory exclusivity for our product candidates; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">commercializing product candidates, if and when approved, whether alone or in collaboration with others; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">continued acceptable safety profile of products following any regulatory approval. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any changes in the outcome of any of these variables with respect to the development of our product candidates in preclinical and clinical development could mean a significant change in the costs and timing associated with the development of these product candidates. We may never succeed in achieving regulatory approval for any of our product candidates. We may obtain unexpected results from our clinical trials. We may elect to discontinue, delay or modify clinical trials of some product candidates or focus on other product candidates. For example, if the U.S. FDA, EMA, or another regulatory authority were to delay the planned start of clinical trials or require us to conduct clinical trials or other testing beyond those that we currently expect or if we experience significant delays in enrollment in any planned clinical trial, we could be required to expend significant additional financial resources and time on the completion of clinical development of that product candidate. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">General and Administrative Expenses </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">General and administrative expenses consist primarily of administrative personnel, legal and other professional expenses, and general corporate expenses. General and administrative expenses also include facility costs not otherwise included in research and development expenses. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We anticipate that our general and administrative expenses will increase in the future as we increase our headcount to support our continued research activities and development of our product candidates. We also anticipate that we will incur significantly increased accounting, audit, legal, regulatory, compliance and director and officer insurance costs as well as investor and public relations expenses associated with operating as a public company. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Results of Operations </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Comparison of the Three Months Ended March&#160;31, 2024 and 2023 </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Grant Revenue </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We recognized $1.7&#160;million and $0.5&#160;million of grant revenue during the three months ended March&#160;31, 2024 and 2023, respectively, which represents CPRIT&#8217;s share of the costs incurred for our rhenium (<sup style="font-size:75%; vertical-align:top">186</sup>Re) obisbemeda development for the treatment of patients with LM. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Research and development expenses </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Research and development expenses include costs associated with the design, development, testing, and enhancement of our product candidates, payment of regulatory fees, laboratory supplies, <span style="white-space:nowrap">pre-clinical</span> studies, and clinical studies. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">49 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table summarizes the components of our research and development expenses for the three months ended March&#160;31, 2024 and 2023 (in thousands): </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">


<tr>

<td style="width:78%"/>

<td style="vertical-align:bottom;width:5%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:5%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="6" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Three&#160;Months&#160;Ended</span><br/><span style="font-weight:bold">March&#160;31,</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">2024</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">2023</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,746</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,963</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Share-based compensation</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">17</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">20</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total research and development expenses</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,763</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,983</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td></tr>
</table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Research and development expenses decreased by approximately $0.2&#160;million during the three months ended March&#160;31, 2024 as compared to the same period in 2023. The decrease was due primarily to a reduction of $0.8&#160;million of licenses fee to NanoTx, offset by an increase of approximately $0.3&#160;million in clinical expenses related to the <span style="white-space:nowrap">ReSPECT-LM</span> trial, and an increase of approximately $0.2&#160;million of professional research and development service fees. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We expect aggregate research and development expenses to largely remain consistent during the remainder of 2024 as compared to the corresponding comparable period ended December&#160;31, 2023. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">General and administrative expenses </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">General and administrative expenses include costs for administrative personnel, legal and other professional expenses, and general corporate expenses. The following table summarizes the general and administrative expenses for the three months ended March&#160;31, 2024 and 2023 (in thousands): </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">


<tr>

<td style="width:78%"/>

<td style="vertical-align:bottom;width:5%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:5%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="6" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Three&#160;Months&#160;Ended</span><br/><span style="font-weight:bold">March&#160;31,</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">2024</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">2023</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,084</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,125</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Share-based compensation</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">129</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">120</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total general and administrative expenses</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,213</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,245</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td></tr>
</table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">General and administrative expenses remained consistent during the three months ended March&#160;31, 2024, as compared to the same period in 2023. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We expect general and administrative expenditures to remain generally consistent during the remainder of 2024 as compared with the corresponding comparable period ended December&#160;31, 2023. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Stock-based compensation expense </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Stock-based compensation expense includes charges related to stock options issued to employees, directors and <span style="white-space:nowrap">non-employees.</span> We measure stock-based compensation expense based on the grant-date fair value of any awards granted to our employees. Such expense is recognized over the requisite service period. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table summarizes the components of our stock-based compensation expenses for the three months ended March&#160;31, 2024 and 2023 (in thousands): </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">


<tr>

<td style="width:78%"/>

<td style="vertical-align:bottom;width:7%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:7%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="6" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Three&#160;Months&#160;Ended<br/>March&#160;31,</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">2024</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">2023</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">17</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">20</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">129</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">120</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total share-based compensation</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">146</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">140</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td></tr>
</table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">50 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our share-based compensation expenses, which are impacted by grants of share-based options, vesting schedule of such grants, as well as grant-date fair value of share-based awards, remained consistent for the three months ended March&#160;31, 2024 and 2023. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Financing items </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table summarizes interest income, interest expense, and other income and expense for the three months ended March&#160;31, 2024 and 2023 (in thousands): </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">


<tr>

<td style="width:79%"/>

<td style="vertical-align:bottom;width:8%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:8%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="6" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Three&#160;Months&#160;Ended<br/>March&#160;31,</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">2024</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">2023</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest income</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">72</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">51</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest expense</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(34</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(134</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">38</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(83</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td></tr>
</table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The decrease in interest expense for the three months ended March&#160;31, 2024 as compared to the same period in 2023 was primarily due to the repayment of debt principal of $1.6&#160;million during the year ended December&#160;31, 2023. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We expect interest expense in 2024 to decrease as compared with 2023 due to scheduled debt payoff by June&#160;1, 2024. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Comparison of the Years Ended December&#160;31, 2023 and 2022 </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Grant Revenue </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On September&#160;19, 2022, we entered into the CPRIT Contract, effective as of August&#160;31, 2022, with CPRIT, pursuant to which CPRIT will provide us the CPRIT Grant of up to $17.6&#160;million over a three-year period to fund the continued development of rhenium (<sup style="font-size:75%; vertical-align:top">186</sup>Re) obisbemeda for the treatment of patients with LM through Phase 2 of the ReSPECT LM clinical trial. The CPRIT Grant is subject to customary CPRIT funding conditions, including, but not limited to, a matching fund requirement (one dollar from us for every two dollars awarded by CPRIT), revenue sharing obligations upon commercialization of rhenium (<sup style="font-size:75%; vertical-align:top">186</sup>Re) obisbemeda based on specific dollar thresholds until CPRIT receives the aggregate amount of 400% of the proceeds awarded under the CPRIT Grant, and certain reporting requirements. We received $7.1&#160;million of the available funding under the CPRIT Grant during 2022 and 2023, of which we recognized $4.9&#160;million and $0.2&#160;million of grant revenue during the years ended December&#160;31, 2023 and 2022, respectively. The amounts recognized represents CPRIT&#8217;s share of the costs incurred for our rhenium (186Re) obisbemeda development for the treatment of patients with LM. As of December&#160;31, 2023, we had $1.9&#160;million of deferred revenue related to the CPRIT Grant. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We expect grant revenue will increase during 2024 and the remaining term of the CPRIT Grant through August 2025, as we continue to expand the LM clinical trial to add clinical sites and enroll patients. The ability to continue to access the grant remains subject to additional FDA approval of the LM clinical trial, ability to deliver expanded drug supply and continued enrollment of patients. In addition, grant revenue amounts will vary quarter to quarter based on enrollment, mandated safety periods between cohorts and required interactions with FDA. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Research and development expenses </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Research and development expenses include costs associated with the design, development, testing, and enhancement of our product candidates, payment of regulatory fees, laboratory supplies, <span style="white-space:nowrap">pre-clinical</span> studies, and clinical studies. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">51 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table summarizes the components of our research and development expenses for the years ended December&#160;31, 2023 and 2022 (in thousands): </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">


<tr>

<td style="width:78%"/>

<td style="vertical-align:bottom;width:5%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:5%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="6" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Years&#160;ended</span><br/><span style="font-weight:bold">December&#160;31,</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">2023</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">2022</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">9,624</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">9,611</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Share-based compensation</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">66</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">87</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total research and development expenses</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">9,690</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">9,698</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td></tr>
</table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Research and development expenses for the year ended December&#160;31, 2023 remained consistent with the same period in 2022, due to a decrease of $3.4&#160;million in development of cGMP rhenium (<sup style="font-size:75%; vertical-align:top">186</sup>Re) obisbemeda, a decrease of $1.9&#160;million of professional and legal expenses, offset by a license agreement payment of $1.7&#160;million to NanoTx Corp., from which we licensed our rhenium (<sup style="font-size:75%; vertical-align:top">186</sup>Re) obisbemeda technology, resulting from the first patient treated in the GBM phase 2 trial and obligation to pay NanoTx 15% of CPRIT grant proceeds received (See Note 6 of the accompanying financial statements for more information), $3.0&#160;million from treatment of patients for LM clinical trial in 2023, and $0.6&#160;million increase of payroll expenses. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We expect aggregate research and development expenditures to increase significantly during 2024 as compared to the corresponding comparable period ended December&#160;31, 2023, due to increased costs for the <span style="font-style:italic"><span style="white-space:nowrap">ReSPECT-LM</span> </span>clinical trial (for which CPRIT grant funding is available), increases in licensing payments, offset by reduced research and development spend on the cGMP development. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="text-decoration:underline">General and administrative expenses </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">General and administrative expenses include costs for administrative personnel, legal and other professional expenses, and general corporate expenses. The following table summarizes the general and administrative expenses for the years ended December&#160;31, 2023 and 2022 (in thousands): </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">


<tr>

<td style="width:76%"/>

<td style="vertical-align:bottom;width:5%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:5%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="6" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Years ended<br/>December&#160;31,</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">2023</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">2022</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">8,041</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">9,719</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Share-based compensation</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">503</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">519</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total general and administrative expenses</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">8,544</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">10,238</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td></tr>
</table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">General and administrative expenses decreased by approximately $1.7&#160;million during the year ended December&#160;31, 2023, as compared to the same period in 2022. The decrease was due primarily to a net decrease of legal and professional expenses of $1.9&#160;million from expenditure incurred in 2022 related to litigation that was settled in the fourth quarter of 2022, offset by an increase of $0.1&#160;million in personnel and related expenses, and an increase of $0.1&#160;million in travel, insurance and other expenses. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We expect general and administrative expenditures to remain generally consistent during 2024 as compared with the corresponding comparable period ended December&#160;31, 2023. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="text-decoration:underline">Share-based compensation expenses </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Share-based compensation expenses include charges related to options and restricted stock awards issued to employees, directors and <span style="white-space:nowrap">non-employees.</span> We measure share-based compensation expenses based on the grant-date fair value of any awards granted to our employees. Such expense is recognized over the requisite service period. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">52 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table summarizes the components of our share-based compensation expenses for the years ended December&#160;31, 2023 and 2022 (in thousands): </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">


<tr>

<td style="width:82%"/>

<td style="vertical-align:bottom;width:5%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:5%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="6" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Years ended<br/>December&#160;31,</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">2023</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">2022</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">66</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">87</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">503</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">519</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total share-based compensation</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">569</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">606</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td></tr>
</table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our stock-based compensation expenses, which are impacted by grants of stock-based options, vesting schedule of such grants, as well as grant-date fair value of stock-based awards, remained consistent for the year ended December&#160;31, 2023 and 2022. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="text-decoration:underline">Other Income (Expense) </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table summarizes interest income, interest expense, and other income and expense for the years ended December&#160;31, 2023 and 2022 (in thousands): </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">


<tr>

<td style="width:79%"/>

<td style="vertical-align:bottom;width:6%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:6%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="6" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Years ended<br/>December&#160;31,</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">2023</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">2022</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest income</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">400</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">147</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest expense</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(395</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(711</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value of liability instruments</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">5</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(563</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td></tr>
</table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The decrease in interest expense for the year ended December&#160;31, 2023 as compared to the same period in 2022 was primarily due to reduced debt principal as the Company continued to pay down its term loan. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Liquidity and Capital Resources </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Short-term and long-term liquidity </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following is a summary of our key liquidity measures at March&#160;31, 2024 and December&#160;31, 2023 (in thousands): </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">


<tr>

<td style="width:59%"/>

<td style="vertical-align:bottom;width:14%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:14%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">March&#160;31,&#160;2024</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">December&#160;31,&#160;2023</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,901</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">8,554</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current assets</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">4,213</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">9,834</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current liabilities</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">10,399</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">10,727</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Working capital</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(6,186</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(893</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td></tr>
</table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We incurred net losses of $3.3&#160;million for the three months ended March&#160;31, 2024. We have an accumulated deficit of $483.8&#160;million as of March&#160;31, 2024. Additionally, we used net cash of $4.5&#160;million to fund our operating activities for the three months ended March&#160;31, 2024. These factors raise substantial doubt about our ability to continue as a going concern. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">May 2024 PIPE Financing </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In May 2024, we entered into the Purchase Agreement with the selling stockholders whereby we issued and sold in a private placement: (i) 3,591,532 shares of common stock (&#8220;Private Placement Shares&#8221;), or, at the election of </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">53 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
each Purchaser, <span style="white-space:nowrap">Pre-Funded</span> Warrants exercisable immediately to purchase shares of common stock. Each Private Placement Share or <span style="white-space:nowrap">Pre-Funded</span> Warrant are accompanied by (i)&#160;Series A Common Stock Warrants to purchase one share of common stock, for an aggregate of 3,591,532 Series A Common Stock Warrants, and (ii)&#160;one Series B Common Warrants to purchase one share of common stock, for an aggregate of 3,591,532 Series B Common Warrants. At the closing of the May 2024 PIPE Financing, we received aggregate upfront gross proceeds of approximately $7.25&#160;million, before deducting fees and other expenses associated with the closing of the May 2024 PIPE Financing. If the Warrants are exercised in full we will receive additional gross proceeds of approximately $12.0&#160;million. None of the Warrants issued in the May 2024 PIPE Financing have been exercised as of the filing of this report. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">CPRIT Grant </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On September&#160;19, 2022, we entered into the CPRIT Contract, pursuant to which CPRIT will provide us with the CPRIT Grant of $17.6&#160;million subject to the terms of the CPRIT Contract, to fund approximately <span style="white-space:nowrap">two-thirds</span> of the continued development of rhenium (<sup style="font-size:75%; vertical-align:top">186</sup>Re) obisbemeda for the treatment of patients with LM. We received $7.1&#160;million of the available funding under the CPRIT Grant during 2022, 2023 and the three months ended March&#160;31, 2024, of which we recognized $1.7&#160;million, $4.9&#160;million and $0.2&#160;million of grant revenue during the three months ended March&#160;31, 2024, and the years ended December&#160;31, 2023 and 2022, respectively. The amounts recognized represents CPRIT&#8217;s share of the costs incurred for our rhenium (186Re) obisbemeda development for the treatment of patients with LM. As of March&#160;31, 2024, we had $0.2&#160;million of deferred revenue related to the CPRIT Grant. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Private Equity Lines </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On September&#160;9, 2022, we entered into an Equity Distribution Agreement (the &#8220;September 2022 Distribution Agreement&#8221;) with Canaccord Genuity LLC (&#8220;Canaccord&#8221;), pursuant to which we could issue and sell, from time to time, shares of our common stock in <span style="white-space:nowrap"><span style="white-space:nowrap">&#8220;at-the-market&#8221;</span></span> offerings, having an aggregate offering price of up to $5,000,000, depending on market demand, with Canaccord acting as an agent for sales. During the period from September&#160;9, 2022 to December&#160;31, 2023, we issued 68,758 shares under the September 2022 Distribution Agreement for net proceeds of approximately $0.6&#160;million. From January&#160;1, 2023 through December&#160;31, 2023, we issued 1,819,993 shares under the September 2022 Distribution Agreement for net proceeds of approximately $4.3&#160;million. We have reached the capacity for sales of our shares under the September 2022 Distribution Agreement. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On August&#160;2, 2022, we entered into the 2022 Purchase Agreement and registration rights agreement pursuant to which Lincoln Park Lincoln Park committed to purchase up to $50.0&#160;million of shares of our common stock. Under the terms and subject to the conditions of the 2022 Purchase Agreement, we have the right, but not the obligation, to sell to Lincoln Park, and Lincoln Park is obligated to purchase up to $50.0&#160;million of shares of our common stock, provided that we cannot sell more than 57.5&#160;million shares pursuant to the 2022 Purchase Agreement. Sales of common stock by us are subject to certain limitations, and can occur from time to time, at our sole discretion, over the <span style="white-space:nowrap">36-month</span> period commencing on August&#160;17, 2022, subject to the satisfaction of certain conditions. Actual sales of shares of common stock to Lincoln Park under the 2022 Purchase Agreement depend on a variety of factors to be determined by us from time to time, including, among others, market conditions, the trading price of the common stock and our determinations as to the appropriate sources of funding for the Company and its operations. As consideration for Lincoln Park&#8217;s irrevocable commitment to purchase shares of our common stock upon the terms of and subject to satisfaction of the conditions set forth in the 2022 Purchase Agreement, we paid $0.1&#160;million in cash as an Initial Commitment Fee and issued 32,846 as the initial commitment shares to Lincoln Park in consideration for its commitment to purchase shares of our common stock at our direction under the 2022 Purchase Agreement. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On August&#160;17, 2022, the First Registration Statement was declared effective covering the resale of up to 633,333 shares of our common stock comprised of (i)&#160;the 32,846 initial commitment shares, and (ii)&#160;up to 600,486 shares </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">54 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
that we have reserved for issuance and sale to Lincoln Park under the 2022 Purchase Agreement. An additional commitment fee equal to 2.5% of the remainder of the $50&#160;million will be paid if and when we sell over $25.0&#160;million of our common stock under the 2022 Purchase Agreement. The additional commitment fee may be paid in cash, common stock, or a combination thereof. We sold approximately 527,166 shares under the First Registration Statement. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On August&#160;18, 2023, the Second Registration Statement was declared effective covering the resale of up to an additional 1,500,000 shares of our common stock that we reserved for issuance and sale to Lincoln Park under the 2022 Purchase Agreement from time to time. We sold 150,000 shares under the Second Registration Statement. We cannot sell more shares than registered under the Second Registration Statement under the 2022 Purchase Agreement without registering additional shares. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">During the period from August&#160;17, 2022 to December&#160;31, 2022, we issued 266,666 shares under the 2022 Purchase Agreement for net proceeds of approximately $3.2&#160;million. We issued 410,500 shares under the 2022 Purchase Agreement for net proceeds of approximately $1.0&#160;million from January&#160;1, 2023 to December&#160;31, 2023. No shares of common stock was purchased under the 2022 Purchase Agreement during the three months ended March&#160;31, 2024. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On January&#160;14, 2022, we entered into an Equity Distribution Agreement (the &#8220;January 2022 Distribution Agreement&#8221;) with Canaccord, pursuant to which we could issue and sell, from time to time, shares of our common stock in <span style="white-space:nowrap"><span style="white-space:nowrap">&#8220;at-the-market&#8221;</span></span> offerings, having an aggregate offering price of up to $5,000,000, depending on market demand, with Canaccord acting as an agent for sales. During the year ended December&#160;31, 2023, we issued 460,151 shares under the January 2022 Distribution Agreement for net proceeds of approximately $4.8&#160;million. The January 2022 Distribution Agreement was terminated after all available registered shares were fully utilized. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Nasdaq Listing Compliance </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On March&#160;8, 2024, we received the Notice from the Nasdaq Staff, notifying us that we no longer complied with the requirement under Nasdaq Listing Rule 5550(b)(1) to maintain a minimum of $2.5&#160;million in stockholders&#8217; equity for continued listing on Nasdaq or the Alternative Requirements. The Notice states that our Annual Report on Form <span style="white-space:nowrap">10-K</span> for the fiscal year ended December&#160;31, 2023, disclosed stockholders&#8217; equity of ($1.3 million) as of December&#160;31, 2023, and that, as of March&#160;8, 2024, we did not meet the Alternative Standards. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On April&#160;22, 2024, we provided Nasdaq with our plan to achieve and sustain compliance with the stockholders&#8217; equity requirement and requested that Nasdaq grant an extension of time until September&#160;4, 2024, to provide evidence of our compliance with the stockholders&#8217; equity requirement. Consistent with that plan, in May 2024, we completed the May 2024 PIPE Financing, which resulted in our stockholders&#8217; equity being greater than $2.5&#160;million as of completion of the offering. Nasdaq has not yet responded to the plan we submitted, and there can be no assurance that Nasdaq will grant an extension or that we will be able to comply with the applicable listing standards of Nasdaq. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Funding and Material Cash Requirements </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To date, our operating losses have been funded primarily from outside sources of invested capital from issuance of our common and preferred stocks, proceeds from debt facilities and grant funding. However, the Company has had, and will continue to have, an ongoing need to raise additional cash from outside sources through a combination of equity offerings, debt financings and potential collaboration, license or development agreements to fund our future clinical development programs and other operations in the next twelve months from the filing of this report. Debt financing and preferred equity financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures, or declaring dividends. There can be no assurance that the Company will be able to continue </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">55 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
to raise additional capital in the future. Our inability to raise additional cash would have a material adverse impact on our operations. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our present and future funding and cash requirements will depend on many factors, including, among other things: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the progress, timing and completion of our ongoing and planned clinical trials and nonclinical studies; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our ability to receive, and the timing of receipt of, future regulatory approvals for our product candidates and the costs related thereto; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our ability to receive, and the timing of receipt of, future regulatory approvals for our product candidates and the costs related thereto; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the scope, progress, results and costs of our ongoing and planned operations; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the costs associated with expanding our operations and building our sales and marketing capabilities; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our ability to establish strategic collaborations; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the cost and timing of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property rights and defending any intellectual property-related claims; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the revenue, if any, received from commercial sales of our product candidates, if approved; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">potential new product candidates that the Company identifies and attempt to develop. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#8217;s condensed financial statements have been prepared assuming that the Company will continue to operate as a going concern, which contemplates the realization of assets and settlement of liabilities in the normal course of business, and do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classifications of liabilities that may result from uncertainty related to our ability to continue as a going concern. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cash (used in) provided by operating, investing, and financing activities for the three months ended March&#160;31, 2024 and 2023 is summarized as follows (in thousands): </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">


<tr>

<td style="width:76%"/>

<td style="vertical-align:bottom;width:5%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:5%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="6" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Three&#160;Months&#160;Ended</span><br/><span style="font-weight:bold">March&#160;31,</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">2024</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">2023</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash used in operating activities</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(4,513</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(5,793</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash used in investing activities</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(364</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(97</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash (used in) provided by financing activities</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(776</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">493</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net decrease in cash and cash equivalents</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(5,653</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(5,397</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td></tr>
</table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Material Cash Obligations </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the CPRIT Contract we receive matching funds for approximately <span style="white-space:nowrap">two-thirds</span> of the development costs for the development of rhenium (<sup style="font-size:75%; vertical-align:top">186</sup>Re) obisbemeda for the treatment of patients with LM, subject to various funding conditions. The CPRIT contract is effective for three years, unless otherwise terminated pursuant to the terms of the contract. CPRIT may require us to repay some or all of the disbursed CPRIT grant proceeds (with interest not to exceed 5% annually) in the event of the early termination of the CPRIT Contract. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, we are obligated to make operating lease payments for our office and laboratory space, and we may be required to make payments under certain of our other contractual agreements. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Other than as described above, we have no purchase commitments or long-term contractual obligations, except for lease obligations as of March&#160;31, 2024. In addition, we have no <span style="white-space:nowrap">off-balance</span> sheet arrangements (as defined in </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">56 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the rules and regulations of the Securities and Exchange Commission) that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that is material to investors. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Operating activities </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Net cash used in operating activities for the three months ended March&#160;31, 2024 was $4.5&#160;million compared to $5.8&#160;million in the same period of 2023. Our operational cash use decreased $1.3&#160;million during the three months ended March&#160;31, 2024 as compared to the same period in 2023, due primarily to increased reimbursement under the CPRIT grant agreement for research and development costs related to the <span style="white-space:nowrap">ReSPECT-LM</span> program. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Investing activities </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Net cash used in investing activities for the three months ended March&#160;31, 2024 was related to purchase of short-term investments of $0.3&#160;million and purchases of fixed assets of $40,000. Net cash used in investing activities for the three months ended March&#160;31, 2023 was related to purchases of fixed assets of $0.1&#160;million. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Financing Activities </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Net cash used in financing activities for the three months ended March&#160;31, 2024 was related to repurchase of treasury stock for approximately $0.4&#160;million and repayment of principle balance under the Oxford Term Loan of $0.4&#160;million. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Net cash provided by financing activities for the three months ended March&#160;31, 2023 was primarily related to sales of common stock of $0.9&#160;million, net of offering cost through the September 2022 Distribution Agreement with Canaccord, and offset by repayment of principle balance under the Oxford Term Loan of $0.4&#160;million. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Critical Accounting Policies and Significant Estimates </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires us to make estimates and assumptions that affect the reported amounts of our assets, liabilities, revenues and expenses, and that affect our recognition and disclosure of contingent assets and liabilities. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">While our estimates are based on assumptions we consider reasonable at the time they were made, our actual results may differ from our estimates, perhaps significantly. If results differ materially from our estimates, we will make adjustments to our financial statements prospectively as we become aware of the necessity for an adjustment. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Goodwill is reviewed for impairment annually or more frequently if indicators of impairment exist. We perform our impairment test annually during the fourth quarter. We operate in a single operating segment and reporting unit. We monitor the fluctuations in our share price and have experienced significant volatility during the year. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We believe it is important for you to understand our most critical accounting policies. Our critical accounting policies and estimates are discussed in our Annual Report on Form <span style="white-space:nowrap">10-K</span> for the fiscal year ended December&#160;31, 2023 and there have been no material changes during the three months ended March&#160;31, 2024. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">57 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="tx840996_11">BUSINESS </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Pipeline </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our most advanced investigational drug, rhenium (<sup style="font-size:75%; vertical-align:top">186</sup>Re) obisbemeda, is a patented radiotherapy potentially useful for patients with CNS and other cancers. Preclinical study data describing the use of<sup style="font-size:75%; vertical-align:top"> </sup>rhenium (<sup style="font-size:75%; vertical-align:top">186</sup>Re) obisbemeda for several cancer targets have been published in peer-reviewed journals and reported at a variety of medical society peer-reviewed meetings. Besides GBM, LM and PBC, rhenium (<sup style="font-size:75%; vertical-align:top">186</sup>Re) obisbemeda has been reported to have potential applications for head and neck cancer, ovarian cancer, breast cancer and peritoneal metastases. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The rhenium (<sup style="font-size:75%; vertical-align:top">186</sup>Re) obisbemeda technology was part of a licensed radiotherapeutic portfolio that we acquired from NanoTx, Corp. (&#8220;NanoTx&#8221;) on May&#160;7, 2020. The licensed radiotherapeutic has been evaluated in preclinical studies for several cancer targets and we have an active $3.0&#160;million award from U.S. National Institutes of Health/National Cancer Institute which is expected to provide financial support for the continued clinical development of rhenium (<sup style="font-size:75%; vertical-align:top">186</sup>Re) obisbemeda for recurrent GBM through the completion of a Phase 2 clinical trial, including enrollment of up to 55 patients. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On August&#160;29, 2022, we announced feedback from a Type C meeting with the FDA regarding CMC practices. The meeting focused on our cGMP clinical and commercial manufacturing process for our lead investigational targeted radiotherapeutic, BMEDA-chelated rhenium (<sup style="font-size:75%; vertical-align:top">186</sup>Re) obisbemeda, for recurrent GBM. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The FDA indicated agreement with our proposed application of cGMP guidance for radiotherapeutics, small molecule drug products and liposome drug products for our novel rhenium (<sup style="font-size:75%; vertical-align:top">186</sup>Re) obisbemeda in support of ongoing and future GBM clinical trials, manufacturing scale up, and commercialization. Alignment with the FDA includes support of our proposed controls and release strategy for new drug substance and new drug product. Because this product is identical for recurrent GBM, LM, and PBC, we believe alignment will be consistent for rhenium (<sup style="font-size:75%; vertical-align:top">186</sup>Re) obisbemeda used in other clinical development programs, including LM and PBC. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Rhenium (<sup style="font-size:75%; vertical-align:top">186</sup>Re) obisbemeda versus External Beam Radiation Therapy for Recurrent GBM </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Rhenium (<sup style="font-size:75%; vertical-align:top">186</sup>Re) obisbemeda is a novel injectable radiotherapy designed to deliver targeted, high dose radiation directly into GBM tumors in a safe, effective, and convenient manner that may ultimately prolong patient survival. Rhenium (<sup style="font-size:75%; vertical-align:top">186</sup>Re) obisbemeda is composed of the radionuclide <span style="white-space:nowrap">Rhenium-186</span> and a nanoliposomal carrier, and is infused in a highly targeted, controlled fashion, directly into the tumor via precision brain mapping and CED catheters. Potential benefits of rhenium (<sup style="font-size:75%; vertical-align:top">186</sup>Re) obisbemeda compared to standard external beam radiotherapy or EBRT include: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">The rhenium (186Re) obisbemeda radiation dose delivered to patients may be up to 20 times greater than what is possible with commonly used EBRT, which, unlike EBRT and proton beam devices, spares normal tissue and the brain from radiation exposure. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Rhenium (186Re) obisbemeda can be visualized in real-time during administration, possibly giving clinicians better control of radiation dosing, distribution and retention. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Rhenium (186Re) obisbemeda potentially more effectively treats a bulk tumor and microscopic disease that has already invaded healthy tissue.</p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Rhenium (186Re) obisbemeda is infused directly into the targeted tumor by CED catheter insertion using MRI guided software to avoid critical patient neurological structures and neural pathways and also bypasses the blood brain barrier, which delivers the therapeutic product where it is needed. Importantly, it reduces radiation exposure to healthy cells, in contrast to EBRT, which passes through normal tissue to reach the tumor, continuing its path through the tumor, hence being less targeted and selective. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">58 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Rhenium (186Re) obisbemeda is given during a single, short, <span style="white-space:nowrap">in-patient</span> hospital visit, and is available in all hospitals with nuclear medicine and neurosurgery, while EBRT requires <span style="white-space:nowrap">out-patient</span> visits five days a week for approximately four to six weeks.</p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic"><span style="white-space:nowrap">ReSPECT-GBM</span> Trial for Recurrent GBM </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Recurrent GBM is the most common, complex, and aggressive primary brain cancer in adults. In the U.S., there are approximately 13,000 GBM cases diagnosed and approximately 10,000 patients succumb to the disease each year. The average length of OS for GBM patients is eight months, with a <span style="white-space:nowrap">one-year</span> survival rate of 40.8% and a five-year survival rate of only 6.8% and these estimates vary and are lower in some publications. GBM routinely presents with headaches, seizures, vision changes and other significant neurological complications, with a significant compromise in quality of life. Despite the best available medical treatments, the disease remains incurable. Even after efforts to manage the presenting signs and symptoms and completely resect the initial brain tumor, some microscopic disease almost always remains and tumor regrowth occurs within months. Approximately 90% or more of patients with primary GBM experience tumor recurrence. Complete surgical removal of GBM is usually not possible and GBM is often resistant or quickly develops resistance to most available current and investigational therapies. Even today, the treatment of GBM remains a significant challenge and it has been nearly a decade since the FDA approved a new therapy for this disease, and these more recent approvals have not improved GBM patients OS over past decades, and a significant unmet medical need persists. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For recurrent GBM, there are few currently approved treatments, which in the aggregate, provide only marginal survival benefit. Furthermore, these therapies are associated with significant side effects, which limit dosing and prolonged use. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">While EBRT has been shown to be safe and has temporary efficacy in many malignancies including GBM, typically at absorbed, fractionated radiation dose of ~30 Gray in GBM, this maximum possible administered dose is always limited by toxicity to the normal tissues surrounding the malignancy and because EBRT requires fractionation to manage toxicity and maximum EBRT limits are typically reached before long-term efficacy reached. Because of this limitation, EBRT cannot provide a cure or long term control of GBM and GBM always recurs within months after EBRT. In contrast, locally delivered and targeted radiopharmaceuticals that precisely deliver radiation in the form of beta particles such as <span style="white-space:nowrap">Iodine-131</span> for thyroid cancer, are known to be safe and effective and minimize exposure to normal cells and tissues especially with optimal administered dose and minimizing exposure to normal tissue. The locally delivered rhenium (<sup style="font-size:75%; vertical-align:top">186</sup>Re) obisbemeda is designed for and provides patient tolerability and safety. Though no rhenium (<sup style="font-size:75%; vertical-align:top">186</sup>Re) obisbemeda <span style="white-space:nowrap"><span style="white-space:nowrap">head-to-head</span></span> trial with chemo, immune, EBRT or systemic radiopharmaceutical products have been conducted, patient tolerability and safety considerations have been reported as expected. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Interim results from our ongoing Phase 1/2a <span style="white-space:nowrap">ReSPECT-GBM</span> trial (ClinicalTrials.gov NCT01906385) show that the beta particle energy from our lead investigational drug rhenium (<sup style="font-size:75%; vertical-align:top">186</sup>Re) obisbemeda has provided preliminary positive data and utility in treating GBM and potential other malignancies. More specifically, the preliminary data from our Phase 1/2a <span style="white-space:nowrap">ReSPECT-GBM</span> trial suggests that radiation, in the form of high energy beta particles or electrons, can be effective against GBM. Thus far, we have been able to deliver up to 740 Gy of absorbed radiation to tumor tissue in humans, without significant or dose limiting toxicities and with what we believe has the capability to go higher if required. In comparison, current EBRT protocols for recurrent GBM typically recommend a total maximum radiation dose of about <span style="white-space:nowrap">~30-35</span> Gray. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In September 2020, the FDA granted both Orphan Drug designation and Fast Track designations to rhenium (<sup style="font-size:75%; vertical-align:top">186</sup>Re) obisbemeda for the treatment of patients with GBM. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Rhenium (<sup style="font-size:75%; vertical-align:top">186</sup>Re) obisbemeda is under clinical investigation in a multicenter, sequential cohort, open-label, volume and dose escalation study of the safety, tolerability, and distribution of rhenium (<sup style="font-size:75%; vertical-align:top">186</sup>Re) obisbemeda given by CED catheters to patients with recurrent or progressive malignant glioma after standard surgical, radiation, </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">59 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
and/or chemotherapy treatment (NCT01906385). The study uses a standard, modified 3x3 Fibonacci dose escalation, followed by a planned Phase 2 expansion trial at the MTD / MFD or <span style="white-space:nowrap">non-</span> DLT if MTD is not reached, to determine efficacy. The trial is funded through Phase 2 in large part by a NIH/NCI grant. These investigations have not reached DLT or MTD/MFD and the study is in its eighth dosing administration cohort. Due to the observation of a preliminary efficacy signal, we have initiated in parallel a Phase 2, <span style="white-space:nowrap">non-DLT</span> dose trial pursuant to the currently funded NIH/NCI grant. This trial will begin at the current <span style="white-space:nowrap">non-DLT</span> rhenium (<sup style="font-size:75%; vertical-align:top">186</sup>Re) obisbemeda dose and will expand exploring higher radiation doses in larger volumes to treat larger tumors. Additionally, two or more rhenium (<sup style="font-size:75%; vertical-align:top">186</sup>Re) obisbemeda administrations, if indicated, will be evaluated, and reviewed with the FDA, as well as expanded safety, imaging and efficacy data to support a planned future registrational trial. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On September&#160;6, 2022, we announced a summary of our Type C clinical meeting with the FDA that focused on the <span style="white-space:nowrap">ReSPECT-GBM</span> trial. The FDA agreed with us that the <span style="white-space:nowrap">ReSPECT-GBM</span> clinical trial should proceed to the planned Phase 2. The key focus areas of clinical investigation of the Phase 2 trial will be (1)&#160;further dose exploration, including both increased dosing and multiple doses, and (2)&#160;collecting additional safety and efficacy data to inform the design of a future registrational trial. Because no DLT administered doses were observed, the FDA and we also agreed to continue to dose cohort eight. There was further agreement with the FDA that in a planned future registrational trial, overall survival should be used as the primary endpoint. We agreed with the FDA to hold future meeting(s) to consider the use of external data to augment the use of a control arm in the registrational trial. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On January&#160;18, 2023, we announced that the first patient has been dosed in the <span style="white-space:nowrap">ReSPECT-GBM</span> Phase 2b dose expansion clinical trial evaluating rhenium obisbemeda for the treatment of recurrent GBM. The Phase 2b trial is expected to enroll up to 31 total patients with small- to <span style="white-space:nowrap">medium-sized</span> tumors and is targeted for full enrollment by the end of 2024. We currently have four clinical sites, with the plan to add additional sites to support the trial, and expect an initial data <span style="white-space:nowrap">read-out</span> by the end of 2024. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In June 2023, we presented data regarding the safety and feasibility results from our Phase 1/2 Clinical Trial of <sup style="font-size:75%; vertical-align:top">186</sup>RNL <span style="white-space:nowrap">(Rhenium-186</span> Nanoliposome) (<sup style="font-size:75%; vertical-align:top">186</sup>Re) Obisbemeda in Recurrent Glioma: The <span style="white-space:nowrap">ReSPECT-GBM</span> Trial at the Society of Nuclear Medicine&#160;&amp; Molecular Imaging Annual Meeting. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On November&#160;20, 2023, we announced positive data from the ongoing <span style="white-space:nowrap">ReSPECT-GBM</span> Phase 2 trial evaluating rhenium (<sup style="font-size:75%; vertical-align:top">186</sup>Re) obisbemeda, for the treatment of recurrent glioblastoma at the Society for NeuroOncology 28th Annual Meeting, which was held <span style="white-space:nowrap">November&#160;15-19,&#160;2023</span> in Vancouver, Canada. Key findings included: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">mOS in 15&#160;patients with rGBM from the Phase 2 study is 13&#160;months, which is 63% better than current standard of care (bevacizumab monotherapy) of 8&#160;months; 9 of the 15&#160;patients remain alive. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">mPFS is 11&#160;months, compared to SOC at 4&#160;months. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Rhenium (186Re) obisbemeda continues to demonstrate a favorable safety profile, despite delivering up to 20x the dose of radiation (up to 740 Gy) typically delivered by EBRT for rGBM patients (up to 35 Gy). </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Imaging data presented by Andrew Brenner, MD, PhD is consistent with the efficacy signal of Rhenium (186Re) obisbemeda in rGBM. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On March&#160;31, 2022, we entered into the Sales Order Medidata Solutions pursuant to which Medidata built a Synthetic Control Arm<sup style="font-size:75%; vertical-align:top">&#174;</sup> platform that facilitates the use of historical clinical data to incorporate into our Phase 2 clinical trial of rhenium (<sup style="font-size:75%; vertical-align:top">186</sup>Re) obisbemeda in GBM. The Sales Order had a term of six (6)&#160;months. Work under this Sales Order has been completed.&#160;As part of this collaboration, we jointly submitted with Medidata a HCA to ASCO which was accepted for publication, further strengthening this collaboration and allowing applications to advance GBM development. We plan to use the HCA for breakthrough therapy designation and Phase 2 and/or a pivotal or registrational Phase 3 trial.</p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">60 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic"><span style="white-space:nowrap">ReSPECT-LM</span> Clinical Trial for LM </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">LM is a rare complication of cancer in which the disease spreads to the membranes (meninges) surrounding the brain and spinal cord. The incidence of LM is growing and occurs in approximately 5%, or more, of people with late-stage cancer, or 110,000 people in the U.S. each year. It is highly lethal with an average <span style="white-space:nowrap">one-year</span> survival of just 7%. All solid cancers, particularly breast, lung, GI, and melanoma, have the potential to spread to the leptomeninges. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The <span style="white-space:nowrap">ReSPECT-LM</span> Phase 1 clinical trial (ClinicalTrials.gov NCT05034497) was preceded with preclinical studies in which tolerance to doses of rhenium (<sup style="font-size:75%; vertical-align:top">186</sup>Re) obisbemeda as high as 1,075 Gy were shown in animal models with LM without significant observed toxicity. Furthermore, treatment led to a marked reduction in tumor burden in both C6 and <span style="white-space:nowrap">MDA-231</span> LM models. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Upon receiving acceptance of our Investigational New Drug application and Fast Track designation by the FDA for rhenium (<sup style="font-size:75%; vertical-align:top">186</sup>Re) obisbemeda for the treatment of LM in November 2021, we initiated the trial and began screening patients for the <span style="white-space:nowrap">ReSPECT-LM</span> Phase 1 clinical trial in Q4 2021. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The <span style="white-space:nowrap">ReSPECT-LM</span> is a multi-center, sequential cohort, open-label, dose escalation study evaluating the safety, tolerability, and efficacy of a single-dose application of rhenium (<sup style="font-size:75%; vertical-align:top">186</sup>Re) obisbemeda administered through intrathecal infusion to the ventricle of patients with LM after standard surgical, radiation, and/or chemotherapy treatment. The primary endpoint of the study is the incidence and severity of adverse events and dose limiting toxicities, together with determining the maximum tolerated and recommended Phase 2 dose. Full enrollment in the Phase 1 trial is expected by the end of 2024, with the plan to add additional clinical sites to support the trial. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On September&#160;19, 2022, we entered into the CPRIT Contract, effective as of August&#160;31, 2022, with CPRIT, pursuant to which CPRIT will provide us the CPRIT Grant over a three-year period to fund the continued development of rhenium (<sup style="font-size:75%; vertical-align:top">186</sup>Re) obisbemeda for the treatment of patients with LM through Phase 2 of the ReSPECT LM clinical trial. The CPRIT Grant is subject to customary CPRIT funding conditions, including, but not limited to, a matching fund requirement (one dollar from us for every two dollars awarded by CPRIT), revenue sharing obligations upon commercialization of rhenium (<sup style="font-size:75%; vertical-align:top">186</sup>Re) obisbemeda based on specific dollar thresholds until CPRIT receives the aggregate amount of 400% of the proceeds awarded under the CPRIT Grant, and certain reporting requirements. To date, we have received approximately $7&#160;million in milestone payments under the CPRIT Contract. We anticipate a continuing flow of milestone payments that throughout 2024 will include $6.9&#160;million upon the continued progression of the Phase 2 of the ReSPECT LM clinical trial. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Interim results showed that a single treatment with rhenium (<sup style="font-size:75%; vertical-align:top">186</sup>Re) obisbemeda resulted in a consistent decreased CSF tumor cell count/ml and was tolerated by all LM patients. Rhenium (<sup style="font-size:75%; vertical-align:top">186</sup>Re) obisbemeda is an outpatient administration and treatment and is easily and safely administered through a standard intraventricular catheter (Ommaya Reservoir), distributed promptly throughout the CSF, and with durable retention in the leptomeninges at least through day seven. All patients have shown well tolerated prompt and durable rhenium (<sup style="font-size:75%; vertical-align:top">186</sup>Re) obisbemeda distribution throughout the subarachnoid space. On March&#160;11, 2024, we announced we had completed Cohort 5 of the <span style="white-space:nowrap">ReSPECT-LM</span> Phase 1/2a dose escalation trial. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A total of 18 patients have received a single-dose of rhenium (186Re) obisbemeda in the <span style="white-space:nowrap">ReSPECT-LM</span> trial as of March&#160;31, 2024. There have been no dose limiting toxicities observed to date with administered radiation doses up to 66.14 millicuries in Cohort 5, a <span style="white-space:nowrap">ten-fold</span> increase over Cohort 1. We plan to initiate dosing in Cohort 6 in the second quarter of 2024, pending Data Safety Monitoring Board (DSMB) approval. In addition, five new clinical trial sites were added to this trial over the last year, bringing the total number of sites to seven. We are planning a new multiple dosing <span style="white-space:nowrap">ReSPECT-LM</span> clinical trial in late 2024 or early 2025. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On August&#160;10, 2023, we presented data from the <span style="white-space:nowrap">ReSPECT-LM</span> clinical trial of rhenium (<sup style="font-size:75%; vertical-align:top">186</sup>Re) obismeda at the Society for Neuro Oncology ASCO CNS Cancer Conference. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">61 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In November 2023, the FDA granted Orphan Drug designation to rhenium (<sup style="font-size:75%; vertical-align:top">186</sup>Re) obisbemeda for the treatment of patients with breast cancer with LM. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On December&#160;12, 2023, we announced our partnership with K2bio to implement novel analysis for CSF tumor and molecular biomarkers for CNS cancers. Initial clinical specimen processing and testing began in the first quarter 2024 in our ongoing Phase 1 <span style="white-space:nowrap">ReSPECT-LM</span> trial of rhenium (<sup style="font-size:75%; vertical-align:top">186</sup>Re) obisbemeda in patients with LM. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic"><span style="white-space:nowrap">ReSPECT-PBC</span> Clinical Trial for Pediatric Brain Cancer </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The average annual age adjusted mortality rate for children aged <span style="white-space:nowrap">0-14</span> for malignant brain (and other CNS) tumors is 0.71/100,000, making it the most common cause of death and cancer death in this age group. The 2021 World Health Organization Classification of CNS Tumors classifies gliomas, glioneuronal tumors, and neuronal tumors into six different families: (1)&#160;adult-type diffuse gliomas; (2)&#160;pediatric-type diffuse <span style="white-space:nowrap">low-grade</span> gliomas; (3)&#160;pediatric-type diffuse HGG; (4)&#160;circumscribed astrocytic gliomas; (5)&#160;glioneuronal and neuronal tumors; and (6)&#160;ependymomas. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In August 2021, we announced plans for treating pediatric brain cancer at the 2021 American Association of Neurological Surgeons Annual Scientific Meeting. In July 2021, we reported that we had received FDA feedback pertaining to a <span style="white-space:nowrap">pre-IND</span> meeting briefing package in which the FDA stated that we are not required to perform any additional preclinical or toxicology studies. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Given the initial FDA feedback, receipt of adult GBM data and experience with rhenium (<sup style="font-size:75%; vertical-align:top">186</sup>Re) obisbemeda and <span style="white-space:nowrap">follow-up</span> communications with the FDA, we plan to submit a pediatric brain tumor IND to investigate the use of rhenium (<sup style="font-size:75%; vertical-align:top">186</sup>Re) obisbemeda in two pediatric brain cancers, high-grade glioma and ependymoma, in the first or second quarter of 2024. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pediatric high-grade gliomas can be found almost anywhere within the CNS; however, they are most commonly found within the supratentorium. The highest incidence of supratentorial, high-grade gliomas in pediatrics appears to occur in children aged 15 to 19 years, with a median age of approximately nine years. Overall, pediatric high-grade glioma confers a three-year PFS of 11 &#177; 3% and three-year OS of 22% &#177;5%. <span style="white-space:nowrap">One-year</span> PFS is as low as 40% in recent trials. Ependymomas are slow-growing central nervous system tumors that involve the ventricular system. Diagnosis is based on MRI and biopsy and survival rate depends on tumor grade and how much of the tumor can be removed. Grade II pathology was associated with significantly improved OS compared to Grade III (anaplastic) pathology (five-year OS = 71 &#177; 5% vs. 57 &#177; 10%; p = 0.026). Gross total resection compared to subtotal resection was associated with significantly improved OS (five-year OS = 75 &#177; 5% vs. 54 &#177; 8%; p = 0.002). </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Overall, pediatric HGG and ependymoma are extremely <span style="white-space:nowrap"><span style="white-space:nowrap">difficult-to-treat</span></span> pediatric brain tumors, frequently aggressive, and in recurrent settings, carry an extremely poor prognosis. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic"><span style="white-space:nowrap">Rhenium-188</span> NanoLiposome Biodegradable Alginate Microsphere Technology </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In January 2022, we announced that we licensed BAM patents and technology from UTHSA to expand our tumor targeting capabilities and precision radiotherapeutics pipeline. We intend to combine our Rhenium NanoLiposome technology with the BAM technology to create a novel radioembolization technology. Initially, we intend to utilize the <span style="white-space:nowrap">Rhenium-188</span> isotope, <sup style="font-size:75%; vertical-align:top">188</sup><span style="white-space:nowrap">RNL-BAM</span> for the intra-arterial embolization and local delivery of a high dose of targeted radiation for a variety of solid organ cancers such as hepatocellular cancer, hepatic metastases, pancreatic cancer and many others. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Preclinical data from an ex vivo embolization experiment in which <span style="white-space:nowrap">Technetium99m-BAM</span> was intra-arterially delivered to a bovine kidney perfusion model was presented at Society of Interventional Radiology Annual Scientific Meeting. The study concluded that the technology required for radiolabeling BAM could successfully </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">62 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
deliver, embolize and retain radiation in the target organ. <sup style="font-size:75%; vertical-align:top">188</sup><span style="white-space:nowrap">RNL-BAM</span> is a preclinical investigational drug we intend to further develop and move into clinical trials. Specifically, in 2022 we transferred the <sup style="font-size:75%; vertical-align:top">188</sup><span style="white-space:nowrap">RNL-BAM</span> technology from UTHSA, and began planning to develop the drug product and complete early preclinical studies to support a future FDA IND submission. Our intended initial clinical target is liver cancer which is the sixth most common and third deadliest cancer worldwide. It is a rare disease with increasing U.S. annual incidence (42,000) and deaths (30,000). </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Facilities </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have one lease agreement for our San Antonio, Texas locations. The lease for this property will expire in February 2025. We also lease certain office space in Austin, Texas under a <span style="white-space:nowrap"><span style="white-space:nowrap">month-to-month</span></span> operating lease agreement. We also have a lease agreement for office space in Charlottesville. We believe that these facilities will be adequate for our near-term needs. If required, we believe that suitable additional or substitute space will be available in the future on commercially reasonable terms to accommodate any such expansion of our operations. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Legal Proceedings </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">From time to time, we may be involved in various other claims and legal proceedings relating to claims arising out of our operations. We are not currently a party to any material legal proceedings. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">63 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="tx840996_12">MANAGEMENT </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Officers and Directors </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Set forth below are the names, ages and positions of each of the individuals who serve as our directors and officers as of June&#160;7, 2024. There are no family relationships among any of our executive officers or directors. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:33%"/>

<td style="vertical-align:bottom;width:2%"/>
<td/>

<td style="vertical-align:bottom;width:2%"/>
<td style="width:61%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold">Name</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Age</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Position</p></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Marc H. Hedrick, M.D.</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">62</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Chief Executive Officer, President and Director</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Andrew Sims</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">51</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Chief Financial Officer</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Norman LaFrance, M.D.</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">76</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Chief Medical Officer</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Howard Clowes</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">70</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Director</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Richard J. Hawkins</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">74</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Chairman of the Board</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">An van <span style="white-space:nowrap">Es-Johansson,</span> M.D.</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">64</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Director</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Robert Lenk, PhD</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">76</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Director</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Greg Petersen</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">61</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Director</td></tr>
</table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">Marc H. Hedrick, M.D.</span>&#160;Dr.&#160;Hedrick joined the Company in October 2002 as Chief Scientific Officer. In May 2004, he was appointed as President of the Company and in April 2014 he was appointed as its Chief Executive Officer. Dr.&#160;Hedrick has served as a member of our Board since joining the Company in October 2002. Previously, Dr.&#160;Hedrick served in a number of executive leadership positions, including President and Chief Executive Officer of StemSource from 2001 to 2003 and Chief Scientific Officer and Medical Director of Macropore Biosurgery from 2002 to 2004. Dr.&#160;Hedrick has also served as a board member for a number of public and private companies since 2000. Prior to his corporate career, Dr.&#160;Hedrick was Associate Professor of Surgery and Pediatrics at the University of California, Los Angeles. While at the University of California, Los Angeles, Dr.&#160;Hedrick&#8217;s academic research received both NIH funding as well as private and public capitalization and was widely acknowledged through scientific publications and the media. Dr.&#160;Hedrick also has first-hand experience as a physician, practicing general, vascular and craniofacial surgery. Dr.&#160;Hedrick has a medical degree from The University of Texas Southwestern Medical School and a Master of Business Administration from The UCLA Anderson School of Management and is a trained general, vascular and plastic surgeon. We believe Dr.&#160;Hedrick&#8217;s qualifications to serve on our Board include his executive, financial, governance and operational leadership experience in medical and pharmaceutical product development. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">Andrew Sims</span>.<span style="font-style:italic"></span>&#160;Mr.&#160;Sims<span style="font-style:italic"></span>&#160;joined us as Chief Financial Officer in February 2020. Prior to his appointment as our Chief Financial Officer, Mr.&#160;Sims held roles at several private equity-backed companies. Between 2012 and 2017, Mr.&#160;Sims was Chief Financial Officer of Amplify LLC, an advisory and management consulting services firm. Following his time at Amplify, Mr.&#160;Sims served as Chief Financial Officer of Verbatim Support Services LLC, a litigation support company, from 2017 to 2019. His focus has been on mergers and acquisitions, integrations, corporate capitalization, and building out and managing teams to support global growth. Previously, Mr.&#160;Sims was Partner at Mazars, a global accounting, advisory, audit, tax and consulting firm. Working from both the Oxford, England and New York offices, Mr.&#160;Sims audited and advised global public clients, including a variety of healthcare companies, with average annual revenues in excess of $1&#160;billion. Further, he was the lead partner on over 50 acquisitions ranging from $5&#160;million to $4&#160;billion in purchase price. He is a Certified Public Accountant in the U.S. and a Chartered Accountant in England and Wales. Mr.&#160;Sims is a graduate of Buckingham University in the United Kingdom. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">Norman LaFrance, M.D.</span>&#160;Dr.&#160;LaFrance joined us as Chief Medical Officer in November 2021. Prior to joining the Company, Dr.&#160;LaFrance served as Chief Medical Officer and Senior Vice President at Jubilant Pharma Ltd. from 2012 to 2022 where he was responsible for all Pharma Medical&#160;&amp; Regulatory Affairs activities. Dr.&#160;LaFrance has spent more than four decades in the pharmaceutical and healthcare industry, academia and medical practice. His background includes strategic planning and management of pharmaceutical development for approval by the FDA as well as clinical and academic experience. In addition, Dr.&#160;LaFrance practiced medicine for 10 years and held academic faculty appointments at Johns Hopkins University School of Medicine </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">64 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
in the Departments of Medicine and Radiology and the Department of Radiological Sciences in the Johns Hopkins School of Hygiene and Public Health. He is double board certified in internal medicine and nuclear medicine. He is a graduate of the medical school at the University of Arizona and received his Bachelor of Science and Master of Engineering degrees in Nuclear Engineering and Science from Rensselaer Polytechnic Institute. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">Howard Clowes</span><span style="font-style:italic">.</span><span style="font-style:italic"></span>&#160;Mr.&#160;Clowes has served on our Board since April&#160;1, 2020. From January 2005 until he retired as a lawyer in December 2018, Mr.&#160;Clowes was a partner in the law firm DLA Piper (US) LLC. From 1982 until the formation of DLA Piper in 2005, he was an associate and then a partner in the predecessor firms of DLA Piper, holding various management positions, including serving on its board of directors. Mr.&#160;Clowes served on the board of Equalize Health and as Chair of its Governance Committee from January 2018 to May 2022 and serves on the board of AFRAC, each of which are nonprofit corporations focused on global healthcare. Mr.&#160;Clowes served on the board of the Law Foundation of Silicon Valley, <span style="white-space:nowrap">a&#160;non-profit&#160;organization</span> located in San Jose, California, that provides free legal services to Silicon Valley residents in need, from 2008 until December 2018, serving during that period in various positions, including President of its board of directors, and Chair of a Strategic Planning and CEO Search Committee. From 2017 to 2021, Mr.&#160;Clowes served as a Lecturer at U.C. Berkeley&#8217;s Berkeley School of Law, teaching a course in International Business Negotiations. Mr.&#160;Clowes earned his J.D. at U.C. Berkeley, his B.A. in Experimental Psychology at U.C. Santa Barbara, and in 2023, Mr.&#160;Clowes received his NACD Directorship Certification. We believe Mr.&#160;Clowes&#8217; qualifications to serve on the Board include his extensive experience as a lawyer advising boards of directors and their audit, compensation and governance committees on a wide range of matters, his experience with a wide range of transactions, and his experience serving on various boards of directors. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">Richard J. Hawkins</span>. Mr.&#160;Hawkins has served on our Board since December 2007 and as Chairman of our Board since January 2018. In 1982, Mr.&#160;Hawkins founded Pharmaco, a clinical research organization, or CRO, where he served as its Chairman, President and Chief Executive Officer until 1991 when it merged with the predecessor <span style="white-space:nowrap">of&#160;PPD-Pharmaco.&#160;In</span> 1992, <span style="white-space:nowrap">Mr.&#160;Hawkins&#160;co-founded&#160;Sensus</span> Drug Development Corporation, or SDDC, a privately-held company focused on the development of drugs to treat endocrine disorders, which developed and received regulatory approval for SOMAVERT, a growth hormone antagonist approved for the treatment of acromegaly, which is now marketed by Pfizer, Inc., where he served as Chairman until 2000. In 1994, Mr. Hawkins <span style="white-space:nowrap">co-founded</span> Corning Biopro, a contract protein manufacturing firm, where he served on its board until Corning BioPro&#8217;s sale to <span style="white-space:nowrap">Akzo-Nobel,</span> N.V., a publicly-held producer of paints, coatings and specialty chemicals, in 2000. In September 2003, Mr. Hawkins founded LabNow, Inc., a privately held company that develops lab-on-a-chip sensor technology, where he served as the Chairman and Chief Executive Officer until October 2009. In February 2011, Mr.&#160;Hawkins became Chief Executive Officer, and is currently Chief Executive Officer, president and chairman of Lumos Pharma, Inc. (NASDAQ: LUMO). Mr.&#160;Hawkins served on the board of SciClone Pharmaceuticals, Inc. (HKD: SCLN), a publicly-held specialty pharmaceutical company, from October 2004 through December 2017. He also served on the Presidential Advisory Committee for the Center for Nano and Molecular Science and Technology at the University of Texas in Austin, and was inducted into the Hall of Honor for the College of Natural Sciences at the University of Texas. Mr.&#160;Hawkins is a member of the National Ernst&#160;&amp; Young Entrepreneur of the Year Hall of Fame. Mr.&#160;Hawkins graduated cum laude with a B.S. in Biology from Ohio University, where he later received the Ohio University Konneker Medal, the highest award given to a faculty member or former student for entrepreneurial excellence. We believe Mr.&#160;Hawkins&#8217;s qualifications to serve on our Board include his executive experience working with life sciences companies, his extensive experience in pharmaceutical research and development, his knowledge, understanding and experience in the regulatory development and approval process, and his service on other public company boards and committees. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">An van</span><span style="font-weight:bold"></span><span style="font-weight:bold"><span style="white-space:nowrap">&#160;Es-Johansson,</span></span><span style="font-weight:bold"></span><span style="font-weight:bold">&#160;M.D.</span> <span style="white-space:nowrap">Dr.&#160;van&#160;Es-Johansson&#160;has</span> served on our Board since January&#160;1, 2020. Dr.&#160;van <span style="white-space:nowrap">Es-Johansson</span> served as the Chief Medical Officer for AlzeCure Pharma, a Swedish pharmaceutical company with a primary focus on Alzheimer&#8217;s disease, from September 2018 through March&#160;1, 2021 following which she has continued to serve AlzeCure Pharma as a Senior Advisor beginning in March 2021. Since 2021&#160;she is a Senior&#160;Advisor for Sinfonia AB, a Swedish Pharmaceutical Company with focus on neuroscience. From May </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">65 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
2005 to September 2018, <span style="white-space:nowrap">Dr.&#160;van&#160;Es-Johansson&#160;served</span> in a range of executive roles of increasing responsibility at Sobi, an international rare disease company headquartered in Stockholm, Sweden, including as Vice President and Head of EMENAR Medical Affairs for Specialty Care and Partner Products from March 2013 to January 2018. Prior to her time at Sobi, <span style="white-space:nowrap">Dr.&#160;van&#160;Es-Johansson&#160;served</span> in leadership positions within large pharmaceutical and smaller biotechnology companies, including Roche, Pharmacia, Eli Lilly, Active Biotech, and BioStratum. From 2004 to 2016, she was a member of the Scientific Advisory Board of Uppsala Bio and currently serves on the board of directors of Savara, Inc. (NASDAQ: SVRA), Lumos Pharma, Inc. (NASDAQ: LUMO) and privately held Agendia BV. She also served on the board of directors at BioInvent International AB (NASDAQ OMX Stockholm BINV), from June 2016 to February 2021 on the board of directors of&#160;Alzecure AB (NASDAQ OMX Stockholm ALZCUR), from 2017-2020, on the board of directors of Medivir AB (NASDAQ OMX -MVIR) from 2019-2022, and on the board of directors of IRLAB&#160;AB (NASDAQOMX Stockholm IRLAB)&#160;from May 2022 to February <span style="white-space:nowrap">2023.&#160;Dr.&#160;van&#160;Es-Johansson&#160;received</span> a M.D. from Erasmus University, Rotterdam, The Netherlands. We believe <span style="white-space:nowrap">Dr.&#160;van&#160;Es-Johansson&#8217;s&#160;qualifications</span> to serve on our Board include her extensive medical knowledge and experience in the pharmaceutical industry. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">Robert Lenk</span><span style="font-weight:bold">, PhD</span>. Dr.&#160;Lenk has served on our Board since April&#160;1, 2020. Since 2016, he has served as President of Lenk Pharmaceuticals, LLC, consulting to clients in the pharmaceuticals industry. <span style="white-space:nowrap">Dr.&#160;Lenk&#160;co-founded&#160;the</span> Liposome Company, in Princeton, New Jersey in 1981 until it was later acquired by Elan Pharmaceuticals. After the Liposome Company went public, <span style="white-space:nowrap">he&#160;co-founded&#160;Argus</span> Pharmaceuticals, a drug delivery company focused on cancer and infectious diseases, in 1989 as Vice President of Research&#160;&amp; Development, until it merged with two other companies to become Aronex Pharmaceuticals.&#160;From 1995 to 2003, Dr.&#160;Lenk served as President and Chief Executive Officer of Therapeutics 2000, Inc. which was later sold to Coller Capital. Dr.&#160;Lenk joined Luna Innovations in 2004 where he served as President of its Nanoworks Division until 2010. In 2010, Dr.&#160;Lenk joined MediVector, Inc. as Chief Science Officer until 2016 when he started Lenk Pharmaceuticals, LLC, a pharmaceutical development consulting company where he currently works. He also currently serves on the board of PoP Biotechnology, a private company that develops vaccines and cancer therapies based on proprietary porphyrin liposome nanoparticle technology. Dr.&#160;Lenk received both his PhD and BSc. from the Massachusetts Institute of Technology. We believe Dr.&#160;Lenk&#8217;s qualifications to serve on our Board include his broad experience in translating research candidates into products, especially in the fields of nanotechnology and liposomal drug products. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">Greg Petersen</span>.&#160;Mr.&#160;Petersen has served on our Board since February&#160;14, 2020. Mr.&#160;Petersen is an accomplished executive and board member with more than 25 years of strategy, operations, finance and compliance leadership experience. His 10 years of board of directors experience includes his current role as compensation committee chair and audit committee member of PROS Holdings, Inc. (NYSE: PRO), a software company. Mr.&#160;Petersen previously served on the boards of publicly traded companies Mohawk Group Holdings (NASDAQ: MWK), a consumer product manufacturing company, from 2019 to 2022, Diligent Corporation (NZX: DIL), a software as a service company, from 2013 to 2016, and Piksel, Inc. (OTC US: PIKL), a video management software and services company, from 2012 to 2017. During his career, Mr.&#160;Petersen has served as Executive Vice Chairman of Diligent Corporation and as Chief Financial Officer of Lombardi Software (now part of IBM) and Activant Solutions (now part of Epicor). He has also held executive positions at American Airlines and other corporations. Mr.&#160;Petersen has a BA from Boston College and an MBA from Duke University&#8217;s Fuqua School of Business. We believe Mr.&#160;Petersen&#8217;s qualifications to serve on our Board include his extensive experience as an executive and a director, including as a director on other public company boards, as well as his strategic, operations, finance, and compliance leadership experience. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Corporate Governance </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Composition of Our Board </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our business and affairs are managed under the direction of our Board, which is comprised of Marc H. Hedrick, Howard Clowes, Richard J. Hawkins, An van <span style="white-space:nowrap">Es-Johansson,</span> Robert Lenk, and Greg Petersen. Mr.&#160;Hawkins serves as the Chairman of our Board. Subject to the terms of our Charter, and our Bylaws, the number of directors will be fixed by our Board. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">66 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">When considering whether directors and director nominees have the experience, qualifications, attributes and skills, taken as a whole, to enable our Board to satisfy its oversight responsibilities effectively in light of its business and structure, our Board expects to focus primarily on each person&#8217;s character, judgment, leadership, business acumen, diversity of backgrounds and perspectives, skills, age, gender, ethnicity, and professional experience, knowledge of or experience in the pharmaceutical industry, sufficient time to devote to Plus&#8217; affairs, and commitment to represent the long-term interests of Plus&#8217; stockholders. in order to provide an appropriate mix of experience and skills relevant to the size and nature of its business. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Director Independence </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our Common Stock is listed on the Nasdaq Capital Market and under the listing rules of Nasdaq, subject to specified exceptions, independent directors must comprise a majority of a listed company&#8217;s board of directors, and each member of a listed company&#8217;s audit, compensation, and nominating and corporate governance committees must be independent. Under Nasdaq listing rules, a director will only qualify as an &#8220;independent director&#8221; if, among other things, the listed company&#8217;s board of directors affirmatively determines that the director does not have a relationship which, in the opinion of the listed company&#8217;s board of directors, would interfere with the exercise of independent judgment in carrying out the responsibilities of a director. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our Board reviews the independence of each director. This review is based primarily on responses of the directors to questions in a directors&#8217; and officers&#8217; questionnaire regarding employment, business, familial, compensation and other relationships with Plus and our management. Our Board has determined that no transactions or relationships existed that would disqualify any of our directors under the Nasdaq rules&#160;or require disclosure under SEC rules, with the exception of Marc H. Hedrick, M.D., our President and Chief Executive Officer, because of his current employment relationship with Plus. Based upon that finding, the Board determined that Ms.&#160;van <span style="white-space:nowrap">Es-Johansson,</span> and Messrs.&#160;Hawkins, Clowes, Lenk and Petersen are &#8220;independent&#8221; and the composition of our Board meets the requirements for independence under Nasdaq. Each of our Audit, Compensation, and Nominating and Governance Committees is composed only of independent directors. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Committees of Our Board </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our Board directs the management of its business and affairs, as provided by Delaware law, and conducts its business through meetings of our Board and its standing committees. Our Board has three standing committees: our Audit Committee, our Compensation Committee, and our Nominating and Corporate Governance Committee, each of which has the composition and the responsibilities described below, and operates under a written charter. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Copies of our standing committee charters are posted on our website, as required by applicable SEC rules and Nasdaq rules. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:22%"/>

<td style="vertical-align:bottom;width:2%"/>
<td/>

<td style="vertical-align:bottom;width:2%"/>
<td/>

<td style="vertical-align:bottom;width:2%"/>
<td style="width:15%"/>

<td style="vertical-align:bottom;width:2%"/>
<td style="width:15%"/>

<td style="vertical-align:bottom;width:2%"/>
<td style="width:15%"/>

<td style="vertical-align:bottom;width:2%"/>
<td style="width:15%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="5" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Board Committees</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman;font-weight:bold">Name</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Age</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Director</span><br/><span style="font-weight:bold">Since</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Independent</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Audit Committee</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Compensation</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Committee</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Nominating and<br/>Corporate</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Governance<br/>Committee</p></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Howard Clowes</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top" align="center">70</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top" align="center">2020</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top" align="center">&#9745;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top" align="center">M</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top" align="center">C</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top" align="center">M</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">An van <span style="white-space:nowrap">Es-Johansson,</span> MD</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top" align="center">64</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top" align="center">2020</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top" align="center">&#9745;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top" align="center">M</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top" align="center">C</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Robert Lenk, PHD</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top" align="center">76</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top" align="center">2020</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top" align="center">&#9745;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top" align="center">M</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Greg Petersen</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top" align="center">61</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top" align="center">2020</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top" align="center">&#9745;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top" align="center">C + FE</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top" align="center">M</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"/></tr>
</table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">I - Independent director under Nasdaq rules </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">C - Chair </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">67 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">M - Member </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">FE - Audit Committee financial expert </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Audit Committee </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our Audit Committee&#8217;s responsibilities include, among other things: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">review management&#8217;s and our independent auditor&#8217;s report on their assessment of the effectiveness of internal control over financial reporting as of the end of each fiscal year; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">selecting our auditors and reviewing the scope of the annual audit; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">resolving any disagreements between management and the auditor regarding financial reporting; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">approving the audit fees <span style="white-space:nowrap">and&#160;non-audit&#160;fees</span> to be paid to our auditors; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">reviewing our financial accounting controls with the staff and the auditors; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">reviewing and monitoring management&#8217;s enterprise risk management assessment; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">reviewing and discussing with management and the auditor, our audited financial statements including our disclosures under the section entitled &#8220;<a href="#tx840996_10"><span style="text-decoration:underline">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></a>&#8221;; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">reviewing our earnings press releases as well as financial information and earnings guidance provided to analysts and rating agencies; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">reviewing and approving our annual budget; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">reviewing all related person transactions which are required to be reported under applicable SEC regulations. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our Audit Committee currently consists of Mr.&#160;Clowes, <span style="white-space:nowrap">Dr.&#160;van&#160;Es-Johansson&#160;and</span> Mr.&#160;Petersen (Chairperson). All members of our Audit Committee meet the requirements for financial literacy under the applicable Nasdaq rules and regulations. Our Board has determined that each member of our Audit Committee qualifies as &#8220;independent&#8221; under Nasdaq&#8217;s additional standards applicable to audit committee members and <span style="white-space:nowrap">Rule&#160;10A-3&#160;of</span> the&#160;Exchange Act. Our Board has also determined that Mr.&#160;Petersen qualifies as an &#8220;audit committee financial expert&#8221; as defined in Item&#160;407(d)(5)&#160;of&#160;Regulation <span style="white-space:nowrap">S-K.</span> </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Compensation Committee </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our Compensation Committee&#8217;s responsibilities include, among other things: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">developing and implementing compensation programs for our executive officers and other employees, subject to the discretion of the full Board; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">establishing base salary rates, benefits and other compensation matters for each of our executive officers; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">administering our equity compensation plans; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">reviewing the relationship between our performance and our compensation policies and assessing any risks associated with such policies; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">reviewing and advising the Board on director compensation matters and on regional and industry-wide compensation practices and trends in order to assess the adequacy of our executive compensation programs; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">reviewing and discussing compensation related disclosures with management and making a recommendation to the Board regarding the inclusion of such disclosures in our annual proxy statement or <span style="white-space:nowrap">Form&#160;10-K,&#160;as</span> applicable. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">68 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our Compensation Committee currently consists of Mr.&#160;Petersen (Chairperson) and Mr.&#160;Clowes. Our Board has determined that each of Mr.&#160;Petersen and Mr.&#160;Clowes qualifies as &#8220;independent&#8221; under Nasdaq&#8217;s additional standards applicable to compensation committee members and that each member of our Compensation Committee is <span style="white-space:nowrap">a&#160;&#8220;non-employee&#160;director&#8221;</span> as defined in&#160;Section <span style="white-space:nowrap">16b-3&#160;of</span> the Exchange Act. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to our Compensation Committee&#8217;s charter, our Compensation Committee has the authority to retain or obtain the advice of compensation consultants, legal counsel and other advisors to assist in carrying out its responsibilities. Before selecting any such consultant, counsel or advisor, our Compensation Committee reviews and considers the independence of such consultant, counsel or advisor in accordance with applicable Nasdaq rules. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Nominating and Corporate Governance Committee </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our Nominating and Corporate Governance Committee is responsible for, among other things: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">evaluating and make recommendations regarding the size and composition of the Board; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">making recommendations to the Board regarding the composition of committees of the Board and the chairperson for each of its committees, with consideration of the desires of individual members of the Board; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">monitoring compliance with Board and Board&#8217;s committee membership criteria; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">identifying, evaluating, recruiting, recommending, and screening candidates for nomination to the Board, including those recommended by stockholders, based on criteria set forth in the Company&#8217;s Corporate Governance Guidelines; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">establishing procedures for the submission and consideration of candidates for nomination to the Board recommended by stockholders; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">identifying, evaluating, recruiting, recommending to the Board for consideration and approval the individuals to constitute the nominees of the Board for election as directors at an annual meeting of stockholders or to fill vacancies on the Board; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">evaluating periodically the Company&#8217;s risk management process and system in light of the nature of the material risks the Company faces and the adequacy of the Company&#8217;s policies and procedures designed to address risk, and recommend to the Board any changes deemed appropriate by the Nominating and Corporate Governance Committee; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">overseeing the annual self-evaluation process of the Board and each of its committees; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">developing and recommend to the Board the qualification standards for directors and committee members, including defining specific criteria for independence, and from time to time or as necessary recommend to the Board any changes deemed appropriate by the Nominating and Corporate Governance Committee; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">reviewing periodically with the Chairman of the Board and the Chief Executive Officer the succession plan relating to the Chief Executive Officer and the management development plan, and thereafter make recommendations to the Board with respect to such plans; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">reviewing and reassess annually at its first meeting following an annual meeting of stockholders the adequacy of the Audit Committee Charter, Compensation Committee Charter, the Insider Trading and Communications Policy, and any such other charters and policies as the Board shall determine and recommend any proposed changes to the Board; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">reviewing and discussing with management disclosure of the Company&#8217;s corporate governance practices, including information regarding the operations of the Nominating and Corporate Governance Committee and other Board committees, director independence, and the director nominations process, and recommend that this disclosure be, included in the Company&#8217;s proxy statement or annual report on Form 10-K, as applicable. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">69 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our Nominating and Corporate Governance Committee currently consists of Dr.&#160;Lenk, Mr.&#160;Clowes and <span style="white-space:nowrap">Dr.&#160;van&#160;Es-Johansson</span> (Chairperson). Our Board has determined that each of Dr.&#160;Lenk, Mr.&#160;Clowes and <span style="white-space:nowrap">Dr.&#160;van&#160;Es-Johansson</span> qualifies as &#8220;independent&#8221; under Nasdaq rules applicable to nominating and corporate governance committee members. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, our Board may from time to time establish other committees when it deems doing so to be necessary or advisable to address specific matters. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Code of Business Conduct and Ethics </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have adopted a Code of Business Conduct and Ethics (the &#8220;Code of Ethics&#8221;) that applies to all of our directors, officers and employees, including our principal executive officer, principal financial officer and principal accounting officer. This Code of Ethics has been posted on our website at www.plustherapeutics.com. To the extent required by SEC rules, we intend to post amendments to this code, or any waivers of its requirements, on our website at <span style="text-decoration:underline">https://ir.plustherapeutics.com/governance/corporate-governance-materials</span>. To date, there have been no waivers under our Code of Ethics. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">70 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="tx840996_13">EXECUTIVE COMPENSATION </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This section discusses the material components of the executive compensation program for our executive officers who are named in the &#8220;Summary Compensation Table&#8221; below. In 2023, our &#8220;named executive officers&#8221; and their positions were as follows: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Marc H. Hedrick, M.D., our President and Chief Executive Officer; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Andrew Sims, our Chief Financial Officer; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Norman LaFrance, M.D., our Chief Medical Officer. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This discussion may contain forward-looking statements that are based on our current plans, considerations, expectations and determinations regarding future compensation programs. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Summary Compensation Table </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table sets forth information concerning the compensation of our named executive officers for our fiscal year ended December&#160;31, 2023. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:36%"/>

<td style="vertical-align:bottom;width:3%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:3%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:3%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:3%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:3%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:3%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman;font-weight:bold">Name and Principal Position</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Year</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Salary&#160;($)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Option<br/>Awards&#160;($)&#160;(1)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold"><span style="white-space:nowrap">Non-Equity</span><br/>Incentive&#160;Plan<br/>Compensation&#160;($)<br/>(2)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">All&#160;Other<br/>Compensation&#160;($)<br/>(3)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Total&#160;($)</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Marc H. Hedrick, M.D.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2023</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">556,400</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">188,692</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">336,622</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">52,313</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,134,027</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">President and Chief Executive Officer</span></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2022</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">535,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">361,928</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">57,723</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">954,651</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Andrew Sims</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2023</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">355,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">40,722</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">125,803</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">17,706</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">539,231</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Chief Financial Officer</span></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2022</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">305,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">125,164</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">16,012</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">446,176</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Norman LaFrance, M.D.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2023</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">440,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">29,244</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">161,700</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">44,321</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">675,265</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Chief Medical Officer</span></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2022</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">440,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">152,460</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">45,351</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">637,811</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
</table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(1)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">The amounts in this column reflect the aggregate grant date fair value&#160;of stock options&#160;granted in the applicable year. In accordance with SEC rules, the amounts shown exclude the impact of estimated forfeitures related to service-based vesting conditions computed in accordance with ASC Topic 718. Assumptions used in the calculation of these amounts are included in Note 13 to our consolidated financial statements included in Part II, Item 8 of on our Annual Report on Form <span style="white-space:nowrap">10-K</span> for fiscal year end December&#160;31, 2023. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(2)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">The amounts in this column represent annual <span style="white-space:nowrap">performance-based</span> bonuses for 2023 and 2022. See the narrative below under &#8220;Annual Bonuses and <span style="white-space:nowrap">Non-Equity</span> Incentive Plan Compensation&#8221; for additional detail. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(3)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">This column includes standard benefits which are 401K match, and health and life insurance premiums. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">2023 Salaries </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The named executive officers receive a base salary to compensate them for services rendered to us. The base salary payable to each named executive officer is reviewed annually by our Compensation Committee and is intended to provide a fixed component of compensation reflecting the executive&#8217;s skill set, experience, role and responsibilities. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto">


<tr>

<td style="width:34%"/>

<td style="vertical-align:bottom;width:4%"/>
<td style="width:29%"/>

<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman;font-weight:bold">Name</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Title</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">2023</span><br/><span style="font-weight:bold">Base</span><br/><span style="font-weight:bold">Salary</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">2022</span><br/><span style="font-weight:bold">Base</span><br/><span style="font-weight:bold">Salary</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Percent</span><br/><span style="font-weight:bold">Increase</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Marc H. Hedrick, M.D.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">Chief Executive Officer</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">556,400</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">535,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">4</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Andrew Sims</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">Chief Financial Officer</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">355,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">305,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">16.39</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Norman LaFrance, M.D.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">Chief Medical Officer</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">440,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">440,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
</table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">71 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">2023 Annual Bonuses and <span style="white-space:nowrap">Non-Equity</span> Incentive Plan Compensation </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In 2023, each of the named executive officers was eligible to receive a cash incentive award expressed as a percentage of annual base salary. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">


<tr>

<td style="width:46%"/>

<td style="vertical-align:bottom;width:6%"/>
<td style="width:41%"/>

<td style="vertical-align:bottom;width:6%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman;font-weight:bold">Name</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Title</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Target<br/>Bonus<br/>for<br/>2023</span><br/><span style="font-weight:bold">(% of<br/>Base<br/>Salary)</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Marc H. Hedrick, M.D.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">Chief Executive Officer</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">55</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Andrew Sims</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">Chief Financial Officer</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">35</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Norman LaFrance, M.D.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">Chief Medical Officer</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">35</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
</table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The corporate objectives upon which the target bonus is based upon was designed by the Compensation Committee to stimulate and support a high-performance environment by tying 2023 cash incentive awards to the attainment of short-term goals related to the Company&#8217;s clinical, financial and operational goals. Our Compensation Committee further determined that the award payout would be determined by measuring our actual performance as compared to corporate and/or individual objectives, and the Compensation Committee used that information, along with the overall corporate performance, to determine what percentage of each named executive officer&#8217;s bonus target was achieved and would be paid out as a bonus for 2023. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For the Company&#8217;s 2023 fiscal year, the corporate goals approved by the Board (upon recommendation of the Compensation Committee for purposes of executive compensation) were determined by the Compensation Committee to have been achieved at a level of 110%. Dr.&#160;Hedrick&#8217;s bonus received $336,622, or 110% of his target cash bonus. Based upon the attainment of 110% of the corporate goals, and upon an attainment of 75% of his individual goals. Mr.&#160;Sims, received $125,803, or 101% of his target cash bonus and upon an attainment of 100% of his individual goals, and Dr.&#160;LaFrance, received $161,700, or 105% of his target cash bonus. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Long-Term Equity Compensation </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For the year ended December&#160;31, 2023, Dr.&#160;Hedrick was awarded stock options covering a total of 6,720 shares, Mr.&#160;Sims was awarded stock options covering a total of 1,451 shares and Dr.&#160;LaFrance was issued a stock option covering 1,047 shares.</p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Personal Benefits and Perquisites </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">All of our executives are eligible to participate in our employee benefit plans, including medical, dental, vision, life insurance, short-term and long-term disability insurance, flexible spending accounts and 401(k). These plans are available to all full-time employees. We offer limited personal benefits and perquisites to executive officers. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Employment Agreements </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Marc H. Hedrick, M.D., Chief Executive Officer </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On March&#160;11, 2020, we entered into an employment agreement with Dr.&#160;Hedrick, providing for his position as Chief Executive Officer. Subsequently, on May&#160;13, 2020, the employment agreement with Dr.&#160;Hedrick was amended on May&#160;13, 2020. Dr.&#160;Hedrick&#8217;s employment with us <span style="white-space:nowrap">is&#160;at-will&#160;and</span> either party may terminate the employment agreement without notice. The employment agreement generally provides for a minimum base salary, a discretionary annual cash bonus based on the achievement of Company performance goals and the ability to participate in, subject to applicable eligibility requirements, all of our benefit plans and fringe benefits and programs that may be provided to our executives from time to time. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">72 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The employment agreement with Dr. Hedrick also provides for potential payments upon termination as described below under &#8220;Potential Payments Upon Termination or <span style="white-space:nowrap"><span style="white-space:nowrap">Change-in-control.&#8221;</span></span> </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Andrew Sims, Chief Financial Officer </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On March&#160;11, 2020, we entered into an employment agreement with Mr.&#160;Sims, providing for his position as Chief Executive Officer. Subsequently, on May&#160;13, 2020, the employment agreement with Mr.&#160;Sims was amended on May&#160;13, 2020. Mr.&#160;Sims&#8217;s employment with us <span style="white-space:nowrap">is&#160;at-will&#160;and</span> either party may terminate the employment agreement without notice. The employment agreement generally provides for a minimum base salary, a discretionary annual cash bonus based on the achievement of Company performance goals and the ability to participate in, subject to applicable eligibility requirements, all of our benefit plans and fringe benefits and programs that may be provided to our executives from time to time. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The employment agreement with Mr.&#160;Sims also provides for potential payments upon termination as described below under &#8220;Potential Payments Upon Termination or <span style="white-space:nowrap"><span style="white-space:nowrap">Change-in-control.&#8221;</span></span> </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Norman LaFrance, M.D., Chief Medical Officer </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On September&#160;7, 2021, we entered into an employment agreement with Mr.&#160;LaFrance providing for his position as Chief Medical Officer. Subsequently, on November&#160;8, 2021, Mr.&#160;LaFrance&#8217;s employment agreement was amended. Mr.&#160;LaFrance&#8217;s employment with us <span style="white-space:nowrap">is&#160;at-will&#160;and</span> either party may terminate the employment agreement without notice. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The employment agreement with Mr.&#160;LaFrance also provides for potential payments upon termination as described below under &#8220;Potential Payments Upon Termination or <span style="white-space:nowrap"><span style="white-space:nowrap">Change-in-control.&#8221;</span></span> </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Potential Payments Upon Termination or <span style="white-space:nowrap"><span style="white-space:nowrap">Change-in-Control</span></span> </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the terms of the employment agreements with Dr.&#160;Hedrick, Mr.&#160;Sims and Dr.&#160;LaFrance (the &#8220;Executive Employment Agreements&#8221;), if one of our named executive officers is terminated without &#8220;cause&#8221; or resigns for &#8220;good reason,&#8221; (a &#8220;Severance Termination&#8221;), then such named executive officer will be eligible to receive: (i)&#160;an amount equal to twelve months of his base salary; (ii)&#160;an amount equal to his target bonus for the year in which such Severance Termination occurs; (iii)&#160;the annual bonus earned for the prior calendar year if not yet paid as of the date of such Severance Termination; (iv)&#160;an amount equal to twelve months of the premiums such named executive officer is required to pay under the Consolidated Omnibus Budget Reconciliation Act of 1985, as amended (&#8220;COBRA&#8221;) to continue coverage for him and his eligible dependents under our group health plans; and (v)&#160;the accelerated vesting of such named executive officer&#8217;s unvested equity incentive awards that would have vested during the period beginning on the date of such Severance Termination and ending on (1)&#160;in case of a Severance Termination of Dr.&#160;Hedrick and Dr.&#160;LaFrance, twelve months thereafter, or (ii)&#160;in the case of a Severance Termination of Mr.&#160;Sims, nine months thereafter. In order to be eligible for the benefits set forth above, such named executive officer must sign (and not revoke) a general release of claims in favor of the Company as of the date of the Severance Termination, as applicable (a &#8220;Release&#8221;). </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If a Severance Termination occurs within the period beginning on the date the Company and an acquiror formally or informally agree on the terms of a transaction which, if consummated, would constitute a &#8220;change in control&#8221; and ending on the closing date of the change in control, or within twelve months following a change in control, upon signing a Release (a &#8220;CoC Termination&#8221;), such named executive officer will be eligible to receive: (i)&#160;those items listed in the above paragraph under subclauses (ii)&#160;and (iii); (ii) an amount equal to (1)&#160;in the case of a CoC Termination of Dr.&#160;Hedrick or Dr.&#160;LaFrance, 18 months of the greater of his base salary in effect immediately prior to the date of such CoC Termination and his base salary in effect on the date the terms of a transaction that results in a change in control are agreed to, or (2)&#160;in the case of a CoC Termination of Mr.&#160;Sims, 12 months of the greater of his base salary in effect immediately prior to the CoC Termination and his base salary in effect on the </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">73 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
date the terms of a transaction that results in a change in control; (iii)&#160;the amounts listed in the above paragraph under subclause (iv)&#160;except that, if the CoC Termination is for Dr.&#160;Hedrick or Dr.&#160;LaFrance, the amount of the COBRA payment will be increased to 18 months; (iv)&#160;the acceleration of such named executive officer&#8217;s remaining unvested equity incentive awards effective on the later of the CoC Termination and the date of the change in control; and (v)&#160;the right to exercise the equity incentive awards granted to him on or after the date of his Executive Employment Agreement until the later of (1)&#160;three months after the CoC Termination, (2)&#160;three months following the change in control with respect to any equity incentive awards that become exercisable upon a change in control due to this acceleration in connection with the change in control, and (3)&#160;any period specified in such named executive officer&#8217;s award agreements (but not beyond the original expiration date of any equity incentive award). Further, even if a CoC Termination does not occur, if any of our named executive officers remain employed by the Company as of the closing of such change in control, all of such named executive officer&#8217;s outstanding unvested incentive stock awards shall automatically accelerate on the date of such change of control. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the Executive Employment Agreements, the term &#8220;cause&#8221; generally refers to the occurrence of certain events including (i)&#160;the employee&#8217;s extended disability, (ii)&#160;employee&#8217;s repudiation of his employment or his Executive Employment Agreement, (iii)&#160;the employee&#8217;s conviction of a felony or certain misdemeanors, (iv)&#160;employee&#8217;s demonstrable and documented fraud, (v)&#160;intentional, reckless or grossly negligent action which causes material harm to the Company, (vi)&#160;intentional failure to substantially perform material employment duties or directives, and (vii)&#160;chronic absence from work for reasons other than illness, permitted vacation or resignation for good reason. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the Executive Employment Agreements, the term &#8220;good reason&#8221; generally refers to: (i)&#160;the Company&#8217;s material breach of its obligation to pay employee the compensation earned for any past service (at the rate which had been stated to be in effect for such period of service); (ii) a change in employee&#8217;s position with the Company which materially reduces the employee&#8217;s duties or stature in the business conducted by the Company; and (iii)&#160;a reduction in the employee&#8217;s level of compensation, provided, however, that a Company-wide reduction of compensation of not more than fifteen percent (15%) that is also applicable to all of the senior management team of the Company and which continues for less than three (3)&#160;months, shall not constitute Good Reason. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the Executive Employment Agreements, the term &#8220;change of control&#8221; generally refers to (i)&#160;a change in the composition of the Board, as a result of which <span style="white-space:nowrap">fewer&#160;than&#160;one-half&#160;of&#160;the</span> incumbent directors are directors who either: (A)&#160;had been directors of the Company; or (B)&#160;were elected, or nominated for election, to the Board with the affirmative votes of at least a majority of the aggregate of the original directors who were still in office at the time of the election or nomination and the directors whose election or nomination was previously so approved; (ii)&#160;any &#8220;person&#8221; who by the acquisition or aggregation of securities, is or becomes the &#8220;beneficial owner&#8221; (as defined <span style="white-space:nowrap">in&#160;Rule&#160;13d-3&#160;under&#160;the</span> Exchange Act), directly or indirectly, of securities of the Company representing 50% or more of the combined voting power of the Company&#8217;s then outstanding securities ordinarily having the right to vote at elections of directors (the &#8220;Base Capital Stock&#8221;); except that any change in the relative beneficial ownership of the Company&#8217;s securities by any person resulting solely from a reduction in the aggregate number of outstanding shares of Base Capital Stock, and any decrease thereafter in such person&#8217;s ownership of securities, shall be disregarded until such person increases in any manner, directly or indirectly, such person&#8217;s beneficial ownership of any securities of the Company; (iii)&#160;the consummation of a merger or consolidation of the Company with or into another entity or any other corporate reorganization, if persons who were not stockholders of the Company immediately prior to such merger, consolidation or other reorganization own immediately after such merger, consolidation or other reorganization 50% or more of the voting power of the outstanding securities of each of (A)&#160;the continuing or surviving entity and (B)&#160;any direct or indirect parent corporation of such continuing or surviving entity; or (iv)&#160;the sale, transfer or other disposition of all or substantially all of the Company&#8217;s assets. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">74 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Resignation, Retirement, Termination for Cause, or Resignation without Good Reason Arrangements </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company does not have any agreements or plans other than the Executive Employment Agreements in place for the named executive officers that would provide additional compensation in connection with a retirement. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Outstanding Equity Awards at Fiscal Year End </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table sets forth the information regarding each outstanding unexercised or unvested equity award held by our named executive officers as of December&#160;31, 2023. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:42%"/>

<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman;font-weight:bold">Name</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Option<br/>Grant&#160;Date&#160;(1)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Number&#160;of<br/>Securities<br/>Underlying<br/>Unexercised<br/>Options (#)<br/>Exercisable&#160;(3)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Number&#160;of<br/>Securities<br/>Underlying<br/>Unexercised<br/>Unearned&#160;Options</span><br/><span style="font-weight:bold">(#)<br/>Unexercisable&#160;(2)(3)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Option<br/>Exercise<br/>Price</span><br/><span style="font-weight:bold">($) (3)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Option<br/>Expiration<br/>Date</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Marc H. Hedrick, M.D.,</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">4/11/2014</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">267,750</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">4/11/2024</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">President and Chief Executive Officer</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">8/21/2014</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">157,500</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">8/21/2024</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1/30/2015</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">54,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1/30/2025</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1/4/2016</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">8</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">21,060</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1/4/2026</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3/8/2017</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">13</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">11,625</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3/8/2027</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">6/25/2020</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">8,170</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,164</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">32</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">6/25/2030</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2/16/2021</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">4,180</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,708</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">55</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2/16/2031</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">5/25/2021</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">8,649</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">4,736</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">34</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">5/25/2031</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2/15/2023</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">6,720</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">25,535</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">6</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2/15/2033</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Andrew Sims</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2/6/2020</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,091</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">576</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">33</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2/6/2030</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Chief Financial Officer</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2/16/2021</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3,154</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,288</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">55</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2/16/2031</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">5/25/2021</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">4,317</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,363</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">34</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">5/25/2031</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2/15/2023</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,451</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">5,510</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">6</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2/15/2033</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Norman LaFrance, M.D.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">11/11/2021</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">4,168</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3,832</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">26</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">11/11/2031</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Chief Medical Officer</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2/15/2023</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,047</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3,952</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">6</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2/15/2033</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
</table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(1)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">For a better understanding of this table, we have included an additional column showing the grant date of the stock options. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(2)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Unless otherwise provided, unvested stock options are subject to four-year vesting (from the grant date), and all stock options have a contractual term of 10 years from the date of grant. Awards presented in this table contain one of the following two vesting provisions: </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">With respect to an initial stock option grant to an employee, 1/4<sup style="font-size:75%; vertical-align:top">th</sup>&#160;of the shares subject to the award vest on <span style="white-space:nowrap">the&#160;one-year&#160;anniversary</span> of the vesting start date, while an additional 1/36th of the remaining option shares vest at the end of each month thereafter for 36 consecutive months, or </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">With respect to stock option grants made to an employee after one full year of employment, 1/48th of the shares subject to the award vest at the end of each month over a four-year period, as measured from the vesting start date. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(3)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">We consummated <span style="white-space:nowrap"><span style="white-space:nowrap">a&#160;1-for-15&#160;reverse</span></span> stock split in May 2016, <span style="white-space:nowrap"><span style="white-space:nowrap">a&#160;1-for-10&#160;reverse</span></span> stock split in May 2018, <span style="white-space:nowrap"><span style="white-space:nowrap">a&#160;1-for-50&#160;reverse</span></span> stock split in August 2019 and a <span style="white-space:nowrap"><span style="white-space:nowrap">1-for-15</span></span> reverse stock split in May 2023. The amounts set forth in this column reflect these four reverse stock splits. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="tx840996_23">Director Compensation </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table sets forth information concerning the compensation of our Board for the year ended December&#160;31, 2023. Please note that Dr.&#160;Hedrick receives no compensation for his role as director, and the entirety of his compensation is reported in the Summary Compensation Table. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">75 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto">


<tr>

<td style="width:60%"/>

<td style="vertical-align:bottom;width:6%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:6%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:6%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman;font-weight:bold">Name</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Fees&#160;Earned<br/>or&#160;Paid&#160;in<br/>Cash&#160;($)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Option<br/>Awards&#160;($)&#160;(1)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Total&#160;($)</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Richard J. Hawkins, Chairman</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">95,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">7,874</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">102,874</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Howard Clowes</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">67,500</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">7,874</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">75,374</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">An van <span style="white-space:nowrap">Es-Johansson,</span> M.D.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">57,500</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">7,874</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">65,374</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Robert Lenk, PhD</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">45,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">7,874</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">52,874</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Greg Petersen</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">72,500</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">7,874</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">80,374</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
</table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(1)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Amounts in this column represent awards of restricted stock options with the aggregate grant date fair value computed in accordance with FASB ASC Topic 718. The fair value determined at the date of grant in accordance with U.S. GAAP based on the closing price of our common stock on the applicable grant date. The vesting of these stock awards are service based and subject to continued participant as Board members. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We pay each <span style="white-space:nowrap">non-employee</span> director: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">$40,000 annual cash retainer for Board members; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">$37,500 annual cash retainer for the Chairman of the Board; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">$27,500 annual cash retainer for the Chairman of the Audit Committee; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">$15,000 annual cash retainer for the Chairman of our Compensation Committee; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">$10,000 annual cash retainer for the Chairman of our Nominating and Corporate Governance Committee; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">$5,000 annual cash retainer for <span style="white-space:nowrap">each&#160;non-Chairman&#160;committee</span> member; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Additional $2,500 annual retainer for <span style="white-space:nowrap">each&#160;non-Chairman&#160;Audit</span> Committee member. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">76 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="tx840996_14">CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">May 2024 PIPE Financing </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In May 2024, we entered into the Purchase Agreement whereby we issued and sold in a private placement: (i) 3,591,532 Private Placement Shares, or, at the election of each Purchaser, <span style="white-space:nowrap">Pre-Funded</span> Warrants exercisable immediately to purchase shares of common stock. Each Private Placement Share or <span style="white-space:nowrap">Pre-Funded</span> Warrant are accompanied by (i)&#160;Series A Common Stock Warrants to purchase one share of common stock, for an aggregate of 3,591,532 Series A Common Stock Warrants, and (ii)&#160;one Series B Common Warrants to purchase one share of common stock, for an aggregate of 3,591,532 Series B Common Warrants, for aggregate gross proceeds of $19.25&#160;million. Among the Purchasers were certain of our directors and officers, and the table below sets forth the number of shares of our common stock purchased by such holders at the closing of the May 2024 PIPE Financing: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">


<tr>

<td style="width:68%"/>

<td style="vertical-align:bottom;width:6%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:6%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom"><span style="font-weight:bold">Participant</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Shares of</span><br/><span style="font-weight:bold">Our</span><br/><span style="font-weight:bold">Common</span><br/><span style="font-weight:bold">Stock<br/>Purchase&#160;in<br/>the&#160;May&#160;2024<br/>PIPE<br/>Financing</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Total</span><br/><span style="font-weight:bold">Purchase</span><br/><span style="font-weight:bold">Price</span><br/><span style="font-weight:bold">($)</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Marc H. Hedrick, MD(1)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">36,765</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">25,000.20</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Andrew Sims(2)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">14,706</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">10,000.08</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Richard J. Hawkins(3)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">14,706</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">10,000.08</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Howard Clowes(4)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">29,412</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">20,000.16</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Robert Lenk, Ph.D.(5)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">12,501</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">8,500.68</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Greg Petersen(6)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">36,765</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">25,000.20</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
</table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(1)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Dr.&#160;Hedrick is the President, Chief Executive Officer and a director of Plus Therapeutics. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(2)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Mr.&#160;Sims is the Chief Financial Officer of Plus Therapeutics. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(3)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Mr.&#160;Hawkins is the Chairman of the Board of Plus Therapeutics. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(4)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Mr.&#160;Clowes is a director Plus Therapeutics. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(5)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Mr.&#160;Lenk is a director of Plus Therapeutics. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(6)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Mr.&#160;Petersen is a director of Plus. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">PIPE Financing Registration Rights </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with the May 2024 PIPE Financing, in May 2024 we entered into the Registration Rights Agreement with each Purchaser in the May 2024 PIPE Financing. Pursuant to the Registration Rights Agreement, we agreed to register the &#8220;registrable securities&#8221; held by the Purchasers on a registration statement, or registration statements, if necessary, to permit resale of such securities on a continuous basis pursuant to Rule 415. The &#8220;registrable securities&#8221; include (a)&#160;all shares of our common stock issued to the purchasers at the closing of the May 2024 PIPE Financing, and (b)&#160;any securities issued or then issuable upon any stock split, dividend or other distribution, recapitalization or similar event with respect to the foregoing. Under this registration rights agreement, we agreed to pay all fees and expenses incident to the performance of our obligations, including the reasonable fees of one counsel for the selling stockholders, excluding any underwriting, broker or similar fees or commissions, legal fees and other costs (except as agreed to be paid by us) of each Purchaser. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Stock Option Grants to Executive Officers and Directors </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have entered into employment agreements with our named executive officers pursuant to which we pay our named executive officers annual salaries and bonuses as more fully described above under &#8220;<a href="#tx840996_13"><span style="text-decoration:underline">Executive Compensation</span></a>.&#8221; Further, we have granted stock options to our executive officers and <span style="white-space:nowrap">non-employee</span> directors as more fully described above under &#8220;<a href="#tx840996_23"><span style="text-decoration:underline">Director Compensation</span></a>.&#8221; </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">77 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Policies for Approval of Related Party Transactions </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have adopted a written Related Person Transactions Policy that sets forth our policies and procedures regarding the identification, review, consideration, and oversight of &#8220;related person transactions.&#8221; For purposes of our Related Person Transactions Policy only, a &#8220;related person transaction&#8221; includes, subject to certain exceptions, a transaction, arrangement, or relationship (or any series of similar transactions, arrangements or relationships) in which we or any of our subsidiaries are participants involving an amount that exceeds $120,000, in which any &#8220;related person&#8221; has a material interest. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Transactions involving compensation for services provided to us as an employee, consultant, or director are not considered related person transactions under this policy. A related person is any executive officer, director, nominee to become a director or a holder of more than 5% of any class of our voting securities (including our common stock), including any of their immediate family members and affiliates, including entities owned or controlled by such persons. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The policy is administered by the Audit Committee that will approve only those transactions that are, in its judgment, appropriate or desirable under the circumstances. Under the policy, the related person in question or, in the case of transactions with a holder of more than 5% of any class of our voting securities, an officer with knowledge of the proposed transaction, must present information regarding the proposed related person transaction to our Audit Committee (or, where review by our Audit Committee would be inappropriate, to another independent body of our Board) for review. To identify related person transactions in advance, we rely on information supplied by our executive officers, directors, and certain significant stockholders. In considering related person transactions, our Audit Committee considers the relevant available facts and circumstances, which may include among other factors: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the risks, costs, and benefits to us; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the impact on a director&#8217;s independence in the event the related person is a director, immediate family member of a director or an entity with which a director is affiliated; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the terms of the transaction; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the availability of other sources for comparable services or products, and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">whether the terms of the transaction are fair to the Company and on terms no less favorable to the Company than terms that could have been reached with an unrelated third party. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Whether a transaction would present an improper conflict of interest for any director, director nominee or executive officer, taking into account the size of the transaction, the overall financial position of the applicable related person, the direct or indirect nature of the applicable related person, the ongoing nature of any proposed relationship and any other relevant factors. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">No director may participate in the discussion or approval of a transaction in which that director, or an immediate family member, has a direct or indirect interest. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our Audit Committee approves only those transactions that it determines are fair to us and in our and our stockholders&#8217; best interests. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">78 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="tx840996_15">SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table sets forth information regarding ownership of our common stock as of June&#160;7, 2024 by (a)&#160;each person known to us to own more than 5% of the outstanding shares of our common stock, (b)&#160;each of our directors, (c)&#160;each of our named executive officers and (d)&#160;all current directors and executive officers as a group. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We believe, based on information provided to us, that each of the stockholders listed below has sole voting and investment power with respect to the shares beneficially owned by the stockholder unless noted otherwise, subject to community property laws where applicable. The information below is based on 5,704,219 shares of common stock issued and outstanding as of May&#160;15, 2024. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:64%"/>

<td style="vertical-align:bottom;width:3%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:3%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:3%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:3%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom"><span style="font-weight:bold">Name and Address of Beneficial Owner (1)</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom" colspan="2" align="center"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Number&#160;of</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Shares of</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Common<br/>Stock</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Owned</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom" colspan="2" align="center"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Number of</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Shares of<br/>Common<br/>Stock</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Subject to<br/>Awards /<br/>Warrants(2)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom" colspan="2" align="center"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Total<br/>Number of<br/>Shares of</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Common<br/>Stock</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Beneficially</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Owned(3)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom" colspan="2" align="center"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Percent</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Ownership</p></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="4"/>
<td style="height:6pt" colspan="4"/>
<td style="height:6pt" colspan="4"/>
<td style="height:6pt" colspan="4"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">Greater than 5% Stockholders</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities associated with AIGH Capital Management, LLC(4)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">568,681</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,300</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">569,981</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">9.99</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">Directors and Named Executive Officers</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Marc H. Hedrick, M.D.(5)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">12,425</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">70,723</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">83,148</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1.44</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Andrew Sims(6)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">5,717</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">25,751</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">31,468</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">*</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Norman LaFrance, M.D.(7)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">9,620</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">9,620</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">*</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Howard Clowes(8)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">21,497</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">24,981</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">46,478</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">*</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">An van <span style="white-space:nowrap">Es-Johansson,</span> M.D. (9)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">5,373</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">5,373</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">*</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Richard J. Hawkins(10)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">4,902</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">17,850</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">22,752</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">*</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Greg Petersen(11)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">36,421</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">29,883</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">66,304</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1.16</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Robert P. Lenk(12)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">29,327</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">13,707</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">43,034</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">*</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">All current executive officers and directors as a group (8 persons)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">110,289</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">197,888</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">308,177</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">5.22</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
</table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:2%;vertical-align:top" align="left">*</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Less than 1%. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(1)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Unless otherwise indicated, the address of each of the persons listed above is c/o Plus Therapeutics, Inc., 4200 Marathon Blvd., Suite 200, Austin, TX 78756. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(2)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Shares of common stock subject to stock options or warrants currently exercisable or exercisable within 60&#160;days of June&#160;7, 2024 are deemed to be outstanding for computing the percentage ownership of the person holding such options or warrants and the percentage ownership of any group of which the holder is a member, but are not deemed outstanding for computing the percentage of any other person or group. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(3)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Reflects beneficial ownership of common stock as defined in Rule <span style="white-space:nowrap">13d-3</span> of the Exchange Act. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(4)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Reflects (i) AIGH Investment Partners, L.P. (&#8220;AIGH LP&#8221;) holdings of: (A) 188,537 shares of common stock, (B) 915,000 shares of common stock issuable upon exercise of <span style="white-space:nowrap">Pre-Funded</span> Warrants, (C)&#160;1,103,537 shares of common stock issuable upon the exercise of Series A Common Stock Warrants, and (D)&#160;1,103,537 shares of common stock issuable upon the exercise of Series B Common Stock Warrants; (ii) WVP Emerging Manager Onshore Fund, LLC &#8211; AIGH Series (&#8220;Onshore &#8211; AIGH&#8221;) holdings of: (A) 294,967 shares of common stock, (B) 294,967 shares of common stock issuable upon the exercise of Series A Common Stock Warrants, and (C) 294,967 shares of common stock issuable upon the exercise of Series B Common Stock Warrants; (iii) WVP Emerging Manager Onshore Fund, LLC &#8211; Optimized Equity Series (&#8220;Onshore &#8211; Optimized Equity&#8221;) holdings of: (A) 85,177 shares of common stock, (B) 85,177 shares of common stock issuable upon the exercise of Series A Common Stock Warrants, and (C) 85,177 shares of common stock issuable upon the exercise of Series B Common Stock Warrants; (iv) AIGH Investment Partners, LLC, a Delaware limited liability company (&#8220;AIGH LLC&#8221;) holdings of: (A) 123,640 shares of common stock issuable upon exercise of Pre-Funded Warrants, (B) 123,640 shares of common stock issuable upon the exercise of Series A Common Stock Warrants, and (C) 123,640 shares of common stock </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">79 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td align="left" style="vertical-align:top">
issuable upon the exercise of Series B Common Stock Warrants. Mr.&#160;Orin&#160;Hirschman (&#8220;Mr. Hirschman&#8221;) is the Managing Member of AIGH Capital Management, LLC, a Maryland limited liability company (&#8220;AIGH CM&#8221;), and president of AIGH LLC. AIGH CM is an advisor or sub-Advisor with respect to shares of the securities of the Company held by AIGH LP, Onshore &#8211; AIGH, Onshore &#8211; Optimized Equity and AIGH LLC. Mr. Hirschman has voting and investment control over the securities indirectly held by AIGH CM, directly held by AIGH LP and directly held by Mr. Hirschman and his family. The address of AIGH CM, AIGH LP, Onshore &#8211; AIGH, Onshore &#8211; Optimized Equity and AIGH LLC is 6006 Berkeley Avenue, Baltimore, MD 21209. The shares of common stock issuable upon exercise of the Pre-Funded Warrants, Series A Common Stock Warrants and Series B Common Stock Warrants held by AIGH LP, Onshore &#8211; AIGH, Onshore &#8211; Optimized Equity and AIGH LLC, are each subject to a beneficial ownership limitation of 9.99% and not reflected in the table above as being beneficially owned. </td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(5)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Reflects (i) 12,425 shares of common stock; (ii) 12,255 shares of common stock issuable upon the exercise of Series A Common Stock Warrants; (iii) 12,255 shares of common stock issuable upon the exercise of Series B Common Stock Warrants; and (iv)&#160;46,213 shares of common stock underlying unvested options to purchase shares of common stock held by Dr.&#160;Hedrick that will vest within 60 days of June&#160;7, 2024. The Common Warrants are subject to a beneficial ownership limitation of 4.99%, which such limitation restricts the selling stockholder from exercising that portion of the Common Warrants that would result in the selling stockholder owning, after exercise, a number of shares of common stock in excess of the beneficial ownership limitation. Dr.&#160;Hedrick is the President, Chief Executive Officer and a director of Plus Therapeutics. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(6)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Reflects (i) 5,717 shares of common stock; (ii) 4,902 shares of common stock issuable upon the exercise of Series A Common Stock Warrants; (iii) 4,902 shares of common stock issuable upon the exercise of Series B Common Stock Warrants; and (iv)&#160;15,947 shares of common stock underlying unvested options to purchase shares of common stock held by Mr.&#160;Sims that will vest within 60 days of June&#160;7, 2024. The Common Warrants are subject to a beneficial ownership limitation of 4.99%, which such limitation restricts the selling stockholder from exercising that portion of the Common Warrants that would result in the selling stockholder owning, after exercise, a number of shares of common stock in excess of the beneficial ownership limitation. Mr.&#160;Sims is the Chief Financial Officer of Plus Therapeutics. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(7)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Reflects 9,620 shares of common stock underlying unvested options to purchase shares of common stock held by Mr.&#160;LaFrance that will vest within 60 days of June&#160;7, 2024. Mr.&#160;LaFrance is the Chief Medical Officer of Plus Therapeutics. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(8)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Reflects (i) 21,497 shares of common stock; (ii) 9,804 shares of common stock issuable upon the exercise of Series A Common Stock Warrants; and (iii) 9,804 shares of common stock issuable upon the exercise of Series B Common Stock Warrants; and (iv)&#160;5,373 shares of common stock underlying unvested options to purchase shares of common stock held by Mr.&#160;Clowes that will vest within 60 days of June&#160;7, 2024. The Common Warrants are subject to a beneficial ownership limitation of 4.99%, which such limitation restricts the selling stockholder from exercising that portion of the Common Warrants that would result in the selling stockholder owning, after exercise, a number of shares of common stock in excess of the beneficial ownership limitation. Mr.&#160;Clowes is a director of Plus Therapeutics. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(9)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Reflects 5,373 shares of common stock underlying unvested options to purchase shares of common stock held by Dr.&#160;van <span style="white-space:nowrap">Es-Johansson</span> that will vest within 60 days of June&#160;7, 2024. Dr.&#160;van <span style="white-space:nowrap">Es-Johansson</span> is a director of Plus Therapeutics. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(10)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Reflects (i) 4,902 shares of common stock; (ii) 4,902 shares of common stock issuable upon the exercise of Series A Common Stock Warrants; (iii) 4,902 shares of common stock issuable upon the exercise of Series B Common Stock Warrants; and (iv)&#160;8,046 shares of common stock underlying unvested options to purchase shares of common stock held by Mr.&#160;Hawkins that will vest within 60 days of June&#160;7, 2024. The Common Warrants are subject to a beneficial ownership limitation of 4.99%, which such limitation restricts the selling stockholder from exercising that portion of the Common Warrants that would result in the selling stockholder owning, after exercise, a number of shares of common stock in excess of the beneficial ownership limitation. Mr.&#160;Hawkins is the Chairman of the Board of Plus Therapeutics. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">80 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(11)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Reflects (i) 36,421 shares of common stock; (ii) 12,255 shares of common stock issuable upon the exercise of Series A Common Stock Warrants; (iii) 12,255 shares of common stock issuable upon the exercise of Series B Common Stock Warrants; and (iv)&#160;5,373 shares of common stock underlying unvested options to purchase shares of common stock held by Mr.&#160;Petersen that will vest within 60 days of June&#160;7, 2024. The Common Warrants are subject to a beneficial ownership limitation of 4.99%, which such limitation restricts the selling stockholder from exercising that portion of the Common Warrants that would result in the selling stockholder owning, after exercise, a number of shares of common stock in excess of the beneficial ownership limitation. Mr.&#160;Petersen is a director of Plus Therapeutics. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(12)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Reflects (i) 29,327 shares of common stock; (ii) 4,167 shares of common stock issuable upon the exercise of Series A Common Stock Warrants; (iii) 4,167 shares of common stock issuable upon the exercise of Series B Common Stock Warrants; and (iv)&#160;5,373 shares of common stock underlying unvested options to purchase shares of common stock held by Mr.&#160;Lenk that will vest within 60 days of June&#160;7, 2024. The Common Warrants are subject to a beneficial ownership limitation of 4.99%, which such limitation restricts the selling stockholder from exercising that portion of the Common Warrants that would result in the selling stockholder owning, after exercise, a number of shares of common stock in excess of the beneficial ownership limitation. Mr.&#160;Lenk is a director of Plus Therapeutics. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">81 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="tx840996_16">DESCRIPTION OF SECURITIES </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">The following summary of the material terms of our capital stock is not intended to be a complete summary of the rights and preferences of such securities, and is qualified by reference to our Charter and Bylaws described herein, which are exhibits to the registration statement of which this prospectus is a part. We urge you to read each of the documents described herein in their entirety for a complete description of the rights and preferences of our securities. </span></p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Authorized and Outstanding Capital Stock </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our Charter authorizes the issuance of 100,000,000 shares of common stock, par value $0.001 per share, and 5,000,000 shares of preferred stock. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Common Stock </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Voting </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Except as otherwise required by our Charter, holders of shares of common stock are generally entitled to vote. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Dividends </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The holders of shares of common stock are entitled to receive dividends, as and if declared by our Board out of our assets that are by law available for such use. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Liquidation or Dissolution </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Upon our liquidation, dissolution or winding up of our affairs, after payment or provision for payment of the debts and other liabilities of ours as required by law and of the preferential and other amounts, if any, to which the holders of preferred stock shall be entitled, the holders of all outstanding shares of common stock will be entitled to receive our remaining assets available for distribution ratably in proportion to the number of shares held by each such stockholder. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Redemption Rights </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Holders of shares of common stock do not have preemptive, subscription, redemption, or conversion rights with respect to such shares of common stock. There are no redemption or sinking fund provisions applicable to common stock. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Preferred Stock </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are authorized to issue up to 5,000,000 shares of preferred stock. Our Board is authorized, subject to limitations prescribed by law, to provide for the issuance of shares of preferred stock in one or more series, and with respect to each series, to establish the number of shares to be included in each such series, and to fix the voting powers (if any), designations, powers, preferences, and relative, participating, optional or other special rights, if any, of the shares of each such series, and any qualifications, limitations or restrictions thereof. The powers (including voting powers), preferences, and relative, participating, optional and other special rights of each series of preferred stock and the qualifications, limitations or restrictions thereof, if any, may differ from those of any other series at any time outstanding. Subject to the rights of the holders of any series of preferred stock, the number of authorized shares of preferred stock may be increased or decreased (but not below the number of shares of preferred stock then outstanding) by the approval of our Board and by the affirmative vote of the holders of a majority in voting power of the outstanding shares of our capital stock entitled to vote generally in an election of directors, without the separate vote of the holders of the preferred stock as a class, irrespective of the provisions of Section&#160;242(b)(2) of the DGCL. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">82 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of June&#160;7, 1,952 shares of preferred stock were issued and outstanding. The preferred stock consists of (i) 13,500 shares designated as Series B Convertible Preferred Stock (&#8220;Series B Preferred Stock&#8221;), out of which 1,014 of the Series B Preferred Stock are outstanding; (ii) 23,500 shares designated as Series C Convertible Preferred Stock (&#8220;Series C Preferred Stock&#8221;), out of which 938 of the Series C Preferred Stock are outstanding of Series; and (iii) 1 share designated as Series F Preferred Stock that is not outstanding. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Series B Preferred Stock </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Voting Rights </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Except as otherwise provided in the certificate of designation for the Series B Preferred Stock or as otherwise required by law, the Series B Preferred Stock has no voting rights. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Dividends </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Holders of Series B Preferred Stock are entitled to receive dividends (on <span style="white-space:nowrap"><span style="white-space:nowrap"><span style="white-space:nowrap"><span style="white-space:nowrap">an&#160;as-if-converted-to-common-stock&#160;basis)</span></span></span></span> in the same form as dividends actually paid on shares of the common stock when, as and if such dividends are paid on shares of common stock. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Liquidation&#160;Preference </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Upon our liquidation, dissolution <span style="white-space:nowrap">or&#160;winding-up,&#160;whether</span> voluntary or involuntary, holders of Series B Preferred Stock will be entitled to receive out of our assets, whether capital or surplus, an amount equal to the $1,000 stated value per share for each share of Series B Preferred Stock before any distribution or payment is paid to the holders of our common stock. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Conversion </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each share of Series B Preferred Stock is convertible, at our option or at the option of the holder, at any time, into the number of shares of our common stock determined by dividing the $1,000 stated value per share of the Series B Preferred Stock by a conversion price of $2,547.74 per share. In addition, the conversion price per share is subject to adjustment for stock dividends, distributions, subdivisions, combinations or reclassifications. Subject to limited exceptions, a holder of the Series B Preferred Stock will not have the right to convert any portion of the Series B Preferred Stock to the extent that, after giving effect to the conversion, the holder, together with its affiliates, would beneficially own in excess of 9.99% of the number of shares of our common stock outstanding immediately after giving effect to its conversion. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Fundamental Transactions </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the event we effect certain mergers, consolidations, sales of substantially all of our assets, tender or exchange offers, reclassifications or share exchanges in which our common stock is effectively converted into or exchanged for other securities, cash or property, we consummate a business combination in which another person acquires 50% of the outstanding shares of our common stock, or any person or group becomes the beneficial owner of 50% of the aggregate ordinary voting power represented by our issued and outstanding common stock, then, upon any subsequent conversion of the Series B Preferred Stock, a holder of the Series B Preferred Stock will have the right to receive any shares of the acquiring corporation or other consideration it would have been entitled to receive if it had been a holder of the number of shares of common stock then issuable upon conversion in full of the Series B Preferred Stock. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Redemption Rights </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are not obligated to redeem or repurchase any shares of Series B Preferred Stock. Shares of Series B Preferred Stock are not otherwise entitled to any redemption rights. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">83 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Series C Preferred Stock </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Voting Rights </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Except as otherwise provided in the certificate of designation for the Series C Preferred Stock or as otherwise required by law, the Series C Preferred Stock has no voting rights. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Dividends </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Holders of Series C Preferred Stock are entitled to receive dividends (on <span style="white-space:nowrap"><span style="white-space:nowrap"><span style="white-space:nowrap"><span style="white-space:nowrap">an&#160;as-if-converted-to-common-stock&#160;basis)</span></span></span></span> in the same form as dividends actually paid on shares of the common stock when, as and if such dividends are paid on shares of common stock. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Liquidation Preference </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Upon our liquidation, dissolution <span style="white-space:nowrap">or&#160;winding-up,&#160;whether</span> voluntary or involuntary, holders of Series C Preferred Stock will be entitled to receive out of our assets, whether capital or surplus, an amount equal to the $1,000 stated value per share for each share of Series C Preferred Stock before any distribution or payment shall be made to the holders of any junior securities. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Conversion</span>. Each share of Series C Preferred Stock is convertible, at our option at any time, subject to certain conditions, or at the option of the holder at any time, into the number of shares of our common stock determined by dividing the $1,000 stated value per share of the Series C Preferred Stock by a conversion price of $33.75. In addition, the conversion price per share is subject to adjustment for stock dividends, distributions, subdivisions, combinations or reclassifications. Subject to limited exceptions, a holder of the Series C Preferred Stock does not have the right to convert any portion of the Series C Preferred Stock to the extent that, after giving effect to the conversion, the holder, together with its affiliates, would beneficially own in excess of 9.99% of the number of shares of our common stock outstanding immediately after giving effect to its conversion. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Fundamental Transactions</span>. In the event we effect certain mergers, consolidations, sales of substantially all of our assets, tender or exchange offers, reclassifications or share exchanges in which our common stock is effectively converted into or exchanged for other securities, cash or property, we consummate a business combination in which another person acquires 50% of the outstanding shares of our common stock, or any person or group becomes the beneficial owner of 50% of the aggregate ordinary voting power represented by our issued and outstanding common stock, then, upon any subsequent conversion of the Series C Preferred Stock, a holder of the Series C Preferred Stock will have the right to receive any shares of the acquiring corporation or other consideration it would have been entitled to receive if it had been a holder of the number of shares of common stock then issuable upon conversion in full of the Series C Preferred Stock. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Anti-Dilution </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Subject to certain exceptions contained in the certificate of designation for the Series C Preferred Stock, including our ability to issue securities in connection with equity awards to service providers, strategic transactions, debt financings, research and development partnerships, an equity line of credit, our &#8220;at the market&#8221; equity offering program and other customary exceptions, if we issue or sell, or are deemed to have issued or sold, any shares of common stock or Common Stock Equivalents (as defined in the certificate of designation) for a consideration per share lower than the conversion price of the Series C Preferred Stock in effect immediately prior to such issuance or sale, or deemed issuance or sale, then the conversion price of the Series C Preferred Stock then in effect will be reduced to an amount equal to such lower price pursuant to the terms of the certificate of designation. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Redemption Rights </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are not obligated to redeem or repurchase any shares of Series C Preferred Stock. Shares of Series C Preferred Stock are not otherwise entitled to any redemption rights. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">84 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Anti-Takeover Effects of Delaware Law and Our Charter and Bylaws </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain provisions of Delaware law, our Charter and Bylaws could have the effect of delaying, deferring or discouraging another party from acquiring control of us. These provisions, which are summarized below, are expected to discourage certain types of coercive takeover practices and inadequate takeover bids. These provisions are also designed, in part, to encourage persons seeking to acquire control of us to first negotiate with our Board. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Charter and Bylaws</span>. Our Charter and Bylaws include provisions that: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:1%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">authorize our Board to issue, without stockholder approval, blank-check preferred stock with such designations, powers, preferences and other rights and qualifications, limitations or restrictions as our Board may authorize, which preferred stock could decrease the amount of earnings and assets available for distribution to holders of our common stock or adversely affect the rights and powers, including voting rights, of the holders of our common stock; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:1%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">establish advance notice requirements for stockholder nominations of directors and for stockholder proposals that can be acted on at stockholder meetings; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:1%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">limit who may call stockholder meetings; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:1%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">require that any action to be taken by our stockholders be effected at a duly called annual or special meeting and not by written consent; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:1%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">provide that vacancies on our Board may be filled only by a majority of directors then in office, even if less than a quorum; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:1%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">authorize us to indemnify officers and directors against losses that they may incur in investigations and legal proceedings resulting from their services to us, which may include services in connection with takeover defense measures. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Anti-takeover statute</span>. We are subject to the provisions of Section&#160;203 of the DGCL regulating corporate takeovers. In general, Section&#160;203 prohibits a publicly-held Delaware corporation from engaging, under certain circumstances, in a business combination with an interested stockholder for a period of three years following the date the person became an interested stockholder unless: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:1%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">prior to the date of the transaction, the board of directors of the corporation approved either the business combination or the transaction which resulted in the stockholder becoming an interested stockholder; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:1%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">upon completion of the transaction that resulted in the stockholder becoming an interested stockholder, the interested stockholder owned at least 85% of the voting stock of the corporation outstanding at the time the transaction commenced, excluding for purposes of determining the voting stock outstanding, but not the outstanding voting stock owned by the interested stockholder, (1)&#160;shares owned by persons who are directors and also officers and (2)&#160;shares owned by employee stock plans in which employee participants do not have the right to determine confidentially whether shares held subject to the plan will be tendered in a tender or exchange offer; or </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:1%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">at or subsequent to the date of the transaction, the business combination is approved by the board of directors of the corporation and authorized at an annual or special meeting of stockholders, and not by written consent, by the affirmative vote of at <span style="white-space:nowrap">least&#160;66-2/3%&#160;of</span> the outstanding voting stock which is not owned by the interested stockholder. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Generally, a &#8220;business combination&#8221; includes a merger, asset or stock sale, or other transaction resulting in a financial benefit to the &#8220;interested stockholder&#8221; and an &#8220;interested stockholder&#8221; is a person who, together with affiliates and associates, owns or, within three years prior to the determination of interested stockholder status, did own 15% or more of a corporation&#8217;s outstanding voting stock. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">85 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We expect the existence of this provision to have an anti-takeover effect with respect to transactions our Board does not approve in advance. We also anticipate that Section&#160;203 may discourage business combinations or other attempts that might result in a premium over the market price for the shares of common stock held by our stockholders. The provisions of DGCL, our Charter and Bylaws could have the effect of discouraging others from attempting hostile takeovers and, as a consequence, they may also inhibit temporary fluctuations in the market price of our common stock that often result from actual or rumored hostile takeover attempts. These provisions may also have the effect of preventing changes in our management. It is possible that these provisions could make it more difficult to accomplish transactions that stockholders may otherwise deem to be in their best interests. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Exclusive Forum Selection </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our Bylaws require, to the fullest extent permitted by law, subject to limited exceptions, that derivative actions brought in our name, actions against directors, officers and employees for breach of fiduciary duty and other similar actions may be brought only in the Court of Chancery in the State of Delaware and, if brought outside of Delaware, the stockholder bringing the suit will be deemed to have consented to service of process on such stockholder&#8217;s counsel in any action brought to enforce the exclusive forum provision. Any person or entity purchasing or otherwise acquiring any interest in shares of our capital stock shall be deemed to have notice of and consented to the forum provisions in our Bylaws. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our Bylaws further provide that unless we consent in writing to the selection of an alternative forum, the federal district courts of the United States will be the sole and exclusive forum for resolving any complaint asserting a cause of action arising under the Securities Act and the respective rules and regulations promulgated thereunder. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Limitations on Liability and Indemnification of Officers and Directors </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our Charter limits the liability of our directors to the fullest extent permitted by the DGCL and provides that we will provide them with customary indemnification and advancement of expenses. We entered into customary indemnification agreements with each of our executive officers and directors that provide them, in general, with customary indemnification in connection with their service to us or on our behalf. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Transfer Agent and Registrar </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The transfer agent for our common stock and preferred stock is Broadridge Corporate Issuer Solutions, Inc. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Listing of Common Stock </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our common stock is listed on Nasdaq under the symbols &#8220;PSTV&#8221;. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">86 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="tx840996_17">SELLING STOCKHOLDERS </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The selling stockholders listed in the table below may from time to time offer and sell up to an aggregate of 10,774,596 shares of common stock pursuant to this prospectus and the applicable prospectus supplements, which consists of: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:1%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">up to 1,439,988 shares of common stock; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:1%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">up to 2,151,544<span style="font-weight:bold"> </span>shares of common stock issuable upon exercise of <span style="white-space:nowrap">Pre-Funded</span> Warrants; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:1%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">up to 3,591,532 shares of common stock issuable upon exercise of Series A Common Stock Warrants; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:1%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">up to 3,591,532 shares of common stock issuable upon exercise of Series B Common Stock Warrants. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For additional information regarding the issuance of these securities, see the section entitled &#8220;Prospectus Summary&#8212;<span style="text-decoration:underline"><a href="#tx840996_24">May 2024 PIPE Financing</a></span>.&#8221; </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The selling stockholders have not had any material relationship with us within the past three years, except for the ownership of our securities, and except that Marc H. Hedrick, M.D., is our President and Chief Executive Officer, and a member of our Board, Andrew Sims is our Chief Financial Officer, Richard J. Hawkins is Chairman of our Board, Robert Lenk, Ph.D., is a member of our Board, Greg Petersen is a member of our Board, and Howard Clowes is a member of our Board. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As used in this prospectus, the term &#8220;selling stockholders&#8221; includes the selling stockholders listed in the table below, together with any additional selling stockholders listed in a subsequent amendment to this prospectus, and their respective donees, pledgees, assignees, transferees or other <span style="white-space:nowrap"><span style="white-space:nowrap">successors-in-interest</span></span> selling shares of common stock or interests in shares of common stock received after the date of this prospectus from a selling stockholder as a gift, pledge, partnership distribution or other transfer. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In accordance with the terms of the Registration Rights Agreement with the selling stockholders, this prospectus covers the resale of the maximum number of shares of common stock issuable upon exercise of the <span style="white-space:nowrap">Pre-Funded</span> Warrants and Common Warrants without regard to any limitations on the exercise of such warrants. Under the terms of the <span style="white-space:nowrap">Pre-Funded</span> Warrants and Common Warrants held by selling stockholders, a selling stockholder may elect to the extent such exercise would cause such selling stockholder, together with its affiliates and attribution parties, to beneficially own a number of shares of common stock which would exceed 4.99% or 9.99%, as applicable, of our then outstanding shares common stock following such exercise, excluding for purposes of such determination shares of common stock issuable upon exercise of such warrants that have not been exercised, to instead receive a <span style="white-space:nowrap">Pre-Funded</span> Warrant in lieu of shares of common stock. The shares reported under &#8220;Number of Shares Owned&#8221; and &#8220;Number of Shares Being Offered&#8221; in the table below do not give effect to any such beneficial ownership limitation. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The table below lists the selling stockholders and other information regarding the beneficial ownership of the shares of common stock by each of the selling stockholders as of June&#160;7, 2024, assuming the full exercise of the <span style="white-space:nowrap">Pre-Funded</span> Warrants and warrants held by the selling stockholders on that date, without regard to any limitations on exercises. As of May&#160;15, 2024, we had 5,704,219 shares of common stock issued and outstanding. The following table also provides the number of shares of common stock that may be sold by each selling stockholder under this prospectus and that each selling stockholder will beneficially own assuming all the shares of common stock that may be offered pursuant to this prospectus are sold. Because each selling stockholder may dispose of all, none or some portion of their shares of common stock, no estimate can be given as to the number of shares of common stock that will be beneficially owned by a selling stockholder upon termination of this offering. For purposes of the table below, however, we have assumed that after termination of this offering none of the shares of common stock covered by this prospectus will be beneficially owned by the selling stockholders and further assumed that the selling stockholders will not acquire beneficial ownership of any additional securities during the offering. In addition, the selling stockholders may have sold, transferred or otherwise disposed of, or may sell, </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">87 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
transfer or otherwise dispose of, at any time and from time to time, our securities in transactions exempt from the registration requirements of the Securities Act after the date on which the information in the table is presented. See the section entitled &#8220;<span style="text-decoration:underline"><a href="#tx840996_18">Plan Of Distribution</a></span>.&#8221; </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain selling stockholders&#160;currently hold and may acquire shares of common stock, and common stock issuable upon the&#160;exercise&#160;of equity awards, in addition to those registered hereby. In accordance with the rules of the SEC, beneficial ownership includes voting or investment power with respect to securities and includes any shares issuable pursuant to stock options that are exercisable that are expected to settle within 60 days of June&#160;7, 2024. These shares are deemed to be outstanding and beneficially owned by the person holding those options for the purpose of computing the percentage ownership of that person, but they are not treated as outstanding for the purpose of computing the percentage ownership of any other person. The information contained in the following table is not necessarily indicative of beneficial ownership for any other purpose. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto">


<tr>

<td style="width:33%"/>

<td style="vertical-align:bottom;width:9%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:9%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:9%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:9%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Beneficial&#160;Ownership<br/>Before&#160;this&#160;Offering</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="6" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Beneficial&#160;Ownership<br/>After&#160;this&#160;Offering</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman;font-weight:bold">Selling Stockholder</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Number of<br/>Shares Owned</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Number&#160;of&#160;Shares&#160;Being<br/>Offered</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Number&#160;of<br/>Shares<br/>Owned</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Percentage&#160;of<br/>Outstanding<br/>Shares</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">AIGH Investment Partners, L.P.(1)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3,310,611</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3,310,611</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">WVP Emerging Manager Onshore Fund, LLC &#8211; AIGH Series(2)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">884,901</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">884,901</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">WVP Emerging Manager Onshore Fund, LLC - Optimized Equity Series(3)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">255,531</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">255,531</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">AIGH Investment Partners, LLC(4)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">370,920</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">370,920</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Iroquois Master Fund Ltd.(5)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,153,050</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,153,050</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Iroquois Capital Investment Group LLC(6)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,761,561</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,761,561</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">The Hewlett Fund LP(7)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,706,229</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,706,229</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Aramas Capital Management LLC(8)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">296,733</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">296,733</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pinz Capital Special Opportunities Fund, L.P.(9)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">296,733</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">296,733</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Globis Capital Partners, L.P.(10)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">593,472</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">593,472</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Marc H. Hedrick, M.D.(11)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">83,148</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">36,765</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">46,383</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">*</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Andrew Sims(12)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">31,468</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">14,706</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">16,762</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">*</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Richard J. Hawkins(13)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">22,753</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">14,706</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">8,047</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">*</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Howard Clowes(14)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">46,478</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">29,412</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">17,066</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">*</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Robert Lenk, Ph.D.(15)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">43,034</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">12,501</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">30,533</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">*</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Greg Petersen(16)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">66,304</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">36,765</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">29,539</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">*</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
</table> <p style="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">*</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Represents beneficial ownership of less than one percent (1%) of the outstanding shares of our common stock. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(1)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">The shares reported under &#8220;Beneficial Ownership Before this Offering&#8221; consist of the following securities purchased by AIGH LP in the May 2024 PIPE Financing: (i) 188,537 shares of common stock; </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">88 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td align="left" style="vertical-align:top">
(ii) 915,000 shares of common stock issuable upon exercise of <span style="white-space:nowrap">Pre-Funded</span> Warrants; (iii) 1,103,537 shares of common stock issuable upon the exercise of Series A Common Stock Warrants; and (iv) 1,103,537 shares of common stock issuable upon the exercise of Series B Common Stock Warrants. The <span style="white-space:nowrap">Pre-Funded</span> Warrants and Common Warrants are subject to a beneficial ownership limitation of 9.99%, which such limitation restricts the selling stockholder from exercising that portion of the <span style="white-space:nowrap">Pre-Funded</span> Warrants and Common Warrants that would result in the selling stockholder and its affiliates owning, after exercise, a number of shares of common stock in excess of the beneficial ownership limitation. Mr.&#160;Orin Hirschman is the managing member of AIGH CM, which is an advisor with respect to the securities held by AIGH LP. Mr.&#160;Hirschman has voting and investment control over the securities indirectly held by AIGH CM, directly held by AIGH LP and directly held by Mr.&#160;Hirschman and his family. The address of Mr.&#160;Hirschman and the entities listed is 6006 Berkeley Avenue, Baltimore, Maryland 21209. </td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(2)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">The shares reported under &#8220;Beneficial Ownership Before this Offering&#8221; include the following securities purchased by Onshore &#8211; AIGH in the May 2024 PIPE Financing: (i) 294,967 shares of common stock; (ii) 294,967 shares of common stock issuable upon the exercise of Series A Common Stock Warrants; and (iii) 294,967 shares of common stock issuable upon the exercise of Series B Common Stock Warrants. The Common Warrants are subject to a beneficial ownership limitation of 9.99%, which such limitation restricts the selling stockholder from exercising that portion of the Common Warrants that would result in the selling stockholder and its affiliates owning, after exercise, a number of shares of common stock in excess of the beneficial ownership limitation. Mr.&#160;Hirschman is the managing member of AIGH CM, which is a <span style="white-space:nowrap">sub-advisor</span> with respect to the securities held by Onshore &#8211; AIGH. Mr.&#160;Hirschman has voting and investment control over the securities indirectly held by AIGH CM and directly held by Mr.&#160;Hirschman and his family directly. The address of Mr.&#160;Hirschman and the entities listed is 6006 Berkeley Avenue, Baltimore, Maryland 21209. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(3)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">The shares reported under &#8220;Beneficial Ownership Before this Offering &#8221; consist of the following securities purchased by Onshore &#8211; Optimized Equity in the May 2024 PIPE Financing: (i) 85,177 shares of common stock; (ii) 85,177 shares of common stock issuable upon the exercise of Series A Common Stock Warrants; and (iii) 85,177 shares of common stock issuable upon the exercise of Series B Common Stock Warrants. The Common Warrants are subject to a beneficial ownership limitation of 9.99%, which such limitation restricts the selling stockholder from exercising that portion of the Common Warrants that would result in the selling stockholder and its affiliates owning, after exercise, a number of shares of common stock in excess of the beneficial ownership limitation. Mr.&#160;Hirschman is the managing member of AIGH CM, who is a <span style="white-space:nowrap">sub-advisor</span> with respect to the securities held by Onshore &#8211; Optimized Equity. Mr.&#160;Hirschman has voting and investment control over the securities indirectly held by AIGH CM and directly held by Mr.&#160;Hirschman and his family directly. The address of Mr.&#160;Hirschman and the entities listed is 6006 Berkeley Avenue, Baltimore, Maryland 21209. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(4)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">The shares reported under &#8220;Beneficial Ownership Before this Offering&#8221; consist of the following securities purchased by AIGH Investment Partners, LLC in the May&#160;2024 PIPE Financing: (i) 123,640 shares of common stock issuable upon exercise of <span style="white-space:nowrap">Pre-Funded</span> Warrants; (ii) 123,640 shares of common stock issuable upon the exercise of Series A Common Stock Warrants; and (iii) 123,640 shares of common stock issuable upon the exercise of Series B Common Stock Warrants. The <span style="white-space:nowrap">Pre-Funded</span> Warrants and Common Warrants are subject to a beneficial ownership limitation of 9.99%, which such limitation restricts the selling stockholder from exercising that portion of the <span style="white-space:nowrap">Pre-Funded</span> Warrants and Common Warrants that would result in the selling stockholder and its affiliates owning, after exercise, a number of shares of common stock in excess of the beneficial ownership limitation. Mr.&#160;Hirschman is the managing member of AIGH LLC. Mr.&#160;Hirschman has voting and investment control over the securities indirectly held by AIGH LLC and directly held by Mr.&#160;Hirschman and his family directly. The address of Mr.&#160;Hirschman and the entities listed is 6006 Berkeley Avenue, Baltimore, Maryland 21209. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(5)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">The shares reported under &#8220;Beneficial Ownership Before this Offering&#8221; consist of the following securities purchased by Iroquois Master Fund Ltd. In the May&#160;2024 PIPE Financing: (i) 75,000 shares of common stock; (ii) 309,350 shares of common stock issuable upon exercise of <span style="white-space:nowrap">Pre-Funded</span> Warrants; (iii) 384,350 shares of common stock issuable upon the exercise of Series A Common Stock Warrants; and (iv) 384,350 shares of common stock issuable upon the exercise of Series B Common Stock Warrants. The <span style="white-space:nowrap">Pre-Funded</span> </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">89 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td align="left" style="vertical-align:top">
Warrants and Common Warrants are subject to a beneficial ownership limitation of 4.99%, which such limitation restricts the selling stockholder from exercising that portion of the <span style="white-space:nowrap">Pre-Funded</span> Warrants and Common Warrants that would result in the selling stockholder and its affiliates owning, after exercise, a number of shares of common stock in excess of the beneficial ownership limitation. Iroquois Capital Management L.L.C. is the investment manager of Iroquois Master Fund, Ltd. Iroquois Capital Management, LLC has voting control and investment discretion over securities held by Iroquois Master Fund. As Managing Members of Iroquois Capital Management, LLC. Richard Abbe and Kimberly Page make voting and investment decisions on behalf of Iroquois Capital Management, LLC in its capacity as investment manager to Iroquois Master Fund Ltd. As a result of the foregoing, Mr.&#160;Abbe and Mrs.&#160;Page may be deemed to have beneficial ownership (as determined under Section&#160;13(d) of the Securities Exchange Act) of the securities held by Iroquois Capital Management and Iroquois Master Fund. The address for Iroquois Master Fund Ltd., Mr.&#160;Abbe and Mrs.&#160;Page is c/o Iroquois Capital Management, LLC, 2 Overhill Road, Suite 400, Scarsdale, New York 10583. </td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(6)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">The shares reported under &#8220;Beneficial Ownership Before this Offering&#8221; consist of the following securities purchased by Iroquois Capital Investment Group LLC in the May&#160;2024 PIPE Financing: (i) 139,000 shares of common stock; (ii) 448,187 shares of common stock issuable upon exercise of <span style="white-space:nowrap">Pre-Funded</span> Warrants; (iii) 587,187 shares of common stock issuable upon the exercise of Series A Common Stock Warrants; and (iv) 587,187 shares of common stock issuable upon the exercise of Series B Common Stock Warrants. The <span style="white-space:nowrap">Pre-Funded</span> Warrants and Common Warrants are subject to a beneficial ownership limitation of 4.99%, which such limitation restricts the selling stockholder from exercising that portion of the <span style="white-space:nowrap">Pre-Funded</span> Warrants and Common Warrants that would result in the selling stockholder and its affiliates owning, after exercise, a number of shares of common stock in excess of the beneficial ownership limitation. Mr.&#160;Richard Abbe is the managing member of&#160;Iroquois Capital Investment Group LLC. Mr.&#160;Abbe has voting control and investment discretion over securities held by&#160;Iroquois Capital Investment Group LLC. The address for Iroquois Capital Investment Group LLC and Mr.&#160;Abbe is 2 Over Hill Rd., Suite 500, Scarsdale, New York 10583. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(7)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">The shares reported under &#8220;Beneficial Ownership Before this Offering&#8221; consist of the following securities purchased by The Hewlett Fund LP in the May&#160;2024 PIPE Financing: (i) 213,376 shares of common stock; (ii) 355,367 shares of common stock issuable upon exercise of <span style="white-space:nowrap">Pre-Funded</span> Warrants; (iii) 568,743 shares of common stock issuable upon the exercise of Series A Common Stock Warrants; and (iv) 568,743 shares of common stock issuable upon the exercise of Series B Common Stock Warrants. The <span style="white-space:nowrap">Pre-Funded</span> Warrants and Common Warrants are subject to a beneficial ownership limitation of 4.99%, which such limitation restricts the selling stockholder from exercising that portion of the <span style="white-space:nowrap">Pre-Funded</span> Warrants and Common Warrants that would result in the selling stockholder and its affiliates owning, after exercise, a number of shares of common stock in excess of the beneficial ownership limitation. Mr.&#160;Martin Chopp, the general partner of the The Hewlett Fund LP, has voting and investment control over the securities held by Hewlett. The address for The Hewlett Fund LP and Mr.&#160;Chopp is 100 Merrick Road, Suite 400W, Rockville Centre, New York 11570. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(8)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">The shares reported under &#8220;Beneficial Ownership Before this Offering&#8221; consist of the following securities purchased by Aramas Capital Management LLC in the May&#160;2024 PIPE Financing: (i) 98,911 shares of common stock; (ii) 98,911 shares of common stock issuable upon the exercise of Series A Common Stock Warrants; and (iii) 98,911 shares of common stock issuable upon the exercise of Series B Common Stock Warrants. The Common Warrants are subject to a beneficial ownership limitation of 4.99%, which such limitation restricts the selling stockholder from exercising that portion of the Common Warrants that would result in the selling stockholder and its affiliates owning, after exercise, a number of shares of common stock in excess of the beneficial ownership limitation. Mr.&#160;Sam Ginzburg has sole voting and dispositive power over the shares held by Aramas Capital Management LLC. The address for Aramas Capital Management LLC and Mr.&#160;Ginzburg is c/o Aramas Capital Holdings LLC, 19 Orchard Street, Manhasset, New York 11030. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(9)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">The shares reported under &#8220;Beneficial Ownership Before this Offering&#8221; consist of the following securities purchased by Pinz Capital Special Opportunities Fund, L.P. in the May&#160;2024 PIPE Financing: (i) 98,911 shares of common stock; (ii) 98,911 shares of common stock issuable upon the exercise of Series A </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">90 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td align="left" style="vertical-align:top">
Common Stock Warrants; and (iii) 98,911 shares of common stock issuable upon the exercise of Series B Common Stock Warrants. The Common Warrants are subject to a beneficial ownership limitation of 4.99%, which such limitation restricts the selling stockholder from exercising that portion of the Common Warrants that would result in the selling stockholder and its affiliates owning, after exercise, a number of shares of common stock in excess of the beneficial ownership limitation. Mr.&#160;Matthew&#160;L. Pinz has sole voting and dispositive power over the shares held by Pinz Capital Special Opportunities Fund. The address for Pinz Capital Special Opportunities Fund and Mr.&#160;Pinz is 80 Dogwood Avenue, Roslyn Harbor, New York 11576. </td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(10)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">The shares reported under &#8220;Beneficial Ownership Before this Offering&#8221; consist of the following securities purchased by Globis Capital Partners, L.P. in the May&#160;2024 PIPE Financing: (i) 197,824 shares of common stock; (ii) 197,824 shares of common stock issuable upon the exercise of Series A Common Stock Warrants; and (iii) 197,824 shares of common stock issuable upon the exercise of Series B Common Stock Warrants. The Common Warrants are subject to a beneficial ownership limitation of 4.99%, which such limitation restricts the selling stockholder from exercising that portion of the Common Warrants that would result in the selling stockholder and its affiliates owning, after exercise, a number of shares of common stock in excess of the beneficial ownership limitation. Mr.&#160;Paul Packer is the managing member of&#160;Globis Capital Partners, L.P. and has voting and investment control over the securities held by&#160;Globis Capital Partners, L.P. The address for Globis Capital Partners, L.P. and Mr.&#160;Packer is 7100 W. Camino Real, Suite <span style="white-space:nowrap">302-48,</span> Boca Raton, FL 33433. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(11)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">The shares reported under &#8220;Beneficial Ownership Before this Offering&#8221; consist of the following securities purchased by Mr.&#160;Marc&#160;H. Hedrick, M.D. in the May 2024 PIPE Financing: (i) 12,255 shares of common stock; (ii) 12,255 shares of common stock issuable upon the exercise of Series A Common Stock Warrants; and (iii) 12,255 shares of common stock issuable upon the exercise of Series B Common Stock Warrants, as well as 170 shares of common stock held by Dr.&#160;Hedrick and 46,213 shares of common stock underlying unvested options to purchase shares of common stock held by Dr.&#160;Hedrick that will vest within 60 days of June&#160;7, 2024. The Common Warrants are subject to a beneficial ownership limitation of 4.99%, which such limitation restricts the selling stockholder from exercising that portion of the Common Warrants that would result in the selling stockholder owning, after exercise, a number of shares of common stock in excess of the beneficial ownership limitation. Dr.&#160;Hedrick is the President, Chief Executive Officer and a director of Plus Therapeutics and his address is c/o Plus Therapeutics, Inc., 4200 Marathon Boulevard, Suite 200, Austin, Texas 78756. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(12)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">The shares reported under &#8220;Beneficial Ownership Before this Offering&#8221; consist of the following securities purchased by Mr.&#160;Andrew Sims in the May 2024 PIPE Financing: (i) 4,902 shares of common stock; (ii) 4,902 shares of common stock issuable upon the exercise of Series A Common Stock Warrants; and (iii) 4,902 shares of common stock issuable upon the exercise of Series B Common Stock Warrants, as well as 815 shares of common stock held by Mr.&#160;Sims and 15,947 shares of common stock underlying unvested options to purchase shares of common stock held by Mr.&#160;Sims that will vest within 60 days of June&#160;7, 2024. The Common Warrants are subject to a beneficial ownership limitation of 4.99%, which such limitation restricts the selling stockholder from exercising that portion of the Common Warrants that would result in the selling stockholder owning, after exercise, a number of shares of common stock in excess of the beneficial ownership limitation. Mr.&#160;Sims is the Chief Financial Officer of Plus Therapeutics and his address is c/o Plus Therapeutics, Inc., 4200 Marathon Boulevard, Suite 200, Austin, Texas 78756. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(13)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">The shares reported under &#8220;Beneficial Ownership Before this Offering&#8221; consist of the following securities purchased by Mr.&#160;Richard Hawkins in the May 2024 PIPE Financing: (i) 4,902 shares of common stock; (ii) 4,902 shares of common stock issuable upon the exercise of Series A Common Stock Warrants; and (iii) 4,902 shares of common stock issuable upon the exercise of Series B Common Stock Warrants, as well as 8,046 shares of common stock underlying unvested options to purchase shares of common stock held by Mr.&#160;Hawkins that will vest within 60 days of June&#160;7, 2024. The Common Warrants are subject to a beneficial ownership limitation of 4.99%, which such limitation restricts the selling stockholder from exercising that portion of the Common Warrants that would result in the selling stockholder owning, after exercise, a number of shares of common stock in excess of the beneficial ownership limitation. Mr.&#160;Hawkins is the Chairman of the Board of Plus Therapeutics and his address is c/o Plus Therapeutics, Inc., 4200 Marathon Boulevard, Suite 200, Austin, Texas 78756. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">91 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(14)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">The shares reported under &#8220;Beneficial Ownership Before this Offering&#8221; consist of the following securities purchased by Mr.&#160;Howard Clowes in the May&#160;2024 PIPE Financing: (i) 9,804 shares of common stock; (ii) 9,804 shares of common stock issuable upon the exercise of Series A Common Stock Warrants; and (iii) 9,804 shares of common stock issuable upon the exercise of Series B Common Stock Warrants, as well as 11,693 shares of common stock held by Mr.&#160;Clowes and 5,373 shares of common stock underlying unvested options to purchase shares of common stock held by Mr.&#160;Clowes that will vest within 60 days of June&#160;7, 2024. The Common Warrants are subject to a beneficial ownership limitation of 4.99%, which such limitation restricts the selling stockholder from exercising that portion of the Common Warrants that would result in the selling stockholder owning, after exercise, a number of shares of common stock in excess of the beneficial ownership limitation. Mr.&#160;Clowes is a director of Plus Therapeutics and his address is c/o Plus Therapeutics, Inc., 4200 Marathon Boulevard, Suite 200, Austin, Texas 78756. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(15)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">The shares reported under &#8220;Beneficial Ownership Before this Offering&#8221; consist of the following securities purchased by Mr.&#160;Robert Lenk, Ph.D. in the May&#160;2024 PIPE Financing: (i) 4,167 shares of common stock; (ii) 4,167 shares of common stock issuable upon the exercise of Series A Common Stock Warrants; and (iii) 4,167 shares of common stock issuable upon the exercise of Series B Common Stock Warrants, as well as 25,160 shares of common stock held by Mr.&#160;Lenk and 5,373 shares of common stock underlying unvested options to purchase shares of common stock held by Mr.&#160;Lenk that will vest within 60 days of June&#160;7, 2024. The Common Warrants are subject to a beneficial ownership limitation of 4.99%, which such limitation restricts the selling stockholder from exercising that portion of the Common Warrants that would result in the selling stockholder owning, after exercise, a number of shares of common stock in excess of the beneficial ownership limitation. Mr.&#160;Lenk is a director of Plus Therapeutics and his address is c/o Plus Therapeutics, Inc., 4200 Marathon Boulevard, Suite 200, Austin, Texas 78756. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(16)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">The shares reported under &#8220;Beneficial Ownership Before this Offering&#8221; consist of the following securities purchased by Mr.&#160;Greg Petersen in the May&#160;2024 PIPE Financing: (i) 12,255 shares of common stock; (ii) 12,255 shares of common stock issuable upon the exercise of Series A Common Stock Warrants; and (iii) 12,255 shares of common stock issuable upon the exercise of Series B Common Stock Warrants, as well as 24,166 shares of common stock held by Mr.&#160;Petersen and 5,373 shares of common stock underlying unvested options to purchase shares of common stock held by Mr.&#160;Petersen that will vest within 60 days of June&#160;7, 2024. The Common Warrants are subject to a beneficial ownership limitation of 4.99%, which such limitation restricts the selling stockholder from exercising that portion of the Common Warrants that would result in the selling stockholder owning, after exercise, a number of shares of common stock in excess of the beneficial ownership limitation. Mr.&#160;Petersen is a director of Plus Therapeutics and his address is c/o Plus Therapeutics, Inc., 4200 Marathon Boulevard, Suite 200, Austin, Texas 78756. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">92 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="tx840996_18">PLAN OF DISTRIBUTION </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The selling stockholders, which as used in this prospectus includes the selling stockholders listed in the section of this prospectus entitled &#8220;<span style="text-decoration:underline"><a href="#tx840996_17">Selling Stockholders</a></span>&#8221;, together with any additional selling stockholders listed in a subsequent amendment to this prospectus, and their respective donees, pledgees, assignees, transferees or other <span style="white-space:nowrap"><span style="white-space:nowrap">successors-in-interest</span></span> selling shares of common stock or interests in shares of common stock received after the date of this prospectus from a selling stockholder as a gift, pledge, partnership distribution or other transfer, may, from time to time, sell, transfer or otherwise dispose of any or all of their shares of common stock or interests in shares of common stock on any stock exchange, market or trading facility on which the shares are traded or in private transactions. These dispositions may be at fixed prices, at prevailing market prices at the time of sale, at prices related to the prevailing market price, at varying prices determined at the time of sale, or at negotiated prices. The selling stockholders may use any one or more of the following methods when disposing of their securities or interests therein: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:1%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">On any national securities exchange or quotation service on which the securities may be listed or quoted at the time of sale; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:1%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">in the <span style="white-space:nowrap"><span style="white-space:nowrap">over-the-counter</span></span> market; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:1%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">ordinary brokerage transactions and transactions in which the broker-dealer solicits purchasers; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:1%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">block trades in which the broker-dealer will attempt to sell the securities as agent but may position and resell a portion of the block as principal to facilitate the transaction; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:1%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">through brokers, dealers or underwriters that may act solely as agents; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:1%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">purchases by a broker-dealer as principal and resale by the broker-dealer for its account; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:1%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">an exchange distribution in accordance with the rules of the applicable exchange; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:1%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">privately negotiated transactions; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:1%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">delivery of shares in settlement of short sales; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:1%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">in transactions through broker-dealers that agree with the Selling Stockholders to sell a specified number of such securities at a stipulated price per security; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:1%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">through the writing or settlement of options or other hedging transactions, whether through an options exchange or otherwise; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:1%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">a combination of any such methods of sale; or </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:1%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">any other method permitted pursuant to applicable law. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The selling stockholders may also sell securities under Rule 144 or any other exemption from registration under the Securities Act, if available, rather than under this prospectus. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Broker-dealers engaged by the selling stockholders may arrange for other brokers-dealers to participate in sales. Broker-dealers, underwriters and other agents may receive commissions or discounts from the selling stockholders (or, if any broker-dealer acts as agent for the purchaser of securities, from the purchaser) in amounts to be negotiated, but, except as set forth in a supplement to this prospectus, in the case of an agency transaction not in excess of a customary brokerage commission in compliance with FINRA Rule 2121; and in the case of a principal transaction a markup or markdown in compliance with FINRA Rule 2121. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The selling stockholders may from time to time pledge or grant a security interest in some or all of the shares of common stock owned by them and the pledgee or other secured party, transferee or other successor in interest may sell shares of common stock from time to time under this prospectus, or under a supplement or amendment to this prospectus under Rule 424(b)(3) or other applicable provision of the Securities Act amending the list of selling stockholders to include the pledgee, secured party, transferee or other successors in interest as selling </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">93 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
stockholders under this prospectus. The selling stockholders also may transfer the shares of common stock in other circumstances in which case the donees, pledgees, assignees, transferees or other <span style="white-space:nowrap"><span style="white-space:nowrap">successors-in-interest</span></span> may be the selling beneficial owners for purposes of this prospectus and may sell such shares of common stock from time to time under this prospectus after an amendment or supplement has been filed under Rule 424(b)(3) under, or another applicable provision of, the Securities Act, amending, if necessary, the list of selling stockholders to include the donees, pledgees, assignees, transferees or other <span style="white-space:nowrap"><span style="white-space:nowrap">successors-in-interest</span></span> as a selling stockholder under this prospectus. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Upon being notified in writing by the selling stockholder that any material arrangement has been entered into with a broker-dealer for the sale of shares of common stock through a block trade, special offering, exchange distribution or secondary distribution or a purchase by a broker or dealer, a supplement to this prospectus, if required, pursuant to Rule 424(b) under the Securities Act will be filed, disclosing (i)&#160;the name of each such selling stockholder and of the participating broker-dealer(s), (ii) the number of shares of common stock involved, (iii)&#160;the price at which such shares of common stock were sold, (iv)&#160;the commissions paid or discounts or concessions allowed to such broker-dealer(s), where applicable, (v)&#160;that such broker-dealer(s) did not conduct any investigation to verify the information set out or incorporated by reference in this prospectus, if applicable, and (vi)&#160;other facts material to the transaction. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The selling stockholders also may transfer the shares of common stock in other circumstances, in which case the donees, pledgees, assignees, transferees or other <span style="white-space:nowrap"><span style="white-space:nowrap">successors-in-interest</span></span> will be the selling beneficial owners for purposes of this prospectus. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with the sale of the securities or interests therein, the selling stockholders may enter into hedging transactions after the effective date of the registration statement of which this prospectus is a part with broker-dealers or other financial institutions, which may in turn engage in short sales of the securities in the course of hedging the positions they assume. The selling stockholders may also sell securities short after the effective date of the registration statement of which this prospectus forms a part and deliver these securities to close out their short positions, or loan or pledge the securities to broker-dealers that in turn may sell these securities. The selling stockholders may also enter into option or other transactions after the effective date of the registration statement of which this prospectus forms a part with broker-dealers or other financial institutions or create one or more derivative securities which require the delivery to such broker-dealer or other financial institution of securities offered by this prospectus, which securities such broker-dealer or other financial institution may resell pursuant to this prospectus (as supplemented or amended to reflect such transaction), including in the short sale transactions. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The selling stockholders and any broker-dealers or agents that are involved in selling the securities may be deemed to be &#8220;underwriters&#8221; within the meaning of the Securities Act in connection with such sales. In such event, any commissions received by such broker-dealers or agents and any profit on the resale of the securities purchased by them may be deemed to be underwriting commissions or discounts under the Securities Act. Each selling stockholder has informed the Company that it does not have any written or oral agreement or understanding, directly or indirectly, with any person to distribute the securities. Any compensation paid to underwriters, broker-dealers or agents in connection with the offering of the securities, and any discounts, concessions or commissions allowed by underwriters to participating dealers will be provided in the applicable prospectus supplement and shall comply with the rules and requirements of the Financial Industry Regulatory Authority. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company is required to pay certain fees and expenses incurred by the Company incident to the registration of the securities. The Company has agreed to indemnify the selling stockholders against certain losses, claims, damages and liabilities to which they may become subject, including liabilities under the Securities Act. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We agreed to keep this prospectus effective until the earlier of (i)&#160;the date that such securities become eligible for resale without volume or <span style="white-space:nowrap"><span style="white-space:nowrap">manner-of-sale</span></span> restrictions and without current public information pursuant to Rule 144 </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">94 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
and certain other conditions have been satisfied, or (ii)&#160;all of the securities have been sold pursuant to this prospectus or Rule 144 under the Securities Act or any other rule of similar effect. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There can be no assurance that any selling stockholder will sell any or all of the shares of common stock registered pursuant to the registration statement of which this prospectus forms a part. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under applicable rules and regulations under the Exchange Act, any person engaged in the distribution of the resale securities may not simultaneously engage in market making activities with respect to the common stock for the applicable restricted period, as defined in Regulation M, prior to the commencement of the distribution. In addition, the selling stockholders will be subject to applicable provisions of the Exchange Act and the rules and regulations thereunder, including Regulation M, which may limit the timing of purchases and sales of the common stock by the selling stockholders or any other person. Regulation M may also restrict the ability of any person engaged in the distribution of the shares of common stock to engage in market-making activities with respect to the shares of common stock. All of the foregoing may affect the marketability of the shares of common stock and the ability of any person or entity to engage in market-making activities with respect to the shares of common stock. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">95 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="tx840996_19">LEGAL MATTERS </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Hogan Lovells US LLP, Houston, Texas, will pass upon the validity of the shares of our common stock offered by this prospectus. </p> <p style="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="tx840996_20">EXPERTS </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The financial statements of Plus Therapeutics, Inc. (the Company) as of December&#160;31, 2023 and 2022 and for the years then ended included in this Prospectus and in the Registration Statement have been so included in reliance on the report of BDO USA, P.C., an independent registered public accounting firm, given on the authority of said firm as experts in auditing and accounting. The report on the financial statements contains an explanatory paragraph regarding the Company&#8217;s ability to continue as a going concern. </p> <p style="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="tx840996_21">WHERE YOU CAN FIND ADDITIONAL INFORMATION </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We file annual, quarterly and current reports, proxy statements and other information with the SEC. We have also filed a registration statement on <span style="white-space:nowrap">Form&#160;S-1,&#160;including</span> exhibits, under the&#160;Securities Act&#160;with respect to the shares of Class&#160;A common stock offered by this prospectus. This prospectus is part of the registration statement, but does not contain all of the information included in the registration statement or the exhibits. Our SEC filings are available to the public on the internet at a website maintained by the SEC located at<span style="font-style:italic">&#160;<span style="text-decoration:underline">www.sec.gov</span></span>. </p> <p style="font-size:18pt; margin-top:0pt; margin-bottom:0pt">&#160;</p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">96 </p>

</div></div>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/><div style="display: none"><ix:header><ix:hidden><ix:nonNumeric name="us-gaap:DebtInstrumentOfferingDate1" id="hidden116199096" contextRef="P01_01_2023To12_31_2023">2015-05-29</ix:nonNumeric><ix:nonNumeric name="us-gaap:DebtInstrumentOfferingDate1" id="hidden116199109" contextRef="P01_01_2022To12_31_2022">2015-05-29</ix:nonNumeric><ix:nonNumeric name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="hidden116200141" contextRef="PAsOn12_31_2023_MinimumMembersrtRangeAxis">P3Y</ix:nonNumeric><ix:nonFraction name="us-gaap:StockholdersEquityNoteStockSplitConversionRatio1" id="hidden116199108" contextRef="P04_20_2023To04_20_2023_MinimumMembersrtRangeAxis" unitRef="Unit_pure" decimals="2">0.33</ix:nonFraction><ix:nonFraction name="us-gaap:StockholdersEquityNoteStockSplitConversionRatio1" id="hidden116199110" contextRef="P04_20_2023To04_20_2023_MaximumMembersrtRangeAxis" unitRef="Unit_pure" decimals="2">0.06</ix:nonFraction><ix:nonFraction name="us-gaap:StockholdersEquityNoteStockSplitConversionRatio1" id="hidden116199113" contextRef="P04_21_2023To04_21_2023" unitRef="Unit_pure" decimals="2">0.06</ix:nonFraction><ix:nonFraction name="us-gaap:StockholdersEquityNoteStockSplitConversionRatio1" id="hidden116200119" contextRef="P04_20_2023To04_20_2023_MinimumMembersrtRangeAxis" unitRef="Unit_pure" decimals="2">0.33</ix:nonFraction><ix:nonFraction name="us-gaap:StockholdersEquityNoteStockSplitConversionRatio1" id="hidden116200122" contextRef="P04_20_2023To04_20_2023_MaximumMembersrtRangeAxis" unitRef="Unit_pure" decimals="2">0.06</ix:nonFraction><ix:nonFraction name="us-gaap:StockholdersEquityNoteStockSplitConversionRatio1" id="hidden116200127" contextRef="P04_21_2023To04_21_2023" unitRef="Unit_pure" decimals="2">0.06</ix:nonFraction></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="pstv-20240331.xsd"/></ix:references></ix:header></div><div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Plus Therapeutics, Inc. </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Index to Financial Statements </div></div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Unaudited Condensed Consolidated Financial Statements for the Quarters Ended March&#160;31, 2024 and March&#160;31, 2023 </div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;">
<tr>
<td style="width: 93%;"/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Page(s)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><a href="#fin840996_1">Condensed Balance Sheets</a></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">F-2</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><a href="#fin840996_2">Condensed Statements of Operations</a></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">F-3</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><a href="#fin840996_3">Condensed Statements of Stockholders&#8217; Equity/(Deficit)</a></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">F-4</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><a href="#fin840996_4">Condensed Consolidated Statements of Cash Flows</a></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">F-5</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><a href="#fin840996_5">Notes to Unaudited Condensed Financial Statements</a></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">F-6</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Consolidated Financial Statements for the Years Ended December&#160;31, 2023 and 2022</div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;">
<tr>
<td style="width: 93%;"/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Page(s)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><a href="#fin840996_6">Report of Independent Registered Public Accounting Firm</a></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">F-19</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><a href="#fin840996_7">Balance Sheets as of December&#160;31, 2023 and 2022</a></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">F-21</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><a href="#fin840996_8">Statements of Operations for the Years Ended December&#160;31, 2023 and 2022</a></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">F-22</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><a href="#fin840996_9">Statements of Stockholders&#8217; Equity (Deficit) for the Years Ended December&#160;31, 2023 and 2022</a></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">F-23</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><a href="#fin840996_10">Statements of Cash Flows for the Years Ended December&#160;31, 2023 and 2022</a></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">F-24</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><a href="#fin840996_11">Notes to Consolidated Financial Statements</a></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">F-25</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">F-1 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"></div></div></div></div> <div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">PLUS THERAPEUTICS, INC. </div></div></div><div id="fin840996_1" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">CONDENSED BALANCE SHEETS </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">(UNAUDITED) </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">(in thousands, except share and par value data) </div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;">
<tr>
<td style="width: 73%;"/>
<td style="width: 8%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 8%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">March&#160;31,&#160;2024</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,&#160;2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Assets</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Current assets:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Cash and cash equivalents</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="PAsOn03_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-22196">2,901</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-22197">8,554</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Investments</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:ShortTermInvestments" contextRef="PAsOn03_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-22198">323</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:ShortTermInvestments" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-22199">&#8212;</ix:nonFraction>&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Other current assets</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:OtherAssetsCurrent" contextRef="PAsOn03_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-22200">989</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:OtherAssetsCurrent" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-22201">1,280</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Total current assets</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="PAsOn03_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-22202">4,213</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-22203">9,834</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Property and equipment, net</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="PAsOn03_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-22204">800</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-22205">906</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Operating lease <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">right-use-of</div></div> assets</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="PAsOn03_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-22206">171</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-22207">202</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Goodwill</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:Goodwill" contextRef="PAsOn03_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-22208">372</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:Goodwill" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-22209">372</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Intangible assets, net</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:OtherIntangibleAssetsNet" contextRef="PAsOn03_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-22210">33</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:OtherIntangibleAssetsNet" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-22211">42</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Other assets</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:OtherAssetsNoncurrent" contextRef="PAsOn03_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-22212">32</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:OtherAssetsNoncurrent" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-22213">32</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Total assets</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:Assets" contextRef="PAsOn03_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-22214">5,621</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:Assets" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-22215">11,388</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Liabilities and Stockholders&#8217; Equity</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Current liabilities:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Accounts payable and accrued expenses</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" contextRef="PAsOn03_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-22216">6,447</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-22217">6,631</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Operating lease liability</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="PAsOn03_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-22218">115</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-22219">120</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Deferred grant liability</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:DeferredIncomeCurrent" contextRef="PAsOn03_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-22220">247</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:DeferredIncomeCurrent" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-22221">&#8212;</ix:nonFraction>&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Term loan obligation, current</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:LongTermDebtCurrent" contextRef="PAsOn03_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-22222">3,590</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:LongTermDebtCurrent" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-22223">3,976</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Total current liabilities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="PAsOn03_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-22224">10,399</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-22225">10,727</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Noncurrent operating lease liability</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="PAsOn03_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-22226">59</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-22227">85</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Deferred grant liability</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:DeferredIncomeNoncurrent" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-22228">1,924</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Total liabilities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:Liabilities" contextRef="PAsOn03_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-22229">10,458</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:Liabilities" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-22230">12,736</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Commitments and contingencies (Note 8)</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"><ix:nonFraction name="us-gaap:CommitmentsAndContingencies" contextRef="PAsOn03_31_2024" unitRef="Unit_USD" xsi:nil="true" id="ixv-22231"/></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"><ix:nonFraction name="us-gaap:CommitmentsAndContingencies" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" xsi:nil="true" id="ixv-22232"/></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Stockholders&#8217; deficit:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Preferred stock, $<ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="PAsOn03_31_2024" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-22233"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="PAsOn12_31_2023" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-22234">0.001</ix:nonFraction></ix:nonFraction>&#160;par value; <ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="PAsOn03_31_2024" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-22235"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="PAsOn12_31_2023" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-22236">5,000,000</ix:nonFraction></ix:nonFraction>&#160;shares authorized; <ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="PAsOn03_31_2024" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-22237"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="PAsOn12_31_2023" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-22238"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="PAsOn03_31_2024" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-22239"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="PAsOn12_31_2023" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-22240">1,952</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction>&#160;shares issued and outstanding at March&#160;31, 2024 and December&#160;31, 2023, respectively</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="PAsOn03_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-22241">&#8212;</ix:nonFraction>&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-22242">&#8212;</ix:nonFraction>&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Common stock, $<ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="PAsOn12_31_2023" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-22243"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="PAsOn03_31_2024" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-22244">0.001</ix:nonFraction></ix:nonFraction>&#160;par value; <ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="PAsOn03_31_2024" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-22245"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="PAsOn12_31_2023" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-22246">100,000,000</ix:nonFraction></ix:nonFraction>&#160;shares authorized; <div style="display:inline;"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="PAsOn03_31_2024" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-22247">4,522,656</ix:nonFraction></div>&#160;and <ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="PAsOn03_31_2024" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-22248">4,264,231</ix:nonFraction>&#160;issued and outstanding at March&#160;31, 2024, and <ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="PAsOn12_31_2023" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-22249">4,522,656</ix:nonFraction>&#160;issued and <ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="PAsOn12_31_2023" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-22250">4,444,097</ix:nonFraction>&#160;outstanding as of December&#160;31, 2023, respectively</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="PAsOn03_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-22251">5</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-22252">5</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Treasury stock (at cost, <ix:nonFraction name="us-gaap:TreasuryStockCommonShares" contextRef="PAsOn03_31_2024" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-22253">258,425</ix:nonFraction>&#160;and <ix:nonFraction name="us-gaap:TreasuryStockCommonShares" contextRef="PAsOn12_31_2023" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-22254">78,559</ix:nonFraction>&#160;shares as of March&#160;31, 2024 and December&#160;31, 2023, respectively)</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">(<ix:nonFraction name="us-gaap:TreasuryStockCommonValue" contextRef="PAsOn03_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-22255">500</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">(<ix:nonFraction name="us-gaap:TreasuryStockCommonValue" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-22256">126</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;">Additional <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">paid-in</div> capital</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="PAsOn03_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-22257">479,420</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-22258">479,274</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Accumulated deficit</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="PAsOn03_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-22259">483,762</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-22260">480,501</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Total stockholders&#8217; deficit</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn03_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-22261">4,837</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-22262">1,348</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Total liabilities and stockholders&#8217; deficit</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="PAsOn03_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-22263">5,621</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-22264">11,388</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">See Accompanying Notes to these Condensed Financial Statements </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">F-2 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">PLUS THERAPEUTICS, INC. </div></div></div><div id="fin840996_2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">CONDENSED STATEMENTS OF OPERATIONS </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">(UNAUDITED) </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">(in thousands, except share and per share data) </div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;">
<tr>
<td style="width: 70%;"/>
<td style="width: 9%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 9%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">For&#160;the&#160;Three&#160;Months&#160;Ended&#160;March&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">&#8195;&#8195;2024&#8195;&#8195;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">&#8195;&#8195;2023&#8195;&#8195;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Grant revenue</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:Revenues" contextRef="P01_01_2024To03_31_2024_GrantMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-22265">1,677</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:Revenues" contextRef="P01_01_2023To03_31_2023_GrantMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-22266">506</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Operating expenses:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Research and development</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="P01_01_2024To03_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-22267">2,763</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="P01_01_2023To03_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-22268">2,983</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">General and administrative</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="P01_01_2024To03_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-22269">2,213</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="P01_01_2023To03_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-22270">2,245</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Total operating expenses</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="P01_01_2024To03_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-22271">4,976</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="P01_01_2023To03_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-22272">5,228</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Operating loss</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="P01_01_2024To03_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-22273">3,299</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="P01_01_2023To03_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-22274">4,722</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Other income (expense):</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Interest income</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:InvestmentIncomeInterest" contextRef="P01_01_2024To03_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-22275">72</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:InvestmentIncomeInterest" contextRef="P01_01_2023To03_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-22276">51</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Interest expense</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">(<ix:nonFraction name="us-gaap:InterestExpense" contextRef="P01_01_2024To03_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-22277">34</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">(<ix:nonFraction name="us-gaap:InterestExpense" contextRef="P01_01_2023To03_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-22278">134</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Total other expense</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="P01_01_2024To03_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-22279">38</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">(<ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="P01_01_2023To03_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-22280">83</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Net loss</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2024To03_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-22281">3,261</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2023To03_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-22282">4,805</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Net loss per share, basic and diluted</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="P01_01_2024To03_31_2024" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:num-dot-decimal" id="ixv-22283"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="P01_01_2024To03_31_2024" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:num-dot-decimal" id="ixv-22284">0.75</ix:nonFraction></ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="P01_01_2023To03_31_2023" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:num-dot-decimal" id="ixv-22285"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="P01_01_2023To03_31_2023" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:num-dot-decimal" id="ixv-22286">2.07</ix:nonFraction></ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Basic and diluted weighted average shares used in calculating net loss per share attributable to common stockholders</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="P01_01_2024To03_31_2024" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-22287"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="P01_01_2024To03_31_2024" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-22288">4,321,731</ix:nonFraction></ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="P01_01_2023To03_31_2023" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-22289"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="P01_01_2023To03_31_2023" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-22290">2,320,017</ix:nonFraction></ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">See Accompanying Notes to these Condensed Financial Statements </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">F-3 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">PLUS THERAPEUTICS, INC. </div></div></div><div id="fin840996_3" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">CONDENSED STATEMENTS OF STOCKHOLDERS&#8217; EQUITY/(DEFICIT) </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">(UNAUDITED) </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">(In thousands, except share data) </div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 100%; font-family: Times New Roman; font-size: 8pt; border-collapse: collapse;">
<tr>
<td style="width: 32%;"/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 7.5pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Preferred&#160;stock</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Convertible<br/> preferred&#160;stock</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Common stock</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Treasury Stock</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" rowspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Additional<br/> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">paid-in</div></div></div><br/> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">capital</div></div></td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" rowspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Accumulated</div></div><br/> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">deficit</div></div></td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" rowspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Total<br/> stockholders&#8217;</div></div><br/> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">(deficit)/<br/> equity</div></div></td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 7.5pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Shares</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Amount</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Shares</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Amount</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Shares</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Amount</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Shares</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Amount</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">Balance at December&#160;31, 2022</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="PAsOn12_31_2022_ConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-22291">1,952</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="PAsOn12_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-22292">2,240,092</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-22293">2</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">&#160;<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-22294">473,628</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-22295">467,185</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-22296">6,445</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">Stock-based compensation</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="P01_01_2023To03_31_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-22297">140</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="P01_01_2023To03_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-22298">140</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">Sale of common stock, net</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="P01_01_2023To03_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-22299">168,164</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="P01_01_2023To03_31_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-22300">895</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="P01_01_2023To03_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-22301">895</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">Issuance of Series F preferred stock</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="P01_01_2023To03_31_2023_PreferredStockMemberusgaapStatementEquityComponentsAxis_SeriesFPreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-22302">1</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="P01_01_2023To03_31_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_SeriesFPreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-22303">1</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="P01_01_2023To03_31_2023_SeriesFPreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-22304">1</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">Net loss</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2023To03_31_2023_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-22305">4,805</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2023To03_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-22306">4,805</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">Balance at March&#160;31, 2023</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="PAsOn03_31_2023_PreferredStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-22307">1</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="PAsOn03_31_2023_ConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-22308">1,952</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="PAsOn03_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-22309">2,408,256</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn03_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-22310">2</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn03_31_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-22311">474,664</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn03_31_2023_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-22312">471,990</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn03_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-22313">2,676</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">Balance at December&#160;31, 2023</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="PAsOn12_31_2023_ConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-22314">1,952</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="PAsOn12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-22315">4,522,656</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-22316">5</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">(<ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="PAsOn12_31_2023_TreasuryStockCommonMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal" id="ixv-22317">78,559</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2023_TreasuryStockCommonMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-22318">126</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-22319">479,274</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2023_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-22320">480,501</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-22321">1,348</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">Stock-based compensation</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="P01_01_2024To03_31_2024_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-22322">146</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="P01_01_2024To03_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-22323">146</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">Purchase of treasury stock</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">(<ix:nonFraction name="us-gaap:TreasuryStockSharesAcquired" contextRef="P01_01_2024To03_31_2024_TreasuryStockCommonMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-22324">179,866</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">(<ix:nonFraction name="us-gaap:TreasuryStockValueAcquiredCostMethod" contextRef="P01_01_2024To03_31_2024_TreasuryStockCommonMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-22325">374</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">(<ix:nonFraction name="us-gaap:TreasuryStockValueAcquiredCostMethod" contextRef="P01_01_2024To03_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-22326">374</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">Net loss</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2024To03_31_2024_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-22327">3,261</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2024To03_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-22328">3,261</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">Balance at March&#160;31, 2024</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="PAsOn03_31_2024_ConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-22329">1,952</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="PAsOn03_31_2024_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-22330">4,522,656</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn03_31_2024_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-22331">5</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">(<ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="PAsOn03_31_2024_TreasuryStockCommonMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal" id="ixv-22332">258,425</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn03_31_2024_TreasuryStockCommonMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-22333">500</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn03_31_2024_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-22334">479,420</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn03_31_2024_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-22335">483,762</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn03_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-22336">4,837</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">See Accompanying Notes to these Condensed Financial Statements </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">F-4 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">PLUS THERAPEUTICS, INC. </div></div></div><div id="fin840996_4" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">CONDENSED STATEMENTS OF CASH FLOWS </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">(UNAUDITED) </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">(In thousands) </div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;">
<tr>
<td style="width: 76%;"/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">For the Three&#160;Months Ended<br/> March&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2024</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Cash flows used in operating activities:</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Net loss</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2024To03_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-22337">3,261</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2023To03_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-22338">4,805</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Adjustments to reconcile net loss to net cash used in operating activities:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Depreciation and amortization</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:DepreciationDepletionAndAmortization" contextRef="P01_01_2024To03_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-22339">155</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:DepreciationDepletionAndAmortization" contextRef="P01_01_2023To03_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-22340">158</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Amortization of deferred financing costs and debt discount</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" contextRef="P01_01_2024To03_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-22341">16</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" contextRef="P01_01_2023To03_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-22342">66</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Share-based compensation expense</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="P01_01_2024To03_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-22343">146</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="P01_01_2023To03_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-22344">140</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Accretion of discount on short-term investments</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" contextRef="P01_01_2024To03_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-22345">1</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;">Reduction in the carrying amount of operating lease <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">right-of-use</div></div> assets</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" contextRef="P01_01_2024To03_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-22346">31</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" contextRef="P01_01_2023To03_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-22347">29</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Loss on disposal of property and equipment</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:GainLossOnDispositionOfAssets" contextRef="P01_01_2023To03_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-22348">2</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Increases (decreases) in cash caused by changes in operating assets and liabilities:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Other current assets</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherCurrentAssets" contextRef="P01_01_2024To03_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-22349">150</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherCurrentAssets" contextRef="P01_01_2023To03_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-22350">2,791</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Accounts payable and accrued expenses</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" contextRef="P01_01_2024To03_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-22351">43</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" contextRef="P01_01_2023To03_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-22352">3,639</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Change in operating lease liabilities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" contextRef="P01_01_2024To03_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-22353">31</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" contextRef="P01_01_2023To03_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-22354">29</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Deferred grant liability</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">(<ix:nonFraction name="pstv:IncreaseDecreaseInDeferredGrantLiability" contextRef="P01_01_2024To03_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-22355">1,677</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">(<ix:nonFraction name="pstv:IncreaseDecreaseInDeferredGrantLiability" contextRef="P01_01_2023To03_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-22356">506</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Net cash used in operating activities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="P01_01_2024To03_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-22357">4,513</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="P01_01_2023To03_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-22358">5,793</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Cash flows used in investing activities:</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Purchases of property and equipment</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">(<ix:nonFraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="P01_01_2024To03_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-22359">40</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">(<ix:nonFraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="P01_01_2023To03_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-22360">97</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Purchase of short-term investments</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">(<ix:nonFraction name="us-gaap:PaymentsToAcquireShortTermInvestments" contextRef="P01_01_2024To03_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-22361">324</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Net cash used in investing activities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="P01_01_2024To03_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-22362">364</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="P01_01_2023To03_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-22363">97</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td colspan="8" style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Cash flows used in/provided by financing activities:</div></div></div></td>
<td style="vertical-align: top;"><div style="text-indent: 0em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Principal payments of term loan obligation</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">(<ix:nonFraction name="us-gaap:RepaymentsOfLongTermDebt" contextRef="P01_01_2024To03_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-22364">402</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">(<ix:nonFraction name="us-gaap:RepaymentsOfLongTermDebt" contextRef="P01_01_2023To03_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-22365">402</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Purchase of treasury stock</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">(<ix:nonFraction name="us-gaap:PaymentsForRepurchaseOfEquity" contextRef="P01_01_2024To03_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-22366">374</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Proceeds from sale of common stock, net</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="P01_01_2023To03_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-22367">895</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Net cash (used in) provided by financing activities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="P01_01_2024To03_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-22368">776</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="P01_01_2023To03_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-22369">493</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Net decrease in cash and cash equivalents</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">(<ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="P01_01_2024To03_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-22370">5,653</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">(<ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="P01_01_2023To03_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-22371">5,397</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Cash and cash equivalents at beginning of period</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-22372">8,554</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-22373">18,120</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Cash and cash equivalents at end of period</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">&#8195;&#8195;<ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="PAsOn03_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-22374">2,901</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">&#8195;&#8195;<ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="PAsOn03_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-22375">12,723</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td colspan="8" style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Supplemental disclosure of cash flows information:</div></div></div></td>
<td style="vertical-align: top;"><div style="text-indent: 0em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td colspan="8" style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Cash paid during period for:</div></div></td>
<td style="vertical-align: top;"><div style="text-indent: 0em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Interest</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:InterestPaidNet" contextRef="P01_01_2024To03_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-22376">23</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:InterestPaidNet" contextRef="P01_01_2023To03_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-22377">73</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td colspan="8" style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;">Supplemental schedule of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">non-cash</div> investing and financing activities:</div></div></td>
<td style="vertical-align: top;"><div style="text-indent: 0em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Unpaid offering cost</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="pstv:UnpaidOfferingCosts" contextRef="P01_01_2024To03_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-22378">141</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="pstv:UnpaidOfferingCosts" contextRef="P01_01_2023To03_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-22379">25</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">Right-of-use</div></div> assets obtained in exchange for operating lease liability</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" contextRef="P01_01_2023To03_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-22380">51</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">See Accompanying Notes to these Condensed Financial Statements </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">F-5 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">PLUS THERAPEUTICS, INC. </div></div></div><div id="fin840996_5" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">NOTES TO CONDENSED FINANCIAL STATEMENTS </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">March&#160;31, 2024 </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">(UNAUDITED) </div></div></div><ix:nonNumeric name="us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" contextRef="P01_01_2024To03_31_2024" escape="true" continuedAt="TextSelection_116200098" id="ixv-10807"><ix:nonNumeric name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" contextRef="P01_01_2024To03_31_2024" escape="true" id="ixv-10808"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">1. Basis of Presentation and New Accounting Standards </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The accompanying unaudited condensed financial statements for the three months ended March&#160;31, 2024 and 2023 have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information. Accordingly, they do not include all of the information and footnotes required by accounting principles generally accepted in the United States of America for annual financial statements. The condensed balance sheet at December&#160;31, 2023 has been derived from the audited financial statements at December&#160;31, 2023, but does not include all of the information and footnotes required by accounting principles generally accepted in the United States of America for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation of the financial position and results of operations of Plus Therapeutics, Inc. (the &#8220;Company&#8221;) have been included. Operating results for the three months ended March&#160;31, 2024 are not necessarily indicative of the results that may be expected for the year ending December&#160;31, 2024. These financial statements should be read in conjunction with the financial statements and notes therein included in the Company&#8217;s Annual Report on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">10-K</div> for the year ended December&#160;31, 2023, filed with the Securities and Exchange Commission on March&#160;5, 2024. </div></ix:nonNumeric><ix:nonNumeric name="pstv:AmendmentsForCertificateofIncorporationAndReverseStockSplitPolicyTextBlock" contextRef="P01_01_2024To03_31_2024" escape="true" id="ixv-10814"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Amendments to Certificate of Incorporation and Reverse Stock Split </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">At the Annual Meeting of Stockholders of the Company held on April&#160;20, 2023 (the &#8220;Annual Meeting&#8221;), the stockholders of the Company approved an amendment to the Company&#8217;s Amended and Restated Certificate of Incorporation (the &#8220;Charter&#8221;) to implement a reverse stock split of the Company&#8217;s then issued and outstanding common stock, par value $<ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="PAsOn04_20_2023" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-22381">0.001</ix:nonFraction> per share, with the ratio to be determined by the Board of Directors (the &#8220;Board&#8221;) of the Company, within a range of not less than <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;"><div style="-sec-ix-hidden:hidden116199108;display:inline;">1-for-3</div></div></div></div> and not greater than <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;"><div style="-sec-ix-hidden:hidden116199110;display:inline;">1-for-15</div></div>.</div></div> Subsequently, on April&#160;21, 2023, the Board determined to fix the ratio for the reverse stock split at <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;"><div style="-sec-ix-hidden:hidden116199113;display:inline;">1-for-15</div></div>,</div></div> without any change to its par value (the &#8220;Reverse Stock Split&#8221;). </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">On April&#160;27, 2023, following stockholder and Board approval, the Company filed a Certificate of Amendment to its Charter (the &#8220;Amendment&#8221;), with the Secretary of State of the State of Delaware to effectuate the Reverse Stock Split. The Amendment became effective on <ix:nonNumeric name="pstv:ReverseStockSplitEffectiveDate" contextRef="P04_27_2023To04_27_2023" format="ixt:date-monthname-day-year-en" id="ixv-22382">May 1, 2023</ix:nonNumeric>. Upon effectiveness of the Reverse Stock Split, the number of shares of the Company&#8217;s common stock (x)&#160;issued and outstanding decreased from approximately <ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="PAsOn04_30_2023" unitRef="Unit_shares" decimals="INF" scale="6" format="ixt:num-dot-decimal" id="ixv-22383">37.4</ix:nonFraction>&#160;million shares to approximately <ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="PAsOn05_01_2023" unitRef="Unit_shares" decimals="INF" scale="6" format="ixt:num-dot-decimal" id="ixv-22384">2.5</ix:nonFraction>&#160;million shares; (y)&#160;reserved for issuance upon exercise of outstanding warrants and options decreased from approximately <ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="PAsOn04_30_2023_OutstandingWarrantsAndOptionsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF" scale="6" format="ixt:num-dot-decimal" id="ixv-22385">2.0</ix:nonFraction>&#160;million shares to approximately <ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="PAsOn05_01_2023_OutstandingWarrantsAndOptionsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF" scale="6" format="ixt:num-dot-decimal" id="ixv-22386">0.1</ix:nonFraction>&#160;million shares, and (z)&#160;reserved but unallocated under the Company&#8217;s current equity incentive plans decreased from approximately <ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="PAsOn04_30_2023_EquityIncentivePlansMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="INF" scale="6" format="ixt:num-dot-decimal" id="ixv-22387">3.0</ix:nonFraction>&#160;million shares of common stock to approximately <ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="PAsOn05_01_2023_EquityIncentivePlansMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="INF" scale="6" format="ixt:num-dot-decimal" id="ixv-22388">0.2</ix:nonFraction>&#160;million shares of common stock. The Company&#8217;s common stock began trading on the Nasdaq Capital Market (&#8220;Nasdaq&#8221;) on a post-split basis on May&#160;1, 2023. The Company&#8217;s <ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="PAsOn03_31_2024" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-22389">5,000,000</ix:nonFraction> shares of authorized Preferred Stock were not affected by the Reverse Stock Split. <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockSplits" contextRef="P01_01_2024To03_31_2024" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt-sec:numwordsen" id="ixv-22390">No</ix:nonFraction> fractional shares were issued in connection with the Reverse Stock Split, and accordingly, the outstanding number of shares post Reverse Stock Split was adjusted down by approximately <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesReverseStockSplits" contextRef="P01_01_2024To03_31_2024" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-22391">1,310</ix:nonFraction> (post-effect of the Reverse Stock Split) shares. Proportional adjustments for the Reverse Stock Split were made to the Company&#8217;s outstanding stock options, warrants and equity incentive plans for the period ended March&#160;31, 2023 as presented in the condensed financial statements in this Quarterly Report on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">10-Q.</div> The Company&#8217;s financial statements, and all references thereto have been retroactively adjusted to reflect the Reverse Stock Split unless specifically stated otherwise. </div></ix:nonNumeric><ix:nonNumeric name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" contextRef="P01_01_2024To03_31_2024" escape="true" continuedAt="TextSelection_116199065" id="ixv-10833"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Grant Revenue Recognition </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">In applying the provisions of Accounting Standards Codification (&#8220;ASC&#8221;) Topic 606, Revenue from Contracts with Customers (&#8220;ASC 606&#8221;), the Company has determined that government grants are out of the scope of ASC </div></div><ix:exclude><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">F-6 </div></div></ix:exclude></ix:nonNumeric></ix:nonNumeric></div></div><ix:continuation id="TextSelection_116199065" continuedAt="TextSelectionAppend_116199065_1"><ix:continuation id="TextSelection_116200098" continuedAt="TextSelectionAppend_116200098_1"><ix:exclude><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_116200098_1" continuedAt="TextSelectionAppend_116200098_2"><ix:exclude><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/></ix:exclude></ix:continuation></ix:continuation><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelectionAppend_116200098_2" continuedAt="TextSelectionAppend_116200098_3"><ix:continuation id="TextSelectionAppend_116199065_1"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">606 because the funding entities do not meet the definition of a &#8220;customer&#8221;, as defined by ASC 606, as the Company does not consider there to be a transfer of control of goods or services. With respect to each grant, the Company determines if it has a collaboration in accordance with ASC Topic 808, Collaborative Arrangements (&#8220;ASC 808&#8221;). For grants outside the scope of ASC 808, the Company applies International Accounting Standards No.&#160;20 (&#8220;IAS 20&#8221;), Accounting for Government Grants and Disclosure of Government Assistance, by analogy, and revenue is recognized when the Company incurs expenses related to the grant for the amount the Company is entitled to under the provisions of the contract. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The Company also considers the guidance in ASC Topic 730, Research and Development, which requires an assessment, at the inception of each grant, of whether each grant agreement is a liability. If the Company is obligated to repay funds received regardless of the outcome of the related research and development activities, then the Company is required to estimate and recognize that liability. Alternatively, if the Company is not required to repay the funds, then payments received are recorded as revenue or contra-expense as the expenses are incurred. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Deferred grant liability represents grant funds received or receivable for which the allowable expenses have not yet been incurred as of the balance sheet date. </div></div></ix:continuation><ix:nonNumeric name="us-gaap:AvailableForSaleSecuritiesPurchasedOptionsPricePolicy" contextRef="P01_01_2024To03_31_2024" escape="true" id="ixv-10861"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">Available-for-Sale</div></div> Securities </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The Company&#8217;s <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">available-for-sale</div></div> securities consist of U.S. government and agency securities. The Company classifies its marketable securities as <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">available-for-sale</div></div> and records such assets at estimated fair value in the condensed balance sheets, with unrealized gains and losses, if any, reported as a component of other comprehensive income (loss) within the condensed statements of operations and comprehensive income/loss and as a separate component of stockholders&#8217; equity. Realized gains and losses are calculated on the specific identification method and recorded as interest income (loss). At each balance sheet date, the Company assesses <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">available-for-sale</div></div> securities in an unrealized loss position to determine whether the decline in fair value below amortized cost is a result of credit losses or other factors, whether the Company expects to recover the amortized cost of the security, the Company&#8217;s intent to sell and if it is more likely than not that the Company will be required to sell the securities before the recovery of amortized cost. The Company records changes in allowance for expected credit loss in other income (expense). As of March&#160;31, 2024, there were no <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">available-for-sale</div></div> securities in an unrealized loss position, and there has been no allowance for expected credit losses recorded during any of the periods presented. </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Any premium arising at purchase is amortized to the earliest call date and any discount arising at purchase is accreted to maturity. Accretion of discounts are recorded in interest income in the condensed statements of operations and comprehensive income/loss. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">During the three months ended March&#160;31, 2024, the unrealized gain on the Company&#8217;s <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">available-for-sale</div></div> securities was less than $<ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain" contextRef="P01_01_2024To03_31_2024_MaximumMembersrtRangeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-22392">1,000</ix:nonFraction>, and not presented separately in the condensed statement of operations and comprehensive income/loss. </div></ix:nonNumeric><ix:nonNumeric name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" contextRef="P01_01_2024To03_31_2024" escape="true" continuedAt="TextSelection_116199075" id="ixv-10880"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Recently Issued Accounting Pronouncements </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">In December 2023, the Financial Accounting Standards Board (the &#8220;FASB&#8221;) issued Accounting Standards Update (ASU) <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">No.&#160;2023-09</div> Income Taxes (Topic 740): Improvements to Income Tax Disclosure. This ASU includes amendments that further enhance income tax disclosures, primarily through standardization and disaggregation of rate reconciliation categories and income taxes paid by jurisdiction. The ASU is effective for years beginning after December&#160;15, 2024, but early adoption is permitted. This ASU should be applied on a prospective basis, although retrospective application is permitted. Management is currently evaluating the impact of the changes required by the new standard on the Company&#8217;s financial statements and related disclosures. </div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><ix:exclude>F-7</ix:exclude> </div></div></ix:nonNumeric></ix:continuation></div></div><ix:continuation id="TextSelection_116199075" continuedAt="TextSelectionAppend_116199075_1"><ix:continuation id="TextSelectionAppend_116200098_3" continuedAt="TextSelectionAppend_116200098_4"><ix:exclude><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_116200098_4" continuedAt="TextSelectionAppend_116200098_5"><ix:exclude><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/></ix:exclude></ix:continuation></ix:continuation> <div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelectionAppend_116200098_5"><ix:continuation id="TextSelectionAppend_116199075_1"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">In November 2023, the FASB issued Accounting Standard Update (ASU) <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">No.&#160;2023-07,</div> Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures. The new standard is intended to improve annual and interim reportable segment disclosure requirements regardless of number of reporting units, primarily through enhanced disclosures of significant expenses. The amendment requires public entities to disclose significant segment expenses that are regularly provided to <div style="display:inline;">the C</div>ODM and included within each reported measure of segment profit and loss. This update is effective for fiscal years beginning after December&#160;15, 2023, and interim periods within those fiscal years starting after December&#160;15, 2024. This ASU must be applied retrospectively to all prior periods presented. Management is <div style="display:inline;">currently </div>evaluating the impact of the changes required by the new standard on the Company&#8217;s financial statements and related <div style="display:inline;">disclosures</div>. </div></ix:continuation></ix:continuation><ix:nonNumeric name="pstv:UseOfEstimatesTextBlock" contextRef="P01_01_2024To03_31_2024" escape="true" id="ixv-10906"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">2. Use of Estimates </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The preparation of financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions affecting the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of r<div style="display:inline;">evenue and ex</div>penses during the reporting period. The Company&#8217;s most significant estimates and critical accounting policies involve reviewing a<div style="display:inline;">ssets for</div> impairment and determining the assumptions used in measuring stock-based compensation expense. </div></div></ix:nonNumeric><ix:nonNumeric name="pstv:DisclosureOfLiquidityAndGoingConcernTextBlock" contextRef="P01_01_2024To03_31_2024" escape="true" continuedAt="TextSelection_116199087" id="ixv-10914"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">3. Liquidity and Going Concern </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The Company incurred a net loss of $<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2024To03_31_2024" unitRef="Unit_USD" decimals="-5" scale="6" sign="-" format="ixt:num-dot-decimal" id="ixv-22394">3.3</ix:nonFraction>&#160;million for the three months ended March&#160;31, 2024. The Company had an accumulated deficit of $<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="PAsOn03_31_2024" unitRef="Unit_USD" decimals="-5" scale="6" sign="-" format="ixt:num-dot-decimal" id="ixv-22395">483.8</ix:nonFraction>&#160;million as of March&#160;31, 2024. Additionally, the Company used net cash of $<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="P01_01_2024To03_31_2024" unitRef="Unit_USD" decimals="-5" scale="6" sign="-" format="ixt:num-dot-decimal" id="ixv-22396">4.5</ix:nonFraction>&#160;million to fund its operating activities for the three months ended March&#160;31, 2024.<div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div> </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">To date, the Company&#8217;s operating losses have been funded primarily from outside sources of invested capital from issuance of its common and preferred stocks, proceeds from its term loan and grant funding. However, the Company has had, and will continue to have, an ongoing need to raise additional cash from outside sources to fund its future clinical development programs and other operations. There can be no assurance that the Company will be able to continue to raise additional capital in the future. The Company&#8217;s inability to raise additional cash would have a material and adverse impact on its operations and could cause the Company to default on its term loan. These factors raise substantial doubt about the Company&#8217;s ability to continue as a going concern. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">On May&#160;9, 2024, the Company closed a private placement of securities of the Company for aggregate gross proceeds of approximately $<ix:nonFraction name="us-gaap:WarrantsAndRightsOutstanding" contextRef="PAsOn05_09_2024_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_USD" decimals="-4" scale="6" format="ixt:num-dot-decimal" id="ixv-22397">7.25</ix:nonFraction>&#160;million, before deducting certain expenses payable by the Company, and excluding the proceeds, if any, from the exercise of warrants issued in the private placement. See Note 12 for further information regarding the private placement. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Nasdaq Listing Compliance </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">On March&#160;8, 2024, the Company received a letter (the &#8220;Notice&#8221;) from the Listing Qualifications staff of Nasdaq, notifying the Company that it no longer complied with the requirement under Nasdaq Listing Rule 5550(b)(1) to maintain a minimum of $<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="P03_08_2024To03_08_2024" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-22398">2.5</ix:nonFraction>&#160;million in stockholders&#8217; equity for continued listing on Nasdaq or the alternative requirements of having a market value of listed securities of $<ix:nonFraction name="pstv:MaintainMinimumMarketValueOfListedSecurities" contextRef="PAsOn03_08_2024" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal" id="ixv-22399">35</ix:nonFraction>&#160;million or net income from continuing operations of $<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperations" contextRef="P03_08_2024To03_08_2024" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-22400">500,000</ix:nonFraction> in the most recently completed fiscal year or two of the last three most recently completed fiscal years (the &#8220;Alternative Standards&#8221;). The Notice states that the Company&#8217;s Annual Report on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">10-K</div> for the fiscal year ended December&#160;31, 2023, disclosed stockholders&#8217; equity of ($<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal" id="ixv-22401">1,348,000</ix:nonFraction>) as of December&#160;31, 2023, and that, as of March&#160;8, 2024, the Company did not meet the Alternative Standards. </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">On April&#160;22, 2024, the Company provided Nasdaq with its plan to achieve and sustain compliance with the stockholders&#8217; equity requirement and requested that Nasdaq grant the Company an extension of time until September&#160;4, 2024, to provide evidence of compliance with the stockholders&#8217; equity requirement. Nasdaq has not yet responded to the Company&#8217;s plan, and there can be no assurance that Nasdaq will grant an extension or that the Company will be able to comply with the applicable listing standards of Nasdaq. </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><ix:exclude>F-8</ix:exclude> </div></div></ix:nonNumeric></div></div><ix:continuation id="TextSelection_116199087" continuedAt="TextSelectionAppend_116199087_1"><ix:exclude><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_116199087_1" continuedAt="TextSelectionAppend_116199087_2"><ix:exclude><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/></ix:exclude></ix:continuation><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelectionAppend_116199087_2"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The Company continues to seek additional capital from other financing alternatives and other sources in order to ensure adequate funding is available to allow the Company to continue research and product development activities at their current levels. If sufficient capital is not raised, the Company will at a minimum need to significantly reduce or curtail its research and development and other operations, and this would negatively affect its ability to achieve corporate growth goals. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Should the Company fail to raise additional cash from outside sources, it would have a material adverse impact on its operations. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The accompanying condensed financial statements have been prepared assuming the Company will continue to operate as a going concern, which contemplates the realization of assets and settlement of liabilities in the normal course of business, and do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classifications of liabilities that may result from uncertainty related to its ability to continue as a going concern. </div></div></ix:continuation><ix:nonNumeric name="us-gaap:FairValueMeasurementInputsDisclosureTextBlock" contextRef="P01_01_2024To03_31_2024" escape="true" id="ixv-10951"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">4. Fair Value Measurements </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Fair value measurements are market-based measurements, not entity-specific measurements. Therefore, fair value measurements are determined based on the assumptions that market participants would use in pricing the asset or liability. The Company follows a three-level hierarchy to prioritize the inputs used in the valuation techniques to derive fair values. The basis for fair value measurements for each level within the hierarchy is described below: </div></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentColor; border-image: none; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Level&#160;1: Quoted prices in active markets for identical assets or liabilities. </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentColor; border-image: none; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Level&#160;2: Quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar instruments in markets that are not active; and model-derived valuations in which all significant inputs are observable in active markets. </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentColor; border-image: none; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Level&#160;3: Valuations derived from valuation techniques in which one or more significant inputs are unobservable in active markets. </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The Company has investments in money market accounts, which are included in cash and cash equivalents on the balance sheets. Fair value inputs for these investments are considered Level&#160;1 measurements within the fair value hierarchy since money market account fair values are known and observable through daily published floating net asset values. </div></div><ix:nonNumeric name="us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock" contextRef="P01_01_2024To03_31_2024" escape="true" id="ixv-10992"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The following table summarizes the Company&#8217;s fair value hierarchy for its financial assets measured at fair value on a recurring basis as of March&#160;31, 2024 and December&#160;31, 2023, respectively (in thousands). </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 92%; font-family: Times New Roman; font-size: 8pt; border-collapse: collapse;">
<tr>
<td style="width: 64%;"/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="14" style="vertical-align: bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Fair Value Measurements Using</div></div></td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">March&#160;31, 2024</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Fair&#160;Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;1</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;2</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;3</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Money market</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="PAsOn03_31_2024_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapCashAndCashEquivalentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-22403">176</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="PAsOn03_31_2024_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapCashAndCashEquivalentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-22404">176</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Treasury bills and government agency bonds</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="PAsOn03_31_2024_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_USTreasurySecuritiesMemberusgaapCashAndCashEquivalentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-22405">323</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="PAsOn03_31_2024_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_USTreasurySecuritiesMemberusgaapCashAndCashEquivalentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-22406">323</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="PAsOn03_31_2024_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-22407">499</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="PAsOn03_31_2024_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-22408">499</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 12pt; font-family: &quot;Times New Roman&quot;;"/>
<td colspan="16" style="height: 12pt; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="14" style="vertical-align: bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Fair Value Measurements Using</div></div></td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31, 2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Fair&#160;Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;1</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;2</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;3</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Money market</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="PAsOn12_31_2023_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapCashAndCashEquivalentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-22409">5,449</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="PAsOn12_31_2023_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapCashAndCashEquivalentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-22410">5,449</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr></table></ix:nonNumeric></ix:nonNumeric><div style="clear:both;max-height:0pt;"></div><ix:nonNumeric name="us-gaap:DebtDisclosureTextBlock" contextRef="P01_01_2024To03_31_2024" escape="true" continuedAt="TextSelection_116199139" id="ixv-11228"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">5. Term Loan Obligations </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">On <ix:nonNumeric name="us-gaap:DebtInstrumentOfferingDate1" contextRef="P01_01_2024To03_31_2024_TermLoanMemberusgaapDebtInstrumentAxis" format="ixt:date-monthname-day-year-en" id="ixv-22411">May 29, 2015</ix:nonNumeric>, the Company entered into the Loan and Security Agreement (the &#8220;Loan and Security Agreement&#8221;), pursuant to which Oxford Finance, LLC (&#8220;Oxford&#8221;) funded an aggregate principal amount of </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><ix:exclude>F-9</ix:exclude> </div></div></ix:nonNumeric></div></div><ix:continuation id="TextSelection_116199139" continuedAt="TextSelectionAppend_116199139_1"><ix:exclude><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_116199139_1" continuedAt="TextSelectionAppend_116199139_2"><ix:exclude><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/></ix:exclude></ix:continuation> <div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelectionAppend_116199139_2"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">$<ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="PAsOn05_29_2015_TermLoanMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-22413">17.7</ix:nonFraction>&#160;million (the &#8220;Term Loan&#8221;), subject to the terms and conditions set forth in the Loan and Security Agreement. The Term Loan accrues interest at a floating rate of at least <ix:nonFraction name="pstv:DebtInstrumentFloatingInterestRatePercentage" contextRef="PAsOn05_29_2015_MinimumMembersrtRangeAxis_TermLoanMemberusgaapDebtInstrumentAxis" unitRef="Unit_pure" decimals="INF" scale="-2" format="ixt:num-dot-decimal" id="ixv-22414">8.95</ix:nonFraction>% per annum, comprised of a three-month LIBOR rate with a floor of <ix:nonFraction name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" contextRef="P05_28_2015To05_29_2015_InterestRateFloorMemberusgaapDerivativeInstrumentRiskAxis_LiborMemberusgaapVariableRateAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal" id="ixv-22415">1.00</ix:nonFraction>% plus <ix:nonFraction name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" contextRef="P05_28_2015To05_29_2015_TermLoanMemberusgaapDebtInstrumentAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal" id="ixv-22416">7.95</ix:nonFraction>%. Pursuant to the Loan and Security Agreement, as amended, the Company made interest only payments through <ix:nonNumeric name="us-gaap:DebtInstrumentMaturityDate" contextRef="P05_28_2015To05_29_2015_TermLoanMemberusgaapDebtInstrumentAxis" format="ixt:date-monthname-day-year-en" id="ixv-22417">May 1, 2021</ix:nonNumeric>, and thereafter is required to make payments of principal and accrued interest in equal monthly installments sufficient to amortize the Term Loan through June&#160;1, 2024, the maturity date. At maturity of the Term Loan, or earlier repayment in full following voluntary prepayment or upon acceleration, the Company is required to make a final payment in an aggregate amount equal to approximately $<ix:nonFraction name="us-gaap:DebtInstrumentFeeAmount" contextRef="PAsOn05_29_2015_TermLoanMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-22418">3.2</ix:nonFraction>&#160;million. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">From September 2017 to March 2020, the Company entered into a total of nine amendments to the Term Loan that, among other things, extended the interest only period, required repayment of $<ix:nonFraction name="us-gaap:PaymentsForLoans" contextRef="P05_28_2015To05_29_2015_LoanAndSecurityAgreementMemberusgaapFinancialInstrumentAxis_SaleOfJapaneseSubsidiaryAndCertainAssetsMemberusgaapDisposalGroupClassificationAxis_TermLoanMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-22419">3.1</ix:nonFraction>&#160;million using the proceeds received from sale of the Company&#8217;s former UK and Japan subsidiaries in April 2019, increased the final payment, increased the final payment fee upon maturity or early repayment of the Term Loan, increased the minimum liquidity covenant level to $<ix:nonFraction name="pstv:MinimumLiquidityCovenantAmount" contextRef="PAsOn03_31_2024_TermLoanMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-22420">2.0</ix:nonFraction>&#160;million and deferred the start date of principal repayment from <ix:nonNumeric name="pstv:DebtPrincipalRepaymentStartDate" contextRef="P03_27_2020To03_28_2020_TermLoanMemberusgaapDebtInstrumentAxis" format="ixt:date-monthname-day-year-en" id="ixv-22421">May 1, 2020</ix:nonNumeric> to <ix:nonNumeric name="pstv:DebtPrincipalRepaymentStartDate" contextRef="P03_29_2020To03_29_2020_TermLoanMemberusgaapDebtInstrumentAxis" format="ixt:date-monthname-day-year-en" id="ixv-22422">May 1, 2021</ix:nonNumeric> and extended the term of the Term Loan from <ix:nonNumeric name="us-gaap:DebtInstrumentMaturityDate" contextRef="P03_27_2020To03_28_2020_TermLoanMemberusgaapDebtInstrumentAxis" format="ixt:date-monthname-day-year-en" id="ixv-22423">September 1, 2021</ix:nonNumeric> to <ix:nonNumeric name="us-gaap:DebtInstrumentMaturityDate" contextRef="P03_29_2020To03_29_2020_TermLoanMemberusgaapDebtInstrumentAxis" format="ixt:date-monthname-day-year-en" id="ixv-22424">June 1, 2024</ix:nonNumeric>. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">On June&#160;28, 2023, the Company and Oxford entered into a tenth amendment to the Loan and Security Agreement, and revised the interest rate of the Loan to the greater of: (1) <ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="PAsOn06_28_2023_TermLoanMemberusgaapDebtInstrumentAxis" unitRef="Unit_pure" decimals="INF" scale="-2" format="ixt:num-dot-decimal" id="ixv-22425">8.95</ix:nonFraction>%, or (2)&#160;the sum of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">1-month</div> Secured Overnight Financing Rate and <ix:nonFraction name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" contextRef="P06_28_2023To06_28_2023_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMemberusgaapVariableRateAxis_TermLoanMemberusgaapDebtInstrumentAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal" id="ixv-22426">8.05</ix:nonFraction>%, effective July&#160;1, 2023. </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The Term Loan, as amended, is collateralized by a security interest in substantially all of the Company&#8217;s existing and subsequently acquired assets, including its intellectual property assets, subject to certain exceptions set forth in the Loan and Security Agreement, as amended. The intellectual property asset collateral will be released upon the Company achieving a certain liquidity level when the total principal outstanding under the Loan and Security Agreement is less than $<ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="PAsOn03_31_2024_MaximumMembersrtRangeAxis_TermLoanMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-22427">3.0</ix:nonFraction>&#160;million. As of March&#160;31, 2024, there was $<ix:nonFraction name="pstv:LongTermDebtOutstandingThresholdAmount" contextRef="P01_01_2024To03_31_2024_MaximumMembersrtRangeAxis_TermLoanMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-22428">0.4</ix:nonFraction>&#160;million principal amount outstanding under the Term Loan, excluding the $<ix:nonFraction name="us-gaap:DebtInstrumentFeeAmount" contextRef="PAsOn03_31_2024_TermLoanMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-22429">3.2</ix:nonFraction>&#160;million final payment fee, and <ix:nonNumeric name="us-gaap:DebtInstrumentCovenantCompliance" contextRef="P01_01_2024To03_31_2024_TermLoanMemberusgaapDebtInstrumentAxis" id="ixv-22430">the Company was in compliance with all of the debt covenants under the Loan and Security Agreement.</ix:nonNumeric> </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Company&#8217;s interest expense for the three ended March&#160;31, 2024 and 2023 was $<ix:nonFraction name="us-gaap:InterestExpense" contextRef="P01_01_2024To03_31_2024" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-22431">34,000</ix:nonFraction> and $<ix:nonFraction name="us-gaap:InterestExpense" contextRef="P01_01_2023To03_31_2023" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-22432">0.1</ix:nonFraction>&#160;million, respectively. Interest expense is calculated using the effective interest method; therefore it is inclusive of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">non-cash</div> amortization in the amount of $<ix:nonFraction name="us-gaap:AmortizationOfDebtDiscountPremium" contextRef="P01_01_2024To03_31_2024" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-22433">21,000</ix:nonFraction> and $<ix:nonFraction name="us-gaap:AmortizationOfDebtDiscountPremium" contextRef="P01_01_2023To03_31_2023" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-22434">0.1</ix:nonFraction>&#160;million for the three ended March&#160;31, 2024 and 2023, respectively, related to the amortization of the debt discount, capitalized loan costs, and accretion of final payment. </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The Loan and Security Agreement, as amended, contains customary indemnification obligations and customary events of default, including, among other things, the Company&#8217;s failure to fulfill certain obligations under the Term Loan, as amended, and the occurrence of a material adverse change, which is defined as a material adverse change in the Company&#8217;s business, operations, or condition (financial or otherwise), a material impairment of the prospect of repayment of any portion of the loan. In the event of default by the Company or a declaration of material adverse change by its lender, under the Term Loan, the lender would be entitled to exercise its remedies thereunder, including the right to accelerate the debt, upon which the Company may be required to repay all amounts then outstanding under the Term Loan, which could materially harm the Company&#8217;s financial condition. As of March&#160;31, 2024, the Company has not received any notification or indication from Oxford that it intends to invoke the material adverse change clause. See Note 12 for further information regarding the repayment of the Term Loan. </div></div></ix:continuation><ix:nonNumeric name="us-gaap:EarningsPerShareTextBlock" contextRef="P01_01_2024To03_31_2024" escape="true" continuedAt="TextSelection_116200096" id="ixv-11259"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">6</div></div>. <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Loss per Share</div></div> </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Basic per share data is computed by dividing net income or loss applicable to common stockholders by the weighted average number of common shares outstanding during the period. Diluted per share data is computed by dividing net income or loss applicable to common stockholders by the weighted average number of common shares outstanding during the period increased to include, if dilutive, the number of additional common shares </div></div><ix:exclude><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">F-10 </div></div></ix:exclude></ix:nonNumeric></div></div><ix:continuation id="TextSelection_116200096" continuedAt="TextSelectionAppend_116200096_1"><ix:exclude><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_116200096_1" continuedAt="TextSelectionAppend_116200096_2"><ix:exclude><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/></ix:exclude></ix:continuation><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelectionAppend_116200096_2"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">that would have been outstanding as calculated using the treasury stock method. Potential common shares were related to outstanding but unexercised options, multiple series of convertible preferred stock, and warrants for all periods presented. </div></div><ix:nonNumeric name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" contextRef="P01_01_2024To03_31_2024" escape="true" id="ixv-11283"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The following were excluded from the diluted loss per share calculation for the periods presented because their effect would be anti-dilutive: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 76%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;">
<tr>
<td style="width: 74%;"/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">As of March&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2024</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Outstanding stock options</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P01_01_2024To03_31_2024_OptionsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-22435">303,133</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P01_01_2023To03_31_2023_OptionsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-22436">134,283</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Preferred stock</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P01_01_2024To03_31_2024_PreferredStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-22437">28,190</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P01_01_2023To03_31_2023_PreferredStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-22438">28,190</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Outstanding warrants</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P01_01_2024To03_31_2024_WarrantMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-22439">142,733</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P01_01_2023To03_31_2023_WarrantMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-22440">142,733</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P01_01_2024To03_31_2024" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-22441">474,056</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P01_01_2023To03_31_2023" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-22442">305,206</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table></ix:nonNumeric></ix:continuation><div style="clear:both;max-height:0pt;"></div><ix:nonNumeric name="us-gaap:RevenueFromContractWithCustomerTextBlock" contextRef="P01_01_2024To03_31_2024" escape="true" id="ixv-11403"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">7. Grant Revenue </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">On September&#160;19, 2022, the Company entered into that certain CPRIT contract (&#8220;CPRIT Contract&#8221;), effective as of <ix:nonNumeric name="pstv:ContractEffectiveDate" contextRef="P09_19_2022To09_19_2022_CancerPreventionAndResearchInstituteOfTexasContractMemberusgaapTypeOfArrangementAxis" format="ixt:date-monthname-day-year-en" id="ixv-22443">August 31, 2022</ix:nonNumeric>, with CPRIT, pursuant to which CPRIT will provide the Company with a CPRIT grant (&#8220;CPRIT Grant&#8221;) over a <ix:nonNumeric name="pstv:GrantFundingTerm" contextRef="P09_19_2022To09_19_2022_CancerPreventionAndResearchInstituteOfTexasContractMemberusgaapTypeOfArrangementAxis" format="ixt-sec:durwordsen" id="ixv-22444">three-year</ix:nonNumeric> period to fund the continued development of rhenium (<div style="font-size: 75%; vertical-align: top;display:inline;font-size:8.3px">186</div>Re) obisbemeda for the treatment of patients with leptomeningeal metastases (&#8220;LM&#8221;). <ix:nonNumeric name="pstv:CpritGrantFundingTerm" contextRef="P01_01_2024To03_31_2024_CancerPreventionAndResearchInstituteOfTexasContractMemberusgaapTypeOfArrangementAxis" id="ixv-11410">The CPRIT Grant is subject to customary CPRIT funding conditions, including, but not limited to, a matching fund requirement (one dollar for every two dollars awarded by CPRIT), revenue sharing obligations upon commercialization of rhenium (<div style="font-size: 75%; vertical-align: top;display:inline;font-size:8.3px">186</div>Re) obisbemeda based on specific dollar thresholds and tiered low single digit royalty rates until CPRIT receives the aggregate amount of <ix:nonFraction name="pstv:PercentageOfAggregateAmountOfProceedsAwardedUnderCpritGrant" contextRef="P09_19_2022To09_19_2022_CancerPreventionAndResearchInstituteOfTexasContractMemberusgaapTypeOfArrangementAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-22445">400</ix:nonFraction>% of the proceeds awarded under the CPRIT Grant, and certain reporting requirements.</ix:nonNumeric> </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The CPRIT Contract will terminate on <ix:nonNumeric name="pstv:ContractTerminationDate" contextRef="P09_19_2022To09_19_2022_CancerPreventionAndResearchInstituteOfTexasContractMemberusgaapTypeOfArrangementAxis" format="ixt:date-monthname-day-year-en" id="ixv-22446">August 30, 2025</ix:nonNumeric>, unless terminated earlier by (a)&#160;the mutual written consent of all parties to the CPRIT Contract, (b)&#160;CPRIT for an event of default by the Company, (c)&#160;CPRIT, if the funds allocated to the CPRIT Grant become legally unavailable during the term of the CPRIT Contract and CPRIT is unable to obtain additional funds for such purposes, and (d)&#160;the Company for convenience. CPRIT may require the Company to repay some or all of the disbursed CPRIT Grant proceeds (with interest not to exceed <ix:nonFraction name="pstv:PercentageOfGrantProceedsWithInterestNotExceedAnnually" contextRef="P09_19_2022To09_19_2022_CancerPreventionAndResearchInstituteOfTexasContractMemberusgaapTypeOfArrangementAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-22447">5</ix:nonFraction>% annually) in the event of the early termination of the CPRIT Contract by CPRIT for an event of default by the Company or by the Company for convenience, or if the Company relocates its principal place of business outside of the state of Texas during the CPRIT Contract term or within three years after the final payment of the grant funds. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Company retains ownership over any intellectual property developed under the CPRIT Contract (each, a &#8220;Project Result&#8221;). With respect to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">non-commercial</div> use of any Project Result, the Company granted to CPRIT a nonexclusive, irrevocable, royalty-free, perpetual, worldwide license with right to sublicense any necessary additional intellectual property rights to exploit all Project Results by CPRIT, other governmental entities and agencies of the State of Texas, and private or independent institutions of higher education located in Texas, for education, research and other <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">non-commercial</div> purposes. </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The Company recognized $<ix:nonFraction name="us-gaap:Revenues" contextRef="P01_01_2024To03_31_2024_CancerPreventionAndResearchInstituteOfTexasContractMemberusgaapTypeOfArrangementAxis_GrantMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-22448">1.7</ix:nonFraction>&#160;million and $<ix:nonFraction name="us-gaap:Revenues" contextRef="P01_01_2023To03_31_2023_CancerPreventionAndResearchInstituteOfTexasContractMemberusgaapTypeOfArrangementAxis_GrantMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-22449">0.5</ix:nonFraction>&#160;million in grant revenue from the CPRIT Contract during the three months ended March&#160;31, 2024 and 2023, respectively. </div></div></ix:nonNumeric><ix:nonNumeric name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" contextRef="P01_01_2024To03_31_2024" escape="true" continuedAt="TextSelection_116199079" id="ixv-11419"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">8. Commitments and Contingencies </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Leases </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The Company leases laboratory, office and storage facilities in San Antonio, Texas, under operating lease agreements that expire in <ix:nonNumeric name="pstv:OperatingLeasesExpiryYear" contextRef="P01_01_2024To03_31_2024" id="ixv-22450">2025</ix:nonNumeric>. The Company also leases certain office space in Austin, Texas under a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">month-to-month</div></div> operating lease agreement and certain office space in Charlottesville, Virginia (the &#8220;Charlottesville Lease&#8221;). <ix:nonNumeric name="us-gaap:LesseeOperatingLeaseOptionToExtend" contextRef="P01_01_2024To03_31_2024_CharlottesvilleMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" id="ixv-11429">The Charlottesville Lease has a term of <ix:nonNumeric name="us-gaap:LesseeOperatingLeaseTermOfContract" contextRef="PAsOn03_31_2024_CharlottesvilleMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" format="ixt-sec:durmonth" id="ixv-22451">12</ix:nonNumeric> months and the Company has the ability to <ix:nonNumeric name="us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend" contextRef="P01_01_2024To03_31_2024_CharlottesvilleMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" format="ixt:fixed-true" id="ixv-22452">renew</ix:nonNumeric> for three additional <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><ix:nonNumeric name="us-gaap:LesseeOperatingLeaseRenewalTerm" contextRef="PAsOn03_31_2024_CharlottesvilleMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" format="ixt-sec:durwordsen" id="ixv-22453">one-year</ix:nonNumeric></div> periods.</ix:nonNumeric> On March&#160;31, 2023, Company believed that it was reasonably </div><ix:exclude><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">F-11 </div></div></ix:exclude></ix:nonNumeric></div></div><ix:continuation id="TextSelection_116199079" continuedAt="TextSelectionAppend_116199079_1"><ix:exclude><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_116199079_1" continuedAt="TextSelectionAppend_116199079_2"><ix:exclude><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/></ix:exclude></ix:continuation> <div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelectionAppend_116199079_2"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">certain that the Charlottesville Lease will be renewed through March&#160;31, 2026, and as a result, it remeasured the related lease liability as of March&#160;31, 2023 to be $<ix:nonFraction name="us-gaap:OperatingLeaseLiability" contextRef="PAsOn03_31_2023_CharlottesvilleMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-22454">80,000</ix:nonFraction> using the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">then-in-effect</div></div> discount rate of <ix:nonFraction name="us-gaap:LesseeOperatingLeaseDiscountRate" contextRef="PAsOn03_31_2023_CharlottesvilleMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal" id="ixv-22455">12.76</ix:nonFraction>%. Effective July&#160;1, 2023, the Company added additional office lease premises in Charlottesville, which was accounted for as a separate operating lease contract with a lease liability and corresponding <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">right-of-use</div></div> asset of $<ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="PAsOn07_01_2023_CharlottesvilleMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-22456">19,000</ix:nonFraction>, as a discount rate of <ix:nonFraction name="us-gaap:LesseeOperatingLeaseDiscountRate" contextRef="PAsOn07_01_2023_CharlottesvilleMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal" id="ixv-22457">13.47</ix:nonFraction>%. </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Piramal Master Services Agreement </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">On <ix:nonNumeric name="pstv:MasterServicesAgreementDate" contextRef="P01_08_2021To01_08_2021_PiramalPharmaSolutionsIncMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" format="ixt:date-monthname-day-year-en" id="ixv-22458">January 8, 2021</ix:nonNumeric>, the Company entered into a Master Services Agreement (the &#8220;MSA&#8221;) with Piramal Pharma Solutions, Inc. (&#8220;Piramal&#8221;), for Piramal to perform certain services related to the development, manufacture, and supply of the Company&#8217;s rhenium (<div style="font-size: 75%; vertical-align: top;display:inline;font-size:8.3px">186</div>Re) obisbemeda intermediate drug product. The MSA includes the transfer of analytical methods, development of microbiological methods, process transfer and optimization, intermediate drug product manufacturing, and stability studies for the Company, which has been initiated at Piramal&#8217;s facility located in Lexington, Kentucky. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><ix:nonNumeric name="pstv:MasterServicesAgreementTermsDescription" contextRef="P01_01_2024To03_31_2024_PiramalPharmaSolutionsIncMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" id="ixv-11457">The MSA has a term of <ix:nonNumeric name="pstv:MasterServicesAgreementInitialTerm" contextRef="P01_08_2021To01_08_2021_PiramalPharmaSolutionsIncMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" format="ixt-sec:durwordsen" id="ixv-22459">five years</ix:nonNumeric> and will automatically renew for successive <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">one-year</div> terms unless either party notifies the other no later than six months prior to the original term or any additional terms of its intention to not renew the MSA. The Company has the right to terminate the MSA for convenience upon thirty days&#8217; prior written notice.</ix:nonNumeric> Either party may terminate the MSA upon an uncured material breach by the other party or upon the bankruptcy or insolvency of the other party. </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Other commitments and contingencies </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The Company has entered into agreements with various research organizations for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">pre-clinical</div> and clinical development studies, which have provisions for cancellation. Under the terms of these agreements, the vendors provide a variety of services including conducting research, recruiting and enrolling patients, monitoring studies and data analysis. Payments under these agreements typically include fees for services and reimbursement of expenses. The timing of payments due under these agreements is estimated based on current study progress. As of March&#160;31, 2024, the Company did <ix:nonFraction name="us-gaap:ContractualObligation" contextRef="PAsOn03_31_2024_PreClinicalResearchStudyObligationsMemberusgaapRecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt-sec:numwordsen" id="ixv-22460">no</ix:nonFraction>t have any clinical research study obligations. </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Legal proceedings </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">From time to time, the Company is subject to legal proceedings and claims, whether asserted or unasserted, that arise in the ordinary course of business. Due to their nature, such legal proceedings involve inherent uncertainties including, but not limited to, court rulings, negotiations between affected parties and governmental actions. Management assesses the probability of loss for such contingencies and accrues a liability and/or discloses the relevant circumstances, as appropriate. </div></div></ix:continuation><ix:nonNumeric name="pstv:LicenseAgreementDisclosureTextBlock" contextRef="P01_01_2024To03_31_2024" escape="true" continuedAt="TextSelection_116200133" id="ixv-11469"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">9. License Agreements </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Biocept License Agreement </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">On September&#160;7, 2023, the Company entered into a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">Non-Exclusive</div> License and Services Agreement (the &#8220;Biocept Agreement&#8221;) with Biocept, Inc (&#8220;Biocept&#8221;), pursuant to which Biocept granted the Company a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">non-exclusive</div> license to use the Biocept proprietary cell enumeration test, CNsideTM (&#8220;CNside&#8221;). In exchange for the license, the Company issued to Biocept <ix:nonFraction name="us-gaap:SharesIssued" contextRef="PAsOn09_07_2023_BioceptAgreementMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-22461">53,381</ix:nonFraction> unregistered shares, the fair value of which was $<ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="P01_01_2024To03_31_2024_BioceptAgreementMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-22462">75,000</ix:nonFraction>. The Biocept Agreement also provides that if Biocept fully transfers the technology to the Company, a tech transfer and validation fee of $<ix:nonFraction name="pstv:PaymentForTechTransferAndValidationFee" contextRef="P09_07_2023To09_07_2023_BioceptAgreementMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-22463">300,000</ix:nonFraction> will be payable. In addition, the Company was granted an option for an exclusive worldwide license for $<ix:nonFraction name="pstv:OptionForExclusiveWorldwideLicense" contextRef="P09_07_2023To09_07_2023_BioceptAgreementMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-22464">1,000,000</ix:nonFraction> on or before December&#160;31, 2024, to process and perform cell enumeration testing for treatments for other patients including those on the Company&#8217;s radiotherapeutic drugs. </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">On October&#160;16, 2023, Biocept filed a voluntary petition for relief under the provisions of Chapter 7 of Title 11 of the United States Bankruptcy Code. See Note 12 for further information regarding the Company&#8217;s acquisition of substantially all right, title and interest in CNside. </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><ix:exclude>F-12</ix:exclude> </div></div></ix:nonNumeric></div></div><ix:continuation id="TextSelection_116200133" continuedAt="TextSelectionAppend_116200133_1"><ix:exclude><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_116200133_1" continuedAt="TextSelectionAppend_116200133_2"><ix:exclude><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/></ix:exclude></ix:continuation><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelectionAppend_116200133_2"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">UT Health Science Center at San Antonio (&#8220;UTHSCSA&#8221;) License Agreement </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">On December&#160;31, 2021, the Company entered into a Patent and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">Know-How</div> License Agreement (the &#8220;UTHSCSA License Agreement&#8221;) with The University of Texas Health Science Center at San Antonio (&#8220;UTHSCSA&#8221;), pursuant to which UTHSCSA granted the Company an irrevocable, perpetual, exclusive, fully <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">paid-up</div> license, with the right to sublicense and to make, develop, commercialize and otherwise exploit certain patents, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">know-how</div> and technology related to the development of biodegradable alginate microspheres (&#8220;BAM&#8221;) containing nanoliposomes loaded with imaging and/or therapeutic payloads. </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">NanoTx License Agreement </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">On March&#160;29, 2020, the Company and NanoTx, Corp. (&#8220;NanoTx&#8221;) entered into a Patent and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">Know-How</div> License Agreement, pursuant to which NanoTx granted the Company an irrevocable, perpetual, exclusive, fully <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">paid-up</div> license, with the right to sublicense and to make, develop, commercialize and otherwise exploit certain patents, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">know-how</div> and technology related to the development of radiolabeled nanoliposomes. </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The transaction terms included an upfront payment of $<ix:nonFraction name="us-gaap:PaymentsForRoyalties" contextRef="P03_29_2020To03_29_2020_NanoTxLicensesAgreementMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-22466">0.4</ix:nonFraction>&#160;million in cash and $<ix:nonFraction name="us-gaap:CommonStockValue" contextRef="PAsOn03_29_2020_NanoTxLicensesAgreementMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-22467">0.3</ix:nonFraction>&#160;million in the Company&#8217;s voting stock. The transaction terms also included success-based milestone and royalty payments contingent on key clinical, regulatory and sales milestones, as well as the requirement to pay <ix:nonFraction name="pstv:PercentageOfNonDilutiveMonetaryAwardsRequiredToPay" contextRef="P03_29_2020To03_29_2020_NanoTxLicensesAgreementMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-22468">15</ix:nonFraction>% of any <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">non-dilutive</div> monetary awards or grants received from external agencies to support product development of the nanoliposome encapsulated BMEDA-chelated radioisotope, which includes grants from CPRIT. As of March&#160;31, 2024, the Company accrued $<ix:nonFraction name="pstv:AccruedLicensePayable" contextRef="PAsOn03_31_2024_NanoTxLicensesAgreementMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-22469">0.5</ix:nonFraction>&#160;million of payments due to NanoTx as a result of the CPRIT grant received (see Note 7, Grant Revenue of the condensed financial statements for additional information). </div></ix:continuation><ix:nonNumeric name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" contextRef="P01_01_2024To03_31_2024" escape="true" continuedAt="TextSelection_116199105" id="ixv-11510"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">10. Stockholders&#8217; Equity </div></div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Preferred Stock </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The Company has authorized <ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="PAsOn03_31_2024" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-22470">5,000,000</ix:nonFraction> shares of preferred stock, par value $<ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="PAsOn03_31_2024" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-22471">0.001</ix:nonFraction> per share. The Company&#8217;s Board is authorized to designate the terms and conditions of any preferred stock the Company issues without further action by the common stockholders. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Series F Preferred Stock </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">On March&#160;3, 2023, the Company filed a certificate of designation (the &#8220;Certificate of Designation&#8221;) with the Secretary of State of the State of Delaware, effective as of the time of filing, designating the rights, preferences, privileges and restrictions of the Series F Preferred Stock, with the total authorization of one (<ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="PAsOn03_03_2023_SeriesFConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-22472">1</ix:nonFraction>)&#160;share of Series F Preferred Stock. The Certificate of Designation provided that the share of Series F Preferred Stock would have <ix:nonFraction name="pstv:NumberOfVotesPerShare" contextRef="PAsOn03_03_2023_SeriesFConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_Votes" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-22473">50,000,000</ix:nonFraction> votes per share of Series F Preferred Stock and would vote together with the Company&#8217;s common stock, as a single class exclusively with respect to any proposal to amend the Company&#8217;s Charter to effect the Reverse Stock Split. On March&#160;3, 2023, the Company entered into a subscription and investment representation agreement with Richard J. Hawkins, chairman of the board of the Company, who is an accredited investor (the &#8220;Series F Preferred Stock Purchaser&#8221;), pursuant to which the Company agreed to issue and sell one (<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="P03_03_2023To03_03_2023_SeriesFConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis_SubscriptionAgreementMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-22474">1</ix:nonFraction>)&#160;share of the Company&#8217;s Series F Preferred Stock, par value $<ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="PAsOn03_03_2023_SeriesFConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis_SubscriptionAgreementMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-22475">0.001</ix:nonFraction> per share, to the Series F Preferred Stock Purchaser for $<ix:nonFraction name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" contextRef="P03_03_2023To03_03_2023_SeriesFConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis_SubscriptionAgreementMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-22476">1,000</ix:nonFraction> in cash. The sale closed on <ix:nonNumeric name="us-gaap:SaleOfStockTransactionDate" contextRef="P03_03_2023To03_03_2023_SeriesFConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis_SubscriptionAgreementMemberusgaapSubsidiarySaleOfStockAxis" format="ixt:date-monthname-day-year-en" id="ixv-22477">March 3, 2023</ix:nonNumeric>. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">At the Company&#8217;s 2023 annual meeting, the Series F Preferred Stock was voted, without action by the holder, on the proposal to approve the Reverse Stock Split in the same proportion as shares of common stock voted to approve the Reverse Stock Split. The Series F Preferred Stock otherwise had <ix:nonNumeric name="us-gaap:PreferredStockVotingRights" contextRef="P03_03_2023To03_03_2023_SeriesFConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" id="ixv-22478">no</ix:nonNumeric> voting rights except as otherwise required by the General Corporation Law of the State of Delaware. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The Series F Preferred Stock was not convertible into, or exchangeable for, shares of any other class or series of stock or other securities of the Company. The Series F Preferred Stock had <ix:nonNumeric name="pstv:RightsRelatedToDistributionOfAssets" contextRef="P03_03_2023To03_03_2023_SeriesFConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" id="ixv-22479">no</ix:nonNumeric> rights with respect to any </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><ix:exclude>F-13</ix:exclude> </div></div></ix:nonNumeric></div></div><ix:continuation id="TextSelection_116199105" continuedAt="TextSelectionAppend_116199105_1"><ix:exclude><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_116199105_1" continuedAt="TextSelectionAppend_116199105_2"><ix:exclude><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/></ix:exclude></ix:continuation> <div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelectionAppend_116199105_2" continuedAt="TextSelectionAppend_116199105_3"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">distribution of assets of the Company, including upon a liquidation, bankruptcy, reorganization, merger, acquisition, sale, dissolution or winding up of the Company, whether voluntarily or involuntarily. The holder of the Series F Preferred Stock was not entitled to receive dividends of any kind. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The outstanding share of Series F Preferred Stock was redeemed in whole, automatically effective upon the approval by the Company&#8217;s stockholders of the Reverse Stock Split. Upon such redemption, the holder of the Series F Preferred Stock received consideration of $<ix:nonFraction name="pstv:ConsiderationPaidToPreferredStockHolders" contextRef="P03_03_2023To03_03_2023_SeriesFConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-22481">1,000</ix:nonFraction> in cash. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Series B and C Preferred Stock </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">As of March&#160;31, 2024, there were <ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="PAsOn03_31_2024_SeriesCConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis_TwoThousandEighteenRightsOfferingMemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-22482">938</ix:nonFraction> outstanding shares of Series C Preferred Stock that can be converted into an aggregate of <ix:nonFraction name="pstv:NumberOfPreferredStockSharesExercised" contextRef="P01_01_2024To03_31_2024_SeriesCConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis_TwoThousandEighteenRightsOfferingMemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-22483">27,792</ix:nonFraction> shares of common stock, and <ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="PAsOn03_31_2024_SeriesBConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis_TwoThousandEighteenRightsOfferingMemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-22484">1,014</ix:nonFraction> shares of Series B Convertible Preferred Stock that can be converted into an aggregate of <ix:nonFraction name="pstv:NumberOfPreferredStockSharesExercised" contextRef="P01_01_2024To03_31_2024_SeriesBConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis_TwoThousandEighteenRightsOfferingMemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-22485">398</ix:nonFraction> shares of common stock. </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Warrants </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">On September&#160;25, 2019, the Company completed an underwritten public offering. The Company issued <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="P01_01_2024To03_31_2024_CommonClassAMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-22486">19,266</ix:nonFraction> shares of its common stock, along with <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">pre-funded</div> warrants to purchase <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="PAsOn03_31_2024_CommonClassBMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-22487">180,733</ix:nonFraction> shares of its common stock and Series U Warrants to purchase <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="P01_01_2024To03_31_2024_SeriesUWarrantsMemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-22488">230,000</ix:nonFraction> shares of its common stock. The Series U Warrants have a term of <ix:nonNumeric name="us-gaap:WarrantsAndRightsOutstandingTerm" contextRef="PAsOn03_31_2024_SeriesUWarrantsMemberusgaapClassOfWarrantOrRightAxis" format="ixt-sec:durwordsen" id="ixv-22489">five years</ix:nonNumeric> from the issuance date. In addition, the Company issued warrants to H.C. Wainwright&#160;&amp; Co., LLC, as representatives of the underwriters, to purchase <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="PAsOn03_31_2024_RepresentativeSeriesUWarrantMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-22490">5,000</ix:nonFraction> shares of its common stock with a term of five years from the issuance date, in the form of Series U Warrants (the &#8220;Representative Warrants&#8221;). As of March&#160;31, 2024, there were <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="PAsOn03_31_2024_SeriesUWarrantsMemberusgaapClassOfWarrantOrRightAxis_WarrantMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-22491">142,733</ix:nonFraction> outstanding Series U Warrants and Representative Warrants which can be exercised into an aggregate of <ix:nonFraction name="pstv:NumberOfWarrantsExercised" contextRef="P01_01_2024To03_31_2024_SeriesUWarrantsMemberusgaapClassOfWarrantOrRightAxis_WarrantMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-22492">142,733</ix:nonFraction> shares of common stock at a weighted average exercise price of $<ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="PAsOn03_31_2024_SeriesUWarrantsMemberusgaapClassOfWarrantOrRightAxis_WarrantMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-22493">34.10</ix:nonFraction> per share. </div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Common Stock </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Lincoln Park Purchase Agreement </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">On August&#160;2, 2022, the Company entered into a purchase agreement (the &#8220;2022 Purchase Agreement&#8221;) and registration rights agreement pursuant to which Lincoln Park Capital Fund (&#8220;Lincoln Park&#8221;) committed to purchase up to $<ix:nonFraction name="pstv:MaximumValueOfSharesToBeIssuedUnderAgreement" contextRef="PAsOn08_02_2022_CommonStockMemberusgaapStatementEquityComponentsAxis_LincolnParkCapitalFundLLCMemberdeiLegalEntityAxis_TwoThousandAndTwentyTwoPurchaseAgreementMemberusgaapInvestmentTypeAxis" unitRef="Unit_USD" decimals="INF" scale="6" format="ixt:num-dot-decimal" id="ixv-22494">50.0</ix:nonFraction>&#160;million of the Company&#8217;s common stock. Under the terms and subject to the conditions of the 2022 Purchase Agreement, the Company has the right, but not the obligation, to sell to Lincoln Park, and Lincoln Park is obligated to purchase up to $<ix:nonFraction name="pstv:MaximumValueOfSharesToBeIssuedUnderAgreement" contextRef="PAsOn08_02_2022_CommonStockMemberusgaapStatementEquityComponentsAxis_LincolnParkCapitalFundLLCMemberdeiLegalEntityAxis_TwoThousandAndTwentyTwoPurchaseAgreementMemberusgaapInvestmentTypeAxis" unitRef="Unit_USD" decimals="INF" scale="6" format="ixt:num-dot-decimal" id="ixv-22495">50.0</ix:nonFraction>&#160;million of the Company&#8217;s common stock. Such sales of common stock by the Company are subject to certain limitations, and can occur from time to time, at the Company&#8217;s sole discretion, over the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><ix:nonNumeric name="pstv:PeriodExercisableFromTheDateOfIssuance" contextRef="P01_01_2024To03_31_2024_CommonStockMemberusgaapStatementEquityComponentsAxis_LincolnParkCapitalFundLLCMemberdeiLegalEntityAxis_TwoThousandAndTwentyTwoPurchaseAgreementMemberusgaapInvestmentTypeAxis" format="ixt-sec:durwordsen" id="ixv-22496">36-month</ix:nonNumeric></div> period commencing on August&#160;17, 2022, subject to the satisfaction of certain conditions. </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">On May&#160;16, 2022, the Company received stockholder approval for purposes of the Nasdaq listing rules to permit issuances of up to <ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="PAsOn05_16_2022_LincolnParkCapitalFundLLCMemberdeiLegalEntityAxis_MaximumMembersrtRangeAxis_TwoThousandAndTwentyTwoPurchaseAgreementMemberusgaapInvestmentTypeAxis" unitRef="Unit_shares" decimals="INF" scale="6" format="ixt:num-dot-decimal" id="ixv-22497">57.5</ix:nonFraction>&#160;million shares of the Company&#8217;s common stock (including the issuance of more than <ix:nonFraction name="pstv:PercentageIssuanceOfCommonStock" contextRef="P05_16_2022To05_16_2022_CommonStockMemberusgaapStatementEquityComponentsAxis_LincolnParkCapitalFundLLCMemberdeiLegalEntityAxis_MinimumMembersrtRangeAxis_TwoThousandAndTwentyTwoPurchaseAgreementMemberusgaapInvestmentTypeAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal" id="ixv-22498">19.99</ix:nonFraction>% of the Company&#8217;s common stock) to Lincoln Park, and it was pursuant to that approval that the Company entered into the 2022 Purchase Agreement. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Upon execution of the 2022 Purchase Agreement, the Company paid $<ix:nonFraction name="pstv:InitialCommitmentFee" contextRef="PAsOn08_02_2022_CommonStockMemberusgaapStatementEquityComponentsAxis_LincolnParkCapitalFundLLCMemberdeiLegalEntityAxis_TwoThousandAndTwentyTwoPurchaseAgreementMemberusgaapInvestmentTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-22499">0.1</ix:nonFraction>&#160;million in cash as the initial commitment fee, and issued <ix:nonFraction name="pstv:InitialCommitmentShares" contextRef="PAsOn08_02_2022_CommonStockMemberusgaapStatementEquityComponentsAxis_LincolnParkCapitalFundLLCMemberdeiLegalEntityAxis_TwoThousandAndTwentyTwoPurchaseAgreementMemberusgaapInvestmentTypeAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-22500">32,846</ix:nonFraction> shares as the initial commitment shares, to Lincoln Park as consideration for its irrevocable commitment to purchase shares of the Company&#8217;s common stock at its direction under the 2022 Purchase Agreement. The Company has agreed to pay an additional commitment fee, which it may elect to pay in cash and/or shares of its common stock, upon receipt of $<ix:nonFraction name="pstv:GrossProceedsFromIssuanceOfCommonStock" contextRef="P08_02_2022To08_02_2022_CommonStockMemberusgaapStatementEquityComponentsAxis_LincolnParkCapitalFundLLCMemberdeiLegalEntityAxis_TwoThousandAndTwentyTwoPurchaseAgreementMemberusgaapInvestmentTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-22501">25.0</ix:nonFraction>&#160;million aggregate gross proceeds from sales of common stock to Lincoln Park under the 2022 Purchase Agreement. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">On August&#160;17, 2022, a registration statement (the &#8220;First Registration Statement&#8221;) was declared effective to cover the resale of up to <ix:nonFraction name="pstv:NumberOfMaximumCommonSharesCanBeResale" contextRef="PAsOn08_17_2022_CommonStockMemberusgaapStatementEquityComponentsAxis_LincolnParkCapitalFundLLCMemberdeiLegalEntityAxis_TwoThousandAndTwentyTwoPurchaseAgreementMemberusgaapInvestmentTypeAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-22502">633,333</ix:nonFraction> shares of the Company&#8217;s common stock comprised of (i)&#160;the <ix:nonFraction name="pstv:InitialCommitmentShares" contextRef="PAsOn07_14_2022_CommonStockMemberusgaapStatementEquityComponentsAxis_LincolnParkCapitalFundLLCMemberdeiLegalEntityAxis_TwoThousandAndTwentyTwoPurchaseAgreementMemberusgaapInvestmentTypeAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-22503">32,846</ix:nonFraction> initial </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><ix:exclude>F-14</ix:exclude> </div></div></ix:continuation></div></div><ix:continuation id="TextSelectionAppend_116199105_3" continuedAt="TextSelectionAppend_116199105_4"><ix:exclude><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_116199105_4" continuedAt="TextSelectionAppend_116199105_5"><ix:exclude><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/></ix:exclude></ix:continuation><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelectionAppend_116199105_5" continuedAt="TextSelectionAppend_116199105_6"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">commitment shares, and (ii)&#160;up to <ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="PAsOn08_17_2022_CommonStockMemberusgaapStatementEquityComponentsAxis_LincolnParkCapitalFundLLCMemberdeiLegalEntityAxis_MaximumMembersrtRangeAxis_TwoThousandAndTwentyTwoPurchaseAgreementMemberusgaapInvestmentTypeAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-22505">600,486</ix:nonFraction> that the Company has reserved for issuance and sale to Lincoln Park under the 2022 Purchase Agreement from time to time from and after the date of the prospectus. The Company sold approximately <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="P08_17_2022To03_31_2024_CommonStockMemberusgaapStatementEquityComponentsAxis_LincolnParkCapitalFundLLCMemberdeiLegalEntityAxis_TwentyTwentyPurchaseAgreementMemberusgaapInvestmentTypeAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-22506">527,166</ix:nonFraction> shares under the First Registration Statement. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">On August&#160;18, 2023, a second registration statement (the &#8220;Second Registration Statement&#8221;) was declared effective to cover the resale of up to an additional <ix:nonFraction name="pstv:NumberOfMaximumCommonSharesCanBeResale" contextRef="PAsOn08_18_2023_CommonStockMemberusgaapStatementEquityComponentsAxis_LincolnParkCapitalFundLLCMemberdeiLegalEntityAxis_MaximumMembersrtRangeAxis_TwoThousandAndTwentyTwoPurchaseAgreementMemberusgaapInvestmentTypeAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-22507">1,500,000</ix:nonFraction> shares of the Company&#8217;s common stock that the Company reserved for issuance and sale to Lincoln Park under the 2022 Purchase Agreement from time to time. The Company sold <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="P08_18_2023To03_31_2024_CommonStockMemberusgaapStatementEquityComponentsAxis_LincolnParkCapitalFundLLCMemberdeiLegalEntityAxis_TwoThousandAndTwentyTwoPurchaseAgreementMemberusgaapInvestmentTypeAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-22508">150,000</ix:nonFraction> shares under the Second Registration Statement. The Company cannot sell more shares than registered under the Second Registration Statement under the 2022 Purchase Agreement without registering additional shares. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Actual sales of shares of common stock to Lincoln Park under the 2022 Purchase Agreement depend on a variety of factors to be determined by the Company from time to time, including, among others, market conditions, the trading price of the common stock and determinations by the Company as to the appropriate sources of funding for the Company and its operations. The net proceeds under the 2022 Purchase Agreement to the Company depend on the frequency and prices at which the Company sells shares of its stock to Lincoln Park. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">During the period from August&#160;17, 2022 to December&#160;31, 2022, the Company issued <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="P08_17_2022To12_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis_LincolnParkCapitalFundLLCMemberdeiLegalEntityAxis_TwoThousandAndTwentyTwoPurchaseAgreementMemberusgaapInvestmentTypeAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-22509">266,666</ix:nonFraction> shares under the 2022 Purchase Agreement for net proceeds of approximately $<ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="P08_17_2022To12_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis_LincolnParkCapitalFundLLCMemberdeiLegalEntityAxis_TwoThousandAndTwentyTwoPurchaseAgreementMemberusgaapInvestmentTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-22510">3.2</ix:nonFraction>&#160;million. The Company issued <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="P01_01_2023To12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis_LincolnParkCapitalFundLLCMemberdeiLegalEntityAxis_TwoThousandAndTwentyTwoPurchaseAgreementMemberusgaapInvestmentTypeAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-22511">410,500</ix:nonFraction> shares under the 2022 Purchase Agreement for net proceeds of approximately $<ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="P01_01_2023To12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis_LincolnParkCapitalFundLLCMemberdeiLegalEntityAxis_TwoThousandAndTwentyTwoPurchaseAgreementMemberusgaapInvestmentTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-22512">1.0</ix:nonFraction>&#160;million from January&#160;1, 2023 to December&#160;31, 2023. The Company did <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="P01_01_2024To03_31_2024_CommonStockMemberusgaapStatementEquityComponentsAxis_LincolnParkCapitalFundLLCMemberdeiLegalEntityAxis_TwoThousandAndTwentyTwoPurchaseAgreementMemberusgaapInvestmentTypeAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt-sec:numwordsen" id="ixv-22513">no</ix:nonFraction>t issue any common stock under the 2022 Purchase Agreement during the three months ended March&#160;31, 2024. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">At-the-market</div></div> Issuances </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">On September&#160;9, 2022, the Company entered into the September 2022 Distribution Agreement with Canaccord, pursuant to which the Company could issue and sell, from time to time, shares of its common stock having an aggregate offering price of up to $<ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="P09_09_2022To09_09_2022_AtTheMarketOfferingProgramMemberusgaapSubsidiarySaleOfStockAxis_CanaccordGenuityLLCMemberdeiLegalEntityAxis_CommonStockMemberusgaapStatementEquityComponentsAxis_MaximumMembersrtRangeAxis_SeptemberTwoThousandAndTwentyTwoDistributionAgreementMemberusgaapInvestmentTypeAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-22514">5,000,000</ix:nonFraction>, depending on market demand, with Canaccord acting as an agent for sales. During the period from September&#160;9, 2022 to December&#160;31, 2022, the Company issued <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="P09_09_2022To12_31_2022_AtTheMarketOfferingProgramMemberusgaapSubsidiarySaleOfStockAxis_CanaccordGenuityLLCMemberdeiLegalEntityAxis_CommonStockMemberusgaapStatementEquityComponentsAxis_SeptemberTwoThousandAndTwentyTwoDistributionAgreementMemberusgaapInvestmentTypeAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-22515">68,758</ix:nonFraction> shares of its common stock under the September 2022 Distribution Agreement for net proceeds of approximately $<ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="P09_09_2022To12_31_2022_AtTheMarketOfferingProgramMemberusgaapSubsidiarySaleOfStockAxis_CanaccordGenuityLLCMemberdeiLegalEntityAxis_CommonStockMemberusgaapStatementEquityComponentsAxis_SeptemberTwoThousandAndTwentyTwoDistributionAgreementMemberusgaapInvestmentTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-22516">0.6</ix:nonFraction>&#160;million. From January&#160;1, 2023 through December&#160;31, 2023, the Company issued <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="P01_01_2023To12_31_2023_AtTheMarketOfferingProgramMemberusgaapSubsidiarySaleOfStockAxis_CanaccordGenuityLLCMemberdeiLegalEntityAxis_CommonStockMemberusgaapStatementEquityComponentsAxis_SeptemberTwoThousandAndTwentyTwoDistributionAgreementMemberusgaapInvestmentTypeAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-22517">1,819,993</ix:nonFraction> shares under the September 2022 Distribution Agreement for net proceeds of approximately $<ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="P01_01_2023To12_31_2023_AtTheMarketOfferingProgramMemberusgaapSubsidiarySaleOfStockAxis_CanaccordGenuityLLCMemberdeiLegalEntityAxis_CommonStockMemberusgaapStatementEquityComponentsAxis_SeptemberTwoThousandAndTwentyTwoDistributionAgreementMemberusgaapInvestmentTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-22518">4.3</ix:nonFraction>&#160;million. The Company has reached the capacity for sales of shares under the September 2022 Distribution Agreement and the agreement has terminated. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Company was obligated to pay Canaccord a commission of up to <ix:nonFraction name="pstv:PercentageOfCommissionOnGrossProceedsFromSaleOfCommonStock" contextRef="P09_09_2022To09_09_2022_AtTheMarketOfferingProgramMemberusgaapSubsidiarySaleOfStockAxis_CanaccordGenuityLLCMemberdeiLegalEntityAxis_CommonStockMemberusgaapStatementEquityComponentsAxis_MaximumMembersrtRangeAxis_SeptemberTwoThousandAndTwentyTwoDistributionAgreementMemberusgaapInvestmentTypeAxis" unitRef="Unit_pure" decimals="INF" scale="-2" format="ixt:num-dot-decimal" id="ixv-22519">3.0</ix:nonFraction>% of the gross proceeds from the sale of its common stock under the September 2022 Distribution Agreement. The Company also agreed to reimburse Canaccord for its reasonable documented <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">out-of-pocket</div></div> expenses, including fees and disbursements of its counsel, in the amount of $<ix:nonFraction name="pstv:AggregateExpenseIncludingFeeAndDisbursementExpenses" contextRef="P09_09_2022To09_09_2022_AtTheMarketOfferingProgramMemberusgaapSubsidiarySaleOfStockAxis_CanaccordGenuityLLCMemberdeiLegalEntityAxis_SeptemberTwoThousandAndTwentyTwoDistributionAgreementMemberusgaapInvestmentTypeAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-22520">50,000</ix:nonFraction>. In addition, the Company agreed to provide customary indemnification rights to Canaccord. </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">On January&#160;14, 2022, the Company entered into the January 2022 Distribution Agreement with Canaccord, pursuant to which the Company could issue and sell, from time to time, shares of its common stock having an aggregate offering price of up to $<ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="P01_14_2022To01_14_2022_AtTheMarketOfferingProgramMemberusgaapSubsidiarySaleOfStockAxis_CanaccordGenuityLLCMemberdeiLegalEntityAxis_CommonStockMemberusgaapStatementEquityComponentsAxis_JanuaryTwoThousandAndTwentyTwoDistributionAgreementMemberusgaapInvestmentTypeAxis_MaximumMembersrtRangeAxis" unitRef="Unit_USD" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-22521">5,000,000</ix:nonFraction>, with Canaccord acting as an agent for sales. The Company had <ix:nonFraction name="pstv:CommonStockSalesAvailableForIssuance" contextRef="PAsOn01_14_2022_AtTheMarketOfferingProgramMemberusgaapSubsidiarySaleOfStockAxis_CanaccordGenuityLLCMemberdeiLegalEntityAxis_CommonStockMemberusgaapStatementEquityComponentsAxis_JanuaryTwoThousandAndTwentyTwoDistributionAgreementMemberusgaapInvestmentTypeAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt-sec:numwordsen" id="ixv-22522">no</ix:nonFraction> obligation to sell any of the Company&#8217;s shares and it could instruct Canaccord not to sell any shares if the sales could not be effected at or above the price designated by the Company from time to time and the Company could at any time suspend sales pursuant to the January 2022 Distribution Agreement. During the year ended December&#160;31, 2023, the Company issued <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="P01_01_2023To12_31_2023_CanaccordGenuityLLCMemberdeiLegalEntityAxis_CommonStockMemberusgaapStatementEquityComponentsAxis_JanuaryTwoThousandAndTwentyTwoDistributionAgreementMemberusgaapInvestmentTypeAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-22523">460,151</ix:nonFraction> shares under the January 2022 Distribution Agreement for net proceeds of approximately $<ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="P01_01_2023To12_31_2023_CanaccordGenuityLLCMemberdeiLegalEntityAxis_CommonStockMemberusgaapStatementEquityComponentsAxis_JanuaryTwoThousandAndTwentyTwoDistributionAgreementMemberusgaapInvestmentTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-22524">4.8</ix:nonFraction>&#160;million. The January 2022 Distribution Agreement has been terminated after all available registered shares were fully utilized. </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><ix:exclude>F-15</ix:exclude> </div></div></ix:continuation></div></div><ix:continuation id="TextSelectionAppend_116199105_6" continuedAt="TextSelectionAppend_116199105_7"><ix:exclude><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_116199105_7" continuedAt="TextSelectionAppend_116199105_8"><ix:exclude><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/></ix:exclude></ix:continuation> <div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelectionAppend_116199105_8"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Share Repurchase Program and Treasury Stock </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">On October&#160;31, 2023, the Company announced that its Board has approved a share repurchase program (the &#8220;Share Repurchase Program&#8221;), with authorization to repurchase up to $<ix:nonFraction name="us-gaap:StockRepurchaseProgramAuthorizedAmount1" contextRef="PAsOn10_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis_MaximumMembersrtRangeAxis" unitRef="Unit_USD" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-22526">500,000</ix:nonFraction> of the outstanding shares of the Company&#8217;s common stock. The Company funded repurchases under the Share Repurchase Program with available cash. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">During the year ended December&#160;31, 2023, the Company purchased <ix:nonFraction name="us-gaap:StockRepurchasedDuringPeriodShares" contextRef="P01_01_2023To12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-22527">78,559</ix:nonFraction> of its common stock for approximately $<ix:nonFraction name="us-gaap:TreasuryStockValue" contextRef="PAsOn12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-22528">0.1</ix:nonFraction>&#160;million as treasury stock. The Company purchased <ix:nonFraction name="us-gaap:StockRepurchasedDuringPeriodShares" contextRef="P01_01_2024To03_31_2024_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-22529">179,866</ix:nonFraction> of its common shares for approximately $<ix:nonFraction name="us-gaap:TreasuryStockValue" contextRef="PAsOn03_31_2024_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-22530">0.4</ix:nonFraction>&#160;million as treasury stock during the three months ended March&#160;31, 2024. As of March&#160;31, 2024, <ix:nonFraction name="us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" contextRef="PAsOn03_31_2024" unitRef="Unit_USD" decimals="0" scale="0" format="ixt-sec:numwordsen" id="ixv-22531">no</ix:nonFraction> amount remained authorized for repurchase. </div></div></ix:continuation><ix:nonNumeric name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" contextRef="P01_01_2024To03_31_2024" escape="true" id="ixv-11622"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">11. Stock-based Compensation </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Under the Company&#8217;s 2015 New Employee Incentive Plan (the &#8220;2015 Plan&#8221;), awards may only be granted to employees who were not previously an employee or director of the Company, or following a bona fide period of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">non-employment,</div> as a material inducement to entering into employment with the Company. As of March&#160;31, 2024, there were <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" contextRef="PAsOn03_31_2024_StockBasedCompensation2015EquityIncentivePlan1MemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-22532">6,024</ix:nonFraction> shares of common stock remaining and available for future issuances under the 2015 Plan. </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The Company&#8217;s 2020 Stock Incentive Plan (the &#8220;2020 Plan&#8221;), which replaced the Company&#8217;s 2014 Equity Incentive Plan, provides for the award or sale of shares of common stock (including restricted stock), the award of stock units and stock appreciation rights, and the grant of both incentive stock options to purchase common stock to directors, officers, employees and consultants of the Company. The 2020 Plan, as amended, provides for the issuance of up to <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="P01_01_2024To03_31_2024_StockBasedCompensation2020EquityIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-22533">236,667</ix:nonFraction> shares of common stock, plus the number of shares available for issuance is increased to the extent that awards granted under the 2020 Plan and the Company&#8217;s 2014 Equity Incentive Plan are forfeited or expire (except as otherwise provided in the 2020 Plan). As of March&#160;31, 2024, there were <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" contextRef="PAsOn03_31_2024_StockBasedCompensation2020EquityIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-22534">17,582</ix:nonFraction> shares remaining and available for future issuances under the 2020 Plan. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Generally, options issued under the 2020 Plan are subject to a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><ix:nonNumeric name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" contextRef="P01_01_2024To03_31_2024_MinimumMembersrtRangeAxis" format="ixt-sec:durwordsen" id="ixv-22535">two-year</ix:nonNumeric></div> or <ix:nonNumeric name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" contextRef="P01_01_2024To03_31_2024_MaximumMembersrtRangeAxis" format="ixt-sec:durwordsen" id="ixv-22536">four-year</ix:nonNumeric> vesting schedule with <ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" contextRef="P01_01_2024To03_31_2024" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-22537">25</ix:nonFraction>% of the options vesting on the one year anniversary of the grant date followed by equal monthly installment vesting, and have a contractual term of <ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" contextRef="P01_01_2024To03_31_2024" format="ixt-sec:duryear" id="ixv-22538">10</ix:nonNumeric> years. </div><ix:nonNumeric name="us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock" contextRef="P01_01_2024To03_31_2024" escape="true" id="ixv-11632"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">A summary of activity for the three months ended March&#160;31, 2024 is as follows: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 92%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;">
<tr>
<td style="width: 55%;"/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Options</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Weighted</div></div><br/> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Average</div></div><br/> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Exercise&#160;Price</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Weighted</div></div><br/> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Average</div></div><br/> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Remaining</div></div><br/> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Contractual</div></div><br/> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Term<br/> (years)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Aggregate</div></div><br/> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Intrinsic<br/> Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Balance as of December&#160;31, 2023</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="PAsOn12_31_2023" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-22539">140,109</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="PAsOn12_31_2023" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-22540">37.48</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" contextRef="P01_01_2023To12_31_2023" format="ixt-sec:duryear" id="ixv-22541">8.07</ix:nonNumeric></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Granted</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="P01_01_2024To03_31_2024" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-22542">163,025</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="P01_01_2024To03_31_2024" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-22543">2.03</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Cancelled/forfeited</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" contextRef="P01_01_2024To03_31_2024" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-22544">1</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" contextRef="P01_01_2024To03_31_2024" unitRef="Unit_USD_per_Share" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-22545">289,125</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Balance as of March&#160;31, 2024</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="PAsOn03_31_2024" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-22546">303,133</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="PAsOn03_31_2024" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-22547">17.46</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" contextRef="P01_01_2024To03_31_2024" format="ixt-sec:duryear" id="ixv-22548">8.94</ix:nonNumeric></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="PAsOn03_31_2024" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-22549">7,600</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Vested and expected to vest at March&#160;31, 2024</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" contextRef="PAsOn03_31_2024" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-22550">278,083</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" contextRef="PAsOn03_31_2024" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-22551">18.64</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" contextRef="P01_01_2024To03_31_2024" format="ixt-sec:duryear" id="ixv-22552">8.87</ix:nonNumeric></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" contextRef="PAsOn03_31_2024" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-22553">6,800</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Exercisable at March&#160;31, 2024</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="PAsOn03_31_2024" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-22554">84,908</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" contextRef="PAsOn03_31_2024" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-22555">50.13</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" contextRef="P01_01_2024To03_31_2024" format="ixt-sec:duryear" id="ixv-22556">7.37</ix:nonNumeric></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" contextRef="PAsOn03_31_2024" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-22557">500</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table></ix:nonNumeric><div style="clear:both;max-height:0pt;"></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">As of March&#160;31, 2024, the total compensation cost related to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">non-vested</div> stock options not yet recognized for all the Company&#8217;s plans is approximately $<ix:nonFraction name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" contextRef="PAsOn03_31_2024" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-22558">0.8</ix:nonFraction>&#160;million, which is expected to be recognized as a result of vesting under service conditions over a weighted average period of <ix:nonNumeric name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" contextRef="P01_01_2024To03_31_2024" format="ixt-sec:duryear" id="ixv-22559">2.3</ix:nonNumeric> years. </div></ix:nonNumeric><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">F-16 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:nonNumeric name="us-gaap:SubsequentEventsTextBlock" contextRef="P01_01_2024To03_31_2024" escape="true" continuedAt="TextSelection_116200100" id="ixv-11968"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">12. Subsequent Events </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Repayment of Term Loan and Use of Pershing Credit Facility </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">On May&#160;31, 2024, the Company drew $<ix:nonFraction name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" contextRef="PAsOn05_31_2024_PershingCreditFacilityMemberusgaapCreditFacilityAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-22560">3.3</ix:nonFraction>&#160;million on the Pershing Credit Facility, to repay the Oxford Term Loan in full, a payment amount that totaled approximately $<ix:nonFraction name="us-gaap:LineOfCreditFacilityPeriodicPayment" contextRef="P05_31_2024To05_31_2024_PershingCreditFacilityMemberusgaapCreditFacilityAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-22561">3.3</ix:nonFraction>&#160;million, which included both the balance of outstanding principal and interest and the final payment fee due. The repayment in full of the Oxford Term Loan terminated Oxford&#8217;s security interest in the Company&#8217;s existing and after-acquired assets, as well as all other certain restrictions and covenants under the Oxford Term Loan. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Borrowings under the Pershing Credit Facility bear interest at the target interest rate set by the Federal Open Market Committee, subject to a floor of <ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="PAsOn05_31_2024_PershingCreditFacilityMemberusgaapCreditFacilityAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal" id="ixv-22562">5.5</ix:nonFraction>%, plus a spread of <ix:nonFraction name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" contextRef="P05_31_2024To05_31_2024_PershingCreditFacilityMemberusgaapCreditFacilityAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal" id="ixv-22563">1.75</ix:nonFraction>% and applicable fees of <ix:nonFraction name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" contextRef="PAsOn05_31_2024_PershingCreditFacilityMemberusgaapCreditFacilityAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal" id="ixv-22564">0.5</ix:nonFraction>%, subject to a maximum interest rate of the then applicable Prime Rate as published in The Wall Street Journal plus <ix:nonFraction name="us-gaap:DebtInstrumentInterestRateDuringPeriod" contextRef="P05_31_2024To05_31_2024_PershingCreditFacilityMemberusgaapCreditFacilityAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal" id="ixv-22565">3.0</ix:nonFraction>%. Interest payments thereunder are calculated on a monthly basis and, unless paid, are added to the outstanding balance under the Pershing Credit Facility. The proceeds under the Pershing Credit Facility are available for working capital needs and other general corporate purposes. The Pershing Credit Facility includes certain covenants and restrictions, which may require the Company, on <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">an&#160;on-going&#160;basis,</div> to deposit additional funds or marketable securities in order to maintain the line of credit extended by Pershing. </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The available credit line limit under the Pershing Credit Facility fluctuates based on the Company&#8217;s request for extensions of credit from time to time, subject to the value of the collateralized marketable securities that the Company holds with Pershing, provided that the amount available to draw under the Pershing Credit Facility cannot exceed <ix:nonFraction name="us-gaap:LineOfCreditFacilityInterestRateDuringPeriod" contextRef="P05_31_2024To05_31_2024_PershingCreditFacilityMemberusgaapCreditFacilityAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal" id="ixv-22566">91.5</ix:nonFraction>% of the value of the Company&#8217;s collateralized marketable securities deposited with Pershing (the &#8220;Collateral&#8221;). Depending on the value of the Collateral that the Company holds with Pershing, Pershing may require the Company, on <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">an&#160;on-going&#160;basis,</div> to deposit additional funds or marketable securities in order to restore the level of the Collateral to an acceptable level. The amounts borrowed under the Pershing Credit Facility are due on demand. </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The Pershing Credit Facility is secured by a general lien and security interest in the Company&#8217;s Collateral held in its account with Pershing. Upon certain customary events of default, Pershing has the right, in its discretion, to liquidate, withdraw or sell all or any part of the Collateral and apply the proceeds to the amounts outstanding under the Pershing Credit Facility. The Pershing Credit Facility is also subject to certain customary terms and conditions. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">May 2024 Private Placement </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">On May&#160;5, 2024, the Company entered into a securities purchase agreement (the &#8220;Securities Purchase Agreement&#8221;) with certain investors, including certain of the Company&#8217;s directors and executive officers (&#8220;Company Insiders&#8221;) (collectively, the &#8220;Purchasers&#8221;), for the sale and issuance by the Company of its securities (the &#8220;Initial Subscription&#8221;). On May&#160;8, 2024, the Company entered into a first amendment to the Securities Purchase Agreement (the &#8220;Amendment&#8221;) for the sale and issuance by the Company of additional securities to two of the Purchasers (the &#8220;Additional Subscription&#8221;, and together with the Initial Subscription, the &#8220;May 2024 Private Placement&#8221;). The Securities Purchase Agreement, as amended, provides for the sale and issuance by the Company of an aggregate of <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="P05_05_2024To05_05_2024_May2024PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-22567">3,591,532</ix:nonFraction> shares (the &#8220;Private Placement Shares&#8221;) of the Company&#8217;s common stock or, at the election of each Purchaser, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">pre-funded</div> warrants (the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">&#8220;Pre-Funded</div> Warrants&#8221;), exercisable immediately at an exercise price of $<ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="PAsOn05_05_2024_May2024PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_USD_per_Share" decimals="3" scale="0" format="ixt:num-dot-decimal" id="ixv-22568">0.001</ix:nonFraction> per share (the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">&#8220;Pre-Funded</div> Warrant Shares&#8221;), with each Private Placement Share or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">Pre-Funded</div> Warrant accompanied by (i)&#160;a Series A common warrant (&#8220;Series A Warrants&#8221;) to purchase one share of common stock (the &#8220;Series A Warrant Shares&#8221;), for an aggregate of <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="P05_05_2024To05_05_2024_May2024PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_SeriesAWarrantMemberusgaapClassOfWarrantOrRightAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-22569">3,591,532</ix:nonFraction> Series A Warrants, and (ii)&#160;one Series B common warrant (&#8220;Series B Warrants&#8221;) to purchase one share of common stock (the &#8220;Series B Warrant Shares,&#8221; and together with the Series A Warrant Shares, the &#8220;Common Warrant Shares&#8221;), for an aggregate of <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="P05_05_2024To05_05_2024_May2024PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_SeriesBWarrantMemberusgaapClassOfWarrantOrRightAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-22570">3,591,532</ix:nonFraction> Series B Warrants. </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The combined purchase price for each Private Placement Share and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">Pre-Funded</div> Warrant from the Initial Subscription was $<ix:nonFraction name="pstv:ClassOfWarrantOrRightPurchasePrice" contextRef="P05_05_2024To05_05_2024_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_USD_per_Share" decimals="3" scale="0" format="ixt:num-dot-decimal" id="ixv-22571">2.022</ix:nonFraction>, and $<ix:nonFraction name="pstv:ClassOfWarrantOrRightPurchasePrice" contextRef="P05_05_2024To05_05_2024_PreFundedWarrantMemberusgaapSubsidiarySaleOfStockAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_USD_per_Share" decimals="3" scale="0" format="ixt:num-dot-decimal" id="ixv-22572">2.158</ix:nonFraction> from the Additional Subscription, in each case together with one </div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><ix:exclude>F-17</ix:exclude> </div></div></ix:nonNumeric></div></div><ix:continuation id="TextSelection_116200100" continuedAt="TextSelectionAppend_116200100_1"><ix:exclude><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_116200100_1" continuedAt="TextSelectionAppend_116200100_2"><ix:exclude><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/></ix:exclude></ix:continuation> <div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelectionAppend_116200100_2"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">accompanying Series A Warrant and one accompanying Series B Warrant, provided, that the Company Insiders participated in the Initial Subscription at an offering price of $<ix:nonFraction name="pstv:ClassOfWarrantOrRightOfferingPrice" contextRef="P05_05_2024To05_05_2024_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-22574">2.04</ix:nonFraction> per Private Placement Share and accompanying Series A Warrant and Series B Warrant. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The exercise price of each Series A Warrant and Series B Warrant from the Initial Subscription is $<ix:nonFraction name="pstv:ClassOfWarrantOrRightExercisePriceInitialSubscription" contextRef="PAsOn05_05_2024_May2024PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_USD_per_Share" decimals="3" scale="0" format="ixt:num-dot-decimal" id="ixv-22575">1.772</ix:nonFraction> per share and $<ix:nonFraction name="pstv:ClassOfWarrantOrRightExercisePriceAdditionalSubscription" contextRef="PAsOn05_05_2024_May2024PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_USD_per_Share" decimals="3" scale="0" format="ixt:num-dot-decimal" id="ixv-22576">1.908</ix:nonFraction> per share in the Additional Subscription, provided that the exercise price for the Series A Warrants and Series B Warrants issued to the Company Insiders is $<ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="PAsOn05_05_2024_May2024PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-22577">1.79</ix:nonFraction> per share. Subject to certain ownership limitations, the Series A Warrants will be exercisable until the five-year anniversary of issuance. Subject to certain ownership limitations, the Series B Warrants will be exercisable until the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">one-year</div> anniversary of the declaration of effectiveness of a registration statement to be filed with the Securities and Exchange Commission covering the resale of the Common Warrant Shares. The <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">Pre-Funded</div> Warrant will not expire until exercised in full. </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The May 2024 Private Offering closed on May&#160;9, 2024 (the &#8220;May 2024 Private Placement Closing&#8221;). The aggregate gross proceeds at the May 2024 Private Placement Closing were approximately $<ix:nonFraction name="us-gaap:WarrantsAndRightsOutstanding" contextRef="PAsOn05_09_2024_May2024PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_USD" decimals="-4" scale="6" format="ixt:num-dot-decimal" id="ixv-22578">7.25</ix:nonFraction>&#160;million, before deducting certain expenses payable by the Company, and excluding the proceeds, if any, from the exercise of the Series A Warrant, the Series B Warrant, and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">Pre-Funded</div> Warrant. </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Company is evaluating the accounting treatment of the Series A Warrants, Series B Warrants and the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">Pre-Funded</div> Warrants under the authoritative accounting guidance. </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Biocept Asset Purchase </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">On April&#160;26, 2024, the Company acquired from Biocept, for a total cash payment of $<ix:nonFraction name="us-gaap:PaymentsToAcquireProductiveAssets" contextRef="P04_26_2024To04_26_2024_BioceptAssetPurchaseMemberusgaapAssetAcquisitionAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-22579">400,000</ix:nonFraction>, substantially all of the right, title and interest in CNside, including (i)&#160;intellectual property, (ii)&#160;inventory and raw materials, and (iii)&#160;data, information, results and reports pertaining to the completed and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">on-going</div> clinical studies involving the use of the CNside test (including, but not limited to, the FORESEE clinical study), related to the development, making, selling, and exporting or importing of CNside, after the Company&#8217;s bid was approved by the United States Bankruptcy Court for the District of Delaware. </div></ix:continuation><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">F-18 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div id="tx840996_22" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div id="fin840996_6" style="letter-spacing: 0px; top: 0px;display:inline;"></div>Report of Independent Registered Public Accounting Firm </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Shareholders and Board of Directors </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Plus Therapeutics, Inc. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Austin, Texas </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Opinion on the Financial Statements </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">We have audited the accompanying balance sheets of Plus Therapeutics, Inc. (the &#8220;Company&#8221;) as of December&#160;31, 2023 and 2022, the related statements of operations, stockholders&#8217; equity (deficit), and cash flows for each of the years then ended and the related notes (collectively referred to as the &#8220;financial statements&#8221;). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company at December&#160;31, 2023 and 2022, and the results of its operations and its cash flows for each of the years then ended, in conformity with accounting principles generally accepted in the United States of America. </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Going Concern Uncertainty </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 1 to the financial statements, the Company has suffered recurring losses and negative cash flows from operations that raise substantial doubt about its ability to continue as a going concern. Management&#8217;s plans in regard to these matters are also described in Note 1. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.<div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div> </div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Basis for Opinion </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">These financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (&#8220;PCAOB&#8221;) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company&#8217;s internal control over financial reporting. Accordingly, we express no such opinion. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion. </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Critical Audit Matter </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The critical audit matter communicated below is a matter arising from the current period audit of the financial statements that was communicated or required to be communicated to the audit committee and that: (1)&#160;relates to accounts or disclosures that are material to the financial statements and (2)&#160;involved our especially challenging, </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">F-19 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"></div></div></div> <div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">subjective, or complex judgments. The communication of the critical audit matter does not alter in any way our opinion on the financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing separate opinions on the critical audit matter or on the accounts or disclosures to which it relates. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;display:inline;">Determination of Research and Development Cost Associated With Recording of Grant Revenue </div></div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As described in Note 9 to the financial statements, in September 2022, the Company entered into a contract with the Cancer Prevention and Research Institute of Texas (&#8220;CPRIT&#8221;) pursuant to which CPRIT will provide the Company a grant of up to $17.6&#160;million (the &#8220;CPRIT Grant&#8221;) over a three-year period. The CPRIT Grant is subject to customary CPRIT funding conditions, including, but not limited to, fund the continued development of rhenium (<div style="font-size:75%; vertical-align:top;display:inline;font-size:8.3px">186</div>Re) obisbemeda for the treatment of patients with leptomeningeal metastases (&#8220;LM&#8221;). The Company recognized $4.9&#160;<div style="display:inline;">million </div>in grant revenue from the CPRIT Grant during the year ended December&#160;31, 2023. </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">We identified the determination of research and development costs incurred associated with the CPRIT Grant as a critical audit matter because of the subjectivity required to appropriately determine whether such costs satisfied the funding conditions. Auditing this element involved especially challenging and subjective auditor judgment due to the nature and extent of auditor effort required to </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">address the matter. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The primary procedures we performed to address this critical audit matter included: </div></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentColor; border-image: none; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Reviewing the CPRIT Grant agreement to understand the conditions for which research and development costs satisfy the funding conditions. </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentColor; border-image: none; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Reviewing evidence of CPRIT&#8217;s approval of costs submitted by the Company that were applied to the CPRIT Grant funding conditions. </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentColor; border-image: none; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Inspecting a sample of vendor agreements and invoice detail to determine whether certain charges satisfy the CPRIT Grant funding conditions. </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">/s/ BDO USA, P.C. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">We have served as the Company&#8217;s auditor since 2016. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Austin, Texas </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">March&#160;5, 2024 </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">F-20 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div id="fin840996_7" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">PLUS THERAPEUTICS, INC. </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">BALANCE SHEETS </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">(in thousands, except share and par value data) </div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;">
<tr>
<td style="width: 80%;"/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">As of December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Assets</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Current assets:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Cash and cash equivalents</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-22580">8,554</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-22581">18,120</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Other current assets</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:OtherAssetsCurrent" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-22582">1,280</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:OtherAssetsCurrent" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-22583">3,697</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Total current assets</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-22584">9,834</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-22585">21,817</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Property and equipment, net</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-22586">906</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-22587">1,324</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Operating lease <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">right-use-of</div></div> assets</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-22588">202</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-22589">248</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Goodwill</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:Goodwill" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-22590">372</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:Goodwill" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-22591">372</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Intangible assets, net</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:OtherIntangibleAssetsNet" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-22592">42</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:OtherIntangibleAssetsNet" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-22593">94</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Other assets</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:OtherAssetsNoncurrent" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-22594">32</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:OtherAssetsNoncurrent" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-22595">12</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Total assets</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:Assets" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-22596">11,388</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:Assets" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-22597">23,867</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Liabilities and Stockholders&#8217; Equity (Deficit)</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Current liabilities:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Accounts payable and accrued expenses</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-22598">6,631</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-22599">10,134</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Operating lease liability</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-22600">120</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-22601">110</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Term loan obligation, current</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:LongTermDebtCurrent" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-22602">3,976</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:LongTermDebtCurrent" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-22603">1,608</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Total current liabilities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-22604">10,727</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-22605">11,852</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Noncurrent operating lease liability</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-22606">85</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-22607">141</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Term loan obligation</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:LongTermDebtNoncurrent" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-22608">&#8212;</ix:nonFraction>&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:LongTermDebtNoncurrent" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-22609">3,786</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Deferred grant liability</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:DeferredIncomeNoncurrent" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-22610">1,924</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:DeferredIncomeNoncurrent" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-22611">1,643</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Total liabilities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:Liabilities" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-22612">12,736</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:Liabilities" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-22613">17,422</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td colspan="8" style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Commitments and contingencies (Note 6)</div></div></td>
<td style="vertical-align: top;"><div style="text-indent: 0em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td colspan="8" style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Stockholders&#8217; equity (deficit):</div></div></td>
<td style="vertical-align: top;"><div style="text-indent: 0em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Preferred stock, $<ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="PAsOn12_31_2023" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-22614"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="PAsOn12_31_2022" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-22615">0.001</ix:nonFraction></ix:nonFraction>&#160;par value; <ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="PAsOn12_31_2023" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-22616"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="PAsOn12_31_2022" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-22617">5,000,000</ix:nonFraction></ix:nonFraction>&#160;shares authorized; <ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="PAsOn12_31_2023" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-22618"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="PAsOn12_31_2022" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-22619"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="PAsOn12_31_2023" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-22620"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="PAsOn12_31_2022" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-22621">1,952</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares issued and outstanding as of December&#160;31, 2023 and 2022</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-22622">&#8212;</ix:nonFraction>&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-22623">&#8212;</ix:nonFraction>&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Common stock, $<ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="PAsOn12_31_2022" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-22624"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="PAsOn12_31_2023" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-22625">0.001</ix:nonFraction></ix:nonFraction>&#160;par value; <ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="PAsOn12_31_2023" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-22626"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="PAsOn12_31_2022" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-22627">100,000,000</ix:nonFraction></ix:nonFraction>&#160;shares authorized; <ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="PAsOn12_31_2023" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-22628">4,522,656</ix:nonFraction>&#160;issued and <ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="PAsOn12_31_2023" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-22629">4,444,097</ix:nonFraction> outstanding as of December&#160;31, 2023, <ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="PAsOn12_31_2022" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-22630"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="PAsOn12_31_2022" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-22631">2,240,092</ix:nonFraction></ix:nonFraction>&#160;shares issued and outstanding as of December&#160;31, 2022, respectively</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-22632">5</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-22633">2</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Treasury stock (at cost, <ix:nonFraction name="us-gaap:TreasuryStockCommonShares" contextRef="PAsOn12_31_2023" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-22634">78,559</ix:nonFraction>&#160;shares as of December&#160;31, 2023)</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">(<ix:nonFraction name="us-gaap:TreasuryStockCommonValue" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-22635">126</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:TreasuryStockCommonValue" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-22636">&#8212;</ix:nonFraction>&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;">Additional <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">paid-in</div> capital</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-22637">479,274</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-22638">473,628</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Accumulated deficit</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-22639">480,501</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-22640">467,185</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Total stockholders&#8217; equity (deficit)</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-22641">1,348</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-22642">6,445</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Total liabilities and stockholders&#8217; equity (deficit)</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-22643">11,388</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-22644">23,867</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">See Accompanying Notes to these Financial Statements </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">F-21 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div id="fin840996_8" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">PLUS THERAPEUTICS, INC. </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">STATEMENTS OF OPERATIONS </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">(in thousands, except share and per share data) </div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;">
<tr>
<td style="width: 78%;"/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">For&#160;the&#160;Years&#160;Ended&#160;December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Grant revenue</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:Revenues" contextRef="P01_01_2023To12_31_2023_GrantMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-22645">4,913</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:Revenues" contextRef="P01_01_2022To12_31_2022_GrantMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-22646">224</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Operating expenses:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Research and development</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-22647">9,690</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-22648">9,698</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">General and administrative</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-22649">8,544</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-22650">10,238</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Total operating expenses</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-22651">18,234</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-22652">19,936</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Operating loss</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-22653">13,321</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-22654">19,712</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Other income (expense):</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Interest income</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:InvestmentIncomeInterest" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-22655">400</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:InvestmentIncomeInterest" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-22656">147</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Interest expense</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">(<ix:nonFraction name="us-gaap:InterestExpense" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-22657">395</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">(<ix:nonFraction name="us-gaap:InterestExpense" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-22658">711</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Change in fair value of liability instruments</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesFairValueAdjustment" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-22659">&#8212;</ix:nonFraction>&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesFairValueAdjustment" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-22660">1</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Total other income (expense)</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-22661">5</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">(<ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-22662">563</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Net loss</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-22663">13,316</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-22664">20,275</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Net loss per share, basic and diluted</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:num-dot-decimal" id="ixv-22665"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:num-dot-decimal" id="ixv-22666">4.24</ix:nonFraction></ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:num-dot-decimal" id="ixv-22667"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:num-dot-decimal" id="ixv-22668">11.58</ix:nonFraction></ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Basic and diluted weighted average shares used in calculating net loss per share attributable to common stockholders</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-22669"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-22670">3,140,925</ix:nonFraction></ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-22671"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-22672">1,750,350</ix:nonFraction></ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">See Accompanying Notes to these Financial Statements </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">F-22 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div id="fin840996_9" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">PLUS THERAPEUTICS, INC. </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">STATEMENTS OF STOCKHOLDERS&#8217; EQUITY (DEFICIT) </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">(in thousands, except share data) </div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 100%; font-family: Times New Roman; font-size: 9pt; border-collapse: collapse;">
<tr>
<td style="width: 39%;"/>
<td style="vertical-align: bottom;"/>
<td/>
<td/>
<td style="width: 1%; vertical-align: bottom;"/>
<td style="vertical-align: bottom;"/>
<td/>
<td/>
<td style="width: 1%; vertical-align: bottom;"/>
<td style="vertical-align: bottom;"/>
<td/>
<td/>
<td style="width: 1%; vertical-align: bottom;"/>
<td style="vertical-align: bottom;"/>
<td/>
<td/>
<td style="width: 1%; vertical-align: bottom;"/>
<td style="vertical-align: bottom;"/>
<td/>
<td/>
<td style="width: 1%; vertical-align: bottom;"/>
<td style="vertical-align: bottom;"/>
<td/>
<td/>
<td style="width: 1%; vertical-align: bottom;"/>
<td style="vertical-align: bottom;"/>
<td/>
<td/>
<td style="width: 1%; vertical-align: bottom;"/>
<td style="vertical-align: bottom;"/>
<td/>
<td/>
<td style="width: 1%; vertical-align: bottom;"/>
<td style="vertical-align: bottom;"/>
<td/>
<td/>
<td style="width: 1%; vertical-align: bottom;"/>
<td style="vertical-align: bottom;"/>
<td/>
<td/>
<td style="width: 1%; vertical-align: bottom;"/>
<td style="vertical-align: bottom;"/>
<td/>
<td/>
<td style="width: 1%; vertical-align: bottom;"/></tr>
<tr style="font-family: Times New Roman; font-size: 7pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Convertible</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td rowspan="3" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" rowspan="3" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Additional</div></div><br/> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">paid-in</div></div></div><br/> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">capital</div></div></td>
<td rowspan="3" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td rowspan="3" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" rowspan="3" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Accumulated</div></div><br/> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">deficit</div></div></td>
<td rowspan="3" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td rowspan="3" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" rowspan="3" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div><br/> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">stockholders&#8217;</div></div><br/> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">equity<br/> (deficit)</div></div></td>
<td rowspan="3" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 7pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Preferred&#160;Stock</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">preferred&#160;stock</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Common&#160;stock</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 7pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Shares</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Amount</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Shares</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Amount</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Shares</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Amount</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Treasury&#160;Stock</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;display:inline;">Balance at December&#160;31, 2021</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="PAsOn12_31_2021_ConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-22673">1,952</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="PAsOn12_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-22674">1,034,002</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-22675">1</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-22676">457,745</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-22677">446,910</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-22678">10,836</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;display:inline;">Share-based compensation</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="P01_01_2022To12_31_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-22679">606</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-22680">606</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;display:inline;">Sale of common stock, net</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="P01_01_2022To12_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-22681">1,206,090</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="P01_01_2022To12_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-22682">1</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="P01_01_2022To12_31_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-22683">15,277</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-22684">15,278</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;display:inline;">Net loss</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2022To12_31_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-22685">20,275</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-22686">20,275</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;display:inline;">Balance at December&#160;31, 2022</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="PAsOn12_31_2022_ConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-22687">1,952</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="PAsOn12_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-22688">2,240,092</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-22689">2</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-22690">473,628</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-22691">467,185</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-22692">6,445</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;display:inline;">Issuance of Series F preferred stock</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="P01_01_2023To12_31_2023_PreferredStockMemberusgaapStatementEquityComponentsAxis_SeriesFPreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-22693">1</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;display:inline;">Redemption of Series F preferred stock</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">(<ix:nonFraction name="us-gaap:StockRedeemedOrCalledDuringPeriodShares" contextRef="P01_01_2023To12_31_2023_PreferredStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-22694">1</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;display:inline;">Share-based compensation</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="P01_01_2023To12_31_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-22695">569</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-22696">569</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;display:inline;">Sale of common stock, net</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="P01_01_2023To12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-22697">2,230,493</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="P01_01_2023To12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-22698">3</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="P01_01_2023To12_31_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-22699">5,002</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-22700">5,005</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;display:inline;">Issuance of common stock for in process research and development</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" contextRef="P01_01_2023To12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-22701">53,381</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="P01_01_2023To12_31_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-22702">75</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-22703">75</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;display:inline;">Fractional adjustment</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">(<ix:nonFraction name="pstv:FractionalAdjustmentOfCommonStock" contextRef="P01_01_2023To12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF" scale="0" sign="-" format="ixt:num-dot-decimal" id="ixv-22704">1,310</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;display:inline;">Purchase of treasury stock</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">(<ix:nonFraction name="us-gaap:TreasuryStockSharesAcquired" contextRef="P01_01_2023To12_31_2023_TreasuryStockCommonMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-22705">78,559</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">(<ix:nonFraction name="us-gaap:TreasuryStockValueAcquiredCostMethod" contextRef="P01_01_2023To12_31_2023_TreasuryStockCommonMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-22706">126</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">(<ix:nonFraction name="us-gaap:TreasuryStockValueAcquiredCostMethod" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-22707">126</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;display:inline;">Net loss</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2023To12_31_2023_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-22708">13,316</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-22709">13,316</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;display:inline;">Balance at December&#160;31, 2023</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="PAsOn12_31_2023_ConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-22710">1,952</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="PAsOn12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-22711">4,522,656</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-22712">5</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">(<ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="PAsOn12_31_2023_TreasuryStockCommonMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal" id="ixv-22713">78,559</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2023_TreasuryStockCommonMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-22714">126</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-22715">479,274</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2023_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-22716">480,501</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-22717">1,348</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">See Accompanying Notes to these Financial Statements </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">F-23 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div id="fin840996_10" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">PLUS THERAPEUTICS, INC. </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">STATEMENTS OF CASH FLOWS </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">(in thousands) </div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;">
<tr>
<td style="width: 78%; font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 4%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 4%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom;text-align:center;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: inline-block; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">For&#160;the&#160;Years&#160;Ended&#160;December&#160;31,</div></div></div></td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Cash flows used in operating activities:</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Net loss</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-22718">13,316</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-22719">20,275</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Adjustments to reconcile net loss to net cash used in operating activities:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Depreciation and amortization</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:DepreciationDepletionAndAmortization" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-22720">628</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:DepreciationDepletionAndAmortization" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-22721">619</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Amortization of deferred financing costs and debt discount</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-22722">190</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-22723">389</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Common stock issued for research and development</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="pstv:CommonStockIssuedForResearchAndDevelopment" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-22724">75</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="pstv:CommonStockIssuedForResearchAndDevelopment" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-22725">&#8212;</ix:nonFraction>&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Change in fair value of liability instruments</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-22726">&#8212;</ix:nonFraction>&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">(<ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-22727">1</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Loss on disposal of property and equipment</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:GainLossOnDispositionOfAssets" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-22728">2</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:GainLossOnDispositionOfAssets" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-22729">&#8212;</ix:nonFraction>&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Share-based compensation expense</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-22730">569</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-22731">606</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;">Reduction in the carrying amount of operating lease <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">right-of-use</div></div> assets</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-22732">117</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-22733">93</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td colspan="8" style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Increases (decreases) in cash caused by changes in operating assets and liabilities:</div></div></td>
<td style="vertical-align: top;"><div style="text-indent: 0em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Other assets</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-22734">2,397</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-22735">2,369</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Accounts payable and accrued expenses</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-22736">3,677</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-22737">6,452</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Change in operating lease liabilities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-22738">117</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-22739">129</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Deferred grant liability</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="pstv:IncreaseDecreaseInDeferredGrantLiability" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-22740">281</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="pstv:IncreaseDecreaseInDeferredGrantLiability" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-22741">1,643</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Net cash used in operating activities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-22742">12,851</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-22743">12,972</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td colspan="8" style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Cash flows used in investing activities:</div></div></div></td>
<td style="vertical-align: top;"><div style="text-indent: 0em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Purchases of property and equipment and intangible assets</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">(<ix:nonFraction name="pstv:PaymentsToAcquirePropertyPlantAndEquipmentAndIntangibleAssets" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-22744">160</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">(<ix:nonFraction name="pstv:PaymentsToAcquirePropertyPlantAndEquipmentAndIntangibleAssets" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-22745">509</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">In process research and development acquired</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="pstv:CashPaidForIPRDAssetAcquiredInAnAssetAcquisition" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-22746">&#8212;</ix:nonFraction>&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">(<ix:nonFraction name="pstv:CashPaidForIPRDAssetAcquiredInAnAssetAcquisition" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-22747">250</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Net cash used in investing activities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-22748">160</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-22749">759</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td colspan="8" style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Cash flows from financing activities:</div></div></div></td>
<td style="vertical-align: top;"><div style="text-indent: 0em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Principal payments of long-term obligations</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">(<ix:nonFraction name="us-gaap:RepaymentsOfLongTermDebt" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-22750">1,608</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">(<ix:nonFraction name="us-gaap:RepaymentsOfLongTermDebt" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-22751">1,608</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Gross proceeds from sale of common stock</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-22752">5,527</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-22753">15,832</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Payment of offering costs related to sale of common stock</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">(<ix:nonFraction name="us-gaap:PaymentsOfStockIssuanceCosts" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-22754">348</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">(<ix:nonFraction name="us-gaap:PaymentsOfStockIssuanceCosts" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-22755">773</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Purchase of treasury stock</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">(<ix:nonFraction name="us-gaap:PaymentsForRepurchaseOfEquity" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-22756">126</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:PaymentsForRepurchaseOfEquity" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-22757">&#8212;</ix:nonFraction>&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Net cash provided by financing activities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-22758">3,445</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-22759">13,451</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Net decrease in cash and cash equivalents</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">(<ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-22760">9,566</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">(<ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-22761">280</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Cash and cash equivalents at beginning of period</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">&#8194;&#8195;<ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-22762">18,120</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">&#8194;&#8195;<ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-22763">18,400</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Cash and cash equivalents at end of period</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-22764">8,554</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-22765">18,120</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td colspan="8" style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Supplemental disclosure of cash flows information:</div></div></div></td>
<td style="vertical-align: top;"><div style="text-indent: 0em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td colspan="8" style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Cash paid during period for:</div></div></td>
<td style="vertical-align: top;"><div style="text-indent: 0em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Interest</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:InterestPaidNet" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-22766">222</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:InterestPaidNet" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-22767">327</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td colspan="8" style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;">Supplemental schedule of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">non-cash</div> investing and financing activities:</div></div></td>
<td style="vertical-align: top;"><div style="text-indent: 0em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Unpaid offering cost</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="pstv:UnpaidOfferingCosts" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-22768">174</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="pstv:UnpaidOfferingCosts" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-22769">&#8212;</ix:nonFraction>&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Common stock issued in payment for in process research and development</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:StockIssued1" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-22770">75</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:StockIssued1" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-22771">&#8212;</ix:nonFraction>&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">Right-of-use</div></div> assets acquired by assuming operating lease liabilities</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-22772">71</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-22773">&#8212;</ix:nonFraction>&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">See Accompanying Notes to these Financial Statements </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">F-24 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">PLUS THERAPEUTICS, INC. </div></div></div><div id="fin840996_11" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">NOTES TO FINANCIAL STATEMENTS </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">December&#160;31, 2023 </div></div></div><ix:nonNumeric name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" contextRef="P01_01_2023To12_31_2023" escape="true" continuedAt="TextSelection_116199156" id="ixv-14761"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">1. Organization and Operations </div></div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The Company </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company focused on the development, manufacture and commercialization of complex and innovative treatments for patients battling cancer and other life-threatening diseases. </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Certain Risks and Uncertainties </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The Company&#8217;s prospects are subject to the risks and uncertainties frequently encountered by companies in the early stages of development and commercialization, especially those companies in rapidly evolving and technologically advanced industries such as the biotech/medical device field. The Company&#8217;s future viability largely depends on its ability to complete development of new products and receive regulatory approvals for those products. No assurance can be given that the Company&#8217;s new products will be successfully developed, regulatory approvals will be granted, or acceptance of these products will be achieved. </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Going Concern </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The Company incurred net losses of $<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-5" scale="6" sign="-" format="ixt:num-dot-decimal" id="ixv-22774">13.3</ix:nonFraction>&#160;million for the year ended December&#160;31, 2023, and as of December&#160;31, 2023, the Company had an accumulated deficit of $<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-5" scale="6" sign="-" format="ixt:num-dot-decimal" id="ixv-22775">480.5</ix:nonFraction>&#160;million and cash and cash equivalents of $<ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-22776">8.6</ix:nonFraction>&#160;million. Additionally, the Company used net cash of $<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-5" scale="6" sign="-" format="ixt:num-dot-decimal" id="ixv-22777">12.9</ix:nonFraction>&#160;million to fund its operating activities for the year ended December&#160;31, 2023. The Company&#8217;s term loan has an outstanding principal of $<ix:nonFraction name="pstv:LongTermDebtOutstandingThresholdAmount" contextRef="P01_01_2023To12_31_2023_TermLoanMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-22778">0.8</ix:nonFraction>&#160;million principal and a $<ix:nonFraction name="us-gaap:DebtInstrumentFeeAmount" contextRef="PAsOn12_31_2023_TermLoanMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-22779">3.2</ix:nonFraction>&#160;million final payment fee due <ix:nonNumeric name="us-gaap:DebtInstrumentMaturityDate" contextRef="P01_01_2023To12_31_2023_TermLoanMemberusgaapDebtInstrumentAxis" format="ixt:date-monthname-day-year-en" id="ixv-22780">June 1, 2024</ix:nonNumeric> (Note 8). The Company expects that its research and development expenditures will increase in absolute dollars in 2024 and beyond. These factors raise substantial doubt about the Company&#8217;s ability to continue as a going concern. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">As disclosed in more detail in Note 12, the Company has entered into various financing agreements and raised capital by issuing its common stock. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Based on the Company&#8217;s stockholders&#8217; deficit of $<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-5" scale="6" sign="-" format="ixt:num-dot-decimal" id="ixv-22781">1.3</ix:nonFraction>&#160;million as of December&#160;31, 2023, the Company does not meet the minimum stockholders&#8217; equity requirement for continued listing on the Nasdaq Capital Market under Nasdaq Listing Rule 5550(b)(1). The Company expects to receive written notice from Nasdaq staff to that effect following the filing of the Annual Report on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">10-K</div> in which these financial statements are included. </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The Company continues to seek additional capital through strategic transactions and from other financing alternatives. Without additional capital, current working capital and cash generated from sales will not provide adequate funding to make debt repayments, for research, sales and marketing efforts and product development activities at their current levels. If sufficient capital is not raised, the Company will at a minimum need to significantly reduce or curtail its research and development and other operations, and this would negatively affect its ability to achieve corporate growth goals. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Should the Company fail to raise additional cash from outside sources, this would have a material adverse impact on its operations. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The accompanying financial statements have been prepared assuming the Company will continue to operate as a going concern, which contemplates the realization of assets and settlement of liabilities in the normal course of business, and do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classifications of liabilities that may result from uncertainty related to its ability to continue as a going concern. </div></div><ix:exclude><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">F-25 </div></div></ix:exclude></ix:nonNumeric></div></div><ix:continuation id="TextSelection_116199156" continuedAt="TextSelectionAppend_116199156_1"><ix:exclude><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_116199156_1" continuedAt="TextSelectionAppend_116199156_2"><ix:exclude><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/></ix:exclude></ix:continuation><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelectionAppend_116199156_2"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Amendments to Certificate of Incorporation and Reverse Stock Split </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">At the Annual Meeting of Stockholders of the Company held on April&#160;20, 2023 (the &#8220;Annual Meeting&#8221;), the stockholders of the Company approved an amendment to the Company&#8217;s Amended and Restated Certificate of Incorporation to implement a reverse stock split of the Company&#8217;s common stock, par value $<ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="PAsOn04_04_2023" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-22782">0.001</ix:nonFraction> per share, with the ratio to be determined by the Board of Directors (the &#8220;Board&#8221;) of the Company, within a range of not less than <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="-sec-ix-hidden:hidden116200119;display:inline;">1-for-3</div></div></div> and not greater than <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="-sec-ix-hidden:hidden116200122;display:inline;">1-for-15</div>.</div></div> Subsequently, on April&#160;21, 2023, the Board determined to fix the ratio for the reverse stock split at <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="-sec-ix-hidden:hidden116200127;display:inline;">1-for-15</div>,</div></div> without any change to its par value (the &#8220;Reverse Stock Split&#8221;). </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">On April&#160;27, 2023, following stockholder and Board approval, the Company filed a Certificate of Amendment to its Charter (the &#8220;Amendment&#8221;), with the Secretary of State of the State of Delaware to effectuate the Reverse Stock Split. The Amendment became effective on May&#160;1, 2023. Upon effectiveness of the Reverse Stock Split, the number of shares of the Company&#8217;s common stock (x)&#160;issued and outstanding decreased from approximately <ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="PAsOn04_30_2023" unitRef="Unit_shares" decimals="INF" scale="6" format="ixt:num-dot-decimal" id="ixv-22783">37.4</ix:nonFraction>&#160;million shares to approximately <ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="PAsOn05_01_2023" unitRef="Unit_shares" decimals="INF" scale="6" format="ixt:num-dot-decimal" id="ixv-22784">2.5</ix:nonFraction>&#160;million shares; (y)&#160;reserved for issuance upon exercise of outstanding warrants and options decreased from approximately <ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="PAsOn04_30_2023_OutstandingWarrantsAndOptionsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF" scale="6" format="ixt:num-dot-decimal" id="ixv-22785">2.0</ix:nonFraction>&#160;million shares to approximately <ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="PAsOn05_01_2023_OutstandingWarrantsAndOptionsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF" scale="6" format="ixt:num-dot-decimal" id="ixv-22786">0.1</ix:nonFraction>&#160;million shares, and (z)&#160;reserved but unallocated under the Company&#8217;s current equity incentive plans decreased from approximately <ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="PAsOn04_30_2023_EquityIncentivePlansMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="INF" scale="6" format="ixt:num-dot-decimal" id="ixv-22787">3.0</ix:nonFraction>&#160;million common shares to approximately <ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="PAsOn05_01_2023_EquityIncentivePlansMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="INF" scale="6" format="ixt:num-dot-decimal" id="ixv-22788">0.2</ix:nonFraction>&#160;million common shares. The Company&#8217;s common stock began trading on the NASDAQ Capital Market on a post-split basis on May&#160;1, 2023. The Company&#8217;s <ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="PAsOn12_31_2023" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-22789">5,000,000</ix:nonFraction> shares of authorized Preferred Stock were not affected by the Reverse Stock Split. <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockSplits" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt-sec:numwordsen" id="ixv-22790">No</ix:nonFraction> fractional shares were issued in connection with the Reverse Stock Split, and accordingly, the outstanding number of shares post Reverse Stock Split was adjusted down by approximately <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesReverseStockSplits" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-22791">1,310</ix:nonFraction> (post-effect of Reverse Stock Split) shares. Proportional adjustments for the reverse <div style="display:inline;">stock split</div> were made to the Company&#8217;s outstanding stock options, warrants and equity incentive plans for all periods presented in the financial statements in this Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">10-K.</div> The Company&#8217;s financial statements, and all references thereto have been retroactively adjusted to reflect the reverse split unless specifically stated otherwise. </div></ix:continuation><ix:nonNumeric name="us-gaap:SignificantAccountingPoliciesTextBlock" contextRef="P01_01_2023To12_31_2023" escape="true" continuedAt="TextSelection_116199141" id="ixv-14820"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">2. Summary of Significant Accounting Policies </div></div></div><ix:nonNumeric name="us-gaap:UseOfEstimates" contextRef="P01_01_2023To12_31_2023" escape="true" id="ixv-14824"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Use of Estimates </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The preparation of financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions affecting the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenue and expenses during the reporting period. The most significant estimates and critical accounting policies involve reviewing assets for impairment, and determining the assumptions used in measuring share-based compensation expense. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Actual results could differ from these estimates. Management&#8217;s estimates and assumptions are reviewed regularly, and the effects of revisions are reflected in the financial statements in the periods they are determined to be necessary. </div></div></ix:nonNumeric><ix:nonNumeric name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" contextRef="P01_01_2023To12_31_2023" escape="true" id="ixv-14832"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Cash and cash equivalents </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The Company considers all highly liquid investments with maturities of three months or less at the time of purchase to be cash equivalents. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Cash and cash equivalents include cash in readily available checking, savings accounts and money market accounts. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. The Company has not experienced any losses in such accounts and believes it is not exposed to significant risk on its cash balances due to the financial position of the depository institution in which those deposits are held. </div></div></ix:nonNumeric><ix:nonNumeric name="us-gaap:FairValueOfFinancialInstrumentsPolicy" contextRef="P01_01_2023To12_31_2023" escape="true" continuedAt="TextSelection_116199149" id="ixv-14840"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Financial Instruments </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Financial instruments include cash equivalents, other current assets, accounts payable, accrued expenses, other liabilities and long-term debt. The carrying values of cash equivalents, other current assets, accounts payable, </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><ix:exclude>F-26</ix:exclude> </div></div></ix:nonNumeric></ix:nonNumeric></div></div><ix:continuation id="TextSelection_116199149" continuedAt="TextSelectionAppend_116199149_1"><ix:continuation id="TextSelection_116199141" continuedAt="TextSelectionAppend_116199141_1"><ix:exclude><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_116199141_1" continuedAt="TextSelectionAppend_116199141_2"><ix:exclude><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/></ix:exclude></ix:continuation></ix:continuation> <div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelectionAppend_116199141_2" continuedAt="TextSelectionAppend_116199141_3"><ix:continuation id="TextSelectionAppend_116199149_1"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">accrued expenses and other liabilities generally approximate fair value due to the short-term nature of these instruments. Based on level 3 inputs and the borrowing rates currently available for loans with similar terms, the Company believes the fair value of the long-term debt is <div style="display:inline;">materially </div>consistent with its carrying value. </div></div></ix:continuation><ix:nonNumeric name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" contextRef="P01_01_2023To12_31_2023" escape="true" id="ixv-14864"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Property and Equipment </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Property and equipment are stated at cost, net of accumulated depreciation. Depreciation expense, which includes the amortization of capitalized leasehold improvements, is provided for on a straight-line basis over the estimated useful lives of the assets, or the life of the lease, whichever is shorter, and range from <div style="-sec-ix-hidden:hidden116200141;display:inline;">three</div> to <ix:nonNumeric name="us-gaap:PropertyPlantAndEquipmentUsefulLife" contextRef="PAsOn12_31_2023_MaximumMembersrtRangeAxis" format="ixt-sec:durwordsen" id="ixv-22793">five years</ix:nonNumeric>. When assets are sold or otherwise disposed of, the cost and related accumulated depreciation are removed from the accounts and the resulting gain or loss, if any, is included in operations. Maintenance and repairs are charged to operations as incurred. </div></div></ix:nonNumeric><ix:nonNumeric name="us-gaap:PropertyPlantAndEquipmentImpairment" contextRef="P01_01_2023To12_31_2023" escape="true" id="ixv-14871"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Impairment </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The Company assesses its property and equipment for potential impairment when there is a change in circumstances that indicates carrying values of assets may not be recoverable. Such long-lived assets are deemed to be impaired when the undiscounted cash flows expected to be generated by the asset (or asset group) are less than the asset&#8217;s carrying amount. Any required impairment loss would be measured as the amount by which the asset&#8217;s carrying value exceeds its fair value and would be recorded as a reduction in the carrying value of the related asset and a charge to operating expense. The Company recognized <ix:nonFraction name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt-sec:numwordsen" id="ixv-22794"><ix:nonFraction name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt-sec:numwordsen" id="ixv-22795">no</ix:nonFraction></ix:nonFraction> impairment losses during any of the periods presented in these financial statements. </div></div></ix:nonNumeric><ix:nonNumeric name="us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock" contextRef="P01_01_2023To12_31_2023" escape="true" id="ixv-14877"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Goodwill </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The Company&#8217;s goodwill represents the excess of the cost over the fair value of net assets acquired from its business combinations. The determination of the value of goodwill arising from business combinations requires extensive use of accounting estimates and judgments to allocate the purchase price to the fair value of the net tangible and intangible assets acquired. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Goodwill is not amortized; however, it is assessed for impairment using fair value measurement techniques on an annual basis or more frequently if facts and circumstance warrant such a review. Goodwill is considered to be impaired if the Company determines that the carrying value of the reporting unit exceeds its fair value. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The Company performs its impairment test annually during the fourth quarter by comparing the Company&#8217;s estimated fair value, calculated from the Company&#8217;s market capitalization, to its carrying amount. The Company&#8217;s annual evaluation for impairment of goodwill consists of <ix:nonFraction name="us-gaap:NumberOfReportingUnits" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_ReportableUnit" decimals="INF" scale="0" format="ixt-sec:numwordsen" id="ixv-22796">one</ix:nonFraction> reporting unit. The Company completed its most recent annual evaluation for impairment as of December&#160;31, 2023, when the Company had stockholders&#8217; deficit within its sole reporting unit of approximately $<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-5" scale="6" sign="-" format="ixt:num-dot-decimal" id="ixv-22797">1.3</ix:nonFraction>&#160;million, and concluded that <ix:nonFraction name="us-gaap:AssetImpairmentCharges" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="INF" scale="0" format="ixt-sec:numwordsen" id="ixv-22798">no</ix:nonFraction> impairment existed. </div></div></ix:nonNumeric><ix:nonNumeric name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" contextRef="P01_01_2023To12_31_2023" escape="true" continuedAt="TextSelection_116199155" id="ixv-14887"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Grant Revenue Recognition </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">In applying the provisions of Accounting Standards Codification (&#8220;ASC&#8221;) Topic 606, Revenue from Contracts with Customers (&#8220;ASC 606&#8221;), the Company has determined that government grants are out of the scope of ASC 606 because the funding entities do not meet the definition of a &#8220;customer,&#8221; as defined by ASC 606, as there is not considered to be a transfer of control of goods or services. With respect to the grant, the Company determines if it is a collaboration arrangement in accordance with ASC Topic 808, Collaborative Arrangements (&#8220;ASC 808&#8221;). For grants outside the scope of ASC 808, the Company applies International Accounting Standards No.&#160;20, Accounting for Government Grants and Disclosure of Government Assistance, by analogy, and revenue is recognized when the Company incurs expenses related to the grant for the amount the Company is entitled to under the provisions of the contract. </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><ix:exclude>F-27</ix:exclude> </div></div></ix:nonNumeric></ix:continuation></div></div><ix:continuation id="TextSelection_116199155" continuedAt="TextSelectionAppend_116199155_1"><ix:continuation id="TextSelectionAppend_116199141_3" continuedAt="TextSelectionAppend_116199141_4"><ix:exclude><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_116199141_4" continuedAt="TextSelectionAppend_116199141_5"><ix:exclude><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/></ix:exclude></ix:continuation></ix:continuation><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelectionAppend_116199141_5" continuedAt="TextSelectionAppend_116199141_6"><ix:continuation id="TextSelectionAppend_116199155_1"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The Company also considers the guidance in ASC Topic 730, Research and Development (&#8220;ASC 730&#8221;), which requires an assessment, at the inception of the grant, of whether the agreement is a liability. If the Company is obligated to repay funds received regardless of the outcome of the related research and development activities, then the Company is required to estimate and recognize that liability. Alternatively, if the Company is not required to repay the funds, then payments received are recorded as revenue or contra-expense as the expenses are incurred. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Deferred grant liability represents grant funds received or receivable for which the allowable expenses have not yet been incurred as of the balance sheet date. </div></div></ix:continuation><ix:nonNumeric name="us-gaap:ResearchAndDevelopmentExpensePolicy" contextRef="P01_01_2023To12_31_2023" escape="true" id="ixv-14912"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Research and Development </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Research and development expenditures, which are charged to operations in the period incurred, include costs associated with the design, development, testing and enhancement of the Company&#8217;s products, regulatory fees, the purchase of laboratory supplies, and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">pre-clinical</div> and clinical studies as well as salaries and benefits for the Company&#8217;s research and development employees. </div></ix:nonNumeric><ix:nonNumeric name="us-gaap:InProcessResearchAndDevelopmentPolicy" contextRef="P01_01_2023To12_31_2023" escape="true" id="ixv-14918"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;">Acquired <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">In-Process</div> Research and Development (IPR&amp;D) </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Acquired IPR&amp;D represents the value assigned to research and development assets that have not reached technological feasibility. Upon the acquisition of IPR&amp;D, the Company completes an assessment of whether the acquisition constitutes the purchase of a single asset or group of assets. The Company considers multiple factors in this assessment, including the nature of the technology acquired, the presence or absence of separate cash flows, the development process and stage of completion, quantitative significance, and the Company&#8217;s rationale for entering into the transaction. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The Company tests IPR&amp;D assets for impairment as of December&#160;31 of each year or more frequently if indicators of impairment are present. The authoritative accounting guidance provides an optional qualitative assessment for any indicators that indefinite-lived intangible assets are impaired. If it is determined that it is more likely than not that the indefinite-lived intangible assets, including IPR&amp;D, are impaired, the fair value of the indefinite-lived intangible assets is compared with the carrying amount and impairment is recorded for any excess of the carrying amount over the fair value of the indefinite-lived intangible assets. There was <ix:nonFraction name="us-gaap:AssetImpairmentCharges" contextRef="P01_01_2022To12_31_2022_InProcessResearchAndDevelopmentMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis" unitRef="Unit_USD" decimals="INF" scale="0" format="ixt-sec:numwordsen" id="ixv-22800"><ix:nonFraction name="us-gaap:AssetImpairmentCharges" contextRef="P01_01_2023To12_31_2023_InProcessResearchAndDevelopmentMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis" unitRef="Unit_USD" decimals="INF" scale="0" format="ixt-sec:numwordsen" id="ixv-22801">no</ix:nonFraction></ix:nonFraction> impairment of the Company&#8217;s IPR&amp;D assets during 2023 or 2022. </div></div></ix:nonNumeric><ix:nonNumeric name="us-gaap:DebtPolicyTextBlock" contextRef="P01_01_2023To12_31_2023" escape="true" id="ixv-14926"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Deferred Financing Costs and Other Debt-Related Costs </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Deferred financing costs are capitalized, recorded as an offset to debt balances and amortized to interest expense over the term of the associated debt instrument using the effective interest method. If the maturity of the debt is accelerated because of default or early debt repayment, then the amortization would be accelerated. </div></div></ix:nonNumeric><ix:nonNumeric name="us-gaap:IncomeTaxPolicyTextBlock" contextRef="P01_01_2023To12_31_2023" escape="true" id="ixv-14932"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Income Taxes </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carry forwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income (loss) in the years in which those temporary differences are expected to be recovered or settled. Due to our history of losses, a full valuation allowance has been recognized against our deferred tax assets. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The Company&#8217;s policy is to recognize interest and penalties related to income tax matters in income tax expense. For the years ended December&#160;31, 2023 and 2022, the Company has <ix:nonFraction name="us-gaap:IncomeTaxExaminationPenaltiesAndInterestExpense" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="INF" scale="0" format="ixt-sec:numwordsen" id="ixv-22802"><ix:nonFraction name="us-gaap:IncomeTaxExaminationPenaltiesAndInterestExpense" contextRef="P01_01_2023To03_31_2023" unitRef="Unit_USD" decimals="INF" scale="0" format="ixt-sec:numwordsen" id="ixv-22803">no</ix:nonFraction></ix:nonFraction>t recorded any interest or penalties related to income tax matters. The Company does not foresee any material changes to unrecognized tax benefits within the next twelve months. </div></div></ix:nonNumeric><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><ix:exclude>F-28</ix:exclude> </div></div></ix:continuation></div></div><ix:continuation id="TextSelectionAppend_116199141_6" continuedAt="TextSelectionAppend_116199141_7"><ix:exclude><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_116199141_7" continuedAt="TextSelectionAppend_116199141_8"><ix:exclude><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/></ix:exclude></ix:continuation> <div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelectionAppend_116199141_8"><ix:nonNumeric name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" contextRef="P01_01_2023To12_31_2023" escape="true" id="ixv-14953"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Share-Based Compensation </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The Company recognizes the fair value of all share-based payment awards in our statements of operations over the requisite vesting period of each award, which approximates the period during which the employee and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">non-employee</div> director is required to provide service in exchange for the award. The Company estimates the fair value of these options using the Black-Scholes option pricing model using assumptions for expected volatility, expected term, and risk-free interest rate. Expected volatility is based primarily on historical volatility and is computed using daily pricing observations for recent periods that correspond to the expected term of the options. The expected term represents the period of time that options are expected to be outstanding. Because the Company does not have historical exercise behavior, it determines the expected life assumption using the simplified method which is an average of the contractual term of the option and its vesting period. The risk-free interest rate is the interest rate for treasury instruments with maturities that approximate the expected term. </div></ix:nonNumeric><ix:nonNumeric name="us-gaap:SegmentReportingPolicyPolicyTextBlock" contextRef="P01_01_2023To12_31_2023" escape="true" id="ixv-14959"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Segment Information </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">For the years ended December&#160;31, 2023 and 2022, the Company is managed as a single operating segment, and therefore reports its results in <ix:nonFraction name="us-gaap:NumberOfOperatingSegments" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_Segment" decimals="INF" scale="0" format="ixt-sec:numwordsen" id="ixv-22805"><ix:nonFraction name="us-gaap:NumberOfOperatingSegments" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_Segment" decimals="INF" scale="0" format="ixt-sec:numwordsen" id="ixv-22806">one</ix:nonFraction></ix:nonFraction> operating segment. </div></div></ix:nonNumeric><ix:nonNumeric name="us-gaap:EarningsPerSharePolicyTextBlock" contextRef="P01_01_2023To12_31_2023" escape="true" id="ixv-14965"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Loss Per Share </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Basic per share data is computed by dividing net income or loss applicable to common stockholders by the weighted average number of common shares outstanding during the period. Diluted per share data is computed by dividing net income or loss applicable to common stockholders by the weighted average number of common shares outstanding during the period increased to include, if dilutive, the number of additional common shares that would have been outstanding as calculated using the treasury stock method. Potential common shares were related entirely to outstanding but unexercised options, warrants and convertible preferred stocks for all periods presented. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The Company excluded all potentially dilutive securities from the calculation of diluted loss per share attributable to common stockholders for the years ended December&#160;31, 2023 and 2022, as their inclusion would be antidilutive. </div></div></ix:nonNumeric><ix:nonNumeric name="us-gaap:ConcentrationRiskCreditRisk" contextRef="P01_01_2023To12_31_2023" escape="true" id="ixv-14973"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Concentration Risk </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Although the Company&#8217;s contracts with its vendors are not exclusive, the Company currently uses sole source providers for core materials used in its clinical trials. </div></div></ix:nonNumeric><ix:nonNumeric name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" contextRef="P01_01_2023To12_31_2023" escape="true" id="ixv-14979"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Recently Issued Accounting Pronouncements </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">In June 2016, the FASB issued ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">2016-13,</div> Financial Instruments&#8212;Credit Losses (Topic 326), Measurement of Credit Losses on Financial Instruments. The standard amends the impairment model by requiring entities to use a forward-looking approach based on expected losses to estimate credit losses for most financial assets and certain other instruments that are not measured at fair value through net income. For <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">available-for-sale</div></div> debt securities, entities will be required to recognize an allowance for credit losses rather than a reduction in carrying value of the asset. Entities will no longer be permitted to consider the length of time that fair value has been less than amortized cost when evaluating when credit losses should be recognized. This new guidance is effective in the first quarter of 2023 for calendar-year SEC filers that are smaller reporting companies as of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">one-time</div> determination date. Early adoption was permitted beginning in 2019. The Company <ix:nonNumeric name="us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" contextRef="PAsOn12_31_2023_AccountingStandardsUpdate201613MemberusgaapAdjustmentsForNewAccountingPronouncementsAxis" format="ixt:fixed-true" id="ixv-22807">adopted</ix:nonNumeric> the new guidance as of <ix:nonNumeric name="us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" contextRef="PAsOn12_31_2023_AccountingStandardsUpdate201613MemberusgaapAdjustmentsForNewAccountingPronouncementsAxis" format="ixt:date-monthname-day-year-en" id="ixv-22808">January 1, 2023</ix:nonNumeric>, which did <ix:nonNumeric name="us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" contextRef="PAsOn12_31_2023_AccountingStandardsUpdate201613MemberusgaapAdjustmentsForNewAccountingPronouncementsAxis" format="ixt:fixed-true" id="ixv-22809">no</ix:nonNumeric>t have a material impact on its financial statements and related disclosures. </div></ix:nonNumeric></ix:continuation><ix:nonNumeric name="us-gaap:FairValueMeasurementInputsDisclosureTextBlock" contextRef="P01_01_2023To12_31_2023" escape="true" continuedAt="TextSelection_116199070" id="ixv-14988"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">3. Fair Value Measurements </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Fair value measurements are market-based measurements, not entity-specific measurements. Therefore, fair value measurements are determined based on the assumptions that market participants would use in pricing the </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><ix:exclude>F-29</ix:exclude> </div></div></ix:nonNumeric></div></div><ix:continuation id="TextSelection_116199070" continuedAt="TextSelectionAppend_116199070_1"><ix:exclude><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_116199070_1" continuedAt="TextSelectionAppend_116199070_2"><ix:exclude><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/></ix:exclude></ix:continuation><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelectionAppend_116199070_2"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">asset or liability. The Company follows a three-level hierarchy to prioritize the inputs used in the valuation techniques to derive fair values. The basis for fair value measurements for each level within the hierarchy is described below: </div></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentColor; border-image: none; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Level&#160;1: Quoted prices in active markets for identical assets or liabilities. </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentColor; border-image: none; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Level&#160;2: Quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar instruments in markets that are not active; and model-derived valuations in which all significant inputs are observable in active markets. </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentColor; border-image: none; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Level&#160;3: Valuations derived from valuation techniques in which one or more significant inputs are unobservable in active markets. </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The Company has investments in money market accounts, which are included in cash and cash equivalents on the balance sheets. Fair value inputs for these investments are considered Level&#160;1 measurements within the fair value hierarchy since money market account fair values are known and observable through daily published floating net asset values. </div></div><ix:nonNumeric name="us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock" contextRef="P01_01_2023To12_31_2023" escape="true" id="ixv-15044"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The following table summarizes the Company&#8217;s fair value hierarchy for its financial assets measured at fair value on a recurring basis as of December&#160;31, 2023 and December&#160;31, 2022, respectively. </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 92%; font-family: Times New Roman; font-size: 8pt; border-collapse: collapse;">
<tr>
<td style="width: 56%;"/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="14" style="vertical-align: bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Fair Value Measurements Using</div></div></td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">As of December&#160;31, 2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Fair Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;1</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;2</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;3</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Money market</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="PAsOn12_31_2023_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapCashAndCashEquivalentsAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-22811">5,448,990</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="PAsOn12_31_2023_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapCashAndCashEquivalentsAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-22812">5,448,990</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 12pt; font-family: &quot;Times New Roman&quot;;"/>
<td colspan="16" style="height: 12pt; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="14" style="vertical-align: bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Fair Value Measurements Using</div></div></td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">As of December&#160;31, 2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Fair Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;1</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;2</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;3</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Money market</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="PAsOn12_31_2022_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapCashAndCashEquivalentsAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-22813">17,573,584</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="PAsOn12_31_2022_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapCashAndCashEquivalentsAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-22814">17,573,584</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr></table></ix:nonNumeric><div style="clear:both;max-height:0pt;"></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Nonfinancial Assets and Liabilities </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The Company applies fair value techniques on a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">non-recurring</div> basis, if and when necessary, associated with: (1)&#160;valuing potential impairment losses related to goodwill which are accounted for pursuant to the authoritative guidance for intangibles&#8212;goodwill and other; and (2)&#160;valuing potential impairment losses related to long-lived assets which are accounted for pursuant to the authoritative guidance for property, plant and equipment. </div></ix:continuation><ix:nonNumeric name="us-gaap:EarningsPerShareTextBlock" contextRef="P01_01_2023To12_31_2023" escape="true" id="ixv-15179"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">4. Loss per Share </div></div></div><ix:nonNumeric name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" contextRef="P01_01_2023To12_31_2023" escape="true" id="ixv-15183"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The following were excluded from the diluted loss per share calculation for the periods presented because their effect would be anti-dilutive: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 76%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;">
<tr>
<td style="width: 74%;"/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">For&#160;the&#160;Year&#160;Ended</div></div><br/> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Outstanding stock options</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P01_01_2023To12_31_2023_OptionsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-22815">140,109</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P01_01_2022To12_31_2022_OptionsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-22816">78,334</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Preferred stock</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P01_01_2023To12_31_2023_PreferredStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-22817">28,190</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P01_01_2022To12_31_2022_PreferredStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-22818">28,190</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Outstanding warrants</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P01_01_2023To12_31_2023_WarrantMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-22819">142,733</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P01_01_2022To12_31_2022_WarrantMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-22820">142,758</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-22821">311,032</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-22822">249,282</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table></ix:nonNumeric></ix:nonNumeric><div style="clear:both;max-height:0pt;"></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">F-30 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:nonNumeric name="us-gaap:SupplementalBalanceSheetDisclosuresTextBlock" contextRef="P01_01_2023To12_31_2023" escape="true" id="ixv-15314"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">5. Composition of Certain Financial Statement Captions </div></div></div><ix:nonNumeric name="us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock" contextRef="P01_01_2023To12_31_2023" escape="true" id="ixv-15318"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Other Current Assets </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">As of December&#160;31, 2023 and 2022, other current assets were comprised of the following (in thousands): </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 76%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;">
<tr>
<td style="width: 78%;"/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Prepaid services</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:OtherPrepaidExpenseCurrent" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-22823">644</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:OtherPrepaidExpenseCurrent" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-22824">2,999</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Prepaid insurance</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:PrepaidInsurance" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-22825">636</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:PrepaidInsurance" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-22826">698</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:OtherAssetsCurrent" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-22827">1,280</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:OtherAssetsCurrent" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-22828">3,697</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table></ix:nonNumeric><div style="clear:both;max-height:0pt;"></div><ix:nonNumeric name="us-gaap:PropertyPlantAndEquipmentTextBlock" contextRef="P01_01_2023To12_31_2023" escape="true" id="ixv-15427"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Property and Equipment, net </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">As of December&#160;31, 2023 and 2022, property and equipment, net, were comprised of the following (in thousands): </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 76%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;">
<tr>
<td style="width: 76%;"/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Office and computer equipment</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="pstv:OfficeAndComputerEquipmentGross" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-22829">1,632</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="pstv:OfficeAndComputerEquipmentGross" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-22830">1,474</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Leasehold improvements</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:LeaseholdImprovementsGross" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-22831">1,810</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:LeaseholdImprovementsGross" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-22832">1,810</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-22833">3,442</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-22834">3,284</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Less accumulated depreciation</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">(<ix:nonFraction name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-22835">2,536</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">(<ix:nonFraction name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-22836">1,960</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-22837">906</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-22838">1,324</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table></ix:nonNumeric><div style="clear:both;max-height:0pt;"></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Depreciation expense totaled $<ix:nonFraction name="us-gaap:Depreciation" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-22839">0.6</ix:nonFraction>&#160;million and $<ix:nonFraction name="us-gaap:Depreciation" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-22840">0.5</ix:nonFraction>&#160;million for the year ended December&#160;31, 2023 and 2022, respectively. </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Intangible Assets, net </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">As of December&#160;31, 2023, intangible assets included the net book value of costs incurred for software upgrades. Amortization expenses totaled $<ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-22841"><ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-22842">0.1</ix:nonFraction></ix:nonFraction>&#160;million for each of the years ended December&#160;31, 2023 and 2022. </div></div><ix:nonNumeric name="us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" contextRef="P01_01_2023To12_31_2023" escape="true" id="ixv-15583"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Accounts Payable and Accrued Expenses </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">As of December&#160;31, 2023 and 2022, accounts payable and accrued expenses were comprised of the following (in thousands): </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 76%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;">
<tr>
<td style="width: 76%;"/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Accounts payable</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-22843">4,758</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-22844">8,364</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Accrued payroll and bonus</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:AccruedBonusesCurrent" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-22845">987</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:AccruedBonusesCurrent" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-22846">989</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Accrued professional fees</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:AccruedProfessionalFeesCurrent" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-22847">128</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:AccruedProfessionalFeesCurrent" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-22848">147</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Accrued vacation and compensation</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="pstv:AccruedVacationAndCompensationCurrent" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-22849">370</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="pstv:AccruedVacationAndCompensationCurrent" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-22850">325</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Accrued R&amp;D studies</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="pstv:AccruedResearchAndDevelopmentStudies" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-22851">388</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="pstv:AccruedResearchAndDevelopmentStudies" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-22852">309</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-22853">6,631</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-22854">10,134</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table></ix:nonNumeric></ix:nonNumeric><div style="clear:both;max-height:0pt;"></div><ix:nonNumeric name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" contextRef="P01_01_2023To12_31_2023" escape="true" continuedAt="TextSelection_116199074" id="ixv-15728"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">6. Commitments and Contingencies </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Leases </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">At the inception of a contractual arrangement, the Company determines whether the contract contains a lease by assessing whether there is an identified asset and whether the contract conveys the right to control the use of the </div></div><ix:exclude><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">F-31 </div></div></ix:exclude></ix:nonNumeric></div></div><ix:continuation id="TextSelection_116199074" continuedAt="TextSelectionAppend_116199074_1"><ix:exclude><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_116199074_1" continuedAt="TextSelectionAppend_116199074_2"><ix:exclude><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/></ix:exclude></ix:continuation><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelectionAppend_116199074_2" continuedAt="TextSelectionAppend_116199074_3"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">identified asset in exchange for consideration over a period of time. If both criteria are met, the Company calculates the associated lease liability and corresponding <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">right-of-use</div></div> asset upon lease commencement using a discount rate based on the rate implicit in the lease or an incremental borrowing rate commensurate with the term of the lease. Lease renewable options are included in the estimation of lease term when it is reasonably certain that the Company will exercise such options. </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Company records lease liabilities within current liabilities or long-term liabilities based upon the length of time associated with the lease payments. The Company records its operating lease <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">right-of-use</div></div> assets as long-term assets. Leases with an initial term of 12 months or less are not recorded on the balance sheets. Instead, the Company recognizes lease expense for these leases on a straight-line basis over the lease term in the statements of operations. </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Company leases laboratory, office and storage facilities in San Antonio, Texas, under operating lease agreements that expire in <ix:nonNumeric name="pstv:OperatingLeasesExpiryYear" contextRef="P01_01_2023To12_31_2023" id="ixv-22855">2025</ix:nonNumeric>. The Company also leases certain office space in Austin, Texas under a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">month-to-month</div></div> operating lease agreement and certain office space in Charlottesville, Virginia (the &#8220;Charlottesville Lease&#8221;). The Company&#8217;s existing operating lease agreements generally provide for periodic rent increases, and renewal and termination options. The Company&#8217;s lease agreements do not contain any material variable lease payments, residual value guarantees or material restrictive covenants. </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><ix:nonNumeric name="us-gaap:LesseeOperatingLeaseOptionToExtend" contextRef="P01_01_2023To12_31_2023_CharlottesvilleMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" id="ixv-15761">The Charlottesville Lease has a term of <ix:nonNumeric name="us-gaap:LesseeOperatingLeaseTermOfContract" contextRef="PAsOn12_31_2023_CharlottesvilleMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" format="ixt-sec:durmonth" id="ixv-22856">12</ix:nonNumeric> months and the Company has the ability to <ix:nonNumeric name="us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend" contextRef="P01_01_2023To12_31_2023_CharlottesvilleMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" format="ixt:fixed-true" id="ixv-22857">renew</ix:nonNumeric> for three additional <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><ix:nonNumeric name="us-gaap:LesseeOperatingLeaseRenewalTerm" contextRef="PAsOn12_31_2023_CharlottesvilleMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" format="ixt-sec:durwordsen" id="ixv-22858">one-year</ix:nonNumeric></div> periods.</ix:nonNumeric> The Charlottesville Lease is currently set to expire on <ix:nonNumeric name="us-gaap:LeaseExpirationDate1" contextRef="P01_01_2023To12_31_2023_CharlottesvilleMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" format="ixt:date-monthname-day-year-en" id="ixv-22859">March 31, 2024</ix:nonNumeric>, and is renewable twice for twelve months each time. On March&#160;31, 2023, Company believed that it was reasonably certain that the Charlottesville Lease will be renewed through March&#160;31, 2026, and as a result, it remeasured the related lease liability as of March&#160;31, 2023 to be $<ix:nonFraction name="us-gaap:OperatingLeaseLiability" contextRef="PAsOn03_31_2023_CharlottesvilleMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-22860">80,000</ix:nonFraction> using the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">then-in-effect</div></div> discount rate of <ix:nonFraction name="us-gaap:LesseeOperatingLeaseDiscountRate" contextRef="PAsOn03_31_2023_CharlottesvilleMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal" id="ixv-22861">12.76</ix:nonFraction>%. Effective July&#160;1, 2023, the Company added additional office lease premises in Charlottesville, which was accounted for as a separate operating lease contract with a lease liability and corresponding <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">right-of-use</div></div> asset of $<ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="PAsOn07_01_2023_CharlottesvilleMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-22862">19,000</ix:nonFraction>, at a discount rate of <ix:nonFraction name="us-gaap:LesseeOperatingLeaseDiscountRate" contextRef="PAsOn07_01_2023_CharlottesvilleMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal" id="ixv-22863">13.47</ix:nonFraction>%. </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Certain leases require the Company to pay taxes, insurance, and maintenance. Payments for the transfer of goods or services such as common area maintenance and utilities represent <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">non-lease</div> components. The Company elected the package of practical expedients and therefore does not separate <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">non-lease</div> components from lease components. </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Company&#8217;s operating lease liabilities and corresponding <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">right-of-use</div></div> assets are included in the balance sheets. As of December&#160;31, 2023, the weighted average discount rate used to measure operating lease liabilities and the operating leases remaining term were <ix:nonFraction name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" contextRef="PAsOn12_31_2023" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal" id="ixv-22864">10.67</ix:nonFraction>% and <ix:nonNumeric name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" contextRef="PAsOn12_31_2023" format="ixt-sec:duryear" id="ixv-22865">1.6</ix:nonNumeric> years, respectively. </div><ix:nonNumeric name="us-gaap:LeaseCostTableTextBlock" contextRef="P01_01_2023To12_31_2023" escape="true" id="ixv-15773"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The table below summarizes the Company&#8217;s operating lease costs from its statements of operations, and cash payments from its statements of cash flows. </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 76%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;">
<tr>
<td style="width: 70%;"/>
<td style="width: 11%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 11%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Year&#160;Ended&#160;December&#160;31,</div></div></td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Lease expense:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Operating lease expense</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseCost" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-22866">141</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseCost" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-22867">159</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Total lease expense</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:LeaseCost" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-22868">141</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:LeaseCost" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-22869">159</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Cash payment information:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Operating cash used for operating leases</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeasePayments" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-22870">141</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeasePayments" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-22871">159</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Total cash paid for amounts included in the measurement of lease liabilities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="pstv:CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-22872">141</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="pstv:CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-22873">159</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table></ix:nonNumeric><div style="clear:both;max-height:0pt;"></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Total rent expenses for each of the years ended December&#160;31, 2023 and 2022 was $<ix:nonFraction name="us-gaap:OperatingLeaseExpense" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-22874"><ix:nonFraction name="us-gaap:OperatingLeaseExpense" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-22875">0.2</ix:nonFraction></ix:nonFraction>&#160;million, which includes leases in the table above, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">month-to-month</div></div> operating leases, and common area maintenance charges. </div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><ix:exclude>F-32</ix:exclude> </div></div></ix:continuation></div></div><ix:continuation id="TextSelectionAppend_116199074_3" continuedAt="TextSelectionAppend_116199074_4"><ix:exclude><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_116199074_4" continuedAt="TextSelectionAppend_116199074_5"><ix:exclude><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/></ix:exclude></ix:continuation> <div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelectionAppend_116199074_5" continuedAt="TextSelectionAppend_116199074_6"><ix:nonNumeric name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" contextRef="P01_01_2023To12_31_2023" escape="true" id="ixv-15969"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The Company&#8217;s future minimum annual lease payments under operating leases at December&#160;31, 2023 are as follows (in thousands): </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 68%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;">
<tr>
<td style="width: 76%;"/>
<td style="width: 20%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Operating&#160;Leases</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">2024</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-22877">146</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">2025</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-22878">60</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">2026</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-22879">11</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Total minimum lease payments</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-22880">217</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Less: amount representing interest</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">(<ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-22881">12</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Present value of obligations under leases</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseLiability" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-22882">205</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Less: current portion</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">(<ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-22883">120</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Noncurrent lease obligations</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-22884">85</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table></ix:nonNumeric><div style="clear:both;max-height:0pt;"></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Services Agreement and Sales Order with Medidata </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">On March&#160;31, 2022, the Company and Medidata Solutions, Inc. (&#8220;Medidata&#8221;) entered into a Sales Order (the &#8220;Sales Order&#8221;), pursuant to which Medidata will build a Synthetic Control Arm<div style="font-size: 75%; vertical-align: top;display:inline;font-size:8.3px">&#174;</div> (&#8220;SCA&#8221;) platform that facilitates the use of historical clinical data to incorporate into the Company&#8217;s Phase 2 clinical trial of rhenium (<div style="font-size: 75%; vertical-align: top;display:inline;font-size:8.3px">186</div>Re) obisbemeda in recurrent glioblastoma (&#8220;GBM&#8221;). The Sales Order is governed under the terms of a services agreement, dated November&#160;5, 2021. The Sales Order had a term of <ix:nonNumeric name="pstv:SalesOrderTerm" contextRef="P03_31_2022To03_31_2022_MedidataSolutionsIncMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_ServicesAgreementMemberusgaapTypeOfArrangementAxis" format="ixt-sec:durwordsen" id="ixv-22885">six months</ix:nonNumeric>, and work under the Sales Order has been completed. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Piramal Master Services Agreement </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">On <ix:nonNumeric name="pstv:MasterServicesAgreementDate" contextRef="P01_08_2021To01_08_2021_PiramalPharmaSolutionsIncMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" format="ixt:date-monthname-day-year-en" id="ixv-22886">January 8, 2021</ix:nonNumeric>, the Company entered into a Master Services Agreement (the &#8220;MSA&#8221;) with Piramal Pharma Solutions, Inc. (&#8220;Piramal&#8221;), for Piramal to perform certain services related to the development, manufacture, and supply of the Company&#8217;s rhenium (<div style="font-size: 75%; vertical-align: top;display:inline;font-size:8.3px">186</div>Re) obisbemeda-Liposome Intermediate Drug Product. The MSA includes the transfer of analytical methods, development of microbiological methods, process transfer and optimization, intermediate drug product manufacturing, and stability studies for the Company, which has been initiated at Piramal&#8217;s facility located in Lexington, Kentucky. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><ix:nonNumeric name="pstv:MasterServicesAgreementTermsDescription" contextRef="P01_01_2023To12_31_2023_PiramalPharmaSolutionsIncMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" id="ixv-16117">The MSA has a term of <ix:nonNumeric name="pstv:MasterServicesAgreementInitialTerm" contextRef="P01_08_2021To01_08_2021_PiramalPharmaSolutionsIncMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" format="ixt-sec:durwordsen" id="ixv-22887">five years</ix:nonNumeric> and will automatically renew for successive <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">one-year</div> terms unless either party notifies the other no later than six months prior to the original term or any additional terms of its intention to not renew the MSA. The Company has the right to terminate the MSA for convenience upon thirty days&#8217; prior written notice.</ix:nonNumeric> Either party may terminate the MSA upon an uncured material breach by the other party or upon the bankruptcy or insolvency of the other party. </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Other Commitments and Contingencies </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The Company has entered into agreements with various research organizations for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">pre-clinical</div> and clinical development studies, which have provisions for cancellation. Under the terms of these agreements, the vendors provide a variety of services including conducting research, recruiting and enrolling patients, monitoring studies and data analysis. Payments under these agreements typically include fees for services and reimbursement of expenses. The timing of payments due under these agreements is estimated based on current study progress. As of December&#160;31, 2023, the Company did <ix:nonFraction name="us-gaap:ContractualObligation" contextRef="PAsOn12_31_2023_PreClinicalResearchStudyObligationsMemberusgaapRecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt-sec:numwordsen" id="ixv-22888">no</ix:nonFraction>t have any clinical research study obligations. </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Legal proceedings </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">On December&#160;9, 2022, the Company entered into a settlement agreement (the &#8220;Settlement Agreement&#8221;) with Lorem Vascular, Pte. Ltd. (&#8220;Lorem&#8221;) to settle a prior litigation matter. Under the terms of the Settlement </div></div></ix:continuation><ix:continuation id="TextSelectionAppend_116199074_6" continuedAt="TextSelectionAppend_116199074_7"><ix:exclude><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">F-33 </div></div></ix:exclude></ix:continuation></div></div><ix:continuation id="TextSelectionAppend_116199074_7" continuedAt="TextSelectionAppend_116199074_8"><ix:exclude><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_116199074_8" continuedAt="TextSelectionAppend_116199074_9"><ix:exclude><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/></ix:exclude></ix:continuation><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelectionAppend_116199074_9"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Agreement, the Company made a payment to Lorem, and Lorem moved to dismiss the lawsuit with prejudice. The Settlement Agreement released the Company from all claims made by Lorem. The parties to the Settlement Agreement recognized that it did not constitute an admission of liability, wrongdoing, or any matter of fact or law. The Settlement was conditioned on the customary terms contained in the Settlement Agreement and was approved by the Court and the case was dismissed on January&#160;17, 2023. As of December&#160;31, 2022, the Company accrued the settlement amount, as well as the accounts that the Company has confirmed to be recoverable under its insurance claims on the matter. The net amount of $<ix:nonFraction name="us-gaap:LitigationSettlementExpense" contextRef="P01_01_2022To12_31_2022_LoremVascularPteLtdMembersrtLitigationCaseAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-22889">1.4</ix:nonFraction>&#160;million that was not recoverable under the Company&#8217;s insurance has been reflected as an expense in the statement of operations for the year ended December&#160;31, 2022. The full settlement amount was paid in January 2023. All legal costs related to the Lorem Claim were expensed as incurred. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The Company is subject to various claims and contingencies related to legal proceedings. Due to their nature, such legal proceedings involve inherent uncertainties including, but not limited to, court rulings, negotiations between affected parties and governmental actions. Management assesses the probability of loss for such contingencies and accrues a liability and/or discloses the relevant circumstances, as appropriate. </div></div></ix:continuation><ix:nonNumeric name="pstv:LicenseAgreementDisclosureTextBlock" contextRef="P01_01_2023To12_31_2023" escape="true" continuedAt="TextSelection_116200135" id="ixv-16148"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">7. License Agreements </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Biocept License Agreement </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">On September&#160;7, 2023, the Company entered into a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">Non-Exclusive</div> License and Services Agreement (the &#8220;Biocept Agreement&#8221;) with Biocept, Inc (&#8220;Biocept&#8221;), pursuant to which Biocept granted the Company a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">non-exclusive</div> license to use the Biocept proprietary cell enumeration test, CNside<div style="font-size: 75%; vertical-align: top;display:inline;font-size:8.3px">TM</div>. In exchange for the license, the Company issued to Biocept <ix:nonFraction name="us-gaap:SharesIssued" contextRef="PAsOn09_07_2023_BioceptAgreementMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-22890">53,381</ix:nonFraction> unregistered shares, the fair value of which was $<ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="P10_01_2023To12_31_2023_BioceptAgreementMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-22891">75,000</ix:nonFraction>. The Biocept Agreement also provides that if Biocept fully transfers the technology to the Company, a tech transfer and validation fee of $<ix:nonFraction name="pstv:PaymentForTechTransferAndValidationFee" contextRef="P09_07_2023To09_07_2023_BioceptAgreementMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-22892">300,000</ix:nonFraction> will be payable. In addition, the Company was granted an option for an exclusive worldwide license for $<ix:nonFraction name="pstv:OptionForExclusiveWorldwideLicense" contextRef="P09_07_2023To09_07_2023_BioceptAgreementMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-22893">1,000,000</ix:nonFraction> on or before December&#160;31, 2024, to process and perform cell enumeration testing for treatments for other patients including those on the Company&#8217;s radiotherapeutic drugs. </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">On October&#160;16, 2023, Biocept filed a voluntary petition for relief under the provisions of Chapter 7 of Title 11 of the United States Bankruptcy Code, making the full transfer of the Biocept technology to the Company unlikely. In addition, the Biocept Agreement is subject to provisions under the Bankruptcy Code. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">UT Health Science Center at San Antonio (&#8220;UTHSA&#8221;) License Agreement </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">On December&#160;31, 2021, the Company entered into a Patent and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">Know-How</div> License Agreement (the &#8220;UTHSA License Agreement&#8221;) with UTHSA, pursuant to which UTHSA granted the Company an irrevocable, perpetual, exclusive, fully <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">paid-up</div> license, with the right to sublicense and to make, develop, commercialize and otherwise exploit certain patents, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">know-how</div> and technology related to the development of biodegradable alginate microspheres (BAM) containing nanoliposomes loaded with imaging and/or therapeutic payloads. </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Pursuant to the UTHSA License Agreement, the Company was required to make an upfront payment, which was recorded as <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">in-process</div> research and development acquired in the statement of operations for the year ended December&#160;31, 2021. The upfront payment of $<ix:nonFraction name="us-gaap:PaymentsForRoyalties" contextRef="P01_01_2022To01_31_2022_UTHSALicenseAgreementMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-22894">0.3</ix:nonFraction>&#160;million was paid in cash in January 2022. </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">NanoTx License Agreement </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">On March&#160;29, 2020, the Company and NanoTx, Corp. (&#8220;NanoTx&#8221;) entered into a Patent and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">Know-How</div> License Agreement (the &#8220;NanoTx License Agreement&#8221;), pursuant to which NanoTx granted the Company an irrevocable, perpetual, exclusive, fully <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">paid-up</div> license, with the right to sublicense and to make, develop, commercialize and otherwise exploit certain patents, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">know-how</div> and technology related to the development of radiolabeled nanoliposomes. </div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><ix:exclude>F-34</ix:exclude> </div></div></ix:nonNumeric></div></div><ix:continuation id="TextSelection_116200135" continuedAt="TextSelectionAppend_116200135_1"><ix:exclude><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_116200135_1" continuedAt="TextSelectionAppend_116200135_2"><ix:exclude><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/></ix:exclude></ix:continuation> <div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelectionAppend_116200135_2"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">The transaction terms included an upfront payment of $<ix:nonFraction name="us-gaap:PaymentsForRoyalties" contextRef="P03_29_2020To03_29_2020_NanoTxLicensesAgreementMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-22896">0.4</ix:nonFraction>&#160;million in cash and $<ix:nonFraction name="us-gaap:CommonStockValue" contextRef="PAsOn03_29_2020_NanoTxLicensesAgreementMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-22897">0.3</ix:nonFraction>&#160;million in the Company&#8217;s voting stock. The transaction terms also included success-based milestone and royalty payments contingent on key clinical, regulatory and sales milestones, as well as the requirement to pay <ix:nonFraction name="pstv:PercentageOfNonDilutiveMonetaryAwardsRequiredToPay" contextRef="P03_29_2020To03_29_2020_NanoTxLicensesAgreementMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-22898">15</ix:nonFraction>% of any <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">non-dilutive</div> monetary awards or grants received from external agencies to support product development of the nanoliposome encapsulated BMEDA-chelated radioisotope, which includes grants from the Cancer Prevention&#160;&amp; Research Institute of Texas (&#8220;CPRIT&#8221;). As of December&#160;31, 2023, the Company accrued $<ix:nonFraction name="pstv:AccruedLicensePayable" contextRef="PAsOn12_31_2023_NanoTxLicensesAgreementMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-22899">0.5</ix:nonFraction>&#160;million of payments due to NanoTx as a result of the CPRIT grant received (Note 9). </div></ix:continuation><ix:nonNumeric name="us-gaap:DebtDisclosureTextBlock" contextRef="P01_01_2023To12_31_2023" escape="true" continuedAt="TextSelection_116200097" id="ixv-16192"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">8. Term Loan Obligations </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">On <ix:nonNumeric name="us-gaap:DebtInstrumentOfferingDate1" contextRef="P01_01_2023To12_31_2023_TermLoanMemberusgaapDebtInstrumentAxis" format="ixt:date-monthname-day-year-en" id="ixv-22900">May 29, 2015</ix:nonNumeric>, the Company entered into the Loan and Security Agreement (the &#8220;Loan and Security Agreement&#8221;), pursuant to which Oxford Finance, LLC (&#8220;Oxford&#8221;) funded an aggregate principal amount of $<ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="PAsOn05_29_2015_TermLoanMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-22901">17.7</ix:nonFraction>&#160;million (the &#8220;Term Loan&#8221;), subject to the terms and conditions set forth in the Loan and Security Agreement. The Term Loan accrued interest at a floating rate of at least <ix:nonFraction name="pstv:DebtInstrumentFloatingInterestRatePercentage" contextRef="PAsOn05_29_2015_MinimumMembersrtRangeAxis_TermLoanMemberusgaapDebtInstrumentAxis" unitRef="Unit_pure" decimals="INF" scale="-2" format="ixt:num-dot-decimal" id="ixv-22902">8.95</ix:nonFraction>% per annum, comprised of a three-month LIBOR rate with a floor of <ix:nonFraction name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" contextRef="P05_28_2015To05_29_2015_InterestRateFloorMemberusgaapDerivativeInstrumentRiskAxis_LiborMemberusgaapVariableRateAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal" id="ixv-22903">1.00</ix:nonFraction>% plus <ix:nonFraction name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" contextRef="P05_28_2015To05_29_2015_TermLoanMemberusgaapDebtInstrumentAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal" id="ixv-22904">7.95</ix:nonFraction>%. Pursuant to the Loan and Security Agreement, as amended, the Company was required to make interest only payments through <ix:nonNumeric name="us-gaap:DebtInstrumentMaturityDate" contextRef="P05_28_2015To05_29_2015_TermLoanMemberusgaapDebtInstrumentAxis" format="ixt:date-monthname-day-year-en" id="ixv-22905">May 1, 2021</ix:nonNumeric> and thereafter it was required to make payments of principal and accrued interest in equal monthly installments sufficient to amortize the Term Loan through June&#160;1, 2024, the maturity date. At maturity of the Term Loan, or earlier repayment in full following voluntary prepayment or upon acceleration, the Company is required to make a final payment in an aggregate amount equal to approximately $<ix:nonFraction name="us-gaap:DebtInstrumentFeeAmount" contextRef="PAsOn05_29_2015_TermLoanMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-22906">3.2</ix:nonFraction>&#160;million. In connection with the Term Loan, on May&#160;29, 2015, the Company issued to Oxford warrants to purchase an aggregate of <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="PAsOn05_29_2015_TermLoanMemberusgaapDebtInstrumentAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-22907">188</ix:nonFraction> shares of the Company&#8217;s common stock at an exercise price of $<ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="PAsOn05_29_2015_TermLoanMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-22908">5,175</ix:nonFraction> per share. These warrants became exercisable as of November&#160;30, 2015 and will expire on May&#160;29, 2025 and, following the authoritative accounting guidance, are equity classified and their respective fair value was recorded as a discount to the debt. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The Term Loan was collateralized by a security interest in substantially all of the Company&#8217;s existing and subsequently acquired assets, including its intellectual property assets, subject to certain exceptions set forth in the Loan and Security Agreement, as amended. The intellectual property asset collateral would be released upon the Company achieving a certain liquidity level when the total principal outstanding under the Loan and Security Agreement is less than $<ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="PAsOn12_31_2023_MaximumMembersrtRangeAxis_TermLoanMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal" id="ixv-22909">3</ix:nonFraction>&#160;million. As of December&#160;31, 2023, there was $<ix:nonFraction name="pstv:LongTermDebtOutstandingThresholdAmount" contextRef="P01_01_2023To12_31_2023_MaximumMembersrtRangeAxis_TermLoanMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-22910">0.8</ix:nonFraction>&#160;million principal amount outstanding under the Term Loan, excluding the $<ix:nonFraction name="us-gaap:DebtInstrumentFeeAmount" contextRef="PAsOn12_31_2023_TermLoanMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-22911">3.2</ix:nonFraction>&#160;million final payment fee, and <ix:nonNumeric name="us-gaap:DebtInstrumentCovenantCompliance" contextRef="P01_01_2023To12_31_2023_TermLoanMemberusgaapDebtInstrumentAxis" id="ixv-22912">the Company was in compliance with all of the debt covenants under the Loan and Security Agreement.</ix:nonNumeric> </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Company&#8217;s interest expense for the years ended December&#160;31, 2023 and 2022 was $<ix:nonFraction name="us-gaap:InterestExpense" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-22913">0.4</ix:nonFraction>&#160;million and $<ix:nonFraction name="us-gaap:InterestExpense" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-22914">0.7</ix:nonFraction>&#160;million, respectively. Interest expense is calculated using the effective interest method; therefore it is inclusive of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">non-cash</div> amortization in the amount of $<ix:nonFraction name="us-gaap:AmortizationOfDebtDiscountPremium" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-22915">0.2</ix:nonFraction>&#160;million and $<ix:nonFraction name="us-gaap:AmortizationOfDebtDiscountPremium" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-22916">0.4</ix:nonFraction>&#160;million for the year ended December&#160;31, 2023 and 2022, respectively, related to the amortization of the debt discount, deferred financing costs, and accretion of final payment. </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The Loan and Security Agreement contains customary indemnification obligations and customary events of default, including, among other things, the Company&#8217;s failure to fulfill certain obligations under the Term Loan, as amended, and the occurrence of a material adverse change, which is defined as a material adverse change in the Company&#8217;s business, operations, or condition (financial or otherwise), a material impairment of the prospect of repayment of any portion of the loan. In the event of default by the Company or a declaration of material adverse change by its lender, under the Term Loan, the lender would be entitled to exercise its remedies thereunder, including the right to accelerate the debt, upon which the Company may be required to repay all amounts then outstanding under the Term Loan, which could materially harm the Company&#8217;s financial condition. As of December&#160;31, 2023, the Company has not received any notification or indication from Oxford to invoke the material adverse change clause. </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><ix:exclude>F-35</ix:exclude> </div></div></ix:nonNumeric></div></div><ix:continuation id="TextSelection_116200097" continuedAt="TextSelectionAppend_116200097_1"><ix:exclude><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_116200097_1" continuedAt="TextSelectionAppend_116200097_2"><ix:exclude><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/></ix:exclude></ix:continuation><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelectionAppend_116200097_2"><ix:nonNumeric name="us-gaap:ScheduleOfDebtInstrumentsTextBlock" contextRef="P01_01_2023To12_31_2023" escape="true" id="ixv-16217"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Additional information relating to the then-outstanding Term Loan as of December&#160;31, 2023 and 2022 is presented in the following table (in thousands, except interest rate): </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 100%; font-family: Times New Roman; font-size: 8pt; border-collapse: collapse;">
<tr>
<td style="width: 53%;"/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;display:inline;">Year ended December&#160;31, 2023</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">Origination Date</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Original</div></div><br/> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Loan</div></div><br/> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Amount</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Interest</div></div><br/> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Rate*</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Current</div></div><br/> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Monthly</div></div><br/> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Payment**</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Amended<br/> expiration<br/> date</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Remaining</div></div><br/> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Principal</div></div><br/> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">(Face&#160;Value)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;"><div style="-sec-ix-hidden:hidden116199096;display:inline;">May 2015</div></div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="PAsOn12_31_2023_TermLoanMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-22918">17,700</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="PAsOn12_31_2023_TermLoanMemberusgaapDebtInstrumentAxis" unitRef="Unit_pure" decimals="INF" scale="-2" format="ixt:num-dot-decimal" id="Fact_116199642">13.39</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:DebtInstrumentPeriodicPayment" contextRef="P01_01_2023To12_31_2023_TermLoanMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="Fact_116199643">134</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonNumeric name="pstv:DebtInstrumentAmendedExpirationDate" contextRef="P01_01_2023To12_31_2023_TermLoanMemberusgaapDebtInstrumentAxis" format="ixt:date-monthname-day-year-en" id="ixv-22921">June 1, 2024</ix:nonNumeric></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:DebtInstrumentCarryingAmount" contextRef="PAsOn12_31_2023_TermLoanMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-22922">804</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;">
<tr>
<td style="width: 52%;"/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;display:inline;">Year ended December&#160;31, 2022</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">Origination Date</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Original</div></div><br/> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Loan</div></div><br/> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Amount</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Interest</div></div><br/> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Rate*</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Monthly</div></div><br/> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Payment**</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Amended<br/> expiration<br/> date</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Remaining</div></div><br/> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Principal</div></div><br/> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">(Face&#160;Value)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;"><div style="-sec-ix-hidden:hidden116199109;display:inline;">May 2015</div></div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="PAsOn12_31_2022_TermLoanMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-22923">17,700</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="PAsOn12_31_2022_TermLoanMemberusgaapDebtInstrumentAxis" unitRef="Unit_pure" decimals="INF" scale="-2" format="ixt:num-dot-decimal" id="Fact_116199647">8.95</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:DebtInstrumentPeriodicPayment" contextRef="P01_01_2022To12_31_2022_TermLoanMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="Fact_116199648">134</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonNumeric name="pstv:DebtInstrumentAmendedExpirationDate" contextRef="P01_01_2022To12_31_2022_TermLoanMemberusgaapDebtInstrumentAxis" format="ixt:date-monthname-day-year-en" id="ixv-22926">June 1, 2024</ix:nonNumeric></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:DebtInstrumentCarryingAmount" contextRef="PAsOn12_31_2022_TermLoanMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-22927">2,412</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentColor; border-image: none; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;text-align:left;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">*</div></div></td>
<td style="vertical-align: top;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Three month LIBOR rate with a floor of 1% plus 7.95% </div></div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentColor; border-image: none; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;text-align:left;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">**</div></div></td>
<td style="vertical-align: top;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Monthly payment reflects principal and interest </div></div></div></td></tr></table></ix:nonNumeric></ix:continuation><div style="clear:both;max-height:0pt;"></div><ix:nonNumeric name="us-gaap:RevenueFromContractWithCustomerTextBlock" contextRef="P01_01_2023To12_31_2023" escape="true" continuedAt="TextSelection_116200134" id="ixv-16489"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">9. Grant Revenue </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">On September&#160;19, 2022, the Company entered into the CPRIT Contract, effective as of <ix:nonNumeric name="pstv:ContractEffectiveDate" contextRef="P09_19_2022To09_19_2022_CancerPreventionAndResearchInstituteOfTexasContractMemberusgaapTypeOfArrangementAxis" format="ixt:date-monthname-day-year-en" id="ixv-22928">August 31, 2022</ix:nonNumeric>, with CPRIT, pursuant to which CPRIT will provide the Company with the CPRIT Grant of up to $<ix:nonFraction name="pstv:MaximumGrantAmountToBeReceivedAsPerGrantContract" contextRef="PAsOn09_19_2022_CancerPreventionAndResearchInstituteOfTexasContractMemberusgaapTypeOfArrangementAxis" unitRef="Unit_USD" decimals="INF" scale="6" format="ixt:num-dot-decimal" id="ixv-22929">17.6</ix:nonFraction>&#160;million over a <ix:nonNumeric name="pstv:GrantFundingTerm" contextRef="P09_19_2022To09_19_2022_CancerPreventionAndResearchInstituteOfTexasContractMemberusgaapTypeOfArrangementAxis" format="ixt-sec:durwordsen" id="ixv-22930">three-year</ix:nonNumeric> period to fund the continued development of rhenium (<div style="font-size: 75%; vertical-align: top;display:inline;font-size:8.3px">186</div>Re) obisbemeda (previously known as <div style="font-size: 75%; vertical-align: top;display:inline;font-size:8.3px">186</div>RNL) for the treatment of patients with leptomeningeal metastases (&#8220;LM&#8221;). <ix:nonNumeric name="pstv:CpritGrantFundingTerm" contextRef="P01_01_2023To12_31_2023_CancerPreventionAndResearchInstituteOfTexasContractMemberusgaapTypeOfArrangementAxis" id="ixv-16497">The CPRIT Grant is subject to customary CPRIT funding conditions, including, but not limited to, a matching fund requirement (one dollar for every two dollars awarded by CPRIT), revenue sharing obligations upon commercialization of rhenium (<div style="font-size: 75%; vertical-align: top;display:inline;font-size:8.3px">186</div>Re) obisbemeda based on specific dollar thresholds and tiered low single digit royalty rates until CPRIT receives the aggregate amount of <ix:nonFraction name="pstv:PercentageOfAggregateAmountOfProceedsAwardedUnderCpritGrant" contextRef="P01_01_2023To12_31_2023_CancerPreventionAndResearchInstituteOfTexasContractMemberusgaapTypeOfArrangementAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-22931">400</ix:nonFraction>% of the proceeds awarded under the CPRIT Grant, and certain reporting requirements.</ix:nonNumeric> </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The CPRIT Contract will terminate on <ix:nonNumeric name="pstv:ContractTerminationDate" contextRef="P09_19_2022To09_19_2022_CancerPreventionAndResearchInstituteOfTexasContractMemberusgaapTypeOfArrangementAxis" format="ixt:date-monthname-day-year-en" id="ixv-22932">August 30, 2025</ix:nonNumeric>, unless terminated earlier by (a)&#160;the mutual written consent of all parties to the CPRIT Contract, (b)&#160;CPRIT for an event of default by the Company, (c)&#160;CPRIT, if the funds allocated to the CPRIT Grant become legally unavailable during the term of the CPRIT Contract and CPRIT is unable to obtain additional funds for such purposes, and (d)&#160;the Company for convenience. CPRIT may require the Company to repay some or all of the disbursed CPRIT Grant proceeds (with interest not to exceed <ix:nonFraction name="pstv:PercentageOfGrantProceedsWithInterestNotExceedAnnually" contextRef="P09_19_2022To09_19_2022_CancerPreventionAndResearchInstituteOfTexasContractMemberusgaapTypeOfArrangementAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-22933">5</ix:nonFraction>% annually) in the event of the early termination of the CPRIT Contract by CPRIT for an event of default by the Company or by the Company for convenience, or if the Company relocates its principal place of business outside of the state of Texas during the CPRIT Contract term or within three years after the final payment of the grant funds. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Company retains ownership over any intellectual property developed under the contract (each, a &#8220;Project Result&#8221;). With respect to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">non-commercial</div> use of any Project Result, the Company granted to CPRIT a nonexclusive, irrevocable, royalty-free, perpetual, worldwide license with right to sublicense any necessary additional intellectual property rights to exploit all Project Results by CPRIT, other governmental entities and agencies of the State of Texas, and private or independent institutions of higher education located in Texas, for education, research and other <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">non-commercial</div> purposes. </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Company determined that the CPRIT Contract is not in the scope of ASC 808, ASC <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">958-605,</div> or ASC 606. Applying IAS 20 by analogy, the Company recognizes proceeds received under the CPRIT Contract as grant revenue on the statement of operations when related costs are incurred. </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">During the three months ended June&#160;30, 2023, the Company identified eligible costs of approximately $<ix:nonFraction name="pstv:ReimbursementCostsIncurred" contextRef="P10_01_2022To12_31_2022_CancerPreventionAndResearchInstituteOfTexasContractMemberusgaapTypeOfArrangementAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-22934">637,000</ix:nonFraction> and $<ix:nonFraction name="pstv:ReimbursementCostsIncurred" contextRef="P01_01_2023To03_31_2023_CancerPreventionAndResearchInstituteOfTexasContractMemberusgaapTypeOfArrangementAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-22935">168,000</ix:nonFraction> that were incurred in the fourth quarter of 2022 and the three months ended March&#160;31, 2023, respectively, that were reimbursable under the CPRIT arrangement. The Company determined that these costs should have been recorded in these respective periods as grant revenue. The Company assessed the impact of this error on the Company&#8217;s previously issued financial statements and determined that it was immaterial. As a result, an <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">out-of-period</div></div> adjustment of approximately $<ix:nonFraction name="pstv:IncreaseDecreaseInGrantRevenue" contextRef="P01_01_2023To12_31_2023_CancerPreventionAndResearchInstituteOfTexasContractMemberusgaapTypeOfArrangementAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-22936">637,000</ix:nonFraction> has been recorded as an increase in grant revenue in the year ended December&#160;31, 2023. </div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><ix:exclude>F-36</ix:exclude> </div></div></ix:nonNumeric></div></div><ix:continuation id="TextSelection_116200134" continuedAt="TextSelectionAppend_116200134_1"><ix:exclude><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_116200134_1" continuedAt="TextSelectionAppend_116200134_2"><ix:exclude><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/></ix:exclude></ix:continuation> <div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelectionAppend_116200134_2"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The Company recognized $<ix:nonFraction name="us-gaap:Revenues" contextRef="P01_01_2023To12_31_2023_CancerPreventionAndResearchInstituteOfTexasContractMemberusgaapTypeOfArrangementAxis_GrantMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-22938">4.9</ix:nonFraction>&#160;million and $<ix:nonFraction name="us-gaap:Revenues" contextRef="P01_01_2022To12_31_2022_CancerPreventionAndResearchInstituteOfTexasContractMemberusgaapTypeOfArrangementAxis_GrantMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-22939">0.2</ix:nonFraction>&#160;million in grant revenue from the CPRIT Contract during the year ended December&#160;31, 2023 and 2022, respectively. </div></div></ix:continuation><ix:nonNumeric name="us-gaap:IncomeTaxDisclosureTextBlock" contextRef="P01_01_2023To12_31_2023" escape="true" continuedAt="TextSelection_116199138" id="ixv-16524"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">10. Income Taxes </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Pursuant to the Internal Revenue Code (&#8220;IRC&#8221;) of 1986, as amended, specifically IRC &#167;382 (&#8220;Section 382&#8221;) and IRC &#167;383, the Company&#8217;s ability to use net operating loss (&#8220;NOLs&#8221;) and R&amp;D tax credit carry forwards (&#8220;tax attribute carry forwards&#8221;) to offset future taxable income is limited if the Company experiences a cumulative change in ownership of more than <ix:nonFraction name="pstv:CumulativeChangeInOwnership" contextRef="PAsOn12_31_2023" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-22940">50</ix:nonFraction>% within a <ix:nonNumeric name="pstv:NetOperatingLossAndResearchAndDevelopmentTaxCreditCarryForwardsToOffsetFutureTaxableIncomePeriod" contextRef="P01_01_2023To12_31_2023" format="ixt-sec:durwordsen" id="ixv-22941">three-year</ix:nonNumeric> testing period. The Company&#8217;s use of federal and state NOLs and research credits could be limited further by the provisions of Section&#160;382 depending upon the timing and amount of additional equity securities that the Company has issued or will issue. State NOL carryforwards may be similarly limited. If a change in ownership were to have occurred, NOL and tax credits carryforwards could be eliminated or restricted. If eliminated, the related asset would be removed from the deferred tax asset schedule with a corresponding reduction in the valuation allowance. Due to the existence of the valuation allowance, limitations created by ownership changes, if any, will not impact the Company&#8217;s effective tax rate. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The Company has recorded a full valuation allowance against its net deferred tax assets and due to our net losses for the years ended December&#160;31, 2023 and 2022, there was <ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt-sec:numwordsen" id="ixv-22942"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt-sec:numwordsen" id="ixv-22943">no</ix:nonFraction></ix:nonFraction> provision or benefit for income taxes recorded. </div></div><ix:nonNumeric name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" contextRef="P01_01_2023To12_31_2023" escape="true" id="ixv-16532"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">A reconciliation of the total income tax provision tax rate to the statutory federal income tax rates of 21% for the years ended December&#160;31, 2023 and 2022, respectively, is as follows: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 76%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;">
<tr>
<td style="width: 81%;"/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Income tax expense (benefit) at federal statutory rate</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_pure" decimals="INF" scale="-2" format="ixt:num-dot-decimal" id="ixv-22944">21.0</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_pure" decimals="INF" scale="-2" format="ixt:num-dot-decimal" id="ixv-22945">21.0</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Change in valuation allowance</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal" id="ixv-22946">25.5</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal" id="ixv-22947">22.5</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Income tax expense (benefit) at state statutory rate</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_pure" decimals="3" scale="-2" sign="-" format="ixt:num-dot-decimal" id="ixv-22948">0.2</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_pure" decimals="3" scale="-2" sign="-" format="ixt:num-dot-decimal" id="ixv-22949">0.2</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Share based compensation</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal" id="ixv-22950">1.0</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal" id="ixv-22951">0.9</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">NOLs expiring and adjustments to NOL</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">(<ix:nonFraction name="pstv:EffectiveIncomeTaxRateReconciliationNetOperatingLossExpiration" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_pure" decimals="3" scale="-2" sign="-" format="ixt:num-dot-decimal" id="ixv-22952">0.1</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="pstv:EffectiveIncomeTaxRateReconciliationNetOperatingLossExpiration" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal" id="ixv-22953">0.5</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Research credit</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal" id="ixv-22954">5.1</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal" id="ixv-22955">2.5</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Return to provision</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">(<ix:nonFraction name="pstv:EffectiveIncomeTaxRateReconciliationTaxReturnToProvision" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_pure" decimals="3" scale="-2" sign="-" format="ixt:num-dot-decimal" id="ixv-22956">0.1</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">(<ix:nonFraction name="pstv:EffectiveIncomeTaxRateReconciliationTaxReturnToProvision" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_pure" decimals="3" scale="-2" sign="-" format="ixt:num-dot-decimal" id="ixv-22957">0.1</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Change in state rate</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxSettlementsStateAndLocal" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_pure" decimals="0" scale="-2" format="ixt:fixed-zero" id="ixv-22958">&#8212;</ix:nonFraction>&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxSettlementsStateAndLocal" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_pure" decimals="3" scale="-2" sign="-" format="ixt:num-dot-decimal" id="ixv-22959">0.1</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)%&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal" id="ixv-22960">0.0</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal" id="ixv-22961">0.0</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table></ix:nonNumeric><div style="clear:both;max-height:0pt;"></div><ix:nonNumeric name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" contextRef="P01_01_2023To12_31_2023" escape="true" continuedAt="TextSelection_116199144" id="ixv-16703"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The tax effects of temporary differences that give rise to significant portions of our deferred tax assets and deferred tax liabilities as of December&#160;31, 2023 and 2022 are as follows (in thousands): </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 76%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;">
<tr>
<td style="width: 72%;"/>
<td style="width: 10%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 10%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Deferred tax assets:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Accrued expenses</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-22962">269</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-22963">262</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Share based compensation</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-22964">99</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-22965">107</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Net operating loss carryforwards</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-22966">13,397</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-22967">12,605</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Income tax credit carryforwards</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwards" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-22968">1,630</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwards" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-22969">956</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Property and equipment, principally due to differences in depreciation</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-22970">154</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-22971">89</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Intangible assets</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-22972">3,527</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-22973">2,073</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Other, net</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOther" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-22974">453</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOther" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-22975">53</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsGross" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-22976">19,529</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsGross" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-22977">16,145</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Valuation allowance</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">(<ix:nonFraction name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-22978">19,486</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">(<ix:nonFraction name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-22979">16,092</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Total deferred tax assets, net of allowance</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsNet" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-22980">43</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsNet" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-22981">53</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><ix:exclude>F-37</ix:exclude> </div></div></ix:nonNumeric></ix:nonNumeric></div></div><ix:continuation id="TextSelection_116199144" continuedAt="TextSelectionAppend_116199144_1"><ix:continuation id="TextSelection_116199138" continuedAt="TextSelectionAppend_116199138_1"><ix:exclude><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_116199138_1" continuedAt="TextSelectionAppend_116199138_2"><ix:exclude><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/></ix:exclude></ix:continuation></ix:continuation><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelectionAppend_116199138_2" continuedAt="TextSelectionAppend_116199138_3"><ix:continuation id="TextSelectionAppend_116199144_1">
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 76%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;">
<tr>
<td style="width: 82%;"/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Deferred tax liabilities:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Other</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">(<ix:nonFraction name="us-gaap:DeferredTaxLiabilitiesOther" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-22983">43</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">(<ix:nonFraction name="us-gaap:DeferredTaxLiabilitiesOther" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-22984">53</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Total deferred tax liability</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">(<ix:nonFraction name="us-gaap:DeferredIncomeTaxLiabilities" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-22985">43</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">(<ix:nonFraction name="us-gaap:DeferredIncomeTaxLiabilities" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-22986">53</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Net deferred tax assets (liability)</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:DeferredTaxLiabilities" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-22987">&#8212;</ix:nonFraction>&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:DeferredTaxLiabilities" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-22988">&#8212;</ix:nonFraction>&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table></ix:continuation><div style="clear:both;max-height:0pt;"></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The Company has established a valuation allowance against its net deferred tax assets due to the uncertainty surrounding the realization of such assets. The Company periodically evaluates the recoverability of the deferred tax assets. At such time as it is determined that it is more likely than not that deferred tax assets are realizable, the valuation allowance will be reduced. The Company has recorded a full valuation allowance of $<ix:nonFraction name="pstv:DeferredTaxAssetsValuationAllowances" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-22989">19.5</ix:nonFraction>&#160;million as of December&#160;31, 2023 as it does not believe it is more likely than not the net deferred tax assets will be realized. The Company increased its valuation allowance by approximately $<ix:nonFraction name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-22990">3.4</ix:nonFraction>&#160;million during the year ended December&#160;31, 2023. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">At December&#160;31, 2023, the Company had federal and state tax loss carry forwards of approximately $<ix:nonFraction name="us-gaap:OperatingLossCarryforwards" contextRef="PAsOn12_31_2023_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-22991">63.2</ix:nonFraction>&#160;million, and $<ix:nonFraction name="us-gaap:OperatingLossCarryforwards" contextRef="PAsOn12_31_2023_StateAndLocalJurisdictionMemberusgaapIncomeTaxAuthorityAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-22992">2.6</ix:nonFraction>&#160;million, respectively. The federal and state net operating loss carry forwards <ix:nonNumeric name="pstv:OperatingLossCarryforwardsExpirationDates1" contextRef="P01_01_2023To12_31_2023_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis" id="ixv-22993">begin to expire in 2037</ix:nonNumeric> and <ix:nonNumeric name="pstv:OperatingLossCarryforwardsExpirationDates1" contextRef="P01_01_2023To12_31_2023_StateAndLocalJurisdictionMemberusgaapIncomeTaxAuthorityAxis" id="ixv-22994">2038</ix:nonNumeric>, if unused, respectively. The federal net operating loss carryover includes $<ix:nonFraction name="pstv:NetOperatingLossCarryforward" contextRef="PAsOn12_31_2023_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-22995">59.8</ix:nonFraction>&#160;million of net operating losses generated after 2017. Federal net operating losses generated from 2018 onwards carryover indefinitely and may generally be used to offset up to <ix:nonFraction name="pstv:PercentageOfNetOperatingLossCarryforwardsAvailableForOffsettingAgainstFutureTaxableIncome" contextRef="P01_01_2023To12_31_2023_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis_MaximumMembersrtRangeAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-22996">80</ix:nonFraction>% of future taxable income. At December&#160;31, 2023, the Company had federal tax credit carry forwards of approximately $<ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic" contextRef="PAsOn12_31_2023_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-22997">1.9</ix:nonFraction>&#160;million, before reduction for uncertain tax positions. The federal credits will <ix:nonNumeric name="pstv:TaxCreditCarryforwardExpirationDate1" contextRef="P01_01_2023To12_31_2023_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis" id="ixv-22998">begin to expire in 2039</ix:nonNumeric>, if unused. In addition, at December&#160;31, 2023, the Company had state tax credit carry forwards of approximately $<ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" contextRef="PAsOn12_31_2023_StateAndLocalJurisdictionMemberusgaapIncomeTaxAuthorityAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-22999">0.2</ix:nonFraction>&#160;million, before reduction for uncertain tax positions. The state credits will <ix:nonNumeric name="pstv:TaxCreditCarryforwardExpirationDate1" contextRef="P01_01_2023To12_31_2023_StateAndLocalJurisdictionMemberusgaapIncomeTaxAuthorityAxis" id="ixv-23000">begin to expire in 2043</ix:nonNumeric>, if unused. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The Company follows the provisions of income tax guidance which provides recognition criteria and a related measurement model for uncertain tax positions taken or expected to be taken in income tax returns. The guidance requires that a position taken or expected to be taken in a tax return be recognized in the financial statements when it is more likely than not that the position would be sustained upon examination by tax authorities. Tax positions that meet the more likely than not threshold are then measured using a probability weighted approach recognizing the largest amount of tax benefit that is greater than 50% likely of being realized upon ultimate settlement. The Company has <ix:nonFraction name="us-gaap:LiabilityForUncertainTaxPositionsCurrent" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt-sec:numwordsen" id="ixv-23001"><ix:nonFraction name="us-gaap:LiabilityForUncertainTaxPositionsCurrent" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt-sec:numwordsen" id="ixv-23002">no</ix:nonFraction></ix:nonFraction>t recognized any liability for uncertain tax positions as of December&#160;31, 2023 and 2022. </div></div><ix:nonNumeric name="us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" contextRef="P01_01_2023To12_31_2023" escape="true" id="ixv-17063"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Following is a tabular reconciliation of the unrecognized tax benefits activity during the years ended December&#160;31, 2023 and 2022 (in thousands): </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 76%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;">
<tr>
<td style="width: 82%;"/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Unrecognized Tax Benefits &#8211; Beginning</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:UnrecognizedTaxBenefits" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-23003">209</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:UnrecognizedTaxBenefits" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-23004">81</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Gross decreases &#8211; tax positions in prior period</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">(<ix:nonFraction name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-23005">16</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">(<ix:nonFraction name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-23006">1</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Gross increase &#8211; current-period tax positions</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-23007">215</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-23008">129</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Unrecognized Tax Benefits &#8211; Ending</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:UnrecognizedTaxBenefits" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-23009">408</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:UnrecognizedTaxBenefits" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-23010">209</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table></ix:nonNumeric><div style="clear:both;max-height:0pt;"></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The unrecognized tax benefit amounts are reflected in the determination of the Company&#8217;s deferred tax assets. If recognized, none of these amounts would affect the Company&#8217;s effective tax rate, since it would be offset by an equal reduction in the deferred tax asset valuation allowance. The Company does not foresee material changes to its liability for uncertain tax benefits within the next <ix:nonNumeric name="pstv:PeriodForMaterialChangesOfLiabilityForUncertainTaxBenefits" contextRef="P01_01_2023To12_31_2023" format="ixt-sec:durwordsen" id="ixv-23011">twelve months</ix:nonNumeric>. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The Company did <ix:nonFraction name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt-sec:numwordsen" id="ixv-23012">no</ix:nonFraction>t recognize interest related to unrecognized tax benefits in interest expense and penalties in operating expenses for the year ended December&#160;31, 2023. </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><ix:exclude>F-38</ix:exclude> </div></div></ix:continuation></div></div><ix:continuation id="TextSelectionAppend_116199138_3" continuedAt="TextSelectionAppend_116199138_4"><ix:exclude><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_116199138_4" continuedAt="TextSelectionAppend_116199138_5"><ix:exclude><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/></ix:exclude></ix:continuation> <div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelectionAppend_116199138_5"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The Company files income tax returns with the United States and various state jurisdictions. To its knowledge, the Company is currently not under examination by the Internal Revenue Service or any other taxing authority. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">With few exceptions, the Company&#8217;s tax years prior to 2020 are no longer open to examination by the taxing authority. While not open to examination, the tax attributes generated in tax years 2018 and forward remain subject to adjustment by the taxing authorities if utilized in tax years which are still open to examination. </div></div></ix:continuation><ix:nonNumeric name="us-gaap:CompensationAndEmployeeBenefitPlansTextBlock" contextRef="P01_01_2023To12_31_2023" escape="true" id="ixv-17197"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">11. Employee Benefit Plan </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The Company implemented a 401(k) retirement savings and profit sharing plan (the &#8220;Plan&#8221;) effective January&#160;1, 1999. During 2022, the Company commenced safe harbor matching contribution for up to <ix:nonFraction name="us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" contextRef="P01_01_2023To12_31_2023_MaximumMembersrtRangeAxis" unitRef="Unit_pure" decimals="INF" scale="-2" format="ixt:num-dot-decimal" id="ixv-23014">4</ix:nonFraction>% of eligible employee contributions. Total matching contribution under the Plan amounted to approximately $<ix:nonFraction name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-23015">107,000</ix:nonFraction> and $<ix:nonFraction name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-23016">100,000</ix:nonFraction> for the year ended December&#160;31, 2023 and 2022, respectively. </div></div></ix:nonNumeric><ix:nonNumeric name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" contextRef="P01_01_2023To12_31_2023" escape="true" continuedAt="TextSelection_116199093" id="ixv-17203"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">12. Stockholders&#8217; Equity </div></div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Preferred Stock </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The Company has authorized <ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="PAsOn12_31_2023" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-23017">5,000,000</ix:nonFraction> shares of preferred stock, par value $<ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="PAsOn12_31_2023" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-23018">0.001</ix:nonFraction> per share. The Board is authorized to designate the terms and conditions of any preferred stock the Company issues without further action by the common stockholders. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Series F Preferred Stock </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">On March&#160;3, 2023, the Company filed a certificate of designation (the &#8220;Certificate of Designation&#8221;) with the Secretary of State of the State of Delaware, effective as of the time of filing, designating the rights, preferences, privileges and restrictions of the Series F Preferred Stock, with the total authorization of one (<ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="PAsOn03_03_2023_SeriesFConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-23019">1</ix:nonFraction>)&#160;share of Series F Preferred Stock. The Certificate of Designation provided that the share of Series F Preferred Stock will have <ix:nonFraction name="pstv:NumberOfVotesPerShare" contextRef="PAsOn03_03_2023_SeriesFConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_Votes" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-23020">50,000,000</ix:nonFraction> votes per share of Series F Preferred Stock and will vote together with the Company&#8217;s common stock, $<ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="PAsOn03_03_2023_SeriesFConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-23021">0.001</ix:nonFraction> par value (the &#8220;Common Stock&#8221;) as a single class exclusively with respect to any proposal to amend the Company&#8217;s Charter to effect a reverse stock split of the Common Stock (the &#8220;Reverse Stock Split&#8221;). On March&#160;3, 2023, the Company entered into a Subscription and Investment Representation Agreement (the &#8220;Subscription Agreement&#8221;) with Richard J. Hawkins, Chairman of the Board, who is an accredited investor (the &#8220;Purchaser&#8221;), pursuant to which the Company agreed to issue and sell one (<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="P03_03_2023To03_03_2023_SeriesFConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis_SubscriptionAgreementMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-23022">1</ix:nonFraction>)&#160;share of the Company&#8217;s Series F Preferred Stock, par value $<ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="PAsOn03_03_2023_SeriesFConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis_SubscriptionAgreementMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-23023">0.001</ix:nonFraction> per share (the &#8220;Preferred Stock&#8221;), to the Purchaser for $<ix:nonFraction name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" contextRef="P03_03_2023To03_03_2023_SeriesFConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis_SubscriptionAgreementMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-23024">1,000</ix:nonFraction> in cash. The sale closed on <ix:nonNumeric name="us-gaap:SaleOfStockTransactionDate" contextRef="P03_03_2023To03_03_2023_SeriesFConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis_SubscriptionAgreementMemberusgaapSubsidiarySaleOfStockAxis" format="ixt:date-monthname-day-year-en" id="ixv-23025">March 3, 2023</ix:nonNumeric>. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">At the Company&#8217;s annual meeting of stockholders held on April&#160;20, 2023, the Series F Preferred Stock was voted, without action by the holder, on the proposal to approve the Reverse Stock Split in the same proportion as shares of Common Stock voted to approve the Reverse Stock Split. The Series F Preferred Stock otherwise had <ix:nonNumeric name="us-gaap:PreferredStockVotingRights" contextRef="P03_03_2023To03_03_2023_SeriesFConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" id="ixv-23026">no</ix:nonNumeric> voting rights except as otherwise required by the General Corporation Law of the State of Delaware. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The Series F Preferred Stock was not convertible into, or exchangeable for, shares of any other class or series of stock or other securities of the Company. The Series F Preferred Stock had <ix:nonNumeric name="pstv:RightsRelatedToDistributionOfAssets" contextRef="P03_03_2023To03_03_2023_SeriesFConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" id="ixv-23027">no</ix:nonNumeric> rights with respect to any distribution of assets of the Company, including upon a liquidation, bankruptcy, reorganization, merger, acquisition, sale, dissolution or winding up of the Company, whether voluntarily or involuntarily. The holder of the Series F Preferred Stock was not entitled to receive dividends of any kind. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The outstanding share of Series F Preferred Stock was redeemed in whole, automatically effective upon the approval by the Company&#8217;s stockholders of a Reverse Stock Split. Upon such redemption, the holder of the Series F Preferred Stock received consideration of $<ix:nonFraction name="pstv:ConsiderationPaidToPreferredStockHolders" contextRef="P03_03_2023To03_03_2023_SeriesFConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-23028">1,000</ix:nonFraction> in cash. </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><ix:exclude>F-39</ix:exclude> </div></div></ix:nonNumeric></div></div><ix:continuation id="TextSelection_116199093" continuedAt="TextSelectionAppend_116199093_1"><ix:exclude><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_116199093_1" continuedAt="TextSelectionAppend_116199093_2"><ix:exclude><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/></ix:exclude></ix:continuation><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelectionAppend_116199093_2" continuedAt="TextSelectionAppend_116199093_3"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Series B and C Preferred Stock </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">As of December&#160;31, 2023, there were <ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="PAsOn12_31_2023_SeriesCConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis_TwoThousandEighteenRightsOfferingMemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-23030">938</ix:nonFraction> outstanding shares of Series C Preferred Stock that can be converted into an aggregate of <ix:nonFraction name="pstv:NumberOfPreferredStockSharesExercised" contextRef="P01_01_2023To12_31_2023_SeriesCConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis_TwoThousandEighteenRightsOfferingMemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-23031">27,792</ix:nonFraction> shares of common stock, and <ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="PAsOn12_31_2023_SeriesBConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis_TwoThousandEighteenRightsOfferingMemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-23032">1,014</ix:nonFraction> shares of Series B Convertible Preferred Stock that can be converted into an aggregate of <ix:nonFraction name="pstv:NumberOfPreferredStockSharesExercised" contextRef="P01_01_2023To12_31_2023_SeriesBConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis_TwoThousandEighteenRightsOfferingMemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-23033">398</ix:nonFraction> shares of common stock. </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Warrants </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">On September&#160;25, 2019, the Company completed an underwritten public offering. The Company issued <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="P01_01_2023To12_31_2023_CommonClassAMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-23034">19,266</ix:nonFraction> shares of its common stock, along with <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">pre-funded</div> warrants to purchase <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="PAsOn12_31_2023_CommonClassBMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-23035">180,733</ix:nonFraction> shares of its common stock and Series U Warrants to purchase <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="P01_01_2023To12_31_2023_SeriesUWarrantsMemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-23036">230,000</ix:nonFraction> shares of its common stock at $<ix:nonFraction name="us-gaap:SaleOfStockPricePerShare" contextRef="PAsOn12_31_2023_SeriesUWarrantsMemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-23037">75.00</ix:nonFraction> per share. The Series U Warrants have a term of <ix:nonNumeric name="us-gaap:WarrantsAndRightsOutstandingTerm" contextRef="PAsOn12_31_2023_SeriesUWarrantsMemberusgaapClassOfWarrantOrRightAxis" format="ixt-sec:durwordsen" id="ixv-23038">five years</ix:nonNumeric> from the issuance date. In addition, the Company issued warrants to H.C. Wainwright&#160;&amp; Co., LLC, as representatives of the underwriters, to purchase <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="PAsOn12_31_2023_RepresentativeSeriesUWarrantMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-23039">5,000</ix:nonFraction> shares of its common stock at $<ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="PAsOn12_31_2023_RepresentativeSeriesUWarrantMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-23040">93.75</ix:nonFraction> per share with a term of <ix:nonNumeric name="us-gaap:WarrantsAndRightsOutstandingTerm" contextRef="PAsOn12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis" format="ixt-sec:duryear" id="ixv-23041">5</ix:nonNumeric> years from the issuance date, in the form of Series U Warrants (the &#8220;Representative Warrants&#8221;). </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">As of December&#160;31, 2023, there were <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="PAsOn12_31_2023_SeriesUWarrantsMemberusgaapClassOfWarrantOrRightAxis_WarrantMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-23042">142,733</ix:nonFraction> outstanding Series U Warrants which can be exercised into an aggregate of <ix:nonFraction name="pstv:NumberOfWarrantsExercised" contextRef="P01_01_2023To12_31_2023_SeriesUWarrantsMemberusgaapClassOfWarrantOrRightAxis_WarrantMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-23043">142,733</ix:nonFraction> shares of common stock at the weighted average exercise price of $<ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="PAsOn12_31_2023_SeriesUWarrantsMemberusgaapClassOfWarrantOrRightAxis_WarrantMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-23044">34.10</ix:nonFraction> per share. </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Common Stock </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">On August&#160;2, 2022, the Company entered into a purchase agreement (the &#8220;2022 Purchase Agreement&#8221;) and registration rights agreement pursuant to which Lincoln Park committed to purchase up to $<ix:nonFraction name="pstv:MaximumValueOfSharesToBeIssuedUnderAgreement" contextRef="PAsOn08_02_2022_CommonStockMemberusgaapStatementEquityComponentsAxis_LincolnParkCapitalFundLLCMemberdeiLegalEntityAxis_TwoThousandAndTwentyTwoPurchaseAgreementMemberusgaapInvestmentTypeAxis" unitRef="Unit_USD" decimals="INF" scale="6" format="ixt:num-dot-decimal" id="ixv-23045">50.0</ix:nonFraction>&#160;million of the Company&#8217;s common stock. Under the terms and subject to the conditions of the 2022 Purchase Agreement, the Company has the right, but not the obligation, to sell to Lincoln Park, and Lincoln Park is obligated to purchase up to $<ix:nonFraction name="pstv:MaximumValueOfSharesToBeIssuedUnderAgreement" contextRef="PAsOn08_02_2022_CommonStockMemberusgaapStatementEquityComponentsAxis_LincolnParkCapitalFundLLCMemberdeiLegalEntityAxis_TwoThousandAndTwentyTwoPurchaseAgreementMemberusgaapInvestmentTypeAxis" unitRef="Unit_USD" decimals="INF" scale="6" format="ixt:num-dot-decimal" id="ixv-23046">50.0</ix:nonFraction>&#160;million of the Company&#8217;s common stock. Such sales of common stock by the Company are subject to certain limitations, and can occur from time to time, at the Company&#8217;s sole discretion, over the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><ix:nonNumeric name="pstv:PeriodExercisableFromTheDateOfIssuance" contextRef="P01_01_2023To12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis_LincolnParkCapitalFundLLCMemberdeiLegalEntityAxis_TwoThousandAndTwentyTwoPurchaseAgreementMemberusgaapInvestmentTypeAxis" format="ixt-sec:durwordsen" id="ixv-23047">36-month</ix:nonNumeric></div> period commencing on August&#160;17, 2022, subject to the satisfaction of certain conditions. Lincoln Park has no right to require the Company to sell any shares of common stock to Lincoln Park, but Lincoln Park is obligated to make purchases as the Company directs, subject to certain conditions. </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">On May&#160;16, 2022, the Company received stockholder approval for purposes of the Nasdaq listing rules to permit issuances of up to <ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="PAsOn05_16_2022_LincolnParkCapitalFundLLCMemberdeiLegalEntityAxis_MaximumMembersrtRangeAxis_TwoThousandAndTwentyTwoPurchaseAgreementMemberusgaapInvestmentTypeAxis" unitRef="Unit_shares" decimals="INF" scale="6" format="ixt:num-dot-decimal" id="ixv-23048">57.5</ix:nonFraction>&#160;million shares of the Company&#8217;s common stock (including the issuance of more than <ix:nonFraction name="pstv:PercentageIssuanceOfCommonStock" contextRef="P05_16_2022To05_16_2022_CommonStockMemberusgaapStatementEquityComponentsAxis_LincolnParkCapitalFundLLCMemberdeiLegalEntityAxis_MinimumMembersrtRangeAxis_TwoThousandAndTwentyTwoPurchaseAgreementMemberusgaapInvestmentTypeAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal" id="ixv-23049">19.99</ix:nonFraction>% of the Company&#8217;s common stock) to Lincoln Park, and it was pursuant to that approval that the Company entered into the 2022 Purchase Agreement. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Upon execution of the 2022 Purchase Agreement, the Company paid $<ix:nonFraction name="pstv:InitialCommitmentFee" contextRef="PAsOn08_02_2022_CommonStockMemberusgaapStatementEquityComponentsAxis_LincolnParkCapitalFundLLCMemberdeiLegalEntityAxis_TwoThousandAndTwentyTwoPurchaseAgreementMemberusgaapInvestmentTypeAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-23050">125,000</ix:nonFraction> in cash as the initial commitment fee, and issued <ix:nonFraction name="pstv:InitialCommitmentShares" contextRef="PAsOn08_02_2022_CommonStockMemberusgaapStatementEquityComponentsAxis_LincolnParkCapitalFundLLCMemberdeiLegalEntityAxis_TwoThousandAndTwentyTwoPurchaseAgreementMemberusgaapInvestmentTypeAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-23051">32,846</ix:nonFraction> shares as the initial commitment shares, to Lincoln Park as consideration for its irrevocable commitment to purchase shares of the Company&#8217;s common stock at its direction under the Purchase Agreement. The Company has agreed to pay an additional commitment fee, which it may elect to pay in cash and/or shares of its common stock, upon receipt of $<ix:nonFraction name="pstv:GrossProceedsFromIssuanceOfCommonStock" contextRef="P08_02_2022To08_02_2022_CommonStockMemberusgaapStatementEquityComponentsAxis_LincolnParkCapitalFundLLCMemberdeiLegalEntityAxis_TwoThousandAndTwentyTwoPurchaseAgreementMemberusgaapInvestmentTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-23052">25.0</ix:nonFraction>&#160;million aggregate gross proceeds from sales of common stock to Lincoln Park under the 2022 Purchase Agreement. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">On August&#160;17, 2022, a registration statement (the &#8220;First Registration Statement&#8221;) was declared effective to cover the resale of up to <ix:nonFraction name="pstv:NumberOfMaximumCommonSharesCanBeResale" contextRef="PAsOn08_17_2022_CommonStockMemberusgaapStatementEquityComponentsAxis_LincolnParkCapitalFundLLCMemberdeiLegalEntityAxis_TwoThousandAndTwentyTwoPurchaseAgreementMemberusgaapInvestmentTypeAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-23053">633,333</ix:nonFraction> shares of the Company&#8217;s common stock comprised of (i)&#160;the <ix:nonFraction name="pstv:InitialCommitmentShares" contextRef="PAsOn07_14_2022_CommonStockMemberusgaapStatementEquityComponentsAxis_LincolnParkCapitalFundLLCMemberdeiLegalEntityAxis_TwoThousandAndTwentyTwoPurchaseAgreementMemberusgaapInvestmentTypeAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-23054">32,846</ix:nonFraction> initial commitment shares, and (ii)&#160;up to <ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="PAsOn08_17_2022_CommonStockMemberusgaapStatementEquityComponentsAxis_LincolnParkCapitalFundLLCMemberdeiLegalEntityAxis_MaximumMembersrtRangeAxis_TwoThousandAndTwentyTwoPurchaseAgreementMemberusgaapInvestmentTypeAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-23055">600,486</ix:nonFraction> that the Company has reserved for issuance and sale to Lincoln Park under the 2022 Purchase Agreement from time to time from and after the date of the prospectus. The Company sold approximately <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="P08_17_2022To12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis_LincolnParkCapitalFundLLCMemberdeiLegalEntityAxis_TwentyTwentyPurchaseAgreementMemberusgaapInvestmentTypeAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-23056">527,166</ix:nonFraction> shares under the First Registration Statement. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">On August&#160;18, 2023, a second registration statement (the &#8220;Second Registration Statement&#8221;) was declared effective to cover the resale of up to an additional <ix:nonFraction name="pstv:NumberOfMaximumCommonSharesCanBeResale" contextRef="PAsOn08_18_2023_CommonStockMemberusgaapStatementEquityComponentsAxis_LincolnParkCapitalFundLLCMemberdeiLegalEntityAxis_MaximumMembersrtRangeAxis_TwoThousandAndTwentyTwoPurchaseAgreementMemberusgaapInvestmentTypeAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-23057">1,500,000</ix:nonFraction> shares of the Company&#8217;s common stock that the Company reserved for issuance and sale to Lincoln Park under the 2022 Purchase Agreement from time to time. </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><ix:exclude>F-40</ix:exclude> </div></div></ix:continuation></div></div><ix:continuation id="TextSelectionAppend_116199093_3" continuedAt="TextSelectionAppend_116199093_4"><ix:exclude><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_116199093_4" continuedAt="TextSelectionAppend_116199093_5"><ix:exclude><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/></ix:exclude></ix:continuation> <div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelectionAppend_116199093_5" continuedAt="TextSelectionAppend_116199093_6"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">We sold <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="P08_18_2023To12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis_LincolnParkCapitalFundLLCMemberdeiLegalEntityAxis_TwoThousandAndTwentyTwoPurchaseAgreementMemberusgaapInvestmentTypeAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-23059">150,000</ix:nonFraction> shares under the Second Registration Statement. The Company cannot sell more shares than registered under the Second Registration Statement under the 2022 Purchase Agreement without registering additional shares. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Actual sales of shares of common stock to Lincoln Park under the 2022 Purchase Agreement depend on a variety of factors to be determined by the Company from time to time, including, among others, market conditions, the trading price of the common stock and determinations by the Company as to the appropriate sources of funding for the Company and its operations. The net proceeds under the 2022 Purchase Agreement to the Company depend on the frequency and prices at which the Company sells shares of its stock to Lincoln Park. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">During the period from August&#160;17, 2022 to December&#160;31, 2022, the Company issued <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="P08_17_2022To12_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis_LincolnParkCapitalFundLLCMemberdeiLegalEntityAxis_TwoThousandAndTwentyTwoPurchaseAgreementMemberusgaapInvestmentTypeAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-23060">266,666</ix:nonFraction> shares under the 2022 Purchase Agreement for net proceeds of approximately $<ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="P08_17_2022To12_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis_LincolnParkCapitalFundLLCMemberdeiLegalEntityAxis_TwoThousandAndTwentyTwoPurchaseAgreementMemberusgaapInvestmentTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-23061">3.2</ix:nonFraction>&#160;million. The Company issued <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="P01_01_2023To12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis_LincolnParkCapitalFundLLCMemberdeiLegalEntityAxis_TwoThousandAndTwentyTwoPurchaseAgreementMemberusgaapInvestmentTypeAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-23062">410,500</ix:nonFraction> shares under the 2022 Purchase Agreement for net proceeds of approximately $<ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="P01_01_2023To12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis_LincolnParkCapitalFundLLCMemberdeiLegalEntityAxis_TwoThousandAndTwentyTwoPurchaseAgreementMemberusgaapInvestmentTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-23063">1.0</ix:nonFraction>&#160;million from January&#160;1, 2023 to December&#160;31, 2023. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">On September&#160;30, 2020, the Company entered into a purchase agreement (the &#8220;2020 Purchase Agreement&#8221;) and registration rights agreement pursuant to which Lincoln Park committed to purchase up to $<ix:nonFraction name="pstv:MaximumValueOfSharesToBeIssuedUnderAgreement" contextRef="PAsOn09_30_2020_CommonStockMemberusgaapStatementEquityComponentsAxis_LincolnParkCapitalFundLLCMemberdeiLegalEntityAxis_TwentyTwentyPurchaseAgreementMemberusgaapInvestmentTypeAxis" unitRef="Unit_USD" decimals="INF" scale="6" format="ixt:num-dot-decimal" id="ixv-23064">25.0</ix:nonFraction>&#160;million of the Company&#8217;s common stock. Under the terms and subject to the conditions of the 2020 Purchase Agreement, the Company had the right, but not the obligation, to sell to Lincoln Park, and Lincoln Park was obligated to purchase up to $<ix:nonFraction name="pstv:MaximumValueOfSharesToBeIssuedUnderAgreement" contextRef="PAsOn09_30_2020_CommonStockMemberusgaapStatementEquityComponentsAxis_LincolnParkCapitalFundLLCMemberdeiLegalEntityAxis_TwentyTwentyPurchaseAgreementMemberusgaapInvestmentTypeAxis" unitRef="Unit_USD" decimals="INF" scale="6" format="ixt:num-dot-decimal" id="ixv-23065">25.0</ix:nonFraction>&#160;million of the Company&#8217;s common stock. Such sales of common stock by the Company were subject to certain limitations, and could occur from time to time, at the Company&#8217;s sole discretion, over the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><ix:nonNumeric name="pstv:PeriodExercisableFromTheDateOfIssuance" contextRef="P01_01_2020To09_30_2020_CommonStockMemberusgaapStatementEquityComponentsAxis_LincolnParkCapitalFundLLCMemberdeiLegalEntityAxis_TwentyTwentyPurchaseAgreementMemberusgaapInvestmentTypeAxis" format="ixt-sec:durwordsen" id="ixv-23066">36-month</ix:nonNumeric></div> period commencing on November&#160;6, 2020, subject to the satisfaction of certain conditions. </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">During the year ended December&#160;31, 2022, the Company issued <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="P01_01_2022To12_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis_LincolnParkCapitalFundLLCMemberdeiLegalEntityAxis_TwentyTwentyPurchaseAgreementMemberusgaapInvestmentTypeAxis" unitRef="Unit_USD" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-23067">377,666</ix:nonFraction> shares of its common stock under the 2020 Purchase Agreement for net proceeds of approximately $<ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="P01_01_2022To12_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis_LincolnParkCapitalFundLLCMemberdeiLegalEntityAxis_TwentyTwentyPurchaseAgreementMemberusgaapInvestmentTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-23068">7.0</ix:nonFraction>&#160;million. The Company <ix:nonFraction name="us-gaap:SharesIssued" contextRef="PAsOn12_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis_LincolnParkCapitalFundLLCMemberdeiLegalEntityAxis_TwentyTwentyPurchaseAgreementMemberusgaapInvestmentTypeAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt-sec:numwordsen" id="ixv-23069">no</ix:nonFraction> longer has any additional shares of common stock registered to sell under the 2020 Purchase Agreement and has terminated the 2020 Purchase Agreement. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">At-the-market</div></div> Issuances </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">On September&#160;9, 2022, the Company entered into an Equity Distribution Agreement (the &#8220;September 2022 Distribution Agreement&#8221;) with Canaccord Genuity LLC (&#8220;Canaccord&#8221;), pursuant to which the Company could issue and sell, from time to time, shares of its common stock having an aggregate offering price of up to $<ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="P09_09_2022To09_09_2022_AtTheMarketOfferingProgramMemberusgaapSubsidiarySaleOfStockAxis_CanaccordGenuityLLCMemberdeiLegalEntityAxis_CommonStockMemberusgaapStatementEquityComponentsAxis_MaximumMembersrtRangeAxis_SeptemberTwoThousandAndTwentyTwoDistributionAgreementMemberusgaapInvestmentTypeAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-23070">5,000,000</ix:nonFraction>, depending on market demand, with Canaccord acting as an agent for sales. During the period from September&#160;9, 2022 to December&#160;31, 2022, the Company issued <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="P09_09_2022To12_31_2022_AtTheMarketOfferingProgramMemberusgaapSubsidiarySaleOfStockAxis_CanaccordGenuityLLCMemberdeiLegalEntityAxis_CommonStockMemberusgaapStatementEquityComponentsAxis_SeptemberTwoThousandAndTwentyTwoDistributionAgreementMemberusgaapInvestmentTypeAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-23071">68,758</ix:nonFraction> shares of its common stock under the September 2022 Distribution Agreement for net proceeds of approximately $<ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="P09_09_2022To12_31_2022_AtTheMarketOfferingProgramMemberusgaapSubsidiarySaleOfStockAxis_CanaccordGenuityLLCMemberdeiLegalEntityAxis_CommonStockMemberusgaapStatementEquityComponentsAxis_SeptemberTwoThousandAndTwentyTwoDistributionAgreementMemberusgaapInvestmentTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-23072">0.6</ix:nonFraction>&#160;million. From January&#160;1, 2023 through December&#160;31, 2023, the Company issued <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="P01_01_2023To12_31_2023_AtTheMarketOfferingProgramMemberusgaapSubsidiarySaleOfStockAxis_CanaccordGenuityLLCMemberdeiLegalEntityAxis_CommonStockMemberusgaapStatementEquityComponentsAxis_SeptemberTwoThousandAndTwentyTwoDistributionAgreementMemberusgaapInvestmentTypeAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-23073">1,819,993</ix:nonFraction> shares under the September 2022 Distribution Agreement for net proceeds of approximately $<ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="P01_01_2023To12_31_2023_AtTheMarketOfferingProgramMemberusgaapSubsidiarySaleOfStockAxis_CanaccordGenuityLLCMemberdeiLegalEntityAxis_CommonStockMemberusgaapStatementEquityComponentsAxis_SeptemberTwoThousandAndTwentyTwoDistributionAgreementMemberusgaapInvestmentTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-23074">4.3</ix:nonFraction>&#160;million. The Company has reached the capacity for sales of shares under the September 2022 Distribution Agreement and the agreement has terminated. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Company was obligated to pay Canaccord a commission of up to <ix:nonFraction name="pstv:PercentageOfCommissionOnGrossProceedsFromSaleOfCommonStock" contextRef="P09_09_2022To09_09_2022_AtTheMarketOfferingProgramMemberusgaapSubsidiarySaleOfStockAxis_CanaccordGenuityLLCMemberdeiLegalEntityAxis_CommonStockMemberusgaapStatementEquityComponentsAxis_MaximumMembersrtRangeAxis_SeptemberTwoThousandAndTwentyTwoDistributionAgreementMemberusgaapInvestmentTypeAxis" unitRef="Unit_pure" decimals="INF" scale="-2" format="ixt:num-dot-decimal" id="ixv-23075">3.0</ix:nonFraction>% of the gross proceeds from the sale of its common stock under the September 2022 Distribution Agreement. The Company also agreed to reimburse Canaccord for its reasonable documented <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">out-of-pocket</div></div> expenses, including fees and disbursements of its counsel, in the amount of $<ix:nonFraction name="pstv:AggregateExpenseIncludingFeeAndDisbursementExpenses" contextRef="P09_09_2022To09_09_2022_AtTheMarketOfferingProgramMemberusgaapSubsidiarySaleOfStockAxis_CanaccordGenuityLLCMemberdeiLegalEntityAxis_SeptemberTwoThousandAndTwentyTwoDistributionAgreementMemberusgaapInvestmentTypeAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-23076">50,000</ix:nonFraction>. In addition, the Company agreed to provide customary indemnification rights to Canaccord. </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">On January&#160;14, 2022, the Company entered into an Equity Distribution Agreement (the &#8220;January 2022 Distribution Agreement&#8221;) with Canaccord, pursuant to which the Company could issue and sell, from time to time, shares of its common stock having an aggregate offering price of up to $<ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="P01_14_2022To01_14_2022_AtTheMarketOfferingProgramMemberusgaapSubsidiarySaleOfStockAxis_CanaccordGenuityLLCMemberdeiLegalEntityAxis_CommonStockMemberusgaapStatementEquityComponentsAxis_JanuaryTwoThousandAndTwentyTwoDistributionAgreementMemberusgaapInvestmentTypeAxis_MaximumMembersrtRangeAxis" unitRef="Unit_USD" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-23077">5,000,000</ix:nonFraction>, with Canaccord acting as an agent for sales. The Company had <ix:nonFraction name="pstv:CommonStockSalesAvailableForIssuance" contextRef="PAsOn01_14_2022_AtTheMarketOfferingProgramMemberusgaapSubsidiarySaleOfStockAxis_CanaccordGenuityLLCMemberdeiLegalEntityAxis_CommonStockMemberusgaapStatementEquityComponentsAxis_JanuaryTwoThousandAndTwentyTwoDistributionAgreementMemberusgaapInvestmentTypeAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt-sec:numwordsen" id="ixv-23078">no</ix:nonFraction> obligation to sell any of the Company&#8217;s shares and it could instruct Canaccord not to sell any shares if the sales could not be effected at or above the price designated by the Company from time to time and the Company could at any time suspend sales pursuant to the January 2022 Distribution Agreement. During the year ended December&#160;31, 2022, the Company issued <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="P01_01_2022To12_31_2022_CanaccordGenuityLLCMemberdeiLegalEntityAxis_CommonStockMemberusgaapStatementEquityComponentsAxis_JanuaryTwoThousandAndTwentyTwoDistributionAgreementMemberusgaapInvestmentTypeAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-23079">460,151</ix:nonFraction> shares under </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><ix:exclude>F-41</ix:exclude> </div></div></ix:continuation></div></div><ix:continuation id="TextSelectionAppend_116199093_6" continuedAt="TextSelectionAppend_116199093_7"><ix:exclude><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_116199093_7" continuedAt="TextSelectionAppend_116199093_8"><ix:exclude><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/></ix:exclude></ix:continuation><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelectionAppend_116199093_8"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">the January 2022 Distribution Agreement for net proceeds of approximately $<ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="P01_01_2022To12_31_2022_CanaccordGenuityLLCMemberdeiLegalEntityAxis_CommonStockMemberusgaapStatementEquityComponentsAxis_JanuaryTwoThousandAndTwentyTwoDistributionAgreementMemberusgaapInvestmentTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-23081">4.8</ix:nonFraction>&#160;million. The January 2022 Distribution Agreement has been terminated after all available registered shares were fully utilized. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Share Repurchase Program and Treasury Stock </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">On October&#160;31, 2023, the Company announced that its Board has approved a share repurchase program (the &#8220;Share Repurchase Program&#8221;), with authorization to repurchase up to $<ix:nonFraction name="us-gaap:StockRepurchaseProgramAuthorizedAmount1" contextRef="PAsOn10_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis_MaximumMembersrtRangeAxis" unitRef="Unit_USD" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-23082">500,000</ix:nonFraction> of the outstanding shares of the Company&#8217;s common stock. The Company intends to fund any repurchases under the Share Repurchase Program with available cash. The timing and amount of any shares repurchased will be determined based on the Company&#8217;s evaluation of market conditions and other factors, including consent of the Company&#8217;s lender. Repurchases may be made from time to time on the open market through October&#160;31, 2024. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">During the year ended December&#160;31, 2023, the Company purchased <ix:nonFraction name="us-gaap:StockRepurchasedDuringPeriodShares" contextRef="P01_01_2023To12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-23083">78,559</ix:nonFraction> of its common shares for approximately $<ix:nonFraction name="us-gaap:TreasuryStockValue" contextRef="PAsOn12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-23084">126,000</ix:nonFraction> as treasury stock. During the period January&#160;1, 2024 through February&#160;26, 2024, the Company purchased <ix:nonFraction name="us-gaap:StockRepurchasedDuringPeriodShares" contextRef="P01_01_2024To02_26_2024_CommonStockMemberusgaapStatementEquityComponentsAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-23085">168,015</ix:nonFraction> of its common shares for approximately $<ix:nonFraction name="us-gaap:TreasuryStockValue" contextRef="PAsOn02_26_2024_CommonStockMemberusgaapStatementEquityComponentsAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-23086">340,000</ix:nonFraction> as treasury stock. </div></div></ix:continuation><ix:nonNumeric name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" contextRef="P01_01_2023To12_31_2023" escape="true" continuedAt="TextSelection_116199064" id="ixv-17318"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">13. Share-based Compensation </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Under the Company&#8217;s 2015 New Employee Incentive Plan (the &#8220;2015 Plan&#8221;), awards may only be granted to employees who were not previously an employee or director of the Company, or following a bona fide period of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">non-employment,</div> as a material inducement to entering into employment with the Company. As of December&#160;31, 2023, there were <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" contextRef="PAsOn12_31_2023_StockBasedCompensation2015EquityIncentivePlan1MemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-23087">6,024</ix:nonFraction> shares of common stock remaining and available for future issuances under the 2015 Plan. </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The Company&#8217;s 2020 Stock Incentive Plan (the &#8220;2020 Plan&#8221;), which replaced the Company&#8217;s 2014 Equity Incentive Plan, provides for the award or sale of shares of common stock (including restricted stock), the award of stock units and stock appreciation rights, and the grant of both incentive stock options to purchase common stock to directors, officers, employees and consultants of the Company. The 2020 Plan, as amended, provides for the issuance of up to <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="P01_01_2023To12_31_2023_StockBasedCompensation2020EquityIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-23088">3,550,000</ix:nonFraction> shares of common stock, plus the number of shares available for issuance is increased to the extent that awards granted under the 2020 Plan and the Company&#8217;s 2014 Equity Incentive Plan are forfeited or expire (except as otherwise provided in the 2020 Plan). As of December&#160;31, 2023, there were <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" contextRef="PAsOn12_31_2023_StockBasedCompensation2020EquityIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-23089">180,607</ix:nonFraction> shares remaining and available for future issuances under the 2020 Plan. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Generally, options issued under the 2020 Plan are subject to a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><ix:nonNumeric name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" contextRef="P01_01_2023To12_31_2023_MinimumMembersrtRangeAxis" format="ixt-sec:durwordsen" id="ixv-23090">two-year</ix:nonNumeric></div> or <ix:nonNumeric name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" contextRef="P01_01_2023To12_31_2023_MaximumMembersrtRangeAxis" format="ixt-sec:durwordsen" id="ixv-23091">four-year</ix:nonNumeric> vesting schedule with <ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-23092">25</ix:nonFraction>% of the options vesting on the one year anniversary of the grant date followed by equal monthly installment vesting, and have a contractual term of <ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" contextRef="P01_01_2023To12_31_2023" format="ixt-sec:duryear" id="ixv-23093">10</ix:nonNumeric> years. </div><ix:nonNumeric name="us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock" contextRef="P01_01_2023To12_31_2023" escape="true" id="ixv-17328"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">A summary of activity for the year ended December&#160;31, 2023 is as follows: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 92%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;">
<tr>
<td style="width: 58%;"/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Options</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Weighted</div></div><br/> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Average</div></div><br/> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Exercise<br/> Price</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Weighted</div></div><br/> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Average</div></div><br/> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Remaining</div></div><br/> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Contractual</div></div><br/> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Term<br/> (years)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Aggregate</div></div><br/> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Intrinsic<br/> Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Balance as of December&#160;31, 2022</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="PAsOn12_31_2022" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-23094">78,334</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="PAsOn12_31_2022" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-23095">68.16</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" contextRef="P01_01_2022To12_31_2022" format="ixt-sec:duryear" id="ixv-23096">8.00</ix:nonNumeric></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Granted</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-23097">68,422</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-23098">5.00</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Cancelled/forfeited</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-23099">6,647</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-23100">283.76</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Balance as of December&#160;31, 2023</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="PAsOn12_31_2023" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-23101">140,109</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="PAsOn12_31_2023" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-23102">37.48</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" contextRef="P01_01_2023To12_31_2023" format="ixt-sec:duryear" id="ixv-23103">8.07</ix:nonNumeric></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-23104">7,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Vested and expected to vest at December&#160;31, 2023</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" contextRef="PAsOn12_31_2023" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-23105">133,810</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" contextRef="PAsOn12_31_2023" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-23106">38.62</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" contextRef="P01_01_2023To12_31_2023" format="ixt-sec:duryear" id="ixv-23107">8.02</ix:nonNumeric></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Exercisable at December&#160;31, 2023</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="PAsOn12_31_2023" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-23108">72,843</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" contextRef="PAsOn12_31_2023" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-23109">60.17</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" contextRef="P01_01_2023To12_31_2023" format="ixt-sec:duryear" id="ixv-23110">7.41</ix:nonNumeric></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-23111">6,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table></ix:nonNumeric><div style="clear:both;max-height:0pt;"></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><ix:exclude>F-42</ix:exclude> </div></div></ix:nonNumeric></div></div><ix:continuation id="TextSelection_116199064" continuedAt="TextSelectionAppend_116199064_1"><ix:exclude><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_116199064_1" continuedAt="TextSelectionAppend_116199064_2"><ix:exclude><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/></ix:exclude></ix:continuation> <div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelectionAppend_116199064_2"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The Company settles exercises of stock options with newly issued shares of its common stock. There were <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt-sec:numwordsen" id="ixv-23113"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt-sec:numwordsen" id="ixv-23114">no</ix:nonFraction></ix:nonFraction> stock options exercised in 2023 or 2022. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;text-indent: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The estimated fair value of options, including the effect of estimated forfeitures, is recognized over the requisite service period, which is typically the vesting period of each option. <ix:nonNumeric name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" contextRef="P01_01_2023To12_31_2023" escape="true" continuedAt="TextSelection_116199071" id="ixv-23115">The fair value of each option awarded during the years ended December&#160;31, 2023 and 2022 was estimated on the date of grant using the Black-Scholes-Merton option valuation model based on the following weighted-average assumptions: </ix:nonNumeric></div></div><ix:continuation id="TextSelection_116199071"><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 76%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;text-indent: 0px;">
<tr>
<td style="width: 55%;"/>
<td style="width: 20%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 19%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,&#160;2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,&#160;2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Expected term</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="P01_01_2023To12_31_2023" format="ixt-sec:duryear" id="ixv-23116">6.0</ix:nonNumeric>&#160;years</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="P01_01_2022To12_31_2022" format="ixt-sec:duryear" id="ixv-23117">6.0</ix:nonNumeric>&#160;years</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Risk-free interest rate</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal" id="ixv-23118">4.06</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal" id="ixv-23119">2.83</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Expected volatility</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal" id="ixv-23120">127.0</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal" id="ixv-23121">123.4</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Dividends</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-23122">0</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-23123">0</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Resulting fair value</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-23124">4.47</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-23125">7.05</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr></table></ix:continuation><div style="clear:both;max-height:0pt;text-indent: 0px;"></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;text-indent: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The weighted average risk-free interest rate represents the interest rate for treasury constant maturity instruments published by the Federal Reserve Board. If the term of available treasury constant maturity instruments is not equal to the expected term of an employee option, the Company uses the weighted average of the two Federal Reserve securities closest to the expected term of the employee option. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;text-indent: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The dividend yield has been assumed to be <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt-sec:numwordsen" id="ixv-23126">zero</ix:nonFraction> as the Company (a)&#160;has never declared or paid any dividends and (b)&#160;does not currently anticipate paying any cash dividends on its outstanding shares of common stock in the foreseeable future. </div></div><ix:nonNumeric name="us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" contextRef="P01_01_2023To12_31_2023" escape="true" id="ixv-17755"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;text-indent: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The following table summarizes share-based compensation recognized during the years ended December&#160;31, 2023 and 2022 in the statement of operations: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 76%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;text-indent: 0px;">
<tr>
<td style="width: 82%;"/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Research and development</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="P01_01_2023To12_31_2023_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-23127">66</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="P01_01_2022To12_31_2022_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-23128">87</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">General and administrative</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="P01_01_2023To12_31_2023_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-23129">503</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="P01_01_2022To12_31_2022_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-23130">519</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Total share-based compensation</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-23131">569</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-23132">606</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table></ix:nonNumeric><div style="clear:both;max-height:0pt;text-indent: 0px;"></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;text-indent: 0px;">As of December&#160;31, 2023, the total compensation cost related to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">non-vested</div> stock options and stock awards not yet recognized for all our plans is approximately $<ix:nonFraction name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-23133">0.7</ix:nonFraction>&#160;million, which is expected to be recognized as a result of vesting under service conditions over a weighted average period of <ix:nonNumeric name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" contextRef="P01_01_2023To12_31_2023" format="ixt-sec:duryear" id="ixv-23134">1.8</ix:nonNumeric> years. </div></ix:continuation><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">F-43 </div></div></div></div>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="line-height:2.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:2.00pt solid #000000">&#160;</p> <p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p> <p style="margin-top:50pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman;font-weight:bold;text-align:center">Plus Therapeutics, Inc. </p> <p style="font-size:24pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt;margin-bottom:0pt;text-align:center">


<img src="g840996g01a00.jpg" alt="LOGO"/>
 </p> <p style="margin-top:24pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman;font-weight:bold;text-align:center">Up to 10,774,596 Shares of Common Stock </p> <p style="font-size:120pt;margin-top:0pt;margin-bottom:0pt">&#160;</p><div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">PRELIMINARY PROSPECTUS </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p><div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:120pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">&#8195;&#8195;&#8195;&#8195;, 2024 </p> <p style="font-size:50pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</p> <p style="line-height:4.5pt;margin-top:0pt;margin-bottom:2pt;border-bottom:2.00pt solid #000000">&#160;</p>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">PART II </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">INFORMATION NOT REQUIRED IN PROSPECTUS </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Item&#8201;13. Other Expenses of Issuance and Distribution. </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table sets forth an estimate of the fees and expenses payable by us in connection with the issuance and distribution of the securities being registered. All the amounts shown are estimates, except for the SEC registration fee. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto">


<tr>

<td style="width:79%"/>

<td style="vertical-align:bottom;width:6%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Amount</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SEC registration fee</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3,459.05</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounting fees and expenses</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">50,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Legal fees and expenses</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">75,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Miscellaneous fees and expenses</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">34,540.95</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">163,000.00</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td></tr>
</table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Item&#8201;14. Indemnification of Directors and Officers. </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company is a Delaware corporation. Section&#160;145(a) of the DGCL provides that a Delaware corporation may indemnify any person who was or is a party or is threatened to be made a party to any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative, other than an action by or in the right of the corporation, by reason of the fact that such person is or was a director, officer, employee or agent of the corporation, or is or was serving at the request of the corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise, against expenses (including attorneys&#8217; fees), judgments, fines and amounts paid in settlement actually and reasonably incurred by the person in connection with such action, suit or proceeding if the person acted in good faith and in a manner the person reasonably believed to be in or not opposed to the best interests of the corporation, and, with respect to any criminal action or proceeding, had no reasonable cause to believe his or her conduct was unlawful. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Section&#160;145(b) of the DGCL provides that a Delaware corporation may indemnify any person who was or is a party or is threatened to be made a party to any threatened, pending or completed action or suit by or in the right of the corporation to procure a judgment in its favor by reason of the fact that such person acted in any of the capacities set forth above, against expenses (including attorneys&#8217; fees) actually and reasonably incurred by such person in connection with the defense or settlement of such action or suit if the person acted in good faith and in a manner the person reasonably believed to be in, or not opposed to, the best interests of the corporation, except that no indemnification shall be made in respect of any claim, issue or matter as to which such person shall have been adjudged to be liable to the corporation, unless and only to the extent that the Court of Chancery or the court in which such action or suit was brought shall determine, upon application, that, despite the adjudication of liability but in view of all the circumstances of the case, such person is fairly and reasonably entitled to indemnity for such expenses which the court shall deem proper. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Further subsections of DGCL Section&#160;145 provide that: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(1)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">to the extent a present or former director or officer of a corporation has been successful on the merits or otherwise in the defense of any action, suit or proceeding referred to in subsections (i)&#160;and (ii) of Section&#160;145 or in the defense of any claim, issue or matter therein, such person shall be indemnified against expenses, including attorneys&#8217; fees, actually and reasonably incurred by such person in connection therewith; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(2)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">the indemnification and advancement of expenses provided for pursuant to Section&#160;145 shall not be deemed exclusive of any other rights to which those seeking indemnification or advancement of expenses may be entitled under any bylaw, agreement, vote of shareholders or disinterested directors or otherwise; and </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">II-1 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(3)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">the corporation shall have the power to purchase and maintain insurance of behalf of any person who is or was a director, officer, employee or agent of the corporation, or is or was serving at the request of the corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise, against any liability asserted against such person and incurred by such person in any such capacity, or arising out of such person&#8217;s status as such, whether or not the corporation would have the power to indemnify such person against such liability under Section&#160;145. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As used in this Item 14, the term &#8220;proceeding&#8221; means any threatened, pending or completed action, suit or proceeding, whether or not by or in the right of the Company, and whether civil, criminal, administrative, investigative or otherwise. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Section&#160;145 of the DGCL makes provision for the indemnification of officers and directors in terms sufficiently broad to indemnify officers and directors of the Company under certain circumstances from liabilities (including reimbursement for expenses incurred) arising under the&#160;Securities Act. The Company&#8217;s organizational documents provide, in effect, that, to the fullest extent and under the circumstances permitted by Section&#160;145 of the DGCL, the Company will indemnify any and all of its officers and directors. The Company has entered into indemnification agreements with its officers and directors. The Company may, in its discretion, similarly indemnify its employees and agents. The Company&#8217;s Charter also relieves its directors from monetary damages to the Company or its stockholders for breach of such director&#8217;s fiduciary duty as a director to the fullest extent permitted by the DGCL. Under Section&#160;102(b)(7) of the DGCL, a corporation may relieve its directors from personal liability to such corporation or its stockholders for monetary damages for any breach of their fiduciary duty as directors except (i)&#160;for a breach of the duty of loyalty, (ii)&#160;for failure to act in good faith, (iii)&#160;for intentional misconduct or knowing violation of law, (iv)&#160;for willful or negligent violations of certain provisions in the DGCL imposing certain requirements with respect to stock repurchases, redemptions and dividends or (v)&#160;for any transactions from which the director derived an improper personal benefit. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company has purchased insurance policies that, within the limits and subject to the terms and conditions thereof, cover certain expenses and liabilities that may be incurred by directors and officers in connection with proceedings that may be brought against them as a result of an act or omission committed or suffered while acting as a director or officer of the Company. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have entered into a registration rights agreement with the stockholders of the shares of common stock registered hereby which obligates the parties to indemnify, under certain circumstances, the other party, its officers, directors, and controlling persons within the meaning of the Securities Act against certain liabilities. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Item&#8201;15. Recent Sales of Unregistered Securities. </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In May 2024, we sold (i)&#160;an aggregate of 1,439,988 shares of common stock, (ii)&#160;up to 2,151,544<span style="font-weight:bold"> </span>shares of common stock issuable upon exercise of the <span style="white-space:nowrap">Pre-Funded</span> Warrants, (iii)&#160;up to 3,591,532<span style="font-weight:bold"> </span>shares of common stock issuable upon exercise of the Series A Common Stock Warrants, and (iv)&#160;up to 3,591,532<span style="font-weight:bold"> </span>shares of common stock issuable upon exercise of the Series B Common Stock Warrants. The combined purchase price for each Private Placement Share and <span style="white-space:nowrap">Pre-Funded</span> Warrant from the Initial Subscription was $2.022, and $2.158 from the Additional Subscription, in each case together with one accompanying Series A Common Stock Warrant and one accompanying Series B Common Stock Warrant, provided, that the Company Insiders participated in the Initial Subscription at an offering price of $2.04 per Private Placement Share and accompanying Series A Common Stock Warrant and Series B Common Stock Warrant. The aggregate gross proceeds from the May 2024 PIPE Financing were approximately $7.25&#160;million, before deducting certain expenses payable by the Company, and excluding the proceeds, if any, from the exercise of the Series A Common Stock Warrant, the Series B Common Stock Warrant, and <span style="white-space:nowrap">Pre-Funded</span> Warrant. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">No underwriters were involved in the foregoing issuances of the securities sold in the May 2024 PIPE Financing. The securities described in this section (a)&#160;of&#160;Item 15 were sold and issued to the Purchasers&#160;in reliance upon the </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">II-2 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
exemption from the registration requirements of the&#160;Securities Act, as set forth in Section&#160;4(a)(2) under the Securities Act and&#160;Regulation D&#160;promulgated thereunder relative to transactions by an issuer not involving any public offering, to the extent an exemption from such registration was required. All of the Purchasers in the May 2024 PIPE Financing represented that they were accredited investors and were acquiring the securities for their own account for investment purposes only and not with a view to, or for sale in connection with, any distribution thereof and that they could bear the risks of the investment and could hold the securities for an indefinite period of time and appropriate legends were affixed to the instruments representing such securities issued in the May 2024 PIPE Financing. All Purchasers either received adequate information about us or had access, through employment or other relationships, to such information. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Item&#8201;16. Exhibits. </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A list of exhibits filed with this registration statement on <span style="white-space:nowrap">Form&#160;S-1&#160;is</span> set forth on the Exhibit Index and is incorporated herein by reference. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td/>

<td style="vertical-align:bottom;width:3%"/>
<td style="width:58%"/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="14" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Incorporated by Reference</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap"><span style="font-weight:bold">Exhibit<br/>Number</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Description</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Form</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">File Number</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Exhibit</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Filing Date</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="4"/>
<td style="height:6pt" colspan="4"/>
<td style="height:6pt" colspan="4"/>
<td style="height:6pt" colspan="4"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;3.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/0001095981/000114036116057505/ex3_1.htm">Composite Certificate of Incorporation. </a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right"><span style="white-space:nowrap">10-K</span></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right"><span style="white-space:nowrap">001-34375</span></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">3.1</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">03/11/2016</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="4"/>
<td style="height:6pt" colspan="4"/>
<td style="height:6pt" colspan="4"/>
<td style="height:6pt" colspan="4"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;3.2</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/0001095981/000109598116000063/ex3_1.htm">Certificate of Amendment to Amended and Restated Certificate. </a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right"><span style="white-space:nowrap">8-K</span></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right"><span style="white-space:nowrap">001-34375</span></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">3.1</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">05/10/2016</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="4"/>
<td style="height:6pt" colspan="4"/>
<td style="height:6pt" colspan="4"/>
<td style="height:6pt" colspan="4"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;3.3</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/0001095981/000156459018014245/cytx-ex31_6.htm">Certificate of Amendment to Amended and Restated Certificate. </a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right"><span style="white-space:nowrap">8-K</span></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right"><span style="white-space:nowrap">001-34375</span></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">3.1</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">05/23/2018</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="4"/>
<td style="height:6pt" colspan="4"/>
<td style="height:6pt" colspan="4"/>
<td style="height:6pt" colspan="4"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;3.4</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1095981/000156459019026454/cytx-ex31_6.htm">Certificate of Amendment to Amended and Restated Certificate. </a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right"><span style="white-space:nowrap">8-K</span></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right"><span style="white-space:nowrap">001-34375</span></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">3.1</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">07/29/2019</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="4"/>
<td style="height:6pt" colspan="4"/>
<td style="height:6pt" colspan="4"/>
<td style="height:6pt" colspan="4"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;3.5</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/0001095981/000156459019028996/pstv-ex31_18.htm">Certificate of Amendment to Amended and Restated Certificate. </a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right"><span style="white-space:nowrap">8-K</span></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right"><span style="white-space:nowrap">001-34375</span></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">3.1</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">08/06/2019</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="4"/>
<td style="height:6pt" colspan="4"/>
<td style="height:6pt" colspan="4"/>
<td style="height:6pt" colspan="4"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;3.6</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/0001095981/000119312523127227/d475493dex31.htm">Certificate of Amendment to Amended and Restated Certificate. </a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right"><span style="white-space:nowrap">8-K</span></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right"><span style="white-space:nowrap">001-34375</span></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">3.1</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">04/28/2023</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="4"/>
<td style="height:6pt" colspan="4"/>
<td style="height:6pt" colspan="4"/>
<td style="height:6pt" colspan="4"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;3.7</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/0001095981/000119312521277718/d164672dex31.htm">Amended and Restated Bylaws of Plus Therapeutics, Inc.</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right"><span style="white-space:nowrap">8-K</span></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right"><span style="white-space:nowrap">001-34375</span></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">3.1</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">09/21/2021</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="4"/>
<td style="height:6pt" colspan="4"/>
<td style="height:6pt" colspan="4"/>
<td style="height:6pt" colspan="4"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;3.8</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1095981/000156459017024297/cytx-ex31_6.htm">Certificate of Designation of Preferences, Rights and Limitations of Series B Convertible Preferred Stock. </a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right"><span style="white-space:nowrap">8-K</span></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right"><span style="white-space:nowrap">001-34375</span></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">3.1</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">11/28/2017</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="4"/>
<td style="height:6pt" colspan="4"/>
<td style="height:6pt" colspan="4"/>
<td style="height:6pt" colspan="4"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;3.9</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1095981/000156459018017443/cytx-ex31_7.htm">Certificate of Designation of Preferences, Rights and Limitations of Series C Convertible Preferred Stock. </a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right"><span style="white-space:nowrap">8-K</span></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right"><span style="white-space:nowrap">001-34375</span></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">3.1</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">07/25/2018</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="4"/>
<td style="height:6pt" colspan="4"/>
<td style="height:6pt" colspan="4"/>
<td style="height:6pt" colspan="4"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;3.10</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1095981/000119312523060090/d449434dex31.htm">Certificate of Designation of Series F Preferred Stock. </a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right"><span style="white-space:nowrap">8-K</span></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right"><span style="white-space:nowrap">001-34375</span></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">3.1</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">03/03/2023</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="4"/>
<td style="height:6pt" colspan="4"/>
<td style="height:6pt" colspan="4"/>
<td style="height:6pt" colspan="4"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;4.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1095981/000156459018005136/cytx-ex433_277.htm">Form of Common Stock Certificate. </a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right"><span style="white-space:nowrap">10-K</span></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right"><span style="white-space:nowrap">001-34375</span></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">4.33</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">03/09/2018</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="4"/>
<td style="height:6pt" colspan="4"/>
<td style="height:6pt" colspan="4"/>
<td style="height:6pt" colspan="4"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;4.2</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1095981/000156459019034798/pstv-ex437_7.htm">Form of Series U Warrant. </a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right"><span style="white-space:nowrap">S-1/A</span></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right"><span style="white-space:nowrap">333-229485</span></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">4.37</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">09/16/2019</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="4"/>
<td style="height:6pt" colspan="4"/>
<td style="height:6pt" colspan="4"/>
<td style="height:6pt" colspan="4"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;4.3</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1095981/000156459020018034/pstv-ex41_6.htm">Form of Warrant Amendment Agreement. </a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right"><span style="white-space:nowrap">8-K</span></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right"><span style="white-space:nowrap">001-34375</span></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">4.1</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">04/23/2020</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="4"/>
<td style="height:6pt" colspan="4"/>
<td style="height:6pt" colspan="4"/>
<td style="height:6pt" colspan="4"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;4.4</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1095981/000156459020045822/pstv-ex41_6.htm">Form of Underwriters&#8217; Warrant Amendment Agreement</a>.</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right"><span style="white-space:nowrap">8-K</span></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right"><span style="white-space:nowrap">001-34375</span></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">4.1</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">10/05/2020</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="4"/>
<td style="height:6pt" colspan="4"/>
<td style="height:6pt" colspan="4"/>
<td style="height:6pt" colspan="4"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;4.5</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/0001095981/000119312524135399/d827838dex41.htm">Form of <span style="white-space:nowrap">Pre-Funded</span> Warrant. </a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right"><span style="white-space:nowrap">8-K</span></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right"><span style="white-space:nowrap">001-34375</span></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">4.1</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">05/09/2024</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="4"/>
<td style="height:6pt" colspan="4"/>
<td style="height:6pt" colspan="4"/>
<td style="height:6pt" colspan="4"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;4.6</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/0001095981/000119312524135399/d827838dex42.htm">Form of Series A Common Warrant</a>.</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right"><span style="white-space:nowrap">8-K</span></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right"><span style="white-space:nowrap">001-34375</span></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">4.2</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">05/09/2024</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="4"/>
<td style="height:6pt" colspan="4"/>
<td style="height:6pt" colspan="4"/>
<td style="height:6pt" colspan="4"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;4.7</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/0001095981/000119312524135399/d827838dex43.htm">Form of Series B Common Warrant</a>.</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right"><span style="white-space:nowrap">8-K</span></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right"><span style="white-space:nowrap">001-34375</span></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">4.3</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">05/09/2024</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">II-3 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td/>

<td style="vertical-align:bottom;width:2%"/>
<td style="width:58%"/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/></tr>

<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="14" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Incorporated by Reference</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap"><span style="font-weight:bold">Exhibit<br/>Number</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Description</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Form</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">File Number</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Exhibit</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Filing Date</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="4"/>
<td style="height:6pt" colspan="4"/>
<td style="height:6pt" colspan="4"/>
<td style="height:6pt" colspan="4"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;5.1*</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d840996dex51.htm">Opinion of Hogan Lovells US LLP. </a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="4"/>
<td style="height:6pt" colspan="4"/>
<td style="height:6pt" colspan="4"/>
<td style="height:6pt" colspan="4"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">10.1+</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/0001095981/000156459020013839/pstv-ex101_34.htm">Patent and <span style="white-space:nowrap">Know-How</span> License Agreement, dated March&#160;29, 2020, by and between Plus Therapeutics, Inc. and NanoTx, Corp</a>.</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right"><span style="white-space:nowrap">8-K</span></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right"><span style="white-space:nowrap">001-34375</span></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">10.1</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">03/30/2020</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="4"/>
<td style="height:6pt" colspan="4"/>
<td style="height:6pt" colspan="4"/>
<td style="height:6pt" colspan="4"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">10.2+</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1095981/000156459022006708/pstv-ex102_69.htm">Patent&#160;&amp; Technology License Agreement, dated December&#160;31, 2021, by and between Plus Therapeutics, Inc. and the University of Texas Health Science Center at San Antonio</a>.</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right"><span style="white-space:nowrap">10-K</span></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right"><span style="white-space:nowrap">001-34375</span></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">10.2</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">02/24/2022</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="4"/>
<td style="height:6pt" colspan="4"/>
<td style="height:6pt" colspan="4"/>
<td style="height:6pt" colspan="4"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">10.3</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1095981/000119312522242028/d359404dex11.htm">Equity Distribution Agreement, dated September&#160;9, 2022, by and between Plus Therapeutics, Inc. and Canaccord Genuity LLC.</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right"><span style="white-space:nowrap">8-K</span></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right"><span style="white-space:nowrap">001-34375</span></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">1.1</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">09/09/2022</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="4"/>
<td style="height:6pt" colspan="4"/>
<td style="height:6pt" colspan="4"/>
<td style="height:6pt" colspan="4"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">10.4</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1095981/000119312522215050/d345162dex101.htm">Purchase Agreement, dated August&#160;2, 2022, by and between Lincoln Park Capital Fund, LLC and Plus Therapeutics, Inc.</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right"><span style="white-space:nowrap">8-K</span></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right"><span style="white-space:nowrap">001-34375</span></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">10.1</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">08/08/2022</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="4"/>
<td style="height:6pt" colspan="4"/>
<td style="height:6pt" colspan="4"/>
<td style="height:6pt" colspan="4"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">10.5</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1095981/000119312522215050/d345162dex102.htm">Registration Rights Agreement, dated August&#160;2, 2022, by and between Plus Therapeutics, Inc. and Lincoln Park Capital Fund</a>.</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right"><span style="white-space:nowrap">8-K</span></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right"><span style="white-space:nowrap">001-34375</span></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">10.2</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">08/08/2022</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="4"/>
<td style="height:6pt" colspan="4"/>
<td style="height:6pt" colspan="4"/>
<td style="height:6pt" colspan="4"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">10.6</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/0001095981/000119312524154380/d840235dex101.htm">LoanAdvance Lending Agreement, dated <span style="text-decoration:underline"></span>April&#160;5, 2024, by and between Plus Therapeutics, Inc. and Pershing LLC</a>.</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right"><span style="white-space:nowrap">8-K</span></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right"><span style="white-space:nowrap">001-34375</span></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">10.1</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">06/04/2024</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="4"/>
<td style="height:6pt" colspan="4"/>
<td style="height:6pt" colspan="4"/>
<td style="height:6pt" colspan="4"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">10.7</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/0001095981/000119312524154380/d840235dex102.htm">LoanAdvance Interest Rate Form, dated May<span style="text-decoration:underline"></span>&#160;24, 2024, by and between Plus Therapeutics, Inc. and Pershing LLC</a>.</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right"><span style="white-space:nowrap">8-K</span></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right"><span style="white-space:nowrap">001-34375</span></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">10.2</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">06/04/2024</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="4"/>
<td style="height:6pt" colspan="4"/>
<td style="height:6pt" colspan="4"/>
<td style="height:6pt" colspan="4"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">10.8</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/0001095981/000119312524154380/d840235dex103.htm">Extension of Credit, dated May<span style="text-decoration:underline"></span>&#160;29, 2024, by and between Plus Therapeutics, Inc. and Pershing LLC</a>.</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right"><span style="white-space:nowrap">8-K</span></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right"><span style="white-space:nowrap">001-34375</span></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">10.3</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">06/04/2024</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="4"/>
<td style="height:6pt" colspan="4"/>
<td style="height:6pt" colspan="4"/>
<td style="height:6pt" colspan="4"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">10.9#</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1095981/000156459020025453/pstv-ex106_107.htm">Amended and Restated Employment Agreement, dated March&#160;11, 2020, by and between Marc Hedrick and Plus Therapeutics, Inc.&#160;</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right"><span style="white-space:nowrap">10-Q</span></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right"><span style="white-space:nowrap">001-34375</span></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">10.6</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">05/16/2020</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="4"/>
<td style="height:6pt" colspan="4"/>
<td style="height:6pt" colspan="4"/>
<td style="height:6pt" colspan="4"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">10.10#</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1095981/000156459020025453/pstv-ex107_106.htm">Amended and Restated Employment Agreement, dated March&#160;11, 2020, by and between Andrew Sims and Plus Therapeutics, Inc.&#160;</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right"><span style="white-space:nowrap">10-Q</span></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right"><span style="white-space:nowrap">001-34375</span></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">10.7</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">05/16/2020</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="4"/>
<td style="height:6pt" colspan="4"/>
<td style="height:6pt" colspan="4"/>
<td style="height:6pt" colspan="4"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">10.11#</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/0001095981/000119312521270847/d151447dex101.htm">Employment Agreement, dated December&#160;8, 2021, by and between Plus Therapeutics, Inc. and Norman LaFrance</a>.</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right"><span style="white-space:nowrap">8-K</span></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right"><span style="white-space:nowrap">001-34375</span></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">10.1</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">09/13/2021</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="4"/>
<td style="height:6pt" colspan="4"/>
<td style="height:6pt" colspan="4"/>
<td style="height:6pt" colspan="4"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">10.12#</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1095981/000109598116000038/ex10_1.htm">2015 New Employee Incentive Plan. </a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right"><span style="white-space:nowrap">8-K</span></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right"><span style="white-space:nowrap">001-34375</span></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">10.1</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">01/05/2016</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="4"/>
<td style="height:6pt" colspan="4"/>
<td style="height:6pt" colspan="4"/>
<td style="height:6pt" colspan="4"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">10.13#</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1095981/000156459017005251/cytx-ex1042_653.htm">First Amendment to the Plus Therapeutics, Inc. 2015 New Employee Incentive Plan, dated January&#160;26, 2017</a>. New Employee Incentive Plan</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right"><span style="white-space:nowrap">10-K</span></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right"><span style="white-space:nowrap">001-34375</span></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">10.42</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">03/24/2017</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="4"/>
<td style="height:6pt" colspan="4"/>
<td style="height:6pt" colspan="4"/>
<td style="height:6pt" colspan="4"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">10.14#</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1095981/000156459020014165/pstv-ex1025_203.htm">Second Amendment to the Plus Therapeutics, Inc. 2015 New Employee Incentive Plan, dated February&#160;6, 2020.</a> New Employee Incentive Plan</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right"><span style="white-space:nowrap">10-K</span></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right"><span style="white-space:nowrap">001-34375</span></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">10.25</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">03/30/2020</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="4"/>
<td style="height:6pt" colspan="4"/>
<td style="height:6pt" colspan="4"/>
<td style="height:6pt" colspan="4"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">10.15*</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d840996dex1015.htm">Third Amendment to The Plus Therapeutics, Inc. 2015 New Employee Incentive Plan </a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">II-4 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td/>

<td style="vertical-align:bottom;width:2%"/>
<td style="width:56%"/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/></tr>

<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="14" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Incorporated by Reference</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap"><span style="font-weight:bold">Exhibit<br/>Number</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Description</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Form</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">File Number</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Exhibit</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Filing Date</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="4"/>
<td style="height:6pt" colspan="4"/>
<td style="height:6pt" colspan="4"/>
<td style="height:6pt" colspan="4"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">10.16#</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1095981/000109598116000054/formofnotice.htm">Form of Notice of Grant of Stock Option under the 2015 New Employee Incentive Plan. </a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right"><span style="white-space:nowrap">S-8</span></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right"><span style="white-space:nowrap">333-210211</span></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">99.5</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">03/15/2016</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="4"/>
<td style="height:6pt" colspan="4"/>
<td style="height:6pt" colspan="4"/>
<td style="height:6pt" colspan="4"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">10.17#</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1095981/000109598116000054/formofstock.htm">Form of Stock Option Agreement under the 2015 New Employee Incentive Plan. </a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right"><span style="white-space:nowrap">S-8</span></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right"><span style="white-space:nowrap">333-210211</span></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">99.4</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">03/15/2016</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="4"/>
<td style="height:6pt" colspan="4"/>
<td style="height:6pt" colspan="4"/>
<td style="height:6pt" colspan="4"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">10.18#</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/0001095981/000119312521167126/d147807dex101.htm">Plus Therapeutics, Inc. 2020 Stock Incentive Plan, as amended and restated. </a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right"><span style="white-space:nowrap">8-K</span></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right"><span style="white-space:nowrap">001-34375</span></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">10.1</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">05/17/2021</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="4"/>
<td style="height:6pt" colspan="4"/>
<td style="height:6pt" colspan="4"/>
<td style="height:6pt" colspan="4"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">10.19#</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1095981/000156459022006708/pstv-ex1026_110.htm">Form of Notice of Grant and Stock Option Agreement under the 2020 Stock Incentive Plan.&#160;</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right"><span style="white-space:nowrap">10-K</span></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right"><span style="white-space:nowrap">001-34375</span></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">10.26</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">02/24/2022</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="4"/>
<td style="height:6pt" colspan="4"/>
<td style="height:6pt" colspan="4"/>
<td style="height:6pt" colspan="4"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">10.20+</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1095981/000156459021007165/pstv-ex1024_87.htm">Master Services Agreement, dated January&#160;24, 2021, by and between Piramal Pharma Solutions, Inc. and Plus Therapeutics, Inc.&#160;</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right"><span style="white-space:nowrap">10-K</span></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right"><span style="white-space:nowrap">001-34275</span></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">10.24</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">02/22/2021</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="4"/>
<td style="height:6pt" colspan="4"/>
<td style="height:6pt" colspan="4"/>
<td style="height:6pt" colspan="4"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">10.21#</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1095981/000156459020003735/pstv-ex101_6.htm">Form of Indemnification Agreement. </a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right"><span style="white-space:nowrap">8-K</span></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right"><span style="white-space:nowrap">001-34375</span></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">10.1</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">02/06/2020</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="4"/>
<td style="height:6pt" colspan="4"/>
<td style="height:6pt" colspan="4"/>
<td style="height:6pt" colspan="4"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">10.22#</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1095981/000114036116057505/ex10_113.htm">Form of Agreement for Acceleration and/or Severance. </a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right"><span style="white-space:nowrap">10-K</span></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right"><span style="white-space:nowrap">001-34375</span></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">10.113</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">03/11/2016</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="4"/>
<td style="height:6pt" colspan="4"/>
<td style="height:6pt" colspan="4"/>
<td style="height:6pt" colspan="4"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">10.23</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1095981/000156459022015075/pstv-ex101_152.htm">Medidata Services Agreement and Statement of Work, dated November&#160;5, 2021, by and between Medidata Solutions, Inc. and Plus Therapeutics, Inc.&#160;</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right"><span style="white-space:nowrap">10-Q</span></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right"><span style="white-space:nowrap">001-34375</span></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">10.1</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">04/21/2022</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="4"/>
<td style="height:6pt" colspan="4"/>
<td style="height:6pt" colspan="4"/>
<td style="height:6pt" colspan="4"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">10.24</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1095981/000119312522248711/d322153dex101.htm">Cancer Research Grant Contract, effective August&#160;31, 2022, by and between the Cancer Prevention and Research Institute of Texas and Plus Therapeutics, Inc</a>.</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right"><span style="white-space:nowrap">8-K</span></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right"><span style="white-space:nowrap">001-34375</span></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">10.1</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">09/22/2022</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="4"/>
<td style="height:6pt" colspan="4"/>
<td style="height:6pt" colspan="4"/>
<td style="height:6pt" colspan="4"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">10.25</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1095981/000119312523060090/d449434dex101.htm">Subscription and Investment Representation Agreement, dated March&#160;3, 2023, by and between Plus Therapeutics, Inc. and the purchaser signatory thereto</a>.</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right"><span style="white-space:nowrap">8-K</span></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right"><span style="white-space:nowrap">001-34375</span></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">10.1</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">03/03/2023</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="4"/>
<td style="height:6pt" colspan="4"/>
<td style="height:6pt" colspan="4"/>
<td style="height:6pt" colspan="4"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">10.26#</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1095981/000095017023013745/pstv-ex10_1.htm">Plus Therapeutics, Inc. 2020 Stock Incentive Plan, as further amended and restated</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right"><span style="white-space:nowrap">8-K</span></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right"><span style="white-space:nowrap">001-34375</span></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">10.1</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">04/20/2023</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="4"/>
<td style="height:6pt" colspan="4"/>
<td style="height:6pt" colspan="4"/>
<td style="height:6pt" colspan="4"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">10.27</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1095981/000095017023042363/pstv-ex10_2.htm">Tenth Amendment to Loan and Security Agreement</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right"><span style="white-space:nowrap">10-Q</span></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right"><span style="white-space:nowrap">001-34375</span></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">10.2</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">08/14/2023</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="4"/>
<td style="height:6pt" colspan="4"/>
<td style="height:6pt" colspan="4"/>
<td style="height:6pt" colspan="4"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">10.28</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/0001095981/000119312524135399/d827838dex101.htm">Securities Purchase Agreement, dated as of May&#160;5, 2024, by and among Plus Therapeutics,&#160;Inc. and the purchasers named therein</a>.</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right"><span style="white-space:nowrap">8-K</span></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right"><span style="white-space:nowrap">001-34375</span></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">10.1</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">05/09/2024</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="4"/>
<td style="height:6pt" colspan="4"/>
<td style="height:6pt" colspan="4"/>
<td style="height:6pt" colspan="4"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">10.29</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/0001095981/000119312524135399/d827838dex102.htm">First Amendment to Securities Purchase Agreement, dated as of May&#160;8, 2024, by and among Plus Therapeutics, Inc. and the purchasers named therein</a>.</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right"><span style="white-space:nowrap">8-K</span></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right"><span style="white-space:nowrap">001-34375</span></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">10.2</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">05/09/2024</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="4"/>
<td style="height:6pt" colspan="4"/>
<td style="height:6pt" colspan="4"/>
<td style="height:6pt" colspan="4"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">10.30</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1095981/000119312524135399/d827838dex103.htm">Registration Rights Agreement, dated as of May<span style="text-decoration:underline"></span>&#160;5, 2024, by and among Plus Therapeutics, Inc., and the purchases named therein. </a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right"><span style="white-space:nowrap">8-K</span></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right"><span style="white-space:nowrap">001-34375</span></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">10.3</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">05/09/2024</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="4"/>
<td style="height:6pt" colspan="4"/>
<td style="height:6pt" colspan="4"/>
<td style="height:6pt" colspan="4"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">23.1*</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d840996dex231.htm">Consent of Independent Registered Public Accounting Firm. </a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="4"/>
<td style="height:6pt" colspan="4"/>
<td style="height:6pt" colspan="4"/>
<td style="height:6pt" colspan="4"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">23.2*</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d840996dex51.htm">Consent of Hogan Lovells US LLP (included in Exhibit 5.1 hereto). </a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="4"/>
<td style="height:6pt" colspan="4"/>
<td style="height:6pt" colspan="4"/>
<td style="height:6pt" colspan="4"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">24.1*</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d840996ds1.htm#sig">Power of Attorney (included on the signature page hereto). </a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">II-5 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td/>

<td style="vertical-align:bottom;width:8%"/>
<td style="width:56%"/>

<td style="vertical-align:bottom;width:7%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:7%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:7%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:7%"/>
<td/>
<td/>
<td/></tr>

<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="14" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Incorporated by Reference</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap"><span style="font-weight:bold">Exhibit<br/>Number</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Description</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Form</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">File&#160;Number</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Exhibit</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Filing&#160;Date</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="4"/>
<td style="height:6pt" colspan="4"/>
<td style="height:6pt" colspan="4"/>
<td style="height:6pt" colspan="4"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">101.INS*</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Inline XBRL Instance Document</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="4"/>
<td style="height:6pt" colspan="4"/>
<td style="height:6pt" colspan="4"/>
<td style="height:6pt" colspan="4"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">101.SCH*</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Inline XBRL Taxonomy Extension Schema Document</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="4"/>
<td style="height:6pt" colspan="4"/>
<td style="height:6pt" colspan="4"/>
<td style="height:6pt" colspan="4"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">101.CAL*</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Inline XBRL Taxonomy Extension Calculation Linkbase Document</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="4"/>
<td style="height:6pt" colspan="4"/>
<td style="height:6pt" colspan="4"/>
<td style="height:6pt" colspan="4"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">101.DEF*</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Inline XBRL Taxonomy Extension Definition Linkbase Document</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="4"/>
<td style="height:6pt" colspan="4"/>
<td style="height:6pt" colspan="4"/>
<td style="height:6pt" colspan="4"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">101.LAB*</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Inline XBRL Taxonomy Extension Label Linkbase Document</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="4"/>
<td style="height:6pt" colspan="4"/>
<td style="height:6pt" colspan="4"/>
<td style="height:6pt" colspan="4"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">101.PRE*</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Inline XBRL Taxonomy Extension Presentation Linkbase Document</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="4"/>
<td style="height:6pt" colspan="4"/>
<td style="height:6pt" colspan="4"/>
<td style="height:6pt" colspan="4"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">104*</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Cover Page Interactive Data File (foirmatted as Inline XBRL and contained in Exhibit 101)</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="4"/>
<td style="height:6pt" colspan="4"/>
<td style="height:6pt" colspan="4"/>
<td style="height:6pt" colspan="4"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">107*</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d840996dexfilingfees.htm">Filing Fee Table. </a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
</table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">*</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Filed herewith </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">#</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Indicates management contract or compensatory plan or arrangement. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">+</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Portions of this exhibit have been redacted pursuant to Item 601(b)(10)(iv). </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Item&#8201;17. Undertakings </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(a)&#160;The undersigned registrant hereby undertakes: </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(1) To file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">(i)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">to include any prospectus required by Section&#160;10(a)(3) of the Securities Act; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">(ii)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">to reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the SEC pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than 20% change in the maximum aggregate offering price set forth in the &#8220;Calculation of Registration Fee&#8221; table in the effective registration statement; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">(iii)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">to include any material information with respect to the plan of distribution not previously disclosed in the registration statement or any material change to such information in the registration statement; </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">provided, however</span>, that Paragraphs (a)(1)(i), (a)(1)(ii), and (1)(a)(iii) of this section do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the SEC by the registrant pursuant to Section&#160;13 or Section&#160;15(d) of the Securities Exchange Act that are incorporated by reference in the registration statement, or is contained in a form of prospectus filed pursuant to Rule 424(b) that is part of the registration statement. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(2) That, for the purpose of determining any liability under the&#160;Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof; </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">II-6 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(3) To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering; </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(4) That, for the purpose of determining liability under the&#160;Securities Act to any purchaser: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">(i)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Each prospectus filed by the registrant pursuant to Rule 424(b)(3) shall be deemed to be part of the registration statement as of the date the filed prospectus was deemed part of and included in the registration statement; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">(ii)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Each prospectus required to be filed pursuant to Rule 424(b)(2), (b)(5), or (b)(7) as part of a registration statement in reliance on Rule 430B relating to an offering made pursuant to Rule 415(a)(1)(i), (vii), or (x)&#160;for the purpose of providing the information required by Section&#160;10(a) of the Securities Act shall be deemed to be part of and included in the registration statement as of the earlier of the date such form of prospectus is first used after effectiveness or the date of the first contract of sale of securities in the offering described in the prospectus. As provided in Rule 430B, for liability purposes of the issuer and any person that is at that date an underwriter, such date shall be deemed to be a new effective date of the registration statement relating to the securities in the registration statement to which that prospectus relates, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.<span style="font-style:italic">&#160;Provided</span>,<span style="font-style:italic">&#160;however</span>, that no statement made in a registration statement or prospectus that is part of the registration statement or made in a document incorporated or deemed incorporated by reference into the registration statement or prospectus that is part of the registration statement will, as to a purchaser with a time of contract of sale prior to such effective date, supersede or modify any statement that was made in the registration statement or prospectus that was part of the registration statement or made in any such document immediately prior to such effective date. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(5) That, for the purpose of determining liability of the registrant under the&#160;Securities Act of to any purchaser in the initial distribution of the securities: The undersigned registrant undertakes that in a primary offering of securities of the undersigned registrant pursuant to this registration statement, regardless of the underwriting method used to sell the securities to the purchaser, if the securities are offered or sold to such purchaser by means of any of the following communications, the undersigned registrant will be a seller to the purchaser and will be considered to offer or sell such securities to such purchaser: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">(i)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Any preliminary prospectus or prospectus of the undersigned registrant relating to the offering required to be filed pursuant to Rule 424; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">(ii)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Any free writing prospectus relating to the offering prepared by or on behalf of the undersigned registrant or used or referred to by the undersigned registrant; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">(iii)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">The portion of any other free writing prospectus relating to the offering containing material information about the undersigned registrant or its securities provided by or on behalf of the undersigned registrant; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">(iv)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Any other communication that is an offer in the offering made by the undersigned registrant to the purchaser. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(b) Insofar as indemnification for liabilities arising under the&#160;Securities Act, as amended, may be permitted to directors, officers and controlling persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the SEC such indemnification is against public policy as expressed in the&#160;Securities Act&#160;and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the&#160;Securities Act&#160;and will be governed by the final adjudication of such issue. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">II-7 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="sig">SIGNATURES </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form <span style="white-space:nowrap">S-1</span> and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Austin, State of Texas, on June&#160;7, 2024. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:40%;border:0">


<tr>

<td style="width:7%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:92%"/></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom" colspan="3"><span style="font-weight:bold">PLUS THERAPEUTICS, INC.</span></td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"/>
<td style="height:12pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom">By:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/<small style="font-weight:inherit;font-style:unset;text-decoration:unset">S</small>/ M<small style="font-weight:inherit;font-style:unset;text-decoration:unset">ARC</small> H. H<small style="font-weight:inherit;font-style:unset;text-decoration:unset">EDRICK</small>, M.D.</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">Marc H. Hedrick, M.D.</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">President and Chief Executive Officer</td></tr>
</table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">II-8 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">POWER OF ATTORNEY </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">KNOW ALL PERSONS BY </span><span style="font-weight:bold">THESE PRESENTS</span>, that each person whose signature appears below constitutes and appoints Marc H. Hedrick, M.D. and Andrew Sims, and each of them, as true and lawful <span style="white-space:nowrap"><span style="white-space:nowrap">attorneys-in-fact</span></span> and agents, with full powers of substitution and resubstitution, for them and in their name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this registration statement (or any registration statement for the same offering that is to be effective upon filing pursuant to Rule&#160;462(b)&#160;under the&#160;Securities Act), and to file the same, with all exhibits thereto, and other documents in connection therewith, with the SEC, and generally to do all such things in their names and behalf in their capacities as officers and directors to enable Plus Therapeutics, Inc. to comply with the provisions of the Securities Act and all requirements of the SEC, granting unto said <span style="white-space:nowrap"><span style="white-space:nowrap">attorneys-in-fact</span></span> and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he might or could do in person, ratifying and confirming all that said <span style="white-space:nowrap"><span style="white-space:nowrap">attorneys-in-fact</span></span> and agents, or any of them, or their or his substitutes or substitute, may lawfully do or cause to be done by virtue hereof. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed below by the following persons in the capacities and on the dates indicated. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0">


<tr>

<td style="width:45%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:35%"/>

<td style="vertical-align:bottom;width:2%"/>
<td style="width:18%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Signature</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Title</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Date</p></td></tr>


<tr style="font-size:1pt">
<td style="height:12pt"/>
<td style="height:12pt" colspan="2"/>
<td style="height:12pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman;text-align:center">/<small style="font-weight:inherit;font-style:unset;text-decoration:unset">S</small>/ M<small style="font-weight:inherit;font-style:unset;text-decoration:unset">ARC</small> H. H<small style="font-weight:inherit;font-style:unset;text-decoration:unset">EDRICK</small>, M.D. </p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;text-align:center">M<small style="font-weight:inherit;font-style:unset;text-decoration:unset">ARC</small> H. H<small style="font-weight:inherit;font-style:unset;text-decoration:unset">EDRICK</small>, M.D.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top" align="center">President, Chief Executive Officer and Director<br/><span style="font-style:italic">(Principal Executive Officer)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap" align="center">June&#160;7, 2024</td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"/>
<td style="height:12pt" colspan="2"/>
<td style="height:12pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman;text-align:center">/<small style="font-weight:inherit;font-style:unset;text-decoration:unset">S</small>/ A<small style="font-weight:inherit;font-style:unset;text-decoration:unset">NDREW</small> S<small style="font-weight:inherit;font-style:unset;text-decoration:unset">IMS</small></p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;text-align:center">Andrew Sims</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top" align="center">Chief Financial Officer<br/><span style="font-style:italic">(Principal Financial and Accounting Officer)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap" align="center">June&#160;7, 2024</td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"/>
<td style="height:12pt" colspan="2"/>
<td style="height:12pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman;text-align:center">/<small style="font-weight:inherit;font-style:unset;text-decoration:unset">S</small>/ R<small style="font-weight:inherit;font-style:unset;text-decoration:unset">ICHARD</small> J. H<small style="font-weight:inherit;font-style:unset;text-decoration:unset">AWKINS</small> </p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;text-align:center">R<small style="font-weight:inherit;font-style:unset;text-decoration:unset">ICHARD</small> J. H<small style="font-weight:inherit;font-style:unset;text-decoration:unset">AWKINS</small></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top" align="center">Chair of the Board of Directors</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap" align="center">June&#160;7, 2024</td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"/>
<td style="height:12pt" colspan="2"/>
<td style="height:12pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman;text-align:center">/<small style="font-weight:inherit;font-style:unset;text-decoration:unset">S</small>/ H<small style="font-weight:inherit;font-style:unset;text-decoration:unset">OWARD</small> C<small style="font-weight:inherit;font-style:unset;text-decoration:unset">LOWES</small> </p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;text-align:center">H<small style="font-weight:inherit;font-style:unset;text-decoration:unset">OWARD</small> C<small style="font-weight:inherit;font-style:unset;text-decoration:unset">LOWES</small></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top" align="center">Director</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap" align="center">June&#160;7, 2024</td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"/>
<td style="height:12pt" colspan="2"/>
<td style="height:12pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman;text-align:center">/<small style="font-weight:inherit;font-style:unset;text-decoration:unset">S</small>/ A<small style="font-weight:inherit;font-style:unset;text-decoration:unset">N</small> <small style="font-weight:inherit;font-style:unset;text-decoration:unset">VAN</small> E<small style="font-weight:inherit;font-style:unset;text-decoration:unset">S</small><span style="white-space:nowrap">-J</span><small style="font-weight:inherit;font-style:unset;text-decoration:unset">OHANSSON</small> </p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;text-align:center">A<small style="font-weight:inherit;font-style:unset;text-decoration:unset">N</small> <small style="font-weight:inherit;font-style:unset;text-decoration:unset">VAN</small> E<small style="font-weight:inherit;font-style:unset;text-decoration:unset">S</small><span style="white-space:nowrap">-J</span><small style="font-weight:inherit;font-style:unset;text-decoration:unset">OHANSSON</small></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top" align="center">Director</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap" align="center">June&#160;7, 2024</td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"/>
<td style="height:12pt" colspan="2"/>
<td style="height:12pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman;text-align:center">/<small style="font-weight:inherit;font-style:unset;text-decoration:unset">S</small>/ R<small style="font-weight:inherit;font-style:unset;text-decoration:unset">OBERT</small> L<small style="font-weight:inherit;font-style:unset;text-decoration:unset">ENK</small>, P<small style="font-weight:inherit;font-style:unset;text-decoration:unset">H</small>.D /</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;text-align:center">R<small style="font-weight:inherit;font-style:unset;text-decoration:unset">OBERT</small> L<small style="font-weight:inherit;font-style:unset;text-decoration:unset">ENK</small>, P<small style="font-weight:inherit;font-style:unset;text-decoration:unset">H</small>.D</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top" align="center">Director</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap" align="center">June&#160;7, 2024</td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"/>
<td style="height:12pt" colspan="2"/>
<td style="height:12pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman;text-align:center">/<small style="font-weight:inherit;font-style:unset;text-decoration:unset">S</small>/ G<small style="font-weight:inherit;font-style:unset;text-decoration:unset">REG</small> P<small style="font-weight:inherit;font-style:unset;text-decoration:unset">ETERSEN</small> </p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;text-align:center">G<small style="font-weight:inherit;font-style:unset;text-decoration:unset">REG</small> P<small style="font-weight:inherit;font-style:unset;text-decoration:unset">ETERSEN</small></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top" align="center">Director</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap" align="center">June&#160;7, 2024</td></tr>
</table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">II-9 </p>

</div></div>

</body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>2
<FILENAME>d840996dex51.htm
<DESCRIPTION>EX-5.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-5.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 5.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="35%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g840996g0606105124424.jpg" ALT="LOGO">
</P> <P STYLE="font-size:18pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">June&nbsp;7, 2024</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Hogan Lovells US LLP</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Harbor East</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">100 International Drive</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Suite 2000</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Baltimore, MD 21202</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">T +1 410 659 2700</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">F +1 410 659 2701</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">www.hoganlovells.com</P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Board of Directors </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Plus
Therapeutics, Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">4200 Marathon Blvd.,&nbsp;Suite 200 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Austin, Texas 78756 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To the addressee referred to above: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are acting as counsel to Plus Therapeutics, Inc., a Delaware corporation (the &#147;Company&#148;), in connection with its registration statement on Form <FONT
STYLE="white-space:nowrap">S-1</FONT> (the &#147;Registration Statement&#148;), filed with the U.S. Securities and Exchange Commission under the Securities Act of 1933, as amended, relating to the proposed public offering and sale by the selling
stockholders listed in the Registration Statement of 10,774,596 shares of common stock, par value $0.001 per share (&#147;Common Stock&#148;), consisting of (i)&nbsp;1,439,988 shares of Common Stock (the &#147;Private Placement Shares&#148;),
(b)&nbsp;2,151,544 shares (the <FONT STYLE="white-space:nowrap">&#147;Pre-Funded</FONT> Warrant Shares&#148;) of Common Stock underlying <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants (the
<FONT STYLE="white-space:nowrap">&#147;Pre-Funded</FONT> Warrants&#148;), (c)&nbsp;3,591,532 shares (the &#147;Series A Warrant Shares&#148;) of Common Stock underlying Series A common stock purchase warrants (the &#147;Series A Warrants&#148;), and
(d)&nbsp;3,591,532 shares (the &#147;Series B Warrant Shares&#148;, together with the <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrant Shares and the Series A Warrant Shares are referred to herein collectively as the &#147;Warrant
Shares&#148;) of Common Stock underlying Series B common stock purchase warrants (the &#147;Series B Warrants&#148; and, together with the <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants and the Series A Warrants, the
&#147;Warrants&#148;). The Private Placement Shares and Warrants were issued pursuant to that certain securities purchase agreement by and among the Company and the purchasers named therein, dated as of May&nbsp;5, 2024 (the &#147;Securities
Purchase Agreement&#148;), as amended on May&nbsp;8, 2024, by that certain First Amendment to the Securities Purchase Agreement (the &#147;Purchase Agreement&#148;). This opinion is being rendered in connection with the filing of the Registration
Statement with the U.S. Securities and Exchange Commission. The Private Placement Shares and Warrant Shares may be sold from time to time and on a delayed or continuous basis, as set forth in the prospectus which forms a part of the Registration
Statement (the &#147;Prospectus&#148;), and as to be set forth in one or more supplements to the Prospectus. This opinion letter is furnished to you at your request to enable you to fulfill the requirements of Item 601(b)(5) of Regulation <FONT
STYLE="white-space:nowrap">S-K,</FONT> 17 C.F.R. &#167; 229.601(b)(5), in connection with the Registration Statement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For purposes of this opinion
letter, we have examined copies of such agreements, instruments and documents as we have deemed an appropriate basis on which to render the opinions hereinafter expressed. In our examination of the aforesaid documents, we have assumed the
genuineness of all signatures, the legal capacity of all natural persons, the accuracy and completeness of all documents submitted to us, the authenticity of all original documents, and the conformity to authentic original documents of all documents
submitted to us as copies (including pdfs). As to all matters of fact, we have relied on the representations and statements of fact made in the documents so reviewed, and we have not independently established the facts so relied on. For purposes of
the opinion set forth below, we have assumed that before the Warrant Shares are issued the Company does not issue shares of Common Stock or reduce the total number of shares of Common Stock the Company is authorized to issue under its Certificate of
Incorporation, as amended (the &#147;Charter&#148;), such that the number of unissued shares of Common Stock authorized under the Charter is less than the number of Warrant Shares. This opinion letter is given, and all statements herein are made, in
the context of the foregoing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This opinion letter is based as to matters of law solely on the applicable provisions of the Delaware General Corporation
Law. We express no opinion herein as to any other statutes, rules or regulations (and in particular, we express no opinion as to any effect that such other statutes, rules or regulations may have on the opinions expressed herein). </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="35%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Board of Directors</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Plus Therapeutics,
Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">&#151;2&#151;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">June&nbsp;7, 2024</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Based upon, subject to and limited by the foregoing, we are of the opinion that, as of the date hereof: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Private Placement Shares have been duly authorized and validly issued and are fully paid and nonassessable,
and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Warrant Shares, when delivered and paid for upon exercise of the Warrants in accordance with the terms of
the Warrants, will have been duly authorized and validly issued and will be fully paid and nonassessable. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This opinion letter has been
prepared for use in connection with the Registration Statement. We assume no obligation to advise of any changes in the foregoing subsequent to the effective date of the Registration Statement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We hereby consent to the filing of this opinion letter as Exhibit 5.1 to the Registration Statement and to the reference to this firm under the caption
&#147;Legal Matters&#148; in the Prospectus. In giving this consent, we do not thereby admit that we are an &#147;expert&#148; within the meaning of the Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Very truly yours, </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">/s/ Hogan Lovells US LLP </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">HOGAN LOVELLS US LLP </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.15
<SEQUENCE>3
<FILENAME>d840996dex1015.htm
<DESCRIPTION>EX-10.15
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.15</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>EXHIBIT 10.15 </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>THIRD AMENDMENT TO </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>THE
PLUS THERAPEUTICS, INC. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>2015 NEW EMPLOYEE INCENTIVE PLAN </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">June&nbsp;6, 2024 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Third
Amendment amends the 2015 New Employee Incentive Plan (as amended, the &#147;<B>Plan</B>&#148;) of Plus Therapeutics, Inc., a Delaware corporation (the &#147;<B>Company</B>&#148;).&nbsp;Unless otherwise specifically defined herein, each capitalized
term used herein shall have the meaning afforded such term under the Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, by unanimous written consent of the Board of
Directors of the Company (the &#147;<B>Board</B>&#148;), effective June&nbsp;6, 2024, the Board determined it to be in the best interests of the Company to amend the Plan to increase the number of shares of common stock, par value $0.001 per shares,
Stock authorized for issuance thereunder by 75,000 shares: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">NOW, THEREFORE, be it resolved that the Plan is hereby amended as follows:
</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Share L</U><U>imit</U>.&nbsp;Section 4.1 of the Plan shall be amended by replacing it with the following:
</P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">&#147;<B>Maximum Number of Shares Issuable</B>.&nbsp;Subject to adjustment as provided in Sections 4.2 and 4.3, and
after having previously adjusted for the Company&#146;s reverse stock splits effected prior to June&nbsp;6, 2024, the maximum aggregate number of shares of Stock that may be issued under the Plan pursuant to Awards shall be equal to 76,024 shares
and shall consist of authorized but unissued or reacquired shares of Stock or any combination thereof.&#148; </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>PLUS THERAPEUTICS, INC.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Marc H. Hedrick, M.D.</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Marc H. Hedrick, M.D.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">President and Chief Executive Officer</TD></TR>
</TABLE></DIV>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>4
<FILENAME>d840996dex231.htm
<DESCRIPTION>EX-23.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-23.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>EXHIBIT 23.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Consent of Independent Registered Public Accounting Firm </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We hereby consent to the use in the Prospectus constituting a part of this Registration Statement of our report dated March&nbsp;5, 2024, relating to the
financial statements of Plus Therapeutics, Inc. (the Company), which is contained in that Prospectus. Our report contains an explanatory paragraph regarding the Company&#146;s ability to continue as a going concern. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We also consent to the reference to us under the caption &#147;Experts&#148; in the Prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">/s/ BDO USA, P.C. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Austin, Texas </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Austin, Texas</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">June&nbsp;7, 2024 </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-FILING FEES
<SEQUENCE>5
<FILENAME>d840996dexfilingfees.htm
<DESCRIPTION>EX-FILING FEES
<TEXT>
<HTML><HEAD>
<TITLE>EX-FILING FEES</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 107 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Calculation of Filing Fee Tables </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>Form <FONT STYLE="white-space:nowrap">S-1</FONT> </U></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(Form Type) </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Plus
Therapeutics, Inc. </U></B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(Exact Name of Registrant as Specified in its Charter) </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>Table 1: Newly Registered Securities </U></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="9%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="8%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="9%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="14%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="8%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="16%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="13%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="11%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="1" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8pt">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>Security</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>Type</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>Security</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>Class</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>Title</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>Fee<BR>&#8194;Calculation&#8194;</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>or Carry</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>Forward</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>Rule</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>Amount</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>Registered (1)</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>Proposed</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>&#8194;Maximum&#8194;</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>Offering</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>Price Per</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>Unit (2)</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>&#8194;Maximum&#8194;</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>Aggregate Offering<BR>Price</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>Fee</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>Rate</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-RIGHT:1px solid #000000; padding-right:2pt"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>Amount of</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>Registration&#8194;</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>Fee</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="1" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-LEFT:1px solid #000000; padding-left:8pt"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Fees&nbsp;to&nbsp;Be&#8194;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Paid</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;">&#8194;Equity&#8194;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Common</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Stock,&nbsp;par</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">value</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">&#8194;$0.0001&nbsp;per&#8194;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">share</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;">457(c)</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;">&#8194;10,774,596(1)&#8194;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;">$2.17505</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;">$23,435,285.02(2)</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;">&#8194;$0.00014760&#8194;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-RIGHT:1px solid #000000; padding-right:2pt">$3,459.05(2)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="1" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-LEFT:1px solid #000000; padding-left:8pt"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Carry</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Forward</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Securities</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;">N/A</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;">&#151;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;">&#151;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;">&#151;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;">&#151;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; padding-right:2pt">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="1" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="6" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="5" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;"><B>Total Offering Amounts</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;">$23,435,285.02</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;">&#151;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-RIGHT:1px solid #000000; padding-right:2pt">$3,459.05</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="1" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="6" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="5" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;"><B>Total Fees Previously Paid</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;">&#151;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-RIGHT:1px solid #000000; padding-right:2pt">&#151;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="1" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="6" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="5" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;"><B>Total Fee Offsets</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;">&#151;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-RIGHT:1px solid #000000; padding-right:2pt">&#151;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="1" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="6" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="5" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-BOTTOM:1px solid #000000"><B>Net Fee Due</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">$3,459.05</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Pursuant to Rule 416(a) of the Securities Act of 1933, as amended, this registration statement also covers such
additional shares as may hereafter be offered or issued to prevent dilution resulting from stock splits, stock dividends, recapitalizations or certain other capital adjustments. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Estimated solely for the purposes of calculating the registration fee. Pursuant to Rule 457(c) under the
Securities Act of 1933, as amended. The price per share and aggregate offering price are based on the average of the high and low prices of the Company&#146;s shares of common stock on May 31, 2024 (a date within five business days prior to the
initial filing of the registration statement), as reported by The Nasdaq Capital Market. </P></TD></TR></TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>6
<FILENAME>pstv-20240331.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--Generated by DFIN XBRL Instance Document - http://www.dfinsolutions.com/ - Version R3.0 - on 07-June-2024 [02:05:21] {PM}-->
<schema targetNamespace="http://plus.com/20240331" elementFormDefault="qualified" xmlns:pstv="http://plus.com/20240331" xmlns="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:country="http://xbrl.sec.gov/country/2023" xmlns:currency="http://xbrl.sec.gov/currency/2023" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:exch="http://xbrl.sec.gov/exch/2023" xmlns:naics="http://xbrl.sec.gov/naics/2023" xmlns:sic="http://xbrl.sec.gov/sic/2023" xmlns:us-types="http://fasb.org/us-types/2023" xmlns:stpr="http://xbrl.sec.gov/stpr/2023" xmlns:deprecated="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" xmlns:srt="http://fasb.org/srt/2023" xmlns:srt-types="http://fasb.org/srt-types/2023" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21">
<annotation>
<appinfo>
<link:roleType roleURI="http://plus.com/role/CoverPage" id="CoverPage">
<link:definition>1001 - Document - Cover Page</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://plus.com/role/CondensedBalanceSheetsUnaudited" id="CondensedBalanceSheetsUnaudited">
<link:definition>1002 - Statement - CONDENSED BALANCE SHEETS (UNAUDITED)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://plus.com/role/CondensedBalanceSheetsUnauditedParenthetical" id="CondensedBalanceSheetsUnauditedParenthetical">
<link:definition>1003 - Statement - CONDENSED BALANCE SHEETS (UNAUDITED) (Parenthetical)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://plus.com/role/CondensedStatementsOfOperationsUnaudited" id="CondensedStatementsOfOperationsUnaudited">
<link:definition>1004 - Statement - CONDENSED STATEMENTS OF OPERATIONS (UNAUDITED)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://plus.com/role/CondensedStatementsOfStockholdersEquityDeficitUnaudited" id="CondensedStatementsOfStockholdersEquityDeficitUnaudited">
<link:definition>1005 - Statement - CONDENSED STATEMENTS OF STOCKHOLDERS' EQUITY/(DEFICIT) (UNAUDITED)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://plus.com/role/CondensedStatementsOfCashFlowsUnaudited" id="CondensedStatementsOfCashFlowsUnaudited">
<link:definition>1006 - Statement - CONDENSED STATEMENTS OF CASH FLOWS (UNAUDITED)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://plus.com/role/BasisOfPresentationAndNewAccountingStandards" id="BasisOfPresentationAndNewAccountingStandards">
<link:definition>1007 - Disclosure - Basis of Presentation and New Accounting Standards</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://plus.com/role/OrganizationAndOperations" id="OrganizationAndOperations">
<link:definition>1008 - Disclosure - Organization and Operations</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://plus.com/role/UseOfEstimates" id="UseOfEstimates">
<link:definition>1009 - Disclosure - Use of Estimates</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://plus.com/role/SummaryOfSignificantAccountingPolicies" id="SummaryOfSignificantAccountingPolicies">
<link:definition>1010 - Disclosure - Summary of Significant Accounting Policies</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://plus.com/role/LiquidityAndGoingConcern" id="LiquidityAndGoingConcern">
<link:definition>1011 - Disclosure - Liquidity and Going Concern</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://plus.com/role/FairValueMeasurements" id="FairValueMeasurements">
<link:definition>1012 - Disclosure - Fair Value Measurements</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://plus.com/role/LossPerShare" id="LossPerShare">
<link:definition>1013 - Disclosure - Loss per Share</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://plus.com/role/CompositionOfCertainFinancialStatementCaptions" id="CompositionOfCertainFinancialStatementCaptions">
<link:definition>1014 - Disclosure - Composition of Certain Financial Statement Captions</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://plus.com/role/CommitmentsAndContingencies" id="CommitmentsAndContingencies">
<link:definition>1015 - Disclosure - Commitments and Contingencies</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://plus.com/role/LicenseAgreements" id="LicenseAgreements">
<link:definition>1016 - Disclosure - License Agreements</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://plus.com/role/TermLoanObligations" id="TermLoanObligations">
<link:definition>1017 - Disclosure - Term Loan Obligations</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://plus.com/role/GrantRevenue" id="GrantRevenue">
<link:definition>1018 - Disclosure - Grant Revenue</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://plus.com/role/IncomeTaxes" id="IncomeTaxes">
<link:definition>1019 - Disclosure - Income Taxes</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://plus.com/role/EmployeeBenefitPlan" id="EmployeeBenefitPlan">
<link:definition>1020 - Disclosure - Employee Benefit Plan</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://plus.com/role/StockholdersEquity" id="StockholdersEquity">
<link:definition>1021 - Disclosure - Stockholders' Equity</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://plus.com/role/SubsequentEvents" id="SubsequentEvents">
<link:definition>1022 - Disclosure - Subsequent Events</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://plus.com/role/StockBasedCompensation" id="StockBasedCompensation">
<link:definition>1023 - Disclosure - Stock-based Compensation</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://plus.com/role/BasisOfPresentationAndNewAccountingStandardsPolicies" id="BasisOfPresentationAndNewAccountingStandardsPolicies">
<link:definition>1024 - Disclosure - Basis of Presentation and New Accounting Standards (Policies)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://plus.com/role/SummaryOfSignificantAccountingPoliciesPolicies" id="SummaryOfSignificantAccountingPoliciesPolicies">
<link:definition>1025 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://plus.com/role/FairValueMeasurementsTables" id="FairValueMeasurementsTables">
<link:definition>1026 - Disclosure - Fair Value Measurements (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://plus.com/role/LossPerShareTables" id="LossPerShareTables">
<link:definition>1027 - Disclosure - Loss per Share (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://plus.com/role/CompositionOfCertainFinancialStatementCaptionsTables" id="CompositionOfCertainFinancialStatementCaptionsTables">
<link:definition>1028 - Disclosure - Composition of Certain Financial Statement Captions (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://plus.com/role/CommitmentsAndContingenciesTables" id="CommitmentsAndContingenciesTables">
<link:definition>1029 - Disclosure - Commitments and Contingencies (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://plus.com/role/TermLoanObligationsTables" id="TermLoanObligationsTables">
<link:definition>1030 - Disclosure - Term Loan Obligations (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://plus.com/role/IncomeTaxesTables" id="IncomeTaxesTables">
<link:definition>1031 - Disclosure - Income Taxes (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://plus.com/role/StockBasedCompensationTables" id="StockBasedCompensationTables">
<link:definition>1032 - Disclosure - Stock-based Compensation (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://plus.com/role/BasisOfPresentationAndNewAccountingStandardsAdditionalInformationDetails" id="BasisOfPresentationAndNewAccountingStandardsAdditionalInformationDetails">
<link:definition>1033 - Disclosure - Basis of Presentation and New Accounting Standards (Additional Information) (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://plus.com/role/OrganizationAndOperationsAdditionalInformationDetails" id="OrganizationAndOperationsAdditionalInformationDetails">
<link:definition>1034 - Disclosure - Organization and Operations - Additional Information (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://plus.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" id="SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails">
<link:definition>1035 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://plus.com/role/LiquidityAndGoingConcernAdditionalInformationDetails" id="LiquidityAndGoingConcernAdditionalInformationDetails">
<link:definition>1036 - Disclosure - Liquidity and Going Concern - Additional Information (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://plus.com/role/FairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails" id="FairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails">
<link:definition>1037 - Disclosure - Fair Value Measurements - Summary of Financial Assets Measured at Fair Value on Recurring Basis (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://plus.com/role/LossPerShareScheduleOfAntidilutiveSecuritiesExcludedFromDilutedIncomeLossPerShareDetails" id="LossPerShareScheduleOfAntidilutiveSecuritiesExcludedFromDilutedIncomeLossPerShareDetails">
<link:definition>1038 - Disclosure - Loss per Share - Schedule of Antidilutive Securities Excluded from Diluted Income (Loss) per Share (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://plus.com/role/CompositionOfCertainFinancialStatementCaptionsOtherCurrentAssetsDetails" id="CompositionOfCertainFinancialStatementCaptionsOtherCurrentAssetsDetails">
<link:definition>1039 - Disclosure - Composition of Certain Financial Statement Captions - Other Current Assets (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://plus.com/role/CompositionOfCertainFinancialStatementCaptionsPropertyAndEquipmentNetDetails" id="CompositionOfCertainFinancialStatementCaptionsPropertyAndEquipmentNetDetails">
<link:definition>1040 - Disclosure - Composition of Certain Financial Statement Captions - Property and Equipment, Net (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://plus.com/role/CompositionOfCertainFinancialStatementCaptionsAdditionalInformationDetails" id="CompositionOfCertainFinancialStatementCaptionsAdditionalInformationDetails">
<link:definition>1041 - Disclosure - Composition of Certain Financial Statement Captions - Additional Information (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://plus.com/role/CompositionOfCertainFinancialStatementCaptionsAccountsPayableAndAccruedExpensesDetails" id="CompositionOfCertainFinancialStatementCaptionsAccountsPayableAndAccruedExpensesDetails">
<link:definition>1042 - Disclosure - Composition of Certain Financial Statement Captions - Accounts Payable and Accrued Expenses (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://plus.com/role/CommitmentsAndContingenciesAdditionalInformationDetails" id="CommitmentsAndContingenciesAdditionalInformationDetails">
<link:definition>1043 - Disclosure - Commitments and Contingencies - Additional Information (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://plus.com/role/CommitmentsAndContingenciesSummaryOfLeaseCostsDetails" id="CommitmentsAndContingenciesSummaryOfLeaseCostsDetails">
<link:definition>1044 - Disclosure - Commitments and Contingencies - Summary of Lease Costs (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://plus.com/role/CommitmentsAndContingenciesSummaryOfFutureMinimumAnnualLeasePaymentsUnderOperatingLeasesDetails" id="CommitmentsAndContingenciesSummaryOfFutureMinimumAnnualLeasePaymentsUnderOperatingLeasesDetails">
<link:definition>1045 - Disclosure - Commitments and Contingencies - Summary of Future Minimum Annual Lease Payments under Operating Leases (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://plus.com/role/LicenseAgreementsAdditionalInformationDetails" id="LicenseAgreementsAdditionalInformationDetails">
<link:definition>1046 - Disclosure - License Agreements - Additional Information (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://plus.com/role/TermLoanObligationsAdditionalInformationDetails" id="TermLoanObligationsAdditionalInformationDetails">
<link:definition>1047 - Disclosure - Term Loan Obligations - Additional Information (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://plus.com/role/TermLoanObligationsTermLoanOutstandingDetails" id="TermLoanObligationsTermLoanOutstandingDetails">
<link:definition>1048 - Disclosure - Term Loan Obligations - Term Loan Outstanding (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://plus.com/role/GrantRevenueAdditionalInformationDetails" id="GrantRevenueAdditionalInformationDetails">
<link:definition>1049 - Disclosure - Grant Revenue - Additional Information (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://plus.com/role/IncomeTaxesAdditionalInformationDetails" id="IncomeTaxesAdditionalInformationDetails">
<link:definition>1050 - Disclosure - Income Taxes - Additional Information (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://plus.com/role/IncomeTaxesReconciliationOfTotalIncomeTaxProvisionDetails" id="IncomeTaxesReconciliationOfTotalIncomeTaxProvisionDetails">
<link:definition>1051 - Disclosure - Income Taxes - Reconciliation of Total Income Tax Provision (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://plus.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails" id="IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails">
<link:definition>1052 - Disclosure - Income Taxes - Deferred Tax Assets and Liabilities (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://plus.com/role/IncomeTaxesUnrecognizedTaxBenefitsActivityDetails" id="IncomeTaxesUnrecognizedTaxBenefitsActivityDetails">
<link:definition>1053 - Disclosure - Income Taxes - Unrecognized Tax Benefits Activity (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://plus.com/role/EmployeeBenefitPlanAdditionalInformationDetails" id="EmployeeBenefitPlanAdditionalInformationDetails">
<link:definition>1054 - Disclosure - Employee Benefit Plan - Additional Information (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://plus.com/role/StockholdersEquityPreferredStockDetails" id="StockholdersEquityPreferredStockDetails">
<link:definition>1055 - Disclosure - Stockholders' Equity - Preferred Stock (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://plus.com/role/StockholdersEquityWarrantsDetails" id="StockholdersEquityWarrantsDetails">
<link:definition>1056 - Disclosure - Stockholders' Equity - Warrants (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://plus.com/role/StockholdersEquityCommonStockDetails" id="StockholdersEquityCommonStockDetails">
<link:definition>1057 - Disclosure - Stockholders' Equity - Common stock (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://plus.com/role/StockBasedCompensationAdditionalInformationDetails" id="StockBasedCompensationAdditionalInformationDetails">
<link:definition>1058 - Disclosure - Stock-based Compensation - Additional Information (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://plus.com/role/StockBasedCompensationStockOptionActivityDetails" id="StockBasedCompensationStockOptionActivityDetails">
<link:definition>1059 - Disclosure - Stock-based Compensation - Stock Option Activity (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://plus.com/role/StockBasedCompensationWeightedAverageAssumptionsDetails" id="StockBasedCompensationWeightedAverageAssumptionsDetails">
<link:definition>1060 - Disclosure - Stock-based Compensation - Weighted-average Assumptions (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://plus.com/role/StockBasedCompensationSummaryOfShareBasedCompensationRecognizedDetails" id="StockBasedCompensationSummaryOfShareBasedCompensationRecognizedDetails">
<link:definition>1061 - Disclosure - Stock-based Compensation - Summary of Share-Based Compensation Recognized (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://plus.com/role/SubsequentEventsAdditionalInformationDetails" id="SubsequentEventsAdditionalInformationDetails">
<link:definition>1062 - Disclosure - Subsequent Events - Additional Information (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://plus.com/role/CommitmentsAndContingenciesSummaryOfFutureMinimumAnnualLeasePaymentsUnderOperatingLeasesDetailsAlternate1" id="CommitmentsAndContingenciesSummaryOfFutureMinimumAnnualLeasePaymentsUnderOperatingLeasesDetailsAlternate1">
<link:definition>1063 - Statement - Commitments and Contingencies - Summary of Future Minimum Annual Lease Payments under Operating Leases (Details) Alternate 1</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:linkbaseRef xlink:type="simple" xlink:href="pstv-20240331_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
<link:linkbaseRef xlink:type="simple" xlink:href="pstv-20240331_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
<link:linkbaseRef xlink:type="simple" xlink:href="pstv-20240331_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
<link:linkbaseRef xlink:type="simple" xlink:href="pstv-20240331_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
</appinfo>
</annotation>
<import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
<import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
<import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
<import namespace="http://fasb.org/us-gaap/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd" />
<import namespace="http://xbrl.sec.gov/country/2023" schemaLocation="https://xbrl.sec.gov/country/2023/country-2023.xsd" />
<import namespace="http://xbrl.sec.gov/currency/2023" schemaLocation="https://xbrl.sec.gov/currency/2023/currency-2023.xsd" />
<import namespace="http://xbrl.sec.gov/exch/2023" schemaLocation="https://xbrl.sec.gov/exch/2023/exch-2023.xsd" />
<import namespace="http://xbrl.sec.gov/naics/2023" schemaLocation="https://xbrl.sec.gov/naics/2023/naics-2023.xsd" />
<import namespace="http://xbrl.sec.gov/sic/2023" schemaLocation="https://xbrl.sec.gov/sic/2023/sic-2023.xsd" />
<import namespace="http://xbrl.sec.gov/stpr/2023" schemaLocation="https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd" />
<import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
<import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" />
<import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" />
<import namespace="http://xbrl.sec.gov/dei/2023" schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd" />
<import namespace="http://fasb.org/us-types/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd" />
<import namespace="http://fasb.org/srt-types/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd" />
<import namespace="http://fasb.org/srt/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd" />
<import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" />
<element name="FractionalAdjustmentOfCommonStock" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="pstv_FractionalAdjustmentOfCommonStock" substitutionGroup="xbrli:item" />
<element name="UnpaidOfferingCosts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="pstv_UnpaidOfferingCosts" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="CashPaidDuringPeriodForAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="pstv_CashPaidDuringPeriodForAbstract" substitutionGroup="xbrli:item" />
<element name="CashPaidForIPRDAssetAcquiredInAnAssetAcquisition" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="pstv_CashPaidForIPRDAssetAcquiredInAnAssetAcquisition" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="PaymentsToAcquirePropertyPlantAndEquipmentAndIntangibleAssets" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="pstv_PaymentsToAcquirePropertyPlantAndEquipmentAndIntangibleAssets" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="CommonStockIssuedForResearchAndDevelopment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="pstv_CommonStockIssuedForResearchAndDevelopment" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="IncreaseDecreaseInDeferredGrantLiability" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="pstv_IncreaseDecreaseInDeferredGrantLiability" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="UseOfEstimatesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="pstv_UseOfEstimatesAbstract" substitutionGroup="xbrli:item" />
<element name="UseOfEstimatesTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="pstv_UseOfEstimatesTextBlock" substitutionGroup="xbrli:item" />
<element name="LiquidityAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="pstv_LiquidityAbstract" substitutionGroup="xbrli:item" />
<element name="DisclosureOfLiquidityAndGoingConcernTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="pstv_DisclosureOfLiquidityAndGoingConcernTextBlock" substitutionGroup="xbrli:item" />
<element name="CompositionOfCertainFinancialStatementCaptionsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="pstv_CompositionOfCertainFinancialStatementCaptionsAbstract" substitutionGroup="xbrli:item" />
<element name="LicenseAgreementAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="pstv_LicenseAgreementAbstract" substitutionGroup="xbrli:item" />
<element name="LicenseAgreementDisclosureTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="pstv_LicenseAgreementDisclosureTextBlock" substitutionGroup="xbrli:item" />
<element name="AmendmentsForCertificateofIncorporationAndReverseStockSplitPolicyTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="pstv_AmendmentsForCertificateofIncorporationAndReverseStockSplitPolicyTextBlock" substitutionGroup="xbrli:item" />
<element name="ReverseStockSplitEffectiveDate" type="xbrli:dateItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="pstv_ReverseStockSplitEffectiveDate" substitutionGroup="xbrli:item" />
<element name="EquityIncentivePlansMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="pstv_EquityIncentivePlansMember" substitutionGroup="xbrli:item" />
<element name="OutstandingWarrantsAndOptionsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="pstv_OutstandingWarrantsAndOptionsMember" substitutionGroup="xbrli:item" />
<element name="OrganizationAndOperationsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="pstv_OrganizationAndOperationsTable" substitutionGroup="xbrldt:hypercubeItem" />
<element name="TermLoanMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="pstv_TermLoanMember" substitutionGroup="xbrli:item" />
<element name="OrganizationAndOperationsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="pstv_OrganizationAndOperationsLineItems" substitutionGroup="xbrli:item" />
<element name="LongTermDebtOutstandingThresholdAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="pstv_LongTermDebtOutstandingThresholdAmount" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="SummaryOfSignificantAccountingPoliciesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="pstv_SummaryOfSignificantAccountingPoliciesTable" substitutionGroup="xbrldt:hypercubeItem" />
<element name="SummaryOfSignificantAccountingPoliciesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="pstv_SummaryOfSignificantAccountingPoliciesLineItems" substitutionGroup="xbrli:item" />
<element name="MaintainMinimumMarketValueOfListedSecurities" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="pstv_MaintainMinimumMarketValueOfListedSecurities" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="OptionsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="pstv_OptionsMember" substitutionGroup="xbrli:item" />
<element name="OfficeAndComputerEquipmentGross" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="pstv_OfficeAndComputerEquipmentGross" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="AccruedResearchAndDevelopmentStudies" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="pstv_AccruedResearchAndDevelopmentStudies" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="AccruedVacationAndCompensationCurrent" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="pstv_AccruedVacationAndCompensationCurrent" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="LoremVascularPteLtdMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="pstv_LoremVascularPteLtdMember" substitutionGroup="xbrli:item" />
<element name="PreClinicalResearchStudyObligationsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="pstv_PreClinicalResearchStudyObligationsMember" substitutionGroup="xbrli:item" />
<element name="MasterServicesAgreementDate" type="xbrli:dateItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="pstv_MasterServicesAgreementDate" substitutionGroup="xbrli:item" />
<element name="MasterServicesAgreementInitialTerm" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="pstv_MasterServicesAgreementInitialTerm" substitutionGroup="xbrli:item" />
<element name="MasterServicesAgreementTermsDescription" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="pstv_MasterServicesAgreementTermsDescription" substitutionGroup="xbrli:item" />
<element name="OperatingLeasesExpiryYear" type="xbrli:gYearItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="pstv_OperatingLeasesExpiryYear" substitutionGroup="xbrli:item" />
<element name="SalesOrderTerm" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="pstv_SalesOrderTerm" substitutionGroup="xbrli:item" />
<element name="CharlottesvilleMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="pstv_CharlottesvilleMember" substitutionGroup="xbrli:item" />
<element name="MedidataSolutionsIncMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="pstv_MedidataSolutionsIncMember" substitutionGroup="xbrli:item" />
<element name="PiramalPharmaSolutionsIncMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="pstv_PiramalPharmaSolutionsIncMember" substitutionGroup="xbrli:item" />
<element name="ServicesAgreementMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="pstv_ServicesAgreementMember" substitutionGroup="xbrli:item" />
<element name="CashPaymentInformationAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="pstv_CashPaymentInformationAbstract" substitutionGroup="xbrli:item" />
<element name="CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="pstv_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="BioceptAgreementMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="pstv_BioceptAgreementMember" substitutionGroup="xbrli:item" />
<element name="NanoTxLicensesAgreementMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="pstv_NanoTxLicensesAgreementMember" substitutionGroup="xbrli:item" />
<element name="UTHSALicenseAgreementMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="pstv_UTHSALicenseAgreementMember" substitutionGroup="xbrli:item" />
<element name="AccruedLicensePayable" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="pstv_AccruedLicensePayable" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="OptionForExclusiveWorldwideLicense" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="pstv_OptionForExclusiveWorldwideLicense" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="PaymentForTechTransferAndValidationFee" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="pstv_PaymentForTechTransferAndValidationFee" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="PercentageOfNonDilutiveMonetaryAwardsRequiredToPay" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="pstv_PercentageOfNonDilutiveMonetaryAwardsRequiredToPay" substitutionGroup="xbrli:item" />
<element name="DebtInstrumentFloatingInterestRatePercentage" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="pstv_DebtInstrumentFloatingInterestRatePercentage" substitutionGroup="xbrli:item" />
<element name="DebtPrincipalRepaymentStartDate" type="xbrli:dateItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="pstv_DebtPrincipalRepaymentStartDate" substitutionGroup="xbrli:item" />
<element name="MinimumLiquidityCovenantAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="pstv_MinimumLiquidityCovenantAmount" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="SaleOfJapaneseSubsidiaryAndCertainAssetsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="pstv_SaleOfJapaneseSubsidiaryAndCertainAssetsMember" substitutionGroup="xbrli:item" />
<element name="LoanAndSecurityAgreementMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="pstv_LoanAndSecurityAgreementMember" substitutionGroup="xbrli:item" />
<element name="LiborMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="pstv_LiborMember" substitutionGroup="xbrli:item" />
<element name="AdditionalDetailsRelatingTermLoanThatIsOutstandingAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="pstv_AdditionalDetailsRelatingTermLoanThatIsOutstandingAbstract" substitutionGroup="xbrli:item" />
<element name="DebtInstrumentAmendedExpirationDate" type="xbrli:dateItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="pstv_DebtInstrumentAmendedExpirationDate" substitutionGroup="xbrli:item" />
<element name="ContractEffectiveDate" type="xbrli:dateItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="pstv_ContractEffectiveDate" substitutionGroup="xbrli:item" />
<element name="ContractTerminationDate" type="xbrli:dateItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="pstv_ContractTerminationDate" substitutionGroup="xbrli:item" />
<element name="CpritGrantFundingTerm" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="pstv_CpritGrantFundingTerm" substitutionGroup="xbrli:item" />
<element name="GrantFundingTerm" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="pstv_GrantFundingTerm" substitutionGroup="xbrli:item" />
<element name="IncreaseDecreaseInGrantRevenue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="pstv_IncreaseDecreaseInGrantRevenue" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="MaximumGrantAmountToBeReceivedAsPerGrantContract" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="pstv_MaximumGrantAmountToBeReceivedAsPerGrantContract" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="PercentageOfAggregateAmountOfProceedsAwardedUnderCpritGrant" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="pstv_PercentageOfAggregateAmountOfProceedsAwardedUnderCpritGrant" substitutionGroup="xbrli:item" />
<element name="PercentageOfGrantProceedsWithInterestNotExceedAnnually" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="pstv_PercentageOfGrantProceedsWithInterestNotExceedAnnually" substitutionGroup="xbrli:item" />
<element name="ReimbursementCostsIncurred" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="pstv_ReimbursementCostsIncurred" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="CancerPreventionAndResearchInstituteOfTexasContractMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="pstv_CancerPreventionAndResearchInstituteOfTexasContractMember" substitutionGroup="xbrli:item" />
<element name="IncomeTaxesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="pstv_IncomeTaxesTable" substitutionGroup="xbrldt:hypercubeItem" />
<element name="IncomeTaxesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="pstv_IncomeTaxesLineItems" substitutionGroup="xbrli:item" />
<element name="CumulativeChangeInOwnership" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="pstv_CumulativeChangeInOwnership" substitutionGroup="xbrli:item" />
<element name="IncomeTaxContingencyAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="pstv_IncomeTaxContingencyAbstract" substitutionGroup="xbrli:item" />
<element name="DeferredTaxAssetsValuationAllowances" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="pstv_DeferredTaxAssetsValuationAllowances" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="NetOperatingLossAndResearchAndDevelopmentTaxCreditCarryForwardsToOffsetFutureTaxableIncomePeriod" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="pstv_NetOperatingLossAndResearchAndDevelopmentTaxCreditCarryForwardsToOffsetFutureTaxableIncomePeriod" substitutionGroup="xbrli:item" />
<element name="NetOperatingLossCarryforward" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="pstv_NetOperatingLossCarryforward" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="OperatingLossCarryforwardsExpirationDates1" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="pstv_OperatingLossCarryforwardsExpirationDates1" substitutionGroup="xbrli:item" />
<element name="PercentageOfNetOperatingLossCarryforwardsAvailableForOffsettingAgainstFutureTaxableIncome" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="pstv_PercentageOfNetOperatingLossCarryforwardsAvailableForOffsettingAgainstFutureTaxableIncome" substitutionGroup="xbrli:item" />
<element name="PeriodForMaterialChangesOfLiabilityForUncertainTaxBenefits" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="pstv_PeriodForMaterialChangesOfLiabilityForUncertainTaxBenefits" substitutionGroup="xbrli:item" />
<element name="TaxCreditCarryforwardExpirationDate1" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="pstv_TaxCreditCarryforwardExpirationDate1" substitutionGroup="xbrli:item" />
<element name="EffectiveIncomeTaxRateReconciliationNetOperatingLossExpiration" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="pstv_EffectiveIncomeTaxRateReconciliationNetOperatingLossExpiration" substitutionGroup="xbrli:item" />
<element name="EffectiveIncomeTaxRateReconciliationTaxReturnToProvision" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="pstv_EffectiveIncomeTaxRateReconciliationTaxReturnToProvision" substitutionGroup="xbrli:item" />
<element name="ConsiderationPaidToPreferredStockHolders" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="pstv_ConsiderationPaidToPreferredStockHolders" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="NumberOfPreferredStockSharesExercised" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="pstv_NumberOfPreferredStockSharesExercised" substitutionGroup="xbrli:item" />
<element name="NumberOfVotesPerShare" type="xbrli:integerItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="pstv_NumberOfVotesPerShare" substitutionGroup="xbrli:item" />
<element name="RightsRelatedToDistributionOfAssets" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="pstv_RightsRelatedToDistributionOfAssets" substitutionGroup="xbrli:item" />
<element name="TwoThousandEighteenRightsOfferingMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="pstv_TwoThousandEighteenRightsOfferingMember" substitutionGroup="xbrli:item" />
<element name="SeriesBConvertiblePreferredStockMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="pstv_SeriesBConvertiblePreferredStockMember" substitutionGroup="xbrli:item" />
<element name="SeriesCConvertiblePreferredStockMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="pstv_SeriesCConvertiblePreferredStockMember" substitutionGroup="xbrli:item" />
<element name="SeriesFConvertiblePreferredStockMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="pstv_SeriesFConvertiblePreferredStockMember" substitutionGroup="xbrli:item" />
<element name="SubscriptionAgreementMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="pstv_SubscriptionAgreementMember" substitutionGroup="xbrli:item" />
<element name="NumberOfWarrantsExercised" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="pstv_NumberOfWarrantsExercised" substitutionGroup="xbrli:item" />
<element name="SeriesUWarrantsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="pstv_SeriesUWarrantsMember" substitutionGroup="xbrli:item" />
<element name="RepresentativeSeriesUWarrantMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="pstv_RepresentativeSeriesUWarrantMember" substitutionGroup="xbrli:item" />
<element name="AggregateExpenseIncludingFeeAndDisbursementExpenses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="pstv_AggregateExpenseIncludingFeeAndDisbursementExpenses" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="CommonStockSalesAvailableForIssuance" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="pstv_CommonStockSalesAvailableForIssuance" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="GrossProceedsFromIssuanceOfCommonStock" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="pstv_GrossProceedsFromIssuanceOfCommonStock" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="InitialCommitmentFee" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="pstv_InitialCommitmentFee" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="InitialCommitmentShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="pstv_InitialCommitmentShares" substitutionGroup="xbrli:item" />
<element name="MaximumValueOfSharesToBeIssuedUnderAgreement" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="pstv_MaximumValueOfSharesToBeIssuedUnderAgreement" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="NumberOfMaximumCommonSharesCanBeResale" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="pstv_NumberOfMaximumCommonSharesCanBeResale" substitutionGroup="xbrli:item" />
<element name="PercentageIssuanceOfCommonStock" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="pstv_PercentageIssuanceOfCommonStock" substitutionGroup="xbrli:item" />
<element name="PercentageOfCommissionOnGrossProceedsFromSaleOfCommonStock" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="pstv_PercentageOfCommissionOnGrossProceedsFromSaleOfCommonStock" substitutionGroup="xbrli:item" />
<element name="PeriodExercisableFromTheDateOfIssuance" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="pstv_PeriodExercisableFromTheDateOfIssuance" substitutionGroup="xbrli:item" />
<element name="JanuaryTwoThousandAndTwentyTwoDistributionAgreementMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="pstv_JanuaryTwoThousandAndTwentyTwoDistributionAgreementMember" substitutionGroup="xbrli:item" />
<element name="SeptemberTwoThousandAndTwentyTwoDistributionAgreementMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="pstv_SeptemberTwoThousandAndTwentyTwoDistributionAgreementMember" substitutionGroup="xbrli:item" />
<element name="TwentyTwentyPurchaseAgreementMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="pstv_TwentyTwentyPurchaseAgreementMember" substitutionGroup="xbrli:item" />
<element name="TwoThousandAndTwentyTwoPurchaseAgreementMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="pstv_TwoThousandAndTwentyTwoPurchaseAgreementMember" substitutionGroup="xbrli:item" />
<element name="CanaccordGenuityLLCMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="pstv_CanaccordGenuityLLCMember" substitutionGroup="xbrli:item" />
<element name="LincolnParkCapitalFundLLCMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="pstv_LincolnParkCapitalFundLLCMember" substitutionGroup="xbrli:item" />
<element name="AtTheMarketOfferingProgramMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="pstv_AtTheMarketOfferingProgramMember" substitutionGroup="xbrli:item" />
<element name="StockBasedCompensation2015EquityIncentivePlan1Member" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="pstv_StockBasedCompensation2015EquityIncentivePlan1Member" substitutionGroup="xbrli:item" />
<element name="StockBasedCompensation2020EquityIncentivePlanMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="pstv_StockBasedCompensation2020EquityIncentivePlanMember" substitutionGroup="xbrli:item" />
<element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="pstv_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" substitutionGroup="xbrli:item" />
<element name="BioceptAssetPurchaseMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="pstv_BioceptAssetPurchaseMember" substitutionGroup="xbrli:item" />
<element name="SeriesAWarrantMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="pstv_SeriesAWarrantMember" substitutionGroup="xbrli:item" />
<element name="SeriesBWarrantMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="pstv_SeriesBWarrantMember" substitutionGroup="xbrli:item" />
<element name="PershingCreditFacilityMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="pstv_PershingCreditFacilityMember" substitutionGroup="xbrli:item" />
<element name="ClassOfWarrantOrRightExercisePriceAdditionalSubscription" type="dtr-types:perShareItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="pstv_ClassOfWarrantOrRightExercisePriceAdditionalSubscription" substitutionGroup="xbrli:item" />
<element name="ClassOfWarrantOrRightExercisePriceInitialSubscription" type="dtr-types:perShareItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="pstv_ClassOfWarrantOrRightExercisePriceInitialSubscription" substitutionGroup="xbrli:item" />
<element name="ClassOfWarrantOrRightOfferingPrice" type="dtr-types:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="pstv_ClassOfWarrantOrRightOfferingPrice" substitutionGroup="xbrli:item" />
<element name="ClassOfWarrantOrRightPurchasePrice" type="dtr-types:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="pstv_ClassOfWarrantOrRightPurchasePrice" substitutionGroup="xbrli:item" />
<element name="May2024PrivatePlacementMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="pstv_May2024PrivatePlacementMember" substitutionGroup="xbrli:item" />
<element name="PreFundedWarrantMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="pstv_PreFundedWarrantMember" substitutionGroup="xbrli:item" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>7
<FILENAME>pstv-20240331_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--Generated by DFIN XBRL Instance Document - http://www.dfinsolutions.com/ - Version R3.0 - on 07-June-2024 [02:05:21] {PM}-->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<roleRef xlink:type="simple" xlink:href="pstv-20240331.xsd#CondensedBalanceSheetsUnaudited" roleURI="http://plus.com/role/CondensedBalanceSheetsUnaudited" />
<roleRef xlink:type="simple" xlink:href="pstv-20240331.xsd#CondensedStatementsOfOperationsUnaudited" roleURI="http://plus.com/role/CondensedStatementsOfOperationsUnaudited" />
<roleRef xlink:type="simple" xlink:href="pstv-20240331.xsd#CondensedStatementsOfCashFlowsUnaudited" roleURI="http://plus.com/role/CondensedStatementsOfCashFlowsUnaudited" />
<roleRef xlink:type="simple" xlink:href="pstv-20240331.xsd#CompositionOfCertainFinancialStatementCaptionsOtherCurrentAssetsDetails" roleURI="http://plus.com/role/CompositionOfCertainFinancialStatementCaptionsOtherCurrentAssetsDetails" />
<roleRef xlink:type="simple" xlink:href="pstv-20240331.xsd#CompositionOfCertainFinancialStatementCaptionsPropertyAndEquipmentNetDetails" roleURI="http://plus.com/role/CompositionOfCertainFinancialStatementCaptionsPropertyAndEquipmentNetDetails" />
<roleRef xlink:type="simple" xlink:href="pstv-20240331.xsd#CompositionOfCertainFinancialStatementCaptionsAccountsPayableAndAccruedExpensesDetails" roleURI="http://plus.com/role/CompositionOfCertainFinancialStatementCaptionsAccountsPayableAndAccruedExpensesDetails" />
<roleRef xlink:type="simple" xlink:href="pstv-20240331.xsd#CommitmentsAndContingenciesSummaryOfLeaseCostsDetails" roleURI="http://plus.com/role/CommitmentsAndContingenciesSummaryOfLeaseCostsDetails" />
<roleRef xlink:type="simple" xlink:href="pstv-20240331.xsd#CommitmentsAndContingenciesSummaryOfFutureMinimumAnnualLeasePaymentsUnderOperatingLeasesDetails" roleURI="http://plus.com/role/CommitmentsAndContingenciesSummaryOfFutureMinimumAnnualLeasePaymentsUnderOperatingLeasesDetails" />
<roleRef xlink:type="simple" xlink:href="pstv-20240331.xsd#IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails" roleURI="http://plus.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails" />
<roleRef xlink:type="simple" xlink:href="pstv-20240331.xsd#CommitmentsAndContingenciesSummaryOfFutureMinimumAnnualLeasePaymentsUnderOperatingLeasesDetailsAlternate1" roleURI="http://plus.com/role/CommitmentsAndContingenciesSummaryOfFutureMinimumAnnualLeasePaymentsUnderOperatingLeasesDetailsAlternate1" />
<calculationLink xlink:type="extended" xlink:role="http://plus.com/role/CondensedBalanceSheetsUnaudited">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_AssetsCurrent" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaap_OtherAssetsCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_OtherAssetsCurrent" use="optional" order="3" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermInvestments" xlink:label="loc_us-gaap_ShortTermInvestments" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_ShortTermInvestments" use="optional" order="4" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet" use="optional" order="5" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset" use="optional" order="6" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_Goodwill" use="optional" order="7" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherIntangibleAssetsNet" xlink:label="loc_us-gaap_OtherIntangibleAssetsNet" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_OtherIntangibleAssetsNet" use="optional" order="8" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_OtherAssetsNoncurrent" use="optional" order="9" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://plus.com/role/CondensedBalanceSheetsUnaudited">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaap_Liabilities" use="optional" order="10" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities" xlink:to="loc_us-gaap_LiabilitiesCurrent" use="optional" order="11" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" use="optional" order="12" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent" use="optional" order="13" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtCurrent" xlink:label="loc_us-gaap_LongTermDebtCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_LongTermDebtCurrent" use="optional" order="14" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeCurrent" xlink:label="loc_us-gaap_DeferredIncomeCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_DeferredIncomeCurrent" use="optional" order="15" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" use="optional" order="16" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="loc_us-gaap_LongTermDebtNoncurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities" xlink:to="loc_us-gaap_LongTermDebtNoncurrent" use="optional" order="17" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeNoncurrent" xlink:label="loc_us-gaap_DeferredIncomeNoncurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities" xlink:to="loc_us-gaap_DeferredIncomeNoncurrent" use="optional" order="18" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaap_StockholdersEquity" use="optional" order="19" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_PreferredStockValue" use="optional" order="20" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_CommonStockValue" use="optional" order="21" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockCommonValue" xlink:label="loc_us-gaap_TreasuryStockCommonValue" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_TreasuryStockCommonValue" use="optional" order="22" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_AdditionalPaidInCapital" use="optional" order="23" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit" use="optional" order="24" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaap_CommitmentsAndContingencies" use="optional" order="25" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://plus.com/role/CommitmentsAndContingenciesSummaryOfFutureMinimumAnnualLeasePaymentsUnderOperatingLeasesDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" use="optional" order="3" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://plus.com/role/CommitmentsAndContingenciesSummaryOfFutureMinimumAnnualLeasePaymentsUnderOperatingLeasesDetailsAlternate1">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" use="optional" order="4" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaap_OperatingLeaseLiability" use="optional" order="5" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://plus.com/role/CommitmentsAndContingenciesSummaryOfLeaseCostsDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCost" xlink:label="loc_us-gaap_LeaseCost" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseCost" xlink:label="loc_us-gaap_OperatingLeaseCost" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost" xlink:to="loc_us-gaap_OperatingLeaseCost" use="optional" order="1" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://plus.com/role/CommitmentsAndContingenciesSummaryOfLeaseCostsDetails">
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities" xlink:label="loc_PSTV_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasePayments" xlink:label="loc_us-gaap_OperatingLeasePayments" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_PSTV_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities" xlink:to="loc_us-gaap_OperatingLeasePayments" use="optional" order="2" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://plus.com/role/CompositionOfCertainFinancialStatementCaptionsAccountsPayableAndAccruedExpensesDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="loc_us-gaap_AccountsPayableCurrent" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedBonusesCurrent" xlink:label="loc_us-gaap_AccruedBonusesCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="loc_us-gaap_AccruedBonusesCurrent" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent" use="optional" order="3" weight="1" />
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_AccruedVacationAndCompensationCurrent" xlink:label="loc_PSTV_AccruedVacationAndCompensationCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="loc_PSTV_AccruedVacationAndCompensationCurrent" use="optional" order="4" weight="1" />
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_AccruedResearchAndDevelopmentStudies" xlink:label="loc_PSTV_AccruedResearchAndDevelopmentStudies" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="loc_PSTV_AccruedResearchAndDevelopmentStudies" use="optional" order="5" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://plus.com/role/CompositionOfCertainFinancialStatementCaptionsOtherCurrentAssetsDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaap_OtherAssetsCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherPrepaidExpenseCurrent" xlink:label="loc_us-gaap_OtherPrepaidExpenseCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherAssetsCurrent" xlink:to="loc_us-gaap_OtherPrepaidExpenseCurrent" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidInsurance" xlink:label="loc_us-gaap_PrepaidInsurance" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherAssetsCurrent" xlink:to="loc_us-gaap_PrepaidInsurance" use="optional" order="2" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://plus.com/role/CompositionOfCertainFinancialStatementCaptionsPropertyAndEquipmentNetDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_OfficeAndComputerEquipmentGross" xlink:label="loc_PSTV_OfficeAndComputerEquipmentGross" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="loc_PSTV_OfficeAndComputerEquipmentGross" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdImprovementsGross" xlink:label="loc_us-gaap_LeaseholdImprovementsGross" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="loc_us-gaap_LeaseholdImprovementsGross" use="optional" order="3" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" use="optional" order="4" weight="-1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://plus.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="loc_us-gaap_DeferredTaxLiabilities" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaap_DeferredTaxAssetsNet" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxLiabilities" xlink:to="loc_us-gaap_DeferredTaxAssetsNet" use="optional" order="1" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaap_DeferredTaxAssetsGross" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet" xlink:to="loc_us-gaap_DeferredTaxAssetsGross" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" use="optional" order="3" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" use="optional" order="4" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" use="optional" order="5" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" use="optional" order="6" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:label="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" use="optional" order="7" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:label="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" use="optional" order="8" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="loc_us-gaap_DeferredTaxAssetsOther" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="loc_us-gaap_DeferredTaxAssetsOther" use="optional" order="9" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance" use="optional" order="10" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxLiabilities" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities" use="optional" order="11" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesOther" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesOther" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesOther" use="optional" order="12" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://plus.com/role/CondensedStatementsOfCashFlowsUnaudited">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" use="optional" order="2" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization" use="optional" order="3" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_NetIncomeLoss" use="optional" order="4" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" use="optional" order="5" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts" use="optional" order="6" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" use="optional" order="7" weight="1" />
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_CommonStockIssuedForResearchAndDevelopment" xlink:label="loc_PSTV_CommonStockIssuedForResearchAndDevelopment" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_PSTV_CommonStockIssuedForResearchAndDevelopment" use="optional" order="8" weight="1" />
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_IncreaseDecreaseInDeferredGrantLiability" xlink:label="loc_PSTV_IncreaseDecreaseInDeferredGrantLiability" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_PSTV_IncreaseDecreaseInDeferredGrantLiability" use="optional" order="9" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants" use="optional" order="10" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnDispositionOfAssets" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_GainLossOnDispositionOfAssets" use="optional" order="11" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_ShareBasedCompensation" use="optional" order="12" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" use="optional" order="13" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherCurrentAssets" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherCurrentAssets" use="optional" order="14" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" use="optional" order="15" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" use="optional" order="16" weight="1" />
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_PaymentsToAcquirePropertyPlantAndEquipmentAndIntangibleAssets" xlink:label="loc_PSTV_PaymentsToAcquirePropertyPlantAndEquipmentAndIntangibleAssets" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="loc_PSTV_PaymentsToAcquirePropertyPlantAndEquipmentAndIntangibleAssets" use="optional" order="17" weight="-1" />
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_CashPaidForIPRDAssetAcquiredInAnAssetAcquisition" xlink:label="loc_PSTV_CashPaidForIPRDAssetAcquiredInAnAssetAcquisition" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="loc_PSTV_CashPaidForIPRDAssetAcquiredInAnAssetAcquisition" use="optional" order="18" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" use="optional" order="19" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireShortTermInvestments" xlink:label="loc_us-gaap_PaymentsToAcquireShortTermInvestments" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaap_PaymentsToAcquireShortTermInvestments" use="optional" order="20" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" use="optional" order="21" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt" use="optional" order="22" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" use="optional" order="23" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts" use="optional" order="24" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForRepurchaseOfEquity" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfEquity" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfEquity" use="optional" order="25" weight="-1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://plus.com/role/CondensedStatementsOfOperationsUnaudited">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="loc_us-gaap_OperatingIncomeLoss" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="loc_us-gaap_OperatingExpenses" use="optional" order="2" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense" use="optional" order="3" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense" use="optional" order="4" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="loc_us-gaap_Revenues" use="optional" order="5" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="loc_us-gaap_NonoperatingIncomeExpense" use="optional" order="6" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="loc_us-gaap_InvestmentIncomeInterest" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="loc_us-gaap_InvestmentIncomeInterest" use="optional" order="7" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="loc_us-gaap_InterestExpense" use="optional" order="8" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesFairValueAdjustment" xlink:label="loc_us-gaap_LiabilitiesFairValueAdjustment" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="loc_us-gaap_LiabilitiesFairValueAdjustment" use="optional" order="9" weight="1" />
</calculationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>8
<FILENAME>pstv-20240331_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--Generated by DFIN XBRL Instance Document - http://www.dfinsolutions.com/ - Version R3.0 - on 07-June-2024 [02:05:21] {PM}-->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
<roleRef xlink:type="simple" xlink:href="pstv-20240331.xsd#CoverPage" roleURI="http://plus.com/role/CoverPage" />
<roleRef xlink:type="simple" xlink:href="pstv-20240331.xsd#CondensedStatementsOfOperationsUnaudited" roleURI="http://plus.com/role/CondensedStatementsOfOperationsUnaudited" />
<roleRef xlink:type="simple" xlink:href="pstv-20240331.xsd#CondensedStatementsOfStockholdersEquityDeficitUnaudited" roleURI="http://plus.com/role/CondensedStatementsOfStockholdersEquityDeficitUnaudited" />
<roleRef xlink:type="simple" xlink:href="pstv-20240331.xsd#BasisOfPresentationAndNewAccountingStandardsAdditionalInformationDetails" roleURI="http://plus.com/role/BasisOfPresentationAndNewAccountingStandardsAdditionalInformationDetails" />
<roleRef xlink:type="simple" xlink:href="pstv-20240331.xsd#OrganizationAndOperationsAdditionalInformationDetails" roleURI="http://plus.com/role/OrganizationAndOperationsAdditionalInformationDetails" />
<roleRef xlink:type="simple" xlink:href="pstv-20240331.xsd#SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" roleURI="http://plus.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" />
<roleRef xlink:type="simple" xlink:href="pstv-20240331.xsd#LiquidityAndGoingConcernAdditionalInformationDetails" roleURI="http://plus.com/role/LiquidityAndGoingConcernAdditionalInformationDetails" />
<roleRef xlink:type="simple" xlink:href="pstv-20240331.xsd#FairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails" roleURI="http://plus.com/role/FairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails" />
<roleRef xlink:type="simple" xlink:href="pstv-20240331.xsd#LossPerShareScheduleOfAntidilutiveSecuritiesExcludedFromDilutedIncomeLossPerShareDetails" roleURI="http://plus.com/role/LossPerShareScheduleOfAntidilutiveSecuritiesExcludedFromDilutedIncomeLossPerShareDetails" />
<roleRef xlink:type="simple" xlink:href="pstv-20240331.xsd#CommitmentsAndContingenciesAdditionalInformationDetails" roleURI="http://plus.com/role/CommitmentsAndContingenciesAdditionalInformationDetails" />
<roleRef xlink:type="simple" xlink:href="pstv-20240331.xsd#LicenseAgreementsAdditionalInformationDetails" roleURI="http://plus.com/role/LicenseAgreementsAdditionalInformationDetails" />
<roleRef xlink:type="simple" xlink:href="pstv-20240331.xsd#TermLoanObligationsAdditionalInformationDetails" roleURI="http://plus.com/role/TermLoanObligationsAdditionalInformationDetails" />
<roleRef xlink:type="simple" xlink:href="pstv-20240331.xsd#TermLoanObligationsTermLoanOutstandingDetails" roleURI="http://plus.com/role/TermLoanObligationsTermLoanOutstandingDetails" />
<roleRef xlink:type="simple" xlink:href="pstv-20240331.xsd#GrantRevenueAdditionalInformationDetails" roleURI="http://plus.com/role/GrantRevenueAdditionalInformationDetails" />
<roleRef xlink:type="simple" xlink:href="pstv-20240331.xsd#IncomeTaxesAdditionalInformationDetails" roleURI="http://plus.com/role/IncomeTaxesAdditionalInformationDetails" />
<roleRef xlink:type="simple" xlink:href="pstv-20240331.xsd#EmployeeBenefitPlanAdditionalInformationDetails" roleURI="http://plus.com/role/EmployeeBenefitPlanAdditionalInformationDetails" />
<roleRef xlink:type="simple" xlink:href="pstv-20240331.xsd#StockholdersEquityPreferredStockDetails" roleURI="http://plus.com/role/StockholdersEquityPreferredStockDetails" />
<roleRef xlink:type="simple" xlink:href="pstv-20240331.xsd#StockholdersEquityWarrantsDetails" roleURI="http://plus.com/role/StockholdersEquityWarrantsDetails" />
<roleRef xlink:type="simple" xlink:href="pstv-20240331.xsd#StockholdersEquityCommonStockDetails" roleURI="http://plus.com/role/StockholdersEquityCommonStockDetails" />
<roleRef xlink:type="simple" xlink:href="pstv-20240331.xsd#StockBasedCompensationAdditionalInformationDetails" roleURI="http://plus.com/role/StockBasedCompensationAdditionalInformationDetails" />
<roleRef xlink:type="simple" xlink:href="pstv-20240331.xsd#StockBasedCompensationSummaryOfShareBasedCompensationRecognizedDetails" roleURI="http://plus.com/role/StockBasedCompensationSummaryOfShareBasedCompensationRecognizedDetails" />
<roleRef xlink:type="simple" xlink:href="pstv-20240331.xsd#SubsequentEventsAdditionalInformationDetails" roleURI="http://plus.com/role/SubsequentEventsAdditionalInformationDetails" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" />
<definitionLink xlink:type="extended" xlink:role="http://plus.com/role/CoverPage">
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationLineItems" xlink:label="loc_dei_DocumentInformationLineItems_1529" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationTable" xlink:label="loc_dei_DocumentInformationTable_1525" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_dei_DocumentInformationLineItems_1529" xlink:to="loc_dei_DocumentInformationTable_1525" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressesAddressTypeAxis" xlink:label="loc_dei_EntityAddressesAddressTypeAxis_1526" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dei_DocumentInformationTable_1525" xlink:to="loc_dei_EntityAddressesAddressTypeAxis_1526" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AddressTypeDomain" xlink:label="loc_dei_AddressTypeDomain_1527" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_EntityAddressesAddressTypeAxis_1526" xlink:to="loc_dei_AddressTypeDomain_1527" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AddressTypeDomain" xlink:label="loc_dei_AddressTypeDomain_1527_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_EntityAddressesAddressTypeAxis_1526" xlink:to="loc_dei_AddressTypeDomain_1527_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_BusinessContactMember" xlink:label="loc_dei_BusinessContactMember_1528" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_AddressTypeDomain_1527" xlink:to="loc_dei_BusinessContactMember_1528" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_116" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_1529" xlink:to="loc_dei_AmendmentFlag_116" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="loc_dei_CityAreaCode_133" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_1529" xlink:to="loc_dei_CityAreaCode_133" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_ContactPersonnelName" xlink:label="loc_dei_ContactPersonnelName_1530" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_1529" xlink:to="loc_dei_ContactPersonnelName_1530" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_115" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_1529" xlink:to="loc_dei_DocumentType_115" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_102" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_1529" xlink:to="loc_dei_EntityRegistrantName_102" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_103" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_1529" xlink:to="loc_dei_EntityCentralIndexKey_103" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_110" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_1529" xlink:to="loc_dei_EntityFilerCategory_110" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="loc_dei_EntitySmallBusiness_119" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_1529" xlink:to="loc_dei_EntitySmallBusiness_119" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_dei_EntityEmergingGrowthCompany_120" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_1529" xlink:to="loc_dei_EntityEmergingGrowthCompany_120" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_dei_EntityIncorporationStateCountryCode_126" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_1529" xlink:to="loc_dei_EntityIncorporationStateCountryCode_126" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_dei_EntityTaxIdentificationNumber_127" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_1529" xlink:to="loc_dei_EntityTaxIdentificationNumber_127" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_dei_EntityAddressAddressLine1_128" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_1529" xlink:to="loc_dei_EntityAddressAddressLine1_128" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_dei_EntityAddressAddressLine2_129" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_1529" xlink:to="loc_dei_EntityAddressAddressLine2_129" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_dei_EntityAddressCityOrTown_130" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_1529" xlink:to="loc_dei_EntityAddressCityOrTown_130" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_dei_EntityAddressStateOrProvince_131" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_1529" xlink:to="loc_dei_EntityAddressStateOrProvince_131" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_dei_EntityAddressPostalZipCode_132" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_1529" xlink:to="loc_dei_EntityAddressPostalZipCode_132" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="loc_dei_LocalPhoneNumber_134" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_1529" xlink:to="loc_dei_LocalPhoneNumber_134" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_dei_EntityPrimarySicNumber_1524" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_1529" xlink:to="loc_dei_EntityPrimarySicNumber_1524" use="optional" order="23" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://plus.com/role/CondensedStatementsOfOperationsUnaudited">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_194" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_187" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_194" xlink:to="loc_us-gaap_StatementTable_187" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_189" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_187" xlink:to="loc_srt_ProductOrServiceAxis_189" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_191" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_189" xlink:to="loc_srt_ProductsAndServicesDomain_191" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_191_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_189" xlink:to="loc_srt_ProductsAndServicesDomain_191_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GrantMember" xlink:label="loc_us-gaap_GrantMember_188" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_191" xlink:to="loc_us-gaap_GrantMember_188" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_190" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_194" xlink:to="loc_us-gaap_Revenues_190" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract_195" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_194" xlink:to="loc_us-gaap_OperatingExpensesAbstract_195" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_186" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_195" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_186" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_193" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_195" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_193" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_197" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_195" xlink:to="loc_us-gaap_OperatingExpenses_197" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_198" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_194" xlink:to="loc_us-gaap_OperatingIncomeLoss_198" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherIncomeAndExpensesAbstract" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract_200" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_194" xlink:to="loc_us-gaap_OtherIncomeAndExpensesAbstract_200" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="loc_us-gaap_InvestmentIncomeInterest_192" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_200" xlink:to="loc_us-gaap_InvestmentIncomeInterest_192" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense_196" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_200" xlink:to="loc_us-gaap_InterestExpense_196" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesFairValueAdjustment" xlink:label="loc_us-gaap_LiabilitiesFairValueAdjustment_199" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_200" xlink:to="loc_us-gaap_LiabilitiesFairValueAdjustment_199" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_201" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_200" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_201" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_203" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_200" xlink:to="loc_us-gaap_NetIncomeLoss_203" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic_202" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_194" xlink:to="loc_us-gaap_EarningsPerShareBasic_202" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted_204" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_194" xlink:to="loc_us-gaap_EarningsPerShareDiluted_204" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_205" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_194" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_205" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_206" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_194" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_206" use="optional" order="21" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://plus.com/role/CondensedStatementsOfStockholdersEquityDeficitUnaudited">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_221" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_209" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_221" xlink:to="loc_us-gaap_StatementTable_209" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_213" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_209" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_213" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_212" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_213" xlink:to="loc_us-gaap_EquityComponentDomain_212" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_212_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_213" xlink:to="loc_us-gaap_EquityComponentDomain_212_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaap_PreferredStockMember_211" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_212" xlink:to="loc_us-gaap_PreferredStockMember_211" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_216" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_212" xlink:to="loc_us-gaap_CommonStockMember_216" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockCommonMember" xlink:label="loc_us-gaap_TreasuryStockCommonMember_225" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_212" xlink:to="loc_us-gaap_TreasuryStockCommonMember_225" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_220" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_212" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_220" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_223" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_212" xlink:to="loc_us-gaap_RetainedEarningsMember_223" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_217" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_209" xlink:to="loc_us-gaap_StatementClassOfStockAxis_217" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_219" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_217" xlink:to="loc_us-gaap_ClassOfStockDomain_219" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_219_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_217" xlink:to="loc_us-gaap_ClassOfStockDomain_219_default" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesFPreferredStockMember" xlink:label="loc_us-gaap_SeriesFPreferredStockMember_210" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_219" xlink:to="loc_us-gaap_SeriesFPreferredStockMember_210" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="loc_us-gaap_ConvertiblePreferredStockMember_215" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_219" xlink:to="loc_us-gaap_ConvertiblePreferredStockMember_215" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_222" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_221" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_222" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_214" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_221" xlink:to="loc_us-gaap_StockholdersEquity_214" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_218" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_221" xlink:to="loc_us-gaap_SharesOutstanding_218" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_224" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_221" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_224" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_226" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_221" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_226" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRedeemedOrCalledDuringPeriodShares" xlink:label="loc_us-gaap_StockRedeemedOrCalledDuringPeriodShares_227" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_221" xlink:to="loc_us-gaap_StockRedeemedOrCalledDuringPeriodShares_227" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_228" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_221" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_228" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_229" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_221" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_229" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_FractionalAdjustmentOfCommonStock" xlink:label="loc_pstv_FractionalAdjustmentOfCommonStock_230" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_221" xlink:to="loc_pstv_FractionalAdjustmentOfCommonStock_230" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_231" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_221" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_231" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockSharesAcquired" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_232" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_221" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_232" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_233" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_221" xlink:to="loc_us-gaap_NetIncomeLoss_233" use="optional" order="26" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://plus.com/role/BasisOfPresentationAndNewAccountingStandardsAdditionalInformationDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_1009" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_981" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_1009" xlink:to="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_981" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_978" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_981" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_978" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_980" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_978" xlink:to="loc_us-gaap_TypeOfAdoptionMember_980" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_980_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_978" xlink:to="loc_us-gaap_TypeOfAdoptionMember_980_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_990" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_981" xlink:to="loc_srt_RangeAxis_990" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_976" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_990" xlink:to="loc_srt_RangeMember_976" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_976_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_990" xlink:to="loc_srt_RangeMember_976_default" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_975" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_976" xlink:to="loc_srt_MinimumMember_975" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_989" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_976" xlink:to="loc_srt_MaximumMember_989" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_1001" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_981" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_1001" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_977" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1001" xlink:to="loc_us-gaap_EquityComponentDomain_977" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_977_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1001" xlink:to="loc_us-gaap_EquityComponentDomain_977_default" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_OutstandingWarrantsAndOptionsMember" xlink:label="loc_pstv_OutstandingWarrantsAndOptionsMember_974" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_977" xlink:to="loc_pstv_OutstandingWarrantsAndOptionsMember_974" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_1003" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_981" xlink:to="loc_us-gaap_PlanNameAxis_1003" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_973" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_1003" xlink:to="loc_us-gaap_PlanNameDomain_973" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_973_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_1003" xlink:to="loc_us-gaap_PlanNameDomain_973_default" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_EquityIncentivePlansMember" xlink:label="loc_pstv_EquityIncentivePlansMember_971" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_973" xlink:to="loc_pstv_EquityIncentivePlansMember_971" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_1002" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_1009" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_1002" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_1014" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_1009" xlink:to="loc_us-gaap_CommonStockSharesIssued_1014" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_1018" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_1009" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_1018" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_1019" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_1009" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_1019" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain_1026" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_1009" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain_1026" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_1008" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_1009" xlink:to="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_1008" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_ReverseStockSplitEffectiveDate" xlink:label="loc_pstv_ReverseStockSplitEffectiveDate_1010" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_1009" xlink:to="loc_pstv_ReverseStockSplitEffectiveDate_1010" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockSplits" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockSplits_1022" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_1009" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockSplits_1022" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits_1023" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_1009" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits_1023" use="optional" order="26" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://plus.com/role/OrganizationAndOperationsAdditionalInformationDetails">
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_OrganizationAndOperationsLineItems" xlink:label="loc_pstv_OrganizationAndOperationsLineItems_392" />
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_OrganizationAndOperationsTable" xlink:label="loc_pstv_OrganizationAndOperationsTable_380" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_pstv_OrganizationAndOperationsLineItems_392" xlink:to="loc_pstv_OrganizationAndOperationsTable_380" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_382" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_pstv_OrganizationAndOperationsTable_380" xlink:to="loc_us-gaap_DebtInstrumentAxis_382" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_387" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_382" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_387" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_387_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_382" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_387_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_TermLoanMember" xlink:label="loc_pstv_TermLoanMember_378" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_387" xlink:to="loc_pstv_TermLoanMember_378" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_385" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_pstv_OrganizationAndOperationsTable_380" xlink:to="loc_srt_RangeAxis_385" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_377" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_385" xlink:to="loc_srt_RangeMember_377" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_377_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_385" xlink:to="loc_srt_RangeMember_377_default" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_376" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_377" xlink:to="loc_srt_MinimumMember_376" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_383" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_377" xlink:to="loc_srt_MaximumMember_383" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_388" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_pstv_OrganizationAndOperationsTable_380" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_388" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_379" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_388" xlink:to="loc_us-gaap_EquityComponentDomain_379" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_379_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_388" xlink:to="loc_us-gaap_EquityComponentDomain_379_default" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_OutstandingWarrantsAndOptionsMember" xlink:label="loc_pstv_OutstandingWarrantsAndOptionsMember_375" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_379" xlink:to="loc_pstv_OutstandingWarrantsAndOptionsMember_375" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_390" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_pstv_OrganizationAndOperationsTable_380" xlink:to="loc_us-gaap_PlanNameAxis_390" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_374" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_390" xlink:to="loc_us-gaap_PlanNameDomain_374" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_374_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_390" xlink:to="loc_us-gaap_PlanNameDomain_374_default" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_EquityIncentivePlansMember" xlink:label="loc_pstv_EquityIncentivePlansMember_373" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_374" xlink:to="loc_pstv_EquityIncentivePlansMember_373" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_381" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pstv_OrganizationAndOperationsLineItems_392" xlink:to="loc_us-gaap_NetIncomeLoss_381" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_386" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pstv_OrganizationAndOperationsLineItems_392" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_386" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_389" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pstv_OrganizationAndOperationsLineItems_392" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_389" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_LongTermDebtOutstandingThresholdAmount" xlink:label="loc_pstv_LongTermDebtOutstandingThresholdAmount_391" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pstv_OrganizationAndOperationsLineItems_392" xlink:to="loc_pstv_LongTermDebtOutstandingThresholdAmount_391" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFeeAmount" xlink:label="loc_us-gaap_DebtInstrumentFeeAmount_393" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pstv_OrganizationAndOperationsLineItems_392" xlink:to="loc_us-gaap_DebtInstrumentFeeAmount_393" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="loc_us-gaap_DebtInstrumentMaturityDate_394" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pstv_OrganizationAndOperationsLineItems_392" xlink:to="loc_us-gaap_DebtInstrumentMaturityDate_394" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_396" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pstv_OrganizationAndOperationsLineItems_392" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_396" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_399" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pstv_OrganizationAndOperationsLineItems_392" xlink:to="loc_us-gaap_CommonStockSharesIssued_399" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_401" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pstv_OrganizationAndOperationsLineItems_392" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_401" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_402" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pstv_OrganizationAndOperationsLineItems_392" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_402" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_384" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pstv_OrganizationAndOperationsLineItems_392" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_384" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_395" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pstv_OrganizationAndOperationsLineItems_392" xlink:to="loc_us-gaap_StockholdersEquity_395" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_397" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pstv_OrganizationAndOperationsLineItems_392" xlink:to="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_397" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockSplits" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockSplits_403" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pstv_OrganizationAndOperationsLineItems_392" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockSplits_403" use="optional" order="32" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits_404" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pstv_OrganizationAndOperationsLineItems_392" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits_404" use="optional" order="33" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://plus.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails">
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_SummaryOfSignificantAccountingPoliciesLineItems" xlink:label="loc_pstv_SummaryOfSignificantAccountingPoliciesLineItems_434" />
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_SummaryOfSignificantAccountingPoliciesTable" xlink:label="loc_pstv_SummaryOfSignificantAccountingPoliciesTable_412" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_pstv_SummaryOfSignificantAccountingPoliciesLineItems_434" xlink:to="loc_pstv_SummaryOfSignificantAccountingPoliciesTable_412" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_417" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_pstv_SummaryOfSignificantAccountingPoliciesTable_412" xlink:to="loc_srt_RangeAxis_417" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_414" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_417" xlink:to="loc_srt_RangeMember_414" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_414_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_417" xlink:to="loc_srt_RangeMember_414_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_413" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_414" xlink:to="loc_srt_MinimumMember_413" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_423" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_414" xlink:to="loc_srt_MaximumMember_423" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_425" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_pstv_SummaryOfSignificantAccountingPoliciesTable_412" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_425" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_410" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_425" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_410" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_410_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_425" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_410_default" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InProcessResearchAndDevelopmentMember" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_411" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_410" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_411" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_428" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_pstv_SummaryOfSignificantAccountingPoliciesTable_412" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_428" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_418" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_428" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_418" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_418_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_428" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_418_default" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_430" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_pstv_SummaryOfSignificantAccountingPoliciesTable_412" xlink:to="loc_srt_ProductOrServiceAxis_430" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_421" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_430" xlink:to="loc_srt_ProductsAndServicesDomain_421" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_421_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_430" xlink:to="loc_srt_ProductsAndServicesDomain_421_default" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_432" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_pstv_SummaryOfSignificantAccountingPoliciesTable_412" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_432" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_422" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_432" xlink:to="loc_us-gaap_TypeOfAdoptionMember_422" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_422_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_432" xlink:to="loc_us-gaap_TypeOfAdoptionMember_422_default" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingStandardsUpdate201613Member" xlink:label="loc_us-gaap_AccountingStandardsUpdate201613Member_426" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfAdoptionMember_422" xlink:to="loc_us-gaap_AccountingStandardsUpdate201613Member_426" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_424" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pstv_SummaryOfSignificantAccountingPoliciesLineItems_434" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_424" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_427" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pstv_SummaryOfSignificantAccountingPoliciesLineItems_434" xlink:to="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_427" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetImpairmentCharges" xlink:label="loc_us-gaap_AssetImpairmentCharges_431" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pstv_SummaryOfSignificantAccountingPoliciesLineItems_434" xlink:to="loc_us-gaap_AssetImpairmentCharges_431" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfReportingUnits" xlink:label="loc_us-gaap_NumberOfReportingUnits_433" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pstv_SummaryOfSignificantAccountingPoliciesLineItems_434" xlink:to="loc_us-gaap_NumberOfReportingUnits_433" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" xlink:label="loc_us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense_437" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pstv_SummaryOfSignificantAccountingPoliciesLineItems_434" xlink:to="loc_us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense_437" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="loc_us-gaap_NumberOfOperatingSegments_438" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pstv_SummaryOfSignificantAccountingPoliciesLineItems_434" xlink:to="loc_us-gaap_NumberOfOperatingSegments_438" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" xlink:label="loc_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted_439" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pstv_SummaryOfSignificantAccountingPoliciesLineItems_434" xlink:to="loc_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted_439" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" xlink:label="loc_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate_440" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pstv_SummaryOfSignificantAccountingPoliciesLineItems_434" xlink:to="loc_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate_440" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" xlink:label="loc_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect_441" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pstv_SummaryOfSignificantAccountingPoliciesLineItems_434" xlink:to="loc_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect_441" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_429" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pstv_SummaryOfSignificantAccountingPoliciesLineItems_434" xlink:to="loc_us-gaap_StockholdersEquity_429" use="optional" order="30" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://plus.com/role/LiquidityAndGoingConcernAdditionalInformationDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_999" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_958" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_999" xlink:to="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_958" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_961" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_958" xlink:to="loc_srt_RangeAxis_961" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_960" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_961" xlink:to="loc_srt_RangeMember_960" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_960_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_961" xlink:to="loc_srt_RangeMember_960_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_993" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_958" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_993" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_956" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_993" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_956" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_956_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_993" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_956_default" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_1532" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_958" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_1532" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1533" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_1532" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1533" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1533_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_1532" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1533_default" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaap_PrivatePlacementMember_1534" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1533" xlink:to="loc_us-gaap_PrivatePlacementMember_1534" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_957" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_999" xlink:to="loc_us-gaap_NetIncomeLoss_957" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_991" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_999" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_991" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_998" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_999" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_998" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperations" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperations_1011" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_999" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperations_1011" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_MaintainMinimumMarketValueOfListedSecurities" xlink:label="loc_pstv_MaintainMinimumMarketValueOfListedSecurities_1013" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_999" xlink:to="loc_pstv_MaintainMinimumMarketValueOfListedSecurities_1013" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_1004" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_999" xlink:to="loc_us-gaap_StockholdersEquity_1004" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_1007" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_999" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_1007" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="loc_us-gaap_WarrantsAndRightsOutstanding_1531" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_999" xlink:to="loc_us-gaap_WarrantsAndRightsOutstanding_1531" use="optional" order="19" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://plus.com/role/FairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_465" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_458" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_465" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_458" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_455" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_458" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_455" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_452" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_455" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_452" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_452_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_455" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_452_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_460" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_452" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_460" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_462" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_458" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_462" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_459" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_462" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_459" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_459_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_462" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_459_default" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_454" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_459" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_454" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_464" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_458" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_464" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_456" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_464" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_456" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_456_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_464" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_456_default" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="loc_us-gaap_MoneyMarketFundsMember_457" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_456" xlink:to="loc_us-gaap_MoneyMarketFundsMember_457" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_1214" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_456" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_1214" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_453" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_465" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_453" use="optional" order="15" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://plus.com/role/LossPerShareScheduleOfAntidilutiveSecuritiesExcludedFromDilutedIncomeLossPerShareDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_473" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_470" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_473" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_470" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_468" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_470" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_468" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_471" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_468" xlink:to="loc_us-gaap_EquityComponentDomain_471" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_471_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_468" xlink:to="loc_us-gaap_EquityComponentDomain_471_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_OptionsMember" xlink:label="loc_pstv_OptionsMember_469" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_471" xlink:to="loc_pstv_OptionsMember_469" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaap_PreferredStockMember_474" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_471" xlink:to="loc_us-gaap_PreferredStockMember_474" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_475" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_471" xlink:to="loc_us-gaap_WarrantMember_475" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_472" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_473" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_472" use="optional" order="8" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://plus.com/role/CommitmentsAndContingenciesAdditionalInformationDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RecordedUnconditionalPurchaseObligationLineItems" xlink:label="loc_us-gaap_RecordedUnconditionalPurchaseObligationLineItems_537" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RecordedUnconditionalPurchaseObligationTable" xlink:label="loc_us-gaap_RecordedUnconditionalPurchaseObligationTable_516" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RecordedUnconditionalPurchaseObligationLineItems_537" xlink:to="loc_us-gaap_RecordedUnconditionalPurchaseObligationTable_516" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_520" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_RecordedUnconditionalPurchaseObligationTable_516" xlink:to="loc_srt_StatementGeographicalAxis_520" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_510" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_520" xlink:to="loc_srt_SegmentGeographicalDomain_510" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_510_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_520" xlink:to="loc_srt_SegmentGeographicalDomain_510_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_526" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_RecordedUnconditionalPurchaseObligationTable_516" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_526" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_518" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_526" xlink:to="loc_us-gaap_RelatedPartyDomain_518" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_518_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_526" xlink:to="loc_us-gaap_RelatedPartyDomain_518_default" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_CharlottesvilleMember" xlink:label="loc_pstv_CharlottesvilleMember_514" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_518" xlink:to="loc_pstv_CharlottesvilleMember_514" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_MedidataSolutionsIncMember" xlink:label="loc_pstv_MedidataSolutionsIncMember_524" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_518" xlink:to="loc_pstv_MedidataSolutionsIncMember_524" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_PiramalPharmaSolutionsIncMember" xlink:label="loc_pstv_PiramalPharmaSolutionsIncMember_527" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_518" xlink:to="loc_pstv_PiramalPharmaSolutionsIncMember_527" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_529" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_RecordedUnconditionalPurchaseObligationTable_516" xlink:to="loc_us-gaap_TypeOfArrangementAxis_529" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_512" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_529" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_512" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_512_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_529" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_512_default" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_ServicesAgreementMember" xlink:label="loc_pstv_ServicesAgreementMember_509" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_512" xlink:to="loc_pstv_ServicesAgreementMember_509" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_531" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_RecordedUnconditionalPurchaseObligationTable_516" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_531" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_519" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_531" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_519" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_519_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_531" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_519_default" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis" xlink:label="loc_us-gaap_RecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis_533" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_RecordedUnconditionalPurchaseObligationTable_516" xlink:to="loc_us-gaap_RecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis_533" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain" xlink:label="loc_us-gaap_UnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain_522" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis_533" xlink:to="loc_us-gaap_UnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain_522" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain" xlink:label="loc_us-gaap_UnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain_522_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis_533" xlink:to="loc_us-gaap_UnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain_522_default" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_PreClinicalResearchStudyObligationsMember" xlink:label="loc_pstv_PreClinicalResearchStudyObligationsMember_523" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_UnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain_522" xlink:to="loc_pstv_PreClinicalResearchStudyObligationsMember_523" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_LitigationCaseAxis" xlink:label="loc_srt_LitigationCaseAxis_535" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_RecordedUnconditionalPurchaseObligationTable_516" xlink:to="loc_srt_LitigationCaseAxis_535" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_LitigationCaseTypeDomain" xlink:label="loc_srt_LitigationCaseTypeDomain_517" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_LitigationCaseAxis_535" xlink:to="loc_srt_LitigationCaseTypeDomain_517" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_LitigationCaseTypeDomain" xlink:label="loc_srt_LitigationCaseTypeDomain_517_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_LitigationCaseAxis_535" xlink:to="loc_srt_LitigationCaseTypeDomain_517_default" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_LoremVascularPteLtdMember" xlink:label="loc_pstv_LoremVascularPteLtdMember_511" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_517" xlink:to="loc_pstv_LoremVascularPteLtdMember_511" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_OperatingLeasesExpiryYear" xlink:label="loc_pstv_OperatingLeasesExpiryYear_515" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RecordedUnconditionalPurchaseObligationLineItems_537" xlink:to="loc_pstv_OperatingLeasesExpiryYear_515" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_525" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RecordedUnconditionalPurchaseObligationLineItems_537" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_525" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:label="loc_us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend_528" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RecordedUnconditionalPurchaseObligationLineItems_537" xlink:to="loc_us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend_528" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:label="loc_us-gaap_LesseeOperatingLeaseOptionToExtend_530" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RecordedUnconditionalPurchaseObligationLineItems_537" xlink:to="loc_us-gaap_LesseeOperatingLeaseOptionToExtend_530" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_532" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RecordedUnconditionalPurchaseObligationLineItems_537" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_532" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_534" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RecordedUnconditionalPurchaseObligationLineItems_537" xlink:to="loc_us-gaap_OperatingLeaseLiability_534" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseDiscountRate" xlink:label="loc_us-gaap_LesseeOperatingLeaseDiscountRate_536" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RecordedUnconditionalPurchaseObligationLineItems_537" xlink:to="loc_us-gaap_LesseeOperatingLeaseDiscountRate_536" use="optional" order="32" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_539" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RecordedUnconditionalPurchaseObligationLineItems_537" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_539" use="optional" order="33" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseExpirationDate1" xlink:label="loc_us-gaap_LeaseExpirationDate1_540" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RecordedUnconditionalPurchaseObligationLineItems_537" xlink:to="loc_us-gaap_LeaseExpirationDate1_540" use="optional" order="34" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_541" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RecordedUnconditionalPurchaseObligationLineItems_537" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_541" use="optional" order="35" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_542" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RecordedUnconditionalPurchaseObligationLineItems_537" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_542" use="optional" order="36" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseExpense" xlink:label="loc_us-gaap_OperatingLeaseExpense_545" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RecordedUnconditionalPurchaseObligationLineItems_537" xlink:to="loc_us-gaap_OperatingLeaseExpense_545" use="optional" order="37" />
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_MasterServicesAgreementDate" xlink:label="loc_pstv_MasterServicesAgreementDate_546" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RecordedUnconditionalPurchaseObligationLineItems_537" xlink:to="loc_pstv_MasterServicesAgreementDate_546" use="optional" order="38" />
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_MasterServicesAgreementInitialTerm" xlink:label="loc_pstv_MasterServicesAgreementInitialTerm_547" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RecordedUnconditionalPurchaseObligationLineItems_537" xlink:to="loc_pstv_MasterServicesAgreementInitialTerm_547" use="optional" order="39" />
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_MasterServicesAgreementTermsDescription" xlink:label="loc_pstv_MasterServicesAgreementTermsDescription_548" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RecordedUnconditionalPurchaseObligationLineItems_537" xlink:to="loc_pstv_MasterServicesAgreementTermsDescription_548" use="optional" order="40" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractualObligation" xlink:label="loc_us-gaap_ContractualObligation_549" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RecordedUnconditionalPurchaseObligationLineItems_537" xlink:to="loc_us-gaap_ContractualObligation_549" use="optional" order="41" />
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_SalesOrderTerm" xlink:label="loc_pstv_SalesOrderTerm_550" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RecordedUnconditionalPurchaseObligationLineItems_537" xlink:to="loc_pstv_SalesOrderTerm_550" use="optional" order="42" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LitigationSettlementExpense" xlink:label="loc_us-gaap_LitigationSettlementExpense_553" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RecordedUnconditionalPurchaseObligationLineItems_537" xlink:to="loc_us-gaap_LitigationSettlementExpense_553" use="optional" order="43" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://plus.com/role/LicenseAgreementsAdditionalInformationDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_582" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_576" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_582" xlink:to="loc_us-gaap_StatementTable_576" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_579" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_576" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_579" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_577" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_579" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_577" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_577_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_579" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_577_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_BioceptAgreementMember" xlink:label="loc_pstv_BioceptAgreementMember_578" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_577" xlink:to="loc_pstv_BioceptAgreementMember_578" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_UTHSALicenseAgreementMember" xlink:label="loc_pstv_UTHSALicenseAgreementMember_581" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_577" xlink:to="loc_pstv_UTHSALicenseAgreementMember_581" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_NanoTxLicensesAgreementMember" xlink:label="loc_pstv_NanoTxLicensesAgreementMember_584" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_577" xlink:to="loc_pstv_NanoTxLicensesAgreementMember_584" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaap_SharesIssued_580" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_582" xlink:to="loc_us-gaap_SharesIssued_580" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_583" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_582" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_583" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_PaymentForTechTransferAndValidationFee" xlink:label="loc_pstv_PaymentForTechTransferAndValidationFee_585" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_582" xlink:to="loc_pstv_PaymentForTechTransferAndValidationFee_585" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_OptionForExclusiveWorldwideLicense" xlink:label="loc_pstv_OptionForExclusiveWorldwideLicense_586" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_582" xlink:to="loc_pstv_OptionForExclusiveWorldwideLicense_586" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForRoyalties" xlink:label="loc_us-gaap_PaymentsForRoyalties_587" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_582" xlink:to="loc_us-gaap_PaymentsForRoyalties_587" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_588" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_582" xlink:to="loc_us-gaap_CommonStockValue_588" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_PercentageOfNonDilutiveMonetaryAwardsRequiredToPay" xlink:label="loc_pstv_PercentageOfNonDilutiveMonetaryAwardsRequiredToPay_589" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_582" xlink:to="loc_pstv_PercentageOfNonDilutiveMonetaryAwardsRequiredToPay_589" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_AccruedLicensePayable" xlink:label="loc_pstv_AccruedLicensePayable_590" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_582" xlink:to="loc_pstv_AccruedLicensePayable_590" use="optional" order="15" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://plus.com/role/TermLoanObligationsAdditionalInformationDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_619" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_597" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_619" xlink:to="loc_us-gaap_DebtInstrumentTable_597" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_593" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_597" xlink:to="loc_us-gaap_DebtInstrumentAxis_593" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_612" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_593" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_612" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_612_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_593" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_612_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_TermLoanMember" xlink:label="loc_pstv_TermLoanMember_600" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_612" xlink:to="loc_pstv_TermLoanMember_600" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_607" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_597" xlink:to="loc_srt_RangeAxis_607" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_599" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_607" xlink:to="loc_srt_RangeMember_599" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_599_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_607" xlink:to="loc_srt_RangeMember_599_default" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_598" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_599" xlink:to="loc_srt_MinimumMember_598" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_608" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_599" xlink:to="loc_srt_MaximumMember_608" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateAxis" xlink:label="loc_us-gaap_VariableRateAxis_610" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_597" xlink:to="loc_us-gaap_VariableRateAxis_610" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateDomain" xlink:label="loc_us-gaap_VariableRateDomain_606" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VariableRateAxis_610" xlink:to="loc_us-gaap_VariableRateDomain_606" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateDomain" xlink:label="loc_us-gaap_VariableRateDomain_606_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VariableRateAxis_610" xlink:to="loc_us-gaap_VariableRateDomain_606_default" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_LiborMember" xlink:label="loc_pstv_LiborMember_603" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_606" xlink:to="loc_pstv_LiborMember_603" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember" xlink:label="loc_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember_1205" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_606" xlink:to="loc_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember_1205" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_613" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_597" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_613" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_596" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_613" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_596" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_596_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_613" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_596_default" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestRateFloorMember" xlink:label="loc_us-gaap_InterestRateFloorMember_594" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_596" xlink:to="loc_us-gaap_InterestRateFloorMember_594" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_615" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_597" xlink:to="loc_us-gaap_FinancialInstrumentAxis_615" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_602" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_615" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_602" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_602_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_615" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_602_default" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_LoanAndSecurityAgreementMember" xlink:label="loc_pstv_LoanAndSecurityAgreementMember_595" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_602" xlink:to="loc_pstv_LoanAndSecurityAgreementMember_595" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationAxis" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_617" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_597" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_617" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationDomain" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_605" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_617" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_605" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationDomain" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_605_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_617" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_605_default" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_SaleOfJapaneseSubsidiaryAndCertainAssetsMember" xlink:label="loc_pstv_SaleOfJapaneseSubsidiaryAndCertainAssetsMember_604" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_605" xlink:to="loc_pstv_SaleOfJapaneseSubsidiaryAndCertainAssetsMember_604" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentOfferingDate1" xlink:label="loc_us-gaap_DebtInstrumentOfferingDate1_601" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_619" xlink:to="loc_us-gaap_DebtInstrumentOfferingDate1_601" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_609" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_619" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_609" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_DebtInstrumentFloatingInterestRatePercentage" xlink:label="loc_pstv_DebtInstrumentFloatingInterestRatePercentage_611" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_619" xlink:to="loc_pstv_DebtInstrumentFloatingInterestRatePercentage_611" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_614" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_619" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_614" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="loc_us-gaap_DebtInstrumentMaturityDate_616" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_619" xlink:to="loc_us-gaap_DebtInstrumentMaturityDate_616" use="optional" order="32" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFeeAmount" xlink:label="loc_us-gaap_DebtInstrumentFeeAmount_618" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_619" xlink:to="loc_us-gaap_DebtInstrumentFeeAmount_618" use="optional" order="33" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_620" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_619" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_620" use="optional" order="34" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_621" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_619" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_621" use="optional" order="35" />
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_LongTermDebtOutstandingThresholdAmount" xlink:label="loc_pstv_LongTermDebtOutstandingThresholdAmount_624" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_619" xlink:to="loc_pstv_LongTermDebtOutstandingThresholdAmount_624" use="optional" order="36" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense_626" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_619" xlink:to="loc_us-gaap_InterestExpense_626" use="optional" order="37" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium_627" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_619" xlink:to="loc_us-gaap_AmortizationOfDebtDiscountPremium_627" use="optional" order="38" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_1445" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_619" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_1445" use="optional" order="39" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForLoans" xlink:label="loc_us-gaap_PaymentsForLoans_1490" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_619" xlink:to="loc_us-gaap_PaymentsForLoans_1490" use="optional" order="40" />
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_MinimumLiquidityCovenantAmount" xlink:label="loc_pstv_MinimumLiquidityCovenantAmount_1503" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_619" xlink:to="loc_pstv_MinimumLiquidityCovenantAmount_1503" use="optional" order="41" />
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_DebtPrincipalRepaymentStartDate" xlink:label="loc_pstv_DebtPrincipalRepaymentStartDate_1504" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_619" xlink:to="loc_pstv_DebtPrincipalRepaymentStartDate_1504" use="optional" order="42" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentCovenantCompliance" xlink:label="loc_us-gaap_DebtInstrumentCovenantCompliance_625" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_619" xlink:to="loc_us-gaap_DebtInstrumentCovenantCompliance_625" use="optional" order="43" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://plus.com/role/TermLoanObligationsTermLoanOutstandingDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_635" />
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_AdditionalDetailsRelatingTermLoanThatIsOutstandingAbstract" xlink:label="loc_pstv_AdditionalDetailsRelatingTermLoanThatIsOutstandingAbstract_633" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_635" xlink:to="loc_pstv_AdditionalDetailsRelatingTermLoanThatIsOutstandingAbstract_633" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentOfferingDate1" xlink:label="loc_us-gaap_DebtInstrumentOfferingDate1_634" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pstv_AdditionalDetailsRelatingTermLoanThatIsOutstandingAbstract_633" xlink:to="loc_us-gaap_DebtInstrumentOfferingDate1_634" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_636" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pstv_AdditionalDetailsRelatingTermLoanThatIsOutstandingAbstract_633" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_636" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_638" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pstv_AdditionalDetailsRelatingTermLoanThatIsOutstandingAbstract_633" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_638" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentPeriodicPayment" xlink:label="loc_us-gaap_DebtInstrumentPeriodicPayment_639" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pstv_AdditionalDetailsRelatingTermLoanThatIsOutstandingAbstract_633" xlink:to="loc_us-gaap_DebtInstrumentPeriodicPayment_639" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_DebtInstrumentAmendedExpirationDate" xlink:label="loc_pstv_DebtInstrumentAmendedExpirationDate_640" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pstv_AdditionalDetailsRelatingTermLoanThatIsOutstandingAbstract_633" xlink:to="loc_pstv_DebtInstrumentAmendedExpirationDate_640" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_641" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pstv_AdditionalDetailsRelatingTermLoanThatIsOutstandingAbstract_633" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_641" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_631" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_635" xlink:to="loc_us-gaap_DebtInstrumentTable_631" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_630" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_631" xlink:to="loc_us-gaap_DebtInstrumentAxis_630" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_637" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_630" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_637" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_637_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_630" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_637_default" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_TermLoanMember" xlink:label="loc_pstv_TermLoanMember_632" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_637" xlink:to="loc_pstv_TermLoanMember_632" use="optional" order="12" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://plus.com/role/GrantRevenueAdditionalInformationDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_667" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_661" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_667" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_661" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_662" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_661" xlink:to="loc_us-gaap_TypeOfArrangementAxis_662" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_659" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_662" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_659" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_659_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_662" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_659_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_CancerPreventionAndResearchInstituteOfTexasContractMember" xlink:label="loc_pstv_CancerPreventionAndResearchInstituteOfTexasContractMember_658" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_659" xlink:to="loc_pstv_CancerPreventionAndResearchInstituteOfTexasContractMember_658" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_665" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_661" xlink:to="loc_srt_ProductOrServiceAxis_665" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_663" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_665" xlink:to="loc_srt_ProductsAndServicesDomain_663" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_663_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_665" xlink:to="loc_srt_ProductsAndServicesDomain_663_default" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GrantMember" xlink:label="loc_us-gaap_GrantMember_660" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_663" xlink:to="loc_us-gaap_GrantMember_660" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_1210" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_661" xlink:to="loc_srt_RangeAxis_1210" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_1140" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_1210" xlink:to="loc_srt_RangeMember_1140" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_1140_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_1210" xlink:to="loc_srt_RangeMember_1140_default" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_MaximumGrantAmountToBeReceivedAsPerGrantContract" xlink:label="loc_pstv_MaximumGrantAmountToBeReceivedAsPerGrantContract_664" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_667" xlink:to="loc_pstv_MaximumGrantAmountToBeReceivedAsPerGrantContract_664" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_GrantFundingTerm" xlink:label="loc_pstv_GrantFundingTerm_666" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_667" xlink:to="loc_pstv_GrantFundingTerm_666" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_CpritGrantFundingTerm" xlink:label="loc_pstv_CpritGrantFundingTerm_668" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_667" xlink:to="loc_pstv_CpritGrantFundingTerm_668" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_ContractEffectiveDate" xlink:label="loc_pstv_ContractEffectiveDate_669" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_667" xlink:to="loc_pstv_ContractEffectiveDate_669" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_ContractTerminationDate" xlink:label="loc_pstv_ContractTerminationDate_670" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_667" xlink:to="loc_pstv_ContractTerminationDate_670" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_PercentageOfAggregateAmountOfProceedsAwardedUnderCpritGrant" xlink:label="loc_pstv_PercentageOfAggregateAmountOfProceedsAwardedUnderCpritGrant_671" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_667" xlink:to="loc_pstv_PercentageOfAggregateAmountOfProceedsAwardedUnderCpritGrant_671" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_PercentageOfGrantProceedsWithInterestNotExceedAnnually" xlink:label="loc_pstv_PercentageOfGrantProceedsWithInterestNotExceedAnnually_672" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_667" xlink:to="loc_pstv_PercentageOfGrantProceedsWithInterestNotExceedAnnually_672" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_673" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_667" xlink:to="loc_us-gaap_Revenues_673" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_ReimbursementCostsIncurred" xlink:label="loc_pstv_ReimbursementCostsIncurred_674" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_667" xlink:to="loc_pstv_ReimbursementCostsIncurred_674" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_IncreaseDecreaseInGrantRevenue" xlink:label="loc_pstv_IncreaseDecreaseInGrantRevenue_675" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_667" xlink:to="loc_pstv_IncreaseDecreaseInGrantRevenue_675" use="optional" order="22" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://plus.com/role/IncomeTaxesAdditionalInformationDetails">
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_IncomeTaxesLineItems" xlink:label="loc_pstv_IncomeTaxesLineItems_695" />
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_IncomeTaxesTable" xlink:label="loc_pstv_IncomeTaxesTable_687" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_pstv_IncomeTaxesLineItems_695" xlink:to="loc_pstv_IncomeTaxesTable_687" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_679" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_pstv_IncomeTaxesTable_687" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_679" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_686" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_679" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_686" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_686_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_679" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_686_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DomesticCountryMember" xlink:label="loc_us-gaap_DomesticCountryMember_682" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_686" xlink:to="loc_us-gaap_DomesticCountryMember_682" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_691" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_686" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_691" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_689" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_pstv_IncomeTaxesTable_687" xlink:to="loc_srt_RangeAxis_689" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_681" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_689" xlink:to="loc_srt_RangeMember_681" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_681_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_689" xlink:to="loc_srt_RangeMember_681_default" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_680" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_681" xlink:to="loc_srt_MaximumMember_680" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityNameAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameAxis_693" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_pstv_IncomeTaxesTable_687" xlink:to="loc_us-gaap_IncomeTaxAuthorityNameAxis_693" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityNameDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameDomain_683" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameAxis_693" xlink:to="loc_us-gaap_IncomeTaxAuthorityNameDomain_683" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityNameDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameDomain_683_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameAxis_693" xlink:to="loc_us-gaap_IncomeTaxAuthorityNameDomain_683_default" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_684" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pstv_IncomeTaxesLineItems_695" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_684" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_IncomeTaxContingencyAbstract" xlink:label="loc_pstv_IncomeTaxContingencyAbstract_692" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pstv_IncomeTaxesLineItems_695" xlink:to="loc_pstv_IncomeTaxContingencyAbstract_692" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_DeferredTaxAssetsValuationAllowances" xlink:label="loc_pstv_DeferredTaxAssetsValuationAllowances_678" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pstv_IncomeTaxContingencyAbstract_692" xlink:to="loc_pstv_DeferredTaxAssetsValuationAllowances_678" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_688" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pstv_IncomeTaxContingencyAbstract_692" xlink:to="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_688" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaap_OperatingLossCarryforwards_694" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pstv_IncomeTaxesLineItems_695" xlink:to="loc_us-gaap_OperatingLossCarryforwards_694" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_OperatingLossCarryforwardsExpirationDates1" xlink:label="loc_pstv_OperatingLossCarryforwardsExpirationDates1_696" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pstv_IncomeTaxesLineItems_695" xlink:to="loc_pstv_OperatingLossCarryforwardsExpirationDates1_696" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_697" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pstv_IncomeTaxesLineItems_695" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_697" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_698" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pstv_IncomeTaxesLineItems_695" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_698" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_NetOperatingLossCarryforward" xlink:label="loc_pstv_NetOperatingLossCarryforward_700" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pstv_IncomeTaxesLineItems_695" xlink:to="loc_pstv_NetOperatingLossCarryforward_700" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_PercentageOfNetOperatingLossCarryforwardsAvailableForOffsettingAgainstFutureTaxableIncome" xlink:label="loc_pstv_PercentageOfNetOperatingLossCarryforwardsAvailableForOffsettingAgainstFutureTaxableIncome_701" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pstv_IncomeTaxesLineItems_695" xlink:to="loc_pstv_PercentageOfNetOperatingLossCarryforwardsAvailableForOffsettingAgainstFutureTaxableIncome_701" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_CumulativeChangeInOwnership" xlink:label="loc_pstv_CumulativeChangeInOwnership_702" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pstv_IncomeTaxesLineItems_695" xlink:to="loc_pstv_CumulativeChangeInOwnership_702" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_NetOperatingLossAndResearchAndDevelopmentTaxCreditCarryForwardsToOffsetFutureTaxableIncomePeriod" xlink:label="loc_pstv_NetOperatingLossAndResearchAndDevelopmentTaxCreditCarryForwardsToOffsetFutureTaxableIncomePeriod_703" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pstv_IncomeTaxesLineItems_695" xlink:to="loc_pstv_NetOperatingLossAndResearchAndDevelopmentTaxCreditCarryForwardsToOffsetFutureTaxableIncomePeriod_703" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilityForUncertainTaxPositionsCurrent" xlink:label="loc_us-gaap_LiabilityForUncertainTaxPositionsCurrent_704" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pstv_IncomeTaxesLineItems_695" xlink:to="loc_us-gaap_LiabilityForUncertainTaxPositionsCurrent_704" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_PeriodForMaterialChangesOfLiabilityForUncertainTaxBenefits" xlink:label="loc_pstv_PeriodForMaterialChangesOfLiabilityForUncertainTaxBenefits_705" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pstv_IncomeTaxesLineItems_695" xlink:to="loc_pstv_PeriodForMaterialChangesOfLiabilityForUncertainTaxBenefits_705" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_TaxCreditCarryforwardExpirationDate1" xlink:label="loc_pstv_TaxCreditCarryforwardExpirationDate1_699" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pstv_IncomeTaxesLineItems_695" xlink:to="loc_pstv_TaxCreditCarryforwardExpirationDate1_699" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_706" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pstv_IncomeTaxesLineItems_695" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_706" use="optional" order="29" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://plus.com/role/EmployeeBenefitPlanAdditionalInformationDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:label="loc_us-gaap_DefinedContributionPlanDisclosureLineItems_753" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanTable" xlink:label="loc_us-gaap_DefinedContributionPlanTable_746" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DefinedContributionPlanDisclosureLineItems_753" xlink:to="loc_us-gaap_DefinedContributionPlanTable_746" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_750" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DefinedContributionPlanTable_746" xlink:to="loc_srt_RangeAxis_750" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_748" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_750" xlink:to="loc_srt_RangeMember_748" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_748_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_750" xlink:to="loc_srt_RangeMember_748_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_751" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_748" xlink:to="loc_srt_MaximumMember_751" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_749" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedContributionPlanDisclosureLineItems_753" xlink:to="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_749" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_752" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedContributionPlanDisclosureLineItems_753" xlink:to="loc_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_752" use="optional" order="7" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://plus.com/role/StockholdersEquityPreferredStockDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_771" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_759" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_771" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_759" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_756" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_759" xlink:to="loc_us-gaap_StatementClassOfStockAxis_756" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_769" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_756" xlink:to="loc_us-gaap_ClassOfStockDomain_769" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_769_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_756" xlink:to="loc_us-gaap_ClassOfStockDomain_769_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_SeriesFConvertiblePreferredStockMember" xlink:label="loc_pstv_SeriesFConvertiblePreferredStockMember_758" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_769" xlink:to="loc_pstv_SeriesFConvertiblePreferredStockMember_758" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_SeriesBConvertiblePreferredStockMember" xlink:label="loc_pstv_SeriesBConvertiblePreferredStockMember_768" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_769" xlink:to="loc_pstv_SeriesBConvertiblePreferredStockMember_768" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_SeriesCConvertiblePreferredStockMember" xlink:label="loc_pstv_SeriesCConvertiblePreferredStockMember_773" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_769" xlink:to="loc_pstv_SeriesCConvertiblePreferredStockMember_773" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_763" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_759" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_763" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_770" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_763" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_770" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_770_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_763" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_770_default" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_TwoThousandEighteenRightsOfferingMember" xlink:label="loc_pstv_TwoThousandEighteenRightsOfferingMember_762" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_770" xlink:to="loc_pstv_TwoThousandEighteenRightsOfferingMember_762" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_766" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_759" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_766" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_760" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_766" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_760" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_760_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_766" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_760_default" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_SubscriptionAgreementMember" xlink:label="loc_pstv_SubscriptionAgreementMember_761" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_760" xlink:to="loc_pstv_SubscriptionAgreementMember_761" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_757" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_771" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_757" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_764" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_771" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_764" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_NumberOfVotesPerShare" xlink:label="loc_pstv_NumberOfVotesPerShare_767" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_771" xlink:to="loc_pstv_NumberOfVotesPerShare_767" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_772" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_771" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_772" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_774" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_771" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_774" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_775" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_771" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_775" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockTransactionDate" xlink:label="loc_us-gaap_SaleOfStockTransactionDate_776" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_771" xlink:to="loc_us-gaap_SaleOfStockTransactionDate_776" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockVotingRights" xlink:label="loc_us-gaap_PreferredStockVotingRights_777" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_771" xlink:to="loc_us-gaap_PreferredStockVotingRights_777" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_RightsRelatedToDistributionOfAssets" xlink:label="loc_pstv_RightsRelatedToDistributionOfAssets_778" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_771" xlink:to="loc_pstv_RightsRelatedToDistributionOfAssets_778" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_ConsiderationPaidToPreferredStockHolders" xlink:label="loc_pstv_ConsiderationPaidToPreferredStockHolders_779" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_771" xlink:to="loc_pstv_ConsiderationPaidToPreferredStockHolders_779" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_780" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_771" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_780" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_NumberOfPreferredStockSharesExercised" xlink:label="loc_pstv_NumberOfPreferredStockSharesExercised_783" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_771" xlink:to="loc_pstv_NumberOfPreferredStockSharesExercised_783" use="optional" order="27" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://plus.com/role/StockholdersEquityWarrantsDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_802" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_790" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_802" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_790" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_786" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_790" xlink:to="loc_us-gaap_StatementClassOfStockAxis_786" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_799" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_786" xlink:to="loc_us-gaap_ClassOfStockDomain_799" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_799_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_786" xlink:to="loc_us-gaap_ClassOfStockDomain_799_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassAMember" xlink:label="loc_us-gaap_CommonClassAMember_788" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_799" xlink:to="loc_us-gaap_CommonClassAMember_788" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassBMember" xlink:label="loc_us-gaap_CommonClassBMember_795" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_799" xlink:to="loc_us-gaap_CommonClassBMember_795" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_793" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_790" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_793" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_791" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_793" xlink:to="loc_us-gaap_EquityComponentDomain_791" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_791_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_793" xlink:to="loc_us-gaap_EquityComponentDomain_791_default" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_RepresentativeSeriesUWarrantMember" xlink:label="loc_pstv_RepresentativeSeriesUWarrantMember_789" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_791" xlink:to="loc_pstv_RepresentativeSeriesUWarrantMember_789" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_796" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_791" xlink:to="loc_us-gaap_CommonStockMember_796" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_800" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_791" xlink:to="loc_us-gaap_WarrantMember_800" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_797" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_790" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_797" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_801" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_797" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_801" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_801_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_797" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_801_default" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_SeriesUWarrantsMember" xlink:label="loc_pstv_SeriesUWarrantsMember_792" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_801" xlink:to="loc_pstv_SeriesUWarrantsMember_792" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_787" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_802" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_787" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_794" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_802" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_794" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_798" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_802" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_798" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm_803" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_802" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingTerm_803" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_804" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_802" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_804" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_805" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_802" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_805" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_NumberOfWarrantsExercised" xlink:label="loc_pstv_NumberOfWarrantsExercised_806" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_802" xlink:to="loc_pstv_NumberOfWarrantsExercised_806" use="optional" order="23" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://plus.com/role/StockholdersEquityCommonStockDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_851" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_818" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_851" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_818" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeAxis" xlink:label="loc_us-gaap_InvestmentTypeAxis_809" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_818" xlink:to="loc_us-gaap_InvestmentTypeAxis_809" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_823" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_InvestmentTypeAxis_809" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_823" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_823_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_InvestmentTypeAxis_809" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_823_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_TwoThousandAndTwentyTwoPurchaseAgreementMember" xlink:label="loc_pstv_TwoThousandAndTwentyTwoPurchaseAgreementMember_835" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_823" xlink:to="loc_pstv_TwoThousandAndTwentyTwoPurchaseAgreementMember_835" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_TwentyTwentyPurchaseAgreementMember" xlink:label="loc_pstv_TwentyTwentyPurchaseAgreementMember_838" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_823" xlink:to="loc_pstv_TwentyTwentyPurchaseAgreementMember_838" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_SeptemberTwoThousandAndTwentyTwoDistributionAgreementMember" xlink:label="loc_pstv_SeptemberTwoThousandAndTwentyTwoDistributionAgreementMember_841" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_823" xlink:to="loc_pstv_SeptemberTwoThousandAndTwentyTwoDistributionAgreementMember_841" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_JanuaryTwoThousandAndTwentyTwoDistributionAgreementMember" xlink:label="loc_pstv_JanuaryTwoThousandAndTwentyTwoDistributionAgreementMember_847" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_823" xlink:to="loc_pstv_JanuaryTwoThousandAndTwentyTwoDistributionAgreementMember_847" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_826" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_818" xlink:to="loc_dei_LegalEntityAxis_826" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_834" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_826" xlink:to="loc_dei_EntityDomain_834" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_834_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_826" xlink:to="loc_dei_EntityDomain_834_default" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_LincolnParkCapitalFundLLCMember" xlink:label="loc_pstv_LincolnParkCapitalFundLLCMember_815" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_834" xlink:to="loc_pstv_LincolnParkCapitalFundLLCMember_815" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_CanaccordGenuityLLCMember" xlink:label="loc_pstv_CanaccordGenuityLLCMember_828" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_834" xlink:to="loc_pstv_CanaccordGenuityLLCMember_828" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_831" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_818" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_831" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_819" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_831" xlink:to="loc_us-gaap_EquityComponentDomain_819" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_819_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_831" xlink:to="loc_us-gaap_EquityComponentDomain_819_default" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_814" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_819" xlink:to="loc_us-gaap_CommonStockMember_814" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_836" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_818" xlink:to="loc_srt_RangeAxis_836" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_817" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_836" xlink:to="loc_srt_RangeMember_817" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_817_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_836" xlink:to="loc_srt_RangeMember_817_default" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_816" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_817" xlink:to="loc_srt_MinimumMember_816" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_829" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_817" xlink:to="loc_srt_MaximumMember_829" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_839" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_818" xlink:to="loc_us-gaap_FinancialInstrumentAxis_839" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_822" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_839" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_822" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_822_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_839" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_822_default" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_842" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_818" xlink:to="loc_us-gaap_StatementClassOfStockAxis_842" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_833" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_842" xlink:to="loc_us-gaap_ClassOfStockDomain_833" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_833_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_842" xlink:to="loc_us-gaap_ClassOfStockDomain_833_default" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_845" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_818" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_845" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_811" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_845" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_811" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_811_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_845" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_811_default" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_824" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_811" xlink:to="loc_us-gaap_SubsequentEventMember_824" use="optional" order="32" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_848" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_818" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_848" use="optional" order="33" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_820" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_848" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_820" use="optional" order="34" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_820_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_848" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_820_default" use="optional" order="35" />
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_AtTheMarketOfferingProgramMember" xlink:label="loc_pstv_AtTheMarketOfferingProgramMember_821" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_820" xlink:to="loc_pstv_AtTheMarketOfferingProgramMember_821" use="optional" order="36" />
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_MaximumValueOfSharesToBeIssuedUnderAgreement" xlink:label="loc_pstv_MaximumValueOfSharesToBeIssuedUnderAgreement_810" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_851" xlink:to="loc_pstv_MaximumValueOfSharesToBeIssuedUnderAgreement_810" use="optional" order="37" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_827" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_851" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_827" use="optional" order="38" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_832" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_851" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_832" use="optional" order="39" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_837" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_851" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_837" use="optional" order="40" />
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_PeriodExercisableFromTheDateOfIssuance" xlink:label="loc_pstv_PeriodExercisableFromTheDateOfIssuance_840" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_851" xlink:to="loc_pstv_PeriodExercisableFromTheDateOfIssuance_840" use="optional" order="41" />
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_NumberOfMaximumCommonSharesCanBeResale" xlink:label="loc_pstv_NumberOfMaximumCommonSharesCanBeResale_843" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_851" xlink:to="loc_pstv_NumberOfMaximumCommonSharesCanBeResale_843" use="optional" order="42" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_846" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_851" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_846" use="optional" order="43" />
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_InitialCommitmentShares" xlink:label="loc_pstv_InitialCommitmentShares_849" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_851" xlink:to="loc_pstv_InitialCommitmentShares_849" use="optional" order="44" />
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_InitialCommitmentFee" xlink:label="loc_pstv_InitialCommitmentFee_852" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_851" xlink:to="loc_pstv_InitialCommitmentFee_852" use="optional" order="45" />
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_PercentageIssuanceOfCommonStock" xlink:label="loc_pstv_PercentageIssuanceOfCommonStock_853" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_851" xlink:to="loc_pstv_PercentageIssuanceOfCommonStock_853" use="optional" order="46" />
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_GrossProceedsFromIssuanceOfCommonStock" xlink:label="loc_pstv_GrossProceedsFromIssuanceOfCommonStock_854" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_851" xlink:to="loc_pstv_GrossProceedsFromIssuanceOfCommonStock_854" use="optional" order="47" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_855" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_851" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_855" use="optional" order="48" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaap_SharesIssued_856" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_851" xlink:to="loc_us-gaap_SharesIssued_856" use="optional" order="49" />
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_AggregateExpenseIncludingFeeAndDisbursementExpenses" xlink:label="loc_pstv_AggregateExpenseIncludingFeeAndDisbursementExpenses_857" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_851" xlink:to="loc_pstv_AggregateExpenseIncludingFeeAndDisbursementExpenses_857" use="optional" order="50" />
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_PercentageOfCommissionOnGrossProceedsFromSaleOfCommonStock" xlink:label="loc_pstv_PercentageOfCommissionOnGrossProceedsFromSaleOfCommonStock_858" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_851" xlink:to="loc_pstv_PercentageOfCommissionOnGrossProceedsFromSaleOfCommonStock_858" use="optional" order="51" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_859" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_851" xlink:to="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_859" use="optional" order="52" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRepurchasedDuringPeriodShares" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodShares_860" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_851" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodShares_860" use="optional" order="53" />
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_CommonStockSalesAvailableForIssuance" xlink:label="loc_pstv_CommonStockSalesAvailableForIssuance_861" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_851" xlink:to="loc_pstv_CommonStockSalesAvailableForIssuance_861" use="optional" order="54" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockValue" xlink:label="loc_us-gaap_TreasuryStockValue_862" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_851" xlink:to="loc_us-gaap_TreasuryStockValue_862" use="optional" order="55" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:label="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_1523" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_851" xlink:to="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_1523" use="optional" order="56" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://plus.com/role/StockBasedCompensationAdditionalInformationDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_877" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_871" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_877" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_871" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_870" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_871" xlink:to="loc_us-gaap_PlanNameAxis_870" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_866" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_870" xlink:to="loc_us-gaap_PlanNameDomain_866" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_866_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_870" xlink:to="loc_us-gaap_PlanNameDomain_866_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_StockBasedCompensation2015EquityIncentivePlan1Member" xlink:label="loc_pstv_StockBasedCompensation2015EquityIncentivePlan1Member_865" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_866" xlink:to="loc_pstv_StockBasedCompensation2015EquityIncentivePlan1Member_865" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_StockBasedCompensation2020EquityIncentivePlanMember" xlink:label="loc_pstv_StockBasedCompensation2020EquityIncentivePlanMember_872" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_866" xlink:to="loc_pstv_StockBasedCompensation2020EquityIncentivePlanMember_872" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_875" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_871" xlink:to="loc_srt_RangeAxis_875" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_869" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_875" xlink:to="loc_srt_RangeMember_869" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_869_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_875" xlink:to="loc_srt_RangeMember_869_default" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_868" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_869" xlink:to="loc_srt_MinimumMember_868" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_874" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_869" xlink:to="loc_srt_MaximumMember_874" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_867" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_877" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_867" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_873" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_877" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_873" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_876" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_877" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_876" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_878" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_877" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_878" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_879" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_877" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_879" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_880" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_877" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_880" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend_881" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_877" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend_881" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_882" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_877" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_882" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_883" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_877" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_883" use="optional" order="20" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://plus.com/role/StockBasedCompensationSummaryOfShareBasedCompensationRecognizedDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_924" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_921" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_924" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_921" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_920" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_921" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_920" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_922" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_920" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_922" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_922_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_920" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_922_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_923" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_922" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_923" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_925" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_922" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_925" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_919" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_924" xlink:to="loc_us-gaap_ShareBasedCompensation_919" use="optional" order="7" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://plus.com/role/SubsequentEventsAdditionalInformationDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaap_SubsequentEventLineItems_939" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaap_SubsequentEventTable_930" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsequentEventLineItems_939" xlink:to="loc_us-gaap_SubsequentEventTable_930" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_935" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_930" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_935" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_928" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_935" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_928" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_928_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_935" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_928_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_933" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_928" xlink:to="loc_us-gaap_SubsequentEventMember_933" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeAxis" xlink:label="loc_us-gaap_InvestmentTypeAxis_937" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_930" xlink:to="loc_us-gaap_InvestmentTypeAxis_937" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_932" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_InvestmentTypeAxis_937" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_932" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_932_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_InvestmentTypeAxis_937" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_932_default" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_938" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_930" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_938" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_931" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_938" xlink:to="loc_us-gaap_EquityComponentDomain_931" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_931_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_938" xlink:to="loc_us-gaap_EquityComponentDomain_931_default" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityAxis" xlink:label="loc_us-gaap_CreditFacilityAxis_1544" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_930" xlink:to="loc_us-gaap_CreditFacilityAxis_1544" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaap_CreditFacilityDomain_1545" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_1544" xlink:to="loc_us-gaap_CreditFacilityDomain_1545" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaap_CreditFacilityDomain_1545_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_1544" xlink:to="loc_us-gaap_CreditFacilityDomain_1545_default" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_PershingCreditFacilityMember" xlink:label="loc_pstv_PershingCreditFacilityMember_1546" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_1545" xlink:to="loc_pstv_PershingCreditFacilityMember_1546" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_1551" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_930" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_1551" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1552" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_1551" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1552" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1552_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_1551" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1552_default" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_May2024PrivatePlacementMember" xlink:label="loc_pstv_May2024PrivatePlacementMember_1553" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1552" xlink:to="loc_pstv_May2024PrivatePlacementMember_1553" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaap_PrivatePlacementMember_1558" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1552" xlink:to="loc_us-gaap_PrivatePlacementMember_1558" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_PreFundedWarrantMember" xlink:label="loc_pstv_PreFundedWarrantMember_1559" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1552" xlink:to="loc_pstv_PreFundedWarrantMember_1559" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_1554" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_930" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_1554" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_1555" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_1554" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_1555" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_1555_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_1554" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_1555_default" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_SeriesAWarrantMember" xlink:label="loc_pstv_SeriesAWarrantMember_1556" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1555" xlink:to="loc_pstv_SeriesAWarrantMember_1556" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_SeriesBWarrantMember" xlink:label="loc_pstv_SeriesBWarrantMember_1557" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1555" xlink:to="loc_pstv_SeriesBWarrantMember_1557" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionAxis" xlink:label="loc_us-gaap_AssetAcquisitionAxis_1560" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_930" xlink:to="loc_us-gaap_AssetAcquisitionAxis_1560" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionDomain" xlink:label="loc_us-gaap_AssetAcquisitionDomain_1561" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AssetAcquisitionAxis_1560" xlink:to="loc_us-gaap_AssetAcquisitionDomain_1561" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionDomain" xlink:label="loc_us-gaap_AssetAcquisitionDomain_1561_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AssetAcquisitionAxis_1560" xlink:to="loc_us-gaap_AssetAcquisitionDomain_1561_default" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_BioceptAssetPurchaseMember" xlink:label="loc_pstv_BioceptAssetPurchaseMember_1562" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionDomain_1561" xlink:to="loc_pstv_BioceptAssetPurchaseMember_1562" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_1537" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_939" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_1537" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityPeriodicPayment" xlink:label="loc_us-gaap_LineOfCreditFacilityPeriodicPayment_1538" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_939" xlink:to="loc_us-gaap_LineOfCreditFacilityPeriodicPayment_1538" use="optional" order="32" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_1539" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_939" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_1539" use="optional" order="33" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_1540" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_939" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_1540" use="optional" order="34" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_1541" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_939" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_1541" use="optional" order="35" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:label="loc_us-gaap_DebtInstrumentInterestRateDuringPeriod_1542" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_939" xlink:to="loc_us-gaap_DebtInstrumentInterestRateDuringPeriod_1542" use="optional" order="36" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityInterestRateDuringPeriod" xlink:label="loc_us-gaap_LineOfCreditFacilityInterestRateDuringPeriod_1543" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_939" xlink:to="loc_us-gaap_LineOfCreditFacilityInterestRateDuringPeriod_1543" use="optional" order="37" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_1547" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_939" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_1547" use="optional" order="38" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_1548" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_939" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_1548" use="optional" order="39" />
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_ClassOfWarrantOrRightPurchasePrice" xlink:label="loc_pstv_ClassOfWarrantOrRightPurchasePrice_1549" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_939" xlink:to="loc_pstv_ClassOfWarrantOrRightPurchasePrice_1549" use="optional" order="40" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireProductiveAssets" xlink:label="loc_us-gaap_PaymentsToAcquireProductiveAssets_1550" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_939" xlink:to="loc_us-gaap_PaymentsToAcquireProductiveAssets_1550" use="optional" order="41" />
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_ClassOfWarrantOrRightOfferingPrice" xlink:label="loc_pstv_ClassOfWarrantOrRightOfferingPrice_1563" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_939" xlink:to="loc_pstv_ClassOfWarrantOrRightOfferingPrice_1563" use="optional" order="42" />
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_ClassOfWarrantOrRightExercisePriceInitialSubscription" xlink:label="loc_pstv_ClassOfWarrantOrRightExercisePriceInitialSubscription_1564" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_939" xlink:to="loc_pstv_ClassOfWarrantOrRightExercisePriceInitialSubscription_1564" use="optional" order="43" />
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_ClassOfWarrantOrRightExercisePriceAdditionalSubscription" xlink:label="loc_pstv_ClassOfWarrantOrRightExercisePriceAdditionalSubscription_1565" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_939" xlink:to="loc_pstv_ClassOfWarrantOrRightExercisePriceAdditionalSubscription_1565" use="optional" order="44" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_1566" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_939" xlink:to="loc_us-gaap_SharesIssuedPricePerShare_1566" use="optional" order="45" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="loc_us-gaap_WarrantsAndRightsOutstanding_1567" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_939" xlink:to="loc_us-gaap_WarrantsAndRightsOutstanding_1567" use="optional" order="46" />
</definitionLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>9
<FILENAME>pstv-20240331_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--Generated by DFIN XBRL Instance Document - http://www.dfinsolutions.com/ - Version R3.0 - on 07-June-2024 [02:05:21] {PM}-->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
<labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="loc_dei_CoverAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_CoverAbstract" xml:lang="en-US">Cover [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationTable" xlink:label="loc_dei_DocumentInformationTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentInformationTable" xml:lang="en-US">Document Information [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentInformationTable" xlink:to="lab_dei_DocumentInformationTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationLineItems" xlink:label="loc_dei_DocumentInformationLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentInformationLineItems" xml:lang="en-US">Document Information [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentInformationLineItems" xlink:to="lab_dei_DocumentInformationLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_AmendmentFlag" xml:lang="en-US">Amendment Flag</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_AmendmentFlag" xml:lang="en-US">Amendment Flag</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="loc_dei_CityAreaCode" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_CityAreaCode" xml:lang="en-US">City Area Code</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_CityAreaCode" xml:lang="en-US">City Area Code</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_ContactPersonnelName" xlink:label="loc_dei_ContactPersonnelName" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_ContactPersonnelName" xml:lang="en-US">Contact Personnel Name</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_ContactPersonnelName" xlink:to="lab_dei_ContactPersonnelName" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentType" xml:lang="en-US">Document Type</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_DocumentType" xml:lang="en-US">Document Type</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_dei_EntityAddressAddressLine1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityAddressAddressLine1" xml:lang="en-US">Entity Address, Address Line One</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_EntityAddressAddressLine1" xml:lang="en-US">Entity Address, Address Line One</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_dei_EntityAddressAddressLine2" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityAddressAddressLine2" xml:lang="en-US">Entity Address, Address Line Two</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_EntityAddressAddressLine2" xml:lang="en-US">Entity Address, Address Line Two</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine2" xlink:to="lab_dei_EntityAddressAddressLine2" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_dei_EntityAddressCityOrTown" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityAddressCityOrTown" xml:lang="en-US">Entity Address, City or Town</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_EntityAddressCityOrTown" xml:lang="en-US">Entity Address, City or Town</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_dei_EntityAddressPostalZipCode" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityAddressPostalZipCode" xml:lang="en-US">Entity Address, Postal Zip Code</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_EntityAddressPostalZipCode" xml:lang="en-US">Entity Address, Postal Zip Code</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_dei_EntityAddressStateOrProvince" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityAddressStateOrProvince" xml:lang="en-US">Entity Address, State or Province</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_EntityAddressStateOrProvince" xml:lang="en-US">Entity Address, State or Province</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityCentralIndexKey" xml:lang="en-US">Entity Central Index Key</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_EntityCentralIndexKey" xml:lang="en-US">Entity Central Index Key</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_dei_EntityEmergingGrowthCompany" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityEmergingGrowthCompany" xml:lang="en-US">Entity Emerging Growth Company</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_EntityEmergingGrowthCompany" xml:lang="en-US">Entity Emerging Growth Company</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityFilerCategory" xml:lang="en-US">Entity Filer Category</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_EntityFilerCategory" xml:lang="en-US">Entity Filer Category</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_dei_EntityIncorporationStateCountryCode" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xml:lang="en-US">Entity Incorporation, State or Country Code</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xml:lang="en-US">Entity Incorporation, State or Country Code</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_dei_EntityPrimarySicNumber" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityPrimarySicNumber" xml:lang="en-US">Entity Primary SIC Number</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityPrimarySicNumber" xlink:to="lab_dei_EntityPrimarySicNumber" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityRegistrantName" xml:lang="en-US">Entity Registrant Name</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_EntityRegistrantName" xml:lang="en-US">Entity Registrant Name</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="loc_dei_EntitySmallBusiness" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntitySmallBusiness" xml:lang="en-US">Entity Small Business</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_EntitySmallBusiness" xml:lang="en-US">Entity Small Business</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_dei_EntityTaxIdentificationNumber" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityTaxIdentificationNumber" xml:lang="en-US">Entity Tax Identification Number</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_EntityTaxIdentificationNumber" xml:lang="en-US">Entity Tax Identification Number</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="loc_dei_LocalPhoneNumber" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_LocalPhoneNumber" xml:lang="en-US">Local Phone Number</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_LocalPhoneNumber" xml:lang="en-US">Local Phone Number</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressesAddressTypeAxis" xlink:label="loc_dei_EntityAddressesAddressTypeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityAddressesAddressTypeAxis" xml:lang="en-US">Entity Addresses, Address Type [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressesAddressTypeAxis" xlink:to="lab_dei_EntityAddressesAddressTypeAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AddressTypeDomain" xlink:label="loc_dei_AddressTypeDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_AddressTypeDomain" xml:lang="en-US">Address Type [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AddressTypeDomain" xlink:to="lab_dei_AddressTypeDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_BusinessContactMember" xlink:label="loc_dei_BusinessContactMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_BusinessContactMember" xml:lang="en-US">Business Contact [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_BusinessContactMember" xlink:to="lab_dei_BusinessContactMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xml:lang="en-US">Statement Of Financial Position [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsAbstract" xml:lang="en-US">Assets [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AssetsAbstract" xml:lang="en-US">Assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_Assets" xml:lang="en-US">Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_Assets" xml:lang="en-US">Total assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xml:lang="en-US">Assets Current [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xml:lang="en-US">Current assets:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsCurrent" xml:lang="en-US">Assets Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_AssetsCurrent" xml:lang="en-US">Total current assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xml:lang="en-US">Cash and cash equivalents</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaap_OtherAssetsCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherAssetsCurrent" xml:lang="en-US">Other Assets, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OtherAssetsCurrent" xml:lang="en-US">Other current assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_OtherAssetsCurrent" xml:lang="en-US">Total other current assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsCurrent" xlink:to="lab_us-gaap_OtherAssetsCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermInvestments" xlink:label="loc_us-gaap_ShortTermInvestments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShortTermInvestments" xml:lang="en-US">Short-Term Investments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShortTermInvestments" xml:lang="en-US">Investments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermInvestments" xlink:to="lab_us-gaap_ShortTermInvestments" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_Goodwill" xml:lang="en-US">Goodwill</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_Goodwill" xml:lang="en-US">Goodwill</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xml:lang="en-US">Operating Lease Right Of Use Asset</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xml:lang="en-US">Operating lease right-use-of assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xml:lang="en-US">Other Assets Noncurrent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xml:lang="en-US">Other assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherIntangibleAssetsNet" xlink:label="loc_us-gaap_OtherIntangibleAssetsNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherIntangibleAssetsNet" xml:lang="en-US">Other Intangible Assets Net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OtherIntangibleAssetsNet" xml:lang="en-US">Intangible assets, net</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherIntangibleAssetsNet" xlink:to="lab_us-gaap_OtherIntangibleAssetsNet" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xml:lang="en-US">Property, Plant and Equipment, Net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xml:lang="en-US">Property and equipment, net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xml:lang="en-US">Property and equipment, net</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xml:lang="en-US">Liabilities And Stockholders Equity [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xml:lang="en-US">Liabilities and Stockholders' Equity</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xml:lang="en-US">Commitments And Contingencies</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xml:lang="en-US">Commitments and contingencies (Note 8)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeNoncurrent" xlink:label="loc_us-gaap_DeferredIncomeNoncurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredIncomeNoncurrent" xml:lang="en-US">Deferred Income, Noncurrent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredIncomeNoncurrent" xml:lang="en-US">Deferred grant liability</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeNoncurrent" xlink:to="lab_us-gaap_DeferredIncomeNoncurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_Liabilities" xml:lang="en-US">Liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_Liabilities" xml:lang="en-US">Total liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xml:lang="en-US">Liabilities And Stockholders Equity</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xml:lang="en-US">Total liabilities and stockholders' deficit</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xml:lang="en-US">Liabilities Current [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xml:lang="en-US">Current liabilities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xml:lang="en-US">Accounts Payable and Accrued Liabilities, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xml:lang="en-US">Accounts payable and accrued expenses</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xml:lang="en-US">Accounts payable and accrued expenses, Total</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeCurrent" xlink:label="loc_us-gaap_DeferredIncomeCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredIncomeCurrent" xml:lang="en-US">Deferred Income, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredIncomeCurrent" xml:lang="en-US">Deferred grant liability</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeCurrent" xlink:to="lab_us-gaap_DeferredIncomeCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesCurrent" xml:lang="en-US">Liabilities Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_LiabilitiesCurrent" xml:lang="en-US">Total current liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtCurrent" xlink:label="loc_us-gaap_LongTermDebtCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LongTermDebtCurrent" xml:lang="en-US">Long Term Debt Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LongTermDebtCurrent" xml:lang="en-US">Term loan obligation, current</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtCurrent" xlink:to="lab_us-gaap_LongTermDebtCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xml:lang="en-US">Operating Lease Liability Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xml:lang="en-US">Operating lease liability</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xml:lang="en-US">Less: current portion</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="loc_us-gaap_LongTermDebtNoncurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xml:lang="en-US">Long Term Debt Noncurrent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xml:lang="en-US">Term loan obligation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtNoncurrent" xlink:to="lab_us-gaap_LongTermDebtNoncurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xml:lang="en-US">Operating Lease Liability Noncurrent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xml:lang="en-US">Noncurrent operating lease liability</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xml:lang="en-US">Noncurrent operating lease liability</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xml:lang="en-US">Stockholders Equity [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xml:lang="en-US">Stockholders' deficit:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xml:lang="en-US">Additional Paid In Capital</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xml:lang="en-US">Additional paid-in capital</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockValue" xml:lang="en-US">Common Stock Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockValue" xml:lang="en-US">Common stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CommonStockValue" xml:lang="en-US">Voting stock, value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockValue" xml:lang="en-US">Preferred Stock Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PreferredStockValue" xml:lang="en-US">Preferred stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xml:lang="en-US">Accumulated deficit</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquity" xml:lang="en-US">Equity, Attributable to Parent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_StockholdersEquity" xml:lang="en-US">Total stockholders' deficit</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_StockholdersEquity" xml:lang="en-US">Balance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_StockholdersEquity" xml:lang="en-US">Balance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockholdersEquity" xml:lang="en-US">Stockholders' deficit</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockCommonValue" xlink:label="loc_us-gaap_TreasuryStockCommonValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TreasuryStockCommonValue" xml:lang="en-US">Treasury Stock, Common, Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_TreasuryStockCommonValue" xml:lang="en-US">Treasury stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockCommonValue" xlink:to="lab_us-gaap_TreasuryStockCommonValue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xml:lang="en-US">Common stock, par value (in dollars per share)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xml:lang="en-US">Common Stock Shares Authorized</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xml:lang="en-US">Common stock, shares authorized (in shares)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockSharesIssued" xml:lang="en-US">Common Stock, Shares, Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockSharesIssued" xml:lang="en-US">Common stock, shares issued (in shares)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xml:lang="en-US">Common Stock Shares Outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xml:lang="en-US">Common stock, shares outstanding (in shares)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xml:lang="en-US">Preferred Stock Par Or Stated Value Per Share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xml:lang="en-US">Preferred stock, par value (in dollars per share)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xml:lang="en-US">Preferred Stock, Shares Authorized</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xml:lang="en-US">Preferred stock, shares authorized (in shares)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xml:lang="en-US">Preferred Stock Shares Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xml:lang="en-US">Preferred stock, shares issued (in shares)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xml:lang="en-US">Preferred Stock Shares Outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xml:lang="en-US">Preferred stock, shares outstanding (in shares)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockCommonShares" xlink:label="loc_us-gaap_TreasuryStockCommonShares" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TreasuryStockCommonShares" xml:lang="en-US">Treasury Stock, Common, Shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_TreasuryStockCommonShares" xml:lang="en-US">Treasury stock, shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockCommonShares" xlink:to="lab_us-gaap_TreasuryStockCommonShares" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeStatementAbstract" xml:lang="en-US">Income Statement [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementTable" xml:lang="en-US">Statement [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StatementTable" xml:lang="en-US">Statement [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_ProductOrServiceAxis" xml:lang="en-US">Product and Service [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_ProductOrServiceAxis" xml:lang="en-US">Product and Service</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_ProductsAndServicesDomain" xml:lang="en-US">Product and Service [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_ProductsAndServicesDomain" xml:lang="en-US">Product and Service</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GrantMember" xlink:label="loc_us-gaap_GrantMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GrantMember" xml:lang="en-US">Grant [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GrantMember" xlink:to="lab_us-gaap_GrantMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementLineItems" xml:lang="en-US">Statement [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StatementLineItems" xml:lang="en-US">Statement [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerShareBasic" xml:lang="en-US">Earnings Per Share Basic</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EarningsPerShareBasic" xml:lang="en-US">Net loss per share, basic</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xml:lang="en-US">Earnings Per Share Diluted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xml:lang="en-US">Net loss per share, diluted</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xml:lang="en-US">Operating Expenses [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xml:lang="en-US">Operating expenses:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xml:lang="en-US">General And Administrative Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xml:lang="en-US">General and administrative</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingExpenses" xml:lang="en-US">Operating Expenses</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_OperatingExpenses" xml:lang="en-US">Total operating expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xml:lang="en-US">Research And Development Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xml:lang="en-US">Research and development</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xml:lang="en-US">Research and development expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingIncomeLoss" xml:lang="en-US">Operating Income Loss</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_OperatingIncomeLoss" xml:lang="en-US">Operating loss</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherIncomeAndExpensesAbstract" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherIncomeAndExpensesAbstract" xml:lang="en-US">Other Income And Expenses [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OtherIncomeAndExpensesAbstract" xml:lang="en-US">Other income (expense):</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="lab_us-gaap_OtherIncomeAndExpensesAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InterestExpense" xml:lang="en-US">Interest Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_InterestExpense" xml:lang="en-US">Interest expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_InterestExpense" xml:lang="en-US">Interest expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="loc_us-gaap_InvestmentIncomeInterest" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xml:lang="en-US">Investment Income Interest</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xml:lang="en-US">Interest income</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeInterest" xlink:to="lab_us-gaap_InvestmentIncomeInterest" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesFairValueAdjustment" xlink:label="loc_us-gaap_LiabilitiesFairValueAdjustment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesFairValueAdjustment" xml:lang="en-US">Liabilities Fair Value Adjustment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LiabilitiesFairValueAdjustment" xml:lang="en-US">Change in fair value of liability instruments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueAdjustment" xlink:to="lab_us-gaap_LiabilitiesFairValueAdjustment" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetIncomeLoss" xml:lang="en-US">Net Income (Loss) Attributable to Parent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetIncomeLoss" xml:lang="en-US">Net loss</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NetIncomeLoss" xml:lang="en-US">Net loss</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_NetIncomeLoss" xml:lang="en-US">Net loss</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xml:lang="en-US">Nonoperating Income Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xml:lang="en-US">Total other expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="lab_us-gaap_NonoperatingIncomeExpense" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_Revenues" xml:lang="en-US">Revenues</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_Revenues" xml:lang="en-US">Revenue</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_Revenues" xml:lang="en-US">Revenue recognized</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Revenues" xlink:to="lab_us-gaap_Revenues" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xml:lang="en-US">Weighted Average Number Of Diluted Shares Outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xml:lang="en-US">Diluted weighted average shares used in calculating net loss per share attributable to common stockholders</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xml:lang="en-US">Weighted Average Number Of Shares Outstanding Basic</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xml:lang="en-US">Basic weighted average shares used in calculating net loss per share attributable to common stockholders</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xml:lang="en-US">Statement Of Stockholders Equity [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xml:lang="en-US">Class of Stock [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xml:lang="en-US">Class of Stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ClassOfStockDomain" xml:lang="en-US">Class of Stock [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ClassOfStockDomain" xml:lang="en-US">Class of Stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="loc_us-gaap_ConvertiblePreferredStockMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConvertiblePreferredStockMember" xml:lang="en-US">Convertible Preferred Stock [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ConvertiblePreferredStockMember" xml:lang="en-US">Convertible Preferred Stock [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertiblePreferredStockMember" xlink:to="lab_us-gaap_ConvertiblePreferredStockMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesFPreferredStockMember" xlink:label="loc_us-gaap_SeriesFPreferredStockMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SeriesFPreferredStockMember" xml:lang="en-US">Series F Preferred Stock [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SeriesFPreferredStockMember" xml:lang="en-US">Series F Preferred Stock [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeriesFPreferredStockMember" xlink:to="lab_us-gaap_SeriesFPreferredStockMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xml:lang="en-US">Equity Components [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xml:lang="en-US">Equity Components</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xml:lang="en-US">Equity Components [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EquityComponentDomain" xml:lang="en-US">Equity Component [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EquityComponentDomain" xml:lang="en-US">Equity Component</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_EquityComponentDomain" xml:lang="en-US">Equity Component [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xml:lang="en-US">Additional Paid In Capital [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xml:lang="en-US">Additional Paid-in Capital [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockMember" xml:lang="en-US">Common Stock [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockMember" xml:lang="en-US">Common Stock [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaap_PreferredStockMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockMember" xml:lang="en-US">Preferred Stock [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_PreferredStockMember" xml:lang="en-US">Preferred Stock [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PreferredStockMember" xml:lang="en-US">Convertible Preferred Stock [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockMember" xlink:to="lab_us-gaap_PreferredStockMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RetainedEarningsMember" xml:lang="en-US">Retained Earnings [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RetainedEarningsMember" xml:lang="en-US">Accumulated Deficit [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockCommonMember" xlink:label="loc_us-gaap_TreasuryStockCommonMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TreasuryStockCommonMember" xml:lang="en-US">Treasury Stock, Common [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_TreasuryStockCommonMember" xml:lang="en-US">Treasury Stock [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockCommonMember" xlink:to="lab_us-gaap_TreasuryStockCommonMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xml:lang="en-US">Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xml:lang="en-US">Stock-based compensation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_FractionalAdjustmentOfCommonStock" xlink:label="loc_pstv_FractionalAdjustmentOfCommonStock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_pstv_FractionalAdjustmentOfCommonStock" xml:lang="en-US">Fractional Adjustment of Common Stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_pstv_FractionalAdjustmentOfCommonStock" xml:lang="en-US">Fractional adjustment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pstv_FractionalAdjustmentOfCommonStock" xlink:to="lab_pstv_FractionalAdjustmentOfCommonStock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_pstv_FractionalAdjustmentOfCommonStock" xml:lang="en-US">Fractional adjustment of common stock.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharesOutstanding" xml:lang="en-US">Shares Outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_SharesOutstanding" xml:lang="en-US">Balance (in shares)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_SharesOutstanding" xml:lang="en-US">Balance (in shares)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesOutstanding" xlink:to="lab_us-gaap_SharesOutstanding" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xml:lang="en-US">Stock Issued During Period, Shares, Issued for Services</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xml:lang="en-US">Issuance of common stock for in process research and development (in shares)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xml:lang="en-US">Sale of common stock, net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xml:lang="en-US">Issue and sale of share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xml:lang="en-US">Issue and sale of share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xml:lang="en-US">Stock Issued During Period, Value, Issued for Services</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xml:lang="en-US">Issuance of common stock for in process research and development</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueIssuedForServices" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xml:lang="en-US">Stockholders' equity requirement</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xml:lang="en-US">Issue and sale of stock, net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xml:lang="en-US">Sale of common stock, net</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRedeemedOrCalledDuringPeriodShares" xlink:label="loc_us-gaap_StockRedeemedOrCalledDuringPeriodShares" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockRedeemedOrCalledDuringPeriodShares" xml:lang="en-US">Stock Redeemed or Called During Period, Shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_StockRedeemedOrCalledDuringPeriodShares" xml:lang="en-US">Redemption of Series F preferred stock (in shares)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRedeemedOrCalledDuringPeriodShares" xlink:to="lab_us-gaap_StockRedeemedOrCalledDuringPeriodShares" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockSharesAcquired" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TreasuryStockSharesAcquired" xml:lang="en-US">Treasury Stock, Shares, Acquired</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_TreasuryStockSharesAcquired" xml:lang="en-US">Purchase of treasury stock (in Shares)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockSharesAcquired" xlink:to="lab_us-gaap_TreasuryStockSharesAcquired" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xml:lang="en-US">Treasury Stock, Value, Acquired, Cost Method</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xml:lang="en-US">Purchase of treasury stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:to="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xml:lang="en-US">Statement Of Cash Flows [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xml:lang="en-US">Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xml:lang="en-US">Cash and cash equivalents at beginning of period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xml:lang="en-US">Cash and cash equivalents at end of period</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xml:lang="en-US">Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xml:lang="en-US">Net decrease in cash and cash equivalents</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xml:lang="en-US">Cash Flow Noncash Investing And Financing Activities Disclosure [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xml:lang="en-US">Supplemental schedule of non-cash investing and financing activities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xml:lang="en-US">Right Of Use Asset Obtained In Exchange For Finance Lease Liability</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xml:lang="en-US">Right-of-use assets obtained in exchange for operating lease liability</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xml:lang="en-US">Right-of-use assets acquired by assuming operating lease liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssued1" xlink:label="loc_us-gaap_StockIssued1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssued1" xml:lang="en-US">Stock Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockIssued1" xml:lang="en-US">Common stock issued in payment for in process research and development</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssued1" xlink:to="lab_us-gaap_StockIssued1" />
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_UnpaidOfferingCosts" xlink:label="loc_pstv_UnpaidOfferingCosts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_pstv_UnpaidOfferingCosts" xml:lang="en-US">Unpaid Offering Costs</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_pstv_UnpaidOfferingCosts" xml:lang="en-US">Unpaid offering cost</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pstv_UnpaidOfferingCosts" xlink:to="lab_pstv_UnpaidOfferingCosts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_pstv_UnpaidOfferingCosts" xml:lang="en-US">Unpaid Offering Costs.</label>
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_CashPaidDuringPeriodForAbstract" xlink:label="loc_pstv_CashPaidDuringPeriodForAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_pstv_CashPaidDuringPeriodForAbstract" xml:lang="en-US">Cash Paid During Period For [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_pstv_CashPaidDuringPeriodForAbstract" xml:lang="en-US">Cash paid during period for:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pstv_CashPaidDuringPeriodForAbstract" xlink:to="lab_pstv_CashPaidDuringPeriodForAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_pstv_CashPaidDuringPeriodForAbstract" xml:lang="en-US">Cash paid during period for:</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPaidNet" xlink:label="loc_us-gaap_InterestPaidNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InterestPaidNet" xml:lang="en-US">Interest Paid Net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_InterestPaidNet" xml:lang="en-US">Interest</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet" xlink:to="lab_us-gaap_InterestPaidNet" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xml:lang="en-US">Net Cash Provided By Used In Financing Activities [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xml:lang="en-US">Cash flows used in/provided by financing activities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xml:lang="en-US">Net Cash Provided By Used In Financing Activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xml:lang="en-US">Net cash (used in) provided by financing activities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForRepurchaseOfEquity" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfEquity" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfEquity" xml:lang="en-US">Payments for Repurchase of Equity</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfEquity" xml:lang="en-US">Purchase of treasury stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRepurchaseOfEquity" xlink:to="lab_us-gaap_PaymentsForRepurchaseOfEquity" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xml:lang="en-US">Payments of Stock Issuance Costs</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xml:lang="en-US">Payment of offering costs related to sale of common stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="lab_us-gaap_PaymentsOfStockIssuanceCosts" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xml:lang="en-US">Proceeds From Issuance Of Common Stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xml:lang="en-US">Proceeds from sale of common stock, net</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xml:lang="en-US">Repayments Of Long Term Debt</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xml:lang="en-US">Principal payments of term loan obligation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfLongTermDebt" xlink:to="lab_us-gaap_RepaymentsOfLongTermDebt" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xml:lang="en-US">Net Cash Provided By Used In Investing Activities [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xml:lang="en-US">Cash flows used in investing activities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_CashPaidForIPRDAssetAcquiredInAnAssetAcquisition" xlink:label="loc_pstv_CashPaidForIPRDAssetAcquiredInAnAssetAcquisition" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_pstv_CashPaidForIPRDAssetAcquiredInAnAssetAcquisition" xml:lang="en-US">Cash Paid For I P R D Asset Acquired In An Asset Acquisition</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_pstv_CashPaidForIPRDAssetAcquiredInAnAssetAcquisition" xml:lang="en-US">In process research and development acquired</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pstv_CashPaidForIPRDAssetAcquiredInAnAssetAcquisition" xlink:to="lab_pstv_CashPaidForIPRDAssetAcquiredInAnAssetAcquisition" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_pstv_CashPaidForIPRDAssetAcquiredInAnAssetAcquisition" xml:lang="en-US">Cash paid for IPRD asset acquired in an asset acquisition.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xml:lang="en-US">Net Cash Provided By Used In Investing Activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xml:lang="en-US">Net cash used in investing activities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xml:lang="en-US">Payments To Acquire Property Plant And Equipment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xml:lang="en-US">Purchases of property and equipment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_PaymentsToAcquirePropertyPlantAndEquipmentAndIntangibleAssets" xlink:label="loc_pstv_PaymentsToAcquirePropertyPlantAndEquipmentAndIntangibleAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_pstv_PaymentsToAcquirePropertyPlantAndEquipmentAndIntangibleAssets" xml:lang="en-US">Payments To Acquire Property Plant And Equipment And Intangible Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_pstv_PaymentsToAcquirePropertyPlantAndEquipmentAndIntangibleAssets" xml:lang="en-US">Purchases of property and equipment and intangible assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pstv_PaymentsToAcquirePropertyPlantAndEquipmentAndIntangibleAssets" xlink:to="lab_pstv_PaymentsToAcquirePropertyPlantAndEquipmentAndIntangibleAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_pstv_PaymentsToAcquirePropertyPlantAndEquipmentAndIntangibleAssets" xml:lang="en-US">Payments to acquire property plant and equipment and intangible assets.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireShortTermInvestments" xlink:label="loc_us-gaap_PaymentsToAcquireShortTermInvestments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentsToAcquireShortTermInvestments" xml:lang="en-US">Payments to Acquire Short-Term Investments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_PaymentsToAcquireShortTermInvestments" xml:lang="en-US">Purchase of short-term investments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireShortTermInvestments" xlink:to="lab_us-gaap_PaymentsToAcquireShortTermInvestments" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">Net Cash Provided By Used In Operating Activities [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">Cash flows used in operating activities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xml:lang="en-US">Accretion (Amortization) of Discounts and Premiums, Investments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xml:lang="en-US">Accretion of discount on short-term investments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:to="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xml:lang="en-US">Amortization Of Financing Costs And Discounts</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xml:lang="en-US">Amortization of deferred financing costs and debt discount</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:to="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" />
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_CommonStockIssuedForResearchAndDevelopment" xlink:label="loc_pstv_CommonStockIssuedForResearchAndDevelopment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_pstv_CommonStockIssuedForResearchAndDevelopment" xml:lang="en-US">Common Stock Issued for Research and Development</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_pstv_CommonStockIssuedForResearchAndDevelopment" xml:lang="en-US">Common stock issued for research and development</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pstv_CommonStockIssuedForResearchAndDevelopment" xlink:to="lab_pstv_CommonStockIssuedForResearchAndDevelopment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_pstv_CommonStockIssuedForResearchAndDevelopment" xml:lang="en-US">Common stock issued for research and development.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xml:lang="en-US">Depreciation Depletion And Amortization</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xml:lang="en-US">Depreciation and amortization</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueAdjustmentOfWarrants" xml:lang="en-US">Fair Value Adjustment Of Warrants</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueAdjustmentOfWarrants" xml:lang="en-US">Change in fair value of liability instruments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAdjustmentOfWarrants" xlink:to="lab_us-gaap_FairValueAdjustmentOfWarrants" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnDispositionOfAssets" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GainLossOnDispositionOfAssets" xml:lang="en-US">Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber Property</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_GainLossOnDispositionOfAssets" xml:lang="en-US">Loss on disposal of property and equipment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnDispositionOfAssets" xlink:to="lab_us-gaap_GainLossOnDispositionOfAssets" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xml:lang="en-US">Increase Decrease In Operating Capital [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xml:lang="en-US">Increases (decreases) in cash caused by changes in operating assets and liabilities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xml:lang="en-US">Increase Decrease In Accounts Payable And Accrued Liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xml:lang="en-US">Accounts payable and accrued expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_IncreaseDecreaseInDeferredGrantLiability" xlink:label="loc_pstv_IncreaseDecreaseInDeferredGrantLiability" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_pstv_IncreaseDecreaseInDeferredGrantLiability" xml:lang="en-US">Increase Decrease In Deferred Grant Liability</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_pstv_IncreaseDecreaseInDeferredGrantLiability" xml:lang="en-US">Deferred grant liability</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pstv_IncreaseDecreaseInDeferredGrantLiability" xlink:to="lab_pstv_IncreaseDecreaseInDeferredGrantLiability" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_pstv_IncreaseDecreaseInDeferredGrantLiability" xml:lang="en-US">Increase (decrease) in deferred grant liability.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xml:lang="en-US">Increase (Decrease) in Operating Lease Liability</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xml:lang="en-US">Change in operating lease liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherCurrentAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherCurrentAssets" xml:lang="en-US">Increase Decrease In Other Current Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherCurrentAssets" xml:lang="en-US">Other current assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherCurrentAssets" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xml:lang="en-US">Increase (Decrease) in Other Noncurrent Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xml:lang="en-US">Other assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xml:lang="en-US">Operating Lease, Right-of-Use Asset, Periodic Reduction</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xml:lang="en-US">Reduction in the carrying amount of operating lease right-of-use assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensation" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensation" xml:lang="en-US">Share-based compensation expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xml:lang="en-US">Net cash used in operating activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xml:lang="en-US">Net cash used in operating activities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xml:lang="en-US">Basis Of Presentation And Significant Accounting Policies [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xml:lang="en-US">Basis of Presentation and New Accounting Standards</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xml:lang="en-US">Organization and Operations</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" />
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_UseOfEstimatesAbstract" xlink:label="loc_pstv_UseOfEstimatesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_pstv_UseOfEstimatesAbstract" xml:lang="en-US">Use Of Estimates [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pstv_UseOfEstimatesAbstract" xlink:to="lab_pstv_UseOfEstimatesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_pstv_UseOfEstimatesAbstract" xml:lang="en-US">Use of Estimates [Abstract]</label>
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_UseOfEstimatesTextBlock" xlink:label="loc_pstv_UseOfEstimatesTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_pstv_UseOfEstimatesTextBlock" xml:lang="en-US">Use Of Estimates [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_pstv_UseOfEstimatesTextBlock" xml:lang="en-US">Use of Estimates</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pstv_UseOfEstimatesTextBlock" xlink:to="lab_pstv_UseOfEstimatesTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_pstv_UseOfEstimatesTextBlock" xml:lang="en-US">Provides an entity's explanation that the preparation of financial statements in conformity with generally accepted accounting principles requires the use of management estimates.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xml:lang="en-US">Accounting Policies [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xml:lang="en-US">Significant Accounting Policies [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xml:lang="en-US">Summary of Significant Accounting Policies</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" />
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_LiquidityAbstract" xlink:label="loc_pstv_LiquidityAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_pstv_LiquidityAbstract" xml:lang="en-US">Liquidity [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pstv_LiquidityAbstract" xlink:to="lab_pstv_LiquidityAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_pstv_LiquidityAbstract" xml:lang="en-US">Liquidity Abstract</label>
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_DisclosureOfLiquidityAndGoingConcernTextBlock" xlink:label="loc_pstv_DisclosureOfLiquidityAndGoingConcernTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_pstv_DisclosureOfLiquidityAndGoingConcernTextBlock" xml:lang="en-US">Disclosure Of Liquidity And Going Concern Text Block</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_pstv_DisclosureOfLiquidityAndGoingConcernTextBlock" xml:lang="en-US">Liquidity and Going Concern</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pstv_DisclosureOfLiquidityAndGoingConcernTextBlock" xlink:to="lab_pstv_DisclosureOfLiquidityAndGoingConcernTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_pstv_DisclosureOfLiquidityAndGoingConcernTextBlock" xml:lang="en-US">Disclosure of liquidity and going concern text block</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xml:lang="en-US">Fair Value Disclosures [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementInputsDisclosureTextBlock" xlink:label="loc_us-gaap_FairValueMeasurementInputsDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueMeasurementInputsDisclosureTextBlock" xml:lang="en-US">Fair Value Measurement Inputs Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueMeasurementInputsDisclosureTextBlock" xml:lang="en-US">Fair Value Measurements</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementInputsDisclosureTextBlock" xlink:to="lab_us-gaap_FairValueMeasurementInputsDisclosureTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xml:lang="en-US">Earnings Per Share [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xml:lang="en-US">Earnings Per Share [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xml:lang="en-US">Loss per Share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" />
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_CompositionOfCertainFinancialStatementCaptionsAbstract" xlink:label="loc_pstv_CompositionOfCertainFinancialStatementCaptionsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_pstv_CompositionOfCertainFinancialStatementCaptionsAbstract" xml:lang="en-US">Composition Of Certain Financial Statement Captions [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pstv_CompositionOfCertainFinancialStatementCaptionsAbstract" xlink:to="lab_pstv_CompositionOfCertainFinancialStatementCaptionsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_pstv_CompositionOfCertainFinancialStatementCaptionsAbstract" xml:lang="en-US">Composition of Certain Financial Statement Captions [Abstract]</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:label="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xml:lang="en-US">Supplemental Balance Sheet Disclosures [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xml:lang="en-US">Composition of Certain Financial Statement Captions</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:to="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xml:lang="en-US">Commitments And Contingencies Disclosure [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xml:lang="en-US">Commitments And Contingencies Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xml:lang="en-US">Commitments and Contingencies</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_LicenseAgreementAbstract" xlink:label="loc_pstv_LicenseAgreementAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_pstv_LicenseAgreementAbstract" xml:lang="en-US">License Agreement [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pstv_LicenseAgreementAbstract" xlink:to="lab_pstv_LicenseAgreementAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_pstv_LicenseAgreementAbstract" xml:lang="en-US">License agreement abstract.</label>
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_LicenseAgreementDisclosureTextBlock" xlink:label="loc_pstv_LicenseAgreementDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_pstv_LicenseAgreementDisclosureTextBlock" xml:lang="en-US">License Agreement Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_pstv_LicenseAgreementDisclosureTextBlock" xml:lang="en-US">License Agreements</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pstv_LicenseAgreementDisclosureTextBlock" xlink:to="lab_pstv_LicenseAgreementDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_pstv_LicenseAgreementDisclosureTextBlock" xml:lang="en-US">Disclosure of accounting policy for license agreement.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xml:lang="en-US">Debt Disclosure [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="loc_us-gaap_DebtDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xml:lang="en-US">Debt Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xml:lang="en-US">Term Loan Obligations</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_us-gaap_DebtDisclosureTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xml:lang="en-US">Revenue from Contract with Customer [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xml:lang="en-US">Grant Revenue</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xml:lang="en-US">Income Tax Disclosure [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xml:lang="en-US">Income Tax Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xml:lang="en-US">Income Taxes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xml:lang="en-US">Retirement Benefits [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:label="loc_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xml:lang="en-US">Compensation and Employee Benefit Plans [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xml:lang="en-US">Employee Benefit Plan</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:to="lab_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquityNoteAbstract" xml:lang="en-US">Stockholders Equity Note [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract" xlink:to="lab_us-gaap_StockholdersEquityNoteAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xml:lang="en-US">Stockholders Equity Note Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xml:lang="en-US">Stockholders' Equity</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xml:lang="en-US">Subsequent Events [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract" xlink:to="lab_us-gaap_SubsequentEventsAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaap_SubsequentEventsTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xml:lang="en-US">Subsequent Events [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xml:lang="en-US">Subsequent Events</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock" xlink:to="lab_us-gaap_SubsequentEventsTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xml:lang="en-US">Disclosure Of Compensation Related Costs Share Based Payments [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xml:lang="en-US">Stock-based Compensation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_AmendmentsForCertificateofIncorporationAndReverseStockSplitPolicyTextBlock" xlink:label="loc_pstv_AmendmentsForCertificateofIncorporationAndReverseStockSplitPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_pstv_AmendmentsForCertificateofIncorporationAndReverseStockSplitPolicyTextBlock" xml:lang="en-US">Amendments For Certificate of Incorporation And Reverse Stock Split [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_pstv_AmendmentsForCertificateofIncorporationAndReverseStockSplitPolicyTextBlock" xml:lang="en-US">Amendments to Certificate of Incorporation and Reverse Stock Split</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pstv_AmendmentsForCertificateofIncorporationAndReverseStockSplitPolicyTextBlock" xlink:to="lab_pstv_AmendmentsForCertificateofIncorporationAndReverseStockSplitPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_pstv_AmendmentsForCertificateofIncorporationAndReverseStockSplitPolicyTextBlock" xml:lang="en-US">Amendments For Certificate of Incorporation And Reverse Stock Split.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesPurchasedOptionsPricePolicy" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesPurchasedOptionsPricePolicy" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesPurchasedOptionsPricePolicy" xml:lang="en-US">Debt Securities, Available-for-Sale, Premium on Purchased Options [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesPurchasedOptionsPricePolicy" xml:lang="en-US">Available-for-Sale Securities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesPurchasedOptionsPricePolicy" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesPurchasedOptionsPricePolicy" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xml:lang="en-US">Basis Of Accounting Policy Policy [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xml:lang="en-US">Basis of Presentation and New Accounting Standards</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xml:lang="en-US">Recently Issued Accounting Pronouncements</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xml:lang="en-US">Revenue from Contract with Customer [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xml:lang="en-US">Grant Revenue Recognition</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xml:lang="en-US">Cash and cash equivalents</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xml:lang="en-US">Concentration Risk</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:to="lab_us-gaap_ConcentrationRiskCreditRisk" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtPolicyTextBlock" xlink:label="loc_us-gaap_DebtPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtPolicyTextBlock" xml:lang="en-US">Debt, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtPolicyTextBlock" xml:lang="en-US">Deferred Financing Costs and Other Debt-Related Costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtPolicyTextBlock" xlink:to="lab_us-gaap_DebtPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xml:lang="en-US">Loss Per Share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xml:lang="en-US">Fair Value of Financial Instruments, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xml:lang="en-US">Financial Instruments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xml:lang="en-US">Goodwill and Intangible Assets, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xml:lang="en-US">Goodwill</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xml:lang="en-US">Income Taxes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InProcessResearchAndDevelopmentPolicy" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentPolicy" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InProcessResearchAndDevelopmentPolicy" xml:lang="en-US">In Process Research and Development, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_InProcessResearchAndDevelopmentPolicy" xml:lang="en-US">Acquired In-Process Research and Development (IPR&amp;D)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InProcessResearchAndDevelopmentPolicy" xlink:to="lab_us-gaap_InProcessResearchAndDevelopmentPolicy" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentImpairment" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentImpairment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentImpairment" xml:lang="en-US">Property, Plant and Equipment, Impairment [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentImpairment" xml:lang="en-US">Impairment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentImpairment" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentImpairment" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xml:lang="en-US">Property and Equipment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xml:lang="en-US">Research and Development</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xml:lang="en-US">Segment Information</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xml:lang="en-US">Share-Based Payment Arrangement [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xml:lang="en-US">Share-Based Compensation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaap_UseOfEstimates" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_UseOfEstimates" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_UseOfEstimates" xml:lang="en-US">Use of Estimates</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xml:lang="en-US">Fair Value, Assets Measured on Recurring Basis [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xml:lang="en-US">Summary of Financial Assets Measured at Fair Value on Recurring Basis</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xml:lang="en-US">Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Diluted Income (Loss) per Share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xml:lang="en-US">Property and Equipment, net</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xml:lang="en-US">Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xml:lang="en-US">Accounts Payable and Accrued Expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xml:lang="en-US">Schedule of Other Current Assets [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xml:lang="en-US">Other Current Assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="loc_us-gaap_LeaseCostTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xml:lang="en-US">Lease Cost Table [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xml:lang="en-US">Summary of Lease Costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostTableTextBlock" xlink:to="lab_us-gaap_LeaseCostTableTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xml:lang="en-US">Lessee Operating Lease Liability Maturity Table [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xml:lang="en-US">Summary of Future Minimum Annual Lease Payments under Operating Leases</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:label="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xml:lang="en-US">Schedule of Long-Term Debt Instruments [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xml:lang="en-US">Term Loan Outstanding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:to="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xml:lang="en-US">Deferred Tax Assets and Liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xml:lang="en-US">Reconciliation of Total Income Tax Provision</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xml:lang="en-US">Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xml:lang="en-US">Unrecognized Tax Benefits Activity</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xml:lang="en-US">Share-Based Payment Arrangement, Cost by Plan [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xml:lang="en-US">Summary of Share-Based Compensation Recognized</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xml:lang="en-US">Schedule Of Share Based Compensation Activity Table [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xml:lang="en-US">Stock Option Activity</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xml:lang="en-US">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xml:lang="en-US">Weighted-average Assumptions</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract" xlink:label="loc_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract" xml:lang="en-US">Accounting Standards Update and Change in Accounting Principle [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract" xlink:to="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xml:lang="en-US">Accounting Standards Update and Change in Accounting Principle [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:to="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xml:lang="en-US">Accounting Standards Update [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xml:lang="en-US">Accounting Standards Update</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TypeOfAdoptionMember" xml:lang="en-US">Accounting Standards Update [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_TypeOfAdoptionMember" xml:lang="en-US">Accounting Standards Update</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfAdoptionMember" xlink:to="lab_us-gaap_TypeOfAdoptionMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xml:lang="en-US">New Accounting Pronouncements or Change in Accounting Principle [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain" xml:lang="en-US">Debt Securities, Available-for-Sale, Unrealized Gain</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain" xml:lang="en-US">Unrealized gain on available-for-sale securities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xml:lang="en-US">Common stock capital shares reserved for future issuance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xml:lang="en-US">Number of shares reserved for issuance and sale</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_ReverseStockSplitEffectiveDate" xlink:label="loc_pstv_ReverseStockSplitEffectiveDate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_pstv_ReverseStockSplitEffectiveDate" xml:lang="en-US">Reverse Stock Split Effective Date</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_pstv_ReverseStockSplitEffectiveDate" xml:lang="en-US">Reverse stock split effective date</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pstv_ReverseStockSplitEffectiveDate" xlink:to="lab_pstv_ReverseStockSplitEffectiveDate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_pstv_ReverseStockSplitEffectiveDate" xml:lang="en-US">Reverse stock split effective date.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xml:lang="en-US">Stockholders' Equity Note, Stock Split, Conversion Ratio</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xml:lang="en-US">Stock split conversion ratio</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:to="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" xml:lang="en-US">Stock Issued During Period, Shares, Reverse Stock Splits</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" xml:lang="en-US">Stock issued during period reverse stock splits, shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockSplits" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockSplits" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockSplits" xml:lang="en-US">Stock Issued During Period, Shares, Stock Splits</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockSplits" xml:lang="en-US">Common stock, reverse stock split, fractional shares issued</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockSplits" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockSplits" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PlanNameAxis" xml:lang="en-US">Plan Name [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PlanNameAxis" xml:lang="en-US">Plan Name</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PlanNameDomain" xml:lang="en-US">Plan Name [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PlanNameDomain" xml:lang="en-US">Plan Name</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" />
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_EquityIncentivePlansMember" xlink:label="loc_pstv_EquityIncentivePlansMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_pstv_EquityIncentivePlansMember" xml:lang="en-US">Equity Incentive Plans [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_pstv_EquityIncentivePlansMember" xml:lang="en-US">Equity Incentive Plans [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pstv_EquityIncentivePlansMember" xlink:to="lab_pstv_EquityIncentivePlansMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_pstv_EquityIncentivePlansMember" xml:lang="en-US">Equity incentive plans.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_RangeAxis" xml:lang="en-US">Statistical Measurement [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_srt_RangeAxis" xml:lang="en-US">Statistical Measurement [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_RangeAxis" xml:lang="en-US">Statistical Measurement</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_RangeMember" xml:lang="en-US">Statistical Measurement [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_srt_RangeMember" xml:lang="en-US">Statistical Measurement [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_RangeMember" xml:lang="en-US">Statistical Measurement</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_MaximumMember" xml:lang="en-US">Maximum [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_MaximumMember" xml:lang="en-US">Maximum [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_MinimumMember" xml:lang="en-US">Minimum [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_MinimumMember" xml:lang="en-US">Minimum [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" />
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_OutstandingWarrantsAndOptionsMember" xlink:label="loc_pstv_OutstandingWarrantsAndOptionsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_pstv_OutstandingWarrantsAndOptionsMember" xml:lang="en-US">Outstanding Warrants and Options [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_pstv_OutstandingWarrantsAndOptionsMember" xml:lang="en-US">Outstanding Warrants and Options [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pstv_OutstandingWarrantsAndOptionsMember" xlink:to="lab_pstv_OutstandingWarrantsAndOptionsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_pstv_OutstandingWarrantsAndOptionsMember" xml:lang="en-US">Outstanding warrants and options.</label>
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_OrganizationAndOperationsTable" xlink:label="loc_pstv_OrganizationAndOperationsTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_pstv_OrganizationAndOperationsTable" xml:lang="en-US">Organization and Operations [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pstv_OrganizationAndOperationsTable" xlink:to="lab_pstv_OrganizationAndOperationsTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_pstv_OrganizationAndOperationsTable" xml:lang="en-US">Organization and Operations [Table]</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentAxis" xml:lang="en-US">Debt Instrument [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtInstrumentAxis" xml:lang="en-US">Debt Instrument</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xml:lang="en-US">Debt Instrument, Name [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xml:lang="en-US">Debt Instrument, Name</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" />
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_TermLoanMember" xlink:label="loc_pstv_TermLoanMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_pstv_TermLoanMember" xml:lang="en-US">Term Loan [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_pstv_TermLoanMember" xml:lang="en-US">Term Loan [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pstv_TermLoanMember" xlink:to="lab_pstv_TermLoanMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_pstv_TermLoanMember" xml:lang="en-US">Second amendment to the amended and restated loan and security agreement.</label>
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_OrganizationAndOperationsLineItems" xlink:label="loc_pstv_OrganizationAndOperationsLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_pstv_OrganizationAndOperationsLineItems" xml:lang="en-US">Organization and Operations [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pstv_OrganizationAndOperationsLineItems" xlink:to="lab_pstv_OrganizationAndOperationsLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_pstv_OrganizationAndOperationsLineItems" xml:lang="en-US">Organization and operations.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFeeAmount" xlink:label="loc_us-gaap_DebtInstrumentFeeAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentFeeAmount" xml:lang="en-US">Debt Instrument, Fee Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtInstrumentFeeAmount" xml:lang="en-US">Fees amount associated with loan</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFeeAmount" xlink:to="lab_us-gaap_DebtInstrumentFeeAmount" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="loc_us-gaap_DebtInstrumentMaturityDate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentMaturityDate" xml:lang="en-US">Debt Instrument, Maturity Date</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtInstrumentMaturityDate" xml:lang="en-US">Maturity date</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentMaturityDate" xlink:to="lab_us-gaap_DebtInstrumentMaturityDate" />
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_LongTermDebtOutstandingThresholdAmount" xlink:label="loc_pstv_LongTermDebtOutstandingThresholdAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_pstv_LongTermDebtOutstandingThresholdAmount" xml:lang="en-US">Long Term Debt Outstanding Threshold Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_pstv_LongTermDebtOutstandingThresholdAmount" xml:lang="en-US">Long term debt outstanding threshold amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_pstv_LongTermDebtOutstandingThresholdAmount" xml:lang="en-US">Long term debt outstanding threshold amount</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pstv_LongTermDebtOutstandingThresholdAmount" xlink:to="lab_pstv_LongTermDebtOutstandingThresholdAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_pstv_LongTermDebtOutstandingThresholdAmount" xml:lang="en-US">Long term debt outstanding threshold amount.</label>
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_SummaryOfSignificantAccountingPoliciesTable" xlink:label="loc_pstv_SummaryOfSignificantAccountingPoliciesTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_pstv_SummaryOfSignificantAccountingPoliciesTable" xml:lang="en-US">Summary Of Significant Accounting Policies [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_pstv_SummaryOfSignificantAccountingPoliciesTable" xml:lang="en-US">Summary Of Significant Accounting Policies [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pstv_SummaryOfSignificantAccountingPoliciesTable" xlink:to="lab_pstv_SummaryOfSignificantAccountingPoliciesTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_pstv_SummaryOfSignificantAccountingPoliciesTable" xml:lang="en-US">Summary of significant accounting policies.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingStandardsUpdate201613Member" xlink:label="loc_us-gaap_AccountingStandardsUpdate201613Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountingStandardsUpdate201613Member" xml:lang="en-US">Accounting Standards Update 2016-13 [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccountingStandardsUpdate201613Member" xml:lang="en-US">ASU 2016-13</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingStandardsUpdate201613Member" xlink:to="lab_us-gaap_AccountingStandardsUpdate201613Member" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xml:lang="en-US">Indefinite-Lived Intangible Assets [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xml:lang="en-US">Indefinite-Lived Intangible Assets, Major Class Name [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InProcessResearchAndDevelopmentMember" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InProcessResearchAndDevelopmentMember" xml:lang="en-US">In Process Research and Development [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InProcessResearchAndDevelopmentMember" xlink:to="lab_us-gaap_InProcessResearchAndDevelopmentMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" />
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_SummaryOfSignificantAccountingPoliciesLineItems" xlink:label="loc_pstv_SummaryOfSignificantAccountingPoliciesLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_pstv_SummaryOfSignificantAccountingPoliciesLineItems" xml:lang="en-US">Summary Of Significant Accounting Policies [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_pstv_SummaryOfSignificantAccountingPoliciesLineItems" xml:lang="en-US">Summary Of Significant Accounting Policies [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pstv_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="lab_pstv_SummaryOfSignificantAccountingPoliciesLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_pstv_SummaryOfSignificantAccountingPoliciesLineItems" xml:lang="en-US">Summary of significant accounting policies.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetImpairmentCharges" xlink:label="loc_us-gaap_AssetImpairmentCharges" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetImpairmentCharges" xml:lang="en-US">Asset Impairment Charges</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AssetImpairmentCharges" xml:lang="en-US">Impairment charges</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetImpairmentCharges" xlink:to="lab_us-gaap_AssetImpairmentCharges" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" xlink:label="loc_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" xml:lang="en-US">Change in Accounting Principle, Accounting Standards Update, Adopted [true false]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" xml:lang="en-US">Change in accounting principle, accounting standards update, adopted</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" xlink:to="lab_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" xlink:label="loc_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" xml:lang="en-US">Change in Accounting Principle, Accounting Standards Update, Adoption Date</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" xml:lang="en-US">Change in accounting principle, accounting standards update, adoption date</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" xlink:to="lab_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" xlink:label="loc_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" xml:lang="en-US">Change in Accounting Principle, Accounting Standards Update, Immaterial Effect [true false]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" xml:lang="en-US">Change in accounting principle, accounting standards update, immaterial effect</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" xlink:to="lab_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xml:lang="en-US">Impairment, Long-Lived Asset, Held-for-Use</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xml:lang="en-US">Impairment loss</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:to="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" xlink:label="loc_us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" xml:lang="en-US">Income Tax Examination, Penalties and Interest Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" xml:lang="en-US">Interest or penalties related to income tax matters</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" xlink:to="lab_us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="loc_us-gaap_NumberOfOperatingSegments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xml:lang="en-US">Number of Operating Segments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xml:lang="en-US">Number of operating segment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments" xlink:to="lab_us-gaap_NumberOfOperatingSegments" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfReportingUnits" xlink:label="loc_us-gaap_NumberOfReportingUnits" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NumberOfReportingUnits" xml:lang="en-US">Number of Reporting Units</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NumberOfReportingUnits" xml:lang="en-US">Number of reporting units</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfReportingUnits" xlink:to="lab_us-gaap_NumberOfReportingUnits" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xml:lang="en-US">Property, Plant and Equipment, Useful Life</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xml:lang="en-US">Useful lives of the assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperations" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperations" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperations" xml:lang="en-US">Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperations" xml:lang="en-US">Net income from continuing operations</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperations" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperations" />
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_MaintainMinimumMarketValueOfListedSecurities" xlink:label="loc_pstv_MaintainMinimumMarketValueOfListedSecurities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_pstv_MaintainMinimumMarketValueOfListedSecurities" xml:lang="en-US">Maintain Minimum Market Value of Listed Securities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_pstv_MaintainMinimumMarketValueOfListedSecurities" xml:lang="en-US">Maintain minimum market value of listed securities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pstv_MaintainMinimumMarketValueOfListedSecurities" xlink:to="lab_pstv_MaintainMinimumMarketValueOfListedSecurities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_pstv_MaintainMinimumMarketValueOfListedSecurities" xml:lang="en-US">Maintain minimum market value of listed securities</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="loc_us-gaap_WarrantsAndRightsOutstanding" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_WarrantsAndRightsOutstanding" xml:lang="en-US">Warrants And Rights Outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_WarrantsAndRightsOutstanding" xml:lang="en-US">Warrant liability</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantsAndRightsOutstanding" xlink:to="lab_us-gaap_WarrantsAndRightsOutstanding" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xml:lang="en-US">Subsequent Event Type [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xml:lang="en-US">Subsequent Event Type</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xml:lang="en-US">Subsequent Event Type [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xml:lang="en-US">Subsequent Event Type</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xml:lang="en-US">Subsidiary Sale Of Stock [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xml:lang="en-US">Sale of Stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xml:lang="en-US">Sale Of Stock Name Of Transaction [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xml:lang="en-US">Sale of Stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaap_PrivatePlacementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PrivatePlacementMember" xml:lang="en-US">Private Placement [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PrivatePlacementMember" xml:lang="en-US">Private Placement [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrivatePlacementMember" xlink:to="lab_us-gaap_PrivatePlacementMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashAndCashEquivalentsAxis" xml:lang="en-US">Cash and Cash Equivalents [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis" xlink:to="lab_us-gaap_CashAndCashEquivalentsAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xml:lang="en-US">Cash and Cash Equivalents [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="loc_us-gaap_MoneyMarketFundsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xml:lang="en-US">Money Market Funds [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xml:lang="en-US">Money Market [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember" xlink:to="lab_us-gaap_MoneyMarketFundsMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="loc_us-gaap_USTreasurySecuritiesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_USTreasurySecuritiesMember" xml:lang="en-US">US Treasury Securities [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_USTreasurySecuritiesMember" xml:lang="en-US">Treasury Bills and Government Agency Bonds [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USTreasurySecuritiesMember" xlink:to="lab_us-gaap_USTreasurySecuritiesMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="loc_us-gaap_AssetsFairValueDisclosure" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xml:lang="en-US">Assets, Fair Value Disclosure</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xml:lang="en-US">Fair Value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure" xlink:to="lab_us-gaap_AssetsFairValueDisclosure" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xml:lang="en-US">Level 1 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xml:lang="en-US">Measurement Frequency [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xml:lang="en-US">Measurement Frequency [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xml:lang="en-US">Fair Value, Recurring [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xml:lang="en-US">Recurring Basis [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xml:lang="en-US">Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xml:lang="en-US">Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xml:lang="en-US">Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xml:lang="en-US">Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xml:lang="en-US">Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xml:lang="en-US">Dilutive common shares excluded from the calculations of diluted loss per share (in shares)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_OptionsMember" xlink:label="loc_pstv_OptionsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_pstv_OptionsMember" xml:lang="en-US">Options [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_pstv_OptionsMember" xml:lang="en-US">Outstanding Stock Options [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pstv_OptionsMember" xlink:to="lab_pstv_OptionsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_pstv_OptionsMember" xml:lang="en-US">Options.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_WarrantMember" xml:lang="en-US">Warrant [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_WarrantMember" xml:lang="en-US">Outstanding Warrants [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantMember" xlink:to="lab_us-gaap_WarrantMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xml:lang="en-US">Prepaid Expense and Other Assets, Current [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xml:lang="en-US">Other Current Assets [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherPrepaidExpenseCurrent" xlink:label="loc_us-gaap_OtherPrepaidExpenseCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherPrepaidExpenseCurrent" xml:lang="en-US">Other Prepaid Expense, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OtherPrepaidExpenseCurrent" xml:lang="en-US">Prepaid services</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherPrepaidExpenseCurrent" xlink:to="lab_us-gaap_OtherPrepaidExpenseCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidInsurance" xlink:label="loc_us-gaap_PrepaidInsurance" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PrepaidInsurance" xml:lang="en-US">Prepaid Insurance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PrepaidInsurance" xml:lang="en-US">Prepaid insurance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidInsurance" xlink:to="lab_us-gaap_PrepaidInsurance" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNetAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNetAbstract" xml:lang="en-US">Property, Plant and Equipment, Net [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNetAbstract" xml:lang="en-US">Property and Equipment, net [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNetAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xml:lang="en-US">Less accumulated depreciation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdImprovementsGross" xlink:label="loc_us-gaap_LeaseholdImprovementsGross" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LeaseholdImprovementsGross" xml:lang="en-US">Leasehold Improvements, Gross</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LeaseholdImprovementsGross" xml:lang="en-US">Leasehold improvements</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsGross" xlink:to="lab_us-gaap_LeaseholdImprovementsGross" />
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_OfficeAndComputerEquipmentGross" xlink:label="loc_pstv_OfficeAndComputerEquipmentGross" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_pstv_OfficeAndComputerEquipmentGross" xml:lang="en-US">Office And Computer Equipment Gross</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_pstv_OfficeAndComputerEquipmentGross" xml:lang="en-US">Office and computer equipment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pstv_OfficeAndComputerEquipmentGross" xlink:to="lab_pstv_OfficeAndComputerEquipmentGross" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_pstv_OfficeAndComputerEquipmentGross" xml:lang="en-US">The gross amount of office and computer equipment cost as of the balance sheet date.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xml:lang="en-US">Property, Plant and Equipment, Gross</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xml:lang="en-US">Property and equipment, gross</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xml:lang="en-US">Amortization of Intangible Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xml:lang="en-US">Amortization</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:to="lab_us-gaap_AmortizationOfIntangibleAssets" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_Depreciation" xml:lang="en-US">Depreciation</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_Depreciation" xml:lang="en-US">Depreciation expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation" xlink:to="lab_us-gaap_Depreciation" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract" xml:lang="en-US">Accounts Payable and Accrued Liabilities [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract" xml:lang="en-US">Accounts Payable and Accrued Expenses [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountsPayableCurrent" xml:lang="en-US">Accounts Payable, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccountsPayableCurrent" xml:lang="en-US">Accounts payable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedBonusesCurrent" xlink:label="loc_us-gaap_AccruedBonusesCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccruedBonusesCurrent" xml:lang="en-US">Accrued Bonuses, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccruedBonusesCurrent" xml:lang="en-US">Accrued payroll and bonus</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedBonusesCurrent" xlink:to="lab_us-gaap_AccruedBonusesCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xml:lang="en-US">Accrued Professional Fees, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xml:lang="en-US">Accrued professional fees</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedProfessionalFeesCurrent" xlink:to="lab_us-gaap_AccruedProfessionalFeesCurrent" />
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_AccruedResearchAndDevelopmentStudies" xlink:label="loc_pstv_AccruedResearchAndDevelopmentStudies" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_pstv_AccruedResearchAndDevelopmentStudies" xml:lang="en-US">Accrued Research And Development Studies</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_pstv_AccruedResearchAndDevelopmentStudies" xml:lang="en-US">Accrued R&amp;D studies</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pstv_AccruedResearchAndDevelopmentStudies" xlink:to="lab_pstv_AccruedResearchAndDevelopmentStudies" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_pstv_AccruedResearchAndDevelopmentStudies" xml:lang="en-US">Carrying value as of the balance sheet date of obligations incurred through that date and payable for research and development studies.</label>
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_AccruedVacationAndCompensationCurrent" xlink:label="loc_pstv_AccruedVacationAndCompensationCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_pstv_AccruedVacationAndCompensationCurrent" xml:lang="en-US">Accrued Vacation And Compensation Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_pstv_AccruedVacationAndCompensationCurrent" xml:lang="en-US">Accrued vacation and compensation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pstv_AccruedVacationAndCompensationCurrent" xlink:to="lab_pstv_AccruedVacationAndCompensationCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_pstv_AccruedVacationAndCompensationCurrent" xml:lang="en-US">Accrued vacation and compensation, current.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RecordedUnconditionalPurchaseObligationTable" xlink:label="loc_us-gaap_RecordedUnconditionalPurchaseObligationTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RecordedUnconditionalPurchaseObligationTable" xml:lang="en-US">Recorded Unconditional Purchase Obligation [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RecordedUnconditionalPurchaseObligationTable" xml:lang="en-US">Recorded Unconditional Purchase Obligation [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RecordedUnconditionalPurchaseObligationTable" xlink:to="lab_us-gaap_RecordedUnconditionalPurchaseObligationTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_LitigationCaseAxis" xlink:label="loc_srt_LitigationCaseAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_LitigationCaseAxis" xml:lang="en-US">Litigation Case [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_LitigationCaseAxis" xml:lang="en-US">Litigation Case</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LitigationCaseAxis" xlink:to="lab_srt_LitigationCaseAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_LitigationCaseTypeDomain" xlink:label="loc_srt_LitigationCaseTypeDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_LitigationCaseTypeDomain" xml:lang="en-US">Litigation Case Type [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_LitigationCaseTypeDomain" xml:lang="en-US">Litigation Case</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LitigationCaseTypeDomain" xlink:to="lab_srt_LitigationCaseTypeDomain" />
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_LoremVascularPteLtdMember" xlink:label="loc_pstv_LoremVascularPteLtdMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_pstv_LoremVascularPteLtdMember" xml:lang="en-US">Lorem Vascular Pte Ltd [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_pstv_LoremVascularPteLtdMember" xml:lang="en-US">Lorem Vascular Pte Ltd [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pstv_LoremVascularPteLtdMember" xlink:to="lab_pstv_LoremVascularPteLtdMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_pstv_LoremVascularPteLtdMember" xml:lang="en-US">Lorem Vascular, Pte. Ltd.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xml:lang="en-US">Long-Lived Tangible Asset</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xml:lang="en-US">Long-Lived Tangible Asset</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis" xlink:label="loc_us-gaap_RecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis" xml:lang="en-US">Recorded Unconditional Purchase Obligation By Category Of Item Purchased [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis" xml:lang="en-US">Recorded Unconditional Purchase Obligation by Category of Item Purchased</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis" xlink:to="lab_us-gaap_RecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain" xlink:label="loc_us-gaap_UnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_UnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain" xml:lang="en-US">Unconditional Purchase Obligation Category Of Goods Or Services Acquired [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_UnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain" xml:lang="en-US">Unconditional Purchase Obligation, Category of Goods or Services Acquired</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain" xlink:to="lab_us-gaap_UnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain" />
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_PreClinicalResearchStudyObligationsMember" xlink:label="loc_pstv_PreClinicalResearchStudyObligationsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_pstv_PreClinicalResearchStudyObligationsMember" xml:lang="en-US">Pre Clinical Research Study Obligations [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_pstv_PreClinicalResearchStudyObligationsMember" xml:lang="en-US">Pre-clinical Research Study Obligations [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pstv_PreClinicalResearchStudyObligationsMember" xlink:to="lab_pstv_PreClinicalResearchStudyObligationsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_pstv_PreClinicalResearchStudyObligationsMember" xml:lang="en-US">Contractual obligation to provide funding of research and development costs over periods that initially exceed one year or the normal operating cycle, if longer.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RecordedUnconditionalPurchaseObligationLineItems" xlink:label="loc_us-gaap_RecordedUnconditionalPurchaseObligationLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RecordedUnconditionalPurchaseObligationLineItems" xml:lang="en-US">Recorded Unconditional Purchase Obligation [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RecordedUnconditionalPurchaseObligationLineItems" xml:lang="en-US">Recorded Unconditional Purchase Obligation [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RecordedUnconditionalPurchaseObligationLineItems" xlink:to="lab_us-gaap_RecordedUnconditionalPurchaseObligationLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractualObligation" xlink:label="loc_us-gaap_ContractualObligation" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ContractualObligation" xml:lang="en-US">Contractual Obligation</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ContractualObligation" xml:lang="en-US">Contractual obligation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractualObligation" xlink:to="lab_us-gaap_ContractualObligation" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseExpirationDate1" xlink:label="loc_us-gaap_LeaseExpirationDate1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LeaseExpirationDate1" xml:lang="en-US">Lease Expiration Date1</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LeaseExpirationDate1" xml:lang="en-US">Operating leases, expiration date</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseExpirationDate1" xlink:to="lab_us-gaap_LeaseExpirationDate1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseDiscountRate" xlink:label="loc_us-gaap_LesseeOperatingLeaseDiscountRate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseDiscountRate" xml:lang="en-US">Lessee, Operating Lease, Discount Rate</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseDiscountRate" xml:lang="en-US">Operating lease discount rate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseDiscountRate" xlink:to="lab_us-gaap_LesseeOperatingLeaseDiscountRate" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:label="loc_us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xml:lang="en-US">Lessee Operating Lease Existence Of Option To Extend</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xml:lang="en-US">Lessee, operating lease, existence of option to extend [true false]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:to="lab_us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:label="loc_us-gaap_LesseeOperatingLeaseOptionToExtend" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseOptionToExtend" xml:lang="en-US">Lessee Operating Lease Option To Extend</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseOptionToExtend" xml:lang="en-US">Lessee, operating lease, option to extend</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:to="lab_us-gaap_LesseeOperatingLeaseOptionToExtend" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xml:lang="en-US">Lessee Operating Lease Renewal Term</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xml:lang="en-US">Lessee, operating lease, renewal term</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xml:lang="en-US">Lessee Operating Lease Term Of Contract</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xml:lang="en-US">Lessee, operating lease, term of contract</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="lab_us-gaap_LesseeOperatingLeaseTermOfContract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LitigationSettlementExpense" xlink:label="loc_us-gaap_LitigationSettlementExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LitigationSettlementExpense" xml:lang="en-US">Litigation Settlement Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LitigationSettlementExpense" xml:lang="en-US">Litigation settlement, expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationSettlementExpense" xlink:to="lab_us-gaap_LitigationSettlementExpense" />
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_MasterServicesAgreementDate" xlink:label="loc_pstv_MasterServicesAgreementDate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_pstv_MasterServicesAgreementDate" xml:lang="en-US">Master Services Agreement Date</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_pstv_MasterServicesAgreementDate" xml:lang="en-US">Master service agreement date</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pstv_MasterServicesAgreementDate" xlink:to="lab_pstv_MasterServicesAgreementDate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_pstv_MasterServicesAgreementDate" xml:lang="en-US">Master services agreement date.</label>
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_MasterServicesAgreementInitialTerm" xlink:label="loc_pstv_MasterServicesAgreementInitialTerm" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_pstv_MasterServicesAgreementInitialTerm" xml:lang="en-US">Master Services Agreement Initial Term</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_pstv_MasterServicesAgreementInitialTerm" xml:lang="en-US">Master services agreement initial term</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pstv_MasterServicesAgreementInitialTerm" xlink:to="lab_pstv_MasterServicesAgreementInitialTerm" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_pstv_MasterServicesAgreementInitialTerm" xml:lang="en-US">Master services agreement initial term.</label>
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_MasterServicesAgreementTermsDescription" xlink:label="loc_pstv_MasterServicesAgreementTermsDescription" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_pstv_MasterServicesAgreementTermsDescription" xml:lang="en-US">Master Services Agreement Terms Description</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_pstv_MasterServicesAgreementTermsDescription" xml:lang="en-US">Master services agreement terms, Description</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pstv_MasterServicesAgreementTermsDescription" xlink:to="lab_pstv_MasterServicesAgreementTermsDescription" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_pstv_MasterServicesAgreementTermsDescription" xml:lang="en-US">Master services agreement Terms description.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseExpense" xlink:label="loc_us-gaap_OperatingLeaseExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseExpense" xml:lang="en-US">Operating Lease Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingLeaseExpense" xml:lang="en-US">Rent expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseExpense" xlink:to="lab_us-gaap_OperatingLeaseExpense" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseLiability" xml:lang="en-US">Operating Lease Liability</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingLeaseLiability" xml:lang="en-US">Lease liability</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OperatingLeaseLiability" xml:lang="en-US">Present value of obligations under leases</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" />
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_OperatingLeasesExpiryYear" xlink:label="loc_pstv_OperatingLeasesExpiryYear" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_pstv_OperatingLeasesExpiryYear" xml:lang="en-US">Operating Leases Expiry Year</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_pstv_OperatingLeasesExpiryYear" xml:lang="en-US">Operating leases expiry year</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pstv_OperatingLeasesExpiryYear" xlink:to="lab_pstv_OperatingLeasesExpiryYear" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_pstv_OperatingLeasesExpiryYear" xml:lang="en-US">Operating leases, expiry year.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xml:lang="en-US">Operating Lease Weighted Average Discount Rate Percent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xml:lang="en-US">Operating lease, weighted average discount rate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xml:lang="en-US">Operating Lease Weighted Average Remaining Lease Term1</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xml:lang="en-US">Operating lease, weighted average remaining term</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" />
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_SalesOrderTerm" xlink:label="loc_pstv_SalesOrderTerm" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_pstv_SalesOrderTerm" xml:lang="en-US">Sales Order Term</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_pstv_SalesOrderTerm" xml:lang="en-US">Sales order term</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pstv_SalesOrderTerm" xlink:to="lab_pstv_SalesOrderTerm" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_pstv_SalesOrderTerm" xml:lang="en-US">Sales order term.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xml:lang="en-US">Related Party Transactions By Related Party [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xml:lang="en-US">Related Party</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyDomain" xml:lang="en-US">Related Party, Type [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RelatedPartyDomain" xml:lang="en-US">Related Party</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyDomain" xlink:to="lab_us-gaap_RelatedPartyDomain" />
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_CharlottesvilleMember" xlink:label="loc_pstv_CharlottesvilleMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_pstv_CharlottesvilleMember" xml:lang="en-US">Charlottesville [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_pstv_CharlottesvilleMember" xml:lang="en-US">Charlottesville [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pstv_CharlottesvilleMember" xlink:to="lab_pstv_CharlottesvilleMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_pstv_CharlottesvilleMember" xml:lang="en-US">Charlottesville</label>
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_MedidataSolutionsIncMember" xlink:label="loc_pstv_MedidataSolutionsIncMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_pstv_MedidataSolutionsIncMember" xml:lang="en-US">Medidata Solutions Inc [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_pstv_MedidataSolutionsIncMember" xml:lang="en-US">Medidata Solutions, Inc. [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pstv_MedidataSolutionsIncMember" xlink:to="lab_pstv_MedidataSolutionsIncMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_pstv_MedidataSolutionsIncMember" xml:lang="en-US">Medidata solutions, inc.</label>
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_PiramalPharmaSolutionsIncMember" xlink:label="loc_pstv_PiramalPharmaSolutionsIncMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_pstv_PiramalPharmaSolutionsIncMember" xml:lang="en-US">Piramal Pharma Solutions Inc [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_pstv_PiramalPharmaSolutionsIncMember" xml:lang="en-US">Piramal Pharma Solutions, Inc. [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pstv_PiramalPharmaSolutionsIncMember" xlink:to="lab_pstv_PiramalPharmaSolutionsIncMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_pstv_PiramalPharmaSolutionsIncMember" xml:lang="en-US">Piramal pharma solutions inc.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_StatementGeographicalAxis" xml:lang="en-US">Geographical [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_StatementGeographicalAxis" xml:lang="en-US">Geographical</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_SegmentGeographicalDomain" xml:lang="en-US">Geographical [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_SegmentGeographicalDomain" xml:lang="en-US">Geographical</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xml:lang="en-US">Type Of Arrangement [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="lab_us-gaap_TypeOfArrangementAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xml:lang="en-US">Arrangements And Nonarrangement Transactions [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_ServicesAgreementMember" xlink:label="loc_pstv_ServicesAgreementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_pstv_ServicesAgreementMember" xml:lang="en-US">Services Agreement [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_pstv_ServicesAgreementMember" xml:lang="en-US">Services Agreement [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pstv_ServicesAgreementMember" xlink:to="lab_pstv_ServicesAgreementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_pstv_ServicesAgreementMember" xml:lang="en-US">Services agreement.</label>
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_CashPaymentInformationAbstract" xlink:label="loc_pstv_CashPaymentInformationAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_pstv_CashPaymentInformationAbstract" xml:lang="en-US">Cash Payment Information [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_pstv_CashPaymentInformationAbstract" xml:lang="en-US">Cash payment information:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pstv_CashPaymentInformationAbstract" xlink:to="lab_pstv_CashPaymentInformationAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_pstv_CashPaymentInformationAbstract" xml:lang="en-US">Cash payment information.</label>
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities" xlink:label="loc_pstv_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_pstv_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities" xml:lang="en-US">Cash Paid For Amounts Included In Measurement Of Lease Liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_pstv_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities" xml:lang="en-US">Total cash paid for amounts included in the measurement of lease liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pstv_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities" xlink:to="lab_pstv_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_pstv_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities" xml:lang="en-US">Cash paid for amounts included in the measurement of lease liabilities.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasePayments" xlink:label="loc_us-gaap_OperatingLeasePayments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeasePayments" xml:lang="en-US">Operating Lease Payments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingLeasePayments" xml:lang="en-US">Operating cash used for operating leases</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasePayments" xlink:to="lab_us-gaap_OperatingLeasePayments" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCostAbstract" xlink:label="loc_us-gaap_LeaseCostAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LeaseCostAbstract" xml:lang="en-US">Lease Cost [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LeaseCostAbstract" xml:lang="en-US">Lease expense:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostAbstract" xlink:to="lab_us-gaap_LeaseCostAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCost" xlink:label="loc_us-gaap_LeaseCost" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LeaseCost" xml:lang="en-US">Lease Cost</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_LeaseCost" xml:lang="en-US">Total lease expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCost" xlink:to="lab_us-gaap_LeaseCost" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseCost" xlink:label="loc_us-gaap_OperatingLeaseCost" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseCost" xml:lang="en-US">Operating Lease, Cost</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingLeaseCost" xml:lang="en-US">Operating lease expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseCost" xlink:to="lab_us-gaap_OperatingLeaseCost" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xml:lang="en-US">Total minimum lease payments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xml:lang="en-US">2024</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xml:lang="en-US">2026</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xml:lang="en-US">2025</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xml:lang="en-US">Lessee Operating Lease Liability Undiscounted Excess Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xml:lang="en-US">Less: amount representing interest</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_BioceptAgreementMember" xlink:label="loc_pstv_BioceptAgreementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_pstv_BioceptAgreementMember" xml:lang="en-US">Biocept Agreement [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_pstv_BioceptAgreementMember" xml:lang="en-US">Biocept Agreement [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pstv_BioceptAgreementMember" xlink:to="lab_pstv_BioceptAgreementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_pstv_BioceptAgreementMember" xml:lang="en-US">Biocept Agreement.</label>
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_NanoTxLicensesAgreementMember" xlink:label="loc_pstv_NanoTxLicensesAgreementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_pstv_NanoTxLicensesAgreementMember" xml:lang="en-US">Nano Tx Licenses Agreement [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_pstv_NanoTxLicensesAgreementMember" xml:lang="en-US">Nano Tx Licenses Agreement [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pstv_NanoTxLicensesAgreementMember" xlink:to="lab_pstv_NanoTxLicensesAgreementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_pstv_NanoTxLicensesAgreementMember" xml:lang="en-US">Nano Tx license agreement Member</label>
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_UTHSALicenseAgreementMember" xlink:label="loc_pstv_UTHSALicenseAgreementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_pstv_UTHSALicenseAgreementMember" xml:lang="en-US">U T H S A License Agreement [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_pstv_UTHSALicenseAgreementMember" xml:lang="en-US">UTHSA License Agreement [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pstv_UTHSALicenseAgreementMember" xlink:to="lab_pstv_UTHSALicenseAgreementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_pstv_UTHSALicenseAgreementMember" xml:lang="en-US">UTHSA License Agreement.</label>
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_AccruedLicensePayable" xlink:label="loc_pstv_AccruedLicensePayable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_pstv_AccruedLicensePayable" xml:lang="en-US">Accrued License Payable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_pstv_AccruedLicensePayable" xml:lang="en-US">Accrued payments due to NanoTx</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pstv_AccruedLicensePayable" xlink:to="lab_pstv_AccruedLicensePayable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_pstv_AccruedLicensePayable" xml:lang="en-US">Accrued license payable.</label>
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_OptionForExclusiveWorldwideLicense" xlink:label="loc_pstv_OptionForExclusiveWorldwideLicense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_pstv_OptionForExclusiveWorldwideLicense" xml:lang="en-US">Option For Exclusive Worldwide License</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_pstv_OptionForExclusiveWorldwideLicense" xml:lang="en-US">Option for exclusive worldwide license</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pstv_OptionForExclusiveWorldwideLicense" xlink:to="lab_pstv_OptionForExclusiveWorldwideLicense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_pstv_OptionForExclusiveWorldwideLicense" xml:lang="en-US">Option for exclusive worldwide license.</label>
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_PaymentForTechTransferAndValidationFee" xlink:label="loc_pstv_PaymentForTechTransferAndValidationFee" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_pstv_PaymentForTechTransferAndValidationFee" xml:lang="en-US">Payment For Tech Transfer And Validation Fee</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_pstv_PaymentForTechTransferAndValidationFee" xml:lang="en-US">Payment for tech transfer and validation fee</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pstv_PaymentForTechTransferAndValidationFee" xlink:to="lab_pstv_PaymentForTechTransferAndValidationFee" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_pstv_PaymentForTechTransferAndValidationFee" xml:lang="en-US">Payment for tech transfer and validation fee.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForRoyalties" xlink:label="loc_us-gaap_PaymentsForRoyalties" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentsForRoyalties" xml:lang="en-US">Payments For Royalties</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PaymentsForRoyalties" xml:lang="en-US">License fee payment in cash</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRoyalties" xlink:to="lab_us-gaap_PaymentsForRoyalties" />
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_PercentageOfNonDilutiveMonetaryAwardsRequiredToPay" xlink:label="loc_pstv_PercentageOfNonDilutiveMonetaryAwardsRequiredToPay" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_pstv_PercentageOfNonDilutiveMonetaryAwardsRequiredToPay" xml:lang="en-US">Percentage of Non-dilutive Monetary awards Required to Pay</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_pstv_PercentageOfNonDilutiveMonetaryAwardsRequiredToPay" xml:lang="en-US">Percentage of non-dilutive monetary awards required to pay</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pstv_PercentageOfNonDilutiveMonetaryAwardsRequiredToPay" xlink:to="lab_pstv_PercentageOfNonDilutiveMonetaryAwardsRequiredToPay" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_pstv_PercentageOfNonDilutiveMonetaryAwardsRequiredToPay" xml:lang="en-US">Percentage of non-dilutive monetary awards required to pay.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaap_SharesIssued" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharesIssued" xml:lang="en-US">Shares Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SharesIssued" xml:lang="en-US">Shares issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SharesIssued" xml:lang="en-US">Remaining common stock issued and sold (in shares)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesIssued" xlink:to="lab_us-gaap_SharesIssued" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentTable" xml:lang="en-US">Schedule of Long-Term Debt Instruments [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtInstrumentTable" xml:lang="en-US">Debt Instrument [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="lab_us-gaap_DebtInstrumentTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xml:lang="en-US">Debt Instrument [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xml:lang="en-US">Debt Instrument [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AmortizationOfDebtDiscountPremium" xml:lang="en-US">Amortization Of Debt Discount Premium</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AmortizationOfDebtDiscountPremium" xml:lang="en-US">Non-cash amortization</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfDebtDiscountPremium" xlink:to="lab_us-gaap_AmortizationOfDebtDiscountPremium" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xml:lang="en-US">Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xml:lang="en-US">Warrant exercise price (in dollars per share)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xml:lang="en-US">Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xml:lang="en-US">Number of shares callable by warrants (in shares)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xml:lang="en-US">Number of securities called by warrant or right</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xml:lang="en-US">Debt Instrument Basis Spread On Variable Rate1</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xml:lang="en-US">Basis variable rate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:to="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentCovenantCompliance" xlink:label="loc_us-gaap_DebtInstrumentCovenantCompliance" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentCovenantCompliance" xml:lang="en-US">Debt Instrument Covenant Compliance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtInstrumentCovenantCompliance" xml:lang="en-US">Debt instrument, covenant compliance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentCovenantCompliance" xlink:to="lab_us-gaap_DebtInstrumentCovenantCompliance" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xml:lang="en-US">Debt Instrument, Face Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xml:lang="en-US">Original loan amount</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount" />
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_DebtInstrumentFloatingInterestRatePercentage" xlink:label="loc_pstv_DebtInstrumentFloatingInterestRatePercentage" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_pstv_DebtInstrumentFloatingInterestRatePercentage" xml:lang="en-US">Debt Instrument Floating Interest Rate Percentage</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_pstv_DebtInstrumentFloatingInterestRatePercentage" xml:lang="en-US">Interest rate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pstv_DebtInstrumentFloatingInterestRatePercentage" xlink:to="lab_pstv_DebtInstrumentFloatingInterestRatePercentage" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_pstv_DebtInstrumentFloatingInterestRatePercentage" xml:lang="en-US">Floating interest rate for funds borrowed, under the debt agreement.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xml:lang="en-US">Interest rate</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xml:lang="en-US">Interest Rate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentOfferingDate1" xlink:label="loc_us-gaap_DebtInstrumentOfferingDate1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentOfferingDate1" xml:lang="en-US">Debt Instrument, Offering Date</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtInstrumentOfferingDate1" xml:lang="en-US">Origination date</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentOfferingDate1" xlink:to="lab_us-gaap_DebtInstrumentOfferingDate1" />
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_DebtPrincipalRepaymentStartDate" xlink:label="loc_pstv_DebtPrincipalRepaymentStartDate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_pstv_DebtPrincipalRepaymentStartDate" xml:lang="en-US">Debt Principal Repayment Start Date</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_pstv_DebtPrincipalRepaymentStartDate" xml:lang="en-US">Debt principal repayment start date</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pstv_DebtPrincipalRepaymentStartDate" xlink:to="lab_pstv_DebtPrincipalRepaymentStartDate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_pstv_DebtPrincipalRepaymentStartDate" xml:lang="en-US">Debt principal repayment start date.</label>
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_MinimumLiquidityCovenantAmount" xlink:label="loc_pstv_MinimumLiquidityCovenantAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_pstv_MinimumLiquidityCovenantAmount" xml:lang="en-US">Minimum Liquidity Covenant Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_pstv_MinimumLiquidityCovenantAmount" xml:lang="en-US">Minimum liquidity covenant</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pstv_MinimumLiquidityCovenantAmount" xlink:to="lab_pstv_MinimumLiquidityCovenantAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_pstv_MinimumLiquidityCovenantAmount" xml:lang="en-US">Minimum liquidity covenant amount.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForLoans" xlink:label="loc_us-gaap_PaymentsForLoans" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentsForLoans" xml:lang="en-US">Payments For Loans</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PaymentsForLoans" xml:lang="en-US">Payments for principal, interest and fees</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForLoans" xlink:to="lab_us-gaap_PaymentsForLoans" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis" xml:lang="en-US">Derivative Instrument Risk [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis" xml:lang="en-US">Derivative Instrument</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis" xlink:to="lab_us-gaap_DerivativeInstrumentRiskAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DerivativeContractTypeDomain" xml:lang="en-US">Derivative Contract Type [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DerivativeContractTypeDomain" xml:lang="en-US">Derivative Contract</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeContractTypeDomain" xlink:to="lab_us-gaap_DerivativeContractTypeDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestRateFloorMember" xlink:label="loc_us-gaap_InterestRateFloorMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InterestRateFloorMember" xml:lang="en-US">Interest Rate Floor [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_InterestRateFloorMember" xml:lang="en-US">Interest Rate Floor [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestRateFloorMember" xlink:to="lab_us-gaap_InterestRateFloorMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationAxis" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DisposalGroupClassificationAxis" xml:lang="en-US">Disposal Group Classification [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DisposalGroupClassificationAxis" xml:lang="en-US">Disposal Group Classification</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis" xlink:to="lab_us-gaap_DisposalGroupClassificationAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationDomain" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DisposalGroupClassificationDomain" xml:lang="en-US">Disposal Group Classification [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DisposalGroupClassificationDomain" xml:lang="en-US">Disposal Group Classification</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain" xlink:to="lab_us-gaap_DisposalGroupClassificationDomain" />
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_SaleOfJapaneseSubsidiaryAndCertainAssetsMember" xlink:label="loc_pstv_SaleOfJapaneseSubsidiaryAndCertainAssetsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_pstv_SaleOfJapaneseSubsidiaryAndCertainAssetsMember" xml:lang="en-US">Sale Of Japanese Subsidiary And Certain Assets [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_pstv_SaleOfJapaneseSubsidiaryAndCertainAssetsMember" xml:lang="en-US">Sale of the Japanese Subsidiary and Certain Assets [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pstv_SaleOfJapaneseSubsidiaryAndCertainAssetsMember" xlink:to="lab_pstv_SaleOfJapaneseSubsidiaryAndCertainAssetsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_pstv_SaleOfJapaneseSubsidiaryAndCertainAssetsMember" xml:lang="en-US">Sale of the japanese subsidiary and certain assets.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xml:lang="en-US">Financial Instrument [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xml:lang="en-US">Financial Instrument</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xml:lang="en-US">Financial Instruments [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xml:lang="en-US">Financial Instruments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_LoanAndSecurityAgreementMember" xlink:label="loc_pstv_LoanAndSecurityAgreementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_pstv_LoanAndSecurityAgreementMember" xml:lang="en-US">Loan And Security Agreement [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_pstv_LoanAndSecurityAgreementMember" xml:lang="en-US">Loan and Security Agreement [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pstv_LoanAndSecurityAgreementMember" xlink:to="lab_pstv_LoanAndSecurityAgreementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_pstv_LoanAndSecurityAgreementMember" xml:lang="en-US">Loan and security agreement.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateAxis" xlink:label="loc_us-gaap_VariableRateAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_VariableRateAxis" xml:lang="en-US">Variable Rate [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_VariableRateAxis" xml:lang="en-US">Variable Rate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateAxis" xlink:to="lab_us-gaap_VariableRateAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateDomain" xlink:label="loc_us-gaap_VariableRateDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_VariableRateDomain" xml:lang="en-US">Variable Rate [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_VariableRateDomain" xml:lang="en-US">Variable Rate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateDomain" xlink:to="lab_us-gaap_VariableRateDomain" />
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_LiborMember" xlink:label="loc_pstv_LiborMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_pstv_LiborMember" xml:lang="en-US">LIBOR [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_pstv_LiborMember" xml:lang="en-US">LIBOR [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pstv_LiborMember" xlink:to="lab_pstv_LiborMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_pstv_LiborMember" xml:lang="en-US">LIBOR.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember" xlink:label="loc_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember" xml:lang="en-US">Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember" xml:lang="en-US">SOFR [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember" xlink:to="lab_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember" />
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_AdditionalDetailsRelatingTermLoanThatIsOutstandingAbstract" xlink:label="loc_pstv_AdditionalDetailsRelatingTermLoanThatIsOutstandingAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_pstv_AdditionalDetailsRelatingTermLoanThatIsOutstandingAbstract" xml:lang="en-US">Additional Details Relating Term Loan That Is Outstanding [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_pstv_AdditionalDetailsRelatingTermLoanThatIsOutstandingAbstract" xml:lang="en-US">Additional details relating term loan that is outstanding [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pstv_AdditionalDetailsRelatingTermLoanThatIsOutstandingAbstract" xlink:to="lab_pstv_AdditionalDetailsRelatingTermLoanThatIsOutstandingAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_pstv_AdditionalDetailsRelatingTermLoanThatIsOutstandingAbstract" xml:lang="en-US">Additional details relating term loan that is outstanding [Abstract]</label>
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_DebtInstrumentAmendedExpirationDate" xlink:label="loc_pstv_DebtInstrumentAmendedExpirationDate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_pstv_DebtInstrumentAmendedExpirationDate" xml:lang="en-US">Debt Instrument Amended Expiration Date</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_pstv_DebtInstrumentAmendedExpirationDate" xml:lang="en-US">Amended expiration date</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pstv_DebtInstrumentAmendedExpirationDate" xlink:to="lab_pstv_DebtInstrumentAmendedExpirationDate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_pstv_DebtInstrumentAmendedExpirationDate" xml:lang="en-US">Debt instrument amended expiration date.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xml:lang="en-US">Long-Term Debt, Gross</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xml:lang="en-US">Remaining Principal (Face Value)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:to="lab_us-gaap_DebtInstrumentCarryingAmount" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentPeriodicPayment" xlink:label="loc_us-gaap_DebtInstrumentPeriodicPayment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentPeriodicPayment" xml:lang="en-US">Debt Instrument, Periodic Payment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtInstrumentPeriodicPayment" xml:lang="en-US">Current Monthly Payment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentPeriodicPayment" xlink:to="lab_us-gaap_DebtInstrumentPeriodicPayment" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xml:lang="en-US">Disaggregation of Revenue [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable" xlink:to="lab_us-gaap_DisaggregationOfRevenueTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xml:lang="en-US">Disaggregation of Revenue [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:to="lab_us-gaap_DisaggregationOfRevenueLineItems" />
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_ContractEffectiveDate" xlink:label="loc_pstv_ContractEffectiveDate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_pstv_ContractEffectiveDate" xml:lang="en-US">Contract Effective Date</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_pstv_ContractEffectiveDate" xml:lang="en-US">Contract effective date</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pstv_ContractEffectiveDate" xlink:to="lab_pstv_ContractEffectiveDate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_pstv_ContractEffectiveDate" xml:lang="en-US">Contract effective date.</label>
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_ContractTerminationDate" xlink:label="loc_pstv_ContractTerminationDate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_pstv_ContractTerminationDate" xml:lang="en-US">Contract Termination Date</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_pstv_ContractTerminationDate" xml:lang="en-US">Contract termination date</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pstv_ContractTerminationDate" xlink:to="lab_pstv_ContractTerminationDate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_pstv_ContractTerminationDate" xml:lang="en-US">Contract termination date.</label>
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_CpritGrantFundingTerm" xlink:label="loc_pstv_CpritGrantFundingTerm" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_pstv_CpritGrantFundingTerm" xml:lang="en-US">CPRIT Grant Funding Term</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_pstv_CpritGrantFundingTerm" xml:lang="en-US">CPRIT grant funding term, description</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pstv_CpritGrantFundingTerm" xlink:to="lab_pstv_CpritGrantFundingTerm" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_pstv_CpritGrantFundingTerm" xml:lang="en-US">CPRIT grant funding term.</label>
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_GrantFundingTerm" xlink:label="loc_pstv_GrantFundingTerm" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_pstv_GrantFundingTerm" xml:lang="en-US">Grant Funding Term</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_pstv_GrantFundingTerm" xml:lang="en-US">Grant funding term</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pstv_GrantFundingTerm" xlink:to="lab_pstv_GrantFundingTerm" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_pstv_GrantFundingTerm" xml:lang="en-US">Grant funding term.</label>
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_IncreaseDecreaseInGrantRevenue" xlink:label="loc_pstv_IncreaseDecreaseInGrantRevenue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_pstv_IncreaseDecreaseInGrantRevenue" xml:lang="en-US">Increase (Decrease) in Grant Revenue</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_pstv_IncreaseDecreaseInGrantRevenue" xml:lang="en-US">Increase in grant revenue</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pstv_IncreaseDecreaseInGrantRevenue" xlink:to="lab_pstv_IncreaseDecreaseInGrantRevenue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_pstv_IncreaseDecreaseInGrantRevenue" xml:lang="en-US">Increase (decrease) in grant revenue.</label>
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_MaximumGrantAmountToBeReceivedAsPerGrantContract" xlink:label="loc_pstv_MaximumGrantAmountToBeReceivedAsPerGrantContract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_pstv_MaximumGrantAmountToBeReceivedAsPerGrantContract" xml:lang="en-US">Maximum Grant Amount to be Received as per Grant Contract</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_pstv_MaximumGrantAmountToBeReceivedAsPerGrantContract" xml:lang="en-US">Maximum grant amount to be received as per grant contract</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pstv_MaximumGrantAmountToBeReceivedAsPerGrantContract" xlink:to="lab_pstv_MaximumGrantAmountToBeReceivedAsPerGrantContract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_pstv_MaximumGrantAmountToBeReceivedAsPerGrantContract" xml:lang="en-US">Maximum grant amount to be received as per grant contract.</label>
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_PercentageOfAggregateAmountOfProceedsAwardedUnderCpritGrant" xlink:label="loc_pstv_PercentageOfAggregateAmountOfProceedsAwardedUnderCpritGrant" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_pstv_PercentageOfAggregateAmountOfProceedsAwardedUnderCpritGrant" xml:lang="en-US">Percentage Of Aggregate Amount Of Proceeds Awarded Under CPRIT Grant</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_pstv_PercentageOfAggregateAmountOfProceedsAwardedUnderCpritGrant" xml:lang="en-US">Percentage of aggregate amount of proceeds awarded under CPRIT grant</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pstv_PercentageOfAggregateAmountOfProceedsAwardedUnderCpritGrant" xlink:to="lab_pstv_PercentageOfAggregateAmountOfProceedsAwardedUnderCpritGrant" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_pstv_PercentageOfAggregateAmountOfProceedsAwardedUnderCpritGrant" xml:lang="en-US">Percentage of aggregate amount of proceeds awarded under CPRIT grant.</label>
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_PercentageOfGrantProceedsWithInterestNotExceedAnnually" xlink:label="loc_pstv_PercentageOfGrantProceedsWithInterestNotExceedAnnually" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_pstv_PercentageOfGrantProceedsWithInterestNotExceedAnnually" xml:lang="en-US">Percentage Of Grant Proceeds With Interest Not Exceed Annually</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_pstv_PercentageOfGrantProceedsWithInterestNotExceedAnnually" xml:lang="en-US">Percentage of grant proceeds with interest not exceed annually</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pstv_PercentageOfGrantProceedsWithInterestNotExceedAnnually" xlink:to="lab_pstv_PercentageOfGrantProceedsWithInterestNotExceedAnnually" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_pstv_PercentageOfGrantProceedsWithInterestNotExceedAnnually" xml:lang="en-US">Percentage of grant proceeds with interest not exceed annually.</label>
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_ReimbursementCostsIncurred" xlink:label="loc_pstv_ReimbursementCostsIncurred" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_pstv_ReimbursementCostsIncurred" xml:lang="en-US">Reimbursement Costs Incurred</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_pstv_ReimbursementCostsIncurred" xml:lang="en-US">Identified eligible reimbursable costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pstv_ReimbursementCostsIncurred" xlink:to="lab_pstv_ReimbursementCostsIncurred" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_pstv_ReimbursementCostsIncurred" xml:lang="en-US">Reimbursement costs incurred.</label>
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_CancerPreventionAndResearchInstituteOfTexasContractMember" xlink:label="loc_pstv_CancerPreventionAndResearchInstituteOfTexasContractMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_pstv_CancerPreventionAndResearchInstituteOfTexasContractMember" xml:lang="en-US">Cancer Prevention And Research Institute Of Texas Contract [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_pstv_CancerPreventionAndResearchInstituteOfTexasContractMember" xml:lang="en-US">CPRIT Contract [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pstv_CancerPreventionAndResearchInstituteOfTexasContractMember" xlink:to="lab_pstv_CancerPreventionAndResearchInstituteOfTexasContractMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_pstv_CancerPreventionAndResearchInstituteOfTexasContractMember" xml:lang="en-US">Cancer prevention and research institute of texas contract.</label>
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_IncomeTaxesTable" xlink:label="loc_pstv_IncomeTaxesTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_pstv_IncomeTaxesTable" xml:lang="en-US">Income Taxes [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_pstv_IncomeTaxesTable" xml:lang="en-US">Income Taxes [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pstv_IncomeTaxesTable" xlink:to="lab_pstv_IncomeTaxesTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_pstv_IncomeTaxesTable" xml:lang="en-US">Income taxes.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xml:lang="en-US">Income Tax Authority [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xml:lang="en-US">Income Tax Authority</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:to="lab_us-gaap_IncomeTaxAuthorityAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xml:lang="en-US">Income Tax Authority [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xml:lang="en-US">Income Tax Authority</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:to="lab_us-gaap_IncomeTaxAuthorityDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DomesticCountryMember" xlink:label="loc_us-gaap_DomesticCountryMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DomesticCountryMember" xml:lang="en-US">Domestic Tax Authority [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DomesticCountryMember" xml:lang="en-US">Federal [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DomesticCountryMember" xlink:to="lab_us-gaap_DomesticCountryMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xml:lang="en-US">State and Local Jurisdiction [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xml:lang="en-US">State [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StateAndLocalJurisdictionMember" xlink:to="lab_us-gaap_StateAndLocalJurisdictionMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityNameAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxAuthorityNameAxis" xml:lang="en-US">Income Tax Authority, Name [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameAxis" xlink:to="lab_us-gaap_IncomeTaxAuthorityNameAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityNameDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxAuthorityNameDomain" xml:lang="en-US">Income Tax Authority, Name [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameDomain" xlink:to="lab_us-gaap_IncomeTaxAuthorityNameDomain" />
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_IncomeTaxesLineItems" xlink:label="loc_pstv_IncomeTaxesLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_pstv_IncomeTaxesLineItems" xml:lang="en-US">Income Taxes [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_pstv_IncomeTaxesLineItems" xml:lang="en-US">Income Taxes [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pstv_IncomeTaxesLineItems" xlink:to="lab_pstv_IncomeTaxesLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_pstv_IncomeTaxesLineItems" xml:lang="en-US">Income taxes.</label>
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_CumulativeChangeInOwnership" xlink:label="loc_pstv_CumulativeChangeInOwnership" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_pstv_CumulativeChangeInOwnership" xml:lang="en-US">Cumulative Change In Ownership</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_pstv_CumulativeChangeInOwnership" xml:lang="en-US">Cumulative change in ownership</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pstv_CumulativeChangeInOwnership" xlink:to="lab_pstv_CumulativeChangeInOwnership" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_pstv_CumulativeChangeInOwnership" xml:lang="en-US">Refers to cumulative change in ownership in percentage.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards, Domestic</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xml:lang="en-US">Federal tax carry forward</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards, State and Local</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xml:lang="en-US">State tax credit carryforwards</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" />
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_IncomeTaxContingencyAbstract" xlink:label="loc_pstv_IncomeTaxContingencyAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_pstv_IncomeTaxContingencyAbstract" xml:lang="en-US">Income Tax Contingency [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_pstv_IncomeTaxContingencyAbstract" xml:lang="en-US">Income Tax Contingency [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pstv_IncomeTaxContingencyAbstract" xlink:to="lab_pstv_IncomeTaxContingencyAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_pstv_IncomeTaxContingencyAbstract" xml:lang="en-US">Income tax contingency.</label>
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_DeferredTaxAssetsValuationAllowances" xlink:label="loc_pstv_DeferredTaxAssetsValuationAllowances" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_pstv_DeferredTaxAssetsValuationAllowances" xml:lang="en-US">Deferred Tax Assets Valuation Allowances</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_pstv_DeferredTaxAssetsValuationAllowances" xml:lang="en-US">Valuation allowance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pstv_DeferredTaxAssetsValuationAllowances" xlink:to="lab_pstv_DeferredTaxAssetsValuationAllowances" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_pstv_DeferredTaxAssetsValuationAllowances" xml:lang="en-US">Deferred tax assets valuation allowances.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xml:lang="en-US">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xml:lang="en-US">Increase (decrease) in valuation allowance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xml:lang="en-US">Income Tax Expense (Benefit)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xml:lang="en-US">Provision or benefit for income taxes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilityForUncertainTaxPositionsCurrent" xlink:label="loc_us-gaap_LiabilityForUncertainTaxPositionsCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilityForUncertainTaxPositionsCurrent" xml:lang="en-US">Liability for Uncertainty in Income Taxes, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LiabilityForUncertainTaxPositionsCurrent" xml:lang="en-US">Liability for uncertain tax positions</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilityForUncertainTaxPositionsCurrent" xlink:to="lab_us-gaap_LiabilityForUncertainTaxPositionsCurrent" />
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_NetOperatingLossAndResearchAndDevelopmentTaxCreditCarryForwardsToOffsetFutureTaxableIncomePeriod" xlink:label="loc_pstv_NetOperatingLossAndResearchAndDevelopmentTaxCreditCarryForwardsToOffsetFutureTaxableIncomePeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_pstv_NetOperatingLossAndResearchAndDevelopmentTaxCreditCarryForwardsToOffsetFutureTaxableIncomePeriod" xml:lang="en-US">Net Operating Loss And Research And Development Tax Credit Carry Forwards To Offset Future Taxable Income Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_pstv_NetOperatingLossAndResearchAndDevelopmentTaxCreditCarryForwardsToOffsetFutureTaxableIncomePeriod" xml:lang="en-US">Period of net operating loss and R&amp;D tax credit carry forwards to offset future taxable income</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pstv_NetOperatingLossAndResearchAndDevelopmentTaxCreditCarryForwardsToOffsetFutureTaxableIncomePeriod" xlink:to="lab_pstv_NetOperatingLossAndResearchAndDevelopmentTaxCreditCarryForwardsToOffsetFutureTaxableIncomePeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_pstv_NetOperatingLossAndResearchAndDevelopmentTaxCreditCarryForwardsToOffsetFutureTaxableIncomePeriod" xml:lang="en-US">Refers to the period of net operating loss and R&amp;D tax credit carry forwards to offset future taxable income.</label>
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_NetOperatingLossCarryforward" xlink:label="loc_pstv_NetOperatingLossCarryforward" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_pstv_NetOperatingLossCarryforward" xml:lang="en-US">Net Operating Loss Carryforward</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_pstv_NetOperatingLossCarryforward" xml:lang="en-US">Net operating losses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pstv_NetOperatingLossCarryforward" xlink:to="lab_pstv_NetOperatingLossCarryforward" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_pstv_NetOperatingLossCarryforward" xml:lang="en-US">Net operating loss carryforward.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaap_OperatingLossCarryforwards" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xml:lang="en-US">Operating Loss Carryforwards</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xml:lang="en-US">Tax loss carryforwards</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwards" xlink:to="lab_us-gaap_OperatingLossCarryforwards" />
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_OperatingLossCarryforwardsExpirationDates1" xlink:label="loc_pstv_OperatingLossCarryforwardsExpirationDates1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_pstv_OperatingLossCarryforwardsExpirationDates1" xml:lang="en-US">Operating Loss Carryforwards Expiration Dates1</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_pstv_OperatingLossCarryforwardsExpirationDates1" xml:lang="en-US">Net operating loss carryforwards, Expire date</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pstv_OperatingLossCarryforwardsExpirationDates1" xlink:to="lab_pstv_OperatingLossCarryforwardsExpirationDates1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_pstv_OperatingLossCarryforwardsExpirationDates1" xml:lang="en-US">The expiration date of each operating loss carryforward included in total operating loss carryforwards, or the applicable range of such expiration dates.</label>
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_PercentageOfNetOperatingLossCarryforwardsAvailableForOffsettingAgainstFutureTaxableIncome" xlink:label="loc_pstv_PercentageOfNetOperatingLossCarryforwardsAvailableForOffsettingAgainstFutureTaxableIncome" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_pstv_PercentageOfNetOperatingLossCarryforwardsAvailableForOffsettingAgainstFutureTaxableIncome" xml:lang="en-US">Percentage Of Net Operating Loss Carryforwards Available For Offsetting Against Future Taxable Income</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_pstv_PercentageOfNetOperatingLossCarryforwardsAvailableForOffsettingAgainstFutureTaxableIncome" xml:lang="en-US">Percentage of federal net operating losses used to offset of future taxable income</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pstv_PercentageOfNetOperatingLossCarryforwardsAvailableForOffsettingAgainstFutureTaxableIncome" xlink:to="lab_pstv_PercentageOfNetOperatingLossCarryforwardsAvailableForOffsettingAgainstFutureTaxableIncome" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_pstv_PercentageOfNetOperatingLossCarryforwardsAvailableForOffsettingAgainstFutureTaxableIncome" xml:lang="en-US">Percentage of net operating loss carryforwards available for offsetting against future taxable income.</label>
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_PeriodForMaterialChangesOfLiabilityForUncertainTaxBenefits" xlink:label="loc_pstv_PeriodForMaterialChangesOfLiabilityForUncertainTaxBenefits" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_pstv_PeriodForMaterialChangesOfLiabilityForUncertainTaxBenefits" xml:lang="en-US">Period For Material Changes Of Liability For Uncertain Tax Benefits</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_pstv_PeriodForMaterialChangesOfLiabilityForUncertainTaxBenefits" xml:lang="en-US">Period for material changes of liability for uncertain tax benefits</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pstv_PeriodForMaterialChangesOfLiabilityForUncertainTaxBenefits" xlink:to="lab_pstv_PeriodForMaterialChangesOfLiabilityForUncertainTaxBenefits" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_pstv_PeriodForMaterialChangesOfLiabilityForUncertainTaxBenefits" xml:lang="en-US">Refers to period for material changes of liability for uncertain tax benefits.</label>
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_TaxCreditCarryforwardExpirationDate1" xlink:label="loc_pstv_TaxCreditCarryforwardExpirationDate1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_pstv_TaxCreditCarryforwardExpirationDate1" xml:lang="en-US">Tax Credit Carryforward Expiration Date1</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_pstv_TaxCreditCarryforwardExpirationDate1" xml:lang="en-US">Tax credit carryforward, expiration date</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pstv_TaxCreditCarryforwardExpirationDate1" xlink:to="lab_pstv_TaxCreditCarryforwardExpirationDate1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_pstv_TaxCreditCarryforwardExpirationDate1" xml:lang="en-US">Expiration date of the tax credit carryforward.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xml:lang="en-US">Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xml:lang="en-US">Interest related to unrecognized tax benefits in interest expense and penalties</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xml:lang="en-US">Reconciliation of the total income tax provision tax rate [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xml:lang="en-US">Total income tax provision</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xml:lang="en-US">Income tax expense (benefit) at federal statutory rate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xml:lang="en-US">Change in valuation allowance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_EffectiveIncomeTaxRateReconciliationNetOperatingLossExpiration" xlink:label="loc_pstv_EffectiveIncomeTaxRateReconciliationNetOperatingLossExpiration" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_pstv_EffectiveIncomeTaxRateReconciliationNetOperatingLossExpiration" xml:lang="en-US">Effective Income Tax Rate Reconciliation Net Operating Loss Expiration</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_pstv_EffectiveIncomeTaxRateReconciliationNetOperatingLossExpiration" xml:lang="en-US">NOLs expiring and adjustments to NOL</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pstv_EffectiveIncomeTaxRateReconciliationNetOperatingLossExpiration" xlink:to="lab_pstv_EffectiveIncomeTaxRateReconciliationNetOperatingLossExpiration" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_pstv_EffectiveIncomeTaxRateReconciliationNetOperatingLossExpiration" xml:lang="en-US">Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to net operating loss expiration.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Percent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xml:lang="en-US">Share based compensation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xml:lang="en-US">Income tax expense (benefit) at state statutory rate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xml:lang="en-US">Research credit</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" />
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_EffectiveIncomeTaxRateReconciliationTaxReturnToProvision" xlink:label="loc_pstv_EffectiveIncomeTaxRateReconciliationTaxReturnToProvision" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_pstv_EffectiveIncomeTaxRateReconciliationTaxReturnToProvision" xml:lang="en-US">Effective Income Tax Rate Reconciliation Tax Return To Provision</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_pstv_EffectiveIncomeTaxRateReconciliationTaxReturnToProvision" xml:lang="en-US">Return to provision</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pstv_EffectiveIncomeTaxRateReconciliationTaxReturnToProvision" xlink:to="lab_pstv_EffectiveIncomeTaxRateReconciliationTaxReturnToProvision" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_pstv_EffectiveIncomeTaxRateReconciliationTaxReturnToProvision" xml:lang="en-US">Effective income tax rate reconciliation tax return to provision.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlementsStateAndLocal" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlementsStateAndLocal" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlementsStateAndLocal" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Settlement, State and Local, Percent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlementsStateAndLocal" xml:lang="en-US">Change in state rate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlementsStateAndLocal" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlementsStateAndLocal" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xml:lang="en-US">Components of Deferred Tax Assets and Liabilities [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xml:lang="en-US">Portions of the deferred tax assets and deferred tax liabilities [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="lab_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xml:lang="en-US">Components of Deferred Tax Assets [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xml:lang="en-US">Deferred tax assets [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="lab_us-gaap_ComponentsOfDeferredTaxAssetsAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:label="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xml:lang="en-US">Deferred Tax Assets, Goodwill and Intangible Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xml:lang="en-US">Intangible assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:to="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaap_DeferredTaxAssetsGross" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xml:lang="en-US">Deferred Tax Assets, Gross</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xml:lang="en-US">Deferred tax assets (Total)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="lab_us-gaap_DeferredTaxAssetsGross" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaap_DeferredTaxAssetsNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xml:lang="en-US">Total deferred tax assets, net of allowance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsNet" xlink:to="lab_us-gaap_DeferredTaxAssetsNet" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xml:lang="en-US">Net operating loss carryforwards</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="loc_us-gaap_DeferredTaxAssetsOther" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xml:lang="en-US">Deferred Tax Assets, Other</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xml:lang="en-US">Other, net</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOther" xlink:to="lab_us-gaap_DeferredTaxAssetsOther" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:label="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xml:lang="en-US">Deferred Tax Assets, Property, Plant and Equipment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xml:lang="en-US">Property and equipment, principally due to differences in depreciation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:to="lab_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xml:lang="en-US">Deferred Tax Assets, Tax Credit Carryforwards</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xml:lang="en-US">Income tax credit carryforwards</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xml:lang="en-US">Share based compensation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Accrued Liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xml:lang="en-US">Accrued expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xml:lang="en-US">Valuation allowance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xml:lang="en-US">Components of Deferred Tax Liabilities [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xml:lang="en-US">Deferred tax liabilities [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:to="lab_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities" xml:lang="en-US">Deferred Tax Liabilities, Gross</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities" xml:lang="en-US">Total deferred tax liability</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilities" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesOther" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesOther" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesOther" xml:lang="en-US">Deferred Tax Liabilities, Other</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesOther" xml:lang="en-US">Other</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesOther" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesOther" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="loc_us-gaap_DeferredTaxLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxLiabilities" xml:lang="en-US">Deferred Tax Liabilities, Net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_DeferredTaxLiabilities" xml:lang="en-US">Net deferred tax assets (liability)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilities" xlink:to="lab_us-gaap_DeferredTaxLiabilities" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:label="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xml:lang="en-US">Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xml:lang="en-US">Schedule of reconciliation of unrecognized tax benefits activity [Roll Forward]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:to="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xml:lang="en-US">Unrecognized Tax Benefits</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xml:lang="en-US">Unrecognized Tax Benefits &#8211; Beginning</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xml:lang="en-US">Unrecognized Tax Benefits &#8211; Ending</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefits" xlink:to="lab_us-gaap_UnrecognizedTaxBenefits" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xml:lang="en-US">Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xml:lang="en-US">Gross decreases &#8211; tax positions in prior period</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xml:lang="en-US">Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xml:lang="en-US">Gross increase &#8211; current-period tax positions</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanTable" xlink:label="loc_us-gaap_DefinedContributionPlanTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DefinedContributionPlanTable" xml:lang="en-US">Defined Contribution Plan [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DefinedContributionPlanTable" xml:lang="en-US">Defined Contribution Plan [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanTable" xlink:to="lab_us-gaap_DefinedContributionPlanTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:label="loc_us-gaap_DefinedContributionPlanDisclosureLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DefinedContributionPlanDisclosureLineItems" xml:lang="en-US">Defined Contribution Plan Disclosure [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DefinedContributionPlanDisclosureLineItems" xml:lang="en-US">Defined Contribution Plan Disclosure [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:to="lab_us-gaap_DefinedContributionPlanDisclosureLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xml:lang="en-US">Defined Contribution Plan, Employer Discretionary Contribution Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xml:lang="en-US">Discretionary or matching contributions</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:to="lab_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xml:lang="en-US">Defined Contribution Plan, Employer Matching Contribution, Percent of Match</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xml:lang="en-US">Percentage of matching contribution for employee contributions</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:to="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xml:lang="en-US">Schedule Of Stock By Class [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xml:lang="en-US">Schedule Of Stock By Class [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ClassOfStockLineItems" xml:lang="en-US">Class Of Stock [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ClassOfStockLineItems" xml:lang="en-US">Class of Stock [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="lab_us-gaap_ClassOfStockLineItems" />
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_ConsiderationPaidToPreferredStockHolders" xlink:label="loc_pstv_ConsiderationPaidToPreferredStockHolders" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_pstv_ConsiderationPaidToPreferredStockHolders" xml:lang="en-US">Consideration Paid To Preferred Stock Holders</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_pstv_ConsiderationPaidToPreferredStockHolders" xml:lang="en-US">Consideration paid to preferred stock holders</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pstv_ConsiderationPaidToPreferredStockHolders" xlink:to="lab_pstv_ConsiderationPaidToPreferredStockHolders" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_pstv_ConsiderationPaidToPreferredStockHolders" xml:lang="en-US">Consideration paid to preferred stock holders.</label>
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_NumberOfPreferredStockSharesExercised" xlink:label="loc_pstv_NumberOfPreferredStockSharesExercised" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_pstv_NumberOfPreferredStockSharesExercised" xml:lang="en-US">Number Of Preferred Stock Shares Exercised</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_pstv_NumberOfPreferredStockSharesExercised" xml:lang="en-US">Number of preferred stock, shares converted</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pstv_NumberOfPreferredStockSharesExercised" xlink:to="lab_pstv_NumberOfPreferredStockSharesExercised" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_pstv_NumberOfPreferredStockSharesExercised" xml:lang="en-US">Number Of Preferred Stock Shares Exercised.</label>
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_NumberOfVotesPerShare" xlink:label="loc_pstv_NumberOfVotesPerShare" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_pstv_NumberOfVotesPerShare" xml:lang="en-US">Number Of Votes Per Share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pstv_NumberOfVotesPerShare" xlink:to="lab_pstv_NumberOfVotesPerShare" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_pstv_NumberOfVotesPerShare" xml:lang="en-US">Number of votes per share.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockVotingRights" xlink:label="loc_us-gaap_PreferredStockVotingRights" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockVotingRights" xml:lang="en-US">Preferred Stock, Voting Rights</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PreferredStockVotingRights" xml:lang="en-US">Preferred stock, voting rights</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockVotingRights" xlink:to="lab_us-gaap_PreferredStockVotingRights" />
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_RightsRelatedToDistributionOfAssets" xlink:label="loc_pstv_RightsRelatedToDistributionOfAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_pstv_RightsRelatedToDistributionOfAssets" xml:lang="en-US">Rights Related To Distribution Of Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_pstv_RightsRelatedToDistributionOfAssets" xml:lang="en-US">Rights related to distribution of assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pstv_RightsRelatedToDistributionOfAssets" xlink:to="lab_pstv_RightsRelatedToDistributionOfAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_pstv_RightsRelatedToDistributionOfAssets" xml:lang="en-US">Rights related to distribution of assets.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xml:lang="en-US">Sale of Stock, Consideration Received on Transaction</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xml:lang="en-US">Consideration to purchaser in cash</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockTransactionDate" xlink:label="loc_us-gaap_SaleOfStockTransactionDate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SaleOfStockTransactionDate" xml:lang="en-US">Sale of Stock, Transaction Date</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SaleOfStockTransactionDate" xml:lang="en-US">Sale closed date</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockTransactionDate" xlink:to="lab_us-gaap_SaleOfStockTransactionDate" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis" xml:lang="en-US">Class Of Warrant Or Right [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis" xml:lang="en-US">Class of Warrant or Right</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis" xlink:to="lab_us-gaap_ClassOfWarrantOrRightAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain" xml:lang="en-US">Class Of Warrant Or Right [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain" xml:lang="en-US">Class of Warrant or Right</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain" xlink:to="lab_us-gaap_ClassOfWarrantOrRightDomain" />
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_TwoThousandEighteenRightsOfferingMember" xlink:label="loc_pstv_TwoThousandEighteenRightsOfferingMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_pstv_TwoThousandEighteenRightsOfferingMember" xml:lang="en-US">Two Thousand Eighteen Rights Offering [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_pstv_TwoThousandEighteenRightsOfferingMember" xml:lang="en-US">2018 Rights Offering [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pstv_TwoThousandEighteenRightsOfferingMember" xlink:to="lab_pstv_TwoThousandEighteenRightsOfferingMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_pstv_TwoThousandEighteenRightsOfferingMember" xml:lang="en-US">Two thousand eighteen rights offering.</label>
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_SeriesBConvertiblePreferredStockMember" xlink:label="loc_pstv_SeriesBConvertiblePreferredStockMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_pstv_SeriesBConvertiblePreferredStockMember" xml:lang="en-US">Series B Convertible Preferred Stock [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_pstv_SeriesBConvertiblePreferredStockMember" xml:lang="en-US">Series B Convertible Preferred Stock [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pstv_SeriesBConvertiblePreferredStockMember" xlink:to="lab_pstv_SeriesBConvertiblePreferredStockMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_pstv_SeriesBConvertiblePreferredStockMember" xml:lang="en-US">Series B convertible preferred stock.</label>
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_SeriesCConvertiblePreferredStockMember" xlink:label="loc_pstv_SeriesCConvertiblePreferredStockMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_pstv_SeriesCConvertiblePreferredStockMember" xml:lang="en-US">Series C Convertible Preferred Stock [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_pstv_SeriesCConvertiblePreferredStockMember" xml:lang="en-US">Series C Convertible Preferred Stock [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pstv_SeriesCConvertiblePreferredStockMember" xlink:to="lab_pstv_SeriesCConvertiblePreferredStockMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_pstv_SeriesCConvertiblePreferredStockMember" xml:lang="en-US">Series C convertible preferred stock.</label>
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_SeriesFConvertiblePreferredStockMember" xlink:label="loc_pstv_SeriesFConvertiblePreferredStockMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_pstv_SeriesFConvertiblePreferredStockMember" xml:lang="en-US">Series F Convertible Preferred Stock [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pstv_SeriesFConvertiblePreferredStockMember" xlink:to="lab_pstv_SeriesFConvertiblePreferredStockMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_pstv_SeriesFConvertiblePreferredStockMember" xml:lang="en-US">Series F Convertible Preferred Stock.</label>
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_SubscriptionAgreementMember" xlink:label="loc_pstv_SubscriptionAgreementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_pstv_SubscriptionAgreementMember" xml:lang="en-US">Subscription Agreement [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pstv_SubscriptionAgreementMember" xlink:to="lab_pstv_SubscriptionAgreementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_pstv_SubscriptionAgreementMember" xml:lang="en-US">Subscription Agreement [Member]</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xml:lang="en-US">Class Of Warrant Or Right Outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xml:lang="en-US">Class of warrant outstanding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="lab_us-gaap_ClassOfWarrantOrRightOutstanding" />
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_NumberOfWarrantsExercised" xlink:label="loc_pstv_NumberOfWarrantsExercised" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_pstv_NumberOfWarrantsExercised" xml:lang="en-US">Number Of Warrants Exercised</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_pstv_NumberOfWarrantsExercised" xml:lang="en-US">Number of warrants exercised</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pstv_NumberOfWarrantsExercised" xlink:to="lab_pstv_NumberOfWarrantsExercised" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_pstv_NumberOfWarrantsExercised" xml:lang="en-US">Number of warrants exercised</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaap_SaleOfStockPricePerShare" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xml:lang="en-US">Sale Of Stock Price Per Share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xml:lang="en-US">Sale of Stock, Price Per Share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockPricePerShare" xlink:to="lab_us-gaap_SaleOfStockPricePerShare" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_WarrantsAndRightsOutstandingTerm" xml:lang="en-US">Warrants And Rights Outstanding Term</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_WarrantsAndRightsOutstandingTerm" xml:lang="en-US">Warrants expected term</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:to="lab_us-gaap_WarrantsAndRightsOutstandingTerm" />
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_SeriesUWarrantsMember" xlink:label="loc_pstv_SeriesUWarrantsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_pstv_SeriesUWarrantsMember" xml:lang="en-US">Series U Warrants [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_pstv_SeriesUWarrantsMember" xml:lang="en-US">Series U Warrants [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pstv_SeriesUWarrantsMember" xlink:to="lab_pstv_SeriesUWarrantsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_pstv_SeriesUWarrantsMember" xml:lang="en-US">Series U warrants member</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassAMember" xlink:label="loc_us-gaap_CommonClassAMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonClassAMember" xml:lang="en-US">Common Class A [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonClassAMember" xml:lang="en-US">Common Class A [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonClassAMember" xlink:to="lab_us-gaap_CommonClassAMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassBMember" xlink:label="loc_us-gaap_CommonClassBMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonClassBMember" xml:lang="en-US">Common Class B [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonClassBMember" xml:lang="en-US">Common Class B [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonClassBMember" xlink:to="lab_us-gaap_CommonClassBMember" />
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_RepresentativeSeriesUWarrantMember" xlink:label="loc_pstv_RepresentativeSeriesUWarrantMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_pstv_RepresentativeSeriesUWarrantMember" xml:lang="en-US">Representative Series U Warrant [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_pstv_RepresentativeSeriesUWarrantMember" xml:lang="en-US">Representative Warrants [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pstv_RepresentativeSeriesUWarrantMember" xlink:to="lab_pstv_RepresentativeSeriesUWarrantMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_pstv_RepresentativeSeriesUWarrantMember" xml:lang="en-US">Representative Series U Warrant.</label>
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_AggregateExpenseIncludingFeeAndDisbursementExpenses" xlink:label="loc_pstv_AggregateExpenseIncludingFeeAndDisbursementExpenses" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_pstv_AggregateExpenseIncludingFeeAndDisbursementExpenses" xml:lang="en-US">Aggregate Expense Including Fee and Disbursement Expenses</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_pstv_AggregateExpenseIncludingFeeAndDisbursementExpenses" xml:lang="en-US">Reimburse of fee and disbursements expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pstv_AggregateExpenseIncludingFeeAndDisbursementExpenses" xlink:to="lab_pstv_AggregateExpenseIncludingFeeAndDisbursementExpenses" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_pstv_AggregateExpenseIncludingFeeAndDisbursementExpenses" xml:lang="en-US">Aggregate expense including fee and disbursement expenses.</label>
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_CommonStockSalesAvailableForIssuance" xlink:label="loc_pstv_CommonStockSalesAvailableForIssuance" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_pstv_CommonStockSalesAvailableForIssuance" xml:lang="en-US">Common Stock Sales Available For Issuance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_pstv_CommonStockSalesAvailableForIssuance" xml:lang="en-US">Remaining availability under financing facility</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pstv_CommonStockSalesAvailableForIssuance" xlink:to="lab_pstv_CommonStockSalesAvailableForIssuance" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_pstv_CommonStockSalesAvailableForIssuance" xml:lang="en-US">Common stock, sales, available for issuance.</label>
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_GrossProceedsFromIssuanceOfCommonStock" xlink:label="loc_pstv_GrossProceedsFromIssuanceOfCommonStock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_pstv_GrossProceedsFromIssuanceOfCommonStock" xml:lang="en-US">Gross Proceeds from Issuance of Common Stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_pstv_GrossProceedsFromIssuanceOfCommonStock" xml:lang="en-US">Aggregate gross proceeds from sales of common stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pstv_GrossProceedsFromIssuanceOfCommonStock" xlink:to="lab_pstv_GrossProceedsFromIssuanceOfCommonStock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_pstv_GrossProceedsFromIssuanceOfCommonStock" xml:lang="en-US">Gross proceeds from issuance of common stock.</label>
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_InitialCommitmentFee" xlink:label="loc_pstv_InitialCommitmentFee" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_pstv_InitialCommitmentFee" xml:lang="en-US">Initial Commitment Fee</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_pstv_InitialCommitmentFee" xml:lang="en-US">Initial commitment fee paid in cash</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pstv_InitialCommitmentFee" xlink:to="lab_pstv_InitialCommitmentFee" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_pstv_InitialCommitmentFee" xml:lang="en-US">Initial commitment fee.</label>
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_InitialCommitmentShares" xlink:label="loc_pstv_InitialCommitmentShares" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_pstv_InitialCommitmentShares" xml:lang="en-US">Initial Commitment Shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_pstv_InitialCommitmentShares" xml:lang="en-US">Initial commitment shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pstv_InitialCommitmentShares" xlink:to="lab_pstv_InitialCommitmentShares" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_pstv_InitialCommitmentShares" xml:lang="en-US">Initial commitment shares.</label>
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_MaximumValueOfSharesToBeIssuedUnderAgreement" xlink:label="loc_pstv_MaximumValueOfSharesToBeIssuedUnderAgreement" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_pstv_MaximumValueOfSharesToBeIssuedUnderAgreement" xml:lang="en-US">Maximum Value of Shares to be Issued Under Agreement</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_pstv_MaximumValueOfSharesToBeIssuedUnderAgreement" xml:lang="en-US">Maximum value of shares to be issued under agreement</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pstv_MaximumValueOfSharesToBeIssuedUnderAgreement" xlink:to="lab_pstv_MaximumValueOfSharesToBeIssuedUnderAgreement" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_pstv_MaximumValueOfSharesToBeIssuedUnderAgreement" xml:lang="en-US">Maximum value of shares to be issued under agreement.</label>
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_NumberOfMaximumCommonSharesCanBeResale" xlink:label="loc_pstv_NumberOfMaximumCommonSharesCanBeResale" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_pstv_NumberOfMaximumCommonSharesCanBeResale" xml:lang="en-US">Number of Maximum Common Shares Can Be Resale</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_pstv_NumberOfMaximumCommonSharesCanBeResale" xml:lang="en-US">Number of maximum common shares can be resale</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pstv_NumberOfMaximumCommonSharesCanBeResale" xlink:to="lab_pstv_NumberOfMaximumCommonSharesCanBeResale" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_pstv_NumberOfMaximumCommonSharesCanBeResale" xml:lang="en-US">Number of maximum common shares can be resale.</label>
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_PercentageIssuanceOfCommonStock" xlink:label="loc_pstv_PercentageIssuanceOfCommonStock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_pstv_PercentageIssuanceOfCommonStock" xml:lang="en-US">Percentage Issuance Of Common Stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_pstv_PercentageIssuanceOfCommonStock" xml:lang="en-US">Percentage issuance of common stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pstv_PercentageIssuanceOfCommonStock" xlink:to="lab_pstv_PercentageIssuanceOfCommonStock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_pstv_PercentageIssuanceOfCommonStock" xml:lang="en-US">Percentage issuance of common stock.</label>
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_PercentageOfCommissionOnGrossProceedsFromSaleOfCommonStock" xlink:label="loc_pstv_PercentageOfCommissionOnGrossProceedsFromSaleOfCommonStock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_pstv_PercentageOfCommissionOnGrossProceedsFromSaleOfCommonStock" xml:lang="en-US">Percentage of Commission on Gross Proceeds from Sale of Common Stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_pstv_PercentageOfCommissionOnGrossProceedsFromSaleOfCommonStock" xml:lang="en-US">Percentage of commission on gross proceeds from sale of common stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pstv_PercentageOfCommissionOnGrossProceedsFromSaleOfCommonStock" xlink:to="lab_pstv_PercentageOfCommissionOnGrossProceedsFromSaleOfCommonStock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_pstv_PercentageOfCommissionOnGrossProceedsFromSaleOfCommonStock" xml:lang="en-US">Percentage of commission on gross proceeds from sale of common stock.</label>
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_PeriodExercisableFromTheDateOfIssuance" xlink:label="loc_pstv_PeriodExercisableFromTheDateOfIssuance" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_pstv_PeriodExercisableFromTheDateOfIssuance" xml:lang="en-US">Period Exercisable From The Date Of Issuance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_pstv_PeriodExercisableFromTheDateOfIssuance" xml:lang="en-US">Period exercisable from the date of issuance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pstv_PeriodExercisableFromTheDateOfIssuance" xlink:to="lab_pstv_PeriodExercisableFromTheDateOfIssuance" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_pstv_PeriodExercisableFromTheDateOfIssuance" xml:lang="en-US">Refers to the period exercisable from the date of issuance.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRepurchasedDuringPeriodShares" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodShares" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodShares" xml:lang="en-US">Stock Repurchased During Period, Shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodShares" xml:lang="en-US">Number of stock repurchased</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchasedDuringPeriodShares" xlink:to="lab_us-gaap_StockRepurchasedDuringPeriodShares" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xml:lang="en-US">Stock Repurchase Program, Authorized Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xml:lang="en-US">Authorized amount of repurchase of stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:to="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:label="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xml:lang="en-US">Stock Repurchase Program, Remaining Authorized Repurchase Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xml:lang="en-US">Remained authorized amount for repurchase</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:to="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockValue" xlink:label="loc_us-gaap_TreasuryStockValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TreasuryStockValue" xml:lang="en-US">Treasury Stock, Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_TreasuryStockValue" xml:lang="en-US">Treasury stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockValue" xlink:to="lab_us-gaap_TreasuryStockValue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeAxis" xlink:label="loc_us-gaap_InvestmentTypeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InvestmentTypeAxis" xml:lang="en-US">Investment Type [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_InvestmentTypeAxis" xml:lang="en-US">Investment Type</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeAxis" xlink:to="lab_us-gaap_InvestmentTypeAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember" xml:lang="en-US">Investments [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember" xml:lang="en-US">Investments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember" xlink:to="lab_us-gaap_InvestmentTypeCategorizationMember" />
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_JanuaryTwoThousandAndTwentyTwoDistributionAgreementMember" xlink:label="loc_pstv_JanuaryTwoThousandAndTwentyTwoDistributionAgreementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_pstv_JanuaryTwoThousandAndTwentyTwoDistributionAgreementMember" xml:lang="en-US">January Two Thousand and Twenty Two Distribution Agreement [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_pstv_JanuaryTwoThousandAndTwentyTwoDistributionAgreementMember" xml:lang="en-US">January 2022 Distribution Agreement [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pstv_JanuaryTwoThousandAndTwentyTwoDistributionAgreementMember" xlink:to="lab_pstv_JanuaryTwoThousandAndTwentyTwoDistributionAgreementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_pstv_JanuaryTwoThousandAndTwentyTwoDistributionAgreementMember" xml:lang="en-US">January two thousand and twenty two distribution agreement.</label>
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_SeptemberTwoThousandAndTwentyTwoDistributionAgreementMember" xlink:label="loc_pstv_SeptemberTwoThousandAndTwentyTwoDistributionAgreementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_pstv_SeptemberTwoThousandAndTwentyTwoDistributionAgreementMember" xml:lang="en-US">September Two Thousand and Twenty Two Distribution Agreement [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_pstv_SeptemberTwoThousandAndTwentyTwoDistributionAgreementMember" xml:lang="en-US">September 2022 Distribution Agreement [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pstv_SeptemberTwoThousandAndTwentyTwoDistributionAgreementMember" xlink:to="lab_pstv_SeptemberTwoThousandAndTwentyTwoDistributionAgreementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_pstv_SeptemberTwoThousandAndTwentyTwoDistributionAgreementMember" xml:lang="en-US">September two thousand and twenty two distribution agreement.</label>
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_TwentyTwentyPurchaseAgreementMember" xlink:label="loc_pstv_TwentyTwentyPurchaseAgreementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_pstv_TwentyTwentyPurchaseAgreementMember" xml:lang="en-US">Twenty Twenty Purchase Agreement [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_pstv_TwentyTwentyPurchaseAgreementMember" xml:lang="en-US">2020 Purchase Agreement [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pstv_TwentyTwentyPurchaseAgreementMember" xlink:to="lab_pstv_TwentyTwentyPurchaseAgreementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_pstv_TwentyTwentyPurchaseAgreementMember" xml:lang="en-US">Twenty twenty purchase agreement.</label>
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_TwoThousandAndTwentyTwoPurchaseAgreementMember" xlink:label="loc_pstv_TwoThousandAndTwentyTwoPurchaseAgreementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_pstv_TwoThousandAndTwentyTwoPurchaseAgreementMember" xml:lang="en-US">Two Thousand and Twenty Two Purchase Agreement [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_pstv_TwoThousandAndTwentyTwoPurchaseAgreementMember" xml:lang="en-US">2022 Purchase Agreement [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pstv_TwoThousandAndTwentyTwoPurchaseAgreementMember" xlink:to="lab_pstv_TwoThousandAndTwentyTwoPurchaseAgreementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_pstv_TwoThousandAndTwentyTwoPurchaseAgreementMember" xml:lang="en-US">Two thousand and twenty two purchase agreement.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_LegalEntityAxis" xml:lang="en-US">Legal Entity [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_LegalEntityAxis" xml:lang="en-US">Legal Entity</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LegalEntityAxis" xlink:to="lab_dei_LegalEntityAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityDomain" xml:lang="en-US">Entity [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_EntityDomain" xml:lang="en-US">Entity</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityDomain" xlink:to="lab_dei_EntityDomain" />
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_CanaccordGenuityLLCMember" xlink:label="loc_pstv_CanaccordGenuityLLCMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_pstv_CanaccordGenuityLLCMember" xml:lang="en-US">Canaccord Genuity L L C [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_pstv_CanaccordGenuityLLCMember" xml:lang="en-US">Canaccord Genuity LLC [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pstv_CanaccordGenuityLLCMember" xlink:to="lab_pstv_CanaccordGenuityLLCMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_pstv_CanaccordGenuityLLCMember" xml:lang="en-US">Canaccord Genuity L L C Member</label>
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_LincolnParkCapitalFundLLCMember" xlink:label="loc_pstv_LincolnParkCapitalFundLLCMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_pstv_LincolnParkCapitalFundLLCMember" xml:lang="en-US">Lincoln Park Capital Fund L L C [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_pstv_LincolnParkCapitalFundLLCMember" xml:lang="en-US">Lincoln Park Capital Fund, LLC [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pstv_LincolnParkCapitalFundLLCMember" xlink:to="lab_pstv_LincolnParkCapitalFundLLCMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_pstv_LincolnParkCapitalFundLLCMember" xml:lang="en-US">Lincoln park capital fund, LLC.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventMember" xml:lang="en-US">Subsequent Event [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SubsequentEventMember" xml:lang="en-US">Subsequent Event [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" />
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_AtTheMarketOfferingProgramMember" xlink:label="loc_pstv_AtTheMarketOfferingProgramMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_pstv_AtTheMarketOfferingProgramMember" xml:lang="en-US">At The Market Offering Program [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_pstv_AtTheMarketOfferingProgramMember" xml:lang="en-US">At The Market Offering Program [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pstv_AtTheMarketOfferingProgramMember" xlink:to="lab_pstv_AtTheMarketOfferingProgramMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_pstv_AtTheMarketOfferingProgramMember" xml:lang="en-US">At the market offering program.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xml:lang="en-US">Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_StockBasedCompensation2015EquityIncentivePlan1Member" xlink:label="loc_pstv_StockBasedCompensation2015EquityIncentivePlan1Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_pstv_StockBasedCompensation2015EquityIncentivePlan1Member" xml:lang="en-US">Stock Based Compensation2015 Equity Incentive Plan1 [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_pstv_StockBasedCompensation2015EquityIncentivePlan1Member" xml:lang="en-US">2015 Plan [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pstv_StockBasedCompensation2015EquityIncentivePlan1Member" xlink:to="lab_pstv_StockBasedCompensation2015EquityIncentivePlan1Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_pstv_StockBasedCompensation2015EquityIncentivePlan1Member" xml:lang="en-US">Stock based compensation 2015 equity incentive plan 1 member.</label>
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_StockBasedCompensation2020EquityIncentivePlanMember" xlink:label="loc_pstv_StockBasedCompensation2020EquityIncentivePlanMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_pstv_StockBasedCompensation2020EquityIncentivePlanMember" xml:lang="en-US">Stock Based Compensation2020 Equity Incentive Plan [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_pstv_StockBasedCompensation2020EquityIncentivePlanMember" xml:lang="en-US">2020 Plan [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pstv_StockBasedCompensation2020EquityIncentivePlanMember" xlink:to="lab_pstv_StockBasedCompensation2020EquityIncentivePlanMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_pstv_StockBasedCompensation2020EquityIncentivePlanMember" xml:lang="en-US">Stock based compensation 2020 equity incentive plan.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xml:lang="en-US">Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xml:lang="en-US">Total unamortized compensation cost related to outstanding unvested stock options and restricted stock awards</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xml:lang="en-US">Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xml:lang="en-US">Weighted average period for recognition of cost</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xml:lang="en-US">Stock option vesting period</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xml:lang="en-US">Sharebased Compensation Arrangement By Sharebased Payment Award Award Vesting Rights Percentage</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xml:lang="en-US">Stock option vesting percentage</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xml:lang="en-US">Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xml:lang="en-US">Stock option contractual term</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Weighted Average Expected Dividend</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend" xml:lang="en-US">Dividend yield assumed</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xml:lang="en-US">Securities remaining and available for future issuances (in shares)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xml:lang="en-US">Common stock shares to be issued (in shares)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xml:lang="en-US">Granted (in shares)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xml:lang="en-US">Stock options exercised</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Options Additional Disclosures [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xml:lang="en-US">Weighted Average Remaining Contractual Life (years) [Roll Forward]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xml:lang="en-US">Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xml:lang="en-US">Exercisable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xml:lang="en-US">Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xml:lang="en-US">Balance as of Weighted Average Remaining Contractual Life (years)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xml:lang="en-US">Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xml:lang="en-US">Vested and expected to vest</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" />
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" xlink:label="loc_pstv_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_pstv_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" xml:lang="en-US">Share Based Compensation Arrangement by Share Based Payment Award Options Aggregate Intrinsic Value [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_pstv_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" xml:lang="en-US">Aggregated Intrinsic Value [Roll Forward]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pstv_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" xlink:to="lab_pstv_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_pstv_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" xml:lang="en-US">Share based compensation arrangement by share based payment award options aggregate intrinsic value.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xml:lang="en-US">Exercisable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xml:lang="en-US">Balance as of Aggregated Intrinsic Value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xml:lang="en-US">Vested and expected to vest</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Roll Forward</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xml:lang="en-US">Options [Roll Forward]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xml:lang="en-US">Exercisable (in shares)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xml:lang="en-US">Cancelled/forfeited (in shares)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xml:lang="en-US">Balance as of Options (in shares)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xml:lang="en-US">Balance as of Options (in shares)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xml:lang="en-US">Vested and expected to vest (in shares)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price Rollforward</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xml:lang="en-US">Weighted Average Exercise Price [Roll Forward]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xml:lang="en-US">Exercisable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xml:lang="en-US">Balance as of Weighted Average Exercise Price (in dollars per share)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xml:lang="en-US">Balance as of Weighted Average Exercise Price (in dollars per share)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xml:lang="en-US">Vested and expected to vest (in dollars per share)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Cancelled/forfeited (in dollars per share)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Granted (in dollars per share)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xml:lang="en-US">Black-Scholes-Merton option valuation model based on weighted-average assumptions [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xml:lang="en-US">Dividends</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xml:lang="en-US">Expected term</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xml:lang="en-US">Risk-free interest rate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xml:lang="en-US">Expected volatility</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xml:lang="en-US">Resulting fair value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xml:lang="en-US">Income Statement Location [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xml:lang="en-US">Income Statement Location</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xml:lang="en-US">Income Statement Location [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xml:lang="en-US">Income Statement Location</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xml:lang="en-US">General and Administrative Expense [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xml:lang="en-US">General and Administrative [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xml:lang="en-US">Research and Development Expense [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xml:lang="en-US">Research and Development [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaap_SubsequentEventTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventTable" xml:lang="en-US">Subsequent Event [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SubsequentEventTable" xml:lang="en-US">Subsequent Event [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTable" xlink:to="lab_us-gaap_SubsequentEventTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionAxis" xlink:label="loc_us-gaap_AssetAcquisitionAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetAcquisitionAxis" xml:lang="en-US">Asset Acquisition [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetAcquisitionAxis" xlink:to="lab_us-gaap_AssetAcquisitionAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionDomain" xlink:label="loc_us-gaap_AssetAcquisitionDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetAcquisitionDomain" xml:lang="en-US">Asset Acquisition [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetAcquisitionDomain" xlink:to="lab_us-gaap_AssetAcquisitionDomain" />
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_BioceptAssetPurchaseMember" xlink:label="loc_pstv_BioceptAssetPurchaseMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_pstv_BioceptAssetPurchaseMember" xml:lang="en-US">Biocept Asset Purchase [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pstv_BioceptAssetPurchaseMember" xlink:to="lab_pstv_BioceptAssetPurchaseMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_pstv_BioceptAssetPurchaseMember" xml:lang="en-US">Biocept Asset Purchase [Member]</label>
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_SeriesAWarrantMember" xlink:label="loc_pstv_SeriesAWarrantMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_pstv_SeriesAWarrantMember" xml:lang="en-US">Series A Warrant [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pstv_SeriesAWarrantMember" xlink:to="lab_pstv_SeriesAWarrantMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_pstv_SeriesAWarrantMember" xml:lang="en-US">Series A Warrant [Member]</label>
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_SeriesBWarrantMember" xlink:label="loc_pstv_SeriesBWarrantMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_pstv_SeriesBWarrantMember" xml:lang="en-US">Series B Warrant [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pstv_SeriesBWarrantMember" xlink:to="lab_pstv_SeriesBWarrantMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_pstv_SeriesBWarrantMember" xml:lang="en-US">Series B Warrant [Member]</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityAxis" xlink:label="loc_us-gaap_CreditFacilityAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CreditFacilityAxis" xml:lang="en-US">Credit Facility [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityAxis" xlink:to="lab_us-gaap_CreditFacilityAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaap_CreditFacilityDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CreditFacilityDomain" xml:lang="en-US">Credit Facility [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityDomain" xlink:to="lab_us-gaap_CreditFacilityDomain" />
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_PershingCreditFacilityMember" xlink:label="loc_pstv_PershingCreditFacilityMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_pstv_PershingCreditFacilityMember" xml:lang="en-US">Pershing Credit Facility [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pstv_PershingCreditFacilityMember" xlink:to="lab_pstv_PershingCreditFacilityMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_pstv_PershingCreditFacilityMember" xml:lang="en-US">Pershing Credit Facility [Member]</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaap_SubsequentEventLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventLineItems" xml:lang="en-US">Subsequent Event [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SubsequentEventLineItems" xml:lang="en-US">Subsequent Event [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventLineItems" xlink:to="lab_us-gaap_SubsequentEventLineItems" />
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_ClassOfWarrantOrRightExercisePriceAdditionalSubscription" xlink:label="loc_pstv_ClassOfWarrantOrRightExercisePriceAdditionalSubscription" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_pstv_ClassOfWarrantOrRightExercisePriceAdditionalSubscription" xml:lang="en-US">Class of Warrant or Right, Exercise Price Additional Subscription</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_pstv_ClassOfWarrantOrRightExercisePriceAdditionalSubscription" xml:lang="en-US">class of warrant or right, exercise price additional subscription</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pstv_ClassOfWarrantOrRightExercisePriceAdditionalSubscription" xlink:to="lab_pstv_ClassOfWarrantOrRightExercisePriceAdditionalSubscription" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_pstv_ClassOfWarrantOrRightExercisePriceAdditionalSubscription" xml:lang="en-US">Class of Warrant or Right, Exercise Price Additional Subscription.</label>
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_ClassOfWarrantOrRightExercisePriceInitialSubscription" xlink:label="loc_pstv_ClassOfWarrantOrRightExercisePriceInitialSubscription" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_pstv_ClassOfWarrantOrRightExercisePriceInitialSubscription" xml:lang="en-US">Class of Warrant or Right, Exercise Price Initial Subscription</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_pstv_ClassOfWarrantOrRightExercisePriceInitialSubscription" xml:lang="en-US">Class of warrant exercise price initial subscription</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pstv_ClassOfWarrantOrRightExercisePriceInitialSubscription" xlink:to="lab_pstv_ClassOfWarrantOrRightExercisePriceInitialSubscription" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_pstv_ClassOfWarrantOrRightExercisePriceInitialSubscription" xml:lang="en-US">Class of Warrant or Right, Exercise Price Initial Subscription.</label>
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_ClassOfWarrantOrRightOfferingPrice" xlink:label="loc_pstv_ClassOfWarrantOrRightOfferingPrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_pstv_ClassOfWarrantOrRightOfferingPrice" xml:lang="en-US">Class Of Warrant Or Right Offering Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_pstv_ClassOfWarrantOrRightOfferingPrice" xml:lang="en-US">Right offering price</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pstv_ClassOfWarrantOrRightOfferingPrice" xlink:to="lab_pstv_ClassOfWarrantOrRightOfferingPrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_pstv_ClassOfWarrantOrRightOfferingPrice" xml:lang="en-US">Class Of Warrant Or Right Offering Price.</label>
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_ClassOfWarrantOrRightPurchasePrice" xlink:label="loc_pstv_ClassOfWarrantOrRightPurchasePrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_pstv_ClassOfWarrantOrRightPurchasePrice" xml:lang="en-US">Class Of Warrant Or Right Purchase Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_pstv_ClassOfWarrantOrRightPurchasePrice" xml:lang="en-US">Class of warrant or right purchase price</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pstv_ClassOfWarrantOrRightPurchasePrice" xlink:to="lab_pstv_ClassOfWarrantOrRightPurchasePrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_pstv_ClassOfWarrantOrRightPurchasePrice" xml:lang="en-US">Class Of Warrant Or Right Purchase Price.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:label="loc_us-gaap_DebtInstrumentInterestRateDuringPeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentInterestRateDuringPeriod" xml:lang="en-US">Debt Instrument, Interest Rate During Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtInstrumentInterestRateDuringPeriod" xml:lang="en-US">Debt instrument, interest rate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:to="lab_us-gaap_DebtInstrumentInterestRateDuringPeriod" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xml:lang="en-US">Debt Instrument, Interest Rate, Effective Percentage</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xml:lang="en-US">Effective interest rate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityInterestRateDuringPeriod" xlink:label="loc_us-gaap_LineOfCreditFacilityInterestRateDuringPeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LineOfCreditFacilityInterestRateDuringPeriod" xml:lang="en-US">Line of Credit Facility, Interest Rate During Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LineOfCreditFacilityInterestRateDuringPeriod" xml:lang="en-US">Line of credit facility, interest rate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityInterestRateDuringPeriod" xlink:to="lab_us-gaap_LineOfCreditFacilityInterestRateDuringPeriod" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xml:lang="en-US">Line of Credit Facility, Maximum Borrowing Capacity</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xml:lang="en-US">Line of credit facility</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityPeriodicPayment" xlink:label="loc_us-gaap_LineOfCreditFacilityPeriodicPayment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LineOfCreditFacilityPeriodicPayment" xml:lang="en-US">Line of Credit Facility, Periodic Payment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LineOfCreditFacilityPeriodicPayment" xml:lang="en-US">Line of credit facility, periodic payment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityPeriodicPayment" xlink:to="lab_us-gaap_LineOfCreditFacilityPeriodicPayment" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireProductiveAssets" xlink:label="loc_us-gaap_PaymentsToAcquireProductiveAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentsToAcquireProductiveAssets" xml:lang="en-US">Payments to Acquire Productive Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PaymentsToAcquireProductiveAssets" xml:lang="en-US">Payments to acquire assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireProductiveAssets" xlink:to="lab_us-gaap_PaymentsToAcquireProductiveAssets" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaap_SharesIssuedPricePerShare" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharesIssuedPricePerShare" xml:lang="en-US">Shares Issued, Price Per Share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SharesIssuedPricePerShare" xml:lang="en-US">Shares Issued, Price Per Share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesIssuedPricePerShare" xlink:to="lab_us-gaap_SharesIssuedPricePerShare" />
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_May2024PrivatePlacementMember" xlink:label="loc_pstv_May2024PrivatePlacementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_pstv_May2024PrivatePlacementMember" xml:lang="en-US">May 2024 Private Placement [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pstv_May2024PrivatePlacementMember" xlink:to="lab_pstv_May2024PrivatePlacementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_pstv_May2024PrivatePlacementMember" xml:lang="en-US">May 2024 Private Placement [Member]</label>
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_PreFundedWarrantMember" xlink:label="loc_pstv_PreFundedWarrantMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_pstv_PreFundedWarrantMember" xml:lang="en-US">Pre Funded Warrant [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_pstv_PreFundedWarrantMember" xml:lang="en-US">Pre-funded Warrant [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pstv_PreFundedWarrantMember" xlink:to="lab_pstv_PreFundedWarrantMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_pstv_PreFundedWarrantMember" xml:lang="en-US">Pre Funded Warrant [Member]</label>
</labelLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>10
<FILENAME>pstv-20240331_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--Generated by DFIN XBRL Instance Document - http://www.dfinsolutions.com/ - Version R3.0 - on 07-June-2024 [02:05:21] {PM}-->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<roleRef xlink:type="simple" xlink:href="pstv-20240331.xsd#CoverPage" roleURI="http://plus.com/role/CoverPage" />
<roleRef xlink:type="simple" xlink:href="pstv-20240331.xsd#CondensedBalanceSheetsUnaudited" roleURI="http://plus.com/role/CondensedBalanceSheetsUnaudited" />
<roleRef xlink:type="simple" xlink:href="pstv-20240331.xsd#CondensedBalanceSheetsUnauditedParenthetical" roleURI="http://plus.com/role/CondensedBalanceSheetsUnauditedParenthetical" />
<roleRef xlink:type="simple" xlink:href="pstv-20240331.xsd#CondensedStatementsOfOperationsUnaudited" roleURI="http://plus.com/role/CondensedStatementsOfOperationsUnaudited" />
<roleRef xlink:type="simple" xlink:href="pstv-20240331.xsd#CondensedStatementsOfStockholdersEquityDeficitUnaudited" roleURI="http://plus.com/role/CondensedStatementsOfStockholdersEquityDeficitUnaudited" />
<roleRef xlink:type="simple" xlink:href="pstv-20240331.xsd#CondensedStatementsOfCashFlowsUnaudited" roleURI="http://plus.com/role/CondensedStatementsOfCashFlowsUnaudited" />
<roleRef xlink:type="simple" xlink:href="pstv-20240331.xsd#BasisOfPresentationAndNewAccountingStandards" roleURI="http://plus.com/role/BasisOfPresentationAndNewAccountingStandards" />
<roleRef xlink:type="simple" xlink:href="pstv-20240331.xsd#OrganizationAndOperations" roleURI="http://plus.com/role/OrganizationAndOperations" />
<roleRef xlink:type="simple" xlink:href="pstv-20240331.xsd#UseOfEstimates" roleURI="http://plus.com/role/UseOfEstimates" />
<roleRef xlink:type="simple" xlink:href="pstv-20240331.xsd#SummaryOfSignificantAccountingPolicies" roleURI="http://plus.com/role/SummaryOfSignificantAccountingPolicies" />
<roleRef xlink:type="simple" xlink:href="pstv-20240331.xsd#LiquidityAndGoingConcern" roleURI="http://plus.com/role/LiquidityAndGoingConcern" />
<roleRef xlink:type="simple" xlink:href="pstv-20240331.xsd#FairValueMeasurements" roleURI="http://plus.com/role/FairValueMeasurements" />
<roleRef xlink:type="simple" xlink:href="pstv-20240331.xsd#LossPerShare" roleURI="http://plus.com/role/LossPerShare" />
<roleRef xlink:type="simple" xlink:href="pstv-20240331.xsd#CompositionOfCertainFinancialStatementCaptions" roleURI="http://plus.com/role/CompositionOfCertainFinancialStatementCaptions" />
<roleRef xlink:type="simple" xlink:href="pstv-20240331.xsd#CommitmentsAndContingencies" roleURI="http://plus.com/role/CommitmentsAndContingencies" />
<roleRef xlink:type="simple" xlink:href="pstv-20240331.xsd#LicenseAgreements" roleURI="http://plus.com/role/LicenseAgreements" />
<roleRef xlink:type="simple" xlink:href="pstv-20240331.xsd#TermLoanObligations" roleURI="http://plus.com/role/TermLoanObligations" />
<roleRef xlink:type="simple" xlink:href="pstv-20240331.xsd#GrantRevenue" roleURI="http://plus.com/role/GrantRevenue" />
<roleRef xlink:type="simple" xlink:href="pstv-20240331.xsd#IncomeTaxes" roleURI="http://plus.com/role/IncomeTaxes" />
<roleRef xlink:type="simple" xlink:href="pstv-20240331.xsd#EmployeeBenefitPlan" roleURI="http://plus.com/role/EmployeeBenefitPlan" />
<roleRef xlink:type="simple" xlink:href="pstv-20240331.xsd#StockholdersEquity" roleURI="http://plus.com/role/StockholdersEquity" />
<roleRef xlink:type="simple" xlink:href="pstv-20240331.xsd#SubsequentEvents" roleURI="http://plus.com/role/SubsequentEvents" />
<roleRef xlink:type="simple" xlink:href="pstv-20240331.xsd#StockBasedCompensation" roleURI="http://plus.com/role/StockBasedCompensation" />
<roleRef xlink:type="simple" xlink:href="pstv-20240331.xsd#BasisOfPresentationAndNewAccountingStandardsPolicies" roleURI="http://plus.com/role/BasisOfPresentationAndNewAccountingStandardsPolicies" />
<roleRef xlink:type="simple" xlink:href="pstv-20240331.xsd#SummaryOfSignificantAccountingPoliciesPolicies" roleURI="http://plus.com/role/SummaryOfSignificantAccountingPoliciesPolicies" />
<roleRef xlink:type="simple" xlink:href="pstv-20240331.xsd#FairValueMeasurementsTables" roleURI="http://plus.com/role/FairValueMeasurementsTables" />
<roleRef xlink:type="simple" xlink:href="pstv-20240331.xsd#LossPerShareTables" roleURI="http://plus.com/role/LossPerShareTables" />
<roleRef xlink:type="simple" xlink:href="pstv-20240331.xsd#CompositionOfCertainFinancialStatementCaptionsTables" roleURI="http://plus.com/role/CompositionOfCertainFinancialStatementCaptionsTables" />
<roleRef xlink:type="simple" xlink:href="pstv-20240331.xsd#CommitmentsAndContingenciesTables" roleURI="http://plus.com/role/CommitmentsAndContingenciesTables" />
<roleRef xlink:type="simple" xlink:href="pstv-20240331.xsd#TermLoanObligationsTables" roleURI="http://plus.com/role/TermLoanObligationsTables" />
<roleRef xlink:type="simple" xlink:href="pstv-20240331.xsd#IncomeTaxesTables" roleURI="http://plus.com/role/IncomeTaxesTables" />
<roleRef xlink:type="simple" xlink:href="pstv-20240331.xsd#StockBasedCompensationTables" roleURI="http://plus.com/role/StockBasedCompensationTables" />
<roleRef xlink:type="simple" xlink:href="pstv-20240331.xsd#BasisOfPresentationAndNewAccountingStandardsAdditionalInformationDetails" roleURI="http://plus.com/role/BasisOfPresentationAndNewAccountingStandardsAdditionalInformationDetails" />
<roleRef xlink:type="simple" xlink:href="pstv-20240331.xsd#OrganizationAndOperationsAdditionalInformationDetails" roleURI="http://plus.com/role/OrganizationAndOperationsAdditionalInformationDetails" />
<roleRef xlink:type="simple" xlink:href="pstv-20240331.xsd#SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" roleURI="http://plus.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" />
<roleRef xlink:type="simple" xlink:href="pstv-20240331.xsd#LiquidityAndGoingConcernAdditionalInformationDetails" roleURI="http://plus.com/role/LiquidityAndGoingConcernAdditionalInformationDetails" />
<roleRef xlink:type="simple" xlink:href="pstv-20240331.xsd#FairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails" roleURI="http://plus.com/role/FairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails" />
<roleRef xlink:type="simple" xlink:href="pstv-20240331.xsd#LossPerShareScheduleOfAntidilutiveSecuritiesExcludedFromDilutedIncomeLossPerShareDetails" roleURI="http://plus.com/role/LossPerShareScheduleOfAntidilutiveSecuritiesExcludedFromDilutedIncomeLossPerShareDetails" />
<roleRef xlink:type="simple" xlink:href="pstv-20240331.xsd#CompositionOfCertainFinancialStatementCaptionsOtherCurrentAssetsDetails" roleURI="http://plus.com/role/CompositionOfCertainFinancialStatementCaptionsOtherCurrentAssetsDetails" />
<roleRef xlink:type="simple" xlink:href="pstv-20240331.xsd#CompositionOfCertainFinancialStatementCaptionsPropertyAndEquipmentNetDetails" roleURI="http://plus.com/role/CompositionOfCertainFinancialStatementCaptionsPropertyAndEquipmentNetDetails" />
<roleRef xlink:type="simple" xlink:href="pstv-20240331.xsd#CompositionOfCertainFinancialStatementCaptionsAdditionalInformationDetails" roleURI="http://plus.com/role/CompositionOfCertainFinancialStatementCaptionsAdditionalInformationDetails" />
<roleRef xlink:type="simple" xlink:href="pstv-20240331.xsd#CompositionOfCertainFinancialStatementCaptionsAccountsPayableAndAccruedExpensesDetails" roleURI="http://plus.com/role/CompositionOfCertainFinancialStatementCaptionsAccountsPayableAndAccruedExpensesDetails" />
<roleRef xlink:type="simple" xlink:href="pstv-20240331.xsd#CommitmentsAndContingenciesAdditionalInformationDetails" roleURI="http://plus.com/role/CommitmentsAndContingenciesAdditionalInformationDetails" />
<roleRef xlink:type="simple" xlink:href="pstv-20240331.xsd#CommitmentsAndContingenciesSummaryOfLeaseCostsDetails" roleURI="http://plus.com/role/CommitmentsAndContingenciesSummaryOfLeaseCostsDetails" />
<roleRef xlink:type="simple" xlink:href="pstv-20240331.xsd#CommitmentsAndContingenciesSummaryOfFutureMinimumAnnualLeasePaymentsUnderOperatingLeasesDetails" roleURI="http://plus.com/role/CommitmentsAndContingenciesSummaryOfFutureMinimumAnnualLeasePaymentsUnderOperatingLeasesDetails" />
<roleRef xlink:type="simple" xlink:href="pstv-20240331.xsd#LicenseAgreementsAdditionalInformationDetails" roleURI="http://plus.com/role/LicenseAgreementsAdditionalInformationDetails" />
<roleRef xlink:type="simple" xlink:href="pstv-20240331.xsd#TermLoanObligationsAdditionalInformationDetails" roleURI="http://plus.com/role/TermLoanObligationsAdditionalInformationDetails" />
<roleRef xlink:type="simple" xlink:href="pstv-20240331.xsd#TermLoanObligationsTermLoanOutstandingDetails" roleURI="http://plus.com/role/TermLoanObligationsTermLoanOutstandingDetails" />
<roleRef xlink:type="simple" xlink:href="pstv-20240331.xsd#GrantRevenueAdditionalInformationDetails" roleURI="http://plus.com/role/GrantRevenueAdditionalInformationDetails" />
<roleRef xlink:type="simple" xlink:href="pstv-20240331.xsd#IncomeTaxesAdditionalInformationDetails" roleURI="http://plus.com/role/IncomeTaxesAdditionalInformationDetails" />
<roleRef xlink:type="simple" xlink:href="pstv-20240331.xsd#IncomeTaxesReconciliationOfTotalIncomeTaxProvisionDetails" roleURI="http://plus.com/role/IncomeTaxesReconciliationOfTotalIncomeTaxProvisionDetails" />
<roleRef xlink:type="simple" xlink:href="pstv-20240331.xsd#IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails" roleURI="http://plus.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails" />
<roleRef xlink:type="simple" xlink:href="pstv-20240331.xsd#IncomeTaxesUnrecognizedTaxBenefitsActivityDetails" roleURI="http://plus.com/role/IncomeTaxesUnrecognizedTaxBenefitsActivityDetails" />
<roleRef xlink:type="simple" xlink:href="pstv-20240331.xsd#EmployeeBenefitPlanAdditionalInformationDetails" roleURI="http://plus.com/role/EmployeeBenefitPlanAdditionalInformationDetails" />
<roleRef xlink:type="simple" xlink:href="pstv-20240331.xsd#StockholdersEquityPreferredStockDetails" roleURI="http://plus.com/role/StockholdersEquityPreferredStockDetails" />
<roleRef xlink:type="simple" xlink:href="pstv-20240331.xsd#StockholdersEquityWarrantsDetails" roleURI="http://plus.com/role/StockholdersEquityWarrantsDetails" />
<roleRef xlink:type="simple" xlink:href="pstv-20240331.xsd#StockholdersEquityCommonStockDetails" roleURI="http://plus.com/role/StockholdersEquityCommonStockDetails" />
<roleRef xlink:type="simple" xlink:href="pstv-20240331.xsd#StockBasedCompensationAdditionalInformationDetails" roleURI="http://plus.com/role/StockBasedCompensationAdditionalInformationDetails" />
<roleRef xlink:type="simple" xlink:href="pstv-20240331.xsd#StockBasedCompensationStockOptionActivityDetails" roleURI="http://plus.com/role/StockBasedCompensationStockOptionActivityDetails" />
<roleRef xlink:type="simple" xlink:href="pstv-20240331.xsd#StockBasedCompensationWeightedAverageAssumptionsDetails" roleURI="http://plus.com/role/StockBasedCompensationWeightedAverageAssumptionsDetails" />
<roleRef xlink:type="simple" xlink:href="pstv-20240331.xsd#StockBasedCompensationSummaryOfShareBasedCompensationRecognizedDetails" roleURI="http://plus.com/role/StockBasedCompensationSummaryOfShareBasedCompensationRecognizedDetails" />
<roleRef xlink:type="simple" xlink:href="pstv-20240331.xsd#SubsequentEventsAdditionalInformationDetails" roleURI="http://plus.com/role/SubsequentEventsAdditionalInformationDetails" />
<presentationLink xlink:type="extended" xlink:role="http://plus.com/role/CoverPage">
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="loc_dei_CoverAbstract_101" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationTable" xlink:label="loc_dei_DocumentInformationTable_1525" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_101" xlink:to="loc_dei_DocumentInformationTable_1525" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressesAddressTypeAxis" xlink:label="loc_dei_EntityAddressesAddressTypeAxis_1526" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationTable_1525" xlink:to="loc_dei_EntityAddressesAddressTypeAxis_1526" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AddressTypeDomain" xlink:label="loc_dei_AddressTypeDomain_1527" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesAddressTypeAxis_1526" xlink:to="loc_dei_AddressTypeDomain_1527" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_BusinessContactMember" xlink:label="loc_dei_BusinessContactMember_1528" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_AddressTypeDomain_1527" xlink:to="loc_dei_BusinessContactMember_1528" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationLineItems" xlink:label="loc_dei_DocumentInformationLineItems_1529" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationTable_1525" xlink:to="loc_dei_DocumentInformationLineItems_1529" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_115" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_1529" xlink:to="loc_dei_DocumentType_115" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_116" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_1529" xlink:to="loc_dei_AmendmentFlag_116" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_102" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_1529" xlink:to="loc_dei_EntityRegistrantName_102" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_103" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_1529" xlink:to="loc_dei_EntityCentralIndexKey_103" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_110" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_1529" xlink:to="loc_dei_EntityFilerCategory_110" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="loc_dei_EntitySmallBusiness_119" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_1529" xlink:to="loc_dei_EntitySmallBusiness_119" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_dei_EntityEmergingGrowthCompany_120" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_1529" xlink:to="loc_dei_EntityEmergingGrowthCompany_120" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_dei_EntityIncorporationStateCountryCode_126" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_1529" xlink:to="loc_dei_EntityIncorporationStateCountryCode_126" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_dei_EntityTaxIdentificationNumber_127" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_1529" xlink:to="loc_dei_EntityTaxIdentificationNumber_127" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_dei_EntityAddressAddressLine1_128" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_1529" xlink:to="loc_dei_EntityAddressAddressLine1_128" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_dei_EntityAddressAddressLine2_129" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_1529" xlink:to="loc_dei_EntityAddressAddressLine2_129" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_dei_EntityAddressCityOrTown_130" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_1529" xlink:to="loc_dei_EntityAddressCityOrTown_130" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_dei_EntityAddressStateOrProvince_131" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_1529" xlink:to="loc_dei_EntityAddressStateOrProvince_131" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_dei_EntityAddressPostalZipCode_132" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_1529" xlink:to="loc_dei_EntityAddressPostalZipCode_132" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="loc_dei_CityAreaCode_133" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_1529" xlink:to="loc_dei_CityAreaCode_133" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="loc_dei_LocalPhoneNumber_134" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_1529" xlink:to="loc_dei_LocalPhoneNumber_134" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_dei_EntityPrimarySicNumber_1524" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_1529" xlink:to="loc_dei_EntityPrimarySicNumber_1524" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_ContactPersonnelName" xlink:label="loc_dei_ContactPersonnelName_1530" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_1529" xlink:to="loc_dei_ContactPersonnelName_1530" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/label" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://plus.com/role/CondensedBalanceSheetsUnaudited">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_141" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_147" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_141" xlink:to="loc_us-gaap_AssetsAbstract_147" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_144" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_147" xlink:to="loc_us-gaap_AssetsCurrentAbstract_144" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_143" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_144" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_143" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermInvestments" xlink:label="loc_us-gaap_ShortTermInvestments_1249" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_144" xlink:to="loc_us-gaap_ShortTermInvestments_1249" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaap_OtherAssetsCurrent_149" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_144" xlink:to="loc_us-gaap_OtherAssetsCurrent_149" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_155" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_144" xlink:to="loc_us-gaap_AssetsCurrent_155" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_150" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_147" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_150" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_156" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_147" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_156" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_160" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_147" xlink:to="loc_us-gaap_Goodwill_160" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherIntangibleAssetsNet" xlink:label="loc_us-gaap_OtherIntangibleAssetsNet_163" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_147" xlink:to="loc_us-gaap_OtherIntangibleAssetsNet_163" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_166" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_147" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_166" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_169" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_147" xlink:to="loc_us-gaap_Assets_169" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_153" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_141" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_153" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_146" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_153" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_146" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_142" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_146" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_142" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_148" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_146" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_148" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeCurrent" xlink:label="loc_us-gaap_DeferredIncomeCurrent_1281" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_146" xlink:to="loc_us-gaap_DeferredIncomeCurrent_1281" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtCurrent" xlink:label="loc_us-gaap_LongTermDebtCurrent_154" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_146" xlink:to="loc_us-gaap_LongTermDebtCurrent_154" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_159" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_146" xlink:to="loc_us-gaap_LiabilitiesCurrent_159" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_152" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_153" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_152" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_158" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_153" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_158" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeNoncurrent" xlink:label="loc_us-gaap_DeferredIncomeNoncurrent_162" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_153" xlink:to="loc_us-gaap_DeferredIncomeNoncurrent_162" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_165" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_153" xlink:to="loc_us-gaap_Liabilities_165" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_168" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_153" xlink:to="loc_us-gaap_CommitmentsAndContingencies_168" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_170" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_153" xlink:to="loc_us-gaap_StockholdersEquityAbstract_170" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue_145" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_170" xlink:to="loc_us-gaap_PreferredStockValue_145" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_151" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_170" xlink:to="loc_us-gaap_CommonStockValue_151" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockCommonValue" xlink:label="loc_us-gaap_TreasuryStockCommonValue_157" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_170" xlink:to="loc_us-gaap_TreasuryStockCommonValue_157" use="optional" order="28" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital_161" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_170" xlink:to="loc_us-gaap_AdditionalPaidInCapital_161" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_164" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_170" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_164" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_167" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_170" xlink:to="loc_us-gaap_StockholdersEquity_167" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_171" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_153" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_171" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://plus.com/role/CondensedBalanceSheetsUnauditedParenthetical">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_173" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_175" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_173" xlink:to="loc_us-gaap_StockholdersEquityAbstract_175" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockCommonShares" xlink:label="loc_us-gaap_TreasuryStockCommonShares_174" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_175" xlink:to="loc_us-gaap_TreasuryStockCommonShares_174" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_176" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_175" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_176" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_177" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_175" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_177" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_178" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_175" xlink:to="loc_us-gaap_PreferredStockSharesIssued_178" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_179" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_175" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_179" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_1577" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_175" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_1577" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_181" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_175" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_181" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_182" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_175" xlink:to="loc_us-gaap_CommonStockSharesIssued_182" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_183" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_175" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_183" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://plus.com/role/CondensedStatementsOfOperationsUnaudited">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_185" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_187" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_185" xlink:to="loc_us-gaap_StatementTable_187" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_189" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_187" xlink:to="loc_srt_ProductOrServiceAxis_189" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_191" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_189" xlink:to="loc_srt_ProductsAndServicesDomain_191" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GrantMember" xlink:label="loc_us-gaap_GrantMember_188" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_191" xlink:to="loc_us-gaap_GrantMember_188" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_194" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_187" xlink:to="loc_us-gaap_StatementLineItems_194" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_190" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_194" xlink:to="loc_us-gaap_Revenues_190" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract_195" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_194" xlink:to="loc_us-gaap_OperatingExpensesAbstract_195" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_186" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_195" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_186" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_193" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_195" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_193" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_197" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_195" xlink:to="loc_us-gaap_OperatingExpenses_197" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_198" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_194" xlink:to="loc_us-gaap_OperatingIncomeLoss_198" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherIncomeAndExpensesAbstract" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract_200" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_194" xlink:to="loc_us-gaap_OtherIncomeAndExpensesAbstract_200" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="loc_us-gaap_InvestmentIncomeInterest_192" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_200" xlink:to="loc_us-gaap_InvestmentIncomeInterest_192" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense_196" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_200" xlink:to="loc_us-gaap_InterestExpense_196" use="optional" order="14" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesFairValueAdjustment" xlink:label="loc_us-gaap_LiabilitiesFairValueAdjustment_199" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_200" xlink:to="loc_us-gaap_LiabilitiesFairValueAdjustment_199" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_201" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_200" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_201" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_203" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_200" xlink:to="loc_us-gaap_NetIncomeLoss_203" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic_202" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_194" xlink:to="loc_us-gaap_EarningsPerShareBasic_202" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted_204" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_194" xlink:to="loc_us-gaap_EarningsPerShareDiluted_204" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_205" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_194" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_205" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_206" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_194" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_206" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://plus.com/role/CondensedStatementsOfStockholdersEquityDeficitUnaudited">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_208" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_209" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_208" xlink:to="loc_us-gaap_StatementTable_209" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_213" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_209" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_213" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_212" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_213" xlink:to="loc_us-gaap_EquityComponentDomain_212" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaap_PreferredStockMember_211" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_212" xlink:to="loc_us-gaap_PreferredStockMember_211" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_216" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_212" xlink:to="loc_us-gaap_CommonStockMember_216" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockCommonMember" xlink:label="loc_us-gaap_TreasuryStockCommonMember_225" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_212" xlink:to="loc_us-gaap_TreasuryStockCommonMember_225" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_220" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_212" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_220" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_223" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_212" xlink:to="loc_us-gaap_RetainedEarningsMember_223" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_217" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_209" xlink:to="loc_us-gaap_StatementClassOfStockAxis_217" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_219" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_217" xlink:to="loc_us-gaap_ClassOfStockDomain_219" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesFPreferredStockMember" xlink:label="loc_us-gaap_SeriesFPreferredStockMember_210" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_219" xlink:to="loc_us-gaap_SeriesFPreferredStockMember_210" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="loc_us-gaap_ConvertiblePreferredStockMember_215" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_219" xlink:to="loc_us-gaap_ConvertiblePreferredStockMember_215" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_221" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_209" xlink:to="loc_us-gaap_StatementLineItems_221" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_214" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_221" xlink:to="loc_us-gaap_StockholdersEquity_214" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_218" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_221" xlink:to="loc_us-gaap_SharesOutstanding_218" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_222" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_221" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_222" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_224" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_221" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_224" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_226" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_221" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_226" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRedeemedOrCalledDuringPeriodShares" xlink:label="loc_us-gaap_StockRedeemedOrCalledDuringPeriodShares_227" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_221" xlink:to="loc_us-gaap_StockRedeemedOrCalledDuringPeriodShares_227" use="optional" order="19" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_228" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_221" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_228" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_229" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_221" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_229" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_FractionalAdjustmentOfCommonStock" xlink:label="loc_pstv_FractionalAdjustmentOfCommonStock_230" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_221" xlink:to="loc_pstv_FractionalAdjustmentOfCommonStock_230" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_231" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_221" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_231" use="optional" order="23" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockSharesAcquired" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_232" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_221" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_232" use="optional" order="24" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_233" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_221" xlink:to="loc_us-gaap_NetIncomeLoss_233" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_234" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_221" xlink:to="loc_us-gaap_StockholdersEquity_234" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_235" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_221" xlink:to="loc_us-gaap_SharesOutstanding_235" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://plus.com/role/CondensedStatementsOfCashFlowsUnaudited">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_237" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_241" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_237" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_241" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_242" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_241" xlink:to="loc_us-gaap_NetIncomeLoss_242" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_249" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_241" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_249" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_240" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_249" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_240" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_247" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_249" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_247" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_CommonStockIssuedForResearchAndDevelopment" xlink:label="loc_pstv_CommonStockIssuedForResearchAndDevelopment_254" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_249" xlink:to="loc_pstv_CommonStockIssuedForResearchAndDevelopment_254" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_261" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_249" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_261" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_267" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_249" xlink:to="loc_us-gaap_ShareBasedCompensation_267" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_1393" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_249" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_1393" use="optional" order="9" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_269" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_249" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_269" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnDispositionOfAssets" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets_264" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_249" xlink:to="loc_us-gaap_GainLossOnDispositionOfAssets_264" use="optional" order="11" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_271" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_249" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_271" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherCurrentAssets_1103" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_271" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherCurrentAssets_1103" use="optional" order="13" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_239" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_271" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_239" use="optional" order="14" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_246" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_271" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_246" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_253" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_271" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_253" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_IncreaseDecreaseInDeferredGrantLiability" xlink:label="loc_pstv_IncreaseDecreaseInDeferredGrantLiability_260" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_271" xlink:to="loc_pstv_IncreaseDecreaseInDeferredGrantLiability_260" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_256" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_241" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_256" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_248" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_237" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_248" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_PaymentsToAcquirePropertyPlantAndEquipmentAndIntangibleAssets" xlink:label="loc_pstv_PaymentsToAcquirePropertyPlantAndEquipmentAndIntangibleAssets_244" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_248" xlink:to="loc_pstv_PaymentsToAcquirePropertyPlantAndEquipmentAndIntangibleAssets_244" use="optional" order="20" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_CashPaidForIPRDAssetAcquiredInAnAssetAcquisition" xlink:label="loc_pstv_CashPaidForIPRDAssetAcquiredInAnAssetAcquisition_251" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_248" xlink:to="loc_pstv_CashPaidForIPRDAssetAcquiredInAnAssetAcquisition_251" use="optional" order="21" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_1108" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_248" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_1108" use="optional" order="22" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireShortTermInvestments" xlink:label="loc_us-gaap_PaymentsToAcquireShortTermInvestments_1225" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_248" xlink:to="loc_us-gaap_PaymentsToAcquireShortTermInvestments_1225" use="optional" order="23" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_258" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_248" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_258" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_255" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_237" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_255" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_243" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_255" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_243" use="optional" order="26" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForRepurchaseOfEquity" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfEquity_263" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_255" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfEquity_263" use="optional" order="27" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_250" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_255" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_250" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_257" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_255" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_257" use="optional" order="29" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_266" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_255" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_266" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_262" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_237" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_262" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_265" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_237" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_265" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_268" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_237" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_268" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_CashPaidDuringPeriodForAbstract" xlink:label="loc_pstv_CashPaidDuringPeriodForAbstract_272" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_237" xlink:to="loc_pstv_CashPaidDuringPeriodForAbstract_272" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPaidNet" xlink:label="loc_us-gaap_InterestPaidNet_238" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pstv_CashPaidDuringPeriodForAbstract_272" xlink:to="loc_us-gaap_InterestPaidNet_238" use="optional" order="35" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_273" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_237" xlink:to="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_273" use="optional" order="36" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_UnpaidOfferingCosts" xlink:label="loc_pstv_UnpaidOfferingCosts_245" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_273" xlink:to="loc_pstv_UnpaidOfferingCosts_245" use="optional" order="37" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssued1" xlink:label="loc_us-gaap_StockIssued1_252" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_273" xlink:to="loc_us-gaap_StockIssued1_252" use="optional" order="38" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_259" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_273" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_259" use="optional" order="39" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_1226" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_273" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_1226" use="optional" order="40" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://plus.com/role/BasisOfPresentationAndNewAccountingStandards">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1568" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_943" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1568" xlink:to="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_943" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://plus.com/role/OrganizationAndOperations">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_279" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_280" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_279" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_280" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://plus.com/role/UseOfEstimates">
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_UseOfEstimatesAbstract" xlink:label="loc_pstv_UseOfEstimatesAbstract_967" />
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_UseOfEstimatesTextBlock" xlink:label="loc_pstv_UseOfEstimatesTextBlock_968" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pstv_UseOfEstimatesAbstract_967" xlink:to="loc_pstv_UseOfEstimatesTextBlock_968" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://plus.com/role/SummaryOfSignificantAccountingPolicies">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_282" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_283" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_282" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_283" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://plus.com/role/LiquidityAndGoingConcern">
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_LiquidityAbstract" xlink:label="loc_pstv_LiquidityAbstract_986" />
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_DisclosureOfLiquidityAndGoingConcernTextBlock" xlink:label="loc_pstv_DisclosureOfLiquidityAndGoingConcernTextBlock_987" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pstv_LiquidityAbstract_986" xlink:to="loc_pstv_DisclosureOfLiquidityAndGoingConcernTextBlock_987" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://plus.com/role/FairValueMeasurements">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_285" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementInputsDisclosureTextBlock" xlink:label="loc_us-gaap_FairValueMeasurementInputsDisclosureTextBlock_286" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_285" xlink:to="loc_us-gaap_FairValueMeasurementInputsDisclosureTextBlock_286" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://plus.com/role/LossPerShare">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_288" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_289" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_288" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_289" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://plus.com/role/CompositionOfCertainFinancialStatementCaptions">
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_CompositionOfCertainFinancialStatementCaptionsAbstract" xlink:label="loc_pstv_CompositionOfCertainFinancialStatementCaptionsAbstract_291" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:label="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_292" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pstv_CompositionOfCertainFinancialStatementCaptionsAbstract_291" xlink:to="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_292" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://plus.com/role/CommitmentsAndContingencies">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_294" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_295" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_294" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_295" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://plus.com/role/LicenseAgreements">
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_LicenseAgreementAbstract" xlink:label="loc_pstv_LicenseAgreementAbstract_297" />
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_LicenseAgreementDisclosureTextBlock" xlink:label="loc_pstv_LicenseAgreementDisclosureTextBlock_298" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pstv_LicenseAgreementAbstract_297" xlink:to="loc_pstv_LicenseAgreementDisclosureTextBlock_298" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://plus.com/role/TermLoanObligations">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_300" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_301" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_300" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_301" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://plus.com/role/GrantRevenue">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_303" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_304" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_303" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_304" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://plus.com/role/IncomeTaxes">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_306" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_307" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_306" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_307" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://plus.com/role/EmployeeBenefitPlan">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_309" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:label="loc_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_310" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_309" xlink:to="loc_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_310" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://plus.com/role/StockholdersEquity">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_312" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_313" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_312" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_313" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://plus.com/role/SubsequentEvents">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract_964" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_965" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_964" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_965" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://plus.com/role/StockBasedCompensation">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_315" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_316" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_315" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_316" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://plus.com/role/BasisOfPresentationAndNewAccountingStandardsPolicies">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1570" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_953" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1570" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_953" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_AmendmentsForCertificateofIncorporationAndReverseStockSplitPolicyTextBlock" xlink:label="loc_pstv_AmendmentsForCertificateofIncorporationAndReverseStockSplitPolicyTextBlock_1535" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1570" xlink:to="loc_pstv_AmendmentsForCertificateofIncorporationAndReverseStockSplitPolicyTextBlock_1535" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_994" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1570" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_994" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesPurchasedOptionsPricePolicy" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesPurchasedOptionsPricePolicy_997" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1570" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesPurchasedOptionsPricePolicy_997" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_1006" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1570" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_1006" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://plus.com/role/SummaryOfSignificantAccountingPoliciesPolicies">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_321" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaap_UseOfEstimates_322" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_321" xlink:to="loc_us-gaap_UseOfEstimates_322" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_323" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_321" xlink:to="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_323" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_324" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_321" xlink:to="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_324" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_325" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_321" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_325" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentImpairment" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentImpairment_326" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_321" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentImpairment_326" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_327" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_321" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_327" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_329" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_321" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_329" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_330" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_321" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_330" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InProcessResearchAndDevelopmentPolicy" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentPolicy_331" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_321" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentPolicy_331" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtPolicyTextBlock" xlink:label="loc_us-gaap_DebtPolicyTextBlock_332" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_321" xlink:to="loc_us-gaap_DebtPolicyTextBlock_332" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_333" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_321" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_333" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_334" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_321" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_334" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_335" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_321" xlink:to="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_335" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_336" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_321" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_336" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_337" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_321" xlink:to="loc_us-gaap_ConcentrationRiskCreditRisk_337" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_338" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_321" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_338" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://plus.com/role/FairValueMeasurementsTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_340" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_341" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_340" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_341" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://plus.com/role/LossPerShareTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_343" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_344" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_343" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_344" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://plus.com/role/CompositionOfCertainFinancialStatementCaptionsTables">
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_CompositionOfCertainFinancialStatementCaptionsAbstract" xlink:label="loc_pstv_CompositionOfCertainFinancialStatementCaptionsAbstract_346" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock_347" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pstv_CompositionOfCertainFinancialStatementCaptionsAbstract_346" xlink:to="loc_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock_347" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_348" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pstv_CompositionOfCertainFinancialStatementCaptionsAbstract_346" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_348" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_349" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pstv_CompositionOfCertainFinancialStatementCaptionsAbstract_346" xlink:to="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_349" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://plus.com/role/CommitmentsAndContingenciesTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_351" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="loc_us-gaap_LeaseCostTableTextBlock_353" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_351" xlink:to="loc_us-gaap_LeaseCostTableTextBlock_353" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_354" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_351" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_354" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://plus.com/role/TermLoanObligationsTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_357" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:label="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock_358" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_357" xlink:to="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock_358" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://plus.com/role/IncomeTaxesTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_362" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_363" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_362" xlink:to="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_363" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_364" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_362" xlink:to="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_364" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_365" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_362" xlink:to="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_365" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://plus.com/role/StockBasedCompensationTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_367" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_368" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_367" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_368" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_369" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_367" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_369" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_370" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_367" xlink:to="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_370" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://plus.com/role/BasisOfPresentationAndNewAccountingStandardsAdditionalInformationDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract" xlink:label="loc_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract_970" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_981" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract_970" xlink:to="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_981" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_978" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_981" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_978" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_980" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_978" xlink:to="loc_us-gaap_TypeOfAdoptionMember_980" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_990" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_981" xlink:to="loc_srt_RangeAxis_990" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_976" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_990" xlink:to="loc_srt_RangeMember_976" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_975" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_976" xlink:to="loc_srt_MinimumMember_975" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_989" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_976" xlink:to="loc_srt_MaximumMember_989" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_1001" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_981" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_1001" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_977" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1001" xlink:to="loc_us-gaap_EquityComponentDomain_977" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_OutstandingWarrantsAndOptionsMember" xlink:label="loc_pstv_OutstandingWarrantsAndOptionsMember_974" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_977" xlink:to="loc_pstv_OutstandingWarrantsAndOptionsMember_974" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_1003" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_981" xlink:to="loc_us-gaap_PlanNameAxis_1003" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_973" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_1003" xlink:to="loc_us-gaap_PlanNameDomain_973" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_EquityIncentivePlansMember" xlink:label="loc_pstv_EquityIncentivePlansMember_971" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_973" xlink:to="loc_pstv_EquityIncentivePlansMember_971" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_1009" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_981" xlink:to="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_1009" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_1002" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_1009" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_1002" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_1008" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_1009" xlink:to="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_1008" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_ReverseStockSplitEffectiveDate" xlink:label="loc_pstv_ReverseStockSplitEffectiveDate_1010" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_1009" xlink:to="loc_pstv_ReverseStockSplitEffectiveDate_1010" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_1014" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_1009" xlink:to="loc_us-gaap_CommonStockSharesIssued_1014" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_1018" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_1009" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_1018" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_1019" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_1009" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_1019" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockSplits" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockSplits_1022" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_1009" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockSplits_1022" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits_1023" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_1009" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits_1023" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain_1026" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_1009" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain_1026" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://plus.com/role/OrganizationAndOperationsAdditionalInformationDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_372" />
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_OrganizationAndOperationsTable" xlink:label="loc_pstv_OrganizationAndOperationsTable_380" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_372" xlink:to="loc_pstv_OrganizationAndOperationsTable_380" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_382" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pstv_OrganizationAndOperationsTable_380" xlink:to="loc_us-gaap_DebtInstrumentAxis_382" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_387" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_382" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_387" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_TermLoanMember" xlink:label="loc_pstv_TermLoanMember_378" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_387" xlink:to="loc_pstv_TermLoanMember_378" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_385" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pstv_OrganizationAndOperationsTable_380" xlink:to="loc_srt_RangeAxis_385" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_377" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_385" xlink:to="loc_srt_RangeMember_377" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_376" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_377" xlink:to="loc_srt_MinimumMember_376" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_383" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_377" xlink:to="loc_srt_MaximumMember_383" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_388" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pstv_OrganizationAndOperationsTable_380" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_388" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_379" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_388" xlink:to="loc_us-gaap_EquityComponentDomain_379" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_OutstandingWarrantsAndOptionsMember" xlink:label="loc_pstv_OutstandingWarrantsAndOptionsMember_375" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_379" xlink:to="loc_pstv_OutstandingWarrantsAndOptionsMember_375" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_390" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pstv_OrganizationAndOperationsTable_380" xlink:to="loc_us-gaap_PlanNameAxis_390" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_374" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_390" xlink:to="loc_us-gaap_PlanNameDomain_374" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_EquityIncentivePlansMember" xlink:label="loc_pstv_EquityIncentivePlansMember_373" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_374" xlink:to="loc_pstv_EquityIncentivePlansMember_373" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_OrganizationAndOperationsLineItems" xlink:label="loc_pstv_OrganizationAndOperationsLineItems_392" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pstv_OrganizationAndOperationsTable_380" xlink:to="loc_pstv_OrganizationAndOperationsLineItems_392" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_381" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pstv_OrganizationAndOperationsLineItems_392" xlink:to="loc_us-gaap_NetIncomeLoss_381" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_384" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pstv_OrganizationAndOperationsLineItems_392" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_384" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_386" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pstv_OrganizationAndOperationsLineItems_392" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_386" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_389" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pstv_OrganizationAndOperationsLineItems_392" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_389" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_LongTermDebtOutstandingThresholdAmount" xlink:label="loc_pstv_LongTermDebtOutstandingThresholdAmount_391" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pstv_OrganizationAndOperationsLineItems_392" xlink:to="loc_pstv_LongTermDebtOutstandingThresholdAmount_391" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFeeAmount" xlink:label="loc_us-gaap_DebtInstrumentFeeAmount_393" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pstv_OrganizationAndOperationsLineItems_392" xlink:to="loc_us-gaap_DebtInstrumentFeeAmount_393" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="loc_us-gaap_DebtInstrumentMaturityDate_394" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pstv_OrganizationAndOperationsLineItems_392" xlink:to="loc_us-gaap_DebtInstrumentMaturityDate_394" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_395" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pstv_OrganizationAndOperationsLineItems_392" xlink:to="loc_us-gaap_StockholdersEquity_395" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_396" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pstv_OrganizationAndOperationsLineItems_392" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_396" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_397" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pstv_OrganizationAndOperationsLineItems_392" xlink:to="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_397" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_399" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pstv_OrganizationAndOperationsLineItems_392" xlink:to="loc_us-gaap_CommonStockSharesIssued_399" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_401" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pstv_OrganizationAndOperationsLineItems_392" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_401" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_402" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pstv_OrganizationAndOperationsLineItems_392" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_402" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockSplits" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockSplits_403" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pstv_OrganizationAndOperationsLineItems_392" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockSplits_403" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits_404" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pstv_OrganizationAndOperationsLineItems_392" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits_404" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://plus.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_409" />
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_SummaryOfSignificantAccountingPoliciesTable" xlink:label="loc_pstv_SummaryOfSignificantAccountingPoliciesTable_412" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_409" xlink:to="loc_pstv_SummaryOfSignificantAccountingPoliciesTable_412" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_417" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pstv_SummaryOfSignificantAccountingPoliciesTable_412" xlink:to="loc_srt_RangeAxis_417" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_414" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_417" xlink:to="loc_srt_RangeMember_414" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_413" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_414" xlink:to="loc_srt_MinimumMember_413" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_423" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_414" xlink:to="loc_srt_MaximumMember_423" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_425" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pstv_SummaryOfSignificantAccountingPoliciesTable_412" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_425" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_410" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_425" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_410" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InProcessResearchAndDevelopmentMember" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_411" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_410" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_411" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_428" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pstv_SummaryOfSignificantAccountingPoliciesTable_412" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_428" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_418" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_428" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_418" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_430" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pstv_SummaryOfSignificantAccountingPoliciesTable_412" xlink:to="loc_srt_ProductOrServiceAxis_430" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_421" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_430" xlink:to="loc_srt_ProductsAndServicesDomain_421" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_432" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pstv_SummaryOfSignificantAccountingPoliciesTable_412" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_432" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_422" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_432" xlink:to="loc_us-gaap_TypeOfAdoptionMember_422" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingStandardsUpdate201613Member" xlink:label="loc_us-gaap_AccountingStandardsUpdate201613Member_426" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfAdoptionMember_422" xlink:to="loc_us-gaap_AccountingStandardsUpdate201613Member_426" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_SummaryOfSignificantAccountingPoliciesLineItems" xlink:label="loc_pstv_SummaryOfSignificantAccountingPoliciesLineItems_434" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pstv_SummaryOfSignificantAccountingPoliciesTable_412" xlink:to="loc_pstv_SummaryOfSignificantAccountingPoliciesLineItems_434" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_424" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pstv_SummaryOfSignificantAccountingPoliciesLineItems_434" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_424" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_427" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pstv_SummaryOfSignificantAccountingPoliciesLineItems_434" xlink:to="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_427" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_429" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pstv_SummaryOfSignificantAccountingPoliciesLineItems_434" xlink:to="loc_us-gaap_StockholdersEquity_429" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetImpairmentCharges" xlink:label="loc_us-gaap_AssetImpairmentCharges_431" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pstv_SummaryOfSignificantAccountingPoliciesLineItems_434" xlink:to="loc_us-gaap_AssetImpairmentCharges_431" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfReportingUnits" xlink:label="loc_us-gaap_NumberOfReportingUnits_433" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pstv_SummaryOfSignificantAccountingPoliciesLineItems_434" xlink:to="loc_us-gaap_NumberOfReportingUnits_433" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" xlink:label="loc_us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense_437" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pstv_SummaryOfSignificantAccountingPoliciesLineItems_434" xlink:to="loc_us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense_437" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="loc_us-gaap_NumberOfOperatingSegments_438" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pstv_SummaryOfSignificantAccountingPoliciesLineItems_434" xlink:to="loc_us-gaap_NumberOfOperatingSegments_438" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" xlink:label="loc_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted_439" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pstv_SummaryOfSignificantAccountingPoliciesLineItems_434" xlink:to="loc_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted_439" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" xlink:label="loc_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate_440" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pstv_SummaryOfSignificantAccountingPoliciesLineItems_434" xlink:to="loc_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate_440" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" xlink:label="loc_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect_441" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pstv_SummaryOfSignificantAccountingPoliciesLineItems_434" xlink:to="loc_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect_441" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://plus.com/role/LiquidityAndGoingConcernAdditionalInformationDetails">
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_LiquidityAbstract" xlink:label="loc_pstv_LiquidityAbstract_955" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_958" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pstv_LiquidityAbstract_955" xlink:to="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_958" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_961" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_958" xlink:to="loc_srt_RangeAxis_961" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_960" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_961" xlink:to="loc_srt_RangeMember_960" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_993" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_958" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_993" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_956" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_993" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_956" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_1532" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_958" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_1532" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1533" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_1532" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1533" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaap_PrivatePlacementMember_1534" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1533" xlink:to="loc_us-gaap_PrivatePlacementMember_1534" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_999" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_958" xlink:to="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_999" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_957" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_999" xlink:to="loc_us-gaap_NetIncomeLoss_957" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_991" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_999" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_991" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_998" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_999" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_998" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_1004" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_999" xlink:to="loc_us-gaap_StockholdersEquity_1004" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_1007" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_999" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_1007" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperations" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperations_1011" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_999" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperations_1011" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_MaintainMinimumMarketValueOfListedSecurities" xlink:label="loc_pstv_MaintainMinimumMarketValueOfListedSecurities_1013" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_999" xlink:to="loc_pstv_MaintainMinimumMarketValueOfListedSecurities_1013" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="loc_us-gaap_WarrantsAndRightsOutstanding_1531" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_999" xlink:to="loc_us-gaap_WarrantsAndRightsOutstanding_1531" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/label" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://plus.com/role/FairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_451" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_458" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_451" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_458" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_455" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_458" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_455" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_452" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_455" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_452" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_460" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_452" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_460" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_462" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_458" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_462" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_459" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_462" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_459" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_454" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_459" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_454" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_464" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_458" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_464" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_456" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_464" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_456" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="loc_us-gaap_MoneyMarketFundsMember_457" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_456" xlink:to="loc_us-gaap_MoneyMarketFundsMember_457" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_1214" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_456" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_1214" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_465" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_458" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_465" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_453" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_465" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_453" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://plus.com/role/LossPerShareScheduleOfAntidilutiveSecuritiesExcludedFromDilutedIncomeLossPerShareDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_467" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_470" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_467" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_470" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_468" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_470" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_468" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_471" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_468" xlink:to="loc_us-gaap_EquityComponentDomain_471" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_OptionsMember" xlink:label="loc_pstv_OptionsMember_469" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_471" xlink:to="loc_pstv_OptionsMember_469" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaap_PreferredStockMember_474" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_471" xlink:to="loc_us-gaap_PreferredStockMember_474" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_475" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_471" xlink:to="loc_us-gaap_WarrantMember_475" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_473" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_470" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_473" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_472" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_473" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_472" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://plus.com/role/CompositionOfCertainFinancialStatementCaptionsOtherCurrentAssetsDetails">
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_CompositionOfCertainFinancialStatementCaptionsAbstract" xlink:label="loc_pstv_CompositionOfCertainFinancialStatementCaptionsAbstract_477" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_479" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pstv_CompositionOfCertainFinancialStatementCaptionsAbstract_477" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_479" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherPrepaidExpenseCurrent" xlink:label="loc_us-gaap_OtherPrepaidExpenseCurrent_478" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_479" xlink:to="loc_us-gaap_OtherPrepaidExpenseCurrent_478" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidInsurance" xlink:label="loc_us-gaap_PrepaidInsurance_480" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_479" xlink:to="loc_us-gaap_PrepaidInsurance_480" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaap_OtherAssetsCurrent_482" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_479" xlink:to="loc_us-gaap_OtherAssetsCurrent_482" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://plus.com/role/CompositionOfCertainFinancialStatementCaptionsPropertyAndEquipmentNetDetails">
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_CompositionOfCertainFinancialStatementCaptionsAbstract" xlink:label="loc_pstv_CompositionOfCertainFinancialStatementCaptionsAbstract_484" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNetAbstract_486" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pstv_CompositionOfCertainFinancialStatementCaptionsAbstract_484" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNetAbstract_486" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_OfficeAndComputerEquipmentGross" xlink:label="loc_pstv_OfficeAndComputerEquipmentGross_485" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNetAbstract_486" xlink:to="loc_pstv_OfficeAndComputerEquipmentGross_485" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdImprovementsGross" xlink:label="loc_us-gaap_LeaseholdImprovementsGross_487" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNetAbstract_486" xlink:to="loc_us-gaap_LeaseholdImprovementsGross_487" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_488" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNetAbstract_486" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_488" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_489" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNetAbstract_486" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_489" use="optional" order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_490" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNetAbstract_486" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_490" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://plus.com/role/CompositionOfCertainFinancialStatementCaptionsAdditionalInformationDetails">
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_CompositionOfCertainFinancialStatementCaptionsAbstract" xlink:label="loc_pstv_CompositionOfCertainFinancialStatementCaptionsAbstract_492" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation_493" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pstv_CompositionOfCertainFinancialStatementCaptionsAbstract_492" xlink:to="loc_us-gaap_Depreciation_493" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_494" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pstv_CompositionOfCertainFinancialStatementCaptionsAbstract_492" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_494" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://plus.com/role/CompositionOfCertainFinancialStatementCaptionsAccountsPayableAndAccruedExpensesDetails">
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_CompositionOfCertainFinancialStatementCaptionsAbstract" xlink:label="loc_pstv_CompositionOfCertainFinancialStatementCaptionsAbstract_496" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract_498" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pstv_CompositionOfCertainFinancialStatementCaptionsAbstract_496" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract_498" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_497" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract_498" xlink:to="loc_us-gaap_AccountsPayableCurrent_497" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedBonusesCurrent" xlink:label="loc_us-gaap_AccruedBonusesCurrent_499" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract_498" xlink:to="loc_us-gaap_AccruedBonusesCurrent_499" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_500" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract_498" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_500" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_AccruedVacationAndCompensationCurrent" xlink:label="loc_pstv_AccruedVacationAndCompensationCurrent_501" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract_498" xlink:to="loc_pstv_AccruedVacationAndCompensationCurrent_501" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_AccruedResearchAndDevelopmentStudies" xlink:label="loc_pstv_AccruedResearchAndDevelopmentStudies_503" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract_498" xlink:to="loc_pstv_AccruedResearchAndDevelopmentStudies_503" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_506" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract_498" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_506" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://plus.com/role/CommitmentsAndContingenciesAdditionalInformationDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_508" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RecordedUnconditionalPurchaseObligationTable" xlink:label="loc_us-gaap_RecordedUnconditionalPurchaseObligationTable_516" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_508" xlink:to="loc_us-gaap_RecordedUnconditionalPurchaseObligationTable_516" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_520" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RecordedUnconditionalPurchaseObligationTable_516" xlink:to="loc_srt_StatementGeographicalAxis_520" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_510" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_520" xlink:to="loc_srt_SegmentGeographicalDomain_510" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_526" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RecordedUnconditionalPurchaseObligationTable_516" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_526" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_518" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_526" xlink:to="loc_us-gaap_RelatedPartyDomain_518" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_CharlottesvilleMember" xlink:label="loc_pstv_CharlottesvilleMember_514" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_518" xlink:to="loc_pstv_CharlottesvilleMember_514" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_MedidataSolutionsIncMember" xlink:label="loc_pstv_MedidataSolutionsIncMember_524" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_518" xlink:to="loc_pstv_MedidataSolutionsIncMember_524" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_PiramalPharmaSolutionsIncMember" xlink:label="loc_pstv_PiramalPharmaSolutionsIncMember_527" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_518" xlink:to="loc_pstv_PiramalPharmaSolutionsIncMember_527" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_529" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RecordedUnconditionalPurchaseObligationTable_516" xlink:to="loc_us-gaap_TypeOfArrangementAxis_529" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_512" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_529" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_512" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_ServicesAgreementMember" xlink:label="loc_pstv_ServicesAgreementMember_509" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_512" xlink:to="loc_pstv_ServicesAgreementMember_509" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_531" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RecordedUnconditionalPurchaseObligationTable_516" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_531" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_519" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_531" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_519" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis" xlink:label="loc_us-gaap_RecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis_533" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RecordedUnconditionalPurchaseObligationTable_516" xlink:to="loc_us-gaap_RecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis_533" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain" xlink:label="loc_us-gaap_UnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain_522" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis_533" xlink:to="loc_us-gaap_UnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain_522" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_PreClinicalResearchStudyObligationsMember" xlink:label="loc_pstv_PreClinicalResearchStudyObligationsMember_523" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain_522" xlink:to="loc_pstv_PreClinicalResearchStudyObligationsMember_523" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_LitigationCaseAxis" xlink:label="loc_srt_LitigationCaseAxis_535" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RecordedUnconditionalPurchaseObligationTable_516" xlink:to="loc_srt_LitigationCaseAxis_535" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_LitigationCaseTypeDomain" xlink:label="loc_srt_LitigationCaseTypeDomain_517" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseAxis_535" xlink:to="loc_srt_LitigationCaseTypeDomain_517" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_LoremVascularPteLtdMember" xlink:label="loc_pstv_LoremVascularPteLtdMember_511" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_517" xlink:to="loc_pstv_LoremVascularPteLtdMember_511" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RecordedUnconditionalPurchaseObligationLineItems" xlink:label="loc_us-gaap_RecordedUnconditionalPurchaseObligationLineItems_537" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RecordedUnconditionalPurchaseObligationTable_516" xlink:to="loc_us-gaap_RecordedUnconditionalPurchaseObligationLineItems_537" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_OperatingLeasesExpiryYear" xlink:label="loc_pstv_OperatingLeasesExpiryYear_515" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RecordedUnconditionalPurchaseObligationLineItems_537" xlink:to="loc_pstv_OperatingLeasesExpiryYear_515" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_525" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RecordedUnconditionalPurchaseObligationLineItems_537" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_525" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:label="loc_us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend_528" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RecordedUnconditionalPurchaseObligationLineItems_537" xlink:to="loc_us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend_528" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:label="loc_us-gaap_LesseeOperatingLeaseOptionToExtend_530" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RecordedUnconditionalPurchaseObligationLineItems_537" xlink:to="loc_us-gaap_LesseeOperatingLeaseOptionToExtend_530" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_532" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RecordedUnconditionalPurchaseObligationLineItems_537" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_532" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_534" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RecordedUnconditionalPurchaseObligationLineItems_537" xlink:to="loc_us-gaap_OperatingLeaseLiability_534" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseDiscountRate" xlink:label="loc_us-gaap_LesseeOperatingLeaseDiscountRate_536" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RecordedUnconditionalPurchaseObligationLineItems_537" xlink:to="loc_us-gaap_LesseeOperatingLeaseDiscountRate_536" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_539" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RecordedUnconditionalPurchaseObligationLineItems_537" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_539" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseExpirationDate1" xlink:label="loc_us-gaap_LeaseExpirationDate1_540" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RecordedUnconditionalPurchaseObligationLineItems_537" xlink:to="loc_us-gaap_LeaseExpirationDate1_540" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_541" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RecordedUnconditionalPurchaseObligationLineItems_537" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_541" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_542" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RecordedUnconditionalPurchaseObligationLineItems_537" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_542" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseExpense" xlink:label="loc_us-gaap_OperatingLeaseExpense_545" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RecordedUnconditionalPurchaseObligationLineItems_537" xlink:to="loc_us-gaap_OperatingLeaseExpense_545" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_MasterServicesAgreementDate" xlink:label="loc_pstv_MasterServicesAgreementDate_546" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RecordedUnconditionalPurchaseObligationLineItems_537" xlink:to="loc_pstv_MasterServicesAgreementDate_546" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_MasterServicesAgreementInitialTerm" xlink:label="loc_pstv_MasterServicesAgreementInitialTerm_547" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RecordedUnconditionalPurchaseObligationLineItems_537" xlink:to="loc_pstv_MasterServicesAgreementInitialTerm_547" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_MasterServicesAgreementTermsDescription" xlink:label="loc_pstv_MasterServicesAgreementTermsDescription_548" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RecordedUnconditionalPurchaseObligationLineItems_537" xlink:to="loc_pstv_MasterServicesAgreementTermsDescription_548" use="optional" order="35" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractualObligation" xlink:label="loc_us-gaap_ContractualObligation_549" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RecordedUnconditionalPurchaseObligationLineItems_537" xlink:to="loc_us-gaap_ContractualObligation_549" use="optional" order="36" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_SalesOrderTerm" xlink:label="loc_pstv_SalesOrderTerm_550" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RecordedUnconditionalPurchaseObligationLineItems_537" xlink:to="loc_pstv_SalesOrderTerm_550" use="optional" order="37" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LitigationSettlementExpense" xlink:label="loc_us-gaap_LitigationSettlementExpense_553" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RecordedUnconditionalPurchaseObligationLineItems_537" xlink:to="loc_us-gaap_LitigationSettlementExpense_553" use="optional" order="38" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://plus.com/role/CommitmentsAndContingenciesSummaryOfLeaseCostsDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_555" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCostAbstract" xlink:label="loc_us-gaap_LeaseCostAbstract_556" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_555" xlink:to="loc_us-gaap_LeaseCostAbstract_556" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseCost" xlink:label="loc_us-gaap_OperatingLeaseCost_557" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseCostAbstract_556" xlink:to="loc_us-gaap_OperatingLeaseCost_557" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCost" xlink:label="loc_us-gaap_LeaseCost_560" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseCostAbstract_556" xlink:to="loc_us-gaap_LeaseCost_560" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_CashPaymentInformationAbstract" xlink:label="loc_pstv_CashPaymentInformationAbstract_559" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_555" xlink:to="loc_pstv_CashPaymentInformationAbstract_559" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasePayments" xlink:label="loc_us-gaap_OperatingLeasePayments_558" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pstv_CashPaymentInformationAbstract_559" xlink:to="loc_us-gaap_OperatingLeasePayments_558" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities" xlink:label="loc_pstv_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities_561" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pstv_CashPaymentInformationAbstract_559" xlink:to="loc_pstv_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities_561" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://plus.com/role/CommitmentsAndContingenciesSummaryOfFutureMinimumAnnualLeasePaymentsUnderOperatingLeasesDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_563" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_565" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_563" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_565" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_566" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_563" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_566" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_567" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_563" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_567" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_569" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_563" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_569" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_570" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_563" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_570" use="optional" order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_571" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_563" xlink:to="loc_us-gaap_OperatingLeaseLiability_571" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_572" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_563" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_572" use="optional" order="7" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_573" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_563" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_573" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://plus.com/role/LicenseAgreementsAdditionalInformationDetails">
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_LicenseAgreementAbstract" xlink:label="loc_pstv_LicenseAgreementAbstract_575" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_576" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pstv_LicenseAgreementAbstract_575" xlink:to="loc_us-gaap_StatementTable_576" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_579" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_576" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_579" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_577" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_579" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_577" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_BioceptAgreementMember" xlink:label="loc_pstv_BioceptAgreementMember_578" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_577" xlink:to="loc_pstv_BioceptAgreementMember_578" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_UTHSALicenseAgreementMember" xlink:label="loc_pstv_UTHSALicenseAgreementMember_581" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_577" xlink:to="loc_pstv_UTHSALicenseAgreementMember_581" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_NanoTxLicensesAgreementMember" xlink:label="loc_pstv_NanoTxLicensesAgreementMember_584" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_577" xlink:to="loc_pstv_NanoTxLicensesAgreementMember_584" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_582" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_576" xlink:to="loc_us-gaap_StatementLineItems_582" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaap_SharesIssued_580" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_582" xlink:to="loc_us-gaap_SharesIssued_580" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_583" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_582" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_583" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_PaymentForTechTransferAndValidationFee" xlink:label="loc_pstv_PaymentForTechTransferAndValidationFee_585" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_582" xlink:to="loc_pstv_PaymentForTechTransferAndValidationFee_585" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_OptionForExclusiveWorldwideLicense" xlink:label="loc_pstv_OptionForExclusiveWorldwideLicense_586" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_582" xlink:to="loc_pstv_OptionForExclusiveWorldwideLicense_586" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForRoyalties" xlink:label="loc_us-gaap_PaymentsForRoyalties_587" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_582" xlink:to="loc_us-gaap_PaymentsForRoyalties_587" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_588" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_582" xlink:to="loc_us-gaap_CommonStockValue_588" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_PercentageOfNonDilutiveMonetaryAwardsRequiredToPay" xlink:label="loc_pstv_PercentageOfNonDilutiveMonetaryAwardsRequiredToPay_589" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_582" xlink:to="loc_pstv_PercentageOfNonDilutiveMonetaryAwardsRequiredToPay_589" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_AccruedLicensePayable" xlink:label="loc_pstv_AccruedLicensePayable_590" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_582" xlink:to="loc_pstv_AccruedLicensePayable_590" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://plus.com/role/TermLoanObligationsAdditionalInformationDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_592" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_597" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_592" xlink:to="loc_us-gaap_DebtInstrumentTable_597" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_593" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_597" xlink:to="loc_us-gaap_DebtInstrumentAxis_593" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_612" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_593" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_612" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_TermLoanMember" xlink:label="loc_pstv_TermLoanMember_600" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_612" xlink:to="loc_pstv_TermLoanMember_600" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_607" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_597" xlink:to="loc_srt_RangeAxis_607" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_599" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_607" xlink:to="loc_srt_RangeMember_599" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_598" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_599" xlink:to="loc_srt_MinimumMember_598" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_608" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_599" xlink:to="loc_srt_MaximumMember_608" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateAxis" xlink:label="loc_us-gaap_VariableRateAxis_610" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_597" xlink:to="loc_us-gaap_VariableRateAxis_610" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateDomain" xlink:label="loc_us-gaap_VariableRateDomain_606" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateAxis_610" xlink:to="loc_us-gaap_VariableRateDomain_606" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_LiborMember" xlink:label="loc_pstv_LiborMember_603" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_606" xlink:to="loc_pstv_LiborMember_603" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember" xlink:label="loc_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember_1205" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_606" xlink:to="loc_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember_1205" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_613" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_597" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_613" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_596" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_613" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_596" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestRateFloorMember" xlink:label="loc_us-gaap_InterestRateFloorMember_594" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_596" xlink:to="loc_us-gaap_InterestRateFloorMember_594" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_615" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_597" xlink:to="loc_us-gaap_FinancialInstrumentAxis_615" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_602" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_615" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_602" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_LoanAndSecurityAgreementMember" xlink:label="loc_pstv_LoanAndSecurityAgreementMember_595" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_602" xlink:to="loc_pstv_LoanAndSecurityAgreementMember_595" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationAxis" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_617" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_597" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_617" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationDomain" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_605" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_617" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_605" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_SaleOfJapaneseSubsidiaryAndCertainAssetsMember" xlink:label="loc_pstv_SaleOfJapaneseSubsidiaryAndCertainAssetsMember_604" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_605" xlink:to="loc_pstv_SaleOfJapaneseSubsidiaryAndCertainAssetsMember_604" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_619" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_597" xlink:to="loc_us-gaap_DebtInstrumentLineItems_619" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentOfferingDate1" xlink:label="loc_us-gaap_DebtInstrumentOfferingDate1_601" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_619" xlink:to="loc_us-gaap_DebtInstrumentOfferingDate1_601" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_609" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_619" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_609" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_DebtInstrumentFloatingInterestRatePercentage" xlink:label="loc_pstv_DebtInstrumentFloatingInterestRatePercentage_611" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_619" xlink:to="loc_pstv_DebtInstrumentFloatingInterestRatePercentage_611" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_614" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_619" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_614" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="loc_us-gaap_DebtInstrumentMaturityDate_616" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_619" xlink:to="loc_us-gaap_DebtInstrumentMaturityDate_616" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFeeAmount" xlink:label="loc_us-gaap_DebtInstrumentFeeAmount_618" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_619" xlink:to="loc_us-gaap_DebtInstrumentFeeAmount_618" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_620" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_619" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_620" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_621" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_619" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_621" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_LongTermDebtOutstandingThresholdAmount" xlink:label="loc_pstv_LongTermDebtOutstandingThresholdAmount_624" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_619" xlink:to="loc_pstv_LongTermDebtOutstandingThresholdAmount_624" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense_626" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_619" xlink:to="loc_us-gaap_InterestExpense_626" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium_627" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_619" xlink:to="loc_us-gaap_AmortizationOfDebtDiscountPremium_627" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_1445" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_619" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_1445" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForLoans" xlink:label="loc_us-gaap_PaymentsForLoans_1490" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_619" xlink:to="loc_us-gaap_PaymentsForLoans_1490" use="optional" order="35" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_MinimumLiquidityCovenantAmount" xlink:label="loc_pstv_MinimumLiquidityCovenantAmount_1503" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_619" xlink:to="loc_pstv_MinimumLiquidityCovenantAmount_1503" use="optional" order="36" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_DebtPrincipalRepaymentStartDate" xlink:label="loc_pstv_DebtPrincipalRepaymentStartDate_1504" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_619" xlink:to="loc_pstv_DebtPrincipalRepaymentStartDate_1504" use="optional" order="37" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentCovenantCompliance" xlink:label="loc_us-gaap_DebtInstrumentCovenantCompliance_625" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_619" xlink:to="loc_us-gaap_DebtInstrumentCovenantCompliance_625" use="optional" order="38" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://plus.com/role/TermLoanObligationsTermLoanOutstandingDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_629" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_631" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_629" xlink:to="loc_us-gaap_DebtInstrumentTable_631" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_630" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_631" xlink:to="loc_us-gaap_DebtInstrumentAxis_630" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_637" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_630" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_637" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_TermLoanMember" xlink:label="loc_pstv_TermLoanMember_632" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_637" xlink:to="loc_pstv_TermLoanMember_632" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_635" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_631" xlink:to="loc_us-gaap_DebtInstrumentLineItems_635" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_AdditionalDetailsRelatingTermLoanThatIsOutstandingAbstract" xlink:label="loc_pstv_AdditionalDetailsRelatingTermLoanThatIsOutstandingAbstract_633" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_635" xlink:to="loc_pstv_AdditionalDetailsRelatingTermLoanThatIsOutstandingAbstract_633" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentOfferingDate1" xlink:label="loc_us-gaap_DebtInstrumentOfferingDate1_634" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pstv_AdditionalDetailsRelatingTermLoanThatIsOutstandingAbstract_633" xlink:to="loc_us-gaap_DebtInstrumentOfferingDate1_634" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_636" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pstv_AdditionalDetailsRelatingTermLoanThatIsOutstandingAbstract_633" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_636" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_638" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pstv_AdditionalDetailsRelatingTermLoanThatIsOutstandingAbstract_633" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_638" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentPeriodicPayment" xlink:label="loc_us-gaap_DebtInstrumentPeriodicPayment_639" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pstv_AdditionalDetailsRelatingTermLoanThatIsOutstandingAbstract_633" xlink:to="loc_us-gaap_DebtInstrumentPeriodicPayment_639" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_DebtInstrumentAmendedExpirationDate" xlink:label="loc_pstv_DebtInstrumentAmendedExpirationDate_640" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pstv_AdditionalDetailsRelatingTermLoanThatIsOutstandingAbstract_633" xlink:to="loc_pstv_DebtInstrumentAmendedExpirationDate_640" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_641" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pstv_AdditionalDetailsRelatingTermLoanThatIsOutstandingAbstract_633" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_641" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://plus.com/role/GrantRevenueAdditionalInformationDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_657" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_661" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_657" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_661" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_662" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_661" xlink:to="loc_us-gaap_TypeOfArrangementAxis_662" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_659" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_662" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_659" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_CancerPreventionAndResearchInstituteOfTexasContractMember" xlink:label="loc_pstv_CancerPreventionAndResearchInstituteOfTexasContractMember_658" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_659" xlink:to="loc_pstv_CancerPreventionAndResearchInstituteOfTexasContractMember_658" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_665" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_661" xlink:to="loc_srt_ProductOrServiceAxis_665" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_663" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_665" xlink:to="loc_srt_ProductsAndServicesDomain_663" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GrantMember" xlink:label="loc_us-gaap_GrantMember_660" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_663" xlink:to="loc_us-gaap_GrantMember_660" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_1210" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_661" xlink:to="loc_srt_RangeAxis_1210" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_1140" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_1210" xlink:to="loc_srt_RangeMember_1140" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_667" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_661" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_667" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_MaximumGrantAmountToBeReceivedAsPerGrantContract" xlink:label="loc_pstv_MaximumGrantAmountToBeReceivedAsPerGrantContract_664" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_667" xlink:to="loc_pstv_MaximumGrantAmountToBeReceivedAsPerGrantContract_664" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_GrantFundingTerm" xlink:label="loc_pstv_GrantFundingTerm_666" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_667" xlink:to="loc_pstv_GrantFundingTerm_666" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_CpritGrantFundingTerm" xlink:label="loc_pstv_CpritGrantFundingTerm_668" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_667" xlink:to="loc_pstv_CpritGrantFundingTerm_668" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_ContractEffectiveDate" xlink:label="loc_pstv_ContractEffectiveDate_669" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_667" xlink:to="loc_pstv_ContractEffectiveDate_669" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_ContractTerminationDate" xlink:label="loc_pstv_ContractTerminationDate_670" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_667" xlink:to="loc_pstv_ContractTerminationDate_670" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_PercentageOfAggregateAmountOfProceedsAwardedUnderCpritGrant" xlink:label="loc_pstv_PercentageOfAggregateAmountOfProceedsAwardedUnderCpritGrant_671" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_667" xlink:to="loc_pstv_PercentageOfAggregateAmountOfProceedsAwardedUnderCpritGrant_671" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_PercentageOfGrantProceedsWithInterestNotExceedAnnually" xlink:label="loc_pstv_PercentageOfGrantProceedsWithInterestNotExceedAnnually_672" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_667" xlink:to="loc_pstv_PercentageOfGrantProceedsWithInterestNotExceedAnnually_672" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_673" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_667" xlink:to="loc_us-gaap_Revenues_673" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_ReimbursementCostsIncurred" xlink:label="loc_pstv_ReimbursementCostsIncurred_674" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_667" xlink:to="loc_pstv_ReimbursementCostsIncurred_674" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_IncreaseDecreaseInGrantRevenue" xlink:label="loc_pstv_IncreaseDecreaseInGrantRevenue_675" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_667" xlink:to="loc_pstv_IncreaseDecreaseInGrantRevenue_675" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://plus.com/role/IncomeTaxesAdditionalInformationDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_677" />
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_IncomeTaxesTable" xlink:label="loc_pstv_IncomeTaxesTable_687" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_677" xlink:to="loc_pstv_IncomeTaxesTable_687" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_679" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pstv_IncomeTaxesTable_687" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_679" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_686" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_679" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_686" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DomesticCountryMember" xlink:label="loc_us-gaap_DomesticCountryMember_682" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_686" xlink:to="loc_us-gaap_DomesticCountryMember_682" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_691" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_686" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_691" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_689" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pstv_IncomeTaxesTable_687" xlink:to="loc_srt_RangeAxis_689" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_681" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_689" xlink:to="loc_srt_RangeMember_681" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_680" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_681" xlink:to="loc_srt_MaximumMember_680" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityNameAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameAxis_693" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pstv_IncomeTaxesTable_687" xlink:to="loc_us-gaap_IncomeTaxAuthorityNameAxis_693" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityNameDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameDomain_683" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameAxis_693" xlink:to="loc_us-gaap_IncomeTaxAuthorityNameDomain_683" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_IncomeTaxesLineItems" xlink:label="loc_pstv_IncomeTaxesLineItems_695" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pstv_IncomeTaxesTable_687" xlink:to="loc_pstv_IncomeTaxesLineItems_695" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_684" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pstv_IncomeTaxesLineItems_695" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_684" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_IncomeTaxContingencyAbstract" xlink:label="loc_pstv_IncomeTaxContingencyAbstract_692" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pstv_IncomeTaxesLineItems_695" xlink:to="loc_pstv_IncomeTaxContingencyAbstract_692" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_DeferredTaxAssetsValuationAllowances" xlink:label="loc_pstv_DeferredTaxAssetsValuationAllowances_678" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pstv_IncomeTaxContingencyAbstract_692" xlink:to="loc_pstv_DeferredTaxAssetsValuationAllowances_678" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_688" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pstv_IncomeTaxContingencyAbstract_692" xlink:to="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_688" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaap_OperatingLossCarryforwards_694" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pstv_IncomeTaxesLineItems_695" xlink:to="loc_us-gaap_OperatingLossCarryforwards_694" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_OperatingLossCarryforwardsExpirationDates1" xlink:label="loc_pstv_OperatingLossCarryforwardsExpirationDates1_696" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pstv_IncomeTaxesLineItems_695" xlink:to="loc_pstv_OperatingLossCarryforwardsExpirationDates1_696" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_697" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pstv_IncomeTaxesLineItems_695" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_697" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_698" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pstv_IncomeTaxesLineItems_695" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_698" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_TaxCreditCarryforwardExpirationDate1" xlink:label="loc_pstv_TaxCreditCarryforwardExpirationDate1_699" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pstv_IncomeTaxesLineItems_695" xlink:to="loc_pstv_TaxCreditCarryforwardExpirationDate1_699" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_NetOperatingLossCarryforward" xlink:label="loc_pstv_NetOperatingLossCarryforward_700" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pstv_IncomeTaxesLineItems_695" xlink:to="loc_pstv_NetOperatingLossCarryforward_700" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_PercentageOfNetOperatingLossCarryforwardsAvailableForOffsettingAgainstFutureTaxableIncome" xlink:label="loc_pstv_PercentageOfNetOperatingLossCarryforwardsAvailableForOffsettingAgainstFutureTaxableIncome_701" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pstv_IncomeTaxesLineItems_695" xlink:to="loc_pstv_PercentageOfNetOperatingLossCarryforwardsAvailableForOffsettingAgainstFutureTaxableIncome_701" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_CumulativeChangeInOwnership" xlink:label="loc_pstv_CumulativeChangeInOwnership_702" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pstv_IncomeTaxesLineItems_695" xlink:to="loc_pstv_CumulativeChangeInOwnership_702" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_NetOperatingLossAndResearchAndDevelopmentTaxCreditCarryForwardsToOffsetFutureTaxableIncomePeriod" xlink:label="loc_pstv_NetOperatingLossAndResearchAndDevelopmentTaxCreditCarryForwardsToOffsetFutureTaxableIncomePeriod_703" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pstv_IncomeTaxesLineItems_695" xlink:to="loc_pstv_NetOperatingLossAndResearchAndDevelopmentTaxCreditCarryForwardsToOffsetFutureTaxableIncomePeriod_703" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilityForUncertainTaxPositionsCurrent" xlink:label="loc_us-gaap_LiabilityForUncertainTaxPositionsCurrent_704" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pstv_IncomeTaxesLineItems_695" xlink:to="loc_us-gaap_LiabilityForUncertainTaxPositionsCurrent_704" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_PeriodForMaterialChangesOfLiabilityForUncertainTaxBenefits" xlink:label="loc_pstv_PeriodForMaterialChangesOfLiabilityForUncertainTaxBenefits_705" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pstv_IncomeTaxesLineItems_695" xlink:to="loc_pstv_PeriodForMaterialChangesOfLiabilityForUncertainTaxBenefits_705" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_706" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pstv_IncomeTaxesLineItems_695" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_706" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://plus.com/role/IncomeTaxesReconciliationOfTotalIncomeTaxProvisionDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_708" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_710" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_708" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_710" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_709" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_710" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_709" use="optional" order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_711" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_710" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_711" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_712" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_710" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_712" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_713" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_710" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_713" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_EffectiveIncomeTaxRateReconciliationNetOperatingLossExpiration" xlink:label="loc_pstv_EffectiveIncomeTaxRateReconciliationNetOperatingLossExpiration_714" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_710" xlink:to="loc_pstv_EffectiveIncomeTaxRateReconciliationNetOperatingLossExpiration_714" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_715" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_710" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_715" use="optional" order="7" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_EffectiveIncomeTaxRateReconciliationTaxReturnToProvision" xlink:label="loc_pstv_EffectiveIncomeTaxRateReconciliationTaxReturnToProvision_716" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_710" xlink:to="loc_pstv_EffectiveIncomeTaxRateReconciliationTaxReturnToProvision_716" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlementsStateAndLocal" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlementsStateAndLocal_717" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_710" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlementsStateAndLocal_717" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_718" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_710" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_718" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://plus.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_720" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_724" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_720" xlink:to="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_724" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_723" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_724" xlink:to="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_723" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_722" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_723" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_722" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_726" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_723" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_726" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_728" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_723" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_728" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_730" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_723" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_730" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:label="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_731" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_723" xlink:to="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_731" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:label="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_732" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_723" xlink:to="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_732" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_733" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_723" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_733" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_734" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_723" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_734" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_735" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_723" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_735" use="optional" order="11" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_736" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_723" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_736" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_727" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_724" xlink:to="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_727" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesOther" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesOther_721" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_727" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesOther_721" use="optional" order="14" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_725" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_727" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_725" use="optional" order="15" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="loc_us-gaap_DeferredTaxLiabilities_729" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_724" xlink:to="loc_us-gaap_DeferredTaxLiabilities_729" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://plus.com/role/IncomeTaxesUnrecognizedTaxBenefitsActivityDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_738" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:label="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_740" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_738" xlink:to="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_740" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_739" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_740" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_739" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_741" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_740" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_741" use="optional" order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_742" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_740" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_742" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_743" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_740" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_743" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://plus.com/role/EmployeeBenefitPlanAdditionalInformationDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_745" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanTable" xlink:label="loc_us-gaap_DefinedContributionPlanTable_746" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_745" xlink:to="loc_us-gaap_DefinedContributionPlanTable_746" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_750" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedContributionPlanTable_746" xlink:to="loc_srt_RangeAxis_750" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_748" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_750" xlink:to="loc_srt_RangeMember_748" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_751" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_748" xlink:to="loc_srt_MaximumMember_751" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:label="loc_us-gaap_DefinedContributionPlanDisclosureLineItems_753" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedContributionPlanTable_746" xlink:to="loc_us-gaap_DefinedContributionPlanDisclosureLineItems_753" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_749" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedContributionPlanDisclosureLineItems_753" xlink:to="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_749" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_752" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedContributionPlanDisclosureLineItems_753" xlink:to="loc_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_752" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://plus.com/role/StockholdersEquityPreferredStockDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_755" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_759" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_755" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_759" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_756" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_759" xlink:to="loc_us-gaap_StatementClassOfStockAxis_756" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_769" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_756" xlink:to="loc_us-gaap_ClassOfStockDomain_769" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_SeriesFConvertiblePreferredStockMember" xlink:label="loc_pstv_SeriesFConvertiblePreferredStockMember_758" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_769" xlink:to="loc_pstv_SeriesFConvertiblePreferredStockMember_758" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_SeriesBConvertiblePreferredStockMember" xlink:label="loc_pstv_SeriesBConvertiblePreferredStockMember_768" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_769" xlink:to="loc_pstv_SeriesBConvertiblePreferredStockMember_768" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_SeriesCConvertiblePreferredStockMember" xlink:label="loc_pstv_SeriesCConvertiblePreferredStockMember_773" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_769" xlink:to="loc_pstv_SeriesCConvertiblePreferredStockMember_773" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_763" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_759" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_763" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_770" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_763" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_770" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_TwoThousandEighteenRightsOfferingMember" xlink:label="loc_pstv_TwoThousandEighteenRightsOfferingMember_762" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_770" xlink:to="loc_pstv_TwoThousandEighteenRightsOfferingMember_762" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_766" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_759" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_766" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_760" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_766" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_760" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_SubscriptionAgreementMember" xlink:label="loc_pstv_SubscriptionAgreementMember_761" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_760" xlink:to="loc_pstv_SubscriptionAgreementMember_761" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_771" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_759" xlink:to="loc_us-gaap_ClassOfStockLineItems_771" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_757" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_771" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_757" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_764" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_771" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_764" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_NumberOfVotesPerShare" xlink:label="loc_pstv_NumberOfVotesPerShare_767" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_771" xlink:to="loc_pstv_NumberOfVotesPerShare_767" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_772" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_771" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_772" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_774" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_771" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_774" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_775" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_771" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_775" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockTransactionDate" xlink:label="loc_us-gaap_SaleOfStockTransactionDate_776" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_771" xlink:to="loc_us-gaap_SaleOfStockTransactionDate_776" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockVotingRights" xlink:label="loc_us-gaap_PreferredStockVotingRights_777" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_771" xlink:to="loc_us-gaap_PreferredStockVotingRights_777" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_RightsRelatedToDistributionOfAssets" xlink:label="loc_pstv_RightsRelatedToDistributionOfAssets_778" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_771" xlink:to="loc_pstv_RightsRelatedToDistributionOfAssets_778" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_ConsiderationPaidToPreferredStockHolders" xlink:label="loc_pstv_ConsiderationPaidToPreferredStockHolders_779" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_771" xlink:to="loc_pstv_ConsiderationPaidToPreferredStockHolders_779" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_780" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_771" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_780" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_NumberOfPreferredStockSharesExercised" xlink:label="loc_pstv_NumberOfPreferredStockSharesExercised_783" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_771" xlink:to="loc_pstv_NumberOfPreferredStockSharesExercised_783" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://plus.com/role/StockholdersEquityWarrantsDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_785" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_790" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_785" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_790" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_786" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_790" xlink:to="loc_us-gaap_StatementClassOfStockAxis_786" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_799" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_786" xlink:to="loc_us-gaap_ClassOfStockDomain_799" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassAMember" xlink:label="loc_us-gaap_CommonClassAMember_788" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_799" xlink:to="loc_us-gaap_CommonClassAMember_788" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassBMember" xlink:label="loc_us-gaap_CommonClassBMember_795" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_799" xlink:to="loc_us-gaap_CommonClassBMember_795" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_793" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_790" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_793" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_791" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_793" xlink:to="loc_us-gaap_EquityComponentDomain_791" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_RepresentativeSeriesUWarrantMember" xlink:label="loc_pstv_RepresentativeSeriesUWarrantMember_789" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_791" xlink:to="loc_pstv_RepresentativeSeriesUWarrantMember_789" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_796" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_791" xlink:to="loc_us-gaap_CommonStockMember_796" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_800" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_791" xlink:to="loc_us-gaap_WarrantMember_800" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_797" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_790" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_797" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_801" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_797" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_801" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_SeriesUWarrantsMember" xlink:label="loc_pstv_SeriesUWarrantsMember_792" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_801" xlink:to="loc_pstv_SeriesUWarrantsMember_792" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_802" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_790" xlink:to="loc_us-gaap_ClassOfStockLineItems_802" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_787" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_802" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_787" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_794" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_802" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_794" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_798" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_802" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_798" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm_803" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_802" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingTerm_803" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_804" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_802" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_804" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_805" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_802" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_805" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_NumberOfWarrantsExercised" xlink:label="loc_pstv_NumberOfWarrantsExercised_806" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_802" xlink:to="loc_pstv_NumberOfWarrantsExercised_806" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://plus.com/role/StockholdersEquityCommonStockDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_808" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_818" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_808" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_818" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeAxis" xlink:label="loc_us-gaap_InvestmentTypeAxis_809" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_818" xlink:to="loc_us-gaap_InvestmentTypeAxis_809" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_823" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeAxis_809" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_823" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_TwoThousandAndTwentyTwoPurchaseAgreementMember" xlink:label="loc_pstv_TwoThousandAndTwentyTwoPurchaseAgreementMember_835" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_823" xlink:to="loc_pstv_TwoThousandAndTwentyTwoPurchaseAgreementMember_835" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_TwentyTwentyPurchaseAgreementMember" xlink:label="loc_pstv_TwentyTwentyPurchaseAgreementMember_838" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_823" xlink:to="loc_pstv_TwentyTwentyPurchaseAgreementMember_838" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_SeptemberTwoThousandAndTwentyTwoDistributionAgreementMember" xlink:label="loc_pstv_SeptemberTwoThousandAndTwentyTwoDistributionAgreementMember_841" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_823" xlink:to="loc_pstv_SeptemberTwoThousandAndTwentyTwoDistributionAgreementMember_841" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_JanuaryTwoThousandAndTwentyTwoDistributionAgreementMember" xlink:label="loc_pstv_JanuaryTwoThousandAndTwentyTwoDistributionAgreementMember_847" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_823" xlink:to="loc_pstv_JanuaryTwoThousandAndTwentyTwoDistributionAgreementMember_847" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_826" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_818" xlink:to="loc_dei_LegalEntityAxis_826" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_834" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_826" xlink:to="loc_dei_EntityDomain_834" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_LincolnParkCapitalFundLLCMember" xlink:label="loc_pstv_LincolnParkCapitalFundLLCMember_815" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_834" xlink:to="loc_pstv_LincolnParkCapitalFundLLCMember_815" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_CanaccordGenuityLLCMember" xlink:label="loc_pstv_CanaccordGenuityLLCMember_828" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_834" xlink:to="loc_pstv_CanaccordGenuityLLCMember_828" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_831" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_818" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_831" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_819" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_831" xlink:to="loc_us-gaap_EquityComponentDomain_819" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_814" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_819" xlink:to="loc_us-gaap_CommonStockMember_814" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_836" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_818" xlink:to="loc_srt_RangeAxis_836" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_817" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_836" xlink:to="loc_srt_RangeMember_817" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_816" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_817" xlink:to="loc_srt_MinimumMember_816" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_829" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_817" xlink:to="loc_srt_MaximumMember_829" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_839" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_818" xlink:to="loc_us-gaap_FinancialInstrumentAxis_839" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_822" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_839" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_822" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_842" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_818" xlink:to="loc_us-gaap_StatementClassOfStockAxis_842" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_833" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_842" xlink:to="loc_us-gaap_ClassOfStockDomain_833" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_845" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_818" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_845" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_811" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_845" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_811" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_824" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_811" xlink:to="loc_us-gaap_SubsequentEventMember_824" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_848" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_818" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_848" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_820" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_848" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_820" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_AtTheMarketOfferingProgramMember" xlink:label="loc_pstv_AtTheMarketOfferingProgramMember_821" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_820" xlink:to="loc_pstv_AtTheMarketOfferingProgramMember_821" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_851" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_818" xlink:to="loc_us-gaap_ClassOfStockLineItems_851" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_MaximumValueOfSharesToBeIssuedUnderAgreement" xlink:label="loc_pstv_MaximumValueOfSharesToBeIssuedUnderAgreement_810" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_851" xlink:to="loc_pstv_MaximumValueOfSharesToBeIssuedUnderAgreement_810" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_827" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_851" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_827" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_832" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_851" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_832" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_837" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_851" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_837" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_PeriodExercisableFromTheDateOfIssuance" xlink:label="loc_pstv_PeriodExercisableFromTheDateOfIssuance_840" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_851" xlink:to="loc_pstv_PeriodExercisableFromTheDateOfIssuance_840" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_NumberOfMaximumCommonSharesCanBeResale" xlink:label="loc_pstv_NumberOfMaximumCommonSharesCanBeResale_843" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_851" xlink:to="loc_pstv_NumberOfMaximumCommonSharesCanBeResale_843" use="optional" order="35" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_846" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_851" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_846" use="optional" order="36" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_InitialCommitmentShares" xlink:label="loc_pstv_InitialCommitmentShares_849" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_851" xlink:to="loc_pstv_InitialCommitmentShares_849" use="optional" order="37" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_InitialCommitmentFee" xlink:label="loc_pstv_InitialCommitmentFee_852" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_851" xlink:to="loc_pstv_InitialCommitmentFee_852" use="optional" order="38" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_PercentageIssuanceOfCommonStock" xlink:label="loc_pstv_PercentageIssuanceOfCommonStock_853" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_851" xlink:to="loc_pstv_PercentageIssuanceOfCommonStock_853" use="optional" order="39" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_GrossProceedsFromIssuanceOfCommonStock" xlink:label="loc_pstv_GrossProceedsFromIssuanceOfCommonStock_854" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_851" xlink:to="loc_pstv_GrossProceedsFromIssuanceOfCommonStock_854" use="optional" order="40" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_855" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_851" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_855" use="optional" order="41" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaap_SharesIssued_856" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_851" xlink:to="loc_us-gaap_SharesIssued_856" use="optional" order="42" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_AggregateExpenseIncludingFeeAndDisbursementExpenses" xlink:label="loc_pstv_AggregateExpenseIncludingFeeAndDisbursementExpenses_857" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_851" xlink:to="loc_pstv_AggregateExpenseIncludingFeeAndDisbursementExpenses_857" use="optional" order="43" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_PercentageOfCommissionOnGrossProceedsFromSaleOfCommonStock" xlink:label="loc_pstv_PercentageOfCommissionOnGrossProceedsFromSaleOfCommonStock_858" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_851" xlink:to="loc_pstv_PercentageOfCommissionOnGrossProceedsFromSaleOfCommonStock_858" use="optional" order="44" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_859" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_851" xlink:to="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_859" use="optional" order="45" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRepurchasedDuringPeriodShares" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodShares_860" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_851" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodShares_860" use="optional" order="46" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_CommonStockSalesAvailableForIssuance" xlink:label="loc_pstv_CommonStockSalesAvailableForIssuance_861" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_851" xlink:to="loc_pstv_CommonStockSalesAvailableForIssuance_861" use="optional" order="47" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockValue" xlink:label="loc_us-gaap_TreasuryStockValue_862" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_851" xlink:to="loc_us-gaap_TreasuryStockValue_862" use="optional" order="48" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:label="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_1523" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_851" xlink:to="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_1523" use="optional" order="49" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://plus.com/role/StockBasedCompensationAdditionalInformationDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_864" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_871" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_864" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_871" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_870" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_871" xlink:to="loc_us-gaap_PlanNameAxis_870" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_866" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_870" xlink:to="loc_us-gaap_PlanNameDomain_866" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_StockBasedCompensation2015EquityIncentivePlan1Member" xlink:label="loc_pstv_StockBasedCompensation2015EquityIncentivePlan1Member_865" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_866" xlink:to="loc_pstv_StockBasedCompensation2015EquityIncentivePlan1Member_865" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_StockBasedCompensation2020EquityIncentivePlanMember" xlink:label="loc_pstv_StockBasedCompensation2020EquityIncentivePlanMember_872" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_866" xlink:to="loc_pstv_StockBasedCompensation2020EquityIncentivePlanMember_872" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_875" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_871" xlink:to="loc_srt_RangeAxis_875" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_869" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_875" xlink:to="loc_srt_RangeMember_869" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_868" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_869" xlink:to="loc_srt_MinimumMember_868" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_874" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_869" xlink:to="loc_srt_MaximumMember_874" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_877" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_871" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_877" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_867" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_877" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_867" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_873" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_877" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_873" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_876" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_877" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_876" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_878" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_877" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_878" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_879" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_877" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_879" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_880" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_877" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_880" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend_881" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_877" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend_881" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_882" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_877" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_882" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_883" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_877" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_883" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://plus.com/role/StockBasedCompensationStockOptionActivityDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_885" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_890" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_885" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_890" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_888" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_890" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_888" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_893" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_890" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_893" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_898" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_890" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_898" use="optional" order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_902" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_890" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_902" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_906" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_890" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_906" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_908" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_890" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_908" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_895" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_885" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_895" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_887" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_895" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_887" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_892" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_895" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_892" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_897" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_895" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_897" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_901" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_895" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_901" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_905" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_895" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_905" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_907" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_895" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_907" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_900" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_885" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_900" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_886" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_900" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_886" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_891" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_900" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_891" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_896" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_900" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_896" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" xlink:label="loc_pstv_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_904" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_885" xlink:to="loc_pstv_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_904" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_889" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pstv_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_904" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_889" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_1312" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pstv_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_904" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_1312" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_899" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pstv_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_904" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_899" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://plus.com/role/StockBasedCompensationWeightedAverageAssumptionsDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_910" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_912" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_910" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_912" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_911" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_912" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_911" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_913" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_912" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_913" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_914" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_912" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_914" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_915" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_912" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_915" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_916" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_912" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_916" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://plus.com/role/StockBasedCompensationSummaryOfShareBasedCompensationRecognizedDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_918" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_921" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_918" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_921" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_920" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_921" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_920" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_922" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_920" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_922" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_923" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_922" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_923" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_925" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_922" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_925" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_924" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_921" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_924" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_919" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_924" xlink:to="loc_us-gaap_ShareBasedCompensation_919" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://plus.com/role/SubsequentEventsAdditionalInformationDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract_927" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaap_SubsequentEventTable_930" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_927" xlink:to="loc_us-gaap_SubsequentEventTable_930" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_935" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_930" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_935" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_928" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_935" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_928" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_933" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_928" xlink:to="loc_us-gaap_SubsequentEventMember_933" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeAxis" xlink:label="loc_us-gaap_InvestmentTypeAxis_937" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_930" xlink:to="loc_us-gaap_InvestmentTypeAxis_937" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_932" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeAxis_937" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_932" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_938" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_930" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_938" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_931" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_938" xlink:to="loc_us-gaap_EquityComponentDomain_931" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityAxis" xlink:label="loc_us-gaap_CreditFacilityAxis_1544" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_930" xlink:to="loc_us-gaap_CreditFacilityAxis_1544" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaap_CreditFacilityDomain_1545" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_1544" xlink:to="loc_us-gaap_CreditFacilityDomain_1545" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_PershingCreditFacilityMember" xlink:label="loc_pstv_PershingCreditFacilityMember_1546" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_1545" xlink:to="loc_pstv_PershingCreditFacilityMember_1546" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_1551" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_930" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_1551" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1552" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_1551" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1552" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_May2024PrivatePlacementMember" xlink:label="loc_pstv_May2024PrivatePlacementMember_1553" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1552" xlink:to="loc_pstv_May2024PrivatePlacementMember_1553" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaap_PrivatePlacementMember_1558" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1552" xlink:to="loc_us-gaap_PrivatePlacementMember_1558" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_PreFundedWarrantMember" xlink:label="loc_pstv_PreFundedWarrantMember_1559" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1552" xlink:to="loc_pstv_PreFundedWarrantMember_1559" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_1554" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_930" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_1554" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_1555" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_1554" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_1555" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_SeriesAWarrantMember" xlink:label="loc_pstv_SeriesAWarrantMember_1556" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1555" xlink:to="loc_pstv_SeriesAWarrantMember_1556" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_SeriesBWarrantMember" xlink:label="loc_pstv_SeriesBWarrantMember_1557" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1555" xlink:to="loc_pstv_SeriesBWarrantMember_1557" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionAxis" xlink:label="loc_us-gaap_AssetAcquisitionAxis_1560" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_930" xlink:to="loc_us-gaap_AssetAcquisitionAxis_1560" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionDomain" xlink:label="loc_us-gaap_AssetAcquisitionDomain_1561" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionAxis_1560" xlink:to="loc_us-gaap_AssetAcquisitionDomain_1561" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_BioceptAssetPurchaseMember" xlink:label="loc_pstv_BioceptAssetPurchaseMember_1562" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionDomain_1561" xlink:to="loc_pstv_BioceptAssetPurchaseMember_1562" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaap_SubsequentEventLineItems_939" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_930" xlink:to="loc_us-gaap_SubsequentEventLineItems_939" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_1537" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_939" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_1537" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityPeriodicPayment" xlink:label="loc_us-gaap_LineOfCreditFacilityPeriodicPayment_1538" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_939" xlink:to="loc_us-gaap_LineOfCreditFacilityPeriodicPayment_1538" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_1539" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_939" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_1539" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_1540" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_939" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_1540" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_1541" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_939" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_1541" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:label="loc_us-gaap_DebtInstrumentInterestRateDuringPeriod_1542" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_939" xlink:to="loc_us-gaap_DebtInstrumentInterestRateDuringPeriod_1542" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityInterestRateDuringPeriod" xlink:label="loc_us-gaap_LineOfCreditFacilityInterestRateDuringPeriod_1543" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_939" xlink:to="loc_us-gaap_LineOfCreditFacilityInterestRateDuringPeriod_1543" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_1547" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_939" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_1547" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_1548" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_939" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_1548" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_ClassOfWarrantOrRightPurchasePrice" xlink:label="loc_pstv_ClassOfWarrantOrRightPurchasePrice_1549" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_939" xlink:to="loc_pstv_ClassOfWarrantOrRightPurchasePrice_1549" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireProductiveAssets" xlink:label="loc_us-gaap_PaymentsToAcquireProductiveAssets_1550" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_939" xlink:to="loc_us-gaap_PaymentsToAcquireProductiveAssets_1550" use="optional" order="35" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_ClassOfWarrantOrRightOfferingPrice" xlink:label="loc_pstv_ClassOfWarrantOrRightOfferingPrice_1563" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_939" xlink:to="loc_pstv_ClassOfWarrantOrRightOfferingPrice_1563" use="optional" order="36" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_ClassOfWarrantOrRightExercisePriceInitialSubscription" xlink:label="loc_pstv_ClassOfWarrantOrRightExercisePriceInitialSubscription_1564" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_939" xlink:to="loc_pstv_ClassOfWarrantOrRightExercisePriceInitialSubscription_1564" use="optional" order="37" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="pstv-20240331.xsd#pstv_ClassOfWarrantOrRightExercisePriceAdditionalSubscription" xlink:label="loc_pstv_ClassOfWarrantOrRightExercisePriceAdditionalSubscription_1565" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_939" xlink:to="loc_pstv_ClassOfWarrantOrRightExercisePriceAdditionalSubscription_1565" use="optional" order="38" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_1566" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_939" xlink:to="loc_us-gaap_SharesIssuedPricePerShare_1566" use="optional" order="39" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="loc_us-gaap_WarrantsAndRightsOutstanding_1567" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_939" xlink:to="loc_us-gaap_WarrantsAndRightsOutstanding_1567" use="optional" order="40" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>g840996g01a00.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g840996g01a00.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1B\4&AO=&]S:&]P(#,N,  X0DE-! 0
M    &*"^8P0X0DE-! 0      !<< 5H  QLE1QP!6@ #&R5'' (   +_OP X
M0DE-!"4      !#)5YQ?M(B@TK&EM/[84/JV.$))300Z      #E    $
M  $       MP<FEN=$]U='!U=     4     4'-T4V)O;VP!     $EN=&5E
M;G5M     $EN=&4     0VQR;0    ]P<FEN=%-I>'1E96Y":71B;V]L
M  MP<FEN=&5R3F%M951%6%0    !       /<')I;G10<F]O9E-E='5P3V)J
M8P    P 4 !R &\ ;P!F "  4P!E '0 =0!P       *<')O;V93971U<
M  $     0FQT;F5N=6T    ,8G5I;'1I;E!R;V]F    "7!R;V]F0TU92P X
M0DE-!#L      BT    0     0      $G!R:6YT3W5T<'5T3W!T:6]N<P
M !<     0W!T;F)O;VP      $-L8G)B;V]L      !29W--8F]O;
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M4'AL0'+            *=F5C=&]R1&%T86)O;VP!     %!G4'-E;G5M
M %!G4',     4&=00P    !,969T56YT1B-2;'0               !4;W @
M56YT1B-2;'0               !38VP@56YT1B-0<F- 60           !!C
M<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T;VUL;VYG
M      QC<F]P4F5C=$QE9G1L;VYG          UC<F]P4F5C=%)I9VAT;&]N
M9P         +8W)O<%)E8W14;W!L;VYG       X0DE- ^T      ! #O_XU
M  (  @.__C4  @ ".$))300F       .             #^    X0DE-! T
M      0    >.$))3009       $    'CA"24T#\P      "0
M 0 X0DE-)Q        H  0         ".$))30/U      !( "]F9@ ! &QF
M9@ &       ! "]F9@ ! *&9F@ &       ! #(    ! %H    &       !
M #4    ! "T    &       !.$))30/X      !P  #_________________
M____________ ^@     _____________________________P/H     /__
M__________________________\#Z     #_________________________
M____ ^@  #A"24T$"       $     $   )    "0      X0DE-!!X
M  0     .$))300:      ,U    !@             !!@   O4
M 0                         !              +U   !!@
M           !                         !     !        ;G5L;
M  (    &8F]U;F1S3V)J8P    $       !28W0Q    !     !4;W @;&]N
M9P          3&5F=&QO;F<          $)T;VUL;VYG   !!@    !29VAT
M;&]N9P   O4    &<VQI8V5S5FQ,<P    %/8FIC     0      !7-L:6-E
M    $@    =S;&EC94E$;&]N9P         '9W)O=7!)1&QO;F<
M!F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'96YE<F%T960
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M;F<         "W)I9VAT3W5T<V5T;&]N9P      .$))300H       ,
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M_\0!/P   04! 0$! 0$          P ! @0%!@<("0H+ 0 !!0$! 0$! 0
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MO,OK8RQP8P
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! 0$! 0$! 0$!_\  $0@ 5 #R P$1  (1 0,1 ?_$ !\   (" @(# 0
M           *" D&!P(% 00+ __$ %\0   & 0,!!0(%"! 2"P    $" P0%
M!@< "!$)$A,4(3$5018B.%%Q"ADC,S9A@;<7&"0G-5=8<GB1EZ&QLK;P)28H
M,D)&5G-U=G>5M<'1U=;A-T5'4U1G@X2&M-/_Q  = 0 ! P4!
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MRKEO%@#T'@35X?Y=_9?^JWVS_NZXP_XHTC[F7[%)^0W[*4][']D3\H?MK;-
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M0UYO/N1445L]1!S2Y]9RI_7.WSRM+1J4TY#W'GFTJ4  /B#V2\:7K?9[P?Q
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M+0:%3.PA'L[WA!CCQCDAY.-:O /"2,H5F:4,S49,9-BW?:9PQK7%7#YL-%U
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M:&JD6=K/O%%D4&39V9PDV.F]33(JDMY#,\+%D"DLI4A@2,$@^!&^VV]#QK(
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82222>I)W)/KI4!@8'0;"NVUY11HHK__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>g840996g0606105124424.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g840996g0606105124424.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !@ & # 2(  A$! Q$!_\0
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DI&,_,7)^7\NM>EGJ:3)]:*Y\3BY5XQB]HWMK=Z^?;L-*Q__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140625255441104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">S-1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">PLUS THERAPEUTICS, INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001095981<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">33-0827593<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">4200 Marathon Blvd.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Austin<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">TX<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">78756<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">737<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">255-7194<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPrimarySicNumber', window );">Entity Primary SIC Number</a></td>
<td class="text">2834<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressesAddressTypeAxis=dei_BusinessContactMember', window );">Business Contact [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">4200 Marathon Blvd.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Austin<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">TX<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">78756<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">737<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">255-7194<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_ContactPersonnelName', window );">Contact Personnel Name</a></td>
<td class="text">Marc H. Hedrick, M.D.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_ContactPersonnelName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of contact personnel</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_ContactPersonnelName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPrimarySicNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Primary Standard Industrial Classification (SIC) Number for the Entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPrimarySicNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:sicNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressesAddressTypeAxis=dei_BusinessContactMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressesAddressTypeAxis=dei_BusinessContactMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140625255395584">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED BALANCE SHEETS (UNAUDITED) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 2,901,000<span></span>
</td>
<td class="nump">$ 8,554,000<span></span>
</td>
<td class="nump">$ 18,120,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Investments</a></td>
<td class="nump">323,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
<td class="nump">989,000<span></span>
</td>
<td class="nump">1,280,000<span></span>
</td>
<td class="nump">3,697,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">4,213,000<span></span>
</td>
<td class="nump">9,834,000<span></span>
</td>
<td class="nump">21,817,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">800,000<span></span>
</td>
<td class="nump">906,000<span></span>
</td>
<td class="nump">1,324,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-use-of assets</a></td>
<td class="nump">171,000<span></span>
</td>
<td class="nump">202,000<span></span>
</td>
<td class="nump">248,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">372,000<span></span>
</td>
<td class="nump">372,000<span></span>
</td>
<td class="nump">372,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherIntangibleAssetsNet', window );">Intangible assets, net</a></td>
<td class="nump">33,000<span></span>
</td>
<td class="nump">42,000<span></span>
</td>
<td class="nump">94,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">32,000<span></span>
</td>
<td class="nump">32,000<span></span>
</td>
<td class="nump">12,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">5,621,000<span></span>
</td>
<td class="nump">11,388,000<span></span>
</td>
<td class="nump">23,867,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Accounts payable and accrued expenses</a></td>
<td class="nump">6,447,000<span></span>
</td>
<td class="nump">6,631,000<span></span>
</td>
<td class="nump">10,134,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liability</a></td>
<td class="nump">115,000<span></span>
</td>
<td class="nump">120,000<span></span>
</td>
<td class="nump">110,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeCurrent', window );">Deferred grant liability</a></td>
<td class="nump">247,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Term loan obligation, current</a></td>
<td class="nump">3,590,000<span></span>
</td>
<td class="nump">3,976,000<span></span>
</td>
<td class="nump">1,608,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">10,399,000<span></span>
</td>
<td class="nump">10,727,000<span></span>
</td>
<td class="nump">11,852,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Noncurrent operating lease liability</a></td>
<td class="nump">59,000<span></span>
</td>
<td class="nump">85,000<span></span>
</td>
<td class="nump">141,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Term loan obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,786,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeNoncurrent', window );">Deferred grant liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,924,000<span></span>
</td>
<td class="nump">1,643,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">10,458,000<span></span>
</td>
<td class="nump">12,736,000<span></span>
</td>
<td class="nump">17,422,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 8)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' deficit:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock</a></td>
<td class="nump">5,000<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonValue', window );">Treasury stock</a></td>
<td class="num">(500,000)<span></span>
</td>
<td class="num">(126,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">479,420,000<span></span>
</td>
<td class="nump">479,274,000<span></span>
</td>
<td class="nump">473,628,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(483,762,000)<span></span>
</td>
<td class="num">(480,501,000)<span></span>
</td>
<td class="num">(467,185,000)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' deficit</a></td>
<td class="num">(4,837,000)<span></span>
</td>
<td class="num">(1,348,000)<span></span>
</td>
<td class="nump">6,445,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' deficit</a></td>
<td class="nump">$ 5,621,000<span></span>
</td>
<td class="nump">$ 11,388,000<span></span>
</td>
<td class="nump">$ 23,867,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 26: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income excluding obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481174/470-10-25-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income excluding obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481174/470-10-25-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482598/350-20-45-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-5<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as current. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated amortization of finite-lived and indefinite-lived intangible assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480842/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockCommonValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount allocated to previously issued common shares repurchased by the issuing entity and held in treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481520/505-30-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481549/505-30-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.30)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockCommonValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140625346926704">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED BALANCE SHEETS (UNAUDITED) (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' deficit:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Treasury stock, shares</a></td>
<td class="nump">258,425<span></span>
</td>
<td class="nump">78,559<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="nump">1,952<span></span>
</td>
<td class="nump">1,952<span></span>
</td>
<td class="nump">1,952<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">1,952<span></span>
</td>
<td class="nump">1,952<span></span>
</td>
<td class="nump">1,952<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">4,522,656<span></span>
</td>
<td class="nump">4,522,656<span></span>
</td>
<td class="nump">2,240,092<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">4,264,231<span></span>
</td>
<td class="nump">4,444,097<span></span>
</td>
<td class="nump">2,240,092<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockCommonShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of previously issued common shares repurchased by the issuing entity and held in treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481549/505-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockCommonShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140625259110576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED STATEMENTS OF OPERATIONS (UNAUDITED) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">$ 2,763,000<span></span>
</td>
<td class="nump">$ 2,983,000<span></span>
</td>
<td class="nump">$ 9,690,000<span></span>
</td>
<td class="nump">$ 9,698,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">2,213,000<span></span>
</td>
<td class="nump">2,245,000<span></span>
</td>
<td class="nump">8,544,000<span></span>
</td>
<td class="nump">10,238,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">4,976,000<span></span>
</td>
<td class="nump">5,228,000<span></span>
</td>
<td class="nump">18,234,000<span></span>
</td>
<td class="nump">19,936,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating loss</a></td>
<td class="num">(3,299,000)<span></span>
</td>
<td class="num">(4,722,000)<span></span>
</td>
<td class="num">(13,321,000)<span></span>
</td>
<td class="num">(19,712,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherIncomeAndExpensesAbstract', window );"><strong>Other income (expense):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">72,000<span></span>
</td>
<td class="nump">51,000<span></span>
</td>
<td class="nump">400,000<span></span>
</td>
<td class="nump">147,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(34,000)<span></span>
</td>
<td class="num">(134,000)<span></span>
</td>
<td class="num">(395,000)<span></span>
</td>
<td class="num">(711,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueAdjustment', window );">Change in fair value of liability instruments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other expense</a></td>
<td class="nump">38,000<span></span>
</td>
<td class="num">(83,000)<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="num">(563,000)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (3,261,000)<span></span>
</td>
<td class="num">$ (4,805,000)<span></span>
</td>
<td class="num">$ (13,316,000)<span></span>
</td>
<td class="num">$ (20,275,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share, basic</a></td>
<td class="num">$ (0.75)<span></span>
</td>
<td class="num">$ (2.07)<span></span>
</td>
<td class="num">$ (4.24)<span></span>
</td>
<td class="num">$ (11.58)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share, diluted</a></td>
<td class="num">$ (0.75)<span></span>
</td>
<td class="num">$ (2.07)<span></span>
</td>
<td class="num">$ (4.24)<span></span>
</td>
<td class="num">$ (11.58)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic weighted average shares used in calculating net loss per share attributable to common stockholders</a></td>
<td class="nump">4,321,731<span></span>
</td>
<td class="nump">2,320,017<span></span>
</td>
<td class="nump">3,140,925<span></span>
</td>
<td class="nump">1,750,350<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted weighted average shares used in calculating net loss per share attributable to common stockholders</a></td>
<td class="nump">4,321,731<span></span>
</td>
<td class="nump">2,320,017<span></span>
</td>
<td class="nump">3,140,925<span></span>
</td>
<td class="nump">1,750,350<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_GrantMember', window );">Grant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">$ 1,677,000<span></span>
</td>
<td class="nump">$ 506,000<span></span>
</td>
<td class="nump">$ 4,913,000<span></span>
</td>
<td class="nump">$ 224,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483013/835-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of addition (reduction) to the amount at which a liability could be incurred (settled) in a current transaction between willing parties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncomeAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482916/730-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482517/912-730-25-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481283/985-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_GrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_GrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140625258805376">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED STATEMENTS OF STOCKHOLDERS' EQUITY/(DEFICIT) (UNAUDITED) - USD ($)<br></strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Series F Preferred Stock [Member]</div></th>
<th class="th"><div>Convertible Preferred Stock [Member]</div></th>
<th class="th"><div>Preferred Stock [Member]</div></th>
<th class="th">
<div>Preferred Stock [Member] </div>
<div>Series F Preferred Stock [Member]</div>
</th>
<th class="th"><div>Common Stock [Member]</div></th>
<th class="th"><div>Treasury Stock [Member]</div></th>
<th class="th"><div>Additional Paid-in Capital [Member]</div></th>
<th class="th">
<div>Additional Paid-in Capital [Member] </div>
<div>Series F Preferred Stock [Member]</div>
</th>
<th class="th"><div>Accumulated Deficit [Member]</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2021</a></td>
<td class="nump">$ 10,836,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 457,745,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (446,910,000)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,952<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,034,002<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">606,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">606,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issue and sale of stock, net</a></td>
<td class="nump">15,278,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,277,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issue and sale of share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,206,090<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(20,275,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(20,275,000)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2022</a></td>
<td class="nump">6,445,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">473,628,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(467,185,000)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,952<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,240,092<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">140,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">140,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issue and sale of stock, net</a></td>
<td class="nump">895,000<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">895,000<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issue and sale of share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">168,164<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(4,805,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,805,000)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Mar. 31, 2023</a></td>
<td class="nump">2,676,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">474,664,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(471,990,000)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Mar. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,952<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,408,256<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2022</a></td>
<td class="nump">6,445,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">473,628,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(467,185,000)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,952<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,240,092<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">569,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">569,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issue and sale of stock, net</a></td>
<td class="nump">5,005,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,002,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issue and sale of share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">2,230,493<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRedeemedOrCalledDuringPeriodShares', window );">Redemption of Series F preferred stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Issuance of common stock for in process research and development</a></td>
<td class="nump">75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Issuance of common stock for in process research and development (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">53,381<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pstv_FractionalAdjustmentOfCommonStock', window );">Fractional adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,310)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Purchase of treasury stock</a></td>
<td class="num">(126,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (126,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Purchase of treasury stock (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(78,559)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(13,316,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(13,316,000)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2023</a></td>
<td class="num">(1,348,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="num">$ (126,000)<span></span>
</td>
<td class="nump">479,274,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(480,501,000)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,952<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,522,656<span></span>
</td>
<td class="num">(78,559)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">146,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">146,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Purchase of treasury stock</a></td>
<td class="num">(374,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (374,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Purchase of treasury stock (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(179,866)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(3,261,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,261,000)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Mar. 31, 2024</a></td>
<td class="num">$ (4,837,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="num">$ (500,000)<span></span>
</td>
<td class="nump">$ 479,420,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (483,762,000)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Mar. 31, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,952<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,522,656<span></span>
</td>
<td class="num">(258,425)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pstv_FractionalAdjustmentOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fractional adjustment of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pstv_FractionalAdjustmentOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pstv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481089/718-20-55-13<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481089/718-20-55-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRedeemedOrCalledDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of stock bought back by the entity at the exercise price or redemption price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRedeemedOrCalledDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockSharesAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and are being held in treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockSharesAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValueAcquiredCostMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481549/505-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValueAcquiredCostMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140625255243424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED STATEMENTS OF CASH FLOWS (UNAUDITED) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (3,261)<span></span>
</td>
<td class="num">$ (4,805)<span></span>
</td>
<td class="num">$ (13,316)<span></span>
</td>
<td class="num">$ (20,275)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">155<span></span>
</td>
<td class="nump">158<span></span>
</td>
<td class="nump">628<span></span>
</td>
<td class="nump">619<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts', window );">Amortization of deferred financing costs and debt discount</a></td>
<td class="nump">16<span></span>
</td>
<td class="nump">66<span></span>
</td>
<td class="nump">190<span></span>
</td>
<td class="nump">389<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pstv_CommonStockIssuedForResearchAndDevelopment', window );">Common stock issued for research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value of liability instruments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation expense</a></td>
<td class="nump">146<span></span>
</td>
<td class="nump">140<span></span>
</td>
<td class="nump">569<span></span>
</td>
<td class="nump">606<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments', window );">Accretion of discount on short-term investments</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense', window );">Reduction in the carrying amount of operating lease right-of-use assets</a></td>
<td class="nump">31<span></span>
</td>
<td class="nump">29<span></span>
</td>
<td class="nump">117<span></span>
</td>
<td class="nump">93<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnDispositionOfAssets', window );">Loss on disposal of property and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Increases (decreases) in cash caused by changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherCurrentAssets', window );">Other current assets</a></td>
<td class="nump">150<span></span>
</td>
<td class="nump">2,791<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets', window );">Other assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,397<span></span>
</td>
<td class="num">(2,369)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable and accrued expenses</a></td>
<td class="num">(43)<span></span>
</td>
<td class="num">(3,639)<span></span>
</td>
<td class="num">(3,677)<span></span>
</td>
<td class="nump">6,452<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Change in operating lease liabilities</a></td>
<td class="num">(31)<span></span>
</td>
<td class="num">(29)<span></span>
</td>
<td class="num">(117)<span></span>
</td>
<td class="num">(129)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pstv_IncreaseDecreaseInDeferredGrantLiability', window );">Deferred grant liability</a></td>
<td class="num">(1,677)<span></span>
</td>
<td class="num">(506)<span></span>
</td>
<td class="nump">281<span></span>
</td>
<td class="nump">1,643<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(4,513)<span></span>
</td>
<td class="num">(5,793)<span></span>
</td>
<td class="num">(12,851)<span></span>
</td>
<td class="num">(12,972)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows used in investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pstv_PaymentsToAcquirePropertyPlantAndEquipmentAndIntangibleAssets', window );">Purchases of property and equipment and intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(160)<span></span>
</td>
<td class="num">(509)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pstv_CashPaidForIPRDAssetAcquiredInAnAssetAcquisition', window );">In process research and development acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(250)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(40)<span></span>
</td>
<td class="num">(97)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireShortTermInvestments', window );">Purchase of short-term investments</a></td>
<td class="num">(324)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(364)<span></span>
</td>
<td class="num">(97)<span></span>
</td>
<td class="num">(160)<span></span>
</td>
<td class="num">(759)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows used in/provided by financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Principal payments of term loan obligation</a></td>
<td class="num">(402)<span></span>
</td>
<td class="num">(402)<span></span>
</td>
<td class="num">(1,608)<span></span>
</td>
<td class="num">(1,608)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfEquity', window );">Purchase of treasury stock</a></td>
<td class="num">(374)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(126)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from sale of common stock, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">895<span></span>
</td>
<td class="nump">5,527<span></span>
</td>
<td class="nump">15,832<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payment of offering costs related to sale of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(348)<span></span>
</td>
<td class="num">(773)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash (used in) provided by financing activities</a></td>
<td class="num">(776)<span></span>
</td>
<td class="nump">493<span></span>
</td>
<td class="nump">3,445<span></span>
</td>
<td class="nump">13,451<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net decrease in cash and cash equivalents</a></td>
<td class="num">(5,653)<span></span>
</td>
<td class="num">(5,397)<span></span>
</td>
<td class="num">(9,566)<span></span>
</td>
<td class="num">(280)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash and cash equivalents at beginning of period</a></td>
<td class="nump">8,554<span></span>
</td>
<td class="nump">18,120<span></span>
</td>
<td class="nump">18,120<span></span>
</td>
<td class="nump">18,400<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash and cash equivalents at end of period</a></td>
<td class="nump">2,901<span></span>
</td>
<td class="nump">12,723<span></span>
</td>
<td class="nump">8,554<span></span>
</td>
<td class="nump">18,120<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pstv_CashPaidDuringPeriodForAbstract', window );"><strong>Cash paid during period for:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Interest</a></td>
<td class="nump">23<span></span>
</td>
<td class="nump">73<span></span>
</td>
<td class="nump">222<span></span>
</td>
<td class="nump">327<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental schedule of non-cash investing and financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pstv_UnpaidOfferingCosts', window );">Unpaid offering cost</a></td>
<td class="nump">$ 141<span></span>
</td>
<td class="nump">25<span></span>
</td>
<td class="nump">174<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssued1', window );">Common stock issued in payment for in process research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right-of-use assets acquired by assuming operating lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 71<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability', window );">Right-of-use assets obtained in exchange for operating lease liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 51<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pstv_CashPaidDuringPeriodForAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash paid during period for:</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pstv_CashPaidDuringPeriodForAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pstv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pstv_CashPaidForIPRDAssetAcquiredInAnAssetAcquisition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash paid for IPRD asset acquired in an asset acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pstv_CashPaidForIPRDAssetAcquiredInAnAssetAcquisition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pstv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pstv_CommonStockIssuedForResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common stock issued for research and development.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pstv_CommonStockIssuedForResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pstv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pstv_IncreaseDecreaseInDeferredGrantLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (decrease) in deferred grant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pstv_IncreaseDecreaseInDeferredGrantLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pstv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pstv_PaymentsToAcquirePropertyPlantAndEquipmentAndIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments to acquire property plant and equipment and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pstv_PaymentsToAcquirePropertyPlantAndEquipmentAndIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pstv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pstv_UnpaidOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Unpaid Offering Costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pstv_UnpaidOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pstv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69E<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69F<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCostsAndDiscounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481877/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 13<br> -SubTopic 10<br> -Topic 480<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481766/480-10-25-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDispositionOfAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, excluding oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482130/360-10-45-5<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDispositionOfAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherCurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherCurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for securities or other assets acquired, which qualify for treatment as an investing activity and are to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value of stock issued in noncash financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140625346548240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and New Accounting Standards<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock', window );">Basis of Presentation and New Accounting Standards</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">1. Basis of Presentation and New Accounting Standards </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The accompanying unaudited condensed financial statements for the three months ended March&#160;31, 2024 and 2023 have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information. Accordingly, they do not include all of the information and footnotes required by accounting principles generally accepted in the United States of America for annual financial statements. The condensed balance sheet at December&#160;31, 2023 has been derived from the audited financial statements at December&#160;31, 2023, but does not include all of the information and footnotes required by accounting principles generally accepted in the United States of America for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation of the financial position and results of operations of Plus Therapeutics, Inc. (the &#8220;Company&#8221;) have been included. Operating results for the three months ended March&#160;31, 2024 are not necessarily indicative of the results that may be expected for the year ending December&#160;31, 2024. These financial statements should be read in conjunction with the financial statements and notes therein included in the Company&#8217;s Annual Report on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">10-K</div> for the year ended December&#160;31, 2023, filed with the Securities and Exchange Commission on March&#160;5, 2024. </div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Amendments to Certificate of Incorporation and Reverse Stock Split </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">At the Annual Meeting of Stockholders of the Company held on April&#160;20, 2023 (the &#8220;Annual Meeting&#8221;), the stockholders of the Company approved an amendment to the Company&#8217;s Amended and Restated Certificate of Incorporation (the &#8220;Charter&#8221;) to implement a reverse stock split of the Company&#8217;s then issued and outstanding common stock, par value $0.001 per share, with the ratio to be determined by the Board of Directors (the &#8220;Board&#8221;) of the Company, within a range of not less than <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;"><div style="-sec-ix-hidden:hidden116199108;display:inline;">1-for-3</div></div></div></div> and not greater than <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;"><div style="-sec-ix-hidden:hidden116199110;display:inline;">1-for-15</div></div>.</div></div> Subsequently, on April&#160;21, 2023, the Board determined to fix the ratio for the reverse stock split at <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;"><div style="-sec-ix-hidden:hidden116199113;display:inline;">1-for-15</div></div>,</div></div> without any change to its par value (the &#8220;Reverse Stock Split&#8221;). </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">On April&#160;27, 2023, following stockholder and Board approval, the Company filed a Certificate of Amendment to its Charter (the &#8220;Amendment&#8221;), with the Secretary of State of the State of Delaware to effectuate the Reverse Stock Split. The Amendment became effective on May 1, 2023. Upon effectiveness of the Reverse Stock Split, the number of shares of the Company&#8217;s common stock (x)&#160;issued and outstanding decreased from approximately 37.4&#160;million shares to approximately 2.5&#160;million shares; (y)&#160;reserved for issuance upon exercise of outstanding warrants and options decreased from approximately 2.0&#160;million shares to approximately 0.1&#160;million shares, and (z)&#160;reserved but unallocated under the Company&#8217;s current equity incentive plans decreased from approximately 3.0&#160;million shares of common stock to approximately 0.2&#160;million shares of common stock. The Company&#8217;s common stock began trading on the Nasdaq Capital Market (&#8220;Nasdaq&#8221;) on a post-split basis on May&#160;1, 2023. The Company&#8217;s 5,000,000 shares of authorized Preferred Stock were not affected by the Reverse Stock Split. No fractional shares were issued in connection with the Reverse Stock Split, and accordingly, the outstanding number of shares post Reverse Stock Split was adjusted down by approximately 1,310 (post-effect of the Reverse Stock Split) shares. Proportional adjustments for the Reverse Stock Split were made to the Company&#8217;s outstanding stock options, warrants and equity incentive plans for the period ended March&#160;31, 2023 as presented in the condensed financial statements in this Quarterly Report on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">10-Q.</div> The Company&#8217;s financial statements, and all references thereto have been retroactively adjusted to reflect the Reverse Stock Split unless specifically stated otherwise. </div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Grant Revenue Recognition </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">In applying the provisions of Accounting Standards Codification (&#8220;ASC&#8221;) Topic 606, Revenue from Contracts with Customers (&#8220;ASC 606&#8221;), the Company has determined that government grants are out of the scope of ASC </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">606 because the funding entities do not meet the definition of a &#8220;customer&#8221;, as defined by ASC 606, as the Company does not consider there to be a transfer of control of goods or services. With respect to each grant, the Company determines if it has a collaboration in accordance with ASC Topic 808, Collaborative Arrangements (&#8220;ASC 808&#8221;). For grants outside the scope of ASC 808, the Company applies International Accounting Standards No.&#160;20 (&#8220;IAS 20&#8221;), Accounting for Government Grants and Disclosure of Government Assistance, by analogy, and revenue is recognized when the Company incurs expenses related to the grant for the amount the Company is entitled to under the provisions of the contract. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The Company also considers the guidance in ASC Topic 730, Research and Development, which requires an assessment, at the inception of each grant, of whether each grant agreement is a liability. If the Company is obligated to repay funds received regardless of the outcome of the related research and development activities, then the Company is required to estimate and recognize that liability. Alternatively, if the Company is not required to repay the funds, then payments received are recorded as revenue or contra-expense as the expenses are incurred. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Deferred grant liability represents grant funds received or receivable for which the allowable expenses have not yet been incurred as of the balance sheet date. </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">Available-for-Sale</div></div> Securities </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The Company&#8217;s <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">available-for-sale</div></div> securities consist of U.S. government and agency securities. The Company classifies its marketable securities as <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">available-for-sale</div></div> and records such assets at estimated fair value in the condensed balance sheets, with unrealized gains and losses, if any, reported as a component of other comprehensive income (loss) within the condensed statements of operations and comprehensive income/loss and as a separate component of stockholders&#8217; equity. Realized gains and losses are calculated on the specific identification method and recorded as interest income (loss). At each balance sheet date, the Company assesses <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">available-for-sale</div></div> securities in an unrealized loss position to determine whether the decline in fair value below amortized cost is a result of credit losses or other factors, whether the Company expects to recover the amortized cost of the security, the Company&#8217;s intent to sell and if it is more likely than not that the Company will be required to sell the securities before the recovery of amortized cost. The Company records changes in allowance for expected credit loss in other income (expense). As of March&#160;31, 2024, there were no <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">available-for-sale</div></div> securities in an unrealized loss position, and there has been no allowance for expected credit losses recorded during any of the periods presented. </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Any premium arising at purchase is amortized to the earliest call date and any discount arising at purchase is accreted to maturity. Accretion of discounts are recorded in interest income in the condensed statements of operations and comprehensive income/loss. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">During the three months ended March&#160;31, 2024, the unrealized gain on the Company&#8217;s <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">available-for-sale</div></div> securities was less than $1,000, and not presented separately in the condensed statement of operations and comprehensive income/loss. </div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Recently Issued Accounting Pronouncements </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">In December 2023, the Financial Accounting Standards Board (the &#8220;FASB&#8221;) issued Accounting Standards Update (ASU) <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">No.&#160;2023-09</div> Income Taxes (Topic 740): Improvements to Income Tax Disclosure. This ASU includes amendments that further enhance income tax disclosures, primarily through standardization and disaggregation of rate reconciliation categories and income taxes paid by jurisdiction. The ASU is effective for years beginning after December&#160;15, 2024, but early adoption is permitted. This ASU should be applied on a prospective basis, although retrospective application is permitted. Management is currently evaluating the impact of the changes required by the new standard on the Company&#8217;s financial statements and related disclosures. </div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"> </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">In November 2023, the FASB issued Accounting Standard Update (ASU) <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">No.&#160;2023-07,</div> Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures. The new standard is intended to improve annual and interim reportable segment disclosure requirements regardless of number of reporting units, primarily through enhanced disclosures of significant expenses. The amendment requires public entities to disclose significant segment expenses that are regularly provided to <div style="display:inline;">the C</div>ODM and included within each reported measure of segment profit and loss. This update is effective for fiscal years beginning after December&#160;15, 2023, and interim periods within those fiscal years starting after December&#160;15, 2024. This ASU must be applied retrospectively to all prior periods presented. Management is <div style="display:inline;">currently </div>evaluating the impact of the changes required by the new standard on the Company&#8217;s financial statements and related <div style="display:inline;">disclosures</div>. </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//235/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140625346548240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Operations<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Organization and Operations</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">1. Organization and Operations </div></div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The Company </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company focused on the development, manufacture and commercialization of complex and innovative treatments for patients battling cancer and other life-threatening diseases. </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Certain Risks and Uncertainties </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The Company&#8217;s prospects are subject to the risks and uncertainties frequently encountered by companies in the early stages of development and commercialization, especially those companies in rapidly evolving and technologically advanced industries such as the biotech/medical device field. The Company&#8217;s future viability largely depends on its ability to complete development of new products and receive regulatory approvals for those products. No assurance can be given that the Company&#8217;s new products will be successfully developed, regulatory approvals will be granted, or acceptance of these products will be achieved. </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Going Concern </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The Company incurred net losses of $13.3&#160;million for the year ended December&#160;31, 2023, and as of December&#160;31, 2023, the Company had an accumulated deficit of $480.5&#160;million and cash and cash equivalents of $8.6&#160;million. Additionally, the Company used net cash of $12.9&#160;million to fund its operating activities for the year ended December&#160;31, 2023. The Company&#8217;s term loan has an outstanding principal of $0.8&#160;million principal and a $3.2&#160;million final payment fee due June 1, 2024 (Note 8). The Company expects that its research and development expenditures will increase in absolute dollars in 2024 and beyond. These factors raise substantial doubt about the Company&#8217;s ability to continue as a going concern. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">As disclosed in more detail in Note 12, the Company has entered into various financing agreements and raised capital by issuing its common stock. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Based on the Company&#8217;s stockholders&#8217; deficit of $1.3&#160;million as of December&#160;31, 2023, the Company does not meet the minimum stockholders&#8217; equity requirement for continued listing on the Nasdaq Capital Market under Nasdaq Listing Rule 5550(b)(1). The Company expects to receive written notice from Nasdaq staff to that effect following the filing of the Annual Report on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">10-K</div> in which these financial statements are included. </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The Company continues to seek additional capital through strategic transactions and from other financing alternatives. Without additional capital, current working capital and cash generated from sales will not provide adequate funding to make debt repayments, for research, sales and marketing efforts and product development activities at their current levels. If sufficient capital is not raised, the Company will at a minimum need to significantly reduce or curtail its research and development and other operations, and this would negatively affect its ability to achieve corporate growth goals. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Should the Company fail to raise additional cash from outside sources, this would have a material adverse impact on its operations. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The accompanying financial statements have been prepared assuming the Company will continue to operate as a going concern, which contemplates the realization of assets and settlement of liabilities in the normal course of business, and do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classifications of liabilities that may result from uncertainty related to its ability to continue as a going concern. </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Amendments to Certificate of Incorporation and Reverse Stock Split </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">At the Annual Meeting of Stockholders of the Company held on April&#160;20, 2023 (the &#8220;Annual Meeting&#8221;), the stockholders of the Company approved an amendment to the Company&#8217;s Amended and Restated Certificate of Incorporation to implement a reverse stock split of the Company&#8217;s common stock, par value $0.001 per share, with the ratio to be determined by the Board of Directors (the &#8220;Board&#8221;) of the Company, within a range of not less than <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="-sec-ix-hidden:hidden116200119;display:inline;">1-for-3</div></div></div> and not greater than <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="-sec-ix-hidden:hidden116200122;display:inline;">1-for-15</div>.</div></div> Subsequently, on April&#160;21, 2023, the Board determined to fix the ratio for the reverse stock split at <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="-sec-ix-hidden:hidden116200127;display:inline;">1-for-15</div>,</div></div> without any change to its par value (the &#8220;Reverse Stock Split&#8221;). </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">On April&#160;27, 2023, following stockholder and Board approval, the Company filed a Certificate of Amendment to its Charter (the &#8220;Amendment&#8221;), with the Secretary of State of the State of Delaware to effectuate the Reverse Stock Split. The Amendment became effective on May&#160;1, 2023. Upon effectiveness of the Reverse Stock Split, the number of shares of the Company&#8217;s common stock (x)&#160;issued and outstanding decreased from approximately 37.4&#160;million shares to approximately 2.5&#160;million shares; (y)&#160;reserved for issuance upon exercise of outstanding warrants and options decreased from approximately 2.0&#160;million shares to approximately 0.1&#160;million shares, and (z)&#160;reserved but unallocated under the Company&#8217;s current equity incentive plans decreased from approximately 3.0&#160;million common shares to approximately 0.2&#160;million common shares. The Company&#8217;s common stock began trading on the NASDAQ Capital Market on a post-split basis on May&#160;1, 2023. The Company&#8217;s 5,000,000 shares of authorized Preferred Stock were not affected by the Reverse Stock Split. No fractional shares were issued in connection with the Reverse Stock Split, and accordingly, the outstanding number of shares post Reverse Stock Split was adjusted down by approximately 1,310 (post-effect of Reverse Stock Split) shares. Proportional adjustments for the reverse <div style="display:inline;">stock split</div> were made to the Company&#8217;s outstanding stock options, warrants and equity incentive plans for all periods presented in the financial statements in this Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">10-K.</div> The Company&#8217;s financial statements, and all references thereto have been retroactively adjusted to reflect the reverse split unless specifically stated otherwise. </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480424/946-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480424/946-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//810/tableOfContent<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//205/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140625254531968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Use of Estimates<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pstv_UseOfEstimatesAbstract', window );"><strong>Use Of Estimates [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pstv_UseOfEstimatesTextBlock', window );">Use of Estimates</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">2. Use of Estimates </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The preparation of financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions affecting the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of r<div style="display:inline;">evenue and ex</div>penses during the reporting period. The Company&#8217;s most significant estimates and critical accounting policies involve reviewing a<div style="display:inline;">ssets for</div> impairment and determining the assumptions used in measuring stock-based compensation expense. </div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pstv_UseOfEstimatesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Use of Estimates [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pstv_UseOfEstimatesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pstv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pstv_UseOfEstimatesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Provides an entity's explanation that the preparation of financial statements in conformity with generally accepted accounting principles requires the use of management estimates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pstv_UseOfEstimatesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pstv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140625253164144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">2. Summary of Significant Accounting Policies </div></div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Use of Estimates </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The preparation of financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions affecting the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenue and expenses during the reporting period. The most significant estimates and critical accounting policies involve reviewing assets for impairment, and determining the assumptions used in measuring share-based compensation expense. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Actual results could differ from these estimates. Management&#8217;s estimates and assumptions are reviewed regularly, and the effects of revisions are reflected in the financial statements in the periods they are determined to be necessary. </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Cash and cash equivalents </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The Company considers all highly liquid investments with maturities of three months or less at the time of purchase to be cash equivalents. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Cash and cash equivalents include cash in readily available checking, savings accounts and money market accounts. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. The Company has not experienced any losses in such accounts and believes it is not exposed to significant risk on its cash balances due to the financial position of the depository institution in which those deposits are held. </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Financial Instruments </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Financial instruments include cash equivalents, other current assets, accounts payable, accrued expenses, other liabilities and long-term debt. The carrying values of cash equivalents, other current assets, accounts payable, </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"> </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">accrued expenses and other liabilities generally approximate fair value due to the short-term nature of these instruments. Based on level 3 inputs and the borrowing rates currently available for loans with similar terms, the Company believes the fair value of the long-term debt is <div style="display:inline;">materially </div>consistent with its carrying value. </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Property and Equipment </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Property and equipment are stated at cost, net of accumulated depreciation. Depreciation expense, which includes the amortization of capitalized leasehold improvements, is provided for on a straight-line basis over the estimated useful lives of the assets, or the life of the lease, whichever is shorter, and range from <div style="-sec-ix-hidden:hidden116200141;display:inline;">three</div> to five years. When assets are sold or otherwise disposed of, the cost and related accumulated depreciation are removed from the accounts and the resulting gain or loss, if any, is included in operations. Maintenance and repairs are charged to operations as incurred. </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Impairment </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The Company assesses its property and equipment for potential impairment when there is a change in circumstances that indicates carrying values of assets may not be recoverable. Such long-lived assets are deemed to be impaired when the undiscounted cash flows expected to be generated by the asset (or asset group) are less than the asset&#8217;s carrying amount. Any required impairment loss would be measured as the amount by which the asset&#8217;s carrying value exceeds its fair value and would be recorded as a reduction in the carrying value of the related asset and a charge to operating expense. The Company recognized no impairment losses during any of the periods presented in these financial statements. </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Goodwill </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The Company&#8217;s goodwill represents the excess of the cost over the fair value of net assets acquired from its business combinations. The determination of the value of goodwill arising from business combinations requires extensive use of accounting estimates and judgments to allocate the purchase price to the fair value of the net tangible and intangible assets acquired. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Goodwill is not amortized; however, it is assessed for impairment using fair value measurement techniques on an annual basis or more frequently if facts and circumstance warrant such a review. Goodwill is considered to be impaired if the Company determines that the carrying value of the reporting unit exceeds its fair value. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The Company performs its impairment test annually during the fourth quarter by comparing the Company&#8217;s estimated fair value, calculated from the Company&#8217;s market capitalization, to its carrying amount. The Company&#8217;s annual evaluation for impairment of goodwill consists of one reporting unit. The Company completed its most recent annual evaluation for impairment as of December&#160;31, 2023, when the Company had stockholders&#8217; deficit within its sole reporting unit of approximately $1.3&#160;million, and concluded that no impairment existed. </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Grant Revenue Recognition </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">In applying the provisions of Accounting Standards Codification (&#8220;ASC&#8221;) Topic 606, Revenue from Contracts with Customers (&#8220;ASC 606&#8221;), the Company has determined that government grants are out of the scope of ASC 606 because the funding entities do not meet the definition of a &#8220;customer,&#8221; as defined by ASC 606, as there is not considered to be a transfer of control of goods or services. With respect to the grant, the Company determines if it is a collaboration arrangement in accordance with ASC Topic 808, Collaborative Arrangements (&#8220;ASC 808&#8221;). For grants outside the scope of ASC 808, the Company applies International Accounting Standards No.&#160;20, Accounting for Government Grants and Disclosure of Government Assistance, by analogy, and revenue is recognized when the Company incurs expenses related to the grant for the amount the Company is entitled to under the provisions of the contract. </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"> </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The Company also considers the guidance in ASC Topic 730, Research and Development (&#8220;ASC 730&#8221;), which requires an assessment, at the inception of the grant, of whether the agreement is a liability. If the Company is obligated to repay funds received regardless of the outcome of the related research and development activities, then the Company is required to estimate and recognize that liability. Alternatively, if the Company is not required to repay the funds, then payments received are recorded as revenue or contra-expense as the expenses are incurred. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Deferred grant liability represents grant funds received or receivable for which the allowable expenses have not yet been incurred as of the balance sheet date. </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Research and Development </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Research and development expenditures, which are charged to operations in the period incurred, include costs associated with the design, development, testing and enhancement of the Company&#8217;s products, regulatory fees, the purchase of laboratory supplies, and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">pre-clinical</div> and clinical studies as well as salaries and benefits for the Company&#8217;s research and development employees. </div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;">Acquired <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">In-Process</div> Research and Development (IPR&amp;D) </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Acquired IPR&amp;D represents the value assigned to research and development assets that have not reached technological feasibility. Upon the acquisition of IPR&amp;D, the Company completes an assessment of whether the acquisition constitutes the purchase of a single asset or group of assets. The Company considers multiple factors in this assessment, including the nature of the technology acquired, the presence or absence of separate cash flows, the development process and stage of completion, quantitative significance, and the Company&#8217;s rationale for entering into the transaction. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The Company tests IPR&amp;D assets for impairment as of December&#160;31 of each year or more frequently if indicators of impairment are present. The authoritative accounting guidance provides an optional qualitative assessment for any indicators that indefinite-lived intangible assets are impaired. If it is determined that it is more likely than not that the indefinite-lived intangible assets, including IPR&amp;D, are impaired, the fair value of the indefinite-lived intangible assets is compared with the carrying amount and impairment is recorded for any excess of the carrying amount over the fair value of the indefinite-lived intangible assets. There was no impairment of the Company&#8217;s IPR&amp;D assets during 2023 or 2022. </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Deferred Financing Costs and Other Debt-Related Costs </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Deferred financing costs are capitalized, recorded as an offset to debt balances and amortized to interest expense over the term of the associated debt instrument using the effective interest method. If the maturity of the debt is accelerated because of default or early debt repayment, then the amortization would be accelerated. </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Income Taxes </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carry forwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income (loss) in the years in which those temporary differences are expected to be recovered or settled. Due to our history of losses, a full valuation allowance has been recognized against our deferred tax assets. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The Company&#8217;s policy is to recognize interest and penalties related to income tax matters in income tax expense. For the years ended December&#160;31, 2023 and 2022, the Company has not recorded any interest or penalties related to income tax matters. The Company does not foresee any material changes to unrecognized tax benefits within the next twelve months. </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"> </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Share-Based Compensation </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The Company recognizes the fair value of all share-based payment awards in our statements of operations over the requisite vesting period of each award, which approximates the period during which the employee and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">non-employee</div> director is required to provide service in exchange for the award. The Company estimates the fair value of these options using the Black-Scholes option pricing model using assumptions for expected volatility, expected term, and risk-free interest rate. Expected volatility is based primarily on historical volatility and is computed using daily pricing observations for recent periods that correspond to the expected term of the options. The expected term represents the period of time that options are expected to be outstanding. Because the Company does not have historical exercise behavior, it determines the expected life assumption using the simplified method which is an average of the contractual term of the option and its vesting period. The risk-free interest rate is the interest rate for treasury instruments with maturities that approximate the expected term. </div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Segment Information </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">For the years ended December&#160;31, 2023 and 2022, the Company is managed as a single operating segment, and therefore reports its results in one operating segment. </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Loss Per Share </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Basic per share data is computed by dividing net income or loss applicable to common stockholders by the weighted average number of common shares outstanding during the period. Diluted per share data is computed by dividing net income or loss applicable to common stockholders by the weighted average number of common shares outstanding during the period increased to include, if dilutive, the number of additional common shares that would have been outstanding as calculated using the treasury stock method. Potential common shares were related entirely to outstanding but unexercised options, warrants and convertible preferred stocks for all periods presented. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The Company excluded all potentially dilutive securities from the calculation of diluted loss per share attributable to common stockholders for the years ended December&#160;31, 2023 and 2022, as their inclusion would be antidilutive. </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Concentration Risk </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Although the Company&#8217;s contracts with its vendors are not exclusive, the Company currently uses sole source providers for core materials used in its clinical trials. </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Recently Issued Accounting Pronouncements </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">In June 2016, the FASB issued ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">2016-13,</div> Financial Instruments&#8212;Credit Losses (Topic 326), Measurement of Credit Losses on Financial Instruments. The standard amends the impairment model by requiring entities to use a forward-looking approach based on expected losses to estimate credit losses for most financial assets and certain other instruments that are not measured at fair value through net income. For <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">available-for-sale</div></div> debt securities, entities will be required to recognize an allowance for credit losses rather than a reduction in carrying value of the asset. Entities will no longer be permitted to consider the length of time that fair value has been less than amortized cost when evaluating when credit losses should be recognized. This new guidance is effective in the first quarter of 2023 for calendar-year SEC filers that are smaller reporting companies as of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">one-time</div> determination date. Early adoption was permitted beginning in 2019. The Company adopted the new guidance as of January 1, 2023, which did not have a material impact on its financial statements and related disclosures. </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//235/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140625259517600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Liquidity and Going Concern<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pstv_LiquidityAbstract', window );"><strong>Liquidity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pstv_DisclosureOfLiquidityAndGoingConcernTextBlock', window );">Liquidity and Going Concern</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">3. Liquidity and Going Concern </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The Company incurred a net loss of $3.3&#160;million for the three months ended March&#160;31, 2024. The Company had an accumulated deficit of $483.8&#160;million as of March&#160;31, 2024. Additionally, the Company used net cash of $4.5&#160;million to fund its operating activities for the three months ended March&#160;31, 2024.<div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div> </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">To date, the Company&#8217;s operating losses have been funded primarily from outside sources of invested capital from issuance of its common and preferred stocks, proceeds from its term loan and grant funding. However, the Company has had, and will continue to have, an ongoing need to raise additional cash from outside sources to fund its future clinical development programs and other operations. There can be no assurance that the Company will be able to continue to raise additional capital in the future. The Company&#8217;s inability to raise additional cash would have a material and adverse impact on its operations and could cause the Company to default on its term loan. These factors raise substantial doubt about the Company&#8217;s ability to continue as a going concern. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">On May&#160;9, 2024, the Company closed a private placement of securities of the Company for aggregate gross proceeds of approximately $7.25&#160;million, before deducting certain expenses payable by the Company, and excluding the proceeds, if any, from the exercise of warrants issued in the private placement. See Note 12 for further information regarding the private placement. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Nasdaq Listing Compliance </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">On March&#160;8, 2024, the Company received a letter (the &#8220;Notice&#8221;) from the Listing Qualifications staff of Nasdaq, notifying the Company that it no longer complied with the requirement under Nasdaq Listing Rule 5550(b)(1) to maintain a minimum of $2.5&#160;million in stockholders&#8217; equity for continued listing on Nasdaq or the alternative requirements of having a market value of listed securities of $35&#160;million or net income from continuing operations of $500,000 in the most recently completed fiscal year or two of the last three most recently completed fiscal years (the &#8220;Alternative Standards&#8221;). The Notice states that the Company&#8217;s Annual Report on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">10-K</div> for the fiscal year ended December&#160;31, 2023, disclosed stockholders&#8217; equity of ($1,348,000) as of December&#160;31, 2023, and that, as of March&#160;8, 2024, the Company did not meet the Alternative Standards. </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">On April&#160;22, 2024, the Company provided Nasdaq with its plan to achieve and sustain compliance with the stockholders&#8217; equity requirement and requested that Nasdaq grant the Company an extension of time until September&#160;4, 2024, to provide evidence of compliance with the stockholders&#8217; equity requirement. Nasdaq has not yet responded to the Company&#8217;s plan, and there can be no assurance that Nasdaq will grant an extension or that the Company will be able to comply with the applicable listing standards of Nasdaq. </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"> </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The Company continues to seek additional capital from other financing alternatives and other sources in order to ensure adequate funding is available to allow the Company to continue research and product development activities at their current levels. If sufficient capital is not raised, the Company will at a minimum need to significantly reduce or curtail its research and development and other operations, and this would negatively affect its ability to achieve corporate growth goals. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Should the Company fail to raise additional cash from outside sources, it would have a material adverse impact on its operations. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The accompanying condensed financial statements have been prepared assuming the Company will continue to operate as a going concern, which contemplates the realization of assets and settlement of liabilities in the normal course of business, and do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classifications of liabilities that may result from uncertainty related to its ability to continue as a going concern. </div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pstv_DisclosureOfLiquidityAndGoingConcernTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of liquidity and going concern text block</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pstv_DisclosureOfLiquidityAndGoingConcernTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pstv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pstv_LiquidityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Liquidity Abstract</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pstv_LiquidityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pstv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140625254721040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementInputsDisclosureTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">4. Fair Value Measurements </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Fair value measurements are market-based measurements, not entity-specific measurements. Therefore, fair value measurements are determined based on the assumptions that market participants would use in pricing the asset or liability. The Company follows a three-level hierarchy to prioritize the inputs used in the valuation techniques to derive fair values. The basis for fair value measurements for each level within the hierarchy is described below: </div></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentColor; border-image: none; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Level&#160;1: Quoted prices in active markets for identical assets or liabilities. </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentColor; border-image: none; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Level&#160;2: Quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar instruments in markets that are not active; and model-derived valuations in which all significant inputs are observable in active markets. </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentColor; border-image: none; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Level&#160;3: Valuations derived from valuation techniques in which one or more significant inputs are unobservable in active markets. </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The Company has investments in money market accounts, which are included in cash and cash equivalents on the balance sheets. Fair value inputs for these investments are considered Level&#160;1 measurements within the fair value hierarchy since money market account fair values are known and observable through daily published floating net asset values. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The following table summarizes the Company&#8217;s fair value hierarchy for its financial assets measured at fair value on a recurring basis as of March&#160;31, 2024 and December&#160;31, 2023, respectively (in thousands). </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 92%; font-family: Times New Roman; font-size: 8pt; border-collapse: collapse;">
<tr>
<td style="width: 64%;"></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="14" style="vertical-align: bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Fair Value Measurements Using</div></div></td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">March&#160;31, 2024</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Fair&#160;Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;1</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;2</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;3</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Money market</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">176</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">176</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Treasury bills and government agency bonds</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">323</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">323</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">499</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">499</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 12pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="16" style="height: 12pt; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="14" style="vertical-align: bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Fair Value Measurements Using</div></div></td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31, 2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Fair&#160;Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;1</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;2</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;3</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Money market</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">5,449</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">5,449</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr></table><span></span>
</td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">3. Fair Value Measurements </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Fair value measurements are market-based measurements, not entity-specific measurements. Therefore, fair value measurements are determined based on the assumptions that market participants would use in pricing the </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"> </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">asset or liability. The Company follows a three-level hierarchy to prioritize the inputs used in the valuation techniques to derive fair values. The basis for fair value measurements for each level within the hierarchy is described below: </div></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentColor; border-image: none; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Level&#160;1: Quoted prices in active markets for identical assets or liabilities. </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentColor; border-image: none; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Level&#160;2: Quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar instruments in markets that are not active; and model-derived valuations in which all significant inputs are observable in active markets. </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentColor; border-image: none; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Level&#160;3: Valuations derived from valuation techniques in which one or more significant inputs are unobservable in active markets. </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The Company has investments in money market accounts, which are included in cash and cash equivalents on the balance sheets. Fair value inputs for these investments are considered Level&#160;1 measurements within the fair value hierarchy since money market account fair values are known and observable through daily published floating net asset values. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The following table summarizes the Company&#8217;s fair value hierarchy for its financial assets measured at fair value on a recurring basis as of December&#160;31, 2023 and December&#160;31, 2022, respectively. </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 92%; font-family: Times New Roman; font-size: 8pt; border-collapse: collapse;">
<tr>
<td style="width: 56%;"></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="14" style="vertical-align: bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Fair Value Measurements Using</div></div></td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">As of December&#160;31, 2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Fair Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;1</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;2</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;3</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Money market</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">5,448,990</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">5,448,990</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 12pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="16" style="height: 12pt; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="14" style="vertical-align: bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Fair Value Measurements Using</div></div></td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">As of December&#160;31, 2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Fair Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;1</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;2</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;3</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Money market</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">17,573,584</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">17,573,584</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Nonfinancial Assets and Liabilities </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The Company applies fair value techniques on a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">non-recurring</div> basis, if and when necessary, associated with: (1)&#160;valuing potential impairment losses related to goodwill which are accounted for pursuant to the authoritative guidance for intangibles&#8212;goodwill and other; and (2)&#160;valuing potential impairment losses related to long-lived assets which are accounted for pursuant to the authoritative guidance for property, plant and equipment. </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementInputsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of the fair value measurement of assets and liabilities, which includes financial instruments measured at fair value that are classified in shareholders' equity, which may be measured on a recurring or nonrecurring basis.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 820<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//820/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementInputsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140625259412592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loss per Share<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Loss per Share</a></td>
<td class="text"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">6</div></div>. <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Loss per Share</div></div> </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Basic per share data is computed by dividing net income or loss applicable to common stockholders by the weighted average number of common shares outstanding during the period. Diluted per share data is computed by dividing net income or loss applicable to common stockholders by the weighted average number of common shares outstanding during the period increased to include, if dilutive, the number of additional common shares </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">that would have been outstanding as calculated using the treasury stock method. Potential common shares were related to outstanding but unexercised options, multiple series of convertible preferred stock, and warrants for all periods presented. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The following were excluded from the diluted loss per share calculation for the periods presented because their effect would be anti-dilutive: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 76%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;">
<tr>
<td style="width: 74%;"></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">As of March&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2024</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Outstanding stock options</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">303,133</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">134,283</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Preferred stock</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">28,190</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">28,190</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Outstanding warrants</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">142,733</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">142,733</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">474,056</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">305,206</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><span></span>
</td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">4. Loss per Share </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The following were excluded from the diluted loss per share calculation for the periods presented because their effect would be anti-dilutive: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 76%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;">
<tr>
<td style="width: 74%;"></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">For&#160;the&#160;Year&#160;Ended</div></div><br/> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Outstanding stock options</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">140,109</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">78,334</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Preferred stock</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">28,190</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">28,190</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Outstanding warrants</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">142,733</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">142,758</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">311,032</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">249,282</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//260/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140625259248432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Composition of Certain Financial Statement Captions<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pstv_CompositionOfCertainFinancialStatementCaptionsAbstract', window );"><strong>Composition Of Certain Financial Statement Captions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock', window );">Composition of Certain Financial Statement Captions</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">5. Composition of Certain Financial Statement Captions </div></div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Other Current Assets </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">As of December&#160;31, 2023 and 2022, other current assets were comprised of the following (in thousands): </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 76%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;">
<tr>
<td style="width: 78%;"></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Prepaid services</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">644</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">2,999</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Prepaid insurance</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">636</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">698</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">1,280</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">3,697</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Property and Equipment, net </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">As of December&#160;31, 2023 and 2022, property and equipment, net, were comprised of the following (in thousands): </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 76%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;">
<tr>
<td style="width: 76%;"></td>
<td style="width: 6%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 6%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Office and computer equipment</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">1,632</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">1,474</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Leasehold improvements</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">1,810</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">1,810</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">3,442</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">3,284</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Less accumulated depreciation</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">(2,536</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">(1,960</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">906</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">1,324</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Depreciation expense totaled $0.6&#160;million and $0.5&#160;million for the year ended December&#160;31, 2023 and 2022, respectively. </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Intangible Assets, net </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">As of December&#160;31, 2023, intangible assets included the net book value of costs incurred for software upgrades. Amortization expenses totaled $0.1&#160;million for each of the years ended December&#160;31, 2023 and 2022. </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Accounts Payable and Accrued Expenses </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">As of December&#160;31, 2023 and 2022, accounts payable and accrued expenses were comprised of the following (in thousands): </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 76%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;">
<tr>
<td style="width: 76%;"></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Accounts payable</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">4,758</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">8,364</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Accrued payroll and bonus</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">987</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">989</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Accrued professional fees</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">128</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">147</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Accrued vacation and compensation</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">370</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">325</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Accrued R&amp;D studies</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">388</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">309</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">6,631</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">10,134</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pstv_CompositionOfCertainFinancialStatementCaptionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Composition of Certain Financial Statement Captions [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pstv_CompositionOfCertainFinancialStatementCaptionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pstv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//210/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalBalanceSheetDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140625387155392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments And Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">8. Commitments and Contingencies </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Leases </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The Company leases laboratory, office and storage facilities in San Antonio, Texas, under operating lease agreements that expire in 2025. The Company also leases certain office space in Austin, Texas under a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">month-to-month</div></div> operating lease agreement and certain office space in Charlottesville, Virginia (the &#8220;Charlottesville Lease&#8221;). The Charlottesville Lease has a term of 12 months and the Company has the ability to renew for three additional <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">one-year</div> periods. On March&#160;31, 2023, Company believed that it was reasonably </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">certain that the Charlottesville Lease will be renewed through March&#160;31, 2026, and as a result, it remeasured the related lease liability as of March&#160;31, 2023 to be $80,000 using the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">then-in-effect</div></div> discount rate of 12.76%. Effective July&#160;1, 2023, the Company added additional office lease premises in Charlottesville, which was accounted for as a separate operating lease contract with a lease liability and corresponding <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">right-of-use</div></div> asset of $19,000, as a discount rate of 13.47%. </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Piramal Master Services Agreement </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">On January 8, 2021, the Company entered into a Master Services Agreement (the &#8220;MSA&#8221;) with Piramal Pharma Solutions, Inc. (&#8220;Piramal&#8221;), for Piramal to perform certain services related to the development, manufacture, and supply of the Company&#8217;s rhenium (<div style="font-size: 75%; vertical-align: top;display:inline;font-size:8.3px">186</div>Re) obisbemeda intermediate drug product. The MSA includes the transfer of analytical methods, development of microbiological methods, process transfer and optimization, intermediate drug product manufacturing, and stability studies for the Company, which has been initiated at Piramal&#8217;s facility located in Lexington, Kentucky. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The MSA has a term of five years and will automatically renew for successive <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">one-year</div> terms unless either party notifies the other no later than six months prior to the original term or any additional terms of its intention to not renew the MSA. The Company has the right to terminate the MSA for convenience upon thirty days&#8217; prior written notice. Either party may terminate the MSA upon an uncured material breach by the other party or upon the bankruptcy or insolvency of the other party. </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Other commitments and contingencies </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The Company has entered into agreements with various research organizations for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">pre-clinical</div> and clinical development studies, which have provisions for cancellation. Under the terms of these agreements, the vendors provide a variety of services including conducting research, recruiting and enrolling patients, monitoring studies and data analysis. Payments under these agreements typically include fees for services and reimbursement of expenses. The timing of payments due under these agreements is estimated based on current study progress. As of March&#160;31, 2024, the Company did not have any clinical research study obligations. </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Legal proceedings </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">From time to time, the Company is subject to legal proceedings and claims, whether asserted or unasserted, that arise in the ordinary course of business. Due to their nature, such legal proceedings involve inherent uncertainties including, but not limited to, court rulings, negotiations between affected parties and governmental actions. Management assesses the probability of loss for such contingencies and accrues a liability and/or discloses the relevant circumstances, as appropriate. </div></div><span></span>
</td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">6. Commitments and Contingencies </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Leases </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">At the inception of a contractual arrangement, the Company determines whether the contract contains a lease by assessing whether there is an identified asset and whether the contract conveys the right to control the use of the </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">identified asset in exchange for consideration over a period of time. If both criteria are met, the Company calculates the associated lease liability and corresponding <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">right-of-use</div></div> asset upon lease commencement using a discount rate based on the rate implicit in the lease or an incremental borrowing rate commensurate with the term of the lease. Lease renewable options are included in the estimation of lease term when it is reasonably certain that the Company will exercise such options. </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Company records lease liabilities within current liabilities or long-term liabilities based upon the length of time associated with the lease payments. The Company records its operating lease <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">right-of-use</div></div> assets as long-term assets. Leases with an initial term of 12 months or less are not recorded on the balance sheets. Instead, the Company recognizes lease expense for these leases on a straight-line basis over the lease term in the statements of operations. </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Company leases laboratory, office and storage facilities in San Antonio, Texas, under operating lease agreements that expire in 2025. The Company also leases certain office space in Austin, Texas under a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">month-to-month</div></div> operating lease agreement and certain office space in Charlottesville, Virginia (the &#8220;Charlottesville Lease&#8221;). The Company&#8217;s existing operating lease agreements generally provide for periodic rent increases, and renewal and termination options. The Company&#8217;s lease agreements do not contain any material variable lease payments, residual value guarantees or material restrictive covenants. </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Charlottesville Lease has a term of 12 months and the Company has the ability to renew for three additional <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">one-year</div> periods. The Charlottesville Lease is currently set to expire on March 31, 2024, and is renewable twice for twelve months each time. On March&#160;31, 2023, Company believed that it was reasonably certain that the Charlottesville Lease will be renewed through March&#160;31, 2026, and as a result, it remeasured the related lease liability as of March&#160;31, 2023 to be $80,000 using the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">then-in-effect</div></div> discount rate of 12.76%. Effective July&#160;1, 2023, the Company added additional office lease premises in Charlottesville, which was accounted for as a separate operating lease contract with a lease liability and corresponding <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">right-of-use</div></div> asset of $19,000, at a discount rate of 13.47%. </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Certain leases require the Company to pay taxes, insurance, and maintenance. Payments for the transfer of goods or services such as common area maintenance and utilities represent <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">non-lease</div> components. The Company elected the package of practical expedients and therefore does not separate <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">non-lease</div> components from lease components. </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Company&#8217;s operating lease liabilities and corresponding <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">right-of-use</div></div> assets are included in the balance sheets. As of December&#160;31, 2023, the weighted average discount rate used to measure operating lease liabilities and the operating leases remaining term were 10.67% and 1.6 years, respectively. </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The table below summarizes the Company&#8217;s operating lease costs from its statements of operations, and cash payments from its statements of cash flows. </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 76%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;">
<tr>
<td style="width: 70%;"></td>
<td style="width: 11%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 11%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Year&#160;Ended&#160;December&#160;31,</div></div></td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Lease expense:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Operating lease expense</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">141</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">159</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Total lease expense</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">141</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">159</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Cash payment information:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Operating cash used for operating leases</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">141</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">159</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Total cash paid for amounts included in the measurement of lease liabilities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">141</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">159</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Total rent expenses for each of the years ended December&#160;31, 2023 and 2022 was $0.2&#160;million, which includes leases in the table above, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">month-to-month</div></div> operating leases, and common area maintenance charges. </div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"> </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The Company&#8217;s future minimum annual lease payments under operating leases at December&#160;31, 2023 are as follows (in thousands): </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 68%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;">
<tr>
<td style="width: 76%;"></td>
<td style="width: 20%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Operating&#160;Leases</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">2024</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">146</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">2025</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">60</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">2026</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">11</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Total minimum lease payments</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">217</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Less: amount representing interest</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">(12</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Present value of obligations under leases</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">205</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Less: current portion</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">(120</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Noncurrent lease obligations</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">85</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Services Agreement and Sales Order with Medidata </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">On March&#160;31, 2022, the Company and Medidata Solutions, Inc. (&#8220;Medidata&#8221;) entered into a Sales Order (the &#8220;Sales Order&#8221;), pursuant to which Medidata will build a Synthetic Control Arm<div style="font-size: 75%; vertical-align: top;display:inline;font-size:8.3px">&#174;</div> (&#8220;SCA&#8221;) platform that facilitates the use of historical clinical data to incorporate into the Company&#8217;s Phase 2 clinical trial of rhenium (<div style="font-size: 75%; vertical-align: top;display:inline;font-size:8.3px">186</div>Re) obisbemeda in recurrent glioblastoma (&#8220;GBM&#8221;). The Sales Order is governed under the terms of a services agreement, dated November&#160;5, 2021. The Sales Order had a term of six months, and work under the Sales Order has been completed. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Piramal Master Services Agreement </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">On January 8, 2021, the Company entered into a Master Services Agreement (the &#8220;MSA&#8221;) with Piramal Pharma Solutions, Inc. (&#8220;Piramal&#8221;), for Piramal to perform certain services related to the development, manufacture, and supply of the Company&#8217;s rhenium (<div style="font-size: 75%; vertical-align: top;display:inline;font-size:8.3px">186</div>Re) obisbemeda-Liposome Intermediate Drug Product. The MSA includes the transfer of analytical methods, development of microbiological methods, process transfer and optimization, intermediate drug product manufacturing, and stability studies for the Company, which has been initiated at Piramal&#8217;s facility located in Lexington, Kentucky. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The MSA has a term of five years and will automatically renew for successive <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">one-year</div> terms unless either party notifies the other no later than six months prior to the original term or any additional terms of its intention to not renew the MSA. The Company has the right to terminate the MSA for convenience upon thirty days&#8217; prior written notice. Either party may terminate the MSA upon an uncured material breach by the other party or upon the bankruptcy or insolvency of the other party. </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Other Commitments and Contingencies </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The Company has entered into agreements with various research organizations for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">pre-clinical</div> and clinical development studies, which have provisions for cancellation. Under the terms of these agreements, the vendors provide a variety of services including conducting research, recruiting and enrolling patients, monitoring studies and data analysis. Payments under these agreements typically include fees for services and reimbursement of expenses. The timing of payments due under these agreements is estimated based on current study progress. As of December&#160;31, 2023, the Company did not have any clinical research study obligations. </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Legal proceedings </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">On December&#160;9, 2022, the Company entered into a settlement agreement (the &#8220;Settlement Agreement&#8221;) with Lorem Vascular, Pte. Ltd. (&#8220;Lorem&#8221;) to settle a prior litigation matter. Under the terms of the Settlement </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Agreement, the Company made a payment to Lorem, and Lorem moved to dismiss the lawsuit with prejudice. The Settlement Agreement released the Company from all claims made by Lorem. The parties to the Settlement Agreement recognized that it did not constitute an admission of liability, wrongdoing, or any matter of fact or law. The Settlement was conditioned on the customary terms contained in the Settlement Agreement and was approved by the Court and the case was dismissed on January&#160;17, 2023. As of December&#160;31, 2022, the Company accrued the settlement amount, as well as the accounts that the Company has confirmed to be recoverable under its insurance claims on the matter. The net amount of $1.4&#160;million that was not recoverable under the Company&#8217;s insurance has been reflected as an expense in the statement of operations for the year ended December&#160;31, 2022. The full settlement amount was paid in January 2023. All legal costs related to the Lorem Claim were expensed as incurred. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The Company is subject to various claims and contingencies related to legal proceedings. Due to their nature, such legal proceedings involve inherent uncertainties including, but not limited to, court rulings, negotiations between affected parties and governmental actions. Management assesses the probability of loss for such contingencies and accrues a liability and/or discloses the relevant circumstances, as appropriate. </div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//450/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480327/954-440-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140625258922752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License Agreements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pstv_LicenseAgreementAbstract', window );"><strong>License Agreement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pstv_LicenseAgreementDisclosureTextBlock', window );">License Agreements</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">9. License Agreements </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Biocept License Agreement </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">On September&#160;7, 2023, the Company entered into a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">Non-Exclusive</div> License and Services Agreement (the &#8220;Biocept Agreement&#8221;) with Biocept, Inc (&#8220;Biocept&#8221;), pursuant to which Biocept granted the Company a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">non-exclusive</div> license to use the Biocept proprietary cell enumeration test, CNsideTM (&#8220;CNside&#8221;). In exchange for the license, the Company issued to Biocept 53,381 unregistered shares, the fair value of which was $75,000. The Biocept Agreement also provides that if Biocept fully transfers the technology to the Company, a tech transfer and validation fee of $300,000 will be payable. In addition, the Company was granted an option for an exclusive worldwide license for $1,000,000 on or before December&#160;31, 2024, to process and perform cell enumeration testing for treatments for other patients including those on the Company&#8217;s radiotherapeutic drugs. </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">On October&#160;16, 2023, Biocept filed a voluntary petition for relief under the provisions of Chapter 7 of Title 11 of the United States Bankruptcy Code. See Note 12 for further information regarding the Company&#8217;s acquisition of substantially all right, title and interest in CNside. </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"> </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">UT Health Science Center at San Antonio (&#8220;UTHSCSA&#8221;) License Agreement </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">On December&#160;31, 2021, the Company entered into a Patent and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">Know-How</div> License Agreement (the &#8220;UTHSCSA License Agreement&#8221;) with The University of Texas Health Science Center at San Antonio (&#8220;UTHSCSA&#8221;), pursuant to which UTHSCSA granted the Company an irrevocable, perpetual, exclusive, fully <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">paid-up</div> license, with the right to sublicense and to make, develop, commercialize and otherwise exploit certain patents, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">know-how</div> and technology related to the development of biodegradable alginate microspheres (&#8220;BAM&#8221;) containing nanoliposomes loaded with imaging and/or therapeutic payloads. </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">NanoTx License Agreement </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">On March&#160;29, 2020, the Company and NanoTx, Corp. (&#8220;NanoTx&#8221;) entered into a Patent and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">Know-How</div> License Agreement, pursuant to which NanoTx granted the Company an irrevocable, perpetual, exclusive, fully <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">paid-up</div> license, with the right to sublicense and to make, develop, commercialize and otherwise exploit certain patents, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">know-how</div> and technology related to the development of radiolabeled nanoliposomes. </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The transaction terms included an upfront payment of $0.4&#160;million in cash and $0.3&#160;million in the Company&#8217;s voting stock. The transaction terms also included success-based milestone and royalty payments contingent on key clinical, regulatory and sales milestones, as well as the requirement to pay 15% of any <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">non-dilutive</div> monetary awards or grants received from external agencies to support product development of the nanoliposome encapsulated BMEDA-chelated radioisotope, which includes grants from CPRIT. As of March&#160;31, 2024, the Company accrued $0.5&#160;million of payments due to NanoTx as a result of the CPRIT grant received (see Note 7, Grant Revenue of the condensed financial statements for additional information). </div><span></span>
</td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">7. License Agreements </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Biocept License Agreement </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">On September&#160;7, 2023, the Company entered into a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">Non-Exclusive</div> License and Services Agreement (the &#8220;Biocept Agreement&#8221;) with Biocept, Inc (&#8220;Biocept&#8221;), pursuant to which Biocept granted the Company a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">non-exclusive</div> license to use the Biocept proprietary cell enumeration test, CNside<div style="font-size: 75%; vertical-align: top;display:inline;font-size:8.3px">TM</div>. In exchange for the license, the Company issued to Biocept 53,381 unregistered shares, the fair value of which was $75,000. The Biocept Agreement also provides that if Biocept fully transfers the technology to the Company, a tech transfer and validation fee of $300,000 will be payable. In addition, the Company was granted an option for an exclusive worldwide license for $1,000,000 on or before December&#160;31, 2024, to process and perform cell enumeration testing for treatments for other patients including those on the Company&#8217;s radiotherapeutic drugs. </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">On October&#160;16, 2023, Biocept filed a voluntary petition for relief under the provisions of Chapter 7 of Title 11 of the United States Bankruptcy Code, making the full transfer of the Biocept technology to the Company unlikely. In addition, the Biocept Agreement is subject to provisions under the Bankruptcy Code. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">UT Health Science Center at San Antonio (&#8220;UTHSA&#8221;) License Agreement </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">On December&#160;31, 2021, the Company entered into a Patent and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">Know-How</div> License Agreement (the &#8220;UTHSA License Agreement&#8221;) with UTHSA, pursuant to which UTHSA granted the Company an irrevocable, perpetual, exclusive, fully <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">paid-up</div> license, with the right to sublicense and to make, develop, commercialize and otherwise exploit certain patents, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">know-how</div> and technology related to the development of biodegradable alginate microspheres (BAM) containing nanoliposomes loaded with imaging and/or therapeutic payloads. </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Pursuant to the UTHSA License Agreement, the Company was required to make an upfront payment, which was recorded as <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">in-process</div> research and development acquired in the statement of operations for the year ended December&#160;31, 2021. The upfront payment of $0.3&#160;million was paid in cash in January 2022. </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">NanoTx License Agreement </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">On March&#160;29, 2020, the Company and NanoTx, Corp. (&#8220;NanoTx&#8221;) entered into a Patent and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">Know-How</div> License Agreement (the &#8220;NanoTx License Agreement&#8221;), pursuant to which NanoTx granted the Company an irrevocable, perpetual, exclusive, fully <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">paid-up</div> license, with the right to sublicense and to make, develop, commercialize and otherwise exploit certain patents, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">know-how</div> and technology related to the development of radiolabeled nanoliposomes. </div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"> </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">The transaction terms included an upfront payment of $0.4&#160;million in cash and $0.3&#160;million in the Company&#8217;s voting stock. The transaction terms also included success-based milestone and royalty payments contingent on key clinical, regulatory and sales milestones, as well as the requirement to pay 15% of any <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">non-dilutive</div> monetary awards or grants received from external agencies to support product development of the nanoliposome encapsulated BMEDA-chelated radioisotope, which includes grants from the Cancer Prevention&#160;&amp; Research Institute of Texas (&#8220;CPRIT&#8221;). As of December&#160;31, 2023, the Company accrued $0.5&#160;million of payments due to NanoTx as a result of the CPRIT grant received (Note 9). </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pstv_LicenseAgreementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>License agreement abstract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pstv_LicenseAgreementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pstv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pstv_LicenseAgreementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for license agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pstv_LicenseAgreementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pstv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140625371758160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Term Loan Obligations<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Term Loan Obligations</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">5. Term Loan Obligations </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">On May 29, 2015, the Company entered into the Loan and Security Agreement (the &#8220;Loan and Security Agreement&#8221;), pursuant to which Oxford Finance, LLC (&#8220;Oxford&#8221;) funded an aggregate principal amount of </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"> </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">$17.7&#160;million (the &#8220;Term Loan&#8221;), subject to the terms and conditions set forth in the Loan and Security Agreement. The Term Loan accrues interest at a floating rate of at least 8.95% per annum, comprised of a three-month LIBOR rate with a floor of 1.00% plus 7.95%. Pursuant to the Loan and Security Agreement, as amended, the Company made interest only payments through May 1, 2021, and thereafter is required to make payments of principal and accrued interest in equal monthly installments sufficient to amortize the Term Loan through June&#160;1, 2024, the maturity date. At maturity of the Term Loan, or earlier repayment in full following voluntary prepayment or upon acceleration, the Company is required to make a final payment in an aggregate amount equal to approximately $3.2&#160;million. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">From September 2017 to March 2020, the Company entered into a total of nine amendments to the Term Loan that, among other things, extended the interest only period, required repayment of $3.1&#160;million using the proceeds received from sale of the Company&#8217;s former UK and Japan subsidiaries in April 2019, increased the final payment, increased the final payment fee upon maturity or early repayment of the Term Loan, increased the minimum liquidity covenant level to $2.0&#160;million and deferred the start date of principal repayment from May 1, 2020 to May 1, 2021 and extended the term of the Term Loan from September 1, 2021 to June 1, 2024. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">On June&#160;28, 2023, the Company and Oxford entered into a tenth amendment to the Loan and Security Agreement, and revised the interest rate of the Loan to the greater of: (1) 8.95%, or (2)&#160;the sum of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">1-month</div> Secured Overnight Financing Rate and 8.05%, effective July&#160;1, 2023. </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The Term Loan, as amended, is collateralized by a security interest in substantially all of the Company&#8217;s existing and subsequently acquired assets, including its intellectual property assets, subject to certain exceptions set forth in the Loan and Security Agreement, as amended. The intellectual property asset collateral will be released upon the Company achieving a certain liquidity level when the total principal outstanding under the Loan and Security Agreement is less than $3.0&#160;million. As of March&#160;31, 2024, there was $0.4&#160;million principal amount outstanding under the Term Loan, excluding the $3.2&#160;million final payment fee, and the Company was in compliance with all of the debt covenants under the Loan and Security Agreement. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Company&#8217;s interest expense for the three ended March&#160;31, 2024 and 2023 was $34,000 and $0.1&#160;million, respectively. Interest expense is calculated using the effective interest method; therefore it is inclusive of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">non-cash</div> amortization in the amount of $21,000 and $0.1&#160;million for the three ended March&#160;31, 2024 and 2023, respectively, related to the amortization of the debt discount, capitalized loan costs, and accretion of final payment. </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The Loan and Security Agreement, as amended, contains customary indemnification obligations and customary events of default, including, among other things, the Company&#8217;s failure to fulfill certain obligations under the Term Loan, as amended, and the occurrence of a material adverse change, which is defined as a material adverse change in the Company&#8217;s business, operations, or condition (financial or otherwise), a material impairment of the prospect of repayment of any portion of the loan. In the event of default by the Company or a declaration of material adverse change by its lender, under the Term Loan, the lender would be entitled to exercise its remedies thereunder, including the right to accelerate the debt, upon which the Company may be required to repay all amounts then outstanding under the Term Loan, which could materially harm the Company&#8217;s financial condition. As of March&#160;31, 2024, the Company has not received any notification or indication from Oxford that it intends to invoke the material adverse change clause. See Note 12 for further information regarding the repayment of the Term Loan. </div></div><span></span>
</td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">8. Term Loan Obligations </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">On May 29, 2015, the Company entered into the Loan and Security Agreement (the &#8220;Loan and Security Agreement&#8221;), pursuant to which Oxford Finance, LLC (&#8220;Oxford&#8221;) funded an aggregate principal amount of $17.7&#160;million (the &#8220;Term Loan&#8221;), subject to the terms and conditions set forth in the Loan and Security Agreement. The Term Loan accrued interest at a floating rate of at least 8.95% per annum, comprised of a three-month LIBOR rate with a floor of 1.00% plus 7.95%. Pursuant to the Loan and Security Agreement, as amended, the Company was required to make interest only payments through May 1, 2021 and thereafter it was required to make payments of principal and accrued interest in equal monthly installments sufficient to amortize the Term Loan through June&#160;1, 2024, the maturity date. At maturity of the Term Loan, or earlier repayment in full following voluntary prepayment or upon acceleration, the Company is required to make a final payment in an aggregate amount equal to approximately $3.2&#160;million. In connection with the Term Loan, on May&#160;29, 2015, the Company issued to Oxford warrants to purchase an aggregate of 188 shares of the Company&#8217;s common stock at an exercise price of $5,175 per share. These warrants became exercisable as of November&#160;30, 2015 and will expire on May&#160;29, 2025 and, following the authoritative accounting guidance, are equity classified and their respective fair value was recorded as a discount to the debt. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The Term Loan was collateralized by a security interest in substantially all of the Company&#8217;s existing and subsequently acquired assets, including its intellectual property assets, subject to certain exceptions set forth in the Loan and Security Agreement, as amended. The intellectual property asset collateral would be released upon the Company achieving a certain liquidity level when the total principal outstanding under the Loan and Security Agreement is less than $3&#160;million. As of December&#160;31, 2023, there was $0.8&#160;million principal amount outstanding under the Term Loan, excluding the $3.2&#160;million final payment fee, and the Company was in compliance with all of the debt covenants under the Loan and Security Agreement. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Company&#8217;s interest expense for the years ended December&#160;31, 2023 and 2022 was $0.4&#160;million and $0.7&#160;million, respectively. Interest expense is calculated using the effective interest method; therefore it is inclusive of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">non-cash</div> amortization in the amount of $0.2&#160;million and $0.4&#160;million for the year ended December&#160;31, 2023 and 2022, respectively, related to the amortization of the debt discount, deferred financing costs, and accretion of final payment. </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The Loan and Security Agreement contains customary indemnification obligations and customary events of default, including, among other things, the Company&#8217;s failure to fulfill certain obligations under the Term Loan, as amended, and the occurrence of a material adverse change, which is defined as a material adverse change in the Company&#8217;s business, operations, or condition (financial or otherwise), a material impairment of the prospect of repayment of any portion of the loan. In the event of default by the Company or a declaration of material adverse change by its lender, under the Term Loan, the lender would be entitled to exercise its remedies thereunder, including the right to accelerate the debt, upon which the Company may be required to repay all amounts then outstanding under the Term Loan, which could materially harm the Company&#8217;s financial condition. As of December&#160;31, 2023, the Company has not received any notification or indication from Oxford to invoke the material adverse change clause. </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"> </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Additional information relating to the then-outstanding Term Loan as of December&#160;31, 2023 and 2022 is presented in the following table (in thousands, except interest rate): </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 100%; font-family: Times New Roman; font-size: 8pt; border-collapse: collapse;">
<tr>
<td style="width: 53%;"></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;display:inline;">Year ended December&#160;31, 2023</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">Origination Date</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Original</div></div><br/> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Loan</div></div><br/> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Amount</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Interest</div></div><br/> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Rate*</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Current</div></div><br/> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Monthly</div></div><br/> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Payment**</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Amended<br/> expiration<br/> date</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Remaining</div></div><br/> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Principal</div></div><br/> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">(Face&#160;Value)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;"><div style="-sec-ix-hidden:hidden116199096;display:inline;">May 2015</div></div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">17,700</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">13.39</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">134</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">June 1, 2024</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">804</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;">
<tr>
<td style="width: 52%;"></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;display:inline;">Year ended December&#160;31, 2022</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">Origination Date</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Original</div></div><br/> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Loan</div></div><br/> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Amount</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Interest</div></div><br/> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Rate*</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Monthly</div></div><br/> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Payment**</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Amended<br/> expiration<br/> date</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Remaining</div></div><br/> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Principal</div></div><br/> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">(Face&#160;Value)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;"><div style="-sec-ix-hidden:hidden116199109;display:inline;">May 2015</div></div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">17,700</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">8.95</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">134</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">June 1, 2024</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">2,412</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentColor; border-image: none; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;text-align:left;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">*</div></div></td>
<td style="vertical-align: top;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Three month LIBOR rate with a floor of 1% plus 7.95% </div></div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentColor; border-image: none; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;text-align:left;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">**</div></div></td>
<td style="vertical-align: top;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Monthly payment reflects principal and interest </div></div></div></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//470/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1C<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1C<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1C<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140625259449312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Grant Revenue<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerTextBlock', window );">Grant Revenue</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">7. Grant Revenue </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">On September&#160;19, 2022, the Company entered into that certain CPRIT contract (&#8220;CPRIT Contract&#8221;), effective as of August 31, 2022, with CPRIT, pursuant to which CPRIT will provide the Company with a CPRIT grant (&#8220;CPRIT Grant&#8221;) over a three-year period to fund the continued development of rhenium (<div style="font-size: 75%; vertical-align: top;display:inline;font-size:8.3px">186</div>Re) obisbemeda for the treatment of patients with leptomeningeal metastases (&#8220;LM&#8221;). The CPRIT Grant is subject to customary CPRIT funding conditions, including, but not limited to, a matching fund requirement (one dollar for every two dollars awarded by CPRIT), revenue sharing obligations upon commercialization of rhenium (<div style="font-size: 75%; vertical-align: top;display:inline;font-size:8.3px">186</div>Re) obisbemeda based on specific dollar thresholds and tiered low single digit royalty rates until CPRIT receives the aggregate amount of 400% of the proceeds awarded under the CPRIT Grant, and certain reporting requirements. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The CPRIT Contract will terminate on August 30, 2025, unless terminated earlier by (a)&#160;the mutual written consent of all parties to the CPRIT Contract, (b)&#160;CPRIT for an event of default by the Company, (c)&#160;CPRIT, if the funds allocated to the CPRIT Grant become legally unavailable during the term of the CPRIT Contract and CPRIT is unable to obtain additional funds for such purposes, and (d)&#160;the Company for convenience. CPRIT may require the Company to repay some or all of the disbursed CPRIT Grant proceeds (with interest not to exceed 5% annually) in the event of the early termination of the CPRIT Contract by CPRIT for an event of default by the Company or by the Company for convenience, or if the Company relocates its principal place of business outside of the state of Texas during the CPRIT Contract term or within three years after the final payment of the grant funds. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Company retains ownership over any intellectual property developed under the CPRIT Contract (each, a &#8220;Project Result&#8221;). With respect to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">non-commercial</div> use of any Project Result, the Company granted to CPRIT a nonexclusive, irrevocable, royalty-free, perpetual, worldwide license with right to sublicense any necessary additional intellectual property rights to exploit all Project Results by CPRIT, other governmental entities and agencies of the State of Texas, and private or independent institutions of higher education located in Texas, for education, research and other <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">non-commercial</div> purposes. </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The Company recognized $1.7&#160;million and $0.5&#160;million in grant revenue from the CPRIT Contract during the three months ended March&#160;31, 2024 and 2023, respectively. </div></div><span></span>
</td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">9. Grant Revenue </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">On September&#160;19, 2022, the Company entered into the CPRIT Contract, effective as of August 31, 2022, with CPRIT, pursuant to which CPRIT will provide the Company with the CPRIT Grant of up to $17.6&#160;million over a three-year period to fund the continued development of rhenium (<div style="font-size: 75%; vertical-align: top;display:inline;font-size:8.3px">186</div>Re) obisbemeda (previously known as <div style="font-size: 75%; vertical-align: top;display:inline;font-size:8.3px">186</div>RNL) for the treatment of patients with leptomeningeal metastases (&#8220;LM&#8221;). The CPRIT Grant is subject to customary CPRIT funding conditions, including, but not limited to, a matching fund requirement (one dollar for every two dollars awarded by CPRIT), revenue sharing obligations upon commercialization of rhenium (<div style="font-size: 75%; vertical-align: top;display:inline;font-size:8.3px">186</div>Re) obisbemeda based on specific dollar thresholds and tiered low single digit royalty rates until CPRIT receives the aggregate amount of 400% of the proceeds awarded under the CPRIT Grant, and certain reporting requirements. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The CPRIT Contract will terminate on August 30, 2025, unless terminated earlier by (a)&#160;the mutual written consent of all parties to the CPRIT Contract, (b)&#160;CPRIT for an event of default by the Company, (c)&#160;CPRIT, if the funds allocated to the CPRIT Grant become legally unavailable during the term of the CPRIT Contract and CPRIT is unable to obtain additional funds for such purposes, and (d)&#160;the Company for convenience. CPRIT may require the Company to repay some or all of the disbursed CPRIT Grant proceeds (with interest not to exceed 5% annually) in the event of the early termination of the CPRIT Contract by CPRIT for an event of default by the Company or by the Company for convenience, or if the Company relocates its principal place of business outside of the state of Texas during the CPRIT Contract term or within three years after the final payment of the grant funds. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Company retains ownership over any intellectual property developed under the contract (each, a &#8220;Project Result&#8221;). With respect to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">non-commercial</div> use of any Project Result, the Company granted to CPRIT a nonexclusive, irrevocable, royalty-free, perpetual, worldwide license with right to sublicense any necessary additional intellectual property rights to exploit all Project Results by CPRIT, other governmental entities and agencies of the State of Texas, and private or independent institutions of higher education located in Texas, for education, research and other <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">non-commercial</div> purposes. </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Company determined that the CPRIT Contract is not in the scope of ASC 808, ASC <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">958-605,</div> or ASC 606. Applying IAS 20 by analogy, the Company recognizes proceeds received under the CPRIT Contract as grant revenue on the statement of operations when related costs are incurred. </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">During the three months ended June&#160;30, 2023, the Company identified eligible costs of approximately $637,000 and $168,000 that were incurred in the fourth quarter of 2022 and the three months ended March&#160;31, 2023, respectively, that were reimbursable under the CPRIT arrangement. The Company determined that these costs should have been recorded in these respective periods as grant revenue. The Company assessed the impact of this error on the Company&#8217;s previously issued financial statements and determined that it was immaterial. As a result, an <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">out-of-period</div></div> adjustment of approximately $637,000 has been recorded as an increase in grant revenue in the year ended December&#160;31, 2023. </div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"> </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The Company recognized $4.9&#160;million and $0.2&#160;million in grant revenue from the CPRIT Contract during the year ended December&#160;31, 2023 and 2022, respectively. </div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-9<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-15<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-12<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-12<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-12<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-13<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 606<br> -Publisher FASB<br> -URI https://asc.fasb.org//606/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140625254666944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">10. Income Taxes </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Pursuant to the Internal Revenue Code (&#8220;IRC&#8221;) of 1986, as amended, specifically IRC &#167;382 (&#8220;Section 382&#8221;) and IRC &#167;383, the Company&#8217;s ability to use net operating loss (&#8220;NOLs&#8221;) and R&amp;D tax credit carry forwards (&#8220;tax attribute carry forwards&#8221;) to offset future taxable income is limited if the Company experiences a cumulative change in ownership of more than 50% within a three-year testing period. The Company&#8217;s use of federal and state NOLs and research credits could be limited further by the provisions of Section&#160;382 depending upon the timing and amount of additional equity securities that the Company has issued or will issue. State NOL carryforwards may be similarly limited. If a change in ownership were to have occurred, NOL and tax credits carryforwards could be eliminated or restricted. If eliminated, the related asset would be removed from the deferred tax asset schedule with a corresponding reduction in the valuation allowance. Due to the existence of the valuation allowance, limitations created by ownership changes, if any, will not impact the Company&#8217;s effective tax rate. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The Company has recorded a full valuation allowance against its net deferred tax assets and due to our net losses for the years ended December&#160;31, 2023 and 2022, there was no provision or benefit for income taxes recorded. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">A reconciliation of the total income tax provision tax rate to the statutory federal income tax rates of 21% for the years ended December&#160;31, 2023 and 2022, respectively, is as follows: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 76%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;">
<tr>
<td style="width: 81%;"></td>
<td style="width: 6%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Income tax expense (benefit) at federal statutory rate</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">(21.0</td>
<td style="vertical-align: bottom; white-space: nowrap;">)%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">(21.0</td>
<td style="vertical-align: bottom; white-space: nowrap;">)%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Change in valuation allowance</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">25.5</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">22.5</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Income tax expense (benefit) at state statutory rate</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">(0.2</td>
<td style="vertical-align: bottom; white-space: nowrap;">)%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">(0.2</td>
<td style="vertical-align: bottom; white-space: nowrap;">)%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Share based compensation</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">1.0</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">0.9</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">NOLs expiring and adjustments to NOL</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">(0.1</td>
<td style="vertical-align: bottom; white-space: nowrap;">)%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">0.5</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Research credit</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">(5.1</td>
<td style="vertical-align: bottom; white-space: nowrap;">)%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">(2.5</td>
<td style="vertical-align: bottom; white-space: nowrap;">)%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Return to provision</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">(0.1</td>
<td style="vertical-align: bottom; white-space: nowrap;">)%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">(0.1</td>
<td style="vertical-align: bottom; white-space: nowrap;">)%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Change in state rate</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">(0.1</td>
<td style="vertical-align: bottom; white-space: nowrap;">)%&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">0.0</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">0.0</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The tax effects of temporary differences that give rise to significant portions of our deferred tax assets and deferred tax liabilities as of December&#160;31, 2023 and 2022 are as follows (in thousands): </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 76%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;">
<tr>
<td style="width: 72%;"></td>
<td style="width: 10%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 10%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Deferred tax assets:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Accrued expenses</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">269</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">262</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Share based compensation</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">99</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">107</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Net operating loss carryforwards</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">13,397</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">12,605</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Income tax credit carryforwards</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">1,630</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">956</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Property and equipment, principally due to differences in depreciation</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">154</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">89</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Intangible assets</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">3,527</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">2,073</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Other, net</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">453</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">53</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">19,529</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">16,145</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Valuation allowance</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">(19,486</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">(16,092</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Total deferred tax assets, net of allowance</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">43</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">53</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"> </div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 76%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;">
<tr>
<td style="width: 82%;"></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Deferred tax liabilities:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Other</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">(43</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">(53</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Total deferred tax liability</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">(43</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">(53</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Net deferred tax assets (liability)</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The Company has established a valuation allowance against its net deferred tax assets due to the uncertainty surrounding the realization of such assets. The Company periodically evaluates the recoverability of the deferred tax assets. At such time as it is determined that it is more likely than not that deferred tax assets are realizable, the valuation allowance will be reduced. The Company has recorded a full valuation allowance of $19.5&#160;million as of December&#160;31, 2023 as it does not believe it is more likely than not the net deferred tax assets will be realized. The Company increased its valuation allowance by approximately $3.4&#160;million during the year ended December&#160;31, 2023. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">At December&#160;31, 2023, the Company had federal and state tax loss carry forwards of approximately $63.2&#160;million, and $2.6&#160;million, respectively. The federal and state net operating loss carry forwards begin to expire in 2037 and 2038, if unused, respectively. The federal net operating loss carryover includes $59.8&#160;million of net operating losses generated after 2017. Federal net operating losses generated from 2018 onwards carryover indefinitely and may generally be used to offset up to 80% of future taxable income. At December&#160;31, 2023, the Company had federal tax credit carry forwards of approximately $1.9&#160;million, before reduction for uncertain tax positions. The federal credits will begin to expire in 2039, if unused. In addition, at December&#160;31, 2023, the Company had state tax credit carry forwards of approximately $0.2&#160;million, before reduction for uncertain tax positions. The state credits will begin to expire in 2043, if unused. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The Company follows the provisions of income tax guidance which provides recognition criteria and a related measurement model for uncertain tax positions taken or expected to be taken in income tax returns. The guidance requires that a position taken or expected to be taken in a tax return be recognized in the financial statements when it is more likely than not that the position would be sustained upon examination by tax authorities. Tax positions that meet the more likely than not threshold are then measured using a probability weighted approach recognizing the largest amount of tax benefit that is greater than 50% likely of being realized upon ultimate settlement. The Company has not recognized any liability for uncertain tax positions as of December&#160;31, 2023 and 2022. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Following is a tabular reconciliation of the unrecognized tax benefits activity during the years ended December&#160;31, 2023 and 2022 (in thousands): </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 76%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;">
<tr>
<td style="width: 82%;"></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Unrecognized Tax Benefits &#8211; Beginning</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">209</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">81</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Gross decreases &#8211; tax positions in prior period</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">(16</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">(1</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Gross increase &#8211; current-period tax positions</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">215</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">129</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Unrecognized Tax Benefits &#8211; Ending</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">408</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">209</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The unrecognized tax benefit amounts are reflected in the determination of the Company&#8217;s deferred tax assets. If recognized, none of these amounts would affect the Company&#8217;s effective tax rate, since it would be offset by an equal reduction in the deferred tax asset valuation allowance. The Company does not foresee material changes to its liability for uncertain tax benefits within the next twelve months. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The Company did not recognize interest related to unrecognized tax benefits in interest expense and penalties in operating expenses for the year ended December&#160;31, 2023. </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"> </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The Company files income tax returns with the United States and various state jurisdictions. To its knowledge, the Company is currently not under examination by the Internal Revenue Service or any other taxing authority. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">With few exceptions, the Company&#8217;s tax years prior to 2020 are no longer open to examination by the taxing authority. While not open to examination, the tax attributes generated in tax years 2018 and forward remain subject to adjustment by the taxing authorities if utilized in tax years which are still open to examination. </div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//740/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-21<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482526/740-270-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-17<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140625258730672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plan<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock', window );">Employee Benefit Plan</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">11. Employee Benefit Plan </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The Company implemented a 401(k) retirement savings and profit sharing plan (the &#8220;Plan&#8221;) effective January&#160;1, 1999. During 2022, the Company commenced safe harbor matching contribution for up to 4% of eligible employee contributions. Total matching contribution under the Plan amounted to approximately $107,000 and $100,000 for the year ended December&#160;31, 2023 and 2022, respectively. </div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for an entity's employee compensation and benefit plans, including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, share-based compensation, life insurance, severance, health care, unemployment and other benefit plans.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 710<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//710/tableOfContent<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 712<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//712/tableOfContent<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 715<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//715/tableOfContent<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//718/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndEmployeeBenefitPlansTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140625259024864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">10. Stockholders&#8217; Equity </div></div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Preferred Stock </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The Company has authorized 5,000,000 shares of preferred stock, par value $0.001 per share. The Company&#8217;s Board is authorized to designate the terms and conditions of any preferred stock the Company issues without further action by the common stockholders. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Series F Preferred Stock </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">On March&#160;3, 2023, the Company filed a certificate of designation (the &#8220;Certificate of Designation&#8221;) with the Secretary of State of the State of Delaware, effective as of the time of filing, designating the rights, preferences, privileges and restrictions of the Series F Preferred Stock, with the total authorization of one (1)&#160;share of Series F Preferred Stock. The Certificate of Designation provided that the share of Series F Preferred Stock would have 50,000,000 votes per share of Series F Preferred Stock and would vote together with the Company&#8217;s common stock, as a single class exclusively with respect to any proposal to amend the Company&#8217;s Charter to effect the Reverse Stock Split. On March&#160;3, 2023, the Company entered into a subscription and investment representation agreement with Richard J. Hawkins, chairman of the board of the Company, who is an accredited investor (the &#8220;Series F Preferred Stock Purchaser&#8221;), pursuant to which the Company agreed to issue and sell one (1)&#160;share of the Company&#8217;s Series F Preferred Stock, par value $0.001 per share, to the Series F Preferred Stock Purchaser for $1,000 in cash. The sale closed on March 3, 2023. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">At the Company&#8217;s 2023 annual meeting, the Series F Preferred Stock was voted, without action by the holder, on the proposal to approve the Reverse Stock Split in the same proportion as shares of common stock voted to approve the Reverse Stock Split. The Series F Preferred Stock otherwise had no voting rights except as otherwise required by the General Corporation Law of the State of Delaware. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The Series F Preferred Stock was not convertible into, or exchangeable for, shares of any other class or series of stock or other securities of the Company. The Series F Preferred Stock had no rights with respect to any </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"> </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">distribution of assets of the Company, including upon a liquidation, bankruptcy, reorganization, merger, acquisition, sale, dissolution or winding up of the Company, whether voluntarily or involuntarily. The holder of the Series F Preferred Stock was not entitled to receive dividends of any kind. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The outstanding share of Series F Preferred Stock was redeemed in whole, automatically effective upon the approval by the Company&#8217;s stockholders of the Reverse Stock Split. Upon such redemption, the holder of the Series F Preferred Stock received consideration of $1,000 in cash. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Series B and C Preferred Stock </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">As of March&#160;31, 2024, there were 938 outstanding shares of Series C Preferred Stock that can be converted into an aggregate of 27,792 shares of common stock, and 1,014 shares of Series B Convertible Preferred Stock that can be converted into an aggregate of 398 shares of common stock. </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Warrants </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">On September&#160;25, 2019, the Company completed an underwritten public offering. The Company issued 19,266 shares of its common stock, along with <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">pre-funded</div> warrants to purchase 180,733 shares of its common stock and Series U Warrants to purchase 230,000 shares of its common stock. The Series U Warrants have a term of five years from the issuance date. In addition, the Company issued warrants to H.C. Wainwright&#160;&amp; Co., LLC, as representatives of the underwriters, to purchase 5,000 shares of its common stock with a term of five years from the issuance date, in the form of Series U Warrants (the &#8220;Representative Warrants&#8221;). As of March&#160;31, 2024, there were 142,733 outstanding Series U Warrants and Representative Warrants which can be exercised into an aggregate of 142,733 shares of common stock at a weighted average exercise price of $34.10 per share. </div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Common Stock </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Lincoln Park Purchase Agreement </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">On August&#160;2, 2022, the Company entered into a purchase agreement (the &#8220;2022 Purchase Agreement&#8221;) and registration rights agreement pursuant to which Lincoln Park Capital Fund (&#8220;Lincoln Park&#8221;) committed to purchase up to $50.0&#160;million of the Company&#8217;s common stock. Under the terms and subject to the conditions of the 2022 Purchase Agreement, the Company has the right, but not the obligation, to sell to Lincoln Park, and Lincoln Park is obligated to purchase up to $50.0&#160;million of the Company&#8217;s common stock. Such sales of common stock by the Company are subject to certain limitations, and can occur from time to time, at the Company&#8217;s sole discretion, over the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">36-month</div> period commencing on August&#160;17, 2022, subject to the satisfaction of certain conditions. </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">On May&#160;16, 2022, the Company received stockholder approval for purposes of the Nasdaq listing rules to permit issuances of up to 57.5&#160;million shares of the Company&#8217;s common stock (including the issuance of more than 19.99% of the Company&#8217;s common stock) to Lincoln Park, and it was pursuant to that approval that the Company entered into the 2022 Purchase Agreement. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Upon execution of the 2022 Purchase Agreement, the Company paid $0.1&#160;million in cash as the initial commitment fee, and issued 32,846 shares as the initial commitment shares, to Lincoln Park as consideration for its irrevocable commitment to purchase shares of the Company&#8217;s common stock at its direction under the 2022 Purchase Agreement. The Company has agreed to pay an additional commitment fee, which it may elect to pay in cash and/or shares of its common stock, upon receipt of $25.0&#160;million aggregate gross proceeds from sales of common stock to Lincoln Park under the 2022 Purchase Agreement. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">On August&#160;17, 2022, a registration statement (the &#8220;First Registration Statement&#8221;) was declared effective to cover the resale of up to 633,333 shares of the Company&#8217;s common stock comprised of (i)&#160;the 32,846 initial </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"> </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">commitment shares, and (ii)&#160;up to 600,486 that the Company has reserved for issuance and sale to Lincoln Park under the 2022 Purchase Agreement from time to time from and after the date of the prospectus. The Company sold approximately 527,166 shares under the First Registration Statement. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">On August&#160;18, 2023, a second registration statement (the &#8220;Second Registration Statement&#8221;) was declared effective to cover the resale of up to an additional 1,500,000 shares of the Company&#8217;s common stock that the Company reserved for issuance and sale to Lincoln Park under the 2022 Purchase Agreement from time to time. The Company sold 150,000 shares under the Second Registration Statement. The Company cannot sell more shares than registered under the Second Registration Statement under the 2022 Purchase Agreement without registering additional shares. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Actual sales of shares of common stock to Lincoln Park under the 2022 Purchase Agreement depend on a variety of factors to be determined by the Company from time to time, including, among others, market conditions, the trading price of the common stock and determinations by the Company as to the appropriate sources of funding for the Company and its operations. The net proceeds under the 2022 Purchase Agreement to the Company depend on the frequency and prices at which the Company sells shares of its stock to Lincoln Park. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">During the period from August&#160;17, 2022 to December&#160;31, 2022, the Company issued 266,666 shares under the 2022 Purchase Agreement for net proceeds of approximately $3.2&#160;million. The Company issued 410,500 shares under the 2022 Purchase Agreement for net proceeds of approximately $1.0&#160;million from January&#160;1, 2023 to December&#160;31, 2023. The Company did not issue any common stock under the 2022 Purchase Agreement during the three months ended March&#160;31, 2024. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">At-the-market</div></div> Issuances </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">On September&#160;9, 2022, the Company entered into the September 2022 Distribution Agreement with Canaccord, pursuant to which the Company could issue and sell, from time to time, shares of its common stock having an aggregate offering price of up to $5,000,000, depending on market demand, with Canaccord acting as an agent for sales. During the period from September&#160;9, 2022 to December&#160;31, 2022, the Company issued 68,758 shares of its common stock under the September 2022 Distribution Agreement for net proceeds of approximately $0.6&#160;million. From January&#160;1, 2023 through December&#160;31, 2023, the Company issued 1,819,993 shares under the September 2022 Distribution Agreement for net proceeds of approximately $4.3&#160;million. The Company has reached the capacity for sales of shares under the September 2022 Distribution Agreement and the agreement has terminated. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Company was obligated to pay Canaccord a commission of up to 3.0% of the gross proceeds from the sale of its common stock under the September 2022 Distribution Agreement. The Company also agreed to reimburse Canaccord for its reasonable documented <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">out-of-pocket</div></div> expenses, including fees and disbursements of its counsel, in the amount of $50,000. In addition, the Company agreed to provide customary indemnification rights to Canaccord. </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">On January&#160;14, 2022, the Company entered into the January 2022 Distribution Agreement with Canaccord, pursuant to which the Company could issue and sell, from time to time, shares of its common stock having an aggregate offering price of up to $5,000,000, with Canaccord acting as an agent for sales. The Company had no obligation to sell any of the Company&#8217;s shares and it could instruct Canaccord not to sell any shares if the sales could not be effected at or above the price designated by the Company from time to time and the Company could at any time suspend sales pursuant to the January 2022 Distribution Agreement. During the year ended December&#160;31, 2023, the Company issued 460,151 shares under the January 2022 Distribution Agreement for net proceeds of approximately $4.8&#160;million. The January 2022 Distribution Agreement has been terminated after all available registered shares were fully utilized. </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"> </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Share Repurchase Program and Treasury Stock </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">On October&#160;31, 2023, the Company announced that its Board has approved a share repurchase program (the &#8220;Share Repurchase Program&#8221;), with authorization to repurchase up to $500,000 of the outstanding shares of the Company&#8217;s common stock. The Company funded repurchases under the Share Repurchase Program with available cash. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">During the year ended December&#160;31, 2023, the Company purchased 78,559 of its common stock for approximately $0.1&#160;million as treasury stock. The Company purchased 179,866 of its common shares for approximately $0.4&#160;million as treasury stock during the three months ended March&#160;31, 2024. As of March&#160;31, 2024, no amount remained authorized for repurchase. </div></div><span></span>
</td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">12. Stockholders&#8217; Equity </div></div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Preferred Stock </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The Company has authorized 5,000,000 shares of preferred stock, par value $0.001 per share. The Board is authorized to designate the terms and conditions of any preferred stock the Company issues without further action by the common stockholders. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Series F Preferred Stock </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">On March&#160;3, 2023, the Company filed a certificate of designation (the &#8220;Certificate of Designation&#8221;) with the Secretary of State of the State of Delaware, effective as of the time of filing, designating the rights, preferences, privileges and restrictions of the Series F Preferred Stock, with the total authorization of one (1)&#160;share of Series F Preferred Stock. The Certificate of Designation provided that the share of Series F Preferred Stock will have 50,000,000 votes per share of Series F Preferred Stock and will vote together with the Company&#8217;s common stock, $0.001 par value (the &#8220;Common Stock&#8221;) as a single class exclusively with respect to any proposal to amend the Company&#8217;s Charter to effect a reverse stock split of the Common Stock (the &#8220;Reverse Stock Split&#8221;). On March&#160;3, 2023, the Company entered into a Subscription and Investment Representation Agreement (the &#8220;Subscription Agreement&#8221;) with Richard J. Hawkins, Chairman of the Board, who is an accredited investor (the &#8220;Purchaser&#8221;), pursuant to which the Company agreed to issue and sell one (1)&#160;share of the Company&#8217;s Series F Preferred Stock, par value $0.001 per share (the &#8220;Preferred Stock&#8221;), to the Purchaser for $1,000 in cash. The sale closed on March 3, 2023. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">At the Company&#8217;s annual meeting of stockholders held on April&#160;20, 2023, the Series F Preferred Stock was voted, without action by the holder, on the proposal to approve the Reverse Stock Split in the same proportion as shares of Common Stock voted to approve the Reverse Stock Split. The Series F Preferred Stock otherwise had no voting rights except as otherwise required by the General Corporation Law of the State of Delaware. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The Series F Preferred Stock was not convertible into, or exchangeable for, shares of any other class or series of stock or other securities of the Company. The Series F Preferred Stock had no rights with respect to any distribution of assets of the Company, including upon a liquidation, bankruptcy, reorganization, merger, acquisition, sale, dissolution or winding up of the Company, whether voluntarily or involuntarily. The holder of the Series F Preferred Stock was not entitled to receive dividends of any kind. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The outstanding share of Series F Preferred Stock was redeemed in whole, automatically effective upon the approval by the Company&#8217;s stockholders of a Reverse Stock Split. Upon such redemption, the holder of the Series F Preferred Stock received consideration of $1,000 in cash. </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"> </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Series B and C Preferred Stock </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">As of December&#160;31, 2023, there were 938 outstanding shares of Series C Preferred Stock that can be converted into an aggregate of 27,792 shares of common stock, and 1,014 shares of Series B Convertible Preferred Stock that can be converted into an aggregate of 398 shares of common stock. </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Warrants </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">On September&#160;25, 2019, the Company completed an underwritten public offering. The Company issued 19,266 shares of its common stock, along with <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">pre-funded</div> warrants to purchase 180,733 shares of its common stock and Series U Warrants to purchase 230,000 shares of its common stock at $75.00 per share. The Series U Warrants have a term of five years from the issuance date. In addition, the Company issued warrants to H.C. Wainwright&#160;&amp; Co., LLC, as representatives of the underwriters, to purchase 5,000 shares of its common stock at $93.75 per share with a term of 5 years from the issuance date, in the form of Series U Warrants (the &#8220;Representative Warrants&#8221;). </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">As of December&#160;31, 2023, there were 142,733 outstanding Series U Warrants which can be exercised into an aggregate of 142,733 shares of common stock at the weighted average exercise price of $34.10 per share. </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Common Stock </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">On August&#160;2, 2022, the Company entered into a purchase agreement (the &#8220;2022 Purchase Agreement&#8221;) and registration rights agreement pursuant to which Lincoln Park committed to purchase up to $50.0&#160;million of the Company&#8217;s common stock. Under the terms and subject to the conditions of the 2022 Purchase Agreement, the Company has the right, but not the obligation, to sell to Lincoln Park, and Lincoln Park is obligated to purchase up to $50.0&#160;million of the Company&#8217;s common stock. Such sales of common stock by the Company are subject to certain limitations, and can occur from time to time, at the Company&#8217;s sole discretion, over the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">36-month</div> period commencing on August&#160;17, 2022, subject to the satisfaction of certain conditions. Lincoln Park has no right to require the Company to sell any shares of common stock to Lincoln Park, but Lincoln Park is obligated to make purchases as the Company directs, subject to certain conditions. </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">On May&#160;16, 2022, the Company received stockholder approval for purposes of the Nasdaq listing rules to permit issuances of up to 57.5&#160;million shares of the Company&#8217;s common stock (including the issuance of more than 19.99% of the Company&#8217;s common stock) to Lincoln Park, and it was pursuant to that approval that the Company entered into the 2022 Purchase Agreement. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Upon execution of the 2022 Purchase Agreement, the Company paid $125,000 in cash as the initial commitment fee, and issued 32,846 shares as the initial commitment shares, to Lincoln Park as consideration for its irrevocable commitment to purchase shares of the Company&#8217;s common stock at its direction under the Purchase Agreement. The Company has agreed to pay an additional commitment fee, which it may elect to pay in cash and/or shares of its common stock, upon receipt of $25.0&#160;million aggregate gross proceeds from sales of common stock to Lincoln Park under the 2022 Purchase Agreement. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">On August&#160;17, 2022, a registration statement (the &#8220;First Registration Statement&#8221;) was declared effective to cover the resale of up to 633,333 shares of the Company&#8217;s common stock comprised of (i)&#160;the 32,846 initial commitment shares, and (ii)&#160;up to 600,486 that the Company has reserved for issuance and sale to Lincoln Park under the 2022 Purchase Agreement from time to time from and after the date of the prospectus. The Company sold approximately 527,166 shares under the First Registration Statement. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">On August&#160;18, 2023, a second registration statement (the &#8220;Second Registration Statement&#8221;) was declared effective to cover the resale of up to an additional 1,500,000 shares of the Company&#8217;s common stock that the Company reserved for issuance and sale to Lincoln Park under the 2022 Purchase Agreement from time to time. </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"> </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">We sold 150,000 shares under the Second Registration Statement. The Company cannot sell more shares than registered under the Second Registration Statement under the 2022 Purchase Agreement without registering additional shares. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Actual sales of shares of common stock to Lincoln Park under the 2022 Purchase Agreement depend on a variety of factors to be determined by the Company from time to time, including, among others, market conditions, the trading price of the common stock and determinations by the Company as to the appropriate sources of funding for the Company and its operations. The net proceeds under the 2022 Purchase Agreement to the Company depend on the frequency and prices at which the Company sells shares of its stock to Lincoln Park. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">During the period from August&#160;17, 2022 to December&#160;31, 2022, the Company issued 266,666 shares under the 2022 Purchase Agreement for net proceeds of approximately $3.2&#160;million. The Company issued 410,500 shares under the 2022 Purchase Agreement for net proceeds of approximately $1.0&#160;million from January&#160;1, 2023 to December&#160;31, 2023. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">On September&#160;30, 2020, the Company entered into a purchase agreement (the &#8220;2020 Purchase Agreement&#8221;) and registration rights agreement pursuant to which Lincoln Park committed to purchase up to $25.0&#160;million of the Company&#8217;s common stock. Under the terms and subject to the conditions of the 2020 Purchase Agreement, the Company had the right, but not the obligation, to sell to Lincoln Park, and Lincoln Park was obligated to purchase up to $25.0&#160;million of the Company&#8217;s common stock. Such sales of common stock by the Company were subject to certain limitations, and could occur from time to time, at the Company&#8217;s sole discretion, over the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">36-month</div> period commencing on November&#160;6, 2020, subject to the satisfaction of certain conditions. </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">During the year ended December&#160;31, 2022, the Company issued 377,666 shares of its common stock under the 2020 Purchase Agreement for net proceeds of approximately $7.0&#160;million. The Company no longer has any additional shares of common stock registered to sell under the 2020 Purchase Agreement and has terminated the 2020 Purchase Agreement. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">At-the-market</div></div> Issuances </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">On September&#160;9, 2022, the Company entered into an Equity Distribution Agreement (the &#8220;September 2022 Distribution Agreement&#8221;) with Canaccord Genuity LLC (&#8220;Canaccord&#8221;), pursuant to which the Company could issue and sell, from time to time, shares of its common stock having an aggregate offering price of up to $5,000,000, depending on market demand, with Canaccord acting as an agent for sales. During the period from September&#160;9, 2022 to December&#160;31, 2022, the Company issued 68,758 shares of its common stock under the September 2022 Distribution Agreement for net proceeds of approximately $0.6&#160;million. From January&#160;1, 2023 through December&#160;31, 2023, the Company issued 1,819,993 shares under the September 2022 Distribution Agreement for net proceeds of approximately $4.3&#160;million. The Company has reached the capacity for sales of shares under the September 2022 Distribution Agreement and the agreement has terminated. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Company was obligated to pay Canaccord a commission of up to 3.0% of the gross proceeds from the sale of its common stock under the September 2022 Distribution Agreement. The Company also agreed to reimburse Canaccord for its reasonable documented <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">out-of-pocket</div></div> expenses, including fees and disbursements of its counsel, in the amount of $50,000. In addition, the Company agreed to provide customary indemnification rights to Canaccord. </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">On January&#160;14, 2022, the Company entered into an Equity Distribution Agreement (the &#8220;January 2022 Distribution Agreement&#8221;) with Canaccord, pursuant to which the Company could issue and sell, from time to time, shares of its common stock having an aggregate offering price of up to $5,000,000, with Canaccord acting as an agent for sales. The Company had no obligation to sell any of the Company&#8217;s shares and it could instruct Canaccord not to sell any shares if the sales could not be effected at or above the price designated by the Company from time to time and the Company could at any time suspend sales pursuant to the January 2022 Distribution Agreement. During the year ended December&#160;31, 2022, the Company issued 460,151 shares under </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"> </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">the January 2022 Distribution Agreement for net proceeds of approximately $4.8&#160;million. The January 2022 Distribution Agreement has been terminated after all available registered shares were fully utilized. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Share Repurchase Program and Treasury Stock </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">On October&#160;31, 2023, the Company announced that its Board has approved a share repurchase program (the &#8220;Share Repurchase Program&#8221;), with authorization to repurchase up to $500,000 of the outstanding shares of the Company&#8217;s common stock. The Company intends to fund any repurchases under the Share Repurchase Program with available cash. The timing and amount of any shares repurchased will be determined based on the Company&#8217;s evaluation of market conditions and other factors, including consent of the Company&#8217;s lender. Repurchases may be made from time to time on the open market through October&#160;31, 2024. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">During the year ended December&#160;31, 2023, the Company purchased 78,559 of its common shares for approximately $126,000 as treasury stock. During the period January&#160;1, 2024 through February&#160;26, 2024, the Company purchased 168,015 of its common shares for approximately $340,000 as treasury stock. </div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480237/815-40-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140625354991632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">12. Subsequent Events </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Repayment of Term Loan and Use of Pershing Credit Facility </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">On May&#160;31, 2024, the Company drew $3.3&#160;million on the Pershing Credit Facility, to repay the Oxford Term Loan in full, a payment amount that totaled approximately $3.3&#160;million, which included both the balance of outstanding principal and interest and the final payment fee due. The repayment in full of the Oxford Term Loan terminated Oxford&#8217;s security interest in the Company&#8217;s existing and after-acquired assets, as well as all other certain restrictions and covenants under the Oxford Term Loan. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Borrowings under the Pershing Credit Facility bear interest at the target interest rate set by the Federal Open Market Committee, subject to a floor of 5.5%, plus a spread of 1.75% and applicable fees of 0.5%, subject to a maximum interest rate of the then applicable Prime Rate as published in The Wall Street Journal plus 3.0%. Interest payments thereunder are calculated on a monthly basis and, unless paid, are added to the outstanding balance under the Pershing Credit Facility. The proceeds under the Pershing Credit Facility are available for working capital needs and other general corporate purposes. The Pershing Credit Facility includes certain covenants and restrictions, which may require the Company, on <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">an&#160;on-going&#160;basis,</div> to deposit additional funds or marketable securities in order to maintain the line of credit extended by Pershing. </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The available credit line limit under the Pershing Credit Facility fluctuates based on the Company&#8217;s request for extensions of credit from time to time, subject to the value of the collateralized marketable securities that the Company holds with Pershing, provided that the amount available to draw under the Pershing Credit Facility cannot exceed 91.5% of the value of the Company&#8217;s collateralized marketable securities deposited with Pershing (the &#8220;Collateral&#8221;). Depending on the value of the Collateral that the Company holds with Pershing, Pershing may require the Company, on <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">an&#160;on-going&#160;basis,</div> to deposit additional funds or marketable securities in order to restore the level of the Collateral to an acceptable level. The amounts borrowed under the Pershing Credit Facility are due on demand. </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The Pershing Credit Facility is secured by a general lien and security interest in the Company&#8217;s Collateral held in its account with Pershing. Upon certain customary events of default, Pershing has the right, in its discretion, to liquidate, withdraw or sell all or any part of the Collateral and apply the proceeds to the amounts outstanding under the Pershing Credit Facility. The Pershing Credit Facility is also subject to certain customary terms and conditions. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">May 2024 Private Placement </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">On May&#160;5, 2024, the Company entered into a securities purchase agreement (the &#8220;Securities Purchase Agreement&#8221;) with certain investors, including certain of the Company&#8217;s directors and executive officers (&#8220;Company Insiders&#8221;) (collectively, the &#8220;Purchasers&#8221;), for the sale and issuance by the Company of its securities (the &#8220;Initial Subscription&#8221;). On May&#160;8, 2024, the Company entered into a first amendment to the Securities Purchase Agreement (the &#8220;Amendment&#8221;) for the sale and issuance by the Company of additional securities to two of the Purchasers (the &#8220;Additional Subscription&#8221;, and together with the Initial Subscription, the &#8220;May 2024 Private Placement&#8221;). The Securities Purchase Agreement, as amended, provides for the sale and issuance by the Company of an aggregate of 3,591,532 shares (the &#8220;Private Placement Shares&#8221;) of the Company&#8217;s common stock or, at the election of each Purchaser, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">pre-funded</div> warrants (the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">&#8220;Pre-Funded</div> Warrants&#8221;), exercisable immediately at an exercise price of $0.001 per share (the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">&#8220;Pre-Funded</div> Warrant Shares&#8221;), with each Private Placement Share or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">Pre-Funded</div> Warrant accompanied by (i)&#160;a Series A common warrant (&#8220;Series A Warrants&#8221;) to purchase one share of common stock (the &#8220;Series A Warrant Shares&#8221;), for an aggregate of 3,591,532 Series A Warrants, and (ii)&#160;one Series B common warrant (&#8220;Series B Warrants&#8221;) to purchase one share of common stock (the &#8220;Series B Warrant Shares,&#8221; and together with the Series A Warrant Shares, the &#8220;Common Warrant Shares&#8221;), for an aggregate of 3,591,532 Series B Warrants. </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The combined purchase price for each Private Placement Share and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">Pre-Funded</div> Warrant from the Initial Subscription was $2.022, and $2.158 from the Additional Subscription, in each case together with one </div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"> </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">accompanying Series A Warrant and one accompanying Series B Warrant, provided, that the Company Insiders participated in the Initial Subscription at an offering price of $2.04 per Private Placement Share and accompanying Series A Warrant and Series B Warrant. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The exercise price of each Series A Warrant and Series B Warrant from the Initial Subscription is $1.772 per share and $1.908 per share in the Additional Subscription, provided that the exercise price for the Series A Warrants and Series B Warrants issued to the Company Insiders is $1.79 per share. Subject to certain ownership limitations, the Series A Warrants will be exercisable until the five-year anniversary of issuance. Subject to certain ownership limitations, the Series B Warrants will be exercisable until the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">one-year</div> anniversary of the declaration of effectiveness of a registration statement to be filed with the Securities and Exchange Commission covering the resale of the Common Warrant Shares. The <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">Pre-Funded</div> Warrant will not expire until exercised in full. </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The May 2024 Private Offering closed on May&#160;9, 2024 (the &#8220;May 2024 Private Placement Closing&#8221;). The aggregate gross proceeds at the May 2024 Private Placement Closing were approximately $7.25&#160;million, before deducting certain expenses payable by the Company, and excluding the proceeds, if any, from the exercise of the Series A Warrant, the Series B Warrant, and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">Pre-Funded</div> Warrant. </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Company is evaluating the accounting treatment of the Series A Warrants, Series B Warrants and the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">Pre-Funded</div> Warrants under the authoritative accounting guidance. </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Biocept Asset Purchase </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">On April&#160;26, 2024, the Company acquired from Biocept, for a total cash payment of $400,000, substantially all of the right, title and interest in CNside, including (i)&#160;intellectual property, (ii)&#160;inventory and raw materials, and (iii)&#160;data, information, results and reports pertaining to the completed and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">on-going</div> clinical studies involving the use of the CNside test (including, but not limited to, the FORESEE clinical study), related to the development, making, selling, and exporting or importing of CNside, after the Company&#8217;s bid was approved by the United States Bankruptcy Court for the District of Delaware. </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//855/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140625252976288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-based Compensation</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">11. Stock-based Compensation </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Under the Company&#8217;s 2015 New Employee Incentive Plan (the &#8220;2015 Plan&#8221;), awards may only be granted to employees who were not previously an employee or director of the Company, or following a bona fide period of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">non-employment,</div> as a material inducement to entering into employment with the Company. As of March&#160;31, 2024, there were 6,024 shares of common stock remaining and available for future issuances under the 2015 Plan. </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The Company&#8217;s 2020 Stock Incentive Plan (the &#8220;2020 Plan&#8221;), which replaced the Company&#8217;s 2014 Equity Incentive Plan, provides for the award or sale of shares of common stock (including restricted stock), the award of stock units and stock appreciation rights, and the grant of both incentive stock options to purchase common stock to directors, officers, employees and consultants of the Company. The 2020 Plan, as amended, provides for the issuance of up to 236,667 shares of common stock, plus the number of shares available for issuance is increased to the extent that awards granted under the 2020 Plan and the Company&#8217;s 2014 Equity Incentive Plan are forfeited or expire (except as otherwise provided in the 2020 Plan). As of March&#160;31, 2024, there were 17,582 shares remaining and available for future issuances under the 2020 Plan. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Generally, options issued under the 2020 Plan are subject to a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">two-year</div> or four-year vesting schedule with 25% of the options vesting on the one year anniversary of the grant date followed by equal monthly installment vesting, and have a contractual term of 10 years. </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">A summary of activity for the three months ended March&#160;31, 2024 is as follows: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 92%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;">
<tr>
<td style="width: 55%;"></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Options</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Weighted</div></div><br/> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Average</div></div><br/> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Exercise&#160;Price</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Weighted</div></div><br/> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Average</div></div><br/> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Remaining</div></div><br/> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Contractual</div></div><br/> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Term<br/> (years)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Aggregate</div></div><br/> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Intrinsic<br/> Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Balance as of December&#160;31, 2023</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">140,109</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">37.48</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">8.07</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Granted</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">163,025</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">2.03</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Cancelled/forfeited</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">(1</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">289,125</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Balance as of March&#160;31, 2024</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">303,133</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">17.46</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">8.94</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">7,600</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Vested and expected to vest at March&#160;31, 2024</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">278,083</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">18.64</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">8.87</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">6,800</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Exercisable at March&#160;31, 2024</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">84,908</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">50.13</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">7.37</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">500</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">As of March&#160;31, 2024, the total compensation cost related to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">non-vested</div> stock options not yet recognized for all the Company&#8217;s plans is approximately $0.8&#160;million, which is expected to be recognized as a result of vesting under service conditions over a weighted average period of 2.3 years. </div><span></span>
</td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">13. Share-based Compensation </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Under the Company&#8217;s 2015 New Employee Incentive Plan (the &#8220;2015 Plan&#8221;), awards may only be granted to employees who were not previously an employee or director of the Company, or following a bona fide period of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">non-employment,</div> as a material inducement to entering into employment with the Company. As of December&#160;31, 2023, there were 6,024 shares of common stock remaining and available for future issuances under the 2015 Plan. </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The Company&#8217;s 2020 Stock Incentive Plan (the &#8220;2020 Plan&#8221;), which replaced the Company&#8217;s 2014 Equity Incentive Plan, provides for the award or sale of shares of common stock (including restricted stock), the award of stock units and stock appreciation rights, and the grant of both incentive stock options to purchase common stock to directors, officers, employees and consultants of the Company. The 2020 Plan, as amended, provides for the issuance of up to 3,550,000 shares of common stock, plus the number of shares available for issuance is increased to the extent that awards granted under the 2020 Plan and the Company&#8217;s 2014 Equity Incentive Plan are forfeited or expire (except as otherwise provided in the 2020 Plan). As of December&#160;31, 2023, there were 180,607 shares remaining and available for future issuances under the 2020 Plan. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Generally, options issued under the 2020 Plan are subject to a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">two-year</div> or four-year vesting schedule with 25% of the options vesting on the one year anniversary of the grant date followed by equal monthly installment vesting, and have a contractual term of 10 years. </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">A summary of activity for the year ended December&#160;31, 2023 is as follows: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 92%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;">
<tr>
<td style="width: 58%;"></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Options</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Weighted</div></div><br/> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Average</div></div><br/> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Exercise<br/> Price</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Weighted</div></div><br/> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Average</div></div><br/> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Remaining</div></div><br/> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Contractual</div></div><br/> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Term<br/> (years)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Aggregate</div></div><br/> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Intrinsic<br/> Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Balance as of December&#160;31, 2022</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">78,334</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">68.16</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">8.00</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Granted</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">68,422</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">5.00</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Cancelled/forfeited</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">(6,647</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">283.76</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Balance as of December&#160;31, 2023</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">140,109</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">37.48</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">8.07</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">7,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Vested and expected to vest at December&#160;31, 2023</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">133,810</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">38.62</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">8.02</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Exercisable at December&#160;31, 2023</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">72,843</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">60.17</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">7.41</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">6,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"> </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The Company settles exercises of stock options with newly issued shares of its common stock. There were no stock options exercised in 2023 or 2022. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;text-indent: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The estimated fair value of options, including the effect of estimated forfeitures, is recognized over the requisite service period, which is typically the vesting period of each option. The fair value of each option awarded during the years ended December&#160;31, 2023 and 2022 was estimated on the date of grant using the Black-Scholes-Merton option valuation model based on the following weighted-average assumptions: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 76%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;text-indent: 0px;">
<tr>
<td style="width: 55%;"></td>
<td style="width: 20%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 19%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,&#160;2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,&#160;2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Expected term</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">6.0&#160;years</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">6.0&#160;years</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Risk-free interest rate</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">4.06</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">2.83</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Expected volatility</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">127.0</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">123.4</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Dividends</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">0</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">0</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Resulting fair value</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">4.47</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">7.05</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr></table><div style="clear:both;max-height:0pt;text-indent: 0px;"></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;text-indent: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The weighted average risk-free interest rate represents the interest rate for treasury constant maturity instruments published by the Federal Reserve Board. If the term of available treasury constant maturity instruments is not equal to the expected term of an employee option, the Company uses the weighted average of the two Federal Reserve securities closest to the expected term of the employee option. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;text-indent: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The dividend yield has been assumed to be zero as the Company (a)&#160;has never declared or paid any dividends and (b)&#160;does not currently anticipate paying any cash dividends on its outstanding shares of common stock in the foreseeable future. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;text-indent: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The following table summarizes share-based compensation recognized during the years ended December&#160;31, 2023 and 2022 in the statement of operations: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 76%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;text-indent: 0px;">
<tr>
<td style="width: 82%;"></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Research and development</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">66</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">87</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">General and administrative</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">503</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">519</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Total share-based compensation</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">569</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">606</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><div style="clear:both;max-height:0pt;text-indent: 0px;"></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;text-indent: 0px;">As of December&#160;31, 2023, the total compensation cost related to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">non-vested</div> stock options and stock awards not yet recognized for all our plans is approximately $0.7&#160;million, which is expected to be recognized as a result of vesting under service conditions over a weighted average period of 1.8 years. </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//718/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140625254677216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and New Accounting Standards (Policies)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation and New Accounting Standards</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">1. Basis of Presentation and New Accounting Standards </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The accompanying unaudited condensed financial statements for the three months ended March&#160;31, 2024 and 2023 have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information. Accordingly, they do not include all of the information and footnotes required by accounting principles generally accepted in the United States of America for annual financial statements. The condensed balance sheet at December&#160;31, 2023 has been derived from the audited financial statements at December&#160;31, 2023, but does not include all of the information and footnotes required by accounting principles generally accepted in the United States of America for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation of the financial position and results of operations of Plus Therapeutics, Inc. (the &#8220;Company&#8221;) have been included. Operating results for the three months ended March&#160;31, 2024 are not necessarily indicative of the results that may be expected for the year ending December&#160;31, 2024. These financial statements should be read in conjunction with the financial statements and notes therein included in the Company&#8217;s Annual Report on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">10-K</div> for the year ended December&#160;31, 2023, filed with the Securities and Exchange Commission on March&#160;5, 2024. </div><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pstv_AmendmentsForCertificateofIncorporationAndReverseStockSplitPolicyTextBlock', window );">Amendments to Certificate of Incorporation and Reverse Stock Split</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Amendments to Certificate of Incorporation and Reverse Stock Split </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">At the Annual Meeting of Stockholders of the Company held on April&#160;20, 2023 (the &#8220;Annual Meeting&#8221;), the stockholders of the Company approved an amendment to the Company&#8217;s Amended and Restated Certificate of Incorporation (the &#8220;Charter&#8221;) to implement a reverse stock split of the Company&#8217;s then issued and outstanding common stock, par value $0.001 per share, with the ratio to be determined by the Board of Directors (the &#8220;Board&#8221;) of the Company, within a range of not less than <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;"><div style="-sec-ix-hidden:hidden116199108;display:inline;">1-for-3</div></div></div></div> and not greater than <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;"><div style="-sec-ix-hidden:hidden116199110;display:inline;">1-for-15</div></div>.</div></div> Subsequently, on April&#160;21, 2023, the Board determined to fix the ratio for the reverse stock split at <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;"><div style="-sec-ix-hidden:hidden116199113;display:inline;">1-for-15</div></div>,</div></div> without any change to its par value (the &#8220;Reverse Stock Split&#8221;). </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">On April&#160;27, 2023, following stockholder and Board approval, the Company filed a Certificate of Amendment to its Charter (the &#8220;Amendment&#8221;), with the Secretary of State of the State of Delaware to effectuate the Reverse Stock Split. The Amendment became effective on May 1, 2023. Upon effectiveness of the Reverse Stock Split, the number of shares of the Company&#8217;s common stock (x)&#160;issued and outstanding decreased from approximately 37.4&#160;million shares to approximately 2.5&#160;million shares; (y)&#160;reserved for issuance upon exercise of outstanding warrants and options decreased from approximately 2.0&#160;million shares to approximately 0.1&#160;million shares, and (z)&#160;reserved but unallocated under the Company&#8217;s current equity incentive plans decreased from approximately 3.0&#160;million shares of common stock to approximately 0.2&#160;million shares of common stock. The Company&#8217;s common stock began trading on the Nasdaq Capital Market (&#8220;Nasdaq&#8221;) on a post-split basis on May&#160;1, 2023. The Company&#8217;s 5,000,000 shares of authorized Preferred Stock were not affected by the Reverse Stock Split. No fractional shares were issued in connection with the Reverse Stock Split, and accordingly, the outstanding number of shares post Reverse Stock Split was adjusted down by approximately 1,310 (post-effect of the Reverse Stock Split) shares. Proportional adjustments for the Reverse Stock Split were made to the Company&#8217;s outstanding stock options, warrants and equity incentive plans for the period ended March&#160;31, 2023 as presented in the condensed financial statements in this Quarterly Report on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">10-Q.</div> The Company&#8217;s financial statements, and all references thereto have been retroactively adjusted to reflect the Reverse Stock Split unless specifically stated otherwise. </div><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Grant Revenue Recognition</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Grant Revenue Recognition </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">In applying the provisions of Accounting Standards Codification (&#8220;ASC&#8221;) Topic 606, Revenue from Contracts with Customers (&#8220;ASC 606&#8221;), the Company has determined that government grants are out of the scope of ASC </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">606 because the funding entities do not meet the definition of a &#8220;customer&#8221;, as defined by ASC 606, as the Company does not consider there to be a transfer of control of goods or services. With respect to each grant, the Company determines if it has a collaboration in accordance with ASC Topic 808, Collaborative Arrangements (&#8220;ASC 808&#8221;). For grants outside the scope of ASC 808, the Company applies International Accounting Standards No.&#160;20 (&#8220;IAS 20&#8221;), Accounting for Government Grants and Disclosure of Government Assistance, by analogy, and revenue is recognized when the Company incurs expenses related to the grant for the amount the Company is entitled to under the provisions of the contract. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The Company also considers the guidance in ASC Topic 730, Research and Development, which requires an assessment, at the inception of each grant, of whether each grant agreement is a liability. If the Company is obligated to repay funds received regardless of the outcome of the related research and development activities, then the Company is required to estimate and recognize that liability. Alternatively, if the Company is not required to repay the funds, then payments received are recorded as revenue or contra-expense as the expenses are incurred. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Deferred grant liability represents grant funds received or receivable for which the allowable expenses have not yet been incurred as of the balance sheet date. </div></div><span></span>
</td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Grant Revenue Recognition </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">In applying the provisions of Accounting Standards Codification (&#8220;ASC&#8221;) Topic 606, Revenue from Contracts with Customers (&#8220;ASC 606&#8221;), the Company has determined that government grants are out of the scope of ASC 606 because the funding entities do not meet the definition of a &#8220;customer,&#8221; as defined by ASC 606, as there is not considered to be a transfer of control of goods or services. With respect to the grant, the Company determines if it is a collaboration arrangement in accordance with ASC Topic 808, Collaborative Arrangements (&#8220;ASC 808&#8221;). For grants outside the scope of ASC 808, the Company applies International Accounting Standards No.&#160;20, Accounting for Government Grants and Disclosure of Government Assistance, by analogy, and revenue is recognized when the Company incurs expenses related to the grant for the amount the Company is entitled to under the provisions of the contract. </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"> </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The Company also considers the guidance in ASC Topic 730, Research and Development (&#8220;ASC 730&#8221;), which requires an assessment, at the inception of the grant, of whether the agreement is a liability. If the Company is obligated to repay funds received regardless of the outcome of the related research and development activities, then the Company is required to estimate and recognize that liability. Alternatively, if the Company is not required to repay the funds, then payments received are recorded as revenue or contra-expense as the expenses are incurred. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Deferred grant liability represents grant funds received or receivable for which the allowable expenses have not yet been incurred as of the balance sheet date. </div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesPurchasedOptionsPricePolicy', window );">Available-for-Sale Securities</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">Available-for-Sale</div></div> Securities </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The Company&#8217;s <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">available-for-sale</div></div> securities consist of U.S. government and agency securities. The Company classifies its marketable securities as <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">available-for-sale</div></div> and records such assets at estimated fair value in the condensed balance sheets, with unrealized gains and losses, if any, reported as a component of other comprehensive income (loss) within the condensed statements of operations and comprehensive income/loss and as a separate component of stockholders&#8217; equity. Realized gains and losses are calculated on the specific identification method and recorded as interest income (loss). At each balance sheet date, the Company assesses <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">available-for-sale</div></div> securities in an unrealized loss position to determine whether the decline in fair value below amortized cost is a result of credit losses or other factors, whether the Company expects to recover the amortized cost of the security, the Company&#8217;s intent to sell and if it is more likely than not that the Company will be required to sell the securities before the recovery of amortized cost. The Company records changes in allowance for expected credit loss in other income (expense). As of March&#160;31, 2024, there were no <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">available-for-sale</div></div> securities in an unrealized loss position, and there has been no allowance for expected credit losses recorded during any of the periods presented. </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Any premium arising at purchase is amortized to the earliest call date and any discount arising at purchase is accreted to maturity. Accretion of discounts are recorded in interest income in the condensed statements of operations and comprehensive income/loss. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">During the three months ended March&#160;31, 2024, the unrealized gain on the Company&#8217;s <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">available-for-sale</div></div> securities was less than $1,000, and not presented separately in the condensed statement of operations and comprehensive income/loss. </div><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Issued Accounting Pronouncements</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Recently Issued Accounting Pronouncements </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">In December 2023, the Financial Accounting Standards Board (the &#8220;FASB&#8221;) issued Accounting Standards Update (ASU) <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">No.&#160;2023-09</div> Income Taxes (Topic 740): Improvements to Income Tax Disclosure. This ASU includes amendments that further enhance income tax disclosures, primarily through standardization and disaggregation of rate reconciliation categories and income taxes paid by jurisdiction. The ASU is effective for years beginning after December&#160;15, 2024, but early adoption is permitted. This ASU should be applied on a prospective basis, although retrospective application is permitted. Management is currently evaluating the impact of the changes required by the new standard on the Company&#8217;s financial statements and related disclosures. </div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"> </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">In November 2023, the FASB issued Accounting Standard Update (ASU) <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">No.&#160;2023-07,</div> Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures. The new standard is intended to improve annual and interim reportable segment disclosure requirements regardless of number of reporting units, primarily through enhanced disclosures of significant expenses. The amendment requires public entities to disclose significant segment expenses that are regularly provided to <div style="display:inline;">the C</div>ODM and included within each reported measure of segment profit and loss. This update is effective for fiscal years beginning after December&#160;15, 2023, and interim periods within those fiscal years starting after December&#160;15, 2024. This ASU must be applied retrospectively to all prior periods presented. Management is <div style="display:inline;">currently </div>evaluating the impact of the changes required by the new standard on the Company&#8217;s financial statements and related <div style="display:inline;">disclosures</div>. </div><span></span>
</td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Recently Issued Accounting Pronouncements </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">In June 2016, the FASB issued ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">2016-13,</div> Financial Instruments&#8212;Credit Losses (Topic 326), Measurement of Credit Losses on Financial Instruments. The standard amends the impairment model by requiring entities to use a forward-looking approach based on expected losses to estimate credit losses for most financial assets and certain other instruments that are not measured at fair value through net income. For <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">available-for-sale</div></div> debt securities, entities will be required to recognize an allowance for credit losses rather than a reduction in carrying value of the asset. Entities will no longer be permitted to consider the length of time that fair value has been less than amortized cost when evaluating when credit losses should be recognized. This new guidance is effective in the first quarter of 2023 for calendar-year SEC filers that are smaller reporting companies as of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">one-time</div> determination date. Early adoption was permitted beginning in 2019. The Company adopted the new guidance as of January 1, 2023, which did not have a material impact on its financial statements and related disclosures. </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pstv_AmendmentsForCertificateofIncorporationAndReverseStockSplitPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amendments For Certificate of Incorporation And Reverse Stock Split.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pstv_AmendmentsForCertificateofIncorporationAndReverseStockSplitPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pstv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesPurchasedOptionsPricePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for premium paid to acquire option for investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480434/815-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesPurchasedOptionsPricePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-19<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-18<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-18<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-20<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-20<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-20<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-20<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 606<br> -Publisher FASB<br> -URI https://asc.fasb.org//606/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140625346494528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Use of Estimates </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The preparation of financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions affecting the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenue and expenses during the reporting period. The most significant estimates and critical accounting policies involve reviewing assets for impairment, and determining the assumptions used in measuring share-based compensation expense. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Actual results could differ from these estimates. Management&#8217;s estimates and assumptions are reviewed regularly, and the effects of revisions are reflected in the financial statements in the periods they are determined to be necessary. </div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Cash and cash equivalents </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The Company considers all highly liquid investments with maturities of three months or less at the time of purchase to be cash equivalents. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Cash and cash equivalents include cash in readily available checking, savings accounts and money market accounts. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. The Company has not experienced any losses in such accounts and believes it is not exposed to significant risk on its cash balances due to the financial position of the depository institution in which those deposits are held. </div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Financial Instruments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Financial Instruments </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Financial instruments include cash equivalents, other current assets, accounts payable, accrued expenses, other liabilities and long-term debt. The carrying values of cash equivalents, other current assets, accounts payable, </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"> </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">accrued expenses and other liabilities generally approximate fair value due to the short-term nature of these instruments. Based on level 3 inputs and the borrowing rates currently available for loans with similar terms, the Company believes the fair value of the long-term debt is <div style="display:inline;">materially </div>consistent with its carrying value. </div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Property and Equipment </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Property and equipment are stated at cost, net of accumulated depreciation. Depreciation expense, which includes the amortization of capitalized leasehold improvements, is provided for on a straight-line basis over the estimated useful lives of the assets, or the life of the lease, whichever is shorter, and range from <div style="-sec-ix-hidden:hidden116200141;display:inline;">three</div> to five years. When assets are sold or otherwise disposed of, the cost and related accumulated depreciation are removed from the accounts and the resulting gain or loss, if any, is included in operations. Maintenance and repairs are charged to operations as incurred. </div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentImpairment', window );">Impairment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Impairment </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The Company assesses its property and equipment for potential impairment when there is a change in circumstances that indicates carrying values of assets may not be recoverable. Such long-lived assets are deemed to be impaired when the undiscounted cash flows expected to be generated by the asset (or asset group) are less than the asset&#8217;s carrying amount. Any required impairment loss would be measured as the amount by which the asset&#8217;s carrying value exceeds its fair value and would be recorded as a reduction in the carrying value of the related asset and a charge to operating expense. The Company recognized no impairment losses during any of the periods presented in these financial statements. </div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Goodwill </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The Company&#8217;s goodwill represents the excess of the cost over the fair value of net assets acquired from its business combinations. The determination of the value of goodwill arising from business combinations requires extensive use of accounting estimates and judgments to allocate the purchase price to the fair value of the net tangible and intangible assets acquired. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Goodwill is not amortized; however, it is assessed for impairment using fair value measurement techniques on an annual basis or more frequently if facts and circumstance warrant such a review. Goodwill is considered to be impaired if the Company determines that the carrying value of the reporting unit exceeds its fair value. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The Company performs its impairment test annually during the fourth quarter by comparing the Company&#8217;s estimated fair value, calculated from the Company&#8217;s market capitalization, to its carrying amount. The Company&#8217;s annual evaluation for impairment of goodwill consists of one reporting unit. The Company completed its most recent annual evaluation for impairment as of December&#160;31, 2023, when the Company had stockholders&#8217; deficit within its sole reporting unit of approximately $1.3&#160;million, and concluded that no impairment existed. </div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Grant Revenue Recognition</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Grant Revenue Recognition </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">In applying the provisions of Accounting Standards Codification (&#8220;ASC&#8221;) Topic 606, Revenue from Contracts with Customers (&#8220;ASC 606&#8221;), the Company has determined that government grants are out of the scope of ASC </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">606 because the funding entities do not meet the definition of a &#8220;customer&#8221;, as defined by ASC 606, as the Company does not consider there to be a transfer of control of goods or services. With respect to each grant, the Company determines if it has a collaboration in accordance with ASC Topic 808, Collaborative Arrangements (&#8220;ASC 808&#8221;). For grants outside the scope of ASC 808, the Company applies International Accounting Standards No.&#160;20 (&#8220;IAS 20&#8221;), Accounting for Government Grants and Disclosure of Government Assistance, by analogy, and revenue is recognized when the Company incurs expenses related to the grant for the amount the Company is entitled to under the provisions of the contract. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The Company also considers the guidance in ASC Topic 730, Research and Development, which requires an assessment, at the inception of each grant, of whether each grant agreement is a liability. If the Company is obligated to repay funds received regardless of the outcome of the related research and development activities, then the Company is required to estimate and recognize that liability. Alternatively, if the Company is not required to repay the funds, then payments received are recorded as revenue or contra-expense as the expenses are incurred. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Deferred grant liability represents grant funds received or receivable for which the allowable expenses have not yet been incurred as of the balance sheet date. </div></div><span></span>
</td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Grant Revenue Recognition </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">In applying the provisions of Accounting Standards Codification (&#8220;ASC&#8221;) Topic 606, Revenue from Contracts with Customers (&#8220;ASC 606&#8221;), the Company has determined that government grants are out of the scope of ASC 606 because the funding entities do not meet the definition of a &#8220;customer,&#8221; as defined by ASC 606, as there is not considered to be a transfer of control of goods or services. With respect to the grant, the Company determines if it is a collaboration arrangement in accordance with ASC Topic 808, Collaborative Arrangements (&#8220;ASC 808&#8221;). For grants outside the scope of ASC 808, the Company applies International Accounting Standards No.&#160;20, Accounting for Government Grants and Disclosure of Government Assistance, by analogy, and revenue is recognized when the Company incurs expenses related to the grant for the amount the Company is entitled to under the provisions of the contract. </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"> </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The Company also considers the guidance in ASC Topic 730, Research and Development (&#8220;ASC 730&#8221;), which requires an assessment, at the inception of the grant, of whether the agreement is a liability. If the Company is obligated to repay funds received regardless of the outcome of the related research and development activities, then the Company is required to estimate and recognize that liability. Alternatively, if the Company is not required to repay the funds, then payments received are recorded as revenue or contra-expense as the expenses are incurred. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Deferred grant liability represents grant funds received or receivable for which the allowable expenses have not yet been incurred as of the balance sheet date. </div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Research and Development </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Research and development expenditures, which are charged to operations in the period incurred, include costs associated with the design, development, testing and enhancement of the Company&#8217;s products, regulatory fees, the purchase of laboratory supplies, and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">pre-clinical</div> and clinical studies as well as salaries and benefits for the Company&#8217;s research and development employees. </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InProcessResearchAndDevelopmentPolicy', window );">Acquired In-Process Research and Development (IPR&amp;D)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;">Acquired <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">In-Process</div> Research and Development (IPR&amp;D) </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Acquired IPR&amp;D represents the value assigned to research and development assets that have not reached technological feasibility. Upon the acquisition of IPR&amp;D, the Company completes an assessment of whether the acquisition constitutes the purchase of a single asset or group of assets. The Company considers multiple factors in this assessment, including the nature of the technology acquired, the presence or absence of separate cash flows, the development process and stage of completion, quantitative significance, and the Company&#8217;s rationale for entering into the transaction. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The Company tests IPR&amp;D assets for impairment as of December&#160;31 of each year or more frequently if indicators of impairment are present. The authoritative accounting guidance provides an optional qualitative assessment for any indicators that indefinite-lived intangible assets are impaired. If it is determined that it is more likely than not that the indefinite-lived intangible assets, including IPR&amp;D, are impaired, the fair value of the indefinite-lived intangible assets is compared with the carrying amount and impairment is recorded for any excess of the carrying amount over the fair value of the indefinite-lived intangible assets. There was no impairment of the Company&#8217;s IPR&amp;D assets during 2023 or 2022. </div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtPolicyTextBlock', window );">Deferred Financing Costs and Other Debt-Related Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Deferred Financing Costs and Other Debt-Related Costs </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Deferred financing costs are capitalized, recorded as an offset to debt balances and amortized to interest expense over the term of the associated debt instrument using the effective interest method. If the maturity of the debt is accelerated because of default or early debt repayment, then the amortization would be accelerated. </div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Income Taxes </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carry forwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income (loss) in the years in which those temporary differences are expected to be recovered or settled. Due to our history of losses, a full valuation allowance has been recognized against our deferred tax assets. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The Company&#8217;s policy is to recognize interest and penalties related to income tax matters in income tax expense. For the years ended December&#160;31, 2023 and 2022, the Company has not recorded any interest or penalties related to income tax matters. The Company does not foresee any material changes to unrecognized tax benefits within the next twelve months. </div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Share-Based Compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Share-Based Compensation </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The Company recognizes the fair value of all share-based payment awards in our statements of operations over the requisite vesting period of each award, which approximates the period during which the employee and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">non-employee</div> director is required to provide service in exchange for the award. The Company estimates the fair value of these options using the Black-Scholes option pricing model using assumptions for expected volatility, expected term, and risk-free interest rate. Expected volatility is based primarily on historical volatility and is computed using daily pricing observations for recent periods that correspond to the expected term of the options. The expected term represents the period of time that options are expected to be outstanding. Because the Company does not have historical exercise behavior, it determines the expected life assumption using the simplified method which is an average of the contractual term of the option and its vesting period. The risk-free interest rate is the interest rate for treasury instruments with maturities that approximate the expected term. </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Information</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Segment Information </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">For the years ended December&#160;31, 2023 and 2022, the Company is managed as a single operating segment, and therefore reports its results in one operating segment. </div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Loss Per Share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Loss Per Share </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Basic per share data is computed by dividing net income or loss applicable to common stockholders by the weighted average number of common shares outstanding during the period. Diluted per share data is computed by dividing net income or loss applicable to common stockholders by the weighted average number of common shares outstanding during the period increased to include, if dilutive, the number of additional common shares that would have been outstanding as calculated using the treasury stock method. Potential common shares were related entirely to outstanding but unexercised options, warrants and convertible preferred stocks for all periods presented. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The Company excluded all potentially dilutive securities from the calculation of diluted loss per share attributable to common stockholders for the years ended December&#160;31, 2023 and 2022, as their inclusion would be antidilutive. </div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration Risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Concentration Risk </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Although the Company&#8217;s contracts with its vendors are not exclusive, the Company currently uses sole source providers for core materials used in its clinical trials. </div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Issued Accounting Pronouncements</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Recently Issued Accounting Pronouncements </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">In December 2023, the Financial Accounting Standards Board (the &#8220;FASB&#8221;) issued Accounting Standards Update (ASU) <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">No.&#160;2023-09</div> Income Taxes (Topic 740): Improvements to Income Tax Disclosure. This ASU includes amendments that further enhance income tax disclosures, primarily through standardization and disaggregation of rate reconciliation categories and income taxes paid by jurisdiction. The ASU is effective for years beginning after December&#160;15, 2024, but early adoption is permitted. This ASU should be applied on a prospective basis, although retrospective application is permitted. Management is currently evaluating the impact of the changes required by the new standard on the Company&#8217;s financial statements and related disclosures. </div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"> </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">In November 2023, the FASB issued Accounting Standard Update (ASU) <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">No.&#160;2023-07,</div> Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures. The new standard is intended to improve annual and interim reportable segment disclosure requirements regardless of number of reporting units, primarily through enhanced disclosures of significant expenses. The amendment requires public entities to disclose significant segment expenses that are regularly provided to <div style="display:inline;">the C</div>ODM and included within each reported measure of segment profit and loss. This update is effective for fiscal years beginning after December&#160;15, 2023, and interim periods within those fiscal years starting after December&#160;15, 2024. This ASU must be applied retrospectively to all prior periods presented. Management is <div style="display:inline;">currently </div>evaluating the impact of the changes required by the new standard on the Company&#8217;s financial statements and related <div style="display:inline;">disclosures</div>. </div><span></span>
</td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Recently Issued Accounting Pronouncements </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">In June 2016, the FASB issued ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">2016-13,</div> Financial Instruments&#8212;Credit Losses (Topic 326), Measurement of Credit Losses on Financial Instruments. The standard amends the impairment model by requiring entities to use a forward-looking approach based on expected losses to estimate credit losses for most financial assets and certain other instruments that are not measured at fair value through net income. For <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">available-for-sale</div></div> debt securities, entities will be required to recognize an allowance for credit losses rather than a reduction in carrying value of the asset. Entities will no longer be permitted to consider the length of time that fair value has been less than amortized cost when evaluating when credit losses should be recognized. This new guidance is effective in the first quarter of 2023 for calendar-year SEC filers that are smaller reporting companies as of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">one-time</div> determination date. Early adoption was permitted beginning in 2019. The Company adopted the new guidance as of January 1, 2023, which did not have a material impact on its financial statements and related disclosures. </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480981/942-825-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy related to debt. Includes, but is not limited to, debt issuance costs, the effects of refinancings, method of amortizing debt issuance costs and original issue discount, and classifications of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 60<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 820<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482053/820-10-60-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 825<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 30<br> -Topic 350<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InProcessResearchAndDevelopmentPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs assigned to identifiable tangible and intangible assets of an acquired entity to be used in the research and development activities of the combined enterprise. An entity also may disclose the appraisal method or significant assumptions used to value acquired research and development assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InProcessResearchAndDevelopmentPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-17<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-25<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-28<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-19<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentImpairment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for assessing and recognizing impairments of its property, plant and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentImpairment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483044/730-10-05-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-19<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-18<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-18<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-20<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-20<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-20<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-20<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 606<br> -Publisher FASB<br> -URI https://asc.fasb.org//606/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482785/280-10-55-47<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.C.Q3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.1.Q5)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.3.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//718/tableOfContent<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-9<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-12<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140625259405696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock', window );">Summary of Financial Assets Measured at Fair Value on Recurring Basis</a></td>
<td class="text"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The following table summarizes the Company&#8217;s fair value hierarchy for its financial assets measured at fair value on a recurring basis as of March&#160;31, 2024 and December&#160;31, 2023, respectively (in thousands). </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 92%; font-family: Times New Roman; font-size: 8pt; border-collapse: collapse;">
<tr>
<td style="width: 64%;"></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="14" style="vertical-align: bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Fair Value Measurements Using</div></div></td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">March&#160;31, 2024</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Fair&#160;Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;1</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;2</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;3</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Money market</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">176</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">176</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Treasury bills and government agency bonds</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">323</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">323</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">499</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">499</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 12pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="16" style="height: 12pt; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="14" style="vertical-align: bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Fair Value Measurements Using</div></div></td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31, 2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Fair&#160;Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;1</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;2</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;3</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Money market</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">5,449</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">5,449</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr></table><span></span>
</td>
<td class="text"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The following table summarizes the Company&#8217;s fair value hierarchy for its financial assets measured at fair value on a recurring basis as of December&#160;31, 2023 and December&#160;31, 2022, respectively. </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 92%; font-family: Times New Roman; font-size: 8pt; border-collapse: collapse;">
<tr>
<td style="width: 56%;"></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="14" style="vertical-align: bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Fair Value Measurements Using</div></div></td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">As of December&#160;31, 2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Fair Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;1</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;2</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;3</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Money market</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">5,448,990</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">5,448,990</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 12pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="16" style="height: 12pt; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="14" style="vertical-align: bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Fair Value Measurements Using</div></div></td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">As of December&#160;31, 2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Fair Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;1</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;2</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;3</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Money market</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">17,573,584</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">17,573,584</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140625253197648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loss per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Antidilutive Securities Excluded from Diluted Income (Loss) per Share</a></td>
<td class="text"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The following were excluded from the diluted loss per share calculation for the periods presented because their effect would be anti-dilutive: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 76%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;">
<tr>
<td style="width: 74%;"></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">As of March&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2024</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Outstanding stock options</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">303,133</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">134,283</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Preferred stock</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">28,190</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">28,190</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Outstanding warrants</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">142,733</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">142,733</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">474,056</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">305,206</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><span></span>
</td>
<td class="text"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The following were excluded from the diluted loss per share calculation for the periods presented because their effect would be anti-dilutive: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 76%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;">
<tr>
<td style="width: 74%;"></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">For&#160;the&#160;Year&#160;Ended</div></div><br/> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Outstanding stock options</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">140,109</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">78,334</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Preferred stock</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">28,190</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">28,190</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Outstanding warrants</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">142,733</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">142,758</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">311,032</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">249,282</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140625373197696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Composition of Certain Financial Statement Captions (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pstv_CompositionOfCertainFinancialStatementCaptionsAbstract', window );"><strong>Composition Of Certain Financial Statement Captions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock', window );">Other Current Assets</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Other Current Assets </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">As of December&#160;31, 2023 and 2022, other current assets were comprised of the following (in thousands): </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 76%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;">
<tr>
<td style="width: 78%;"></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Prepaid services</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">644</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">2,999</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Prepaid insurance</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">636</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">698</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">1,280</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">3,697</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Property and Equipment, net</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Property and Equipment, net </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">As of December&#160;31, 2023 and 2022, property and equipment, net, were comprised of the following (in thousands): </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 76%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;">
<tr>
<td style="width: 76%;"></td>
<td style="width: 6%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 6%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Office and computer equipment</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">1,632</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">1,474</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Leasehold improvements</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">1,810</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">1,810</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">3,442</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">3,284</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Less accumulated depreciation</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">(2,536</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">(1,960</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">906</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">1,324</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock', window );">Accounts Payable and Accrued Expenses</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Accounts Payable and Accrued Expenses </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">As of December&#160;31, 2023 and 2022, accounts payable and accrued expenses were comprised of the following (in thousands): </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 76%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;">
<tr>
<td style="width: 76%;"></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Accounts payable</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">4,758</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">8,364</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Accrued payroll and bonus</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">987</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">989</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Accrued professional fees</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">128</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">147</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Accrued vacation and compensation</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">370</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">325</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Accrued R&amp;D studies</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">388</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">309</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">6,631</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">10,134</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pstv_CompositionOfCertainFinancialStatementCaptionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Composition of Certain Financial Statement Captions [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pstv_CompositionOfCertainFinancialStatementCaptionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pstv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amounts of other current assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140625253097744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments And Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Summary of Lease Costs</a></td>
<td class="text"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The table below summarizes the Company&#8217;s operating lease costs from its statements of operations, and cash payments from its statements of cash flows. </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 76%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;">
<tr>
<td style="width: 70%;"></td>
<td style="width: 11%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 11%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Year&#160;Ended&#160;December&#160;31,</div></div></td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Lease expense:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Operating lease expense</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">141</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">159</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Total lease expense</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">141</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">159</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Cash payment information:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Operating cash used for operating leases</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">141</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">159</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Total cash paid for amounts included in the measurement of lease liabilities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">141</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">159</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Summary of Future Minimum Annual Lease Payments under Operating Leases</a></td>
<td class="text"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The Company&#8217;s future minimum annual lease payments under operating leases at December&#160;31, 2023 are as follows (in thousands): </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 68%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;">
<tr>
<td style="width: 76%;"></td>
<td style="width: 20%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Operating&#160;Leases</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">2024</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">146</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">2025</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">60</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">2026</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">11</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Total minimum lease payments</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">217</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Less: amount representing interest</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">(12</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Present value of obligations under leases</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">205</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Less: current portion</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">(120</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Noncurrent lease obligations</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">85</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140625253156160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Term Loan Obligations (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock', window );">Term Loan Outstanding</a></td>
<td class="text"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Additional information relating to the then-outstanding Term Loan as of December&#160;31, 2023 and 2022 is presented in the following table (in thousands, except interest rate): </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 100%; font-family: Times New Roman; font-size: 8pt; border-collapse: collapse;">
<tr>
<td style="width: 53%;"></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;display:inline;">Year ended December&#160;31, 2023</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">Origination Date</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Original</div></div><br/> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Loan</div></div><br/> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Amount</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Interest</div></div><br/> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Rate*</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Current</div></div><br/> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Monthly</div></div><br/> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Payment**</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Amended<br/> expiration<br/> date</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Remaining</div></div><br/> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Principal</div></div><br/> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">(Face&#160;Value)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;"><div style="-sec-ix-hidden:hidden116199096;display:inline;">May 2015</div></div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">17,700</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">13.39</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">134</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">June 1, 2024</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">804</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;">
<tr>
<td style="width: 52%;"></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;display:inline;">Year ended December&#160;31, 2022</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">Origination Date</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Original</div></div><br/> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Loan</div></div><br/> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Amount</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Interest</div></div><br/> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Rate*</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Monthly</div></div><br/> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Payment**</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Amended<br/> expiration<br/> date</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Remaining</div></div><br/> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Principal</div></div><br/> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">(Face&#160;Value)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;"><div style="-sec-ix-hidden:hidden116199109;display:inline;">May 2015</div></div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">17,700</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">8.95</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">134</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">June 1, 2024</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">2,412</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentColor; border-image: none; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;text-align:left;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">*</div></div></td>
<td style="vertical-align: top;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Three month LIBOR rate with a floor of 1% plus 7.95% </div></div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentColor; border-image: none; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;text-align:left;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">**</div></div></td>
<td style="vertical-align: top;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Monthly payment reflects principal and interest </div></div></div></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69E<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-1A<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482949/835-30-55-8<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480848/942-470-50-3<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-8<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-6<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtInstrumentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140625255261824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Reconciliation of Total Income Tax Provision</a></td>
<td class="text"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">A reconciliation of the total income tax provision tax rate to the statutory federal income tax rates of 21% for the years ended December&#160;31, 2023 and 2022, respectively, is as follows: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 76%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;">
<tr>
<td style="width: 81%;"></td>
<td style="width: 6%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Income tax expense (benefit) at federal statutory rate</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">(21.0</td>
<td style="vertical-align: bottom; white-space: nowrap;">)%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">(21.0</td>
<td style="vertical-align: bottom; white-space: nowrap;">)%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Change in valuation allowance</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">25.5</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">22.5</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Income tax expense (benefit) at state statutory rate</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">(0.2</td>
<td style="vertical-align: bottom; white-space: nowrap;">)%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">(0.2</td>
<td style="vertical-align: bottom; white-space: nowrap;">)%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Share based compensation</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">1.0</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">0.9</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">NOLs expiring and adjustments to NOL</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">(0.1</td>
<td style="vertical-align: bottom; white-space: nowrap;">)%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">0.5</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Research credit</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">(5.1</td>
<td style="vertical-align: bottom; white-space: nowrap;">)%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">(2.5</td>
<td style="vertical-align: bottom; white-space: nowrap;">)%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Return to provision</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">(0.1</td>
<td style="vertical-align: bottom; white-space: nowrap;">)%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">(0.1</td>
<td style="vertical-align: bottom; white-space: nowrap;">)%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Change in state rate</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">(0.1</td>
<td style="vertical-align: bottom; white-space: nowrap;">)%&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">0.0</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">0.0</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Deferred Tax Assets and Liabilities</a></td>
<td class="text"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The tax effects of temporary differences that give rise to significant portions of our deferred tax assets and deferred tax liabilities as of December&#160;31, 2023 and 2022 are as follows (in thousands): </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 76%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;">
<tr>
<td style="width: 72%;"></td>
<td style="width: 10%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 10%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Deferred tax assets:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Accrued expenses</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">269</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">262</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Share based compensation</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">99</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">107</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Net operating loss carryforwards</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">13,397</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">12,605</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Income tax credit carryforwards</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">1,630</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">956</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Property and equipment, principally due to differences in depreciation</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">154</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">89</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Intangible assets</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">3,527</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">2,073</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Other, net</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">453</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">53</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">19,529</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">16,145</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Valuation allowance</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">(19,486</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">(16,092</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Total deferred tax assets, net of allowance</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">43</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">53</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"> </div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 76%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;">
<tr>
<td style="width: 82%;"></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Deferred tax liabilities:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Other</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">(43</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">(53</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Total deferred tax liability</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">(43</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">(53</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Net deferred tax assets (liability)</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock', window );">Unrecognized Tax Benefits Activity</a></td>
<td class="text"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Following is a tabular reconciliation of the unrecognized tax benefits activity during the years ended December&#160;31, 2023 and 2022 (in thousands): </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 76%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;">
<tr>
<td style="width: 82%;"></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Unrecognized Tax Benefits &#8211; Beginning</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">209</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">81</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Gross decreases &#8211; tax positions in prior period</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">(16</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">(1</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Gross increase &#8211; current-period tax positions</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">215</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">129</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Unrecognized Tax Benefits &#8211; Ending</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">408</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">209</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Paragraph 12<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140625259473408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock', window );">Stock Option Activity</a></td>
<td class="text"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">A summary of activity for the three months ended March&#160;31, 2024 is as follows: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 92%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;">
<tr>
<td style="width: 55%;"></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Options</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Weighted</div></div><br/> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Average</div></div><br/> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Exercise&#160;Price</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Weighted</div></div><br/> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Average</div></div><br/> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Remaining</div></div><br/> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Contractual</div></div><br/> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Term<br/> (years)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Aggregate</div></div><br/> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Intrinsic<br/> Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Balance as of December&#160;31, 2023</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">140,109</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">37.48</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">8.07</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Granted</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">163,025</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">2.03</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Cancelled/forfeited</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">(1</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">289,125</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Balance as of March&#160;31, 2024</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">303,133</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">17.46</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">8.94</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">7,600</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Vested and expected to vest at March&#160;31, 2024</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">278,083</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">18.64</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">8.87</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">6,800</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Exercisable at March&#160;31, 2024</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">84,908</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">50.13</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">7.37</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">500</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><span></span>
</td>
<td class="text"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">A summary of activity for the year ended December&#160;31, 2023 is as follows: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 92%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;">
<tr>
<td style="width: 58%;"></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Options</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Weighted</div></div><br/> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Average</div></div><br/> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Exercise<br/> Price</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Weighted</div></div><br/> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Average</div></div><br/> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Remaining</div></div><br/> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Contractual</div></div><br/> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Term<br/> (years)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Aggregate</div></div><br/> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Intrinsic<br/> Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Balance as of December&#160;31, 2022</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">78,334</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">68.16</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">8.00</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Granted</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">68,422</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">5.00</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Cancelled/forfeited</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">(6,647</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">283.76</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Balance as of December&#160;31, 2023</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">140,109</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">37.48</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">8.07</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">7,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Vested and expected to vest at December&#160;31, 2023</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">133,810</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">38.62</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">8.02</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Exercisable at December&#160;31, 2023</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">72,843</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">60.17</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">7.41</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">6,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Weighted-average Assumptions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The fair value of each option awarded during the years ended December&#160;31, 2023 and 2022 was estimated on the date of grant using the Black-Scholes-Merton option valuation model based on the following weighted-average assumptions: <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 76%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;text-indent: 0px;">
<tr>
<td style="width: 55%;"></td>
<td style="width: 20%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 19%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,&#160;2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,&#160;2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Expected term</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">6.0&#160;years</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">6.0&#160;years</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Risk-free interest rate</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">4.06</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">2.83</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Expected volatility</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">127.0</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">123.4</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Dividends</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">0</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">0</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Resulting fair value</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">4.47</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">7.05</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock', window );">Summary of Share-Based Compensation Recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;text-indent: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The following table summarizes share-based compensation recognized during the years ended December&#160;31, 2023 and 2022 in the statement of operations: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 76%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;text-indent: 0px;">
<tr>
<td style="width: 82%;"></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Research and development</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">66</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">87</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">General and administrative</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">503</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">519</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Total share-based compensation</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">569</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">606</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of activity for award under share-based payment arrangement. Includes, but is not limited to, outstanding award at beginning and end of year, granted, exercised, forfeited, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (f)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140625346882656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and New Accounting Standards (Additional Information) (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Apr. 27, 2023</div></th>
<th class="th"><div>Apr. 21, 2023</div></th>
<th class="th">
<div>Apr. 20, 2023 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>May 01, 2023 </div>
<div>shares</div>
</th>
<th class="th">
<div>Apr. 30, 2023 </div>
<div>shares</div>
</th>
<th class="th">
<div>Apr. 04, 2023 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Stock split conversion ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.06<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pstv_ReverseStockSplitEffectiveDate', window );">Reverse stock split effective date</a></td>
<td class="text">May  01,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,522,656<span></span>
</td>
<td class="nump">4,522,656<span></span>
</td>
<td class="nump">2,500,000<span></span>
</td>
<td class="nump">37,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,240,092<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockSplits', window );">Common stock, reverse stock split, fractional shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits', window );">Stock issued during period reverse stock splits, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,310<span></span>
</td>
<td class="nump">1,310<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=pstv_EquityIncentivePlansMember', window );">Equity Incentive Plans [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock capital shares reserved for future issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="nump">3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=pstv_OutstandingWarrantsAndOptionsMember', window );">Outstanding Warrants and Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock capital shares reserved for future issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Stock split conversion ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.33<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Stock split conversion ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.06<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain', window );">Unrealized gain on available-for-sale securities | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pstv_ReverseStockSplitEffectiveDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reverse stock split effective date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pstv_ReverseStockSplitEffectiveDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pstv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147477123/405-50-65-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482477/820-10-65-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482477/820-10-65-13<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-5<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-5<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-5<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (i)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (i)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 832<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483482/832-10-65-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 832<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483482/832-10-65-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479845/805-20-65-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479845/805-20-65-3<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479845/805-20-65-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479832/842-10-65-5<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479832/842-10-65-5<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479832/842-10-65-5<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479832/842-10-65-5<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-2<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483550/848-10-65-2<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483550/848-10-65-2<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483550/848-10-65-2<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483550/848-10-65-2<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483550/848-10-65-2<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 45: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 49: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 50: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 51: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 11.M.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480530/250-10-S99-5<br><br>Reference 52: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-4<br><br>Reference 53: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-4<br><br>Reference 54: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-4<br><br>Reference 55: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8<br><br>Reference 56: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8<br><br>Reference 57: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8<br><br>Reference 58: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8<br><br>Reference 59: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-4<br><br>Reference 60: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-4<br><br>Reference 61: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-4<br><br>Reference 62: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 63: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 64: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 65: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483194/926-20-65-2<br><br>Reference 66: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483194/926-20-65-2<br><br>Reference 67: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483194/926-20-65-2<br><br>Reference 68: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 69: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 70: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 71: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 72: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 73: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 74: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483421/250-10-45-6<br><br>Reference 75: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482833/825-10-65-6<br><br>Reference 76: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482833/825-10-65-6<br><br>Reference 77: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482833/825-10-65-6<br><br>Reference 78: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482833/825-10-65-6<br><br>Reference 79: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 80: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 81: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 82: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 83: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 84: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 85: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 86: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 87: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 88: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 89: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 90: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481925/310-20-65-2<br><br>Reference 91: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481925/310-20-65-2<br><br>Reference 92: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480424/946-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reduction in the number of shares during the period as a result of a reverse stock split.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockSplits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of a stock split.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockSplits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB TOPIC 4.C)<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteStockSplitConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=pstv_EquityIncentivePlansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=pstv_EquityIncentivePlansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=pstv_OutstandingWarrantsAndOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=pstv_OutstandingWarrantsAndOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140625245457584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Operations - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Apr. 21, 2023</div></th>
<th class="th">
<div>Apr. 20, 2023 </div>
<div>$ / shares</div>
</th>
<th class="th"><div>Mar. 29, 2020</div></th>
<th class="th"><div>Mar. 28, 2020</div></th>
<th class="th">
<div>May 29, 2015 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>May 01, 2023 </div>
<div>shares</div>
</th>
<th class="th">
<div>Apr. 30, 2023 </div>
<div>shares</div>
</th>
<th class="th">
<div>Apr. 04, 2023 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pstv_OrganizationAndOperationsLineItems', window );"><strong>Organization and Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (3,261,000)<span></span>
</td>
<td class="num">$ (4,805,000)<span></span>
</td>
<td class="num">$ (13,316,000)<span></span>
</td>
<td class="num">$ (20,275,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(483,762,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(480,501,000)<span></span>
</td>
<td class="num">(467,185,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,901,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,554,000<span></span>
</td>
<td class="nump">18,120,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,513,000)<span></span>
</td>
<td class="num">(5,793,000)<span></span>
</td>
<td class="num">(12,851,000)<span></span>
</td>
<td class="num">(12,972,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Stockholders' deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (4,837,000)<span></span>
</td>
<td class="nump">$ 2,676,000<span></span>
</td>
<td class="num">$ (1,348,000)<span></span>
</td>
<td class="nump">$ 6,445,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,836,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Stock split conversion ratio</a></td>
<td class="nump">0.06<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,522,656<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,522,656<span></span>
</td>
<td class="nump">2,240,092<span></span>
</td>
<td class="nump">2,500,000<span></span>
</td>
<td class="nump">37,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockSplits', window );">Common stock, reverse stock split, fractional shares issued | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits', window );">Stock issued during period reverse stock splits, shares | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,310<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,310<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=pstv_EquityIncentivePlansMember', window );">Equity Incentive Plans [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pstv_OrganizationAndOperationsLineItems', window );"><strong>Organization and Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common Stock, Capital Shares Reserved for Future Issuance | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="nump">3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=pstv_OutstandingWarrantsAndOptionsMember', window );">Outstanding Warrants and Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pstv_OrganizationAndOperationsLineItems', window );"><strong>Organization and Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common Stock, Capital Shares Reserved for Future Issuance | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pstv_OrganizationAndOperationsLineItems', window );"><strong>Organization and Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Stock split conversion ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.33<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pstv_OrganizationAndOperationsLineItems', window );"><strong>Organization and Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Stock split conversion ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.06<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=pstv_TermLoanMember', window );">Term Loan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pstv_OrganizationAndOperationsLineItems', window );"><strong>Organization and Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pstv_LongTermDebtOutstandingThresholdAmount', window );">Long term debt outstanding threshold amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFeeAmount', window );">Fees amount associated with loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,200,000<span></span>
</td>
<td class="nump">$ 3,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Maturity date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jun.  01,  2024<span></span>
</td>
<td class="text">Sep.  01,  2021<span></span>
</td>
<td class="text">May  01,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jun.  01,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=pstv_TermLoanMember', window );">Term Loan [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pstv_OrganizationAndOperationsLineItems', window );"><strong>Organization and Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pstv_LongTermDebtOutstandingThresholdAmount', window );">Long term debt outstanding threshold amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pstv_LongTermDebtOutstandingThresholdAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Long term debt outstanding threshold amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pstv_LongTermDebtOutstandingThresholdAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pstv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pstv_OrganizationAndOperationsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Organization and operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pstv_OrganizationAndOperationsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pstv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFeeAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the fee that accompanies borrowing money under the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFeeAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(2))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reduction in the number of shares during the period as a result of a reverse stock split.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockSplits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of a stock split.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockSplits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB TOPIC 4.C)<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteStockSplitConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=pstv_EquityIncentivePlansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=pstv_EquityIncentivePlansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=pstv_OutstandingWarrantsAndOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=pstv_OutstandingWarrantsAndOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=pstv_TermLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=pstv_TermLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140625346832176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>ReportableUnit </div>
<div>Segment</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>Segment</div>
</th>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pstv_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse', window );">Impairment loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Stockholders' deficit</a></td>
<td class="nump">$ 2,676,000<span></span>
</td>
<td class="num">(1,348,000)<span></span>
</td>
<td class="nump">6,445,000<span></span>
</td>
<td class="num">$ (4,837,000)<span></span>
</td>
<td class="nump">$ 10,836,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Impairment charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfReportingUnits', window );">Number of reporting units | ReportableUnit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense', window );">Interest or penalties related to income tax matters</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segment | Segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201613Member', window );">ASU 2016-13</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pstv_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted', window );">Change in accounting principle, accounting standards update, adopted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate', window );">Change in accounting principle, accounting standards update, adoption date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jan.  01,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect', window );">Change in accounting principle, accounting standards update, immaterial effect</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember', window );">In Process Research and Development [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pstv_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Impairment charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pstv_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful lives of the assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pstv_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful lives of the assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pstv_SummaryOfSignificantAccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Summary of significant accounting policies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pstv_SummaryOfSignificantAccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pstv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482130/360-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates (true false) whether accounting standards update was adopted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147477123/405-50-65-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482477/820-10-65-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482477/820-10-65-13<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-5<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-5<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 832<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483482/832-10-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479845/805-20-65-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479845/805-20-65-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479832/842-10-65-5<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479832/842-10-65-5<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479832/842-10-65-5<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483550/848-10-65-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-4<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-4<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483194/926-20-65-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483194/926-20-65-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482833/825-10-65-6<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482833/825-10-65-6<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481925/310-20-65-2<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481925/310-20-65-2<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-5<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482833/825-10-65-5<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-2<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 326<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-3<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 326<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-3<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479832/842-10-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date accounting standards update was adopted, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147477123/405-50-65-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482477/820-10-65-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482477/820-10-65-13<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-5<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-5<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-5<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 832<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483482/832-10-65-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479845/805-20-65-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479845/805-20-65-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479845/805-20-65-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479832/842-10-65-5<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479832/842-10-65-5<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479832/842-10-65-5<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483550/848-10-65-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-4<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-4<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483194/926-20-65-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483194/926-20-65-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482833/825-10-65-6<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482833/825-10-65-6<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481925/310-20-65-2<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481925/310-20-65-2<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-5<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482833/825-10-65-5<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-2<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 326<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-3<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 326<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-3<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479832/842-10-65-4<br><br>Reference 42: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -SubTopic 10<br> -Topic 250<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates (true false) whether effect from applying amendment to accounting standards is immaterial.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (e)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -SubTopic 20<br> -Topic 310<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481925/310-20-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480530/250-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482130/360-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfLongLivedAssetsHeldForUse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The sum of the amounts of estimated penalties and interest recognized in the period arising from income tax examinations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportingUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of reporting units tested for impairment of goodwill. A reporting unit is an operating segment or one level below an operating segment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportingUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201613Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201613Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140625254765552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Liquidity and Going Concern - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 08, 2024</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>May 09, 2024</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (3,261,000)<span></span>
</td>
<td class="num">$ (4,805,000)<span></span>
</td>
<td class="num">$ (13,316,000)<span></span>
</td>
<td class="num">$ (20,275,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(483,762,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(480,501,000)<span></span>
</td>
<td class="num">(467,185,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,513,000)<span></span>
</td>
<td class="num">(5,793,000)<span></span>
</td>
<td class="num">(12,851,000)<span></span>
</td>
<td class="num">(12,972,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Stockholders' deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (4,837,000)<span></span>
</td>
<td class="nump">2,676,000<span></span>
</td>
<td class="num">(1,348,000)<span></span>
</td>
<td class="nump">6,445,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,836,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Stockholders' equity requirement</a></td>
<td class="nump">$ 2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 895,000<span></span>
</td>
<td class="nump">$ 5,005,000<span></span>
</td>
<td class="nump">$ 15,278,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperations', window );">Net income from continuing operations</a></td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pstv_MaintainMinimumMarketValueOfListedSecurities', window );">Maintain minimum market value of listed securities</a></td>
<td class="nump">$ 35,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Warrants And Rights Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pstv_MaintainMinimumMarketValueOfListedSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maintain minimum market value of listed securities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pstv_MaintainMinimumMarketValueOfListedSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pstv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from continuing operations attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-18<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.13)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147477123/405-50-65-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482477/820-10-65-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482477/820-10-65-13<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-5<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-5<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-5<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (i)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (i)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 832<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483482/832-10-65-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 832<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483482/832-10-65-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479845/805-20-65-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479845/805-20-65-3<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479845/805-20-65-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479832/842-10-65-5<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479832/842-10-65-5<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479832/842-10-65-5<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479832/842-10-65-5<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-2<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483550/848-10-65-2<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483550/848-10-65-2<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483550/848-10-65-2<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483550/848-10-65-2<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483550/848-10-65-2<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 45: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 49: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 50: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 51: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 11.M.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480530/250-10-S99-5<br><br>Reference 52: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-4<br><br>Reference 53: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-4<br><br>Reference 54: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-4<br><br>Reference 55: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8<br><br>Reference 56: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8<br><br>Reference 57: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8<br><br>Reference 58: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8<br><br>Reference 59: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-4<br><br>Reference 60: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-4<br><br>Reference 61: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-4<br><br>Reference 62: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 63: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 64: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 65: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483194/926-20-65-2<br><br>Reference 66: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483194/926-20-65-2<br><br>Reference 67: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483194/926-20-65-2<br><br>Reference 68: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 69: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 70: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 71: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 72: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 73: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 74: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483421/250-10-45-6<br><br>Reference 75: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482833/825-10-65-6<br><br>Reference 76: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482833/825-10-65-6<br><br>Reference 77: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482833/825-10-65-6<br><br>Reference 78: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482833/825-10-65-6<br><br>Reference 79: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 80: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 81: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 82: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 83: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 84: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 85: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 86: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 87: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 88: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 89: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 90: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481925/310-20-65-2<br><br>Reference 91: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481925/310-20-65-2<br><br>Reference 92: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480424/946-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140625254754224">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Summary of Financial Assets Measured at Fair Value on Recurring Basis (Details) - Recurring Basis [Member] - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair Value</a></td>
<td class="nump">$ 499,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Money Market [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair Value</a></td>
<td class="nump">176,000<span></span>
</td>
<td class="nump">$ 5,448,990<span></span>
</td>
<td class="nump">$ 17,573,584<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Treasury Bills and Government Agency Bonds [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair Value</a></td>
<td class="nump">323,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair Value</a></td>
<td class="nump">499,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 1 [Member] | Money Market [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair Value</a></td>
<td class="nump">176,000<span></span>
</td>
<td class="nump">$ 5,448,990<span></span>
</td>
<td class="nump">$ 17,573,584<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 1 [Member] | Treasury Bills and Government Agency Bonds [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair Value</a></td>
<td class="nump">$ 323,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140625346831008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loss per Share - Schedule of Antidilutive Securities Excluded from Diluted Income (Loss) per Share (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Dilutive common shares excluded from the calculations of diluted loss per share (in shares)</a></td>
<td class="nump">474,056<span></span>
</td>
<td class="nump">305,206<span></span>
</td>
<td class="nump">311,032<span></span>
</td>
<td class="nump">249,282<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=pstv_OptionsMember', window );">Outstanding Stock Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Dilutive common shares excluded from the calculations of diluted loss per share (in shares)</a></td>
<td class="nump">303,133<span></span>
</td>
<td class="nump">134,283<span></span>
</td>
<td class="nump">140,109<span></span>
</td>
<td class="nump">78,334<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember', window );">Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Dilutive common shares excluded from the calculations of diluted loss per share (in shares)</a></td>
<td class="nump">28,190<span></span>
</td>
<td class="nump">28,190<span></span>
</td>
<td class="nump">28,190<span></span>
</td>
<td class="nump">28,190<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Outstanding Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Dilutive common shares excluded from the calculations of diluted loss per share (in shares)</a></td>
<td class="nump">142,733<span></span>
</td>
<td class="nump">142,733<span></span>
</td>
<td class="nump">142,733<span></span>
</td>
<td class="nump">142,758<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=pstv_OptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=pstv_OptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140625259278368">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Composition of Certain Financial Statement Captions - Other Current Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract', window );"><strong>Other Current Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherPrepaidExpenseCurrent', window );">Prepaid services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 644<span></span>
</td>
<td class="nump">$ 2,999<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidInsurance', window );">Prepaid insurance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">636<span></span>
</td>
<td class="nump">698<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Total other current assets</a></td>
<td class="nump">$ 989<span></span>
</td>
<td class="nump">$ 1,280<span></span>
</td>
<td class="nump">$ 3,697<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherPrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483032/340-10-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherPrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidInsurance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483032/340-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482955/340-10-05-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidInsurance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140625348024080">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Composition of Certain Financial Statement Captions - Property and Equipment, Net (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNetAbstract', window );"><strong>Property and Equipment, net [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pstv_OfficeAndComputerEquipmentGross', window );">Office and computer equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,632<span></span>
</td>
<td class="nump">$ 1,474<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseholdImprovementsGross', window );">Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,810<span></span>
</td>
<td class="nump">1,810<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,442<span></span>
</td>
<td class="nump">3,284<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less accumulated depreciation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,536)<span></span>
</td>
<td class="num">(1,960)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">$ 800<span></span>
</td>
<td class="nump">$ 906<span></span>
</td>
<td class="nump">$ 1,324<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pstv_OfficeAndComputerEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The gross amount of office and computer equipment cost as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pstv_OfficeAndComputerEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pstv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseholdImprovementsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation of additions or improvements to assets held under a lease arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseholdImprovementsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480842/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140625259693744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Composition of Certain Financial Statement Captions - Additional Information (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pstv_CompositionOfCertainFinancialStatementCaptionsAbstract', window );"><strong>Composition Of Certain Financial Statement Captions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">$ 0.6<span></span>
</td>
<td class="nump">$ 0.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization</a></td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pstv_CompositionOfCertainFinancialStatementCaptionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Composition of Certain Financial Statement Captions [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pstv_CompositionOfCertainFinancialStatementCaptionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pstv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482686/350-30-45-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140625346479600">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Composition of Certain Financial Statement Captions - Accounts Payable and Accrued Expenses (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract', window );"><strong>Accounts Payable and Accrued Expenses [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,758<span></span>
</td>
<td class="nump">$ 8,364<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedBonusesCurrent', window );">Accrued payroll and bonus</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">987<span></span>
</td>
<td class="nump">989<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Accrued professional fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">128<span></span>
</td>
<td class="nump">147<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pstv_AccruedVacationAndCompensationCurrent', window );">Accrued vacation and compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">370<span></span>
</td>
<td class="nump">325<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pstv_AccruedResearchAndDevelopmentStudies', window );">Accrued R&amp;D studies</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">388<span></span>
</td>
<td class="nump">309<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Accounts payable and accrued expenses, Total</a></td>
<td class="nump">$ 6,447<span></span>
</td>
<td class="nump">$ 6,631<span></span>
</td>
<td class="nump">$ 10,134<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pstv_AccruedResearchAndDevelopmentStudies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for research and development studies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pstv_AccruedResearchAndDevelopmentStudies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pstv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pstv_AccruedVacationAndCompensationCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued vacation and compensation, current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pstv_AccruedVacationAndCompensationCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pstv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedBonusesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for incentive compensation awarded to employees and directors or earned by them based on the terms of one or more relevant arrangements. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedBonusesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140625250208048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Jan. 08, 2021</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Jul. 01, 2023</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RecordedUnconditionalPurchaseObligationLineItems', window );"><strong>Recorded Unconditional Purchase Obligation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pstv_OperatingLeasesExpiryYear', window );">Operating leases expiry year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2025<span></span>
</td>
<td class="text">2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Lease liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 205,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-use-of assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 171,000<span></span>
</td>
<td class="nump">$ 202,000<span></span>
</td>
<td class="nump">$ 248,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Operating lease, weighted average discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.67%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Operating lease, weighted average remaining term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 7 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Rent expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=pstv_LoremVascularPteLtdMember', window );">Lorem Vascular Pte Ltd [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RecordedUnconditionalPurchaseObligationLineItems', window );"><strong>Recorded Unconditional Purchase Obligation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LitigationSettlementExpense', window );">Litigation settlement, expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis=pstv_PreClinicalResearchStudyObligationsMember', window );">Pre-clinical Research Study Obligations [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RecordedUnconditionalPurchaseObligationLineItems', window );"><strong>Recorded Unconditional Purchase Obligation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractualObligation', window );">Contractual obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=pstv_CharlottesvilleMember', window );">Charlottesville [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RecordedUnconditionalPurchaseObligationLineItems', window );"><strong>Recorded Unconditional Purchase Obligation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lessee, operating lease, term of contract</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 months<span></span>
</td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend', window );">Lessee, operating lease, existence of option to extend [true false]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">true<span></span>
</td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseOptionToExtend', window );">Lessee, operating lease, option to extend</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The Charlottesville Lease has a term of 12 months and the Company has the ability to renew for three additional one-year periods.<span></span>
</td>
<td class="text">The Charlottesville Lease has a term of 12 months and the Company has the ability to renew for three additional one-year periods.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Lessee, operating lease, renewal term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Lease liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 80,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseDiscountRate', window );">Operating lease discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13.47%<span></span>
</td>
<td class="nump">12.76%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-use-of assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseExpirationDate1', window );">Operating leases, expiration date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Mar. 31,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=pstv_MedidataSolutionsIncMember', window );">Medidata Solutions, Inc. [Member] | Services Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RecordedUnconditionalPurchaseObligationLineItems', window );"><strong>Recorded Unconditional Purchase Obligation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pstv_SalesOrderTerm', window );">Sales order term</a></td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=pstv_PiramalPharmaSolutionsIncMember', window );">Piramal Pharma Solutions, Inc. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RecordedUnconditionalPurchaseObligationLineItems', window );"><strong>Recorded Unconditional Purchase Obligation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pstv_MasterServicesAgreementDate', window );">Master service agreement date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jan.  08,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pstv_MasterServicesAgreementInitialTerm', window );">Master services agreement initial term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pstv_MasterServicesAgreementTermsDescription', window );">Master services agreement terms, Description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The MSA has a term of five years and will automatically renew for successive one-year terms unless either party notifies the other no later than six months prior to the original term or any additional terms of its intention to not renew the MSA. The Company has the right to terminate the MSA for convenience upon thirty days&#8217; prior written notice.<span></span>
</td>
<td class="text">The MSA has a term of five years and will automatically renew for successive one-year terms unless either party notifies the other no later than six months prior to the original term or any additional terms of its intention to not renew the MSA. The Company has the right to terminate the MSA for convenience upon thirty days&#8217; prior written notice.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pstv_MasterServicesAgreementDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Master services agreement date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pstv_MasterServicesAgreementDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pstv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pstv_MasterServicesAgreementInitialTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Master services agreement initial term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pstv_MasterServicesAgreementInitialTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pstv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pstv_MasterServicesAgreementTermsDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Master services agreement Terms description.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pstv_MasterServicesAgreementTermsDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pstv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pstv_OperatingLeasesExpiryYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating leases, expiry year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pstv_OperatingLeasesExpiryYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pstv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pstv_SalesOrderTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sales order term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pstv_SalesOrderTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pstv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractualObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of contractual obligation, including, but not limited to, long-term debt, lease obligation, purchase obligation, and other commitments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractualObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseExpirationDate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date which lease or group of leases is set to expire, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseExpirationDate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Discount rate used by lessee to determine present value of operating lease payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates (true false) whether lessee has option to extend operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseOptionToExtend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of terms and conditions of option to extend lessee's operating lease. Includes, but is not limited to, information about option recognized as part of right-of-use asset and lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseOptionToExtend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationSettlementExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of litigation expense, including but not limited to legal, forensic, accounting, and investigative fees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationSettlementExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease expense. Excludes sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RecordedUnconditionalPurchaseObligationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482648/440-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RecordedUnconditionalPurchaseObligationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=pstv_LoremVascularPteLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=pstv_LoremVascularPteLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis=pstv_PreClinicalResearchStudyObligationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis=pstv_PreClinicalResearchStudyObligationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=pstv_CharlottesvilleMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=pstv_CharlottesvilleMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=pstv_MedidataSolutionsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=pstv_MedidataSolutionsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=pstv_ServicesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=pstv_ServicesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=pstv_PiramalPharmaSolutionsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=pstv_PiramalPharmaSolutionsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140625346499584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Summary of Lease Costs (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostAbstract', window );"><strong>Lease expense:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease expense</a></td>
<td class="nump">$ 141<span></span>
</td>
<td class="nump">$ 159<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Total lease expense</a></td>
<td class="nump">141<span></span>
</td>
<td class="nump">159<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pstv_CashPaymentInformationAbstract', window );"><strong>Cash payment information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating cash used for operating leases</a></td>
<td class="nump">141<span></span>
</td>
<td class="nump">159<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pstv_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities', window );">Total cash paid for amounts included in the measurement of lease liabilities</a></td>
<td class="nump">$ 141<span></span>
</td>
<td class="nump">$ 159<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pstv_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash paid for amounts included in the measurement of lease liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pstv_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pstv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pstv_CashPaymentInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash payment information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pstv_CashPaymentInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pstv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140625258792304">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies - Summary of Future Minimum Annual Lease Payments under Operating Leases (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments And Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 146<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2026</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total minimum lease payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">217<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: amount representing interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(12)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of obligations under leases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">205<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Less: current portion</a></td>
<td class="num">$ (115)<span></span>
</td>
<td class="num">(120)<span></span>
</td>
<td class="num">$ (110)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Noncurrent operating lease liability</a></td>
<td class="nump">$ 59<span></span>
</td>
<td class="nump">$ 85<span></span>
</td>
<td class="nump">$ 141<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140625258894064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License Agreements - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 07, 2023</div></th>
<th class="th"><div>Mar. 29, 2020</div></th>
<th class="th"><div>Jan. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,763,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,983,000<span></span>
</td>
<td class="nump">$ 9,690,000<span></span>
</td>
<td class="nump">$ 9,698,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Voting stock, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="nump">$ 2,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=pstv_BioceptAgreementMember', window );">Biocept Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Shares issued</a></td>
<td class="nump">53,381<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75,000<span></span>
</td>
<td class="nump">75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pstv_PaymentForTechTransferAndValidationFee', window );">Payment for tech transfer and validation fee</a></td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pstv_OptionForExclusiveWorldwideLicense', window );">Option for exclusive worldwide license</a></td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=pstv_UTHSALicenseAgreementMember', window );">UTHSA License Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRoyalties', window );">License fee payment in cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=pstv_NanoTxLicensesAgreementMember', window );">Nano Tx Licenses Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRoyalties', window );">License fee payment in cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Voting stock, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pstv_PercentageOfNonDilutiveMonetaryAwardsRequiredToPay', window );">Percentage of non-dilutive monetary awards required to pay</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pstv_AccruedLicensePayable', window );">Accrued payments due to NanoTx</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pstv_AccruedLicensePayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued license payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pstv_AccruedLicensePayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pstv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pstv_OptionForExclusiveWorldwideLicense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Option for exclusive worldwide license.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pstv_OptionForExclusiveWorldwideLicense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pstv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pstv_PaymentForTechTransferAndValidationFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payment for tech transfer and validation fee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pstv_PaymentForTechTransferAndValidationFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pstv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pstv_PercentageOfNonDilutiveMonetaryAwardsRequiredToPay">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of non-dilutive monetary awards required to pay.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pstv_PercentageOfNonDilutiveMonetaryAwardsRequiredToPay</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pstv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRoyalties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid for royalties during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRoyalties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482916/730-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482517/912-730-25-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481283/985-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=pstv_BioceptAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=pstv_BioceptAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=pstv_UTHSALicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=pstv_UTHSALicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=pstv_NanoTxLicensesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=pstv_NanoTxLicensesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140625251739680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Term Loan Obligations - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="4">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 28, 2023</div></th>
<th class="th"><div>Mar. 29, 2020</div></th>
<th class="th"><div>Mar. 28, 2020</div></th>
<th class="th"><div>May 29, 2015</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2023</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentOfferingDate1', window );">Origination date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">May 29,  2015<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">May 29,  2015<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 34,000<span></span>
</td>
<td class="nump">$ 134,000<span></span>
</td>
<td class="nump">$ 395,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 711,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Non-cash amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21,000<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">400,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableRateAxis=pstv_LiborMember', window );">LIBOR [Member] | Interest Rate Floor [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis variable rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=pstv_TermLoanMember', window );">Term Loan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentOfferingDate1', window );">Origination date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">May 29,  2015<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">May 29,  2015<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Original loan amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,700,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 17,700,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis variable rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.95%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Maturity date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jun.  01,  2024<span></span>
</td>
<td class="text">Sep.  01,  2021<span></span>
</td>
<td class="text">May  01,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jun.  01,  2024<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFeeAmount', window );">Fees amount associated with loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,200,000<span></span>
</td>
<td class="nump">$ 3,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,200,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of shares callable by warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">188<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,175<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pstv_LongTermDebtOutstandingThresholdAmount', window );">Long term debt outstanding threshold amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 800,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate</a></td>
<td class="nump">8.95%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13.39%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">8.95%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pstv_MinimumLiquidityCovenantAmount', window );">Minimum liquidity covenant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pstv_DebtPrincipalRepaymentStartDate', window );">Debt principal repayment start date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">May  01,  2021<span></span>
</td>
<td class="text">May  01,  2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCovenantCompliance', window );">Debt instrument, covenant compliance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">the Company was in compliance with all of the debt covenants under the Loan and Security Agreement.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">the Company was in compliance with all of the debt covenants under the Loan and Security Agreement.<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=pstv_TermLoanMember', window );">Term Loan [Member] | Loan and Security Agreement [Member] | Sale of the Japanese Subsidiary and Certain Assets [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForLoans', window );">Payments for principal, interest and fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=pstv_TermLoanMember', window );">Term Loan [Member] | SOFR [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis variable rate</a></td>
<td class="nump">8.05%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=pstv_TermLoanMember', window );">Term Loan [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pstv_DebtInstrumentFloatingInterestRatePercentage', window );">Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.95%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=pstv_TermLoanMember', window );">Term Loan [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Original loan amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pstv_LongTermDebtOutstandingThresholdAmount', window );">Long term debt outstanding threshold amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 800,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr><td colspan="11"></td></tr>
<tr><td colspan="11"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Three month LIBOR rate with a floor of 1% plus 7.95%</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pstv_DebtInstrumentFloatingInterestRatePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Floating interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pstv_DebtInstrumentFloatingInterestRatePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pstv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pstv_DebtPrincipalRepaymentStartDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt principal repayment start date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pstv_DebtPrincipalRepaymentStartDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pstv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pstv_LongTermDebtOutstandingThresholdAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Long term debt outstanding threshold amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pstv_LongTermDebtOutstandingThresholdAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pstv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pstv_MinimumLiquidityCovenantAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Minimum liquidity covenant amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pstv_MinimumLiquidityCovenantAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pstv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDebtDiscountPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-1A<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfDebtDiscountPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCovenantCompliance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>States whether the entity was in compliance with the debt covenants throughout the reporting period, and describes facts and circumstances of any compliance failure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480848/942-470-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCovenantCompliance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-2<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482949/835-30-55-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFeeAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the fee that accompanies borrowing money under the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFeeAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69E<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69F<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(2))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentOfferingDate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date the debt instrument was offered for sale, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentOfferingDate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483013/835-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForLoans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash payments for and related to principal collection on loans related to operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForLoans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=pstv_LiborMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=pstv_LiborMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateFloorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateFloorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=pstv_TermLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=pstv_TermLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=pstv_LoanAndSecurityAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=pstv_LoanAndSecurityAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupClassificationAxis=pstv_SaleOfJapaneseSubsidiaryAndCertainAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupClassificationAxis=pstv_SaleOfJapaneseSubsidiaryAndCertainAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140625346829616">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Term Loan Obligations - Term Loan Outstanding (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="4">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2023</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Jun. 28, 2023</div></th>
<th class="th"><div>May 29, 2015</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pstv_AdditionalDetailsRelatingTermLoanThatIsOutstandingAbstract', window );"><strong>Additional details relating term loan that is outstanding [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentOfferingDate1', window );">Origination date</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">May 29,  2015<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">May 29,  2015<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=pstv_TermLoanMember', window );">Term Loan [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pstv_AdditionalDetailsRelatingTermLoanThatIsOutstandingAbstract', window );"><strong>Additional details relating term loan that is outstanding [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentOfferingDate1', window );">Origination date</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">May 29,  2015<span></span>
</td>
<td class="text">May 29,  2015<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Original loan amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,700<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 17,700<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,700<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest Rate</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13.39%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">8.95%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">8.95%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentPeriodicPayment', window );">Current Monthly Payment</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 134<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 134<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pstv_DebtInstrumentAmendedExpirationDate', window );">Amended expiration date</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jun.  01,  2024<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">Jun.  01,  2024<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Remaining Principal (Face Value)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 804<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 2,412<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="8"></td></tr>
<tr><td colspan="8"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Three month LIBOR rate with a floor of 1% plus 7.95%</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">Monthly payment reflects principal and interest</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pstv_AdditionalDetailsRelatingTermLoanThatIsOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional details relating term loan that is outstanding [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pstv_AdditionalDetailsRelatingTermLoanThatIsOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pstv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pstv_DebtInstrumentAmendedExpirationDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt instrument amended expiration date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pstv_DebtInstrumentAmendedExpirationDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pstv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-2<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482949/835-30-55-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentOfferingDate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date the debt instrument was offered for sale, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentOfferingDate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentPeriodicPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the required periodic payments including both interest and principal payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480848/942-470-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentPeriodicPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=pstv_TermLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=pstv_TermLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140625346260880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Grant Revenue - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 19, 2022</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_GrantMember', window );">Grant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,677,000<span></span>
</td>
<td class="nump">$ 506,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,913,000<span></span>
</td>
<td class="nump">$ 224,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=pstv_CancerPreventionAndResearchInstituteOfTexasContractMember', window );">CPRIT Contract [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pstv_MaximumGrantAmountToBeReceivedAsPerGrantContract', window );">Maximum grant amount to be received as per grant contract</a></td>
<td class="nump">$ 17,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pstv_GrantFundingTerm', window );">Grant funding term</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pstv_CpritGrantFundingTerm', window );">CPRIT grant funding term, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The CPRIT Grant is subject to customary CPRIT funding conditions, including, but not limited to, a matching fund requirement (one dollar for every two dollars awarded by CPRIT), revenue sharing obligations upon commercialization of rhenium (186Re) obisbemeda based on specific dollar thresholds and tiered low single digit royalty rates until CPRIT receives the aggregate amount of 400% of the proceeds awarded under the CPRIT Grant, and certain reporting requirements.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The CPRIT Grant is subject to customary CPRIT funding conditions, including, but not limited to, a matching fund requirement (one dollar for every two dollars awarded by CPRIT), revenue sharing obligations upon commercialization of rhenium (186Re) obisbemeda based on specific dollar thresholds and tiered low single digit royalty rates until CPRIT receives the aggregate amount of 400% of the proceeds awarded under the CPRIT Grant, and certain reporting requirements.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pstv_ContractEffectiveDate', window );">Contract effective date</a></td>
<td class="text">Aug. 31,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pstv_ContractTerminationDate', window );">Contract termination date</a></td>
<td class="text">Aug. 30,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pstv_PercentageOfAggregateAmountOfProceedsAwardedUnderCpritGrant', window );">Percentage of aggregate amount of proceeds awarded under CPRIT grant</a></td>
<td class="nump">400.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pstv_PercentageOfGrantProceedsWithInterestNotExceedAnnually', window );">Percentage of grant proceeds with interest not exceed annually</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pstv_ReimbursementCostsIncurred', window );">Identified eligible reimbursable costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">168,000<span></span>
</td>
<td class="nump">$ 637,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pstv_IncreaseDecreaseInGrantRevenue', window );">Increase in grant revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 637,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=pstv_CancerPreventionAndResearchInstituteOfTexasContractMember', window );">CPRIT Contract [Member] | Grant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,700,000<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,900,000<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pstv_ContractEffectiveDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contract effective date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pstv_ContractEffectiveDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pstv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pstv_ContractTerminationDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contract termination date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pstv_ContractTerminationDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pstv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pstv_CpritGrantFundingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>CPRIT grant funding term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pstv_CpritGrantFundingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pstv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pstv_GrantFundingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Grant funding term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pstv_GrantFundingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pstv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pstv_IncreaseDecreaseInGrantRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (decrease) in grant revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pstv_IncreaseDecreaseInGrantRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pstv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pstv_MaximumGrantAmountToBeReceivedAsPerGrantContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum grant amount to be received as per grant contract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pstv_MaximumGrantAmountToBeReceivedAsPerGrantContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pstv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pstv_PercentageOfAggregateAmountOfProceedsAwardedUnderCpritGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of aggregate amount of proceeds awarded under CPRIT grant.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pstv_PercentageOfAggregateAmountOfProceedsAwardedUnderCpritGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pstv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pstv_PercentageOfGrantProceedsWithInterestNotExceedAnnually">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of grant proceeds with interest not exceed annually.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pstv_PercentageOfGrantProceedsWithInterestNotExceedAnnually</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pstv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pstv_ReimbursementCostsIncurred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reimbursement costs incurred.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pstv_ReimbursementCostsIncurred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pstv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_GrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_GrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=pstv_CancerPreventionAndResearchInstituteOfTexasContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=pstv_CancerPreventionAndResearchInstituteOfTexasContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140625258772800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pstv_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision or benefit for income taxes</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pstv_IncomeTaxContingencyAbstract', window );"><strong>Income Tax Contingency [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pstv_DeferredTaxAssetsValuationAllowances', window );">Valuation allowance</a></td>
<td class="nump">19,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Increase (decrease) in valuation allowance</a></td>
<td class="nump">$ 3,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pstv_CumulativeChangeInOwnership', window );">Cumulative change in ownership</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pstv_NetOperatingLossAndResearchAndDevelopmentTaxCreditCarryForwardsToOffsetFutureTaxableIncomePeriod', window );">Period of net operating loss and R&amp;D tax credit carry forwards to offset future taxable income</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForUncertainTaxPositionsCurrent', window );">Liability for uncertain tax positions</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pstv_PeriodForMaterialChangesOfLiabilityForUncertainTaxBenefits', window );">Period for material changes of liability for uncertain tax benefits</a></td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense', window );">Interest related to unrecognized tax benefits in interest expense and penalties</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pstv_IncomeTaxContingencyAbstract', window );"><strong>Income Tax Contingency [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Tax loss carryforwards</a></td>
<td class="nump">$ 63,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pstv_OperatingLossCarryforwardsExpirationDates1', window );">Net operating loss carryforwards, Expire date</a></td>
<td class="text">begin to expire in 2037<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic', window );">Federal tax carry forward</a></td>
<td class="nump">$ 1,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pstv_TaxCreditCarryforwardExpirationDate1', window );">Tax credit carryforward, expiration date</a></td>
<td class="text">begin to expire in 2039<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pstv_NetOperatingLossCarryforward', window );">Net operating losses</a></td>
<td class="nump">$ 59,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pstv_IncomeTaxContingencyAbstract', window );"><strong>Income Tax Contingency [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pstv_PercentageOfNetOperatingLossCarryforwardsAvailableForOffsettingAgainstFutureTaxableIncome', window );">Percentage of federal net operating losses used to offset of future taxable income</a></td>
<td class="nump">80.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pstv_IncomeTaxContingencyAbstract', window );"><strong>Income Tax Contingency [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Tax loss carryforwards</a></td>
<td class="nump">$ 2,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pstv_OperatingLossCarryforwardsExpirationDates1', window );">Net operating loss carryforwards, Expire date</a></td>
<td class="text">2038<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal', window );">State tax credit carryforwards</a></td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pstv_TaxCreditCarryforwardExpirationDate1', window );">Tax credit carryforward, expiration date</a></td>
<td class="text">begin to expire in 2043<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pstv_CumulativeChangeInOwnership">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Refers to cumulative change in ownership in percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pstv_CumulativeChangeInOwnership</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pstv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pstv_DeferredTaxAssetsValuationAllowances">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets valuation allowances.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pstv_DeferredTaxAssetsValuationAllowances</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pstv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pstv_IncomeTaxContingencyAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income tax contingency.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pstv_IncomeTaxContingencyAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pstv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pstv_IncomeTaxesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income taxes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pstv_IncomeTaxesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pstv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pstv_NetOperatingLossAndResearchAndDevelopmentTaxCreditCarryForwardsToOffsetFutureTaxableIncomePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Refers to the period of net operating loss and R&amp;D tax credit carry forwards to offset future taxable income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pstv_NetOperatingLossAndResearchAndDevelopmentTaxCreditCarryForwardsToOffsetFutureTaxableIncomePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pstv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pstv_NetOperatingLossCarryforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net operating loss carryforward.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pstv_NetOperatingLossCarryforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pstv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pstv_OperatingLossCarryforwardsExpirationDates1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The expiration date of each operating loss carryforward included in total operating loss carryforwards, or the applicable range of such expiration dates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pstv_OperatingLossCarryforwardsExpirationDates1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pstv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pstv_PercentageOfNetOperatingLossCarryforwardsAvailableForOffsettingAgainstFutureTaxableIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of net operating loss carryforwards available for offsetting against future taxable income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pstv_PercentageOfNetOperatingLossCarryforwardsAvailableForOffsettingAgainstFutureTaxableIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pstv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pstv_PeriodForMaterialChangesOfLiabilityForUncertainTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Refers to period for material changes of liability for uncertain tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pstv_PeriodForMaterialChangesOfLiabilityForUncertainTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pstv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pstv_TaxCreditCarryforwardExpirationDate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expiration date of the tax credit carryforward.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pstv_TaxCreditCarryforwardExpirationDate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pstv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible domestic operating loss carryforwards. Excludes state and local operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible state and local operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482659/740-20-45-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForUncertainTaxPositionsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount recognized for uncertainty in income taxes classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForUncertainTaxPositionsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140625255073216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Reconciliation of Total Income Tax Provision (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract', window );"><strong>Reconciliation of the total income tax provision tax rate [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Income tax expense (benefit) at federal statutory rate</a></td>
<td class="num">(21.00%)<span></span>
</td>
<td class="num">(21.00%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="nump">25.50%<span></span>
</td>
<td class="nump">22.50%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">Income tax expense (benefit) at state statutory rate</a></td>
<td class="num">(0.20%)<span></span>
</td>
<td class="num">(0.20%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost', window );">Share based compensation</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">0.90%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pstv_EffectiveIncomeTaxRateReconciliationNetOperatingLossExpiration', window );">NOLs expiring and adjustments to NOL</a></td>
<td class="num">(0.10%)<span></span>
</td>
<td class="nump">0.50%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch', window );">Research credit</a></td>
<td class="num">(5.10%)<span></span>
</td>
<td class="num">(2.50%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pstv_EffectiveIncomeTaxRateReconciliationTaxReturnToProvision', window );">Return to provision</a></td>
<td class="num">(0.10%)<span></span>
</td>
<td class="num">(0.10%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlementsStateAndLocal', window );">Change in state rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="num">(0.10%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Total income tax provision</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pstv_EffectiveIncomeTaxRateReconciliationNetOperatingLossExpiration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to net operating loss expiration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pstv_EffectiveIncomeTaxRateReconciliationNetOperatingLossExpiration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pstv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pstv_EffectiveIncomeTaxRateReconciliationTaxReturnToProvision">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective income tax rate reconciliation tax return to provision.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pstv_EffectiveIncomeTaxRateReconciliationTaxReturnToProvision</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pstv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlementsStateAndLocal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax settlement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlementsStateAndLocal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140625247183856">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Deferred Tax Assets and Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComponentsOfDeferredTaxAssetsAbstract', window );"><strong>Deferred tax assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities', window );">Accrued expenses</a></td>
<td class="nump">$ 269<span></span>
</td>
<td class="nump">$ 262<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Share based compensation</a></td>
<td class="nump">99<span></span>
</td>
<td class="nump">107<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">13,397<span></span>
</td>
<td class="nump">12,605<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards', window );">Income tax credit carryforwards</a></td>
<td class="nump">1,630<span></span>
</td>
<td class="nump">956<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment', window );">Property and equipment, principally due to differences in depreciation</a></td>
<td class="nump">154<span></span>
</td>
<td class="nump">89<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets', window );">Intangible assets</a></td>
<td class="nump">3,527<span></span>
</td>
<td class="nump">2,073<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other, net</a></td>
<td class="nump">453<span></span>
</td>
<td class="nump">53<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Deferred tax assets (Total)</a></td>
<td class="nump">19,529<span></span>
</td>
<td class="nump">16,145<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(19,486)<span></span>
</td>
<td class="num">(16,092)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Total deferred tax assets, net of allowance</a></td>
<td class="nump">43<span></span>
</td>
<td class="nump">53<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract', window );"><strong>Deferred tax liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesOther', window );">Other</a></td>
<td class="num">(43)<span></span>
</td>
<td class="num">(53)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Total deferred tax liability</a></td>
<td class="num">(43)<span></span>
</td>
<td class="num">(53)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilities', window );">Net deferred tax assets (liability)</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComponentsOfDeferredTaxAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComponentsOfDeferredTaxAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140625254672592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Unrecognized Tax Benefits Activity (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward', window );"><strong>Schedule of reconciliation of unrecognized tax benefits activity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized Tax Benefits &#8211; Beginning</a></td>
<td class="nump">$ 209<span></span>
</td>
<td class="nump">$ 81<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions', window );">Gross decreases &#8211; tax positions in prior period</a></td>
<td class="num">(16)<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions', window );">Gross increase &#8211; current-period tax positions</a></td>
<td class="nump">215<span></span>
</td>
<td class="nump">129<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized Tax Benefits &#8211; Ending</a></td>
<td class="nump">$ 408<span></span>
</td>
<td class="nump">$ 209<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-10B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140625371762480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plan - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanDisclosureLineItems', window );"><strong>Defined Contribution Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount', window );">Discretionary or matching contributions</a></td>
<td class="nump">$ 107,000<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanDisclosureLineItems', window );"><strong>Defined Contribution Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch', window );">Percentage of matching contribution for employee contributions</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 70<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480794/715-70-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of discretionary contributions made by an employer to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage employer matches of the employee's percentage contribution matched.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140625346227440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Preferred Stock (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Mar. 03, 2023 </div>
<div>USD ($) </div>
<div>Votes </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Apr. 20, 2023 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Apr. 04, 2023 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,952<span></span>
</td>
<td class="nump">1,952<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,952<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=pstv_SeriesFConvertiblePreferredStockMember', window );">Series F Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pstv_NumberOfVotesPerShare', window );">Number Of Votes Per Share | Votes</a></td>
<td class="nump">50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockVotingRights', window );">Preferred stock, voting rights</a></td>
<td class="text">no<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pstv_RightsRelatedToDistributionOfAssets', window );">Rights related to distribution of assets</a></td>
<td class="text">no<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pstv_ConsiderationPaidToPreferredStockHolders', window );">Consideration paid to preferred stock holders | $</a></td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=pstv_SeriesFConvertiblePreferredStockMember', window );">Series F Convertible Preferred Stock [Member] | Subscription Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issue and sale of share</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Consideration to purchaser in cash | $</a></td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockTransactionDate', window );">Sale closed date</a></td>
<td class="text">Mar.  03,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=pstv_SeriesBConvertiblePreferredStockMember', window );">Series B Convertible Preferred Stock [Member] | 2018 Rights Offering [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,014<span></span>
</td>
<td class="nump">1,014<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pstv_NumberOfPreferredStockSharesExercised', window );">Number of preferred stock, shares converted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">398<span></span>
</td>
<td class="nump">398<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=pstv_SeriesCConvertiblePreferredStockMember', window );">Series C Convertible Preferred Stock [Member] | 2018 Rights Offering [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">938<span></span>
</td>
<td class="nump">938<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pstv_NumberOfPreferredStockSharesExercised', window );">Number of preferred stock, shares converted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,792<span></span>
</td>
<td class="nump">27,792<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pstv_ConsiderationPaidToPreferredStockHolders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Consideration paid to preferred stock holders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pstv_ConsiderationPaidToPreferredStockHolders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pstv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pstv_NumberOfPreferredStockSharesExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Preferred Stock Shares Exercised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pstv_NumberOfPreferredStockSharesExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pstv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pstv_NumberOfVotesPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of votes per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pstv_NumberOfVotesPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pstv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pstv_RightsRelatedToDistributionOfAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Rights related to distribution of assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pstv_RightsRelatedToDistributionOfAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pstv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483014/272-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482987/272-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockVotingRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of voting rights of nonredeemable preferred stock. Includes eligibility to vote and votes per share owned. Include also, if any, unusual voting rights.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockVotingRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockTransactionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date the subsidiary or equity investee issued or sold stock, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockTransactionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=pstv_SeriesFConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=pstv_SeriesFConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=pstv_SubscriptionAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=pstv_SubscriptionAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=pstv_SeriesBConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=pstv_SeriesBConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=pstv_TwoThousandEighteenRightsOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=pstv_TwoThousandEighteenRightsOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=pstv_SeriesCConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=pstv_SeriesCConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140625249789040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Warrants (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=pstv_SeriesUWarrantsMember', window );">Series U Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issue and sale of share</a></td>
<td class="nump">230,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">230,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of Stock, Price Per Share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants expected term</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=pstv_RepresentativeSeriesUWarrantMember', window );">Representative Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of securities called by warrant or right</a></td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 93.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issue and sale of share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">168,164<span></span>
</td>
<td class="nump">2,230,493<span></span>
</td>
<td class="nump">1,206,090<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants expected term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Outstanding Warrants [Member] | Series U Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price (in dollars per share)</a></td>
<td class="nump">$ 34.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 34.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Class of warrant outstanding</a></td>
<td class="nump">142,733<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">142,733<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pstv_NumberOfWarrantsExercised', window );">Number of warrants exercised</a></td>
<td class="nump">142,733<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">142,733<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Common Class A [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issue and sale of share</a></td>
<td class="nump">19,266<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,266<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember', window );">Common Class B [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of securities called by warrant or right</a></td>
<td class="nump">180,733<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">180,733<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pstv_NumberOfWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants exercised</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pstv_NumberOfWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pstv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483014/272-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482987/272-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=pstv_SeriesUWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=pstv_SeriesUWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=pstv_RepresentativeSeriesUWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=pstv_RepresentativeSeriesUWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140625239149712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Common stock (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">2 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="3">4 Months Ended</th>
<th class="th" colspan="1">7 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1">16 Months Ended</th>
<th class="th" colspan="1">19 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 08, 2024</div></th>
<th class="th"><div>Sep. 09, 2022</div></th>
<th class="th"><div>Aug. 02, 2022</div></th>
<th class="th"><div>May 16, 2022</div></th>
<th class="th"><div>Jan. 14, 2022</div></th>
<th class="th"><div>Feb. 26, 2024</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Oct. 31, 2023</div></th>
<th class="th"><div>Aug. 18, 2023</div></th>
<th class="th"><div>Aug. 17, 2022</div></th>
<th class="th"><div>Jul. 14, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Sale of common stock, net</a></td>
<td class="nump">$ 2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 895,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,005,000<span></span>
</td>
<td class="nump">$ 15,278,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from sale of common stock, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 895,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,527,000<span></span>
</td>
<td class="nump">$ 15,832,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1', window );">Remained authorized amount for repurchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issue and sale of share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">168,164<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,230,493<span></span>
</td>
<td class="nump">1,206,090<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Sale of common stock, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Number of stock repurchased</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">179,866<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">78,559<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockValue', window );">Treasury stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 126,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 126,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 126,000<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Number of stock repurchased</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">168,015<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockValue', window );">Treasury stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 340,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1', window );">Authorized amount of repurchase of stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=pstv_TwoThousandAndTwentyTwoPurchaseAgreementMember', window );">2022 Purchase Agreement [Member] | Lincoln Park Capital Fund, LLC [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">57,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=pstv_TwoThousandAndTwentyTwoPurchaseAgreementMember', window );">2022 Purchase Agreement [Member] | Lincoln Park Capital Fund, LLC [Member] | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pstv_MaximumValueOfSharesToBeIssuedUnderAgreement', window );">Maximum value of shares to be issued under agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issue and sale of share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150,000<span></span>
</td>
<td class="nump">266,666<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">410,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pstv_PeriodExercisableFromTheDateOfIssuance', window );">Period exercisable from the date of issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">36 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">36 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pstv_NumberOfMaximumCommonSharesCanBeResale', window );">Number of maximum common shares can be resale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">633,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pstv_InitialCommitmentShares', window );">Initial commitment shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32,846<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32,846<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pstv_InitialCommitmentFee', window );">Initial commitment fee paid in cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 125,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pstv_GrossProceedsFromIssuanceOfCommonStock', window );">Aggregate gross proceeds from sales of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from sale of common stock, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=pstv_TwoThousandAndTwentyTwoPurchaseAgreementMember', window );">2022 Purchase Agreement [Member] | Lincoln Park Capital Fund, LLC [Member] | Common Stock [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pstv_PercentageIssuanceOfCommonStock', window );">Percentage issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=pstv_TwoThousandAndTwentyTwoPurchaseAgreementMember', window );">2022 Purchase Agreement [Member] | Lincoln Park Capital Fund, LLC [Member] | Common Stock [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pstv_NumberOfMaximumCommonSharesCanBeResale', window );">Number of maximum common shares can be resale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Number of shares reserved for issuance and sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600,486<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=pstv_TwentyTwentyPurchaseAgreementMember', window );">2020 Purchase Agreement [Member] | Lincoln Park Capital Fund, LLC [Member] | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pstv_MaximumValueOfSharesToBeIssuedUnderAgreement', window );">Maximum value of shares to be issued under agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issue and sale of share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">527,166<span></span>
</td>
<td class="nump">527,166<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Sale of common stock, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">377,666<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pstv_PeriodExercisableFromTheDateOfIssuance', window );">Period exercisable from the date of issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">36 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from sale of common stock, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Remaining common stock issued and sold (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=pstv_SeptemberTwoThousandAndTwentyTwoDistributionAgreementMember', window );">September 2022 Distribution Agreement [Member] | Canaccord Genuity LLC [Member] | At The Market Offering Program [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pstv_AggregateExpenseIncludingFeeAndDisbursementExpenses', window );">Reimburse of fee and disbursements expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=pstv_SeptemberTwoThousandAndTwentyTwoDistributionAgreementMember', window );">September 2022 Distribution Agreement [Member] | Canaccord Genuity LLC [Member] | Common Stock [Member] | At The Market Offering Program [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issue and sale of share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">68,758<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,819,993<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from sale of common stock, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=pstv_SeptemberTwoThousandAndTwentyTwoDistributionAgreementMember', window );">September 2022 Distribution Agreement [Member] | Canaccord Genuity LLC [Member] | Common Stock [Member] | Maximum [Member] | At The Market Offering Program [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from sale of common stock, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pstv_PercentageOfCommissionOnGrossProceedsFromSaleOfCommonStock', window );">Percentage of commission on gross proceeds from sale of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=pstv_JanuaryTwoThousandAndTwentyTwoDistributionAgreementMember', window );">January 2022 Distribution Agreement [Member] | Canaccord Genuity LLC [Member] | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issue and sale of share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">460,151<span></span>
</td>
<td class="nump">460,151<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from sale of common stock, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,800,000<span></span>
</td>
<td class="nump">$ 4,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=pstv_JanuaryTwoThousandAndTwentyTwoDistributionAgreementMember', window );">January 2022 Distribution Agreement [Member] | Canaccord Genuity LLC [Member] | Common Stock [Member] | At The Market Offering Program [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pstv_CommonStockSalesAvailableForIssuance', window );">Remaining availability under financing facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=pstv_JanuaryTwoThousandAndTwentyTwoDistributionAgreementMember', window );">January 2022 Distribution Agreement [Member] | Canaccord Genuity LLC [Member] | Common Stock [Member] | Maximum [Member] | At The Market Offering Program [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from sale of common stock, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pstv_AggregateExpenseIncludingFeeAndDisbursementExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate expense including fee and disbursement expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pstv_AggregateExpenseIncludingFeeAndDisbursementExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pstv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pstv_CommonStockSalesAvailableForIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common stock, sales, available for issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pstv_CommonStockSalesAvailableForIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pstv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pstv_GrossProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross proceeds from issuance of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pstv_GrossProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pstv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pstv_InitialCommitmentFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Initial commitment fee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pstv_InitialCommitmentFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pstv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pstv_InitialCommitmentShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Initial commitment shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pstv_InitialCommitmentShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pstv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pstv_MaximumValueOfSharesToBeIssuedUnderAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum value of shares to be issued under agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pstv_MaximumValueOfSharesToBeIssuedUnderAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pstv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pstv_NumberOfMaximumCommonSharesCanBeResale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of maximum common shares can be resale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pstv_NumberOfMaximumCommonSharesCanBeResale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pstv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pstv_PercentageIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage issuance of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pstv_PercentageIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pstv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pstv_PercentageOfCommissionOnGrossProceedsFromSaleOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of commission on gross proceeds from sale of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pstv_PercentageOfCommissionOnGrossProceedsFromSaleOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pstv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pstv_PeriodExercisableFromTheDateOfIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Refers to the period exercisable from the date of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pstv_PeriodExercisableFromTheDateOfIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pstv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483014/272-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482987/272-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of stock repurchase plan authorized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchaseProgramAuthorizedAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount remaining of a stock repurchase plan authorized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481520/505-30-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481549/505-30-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29,30)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=pstv_TwoThousandAndTwentyTwoPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=pstv_TwoThousandAndTwentyTwoPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=pstv_LincolnParkCapitalFundLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=pstv_LincolnParkCapitalFundLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=pstv_TwentyTwentyPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=pstv_TwentyTwentyPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=pstv_SeptemberTwoThousandAndTwentyTwoDistributionAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=pstv_SeptemberTwoThousandAndTwentyTwoDistributionAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=pstv_CanaccordGenuityLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=pstv_CanaccordGenuityLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=pstv_AtTheMarketOfferingProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=pstv_AtTheMarketOfferingProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=pstv_JanuaryTwoThousandAndTwentyTwoDistributionAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=pstv_JanuaryTwoThousandAndTwentyTwoDistributionAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140625255379920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Common stock shares to be issued (in shares)</a></td>
<td class="nump">163,025<span></span>
</td>
<td class="nump">68,422<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Stock option contractual term</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Stock option vesting percentage</a></td>
<td class="nump">25.00%<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Stock options exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend', window );">Dividend yield assumed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Total unamortized compensation cost related to outstanding unvested stock options and restricted stock awards</a></td>
<td class="nump">$ 800,000<span></span>
</td>
<td class="nump">$ 700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted average period for recognition of cost</a></td>
<td class="text">2 years 3 months 18 days<span></span>
</td>
<td class="text">1 year 9 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Stock option vesting period</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Stock option vesting period</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=pstv_StockBasedCompensation2015EquityIncentivePlan1Member', window );">2015 Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Securities remaining and available for future issuances (in shares)</a></td>
<td class="nump">6,024<span></span>
</td>
<td class="nump">6,024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=pstv_StockBasedCompensation2020EquityIncentivePlanMember', window );">2020 Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Securities remaining and available for future issuances (in shares)</a></td>
<td class="nump">17,582<span></span>
</td>
<td class="nump">180,607<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Common stock shares to be issued (in shares)</a></td>
<td class="nump">236,667<span></span>
</td>
<td class="nump">3,550,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of the weighted average expected dividend for an entity using a valuation technique with different dividend rates during the contractual term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=pstv_StockBasedCompensation2015EquityIncentivePlan1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=pstv_StockBasedCompensation2015EquityIncentivePlan1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=pstv_StockBasedCompensation2020EquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=pstv_StockBasedCompensation2020EquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140625346200880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation - Stock Option Activity (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Options [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Balance as of Options (in shares)</a></td>
<td class="nump">140,109<span></span>
</td>
<td class="nump">78,334<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="nump">163,025<span></span>
</td>
<td class="nump">68,422<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Cancelled/forfeited (in shares)</a></td>
<td class="num">(1)<span></span>
</td>
<td class="num">(6,647)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Balance as of Options (in shares)</a></td>
<td class="nump">303,133<span></span>
</td>
<td class="nump">140,109<span></span>
</td>
<td class="nump">78,334<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Vested and expected to vest (in shares)</a></td>
<td class="nump">278,083<span></span>
</td>
<td class="nump">133,810<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable (in shares)</a></td>
<td class="nump">84,908<span></span>
</td>
<td class="nump">72,843<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted Average Exercise Price [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Balance as of Weighted Average Exercise Price (in dollars per share)</a></td>
<td class="nump">$ 37.48<span></span>
</td>
<td class="nump">$ 68.16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in dollars per share)</a></td>
<td class="nump">2.03<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Cancelled/forfeited (in dollars per share)</a></td>
<td class="nump">289,125<span></span>
</td>
<td class="nump">283.76<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Balance as of Weighted Average Exercise Price (in dollars per share)</a></td>
<td class="nump">17.46<span></span>
</td>
<td class="nump">37.48<span></span>
</td>
<td class="nump">$ 68.16<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice', window );">Vested and expected to vest (in dollars per share)</a></td>
<td class="nump">18.64<span></span>
</td>
<td class="nump">38.62<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercisable</a></td>
<td class="nump">$ 50.13<span></span>
</td>
<td class="nump">$ 60.17<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Weighted Average Remaining Contractual Life (years) [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Balance as of Weighted Average Remaining Contractual Life (years)</a></td>
<td class="text">8 years 11 months 8 days<span></span>
</td>
<td class="text">8 years 25 days<span></span>
</td>
<td class="text">8 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Vested and expected to vest</a></td>
<td class="text">8 years 10 months 13 days<span></span>
</td>
<td class="text">8 years 7 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Exercisable</a></td>
<td class="text">7 years 4 months 13 days<span></span>
</td>
<td class="text">7 years 4 months 28 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pstv_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract', window );"><strong>Aggregated Intrinsic Value [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Balance as of Aggregated Intrinsic Value</a></td>
<td class="nump">$ 7,600<span></span>
</td>
<td class="nump">$ 7,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Vested and expected to vest</a></td>
<td class="nump">6,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Exercisable</a></td>
<td class="nump">$ 500<span></span>
</td>
<td class="nump">$ 6,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pstv_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award options aggregate intrinsic value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pstv_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pstv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140625259659232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation - Weighted-average Assumptions (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Black-Scholes-Merton option valuation model based on weighted-average assumptions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
<td class="text">6 years<span></span>
</td>
<td class="text">6 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">4.06%<span></span>
</td>
<td class="nump">2.83%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">127.00%<span></span>
</td>
<td class="nump">123.40%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividends</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Resulting fair value</a></td>
<td class="nump">$ 4.47<span></span>
</td>
<td class="nump">$ 7.05<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Rate of weighted-average expected volatility for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140625259126176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation - Summary of Share-Based Compensation Recognized (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation expense</a></td>
<td class="nump">$ 146<span></span>
</td>
<td class="nump">$ 140<span></span>
</td>
<td class="nump">$ 569<span></span>
</td>
<td class="nump">$ 606<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">66<span></span>
</td>
<td class="nump">87<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 503<span></span>
</td>
<td class="nump">$ 519<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140625346942864">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Subsequent Events - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>May 31, 2024</div></th>
<th class="th"><div>May 05, 2024</div></th>
<th class="th"><div>Apr. 26, 2024</div></th>
<th class="th"><div>May 09, 2024</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Warrant liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,250,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Biocept Asset Purchase [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireProductiveAssets', window );">Payments to acquire assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | May 2024 Private Placement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issue and sale of share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,591,532<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pstv_ClassOfWarrantOrRightExercisePriceInitialSubscription', window );">Class of warrant exercise price initial subscription</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.772<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pstv_ClassOfWarrantOrRightExercisePriceAdditionalSubscription', window );">class of warrant or right, exercise price additional subscription</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.908<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares Issued, Price Per Share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.79<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Warrant liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,250,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | May 2024 Private Placement [Member] | Series A Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issue and sale of share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,591,532<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | May 2024 Private Placement [Member] | Series B Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issue and sale of share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,591,532<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Private Placement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pstv_ClassOfWarrantOrRightPurchasePrice', window );">Class of warrant or right purchase price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pstv_ClassOfWarrantOrRightOfferingPrice', window );">Right offering price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.04<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Pre-funded Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pstv_ClassOfWarrantOrRightPurchasePrice', window );">Class of warrant or right purchase price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.158<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Pershing Credit Facility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Line of credit facility</a></td>
<td class="nump">$ 3,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityPeriodicPayment', window );">Line of credit facility, periodic payment</a></td>
<td class="nump">$ 3,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate</a></td>
<td class="nump">5.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis variable rate</a></td>
<td class="nump">1.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate</a></td>
<td class="nump">0.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateDuringPeriod', window );">Debt instrument, interest rate</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityInterestRateDuringPeriod', window );">Line of credit facility, interest rate</a></td>
<td class="nump">91.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pstv_ClassOfWarrantOrRightExercisePriceAdditionalSubscription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right, Exercise Price Additional Subscription.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pstv_ClassOfWarrantOrRightExercisePriceAdditionalSubscription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pstv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pstv_ClassOfWarrantOrRightExercisePriceInitialSubscription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right, Exercise Price Initial Subscription.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pstv_ClassOfWarrantOrRightExercisePriceInitialSubscription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pstv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pstv_ClassOfWarrantOrRightOfferingPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class Of Warrant Or Right Offering Price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pstv_ClassOfWarrantOrRightOfferingPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pstv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pstv_ClassOfWarrantOrRightPurchasePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class Of Warrant Or Right Purchase Price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pstv_ClassOfWarrantOrRightPurchasePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pstv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average effective interest rate during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateEffectivePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityInterestRateDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The effective interest rate during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityInterestRateDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityPeriodicPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the required periodic payments of both interest and principal.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityPeriodicPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireProductiveAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480060/805-50-25-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480027/805-50-30-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480027/805-50-30-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireProductiveAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481674/830-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAxis=pstv_BioceptAssetPurchaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAxis=pstv_BioceptAssetPurchaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=pstv_May2024PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=pstv_May2024PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=pstv_SeriesAWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=pstv_SeriesAWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=pstv_SeriesBWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=pstv_SeriesBWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=pstv_PreFundedWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=pstv_PreFundedWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=pstv_PershingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=pstv_PershingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>76
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
M6'!VULS2 Y9>*?IUE!K9';O=05SP6.XYB1'^QL4$UFG2&98T1G*=D 4. #?$
MT4Q0?*]!MHK@PI+27)#6SRFU4!H(FLB!]4>"(<7<K_WUE[O)I#-ZG7TZSFN4
M?VFK :?MNYO/D_QSZ.2?IY/734+.<+PL"?'[(UMAAR=N.Q-R.AQG0GS/]O:1
MI24RS^_Y"NM./&<?5I:P7<_/Y)Z,<B.[W?98??9/1VXCUZG LR+7E$8D19_(
M+;KD$3BU20TR$S\(G8:8:E < J0),9:AAOBTQJP1X!-]M[X(R-^-B/>K;YH]
M5Z%82=J$^!!&&N*<<^9ST6S[!Z5&T?95O-RCEU@5 9<8WS2J-2S%UGB5P/&M
MG#P=$Q+-E L&08:7)"82J3E^34@3_BNEVOZ<TT#PE"\D^DJ1CVFS(Z=T)LWH
M,QK!1J\;=8=HTCQZ_@7YG#4*')$;'0)G&[-&(81IN_ >KR2.FJW"$2M"/F(9
M-AIRM1:!MG&IA&!:$L;1>$[2M!'\6:PUDSY@R.S-D77.UI$.$9)>-T(^8LZ+
MD!&_'H8X2IKMHG%8!/V>7L-)P>B"RV;]N'Z&U3-L+([W1]072N0/)J<_Z3(T
M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
M.7\N?<^E[[GT/:'2MS<C?6?!TXM;WD9N6\3[KC':US0N*&-7<LW(QU2ODRG8
M.9_ [/UH/I[Q[?K9)(2OFEDM(Q:02X&S022X_(O*\"K$">AD6R4)RU3393>*
M$IY"&V[I4_5*E=?EK[DHN#Q;Y.FOH70^+,_Y/%_GM,T+,T.W<DOJMI2^M28X
M2O2QS'!.'LL,.V<\DAVV=Z =-?OV77;D(Z4P4Y=#N!I"O@-MNIW<.CB>F)&Y
M"M-2D&_#^>G%>!KB.=D$N7V85VWGV-'1^^?!4;"C[SR6'<>(\J(A[J&&F,_#
M0X=Y>U^89Y7&4#04;6RL)"Q&MV"XU_$L%.!D8"V@!X.O40+R4E5@,5O& RN0
MHGQ,C$7H<.>77%_CT9+CVZ9EM6ZO*7<9;2)2.<)IF!-GJ\K>9;'!51W/55OR
ML+YJ/;053L_^6:W(GPP13A8+$DACE!>F2J+S&5.^YRM)Q%4XOT4SMA*7&+SC
MYL=Q3E.X$G:V#P(RN;LYJ7IE,6>F\M\M# DL6XA9$N)-7>W5YYN<KGHB=OJ7
M=\%@\OUPR4</Y3OG7_1=0ZY^]MWC^FZ3.TA,G'G%$0%T10(CE1P&%A<RY%#N
MDI &$P'-E,E$\ *"9*8<@)CZ"[WR#+DI%<ZM/CE_12R#ADY>TB42%(JP# 4A
M%W+C[^^3:G>,U_HL@6V$5#)DU1?*0XG!/3-R0]A4)?.NVB8+A=OB5,V[&KXF
M8$O#>FZ=+2?_VU[4/;07/4;SHYG@'K.'<YMZN,)%K/]8UA[Y,M\Y<-LZW@->
MYA,L0Z1^P7V*BH 1JV*^NJ]/^26<.[1[\8$@F_S6VZ3VW> ,?-2K6J5D*Q$_
M2P=\'Y(&8XQ;]#1?CQ1BK::QK<;:,0QY@%CS#*%F.-^'19H:,]6+K#F-"F]!
MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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MZ3CX<@]OD;GAB?ZKJLZY9+M:,ITDUWK+ CZT8!9HKMZX-?KQ!_?*^0D!;A?
M;4R]!%Y^;"L[! ]?7+H(1*> Z* J8R (,XK;F*VK*/#X%8LU1SBN"HXK5&<F
M3&0^R!-?1]HH!CR/+*EL%5S'OW]>D.7=[&GLSYZ7\^GB@LP?IRV$L%L0=IL0
M3J&M%(MAE(7\G?S"/ZH8<27'<5RGW^GWL [L%5B])EBW40Q3>\H,7TM5R83+
M/$IQR8( $J@"C3#70_#Z!5Z_"=XB87%,)CL-C[6NPL-EC-IAH\QUR@SH-.&9
M)5RM([$F/X."V9"I3+9,5+9;C6#=!' _)6>W"=I<!%)MI<H2V 59&.@/(J%O
MY0Y&'@Q &5:G;US]9H9!TA*2-H%<LG<R#V$J1*LHR%/MXRYY^7;(',AP2<^[
M='JTV^E[&&%I RZ:M(^$XS"$E*TOCA<D<X)?177;X9)M6/80\"MF-E#12?P6
M8@G%+0W Q5,XBKK<RTK4&E?813!<@!<#+,W!Q;/[MX#3M 1C<2GWHA*NQFQ@
MB1,)C*RT"[>17Q1DQ33QE7R+1%#=S;CF\@\,K?0)MY%1%&B^U 8,X\]H>WKN
MXHK=7K=SA;&59N'B:3[KP#&LZ$^CX )=KXN!E+;@X@G]7@;0)C[,)XYE#ER$
M=CJ77;>/K1YIZ0RTD3/X*DIW+&0QGR)@-5JTYZ%0I2=0/&L?'1.Z2QC8U) O
M#SQEJES,XEK?N9JEI350>OX%.$6]X7N92[.@YS>+&LE_9Q:T- MZ?K.HD6QB
M%K0T"WI>LZB1JS4+6IH%_1_,HD83-0M:F@4]NUG4*-:9!2W-@OY7LZ@1P,V"
MEF9!SV$6-2(-S,(KS<+#$_PQ'?M<:2D$CT]N5VN$(%$$Y*Y%[GBHHN#U@CRT
M;BKSA?WIV"?=O&2'6YH$Z:X@/P$J[A8':./\V*A\/3]]@V_"WD>3F*\@U&EU
M82*J_$ K+QBYS0Z17J0Q,LDN-YR%7*4OP/.5E.982#]0'"N._@902P,$%
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M$#HJ@H280,N;+>SST6$5<6/5Y6S&S7ZL%^PEY;,S7J&<+KE>P$%/-@,%<1H
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M<VAE970S+GAM;*V787.3,!S&OTH./=WN=(04:#M;[K:FGM[I[-E-7V>0EMR
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MY@0>:J8RF73?+Z34'K B-H$[EH).ISC2%9Q":9;"L3;9U2#>5LU-'.ANN9R
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M0&DNE.9!:3Z4%D!IX5FIV91$?1< >55=-_>N1\*IR554C?,,'''0W@J!W@<
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M%.QH>+S]\'BVZ/,[N81D10G.NZ:E7[=4Z\3+?$C)!%^.7@YY!5#>=.P?HT(
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M1K45"*G9NI;U:UAQL9&Y],+;Q1?D 9M=U%FP_HAS4\1IM,A5M.,!(-T $.L
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MGN'0 1#U/'W#%T!AZOD]VY3TX"26W9,H/MX?\>\?\"OQ7']0"OI%IER/[*.
MHO<GOOZH H093R!#"#;S]2,'$00CT[Y2U=D(:K<1B[Z.(U:A)_Z<YKE*"^4Q
MY-PL0(-&3;LP]7V]N ,H/,5$W\(]#1:!,&_<QT=G!*C="%CYX/*ZG0E@BV V
MUA]= BA, F+,$!-FTAI!P8[X.B:BD^9T\K$RW;)4^O1=792;7JOS)O !1:=;
M 4ZCA4ZC1:ZB'0],9QFH?6?A-I=J4YHD<!#,)_EZ6BT 3&"D'A"'Z#NP (@>
MR(;C[G4"FTZM>;?<;;<95Y) :FQUAC_9-6M_7N3#>E(>>,0\.=TB4:<GGYQ&
M"YU&BUQ%.Q[!SAE0NS-XS.NR<:3FP %IPAR><,6>42N!O0Q#P );&;JWB !0
M3XWT.IWOV74^=!Y/BHG6&=9'\]*/'WZ"YXV=V@"GT4+/= +&03T T\=VYQ0\
MNU/X81[6V3\W5B)67MIM:K%RWG:C_;9G<^W4-+31#N=(H.]A 9@^KCN_X'UP
MF K@NGBJF(35*<Y_-6=@ZASOXQO<Z;3?^&RVB=%W?8\O='K'R%6T9F!&!V\9
M;;AXKE_O*E%]=J!YL61_=?\*V77]XI1V_09?+#!P/<074?."6!>^>5_M&Q-2
MW9=RS%;R5N,O@211-*^ -5^J8EN_X_145%6QJ3^N.4NX4 #Y]U515.]?U WV
M+^+-_P=02P,$%     @ )HC'6->OJ6MW"@   !T  !@   !X;"]W;W)K<VAE
M971S+W-H965T-RYX;6S-65MSV[@5_BL8;6?'F9%E79PXS<4SLMVDF4XN&V^Z
M#YT^0"0D80,!# #:5GY]OW, 4I1,.]W./O0AL4@"Y_*=[UQ OKIU_FM8*Q7%
MW<;8\'JPCK%Z<7(2BK7:R#!RE;)XLG1^(R,N_>HD5%[)DC=MS,ET/'YVLI':
M#LY?\;U/_OR5JZ/15GWR(M2;C?3;"V7<[>O!9-#<^*Q7ZT@W3LY?57*EKE7\
M4GWRN#III91ZHVS0S@JOEJ\'\\F+BU-:SPO^J=5MZ/P6Y,G"N:]T\:Y\/1B3
M0<JH(I($B3\WZE(90X)@QK<L<]"JI(W=WXWT-^P[?%G(H"Z=^4V7<?UZ\'P@
M2K64M8F?W>W?5?;G*<DKG G\O[C-:\<#4=0ANDW># LVVJ:_\B[C\-]LF.8-
M4[8[*6(KKV24YZ^\NQ6>5D,:_6!7>3>,TY:"<AT]GFKLB^<7,N@@W%)\\BHH
M&V7"RI;B Q"=%X6K;=1V):XC;DI?AE<G$7II]TF1=5PD'=,'=,S$>V?C.HB_
MV5*5^_M/8&]K]+0Q^F+ZJ,#WTH_$;#(4T_'T]!%YLQ:$&<N;/2#OHU])J[^S
M[T-QZ6QP1I<[*/:P 59OM)6VT-(0*E&!HS&(?\T7(7JP[-]]""4#3OL-H,Q[
M$2I9J->#BG3Y&S4X__FGR;/QRT?<.VW=.WU,^I\4X\=U3$;BCZL1OZX5\K)P
MFTK:+3VJK:Q+'54I"@>RV(!?RQ;ML$,;Y4A$[(YKKY38)'XIXI< .XIU2P\V
M #]F8BUOE%@H904PKJ3'4FU9O2^A0"'SXIJOLYV5U]!;&17$2EGEI3%;>JZJ
MF/:2 5\LF\M$8._G&^5U(=E";2,N-AT7M$V%%-",&!-?0I79#DG85I1.6!>Q
MJC!U"6R,(9&DI[.175HZ%[$4.KWZ5FOR9K']<ZV7UM8PN0__$8=N%Z.%- QA
M:B0RBBM5J,U"^28.!'](Z)?0<$-Q]6[#1C0A[PUTGZRA6-016,'D_Q^TB,5&
M1?4 7N^2"%=IFZO(1EJT/7H\9--E^3OJ??+Z"- BF]@T++7DC('M1>T]W>NL
M?2)X+5"%:190A8#NF@(HEE)[41V4+[)C9V3E@FYQPDJT,_8-?=_SEI33IN9T
M];)2==1%&,*C8B2.2-C//SV?3L<O+U,>\]7DY9-.PN4(E2/Q,4F%"XVJ/Y#)
M7G&\&R<U0J1MB0!09V\\:^3&-:BSD5M8(-1=A2F *):5;97TI(0,.:37*9,[
M] <2#'>U*4DHS4#$#,#_>VW3D,$E9!_?+I>!<&(AEGBE=\ T#.M .#E[&<0\
MI>!G53D?!130*"(FX^-_$/=LF>1&)RZ5CWI)4# 0B(WSV+/+@,_J1GDX=1U=
M\55<5T9',8^L-"MYC]3-?.-%:V= JM#@FDT3:P7W(72.E#' *Z=WEPC[ AL^
M<(D#' ^+EE7E'94&"9L;]\B[7F@VB23).4:Y?!R&/:ZNI4=M;KD*)9KRES5*
MQ#:AQ=:*P&CM&]O:@7N(8PAUM@63;Z &1U"B)H#02<I0H.>(&VEJ)?XR'HW'
M$X%< )] Z^&..&PKF0.&E2@G'D-?JE;T],*A;Y(E5ZAA173 L.L5/VY]VC<X
MZ:".!QUVI5)=B0(ECY/%BLDQTN-XEO].GNY^?&S#?=94X*4S&.C)R4Y$&8!D
M8XJE-,.]""^U(9@.XS3O!EN#T3D\^ZQJ%NT(U:)VK0JO(M4]9F\6RT^:BRME
MY"V5$*A0RR70J^D)K>G)C=3@=G8M5 %&YHU<;2S*TU;DCC027RK<:1]; C5;
MT",]@6)K+CM8QB0X3(>685T6B:.[)P^QK2009&A:*T?@3J,+*A3*V=GH% <(
M8R@3LCX@L;]H.GIZL.:E.-H^$7DF3?63M'.SK]GE.^4+'1CBKC& &C3+1<]5
MJ9$\:N%T-/ZA@>/1Y&#-D!4<?>\82<,!!DGPL^"B4%NB9B^R:*<479H)(C63
M E<4W0KCS _,G=TW%Q#LQ:K'_.D/]B3>/<J A<)I1>"HP3B[U#@^R%#*;^)2
M5CI2Z97^*P:QHYPZZ>FN,% 10-^/QZFR+=+D?L#H/D.>#L?C,?WKF"_KN'9>
M?U=\4%HJ[WE&(E-O56[9DA-C5\=Z,^Z# \Z2&RGUS:2 163"IV9KU4&O[4TP
M8H4\F*_W"'HO^PB0WC9YB\DU#5RPH72WEF?'O<!.AK/)6!PQIJD(/)+]3[+&
M$?!RU-B3P]WYKYE3>LTA1#:R5 ]UQJZ7B3(Y_X;[6?D ZQO=Z$[:E7VCV$P
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M9T\'PJ?O;>DBNHJ_<2U<Q+S#/]<*([*G!7A.[W^;"U+0?O0\_P]02P,$%
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M9&@R^7 :@>W'3A^0:8/5UX9X<(1ES9,:K4_@\](8V@:^P#C[LS=02P,$%
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M80;ZNR:ES5SI[,U,*+GD0S;3&0E+H.1._#ODEDF!AG85!]FQA]I%6"%!"B+
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M.HCS.]^WE=4Q#=/MJYOC$2IN1_'?@3M*0#/V(,F$F('#@$A,[$]X=R"46^>
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MK[0!W\\T]NCJ@134!Y^3OP!02P,$%     @ )HC'6.D]S;;W P  X0H  !D
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M1N\^WUWSU?C=:[@+/J[UN(5'2RGN;%%1MP(0/AH4DE>)+AVK:?L"[;BAA7S
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MKZ,#>#ZS-M1?2$#S$_35[U!+ P04    "  FB,=8G4;A!9,$  "9#@  &0
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M)17^NNA3+TC9P#T<T()E+HBOZN5<FT 5GC:.*(1^K_Y/=O\9LJOO9/'.[;]
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M&XC)N"^247*PS:#=XJ]4VHA/=I@S:>(\87V3._5-@WBE?6JL+YT2?S^?^N
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M1!H'XK(3^L_XT!<2,<!O"/<Z.G*9J=856Y@;L90W)./),EO.%XRM2 SX20^
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M^$.CFRKN/:F:*2Z\V#@?>K3,$:]'E8%7Y.?!Z>"L'451.>5ZIZ/P$N OD?9
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MF#H>GAP/HM_:FV!K/N&>V@!^SI<+)5'G: #>SZP-[0TMT/W+X_+_4$L#!!0
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M[+TG9^<[ZL ;*OC"<Y"W--TANX&]X<[=B!#J[L#G8AOLLB4R2GAS7[BIF1U
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MX#BBDG1'[7G7%*2[&LRF73&2%8TUW"7D9,K0M#E0KDG9W?DAT=*D.=OF8C=
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MP@"_+238UJ; -DEB;^0659R^L9U*(2FLW(V9E:F7Q^C\0#SSEG6ND-9N,1S
MKAW;[/,A0KONXY+E%4UCS0/%![& 6,98Y(KH5A!1&>D:/4N(WJ!C&1.GXB/%
M,5#$"JR@$N=PM^F\;2"<N;&@;$BHI6#DB>GY"HRIE9&U]V0.3!-"DL#-@=PV
ML]!H;60K"7%O(WU&HSTBA583S2-V\";:P9M1.[BU4");R-60NI] 4@UR8<@0
M1N$\UA">@I3H?:WBU^@7*%B7& X*2)$F$(A;ROJ*HEM#,H#WP(]8!2:#/F8J
MKK.KH&03[W>\&;%((&>#/.R?,>TM9*-;6>E_HL>%#$BM#*0RD#]9<Q\2/Y 2
M7D*@*TD3L'X76-M@D7V,U&(M#D_!$LL)BD]M2LRN%ET%2GX?PIZ*9F+XX4HO
MDGX@"AYQA=  *BFZLIS^6 G);,BQ((*.Z,S;J#-O1\5S$Y/%(3T97?M8/7D"
ML(1=+Q(B#SGFM22=(4U"636FA8_D61.@S4I1"@B:!OR5D H05[':T194#-2/
MPEZ[ @W4=0GAD3S#OD?T.?=:;BFPSC$%+5 -T&U,Q1U&8[)Y5( REB"4;()Z
MA423<8/+@)GH:JQCT(LJG]TL*K-QI-N4X/)"=IAX/=\FW1(O@'+^M+2F:U[2
MCI1A 4EU>C#FXI$TKFD@PP<>^^*MS%F'F8;84+X/VW/-0(0%ZX+5B$L(^0<W
M8K>("9 J68J9MT0YQDV0H[;D321<E5T1$HMV+TX%0[**W01S@0H,%+-=4OQ
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M=TN/)I1&@-9+(?1A8 P,S[#Y/U!+ P04    "  FB,=8XYTVS9,#  "8"
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M7<2+Y95C.5$\+P_A>Z[P2"^',=[20.@ ?!]QKE83?:[7][[@+U!+ P04
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M841NI3"E)I]% <53 A^+[2J.#A7/HI.,<\@') [?D2B(XAY!V>OAT0DY<7<
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MG;4Y,;2OMU]1J2_#1!:/+8163RU=C])VWL$:M+<NWTXGWT^G<T,=:'M\*"V
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MZ(P)4T!_/L\R]?S&5%#MVWKQ-U!+ P04    "  FB,=8C DYZ.@"  #6"
M&0   'AL+W=O<FMS:&5E=',O<VAE970T-"YX;6RM5FUOVC 0_BM65DV=M#4D
MO(Y!I *;-FG5JM)NGTUR$*N.G=D.M/]^9QLRZ +C0[\DMG/W^'E\Y[N,-E(]
MZAS D*>""ST.<F/*81CJ-(>"ZBM9@L O2ZD*:G"J5J$N%=#,.14\C%NM7EA0
M)H)DY-9N53*2E>%,P*TBNBH*JIXGP.5F'$3!;N&.K7)C%\)D5-(5S,$\E+<*
M9V&-DK$"A&92$ 7+<7 =#:<#:^\,?C+8Z+TQL4H64C[:R;=L'+0L(>"0&HM
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MTA3& =Y8#6H-0?+V3=1K?6H2]TI@!U([M=3.*?3D1PF*VD0B?%]TDV8/U'5
MMN:LDZ@3C<+UOI0&F^['VN: 8;=FV#W)\%X:RO_/SH/T3K)KL#G&KE>SZYU,
ME2G5.2GIL[V8>*U\M<:RUY@UO=?,FE<".U#=KU7WS\R:U.JO-&0$I1-YF$V-
MM:5_1J :;(X%:E!3'IR11JD/%_-T:2$K6T^92'F%E<S619,#*9!\I<#%%.NI
MSSW.Z()Q9EBSK,$9MZ/!YA]9X5Z+*$"M7.?4)+5,?4&M5^OF?.UZTHOU"39M
MWV/_POB.?T/5B@F-NI8(V;KJ(R/ENZB?&%FZ1K20!MN:&^;XXP'*&N#WI91F
M-[$;U+\RR1]02P,$%     @ )HC'6.A0CI-V P  F T  !D   !X;"]W;W)K
M<VAE971S+W-H965T-#4N>&ULK9=K;]HP%(;_BI5-TR:MS840H(-(+6C:I%W0
MNLN':1],.( UQ\YL!]I_/]L)&0EI!A)?2ISX?8_/8_?D9+SCXK?< "CTD%(F
M)\Y&J>S&=66R@13+:YX!TT]67*18Z:%8NS(3@)=6E%(W\+S(33%A3CRV]^8B
M'O-<4<)@+I#,TQ2+QSN@?#=Q?&=_XPM9;Y2YX<;C#*_A'M2W;"[TR*U<EB0%
M)@EG2,!JXMSZ-S/?,P([XSN!G3RX1B:5!>>_S>#]<N)X9D5 (5'& NN?+4R!
M4N.DU_&G-'6JF$9X>+UW?VN3U\DLL(0IIS_(4FTFSM!!2UCAG*HO?/<.RH3Z
MQB_A5-J_:%?.]1R4Y%+QM!3K%:2$%;_XH01Q(/##)P1!*0A.%?1*0>]405@*
M0DNF2,5RF&&%X['@.R3,;.UF+BQ,J];I$V;V_5X)_91HG8JG/$V)TANI),)L
MB::<*<+6P!("$EVA^^(\(+Y";W.5"T ?"2-IGJ);QG),T0?0U-$</Q8>.5N"
M0)\S$-CX%(\E>CD#A0F5K[3EM_L9>OG\%7J."$-?-SR7.K <NTJG8Q;E)N72
M[XJE!T\L_2,6UZCGOT:!%X0M\FFW? 9))>^UR&>GRX.ZW-5[4&U$4&U$8/UZ
M)VS$[=%&S(A,*)>&_\_;A51"_[_\:D-6! G;@Y@B<B,SG,#$T55"@MB"$[]X
MYD?>FS: ES2;7<BL!K=7P>UUN<=/G)"[3M6YM JSOC4SY78;^V$T=K>'$"X4
ML 8AK""$_X/0;X/0J3H70F$6'4"(O :#"\6K,>A7#/K_8Q"U,>A4G<N@?\3
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MA\[*E:#EAJ!YL4SPB0I!T^+EAN"(,-5 OK^B5+QNJ +U>MS%?U!+ P04
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M663AA!5JG:92QADG"RGN0KEJX4)M)BC-AM*<BK9Y/QH8PYW6)M1"@M)\*"U
MT9K*K6TD0^\C?4J39R+R,?MI/N*9+@47-)F&^=:YS'">1E-=)QQJ,$%I-I3F
M0&DNE.9!:7Y%V[Q"1\H&P]]A-)FUT63JC:;U?)1]G?@J?KMK.]KNVM[H,VHK
M.RC-@=)<*,V#TGSUZ3(LZZQYNFX/Z.*KH3)H@F/5<-<6WY1O;3"9VO'^\7V8
MA/$R)E'XQS*<YOW]2?K"$JJ^S^IA;>^S4)H-I3E0FEO1=N?0;7>ZH-GZ4%J
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M9P;@^XD0>GUC)BC.#8?_ U!+ P04    "  FB,=8X*"MWX4#   I#   &0
M 'AL+W=O<FMS:&5E=',O<VAE970U,2YX;6RM5VUOVS80_BN$A@TNL%D2';\D
MLPTDSHH66+L@R=8/PS[0TMGB*I$N>;;3?]\C9<MV)BE&5G^P1>KNN7N>X\MY
MO-7FL\T D#T5N;*3($-<786A33(HA.WJ%2AZL]"F$$A#LPSMRH!(O5.1ASR*
M!F$AI JF8S]W9Z9CO<9<*K@SS*Z+0IBO-Y#K[22(@_W$O5QFZ";"Z7@EEO
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M[P,  !8.   9    >&PO=V]R:W-H965T<R]S:&5E=#4R+GAM;*V7;6_C-@R
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M[I*,G<R4Z="C:-)S:"@S2^S^S#I_9F^$7M-RS98<VOIB0YL-I@VCH)\90Z'
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M1$->*$H8W LDBRS#XG4,E*]'CN]L# ]DF2IC<*-ACI<P _64WPN]<VN5A&3
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MJD]V$,9!WU]PKC8;\X#ZOT+T%U!+ P04    "  FB,=88ON#;L\"  #)"
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M./3W#GU'M,K,T5I@C>.)%#LDK;5!LP.GC?,V; BWIWBGI=DEQD_'UZR@XAD
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MJE1NXYK6R^;ZVZY]H#0/2O.AM !*"U$T7665P^OTD.ME!^E:3J T#TKSH;0
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MWA"TXT/ZUP4H+02E$2B:69?:)'MVE_S_MZ<%/]ME5YW6#ZZ\TYT_J!MNEY1
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MSJ@#(K+$62R_L-UOI#"HK_%"%@OS'^P*6:\#PDQ(EA3*:@8)3?-?_%P0<:
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M06O<X!IZ_/FIQ*N.?FB0>9?2Z^D1>08JNT[DXA\23Q0,6P7#JT@/3&U[:PE
M6($B0&DBJ88N+3607]]2\_)6L=?W!EXT<:MCZMUQP3ALXTZ81BW3Z'5>5X+C
M@>1,/W>QK$'\X&AUOQ^,SCA&+SEB5#CHICAJ*8ZN4KQE%4NA2#O?F-%+8MX9
MJZLA)XS&+:/Q]>T%A;6"%1NRIDS:R]RYMS7*^&CA07]P;MK+H%'?&YX1=(_>
M^1SDQI8_11*Q*W3]0+:C;86=V<)R-C['REL7RK\P==F^HW+#\)'AL$9(KS_"
M$R?K4EAWM"AM-5D)C;7)-C/\>@!I G!^+80^=,P"[?=(_ =02P,$%     @
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M2%B$A,4@F&5(N#$DK.CAD:<"^?JWWH+<*I;+5D]"I"=(6(2$Q2"8Y<E@X\G
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M4-SL5K.,+ZK^(FL,8.IM7)T6A5A^$7PJ<^8F?W#"89^N>,%,:?YDLT&I3&R
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MJMZ#.^^C</6>"M?_P1P^ U!+ P04    "  FB,=8EXJ[',     3 @  "P
M %]R96QS+RYR96QSG9*Y;L,P#$!_Q=">, ?0(8@S9?$6!/D!5J(/V!(%BD6=
MOZ_:I7&0"QEY/3P2W!YI0.TXI+:+J1C]$%)I6M6X 4BV)8]ISI%"KM0L'C6'
MTD!$VV-#L%HL/D N&6:WO606IW.D5XA<UYVE/=LO3T%O@*\Z3'%":4A+,P[P
MS=)_,O?S##5%Y4HCE5L:>-/E_G;@2=&A(E@6FD7)TZ(=I7\=Q_:0T^FO8R*T
M>EOH^7%H5 J.W&,EC'%BM/XU@LD/['X 4$L#!!0    ( ":(QUC,\].7(04
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M///6U-TAGPU_,IJ] 5!+ 0(4 Q0    ( ":(QU@'04UB@0   +$    0
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M965T,RYX;6Q02P$"% ,4    "  FB,=815F[AV,%  "%&   &
M    @(&V%@  >&PO=V]R:W-H965T<R]S:&5E=#0N>&UL4$L! A0#%     @
M)HC'6,J\%'(<"@  TF\  !@              ("!3QP  'AL+W=O<FMS:&5E
M=',O<VAE970U+GAM;%!+ 0(4 Q0    ( ":(QU@2R&U L@D  )0W   8
M          " @:$F  !X;"]W;W)K<VAE971S+W-H965T-BYX;6Q02P$"% ,4
M    "  FB,=8UZ^I:W<*    '0  &               @(&),   >&PO=V]R
M:W-H965T<R]S:&5E=#<N>&UL4$L! A0#%     @ )HC'6!UIE4)2"@  [!D
M !@              ("!-CL  'AL+W=O<FMS:&5E=',O<VAE970X+GAM;%!+
M 0(4 Q0    ( ":(QUCT@T4&G@(   <&   8              " @;Y%  !X
M;"]W;W)K<VAE971S+W-H965T.2YX;6Q02P$"% ,4    "  FB,=8L[C>I[L0
M   $+P  &0              @(&22   >&PO=V]R:W-H965T<R]S:&5E=#$P
M+GAM;%!+ 0(4 Q0    ( ":(QUB %+0YU@<  ,H3   9              "
M@819  !X;"]W;W)K<VAE971S+W-H965T,3$N>&UL4$L! A0#%     @ )HC'
M6,:HZ\1+!0  !!4  !D              ("!D6$  'AL+W=O<FMS:&5E=',O
M<VAE970Q,BYX;6Q02P$"% ,4    "  FB,=8Z3W-MO<#  #A"@  &0
M        @($39P  >&PO=V]R:W-H965T<R]S:&5E=#$S+GAM;%!+ 0(4 Q0
M   ( ":(QUB# O;>&P0  !D*   9              " @4%K  !X;"]W;W)K
M<VAE971S+W-H965T,30N>&UL4$L! A0#%     @ )HC'6(;;&PL7"@  CAX
M !D              ("!DV\  'AL+W=O<FMS:&5E=',O<VAE970Q-2YX;6Q0
M2P$"% ,4    "  FB,=8G4;A!9,$  "9#@  &0              @('A>0
M>&PO=V]R:W-H965T<R]S:&5E=#$V+GAM;%!+ 0(4 Q0    ( ":(QUB\VR(D
M^0D  /\E   9              " @:M^  !X;"]W;W)K<VAE971S+W-H965T
M,3<N>&UL4$L! A0#%     @ )HC'6"GKRMXS!@  H10  !D
M ("!VX@  'AL+W=O<FMS:&5E=',O<VAE970Q."YX;6Q02P$"% ,4    "  F
MB,=8I)3-(B0+  #O'@  &0              @(%%CP  >&PO=V]R:W-H965T
M<R]S:&5E=#$Y+GAM;%!+ 0(4 Q0    ( ":(QUBK)([VV@(  %0&   9
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M970R-"YX;6Q02P$"% ,4    "  FB,=8;#R9V T3  "V10  &0
M    @(&_R@  >&PO=V]R:W-H965T<R]S:&5E=#(U+GAM;%!+ 0(4 Q0    (
M ":(QUCC\*U!9@,  *P*   9              " @0/>  !X;"]W;W)K<VAE
M971S+W-H965T,C8N>&UL4$L! A0#%     @ )HC'6'9&U*$V P  : @  !D
M             ("!H.$  'AL+W=O<FMS:&5E=',O<VAE970R-RYX;6Q02P$"
M% ,4    "  FB,=8*P!/5+@#  "2"0  &0              @($-Y0  >&PO
M=V]R:W-H965T<R]S:&5E=#(X+GAM;%!+ 0(4 Q0    ( ":(QUCCG3;-DP,
M )@(   9              " @?SH  !X;"]W;W)K<VAE971S+W-H965T,CDN
M>&UL4$L! A0#%     @ )HC'6 9;^\(L P  40<  !D              ("!
MQNP  'AL+W=O<FMS:&5E=',O<VAE970S,"YX;6Q02P$"% ,4    "  FB,=8
MF[HS#2P%  #0#   &0              @($I\   >&PO=V]R:W-H965T<R]S
M:&5E=#,Q+GAM;%!+ 0(4 Q0    ( ":(QUAN1Q -(@4  $4.   9
M      " @8SU  !X;"]W;W)K<VAE971S+W-H965T,S(N>&UL4$L! A0#%
M  @ )HC'6(CE9QY6!P  !D<  !D              ("!Y?H  'AL+W=O<FMS
M:&5E=',O<VAE970S,RYX;6Q02P$"% ,4    "  FB,=8F@"A&DD+   2C@
M&0              @(%R @$ >&PO=V]R:W-H965T<R]S:&5E=#,T+GAM;%!+
M 0(4 Q0    ( ":(QUC63D>\UP4  .LK   9              " @?(- 0!X
M;"]W;W)K<VAE971S+W-H965T,S4N>&UL4$L! A0#%     @ )HC'6. Y3*TK
M!0  ,A\  !D              ("! !0! 'AL+W=O<FMS:&5E=',O<VAE970S
M-BYX;6Q02P$"% ,4    "  FB,=8>0)RA_P#  #7&0  &0
M@(%B&0$ >&PO=V]R:W-H965T<R]S:&5E=#,W+GAM;%!+ 0(4 Q0    ( ":(
MQUCP9-T/%P0  &\6   9              " @94= 0!X;"]W;W)K<VAE971S
M+W-H965T,S@N>&UL4$L! A0#%     @ )HC'6,-:#QBE @  \ <  !D
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M=#0S+GAM;%!+ 0(4 Q0    ( ":(QUB,"3GHZ (  -8(   9
M  " @8\W 0!X;"]W;W)K<VAE971S+W-H965T-#0N>&UL4$L! A0#%     @
M)HC'6.A0CI-V P  F T  !D              ("!KCH! 'AL+W=O<FMS:&5E
M=',O<VAE970T-2YX;6Q02P$"% ,4    "  FB,=8TDK)=(H%  ";*P  &0
M            @(%;/@$ >&PO=V]R:W-H965T<R]S:&5E=#0V+GAM;%!+ 0(4
M Q0    ( ":(QU@8?);GK@D  $ED   9              " @1Q$ 0!X;"]W
M;W)K<VAE971S+W-H965T-#<N>&UL4$L! A0#%     @ )HC'6)LEL+JU!
M&!D  !D              ("! 4X! 'AL+W=O<FMS:&5E=',O<VAE970T."YX
M;6Q02P$"% ,4    "  FB,=84'HPQ:0&  #C+   &0              @('M
M4@$ >&PO=V]R:W-H965T<R]S:&5E=#0Y+GAM;%!+ 0(4 Q0    ( ":(QUC@
MP+'S= 4  $,<   9              " @<A9 0!X;"]W;W)K<VAE971S+W-H
M965T-3 N>&UL4$L! A0#%     @ )HC'6."@K=^% P  *0P  !D
M     ("!<U\! 'AL+W=O<FMS:&5E=',O<VAE970U,2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( ":(QU@EP:#3=@4  (XH   9              "
M@<5T 0!X;"]W;W)K<VAE971S+W-H965T-38N>&UL4$L! A0#%     @ )HC'
M6!5(D4\:&   0\X! !D              ("!<GH! 'AL+W=O<FMS:&5E=',O
M<VAE970U-RYX;6Q02P$"% ,4    "  FB,=8IRP2QU %  "6'@  &0
M        @('#D@$ >&PO=V]R:W-H965T<R]S:&5E=#4X+GAM;%!+ 0(4 Q0
M   ( ":(QUB#;C?]5P4  -H<   9              " @4J8 0!X;"]W;W)K
M<VAE971S+W-H965T-3DN>&UL4$L! A0#%     @ )HC'6# JA:@( P  FP@
M !D              ("!V)T! 'AL+W=O<FMS:&5E=',O<VAE970V,"YX;6Q0
M2P$"% ,4    "  FB,=8(W.@Y(@#  !Y$0  &0              @($7H0$
M>&PO=V]R:W-H965T<R]S:&5E=#8Q+GAM;%!+ 0(4 Q0    ( ":(QUC!>;A^
MP 8  /$[   9              " @=:D 0!X;"]W;W)K<VAE971S+W-H965T
M-C(N>&UL4$L! A0#%     @ )HC'6!V7=?5) P  SA0   T
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;72YX;6Q02P4&     $8 1@ A$P  RKD!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.1.1.u2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>233</ContextCount>
  <ElementCount>358</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>67</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>9</UnitCount>
  <MyReports>
    <Report instance="d840996ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>1001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://plus.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="d840996ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1002 - Statement - CONDENSED BALANCE SHEETS (UNAUDITED)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://plus.com/role/CondensedBalanceSheetsUnaudited</Role>
      <ShortName>CONDENSED BALANCE SHEETS (UNAUDITED)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="d840996ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1003 - Statement - CONDENSED BALANCE SHEETS (UNAUDITED) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://plus.com/role/CondensedBalanceSheetsUnauditedParenthetical</Role>
      <ShortName>CONDENSED BALANCE SHEETS (UNAUDITED) (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="d840996ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1004 - Statement - CONDENSED STATEMENTS OF OPERATIONS (UNAUDITED)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://plus.com/role/CondensedStatementsOfOperationsUnaudited</Role>
      <ShortName>CONDENSED STATEMENTS OF OPERATIONS (UNAUDITED)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="d840996ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1005 - Statement - CONDENSED STATEMENTS OF STOCKHOLDERS' EQUITY/(DEFICIT) (UNAUDITED)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://plus.com/role/CondensedStatementsOfStockholdersEquityDeficitUnaudited</Role>
      <ShortName>CONDENSED STATEMENTS OF STOCKHOLDERS' EQUITY/(DEFICIT) (UNAUDITED)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="d840996ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1006 - Statement - CONDENSED STATEMENTS OF CASH FLOWS (UNAUDITED)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://plus.com/role/CondensedStatementsOfCashFlowsUnaudited</Role>
      <ShortName>CONDENSED STATEMENTS OF CASH FLOWS (UNAUDITED)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="d840996ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>1007 - Disclosure - Basis of Presentation and New Accounting Standards</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://plus.com/role/BasisOfPresentationAndNewAccountingStandards</Role>
      <ShortName>Basis of Presentation and New Accounting Standards</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="d840996ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>1008 - Disclosure - Organization and Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://plus.com/role/OrganizationAndOperations</Role>
      <ShortName>Organization and Operations</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="d840996ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>1009 - Disclosure - Use of Estimates</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://plus.com/role/UseOfEstimates</Role>
      <ShortName>Use of Estimates</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="d840996ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>1010 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://plus.com/role/SummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="d840996ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>1011 - Disclosure - Liquidity and Going Concern</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://plus.com/role/LiquidityAndGoingConcern</Role>
      <ShortName>Liquidity and Going Concern</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="d840996ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>1012 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://plus.com/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="d840996ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>1013 - Disclosure - Loss per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://plus.com/role/LossPerShare</Role>
      <ShortName>Loss per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="d840996ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>1014 - Disclosure - Composition of Certain Financial Statement Captions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://plus.com/role/CompositionOfCertainFinancialStatementCaptions</Role>
      <ShortName>Composition of Certain Financial Statement Captions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="d840996ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>1015 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://plus.com/role/CommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="d840996ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>1016 - Disclosure - License Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://plus.com/role/LicenseAgreements</Role>
      <ShortName>License Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="d840996ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>1017 - Disclosure - Term Loan Obligations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://plus.com/role/TermLoanObligations</Role>
      <ShortName>Term Loan Obligations</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="d840996ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>1018 - Disclosure - Grant Revenue</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://plus.com/role/GrantRevenue</Role>
      <ShortName>Grant Revenue</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="d840996ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>1019 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://plus.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="d840996ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>1020 - Disclosure - Employee Benefit Plan</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://plus.com/role/EmployeeBenefitPlan</Role>
      <ShortName>Employee Benefit Plan</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="d840996ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>1021 - Disclosure - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://plus.com/role/StockholdersEquity</Role>
      <ShortName>Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="d840996ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>1022 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://plus.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="d840996ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>1023 - Disclosure - Stock-based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://plus.com/role/StockBasedCompensation</Role>
      <ShortName>Stock-based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="d840996ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>1024 - Disclosure - Basis of Presentation and New Accounting Standards (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://plus.com/role/BasisOfPresentationAndNewAccountingStandardsPolicies</Role>
      <ShortName>Basis of Presentation and New Accounting Standards (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://plus.com/role/BasisOfPresentationAndNewAccountingStandards</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="d840996ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>1025 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://plus.com/role/SummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://plus.com/role/BasisOfPresentationAndNewAccountingStandards</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="d840996ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>1026 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://plus.com/role/FairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://plus.com/role/FairValueMeasurements</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="d840996ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>1027 - Disclosure - Loss per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://plus.com/role/LossPerShareTables</Role>
      <ShortName>Loss per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://plus.com/role/LossPerShare</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="d840996ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>1028 - Disclosure - Composition of Certain Financial Statement Captions (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://plus.com/role/CompositionOfCertainFinancialStatementCaptionsTables</Role>
      <ShortName>Composition of Certain Financial Statement Captions (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://plus.com/role/CompositionOfCertainFinancialStatementCaptions</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="d840996ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>1029 - Disclosure - Commitments and Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://plus.com/role/CommitmentsAndContingenciesTables</Role>
      <ShortName>Commitments and Contingencies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://plus.com/role/CommitmentsAndContingencies</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="d840996ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>1030 - Disclosure - Term Loan Obligations (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://plus.com/role/TermLoanObligationsTables</Role>
      <ShortName>Term Loan Obligations (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://plus.com/role/TermLoanObligations</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="d840996ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>1031 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://plus.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://plus.com/role/IncomeTaxes</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="d840996ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>1032 - Disclosure - Stock-based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://plus.com/role/StockBasedCompensationTables</Role>
      <ShortName>Stock-based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://plus.com/role/StockBasedCompensation</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="d840996ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>1033 - Disclosure - Basis of Presentation and New Accounting Standards (Additional Information) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://plus.com/role/BasisOfPresentationAndNewAccountingStandardsAdditionalInformationDetails</Role>
      <ShortName>Basis of Presentation and New Accounting Standards (Additional Information) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://plus.com/role/BasisOfPresentationAndNewAccountingStandardsPolicies</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="d840996ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>1034 - Disclosure - Organization and Operations - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://plus.com/role/OrganizationAndOperationsAdditionalInformationDetails</Role>
      <ShortName>Organization and Operations - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="d840996ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>1035 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://plus.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="d840996ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>1036 - Disclosure - Liquidity and Going Concern - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://plus.com/role/LiquidityAndGoingConcernAdditionalInformationDetails</Role>
      <ShortName>Liquidity and Going Concern - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="d840996ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>1037 - Disclosure - Fair Value Measurements - Summary of Financial Assets Measured at Fair Value on Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://plus.com/role/FairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails</Role>
      <ShortName>Fair Value Measurements - Summary of Financial Assets Measured at Fair Value on Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="d840996ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>1038 - Disclosure - Loss per Share - Schedule of Antidilutive Securities Excluded from Diluted Income (Loss) per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://plus.com/role/LossPerShareScheduleOfAntidilutiveSecuritiesExcludedFromDilutedIncomeLossPerShareDetails</Role>
      <ShortName>Loss per Share - Schedule of Antidilutive Securities Excluded from Diluted Income (Loss) per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="d840996ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>1039 - Disclosure - Composition of Certain Financial Statement Captions - Other Current Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://plus.com/role/CompositionOfCertainFinancialStatementCaptionsOtherCurrentAssetsDetails</Role>
      <ShortName>Composition of Certain Financial Statement Captions - Other Current Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="d840996ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>1040 - Disclosure - Composition of Certain Financial Statement Captions - Property and Equipment, Net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://plus.com/role/CompositionOfCertainFinancialStatementCaptionsPropertyAndEquipmentNetDetails</Role>
      <ShortName>Composition of Certain Financial Statement Captions - Property and Equipment, Net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="d840996ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>1041 - Disclosure - Composition of Certain Financial Statement Captions - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://plus.com/role/CompositionOfCertainFinancialStatementCaptionsAdditionalInformationDetails</Role>
      <ShortName>Composition of Certain Financial Statement Captions - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="d840996ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>1042 - Disclosure - Composition of Certain Financial Statement Captions - Accounts Payable and Accrued Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://plus.com/role/CompositionOfCertainFinancialStatementCaptionsAccountsPayableAndAccruedExpensesDetails</Role>
      <ShortName>Composition of Certain Financial Statement Captions - Accounts Payable and Accrued Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="d840996ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>1043 - Disclosure - Commitments and Contingencies - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://plus.com/role/CommitmentsAndContingenciesAdditionalInformationDetails</Role>
      <ShortName>Commitments and Contingencies - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="d840996ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>1044 - Disclosure - Commitments and Contingencies - Summary of Lease Costs (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://plus.com/role/CommitmentsAndContingenciesSummaryOfLeaseCostsDetails</Role>
      <ShortName>Commitments and Contingencies - Summary of Lease Costs (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="d840996ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>1045 - Disclosure - Commitments and Contingencies - Summary of Future Minimum Annual Lease Payments under Operating Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://plus.com/role/CommitmentsAndContingenciesSummaryOfFutureMinimumAnnualLeasePaymentsUnderOperatingLeasesDetails</Role>
      <ShortName>Commitments and Contingencies - Summary of Future Minimum Annual Lease Payments under Operating Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="d840996ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>1046 - Disclosure - License Agreements - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://plus.com/role/LicenseAgreementsAdditionalInformationDetails</Role>
      <ShortName>License Agreements - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="d840996ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>1047 - Disclosure - Term Loan Obligations - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://plus.com/role/TermLoanObligationsAdditionalInformationDetails</Role>
      <ShortName>Term Loan Obligations - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="d840996ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>1048 - Disclosure - Term Loan Obligations - Term Loan Outstanding (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://plus.com/role/TermLoanObligationsTermLoanOutstandingDetails</Role>
      <ShortName>Term Loan Obligations - Term Loan Outstanding (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="d840996ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>1049 - Disclosure - Grant Revenue - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://plus.com/role/GrantRevenueAdditionalInformationDetails</Role>
      <ShortName>Grant Revenue - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="d840996ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>1050 - Disclosure - Income Taxes - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://plus.com/role/IncomeTaxesAdditionalInformationDetails</Role>
      <ShortName>Income Taxes - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="d840996ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>1051 - Disclosure - Income Taxes - Reconciliation of Total Income Tax Provision (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://plus.com/role/IncomeTaxesReconciliationOfTotalIncomeTaxProvisionDetails</Role>
      <ShortName>Income Taxes - Reconciliation of Total Income Tax Provision (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="d840996ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>1052 - Disclosure - Income Taxes - Deferred Tax Assets and Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://plus.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails</Role>
      <ShortName>Income Taxes - Deferred Tax Assets and Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="d840996ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>1053 - Disclosure - Income Taxes - Unrecognized Tax Benefits Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://plus.com/role/IncomeTaxesUnrecognizedTaxBenefitsActivityDetails</Role>
      <ShortName>Income Taxes - Unrecognized Tax Benefits Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="d840996ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>1054 - Disclosure - Employee Benefit Plan - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://plus.com/role/EmployeeBenefitPlanAdditionalInformationDetails</Role>
      <ShortName>Employee Benefit Plan - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="d840996ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>1055 - Disclosure - Stockholders' Equity - Preferred Stock (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://plus.com/role/StockholdersEquityPreferredStockDetails</Role>
      <ShortName>Stockholders' Equity - Preferred Stock (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="d840996ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>1056 - Disclosure - Stockholders' Equity - Warrants (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://plus.com/role/StockholdersEquityWarrantsDetails</Role>
      <ShortName>Stockholders' Equity - Warrants (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="d840996ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>1057 - Disclosure - Stockholders' Equity - Common stock (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://plus.com/role/StockholdersEquityCommonStockDetails</Role>
      <ShortName>Stockholders' Equity - Common stock (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="d840996ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>1058 - Disclosure - Stock-based Compensation - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://plus.com/role/StockBasedCompensationAdditionalInformationDetails</Role>
      <ShortName>Stock-based Compensation - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="d840996ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>1059 - Disclosure - Stock-based Compensation - Stock Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://plus.com/role/StockBasedCompensationStockOptionActivityDetails</Role>
      <ShortName>Stock-based Compensation - Stock Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="d840996ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>1060 - Disclosure - Stock-based Compensation - Weighted-average Assumptions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://plus.com/role/StockBasedCompensationWeightedAverageAssumptionsDetails</Role>
      <ShortName>Stock-based Compensation - Weighted-average Assumptions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="d840996ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>1061 - Disclosure - Stock-based Compensation - Summary of Share-Based Compensation Recognized (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://plus.com/role/StockBasedCompensationSummaryOfShareBasedCompensationRecognizedDetails</Role>
      <ShortName>Stock-based Compensation - Summary of Share-Based Compensation Recognized (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="d840996ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>1062 - Disclosure - Subsequent Events - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://plus.com/role/SubsequentEventsAdditionalInformationDetails</Role>
      <ShortName>Subsequent Events - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Warning">[ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 9 fact(s) appearing in ix:hidden were eligible for transformation: us-gaap:DebtInstrumentOfferingDate1, us-gaap:PropertyPlantAndEquipmentUsefulLife, us-gaap:StockholdersEquityNoteStockSplitConversionRatio1 -  d840996ds1.htm 6193</Log>
  </Logs>
  <InputFiles>
    <File doctype="S-1" isDefinitelyFs="true" isUsgaap="true" original="d840996ds1.htm">d840996ds1.htm</File>
    <File>pstv-20240331.xsd</File>
    <File>pstv-20240331_cal.xml</File>
    <File>pstv-20240331_def.xml</File>
    <File>pstv-20240331_lab.xml</File>
    <File>pstv-20240331_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>g840996g01a00.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="861">http://fasb.org/us-gaap/2023</BaseTaxonomy>
    <BaseTaxonomy items="25">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>83
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "d840996ds1.htm": {
   "nsprefix": "pstv",
   "nsuri": "http://plus.com/20240331",
   "dts": {
    "inline": {
     "local": [
      "d840996ds1.htm"
     ]
    },
    "schema": {
     "local": [
      "pstv-20240331.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/currency/2023/currency-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd",
      "https://xbrl.sec.gov/exch/2023/exch-2023.xsd",
      "https://xbrl.sec.gov/naics/2023/naics-2023.xsd",
      "https://xbrl.sec.gov/sic/2023/sic-2023.xsd",
      "https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "pstv-20240331_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "pstv-20240331_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "pstv-20240331_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "pstv-20240331_pre.xml"
     ]
    }
   },
   "keyStandard": 290,
   "keyCustom": 68,
   "axisStandard": 30,
   "axisCustom": 0,
   "memberStandard": 28,
   "memberCustom": 39,
   "hidden": {
    "total": 11,
    "http://fasb.org/us-gaap/2023": 9,
    "http://xbrl.sec.gov/dei/2023": 2
   },
   "contextCount": 233,
   "entityCount": 1,
   "segmentCount": 67,
   "elementCount": 574,
   "unitCount": 9,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2023": 861,
    "http://xbrl.sec.gov/dei/2023": 25
   },
   "report": {
    "R1": {
     "role": "http://plus.com/role/CoverPage",
     "longName": "1001 - Document - Cover Page",
     "shortName": "Cover Page",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "P01_01_2024To03_31_2024",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d840996ds1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2024To03_31_2024",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d840996ds1.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://plus.com/role/CondensedBalanceSheetsUnaudited",
     "longName": "1002 - Statement - CONDENSED BALANCE SHEETS (UNAUDITED)",
     "shortName": "CONDENSED BALANCE SHEETS (UNAUDITED)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "PAsOn03_31_2024",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d840996ds1.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "PAsOn03_31_2024",
      "name": "us-gaap:ShortTermInvestments",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d840996ds1.htm",
      "unique": true
     }
    },
    "R3": {
     "role": "http://plus.com/role/CondensedBalanceSheetsUnauditedParenthetical",
     "longName": "1003 - Statement - CONDENSED BALANCE SHEETS (UNAUDITED) (Parenthetical)",
     "shortName": "CONDENSED BALANCE SHEETS (UNAUDITED) (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "PAsOn03_31_2024",
      "name": "us-gaap:TreasuryStockCommonShares",
      "unitRef": "Unit_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d840996ds1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "PAsOn03_31_2024",
      "name": "us-gaap:TreasuryStockCommonShares",
      "unitRef": "Unit_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d840996ds1.htm",
      "first": true,
      "unique": true
     }
    },
    "R4": {
     "role": "http://plus.com/role/CondensedStatementsOfOperationsUnaudited",
     "longName": "1004 - Statement - CONDENSED STATEMENTS OF OPERATIONS (UNAUDITED)",
     "shortName": "CONDENSED STATEMENTS OF OPERATIONS (UNAUDITED)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "P01_01_2024To03_31_2024",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d840996ds1.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2024To03_31_2024",
      "name": "us-gaap:GeneralAndAdministrativeExpense",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d840996ds1.htm",
      "unique": true
     }
    },
    "R5": {
     "role": "http://plus.com/role/CondensedStatementsOfStockholdersEquityDeficitUnaudited",
     "longName": "1005 - Statement - CONDENSED STATEMENTS OF STOCKHOLDERS' EQUITY/(DEFICIT) (UNAUDITED)",
     "shortName": "CONDENSED STATEMENTS OF STOCKHOLDERS' EQUITY/(DEFICIT) (UNAUDITED)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "PAsOn12_31_2021",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d840996ds1.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "PAsOn12_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d840996ds1.htm",
      "unique": true
     }
    },
    "R6": {
     "role": "http://plus.com/role/CondensedStatementsOfCashFlowsUnaudited",
     "longName": "1006 - Statement - CONDENSED STATEMENTS OF CASH FLOWS (UNAUDITED)",
     "shortName": "CONDENSED STATEMENTS OF CASH FLOWS (UNAUDITED)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "P01_01_2024To03_31_2024",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d840996ds1.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2024To03_31_2024",
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d840996ds1.htm",
      "unique": true
     }
    },
    "R7": {
     "role": "http://plus.com/role/BasisOfPresentationAndNewAccountingStandards",
     "longName": "1007 - Disclosure - Basis of Presentation and New Accounting Standards",
     "shortName": "Basis of Presentation and New Accounting Standards",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "7",
     "firstAnchor": {
      "contextRef": "P01_01_2024To03_31_2024",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d840996ds1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2024To03_31_2024",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d840996ds1.htm",
      "first": true,
      "unique": true
     }
    },
    "R8": {
     "role": "http://plus.com/role/OrganizationAndOperations",
     "longName": "1008 - Disclosure - Organization and Operations",
     "shortName": "Organization and Operations",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d840996ds1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d840996ds1.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://plus.com/role/UseOfEstimates",
     "longName": "1009 - Disclosure - Use of Estimates",
     "shortName": "Use of Estimates",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "P01_01_2024To03_31_2024",
      "name": "pstv:UseOfEstimatesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d840996ds1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2024To03_31_2024",
      "name": "pstv:UseOfEstimatesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d840996ds1.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://plus.com/role/SummaryOfSignificantAccountingPolicies",
     "longName": "1010 - Disclosure - Summary of Significant Accounting Policies",
     "shortName": "Summary of Significant Accounting Policies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d840996ds1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d840996ds1.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://plus.com/role/LiquidityAndGoingConcern",
     "longName": "1011 - Disclosure - Liquidity and Going Concern",
     "shortName": "Liquidity and Going Concern",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "P01_01_2024To03_31_2024",
      "name": "pstv:DisclosureOfLiquidityAndGoingConcernTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d840996ds1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2024To03_31_2024",
      "name": "pstv:DisclosureOfLiquidityAndGoingConcernTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d840996ds1.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://plus.com/role/FairValueMeasurements",
     "longName": "1012 - Disclosure - Fair Value Measurements",
     "shortName": "Fair Value Measurements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "P01_01_2024To03_31_2024",
      "name": "us-gaap:FairValueMeasurementInputsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d840996ds1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2024To03_31_2024",
      "name": "us-gaap:FairValueMeasurementInputsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d840996ds1.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://plus.com/role/LossPerShare",
     "longName": "1013 - Disclosure - Loss per Share",
     "shortName": "Loss per Share",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "P01_01_2024To03_31_2024",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d840996ds1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2024To03_31_2024",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d840996ds1.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://plus.com/role/CompositionOfCertainFinancialStatementCaptions",
     "longName": "1014 - Disclosure - Composition of Certain Financial Statement Captions",
     "shortName": "Composition of Certain Financial Statement Captions",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d840996ds1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d840996ds1.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://plus.com/role/CommitmentsAndContingencies",
     "longName": "1015 - Disclosure - Commitments and Contingencies",
     "shortName": "Commitments and Contingencies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "P01_01_2024To03_31_2024",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d840996ds1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2024To03_31_2024",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d840996ds1.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://plus.com/role/LicenseAgreements",
     "longName": "1016 - Disclosure - License Agreements",
     "shortName": "License Agreements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "P01_01_2024To03_31_2024",
      "name": "pstv:LicenseAgreementDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d840996ds1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2024To03_31_2024",
      "name": "pstv:LicenseAgreementDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d840996ds1.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://plus.com/role/TermLoanObligations",
     "longName": "1017 - Disclosure - Term Loan Obligations",
     "shortName": "Term Loan Obligations",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "P01_01_2024To03_31_2024",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d840996ds1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2024To03_31_2024",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d840996ds1.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://plus.com/role/GrantRevenue",
     "longName": "1018 - Disclosure - Grant Revenue",
     "shortName": "Grant Revenue",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "P01_01_2024To03_31_2024",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d840996ds1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2024To03_31_2024",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d840996ds1.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://plus.com/role/IncomeTaxes",
     "longName": "1019 - Disclosure - Income Taxes",
     "shortName": "Income Taxes",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d840996ds1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d840996ds1.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://plus.com/role/EmployeeBenefitPlan",
     "longName": "1020 - Disclosure - Employee Benefit Plan",
     "shortName": "Employee Benefit Plan",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d840996ds1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d840996ds1.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://plus.com/role/StockholdersEquity",
     "longName": "1021 - Disclosure - Stockholders' Equity",
     "shortName": "Stockholders' Equity",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "21",
     "firstAnchor": {
      "contextRef": "P01_01_2024To03_31_2024",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d840996ds1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2024To03_31_2024",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d840996ds1.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://plus.com/role/SubsequentEvents",
     "longName": "1022 - Disclosure - Subsequent Events",
     "shortName": "Subsequent Events",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "22",
     "firstAnchor": {
      "contextRef": "P01_01_2024To03_31_2024",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d840996ds1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2024To03_31_2024",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d840996ds1.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://plus.com/role/StockBasedCompensation",
     "longName": "1023 - Disclosure - Stock-based Compensation",
     "shortName": "Stock-based Compensation",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "23",
     "firstAnchor": {
      "contextRef": "P01_01_2024To03_31_2024",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d840996ds1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2024To03_31_2024",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d840996ds1.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://plus.com/role/BasisOfPresentationAndNewAccountingStandardsPolicies",
     "longName": "1024 - Disclosure - Basis of Presentation and New Accounting Standards (Policies)",
     "shortName": "Basis of Presentation and New Accounting Standards (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "24",
     "firstAnchor": {
      "contextRef": "P01_01_2024To03_31_2024",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d840996ds1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2024To03_31_2024",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d840996ds1.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://plus.com/role/SummaryOfSignificantAccountingPoliciesPolicies",
     "longName": "1025 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "25",
     "firstAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "us-gaap:UseOfEstimates",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d840996ds1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "us-gaap:UseOfEstimates",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d840996ds1.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://plus.com/role/FairValueMeasurementsTables",
     "longName": "1026 - Disclosure - Fair Value Measurements (Tables)",
     "shortName": "Fair Value Measurements (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "26",
     "firstAnchor": {
      "contextRef": "P01_01_2024To03_31_2024",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:FairValueMeasurementInputsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d840996ds1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2024To03_31_2024",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:FairValueMeasurementInputsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d840996ds1.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://plus.com/role/LossPerShareTables",
     "longName": "1027 - Disclosure - Loss per Share (Tables)",
     "shortName": "Loss per Share (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "27",
     "firstAnchor": {
      "contextRef": "P01_01_2024To03_31_2024",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d840996ds1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2024To03_31_2024",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d840996ds1.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://plus.com/role/CompositionOfCertainFinancialStatementCaptionsTables",
     "longName": "1028 - Disclosure - Composition of Certain Financial Statement Captions (Tables)",
     "shortName": "Composition of Certain Financial Statement Captions (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "28",
     "firstAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d840996ds1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d840996ds1.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://plus.com/role/CommitmentsAndContingenciesTables",
     "longName": "1029 - Disclosure - Commitments and Contingencies (Tables)",
     "shortName": "Commitments and Contingencies (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "29",
     "firstAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d840996ds1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d840996ds1.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://plus.com/role/TermLoanObligationsTables",
     "longName": "1030 - Disclosure - Term Loan Obligations (Tables)",
     "shortName": "Term Loan Obligations (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "30",
     "firstAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d840996ds1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d840996ds1.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://plus.com/role/IncomeTaxesTables",
     "longName": "1031 - Disclosure - Income Taxes (Tables)",
     "shortName": "Income Taxes (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "31",
     "firstAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d840996ds1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d840996ds1.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://plus.com/role/StockBasedCompensationTables",
     "longName": "1032 - Disclosure - Stock-based Compensation (Tables)",
     "shortName": "Stock-based Compensation (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "32",
     "firstAnchor": {
      "contextRef": "P01_01_2024To03_31_2024",
      "name": "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d840996ds1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2024To03_31_2024",
      "name": "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d840996ds1.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://plus.com/role/BasisOfPresentationAndNewAccountingStandardsAdditionalInformationDetails",
     "longName": "1033 - Disclosure - Basis of Presentation and New Accounting Standards (Additional Information) (Details)",
     "shortName": "Basis of Presentation and New Accounting Standards (Additional Information) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "33",
     "firstAnchor": {
      "contextRef": "PAsOn04_20_2023",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "unitRef": "Unit_USD_per_Share",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "div",
       "pstv:AmendmentsForCertificateofIncorporationAndReverseStockSplitPolicyTextBlock",
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d840996ds1.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "P04_27_2023To04_27_2023",
      "name": "pstv:ReverseStockSplitEffectiveDate",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "pstv:AmendmentsForCertificateofIncorporationAndReverseStockSplitPolicyTextBlock",
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d840996ds1.htm",
      "unique": true
     }
    },
    "R34": {
     "role": "http://plus.com/role/OrganizationAndOperationsAdditionalInformationDetails",
     "longName": "1034 - Disclosure - Organization and Operations - Additional Information (Details)",
     "shortName": "Organization and Operations - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "34",
     "firstAnchor": {
      "contextRef": "P01_01_2024To03_31_2024",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d840996ds1.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R35": {
     "role": "http://plus.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
     "longName": "1035 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)",
     "shortName": "Summary of Significant Accounting Policies - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "35",
     "firstAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "us-gaap:ImpairmentOfLongLivedAssetsHeldForUse",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "us-gaap:ImpairmentOfLongLivedAssetsHeldForUse",
       "div",
       "div",
       "us-gaap:PropertyPlantAndEquipmentImpairment",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d840996ds1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "us-gaap:ImpairmentOfLongLivedAssetsHeldForUse",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "us-gaap:ImpairmentOfLongLivedAssetsHeldForUse",
       "div",
       "div",
       "us-gaap:PropertyPlantAndEquipmentImpairment",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d840996ds1.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://plus.com/role/LiquidityAndGoingConcernAdditionalInformationDetails",
     "longName": "1036 - Disclosure - Liquidity and Going Concern - Additional Information (Details)",
     "shortName": "Liquidity and Going Concern - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "36",
     "firstAnchor": {
      "contextRef": "P01_01_2024To03_31_2024",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d840996ds1.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "P03_08_2024To03_08_2024",
      "name": "us-gaap:IncomeLossFromContinuingOperations",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "div",
       "pstv:DisclosureOfLiquidityAndGoingConcernTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d840996ds1.htm",
      "unique": true
     }
    },
    "R37": {
     "role": "http://plus.com/role/FairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails",
     "longName": "1037 - Disclosure - Fair Value Measurements - Summary of Financial Assets Measured at Fair Value on Recurring Basis (Details)",
     "shortName": "Fair Value Measurements - Summary of Financial Assets Measured at Fair Value on Recurring Basis (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "37",
     "firstAnchor": {
      "contextRef": "PAsOn03_31_2024_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis",
      "name": "us-gaap:AssetsFairValueDisclosure",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
       "us-gaap:FairValueMeasurementInputsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d840996ds1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "PAsOn03_31_2024_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis",
      "name": "us-gaap:AssetsFairValueDisclosure",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
       "us-gaap:FairValueMeasurementInputsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d840996ds1.htm",
      "first": true,
      "unique": true
     }
    },
    "R38": {
     "role": "http://plus.com/role/LossPerShareScheduleOfAntidilutiveSecuritiesExcludedFromDilutedIncomeLossPerShareDetails",
     "longName": "1038 - Disclosure - Loss per Share - Schedule of Antidilutive Securities Excluded from Diluted Income (Loss) per Share (Details)",
     "shortName": "Loss per Share - Schedule of Antidilutive Securities Excluded from Diluted Income (Loss) per Share (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "38",
     "firstAnchor": {
      "contextRef": "P01_01_2024To03_31_2024",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "Unit_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d840996ds1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2024To03_31_2024",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "Unit_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d840996ds1.htm",
      "first": true,
      "unique": true
     }
    },
    "R39": {
     "role": "http://plus.com/role/CompositionOfCertainFinancialStatementCaptionsOtherCurrentAssetsDetails",
     "longName": "1039 - Disclosure - Composition of Certain Financial Statement Captions - Other Current Assets (Details)",
     "shortName": "Composition of Certain Financial Statement Captions - Other Current Assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "39",
     "firstAnchor": {
      "contextRef": "PAsOn12_31_2023",
      "name": "us-gaap:OtherPrepaidExpenseCurrent",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d840996ds1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "PAsOn12_31_2023",
      "name": "us-gaap:OtherPrepaidExpenseCurrent",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d840996ds1.htm",
      "first": true,
      "unique": true
     }
    },
    "R40": {
     "role": "http://plus.com/role/CompositionOfCertainFinancialStatementCaptionsPropertyAndEquipmentNetDetails",
     "longName": "1040 - Disclosure - Composition of Certain Financial Statement Captions - Property and Equipment, Net (Details)",
     "shortName": "Composition of Certain Financial Statement Captions - Property and Equipment, Net (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "40",
     "firstAnchor": {
      "contextRef": "PAsOn12_31_2023",
      "name": "pstv:OfficeAndComputerEquipmentGross",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d840996ds1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "PAsOn12_31_2023",
      "name": "pstv:OfficeAndComputerEquipmentGross",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d840996ds1.htm",
      "first": true,
      "unique": true
     }
    },
    "R41": {
     "role": "http://plus.com/role/CompositionOfCertainFinancialStatementCaptionsAdditionalInformationDetails",
     "longName": "1041 - Disclosure - Composition of Certain Financial Statement Captions - Additional Information (Details)",
     "shortName": "Composition of Certain Financial Statement Captions - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "41",
     "firstAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "us-gaap:Depreciation",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "div",
       "div",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d840996ds1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "us-gaap:Depreciation",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "div",
       "div",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d840996ds1.htm",
      "first": true,
      "unique": true
     }
    },
    "R42": {
     "role": "http://plus.com/role/CompositionOfCertainFinancialStatementCaptionsAccountsPayableAndAccruedExpensesDetails",
     "longName": "1042 - Disclosure - Composition of Certain Financial Statement Captions - Accounts Payable and Accrued Expenses (Details)",
     "shortName": "Composition of Certain Financial Statement Captions - Accounts Payable and Accrued Expenses (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "42",
     "firstAnchor": {
      "contextRef": "PAsOn12_31_2023",
      "name": "us-gaap:AccountsPayableCurrent",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d840996ds1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "PAsOn12_31_2023",
      "name": "us-gaap:AccountsPayableCurrent",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d840996ds1.htm",
      "first": true,
      "unique": true
     }
    },
    "R43": {
     "role": "http://plus.com/role/CommitmentsAndContingenciesAdditionalInformationDetails",
     "longName": "1043 - Disclosure - Commitments and Contingencies - Additional Information (Details)",
     "shortName": "Commitments and Contingencies - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "43",
     "firstAnchor": {
      "contextRef": "P01_01_2024To03_31_2024",
      "name": "pstv:OperatingLeasesExpiryYear",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d840996ds1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2024To03_31_2024",
      "name": "pstv:OperatingLeasesExpiryYear",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d840996ds1.htm",
      "first": true,
      "unique": true
     }
    },
    "R44": {
     "role": "http://plus.com/role/CommitmentsAndContingenciesSummaryOfLeaseCostsDetails",
     "longName": "1044 - Disclosure - Commitments and Contingencies - Summary of Lease Costs (Details)",
     "shortName": "Commitments and Contingencies - Summary of Lease Costs (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "44",
     "firstAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "us-gaap:OperatingLeaseCost",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d840996ds1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "us-gaap:OperatingLeaseCost",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d840996ds1.htm",
      "first": true,
      "unique": true
     }
    },
    "R45": {
     "role": "http://plus.com/role/CommitmentsAndContingenciesSummaryOfFutureMinimumAnnualLeasePaymentsUnderOperatingLeasesDetails",
     "longName": "1045 - Disclosure - Commitments and Contingencies - Summary of Future Minimum Annual Lease Payments under Operating Leases (Details)",
     "shortName": "Commitments and Contingencies - Summary of Future Minimum Annual Lease Payments under Operating Leases (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "45",
     "firstAnchor": {
      "contextRef": "PAsOn12_31_2023",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d840996ds1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "PAsOn12_31_2023",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d840996ds1.htm",
      "first": true,
      "unique": true
     }
    },
    "R46": {
     "role": "http://plus.com/role/LicenseAgreementsAdditionalInformationDetails",
     "longName": "1046 - Disclosure - License Agreements - Additional Information (Details)",
     "shortName": "License Agreements - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "P01_01_2024To03_31_2024",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d840996ds1.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "PAsOn09_07_2023_BioceptAgreementMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis",
      "name": "us-gaap:SharesIssued",
      "unitRef": "Unit_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "div",
       "pstv:LicenseAgreementDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d840996ds1.htm",
      "unique": true
     }
    },
    "R47": {
     "role": "http://plus.com/role/TermLoanObligationsAdditionalInformationDetails",
     "longName": "1047 - Disclosure - Term Loan Obligations - Additional Information (Details)",
     "shortName": "Term Loan Obligations - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "47",
     "firstAnchor": {
      "contextRef": "P01_01_2024To03_31_2024",
      "name": "us-gaap:InterestExpense",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d840996ds1.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2024To03_31_2024",
      "name": "us-gaap:AmortizationOfDebtDiscountPremium",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d840996ds1.htm",
      "unique": true
     }
    },
    "R48": {
     "role": "http://plus.com/role/TermLoanObligationsTermLoanOutstandingDetails",
     "longName": "1048 - Disclosure - Term Loan Obligations - Term Loan Outstanding (Details)",
     "shortName": "Term Loan Obligations - Term Loan Outstanding (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "48",
     "firstAnchor": {
      "contextRef": "P01_01_2024To03_31_2024_TermLoanMemberusgaapDebtInstrumentAxis",
      "name": "us-gaap:DebtInstrumentOfferingDate1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d840996ds1.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2023To12_31_2023_TermLoanMemberusgaapDebtInstrumentAxis",
      "name": "us-gaap:DebtInstrumentPeriodicPayment",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d840996ds1.htm",
      "unique": true
     }
    },
    "R49": {
     "role": "http://plus.com/role/GrantRevenueAdditionalInformationDetails",
     "longName": "1049 - Disclosure - Grant Revenue - Additional Information (Details)",
     "shortName": "Grant Revenue - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "49",
     "firstAnchor": {
      "contextRef": "P01_01_2024To03_31_2024_GrantMembersrtProductOrServiceAxis",
      "name": "us-gaap:Revenues",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d840996ds1.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "PAsOn09_19_2022_CancerPreventionAndResearchInstituteOfTexasContractMemberusgaapTypeOfArrangementAxis",
      "name": "pstv:MaximumGrantAmountToBeReceivedAsPerGrantContract",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "div",
       "div",
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d840996ds1.htm",
      "unique": true
     }
    },
    "R50": {
     "role": "http://plus.com/role/IncomeTaxesAdditionalInformationDetails",
     "longName": "1050 - Disclosure - Income Taxes - Additional Information (Details)",
     "shortName": "Income Taxes - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "50",
     "firstAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "us-gaap:IncomeTaxExpenseBenefit",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "div",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d840996ds1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "us-gaap:IncomeTaxExpenseBenefit",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "div",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d840996ds1.htm",
      "first": true,
      "unique": true
     }
    },
    "R51": {
     "role": "http://plus.com/role/IncomeTaxesReconciliationOfTotalIncomeTaxProvisionDetails",
     "longName": "1051 - Disclosure - Income Taxes - Reconciliation of Total Income Tax Provision (Details)",
     "shortName": "Income Taxes - Reconciliation of Total Income Tax Provision (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "51",
     "firstAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "unitRef": "Unit_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d840996ds1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "unitRef": "Unit_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d840996ds1.htm",
      "first": true,
      "unique": true
     }
    },
    "R52": {
     "role": "http://plus.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails",
     "longName": "1052 - Disclosure - Income Taxes - Deferred Tax Assets and Liabilities (Details)",
     "shortName": "Income Taxes - Deferred Tax Assets and Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "52",
     "firstAnchor": {
      "contextRef": "PAsOn12_31_2023",
      "name": "us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d840996ds1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "PAsOn12_31_2023",
      "name": "us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d840996ds1.htm",
      "first": true,
      "unique": true
     }
    },
    "R53": {
     "role": "http://plus.com/role/IncomeTaxesUnrecognizedTaxBenefitsActivityDetails",
     "longName": "1053 - Disclosure - Income Taxes - Unrecognized Tax Benefits Activity (Details)",
     "shortName": "Income Taxes - Unrecognized Tax Benefits Activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "53",
     "firstAnchor": {
      "contextRef": "PAsOn12_31_2022",
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d840996ds1.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "PAsOn12_31_2021",
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d840996ds1.htm",
      "unique": true
     }
    },
    "R54": {
     "role": "http://plus.com/role/EmployeeBenefitPlanAdditionalInformationDetails",
     "longName": "1054 - Disclosure - Employee Benefit Plan - Additional Information (Details)",
     "shortName": "Employee Benefit Plan - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "54",
     "firstAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "div",
       "div",
       "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d840996ds1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "div",
       "div",
       "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d840996ds1.htm",
      "first": true,
      "unique": true
     }
    },
    "R55": {
     "role": "http://plus.com/role/StockholdersEquityPreferredStockDetails",
     "longName": "1055 - Disclosure - Stockholders' Equity - Preferred Stock (Details)",
     "shortName": "Stockholders' Equity - Preferred Stock (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "55",
     "firstAnchor": {
      "contextRef": "PAsOn03_31_2024",
      "name": "us-gaap:PreferredStockSharesAuthorized",
      "unitRef": "Unit_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d840996ds1.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "PAsOn03_03_2023_SeriesFConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis",
      "name": "us-gaap:PreferredStockSharesAuthorized",
      "unitRef": "Unit_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "div",
       "div",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d840996ds1.htm",
      "unique": true
     }
    },
    "R56": {
     "role": "http://plus.com/role/StockholdersEquityWarrantsDetails",
     "longName": "1056 - Disclosure - Stockholders' Equity - Warrants (Details)",
     "shortName": "Stockholders' Equity - Warrants (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "56",
     "firstAnchor": {
      "contextRef": "P01_01_2024To03_31_2024_SeriesUWarrantsMemberusgaapClassOfWarrantOrRightAxis",
      "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues",
      "unitRef": "Unit_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d840996ds1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2024To03_31_2024_SeriesUWarrantsMemberusgaapClassOfWarrantOrRightAxis",
      "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues",
      "unitRef": "Unit_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d840996ds1.htm",
      "first": true,
      "unique": true
     }
    },
    "R57": {
     "role": "http://plus.com/role/StockholdersEquityCommonStockDetails",
     "longName": "1057 - Disclosure - Stockholders' Equity - Common stock (Details)",
     "shortName": "Stockholders' Equity - Common stock (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "57",
     "firstAnchor": {
      "contextRef": "P03_08_2024To03_08_2024",
      "name": "us-gaap:StockIssuedDuringPeriodValueNewIssues",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "div",
       "pstv:DisclosureOfLiquidityAndGoingConcernTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d840996ds1.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2024To03_31_2024_CommonStockMemberusgaapStatementEquityComponentsAxis",
      "name": "us-gaap:StockRepurchasedDuringPeriodShares",
      "unitRef": "Unit_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d840996ds1.htm",
      "unique": true
     }
    },
    "R58": {
     "role": "http://plus.com/role/StockBasedCompensationAdditionalInformationDetails",
     "longName": "1058 - Disclosure - Stock-based Compensation - Additional Information (Details)",
     "shortName": "Stock-based Compensation - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "58",
     "firstAnchor": {
      "contextRef": "P01_01_2024To03_31_2024",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "unitRef": "Unit_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d840996ds1.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2024To03_31_2024",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d840996ds1.htm",
      "unique": true
     }
    },
    "R59": {
     "role": "http://plus.com/role/StockBasedCompensationStockOptionActivityDetails",
     "longName": "1059 - Disclosure - Stock-based Compensation - Stock Option Activity (Details)",
     "shortName": "Stock-based Compensation - Stock Option Activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "59",
     "firstAnchor": {
      "contextRef": "PAsOn12_31_2023",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "Unit_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d840996ds1.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2024To03_31_2024",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
      "unitRef": "Unit_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d840996ds1.htm",
      "unique": true
     }
    },
    "R60": {
     "role": "http://plus.com/role/StockBasedCompensationWeightedAverageAssumptionsDetails",
     "longName": "1060 - Disclosure - Stock-based Compensation - Weighted-average Assumptions (Details)",
     "shortName": "Stock-based Compensation - Weighted-average Assumptions (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "60",
     "firstAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d840996ds1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d840996ds1.htm",
      "first": true,
      "unique": true
     }
    },
    "R61": {
     "role": "http://plus.com/role/StockBasedCompensationSummaryOfShareBasedCompensationRecognizedDetails",
     "longName": "1061 - Disclosure - Stock-based Compensation - Summary of Share-Based Compensation Recognized (Details)",
     "shortName": "Stock-based Compensation - Summary of Share-Based Compensation Recognized (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "61",
     "firstAnchor": {
      "contextRef": "P01_01_2024To03_31_2024",
      "name": "us-gaap:ShareBasedCompensation",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d840996ds1.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2023To12_31_2023_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis",
      "name": "us-gaap:ShareBasedCompensation",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d840996ds1.htm",
      "unique": true
     }
    },
    "R62": {
     "role": "http://plus.com/role/SubsequentEventsAdditionalInformationDetails",
     "longName": "1062 - Disclosure - Subsequent Events - Additional Information (Details)",
     "shortName": "Subsequent Events - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "62",
     "firstAnchor": {
      "contextRef": "PAsOn05_09_2024_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis",
      "name": "us-gaap:WarrantsAndRightsOutstanding",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-4",
      "ancestors": [
       "div",
       "div",
       "pstv:DisclosureOfLiquidityAndGoingConcernTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d840996ds1.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "P04_26_2024To04_26_2024_BioceptAssetPurchaseMemberusgaapAssetAcquisitionAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis",
      "name": "us-gaap:PaymentsToAcquireProductiveAssets",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d840996ds1.htm",
      "unique": true
     }
    }
   },
   "tag": {
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountingStandardsUpdate201613Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountingStandardsUpdate201613Member",
     "presentation": [
      "http://plus.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Standards Update 2016-13 [Member]",
        "terseLabel": "ASU 2016-13",
        "documentation": "Accounting Standards Update 2016-13 Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments."
       }
      }
     },
     "auth_ref": [
      "r295"
     ]
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsPayableAndAccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://plus.com/role/CondensedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 12.0
      },
      "http://plus.com/role/CompositionOfCertainFinancialStatementCaptionsAccountsPayableAndAccruedExpensesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://plus.com/role/CompositionOfCertainFinancialStatementCaptionsAccountsPayableAndAccruedExpensesDetails",
      "http://plus.com/role/CondensedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Payable and Accrued Liabilities, Current",
        "terseLabel": "Accounts payable and accrued expenses",
        "totalLabel": "Accounts payable and accrued expenses, Total",
        "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract",
     "presentation": [
      "http://plus.com/role/CompositionOfCertainFinancialStatementCaptionsAccountsPayableAndAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Payable and Accrued Liabilities [Abstract]",
        "terseLabel": "Accounts Payable and Accrued Expenses [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://plus.com/role/CompositionOfCertainFinancialStatementCaptionsAccountsPayableAndAccruedExpensesDetails": {
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://plus.com/role/CompositionOfCertainFinancialStatementCaptionsAccountsPayableAndAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r829"
     ]
    },
    "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments",
     "crdr": "credit",
     "calculation": {
      "http://plus.com/role/CondensedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 15.0
      }
     },
     "presentation": [
      "http://plus.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accretion (Amortization) of Discounts and Premiums, Investments",
        "negatedLabel": "Accretion of discount on short-term investments",
        "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method."
       }
      }
     },
     "auth_ref": [
      "r111"
     ]
    },
    "us-gaap_AccruedBonusesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccruedBonusesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://plus.com/role/CompositionOfCertainFinancialStatementCaptionsAccountsPayableAndAccruedExpensesDetails": {
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://plus.com/role/CompositionOfCertainFinancialStatementCaptionsAccountsPayableAndAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Bonuses, Current",
        "terseLabel": "Accrued payroll and bonus",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for incentive compensation awarded to employees and directors or earned by them based on the terms of one or more relevant arrangements. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r21"
     ]
    },
    "pstv_AccruedLicensePayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://plus.com/20240331",
     "localname": "AccruedLicensePayable",
     "crdr": "credit",
     "presentation": [
      "http://plus.com/role/LicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued License Payable",
        "terseLabel": "Accrued payments due to NanoTx",
        "documentation": "Accrued license payable."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccruedProfessionalFeesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://plus.com/role/CompositionOfCertainFinancialStatementCaptionsAccountsPayableAndAccruedExpensesDetails": {
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://plus.com/role/CompositionOfCertainFinancialStatementCaptionsAccountsPayableAndAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Professional Fees, Current",
        "terseLabel": "Accrued professional fees",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r21"
     ]
    },
    "pstv_AccruedResearchAndDevelopmentStudies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://plus.com/20240331",
     "localname": "AccruedResearchAndDevelopmentStudies",
     "crdr": "credit",
     "calculation": {
      "http://plus.com/role/CompositionOfCertainFinancialStatementCaptionsAccountsPayableAndAccruedExpensesDetails": {
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://plus.com/role/CompositionOfCertainFinancialStatementCaptionsAccountsPayableAndAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Research And Development Studies",
        "terseLabel": "Accrued R&amp;D studies",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for research and development studies."
       }
      }
     },
     "auth_ref": []
    },
    "pstv_AccruedVacationAndCompensationCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://plus.com/20240331",
     "localname": "AccruedVacationAndCompensationCurrent",
     "crdr": "credit",
     "calculation": {
      "http://plus.com/role/CompositionOfCertainFinancialStatementCaptionsAccountsPayableAndAccruedExpensesDetails": {
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://plus.com/role/CompositionOfCertainFinancialStatementCaptionsAccountsPayableAndAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Vacation And Compensation Current",
        "terseLabel": "Accrued vacation and compensation",
        "documentation": "Accrued vacation and compensation, current."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://plus.com/role/CompositionOfCertainFinancialStatementCaptionsPropertyAndEquipmentNetDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://plus.com/role/CompositionOfCertainFinancialStatementCaptionsPropertyAndEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedLabel": "Less accumulated depreciation",
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services."
       }
      }
     },
     "auth_ref": [
      "r51",
      "r171",
      "r638"
     ]
    },
    "pstv_AdditionalDetailsRelatingTermLoanThatIsOutstandingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://plus.com/20240331",
     "localname": "AdditionalDetailsRelatingTermLoanThatIsOutstandingAbstract",
     "presentation": [
      "http://plus.com/role/TermLoanObligationsTermLoanOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Details Relating Term Loan That Is Outstanding [Abstract]",
        "terseLabel": "Additional details relating term loan that is outstanding [Abstract]",
        "documentation": "Additional details relating term loan that is outstanding [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdditionalPaidInCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdditionalPaidInCapital",
     "crdr": "credit",
     "calculation": {
      "http://plus.com/role/CondensedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 23.0
      }
     },
     "presentation": [
      "http://plus.com/role/CondensedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Paid In Capital",
        "terseLabel": "Additional paid-in capital",
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock."
       }
      }
     },
     "auth_ref": [
      "r95",
      "r829",
      "r955"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://plus.com/role/CondensedStatementsOfStockholdersEquityDeficitUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Paid In Capital [Member]",
        "terseLabel": "Additional Paid-in Capital [Member]",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r453",
      "r454",
      "r455",
      "r674",
      "r870",
      "r871",
      "r872",
      "r935",
      "r957"
     ]
    },
    "dei_AddressTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AddressTypeDomain",
     "presentation": [
      "http://plus.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Address Type [Domain]",
        "documentation": "An entity may have several addresses for different purposes and this domain represents all such types."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsForNewAccountingPronouncementsAxis",
     "presentation": [
      "http://plus.com/role/BasisOfPresentationAndNewAccountingStandardsAdditionalInformationDetails",
      "http://plus.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Standards Update [Axis]",
        "terseLabel": "Accounting Standards Update",
        "documentation": "Information by amendment to accounting standards."
       }
      }
     },
     "auth_ref": [
      "r160",
      "r161",
      "r162",
      "r163",
      "r164",
      "r207",
      "r208",
      "r209",
      "r210",
      "r220",
      "r262",
      "r263",
      "r297",
      "r298",
      "r299",
      "r300",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r320",
      "r453",
      "r454",
      "r455",
      "r483",
      "r484",
      "r485",
      "r486",
      "r494",
      "r495",
      "r496",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r516",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527",
      "r535",
      "r536",
      "r539",
      "r540",
      "r541",
      "r542",
      "r550",
      "r551",
      "r555",
      "r556",
      "r557",
      "r558",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r612",
      "r613",
      "r614",
      "r651",
      "r652",
      "r653",
      "r654",
      "r655",
      "r656",
      "r657",
      "r658",
      "r659",
      "r660",
      "r661",
      "r662"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "crdr": "credit",
     "presentation": [
      "http://plus.com/role/CondensedStatementsOfStockholdersEquityDeficitUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value",
        "terseLabel": "Stock-based compensation",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r66",
      "r67",
      "r417"
     ]
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://plus.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "auth_ref": []
    },
    "pstv_AggregateExpenseIncludingFeeAndDisbursementExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://plus.com/20240331",
     "localname": "AggregateExpenseIncludingFeeAndDisbursementExpenses",
     "crdr": "debit",
     "presentation": [
      "http://plus.com/role/StockholdersEquityCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Expense Including Fee and Disbursement Expenses",
        "terseLabel": "Reimburse of fee and disbursements expenses",
        "documentation": "Aggregate expense including fee and disbursement expenses."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://plus.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "pstv_AmendmentsForCertificateofIncorporationAndReverseStockSplitPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://plus.com/20240331",
     "localname": "AmendmentsForCertificateofIncorporationAndReverseStockSplitPolicyTextBlock",
     "presentation": [
      "http://plus.com/role/BasisOfPresentationAndNewAccountingStandardsPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendments For Certificate of Incorporation And Reverse Stock Split [Policy Text Block]",
        "terseLabel": "Amendments to Certificate of Incorporation and Reverse Stock Split",
        "documentation": "Amendments For Certificate of Incorporation And Reverse Stock Split."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AmortizationOfDebtDiscountPremium": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AmortizationOfDebtDiscountPremium",
     "crdr": "debit",
     "presentation": [
      "http://plus.com/role/TermLoanObligationsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amortization Of Debt Discount Premium",
        "terseLabel": "Non-cash amortization",
        "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r78",
      "r106",
      "r362"
     ]
    },
    "us-gaap_AmortizationOfFinancingCostsAndDiscounts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AmortizationOfFinancingCostsAndDiscounts",
     "crdr": "debit",
     "calculation": {
      "http://plus.com/role/CondensedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://plus.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amortization Of Financing Costs And Discounts",
        "terseLabel": "Amortization of deferred financing costs and debt discount",
        "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs."
       }
      }
     },
     "auth_ref": [
      "r362",
      "r553",
      "r810",
      "r811",
      "r864"
     ]
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AmortizationOfIntangibleAssets",
     "crdr": "debit",
     "presentation": [
      "http://plus.com/role/CompositionOfCertainFinancialStatementCaptionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amortization of Intangible Assets",
        "terseLabel": "Amortization",
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r46",
      "r48"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://plus.com/role/LossPerShareScheduleOfAntidilutiveSecuritiesExcludedFromDilutedIncomeLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount",
        "terseLabel": "Dilutive common shares excluded from the calculations of diluted loss per share (in shares)",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r230"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "presentation": [
      "http://plus.com/role/LossPerShareScheduleOfAntidilutiveSecuritiesExcludedFromDilutedIncomeLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "presentation": [
      "http://plus.com/role/CommitmentsAndContingenciesAdditionalInformationDetails",
      "http://plus.com/role/GrantRevenueAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Arrangements And Nonarrangement Transactions [Member]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative",
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r497"
     ]
    },
    "us-gaap_AssetAcquisitionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetAcquisitionAxis",
     "presentation": [
      "http://plus.com/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Acquisition [Axis]",
        "documentation": "Information by asset acquisition."
       }
      }
     },
     "auth_ref": [
      "r930"
     ]
    },
    "us-gaap_AssetAcquisitionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetAcquisitionDomain",
     "presentation": [
      "http://plus.com/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Acquisition [Domain]",
        "documentation": "Asset acquisition."
       }
      }
     },
     "auth_ref": [
      "r930"
     ]
    },
    "us-gaap_AssetImpairmentCharges": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetImpairmentCharges",
     "crdr": "debit",
     "presentation": [
      "http://plus.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Impairment Charges",
        "terseLabel": "Impairment charges",
        "documentation": "Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r49"
     ]
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://plus.com/role/CondensedBalanceSheetsUnaudited": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://plus.com/role/CondensedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets",
        "totalLabel": "Total assets",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r134",
      "r174",
      "r199",
      "r237",
      "r252",
      "r256",
      "r294",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r498",
      "r500",
      "r537",
      "r631",
      "r717",
      "r829",
      "r842",
      "r890",
      "r891",
      "r943"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://plus.com/role/CondensedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://plus.com/role/CondensedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://plus.com/role/CondensedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets Current",
        "totalLabel": "Total current assets",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r167",
      "r181",
      "r199",
      "r294",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r498",
      "r500",
      "r537",
      "r829",
      "r890",
      "r891",
      "r943"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://plus.com/role/CondensedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsFairValueDisclosure",
     "crdr": "debit",
     "presentation": [
      "http://plus.com/role/FairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Fair Value Disclosure",
        "terseLabel": "Fair Value",
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r77"
     ]
    },
    "pstv_AtTheMarketOfferingProgramMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://plus.com/20240331",
     "localname": "AtTheMarketOfferingProgramMember",
     "presentation": [
      "http://plus.com/role/StockholdersEquityCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "At The Market Offering Program [Member]",
        "terseLabel": "At The Market Offering Program [Member]",
        "documentation": "At the market offering program."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleDebtSecuritiesGrossUnrealizedGain",
     "crdr": "credit",
     "presentation": [
      "http://plus.com/role/BasisOfPresentationAndNewAccountingStandardsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Unrealized Gain",
        "terseLabel": "Unrealized gain on available-for-sale securities",
        "documentation": "Amount of unrealized gain on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r875"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesPurchasedOptionsPricePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleSecuritiesPurchasedOptionsPricePolicy",
     "presentation": [
      "http://plus.com/role/BasisOfPresentationAndNewAccountingStandardsPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Premium on Purchased Options [Policy Text Block]",
        "terseLabel": "Available-for-Sale Securities",
        "documentation": "Disclosure of accounting policy for premium paid to acquire option for investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r76"
     ]
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "presentation": [
      "http://plus.com/role/BasisOfPresentationAndNewAccountingStandardsPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basis Of Accounting Policy Policy [Text Block]",
        "terseLabel": "Basis of Presentation and New Accounting Standards",
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://plus.com/role/BasisOfPresentationAndNewAccountingStandards"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basis Of Presentation And Significant Accounting Policies [Text Block]",
        "terseLabel": "Basis of Presentation and New Accounting Standards",
        "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r112"
     ]
    },
    "pstv_BioceptAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://plus.com/20240331",
     "localname": "BioceptAgreementMember",
     "presentation": [
      "http://plus.com/role/LicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Biocept Agreement [Member]",
        "terseLabel": "Biocept Agreement [Member]",
        "documentation": "Biocept Agreement."
       }
      }
     },
     "auth_ref": []
    },
    "pstv_BioceptAssetPurchaseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://plus.com/20240331",
     "localname": "BioceptAssetPurchaseMember",
     "presentation": [
      "http://plus.com/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Biocept Asset Purchase [Member]",
        "documentation": "Biocept Asset Purchase [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_BusinessContactMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "BusinessContactMember",
     "presentation": [
      "http://plus.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Contact [Member]",
        "documentation": "Business contact for the entity"
       }
      }
     },
     "auth_ref": [
      "r844",
      "r845"
     ]
    },
    "pstv_CanaccordGenuityLLCMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://plus.com/20240331",
     "localname": "CanaccordGenuityLLCMember",
     "presentation": [
      "http://plus.com/role/StockholdersEquityCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Canaccord Genuity L L C [Member]",
        "terseLabel": "Canaccord Genuity LLC [Member]",
        "documentation": "Canaccord Genuity L L C Member"
       }
      }
     },
     "auth_ref": []
    },
    "pstv_CancerPreventionAndResearchInstituteOfTexasContractMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://plus.com/20240331",
     "localname": "CancerPreventionAndResearchInstituteOfTexasContractMember",
     "presentation": [
      "http://plus.com/role/GrantRevenueAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cancer Prevention And Research Institute Of Texas Contract [Member]",
        "terseLabel": "CPRIT Contract [Member]",
        "documentation": "Cancer prevention and research institute of texas contract."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://plus.com/role/CondensedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://plus.com/role/CondensedBalanceSheetsUnaudited",
      "http://plus.com/role/OrganizationAndOperationsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r34",
      "r169",
      "r795"
     ]
    },
    "us-gaap_CashAndCashEquivalentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsAxis",
     "presentation": [
      "http://plus.com/role/FairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents [Axis]",
        "documentation": "Information by type of cash and cash equivalent balance."
       }
      }
     },
     "auth_ref": [
      "r169"
     ]
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "presentation": [
      "http://plus.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash and cash equivalents",
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value."
       }
      }
     },
     "auth_ref": [
      "r35"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "crdr": "debit",
     "presentation": [
      "http://plus.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations",
        "periodStartLabel": "Cash and cash equivalents at beginning of period",
        "periodEndLabel": "Cash and cash equivalents at end of period",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r34",
      "r109",
      "r195"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://plus.com/role/CondensedStatementsOfCashFlowsUnaudited": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://plus.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect",
        "totalLabel": "Net decrease in cash and cash equivalents",
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r109"
     ]
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "presentation": [
      "http://plus.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flow Noncash Investing And Financing Activities Disclosure [Abstract]",
        "terseLabel": "Supplemental schedule of non-cash investing and financing activities:"
       }
      }
     },
     "auth_ref": []
    },
    "pstv_CashPaidDuringPeriodForAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://plus.com/20240331",
     "localname": "CashPaidDuringPeriodForAbstract",
     "presentation": [
      "http://plus.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Paid During Period For [Abstract]",
        "terseLabel": "Cash paid during period for:",
        "documentation": "Cash paid during period for:"
       }
      }
     },
     "auth_ref": []
    },
    "pstv_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://plus.com/20240331",
     "localname": "CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://plus.com/role/CommitmentsAndContingenciesSummaryOfLeaseCostsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://plus.com/role/CommitmentsAndContingenciesSummaryOfLeaseCostsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Paid For Amounts Included In Measurement Of Lease Liabilities",
        "totalLabel": "Total cash paid for amounts included in the measurement of lease liabilities",
        "documentation": "Cash paid for amounts included in the measurement of lease liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "pstv_CashPaidForIPRDAssetAcquiredInAnAssetAcquisition": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://plus.com/20240331",
     "localname": "CashPaidForIPRDAssetAcquiredInAnAssetAcquisition",
     "crdr": "credit",
     "calculation": {
      "http://plus.com/role/CondensedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 18.0
      }
     },
     "presentation": [
      "http://plus.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Paid For I P R D Asset Acquired In An Asset Acquisition",
        "negatedLabel": "In process research and development acquired",
        "documentation": "Cash paid for IPRD asset acquired in an asset acquisition."
       }
      }
     },
     "auth_ref": []
    },
    "pstv_CashPaymentInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://plus.com/20240331",
     "localname": "CashPaymentInformationAbstract",
     "presentation": [
      "http://plus.com/role/CommitmentsAndContingenciesSummaryOfLeaseCostsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Payment Information [Abstract]",
        "terseLabel": "Cash payment information:",
        "documentation": "Cash payment information."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted",
     "presentation": [
      "http://plus.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in Accounting Principle, Accounting Standards Update, Adopted [true false]",
        "terseLabel": "Change in accounting principle, accounting standards update, adopted",
        "documentation": "Indicates (true false) whether accounting standards update was adopted."
       }
      }
     },
     "auth_ref": [
      "r153",
      "r154",
      "r155",
      "r160",
      "r161",
      "r206",
      "r262",
      "r263",
      "r296",
      "r297",
      "r298",
      "r304",
      "r305",
      "r320",
      "r483",
      "r494",
      "r495",
      "r502",
      "r503",
      "r504",
      "r516",
      "r517",
      "r527",
      "r535",
      "r536",
      "r538",
      "r539",
      "r540",
      "r550",
      "r555",
      "r556",
      "r557",
      "r570",
      "r612",
      "r613",
      "r651",
      "r652"
     ]
    },
    "us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate",
     "presentation": [
      "http://plus.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in Accounting Principle, Accounting Standards Update, Adoption Date",
        "terseLabel": "Change in accounting principle, accounting standards update, adoption date",
        "documentation": "Date accounting standards update was adopted, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": [
      "r153",
      "r154",
      "r155",
      "r160",
      "r161",
      "r262",
      "r263",
      "r296",
      "r297",
      "r298",
      "r304",
      "r305",
      "r306",
      "r320",
      "r483",
      "r494",
      "r495",
      "r496",
      "r502",
      "r503",
      "r504",
      "r505",
      "r516",
      "r517",
      "r518",
      "r521",
      "r527",
      "r535",
      "r536",
      "r538",
      "r539",
      "r540",
      "r550",
      "r555",
      "r556",
      "r557",
      "r570",
      "r612",
      "r613",
      "r651",
      "r652",
      "r848"
     ]
    },
    "us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect",
     "presentation": [
      "http://plus.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in Accounting Principle, Accounting Standards Update, Immaterial Effect [true false]",
        "terseLabel": "Change in accounting principle, accounting standards update, immaterial effect",
        "documentation": "Indicates (true false) whether effect from applying amendment to accounting standards is immaterial."
       }
      }
     },
     "auth_ref": [
      "r152",
      "r207",
      "r219",
      "r301",
      "r487"
     ]
    },
    "pstv_CharlottesvilleMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://plus.com/20240331",
     "localname": "CharlottesvilleMember",
     "presentation": [
      "http://plus.com/role/CommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Charlottesville [Member]",
        "terseLabel": "Charlottesville [Member]",
        "documentation": "Charlottesville"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://plus.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "terseLabel": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfStockDomain",
     "presentation": [
      "http://plus.com/role/CondensedStatementsOfStockholdersEquityDeficitUnaudited",
      "http://plus.com/role/StockholdersEquityCommonStockDetails",
      "http://plus.com/role/StockholdersEquityPreferredStockDetails",
      "http://plus.com/role/StockholdersEquityWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Domain]",
        "terseLabel": "Class of Stock",
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock."
       }
      }
     },
     "auth_ref": [
      "r159",
      "r177",
      "r178",
      "r179",
      "r199",
      "r224",
      "r225",
      "r227",
      "r229",
      "r235",
      "r236",
      "r294",
      "r331",
      "r333",
      "r334",
      "r335",
      "r338",
      "r339",
      "r370",
      "r371",
      "r374",
      "r377",
      "r384",
      "r537",
      "r668",
      "r669",
      "r670",
      "r671",
      "r674",
      "r675",
      "r676",
      "r677",
      "r678",
      "r679",
      "r680",
      "r681",
      "r682",
      "r683",
      "r684",
      "r685",
      "r705",
      "r726",
      "r745",
      "r772",
      "r773",
      "r774",
      "r775",
      "r776",
      "r846",
      "r865",
      "r873"
     ]
    },
    "us-gaap_ClassOfStockLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfStockLineItems",
     "presentation": [
      "http://plus.com/role/StockholdersEquityCommonStockDetails",
      "http://plus.com/role/StockholdersEquityPreferredStockDetails",
      "http://plus.com/role/StockholdersEquityWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class Of Stock [Line Items]",
        "terseLabel": "Class of Stock [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r177",
      "r178",
      "r179",
      "r235",
      "r370",
      "r371",
      "r372",
      "r374",
      "r377",
      "r382",
      "r384",
      "r668",
      "r669",
      "r670",
      "r671",
      "r812",
      "r846",
      "r865"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightAxis",
     "presentation": [
      "http://plus.com/role/StockholdersEquityPreferredStockDetails",
      "http://plus.com/role/StockholdersEquityWarrantsDetails",
      "http://plus.com/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class Of Warrant Or Right [Axis]",
        "terseLabel": "Class of Warrant or Right",
        "documentation": "Information by type of warrant or right issued."
       }
      }
     },
     "auth_ref": [
      "r62"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightDomain",
     "presentation": [
      "http://plus.com/role/StockholdersEquityPreferredStockDetails",
      "http://plus.com/role/StockholdersEquityWarrantsDetails",
      "http://plus.com/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class Of Warrant Or Right [Domain]",
        "terseLabel": "Class of Warrant or Right",
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months."
       }
      }
     },
     "auth_ref": []
    },
    "pstv_ClassOfWarrantOrRightExercisePriceAdditionalSubscription": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://plus.com/20240331",
     "localname": "ClassOfWarrantOrRightExercisePriceAdditionalSubscription",
     "presentation": [
      "http://plus.com/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right, Exercise Price Additional Subscription",
        "terseLabel": "class of warrant or right, exercise price additional subscription",
        "documentation": "Class of Warrant or Right, Exercise Price Additional Subscription."
       }
      }
     },
     "auth_ref": []
    },
    "pstv_ClassOfWarrantOrRightExercisePriceInitialSubscription": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://plus.com/20240331",
     "localname": "ClassOfWarrantOrRightExercisePriceInitialSubscription",
     "presentation": [
      "http://plus.com/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right, Exercise Price Initial Subscription",
        "terseLabel": "Class of warrant exercise price initial subscription",
        "documentation": "Class of Warrant or Right, Exercise Price Initial Subscription."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "presentation": [
      "http://plus.com/role/StockholdersEquityWarrantsDetails",
      "http://plus.com/role/SubsequentEventsAdditionalInformationDetails",
      "http://plus.com/role/TermLoanObligationsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1",
        "terseLabel": "Warrant exercise price (in dollars per share)",
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": [
      "r385"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "presentation": [
      "http://plus.com/role/StockholdersEquityWarrantsDetails",
      "http://plus.com/role/TermLoanObligationsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights",
        "terseLabel": "Number of shares callable by warrants (in shares)",
        "verboseLabel": "Number of securities called by warrant or right",
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares."
       }
      }
     },
     "auth_ref": [
      "r385"
     ]
    },
    "pstv_ClassOfWarrantOrRightOfferingPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://plus.com/20240331",
     "localname": "ClassOfWarrantOrRightOfferingPrice",
     "presentation": [
      "http://plus.com/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class Of Warrant Or Right Offering Price",
        "terseLabel": "Right offering price",
        "documentation": "Class Of Warrant Or Right Offering Price."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightOutstanding",
     "presentation": [
      "http://plus.com/role/StockholdersEquityWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class Of Warrant Or Right Outstanding",
        "terseLabel": "Class of warrant outstanding",
        "documentation": "Number of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "pstv_ClassOfWarrantOrRightPurchasePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://plus.com/20240331",
     "localname": "ClassOfWarrantOrRightPurchasePrice",
     "presentation": [
      "http://plus.com/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class Of Warrant Or Right Purchase Price",
        "terseLabel": "Class of warrant or right purchase price",
        "documentation": "Class Of Warrant Or Right Purchase Price."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "calculation": {
      "http://plus.com/role/CondensedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 25.0
      }
     },
     "presentation": [
      "http://plus.com/role/CondensedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments And Contingencies",
        "terseLabel": "Commitments and contingencies (Note 8)",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r26",
      "r82",
      "r632",
      "r704"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments And Contingencies Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://plus.com/role/CommitmentsAndContingencies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments And Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r117",
      "r322",
      "r324",
      "r779",
      "r887"
     ]
    },
    "us-gaap_CommonClassAMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonClassAMember",
     "presentation": [
      "http://plus.com/role/StockholdersEquityWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Class A [Member]",
        "terseLabel": "Common Class A [Member]",
        "documentation": "Classification of common stock representing ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r957"
     ]
    },
    "us-gaap_CommonClassBMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonClassBMember",
     "presentation": [
      "http://plus.com/role/StockholdersEquityWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Class B [Member]",
        "terseLabel": "Common Class B [Member]",
        "documentation": "Classification of common stock that has different rights than Common Class A, representing ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r957"
     ]
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "presentation": [
      "http://plus.com/role/BasisOfPresentationAndNewAccountingStandardsAdditionalInformationDetails",
      "http://plus.com/role/OrganizationAndOperationsAdditionalInformationDetails",
      "http://plus.com/role/StockholdersEquityCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "verboseLabel": "Common stock capital shares reserved for future issuance",
        "terseLabel": "Number of shares reserved for issuance and sale",
        "documentation": "Aggregate number of common shares reserved for future issuance."
       }
      }
     },
     "auth_ref": [
      "r27"
     ]
    },
    "pstv_CommonStockIssuedForResearchAndDevelopment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://plus.com/20240331",
     "localname": "CommonStockIssuedForResearchAndDevelopment",
     "crdr": "debit",
     "calculation": {
      "http://plus.com/role/CondensedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://plus.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock Issued for Research and Development",
        "terseLabel": "Common stock issued for research and development",
        "documentation": "Common stock issued for research and development."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockMember",
     "presentation": [
      "http://plus.com/role/CondensedStatementsOfStockholdersEquityDeficitUnaudited",
      "http://plus.com/role/StockholdersEquityCommonStockDetails",
      "http://plus.com/role/StockholdersEquityWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock [Member]",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r832",
      "r833",
      "r834",
      "r836",
      "r837",
      "r838",
      "r839",
      "r870",
      "r871",
      "r935",
      "r954",
      "r957"
     ]
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://plus.com/role/BasisOfPresentationAndNewAccountingStandardsAdditionalInformationDetails",
      "http://plus.com/role/CondensedBalanceSheetsUnauditedParenthetical",
      "http://plus.com/role/OrganizationAndOperationsAdditionalInformationDetails",
      "http://plus.com/role/StockholdersEquityPreferredStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in dollars per share)",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r94"
     ]
    },
    "pstv_CommonStockSalesAvailableForIssuance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://plus.com/20240331",
     "localname": "CommonStockSalesAvailableForIssuance",
     "crdr": "credit",
     "presentation": [
      "http://plus.com/role/StockholdersEquityCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock Sales Available For Issuance",
        "terseLabel": "Remaining availability under financing facility",
        "documentation": "Common stock, sales, available for issuance."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://plus.com/role/CondensedBalanceSheetsUnauditedParenthetical",
      "http://plus.com/role/StockholdersEquityCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock Shares Authorized",
        "terseLabel": "Common stock, shares authorized (in shares)",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r94",
      "r705"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://plus.com/role/BasisOfPresentationAndNewAccountingStandardsAdditionalInformationDetails",
      "http://plus.com/role/CondensedBalanceSheetsUnauditedParenthetical",
      "http://plus.com/role/OrganizationAndOperationsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares issued (in shares)",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r94"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://plus.com/role/CondensedBalanceSheetsUnauditedParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock Shares Outstanding",
        "terseLabel": "Common stock, shares outstanding (in shares)",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r94",
      "r705",
      "r723",
      "r957",
      "r958"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://plus.com/role/CondensedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 21.0
      }
     },
     "presentation": [
      "http://plus.com/role/CondensedBalanceSheetsUnaudited",
      "http://plus.com/role/LicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock Value",
        "terseLabel": "Common stock",
        "verboseLabel": "Voting stock, value",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r94",
      "r634",
      "r829"
     ]
    },
    "us-gaap_CompensationAndEmployeeBenefitPlansTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CompensationAndEmployeeBenefitPlansTextBlock",
     "presentation": [
      "http://plus.com/role/EmployeeBenefitPlan"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation and Employee Benefit Plans [Text Block]",
        "terseLabel": "Employee Benefit Plan",
        "documentation": "The entire disclosure for an entity's employee compensation and benefit plans, including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, share-based compensation, life insurance, severance, health care, unemployment and other benefit plans."
       }
      }
     },
     "auth_ref": [
      "r123",
      "r124",
      "r125",
      "r126"
     ]
    },
    "us-gaap_CompensationAndRetirementDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CompensationAndRetirementDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Retirement Benefits [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComponentsOfDeferredTaxAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ComponentsOfDeferredTaxAssetsAbstract",
     "presentation": [
      "http://plus.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Components of Deferred Tax Assets [Abstract]",
        "terseLabel": "Deferred tax assets [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract",
     "presentation": [
      "http://plus.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Components of Deferred Tax Assets and Liabilities [Abstract]",
        "terseLabel": "Portions of the deferred tax assets and deferred tax liabilities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ComponentsOfDeferredTaxLiabilitiesAbstract",
     "presentation": [
      "http://plus.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Components of Deferred Tax Liabilities [Abstract]",
        "terseLabel": "Deferred tax liabilities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "pstv_CompositionOfCertainFinancialStatementCaptionsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://plus.com/20240331",
     "localname": "CompositionOfCertainFinancialStatementCaptionsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Composition Of Certain Financial Statement Captions [Abstract]",
        "documentation": "Composition of Certain Financial Statement Captions [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskCreditRisk",
     "presentation": [
      "http://plus.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "terseLabel": "Concentration Risk",
        "documentation": "Disclosure of accounting policy for credit risk."
       }
      }
     },
     "auth_ref": [
      "r86",
      "r147"
     ]
    },
    "pstv_ConsiderationPaidToPreferredStockHolders": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://plus.com/20240331",
     "localname": "ConsiderationPaidToPreferredStockHolders",
     "crdr": "credit",
     "presentation": [
      "http://plus.com/role/StockholdersEquityPreferredStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consideration Paid To Preferred Stock Holders",
        "terseLabel": "Consideration paid to preferred stock holders",
        "documentation": "Consideration paid to preferred stock holders."
       }
      }
     },
     "auth_ref": []
    },
    "dei_ContactPersonnelName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "ContactPersonnelName",
     "presentation": [
      "http://plus.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contact Personnel Name",
        "documentation": "Name of contact personnel"
       }
      }
     },
     "auth_ref": []
    },
    "pstv_ContractEffectiveDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://plus.com/20240331",
     "localname": "ContractEffectiveDate",
     "presentation": [
      "http://plus.com/role/GrantRevenueAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contract Effective Date",
        "terseLabel": "Contract effective date",
        "documentation": "Contract effective date."
       }
      }
     },
     "auth_ref": []
    },
    "pstv_ContractTerminationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://plus.com/20240331",
     "localname": "ContractTerminationDate",
     "presentation": [
      "http://plus.com/role/GrantRevenueAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contract Termination Date",
        "terseLabel": "Contract termination date",
        "documentation": "Contract termination date."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ContractualObligation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ContractualObligation",
     "crdr": "credit",
     "presentation": [
      "http://plus.com/role/CommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contractual Obligation",
        "terseLabel": "Contractual obligation",
        "documentation": "Amount of contractual obligation, including, but not limited to, long-term debt, lease obligation, purchase obligation, and other commitments."
       }
      }
     },
     "auth_ref": [
      "r868"
     ]
    },
    "us-gaap_ConvertiblePreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConvertiblePreferredStockMember",
     "presentation": [
      "http://plus.com/role/CondensedStatementsOfStockholdersEquityDeficitUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Preferred Stock [Member]",
        "terseLabel": "Convertible Preferred Stock [Member]",
        "documentation": "Preferred stock that may be exchanged into common shares or other types of securities at the owner's option."
       }
      }
     },
     "auth_ref": [
      "r370",
      "r371",
      "r374",
      "r836",
      "r837",
      "r838",
      "r839"
     ]
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "pstv_CpritGrantFundingTerm": {
     "xbrltype": "stringItemType",
     "nsuri": "http://plus.com/20240331",
     "localname": "CpritGrantFundingTerm",
     "presentation": [
      "http://plus.com/role/GrantRevenueAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "CPRIT Grant Funding Term",
        "terseLabel": "CPRIT grant funding term, description",
        "documentation": "CPRIT grant funding term."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CreditFacilityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CreditFacilityAxis",
     "presentation": [
      "http://plus.com/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Credit Facility [Axis]",
        "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CreditFacilityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CreditFacilityDomain",
     "presentation": [
      "http://plus.com/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Credit Facility [Domain]",
        "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing."
       }
      }
     },
     "auth_ref": []
    },
    "pstv_CumulativeChangeInOwnership": {
     "xbrltype": "percentItemType",
     "nsuri": "http://plus.com/20240331",
     "localname": "CumulativeChangeInOwnership",
     "presentation": [
      "http://plus.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cumulative Change In Ownership",
        "terseLabel": "Cumulative change in ownership",
        "documentation": "Refers to cumulative change in ownership in percentage."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtDisclosureTextBlock",
     "presentation": [
      "http://plus.com/role/TermLoanObligations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Text Block]",
        "terseLabel": "Term Loan Obligations",
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants."
       }
      }
     },
     "auth_ref": [
      "r118",
      "r197",
      "r340",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r356",
      "r363",
      "r364",
      "r366"
     ]
    },
    "pstv_DebtInstrumentAmendedExpirationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://plus.com/20240331",
     "localname": "DebtInstrumentAmendedExpirationDate",
     "presentation": [
      "http://plus.com/role/TermLoanObligationsTermLoanOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument Amended Expiration Date",
        "terseLabel": "Amended expiration date",
        "documentation": "Debt instrument amended expiration date."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentAxis",
     "presentation": [
      "http://plus.com/role/OrganizationAndOperationsAdditionalInformationDetails",
      "http://plus.com/role/TermLoanObligationsAdditionalInformationDetails",
      "http://plus.com/role/TermLoanObligationsTermLoanOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument",
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r89",
      "r90",
      "r135",
      "r137",
      "r201",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r347",
      "r352",
      "r353",
      "r354",
      "r355",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r554",
      "r807",
      "r808",
      "r809",
      "r810",
      "r811",
      "r866"
     ]
    },
    "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentBasisSpreadOnVariableRate1",
     "presentation": [
      "http://plus.com/role/SubsequentEventsAdditionalInformationDetails",
      "http://plus.com/role/TermLoanObligationsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument Basis Spread On Variable Rate1",
        "terseLabel": "Basis variable rate",
        "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentCarryingAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentCarryingAmount",
     "crdr": "credit",
     "presentation": [
      "http://plus.com/role/TermLoanObligationsTermLoanOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Term Debt, Gross",
        "terseLabel": "Remaining Principal (Face Value)",
        "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r137",
      "r367"
     ]
    },
    "us-gaap_DebtInstrumentCovenantCompliance": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentCovenantCompliance",
     "presentation": [
      "http://plus.com/role/TermLoanObligationsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument Covenant Compliance",
        "terseLabel": "Debt instrument, covenant compliance",
        "documentation": "States whether the entity was in compliance with the debt covenants throughout the reporting period, and describes facts and circumstances of any compliance failure."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r85"
     ]
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentFaceAmount",
     "crdr": "credit",
     "presentation": [
      "http://plus.com/role/TermLoanObligationsAdditionalInformationDetails",
      "http://plus.com/role/TermLoanObligationsTermLoanOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Face Amount",
        "verboseLabel": "Original loan amount",
        "documentation": "Face (par) amount of debt instrument at time of issuance."
       }
      }
     },
     "auth_ref": [
      "r79",
      "r81",
      "r341",
      "r554",
      "r808",
      "r809"
     ]
    },
    "us-gaap_DebtInstrumentFeeAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentFeeAmount",
     "crdr": "debit",
     "presentation": [
      "http://plus.com/role/OrganizationAndOperationsAdditionalInformationDetails",
      "http://plus.com/role/TermLoanObligationsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Fee Amount",
        "terseLabel": "Fees amount associated with loan",
        "documentation": "Amount of the fee that accompanies borrowing money under the debt instrument."
       }
      }
     },
     "auth_ref": [
      "r24"
     ]
    },
    "pstv_DebtInstrumentFloatingInterestRatePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://plus.com/20240331",
     "localname": "DebtInstrumentFloatingInterestRatePercentage",
     "presentation": [
      "http://plus.com/role/TermLoanObligationsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument Floating Interest Rate Percentage",
        "terseLabel": "Interest rate",
        "documentation": "Floating interest rate for funds borrowed, under the debt agreement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentInterestRateDuringPeriod": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentInterestRateDuringPeriod",
     "presentation": [
      "http://plus.com/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Interest Rate During Period",
        "terseLabel": "Debt instrument, interest rate",
        "documentation": "The average effective interest rate during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r23",
      "r79",
      "r359"
     ]
    },
    "us-gaap_DebtInstrumentInterestRateEffectivePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentInterestRateEffectivePercentage",
     "presentation": [
      "http://plus.com/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Interest Rate, Effective Percentage",
        "terseLabel": "Effective interest rate",
        "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium."
       }
      }
     },
     "auth_ref": [
      "r23",
      "r79",
      "r368",
      "r554"
     ]
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "presentation": [
      "http://plus.com/role/SubsequentEventsAdditionalInformationDetails",
      "http://plus.com/role/TermLoanObligationsAdditionalInformationDetails",
      "http://plus.com/role/TermLoanObligationsTermLoanOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "terseLabel": "Interest rate",
        "verboseLabel": "Interest Rate",
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement."
       }
      }
     },
     "auth_ref": [
      "r23",
      "r342"
     ]
    },
    "us-gaap_DebtInstrumentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentLineItems",
     "presentation": [
      "http://plus.com/role/TermLoanObligationsAdditionalInformationDetails",
      "http://plus.com/role/TermLoanObligationsTermLoanOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument [Line Items]",
        "terseLabel": "Debt Instrument [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r201",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r347",
      "r352",
      "r353",
      "r354",
      "r355",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r365",
      "r554",
      "r807",
      "r808",
      "r809",
      "r810",
      "r811",
      "r866"
     ]
    },
    "us-gaap_DebtInstrumentMaturityDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentMaturityDate",
     "presentation": [
      "http://plus.com/role/OrganizationAndOperationsAdditionalInformationDetails",
      "http://plus.com/role/TermLoanObligationsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Maturity Date",
        "terseLabel": "Maturity date",
        "documentation": "Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": [
      "r157",
      "r807",
      "r936"
     ]
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentNameDomain",
     "presentation": [
      "http://plus.com/role/OrganizationAndOperationsAdditionalInformationDetails",
      "http://plus.com/role/TermLoanObligationsAdditionalInformationDetails",
      "http://plus.com/role/TermLoanObligationsTermLoanOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Name [Domain]",
        "terseLabel": "Debt Instrument, Name",
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r25",
      "r201",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r347",
      "r352",
      "r353",
      "r354",
      "r355",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r554",
      "r807",
      "r808",
      "r809",
      "r810",
      "r811",
      "r866"
     ]
    },
    "us-gaap_DebtInstrumentOfferingDate1": {
     "xbrltype": "dateItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentOfferingDate1",
     "presentation": [
      "http://plus.com/role/TermLoanObligationsAdditionalInformationDetails",
      "http://plus.com/role/TermLoanObligationsTermLoanOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Offering Date",
        "terseLabel": "Origination date",
        "documentation": "Date the debt instrument was offered for sale, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r56"
     ]
    },
    "us-gaap_DebtInstrumentPeriodicPayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentPeriodicPayment",
     "crdr": "debit",
     "presentation": [
      "http://plus.com/role/TermLoanObligationsTermLoanOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Periodic Payment",
        "terseLabel": "Current Monthly Payment",
        "documentation": "Amount of the required periodic payments including both interest and principal payments."
       }
      }
     },
     "auth_ref": [
      "r25",
      "r84"
     ]
    },
    "us-gaap_DebtInstrumentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentTable",
     "presentation": [
      "http://plus.com/role/TermLoanObligationsAdditionalInformationDetails",
      "http://plus.com/role/TermLoanObligationsTermLoanOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Long-Term Debt Instruments [Table]",
        "terseLabel": "Debt Instrument [Table]",
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer."
       }
      }
     },
     "auth_ref": [
      "r25",
      "r56",
      "r59",
      "r78",
      "r79",
      "r81",
      "r83",
      "r120",
      "r121",
      "r201",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r347",
      "r352",
      "r353",
      "r354",
      "r355",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r365",
      "r554",
      "r807",
      "r808",
      "r809",
      "r810",
      "r811",
      "r866"
     ]
    },
    "us-gaap_DebtPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtPolicyTextBlock",
     "presentation": [
      "http://plus.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt, Policy [Policy Text Block]",
        "terseLabel": "Deferred Financing Costs and Other Debt-Related Costs",
        "documentation": "Disclosure of accounting policy related to debt. Includes, but is not limited to, debt issuance costs, the effects of refinancings, method of amortizing debt issuance costs and original issue discount, and classifications of debt."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "pstv_DebtPrincipalRepaymentStartDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://plus.com/20240331",
     "localname": "DebtPrincipalRepaymentStartDate",
     "presentation": [
      "http://plus.com/role/TermLoanObligationsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Principal Repayment Start Date",
        "terseLabel": "Debt principal repayment start date",
        "documentation": "Debt principal repayment start date."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredIncomeCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredIncomeCurrent",
     "crdr": "credit",
     "calculation": {
      "http://plus.com/role/CondensedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 15.0
      }
     },
     "presentation": [
      "http://plus.com/role/CondensedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Income, Current",
        "terseLabel": "Deferred grant liability",
        "documentation": "Amount of deferred income excluding obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current."
       }
      }
     },
     "auth_ref": [
      "r847"
     ]
    },
    "us-gaap_DeferredIncomeNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredIncomeNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://plus.com/role/CondensedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 18.0
      }
     },
     "presentation": [
      "http://plus.com/role/CondensedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Income, Noncurrent",
        "terseLabel": "Deferred grant liability",
        "documentation": "Amount of deferred income excluding obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r847"
     ]
    },
    "us-gaap_DeferredIncomeTaxLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredIncomeTaxLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://plus.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": 1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://plus.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Liabilities, Gross",
        "negatedTotalLabel": "Total deferred tax liability",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences."
       }
      }
     },
     "auth_ref": [
      "r91",
      "r92",
      "r136",
      "r477"
     ]
    },
    "us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsGoodwillAndIntangibleAssets",
     "crdr": "debit",
     "calculation": {
      "http://plus.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://plus.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Goodwill and Intangible Assets",
        "terseLabel": "Intangible assets",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsGross",
     "crdr": "debit",
     "calculation": {
      "http://plus.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://plus.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Gross",
        "totalLabel": "Deferred tax assets (Total)",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r478"
     ]
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://plus.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://plus.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "totalLabel": "Total deferred tax assets, net of allowance",
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r927"
     ]
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "crdr": "debit",
     "calculation": {
      "http://plus.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://plus.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "terseLabel": "Net operating loss carryforwards",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r70",
      "r928"
     ]
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsDomestic",
     "crdr": "debit",
     "presentation": [
      "http://plus.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Operating Loss Carryforwards, Domestic",
        "terseLabel": "Federal tax carry forward",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible domestic operating loss carryforwards. Excludes state and local operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r70",
      "r928"
     ]
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal",
     "crdr": "debit",
     "presentation": [
      "http://plus.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Operating Loss Carryforwards, State and Local",
        "terseLabel": "State tax credit carryforwards",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible state and local operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r70",
      "r928"
     ]
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsOther",
     "crdr": "debit",
     "calculation": {
      "http://plus.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://plus.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Other",
        "terseLabel": "Other, net",
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other."
       }
      }
     },
     "auth_ref": [
      "r70",
      "r928"
     ]
    },
    "us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsPropertyPlantAndEquipment",
     "crdr": "debit",
     "calculation": {
      "http://plus.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://plus.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Property, Plant and Equipment",
        "terseLabel": "Property and equipment, principally due to differences in depreciation",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from property, plant, and equipment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsTaxCreditCarryforwards",
     "crdr": "debit",
     "calculation": {
      "http://plus.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://plus.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Tax Credit Carryforwards",
        "terseLabel": "Income tax credit carryforwards",
        "documentation": "Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards."
       }
      }
     },
     "auth_ref": [
      "r69",
      "r70",
      "r928"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "crdr": "debit",
     "calculation": {
      "http://plus.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://plus.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost",
        "terseLabel": "Share based compensation",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation."
       }
      }
     },
     "auth_ref": [
      "r70",
      "r928"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://plus.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://plus.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Accrued Liabilities",
        "terseLabel": "Accrued expenses",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accrued liabilities."
       }
      }
     },
     "auth_ref": [
      "r70",
      "r928"
     ]
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsValuationAllowance",
     "crdr": "credit",
     "calculation": {
      "http://plus.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://plus.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Valuation Allowance",
        "negatedLabel": "Valuation allowance",
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized."
       }
      }
     },
     "auth_ref": [
      "r479"
     ]
    },
    "pstv_DeferredTaxAssetsValuationAllowances": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://plus.com/20240331",
     "localname": "DeferredTaxAssetsValuationAllowances",
     "crdr": "credit",
     "presentation": [
      "http://plus.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets Valuation Allowances",
        "terseLabel": "Valuation allowance",
        "documentation": "Deferred tax assets valuation allowances."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://plus.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://plus.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Liabilities, Net",
        "totalLabel": "Net deferred tax assets (liability)",
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r68",
      "r927"
     ]
    },
    "us-gaap_DeferredTaxLiabilitiesOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxLiabilitiesOther",
     "crdr": "credit",
     "calculation": {
      "http://plus.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://plus.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Liabilities, Other",
        "negatedLabel": "Other",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences classified as other."
       }
      }
     },
     "auth_ref": [
      "r70",
      "r928"
     ]
    },
    "us-gaap_DefinedContributionPlanDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedContributionPlanDisclosureLineItems",
     "presentation": [
      "http://plus.com/role/EmployeeBenefitPlanAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Contribution Plan Disclosure [Line Items]",
        "terseLabel": "Defined Contribution Plan Disclosure [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r413"
     ]
    },
    "us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedContributionPlanEmployerDiscretionaryContributionAmount",
     "crdr": "debit",
     "presentation": [
      "http://plus.com/role/EmployeeBenefitPlanAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Contribution Plan, Employer Discretionary Contribution Amount",
        "terseLabel": "Discretionary or matching contributions",
        "documentation": "Amount of discretionary contributions made by an employer to a defined contribution plan."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedContributionPlanEmployerMatchingContributionPercentOfMatch",
     "presentation": [
      "http://plus.com/role/EmployeeBenefitPlanAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Contribution Plan, Employer Matching Contribution, Percent of Match",
        "terseLabel": "Percentage of matching contribution for employee contributions",
        "documentation": "Percentage employer matches of the employee's percentage contribution matched."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DefinedContributionPlanTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedContributionPlanTable",
     "presentation": [
      "http://plus.com/role/EmployeeBenefitPlanAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Contribution Plan [Table]",
        "terseLabel": "Defined Contribution Plan [Table]",
        "documentation": "Disclosure of information about defined contribution pension plans or defined contribution other postretirement plans, separately for pension plans and other postretirement benefit plans."
       }
      }
     },
     "auth_ref": [
      "r413"
     ]
    },
    "us-gaap_Depreciation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Depreciation",
     "crdr": "debit",
     "presentation": [
      "http://plus.com/role/CompositionOfCertainFinancialStatementCaptionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Depreciation",
        "terseLabel": "Depreciation expense",
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r50"
     ]
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DepreciationDepletionAndAmortization",
     "crdr": "debit",
     "calculation": {
      "http://plus.com/role/CondensedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://plus.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Depreciation Depletion And Amortization",
        "terseLabel": "Depreciation and amortization",
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r242"
     ]
    },
    "us-gaap_DerivativeContractTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DerivativeContractTypeDomain",
     "presentation": [
      "http://plus.com/role/TermLoanObligationsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative Contract Type [Domain]",
        "terseLabel": "Derivative Contract",
        "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset."
       }
      }
     },
     "auth_ref": [
      "r693",
      "r696",
      "r710",
      "r711",
      "r712",
      "r713",
      "r714",
      "r715",
      "r716",
      "r718",
      "r719",
      "r720",
      "r721",
      "r733",
      "r734",
      "r735",
      "r736",
      "r739",
      "r740",
      "r741",
      "r742",
      "r760",
      "r761",
      "r762",
      "r763",
      "r832",
      "r834"
     ]
    },
    "us-gaap_DerivativeInstrumentRiskAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DerivativeInstrumentRiskAxis",
     "presentation": [
      "http://plus.com/role/TermLoanObligationsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative Instrument Risk [Axis]",
        "terseLabel": "Derivative Instrument",
        "documentation": "Information by type of derivative contract."
       }
      }
     },
     "auth_ref": [
      "r72",
      "r73",
      "r74",
      "r75",
      "r693",
      "r696",
      "r710",
      "r711",
      "r712",
      "r713",
      "r714",
      "r715",
      "r716",
      "r718",
      "r719",
      "r720",
      "r721",
      "r733",
      "r734",
      "r735",
      "r736",
      "r739",
      "r740",
      "r741",
      "r742",
      "r760",
      "r761",
      "r762",
      "r763",
      "r797",
      "r832",
      "r834"
     ]
    },
    "us-gaap_DisaggregationOfRevenueLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisaggregationOfRevenueLineItems",
     "presentation": [
      "http://plus.com/role/GrantRevenueAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disaggregation of Revenue [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r403",
      "r813",
      "r814",
      "r815",
      "r816",
      "r817",
      "r818",
      "r819"
     ]
    },
    "us-gaap_DisaggregationOfRevenueTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisaggregationOfRevenueTable",
     "presentation": [
      "http://plus.com/role/GrantRevenueAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disaggregation of Revenue [Table]",
        "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor."
       }
      }
     },
     "auth_ref": [
      "r403",
      "r813",
      "r814",
      "r815",
      "r816",
      "r817",
      "r818",
      "r819"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "presentation": [
      "http://plus.com/role/StockBasedCompensation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure Of Compensation Related Costs Share Based Payments [Text Block]",
        "terseLabel": "Stock-based Compensation",
        "documentation": "The entire disclosure for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r415",
      "r419",
      "r449",
      "r450",
      "r452",
      "r824"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "pstv_DisclosureOfLiquidityAndGoingConcernTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://plus.com/20240331",
     "localname": "DisclosureOfLiquidityAndGoingConcernTextBlock",
     "presentation": [
      "http://plus.com/role/LiquidityAndGoingConcern"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure Of Liquidity And Going Concern Text Block",
        "terseLabel": "Liquidity and Going Concern",
        "documentation": "Disclosure of liquidity and going concern text block"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisposalGroupClassificationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisposalGroupClassificationAxis",
     "presentation": [
      "http://plus.com/role/TermLoanObligationsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disposal Group Classification [Axis]",
        "terseLabel": "Disposal Group Classification",
        "documentation": "Information by disposal group classification."
       }
      }
     },
     "auth_ref": [
      "r165"
     ]
    },
    "us-gaap_DisposalGroupClassificationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisposalGroupClassificationDomain",
     "presentation": [
      "http://plus.com/role/TermLoanObligationsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disposal Group Classification [Domain]",
        "terseLabel": "Disposal Group Classification",
        "documentation": "Component or group of components disposed of, including but not limited to, disposal group held-for-sale or disposed of by sale, disposed of by means other than sale, and discontinued operations."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentInformationLineItems",
     "presentation": [
      "http://plus.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentInformationTable",
     "presentation": [
      "http://plus.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Information [Table]",
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://plus.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "terseLabel": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DomesticCountryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DomesticCountryMember",
     "presentation": [
      "http://plus.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Domestic Tax Authority [Member]",
        "terseLabel": "Federal [Member]",
        "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://plus.com/role/CondensedStatementsOfOperationsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share Basic",
        "terseLabel": "Net loss per share, basic",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r190",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r222",
      "r224",
      "r227",
      "r228",
      "r229",
      "r233",
      "r525",
      "r526",
      "r628",
      "r642",
      "r799"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://plus.com/role/CondensedStatementsOfOperationsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share Diluted",
        "terseLabel": "Net loss per share, diluted",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r190",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r224",
      "r227",
      "r228",
      "r229",
      "r233",
      "r525",
      "r526",
      "r628",
      "r642",
      "r799"
     ]
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerSharePolicyTextBlock",
     "presentation": [
      "http://plus.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Loss Per Share",
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r40",
      "r41"
     ]
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareTextBlock",
     "presentation": [
      "http://plus.com/role/LossPerShare"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Loss per Share",
        "documentation": "The entire disclosure for earnings per share."
       }
      }
     },
     "auth_ref": [
      "r221",
      "r230",
      "r231",
      "r232"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "presentation": [
      "http://plus.com/role/IncomeTaxesReconciliationOfTotalIncomeTaxProvisionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "verboseLabel": "Total income tax provision",
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r468"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract",
     "presentation": [
      "http://plus.com/role/IncomeTaxesReconciliationOfTotalIncomeTaxProvisionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Percent [Abstract]",
        "terseLabel": "Reconciliation of the total income tax provision tax rate [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "presentation": [
      "http://plus.com/role/IncomeTaxesReconciliationOfTotalIncomeTaxProvisionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "negatedLabel": "Income tax expense (benefit) at federal statutory rate",
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss)."
       }
      }
     },
     "auth_ref": [
      "r200",
      "r468",
      "r490"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "presentation": [
      "http://plus.com/role/IncomeTaxesReconciliationOfTotalIncomeTaxProvisionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent",
        "terseLabel": "Change in valuation allowance",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r924",
      "r929"
     ]
    },
    "pstv_EffectiveIncomeTaxRateReconciliationNetOperatingLossExpiration": {
     "xbrltype": "percentItemType",
     "nsuri": "http://plus.com/20240331",
     "localname": "EffectiveIncomeTaxRateReconciliationNetOperatingLossExpiration",
     "presentation": [
      "http://plus.com/role/IncomeTaxesReconciliationOfTotalIncomeTaxProvisionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation Net Operating Loss Expiration",
        "terseLabel": "NOLs expiring and adjustments to NOL",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to net operating loss expiration."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost",
     "presentation": [
      "http://plus.com/role/IncomeTaxesReconciliationOfTotalIncomeTaxProvisionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Percent",
        "terseLabel": "Share based compensation",
        "documentation": "Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r924",
      "r929"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "presentation": [
      "http://plus.com/role/IncomeTaxesReconciliationOfTotalIncomeTaxProvisionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent",
        "terseLabel": "Income tax expense (benefit) at state statutory rate",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit)."
       }
      }
     },
     "auth_ref": [
      "r924",
      "r929"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCreditsResearch",
     "presentation": [
      "http://plus.com/role/IncomeTaxesReconciliationOfTotalIncomeTaxProvisionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent",
        "negatedLabel": "Research credit",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit."
       }
      }
     },
     "auth_ref": [
      "r924",
      "r929"
     ]
    },
    "pstv_EffectiveIncomeTaxRateReconciliationTaxReturnToProvision": {
     "xbrltype": "percentItemType",
     "nsuri": "http://plus.com/20240331",
     "localname": "EffectiveIncomeTaxRateReconciliationTaxReturnToProvision",
     "presentation": [
      "http://plus.com/role/IncomeTaxesReconciliationOfTotalIncomeTaxProvisionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation Tax Return To Provision",
        "terseLabel": "Return to provision",
        "documentation": "Effective income tax rate reconciliation tax return to provision."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlementsStateAndLocal": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationTaxSettlementsStateAndLocal",
     "presentation": [
      "http://plus.com/role/IncomeTaxesReconciliationOfTotalIncomeTaxProvisionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Tax Settlement, State and Local, Percent",
        "terseLabel": "Change in state rate",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax settlement."
       }
      }
     },
     "auth_ref": [
      "r924",
      "r929"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "crdr": "debit",
     "presentation": [
      "http://plus.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized",
        "verboseLabel": "Total unamortized compensation cost related to outstanding unvested stock options and restricted stock awards",
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r451"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "presentation": [
      "http://plus.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1",
        "verboseLabel": "Weighted average period for recognition of cost",
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r451"
     ]
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://plus.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://plus.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://plus.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://plus.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://plus.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressesAddressTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressesAddressTypeAxis",
     "presentation": [
      "http://plus.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Addresses, Address Type [Axis]",
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://plus.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r843"
     ]
    },
    "dei_EntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityDomain",
     "presentation": [
      "http://plus.com/role/StockholdersEquityCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity [Domain]",
        "terseLabel": "Entity",
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://plus.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r843"
     ]
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://plus.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r843"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://plus.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityPrimarySicNumber": {
     "xbrltype": "sicNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityPrimarySicNumber",
     "presentation": [
      "http://plus.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Primary SIC Number",
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity."
       }
      }
     },
     "auth_ref": [
      "r845"
     ]
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://plus.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r843"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://plus.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r843"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://plus.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r843"
     ]
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://plus.com/role/BasisOfPresentationAndNewAccountingStandardsAdditionalInformationDetails",
      "http://plus.com/role/CondensedStatementsOfStockholdersEquityDeficitUnaudited",
      "http://plus.com/role/LossPerShareScheduleOfAntidilutiveSecuritiesExcludedFromDilutedIncomeLossPerShareDetails",
      "http://plus.com/role/OrganizationAndOperationsAdditionalInformationDetails",
      "http://plus.com/role/StockholdersEquityCommonStockDetails",
      "http://plus.com/role/StockholdersEquityWarrantsDetails",
      "http://plus.com/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component",
        "verboseLabel": "Equity Component [Domain]",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r162",
      "r185",
      "r186",
      "r187",
      "r202",
      "r203",
      "r204",
      "r208",
      "r216",
      "r218",
      "r234",
      "r300",
      "r307",
      "r386",
      "r453",
      "r454",
      "r455",
      "r485",
      "r486",
      "r506",
      "r508",
      "r509",
      "r510",
      "r511",
      "r513",
      "r524",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r574",
      "r653",
      "r654",
      "r655",
      "r674",
      "r745"
     ]
    },
    "pstv_EquityIncentivePlansMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://plus.com/20240331",
     "localname": "EquityIncentivePlansMember",
     "presentation": [
      "http://plus.com/role/BasisOfPresentationAndNewAccountingStandardsAdditionalInformationDetails",
      "http://plus.com/role/OrganizationAndOperationsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Incentive Plans [Member]",
        "terseLabel": "Equity Incentive Plans [Member]",
        "documentation": "Equity incentive plans."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueAdjustmentOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAdjustmentOfWarrants",
     "crdr": "debit",
     "calculation": {
      "http://plus.com/role/CondensedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://plus.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Adjustment Of Warrants",
        "terseLabel": "Change in fair value of liability instruments",
        "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r5"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "presentation": [
      "http://plus.com/role/FairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r529",
      "r530",
      "r533"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "presentation": [
      "http://plus.com/role/FairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r529",
      "r530",
      "r533"
     ]
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsMeasuredOnRecurringBasisTextBlock",
     "presentation": [
      "http://plus.com/role/FairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Assets Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Summary of Financial Assets Measured at Fair Value on Recurring Basis",
        "documentation": "Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)."
       }
      }
     },
     "auth_ref": [
      "r77",
      "r133"
     ]
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "presentation": [
      "http://plus.com/role/FairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient."
       }
      }
     },
     "auth_ref": [
      "r354",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r530",
      "r583",
      "r584",
      "r585",
      "r808",
      "r809",
      "r820",
      "r821",
      "r822"
     ]
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueByMeasurementFrequencyAxis",
     "presentation": [
      "http://plus.com/role/FairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Frequency [Axis]",
        "documentation": "Information by measurement frequency."
       }
      }
     },
     "auth_ref": [
      "r529",
      "r530",
      "r531",
      "r532",
      "r534"
     ]
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueDisclosuresAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueInputsLevel1Member",
     "presentation": [
      "http://plus.com/role/FairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level 1 [Member]",
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date."
       }
      }
     },
     "auth_ref": [
      "r354",
      "r406",
      "r411",
      "r530",
      "r583",
      "r820",
      "r821",
      "r822"
     ]
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementFrequencyDomain",
     "presentation": [
      "http://plus.com/role/FairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Frequency [Domain]",
        "documentation": "Measurement frequency."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueMeasurementInputsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementInputsDisclosureTextBlock",
     "presentation": [
      "http://plus.com/role/FairValueMeasurements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurement Inputs Disclosure [Text Block]",
        "terseLabel": "Fair Value Measurements",
        "documentation": "The entire disclosure of the fair value measurement of assets and liabilities, which includes financial instruments measured at fair value that are classified in shareholders' equity, which may be measured on a recurring or nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r132"
     ]
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "presentation": [
      "http://plus.com/role/FairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "auth_ref": [
      "r354",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r583",
      "r584",
      "r585",
      "r808",
      "r809",
      "r820",
      "r821",
      "r822"
     ]
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementsRecurringMember",
     "presentation": [
      "http://plus.com/role/FairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Recurring Basis [Member]",
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value."
       }
      }
     },
     "auth_ref": [
      "r528",
      "r534"
     ]
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "presentation": [
      "http://plus.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]",
        "terseLabel": "Financial Instruments",
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r14"
     ]
    },
    "us-gaap_FinancialInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinancialInstrumentAxis",
     "presentation": [
      "http://plus.com/role/StockholdersEquityCommonStockDetails",
      "http://plus.com/role/TermLoanObligationsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instrument [Axis]",
        "terseLabel": "Financial Instrument",
        "documentation": "Information by type of financial instrument."
       }
      }
     },
     "auth_ref": [
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r365",
      "r382",
      "r514",
      "r580",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597",
      "r598",
      "r599",
      "r600",
      "r601",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r607",
      "r608",
      "r609",
      "r641",
      "r804",
      "r851",
      "r852",
      "r853",
      "r854",
      "r855",
      "r856",
      "r857",
      "r876",
      "r877",
      "r878",
      "r879"
     ]
    },
    "pstv_FractionalAdjustmentOfCommonStock": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://plus.com/20240331",
     "localname": "FractionalAdjustmentOfCommonStock",
     "presentation": [
      "http://plus.com/role/CondensedStatementsOfStockholdersEquityDeficitUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fractional Adjustment of Common Stock",
        "terseLabel": "Fractional adjustment",
        "documentation": "Fractional adjustment of common stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GainLossOnDispositionOfAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GainLossOnDispositionOfAssets",
     "crdr": "credit",
     "calculation": {
      "http://plus.com/role/CondensedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://plus.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber Property",
        "negatedLabel": "Loss on disposal of property and equipment",
        "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, excluding oil and gas property and timber property."
       }
      }
     },
     "auth_ref": [
      "r864",
      "r884",
      "r885"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://plus.com/role/CondensedStatementsOfOperationsUnaudited": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://plus.com/role/CondensedStatementsOfOperationsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General And Administrative Expense",
        "terseLabel": "General and administrative",
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": [
      "r103",
      "r728"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GeneralAndAdministrativeExpenseMember",
     "presentation": [
      "http://plus.com/role/StockBasedCompensationSummaryOfShareBasedCompensationRecognizedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and Administrative Expense [Member]",
        "terseLabel": "General and Administrative [Member]",
        "documentation": "Primary financial statement caption encompassing general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r101"
     ]
    },
    "us-gaap_Goodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Goodwill",
     "crdr": "debit",
     "calculation": {
      "http://plus.com/role/CondensedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://plus.com/role/CondensedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill",
        "terseLabel": "Goodwill",
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized."
       }
      }
     },
     "auth_ref": [
      "r172",
      "r316",
      "r627",
      "r806",
      "r829",
      "r882",
      "r883"
     ]
    },
    "us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GoodwillAndIntangibleAssetsPolicyTextBlock",
     "presentation": [
      "http://plus.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill and Intangible Assets, Policy [Policy Text Block]",
        "terseLabel": "Goodwill",
        "documentation": "Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r45"
     ]
    },
    "pstv_GrantFundingTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://plus.com/20240331",
     "localname": "GrantFundingTerm",
     "presentation": [
      "http://plus.com/role/GrantRevenueAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Grant Funding Term",
        "terseLabel": "Grant funding term",
        "documentation": "Grant funding term."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GrantMember",
     "presentation": [
      "http://plus.com/role/CondensedStatementsOfOperationsUnaudited",
      "http://plus.com/role/GrantRevenueAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Grant [Member]",
        "documentation": "Award of money not required to be repaid."
       }
      }
     },
     "auth_ref": [
      "r895"
     ]
    },
    "pstv_GrossProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://plus.com/20240331",
     "localname": "GrossProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "presentation": [
      "http://plus.com/role/StockholdersEquityCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gross Proceeds from Issuance of Common Stock",
        "terseLabel": "Aggregate gross proceeds from sales of common stock",
        "documentation": "Gross proceeds from issuance of common stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ImpairmentOfLongLivedAssetsHeldForUse": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ImpairmentOfLongLivedAssetsHeldForUse",
     "crdr": "debit",
     "presentation": [
      "http://plus.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Impairment, Long-Lived Asset, Held-for-Use",
        "terseLabel": "Impairment loss",
        "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale)."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r49",
      "r116"
     ]
    },
    "us-gaap_InProcessResearchAndDevelopmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InProcessResearchAndDevelopmentMember",
     "presentation": [
      "http://plus.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "In Process Research and Development [Member]",
        "documentation": "In process investigation of new knowledge useful in developing new product or service or new process or technique or improvement to existing product or process, and translation of knowledge into plan or design for new product or process or for improvement to existing product or process."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InProcessResearchAndDevelopmentPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InProcessResearchAndDevelopmentPolicy",
     "presentation": [
      "http://plus.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "In Process Research and Development, Policy [Policy Text Block]",
        "terseLabel": "Acquired In-Process Research and Development (IPR&amp;D)",
        "documentation": "Disclosure of accounting policy for costs assigned to identifiable tangible and intangible assets of an acquired entity to be used in the research and development activities of the combined enterprise. An entity also may disclose the appraisal method or significant assumptions used to value acquired research and development assets."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeLossFromContinuingOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeLossFromContinuingOperations",
     "crdr": "credit",
     "presentation": [
      "http://plus.com/role/LiquidityAndGoingConcernAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent",
        "terseLabel": "Net income from continuing operations",
        "documentation": "Amount after tax of income (loss) from continuing operations attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r71",
      "r102",
      "r111",
      "r211",
      "r212",
      "r213",
      "r214",
      "r226",
      "r229"
     ]
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://plus.com/role/StockBasedCompensationSummaryOfShareBasedCompensationRecognizedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location",
        "documentation": "Information by location in the income statement."
       }
      }
     },
     "auth_ref": [
      "r319",
      "r321",
      "r729"
     ]
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://plus.com/role/StockBasedCompensationSummaryOfShareBasedCompensationRecognizedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location",
        "documentation": "Location in the income statement."
       }
      }
     },
     "auth_ref": [
      "r321",
      "r729"
     ]
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxAuthorityAxis",
     "presentation": [
      "http://plus.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Authority [Axis]",
        "terseLabel": "Income Tax Authority",
        "documentation": "Information by tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxAuthorityDomain",
     "presentation": [
      "http://plus.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Authority [Domain]",
        "terseLabel": "Income Tax Authority",
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxAuthorityNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxAuthorityNameAxis",
     "presentation": [
      "http://plus.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Authority, Name [Axis]",
        "documentation": "Information by name of taxing authority."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "us-gaap_IncomeTaxAuthorityNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxAuthorityNameDomain",
     "presentation": [
      "http://plus.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Authority, Name [Domain]",
        "documentation": "Named agency, division or body that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes."
       }
      }
     },
     "auth_ref": []
    },
    "pstv_IncomeTaxContingencyAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://plus.com/20240331",
     "localname": "IncomeTaxContingencyAbstract",
     "presentation": [
      "http://plus.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Contingency [Abstract]",
        "terseLabel": "Income Tax Contingency [Abstract]",
        "documentation": "Income tax contingency."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://plus.com/role/IncomeTaxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes",
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information."
       }
      }
     },
     "auth_ref": [
      "r200",
      "r463",
      "r469",
      "r474",
      "r481",
      "r488",
      "r491",
      "r492",
      "r493",
      "r673"
     ]
    },
    "us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxExaminationPenaltiesAndInterestExpense",
     "crdr": "debit",
     "presentation": [
      "http://plus.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Examination, Penalties and Interest Expense",
        "terseLabel": "Interest or penalties related to income tax matters",
        "documentation": "The sum of the amounts of estimated penalties and interest recognized in the period arising from income tax examinations."
       }
      }
     },
     "auth_ref": [
      "r925"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxExpenseBenefit",
     "crdr": "debit",
     "presentation": [
      "http://plus.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Expense (Benefit)",
        "terseLabel": "Provision or benefit for income taxes",
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r144",
      "r156",
      "r217",
      "r218",
      "r243",
      "r467",
      "r489",
      "r643"
     ]
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxPolicyTextBlock",
     "presentation": [
      "http://plus.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income Taxes",
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements."
       }
      }
     },
     "auth_ref": [
      "r184",
      "r465",
      "r466",
      "r474",
      "r475",
      "r480",
      "r482",
      "r667"
     ]
    },
    "pstv_IncomeTaxesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://plus.com/20240331",
     "localname": "IncomeTaxesLineItems",
     "presentation": [
      "http://plus.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Taxes [Line Items]",
        "terseLabel": "Income Taxes [Line Items]",
        "documentation": "Income taxes."
       }
      }
     },
     "auth_ref": []
    },
    "pstv_IncomeTaxesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://plus.com/20240331",
     "localname": "IncomeTaxesTable",
     "presentation": [
      "http://plus.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Taxes [Table]",
        "terseLabel": "Income Taxes [Table]",
        "documentation": "Income taxes."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://plus.com/role/CondensedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://plus.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase Decrease In Accounts Payable And Accrued Liabilities",
        "terseLabel": "Accounts payable and accrued expenses",
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "pstv_IncreaseDecreaseInDeferredGrantLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://plus.com/20240331",
     "localname": "IncreaseDecreaseInDeferredGrantLiability",
     "crdr": "debit",
     "calculation": {
      "http://plus.com/role/CondensedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://plus.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase Decrease In Deferred Grant Liability",
        "terseLabel": "Deferred grant liability",
        "documentation": "Increase (decrease) in deferred grant liability."
       }
      }
     },
     "auth_ref": []
    },
    "pstv_IncreaseDecreaseInGrantRevenue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://plus.com/20240331",
     "localname": "IncreaseDecreaseInGrantRevenue",
     "crdr": "debit",
     "presentation": [
      "http://plus.com/role/GrantRevenueAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Grant Revenue",
        "terseLabel": "Increase in grant revenue",
        "documentation": "Increase (decrease) in grant revenue."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://plus.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase Decrease In Operating Capital [Abstract]",
        "terseLabel": "Increases (decreases) in cash caused by changes in operating assets and liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "crdr": "debit",
     "calculation": {
      "http://plus.com/role/CondensedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://plus.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Lease Liability",
        "terseLabel": "Change in operating lease liabilities",
        "documentation": "Amount of increase (decrease) in obligation for operating lease."
       }
      }
     },
     "auth_ref": [
      "r849",
      "r863"
     ]
    },
    "us-gaap_IncreaseDecreaseInOtherCurrentAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOtherCurrentAssets",
     "crdr": "credit",
     "calculation": {
      "http://plus.com/role/CondensedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 14.0
      }
     },
     "presentation": [
      "http://plus.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase Decrease In Other Current Assets",
        "negatedLabel": "Other current assets",
        "documentation": "Amount of increase (decrease) in current assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r863"
     ]
    },
    "us-gaap_IncreaseDecreaseInOtherNoncurrentAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOtherNoncurrentAssets",
     "crdr": "credit",
     "calculation": {
      "http://plus.com/role/CondensedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://plus.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Other Noncurrent Assets",
        "negatedLabel": "Other assets",
        "documentation": "Amount of increase (decrease) in noncurrent assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r863"
     ]
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IndefiniteLivedIntangibleAssetsByMajorClassAxis",
     "presentation": [
      "http://plus.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Indefinite-Lived Intangible Assets [Axis]",
        "documentation": "Information by type or class of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit."
       }
      }
     },
     "auth_ref": [
      "r317",
      "r318"
     ]
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IndefiniteLivedIntangibleAssetsMajorClassNameDomain",
     "presentation": [
      "http://plus.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Indefinite-Lived Intangible Assets, Major Class Name [Domain]",
        "documentation": "The major class of indefinite-lived intangible asset (for example, trade names, etc. but not all-inclusive), excluding goodwill. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company."
       }
      }
     },
     "auth_ref": [
      "r47",
      "r114"
     ]
    },
    "pstv_InitialCommitmentFee": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://plus.com/20240331",
     "localname": "InitialCommitmentFee",
     "crdr": "credit",
     "presentation": [
      "http://plus.com/role/StockholdersEquityCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Initial Commitment Fee",
        "terseLabel": "Initial commitment fee paid in cash",
        "documentation": "Initial commitment fee."
       }
      }
     },
     "auth_ref": []
    },
    "pstv_InitialCommitmentShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://plus.com/20240331",
     "localname": "InitialCommitmentShares",
     "presentation": [
      "http://plus.com/role/StockholdersEquityCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Initial Commitment Shares",
        "terseLabel": "Initial commitment shares",
        "documentation": "Initial commitment shares."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InterestExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestExpense",
     "crdr": "debit",
     "calculation": {
      "http://plus.com/role/CondensedStatementsOfOperationsUnaudited": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://plus.com/role/CondensedStatementsOfOperationsUnaudited",
      "http://plus.com/role/TermLoanObligationsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest Expense",
        "negatedLabel": "Interest expense",
        "terseLabel": "Interest expense",
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense."
       }
      }
     },
     "auth_ref": [
      "r80",
      "r142",
      "r188",
      "r241",
      "r552",
      "r730",
      "r840",
      "r956"
     ]
    },
    "us-gaap_InterestPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://plus.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest Paid Net",
        "terseLabel": "Interest",
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount."
       }
      }
     },
     "auth_ref": [
      "r191",
      "r193",
      "r194"
     ]
    },
    "us-gaap_InterestRateFloorMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestRateFloorMember",
     "presentation": [
      "http://plus.com/role/TermLoanObligationsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest Rate Floor [Member]",
        "terseLabel": "Interest Rate Floor [Member]",
        "documentation": "Contracts in which the floor writer, in return for a premium, agrees to limit the risk associated with a decline in interest rates based on a notional amount. If rates fall below an agreed rate, the floor holder will receive cash payments from the floor writer equal to the difference between the market rate and an agreed rate multiplied by the notional principal amount."
       }
      }
     },
     "auth_ref": [
      "r792"
     ]
    },
    "us-gaap_InvestmentIncomeInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InvestmentIncomeInterest",
     "crdr": "credit",
     "calculation": {
      "http://plus.com/role/CondensedStatementsOfOperationsUnaudited": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://plus.com/role/CondensedStatementsOfOperationsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Income Interest",
        "terseLabel": "Interest income",
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities."
       }
      }
     },
     "auth_ref": [
      "r104",
      "r240"
     ]
    },
    "us-gaap_InvestmentTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InvestmentTypeAxis",
     "presentation": [
      "http://plus.com/role/StockholdersEquityCommonStockDetails",
      "http://plus.com/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Type [Axis]",
        "terseLabel": "Investment Type",
        "documentation": "Information by type of investments."
       }
      }
     },
     "auth_ref": [
      "r686",
      "r688",
      "r689",
      "r691",
      "r694",
      "r751",
      "r753",
      "r755",
      "r758",
      "r759",
      "r764",
      "r765",
      "r767",
      "r768",
      "r769",
      "r770",
      "r771",
      "r834"
     ]
    },
    "us-gaap_InvestmentTypeCategorizationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InvestmentTypeCategorizationMember",
     "presentation": [
      "http://plus.com/role/StockholdersEquityCommonStockDetails",
      "http://plus.com/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments [Domain]",
        "terseLabel": "Investments",
        "documentation": "Asset obtained to generate income or appreciate in value."
       }
      }
     },
     "auth_ref": [
      "r686",
      "r688",
      "r689",
      "r691",
      "r694",
      "r751",
      "r753",
      "r755",
      "r758",
      "r759",
      "r764",
      "r765",
      "r767",
      "r768",
      "r769",
      "r770",
      "r771",
      "r834"
     ]
    },
    "pstv_JanuaryTwoThousandAndTwentyTwoDistributionAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://plus.com/20240331",
     "localname": "JanuaryTwoThousandAndTwentyTwoDistributionAgreementMember",
     "presentation": [
      "http://plus.com/role/StockholdersEquityCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "January Two Thousand and Twenty Two Distribution Agreement [Member]",
        "terseLabel": "January 2022 Distribution Agreement [Member]",
        "documentation": "January two thousand and twenty two distribution agreement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeaseCost",
     "crdr": "debit",
     "calculation": {
      "http://plus.com/role/CommitmentsAndContingenciesSummaryOfLeaseCostsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://plus.com/role/CommitmentsAndContingenciesSummaryOfLeaseCostsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease Cost",
        "totalLabel": "Total lease expense",
        "documentation": "Amount of lease cost recognized by lessee for lease contract."
       }
      }
     },
     "auth_ref": [
      "r563",
      "r828"
     ]
    },
    "us-gaap_LeaseCostAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeaseCostAbstract",
     "presentation": [
      "http://plus.com/role/CommitmentsAndContingenciesSummaryOfLeaseCostsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease Cost [Abstract]",
        "terseLabel": "Lease expense:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeaseCostTableTextBlock",
     "presentation": [
      "http://plus.com/role/CommitmentsAndContingenciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease Cost Table [Text Block]",
        "terseLabel": "Summary of Lease Costs",
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income."
       }
      }
     },
     "auth_ref": [
      "r940"
     ]
    },
    "us-gaap_LeaseExpirationDate1": {
     "xbrltype": "dateItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeaseExpirationDate1",
     "presentation": [
      "http://plus.com/role/CommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease Expiration Date1",
        "terseLabel": "Operating leases, expiration date",
        "documentation": "Date which lease or group of leases is set to expire, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseholdImprovementsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeaseholdImprovementsGross",
     "crdr": "debit",
     "calculation": {
      "http://plus.com/role/CompositionOfCertainFinancialStatementCaptionsPropertyAndEquipmentNetDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentGross",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://plus.com/role/CompositionOfCertainFinancialStatementCaptionsPropertyAndEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leasehold Improvements, Gross",
        "terseLabel": "Leasehold improvements",
        "documentation": "Amount before accumulated depreciation of additions or improvements to assets held under a lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r115"
     ]
    },
    "dei_LegalEntityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LegalEntityAxis",
     "presentation": [
      "http://plus.com/role/StockholdersEquityCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Legal Entity [Axis]",
        "terseLabel": "Legal Entity",
        "documentation": "The set of legal entities associated with a report."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeOperatingLeaseDiscountRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseDiscountRate",
     "presentation": [
      "http://plus.com/role/CommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Discount Rate",
        "terseLabel": "Operating lease discount rate",
        "documentation": "Discount rate used by lessee to determine present value of operating lease payments."
       }
      }
     },
     "auth_ref": [
      "r827"
     ]
    },
    "us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseExistenceOfOptionToExtend",
     "presentation": [
      "http://plus.com/role/CommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee Operating Lease Existence Of Option To Extend",
        "terseLabel": "Lessee, operating lease, existence of option to extend [true false]",
        "documentation": "Indicates (true false) whether lessee has option to extend operating lease."
       }
      }
     },
     "auth_ref": [
      "r562"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "presentation": [
      "http://plus.com/role/CommitmentsAndContingenciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee Operating Lease Liability Maturity Table [Text Block]",
        "terseLabel": "Summary of Future Minimum Annual Lease Payments under Operating Leases",
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position."
       }
      }
     },
     "auth_ref": [
      "r941"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "calculation": {
      "http://plus.com/role/CommitmentsAndContingenciesSummaryOfFutureMinimumAnnualLeasePaymentsUnderOperatingLeasesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://plus.com/role/CommitmentsAndContingenciesSummaryOfFutureMinimumAnnualLeasePaymentsUnderOperatingLeasesDetailsAlternate1": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://plus.com/role/CommitmentsAndContingenciesSummaryOfFutureMinimumAnnualLeasePaymentsUnderOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total minimum lease payments",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease."
       }
      }
     },
     "auth_ref": [
      "r569"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "calculation": {
      "http://plus.com/role/CommitmentsAndContingenciesSummaryOfFutureMinimumAnnualLeasePaymentsUnderOperatingLeasesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://plus.com/role/CommitmentsAndContingenciesSummaryOfFutureMinimumAnnualLeasePaymentsUnderOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "2024",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r569"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "crdr": "credit",
     "calculation": {
      "http://plus.com/role/CommitmentsAndContingenciesSummaryOfFutureMinimumAnnualLeasePaymentsUnderOperatingLeasesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://plus.com/role/CommitmentsAndContingenciesSummaryOfFutureMinimumAnnualLeasePaymentsUnderOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2026",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r569"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "crdr": "credit",
     "calculation": {
      "http://plus.com/role/CommitmentsAndContingenciesSummaryOfFutureMinimumAnnualLeasePaymentsUnderOperatingLeasesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://plus.com/role/CommitmentsAndContingenciesSummaryOfFutureMinimumAnnualLeasePaymentsUnderOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2025",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r569"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "crdr": "credit",
     "calculation": {
      "http://plus.com/role/CommitmentsAndContingenciesSummaryOfFutureMinimumAnnualLeasePaymentsUnderOperatingLeasesDetailsAlternate1": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://plus.com/role/CommitmentsAndContingenciesSummaryOfFutureMinimumAnnualLeasePaymentsUnderOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee Operating Lease Liability Undiscounted Excess Amount",
        "negatedLabel": "Less: amount representing interest",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease."
       }
      }
     },
     "auth_ref": [
      "r569"
     ]
    },
    "us-gaap_LesseeOperatingLeaseOptionToExtend": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseOptionToExtend",
     "presentation": [
      "http://plus.com/role/CommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee Operating Lease Option To Extend",
        "terseLabel": "Lessee, operating lease, option to extend",
        "documentation": "Description of terms and conditions of option to extend lessee's operating lease. Includes, but is not limited to, information about option recognized as part of right-of-use asset and lease liability."
       }
      }
     },
     "auth_ref": [
      "r562"
     ]
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "presentation": [
      "http://plus.com/role/CommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee Operating Lease Renewal Term",
        "terseLabel": "Lessee, operating lease, renewal term",
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r939"
     ]
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseTermOfContract",
     "presentation": [
      "http://plus.com/role/CommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee Operating Lease Term Of Contract",
        "terseLabel": "Lessee, operating lease, term of contract",
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r939"
     ]
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://plus.com/role/CondensedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://plus.com/role/CondensedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities",
        "totalLabel": "Total liabilities",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r199",
      "r294",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r499",
      "r500",
      "r501",
      "r537",
      "r703",
      "r800",
      "r842",
      "r890",
      "r943",
      "r944"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://plus.com/role/CondensedBalanceSheetsUnaudited": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://plus.com/role/CondensedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities And Stockholders Equity",
        "totalLabel": "Total liabilities and stockholders' deficit",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r99",
      "r138",
      "r636",
      "r829",
      "r867",
      "r880",
      "r937"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://plus.com/role/CondensedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities And Stockholders Equity [Abstract]",
        "terseLabel": "Liabilities and Stockholders' Equity"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://plus.com/role/CondensedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://plus.com/role/CondensedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities Current",
        "totalLabel": "Total current liabilities",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r22",
      "r168",
      "r199",
      "r294",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r499",
      "r500",
      "r501",
      "r537",
      "r829",
      "r890",
      "r943",
      "r944"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://plus.com/role/CondensedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesFairValueAdjustment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesFairValueAdjustment",
     "crdr": "credit",
     "calculation": {
      "http://plus.com/role/CondensedStatementsOfOperationsUnaudited": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://plus.com/role/CondensedStatementsOfOperationsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities Fair Value Adjustment",
        "terseLabel": "Change in fair value of liability instruments",
        "documentation": "Amount of addition (reduction) to the amount at which a liability could be incurred (settled) in a current transaction between willing parties."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilityForUncertainTaxPositionsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilityForUncertainTaxPositionsCurrent",
     "crdr": "credit",
     "presentation": [
      "http://plus.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liability for Uncertainty in Income Taxes, Current",
        "terseLabel": "Liability for uncertain tax positions",
        "documentation": "Amount recognized for uncertainty in income taxes classified as current."
       }
      }
     },
     "auth_ref": [
      "r21"
     ]
    },
    "pstv_LiborMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://plus.com/20240331",
     "localname": "LiborMember",
     "presentation": [
      "http://plus.com/role/TermLoanObligationsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "LIBOR [Member]",
        "terseLabel": "LIBOR [Member]",
        "documentation": "LIBOR."
       }
      }
     },
     "auth_ref": []
    },
    "pstv_LicenseAgreementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://plus.com/20240331",
     "localname": "LicenseAgreementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "License Agreement [Abstract]",
        "documentation": "License agreement abstract."
       }
      }
     },
     "auth_ref": []
    },
    "pstv_LicenseAgreementDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://plus.com/20240331",
     "localname": "LicenseAgreementDisclosureTextBlock",
     "presentation": [
      "http://plus.com/role/LicenseAgreements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "License Agreement Disclosure [Text Block]",
        "terseLabel": "License Agreements",
        "documentation": "Disclosure of accounting policy for license agreement."
       }
      }
     },
     "auth_ref": []
    },
    "pstv_LincolnParkCapitalFundLLCMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://plus.com/20240331",
     "localname": "LincolnParkCapitalFundLLCMember",
     "presentation": [
      "http://plus.com/role/StockholdersEquityCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lincoln Park Capital Fund L L C [Member]",
        "terseLabel": "Lincoln Park Capital Fund, LLC [Member]",
        "documentation": "Lincoln park capital fund, LLC."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LineOfCreditFacilityInterestRateDuringPeriod": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LineOfCreditFacilityInterestRateDuringPeriod",
     "presentation": [
      "http://plus.com/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Line of Credit Facility, Interest Rate During Period",
        "terseLabel": "Line of credit facility, interest rate",
        "documentation": "The effective interest rate during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    },
    "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacity",
     "crdr": "credit",
     "presentation": [
      "http://plus.com/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Line of Credit Facility, Maximum Borrowing Capacity",
        "terseLabel": "Line of credit facility",
        "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    },
    "us-gaap_LineOfCreditFacilityPeriodicPayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LineOfCreditFacilityPeriodicPayment",
     "crdr": "debit",
     "presentation": [
      "http://plus.com/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Line of Credit Facility, Periodic Payment",
        "terseLabel": "Line of credit facility, periodic payment",
        "documentation": "Amount of the required periodic payments of both interest and principal."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    },
    "pstv_LiquidityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://plus.com/20240331",
     "localname": "LiquidityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Liquidity [Abstract]",
        "documentation": "Liquidity Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "srt_LitigationCaseAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "LitigationCaseAxis",
     "presentation": [
      "http://plus.com/role/CommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Litigation Case [Axis]",
        "terseLabel": "Litigation Case"
       }
      }
     },
     "auth_ref": []
    },
    "srt_LitigationCaseTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "LitigationCaseTypeDomain",
     "presentation": [
      "http://plus.com/role/CommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Litigation Case Type [Domain]",
        "terseLabel": "Litigation Case"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LitigationSettlementExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LitigationSettlementExpense",
     "crdr": "debit",
     "presentation": [
      "http://plus.com/role/CommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Litigation Settlement Expense",
        "terseLabel": "Litigation settlement, expense",
        "documentation": "Amount of litigation expense, including but not limited to legal, forensic, accounting, and investigative fees."
       }
      }
     },
     "auth_ref": []
    },
    "pstv_LoanAndSecurityAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://plus.com/20240331",
     "localname": "LoanAndSecurityAgreementMember",
     "presentation": [
      "http://plus.com/role/TermLoanObligationsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loan And Security Agreement [Member]",
        "terseLabel": "Loan and Security Agreement [Member]",
        "documentation": "Loan and security agreement."
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://plus.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongTermDebtCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermDebtCurrent",
     "crdr": "credit",
     "calculation": {
      "http://plus.com/role/CondensedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 14.0
      }
     },
     "presentation": [
      "http://plus.com/role/CondensedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long Term Debt Current",
        "terseLabel": "Term loan obligation, current",
        "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as current. Excludes lease obligation."
       }
      }
     },
     "auth_ref": [
      "r175"
     ]
    },
    "us-gaap_LongTermDebtNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermDebtNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://plus.com/role/CondensedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 17.0
      }
     },
     "presentation": [
      "http://plus.com/role/CondensedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long Term Debt Noncurrent",
        "terseLabel": "Term loan obligation",
        "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation."
       }
      }
     },
     "auth_ref": [
      "r176"
     ]
    },
    "pstv_LongTermDebtOutstandingThresholdAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://plus.com/20240331",
     "localname": "LongTermDebtOutstandingThresholdAmount",
     "crdr": "credit",
     "presentation": [
      "http://plus.com/role/OrganizationAndOperationsAdditionalInformationDetails",
      "http://plus.com/role/TermLoanObligationsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long Term Debt Outstanding Threshold Amount",
        "terseLabel": "Long term debt outstanding threshold amount",
        "verboseLabel": "Long term debt outstanding threshold amount",
        "documentation": "Long term debt outstanding threshold amount."
       }
      }
     },
     "auth_ref": []
    },
    "pstv_LoremVascularPteLtdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://plus.com/20240331",
     "localname": "LoremVascularPteLtdMember",
     "presentation": [
      "http://plus.com/role/CommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lorem Vascular Pte Ltd [Member]",
        "terseLabel": "Lorem Vascular Pte Ltd [Member]",
        "documentation": "Lorem Vascular, Pte. Ltd."
       }
      }
     },
     "auth_ref": []
    },
    "pstv_MaintainMinimumMarketValueOfListedSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://plus.com/20240331",
     "localname": "MaintainMinimumMarketValueOfListedSecurities",
     "crdr": "debit",
     "presentation": [
      "http://plus.com/role/LiquidityAndGoingConcernAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maintain Minimum Market Value of Listed Securities",
        "terseLabel": "Maintain minimum market value of listed securities",
        "documentation": "Maintain minimum market value of listed securities"
       }
      }
     },
     "auth_ref": []
    },
    "pstv_MasterServicesAgreementDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://plus.com/20240331",
     "localname": "MasterServicesAgreementDate",
     "presentation": [
      "http://plus.com/role/CommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Master Services Agreement Date",
        "terseLabel": "Master service agreement date",
        "documentation": "Master services agreement date."
       }
      }
     },
     "auth_ref": []
    },
    "pstv_MasterServicesAgreementInitialTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://plus.com/20240331",
     "localname": "MasterServicesAgreementInitialTerm",
     "presentation": [
      "http://plus.com/role/CommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Master Services Agreement Initial Term",
        "terseLabel": "Master services agreement initial term",
        "documentation": "Master services agreement initial term."
       }
      }
     },
     "auth_ref": []
    },
    "pstv_MasterServicesAgreementTermsDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://plus.com/20240331",
     "localname": "MasterServicesAgreementTermsDescription",
     "presentation": [
      "http://plus.com/role/CommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Master Services Agreement Terms Description",
        "terseLabel": "Master services agreement terms, Description",
        "documentation": "Master services agreement Terms description."
       }
      }
     },
     "auth_ref": []
    },
    "pstv_MaximumGrantAmountToBeReceivedAsPerGrantContract": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://plus.com/20240331",
     "localname": "MaximumGrantAmountToBeReceivedAsPerGrantContract",
     "crdr": "debit",
     "presentation": [
      "http://plus.com/role/GrantRevenueAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum Grant Amount to be Received as per Grant Contract",
        "terseLabel": "Maximum grant amount to be received as per grant contract",
        "documentation": "Maximum grant amount to be received as per grant contract."
       }
      }
     },
     "auth_ref": []
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MaximumMember",
     "presentation": [
      "http://plus.com/role/BasisOfPresentationAndNewAccountingStandardsAdditionalInformationDetails",
      "http://plus.com/role/EmployeeBenefitPlanAdditionalInformationDetails",
      "http://plus.com/role/IncomeTaxesAdditionalInformationDetails",
      "http://plus.com/role/OrganizationAndOperationsAdditionalInformationDetails",
      "http://plus.com/role/StockBasedCompensationAdditionalInformationDetails",
      "http://plus.com/role/StockholdersEquityCommonStockDetails",
      "http://plus.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://plus.com/role/TermLoanObligationsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum [Member]"
       }
      }
     },
     "auth_ref": [
      "r327",
      "r328",
      "r329",
      "r330",
      "r414",
      "r610",
      "r650",
      "r695",
      "r696",
      "r752",
      "r754",
      "r756",
      "r757",
      "r766",
      "r789",
      "r790",
      "r803",
      "r812",
      "r823",
      "r831",
      "r892",
      "r945",
      "r946",
      "r947",
      "r948",
      "r949",
      "r950"
     ]
    },
    "pstv_MaximumValueOfSharesToBeIssuedUnderAgreement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://plus.com/20240331",
     "localname": "MaximumValueOfSharesToBeIssuedUnderAgreement",
     "crdr": "credit",
     "presentation": [
      "http://plus.com/role/StockholdersEquityCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum Value of Shares to be Issued Under Agreement",
        "terseLabel": "Maximum value of shares to be issued under agreement",
        "documentation": "Maximum value of shares to be issued under agreement."
       }
      }
     },
     "auth_ref": []
    },
    "pstv_May2024PrivatePlacementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://plus.com/20240331",
     "localname": "May2024PrivatePlacementMember",
     "presentation": [
      "http://plus.com/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "May 2024 Private Placement [Member]",
        "documentation": "May 2024 Private Placement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "pstv_MedidataSolutionsIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://plus.com/20240331",
     "localname": "MedidataSolutionsIncMember",
     "presentation": [
      "http://plus.com/role/CommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Medidata Solutions Inc [Member]",
        "terseLabel": "Medidata Solutions, Inc. [Member]",
        "documentation": "Medidata solutions, inc."
       }
      }
     },
     "auth_ref": []
    },
    "pstv_MinimumLiquidityCovenantAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://plus.com/20240331",
     "localname": "MinimumLiquidityCovenantAmount",
     "crdr": "debit",
     "presentation": [
      "http://plus.com/role/TermLoanObligationsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum Liquidity Covenant Amount",
        "terseLabel": "Minimum liquidity covenant",
        "documentation": "Minimum liquidity covenant amount."
       }
      }
     },
     "auth_ref": []
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MinimumMember",
     "presentation": [
      "http://plus.com/role/BasisOfPresentationAndNewAccountingStandardsAdditionalInformationDetails",
      "http://plus.com/role/OrganizationAndOperationsAdditionalInformationDetails",
      "http://plus.com/role/StockBasedCompensationAdditionalInformationDetails",
      "http://plus.com/role/StockholdersEquityCommonStockDetails",
      "http://plus.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://plus.com/role/TermLoanObligationsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum [Member]"
       }
      }
     },
     "auth_ref": [
      "r327",
      "r328",
      "r329",
      "r330",
      "r414",
      "r610",
      "r650",
      "r695",
      "r696",
      "r752",
      "r754",
      "r756",
      "r757",
      "r766",
      "r789",
      "r790",
      "r803",
      "r812",
      "r823",
      "r831",
      "r892",
      "r945",
      "r946",
      "r947",
      "r948",
      "r949",
      "r950"
     ]
    },
    "us-gaap_MoneyMarketFundsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MoneyMarketFundsMember",
     "presentation": [
      "http://plus.com/role/FairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money Market [Member]",
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities."
       }
      }
     },
     "auth_ref": [
      "r896"
     ]
    },
    "pstv_NanoTxLicensesAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://plus.com/20240331",
     "localname": "NanoTxLicensesAgreementMember",
     "presentation": [
      "http://plus.com/role/LicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nano Tx Licenses Agreement [Member]",
        "terseLabel": "Nano Tx Licenses Agreement [Member]",
        "documentation": "Nano Tx license agreement Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://plus.com/role/CondensedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 21.0
      }
     },
     "presentation": [
      "http://plus.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided By Used In Financing Activities",
        "totalLabel": "Net cash (used in) provided by financing activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r192"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://plus.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided By Used In Financing Activities [Abstract]",
        "terseLabel": "Cash flows used in/provided by financing activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://plus.com/role/CondensedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 16.0
      }
     },
     "presentation": [
      "http://plus.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided By Used In Investing Activities",
        "totalLabel": "Net cash used in investing activities",
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r192"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://plus.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided By Used In Investing Activities [Abstract]",
        "terseLabel": "Cash flows used in investing activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://plus.com/role/CondensedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://plus.com/role/CondensedStatementsOfCashFlowsUnaudited",
      "http://plus.com/role/LiquidityAndGoingConcernAdditionalInformationDetails",
      "http://plus.com/role/OrganizationAndOperationsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities",
        "terseLabel": "Net cash used in operating activities",
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r109",
      "r110",
      "r111"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://plus.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided By Used In Operating Activities [Abstract]",
        "terseLabel": "Cash flows used in operating activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://plus.com/role/CondensedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 4.0
      },
      "http://plus.com/role/CondensedStatementsOfOperationsUnaudited": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://plus.com/role/CondensedStatementsOfCashFlowsUnaudited",
      "http://plus.com/role/CondensedStatementsOfOperationsUnaudited",
      "http://plus.com/role/CondensedStatementsOfStockholdersEquityDeficitUnaudited",
      "http://plus.com/role/LiquidityAndGoingConcernAdditionalInformationDetails",
      "http://plus.com/role/OrganizationAndOperationsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss) Attributable to Parent",
        "totalLabel": "Net loss",
        "terseLabel": "Net loss",
        "verboseLabel": "Net loss",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r100",
      "r111",
      "r141",
      "r166",
      "r182",
      "r183",
      "r187",
      "r199",
      "r207",
      "r211",
      "r212",
      "r213",
      "r214",
      "r217",
      "r218",
      "r226",
      "r237",
      "r251",
      "r255",
      "r257",
      "r294",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r526",
      "r537",
      "r640",
      "r725",
      "r743",
      "r744",
      "r801",
      "r840",
      "r890"
     ]
    },
    "pstv_NetOperatingLossAndResearchAndDevelopmentTaxCreditCarryForwardsToOffsetFutureTaxableIncomePeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://plus.com/20240331",
     "localname": "NetOperatingLossAndResearchAndDevelopmentTaxCreditCarryForwardsToOffsetFutureTaxableIncomePeriod",
     "presentation": [
      "http://plus.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Operating Loss And Research And Development Tax Credit Carry Forwards To Offset Future Taxable Income Period",
        "terseLabel": "Period of net operating loss and R&amp;D tax credit carry forwards to offset future taxable income",
        "documentation": "Refers to the period of net operating loss and R&amp;D tax credit carry forwards to offset future taxable income."
       }
      }
     },
     "auth_ref": []
    },
    "pstv_NetOperatingLossCarryforward": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://plus.com/20240331",
     "localname": "NetOperatingLossCarryforward",
     "crdr": "credit",
     "presentation": [
      "http://plus.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Operating Loss Carryforward",
        "terseLabel": "Net operating losses",
        "documentation": "Net operating loss carryforward."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Standards Update and Change in Accounting Principle [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems",
     "presentation": [
      "http://plus.com/role/BasisOfPresentationAndNewAccountingStandardsAdditionalInformationDetails",
      "http://plus.com/role/LiquidityAndGoingConcernAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r160",
      "r161",
      "r162",
      "r163",
      "r164",
      "r205",
      "r207",
      "r208",
      "r209",
      "r210",
      "r213",
      "r220",
      "r233",
      "r262",
      "r263",
      "r297",
      "r298",
      "r299",
      "r300",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r320",
      "r453",
      "r454",
      "r455",
      "r483",
      "r484",
      "r485",
      "r486",
      "r494",
      "r495",
      "r496",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r516",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527",
      "r535",
      "r536",
      "r539",
      "r540",
      "r541",
      "r542",
      "r550",
      "r551",
      "r555",
      "r556",
      "r557",
      "r558",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r612",
      "r613",
      "r614",
      "r651",
      "r652",
      "r653",
      "r654",
      "r655",
      "r656",
      "r657",
      "r658",
      "r659",
      "r660",
      "r661",
      "r662",
      "r665"
     ]
    },
    "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleTable",
     "presentation": [
      "http://plus.com/role/BasisOfPresentationAndNewAccountingStandardsAdditionalInformationDetails",
      "http://plus.com/role/LiquidityAndGoingConcernAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Standards Update and Change in Accounting Principle [Table]",
        "documentation": "Summarization of the changes in an accounting principle or a new accounting pronouncement, including the line items affected by the change and the financial effects of the change on those particular line items."
       }
      }
     },
     "auth_ref": [
      "r39",
      "r160",
      "r161",
      "r162",
      "r163",
      "r164",
      "r205",
      "r207",
      "r208",
      "r209",
      "r210",
      "r213",
      "r220",
      "r233",
      "r262",
      "r263",
      "r297",
      "r298",
      "r299",
      "r300",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r320",
      "r453",
      "r454",
      "r455",
      "r483",
      "r484",
      "r485",
      "r486",
      "r494",
      "r495",
      "r496",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r516",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527",
      "r535",
      "r536",
      "r539",
      "r540",
      "r541",
      "r542",
      "r550",
      "r551",
      "r555",
      "r556",
      "r557",
      "r558",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r612",
      "r613",
      "r614",
      "r651",
      "r652",
      "r653",
      "r654",
      "r655",
      "r656",
      "r657",
      "r658",
      "r659",
      "r660",
      "r661",
      "r662",
      "r665"
     ]
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://plus.com/role/BasisOfPresentationAndNewAccountingStandardsPolicies",
      "http://plus.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recently Issued Accounting Pronouncements",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://plus.com/role/CondensedStatementsOfOperationsUnaudited": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://plus.com/role/CondensedStatementsOfOperationsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonoperating Income Expense",
        "totalLabel": "Total other expense",
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)."
       }
      }
     },
     "auth_ref": [
      "r105"
     ]
    },
    "pstv_NumberOfMaximumCommonSharesCanBeResale": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://plus.com/20240331",
     "localname": "NumberOfMaximumCommonSharesCanBeResale",
     "presentation": [
      "http://plus.com/role/StockholdersEquityCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of Maximum Common Shares Can Be Resale",
        "terseLabel": "Number of maximum common shares can be resale",
        "documentation": "Number of maximum common shares can be resale."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NumberOfOperatingSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NumberOfOperatingSegments",
     "presentation": [
      "http://plus.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of Operating Segments",
        "terseLabel": "Number of operating segment",
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues."
       }
      }
     },
     "auth_ref": [
      "r874"
     ]
    },
    "pstv_NumberOfPreferredStockSharesExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://plus.com/20240331",
     "localname": "NumberOfPreferredStockSharesExercised",
     "presentation": [
      "http://plus.com/role/StockholdersEquityPreferredStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number Of Preferred Stock Shares Exercised",
        "terseLabel": "Number of preferred stock, shares converted",
        "documentation": "Number Of Preferred Stock Shares Exercised."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NumberOfReportingUnits": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NumberOfReportingUnits",
     "presentation": [
      "http://plus.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of Reporting Units",
        "terseLabel": "Number of reporting units",
        "documentation": "Number of reporting units tested for impairment of goodwill. A reporting unit is an operating segment or one level below an operating segment."
       }
      }
     },
     "auth_ref": []
    },
    "pstv_NumberOfVotesPerShare": {
     "xbrltype": "integerItemType",
     "nsuri": "http://plus.com/20240331",
     "localname": "NumberOfVotesPerShare",
     "presentation": [
      "http://plus.com/role/StockholdersEquityPreferredStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number Of Votes Per Share",
        "documentation": "Number of votes per share."
       }
      }
     },
     "auth_ref": []
    },
    "pstv_NumberOfWarrantsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://plus.com/20240331",
     "localname": "NumberOfWarrantsExercised",
     "presentation": [
      "http://plus.com/role/StockholdersEquityWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number Of Warrants Exercised",
        "terseLabel": "Number of warrants exercised",
        "documentation": "Number of warrants exercised"
       }
      }
     },
     "auth_ref": []
    },
    "pstv_OfficeAndComputerEquipmentGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://plus.com/20240331",
     "localname": "OfficeAndComputerEquipmentGross",
     "crdr": "debit",
     "calculation": {
      "http://plus.com/role/CompositionOfCertainFinancialStatementCaptionsPropertyAndEquipmentNetDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentGross",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://plus.com/role/CompositionOfCertainFinancialStatementCaptionsPropertyAndEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Office And Computer Equipment Gross",
        "terseLabel": "Office and computer equipment",
        "documentation": "The gross amount of office and computer equipment cost as of the balance sheet date."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingExpenses",
     "crdr": "debit",
     "calculation": {
      "http://plus.com/role/CondensedStatementsOfOperationsUnaudited": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://plus.com/role/CondensedStatementsOfOperationsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://plus.com/role/CondensedStatementsOfOperationsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://plus.com/role/CondensedStatementsOfOperationsUnaudited": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://plus.com/role/CondensedStatementsOfOperationsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Income Loss",
        "totalLabel": "Operating loss",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r237",
      "r251",
      "r255",
      "r257",
      "r801"
     ]
    },
    "us-gaap_OperatingLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseCost",
     "crdr": "debit",
     "calculation": {
      "http://plus.com/role/CommitmentsAndContingenciesSummaryOfLeaseCostsDetails": {
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://plus.com/role/CommitmentsAndContingenciesSummaryOfLeaseCostsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Cost",
        "terseLabel": "Operating lease expense",
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability."
       }
      }
     },
     "auth_ref": [
      "r564",
      "r828"
     ]
    },
    "us-gaap_OperatingLeaseExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseExpense",
     "crdr": "debit",
     "presentation": [
      "http://plus.com/role/CommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease Expense",
        "terseLabel": "Rent expense",
        "documentation": "Amount of operating lease expense. Excludes sublease income."
       }
      }
     },
     "auth_ref": [
      "r938"
     ]
    },
    "us-gaap_OperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiability",
     "crdr": "credit",
     "calculation": {
      "http://plus.com/role/CommitmentsAndContingenciesSummaryOfFutureMinimumAnnualLeasePaymentsUnderOperatingLeasesDetailsAlternate1": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://plus.com/role/CommitmentsAndContingenciesAdditionalInformationDetails",
      "http://plus.com/role/CommitmentsAndContingenciesSummaryOfFutureMinimumAnnualLeasePaymentsUnderOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease Liability",
        "terseLabel": "Lease liability",
        "verboseLabel": "Present value of obligations under leases",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease."
       }
      }
     },
     "auth_ref": [
      "r560"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://plus.com/role/CondensedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://plus.com/role/CommitmentsAndContingenciesSummaryOfFutureMinimumAnnualLeasePaymentsUnderOperatingLeasesDetails",
      "http://plus.com/role/CondensedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease Liability Current",
        "terseLabel": "Operating lease liability",
        "negatedLabel": "Less: current portion",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r560"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://plus.com/role/CondensedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 16.0
      }
     },
     "presentation": [
      "http://plus.com/role/CommitmentsAndContingenciesSummaryOfFutureMinimumAnnualLeasePaymentsUnderOperatingLeasesDetails",
      "http://plus.com/role/CondensedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease Liability Noncurrent",
        "terseLabel": "Noncurrent operating lease liability",
        "verboseLabel": "Noncurrent operating lease liability",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r560"
     ]
    },
    "us-gaap_OperatingLeasePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeasePayments",
     "crdr": "credit",
     "calculation": {
      "http://plus.com/role/CommitmentsAndContingenciesSummaryOfLeaseCostsDetails": {
       "parentTag": "pstv_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://plus.com/role/CommitmentsAndContingenciesSummaryOfLeaseCostsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease Payments",
        "terseLabel": "Operating cash used for operating leases",
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use."
       }
      }
     },
     "auth_ref": [
      "r561",
      "r565"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://plus.com/role/CondensedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://plus.com/role/CommitmentsAndContingenciesAdditionalInformationDetails",
      "http://plus.com/role/CondensedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease Right Of Use Asset",
        "terseLabel": "Operating lease right-use-of assets",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r559"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense",
     "crdr": "debit",
     "calculation": {
      "http://plus.com/role/CondensedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://plus.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Right-of-Use Asset, Periodic Reduction",
        "terseLabel": "Reduction in the carrying amount of operating lease right-of-use assets",
        "documentation": "Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease."
       }
      }
     },
     "auth_ref": [
      "r864"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "presentation": [
      "http://plus.com/role/CommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease Weighted Average Discount Rate Percent",
        "terseLabel": "Operating lease, weighted average discount rate",
        "documentation": "Weighted average discount rate for operating lease calculated at point in time."
       }
      }
     },
     "auth_ref": [
      "r568",
      "r828"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "presentation": [
      "http://plus.com/role/CommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease Weighted Average Remaining Lease Term1",
        "terseLabel": "Operating lease, weighted average remaining term",
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r567",
      "r828"
     ]
    },
    "pstv_OperatingLeasesExpiryYear": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://plus.com/20240331",
     "localname": "OperatingLeasesExpiryYear",
     "presentation": [
      "http://plus.com/role/CommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Leases Expiry Year",
        "terseLabel": "Operating leases expiry year",
        "documentation": "Operating leases, expiry year."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLossCarryforwards",
     "crdr": "debit",
     "presentation": [
      "http://plus.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Loss Carryforwards",
        "terseLabel": "Tax loss carryforwards",
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r69"
     ]
    },
    "pstv_OperatingLossCarryforwardsExpirationDates1": {
     "xbrltype": "stringItemType",
     "nsuri": "http://plus.com/20240331",
     "localname": "OperatingLossCarryforwardsExpirationDates1",
     "presentation": [
      "http://plus.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Loss Carryforwards Expiration Dates1",
        "terseLabel": "Net operating loss carryforwards, Expire date",
        "documentation": "The expiration date of each operating loss carryforward included in total operating loss carryforwards, or the applicable range of such expiration dates."
       }
      }
     },
     "auth_ref": []
    },
    "pstv_OptionForExclusiveWorldwideLicense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://plus.com/20240331",
     "localname": "OptionForExclusiveWorldwideLicense",
     "crdr": "credit",
     "presentation": [
      "http://plus.com/role/LicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Option For Exclusive Worldwide License",
        "terseLabel": "Option for exclusive worldwide license",
        "documentation": "Option for exclusive worldwide license."
       }
      }
     },
     "auth_ref": []
    },
    "pstv_OptionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://plus.com/20240331",
     "localname": "OptionsMember",
     "presentation": [
      "http://plus.com/role/LossPerShareScheduleOfAntidilutiveSecuritiesExcludedFromDilutedIncomeLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Options [Member]",
        "terseLabel": "Outstanding Stock Options [Member]",
        "documentation": "Options."
       }
      }
     },
     "auth_ref": []
    },
    "pstv_OrganizationAndOperationsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://plus.com/20240331",
     "localname": "OrganizationAndOperationsLineItems",
     "presentation": [
      "http://plus.com/role/OrganizationAndOperationsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization and Operations [Line Items]",
        "documentation": "Organization and operations."
       }
      }
     },
     "auth_ref": []
    },
    "pstv_OrganizationAndOperationsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://plus.com/20240331",
     "localname": "OrganizationAndOperationsTable",
     "presentation": [
      "http://plus.com/role/OrganizationAndOperationsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization and Operations [Table]",
        "documentation": "Organization and Operations [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "presentation": [
      "http://plus.com/role/OrganizationAndOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "terseLabel": "Organization and Operations",
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure."
       }
      }
     },
     "auth_ref": [
      "r88",
      "r131",
      "r663",
      "r664"
     ]
    },
    "us-gaap_OtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://plus.com/role/CondensedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      },
      "http://plus.com/role/CompositionOfCertainFinancialStatementCaptionsOtherCurrentAssetsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://plus.com/role/CompositionOfCertainFinancialStatementCaptionsOtherCurrentAssetsDetails",
      "http://plus.com/role/CondensedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Assets, Current",
        "terseLabel": "Other current assets",
        "totalLabel": "Total other current assets",
        "documentation": "Amount of current assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r180",
      "r829"
     ]
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherAssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://plus.com/role/CondensedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://plus.com/role/CondensedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Assets Noncurrent",
        "terseLabel": "Other assets",
        "documentation": "Amount of noncurrent assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r173"
     ]
    },
    "us-gaap_OtherIncomeAndExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherIncomeAndExpensesAbstract",
     "presentation": [
      "http://plus.com/role/CondensedStatementsOfOperationsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Income And Expenses [Abstract]",
        "terseLabel": "Other income (expense):"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherIntangibleAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherIntangibleAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://plus.com/role/CondensedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://plus.com/role/CondensedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Intangible Assets Net",
        "terseLabel": "Intangible assets, net",
        "documentation": "Amount after accumulated amortization of finite-lived and indefinite-lived intangible assets classified as other."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherPrepaidExpenseCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherPrepaidExpenseCurrent",
     "crdr": "debit",
     "calculation": {
      "http://plus.com/role/CompositionOfCertainFinancialStatementCaptionsOtherCurrentAssetsDetails": {
       "parentTag": "us-gaap_OtherAssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://plus.com/role/CompositionOfCertainFinancialStatementCaptionsOtherCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Prepaid Expense, Current",
        "terseLabel": "Prepaid services",
        "documentation": "Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r861",
      "r881"
     ]
    },
    "pstv_OutstandingWarrantsAndOptionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://plus.com/20240331",
     "localname": "OutstandingWarrantsAndOptionsMember",
     "presentation": [
      "http://plus.com/role/BasisOfPresentationAndNewAccountingStandardsAdditionalInformationDetails",
      "http://plus.com/role/OrganizationAndOperationsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Warrants and Options [Member]",
        "terseLabel": "Outstanding Warrants and Options [Member]",
        "documentation": "Outstanding warrants and options."
       }
      }
     },
     "auth_ref": []
    },
    "pstv_PaymentForTechTransferAndValidationFee": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://plus.com/20240331",
     "localname": "PaymentForTechTransferAndValidationFee",
     "crdr": "credit",
     "presentation": [
      "http://plus.com/role/LicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payment For Tech Transfer And Validation Fee",
        "terseLabel": "Payment for tech transfer and validation fee",
        "documentation": "Payment for tech transfer and validation fee."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsForLoans": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsForLoans",
     "crdr": "credit",
     "presentation": [
      "http://plus.com/role/TermLoanObligationsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments For Loans",
        "terseLabel": "Payments for principal, interest and fees",
        "documentation": "Cash payments for and related to principal collection on loans related to operating activities."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_PaymentsForRepurchaseOfEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsForRepurchaseOfEquity",
     "crdr": "credit",
     "calculation": {
      "http://plus.com/role/CondensedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 25.0
      }
     },
     "presentation": [
      "http://plus.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments for Repurchase of Equity",
        "negatedLabel": "Purchase of treasury stock",
        "documentation": "The cash outflow to reacquire common and preferred stock."
       }
      }
     },
     "auth_ref": [
      "r32",
      "r671"
     ]
    },
    "us-gaap_PaymentsForRoyalties": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsForRoyalties",
     "crdr": "credit",
     "presentation": [
      "http://plus.com/role/LicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments For Royalties",
        "terseLabel": "License fee payment in cash",
        "documentation": "The amount of cash paid for royalties during the current period."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsOfStockIssuanceCosts",
     "crdr": "credit",
     "calculation": {
      "http://plus.com/role/CondensedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 24.0
      }
     },
     "presentation": [
      "http://plus.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments of Stock Issuance Costs",
        "negatedLabel": "Payment of offering costs related to sale of common stock",
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security."
       }
      }
     },
     "auth_ref": [
      "r31"
     ]
    },
    "us-gaap_PaymentsToAcquireProductiveAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsToAcquireProductiveAssets",
     "crdr": "credit",
     "presentation": [
      "http://plus.com/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments to Acquire Productive Assets",
        "terseLabel": "Payments to acquire assets",
        "documentation": "The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets."
       }
      }
     },
     "auth_ref": [
      "r143",
      "r931",
      "r932",
      "r933"
     ]
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://plus.com/role/CondensedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 19.0
      }
     },
     "presentation": [
      "http://plus.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments To Acquire Property Plant And Equipment",
        "negatedLabel": "Purchases of property and equipment",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r108"
     ]
    },
    "pstv_PaymentsToAcquirePropertyPlantAndEquipmentAndIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://plus.com/20240331",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipmentAndIntangibleAssets",
     "crdr": "credit",
     "calculation": {
      "http://plus.com/role/CondensedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 17.0
      }
     },
     "presentation": [
      "http://plus.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments To Acquire Property Plant And Equipment And Intangible Assets",
        "negatedLabel": "Purchases of property and equipment and intangible assets",
        "documentation": "Payments to acquire property plant and equipment and intangible assets."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsToAcquireShortTermInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsToAcquireShortTermInvestments",
     "crdr": "credit",
     "calculation": {
      "http://plus.com/role/CondensedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 20.0
      }
     },
     "presentation": [
      "http://plus.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments to Acquire Short-Term Investments",
        "negatedLabel": "Purchase of short-term investments",
        "documentation": "The cash outflow for securities or other assets acquired, which qualify for treatment as an investing activity and are to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term."
       }
      }
     },
     "auth_ref": [
      "r107"
     ]
    },
    "pstv_PercentageIssuanceOfCommonStock": {
     "xbrltype": "percentItemType",
     "nsuri": "http://plus.com/20240331",
     "localname": "PercentageIssuanceOfCommonStock",
     "presentation": [
      "http://plus.com/role/StockholdersEquityCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Percentage Issuance Of Common Stock",
        "terseLabel": "Percentage issuance of common stock",
        "documentation": "Percentage issuance of common stock."
       }
      }
     },
     "auth_ref": []
    },
    "pstv_PercentageOfAggregateAmountOfProceedsAwardedUnderCpritGrant": {
     "xbrltype": "percentItemType",
     "nsuri": "http://plus.com/20240331",
     "localname": "PercentageOfAggregateAmountOfProceedsAwardedUnderCpritGrant",
     "presentation": [
      "http://plus.com/role/GrantRevenueAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Percentage Of Aggregate Amount Of Proceeds Awarded Under CPRIT Grant",
        "terseLabel": "Percentage of aggregate amount of proceeds awarded under CPRIT grant",
        "documentation": "Percentage of aggregate amount of proceeds awarded under CPRIT grant."
       }
      }
     },
     "auth_ref": []
    },
    "pstv_PercentageOfCommissionOnGrossProceedsFromSaleOfCommonStock": {
     "xbrltype": "percentItemType",
     "nsuri": "http://plus.com/20240331",
     "localname": "PercentageOfCommissionOnGrossProceedsFromSaleOfCommonStock",
     "presentation": [
      "http://plus.com/role/StockholdersEquityCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Percentage of Commission on Gross Proceeds from Sale of Common Stock",
        "terseLabel": "Percentage of commission on gross proceeds from sale of common stock",
        "documentation": "Percentage of commission on gross proceeds from sale of common stock."
       }
      }
     },
     "auth_ref": []
    },
    "pstv_PercentageOfGrantProceedsWithInterestNotExceedAnnually": {
     "xbrltype": "percentItemType",
     "nsuri": "http://plus.com/20240331",
     "localname": "PercentageOfGrantProceedsWithInterestNotExceedAnnually",
     "presentation": [
      "http://plus.com/role/GrantRevenueAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Percentage Of Grant Proceeds With Interest Not Exceed Annually",
        "terseLabel": "Percentage of grant proceeds with interest not exceed annually",
        "documentation": "Percentage of grant proceeds with interest not exceed annually."
       }
      }
     },
     "auth_ref": []
    },
    "pstv_PercentageOfNetOperatingLossCarryforwardsAvailableForOffsettingAgainstFutureTaxableIncome": {
     "xbrltype": "percentItemType",
     "nsuri": "http://plus.com/20240331",
     "localname": "PercentageOfNetOperatingLossCarryforwardsAvailableForOffsettingAgainstFutureTaxableIncome",
     "presentation": [
      "http://plus.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Percentage Of Net Operating Loss Carryforwards Available For Offsetting Against Future Taxable Income",
        "terseLabel": "Percentage of federal net operating losses used to offset of future taxable income",
        "documentation": "Percentage of net operating loss carryforwards available for offsetting against future taxable income."
       }
      }
     },
     "auth_ref": []
    },
    "pstv_PercentageOfNonDilutiveMonetaryAwardsRequiredToPay": {
     "xbrltype": "percentItemType",
     "nsuri": "http://plus.com/20240331",
     "localname": "PercentageOfNonDilutiveMonetaryAwardsRequiredToPay",
     "presentation": [
      "http://plus.com/role/LicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Percentage of Non-dilutive Monetary awards Required to Pay",
        "terseLabel": "Percentage of non-dilutive monetary awards required to pay",
        "documentation": "Percentage of non-dilutive monetary awards required to pay."
       }
      }
     },
     "auth_ref": []
    },
    "pstv_PeriodExercisableFromTheDateOfIssuance": {
     "xbrltype": "durationItemType",
     "nsuri": "http://plus.com/20240331",
     "localname": "PeriodExercisableFromTheDateOfIssuance",
     "presentation": [
      "http://plus.com/role/StockholdersEquityCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Period Exercisable From The Date Of Issuance",
        "terseLabel": "Period exercisable from the date of issuance",
        "documentation": "Refers to the period exercisable from the date of issuance."
       }
      }
     },
     "auth_ref": []
    },
    "pstv_PeriodForMaterialChangesOfLiabilityForUncertainTaxBenefits": {
     "xbrltype": "durationItemType",
     "nsuri": "http://plus.com/20240331",
     "localname": "PeriodForMaterialChangesOfLiabilityForUncertainTaxBenefits",
     "presentation": [
      "http://plus.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Period For Material Changes Of Liability For Uncertain Tax Benefits",
        "terseLabel": "Period for material changes of liability for uncertain tax benefits",
        "documentation": "Refers to period for material changes of liability for uncertain tax benefits."
       }
      }
     },
     "auth_ref": []
    },
    "pstv_PershingCreditFacilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://plus.com/20240331",
     "localname": "PershingCreditFacilityMember",
     "presentation": [
      "http://plus.com/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pershing Credit Facility [Member]",
        "documentation": "Pershing Credit Facility [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "pstv_PiramalPharmaSolutionsIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://plus.com/20240331",
     "localname": "PiramalPharmaSolutionsIncMember",
     "presentation": [
      "http://plus.com/role/CommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Piramal Pharma Solutions Inc [Member]",
        "terseLabel": "Piramal Pharma Solutions, Inc. [Member]",
        "documentation": "Piramal pharma solutions inc."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://plus.com/role/BasisOfPresentationAndNewAccountingStandardsAdditionalInformationDetails",
      "http://plus.com/role/OrganizationAndOperationsAdditionalInformationDetails",
      "http://plus.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r897",
      "r898",
      "r899",
      "r900",
      "r901",
      "r902",
      "r903",
      "r904",
      "r905",
      "r906",
      "r907",
      "r908",
      "r909",
      "r910",
      "r911",
      "r912",
      "r913",
      "r914",
      "r915",
      "r916",
      "r917",
      "r918",
      "r919",
      "r920",
      "r921",
      "r922"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://plus.com/role/BasisOfPresentationAndNewAccountingStandardsAdditionalInformationDetails",
      "http://plus.com/role/OrganizationAndOperationsAdditionalInformationDetails",
      "http://plus.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name",
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r897",
      "r898",
      "r899",
      "r900",
      "r901",
      "r902",
      "r903",
      "r904",
      "r905",
      "r906",
      "r907",
      "r908",
      "r909",
      "r910",
      "r911",
      "r912",
      "r913",
      "r914",
      "r915",
      "r916",
      "r917",
      "r918",
      "r919",
      "r920",
      "r921",
      "r922"
     ]
    },
    "pstv_PreClinicalResearchStudyObligationsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://plus.com/20240331",
     "localname": "PreClinicalResearchStudyObligationsMember",
     "presentation": [
      "http://plus.com/role/CommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre Clinical Research Study Obligations [Member]",
        "terseLabel": "Pre-clinical Research Study Obligations [Member]",
        "documentation": "Contractual obligation to provide funding of research and development costs over periods that initially exceed one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": []
    },
    "pstv_PreFundedWarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://plus.com/20240331",
     "localname": "PreFundedWarrantMember",
     "presentation": [
      "http://plus.com/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre Funded Warrant [Member]",
        "terseLabel": "Pre-funded Warrant [Member]",
        "documentation": "Pre Funded Warrant [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockMember",
     "presentation": [
      "http://plus.com/role/CondensedStatementsOfStockholdersEquityDeficitUnaudited",
      "http://plus.com/role/LossPerShareScheduleOfAntidilutiveSecuritiesExcludedFromDilutedIncomeLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock [Member]",
        "verboseLabel": "Preferred Stock [Member]",
        "terseLabel": "Convertible Preferred Stock [Member]",
        "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company."
       }
      }
     },
     "auth_ref": [
      "r832",
      "r833",
      "r836",
      "r837",
      "r838",
      "r839",
      "r954",
      "r957"
     ]
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockParOrStatedValuePerShare",
     "presentation": [
      "http://plus.com/role/CondensedBalanceSheetsUnauditedParenthetical",
      "http://plus.com/role/StockholdersEquityPreferredStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock Par Or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value (in dollars per share)",
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer."
       }
      }
     },
     "auth_ref": [
      "r93",
      "r370"
     ]
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockSharesAuthorized",
     "presentation": [
      "http://plus.com/role/BasisOfPresentationAndNewAccountingStandardsAdditionalInformationDetails",
      "http://plus.com/role/CondensedBalanceSheetsUnauditedParenthetical",
      "http://plus.com/role/OrganizationAndOperationsAdditionalInformationDetails",
      "http://plus.com/role/StockholdersEquityPreferredStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized (in shares)",
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r93",
      "r705"
     ]
    },
    "us-gaap_PreferredStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockSharesIssued",
     "presentation": [
      "http://plus.com/role/CondensedBalanceSheetsUnauditedParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock Shares Issued",
        "terseLabel": "Preferred stock, shares issued (in shares)",
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt."
       }
      }
     },
     "auth_ref": [
      "r93",
      "r370"
     ]
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockSharesOutstanding",
     "presentation": [
      "http://plus.com/role/CondensedBalanceSheetsUnauditedParenthetical",
      "http://plus.com/role/StockholdersEquityPreferredStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock Shares Outstanding",
        "terseLabel": "Preferred stock, shares outstanding (in shares)",
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased."
       }
      }
     },
     "auth_ref": [
      "r93",
      "r705",
      "r723",
      "r957",
      "r958"
     ]
    },
    "us-gaap_PreferredStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockValue",
     "crdr": "credit",
     "calculation": {
      "http://plus.com/role/CondensedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 20.0
      }
     },
     "presentation": [
      "http://plus.com/role/CondensedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock Value",
        "terseLabel": "Preferred stock",
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r93",
      "r633",
      "r829"
     ]
    },
    "us-gaap_PreferredStockVotingRights": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockVotingRights",
     "presentation": [
      "http://plus.com/role/StockholdersEquityPreferredStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Voting Rights",
        "terseLabel": "Preferred stock, voting rights",
        "documentation": "Description of voting rights of nonredeemable preferred stock. Includes eligibility to vote and votes per share owned. Include also, if any, unusual voting rights."
       }
      }
     },
     "auth_ref": [
      "r56",
      "r93"
     ]
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PrepaidExpenseAndOtherAssetsCurrentAbstract",
     "presentation": [
      "http://plus.com/role/CompositionOfCertainFinancialStatementCaptionsOtherCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid Expense and Other Assets, Current [Abstract]",
        "terseLabel": "Other Current Assets [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PrepaidInsurance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PrepaidInsurance",
     "crdr": "debit",
     "calculation": {
      "http://plus.com/role/CompositionOfCertainFinancialStatementCaptionsOtherCurrentAssetsDetails": {
       "parentTag": "us-gaap_OtherAssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://plus.com/role/CompositionOfCertainFinancialStatementCaptionsOtherCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid Insurance",
        "terseLabel": "Prepaid insurance",
        "documentation": "Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r796",
      "r805",
      "r881"
     ]
    },
    "us-gaap_PrivatePlacementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PrivatePlacementMember",
     "presentation": [
      "http://plus.com/role/LiquidityAndGoingConcernAdditionalInformationDetails",
      "http://plus.com/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Private Placement [Member]",
        "terseLabel": "Private Placement [Member]",
        "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "calculation": {
      "http://plus.com/role/CondensedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 23.0
      }
     },
     "presentation": [
      "http://plus.com/role/CondensedStatementsOfCashFlowsUnaudited",
      "http://plus.com/role/StockholdersEquityCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds From Issuance Of Common Stock",
        "terseLabel": "Proceeds from sale of common stock, net",
        "documentation": "The cash inflow from the additional capital contribution to the entity."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "srt_ProductOrServiceAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ProductOrServiceAxis",
     "presentation": [
      "http://plus.com/role/CondensedStatementsOfOperationsUnaudited",
      "http://plus.com/role/GrantRevenueAdditionalInformationDetails",
      "http://plus.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service"
       }
      }
     },
     "auth_ref": [
      "r258",
      "r611",
      "r644",
      "r645",
      "r646",
      "r647",
      "r648",
      "r649",
      "r793",
      "r813",
      "r830",
      "r850",
      "r888",
      "r889",
      "r894",
      "r953"
     ]
    },
    "srt_ProductsAndServicesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ProductsAndServicesDomain",
     "presentation": [
      "http://plus.com/role/CondensedStatementsOfOperationsUnaudited",
      "http://plus.com/role/GrantRevenueAdditionalInformationDetails",
      "http://plus.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service"
       }
      }
     },
     "auth_ref": [
      "r258",
      "r611",
      "r644",
      "r645",
      "r646",
      "r647",
      "r648",
      "r649",
      "r793",
      "r813",
      "r830",
      "r850",
      "r888",
      "r889",
      "r894",
      "r953"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "presentation": [
      "http://plus.com/role/CommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Lived Tangible Asset [Axis]",
        "terseLabel": "Long-Lived Tangible Asset",
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentGross",
     "crdr": "debit",
     "calculation": {
      "http://plus.com/role/CompositionOfCertainFinancialStatementCaptionsPropertyAndEquipmentNetDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://plus.com/role/CompositionOfCertainFinancialStatementCaptionsPropertyAndEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Gross",
        "totalLabel": "Property and equipment, gross",
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r115",
      "r170",
      "r639"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentImpairment": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentImpairment",
     "presentation": [
      "http://plus.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Impairment [Policy Text Block]",
        "terseLabel": "Impairment",
        "documentation": "Disclosure of accounting policy for assessing and recognizing impairments of its property, plant and equipment."
       }
      }
     },
     "auth_ref": [
      "r52"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://plus.com/role/CondensedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 5.0
      },
      "http://plus.com/role/CompositionOfCertainFinancialStatementCaptionsPropertyAndEquipmentNetDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://plus.com/role/CompositionOfCertainFinancialStatementCaptionsPropertyAndEquipmentNetDetails",
      "http://plus.com/role/CondensedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Property and equipment, net",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r630",
      "r639",
      "r829"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentNetAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentNetAbstract",
     "presentation": [
      "http://plus.com/role/CompositionOfCertainFinancialStatementCaptionsPropertyAndEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Net [Abstract]",
        "terseLabel": "Property and Equipment, net [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "presentation": [
      "http://plus.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "terseLabel": "Property and Equipment",
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r148",
      "r151",
      "r637"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "presentation": [
      "http://plus.com/role/CompositionOfCertainFinancialStatementCaptionsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Property and Equipment, net",
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "presentation": [
      "http://plus.com/role/CommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Lived Tangible Asset [Domain]",
        "terseLabel": "Long-Lived Tangible Asset",
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "auth_ref": [
      "r115"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "presentation": [
      "http://plus.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Useful Life",
        "terseLabel": "Useful lives of the assets",
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment."
       }
      }
     },
     "auth_ref": []
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RangeAxis",
     "presentation": [
      "http://plus.com/role/BasisOfPresentationAndNewAccountingStandardsAdditionalInformationDetails",
      "http://plus.com/role/EmployeeBenefitPlanAdditionalInformationDetails",
      "http://plus.com/role/GrantRevenueAdditionalInformationDetails",
      "http://plus.com/role/IncomeTaxesAdditionalInformationDetails",
      "http://plus.com/role/LiquidityAndGoingConcernAdditionalInformationDetails",
      "http://plus.com/role/OrganizationAndOperationsAdditionalInformationDetails",
      "http://plus.com/role/StockBasedCompensationAdditionalInformationDetails",
      "http://plus.com/role/StockholdersEquityCommonStockDetails",
      "http://plus.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://plus.com/role/TermLoanObligationsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "verboseLabel": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement"
       }
      }
     },
     "auth_ref": [
      "r327",
      "r328",
      "r329",
      "r330",
      "r405",
      "r414",
      "r445",
      "r446",
      "r447",
      "r586",
      "r610",
      "r650",
      "r695",
      "r696",
      "r752",
      "r754",
      "r756",
      "r757",
      "r766",
      "r789",
      "r790",
      "r803",
      "r812",
      "r823",
      "r831",
      "r834",
      "r886",
      "r892",
      "r946",
      "r947",
      "r948",
      "r949",
      "r950"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RangeMember",
     "presentation": [
      "http://plus.com/role/BasisOfPresentationAndNewAccountingStandardsAdditionalInformationDetails",
      "http://plus.com/role/EmployeeBenefitPlanAdditionalInformationDetails",
      "http://plus.com/role/GrantRevenueAdditionalInformationDetails",
      "http://plus.com/role/IncomeTaxesAdditionalInformationDetails",
      "http://plus.com/role/LiquidityAndGoingConcernAdditionalInformationDetails",
      "http://plus.com/role/OrganizationAndOperationsAdditionalInformationDetails",
      "http://plus.com/role/StockBasedCompensationAdditionalInformationDetails",
      "http://plus.com/role/StockholdersEquityCommonStockDetails",
      "http://plus.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://plus.com/role/TermLoanObligationsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "verboseLabel": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement"
       }
      }
     },
     "auth_ref": [
      "r327",
      "r328",
      "r329",
      "r330",
      "r405",
      "r414",
      "r445",
      "r446",
      "r447",
      "r586",
      "r610",
      "r650",
      "r695",
      "r696",
      "r752",
      "r754",
      "r756",
      "r757",
      "r766",
      "r789",
      "r790",
      "r803",
      "r812",
      "r823",
      "r831",
      "r834",
      "r886",
      "r892",
      "r946",
      "r947",
      "r948",
      "r949",
      "r950"
     ]
    },
    "us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward",
     "presentation": [
      "http://plus.com/role/IncomeTaxesUnrecognizedTaxBenefitsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]",
        "terseLabel": "Schedule of reconciliation of unrecognized tax benefits activity [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis",
     "presentation": [
      "http://plus.com/role/CommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Recorded Unconditional Purchase Obligation By Category Of Item Purchased [Axis]",
        "terseLabel": "Recorded Unconditional Purchase Obligation by Category of Item Purchased",
        "documentation": "Pertinent information about recorded unconditional purchase arrangements to acquire goods or services, by category of goods or services."
       }
      }
     },
     "auth_ref": [
      "r326"
     ]
    },
    "us-gaap_RecordedUnconditionalPurchaseObligationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RecordedUnconditionalPurchaseObligationLineItems",
     "presentation": [
      "http://plus.com/role/CommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Recorded Unconditional Purchase Obligation [Line Items]",
        "terseLabel": "Recorded Unconditional Purchase Obligation [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r326"
     ]
    },
    "us-gaap_RecordedUnconditionalPurchaseObligationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RecordedUnconditionalPurchaseObligationTable",
     "presentation": [
      "http://plus.com/role/CommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Recorded Unconditional Purchase Obligation [Table]",
        "terseLabel": "Recorded Unconditional Purchase Obligation [Table]",
        "documentation": "Describes each recorded unconditional purchase obligation arrangement to purchase goods and services that extend over multiple periods, any assets pledged to secure payment, and the fixed or determinable amount of payments due in each of the next five years and thereafter."
       }
      }
     },
     "auth_ref": [
      "r326"
     ]
    },
    "pstv_ReimbursementCostsIncurred": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://plus.com/20240331",
     "localname": "ReimbursementCostsIncurred",
     "crdr": "debit",
     "presentation": [
      "http://plus.com/role/GrantRevenueAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reimbursement Costs Incurred",
        "terseLabel": "Identified eligible reimbursable costs",
        "documentation": "Reimbursement costs incurred."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyDomain",
     "presentation": [
      "http://plus.com/role/CommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party, Type [Domain]",
        "terseLabel": "Related Party",
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests."
       }
      }
     },
     "auth_ref": [
      "r412",
      "r575",
      "r576",
      "r698",
      "r699",
      "r700",
      "r701",
      "r702",
      "r722",
      "r724",
      "r750"
     ]
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "presentation": [
      "http://plus.com/role/CommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions By Related Party [Axis]",
        "terseLabel": "Related Party",
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests."
       }
      }
     },
     "auth_ref": [
      "r412",
      "r575",
      "r576",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619",
      "r620",
      "r621",
      "r622",
      "r623",
      "r624",
      "r625",
      "r626",
      "r698",
      "r699",
      "r700",
      "r701",
      "r702",
      "r722",
      "r724",
      "r750",
      "r942"
     ]
    },
    "us-gaap_RepaymentsOfLongTermDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RepaymentsOfLongTermDebt",
     "crdr": "credit",
     "calculation": {
      "http://plus.com/role/CondensedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 22.0
      }
     },
     "presentation": [
      "http://plus.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Repayments Of Long Term Debt",
        "negatedLabel": "Principal payments of term loan obligation",
        "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r33",
      "r671"
     ]
    },
    "pstv_RepresentativeSeriesUWarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://plus.com/20240331",
     "localname": "RepresentativeSeriesUWarrantMember",
     "presentation": [
      "http://plus.com/role/StockholdersEquityWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Representative Series U Warrant [Member]",
        "terseLabel": "Representative Warrants [Member]",
        "documentation": "Representative Series U Warrant."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis",
     "presentation": [
      "http://plus.com/role/LicenseAgreementsAdditionalInformationDetails",
      "http://plus.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Axis]",
        "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type",
        "documentation": "Information by form of arrangement related to research and development."
       }
      }
     },
     "auth_ref": [
      "r462",
      "r923"
     ]
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain",
     "presentation": [
      "http://plus.com/role/LicenseAgreementsAdditionalInformationDetails",
      "http://plus.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Domain]",
        "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type",
        "documentation": "Listing of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others."
       }
      }
     },
     "auth_ref": [
      "r462",
      "r923"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://plus.com/role/CondensedStatementsOfOperationsUnaudited": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://plus.com/role/CondensedStatementsOfOperationsUnaudited",
      "http://plus.com/role/LicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research And Development Expense",
        "terseLabel": "Research and development",
        "verboseLabel": "Research and development expense",
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use."
       }
      }
     },
     "auth_ref": [
      "r87",
      "r461",
      "r951"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpenseMember",
     "presentation": [
      "http://plus.com/role/StockBasedCompensationSummaryOfShareBasedCompensationRecognizedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and Development [Member]",
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "presentation": [
      "http://plus.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and Development",
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process."
       }
      }
     },
     "auth_ref": [
      "r460"
     ]
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember",
     "presentation": [
      "http://plus.com/role/FairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents [Domain]",
        "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r169"
     ]
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://plus.com/role/CondensedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 24.0
      }
     },
     "presentation": [
      "http://plus.com/role/CondensedBalanceSheetsUnaudited",
      "http://plus.com/role/LiquidityAndGoingConcernAdditionalInformationDetails",
      "http://plus.com/role/OrganizationAndOperationsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r96",
      "r122",
      "r635",
      "r657",
      "r662",
      "r672",
      "r706",
      "r829"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://plus.com/role/CondensedStatementsOfStockholdersEquityDeficitUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit [Member]",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r162",
      "r202",
      "r203",
      "r204",
      "r208",
      "r216",
      "r218",
      "r300",
      "r307",
      "r453",
      "r454",
      "r455",
      "r485",
      "r486",
      "r506",
      "r509",
      "r510",
      "r513",
      "r524",
      "r653",
      "r655",
      "r674",
      "r957"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenueFromContractWithCustomerAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from Contract with Customer [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "presentation": [
      "http://plus.com/role/BasisOfPresentationAndNewAccountingStandardsPolicies",
      "http://plus.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from Contract with Customer [Policy Text Block]",
        "terseLabel": "Grant Revenue Recognition",
        "documentation": "Disclosure of accounting policy for revenue from contract with customer."
       }
      }
     },
     "auth_ref": [
      "r158",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r791"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenueFromContractWithCustomerTextBlock",
     "presentation": [
      "http://plus.com/role/GrantRevenue"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from Contract with Customer [Text Block]",
        "terseLabel": "Grant Revenue",
        "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts."
       }
      }
     },
     "auth_ref": [
      "r158",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r404"
     ]
    },
    "us-gaap_Revenues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Revenues",
     "crdr": "credit",
     "calculation": {
      "http://plus.com/role/CondensedStatementsOfOperationsUnaudited": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://plus.com/role/CondensedStatementsOfOperationsUnaudited",
      "http://plus.com/role/GrantRevenueAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues",
        "terseLabel": "Revenue",
        "verboseLabel": "Revenue recognized",
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss)."
       }
      }
     },
     "auth_ref": [
      "r189",
      "r199",
      "r238",
      "r239",
      "r250",
      "r253",
      "r254",
      "r258",
      "r259",
      "r261",
      "r294",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r537",
      "r629",
      "r890"
     ]
    },
    "pstv_ReverseStockSplitEffectiveDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://plus.com/20240331",
     "localname": "ReverseStockSplitEffectiveDate",
     "presentation": [
      "http://plus.com/role/BasisOfPresentationAndNewAccountingStandardsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reverse Stock Split Effective Date",
        "terseLabel": "Reverse stock split effective date",
        "documentation": "Reverse stock split effective date."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability",
     "crdr": "debit",
     "presentation": [
      "http://plus.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Right Of Use Asset Obtained In Exchange For Finance Lease Liability",
        "terseLabel": "Right-of-use assets obtained in exchange for operating lease liability",
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for finance lease liability."
       }
      }
     },
     "auth_ref": [
      "r566",
      "r828"
     ]
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "crdr": "debit",
     "presentation": [
      "http://plus.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "Right-of-use assets acquired by assuming operating lease liabilities",
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r566",
      "r828"
     ]
    },
    "pstv_RightsRelatedToDistributionOfAssets": {
     "xbrltype": "stringItemType",
     "nsuri": "http://plus.com/20240331",
     "localname": "RightsRelatedToDistributionOfAssets",
     "presentation": [
      "http://plus.com/role/StockholdersEquityPreferredStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rights Related To Distribution Of Assets",
        "terseLabel": "Rights related to distribution of assets",
        "documentation": "Rights related to distribution of assets."
       }
      }
     },
     "auth_ref": []
    },
    "pstv_SaleOfJapaneseSubsidiaryAndCertainAssetsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://plus.com/20240331",
     "localname": "SaleOfJapaneseSubsidiaryAndCertainAssetsMember",
     "presentation": [
      "http://plus.com/role/TermLoanObligationsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale Of Japanese Subsidiary And Certain Assets [Member]",
        "terseLabel": "Sale of the Japanese Subsidiary and Certain Assets [Member]",
        "documentation": "Sale of the japanese subsidiary and certain assets."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "crdr": "debit",
     "presentation": [
      "http://plus.com/role/StockholdersEquityPreferredStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock, Consideration Received on Transaction",
        "terseLabel": "Consideration to purchaser in cash",
        "documentation": "Cash received on stock transaction after deduction of issuance costs."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SaleOfStockNameOfTransactionDomain",
     "presentation": [
      "http://plus.com/role/LiquidityAndGoingConcernAdditionalInformationDetails",
      "http://plus.com/role/StockholdersEquityCommonStockDetails",
      "http://plus.com/role/StockholdersEquityPreferredStockDetails",
      "http://plus.com/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale Of Stock Name Of Transaction [Domain]",
        "terseLabel": "Sale of Stock",
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SaleOfStockPricePerShare",
     "presentation": [
      "http://plus.com/role/StockholdersEquityWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale Of Stock Price Per Share",
        "terseLabel": "Sale of Stock, Price Per Share",
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockTransactionDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SaleOfStockTransactionDate",
     "presentation": [
      "http://plus.com/role/StockholdersEquityPreferredStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock, Transaction Date",
        "terseLabel": "Sale closed date",
        "documentation": "Date the subsidiary or equity investee issued or sold stock, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "pstv_SalesOrderTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://plus.com/20240331",
     "localname": "SalesOrderTerm",
     "presentation": [
      "http://plus.com/role/CommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sales Order Term",
        "terseLabel": "Sales order term",
        "documentation": "Sales order term."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
     "presentation": [
      "http://plus.com/role/CompositionOfCertainFinancialStatementCaptionsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]",
        "terseLabel": "Accounts Payable and Accrued Expenses",
        "documentation": "Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "presentation": [
      "http://plus.com/role/LossPerShareScheduleOfAntidilutiveSecuritiesExcludedFromDilutedIncomeLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]",
        "terseLabel": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]",
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities."
       }
      }
     },
     "auth_ref": [
      "r40"
     ]
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "presentation": [
      "http://plus.com/role/LossPerShareTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Text Block]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Diluted Income (Loss) per Share",
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities."
       }
      }
     },
     "auth_ref": [
      "r40"
     ]
    },
    "us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
     "presentation": [
      "http://plus.com/role/StockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Cost by Plan [Table Text Block]",
        "terseLabel": "Summary of Share-Based Compensation Recognized",
        "documentation": "Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit."
       }
      }
     },
     "auth_ref": [
      "r65"
     ]
    },
    "us-gaap_ScheduleOfDebtInstrumentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfDebtInstrumentsTextBlock",
     "presentation": [
      "http://plus.com/role/TermLoanObligationsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Long-Term Debt Instruments [Table Text Block]",
        "terseLabel": "Term Loan Outstanding",
        "documentation": "Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer."
       }
      }
     },
     "auth_ref": [
      "r25",
      "r56",
      "r59",
      "r78",
      "r79",
      "r81",
      "r83",
      "r120",
      "r121",
      "r808",
      "r810",
      "r869"
     ]
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "presentation": [
      "http://plus.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "terseLabel": "Deferred Tax Assets and Liabilities",
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r130"
     ]
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "presentation": [
      "http://plus.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "terseLabel": "Reconciliation of Total Income Tax Provision",
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r129"
     ]
    },
    "us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfOtherCurrentAssetsTableTextBlock",
     "presentation": [
      "http://plus.com/role/CompositionOfCertainFinancialStatementCaptionsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Other Current Assets [Table Text Block]",
        "terseLabel": "Other Current Assets",
        "documentation": "Tabular disclosure of the carrying amounts of other current assets."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedCompensationActivityTableTextBlock",
     "presentation": [
      "http://plus.com/role/StockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Share Based Compensation Activity Table [Text Block]",
        "terseLabel": "Stock Option Activity",
        "documentation": "Tabular disclosure of activity for award under share-based payment arrangement. Includes, but is not limited to, outstanding award at beginning and end of year, granted, exercised, forfeited, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r13",
      "r64"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "presentation": [
      "http://plus.com/role/StockBasedCompensationAdditionalInformationDetails",
      "http://plus.com/role/StockBasedCompensationSummaryOfShareBasedCompensationRecognizedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "terseLabel": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]",
        "documentation": "Disclosure of information about share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r416",
      "r418",
      "r420",
      "r421",
      "r422",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448"
     ]
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "presentation": [
      "http://plus.com/role/StockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Weighted-average Assumptions",
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions."
       }
      }
     },
     "auth_ref": [
      "r128"
     ]
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfStockByClassTable",
     "presentation": [
      "http://plus.com/role/StockholdersEquityCommonStockDetails",
      "http://plus.com/role/StockholdersEquityPreferredStockDetails",
      "http://plus.com/role/StockholdersEquityWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Stock By Class [Table]",
        "terseLabel": "Schedule Of Stock By Class [Table]",
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r53",
      "r54",
      "r55",
      "r56",
      "r57",
      "r58",
      "r59",
      "r120",
      "r121",
      "r122",
      "r177",
      "r178",
      "r179",
      "r235",
      "r370",
      "r371",
      "r372",
      "r374",
      "r377",
      "r382",
      "r384",
      "r668",
      "r669",
      "r670",
      "r671",
      "r812",
      "r846",
      "r865"
     ]
    },
    "us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
     "presentation": [
      "http://plus.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]",
        "terseLabel": "Unrecognized Tax Benefits Activity",
        "documentation": "Tabular disclosure of the change in unrecognized tax benefits."
       }
      }
     },
     "auth_ref": [
      "r826",
      "r926"
     ]
    },
    "us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember",
     "presentation": [
      "http://plus.com/role/TermLoanObligationsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate [Member]",
        "terseLabel": "SOFR [Member]",
        "documentation": "Fixed rate on U.S. dollar, constant-notional interest rate swap that has its variable-rate leg referenced to Secured Overnight Financing Rate (SOFR) with no additional spread over SOFR on variable-rate leg."
       }
      }
     },
     "auth_ref": [
      "r934"
     ]
    },
    "srt_SegmentGeographicalDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "SegmentGeographicalDomain",
     "presentation": [
      "http://plus.com/role/CommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]",
        "terseLabel": "Geographical"
       }
      }
     },
     "auth_ref": [
      "r259",
      "r260",
      "r687",
      "r690",
      "r692",
      "r753",
      "r755",
      "r759",
      "r767",
      "r780",
      "r781",
      "r782",
      "r783",
      "r784",
      "r785",
      "r786",
      "r787",
      "r788",
      "r794",
      "r814",
      "r834",
      "r894",
      "r953"
     ]
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "presentation": [
      "http://plus.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "terseLabel": "Segment Information",
        "documentation": "Disclosure of accounting policy for segment reporting."
       }
      }
     },
     "auth_ref": [
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r259",
      "r802"
     ]
    },
    "pstv_SeptemberTwoThousandAndTwentyTwoDistributionAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://plus.com/20240331",
     "localname": "SeptemberTwoThousandAndTwentyTwoDistributionAgreementMember",
     "presentation": [
      "http://plus.com/role/StockholdersEquityCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "September Two Thousand and Twenty Two Distribution Agreement [Member]",
        "terseLabel": "September 2022 Distribution Agreement [Member]",
        "documentation": "September two thousand and twenty two distribution agreement."
       }
      }
     },
     "auth_ref": []
    },
    "pstv_SeriesAWarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://plus.com/20240331",
     "localname": "SeriesAWarrantMember",
     "presentation": [
      "http://plus.com/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series A Warrant [Member]",
        "documentation": "Series A Warrant [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "pstv_SeriesBConvertiblePreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://plus.com/20240331",
     "localname": "SeriesBConvertiblePreferredStockMember",
     "presentation": [
      "http://plus.com/role/StockholdersEquityPreferredStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series B Convertible Preferred Stock [Member]",
        "terseLabel": "Series B Convertible Preferred Stock [Member]",
        "documentation": "Series B convertible preferred stock."
       }
      }
     },
     "auth_ref": []
    },
    "pstv_SeriesBWarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://plus.com/20240331",
     "localname": "SeriesBWarrantMember",
     "presentation": [
      "http://plus.com/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series B Warrant [Member]",
        "documentation": "Series B Warrant [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "pstv_SeriesCConvertiblePreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://plus.com/20240331",
     "localname": "SeriesCConvertiblePreferredStockMember",
     "presentation": [
      "http://plus.com/role/StockholdersEquityPreferredStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series C Convertible Preferred Stock [Member]",
        "terseLabel": "Series C Convertible Preferred Stock [Member]",
        "documentation": "Series C convertible preferred stock."
       }
      }
     },
     "auth_ref": []
    },
    "pstv_SeriesFConvertiblePreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://plus.com/20240331",
     "localname": "SeriesFConvertiblePreferredStockMember",
     "presentation": [
      "http://plus.com/role/StockholdersEquityPreferredStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series F Convertible Preferred Stock [Member]",
        "documentation": "Series F Convertible Preferred Stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SeriesFPreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SeriesFPreferredStockMember",
     "presentation": [
      "http://plus.com/role/CondensedStatementsOfStockholdersEquityDeficitUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series F Preferred Stock [Member]",
        "terseLabel": "Series F Preferred Stock [Member]",
        "documentation": "Series F preferred stock."
       }
      }
     },
     "auth_ref": [
      "r859",
      "r860",
      "r893"
     ]
    },
    "pstv_SeriesUWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://plus.com/20240331",
     "localname": "SeriesUWarrantsMember",
     "presentation": [
      "http://plus.com/role/StockholdersEquityWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series U Warrants [Member]",
        "terseLabel": "Series U Warrants [Member]",
        "documentation": "Series U warrants member"
       }
      }
     },
     "auth_ref": []
    },
    "pstv_ServicesAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://plus.com/20240331",
     "localname": "ServicesAgreementMember",
     "presentation": [
      "http://plus.com/role/CommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Services Agreement [Member]",
        "terseLabel": "Services Agreement [Member]",
        "documentation": "Services agreement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://plus.com/role/CondensedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://plus.com/role/CondensedStatementsOfCashFlowsUnaudited",
      "http://plus.com/role/StockBasedCompensationSummaryOfShareBasedCompensationRecognizedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "terseLabel": "Share-based compensation expense",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "presentation": [
      "http://plus.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1",
        "terseLabel": "Stock option vesting period",
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition."
       }
      }
     },
     "auth_ref": [
      "r824"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract",
     "presentation": [
      "http://plus.com/role/StockBasedCompensationWeightedAverageAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology [Abstract]",
        "terseLabel": "Black-Scholes-Merton option valuation model based on weighted-average assumptions [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "presentation": [
      "http://plus.com/role/StockBasedCompensationWeightedAverageAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Dividends",
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term."
       }
      }
     },
     "auth_ref": [
      "r446"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "presentation": [
      "http://plus.com/role/StockBasedCompensationWeightedAverageAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk-free interest rate",
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": [
      "r447"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend",
     "crdr": "debit",
     "presentation": [
      "http://plus.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Weighted Average Expected Dividend",
        "terseLabel": "Dividend yield assumed",
        "documentation": "Disclosure of the weighted average expected dividend for an entity using a valuation technique with different dividend rates during the contractual term."
       }
      }
     },
     "auth_ref": [
      "r446"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate",
     "presentation": [
      "http://plus.com/role/StockBasedCompensationWeightedAverageAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate",
        "terseLabel": "Expected volatility",
        "documentation": "Rate of weighted-average expected volatility for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r445"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://plus.com/role/StockBasedCompensationAdditionalInformationDetails",
      "http://plus.com/role/StockBasedCompensationSummaryOfShareBasedCompensationRecognizedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "terseLabel": "Share Based Compensation Arrangement By Share Based Payment Award [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r416",
      "r418",
      "r420",
      "r421",
      "r422",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "presentation": [
      "http://plus.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant",
        "verboseLabel": "Securities remaining and available for future issuances (in shares)",
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable."
       }
      }
     },
     "auth_ref": [
      "r63"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract",
     "presentation": [
      "http://plus.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Additional Disclosures [Abstract]",
        "terseLabel": "Weighted Average Remaining Contractual Life (years) [Roll Forward]"
       }
      }
     },
     "auth_ref": []
    },
    "pstv_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://plus.com/20240331",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract",
     "presentation": [
      "http://plus.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Based Compensation Arrangement by Share Based Payment Award Options Aggregate Intrinsic Value [Abstract]",
        "terseLabel": "Aggregated Intrinsic Value [Roll Forward]",
        "documentation": "Share based compensation arrangement by share based payment award options aggregate intrinsic value."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "presentation": [
      "http://plus.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number",
        "terseLabel": "Exercisable (in shares)",
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan."
       }
      }
     },
     "auth_ref": [
      "r426"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://plus.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price",
        "terseLabel": "Exercisable",
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r426"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "presentation": [
      "http://plus.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period",
        "negatedLabel": "Cancelled/forfeited (in shares)",
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r430"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://plus.com/role/StockBasedCompensationAdditionalInformationDetails",
      "http://plus.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross",
        "terseLabel": "Common stock shares to be issued (in shares)",
        "verboseLabel": "Granted (in shares)",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r428"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://plus.com/role/StockBasedCompensationWeightedAverageAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Resulting fair value",
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology."
       }
      }
     },
     "auth_ref": [
      "r438"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://plus.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "terseLabel": "Balance as of Aggregated Intrinsic Value",
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding."
       }
      }
     },
     "auth_ref": [
      "r63"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://plus.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number",
        "periodStartLabel": "Balance as of Options (in shares)",
        "periodEndLabel": "Balance as of Options (in shares)",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r424",
      "r425"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "presentation": [
      "http://plus.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Roll Forward",
        "terseLabel": "Options [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://plus.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price",
        "periodStartLabel": "Balance as of Weighted Average Exercise Price (in dollars per share)",
        "periodEndLabel": "Balance as of Weighted Average Exercise Price (in dollars per share)",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r424",
      "r425"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "presentation": [
      "http://plus.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price Rollforward",
        "terseLabel": "Weighted Average Exercise Price [Roll Forward]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://plus.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price",
        "terseLabel": "Vested and expected to vest (in dollars per share)",
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r441"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://plus.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value",
        "verboseLabel": "Vested and expected to vest",
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r440"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "presentation": [
      "http://plus.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number",
        "terseLabel": "Vested and expected to vest (in shares)",
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r440"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://plus.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price",
        "terseLabel": "Cancelled/forfeited (in dollars per share)",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated."
       }
      }
     },
     "auth_ref": [
      "r430"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://plus.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price",
        "verboseLabel": "Granted (in dollars per share)",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r428"
     ]
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "presentation": [
      "http://plus.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Policy Text Block]",
        "terseLabel": "Share-Based Compensation",
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost."
       }
      }
     },
     "auth_ref": [
      "r415",
      "r423",
      "r442",
      "r443",
      "r444",
      "r445",
      "r448",
      "r456",
      "r457",
      "r458",
      "r459"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage",
     "presentation": [
      "http://plus.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Award Vesting Rights Percentage",
        "terseLabel": "Stock option vesting percentage",
        "documentation": "Percentage of vesting of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r897"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "presentation": [
      "http://plus.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period",
        "terseLabel": "Stock option contractual term",
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r825"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "presentation": [
      "http://plus.com/role/StockBasedCompensationWeightedAverageAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected term",
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r444"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "crdr": "debit",
     "presentation": [
      "http://plus.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value",
        "terseLabel": "Exercisable",
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable."
       }
      }
     },
     "auth_ref": [
      "r63"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://plus.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1",
        "terseLabel": "Exercisable",
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r63"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://plus.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2",
        "terseLabel": "Balance as of Weighted Average Remaining Contractual Life (years)",
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r127"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://plus.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1",
        "terseLabel": "Vested and expected to vest",
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r440"
     ]
    },
    "us-gaap_SharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharesIssued",
     "presentation": [
      "http://plus.com/role/LicenseAgreementsAdditionalInformationDetails",
      "http://plus.com/role/StockholdersEquityCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares Issued",
        "verboseLabel": "Shares issued",
        "terseLabel": "Remaining common stock issued and sold (in shares)",
        "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r11"
     ]
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharesIssuedPricePerShare",
     "presentation": [
      "http://plus.com/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares Issued, Price Per Share",
        "terseLabel": "Shares Issued, Price Per Share",
        "documentation": "Per share or per unit amount of equity securities issued."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharesOutstanding",
     "presentation": [
      "http://plus.com/role/CondensedStatementsOfStockholdersEquityDeficitUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares Outstanding",
        "periodStartLabel": "Balance (in shares)",
        "periodEndLabel": "Balance (in shares)",
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShortTermInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShortTermInvestments",
     "crdr": "debit",
     "calculation": {
      "http://plus.com/role/CondensedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://plus.com/role/CondensedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Short-Term Investments",
        "terseLabel": "Investments",
        "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current."
       }
      }
     },
     "auth_ref": [
      "r139",
      "r140",
      "r862"
     ]
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://plus.com/role/SummaryOfSignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Summary of Significant Accounting Policies",
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r112",
      "r196"
     ]
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StateAndLocalJurisdictionMember",
     "presentation": [
      "http://plus.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "State and Local Jurisdiction [Member]",
        "terseLabel": "State [Member]",
        "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementClassOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementClassOfStockAxis",
     "presentation": [
      "http://plus.com/role/CondensedStatementsOfStockholdersEquityDeficitUnaudited",
      "http://plus.com/role/StockholdersEquityCommonStockDetails",
      "http://plus.com/role/StockholdersEquityPreferredStockDetails",
      "http://plus.com/role/StockholdersEquityWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Axis]",
        "terseLabel": "Class of Stock",
        "documentation": "Information by the different classes of stock of the entity."
       }
      }
     },
     "auth_ref": [
      "r159",
      "r177",
      "r178",
      "r179",
      "r199",
      "r224",
      "r225",
      "r227",
      "r229",
      "r235",
      "r236",
      "r294",
      "r331",
      "r333",
      "r334",
      "r335",
      "r338",
      "r339",
      "r370",
      "r371",
      "r374",
      "r377",
      "r384",
      "r537",
      "r668",
      "r669",
      "r670",
      "r671",
      "r674",
      "r675",
      "r676",
      "r677",
      "r678",
      "r679",
      "r680",
      "r681",
      "r682",
      "r683",
      "r684",
      "r685",
      "r705",
      "r726",
      "r745",
      "r772",
      "r773",
      "r774",
      "r775",
      "r776",
      "r846",
      "r865",
      "r873"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://plus.com/role/BasisOfPresentationAndNewAccountingStandardsAdditionalInformationDetails",
      "http://plus.com/role/CondensedStatementsOfStockholdersEquityDeficitUnaudited",
      "http://plus.com/role/LossPerShareScheduleOfAntidilutiveSecuritiesExcludedFromDilutedIncomeLossPerShareDetails",
      "http://plus.com/role/OrganizationAndOperationsAdditionalInformationDetails",
      "http://plus.com/role/StockholdersEquityCommonStockDetails",
      "http://plus.com/role/StockholdersEquityWarrantsDetails",
      "http://plus.com/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components",
        "verboseLabel": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r29",
      "r162",
      "r185",
      "r186",
      "r187",
      "r202",
      "r203",
      "r204",
      "r208",
      "r216",
      "r218",
      "r234",
      "r300",
      "r307",
      "r386",
      "r453",
      "r454",
      "r455",
      "r485",
      "r486",
      "r506",
      "r508",
      "r509",
      "r510",
      "r511",
      "r513",
      "r524",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r574",
      "r653",
      "r654",
      "r655",
      "r674",
      "r745"
     ]
    },
    "srt_StatementGeographicalAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "StatementGeographicalAxis",
     "presentation": [
      "http://plus.com/role/CommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]",
        "terseLabel": "Geographical"
       }
      }
     },
     "auth_ref": [
      "r259",
      "r260",
      "r687",
      "r690",
      "r692",
      "r753",
      "r755",
      "r759",
      "r767",
      "r778",
      "r780",
      "r781",
      "r782",
      "r783",
      "r784",
      "r785",
      "r786",
      "r787",
      "r788",
      "r794",
      "r814",
      "r834",
      "r894",
      "r953"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementLineItems",
     "presentation": [
      "http://plus.com/role/CondensedStatementsOfOperationsUnaudited",
      "http://plus.com/role/CondensedStatementsOfStockholdersEquityDeficitUnaudited",
      "http://plus.com/role/LicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r202",
      "r203",
      "r204",
      "r234",
      "r611",
      "r666",
      "r685",
      "r697",
      "r698",
      "r699",
      "r700",
      "r701",
      "r702",
      "r705",
      "r708",
      "r709",
      "r710",
      "r711",
      "r712",
      "r713",
      "r714",
      "r715",
      "r716",
      "r718",
      "r719",
      "r720",
      "r721",
      "r722",
      "r724",
      "r727",
      "r728",
      "r731",
      "r732",
      "r733",
      "r734",
      "r735",
      "r736",
      "r737",
      "r738",
      "r739",
      "r740",
      "r741",
      "r742",
      "r745",
      "r835"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement Of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement Of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement Of Stockholders Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementTable",
     "presentation": [
      "http://plus.com/role/CondensedStatementsOfOperationsUnaudited",
      "http://plus.com/role/CondensedStatementsOfStockholdersEquityDeficitUnaudited",
      "http://plus.com/role/LicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]",
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed."
       }
      }
     },
     "auth_ref": [
      "r202",
      "r203",
      "r204",
      "r234",
      "r611",
      "r666",
      "r685",
      "r697",
      "r698",
      "r699",
      "r700",
      "r701",
      "r702",
      "r705",
      "r708",
      "r709",
      "r710",
      "r711",
      "r712",
      "r713",
      "r714",
      "r715",
      "r716",
      "r718",
      "r719",
      "r720",
      "r721",
      "r722",
      "r724",
      "r727",
      "r728",
      "r731",
      "r732",
      "r733",
      "r734",
      "r735",
      "r736",
      "r737",
      "r738",
      "r739",
      "r740",
      "r741",
      "r742",
      "r745",
      "r835"
     ]
    },
    "pstv_StockBasedCompensation2015EquityIncentivePlan1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://plus.com/20240331",
     "localname": "StockBasedCompensation2015EquityIncentivePlan1Member",
     "presentation": [
      "http://plus.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Based Compensation2015 Equity Incentive Plan1 [Member]",
        "terseLabel": "2015 Plan [Member]",
        "documentation": "Stock based compensation 2015 equity incentive plan 1 member."
       }
      }
     },
     "auth_ref": []
    },
    "pstv_StockBasedCompensation2020EquityIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://plus.com/20240331",
     "localname": "StockBasedCompensation2020EquityIncentivePlanMember",
     "presentation": [
      "http://plus.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Based Compensation2020 Equity Incentive Plan [Member]",
        "terseLabel": "2020 Plan [Member]",
        "documentation": "Stock based compensation 2020 equity incentive plan."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssued1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssued1",
     "crdr": "credit",
     "presentation": [
      "http://plus.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued",
        "terseLabel": "Common stock issued in payment for in process research and development",
        "documentation": "The fair value of stock issued in noncash financing activities."
       }
      }
     },
     "auth_ref": [
      "r36",
      "r37",
      "r38"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesIssuedForServices",
     "presentation": [
      "http://plus.com/role/CondensedStatementsOfStockholdersEquityDeficitUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Shares, Issued for Services",
        "terseLabel": "Issuance of common stock for in process research and development (in shares)",
        "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://plus.com/role/CondensedStatementsOfStockholdersEquityDeficitUnaudited",
      "http://plus.com/role/StockholdersEquityCommonStockDetails",
      "http://plus.com/role/StockholdersEquityPreferredStockDetails",
      "http://plus.com/role/StockholdersEquityWarrantsDetails",
      "http://plus.com/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of common stock, net",
        "verboseLabel": "Issue and sale of share",
        "terseLabel": "Issue and sale of share",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r93",
      "r94",
      "r122",
      "r668",
      "r745",
      "r773"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesReverseStockSplits",
     "presentation": [
      "http://plus.com/role/BasisOfPresentationAndNewAccountingStandardsAdditionalInformationDetails",
      "http://plus.com/role/OrganizationAndOperationsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Shares, Reverse Stock Splits",
        "terseLabel": "Stock issued during period reverse stock splits, shares",
        "documentation": "Reduction in the number of shares during the period as a result of a reverse stock split."
       }
      }
     },
     "auth_ref": [
      "r11"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockSplits": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesStockSplits",
     "presentation": [
      "http://plus.com/role/BasisOfPresentationAndNewAccountingStandardsAdditionalInformationDetails",
      "http://plus.com/role/OrganizationAndOperationsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Shares, Stock Splits",
        "terseLabel": "Common stock, reverse stock split, fractional shares issued",
        "documentation": "Number of shares issued during the period as a result of a stock split."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r93",
      "r94",
      "r122"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueIssuedForServices": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueIssuedForServices",
     "crdr": "credit",
     "presentation": [
      "http://plus.com/role/CondensedStatementsOfStockholdersEquityDeficitUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Value, Issued for Services",
        "terseLabel": "Issuance of common stock for in process research and development",
        "documentation": "Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://plus.com/role/CondensedStatementsOfStockholdersEquityDeficitUnaudited",
      "http://plus.com/role/LiquidityAndGoingConcernAdditionalInformationDetails",
      "http://plus.com/role/StockholdersEquityCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' equity requirement",
        "verboseLabel": "Issue and sale of stock, net",
        "terseLabel": "Sale of common stock, net",
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r93",
      "r94",
      "r122",
      "r674",
      "r745",
      "r773",
      "r841"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "crdr": "credit",
     "presentation": [
      "http://plus.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "verboseLabel": "Stock options exercised",
        "documentation": "Value of stock issued as a result of the exercise of stock options."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r29",
      "r122"
     ]
    },
    "us-gaap_StockRedeemedOrCalledDuringPeriodShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockRedeemedOrCalledDuringPeriodShares",
     "presentation": [
      "http://plus.com/role/CondensedStatementsOfStockholdersEquityDeficitUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Redeemed or Called During Period, Shares",
        "negatedLabel": "Redemption of Series F preferred stock (in shares)",
        "documentation": "Number of stock bought back by the entity at the exercise price or redemption price."
       }
      }
     },
     "auth_ref": [
      "r11"
     ]
    },
    "us-gaap_StockRepurchaseProgramAuthorizedAmount1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockRepurchaseProgramAuthorizedAmount1",
     "crdr": "credit",
     "presentation": [
      "http://plus.com/role/StockholdersEquityCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Repurchase Program, Authorized Amount",
        "terseLabel": "Authorized amount of repurchase of stock",
        "documentation": "Amount of stock repurchase plan authorized."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1",
     "crdr": "credit",
     "presentation": [
      "http://plus.com/role/StockholdersEquityCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Repurchase Program, Remaining Authorized Repurchase Amount",
        "terseLabel": "Remained authorized amount for repurchase",
        "documentation": "Amount remaining of a stock repurchase plan authorized."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockRepurchasedDuringPeriodShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockRepurchasedDuringPeriodShares",
     "presentation": [
      "http://plus.com/role/StockholdersEquityCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Repurchased During Period, Shares",
        "terseLabel": "Number of stock repurchased",
        "documentation": "Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r93",
      "r94",
      "r122",
      "r671",
      "r745",
      "r775"
     ]
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://plus.com/role/CondensedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 19.0
      }
     },
     "presentation": [
      "http://plus.com/role/CondensedBalanceSheetsUnaudited",
      "http://plus.com/role/CondensedStatementsOfStockholdersEquityDeficitUnaudited",
      "http://plus.com/role/LiquidityAndGoingConcernAdditionalInformationDetails",
      "http://plus.com/role/OrganizationAndOperationsAdditionalInformationDetails",
      "http://plus.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity, Attributable to Parent",
        "totalLabel": "Total stockholders' deficit",
        "periodStartLabel": "Balance",
        "periodEndLabel": "Balance",
        "terseLabel": "Stockholders' deficit",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r94",
      "r97",
      "r98",
      "r113",
      "r707",
      "r723",
      "r746",
      "r747",
      "r829",
      "r842",
      "r867",
      "r880",
      "r937",
      "r957"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://plus.com/role/CondensedBalanceSheetsUnaudited",
      "http://plus.com/role/CondensedBalanceSheetsUnauditedParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders Equity [Abstract]",
        "terseLabel": "Stockholders' deficit:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityNoteAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders Equity Note [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://plus.com/role/StockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders Equity Note Disclosure [Text Block]",
        "terseLabel": "Stockholders' Equity",
        "documentation": "The entire disclosure for equity."
       }
      }
     },
     "auth_ref": [
      "r119",
      "r198",
      "r369",
      "r371",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r383",
      "r386",
      "r515",
      "r748",
      "r749",
      "r777"
     ]
    },
    "us-gaap_StockholdersEquityNoteStockSplitConversionRatio1": {
     "xbrltype": "pureItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityNoteStockSplitConversionRatio1",
     "presentation": [
      "http://plus.com/role/BasisOfPresentationAndNewAccountingStandardsAdditionalInformationDetails",
      "http://plus.com/role/OrganizationAndOperationsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Note, Stock Split, Conversion Ratio",
        "terseLabel": "Stock split conversion ratio",
        "documentation": "Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "pstv_SubscriptionAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://plus.com/20240331",
     "localname": "SubscriptionAgreementMember",
     "presentation": [
      "http://plus.com/role/StockholdersEquityPreferredStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subscription Agreement [Member]",
        "documentation": "Subscription Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventLineItems",
     "presentation": [
      "http://plus.com/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Line Items]",
        "terseLabel": "Subsequent Event [Line Items]",
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event."
       }
      }
     },
     "auth_ref": [
      "r549",
      "r578"
     ]
    },
    "us-gaap_SubsequentEventMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventMember",
     "presentation": [
      "http://plus.com/role/StockholdersEquityCommonStockDetails",
      "http://plus.com/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event [Member]",
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r549",
      "r578"
     ]
    },
    "us-gaap_SubsequentEventTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventTable",
     "presentation": [
      "http://plus.com/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Table]",
        "terseLabel": "Subsequent Event [Table]",
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued."
       }
      }
     },
     "auth_ref": [
      "r549",
      "r578"
     ]
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventTypeAxis",
     "presentation": [
      "http://plus.com/role/LiquidityAndGoingConcernAdditionalInformationDetails",
      "http://plus.com/role/StockholdersEquityCommonStockDetails",
      "http://plus.com/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Axis]",
        "terseLabel": "Subsequent Event Type",
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r549",
      "r578"
     ]
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventTypeDomain",
     "presentation": [
      "http://plus.com/role/LiquidityAndGoingConcernAdditionalInformationDetails",
      "http://plus.com/role/StockholdersEquityCommonStockDetails",
      "http://plus.com/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Domain]",
        "terseLabel": "Subsequent Event Type",
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r549",
      "r578"
     ]
    },
    "us-gaap_SubsequentEventsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventsTextBlock",
     "presentation": [
      "http://plus.com/role/SubsequentEvents"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "Subsequent Events",
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business."
       }
      }
     },
     "auth_ref": [
      "r577",
      "r579"
     ]
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsidiarySaleOfStockAxis",
     "presentation": [
      "http://plus.com/role/LiquidityAndGoingConcernAdditionalInformationDetails",
      "http://plus.com/role/StockholdersEquityCommonStockDetails",
      "http://plus.com/role/StockholdersEquityPreferredStockDetails",
      "http://plus.com/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsidiary Sale Of Stock [Axis]",
        "terseLabel": "Sale of Stock",
        "documentation": "Information by type of sale of the entity's stock."
       }
      }
     },
     "auth_ref": []
    },
    "pstv_SummaryOfSignificantAccountingPoliciesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://plus.com/20240331",
     "localname": "SummaryOfSignificantAccountingPoliciesLineItems",
     "presentation": [
      "http://plus.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary Of Significant Accounting Policies [Line Items]",
        "terseLabel": "Summary Of Significant Accounting Policies [Line Items]",
        "documentation": "Summary of significant accounting policies."
       }
      }
     },
     "auth_ref": []
    },
    "pstv_SummaryOfSignificantAccountingPoliciesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://plus.com/20240331",
     "localname": "SummaryOfSignificantAccountingPoliciesTable",
     "presentation": [
      "http://plus.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary Of Significant Accounting Policies [Table]",
        "terseLabel": "Summary Of Significant Accounting Policies [Table]",
        "documentation": "Summary of significant accounting policies."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SupplementalBalanceSheetDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SupplementalBalanceSheetDisclosuresTextBlock",
     "presentation": [
      "http://plus.com/role/CompositionOfCertainFinancialStatementCaptions"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Balance Sheet Disclosures [Text Block]",
        "terseLabel": "Composition of Certain Financial Statement Captions",
        "documentation": "The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity."
       }
      }
     },
     "auth_ref": [
      "r858"
     ]
    },
    "pstv_TaxCreditCarryforwardExpirationDate1": {
     "xbrltype": "stringItemType",
     "nsuri": "http://plus.com/20240331",
     "localname": "TaxCreditCarryforwardExpirationDate1",
     "presentation": [
      "http://plus.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Credit Carryforward Expiration Date1",
        "terseLabel": "Tax credit carryforward, expiration date",
        "documentation": "Expiration date of the tax credit carryforward."
       }
      }
     },
     "auth_ref": []
    },
    "pstv_TermLoanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://plus.com/20240331",
     "localname": "TermLoanMember",
     "presentation": [
      "http://plus.com/role/OrganizationAndOperationsAdditionalInformationDetails",
      "http://plus.com/role/TermLoanObligationsAdditionalInformationDetails",
      "http://plus.com/role/TermLoanObligationsTermLoanOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Term Loan [Member]",
        "terseLabel": "Term Loan [Member]",
        "documentation": "Second amendment to the amended and restated loan and security agreement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "presentation": [
      "http://plus.com/role/StockholdersEquityCommonStockDetails",
      "http://plus.com/role/TermLoanObligationsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instruments [Domain]",
        "terseLabel": "Financial Instruments",
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms."
       }
      }
     },
     "auth_ref": [
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r365",
      "r382",
      "r514",
      "r580",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597",
      "r598",
      "r599",
      "r600",
      "r601",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r607",
      "r608",
      "r609",
      "r641",
      "r851",
      "r852",
      "r853",
      "r854",
      "r855",
      "r856",
      "r857",
      "r876",
      "r877",
      "r878",
      "r879"
     ]
    },
    "us-gaap_TreasuryStockCommonMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TreasuryStockCommonMember",
     "presentation": [
      "http://plus.com/role/CondensedStatementsOfStockholdersEquityDeficitUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Treasury Stock, Common [Member]",
        "terseLabel": "Treasury Stock [Member]",
        "documentation": "Previously issued common shares repurchased by the issuing entity and held in treasury."
       }
      }
     },
     "auth_ref": [
      "r60"
     ]
    },
    "us-gaap_TreasuryStockCommonShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TreasuryStockCommonShares",
     "presentation": [
      "http://plus.com/role/CondensedBalanceSheetsUnauditedParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Treasury Stock, Common, Shares",
        "terseLabel": "Treasury stock, shares",
        "documentation": "Number of previously issued common shares repurchased by the issuing entity and held in treasury."
       }
      }
     },
     "auth_ref": [
      "r60"
     ]
    },
    "us-gaap_TreasuryStockCommonValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TreasuryStockCommonValue",
     "crdr": "debit",
     "calculation": {
      "http://plus.com/role/CondensedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": -1.0,
       "order": 22.0
      }
     },
     "presentation": [
      "http://plus.com/role/CondensedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Treasury Stock, Common, Value",
        "negatedLabel": "Treasury stock",
        "documentation": "Amount allocated to previously issued common shares repurchased by the issuing entity and held in treasury."
       }
      }
     },
     "auth_ref": [
      "r30",
      "r60",
      "r61"
     ]
    },
    "us-gaap_TreasuryStockSharesAcquired": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TreasuryStockSharesAcquired",
     "presentation": [
      "http://plus.com/role/CondensedStatementsOfStockholdersEquityDeficitUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Treasury Stock, Shares, Acquired",
        "negatedLabel": "Purchase of treasury stock (in Shares)",
        "documentation": "Number of shares that have been repurchased during the period and are being held in treasury."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r94",
      "r122"
     ]
    },
    "us-gaap_TreasuryStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TreasuryStockValue",
     "crdr": "debit",
     "presentation": [
      "http://plus.com/role/StockholdersEquityCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Treasury Stock, Value",
        "terseLabel": "Treasury stock",
        "documentation": "The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury."
       }
      }
     },
     "auth_ref": [
      "r28",
      "r60",
      "r61"
     ]
    },
    "us-gaap_TreasuryStockValueAcquiredCostMethod": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TreasuryStockValueAcquiredCostMethod",
     "crdr": "debit",
     "presentation": [
      "http://plus.com/role/CondensedStatementsOfStockholdersEquityDeficitUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Treasury Stock, Value, Acquired, Cost Method",
        "negatedLabel": "Purchase of treasury stock",
        "documentation": "Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r60",
      "r122"
     ]
    },
    "pstv_TwentyTwentyPurchaseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://plus.com/20240331",
     "localname": "TwentyTwentyPurchaseAgreementMember",
     "presentation": [
      "http://plus.com/role/StockholdersEquityCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Twenty Twenty Purchase Agreement [Member]",
        "terseLabel": "2020 Purchase Agreement [Member]",
        "documentation": "Twenty twenty purchase agreement."
       }
      }
     },
     "auth_ref": []
    },
    "pstv_TwoThousandAndTwentyTwoPurchaseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://plus.com/20240331",
     "localname": "TwoThousandAndTwentyTwoPurchaseAgreementMember",
     "presentation": [
      "http://plus.com/role/StockholdersEquityCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Two Thousand and Twenty Two Purchase Agreement [Member]",
        "terseLabel": "2022 Purchase Agreement [Member]",
        "documentation": "Two thousand and twenty two purchase agreement."
       }
      }
     },
     "auth_ref": []
    },
    "pstv_TwoThousandEighteenRightsOfferingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://plus.com/20240331",
     "localname": "TwoThousandEighteenRightsOfferingMember",
     "presentation": [
      "http://plus.com/role/StockholdersEquityPreferredStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Two Thousand Eighteen Rights Offering [Member]",
        "terseLabel": "2018 Rights Offering [Member]",
        "documentation": "Two thousand eighteen rights offering."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TypeOfAdoptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TypeOfAdoptionMember",
     "presentation": [
      "http://plus.com/role/BasisOfPresentationAndNewAccountingStandardsAdditionalInformationDetails",
      "http://plus.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Standards Update [Domain]",
        "terseLabel": "Accounting Standards Update",
        "documentation": "Amendment to accounting standards."
       }
      }
     },
     "auth_ref": [
      "r160",
      "r161",
      "r162",
      "r163",
      "r164",
      "r207",
      "r208",
      "r209",
      "r210",
      "r220",
      "r262",
      "r263",
      "r297",
      "r298",
      "r299",
      "r300",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r320",
      "r453",
      "r454",
      "r455",
      "r483",
      "r484",
      "r485",
      "r486",
      "r494",
      "r495",
      "r496",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r516",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527",
      "r535",
      "r536",
      "r539",
      "r540",
      "r541",
      "r542",
      "r550",
      "r551",
      "r555",
      "r556",
      "r557",
      "r558",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r612",
      "r613",
      "r614",
      "r651",
      "r652",
      "r653",
      "r654",
      "r655",
      "r656",
      "r657",
      "r658",
      "r659",
      "r660",
      "r661",
      "r662"
     ]
    },
    "us-gaap_TypeOfArrangementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TypeOfArrangementAxis",
     "presentation": [
      "http://plus.com/role/CommitmentsAndContingenciesAdditionalInformationDetails",
      "http://plus.com/role/GrantRevenueAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Type Of Arrangement [Axis]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative",
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r497"
     ]
    },
    "us-gaap_USTreasurySecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "USTreasurySecuritiesMember",
     "presentation": [
      "http://plus.com/role/FairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "US Treasury Securities [Member]",
        "terseLabel": "Treasury Bills and Government Agency Bonds [Member]",
        "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years)."
       }
      }
     },
     "auth_ref": [
      "r798",
      "r820",
      "r822",
      "r952"
     ]
    },
    "pstv_UTHSALicenseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://plus.com/20240331",
     "localname": "UTHSALicenseAgreementMember",
     "presentation": [
      "http://plus.com/role/LicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "U T H S A License Agreement [Member]",
        "terseLabel": "UTHSA License Agreement [Member]",
        "documentation": "UTHSA License Agreement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain",
     "presentation": [
      "http://plus.com/role/CommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unconditional Purchase Obligation Category Of Goods Or Services Acquired [Domain]",
        "terseLabel": "Unconditional Purchase Obligation, Category of Goods or Services Acquired",
        "documentation": "General description of the goods or services to be purchased from the counterparty to the unconditional purchase arrangement."
       }
      }
     },
     "auth_ref": [
      "r322",
      "r323",
      "r325",
      "r326"
     ]
    },
    "pstv_UnpaidOfferingCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://plus.com/20240331",
     "localname": "UnpaidOfferingCosts",
     "crdr": "debit",
     "presentation": [
      "http://plus.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unpaid Offering Costs",
        "terseLabel": "Unpaid offering cost",
        "documentation": "Unpaid Offering Costs."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnrecognizedTaxBenefits",
     "crdr": "credit",
     "presentation": [
      "http://plus.com/role/IncomeTaxesUnrecognizedTaxBenefitsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrecognized Tax Benefits",
        "periodStartLabel": "Unrecognized Tax Benefits \u2013 Beginning",
        "periodEndLabel": "Unrecognized Tax Benefits \u2013 Ending",
        "documentation": "Amount of unrecognized tax benefits."
       }
      }
     },
     "auth_ref": [
      "r464",
      "r471"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions",
     "crdr": "debit",
     "presentation": [
      "http://plus.com/role/IncomeTaxesUnrecognizedTaxBenefitsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions",
        "negatedLabel": "Gross decreases \u2013 tax positions in prior period",
        "documentation": "Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns."
       }
      }
     },
     "auth_ref": [
      "r472"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense",
     "crdr": "debit",
     "presentation": [
      "http://plus.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense",
        "terseLabel": "Interest related to unrecognized tax benefits in interest expense and penalties",
        "documentation": "Amount of expense for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return."
       }
      }
     },
     "auth_ref": [
      "r470"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions",
     "crdr": "credit",
     "presentation": [
      "http://plus.com/role/IncomeTaxesUnrecognizedTaxBenefitsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions",
        "terseLabel": "Gross increase \u2013 current-period tax positions",
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return."
       }
      }
     },
     "auth_ref": [
      "r473"
     ]
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://plus.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r42",
      "r43",
      "r44",
      "r145",
      "r146",
      "r149",
      "r150"
     ]
    },
    "pstv_UseOfEstimatesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://plus.com/20240331",
     "localname": "UseOfEstimatesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Use Of Estimates [Abstract]",
        "documentation": "Use of Estimates [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "pstv_UseOfEstimatesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://plus.com/20240331",
     "localname": "UseOfEstimatesTextBlock",
     "presentation": [
      "http://plus.com/role/UseOfEstimates"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Use Of Estimates [Text Block]",
        "terseLabel": "Use of Estimates",
        "documentation": "Provides an entity's explanation that the preparation of financial statements in conformity with generally accepted accounting principles requires the use of management estimates."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount",
     "crdr": "credit",
     "presentation": [
      "http://plus.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount",
        "terseLabel": "Increase (decrease) in valuation allowance",
        "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset."
       }
      }
     },
     "auth_ref": [
      "r476"
     ]
    },
    "us-gaap_VariableRateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "VariableRateAxis",
     "presentation": [
      "http://plus.com/role/TermLoanObligationsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Variable Rate [Axis]",
        "terseLabel": "Variable Rate",
        "documentation": "Information by type of variable rate."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_VariableRateDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "VariableRateDomain",
     "presentation": [
      "http://plus.com/role/TermLoanObligationsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Variable Rate [Domain]",
        "terseLabel": "Variable Rate",
        "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WarrantMember",
     "presentation": [
      "http://plus.com/role/LossPerShareScheduleOfAntidilutiveSecuritiesExcludedFromDilutedIncomeLossPerShareDetails",
      "http://plus.com/role/StockholdersEquityWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant [Member]",
        "terseLabel": "Outstanding Warrants [Member]",
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount."
       }
      }
     },
     "auth_ref": [
      "r832",
      "r833",
      "r836",
      "r837",
      "r838",
      "r839"
     ]
    },
    "us-gaap_WarrantsAndRightsOutstanding": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WarrantsAndRightsOutstanding",
     "crdr": "credit",
     "presentation": [
      "http://plus.com/role/LiquidityAndGoingConcernAdditionalInformationDetails",
      "http://plus.com/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants And Rights Outstanding",
        "terseLabel": "Warrant liability",
        "documentation": "Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WarrantsAndRightsOutstandingTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WarrantsAndRightsOutstandingTerm",
     "presentation": [
      "http://plus.com/role/StockholdersEquityWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants And Rights Outstanding Term",
        "terseLabel": "Warrants expected term",
        "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r936"
     ]
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "presentation": [
      "http://plus.com/role/CondensedStatementsOfOperationsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number Of Diluted Shares Outstanding",
        "terseLabel": "Diluted weighted average shares used in calculating net loss per share attributable to common stockholders",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r223",
      "r229"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://plus.com/role/CondensedStatementsOfOperationsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number Of Shares Outstanding Basic",
        "terseLabel": "Basic weighted average shares used in calculating net loss per share attributable to common stockholders",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r222",
      "r229"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "13",
   "SubTopic": "10",
   "Topic": "480",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481766/480-10-25-13"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(g)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "470",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481544/470-10-50-1"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "825",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-1"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "30",
   "Topic": "350",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "60",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "820",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482053/820-10-60-1"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SAB TOPIC 4.C)",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-4"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19(b),22(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.20)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.21)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.22(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.22)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.25)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.29)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.29,30)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.30)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-1"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-3"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-4"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-5"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "250",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-4"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-8"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-9"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482686/350-30-45-2"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482130/360-10-45-4"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-2"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "480",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(CFRR 211.02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480244/480-10-S99-1"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481142/505-10-45-2"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-10"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-4"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-5"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-8"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481549/505-30-45-1"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481520/505-30-50-4"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-1"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-12"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-13"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-6"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-3"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-8"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-18"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4A"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4B"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4C"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4D"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-9"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "820",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "835",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-1A"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "835",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-2"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "835",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "835",
   "SubTopic": "30",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482949/835-30-55-8"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "210",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03.17)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "470",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480848/942-470-50-3"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "470",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480848/942-470-50-3"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "470",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480848/942-470-50-3"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "825",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480981/942-825-50-1"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "985",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481283/985-20-50-1"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//205/tableOfContent"
  },
  "r89": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r90": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r91": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r92": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r93": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r94": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r95": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r96": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r97": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r98": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r99": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r100": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r101": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r102": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.13)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r103": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r104": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.7(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r105": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r106": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.8)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r107": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13"
  },
  "r108": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13"
  },
  "r109": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24"
  },
  "r110": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25"
  },
  "r111": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r112": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//235/tableOfContent"
  },
  "r113": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2"
  },
  "r114": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r115": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r116": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-2"
  },
  "r117": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//440/tableOfContent"
  },
  "r118": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//470/tableOfContent"
  },
  "r119": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//505/tableOfContent"
  },
  "r120": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6"
  },
  "r121": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-7"
  },
  "r122": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1"
  },
  "r123": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "710",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//710/tableOfContent"
  },
  "r124": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "712",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//712/tableOfContent"
  },
  "r125": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "715",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//715/tableOfContent"
  },
  "r126": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//718/tableOfContent"
  },
  "r127": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r128": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r129": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12"
  },
  "r130": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r131": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//810/tableOfContent"
  },
  "r132": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "820",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//820/tableOfContent"
  },
  "r133": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r134": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r135": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r136": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(15)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r137": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r138": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r139": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r140": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r141": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r142": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04.9)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482659/740-20-45-2"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-1"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-11"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-12"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-6"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "SubTopic": "20",
   "Topic": "310",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481925/310-20-65-2"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "326",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-3"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "326",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-3"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-4"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h))",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.22(a)(2))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "606",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//606/tableOfContent"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(a)",
   "Publisher": "SEC"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5C",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5C"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-1"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(210.5-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-17"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-1"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-6"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480530/250-10-S99-3"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480530/250-10-S99-5"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//260/tableOfContent"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-3"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-3"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-1"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-3"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-42"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481925/310-20-65-2"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481925/310-20-65-2"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-1"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-2"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-11"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-14"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-16"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-5"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-4"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-7"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-9"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482598/350-20-45-1"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147477123/405-50-65-1"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-6"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-4"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-6"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-10"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-13"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-15"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-17"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-18"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-18"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-19"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-9"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "70",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480794/715-70-50-1"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//718/tableOfContent"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-1D"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-2"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-3"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.C.Q3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.1.Q5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.3.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483044/730-10-05-1"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483041/730-20-50-1"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//740/tableOfContent"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-10B"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-25"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-28"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-10"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-14"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-17"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-19"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-20"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-21"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-2"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482526/740-270-50-1"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482603/740-30-50-2"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479845/805-20-65-3"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479845/805-20-65-3"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479845/805-20-65-3"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-5"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-5"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-6"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-2"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-6A"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482477/820-10-65-13"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482477/820-10-65-13"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482833/825-10-65-5"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482833/825-10-65-6"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482833/825-10-65-6"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482833/825-10-65-6"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482833/825-10-65-6"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-2"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "832",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483482/832-10-65-1"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "832",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483482/832-10-65-1"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483013/835-20-50-1"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482900/835-30-50-1"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-5"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-5"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-5"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-5"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-5"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//855/tableOfContent"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481444/860-30-45-1"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481420/860-30-50-7"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(4)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483194/926-20-65-2"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483194/926-20-65-2"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483194/926-20-65-2"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "33",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "33",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "35A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "35A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480842/942-360-50-1"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-1"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-2"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-3"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r670": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r671": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r672": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11"
  },
  "r673": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-13"
  },
  "r674": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4"
  },
  "r675": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-2"
  },
  "r676": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-27"
  },
  "r677": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r678": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r679": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r680": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r681": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r682": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r683": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r684": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r685": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4"
  },
  "r686": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r687": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r688": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r689": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r690": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-2"
  },
  "r691": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r692": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r693": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r694": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r695": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r696": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r697": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r698": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r699": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r700": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r701": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r702": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r703": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r704": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r705": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r706": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r707": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r708": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r709": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r710": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r711": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r712": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r713": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r714": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r715": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r716": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r717": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r718": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r719": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r720": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r721": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r722": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2"
  },
  "r723": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2"
  },
  "r724": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3"
  },
  "r725": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7"
  },
  "r726": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483580/946-220-50-3"
  },
  "r727": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r728": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r729": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r730": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r731": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r732": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r733": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r734": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r735": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r736": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r737": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r738": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r739": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r740": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r741": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r742": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r743": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r744": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r745": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r746": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r747": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r748": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r749": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r750": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1"
  },
  "r751": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r752": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r753": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r754": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r755": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r756": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r757": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r758": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r759": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r760": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SX 210.12-13(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5"
  },
  "r761": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SX 210.12-13(Column G)(Footnote 8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5"
  },
  "r762": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5B",
   "Subparagraph": "(SX 210.12-13B(Column E)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5B"
  },
  "r763": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5C",
   "Subparagraph": "(SX 210.12-13C(Column H)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5C"
  },
  "r764": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5D",
   "Subparagraph": "(SX 210.12-13D(Column B)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5D"
  },
  "r765": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5D",
   "Subparagraph": "(SX 210.12-13D(Column C)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5D"
  },
  "r766": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r767": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r768": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7"
  },
  "r769": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7"
  },
  "r770": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7"
  },
  "r771": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7"
  },
  "r772": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-1"
  },
  "r773": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r774": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r775": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r776": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r777": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-6"
  },
  "r778": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479851/948-310-S99-1"
  },
  "r779": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480327/954-440-50-1"
  },
  "r780": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r781": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r782": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r783": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r784": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r785": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r786": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r787": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r788": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r789": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482856/976-310-50-1"
  },
  "r790": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482707/978-310-50-1"
  },
  "r791": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4"
  },
  "r792": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)(1)",
   "SubTopic": "10",
   "Topic": "815",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4D"
  },
  "r793": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(a)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H"
  },
  "r794": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(b)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H"
  },
  "r795": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r796": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r797": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-22"
  },
  "r798": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r799": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52"
  },
  "r800": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r801": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31"
  },
  "r802": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482785/280-10-55-47"
  },
  "r803": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481933/310-10-55-12A"
  },
  "r804": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479081/326-30-55-8"
  },
  "r805": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482955/340-10-05-5"
  },
  "r806": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482548/350-20-55-24"
  },
  "r807": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r808": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69B"
  },
  "r809": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69C"
  },
  "r810": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69E"
  },
  "r811": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69F"
  },
  "r812": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r813": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r814": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r815": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r816": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r817": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r818": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r819": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r820": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r821": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r822": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-17"
  },
  "r823": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480547/715-80-55-8"
  },
  "r824": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r825": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r826": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "217",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482663/740-10-55-217"
  },
  "r827": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3"
  },
  "r828": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "53",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479589/842-20-55-53"
  },
  "r829": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10"
  },
  "r830": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479401/944-30-55-2"
  },
  "r831": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29F"
  },
  "r832": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r833": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r834": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1"
  },
  "r835": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1"
  },
  "r836": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r837": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r838": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r839": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r840": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10"
  },
  "r841": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-11"
  },
  "r842": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12"
  },
  "r843": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r844": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r845": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r846": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-3"
  },
  "r847": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "470",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481174/470-10-25-2"
  },
  "r848": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "SubTopic": "10",
   "Topic": "250",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3"
  },
  "r849": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "SubTopic": "20",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r850": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4H",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-4H"
  },
  "r851": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(a)",
   "Publisher": "SEC"
  },
  "r852": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(b)",
   "Subparagraph": "(1)",
   "Publisher": "SEC"
  },
  "r853": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(b)",
   "Subparagraph": "(2)",
   "Publisher": "SEC"
  },
  "r854": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(b)",
   "Subparagraph": "(3)",
   "Publisher": "SEC"
  },
  "r855": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(c)",
   "Subparagraph": "(2)(i)",
   "Publisher": "SEC"
  },
  "r856": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(c)",
   "Subparagraph": "(2)(ii)",
   "Publisher": "SEC"
  },
  "r857": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(c)",
   "Subparagraph": "(2)(iii)",
   "Publisher": "SEC"
  },
  "r858": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//210/tableOfContent"
  },
  "r859": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r860": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r861": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r862": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r863": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r864": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r865": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r866": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(f))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r867": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r868": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3"
  },
  "r869": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3"
  },
  "r870": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23"
  },
  "r871": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24"
  },
  "r872": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5"
  },
  "r873": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "55",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-55"
  },
  "r874": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-18"
  },
  "r875": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r876": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-9"
  },
  "r877": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3"
  },
  "r878": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3"
  },
  "r879": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3"
  },
  "r880": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r881": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483032/340-10-45-1"
  },
  "r882": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r883": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r884": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482130/360-10-45-5"
  },
  "r885": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3"
  },
  "r886": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10"
  },
  "r887": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//450/tableOfContent"
  },
  "r888": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9"
  },
  "r889": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r890": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r891": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r892": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r893": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2"
  },
  "r894": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5"
  },
  "r895": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r896": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r897": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r898": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r899": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r900": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r901": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r902": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r903": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r904": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r905": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r906": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r907": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r908": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r909": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r910": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r911": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r912": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r913": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r914": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r915": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r916": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r917": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r918": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r919": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r920": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r921": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r922": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r923": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "730",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483041/730-20-50-1"
  },
  "r924": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12"
  },
  "r925": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15"
  },
  "r926": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A"
  },
  "r927": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r928": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-6"
  },
  "r929": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r930": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "15",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480123/805-50-15-3"
  },
  "r931": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480060/805-50-25-1"
  },
  "r932": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "30",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480027/805-50-30-1"
  },
  "r933": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "30",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480027/805-50-30-2"
  },
  "r934": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480682/815-20-25-6A"
  },
  "r935": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r936": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r937": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28"
  },
  "r938": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-4"
  },
  "r939": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3"
  },
  "r940": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r941": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6"
  },
  "r942": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3"
  },
  "r943": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7"
  },
  "r944": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7"
  },
  "r945": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r946": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r947": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r948": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r949": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r950": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r951": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482517/912-730-25-1"
  },
  "r952": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480832/942-320-50-2"
  },
  "r953": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479432/944-30-50-2B"
  },
  "r954": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4"
  },
  "r955": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r956": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3"
  },
  "r957": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r958": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>84
<FILENAME>0001193125-24-157500-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001193125-24-157500-xbrl.zip
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M/U@#>WACU&NUMT;JSPPO?^M3N $C)DM:7F#"?$'@!7-IBZPCYF:"@URY^=:
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MG40_M2<>?I>A_+#2\W[<KB(#:I-ZT*YF/Y&D3%!5/[/@HOYYYE]02P,$%
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M\+!1/3K:'U;WJ_NUZEZMWFC4&Y7?PR'9OW=6ZMY?W9=T2JT*L\-"F*\.^[E
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M^\]4/!:X+IE 3W?H2[-XJ;]J^U]02P,$%     @ )HC'6.].OO]^!P  RUH
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M.SN'A>^*4DV($]<7:C^R/%<FO8Q"[KDX:QGD >AUR+WC),*('"J5I"IRY'G
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M$>=S;I'F2"\^AF5"(2E]=WK'TXBWL?LS6,SNUO$-8# H-B/4,U;+6TIFR]Z
MK4;*__0W[R^#J=UZ0& =RNCG8-+9<I@-:7NC 0-@VO0YV=+B+F14@J)D:.Y3
M"R'FN$&L/T;,"1/M6)RT^"I7*4BV&-Y^2&E6X7V $V+&$7"*5(T\O6XK-1)]
MS& R \[<4)<B+#RD]S(QQX>"='IC :U:@3:5*V2@&@@QWH'F/X$AB17CV-U
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M=! [MKP =DU#XB0ICRVX.OB$0J2R">/\5CQS%^"@&P=-SJ!719THE5^B;8]
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MU0G&4;8)0_.&YI<@P:B\1TBKL6C"\(./B_.71?,6&JRCA3@J8%;]F;@RMR_
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MD#2ZP=LCAU2B?%">Q5/>NMS CL>&MZMJWNL(6NC99WT]%(M&SKTGB\?C#8F
MCN1P@BH7CKXF4N-<) T;[G!R=:'@K''[@U_ A 4F^08/:95JAX[Q>5>C![#H
MAJD>SL'6=TW$W4T(S+LW7:NV9&155:>(C\4T"*G& PQC#3,ISHLFZ7)L?I#B
M:#$B\VZ" D;]',7AAK2T/?A2?,=7EF?64#$9 ))ZL"+C&A^$B_L+ZN2J#@<=
M;!XFX=C>D%/&U>?--\L;#SR2K_<L)D*S& NI]GL8Z:X48%0&T<&!0$KKL<@*
MOPE[0BN]9/@3>'4#:KKJ1/SG1$"_N^/TT9H(8"MJP#BJKM&0$=U4V.-D7(03
M3C8[XW#87,4T[RNFD;Y0L?W&4VW3/J3]4D/F[T"\33K;&9]%( Q(*:= HX3]
M F!&[L-JBXZ-\.^-BP(&62&($@<7OA&3Q%UU Q:E]#64'UB@;@S^:YE+@Z&O
M]?0Z&A=?(3L'1N)"?/H YT$:#7 Y[;J=N8IY'L'W/Y3$@FNY$\EG]-;@D*M+
M[K%"+VA?Y6_QXVK0 @%7C BECK*1N)"WE:?15;[Z^LD@6),4O6<"E,$.](1/
M<6W!KDL7>')VEIS!8% ]N"5V'=P#+F3_A1' W?2RH@"&L6OP@[RN_)5>E?Y.
M:14(>!\G?-ZBE%Q&_/$KV8J6D@/%[U]SQC!P7J,<4"D]#OWYPV]]?48-+/"6
MY C]Z3-+#YP"+2N(6<#,:H$G:5*5SFC')AV"UFW.*4T80F(-HMB P]45\K 1
M\E'".\XD:I_=6\?Y1=9B.(?[MHL'*7^]U*:-AYJAS+%S@8*>6LHP)N8Q0EZ>
MMZF/M*)'T[6G:.(IH&:/1'QP F$<<P\6S5TJ?2/#2PT,C2X@,]8W5$'20P1!
MAP$* HT!2KZ^X+#>VU>T4I\5,-PE[WOGZFYTA=Y#[K2T)[WOS4'/VWT*:QR/
M%-%C_T*+P7L2SZOPLSC6_^J0%-!#FV$RU^N@7N";,E[S##S0JTK[/GY:KYVP
M<,-!B=?%F(XM!&/V$H7+A?7IWG9@@4^>/#E[L'SXX-'#R!A3OX[0QWZ<7Z,U
M/!1T@*^IX(0<",RD1QL%B<=RIOAJ%T@/./"=M;5 FA=YH#@(H2\;OTD.I&JX
M!$$'6@5Y8=ZKP0B'3G^Q[S2F?8TO?Y3EXP)E*^-SEA%@>U:6'77T8&2&H_L2
M,=I7<LD].COYO\H9I\<K^VK' >%!T^W(_,.P/$!GLY#I>(AGLB/.B]-K:9O(
MYR;6HCH8W*SIL4?'[O1+3N9_,R?S[SZ9#][^&40&A1 J/C8F1B2W:/_BJ7RI
M=H^M[0;=SP2NS<3&[8ZM#NN7&0OUC\Z14Z.E+7<F?!+GE+FNJ^0&E&3OP)<5
MBW,LB(<%]8WO\*CT118._RL-J)_^G)Q[0\];MOI=Y .!04F4E-:/87!Z> /]
MT^+-JS<_:7<BXKOY*.5;>N1T?.1YE@Y]]P:,FC-O,###C2EM_)LZ/>9:CH13
M'5]L,T)G<G ME0DJ<GLJP4<O)EG_&L]I&*Z.Q'/>3""FXQF+IZN>#/MZTN81
MKEXVS!'!H_M(N"2^MH0]6)A:UK=TM90P\ EYNL(VS,%/G6:RU]OCH(:(,71!
MDFXF/DA+/A1RZ04_5BH]M;F37C4A#4=-AV!(0N>=VJC.F%,<YLVH(3OA/D;/
MZ3Y,]HPE>JQASLTX,]+IHY%.(3<4P'>:$!KIK)^QI+/5W8+5747@,)O9;&9W
MTI'B*V7^D"D'\*B-+YS$9T.<#?$6_%UHJ\Z%9I[#1]QSM87?@X\D.)<B-!,F
MY<?(F&8CG8WT5HU4MN==^M[5S6QQL\7=D<4)#,N?-HZP2>H17IA?J?V^*KK=
M1/@X=P+-)GK+3G%95^ .3S*7%DIN+$!4]P%KPFRC#)(^SM=ZWTU!42,"M]D@
M\$7)P!R\<B[)+WJ%4!-+%+S,D.EJL>]JE#(T"36L0#8(S%U5FQ(>B+I9?5<4
M[R2)H)^$TU%+_]+'(1]J3+E8$>GT.*)D)I6IO2L1386?\F2(%O^"FQ9^KVS2
M&.$D%R;61&TM81@I33%FZ1)+OQ8!XE/">'G$*;RWP9P1"HUAHFE14+DH=)K8
MH3*%(7EGO=-%[B[Y16DTTQ:^1HQ=AI90('E"L60ZMZAG1L:88D?W09.7H?F&
MKV6#SQ!PRD/0K57JFI+?B5QAFR]S11TEQX-1+ [F3: U#%B,*UD;/VL<NI<O
M<"Z+D+L&TX=H2B\A2RBZJ88RAN27#&(+77$]@#/AF?:8(<9#:==2ZAUO0%*B
MU;(075O??S":R::$,^$\ Q\#/B%BZQ)C[19\2$@Z,*D52C$L4Y:,=TC\5/:)
M>29(MD)/>WB@T(%FNS=B\-U]TA%NT\PO^1CTB]W*\ G\*ZQ<ANW2S =,IX5R
M(BB9X,@P1UC?:N %5ZZ)WEF-(TXP],EK#1[ &MED)T\@F<.FMPI+8=P#,^CA
MC%M^!A!Y)2CUA7QZJV5:2&6.ZT0&0Z]X^7XC=\@C$TF<8&&M<=54Z>@SD;5;
MQ+[CX!+$8H"4E3Y-<L2,))5!1K(RG]81>R\1,\"+2H#AO,#&6@;Z+&@[+#()
M_9F9GKF\,H>/-\E 1MC:J6X3[$*@<((CJ(!I3T* ,1^^9].\!=.D-D$"$:I-
MEB3#--:B:/T[^.U-G>X:Z>T"7TG!0D/AHF]VO_"LZ^X#>6QLWJD:AM%1I*K7
M@6WE4.$>/.#,#I0VL\G/)G^[WA@.,##GN70=&K2S[7<*3++78+>! UG.M/M+
MA/1H0#?&)E%9EAL^"3>M7QC1O:1_#^%5\R*8%\$-%P%[X 'I2V#<YM#_'$X]
MS\JV*G,X(+)6-,3#M'9F(YR-\!;2JNKP(G;=:W#K]<&BFZK*>A?94^:,B@0!
MO*@(RIEI<K;GV[9GGX*I@^8)\5YIB*'B DPW%>='(/;FJ$2)Z<>2A9=ISNY9
MZ*9,"^R 4U)IRB8-^\ML07@RMR!H"\+L5/X'.!7B5.(>3TM)9BDRK4C77/&>
MK>[V#\EP**9=1AJ+')6_+OW6\V?4LK'S,-UAX9@/SUB1\GP/DN372LLG)/FY
MZ3Q=*1^TIV;$OA%/)S'"@7E_=#G4<F*R=DR>(WR%5"/AEA]1CDEL3@,E345N
M/9%2TI('TO=(<D,2O,^[,?X9RUJ"Y3W! ^AE_HI5POA*)E]('"(._!@\4KVO
MB(Y3*66V^9X^H91O:Y<1*G(\\PAA/?8R84ADDB7\2AQE(3=5TSB5,\1RJ7^T
MT+1#I3"(M+ 4MG2>6H)"JI$*E.^6\O11U\G7Q\796Z"+&:G7?C19C.>3&Z.*
M20U=RQAKS'V1QE K8."+N3$US!%>&$OJ2BO?\KY[GMM (,,Q/3+(-$W CM\C
ML>H+<F6"+*$4X6$?9,T$D\+RGJ$ZBKVDM&*3Q5A+HPRM7L1WM\,/N17('%6$
M-213N&4@-X2Y,_]55&.9T*1F, X^-U<%0B]==.#WMT!75M(>B9:IB_J27$ K
M*E?,0#40/6V<O;Q_5*8ZH[17+3P2-'I;Y@H;4YT?)1#ID;TRQHHN[MTU/6YX
M!C9N&7]M"Z3/7!HB3+#4--]YLD-V: P/UU<0AI1*V'-I G$PS?1*7ZZ_ U*^
MI7F&#\U8'S&AQO6?4FZCPG=2P;&,;.!*E)1SE!03;XH#D4JW+\8/YOJZPX)!
M93FYC"T!FG2)FP'JC_E'2<%BFVS_B>^#XPZ;NKM-U[32U9T$[AHG',809%7H
M<3MPI*FRF]$JLX0,^+7%&_W,,_U,1!<$/DQ<+KR]KF5_-5KX*0,W&##W,Q)1
M%.7B#8RA9_UXB55IY?RPG_"WPN'-6TET^,?N]OCC5T_.3L_BWN=C6,C?/ V?
M[*+4O[[\0TJ/TI_#R\JODHFA,-2NNA*"9!WA#CU>*F'^NX+*\/8=.8*(Q@7U
MFOF+-W_A)'3R>X5@#C[H8=@=8@?YD^_Z'>1R43N)1\;B='&N45"T&):'A9 \
MFE'6J(=D_125Q/R:)?<F2Q=UQ*,KI8*F0E><-^ @A.A:T9U74GY\_>T)D28J
M[<<>F<LRAB[QIE'%J^?1=[I\>C:".W"S3GTLH6\4;(>(BK2;AA<(^O&^?1-_
M;@X!QT7%>6.V]9W@G?S<3T\Q\SCVMN#(J/L/VS-R</'X:.U6H4P3EHX>?/'5
MV>FC 04.<ZD21<,K#'](9-R_QDLG;/J\]7WSP^/DVQ^^MY\XYY?K+0U6W>L/
M(!V+/GJ,Q'8RV*IY& (=YY@MW[.3#F:6QB[54XI&GOEE7L,.^M9^\%P_Z'WF
M)1%RP6Z.'E_XNP@1<<&')&9&PJ,+<3:3:_DA40J@(T.)>:(Z1^8;I+?)'_(K
MX.4F9Y87]X-</ZQW.SO[+OGZ[+'>33T4!OGUA6@H^JU<3UH#,SD^E;^/>#RY
M7_CBA%,+&$$::QXX<T3BZ] ]P"OU:8>?//XN>?3MM\.['9N_^[>][SW[$(9)
M57]7'S?!<_[D'=A@&IW^'UW'(F]L-U/3/]B$PE0_>A(]5KC6T9$Y:H[7W&EY
MOTZ);)^M,F(7/GK_ZQKT7=O@3Q>N-)0O%GZ2.=C9\R6>D9;5!5,*!QB\$L:@
MVJ2%P?M3WZ /0VDZ1[5(^)P6W=^W$4B&QN"/#=+W!/?:T\7?P9S+<1Y/VF09
M6+90/379>B7NU88,945EMK2%Y<D7P6EOQ^$]-;,5V/XE,8;_'#[Z!/C38I?Q
MC92S<83G)[CG+YA6[-NYIG</&B%]BB=.2(RNUT1TF'Q^,V$SR]N)!@#BO",I
M=8*.4A)EI#D*HF]_-R3)YSV#$2!1;E7R\Q1#>^VJ:RF12[*PA16^:;>>9\G3
MP?L>LTU1+?W/)O"V^<^\7!?,\%0?, ^$JXYQ*)(OH=3UNNB0NUR^+3X#-]-#
M3Y#$^(U$=EGS.>M5/#-Z!A%!3;RO2@^@23F<=VS,J33;%U= _$UI1L;[@K29
M3?RAGWZ:0#$/+:7XO_45+D4PB]FL8 .K./.#U%PL84(3*FDLS]\?"[@8-O\1
M,FIO7.&EHI:GEV"D'7-_Q=CZE"]'PF(X#"Y+KNC8BW)N-N4]\>!3XER]-SC>
M!/89-KG]6-4U\9)I#,6LNTP_O4)-MS:D6%30;,W+4 %<(C_G%3V44ZIP4>'E
M?CN]B/].FB+YFHNB2DL/:Y373?LO:Z/L-U2F@@L\Y[^]E.^& !M#*/^IGW]^
M[O-H^LO FXM!(WC2@C2.X'Y8U_PQ+8D\')___U40$[^&H!0LZ[E4RSPW<J@_
MR6/24],L^-@S#YA-[ZE@;%AGK-+Z#7$\TGKV](#-6+:GEW"QE0&N+[;HI*C]
M=W2^*3>'D7HT1OU\6&N*N_X5<1W5Z:4)JOU[2>R.'09PB1\>G3[YBS[4QS\A
M[#TH0N!ZSWBZ&%1:HFM_U.MZX^C)9="(7YDPN_(#.%>P=D[P_WY]<7*-O!&]
M8+]A55HUQ]XB)M;',C.O?-*MX^2B#JP>%D,9E#[DZ2IE7L$ R<5$AR0_G[A-
M91U%$)E#?>/3Q7]7N!/37R4\CC9PK>6$+N-XC\9(6XU_:-=:V C-EXU6^<Q5
M_:2)XDAH@36NGE^+![17#5KVG2HE1R:<R>VYU\]L:R&9.>FR\'M_VIJMU'2G
MXR2LP1]1-P6WH#;:VDYK7> !6,LI&ZJOT2#=V[[RC%5KI,V)RYHX0QJ0>EI%
MK#RO4ZQQ)5<O\+(J3TPXJ&O7"Z5H=Y5%?@E8@8UE<C#U"I$"9APA8[:&8-,^
M^O0TW-,?D>B4@OI:.5NXH-[M,&AG12L,%F6LV&W"2[S/Q??PDS4P<D5:*YD!
M+0-YQCT2F;.M>R^@,K(NS4(_S<DE-E\'2DO876!=[!I5%/BCJBVO)5H@;)-;
M1R5.]%WLHF \?SL]/P7+*]_S<2",I3]W:[\T^BQDAH>EL/@'$NNWA]/%<[RT
M7E?\+D$+]!;X)F+*^#9?/98$UDN!O;P07_VJ5&)?$P3XL.+EBU?/??21^X_J
M4G@E#46C[Z&TN6O89X4@&5T>LJ@S4VU-,) ZE"GH+^+%]=VXN<^W+O6>02/U
M'P^+2T9?N \IYHOX&(2/#X]0O:=T4%W1EG(.;A!^7/PWRG$<.";2]SW_[Q_]
MZU:1.,*C,\Z;GL+WR8[((N.//-;4ZCD$^"F9#UT=+0ON"DL+BWR^$(H#?LK#
M1/WJS27L;%RM%?D%0BV=(M_[EN2S_$23"<'#&IT&/G)Q^)37O$\D1HR9SX+!
M=/U2$GM?UE6:N?KH8F3M&]Q]Y/C*56'4N?4E?+I@M$>*/EK!^;Q4*3CTQLI?
MXH,>Q$6(PI#4D#9XF"TIHVE#H)QJ6-&=&&*A!T\Y@\>?X;5*Z^\%BK6UBIY_
MA\_?U3"O9#?X:KI:WG*J>?%CE=9>0[2L.E+N314W9@G(I7C[6*JLRR!N@\<"
M5AT<]:4>SZ&:PN,O3^MC>9BZ"'HL^."&-?I8]9C&UA,XJ#YV*05.3LKK(FO!
MN[+:X7] + 4/ "L87JN!N4DSB9VXG6 %IE'MP'!P.C".%KP3.UU)VZRGGI-2
M]UZ*-5AGSWUA$\-*/*OM[:6Y]*(SFRY%H(XSLH0WF6;*+^A\AO75E1H1<' ;
M[Q?R$^U%_G0 8]VQ%^=107])@S0Q*E8%=PV>7CC5%>T7Y[JB^W.:*#QLV(9*
M[UIAF?^CT]B5'L#U$\4>TV)2%0)KR<4VXXT[]ORX,(4R28_'4<Z?RK+T;BN.
M:8Q3PDQW7C*L<LT)&$SOE0</-233]=LD6PJ6]HGO/YX-J_F[N$(P?2KE,L Y
M:J8FCL\]BXZ.(D9OVKA#!Z#W3J8?/BJ+Z[,+HGOBDAV>C/[I) -K(5@T!RN8
MU@,LX4MBZZ?!$F"$%$?2#\0TE2\[=,[* L4A[#UF:(2+AL66.9I[[X0?)JZ*
M**,+XX;.&3T@NBW?/]8%3;"VDAP&0:!A*\]H>3_ZX?MOB9XKW9&>#"'U4H]&
M]DB$345]6IKXJ2X%H;Q@AG^E'7O@HU\OML4JGU8,XLG97Q8J# #K\@LNUWPW
MEVONH5Q#<19M&R15(6!Z;X$$KX+=QRN6"6Q*T-+&E#V>R3H,<*MXV2M/HA!(
MG+#5ZB'T6OZ%_<HG7+WGBG!K7*\1"H5/"U%U*Y_'#U*N0S2T*+N4?ACQ7IKY
ME05=NJG5K+)6O'89D$J!S#9?L_L154?_/7,L5<&8>"/6+$!O#\+1O\]AY'W9
MI/OZKZ[RT8P,!@_F-5@'KI4K)"IKS:GFF[U>_UF)-E">:Z@FC/NW]H3(W/.\
M(ZD[1Q.L8H91, R5%9).^4$PF!U> BOU8&!\)093B]#DO>_^;S'U 9N6[R+&
M[?Y'I<G#D7NE1[T[W90_(3#A,B,&A)%>'ZLZ<X.1!QSENCW+J5^*IS98TZXS
M!)]2YG9,UKLR8?@R;7*+ZY=(^!Z#F!ZHELN\E#_I=Z))E'(>3HL_J2#1,T[X
M/OKAZV]LG!*5H>R'0SV)KIC6<'1QS<FO'S!U@A?3['O=:>NY-+HHH%H%G-Z-
M?U]%>:=0-1KDRWR'219%/H[R>9JYVHWM9QF>&AB%VK,%WM_"=/LA)(>^ ^/7
M>OFB.31@">&BL$0<;IXA\]$*2ZG1&[_6O2@/@@)-V"68;IQ"6VNO:1CR\P@Y
MD@S8V#V:Z9M('OSCY1'I2'S=;_U7XK]F2!@A$(T\_#=GWWBS'!C!/?0R=1Z
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M?#7C=;0GQFZ"6Z[V&FI9N5EZHN#;[URXM!P):TQ54N2FQS1J3?C*!W0<<CY
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M5_1XBN1C+AFHC'TD&>!]H5F>]V"[1VR4=2DK'(%KB5(2<DO$'U4*CB62>G4
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ME@U&@G0XU87"V%5B^@MP!'WQ(M?EOBK2?">!E(>/\I/8W7MY6'3-%/M'HFT
M1S3)*>)'H,1A[^(&F_YK3TWJQZ#H80ZFA]^3I- ,3#14T(+C@X+AD;M,:PS2
M&CV(00#KBL%"\[)N@FL:D05 9UT0J4![PBLW,/$V_>_[+B\*M^$UTJ+C::%:
M>$[8:/Q1>M,.BP>4+3M[^O:GU^?TST=/'\(L[2K<7;AO2N?:TJA0^-N.=?MQ
MUT,!NTZ&;LF5OI*G5MICT%;M[Y(W!>6T282"AI9YK \>AB&BR3:YJ[$>1,3
MC'9#F,97ZO3%SC[;\3,- !QYDH3.+TU><R[62-?2^X:#J%Q5RC&-C6 O=,V=
M+M[H"4./=I=Y0Z(G71,A;1)[D/$58I65CC^IL6[M]ITPZC#?&/:I]'9FLQ#B
MOI)Q..I(#_'GN?L>Z=;PY!:YF>@QEX(%,:F_I:MM#D.U6-95F@TWV&3A*&%
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MPBSO403)EUD)_GZN!&LE>'8I_P-<2D[8V4!_M!614<R<%6Z3-^%@Q1MFSE+
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M]K7&#-=L1[,=W=".FJXA5"]WAL1;Y!A<>S:YV>1NU>1B$2O;=ZEYT1Z:>+;
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MJQ%22V&?F(X]O0LQ.=^[-YE74]1<V!I$CSZDZ*+=N';<VLQ2YD8)V)Y,38<
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ML%XE@[>+3<,N+/)U(MBTNU(])W.(-&[Z(01:,3I%+]%A93\^=AG80WSP?1@
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M,V@YR)0.99<3WLVFS8LK1+M*B@R]IOAAFM1/LR3787K330FKBSI?G8DH0NF
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MN80Y:J^2R]%&"&J[/TJ7@FY=I0W./NXEG,BPEP%)IV'FC33"W#HWKY ,5YO
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M/H#1$G7F'RU<]3&W IA/R >*=<JYH!<^?!'5*^EL$H[6?+$"OIB1=&R9%7-
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M@UIV-<I%NKD.Y^:+)XC@4(8T?*1_Q24<H.%,MQESB$8J9!N'O5TK:Y=MOZ+
MD=^!55;6D?)C699EQ#-MTM+PTS!?F7C5^SW+=>K2AZK?'>$7X3;[5SFY-G7?
MO35OT0:C85)502>SAXC0@I@M-286U2&UMR)7\$AZ/U]XZ3-Z.D7>N=K_)O =
M[U6T!F#";L5>Z)C>".<?$>6GVE'N.HZ[#$!KNWVX",[U6P5G+9= -,MJ%Z7V
MH31[S'"'\$X@LWY"=65LD>/EX;4EAX^$((AZBS#;VS"V0(-2"^6O E/FXB?H
M^F,H<N'.<P_U4K]#YYL8W$9/-'(D'G28J!BA[(\QUJ@"Z,I?9A 5F'4)S*'E
M[O&@="GNW"@ZNB/E+AB&C6LK7@GOP GXL+Y18%*P@@7+,V;.V#+^=3MEWD?$
MQR_M'>_<W@K<H(Y)ZG$!U&1!"OT),VXE^:)NQ'2],C6I9EA>8GB4R(:^'6FS
MC,V:Q6@WKLRM+6? .=F1C;T=H7@;T>ENP=X/9"&,>'MGJVYK2XG*9Q4+AZ0V
M4ZN@/%6 YX#G"$N2+[@PX5HQI?D P+/$;PQAQ(51RL>O#P0(%;2MU!&>!RWX
M(ZN.:^.X.*54F'RDUVM7*?F[E"MX(>XJR:1Z9D(=F$'405YI.BC58:COX0B-
M8^6E^&89C5][D43AZ) K6TSWU>5/ZFQY:8W&IB10/N4>[4M4)5@$[+QXZ]H7
MK!P]J;C^A@F-W[<!GKI"4],:4)"'DU6Q@E3'/>)+9?S^FI=%-P:&65:J4-<B
M8-$+G=;\[GXLP53Y97,$5Q5[-5EBIY%)1%$H38>08G4?2\IW*>S8S8WYSNIN
M](NH&[KUUHUKV0N]%TP&+FDP<X)Z5EM;%J__#N%$7MB(E^_.\S.;Q1RS&[D@
M'U@@'!X!G39#):U%,T6\8M2;7$,GYY]NSW 07HX:) &5"/.8P:BC/+E$^N",
MN7"(3E(L$0UI>)0K2OSHX4318<'/T?5(>Y=B$B+I>'W>#C!BK;3I[8@1"OVL
MB8DNZ8 &=#"RD/D,-+&M8:6,C?346SQ<#CEVN X8$KQ[A]*"T&(H!_8BI ^C
M#_N%YEZ01%Y@<OG9;F@NDAH6&ZV 6NI$1"9LU*J1&E; NV1!9UOLO&ATX6E]
M:'O'.<K,((9:1F2!S Z4/K2M8]T>[S[H)M-Q!3U_+# X5UY=I-S8 %9,U=XT
MRD\W*+4@ IG=_$(E8<5RBS835>5=D3>$ME97?$F=*%%HV-I0XAI#)ZU2XDT:
M,V5GF>6Y,+G>(QV71",&?.7Z,8-KXQ7(VF"=-LP3GTGM7R/J6_1%"_SN WX3
M-<>AV*JJT"<JI#^3WEA&L0XJA0TH! 9JK]-E9X@W]$VOG2?\;!>1=B13J#M%
MZ)C%2FAYO.]V)[N%8ON)%AKM](V ]><$,4K8++:*IH=X8J7$<_](1B78'58N
M4V!;L]+%\RI[7)&I+JHNHI/Z(,_IBY>Y0>6VM5D*)P1#;0NN-Y+HE?'KK6QG
M1-!H!;K:?N '-FR7.&<!>\FY\-X2&IH^-[L3#- ]F8*%SDTI> @DWH\1%.9.
MHWH")ISV,\VXH/QRYJ .[@)8CVDV8HJ#9;8+CBUP!=:JS>]NN%11N?L[:DBU
MB-<,NY5U+R18M85)4"-<)XO'''@_VAL"[P\=>%^'6(G:%5U@Z*V4K(DC^9IB
M0UI>C7)]QM&;"XS>?)O<2S@R/OYLH6+8'_08)F;]2%6:Y:U?_&>;U-3D<#,G
M/YX1-;V&^WJ:5,8U]@FO,;T^+%%?"FMR9Q-'__VVI&YT#/?G#3RIS(OH/!'>
M7_=CB:_:800_]2LD;WS&TDOA!TAU3BUV6_7VL7-]PH3W5/8  YA+1I,*NY,9
M5J>FT1,<OG+KP>SA3"JY'C?VU6*G\Y8Q2SP<[GB/_Z^[<\&R\24NFTU4>=A&
MC&-JIL:%9V+:R;)M?'GCXO$K[!3GEQ[WO!+NH(FI*J9,Q0CH1XVS>;(ETF1S
M[*%'55.5\$I)].=CKS8O^ OB2"@!>,\QS1R2\' WK*7^7%Z9AL.X7K,9]E!Z
M/5GR\3S)2.K,9VIWO@Q.9*S-[QIR;BMX,5V@.HN>$8?3]X*9LA]UBT><BY=6
MO/;VTAFK$$0K*J,C+6SO4Q_>]'Q?1*?M95LW?$L?Q,A;>< %IS0\Z6K&\>(G
MT3FOIXE.D3&*U!>I'%\%Q+CJJ'4\FJQ 1>"^9XU<$'-](HOT#\=[NWL\FAD6
MG&/?D'\>Z:?TWE-*]MB3V2.=<5!6*M$6ZIC0PH+3FA$,4B7'1-'TQVIM\0R.
MU%7)]+IC-PA_ C<<$TL?1D8G!]!3?W0UO+Z>)*YA@]F/4\&*J UUR%/*ZJ;-
MB/E-YC/(MO^HE5_'\"+^ES7R.[I<\@"Y/^>),6C)PA]1[^T>_U7?LK0YW,.[
MXA'7B9SE.PW9UDYU>VZ/GA_$)\^?K;RO8+U_V-O=#T4++\^DGDI"VZG'%9,]
M\";+>!BHE5?-W@;4:98^VO"UZ%ARY7XX..Y*?*\(T;MN6!E>[-6SD+ -#X;G
M'7>."Y4/PI]&7CH?OR<NWS;S:A_M$ONZN\^&\=KN)4YVZU+9NK(RURK.)5.(
M0S@8O:V,:]VEA @J1/Q?VK[D]D#KX<D.!9@M?"=>)KR@8#;B_'PEO/]4M? -
M^L$RGEL=(? ..E=.B2J_F*R?!H1P^B2 W5G?OG(DTY.\Q5@9&"VCA&KM;TW#
MOC#JA%+P%)T T,1@0E*]KQ:H9%C(B89C;:G%9>3$GZ!93RKG9R3(%2^DXIW;
MJ&4W%KSQCG7*!)1VP<O.S<@9AF#-$>TF8,?FW\;AMZ3T@RRSG"L-)//,E8CR
MPH1! 5@\JQZ9Q9KBIO;D6@**$ZHRY+7O2@6?D"^V;=C<4I>I5SQ.K=9"Q W?
M?>BTUK:S$6O<FS1"=]'E$%BRXLRCKJ<9:_6P8M1TRE <7 &M/T5QJ.6$_[6C
M]44K+4IN)<3E9S0 "A514;8>2,*2<6GM:X(V*35'BH/\!A/0K\1=T .[M!-<
MOS8G "4"S)\*?<_8;+$'"T;VPHP-2@YKV,-]TK"',3<3I7IO',7'H'9/CD]N
MD"Z/0>@H/CHZBO>>/]6O4Z 6ZYZ:A'3=;G2A2Y/TBFZP6(H/P_4ZHB-9+IWF
MDS_?J/BP-2 KC"WSHG1VUZ?K>G&W^F\8VJVUIG#)G>O.! \MG XJ;.0)43HF
MNV+OF^EZ/6<,-'I12ZVYCPJ\E%=99Q&^P:/R<9V]$ZOD"A,36'E*W23VJO7@
MQ@B6Z%:'$QL!).?1]2JW<?+6FC)>?HC)XI*[MNR'JA="(\@#7--U$3]N5DK:
M:B*0LM8LO-O9<<NM0/ 51313 _=E-E(8IZQ6AQ0#GM$K?JGXHGB6;.$4B_=$
M^]QMW&Z@(QYP+^^$>^D+O ;+):M,"%J2:F93I^>#I1+%[XMA^&A_R/<,#,-_
M(GW0>'@A!$*8<:4(I7AK02[28@ZIEU^5. X;_A']K2[)&Z5G#=#B@[#>4U@]
MX%4$'9XEC?.N7.VU=XE5AJ-CJ5QXHT5?>\$@F8-DWE,RKQ+0<9A"T#Y9*XU@
M0E$##WYHVR(PV3_V &P'H1R$\D'5)0F=KS+]/#T6VJ&3>5F5UPAA)Z4-W.Y'
MA3:#, ["N#EAQ*(=[)S@U(LR WA Z?THW[:XP?VH PS0!SHDUL @P8,$WU>"
M72$%U5\A!8)5K@JB=^TW6=6FNJ) MVW"(I1)KFAD\#TJ>^EWJ :1'41V<TKW
MTA2F GT('E%1SK)QK-" "XF92Z)(97R0OD'Z[BE]V@TK/>H6SU1AE*AX#50D
MUF,.XC:(V^:4G6@S+)9WK9,FJ0I.%Z^?Q!BD;Y"^]:1O"1G%3S,C]ID#,U/(
M<BPSQXHM2^6&6X/>]R4BK2 E9S%FCA?7HC@([2"T&^2U9^@AK)2@SCX'2I%G
MPJ7AA2:I%@'#2(GB'XB>]4IY!J$<A'(#*<D&^U\O!<_>9B<K<XDD[27A<2'7
MEV6PHWZF>G5R<A#+02PW()92:\\U['0C6]GT "I<TEQO[*18,*^#>N'6]R8>
M[F8ZR.<@GYMS?\).WPHKOJ@L'RO5DUKS/MKVU,U 2O$70>$S4C16'KN:W]2,
MFD%>!WF]K\/$.#ED.V(V'#L?5K8 "-#+#=T?/S-:U2"5@U3>V_B4OC"XQ=O9
M#:T!VV5_[V(;>3E.33YU<"0<B+]VLEN<6:;A<)U"WJ^T<C[5#@)JK2.,@8;:
MUP5-]O3&IX<8P[#*Q#3.1?-$TL%KVU>.O-R7R8P"VA_%E#R(^U-6="4U%L?'
M%2S[93=+U*@K:&FX8JP7V=.UDG@4W 2VOU9+@ .E7[N[P@(5)TJ)M/34K&9&
M(MLY^2ZIT^0/#_G*I2(3R_$G@^U'3V \%4+:LM,B*"2D!%.LWF^P,<;AR:%!
M;<@HIZ/,6=;0P/'!F"SK?0>NU&&N.SZF;;6\O%:*[[I!]E/$"A&1SA"'B0#>
M.+[M#FC6Z9U-U.^PT -N 6+I/*?S@U[*)(!B+8S0UEM%(*U@3 RR]%R2''IQ
MK"]9V)N:\"\8U!+Y/K*F)9[)/$&J!NYO\2&JO6Z?@([=VSWL]:D; RJ:^/]H
M9*G'6 FKQ@QV<+H8A(H(9)'.,#/,5<,$E-R^VM;8>FSRVC"@^/J-.2H\7+%O
M"FY.]/Q [/E14I1)0L ^ 3^-AY^VS#M%))$>('L(OFY7W^'^.4(.0@54$@Y/
M+3I( *<*L:])/57+H4%(T]A=Q^B5_1C]1#[0R[F#?V8,=8%FH);7IJ%>-/F%
ML_X\Q,<><C(&M'0=YY^"#C;$FIC="J_W=1G%"*,'?2;:1NGZ#=VMF[HFEW[0
MX7U1# )3"++,LE)G$G3$\L]&K2M@(103[)T/5"$OO,*HAQV3P9'LVD-;U(SL
MP%K8(3P#L[E PH[Q<)O !;8(YH3W$Y#2T+X0"OVHV<FS3]:J4F10HL*@Q6?+
M0_^)21E"FJ$V>EX1T&G*!SU:*/=#UW-V#=_!GOJ+SWT4?0XZC\$-R(.>GB=S
MM!:0;+B=[>!!1?Q"?+2(AOY7BRX''F*3/F9@OH.A4>OA&7'^EPC-99M4H&X-
M8X,&R&!Q-%V,JBP-I'F=3O!.Z_?2F2 @S8#+@J]73V/1'Q!M33BG.^$!JW2]
M(;M1*>D?<TF$ZE$/M$7^Y*,=L81TOBR^QXW(%(I^SL,:9[6@7/"];P?*ET4(
M "'1.M?MKB@U!3A/Z&N1,EJJWUIN&X8?+4JQ)(3HVX<2%Z)HVARI%&>\"[K)
M8TW)H"91J')VI+KC$W7J-*GOS2R/,[SI&2"#\569,-IC^B/4*P6CZ4(2KH+-
M^ 9- \01%$C *"W'[4SPN L&@ 5[;J<!2X=L6DQMD;ALK>/^S+&OR9MUB77,
MY"8*S*&XM@W=)Z,%T8G[4&N_T)\LOAKO-J'9MU6")-W$'^>QQR')@P&OK0JJ
M(QS& ^L-+BICMGIFT^D":BHBFQ,@Q>#V)B:%XPAMH:\GO)N6"S'4M*@5%S]X
M"U*/&.;AILC!K$2GF1!"[)+]4B952M@A(-U\#(/5P8]U<789KU0?3\3,@N#2
MX?-L:!X^VH4%+&8&4#+ZT;]K"TGH(Z10N;P" X# $""]6]B^;:9EI=C<+-X6
MBO0FM-'UP4;C$,14J^<%!L]C A7 +P]=33J;:%A#CFH0]GL*>Q!_"(1:M2Y<
M% 1^3TZR$52NM,T1,2;/5:+E5S-C&BUK<00N>-43J\5UA7"FA,8'/MN08QWD
M][[R:VOU,(9'QC+('$:(1;#9\.PD'R+L#RD2Z]QX9DRU]%U*P]18>T5G1#A,
M$SH+6"_8]!V >DC6#N*] ?&FE!;9R0S1E>>]TO8ULK6_,_37)?IPA<=4$_A4
M%YQ($-3LO4,U7UZ 2X3L;-&O4BYVYC#FHS?)=?1$W(<7OYZ]4>_!2U+&2GYB
M\5VKC+*6-*:9:6)'$Y)CABSP:RQ9'3.R"C)H>4T0NOL(7>QH=BDJ7#)$E-AK
MRTG<6(A(#"[I):>6$!P8_X/Z'UO-T2#&HP"D";HMO@/6]AMTXG\W-%Q.KX)W
MQ9S'VMXY)X$$Q9MF5Y@23WM79ELN_>]"<<EI7,K)= :7^3E'@J+U&UDMYJF8
M0D79_7T 4ETJ0^DR+B7&SVHC83^)SWR<9NJ)4X*'\,*[C!Z=ASEJ80X?UDP>
M*8#]#@>06W"1?IZ(G;D\N&R$:5?S F&!F^0-=J/?IUDN,3N9*/P6-G]AIQL
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MQ7=[.G,#7F"I[5U7E/XKB<!$FOR?O_QOJXI/_O)WWT'ZKY^2OXN@*82)HIS
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M)51XA?[F.]BOZ(.Y3"H:R"N9S1N9S86=38]7A\MZ VXE5PZS,L/^3HDT=40
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M9_AZ(\\RXBM]>0OG539+A#&\1B;Q-*%K!,T^_?9HP8NT0UBA7'_S;W::'G4
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MH7 O(4UO7'M3@)?A[#290ZJ*D+G%Q^?%$L6@@M"G^/QD/<%<+0E?? /8S!K
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MH)]* MEUK/>(Z8/C$>L%4X->B]V:F?ABK52M=(#,3,+X3P[^@,>J0Y7\G6-
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M>QZ?'/S)D:AA"?:'8K !B?I603EYC)V;FUZ$9YL"!/E^BP >;P73L)I#/=A
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MH]"J]BX#2EL^N'6)UB*7_Y$R$9TV\6Y*&G_E7Y!TL%P^>8:'3?+(J]+#J,5
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MA,I0!R/PEYD*-4IK(7!-AJ!R<1 #H3EHN>IVA'ZHN-7VS[**:!Z,$S2>B&)
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MQ2@<+:(Z$1#.5S$'R^)^^6&J7#&>FRSW_7S44]5,2A,G <SICN@?\C#,?A6
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M+T% Z(#5#E6^-L(.2]'D_<L?8:+8)<39^Q6!/!&(.](5 MCYA#)<T9,;307
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MWRJK>&'2* OK<A*(3L!6/OU)0:(S2 ]ZCCB("4H_R#GI&I^9O.Z*$@D\C*N
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M ^Z)4,B+U?P[3D98=)(Q_#E2I&&T;DFV  5/)FG8RR<B)+/O0*E(R-YW+$%
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MBR$ OLXV[=A_4PRN1$F5/B#KM6)U\5#\!?854-=B1J+U@\P'NPKW#EN)N!;
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M&-^L,>!32SG6T@>.AA[<KRW8*Q_V(TVBAI2N:PG%K.W1Q?XR@6OYX)68G?&
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M%2Z;5DO@BFH62OF;N[6O GU7^W7N.8&:U9N@.<0K-@:>B93AT,!9T,?IO;;
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MMDRW)<>3S$GT%/HF4UO+:.+)P6D+&+<Q3B::B&& !80J,HL48[HTTX;3+;^
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MY%'</4."=-JO@[.M8T*'EOK\Y/>!V.S]<-Q^3H*_"%+\Y[,X.++8[WMR?Z^
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MAMDG7D6*=/')3>.X*D:KR.0%^9",!J*+AW)^,GY("BAF%+[C6L%"###KCYE
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MZCG?,+ "%TMV!5_#]"M!YR(J:DK)B'5%"!=1:CE",1E%2C.(R?$)$Q6BA A
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M<AT[+ZMZS]?\]_!!6*L>T4WC4>/'?\NYQ?,&%N,^Q33K5QK21U..E;_C$/O
MZ1?/&.9S L6Y^30PG"^6&:VZ\F/R8:HTFQLV&+N1Y-AY&Z3Y<-EAX0 *^)8I
M1A6FT[<7F ON>#0./$SFVLT="?TC..67[09DD_&;$X3]9^ !.->,SZ7W+.J;
M.F3RU22&SG](G#@(!,.R7YS0GYZ$)^8D2GDF1QX+4::\/GTSR#LY:X\/STMZ
MJN PML"'D[R($8Z9.9&V$\!+<1BA^A+<:/Y?0)+B^E-_S-D2?@]%..>7_'(
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M4DF5P0P?U6B/\(N1,XK=-+AEC-+9*&--XIK$5V1P(\VB;4U!SF""J\I,NB2
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M<L$>H\WQ5TQ--IM=W6*B7#26K-S6,#?9[+;7WUOB$-->MB%Q<_]/N-U)+]L
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M'7^,6/"'>#(U+JZNOR76164)ZZ(^?^3:.P\Q4QJO]A"-H[/*::625W8[5:&
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MI3M=XL*/E\%J:/@#;9XL@. 2;9.9" 4#13?6*A%_):>8-&OEXD_'/7;;7'D
MT(=Q,.8&BW$,8K;OAY$Y1_+(QXBT!94+&;()O:()=DJMV3$;M6E:7U1;6N9(
MZY"D8+BT.V8SIP0MJP23!/V(XV^=N4/K9,W'2^-[4S(6#+=FKO7S(:A^VB,Q
MNSI<EBUOT:*MK3R?\Y/V_2TE3'NV[2#<+3?C&<@#[K(2<V0Y-IR:LTNC;XV<
MR'+WCGG.Z=2=@/<6H''EG7,H;(!UHKNDW07!K[NBE8_,LGEGAR.SUEY_1:.V
M6';%8NGU^_$P=C',(),Z#U.!O6.1!2"Q+ZW  \"%"F N.%Q6QX]#V!=\ML1=
M1C]GIVZV6RL?PWY >NV[4/Q.+KTTBEOHZ^U4S&9N<*UD=5=7H.OJ8UV!KFE
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MXTK&%'<*QQ1OG_JX=Q'<7T9"W&(;H'1RQL>BN7/P5ED[VBJ[C;:\&YL@0AN
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MJ\WK03,S7BPW9L;?YA3!I?W+;ZW@)B!A;/\+'[UEP3ULG>75KC7@ A<YZ_\
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M:&VO3+C>+=+P4B]%KH([&T;T5:YP7%!)-N_3S(&5*K;OJTA8!FIHAR'D7OW
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MMHQ ,OEL3H0=@I6T<+@;20I4>V @200[QU GEJ$]^VD4Q B4K&'*M4F_"4:
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MUG##2!@S6V]=6,TDW#F1[/<93<ODHEUQ,*L)0I39C5$*[/^&-3[/8]!=2YK
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M!M3IZSBQT>7-J&H"\..(V;\Z2?@*XB.:!'(':V5P9 6B8*KKCRA0I,X%HOM
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M3U2C (,+2A7@QZ&N79;WR%,;*(4K&F/X(.NE^>DL;:9)$@$.A2J6;\&;W'&
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M1FPEGUM@BFP7F22C)GF9AHN)!_"=5$E,):*XFY.LM)B_F1OUW&[V$DJQCGU
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M?[MBZM>Y*3OL_I#T8'F&E>9G:9_&@3 X#1<-%PV7]\.EI/'+.(I??LTX;)8
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M=OYS6:PIT.QC+X #.+!1OEM!'('^XSM4/93,3)X,?,K-,B?+7J</N ?]7PY
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ME$J\A'?>X5RWR Y?6,:JQ](O^H^O8,(]H3\47L'&);G4\)H"0+/K.%U75_1
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M!&IHMR#DGH+0D;FTKI/JP>F/8!Q:??4)@U$,. )-VI\+UNRSZS+5O L56\H
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M?IMYQ@R.8:ZA,B'#9XZM4*;(D >>)<I3+C& DX-2Q"@W<Z@K/'C29R;;*O>
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MZ-?ZZ0IW\\6+\U:^NGD)EGYKEM-BX85/K5=>WL(GE,V/1V''\/F&(,J%'>+
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M\1%T&U=VX>PX-E:$AD)K/@^>"VJ/#;L;V@EX_O;ENP8/CP WT>]*ZR& ]?A
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M* PP7)T^#X$4C")WZ/Z'#/P*Q_WUTAQ<VHB79D 7#IB";Z0,8O@4.Z[JH6'
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M04EOO3C$7-IBQ]*4ZZ;YEJZ?84N.=>GZ*"PJUK=OYPG[Y]\2CUH_]I6)8#_
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M[">;9JUUU0H^XB "%M$X8@Z?FFE(CXW(<6X?=C<'\DCG$ZR=K+LTU OG!XZ
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M,6-?]7D8/+H>B-GSGY:_'M;3CLZZK>9L&8X,[S6(;FLBQ!UNQ[EC?G9A]O\
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MSA;16:82VWJ6O4HDS^N6C7&=JEJ\[*7MYSC'-E^M:P8VT][4N8G8 : A5AV
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MT<AY095YD2>BS@G%[H,:3B+CWOW N '^#77]>+9%,?W][ZI.52Q>I0=]%VO
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M"8>%L@70!YZ_4IG13U*W.Y'FNOB\H8)"E0B$WYZ9\QX_K"[NE2M:%8]W'IS
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M3:9GTP^CZ>*(<SH!?A-7(_#-#X>G&CQ9U(=8>"_1*'IG/:5&P -%+A9  _8
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M6!K$RO<<H@@;Y5NZI/AN(\G=B79Z?@C"<R$E6JW6B:X/VOU#P9*J[BWJN4
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MW:=4'>).B><M&?X ?6ZR9OY!XMA>+Q ;DFGRHF@?4:S 5UP+%!/!<KK>[O=
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M&A9)4R/>P'C_>!9*?O<*-D_0&&8W OJ,0["Z0?-PN*6/ &*0FQ=]+%;D&L'
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M@[L,RUV/PJLA%!L4L8$?Z=BSFH] N! ]_?0"8*5'UP/RFW&T]H5P[)Z'(-0
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M?.U+>LV@)+WF]].A:[[ OQ^#B7WV_P%02P,$%     @ )HC'6"<+0<(R70
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M3YT0A):U*\1 V<3@%]@/ 1T$#&:G#_'PA&O;.('/V#B #H  8&=_[ !Z0!^
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MK]#=J#OC2;WNU;59-,R\&2"))3%3S6^^J^NI+N-5M<:,M&*T;6GNP5HRW"O
M:PQZ38833N5/7;9I]5#G;?^!IU"$4&RV$\W( C&0P+6]1-#NSBI7NZL(W42Z
M(E1)$EU.<F]5X'Y:;Y>4,Q,-_7C3*B'.#>:MQ%6M$<8MBRJ/X#'Y?F,V-N4X
M>%2XFFV,,I%XA!5!'']/0I8Z44X\Z!XS0N7EB!*<@H9&S4A%C\)4#0>3/LZ)
MKY_XF3JSH"JSH")3)Y=>MBJ77E<G<PQH#D.-X*6Q"E)RL!$0PCDE%H'_CE8!
MC2_H^!/2DN%XHV:O5J9YGXJ6,G$=BC>C0XM/.@2YS>MZ.I28_?K-]Z!/J "P
M1P#@"J/S^*LO5=<_)HN$C>OY&LJ1?D.R"*)ZF0  L,ENO_?SK;:/'S;C"\)3
M'I@^C7Z0Z)EPG9WY%'@GI3; GZI9\C"@O\FP>+[2\(G*@K._76.5IRCGXG>;
M 7#^7(UM\'<![N%-$:A"3@:$GK8'P<BT5J@\;5E>Z'R+QK[ J0YA^4;-\W:L
M&R^K)+,Q3WQH3T&](7"U$KWKZ9#+(4MB^YQO8)Y#K<[Z/H&I8X*J*X9XM*6S
M4H(1]>96*L)D)6;-Z8F?FV-1MC*Q0U8TL5ZP[?SA1V0J9ENVB.8]#WLJ$M_:
M+E4A#0;_O!(3$V;*:I=4)^9NXMDZ3:'(&2*J2KDM\C;J^TP3DJI+]P+,#>K"
M(SXNA=$H[+-E6RY=H?868*1_Q;QH*$<A_N)+^GMH^+2VO;<$3ZR[+)9CI:9;
M[OKN !/5$_L4<Y!M_" K"L_F*[?@Q&?%L^NNJ0@MQ]G[ TWLLSG;M2H'UWNQ
M[C<_$\9@[Q0,+FQTZ7E.T&30E'1#QJL059]H/U66%7\S"%36XUEJ;+FH!JNY
M-UV^W57N"SRY;>F& S>M5!$G(4LV4V6"EB"<./?7VF=XK[H]?I[QU/&38ZWV
M4Y.YFF;J[V&^/#6HOMH^VW.OXE7P:KN(77"=>JK7]855HC@+,BSLG@E"S0ML
M'XE&)%B@J7<["L?;54:R6<HI5BLFY>'**<;M(ETU;;!3]P_7#P-!($P%$!7Z
MHPX4XRU#RXUI:G35)R00:0HS91Q</K@\_8@;AH[K&B;&GOP;C![Q;\\R1,O?
MJPZOK\K<<B_@_SRP-%1K?@J$+'RW^O8A^^9O:4'PIO;W8/<^<]6.NI)0*W_'
MNL%\!(7O-.U2EPSY]V#G*%M.'P\=U5TI?])HM2E0!ECN<=GPD0J%ZW17;D#Q
M)\O(@@UC 8LW<]U>]O6IJ4\4TN_.@<R3.(Y,AHFMD.Z27/$W&Q&:QZZ^&GA]
MA)NQ8G3+7.NSOXGO47W3%D>7K[CO].QL/W,,HGN6OPM]7,"S:=3-T.TY;JXG
M3:6L>W3%ICE.Z(.(>6'F67$/Q+A#+B*N:':1\GX29R]%C;X #U&IH$5"H: %
M:X* !I)*=(:01>9^*;A-0"8U7YDVO^RN/I?+LIGCXB0;- U/*C&^K]^90@7S
MY4H*GZ[%[F9[A:MB]#M->^,GKDSAV)7MC"I73PIT&V[VI.B PZ9!ML[3I(8"
M[#'D$$;5J)#/*L=?O9-H.5:]Q2P8J-@\T=BBF(,+^#7C99W#WD9K3T-IF>5H
M>[79-N2[J;V+"V3 5#66(_4+QO%/;M.WU"IH<U&Z?X^YBS14@SS:Z(TBAF[*
M?,L3K->NLIE1-8_+E]+,FS?7DXE>/VY-6;W=3COW<%="15N//H9XQP"Y1I&[
M%\HB#$>T2ZUZW4N2FZ]&W)WG)T BH'WM#T=2B 48]8."0^/X,+U"31SJZZ*L
MX3MNM/7W!4.$S3_2B0G&J6:&<,KRHL$]UN?[VVX),U)OSM ^<%NL^'PCNNKU
M?8.JCF,#4?=HFFKF@?$G!L%R(&P%6_+:V!LE07!#R6(I,]T)'81-^-2D_S7F
M>+R=P7&K+>+9)_=FZ2C7><D;6NZ9UNJ)9XY9J\2G=G#/,7+&3;T?D2K"7:%\
M>!SX+&;(LV!9I-&E\>KL<NE@HE0D95V8B[UC28/@.&,8*9/5AT5_28T-_KO>
M2MD216$RPGW]K%^O@&_/V^W>P\^36$#AHG^H,D' "!'(BS8ML=TATFSKB+1(
MA-QT4H;;.QYBD"55HZ[[O;3X\B%??R%.H*OO+2*W![#M,A)_T;L=Q>YW3RIP
MZB,1G"WA&U*I T/KFUI=B9JB!.3HZZ,"TD_4L%@(-9U,L@X4^MYQ/",QEJ>5
M7$E0KQFR;]&)W*]?>B*I@NNS++XT&G?P99G4L%N08RT/1+%GEZY3,KUBY.+Y
M@I6VV5B 31FE.JT'CH^$Q!#T@IZA!X^>D1K3-^BH_97P>_HO]%\DJ3?]Z +;
MFNEC,F-:5"2HZ8(V X20>JQ0B#L)(X"@X""YLWL<'Y\6%57JA6*/HN7>NJ7'
MAQO5NBI1'&&[,;CKHJ(//M]ZKO^&QB\WP;;<R+ZNJ/%@E$*!]V9-0XI'R;+$
M,"'?/=G[NG>"4UWL>(T,1ZTU]$Q6=?((G#VU.L7 9F.P&N?L,E^57'?AY?G.
ML2N8"8NOHN?9*[T,T&+9>#IP<T9'L[V.N_QP$_,=4MS@Z]4CFZ6;W .=R?V#
MUC61-HJ"/-F4U7<-W"N[HDP><407<W5:"#;ZK4D<]5M2#GA39YO&IEBB?=DC
M8QUV&=9D>2AL=]RA'[YC2 9B/D9'<-&PC6T@=\@O090RE4%,]Z$OZX5Q:2U\
MM03#6FHQ:&]1X2E#,"I58Q] 7+\YAC_V.&J3.E8I-!?](+"E>)3UZDWS\<1$
M@.HI<.<4D)7-,/B>5<^Y.?-Q[P/L"\G' ;H9C%- LSUP>K)U]_J(N'$61-XA
MO.Q3F7F%ZA!C2-2SNSV;2]>>+E,3AQ'/<(I;QH8'X*;G(2=9X@A-Y=&6XJ#T
M>AZ#G]%(+\9_H;';QD[6 X?J@_)#5&@(\NMB*!@P\F4]920^$YBKA&ZFC26\
M8_N6*E>9/OR(:]),*-%\KNW._9[:.O<;RG #V+RO<KGH-(:B@C@1[0U^Z9GN
MF(^ORS@G-G*BXJMTM93"!3B3[IB2/.2)3(+NA$X4TQ^*[T)(G [NA7VDXBC"
M9G&+GBE+#LQR(C.SS(=.3-8BR%<CG\'A%!;D$-LH)4YF/7:.]WU](&'.+P%@
MK<DO_=)@M0;U%ID3 NGJ]3@*A&'R>)#/2I2R3UYD6[->=M=&20[VY_?3#:8/
MN0RK7%-Z27*N:D51Y8E;S+05;7&RQ#G3V)3F@;^[0<C8KU%=(TYU6%465Q/"
MO%+E,,V<DV%]RU1ZJV8-V[)OI#:#+&4]FHG4LTJ RY@T\_$!]VJ".".%5+%@
M9IM*IM(I8.N--FMZP\0M]PXGYEC^ 54)E_/=A&_*S+6I=Z[>27R)^GIP"BD=
MTV15C?KAB/Z6T^UG"YTT(+-[!J'Z=%F?G[1F\=XZ!;YR' 30R@^-#C4]=K_]
M\7U3>1O+,9.QB>OML+I=;P+74V#IYD*N\(*:=CQ$\#NL1[;//CU-^EX @\EM
MJL*3NFMRL;88X[QZWV_FW,ZF,84^]H,X#"M3LIVM.2+%;_GTFX)4,PY5F@\/
M#FZQ)GWY>KBS3==&C=LP71[8*IS1U1C^ 7%R"E0V9K1GJ,_@O7/E;3\KA:1)
M9HNY51^< I\'H,>MH08Q@8%Z=<_*<PI;:6^>E(-UFJ;I]N1J3H%1/^\/C;GF
M*D^<K,Y /8QB&XK)OF'=/*9=>G]"P]IT2/CADV^KREA1__M9[;;24^!ZTAV
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M"7$6BV2UDIR],[<I,6+CBXGIOBP5/MPM&S@ZNKXVU-]#[^J1\K )/+O0?K!
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MM:_Y3;MZK6)'+\Z>7U96!HY:L\H",1]^B;:PKAU*-#_!(VN?+Y.]-6KID7A
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MG:Z@V\@\WS+-[(\'9E9MW4VK(S(8!D^M1>%LY_PJ=D(F&>&^_NVN][H)<:;
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MOID5JDAA?T?7ZEE;B&.IS0,A?2?W O$H-OSZ&CN*)^\9,VUCO".;7@ H0;B
M5!#*:Y35L8DR_^%?;R1U1#S?8X?MEMGW^3ZY*;/\GETC/Z#ZIBT#V'E<E6!'
MFYMP.W>.S[8I"SOYH;#A<+RR\DF?;9^N;!?!R/)S#V6Y*(4"'<0TO>MS7%F1
M /$WB3655:1<+Q*TIG:^%G75DE1B/6ESH[E',%I.RKGI>H]>;1EM9?,5$]."
MB#\KDEEY(6T"OYS1JE."<-XVYM.3/HX&D[QO=UD2A_@?MR=C^2J\M:<B=&\M
M*U,EOX]_15R\=P])/]#(:>6/ET'-Y)+*_*JO7S <67=%<23.?]'H&)P7]W"9
MC+]NST,*OX9YO2<8IS),Y[HNL>_;+"@0H!JC.J3!W!+L@.AESK<8EX^?[\&?
M?DMFTX'3I84D:3OV('9:L(.@FQH<5HU@4I;3'-@&Z9"QSOHL[1LO[L7S\Z[/
MQK>^2LXX!7BU6]:+9.R/L0_\C4["AKXWEJ\^>D=7\YCJ<.#K=X, 6PWU0Z]E
M6."QFNG7LU5'P#&=X,G=[RW%@8KV)Q9T0FOXQR7O%R9@K>_*Z4SQ"&\_3B._
M_>!ZSRF 9?:[3AG'088CT^'6DH7 3LO;E2S7CB41H@<)55].@?E V9?9JX&O
M6U-K8.]=3H'^[-_P#1$&1>U^AB*YF@XK]J5.A@\HV^UCL-*H)6$HQ"/L9)SQ
M]*@1E>O5'$7)?*A][@\P 9VK,BDBQ6"(O4W,8(I7[7[!-F!O[J-'XH5B]0J?
M$'V:E<K ;:S\IMX8;(^" )RHT]+8XO,Z(;YE[+-6SYUM0TJ%(JUO*)(3FKD&
M45FW%[UTZZ(',*)[B;.8G!BOR;=\+FIPGB1.9)"+9%E50S5R%@E%8$"*S:FN
MI)0"&MPZ2EW\X5KOH"B+,5S4A[5/GAN1)0MCJWQV7@&LT-.03,=5^E+Y!R/W
MBG#WGG\*=[QE_5)68MA3P 6;+(#C0*I*TXZ5JQ>ELJ6JX8T:UTIM@@;NSA3
M4;YE@<>4Y%4Y%M#VW+:CB^\IG7/WU@I-CI8O@V%J1%4'8T/0<Q5^^MF@"*^@
MX"';4I*/%9_1O5QE(R'15_8KWCCV"K+M4CQMO,._IU#];<J?=<UDW%.+(,Q4
MCGK7Q&D(6= GN:Z^HMZ68@X%L=8N(QRK["'^4&!Y?W7)YK43.NXGQHKL.BB.
M'!X?P^-Y4Q9%JM%JFP(TNN@IO@-'+MKNAGMX[.\BQ@5;W7(%1:31U9>!M6X,
M&KA;2.72M#R4^( 7_=50='17;7R!#()IE)D9CX])6D!B;.GE8PZ1EO",9\^T
M5=3ML"51DKVV/Q-&4QM3-O+&<4T\>MGDXWV-=Z\WWYH*#UZ.3>\QSFC/%-[>
M$@L/N\OL+=@N4N-+@5/I!*&=IJ9)X\I6#EHJ(*/5#=T*1L41_JX_VTV]0ZTW
M8S8$:Y\0""FGC:N\MM1UNU93Q=@_B36;2M&!W-](+R<4XIB7SIX7Q1[/G,!
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M+)/'\7%/#IRD=&M99LT?H*)KF0J8P$56 +<JX+9'0[GXLGQ)JU'"H(<EF*G
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M49H]R7< 4MQ!\3$6(\Q)[^2T=W9ZA/V=,.9+@L.&^FN]=MG<QY_8*3ZA+#.
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M2E G:D42*C>_2*/9LUW-(K2EP*TD?#>T>NT+,:%\N@0G,VJIR2\:'9YG6B<
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MQBA?U*7B CKY(YZJ!^KIMMYV^F@E9DS%O/R6Q"QGQE3,JV])S')F#,0$B/A
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M79AX>UBIZ[-H&O&.%IEJ6@/,LZ7*#QS/\V?:UXUNE_-27\I?" M@!$IX[K"
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M9/1%\)BS:T)#3=(05-0"*-!9<_T[-8=T1J,HYV801+#Z70;3* UTFU5*BH:
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M?5M>/?A>3J5E-"=H,F"%"-;7X3J"AM_)D/=M').Y88O0BMHOT*KXRS)IS'?
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MWY%.>@7++ ]Z<)4M1D/=;)X$@'QXWC;&CR\G9_-$&7VNYC@*C,I&^:>C_4(
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M3QU2V0W&975YEZ\?E_73B:=AB2I:%%C<PK 6?JLU'QTC?YZXSO?'T[0*+[M
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M79@X,-2:YAD-,<M-/IW;,1%E6@E)M,#N8@QY#]8.: -G6.0O61GQ7VP(Q*X
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M:]TO&<'M/M)/T;1#__K_ %!+ P04    "  FB,=8.%&-&G"'   /R0< %0
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MBY/LR0?V S%,[ _U=YD$>A*!<,#)AB$1\DXD6#9,0,M*B0E<(=S\S-ALN%:
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M[K/O=6B?@L>"5]B_9,<HB;=L5\T=?/A5[-05D[XHU$OK:3W'$)"E2%-,.
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MFQTY@T,W(-@X';C-:?^D;?\C+[[2 5M95+WY@/W4S07LAS_?\8M^S5)D]'<
MZHTU4A?JK-7+*MFQ56J=]T(&)3_/4L1R'1:8ML918::N&-R?A&7#]$E,GI<=
MVLE**0')$.UHHD7=N99(KBP)1V,WIOCJB\J5Z7E1@]"S\>7GZ"L/OVEDS*@,
M$&?&FHW[M/X[TIIM#0VAX#;9QWW 37;P^2 G([Z:(3<L P6YD69*A]:Q:A$A
MMU!#,,A-]?$ <E,=O&#/V@M>^J>(Q\<03_3JIZWFS:N3*-0NULT.)9I_)T4:
M,>&6M&W>>^-M;($M MOK>B!NL.F%AIO3[G=Y)WWI=Y)\HN&_(=:1NWB*LN3O
M49VRMXZ8W;Q/U_+:(@5&:9OV2K/V!&K,-R*8+TH]NF((>+A^<,/ZF?L#Y#9@
M&.':<C,U51CP5F!2U\D7$%TIU+NJ.0ICWA/HP3"^*] C 0&U3K=9>A$T!!LO
MCD:PV(1PV[54_7"P;;\-L^%EP3*$ITK@F1+,VXEQ*:AEAJ*=/M,#XFY@!2W!
MUCK3_3U8VYRQLYW6,M;FO.>1LV/":)#%8EZM<E(]4_D+GGX]XZY];!7/DR"G
MO-G%:Q;Y+NV51$\%%4>E9U_*WQ@>23M+HB_I;PP/G(W+R!O<Q\N>?>.VOC]/
MQRQ;XWMU4-Z*P;^=&,YCGRB]./"'W<XKI9X$VD*IK[5UH<$*$UDZA$62277V
MMY(-H/RO)"K+?)>(T?-+4CV+(32<Y9("&_-J2<$, M*;O&>:EW\N0FAX'^EN
MA7R;Y _^S=\L UI]L</&V"%C!OH47A8L:GAN.+X2XQ_IG8D^,*&2/P'2#MU>
MTE"+&V=KE*263)!T*?+ZI\.M,,H0OX)9%3<KYF;E/;.JUJSH/&99/#70# -;
MD_I1:[ N1>"5T]H4HK_6VJ[5^1RV^_OD*4OVR2[*JEZ(H3Q-=DU"-MWPYE4%
MU!CG9Y<NRP4/Q]_)#\)2U37H[FL QCML$\&&B!D8'8P36 !U&BS6Z44>P:37
MBU'7B\>Z!O@-;F=%&Y!0QB/\X?OW__S^1VOH2$=YR$!@CA;Y!)?DHN_>_XAT
M9+O8LOM?&@M08WCY0$V)V^6#,Q#F7&<QW2=94M&;Y(7&UVP(R9X2-@+(9*D?
M7G^._I(7EVE4VJ(:>]<$R"9_*\?HZVIX)ZH@71U--MWI6V9(;,[LS#%*9_9D
M"'CM-'.Z$)Y56SBXU5CKCUU^?/07'A:5UV6^90X(SZ;.]L2TJ:>!<'U;Y#M:
MBMAHK)F>+[+XBK[0-#^*0R;;"L91'A2[;A:I:"6U(&DDQ05*3Q;U.G=6CZEP
M].@N$ !.*])+#WB99R(+R4-^2XM]7AP^Y<6V>F9+O@^O/)RV97FP4OV  %ZK
M1=3H:AI4CU*#RLKY)7M=O8@4*3^P(?P#J(YMX3</YNBP*IW&H\>J7 I]=.'Z
M6A=R*]7_-D:708N<<W1!=30,OX'>Z/BB$FK%\45ET]EO#&YLWE[>U81U<W!C
M<#/R.5J_T;N%!7.% &!K8'<)"GIGW"><![HKWBFX=&N0]PK\<.#Z<(R20@Q[
MSU'Q1(VIW30"D#<'.IV5 W5>D'0E25T4Z5K 5>V>PKMIA4&O XP(4<[_C?"
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M,.>X.3@=>,:A@=3)+0ZU(T$FZ%YH][ODZ;DJ>^%'#%.S60QP4K;H/^Z1-F\
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MN3D3STMN\\=O-<P[>VUQL/M]K;[*O:_ZK EQ_WX6O>'\ ,PH&3H$ $#$S3/
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M3,<4FQ04;ZS:JS%!9$'R32/R+4FR>I:JQ1!X-=\.IKP<.(MIY<'(Y@:D ?4
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M<,]DU'W<\J;[:YS]D)?Z?$&GP 5URV-'SGB38X?-@NE'7_DPDV3Y7C<9^=0
M-35Y6>4#^7$FUO(]PKRUR#K+4%INI(G(B7;\83F8[) PZ33U+>J]![:V'65J
MY8M<&K'-K*%7^9HU/?%HB/ST)Z^BU(*!O!#+Z.AX3).=6/46PKN4?:L\L6^-
M=%C- ;P?>,VT1B@O7J(DY8JQ/8/<+/!B%T\1CY4RL6_0C5YG_"!&9,:UV\P<
MO-&RI"])^T5^D$*Z;Y+ZH].'*<@Q'@';D-%I7SN^JOM46I)3R>^[VXTH+Q[4
M<<G9Z:J-'ADN5[T#3,+B;>(\9##VDZCE++\TR#O.1C5GSWH<(L]WF+$_LVFE
M2*)47A*7V[WNK+^^3M,Z6"VI$7 (GV^UYGB6C[A-=?4[HY(/VMVET*?^O9<X
M^VYJQ1F!5V\"#N!#TP2[N@D8!U+#O=BCI@D@Q]2%#!@/FB' WW547 \#W8'P
M<3D:UAK>AN?=]9@[7/=K-]INLE!#EJ,E4P<R_1NV9H,RVE=C;*L76#3QVF$S
MWB.A#2@^F!L,'>" <QHD9G;31W77S'>XFK<J\"?*OV0%W>5/6?)WX2#7#&RM
M\] MS:*T2BB_2VLBD-<.188CYT6U IY)+[-^W-?]V@;KFDW/L8>T=8H+P3;I
M0%TMSN'VNNW0VE30E&%>;"5/_;;I3W'\:*@-1D]KIT'>,L?FFYC'YBO08WRN
MO@(W0$:&-G=WJ]D=ZTSY[N7$-F;UYC'/ROI/=Y0W*EO22/=;_=.PU;\ .&*L
MURK*3-&F0.\-%KP&,JQB0^J=-=J+M/.WQ;!@.VF*$^3.'9>GM*A==OE/A8A8
MAOK$[4S<&0\A*Q,GL.%DE1$CT$%A#=ZO3O876CSF:])]:KNBY>[;X.ER*@;
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MD4/1+T&;\#(SFN\C.22'NY46A=IJ4%C4R]\;QGD-1*N@L@ZBE?PCTZ(R%_,
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M/VQY++-:H2_X ITHAFE,\R8Y)BN\TW(-F!@A+,3&V=?Z3N0%HH*4+],V1+E
M=3BFE 95XJ!*GL"6<W8L7OT)O2=XLT(1;<OSFP\>(&YM)3@!W_/FS^JU3?YV
MQN(8)1OVO$V:_4GJBMZ_=M]E"+RHMYO]8%7YF,M#_3!WW2V+SK..?87E(0V)
MXT.6% DQ0%:_7, 2F]3FH+'X]:$X9*>')'/T6U(]!?M[D#QH"%5KG&>(TWGS
MVP/G:B9Q?E=.;=DK?RZH3=5;"*RFM)9]0BN[X\R5H[MJ/<J?#PULWC;(=M>-
MIQ^%K]8KR&KVE#[($JR46N$@V%E/--:(6<\R<"\SW3%W;;["QJ;)[&^EG.6K
MB<JC="/:@GZ'::"FXH@4;Z3[K"!KZ((_$U.38MV8-_Q;T[HZ8X9E*H&_KS3&
M;87/*HWQV2!F3(O5BAVHB#8W21YOTOQ )X'+G$52'<Z=-/T&-(O26=#=?.K4
M,VITC5ZJSD,[RS_2H+W0X.FAN^O&EL"79(W1;^\XRO+?T<M3NMG0Y33M-\RC
M_4, ;'M.8H3>>6]-MEF;KG@[@;[:BQI.](RSK?8$%[0T(6QW3K*V[8W1SM2+
MA9(,282)%-@^JE7;-UKQSII^8&]M)W8ZYH-@V(?3I11#_3XY9-A1T@3$L..L
M[8IA&](,8=A/83*L'=M?11NZD8&BG-XM&#&Y#9F7)Y"%;5Z>P!1!\/(W?@]C
MMZIVM)]3^JOA:KN<$-L4,B 6M_IM7)'[M_*JV6YU.HSSG+)?CR7^0*?63C]7
M:6:Z\XTK,Q<I.U =,M/;IQ_; X!][IF2RFEJQ.;U-<.O48'OB&C)+D]B?LY)
M'NF%Z18L191S^XV*\RZ-XKQ5WZCNO#PBZ2O4Z\FD=8U5WQ+> [J0,&TGO H(
MHV;)L3QAE4]V6ADVHC96\T:Y?8E5ECSCE%^CQFI2>^B1]NXI\9:=P%3;D$ 1
M\%ZG 4W@E;9S<&S^H3HGW^CXHDN284ZN!YGR_,+3$N@YC$)+<!?$<8;&Y+RM
MAL.C#(H^ SK&H+*<2\)J]#LGP@*R9#O8*Y_?>B<SEYBT?3I!"\@@J$P??I#,
M<QU2W029 J+"*99W296-2.!M(Q)(?]WA46G$(-1#YC8_R9P#JC[YPC8-3R:+
M(&BZH0X-0941*)CI9JO#@ A6:C-W9V6;&U+-4&'P4TRU 2OU_8='8?#F<"HI
M %L0!-58V?.KG@ZY2=!70+0DLI0[1FJ>/N7=A<E%)E9KZGHF-P"EL+)-05),
M!<$^A#'7.*%7].LKC [Y1]A;0 PDMI8[#FKT=[J6;8^&_L.MMN,Q+==$9&:\
M:QIOVVSPZI]K7OY\+B4KL&:;E!1 "X*6&O,ZYY,B05\!49+(4C#+-$>3(IX,
M^6L1907@,DUJN_8.0&4'EWDAN %N=\X)V8GZ(1&RE&4<+E,#G"/J X7..=I<
MA("H>X!=W3&ZZ2GQD)? $PRMV(PX%Q8<"F_X?8@ .5-^"KW*0_*8)3&F0<LU
MY):$L3 !\>@H6\/,D05I<;E$B(F$&C*%2:U6;*^STEGNC@RD!8=3TH&<$ 3_
MRF_MM]2#V6M12Q 0TYI;%69?1D,<85+J>"//Z70U''8=;NB8 #<(.C1D>_]S
MT*#HT-RJLYAMGDFH=J"I-?DZ.E--NJ9?D3E/E.7T+2R^OC^/&.\,[!;2*#20
M,CW-SX,:A221'O]S]:F"!31F3?X&?D+19S_KM_Y==)'K\V)K.]0"%-H.<H61
M#S]RXHK-K8LR)_ZV;^<QC)U/.* 6*$&[-[SL;%M@5.R("0:3KR,:"(-NV\^.
M^&+:(5*$1+*#K.N07WM/,D%3JZW[HTX-WGR\Z,RX=#C,K=/H<(S/@T%E:HD>
M$253]'M<O*7$>]+7=Y?OJPSI?4Z,:<6:8 \2LV5O0X9P'UV99-^K311_O_P:
MOQ$Y\\M[G!7$MCP5&LMZQHV]35?$#$MF7?+?GR7"+Z-RB(D:=I7;<5:T:@_[
M3M\N5@,_/!KM/K[\%!5.PK;F?8=*H1)+ K[HWGO '5$9SH ]#4U;_;GW &JP
M1*="IU.:4T%SWJDV5=HXRZUOT&D(J39-;.>#SVC?@:7:'&/*4PHJ@;Y!)-LT
M!I^U9)O&R MO:O:4Y-\_9YBF<L+$P0O(J9FX[U"G9A)+ E(9E0!1$5 EP[G,
MS0QM2XM=KJD!DLH F<  P<[45&!U.E-3(34\SNO$*K^E&]+:)BG>(<E/(T2H
M+*BS+2 =]O9$3L*<"R\.M78]^3O6)<^&'(U0[90EC2 ];[HTV=MA?[PA*M4V
M<'@$<[ D(1#G:"N[3%-<[BDGU9ZR@$!9$42%:I!N8#1JS?9/.#]L"GJ_8DUM
M<0P]W_M(S-L^&SD2\""T>K>+TRW^6A !J-A?:"=4N5])KJ! 92U NE)+WW5O
M7AK5Q5%5'KW0&I[V2RWIX!.G!D[4Q92!!_GT_YN4/J X' %5/?\8J#48@ )>
M9UXX&*['#)'0=B=#++1]"00-?^(=&90VB]UJL=HFNX3NTA?)$=-%UB[']UB3
M_,JP/B Z3#7J';3C]=CIFG9-5%9%+[RR)[@X4$RF$"2 !GE@%TB#W \$4&1&
MC8D%WHA(-_B(-^F>(MP43D:U <%DIHU@5<%J,9=KU)L)D"PK-0<0#?"Z+H0&
MN!Q,V.>PS/&/ Y7A2'X\TYMDJMB,L#AD $4L;R_*41=#K!QZ825]'=FT*S1H
MB$#A'[UUO,(Y0)QYD>>X6,0_#DF>&*RRQ<4!G5DB;^\Q;%H,-<I)UM.0?J$R
M==<O5';VXA?:U:>L@D??D*[3!-XA66?Z] _U"DUM;Q,?H<^)TP__KP]__/&1
M?7SVP/A5DE)I6?N/Y!.]18IIH;8&P.?72]T[F<\+(^X'57&O\R1#T[?>M@>R
MN]&S]*[L/\&1O^(LP?GB[XA&Q0NU"XO+0CFO1-+>9(<50PM4%O3OL"H3MUS5
MN7V-G-2FG2<[YM4 Q^R6A77,GJ02@UW-S3'%)A8XID/[#G!,.W8&F1Y>9WB5
M%)^CF)V\T"P:1(4!IX5"67O9(5@A5)6:P7)!;N+N5%!N7P^^H%THB(M[\P?I
M(J'G$3-8(JA,K?8*:\N#1YSE;\GNM=V\>A!3UX$:S#22=[]_51SU','WX&;R
M"5J#')C]C08[E]_!1P#X2[+#=P7>JH9 >15_@>"FW/JX*BV-6/%Y1(2M2>\Q
M--SS'$UXN.<V$WC\>A/E^<.ZG$D^9$_T"%@KH<ABM6*1I6A#Q8BS9"]"=45*
MX]N#XO\)&O?F!K0IEIFWG(BG&6+-7713\YZ:1,TV82%D6_VX4O_G2?V,JX\K
M]?=,_>BD?JY0'VSHG.KUK6%U%BYO-.3.R?7_82F*HM?I;D?ZM\5>PL;F0UUB
M7<=_O+*]^9/60,4KQNKP5%*J&PA)*3Q[($.Y=FM+] 3AWDZ)Z6&]QAE9Q<B2
M0AK7]$HY72W$'^#A] $>R@^ JIH^DM".UX?+GE:R[T6R^Z4%H5_I.<"=4XT'
MO"WG<HKC:K-R.(X[-;WBN*N%N:GKS=I9X=A,'\&"!>TK?6:(;:&OZ;'MSM'&
M8]N6PPW&]N1@WPU>%G>[O,B8YLW4##<'QE;L!ITB]&?: & @T%BG7EHV4A&=
M:EZT4Z @7KN\V>HG2CA-M:2AVFR2FPSSP&X(<9C[>8;4+1G(8WH]@D@54Z)Y
M59VL'MC.+  FUG 8SLAJIFH%G9J9&][,-#UI$@#>%.YI#CN%;X*@CVXB/*S;
MFV\CAK5AS0!B;Z!^78=D.T5DIMC9;9SA4&=)T9@KNJX5G0T0QWAJ%X=CW-0;
M#.^C7\GVL+U*LRS]27?(HSWY2_$^$(;R9CS#4*&?,0S+-E#="*I:F0\*1^C9
M0>'<8*?S3!/8Z=S2&^PX^I.XS),R$&V]VIY!UM?&&%M5U2I[T7P09:Y4;SC;
M5TKMQ4KYAI;$^TP0)7$]$""5?>;/*;N$E.''+%T=V,267>M0G88RJ L((A--
M>H?2RCKT4<^R%CI5XQ=;>KGK8> S59VH5"<2Z@")%F,7ZV+%V+_@T@3F=WE^
MP"L6Q"2P9;]3($11!SKUGD1R89*\'/'"%^4V*RG/L^)Y3%_G1'[PE',J_Q$F
MAU,YSX1-L?OHG?Z2-'LDJZ?'312S!$'J\]^:2E!;83K9NRY!RB-: 94U4%W%
M_QEPH^_0VBN"^PA&VT2./\:4&PX9_GS8K?#*Z(*>K#38K0:9M+TQGHSIO*3V
MFA[ -NX0L2_79F+#7<!0>DC[ZH5[]S"[=&'73?B_R)KD._\?^0=]S^.__P=0
M2P,$%     @ )HC'6);Y*OY\8   GT8& !4   !P<W1V+3(P,C0P,S,Q7W!R
M92YX;6SMO6MSX[C2)OA](_8_]/9^[M-ERW;9)^;,A'RKU^^X2@K;U3VS&QL*
M6H1D3E.DFA>7?3;VOV^"U(62D+B0()-P]X=SVF4#()Y\$K=$9N*__+>W1?C3
M*TO2(([^]?/1/S[]_!.+IK$?1/-__9QGLU_.?_YO__5__]_^R__QRR]?6,02
M+V/^3\_O/UW?WGW[Z7]</MS_=!>EF1=-V4_7\31?L"C[Z9>?7K)L^<]??_WQ
MX\<__%D0I7&89_"!]!_3>/$K_/VW\H,_/0S^\0G^"3]]^OS+?^81^^7XT_')
M3__WI^-_?CK]Y_'1__/3_SO^^O_]\@OO01A$?SQ[*?L)>ARE__JY\HVWYR3\
M1YS,?SW^]&GPZ[K@SV7)?[ZEP4[I'X-UV:-?_\?7^\?I"UMXOP0K&)M:O!E1
MO:.+BXM?B[]"T33X9UK4OX^G7E;(4-FOG] 2_%^_K(O]PG_UR]'Q+X.C?[RE
M_L]<!DD<L@<V^ZGX_#^S]R7[U\]IL%B&O-O%[UX2-OO7S\LT>RU$^6E0UOX_
MKV(@>>S-H2!OY/O#W::GRS OB>%_^+52\->FGXQ\%J7,O_1"+MG'%\:R]'OD
MY7X 6J3NB*)ZN]T;>PGH\@O+@JD7-NSK7ENV.OZ8P6CD(RX=S49+/C;Y&#,7
ML+*=-CK\F,73/U[BT(>IX.;//,C>K]DLF 99L_[K--L&G"LO?;D-XQ\-Q2]J
MIF%W+[TT@);'"4OA&P6WP\C_QGX,I],XCS*8Z:$'D>\E?JKJLUE;#3L^2N9>
M%/Q[_96M9JIZ*:G8L$O?4S::W:19L #*E/W8+]WPXX_Y8N$E[Z#CP3P*0*F]
M*-O*?1R'H.;J3NFVTK"S]P$,/E#@=R#@2PPM@[I/61*INH?7:]BA6R](?O/"
MG'UE7IHGY8!3]0:IU%0V<9J.6?+X LN"4AX[91O/7(MEG 9\+,!4PY+,"Z+;
M(((5*_#"S31TY2VUAIEI:\T[OPBR@@'0#5 +KJ^P5]70>6G5QHH^Y;/X<)XP
M/9T25&C8A2>6+.YC+QH]A\%<;XH45FG8C2\)3"4/[)5%N5*M=\LV_/ ='%@6
M[,E[4VO"3M&&G[V!0O$[8Y=P+IH%V1AV?JK/"ZLT718.=CS*)4!0H_':])RR
M/W-0YYM7G4%P6-Z&%&![PGP^+<$ *Y1:2Q*"6AUNN737[7IM=K+EL+OUL-9Y
MX>+]Y#V'ZIY*JUI<_?5Z(ZK1Z4Y KYOUVFQO5Z#=:U4#]I=GO:Y)*MI;,?6Z
M(JC0RH2MUQMYW0XG[Z'O%_KNA7?1+$X61>EK!IH?6IW0Y=]IZYS=!%W-1CM9
MKYK@LO&%EH[636#5:[.-!7HCX,W2,4Q3EJ6K,OXPVU0;10]LFB<)=+<83)I8
M6_NLQ8T!OY3P\Y"-9D-0+#_@]R>O[)%_%_A@Z<W;-,Q]YM\F\>*:_Y7YY11=
M;427^]:^V^DF992]L.0*>('?E=QIXK?VF4[ACI,8YM1BP/(SW)+_[1O+6L&L
M^E:GP)M,<S:_U"WH<HE)Q]X[W^4 $?";)&?^S1O?_[!V=%W_J^WMXAO27:_9
M]N!LUIE[6%C859R:3%-U&NT RFV>P1+Y-8B"1;X81E'NA45'0&V*BM\CGR6K
M'6 T+_YD$W2CS]NV_C;;A!DU9O]8VJ3SQLVU<*I>_RK/N"\']V&IWWE98Q8-
MY4U$KM^./7-!D_YJ-V.ON[!3AX-,$ 9>N>0]Q1G_Y.KOL*]Y#=): $P;M@?I
MFLT8[#Y]^$>Y_X2)\3[PGJ$O?(=N#D6W07L0OD<)B _.S_\NOKJZ#8'M!APV
M"H\-4PBZ#=J_\6DR'HR;LWY3-$Y6W!=_TC6!Z#9CO;N_>PF?\G1U7*,!ZUWD
M&Y8X:B9.41NM6%L;&<)JM-@*B.*WH^+ 8CB!F+?7"H#?63!_R9@_?(4MZIS!
M')PORO-7(QP:S;;#Q\9"RFU!!W]^V$S4S5@R_HKE&^YF1F23MHJ.+RO7!/?0
MSQT$["UC<,CQUQCX1Y3NO85/=3S=:2CD7LQQLBL+WDX*#16^RBF;_F,>O_[J
ML^!7D,^ _\ %-2B$!/^8%%\8/J=9XDVS=4NA]\S"HOW)09G)T:>C%<HV^K-V
M2Z^(MK@I0KJ&%9\<G1Z?"L@8)KM=]I+INF7X<8>)0X?O58E?EX6#\"_3ER#<
MD#A+XH548JNOQMI]SU/H2[PL->WGG^($EIQ__0PM+=?K]WTI"[2_16<+@;5(
MV T<\K-W&!,@Y;0X*O ?GJ#]X5N0(K3)*W$!G-&1I^#ED$@M-&(ZC_M&9Z7S
MU_'""R*$P8-R'.9G.M*T.#BD#H,A9FO0-[8N\S2(H/_<U 8SS5>V>&8)PIBP
M+(=[3L<:)OY#HF2]%Y-UTC>R!/,*[ W87<86V#PIJ\+!7S@T2VI@$1-YVE<B
MN=HJB.-%)D='A%L1#;'C7&V[+Z;FS)2:#([-[+[M-0RZ[O/NWX;>'%N_JF4
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M"%E]MN&,DX![KCT&4XV#X'YA+A[7F),B00CLG1?+RDM@#'H21Q$+)==+HJ*
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ME8"W"PN&=3T12D,A#9J8G!P1)UA0"51@73?&U\/7)*T%]9P<49ZNC:G8I5,
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MJ?[?_6NIA0%<QP.EFT98G1Q3>M1;I!S#1AOMW'P_R)5VJ\Y7+UXREP:]BRN
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MEYKT*K(^'LBO7KPDC+.,I:]!&#)Y#@EA8<!&GKQ0+&_!(5J"@/34C+W QOS
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M1EX*[1VX^EZ+CPVJ*@#T QP7]% B=-(^!XWT^BX"2:"V(,V: -N-F\3:Y!Z
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M:NU2KAMZ5XL4OXG3O(1 :L @(5ZM#>=I*0Z$55=\L-<.<SPLN'S6 +8AHYD
M<N&RGHK_I)S2;7X&=E;$]QY2A1#KD'T!((K7D94+.\K%7E0@A UND+UKAGG(
M:\'0))XO[),G.BIJ" 'AW!43VG60+N/4"[\D<;Z\"KTT#6;!M&13L>^7UX21
MY\:5CA$>A&U7#&X2C.HC@*HN#"/J380.A<;L5]$AG@ZTQCK^ILIH]I_>THM
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MI&S%: PB(TYM3:96N#AL!>(*DCIV=>=S8-+A8V1U71KP/W^ NY[C3YV.3'[
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M$B?<YU)"L+PB"),Z?ARG3,RQ#J#&P<%](GOL):.D,,7Z/"L&?VB\0*U-.M8
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MPZH=A$'VWN58D'8"*".V.W^D0:$A:M)'6/LU.O8S&'<Y*$3?!H)<]2WNX5C
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M4$L! A0#%     @ )HC'6./3$L3#!0  I1$  !(              ( !
M &0X-# Y.39D97@Q,#$U+FAT;5!+ 0(4 Q0    ( ":(QUCY6#H65 (  #\&
M   1              "  ?,%  !D.#0P.3DV9&5X,C,Q+FAT;5!+ 0(4 Q0
M   ( ":(QUBXO>W%30L  '$K   0              "  78(  !D.#0P.3DV
M9&5X-3$N:'1M4$L! A0#%     @ )HC'6.].OO]^!P  RUH  !@
M     ( !\1,  &0X-# Y.39D97AF:6QI;F=F965S+FAT;5!+ 0(4 Q0    (
M ":(QUBH8U%6R(L# ,3#(P .              "  :4;  !D.#0P.3DV9',Q
M+FAT;5!+ 0(4 Q0    ( ":(QU@G"T'",ET  -6K   1              "
M 9FG P!G.#0P.3DV9S Q83 P+FIP9U!+ 0(4 Q0    ( ":(QUCTN(K! 18
M %7E   1              "  ?H$! !P<W1V+3(P,C0P,S,Q+GAS9%!+ 0(4
M Q0    ( ":(QU@MM:URE0P  "JV   5              "  2H;! !P<W1V
M+3(P,C0P,S,Q7V-A;"YX;6Q02P$"% ,4    "  FB,=8^A$4YB-!   CX@,
M%0              @ 'R)P0 <'-T=BTR,#(T,#,S,5]D968N>&UL4$L! A0#
M%     @ )HC'6#A1C1IPAP  #\D' !4              ( !2&D$ '!S='8M
M,C R-# S,S%?;&%B+GAM;%!+ 0(4 Q0    ( ":(QUB6^2K^?&   )]&!@ 5
M              "  >OP! !P<W1V+3(P,C0P,S,Q7W!R92YX;6Q02P4&
/  L "P#) @  FE$%

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>d840996ds1_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:pstv="http://plus.com/20240331"
  xmlns:srt="http://fasb.org/srt/2023"
  xmlns:us-gaap="http://fasb.org/us-gaap/2023"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="pstv-20240331.xsd" xlink:type="simple"/>
    <context id="PAsOn12_31_2023">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2024">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="P01_01_2024To03_31_2024">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To03_31_2023">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="PAsOn04_20_2023">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
        </entity>
        <period>
            <instant>2023-04-20</instant>
        </period>
    </context>
    <context id="P03_08_2024To03_08_2024">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
        </entity>
        <period>
            <startDate>2024-03-08</startDate>
            <endDate>2024-03-08</endDate>
        </period>
    </context>
    <context id="P04_21_2023To04_21_2023">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
        </entity>
        <period>
            <startDate>2023-04-21</startDate>
            <endDate>2023-04-21</endDate>
        </period>
    </context>
    <context id="P04_27_2023To04_27_2023">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
        </entity>
        <period>
            <startDate>2023-04-27</startDate>
            <endDate>2023-04-27</endDate>
        </period>
    </context>
    <context id="PAsOn03_08_2024">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
        </entity>
        <period>
            <instant>2024-03-08</instant>
        </period>
    </context>
    <context id="PAsOn04_30_2023">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
        </entity>
        <period>
            <instant>2023-04-30</instant>
        </period>
    </context>
    <context id="PAsOn05_01_2023">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
        </entity>
        <period>
            <instant>2023-05-01</instant>
        </period>
    </context>
    <context id="PAsOn04_04_2023">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
        </entity>
        <period>
            <instant>2023-04-04</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2023">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapCashAndCashEquivalentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapCashAndCashEquivalentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_StockBasedCompensation2015EquityIncentivePlan1MemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pstv:StockBasedCompensation2015EquityIncentivePlan1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_StockBasedCompensation2020EquityIncentivePlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pstv:StockBasedCompensation2020EquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_CommonClassBMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_RepresentativeSeriesUWarrantMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">pstv:RepresentativeSeriesUWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_TermLoanMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pstv:TermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_MaximumMembersrtRangeAxis_TermLoanMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pstv:TermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_CharlottesvilleMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">pstv:CharlottesvilleMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_MinimumMembersrtRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_MaximumMembersrtRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_StateAndLocalJurisdictionMemberusgaapIncomeTaxAuthorityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_SeriesUWarrantsMemberusgaapClassOfWarrantOrRightAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">pstv:SeriesUWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_SeriesUWarrantsMemberusgaapClassOfWarrantOrRightAxis_WarrantMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">pstv:SeriesUWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_NanoTxLicensesAgreementMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">pstv:NanoTxLicensesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_AccountingStandardsUpdate201613MemberusgaapAdjustmentsForNewAccountingPronouncementsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201613Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_SeriesCConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis_TwoThousandEighteenRightsOfferingMemberusgaapClassOfWarrantOrRightAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">pstv:TwoThousandEighteenRightsOfferingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pstv:SeriesCConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_SeriesBConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis_TwoThousandEighteenRightsOfferingMemberusgaapClassOfWarrantOrRightAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">pstv:TwoThousandEighteenRightsOfferingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pstv:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_PreClinicalResearchStudyObligationsMemberusgaapRecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis">pstv:PreClinicalResearchStudyObligationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapCashAndCashEquivalentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapCashAndCashEquivalentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_TermLoanMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pstv:TermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis_LincolnParkCapitalFundLLCMemberdeiLegalEntityAxis_TwentyTwentyPurchaseAgreementMemberusgaapInvestmentTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">pstv:TwentyTwentyPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">pstv:LincolnParkCapitalFundLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_GrantMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_OptionsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">pstv:OptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_PreferredStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_WarrantMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_CanaccordGenuityLLCMemberdeiLegalEntityAxis_CommonStockMemberusgaapStatementEquityComponentsAxis_JanuaryTwoThousandAndTwentyTwoDistributionAgreementMemberusgaapInvestmentTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">pstv:JanuaryTwoThousandAndTwentyTwoDistributionAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">pstv:CanaccordGenuityLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis_LincolnParkCapitalFundLLCMemberdeiLegalEntityAxis_TwentyTwentyPurchaseAgreementMemberusgaapInvestmentTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">pstv:TwentyTwentyPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">pstv:LincolnParkCapitalFundLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_TermLoanMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pstv:TermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_InProcessResearchAndDevelopmentMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_CancerPreventionAndResearchInstituteOfTexasContractMemberusgaapTypeOfArrangementAxis_GrantMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pstv:CancerPreventionAndResearchInstituteOfTexasContractMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_LoremVascularPteLtdMembersrtLitigationCaseAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">pstv:LoremVascularPteLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_GrantMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_OptionsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">pstv:OptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_PreferredStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_WarrantMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_TermLoanMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pstv:TermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_CommonClassAMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_SeriesUWarrantsMemberusgaapClassOfWarrantOrRightAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">pstv:SeriesUWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_MaximumMembersrtRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_StockBasedCompensation2020EquityIncentivePlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pstv:StockBasedCompensation2020EquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis_LincolnParkCapitalFundLLCMemberdeiLegalEntityAxis_TwoThousandAndTwentyTwoPurchaseAgreementMemberusgaapInvestmentTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">pstv:TwoThousandAndTwentyTwoPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">pstv:LincolnParkCapitalFundLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_CanaccordGenuityLLCMemberdeiLegalEntityAxis_CommonStockMemberusgaapStatementEquityComponentsAxis_JanuaryTwoThousandAndTwentyTwoDistributionAgreementMemberusgaapInvestmentTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">pstv:JanuaryTwoThousandAndTwentyTwoDistributionAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">pstv:CanaccordGenuityLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_AtTheMarketOfferingProgramMemberusgaapSubsidiarySaleOfStockAxis_CanaccordGenuityLLCMemberdeiLegalEntityAxis_CommonStockMemberusgaapStatementEquityComponentsAxis_SeptemberTwoThousandAndTwentyTwoDistributionAgreementMemberusgaapInvestmentTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">pstv:SeptemberTwoThousandAndTwentyTwoDistributionAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pstv:AtTheMarketOfferingProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">pstv:CanaccordGenuityLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_CharlottesvilleMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">pstv:CharlottesvilleMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_CancerPreventionAndResearchInstituteOfTexasContractMemberusgaapTypeOfArrangementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pstv:CancerPreventionAndResearchInstituteOfTexasContractMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_MinimumMembersrtRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_StateAndLocalJurisdictionMemberusgaapIncomeTaxAuthorityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_PreferredStockMemberusgaapStatementEquityComponentsAxis_SeriesFPreferredStockMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesFPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_InProcessResearchAndDevelopmentMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_SeriesUWarrantsMemberusgaapClassOfWarrantOrRightAxis_WarrantMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">pstv:SeriesUWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_CancerPreventionAndResearchInstituteOfTexasContractMemberusgaapTypeOfArrangementAxis_GrantMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pstv:CancerPreventionAndResearchInstituteOfTexasContractMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis_MaximumMembersrtRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_TreasuryStockCommonMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_MaximumMembersrtRangeAxis_TermLoanMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pstv:TermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_SeriesBConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis_TwoThousandEighteenRightsOfferingMemberusgaapClassOfWarrantOrRightAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">pstv:TwoThousandEighteenRightsOfferingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pstv:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_SeriesCConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis_TwoThousandEighteenRightsOfferingMemberusgaapClassOfWarrantOrRightAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">pstv:TwoThousandEighteenRightsOfferingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pstv:SeriesCConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_PiramalPharmaSolutionsIncMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">pstv:PiramalPharmaSolutionsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="PAsOn04_30_2023_OutstandingWarrantsAndOptionsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">pstv:OutstandingWarrantsAndOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-30</instant>
        </period>
    </context>
    <context id="PAsOn04_30_2023_EquityIncentivePlansMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pstv:EquityIncentivePlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-30</instant>
        </period>
    </context>
    <context id="PAsOn05_01_2023_OutstandingWarrantsAndOptionsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">pstv:OutstandingWarrantsAndOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-05-01</instant>
        </period>
    </context>
    <context id="PAsOn05_01_2023_EquityIncentivePlansMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pstv:EquityIncentivePlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-05-01</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2023_CharlottesvilleMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">pstv:CharlottesvilleMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="PAsOn07_01_2023_CharlottesvilleMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">pstv:CharlottesvilleMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-07-01</instant>
        </period>
    </context>
    <context id="P09_07_2023To09_07_2023_BioceptAgreementMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">pstv:BioceptAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-09-07</startDate>
            <endDate>2023-09-07</endDate>
        </period>
    </context>
    <context id="PAsOn09_07_2023_BioceptAgreementMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">pstv:BioceptAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-07</instant>
        </period>
    </context>
    <context id="P10_01_2023To12_31_2023_BioceptAgreementMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">pstv:BioceptAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To01_31_2022_UTHSALicenseAgreementMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">pstv:UTHSALicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-01-31</endDate>
        </period>
    </context>
    <context id="P03_29_2020To03_29_2020_NanoTxLicensesAgreementMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">pstv:NanoTxLicensesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-29</startDate>
            <endDate>2020-03-29</endDate>
        </period>
    </context>
    <context id="P03_29_2020To03_29_2020_TermLoanMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pstv:TermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-29</startDate>
            <endDate>2020-03-29</endDate>
        </period>
    </context>
    <context id="PAsOn03_29_2020_NanoTxLicensesAgreementMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">pstv:NanoTxLicensesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-29</instant>
        </period>
    </context>
    <context id="P05_28_2015To05_29_2015_InterestRateFloorMemberusgaapDerivativeInstrumentRiskAxis_LiborMemberusgaapVariableRateAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateFloorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">pstv:LiborMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-05-28</startDate>
            <endDate>2015-05-29</endDate>
        </period>
    </context>
    <context id="P05_28_2015To05_29_2015_TermLoanMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pstv:TermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-05-28</startDate>
            <endDate>2015-05-29</endDate>
        </period>
    </context>
    <context id="P05_28_2015To05_29_2015_LoanAndSecurityAgreementMemberusgaapFinancialInstrumentAxis_SaleOfJapaneseSubsidiaryAndCertainAssetsMemberusgaapDisposalGroupClassificationAxis_TermLoanMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pstv:TermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">pstv:SaleOfJapaneseSubsidiaryAndCertainAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">pstv:LoanAndSecurityAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-05-28</startDate>
            <endDate>2015-05-29</endDate>
        </period>
    </context>
    <context id="PAsOn05_29_2015_TermLoanMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pstv:TermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2015-05-29</instant>
        </period>
    </context>
    <context id="PAsOn05_29_2015_MinimumMembersrtRangeAxis_TermLoanMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pstv:TermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2015-05-29</instant>
        </period>
    </context>
    <context id="P09_19_2022To09_19_2022_CancerPreventionAndResearchInstituteOfTexasContractMemberusgaapTypeOfArrangementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pstv:CancerPreventionAndResearchInstituteOfTexasContractMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-09-19</startDate>
            <endDate>2022-09-19</endDate>
        </period>
    </context>
    <context id="PAsOn09_19_2022_CancerPreventionAndResearchInstituteOfTexasContractMemberusgaapTypeOfArrangementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pstv:CancerPreventionAndResearchInstituteOfTexasContractMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-19</instant>
        </period>
    </context>
    <context id="P10_01_2022To12_31_2022_CancerPreventionAndResearchInstituteOfTexasContractMemberusgaapTypeOfArrangementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pstv:CancerPreventionAndResearchInstituteOfTexasContractMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To03_31_2023_GrantMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To03_31_2023_OptionsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">pstv:OptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To03_31_2023_PreferredStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To03_31_2023_WarrantMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To03_31_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To03_31_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_SeriesFPreferredStockMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesFPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To03_31_2023_SeriesFPreferredStockMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesFPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To03_31_2023_PreferredStockMemberusgaapStatementEquityComponentsAxis_SeriesFPreferredStockMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesFPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To03_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To03_31_2023_CancerPreventionAndResearchInstituteOfTexasContractMemberusgaapTypeOfArrangementAxis_GrantMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pstv:CancerPreventionAndResearchInstituteOfTexasContractMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To03_31_2023_CancerPreventionAndResearchInstituteOfTexasContractMemberusgaapTypeOfArrangementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pstv:CancerPreventionAndResearchInstituteOfTexasContractMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To03_31_2023_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="P03_03_2023To03_03_2023_SeriesFConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis_SubscriptionAgreementMemberusgaapSubsidiarySaleOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pstv:SeriesFConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pstv:SubscriptionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-03-03</startDate>
            <endDate>2023-03-03</endDate>
        </period>
    </context>
    <context id="P03_03_2023To03_03_2023_SeriesFConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pstv:SeriesFConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-03-03</startDate>
            <endDate>2023-03-03</endDate>
        </period>
    </context>
    <context id="PAsOn03_03_2023_SeriesFConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pstv:SeriesFConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-03</instant>
        </period>
    </context>
    <context id="PAsOn03_03_2023_SeriesFConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis_SubscriptionAgreementMemberusgaapSubsidiarySaleOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pstv:SeriesFConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pstv:SubscriptionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-03</instant>
        </period>
    </context>
    <context id="P05_16_2022To05_16_2022_CommonStockMemberusgaapStatementEquityComponentsAxis_LincolnParkCapitalFundLLCMemberdeiLegalEntityAxis_MinimumMembersrtRangeAxis_TwoThousandAndTwentyTwoPurchaseAgreementMemberusgaapInvestmentTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">pstv:TwoThousandAndTwentyTwoPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">pstv:LincolnParkCapitalFundLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-16</startDate>
            <endDate>2022-05-16</endDate>
        </period>
    </context>
    <context id="PAsOn05_16_2022_LincolnParkCapitalFundLLCMemberdeiLegalEntityAxis_MaximumMembersrtRangeAxis_TwoThousandAndTwentyTwoPurchaseAgreementMemberusgaapInvestmentTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">pstv:TwoThousandAndTwentyTwoPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">pstv:LincolnParkCapitalFundLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-16</instant>
        </period>
    </context>
    <context id="PAsOn08_02_2022_CommonStockMemberusgaapStatementEquityComponentsAxis_LincolnParkCapitalFundLLCMemberdeiLegalEntityAxis_TwoThousandAndTwentyTwoPurchaseAgreementMemberusgaapInvestmentTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">pstv:TwoThousandAndTwentyTwoPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">pstv:LincolnParkCapitalFundLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-08-02</instant>
        </period>
    </context>
    <context id="PAsOn07_14_2022_CommonStockMemberusgaapStatementEquityComponentsAxis_LincolnParkCapitalFundLLCMemberdeiLegalEntityAxis_TwoThousandAndTwentyTwoPurchaseAgreementMemberusgaapInvestmentTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">pstv:TwoThousandAndTwentyTwoPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">pstv:LincolnParkCapitalFundLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-14</instant>
        </period>
    </context>
    <context id="P08_02_2022To08_02_2022_CommonStockMemberusgaapStatementEquityComponentsAxis_LincolnParkCapitalFundLLCMemberdeiLegalEntityAxis_TwoThousandAndTwentyTwoPurchaseAgreementMemberusgaapInvestmentTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">pstv:TwoThousandAndTwentyTwoPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">pstv:LincolnParkCapitalFundLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-02</startDate>
            <endDate>2022-08-02</endDate>
        </period>
    </context>
    <context id="PAsOn08_17_2022_CommonStockMemberusgaapStatementEquityComponentsAxis_LincolnParkCapitalFundLLCMemberdeiLegalEntityAxis_TwoThousandAndTwentyTwoPurchaseAgreementMemberusgaapInvestmentTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">pstv:TwoThousandAndTwentyTwoPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">pstv:LincolnParkCapitalFundLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-08-17</instant>
        </period>
    </context>
    <context id="PAsOn08_17_2022_CommonStockMemberusgaapStatementEquityComponentsAxis_LincolnParkCapitalFundLLCMemberdeiLegalEntityAxis_MaximumMembersrtRangeAxis_TwoThousandAndTwentyTwoPurchaseAgreementMemberusgaapInvestmentTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">pstv:TwoThousandAndTwentyTwoPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">pstv:LincolnParkCapitalFundLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-08-17</instant>
        </period>
    </context>
    <context id="P08_17_2022To12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis_LincolnParkCapitalFundLLCMemberdeiLegalEntityAxis_TwentyTwentyPurchaseAgreementMemberusgaapInvestmentTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">pstv:TwentyTwentyPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">pstv:LincolnParkCapitalFundLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-17</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="PAsOn08_18_2023_CommonStockMemberusgaapStatementEquityComponentsAxis_LincolnParkCapitalFundLLCMemberdeiLegalEntityAxis_MaximumMembersrtRangeAxis_TwoThousandAndTwentyTwoPurchaseAgreementMemberusgaapInvestmentTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">pstv:TwoThousandAndTwentyTwoPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">pstv:LincolnParkCapitalFundLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-08-18</instant>
        </period>
    </context>
    <context id="P08_18_2023To12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis_LincolnParkCapitalFundLLCMemberdeiLegalEntityAxis_TwoThousandAndTwentyTwoPurchaseAgreementMemberusgaapInvestmentTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">pstv:TwoThousandAndTwentyTwoPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">pstv:LincolnParkCapitalFundLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-18</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="PAsOn09_30_2020_CommonStockMemberusgaapStatementEquityComponentsAxis_LincolnParkCapitalFundLLCMemberdeiLegalEntityAxis_TwentyTwentyPurchaseAgreementMemberusgaapInvestmentTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">pstv:TwentyTwentyPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">pstv:LincolnParkCapitalFundLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="P08_17_2022To12_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis_LincolnParkCapitalFundLLCMemberdeiLegalEntityAxis_TwoThousandAndTwentyTwoPurchaseAgreementMemberusgaapInvestmentTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">pstv:TwoThousandAndTwentyTwoPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">pstv:LincolnParkCapitalFundLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-17</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_14_2022To01_14_2022_AtTheMarketOfferingProgramMemberusgaapSubsidiarySaleOfStockAxis_CanaccordGenuityLLCMemberdeiLegalEntityAxis_CommonStockMemberusgaapStatementEquityComponentsAxis_JanuaryTwoThousandAndTwentyTwoDistributionAgreementMemberusgaapInvestmentTypeAxis_MaximumMembersrtRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">pstv:JanuaryTwoThousandAndTwentyTwoDistributionAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pstv:AtTheMarketOfferingProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">pstv:CanaccordGenuityLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-14</startDate>
            <endDate>2022-01-14</endDate>
        </period>
    </context>
    <context id="P09_09_2022To09_09_2022_AtTheMarketOfferingProgramMemberusgaapSubsidiarySaleOfStockAxis_CanaccordGenuityLLCMemberdeiLegalEntityAxis_CommonStockMemberusgaapStatementEquityComponentsAxis_MaximumMembersrtRangeAxis_SeptemberTwoThousandAndTwentyTwoDistributionAgreementMemberusgaapInvestmentTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">pstv:SeptemberTwoThousandAndTwentyTwoDistributionAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pstv:AtTheMarketOfferingProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">pstv:CanaccordGenuityLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-09-09</startDate>
            <endDate>2022-09-09</endDate>
        </period>
    </context>
    <context id="P09_09_2022To09_09_2022_AtTheMarketOfferingProgramMemberusgaapSubsidiarySaleOfStockAxis_CanaccordGenuityLLCMemberdeiLegalEntityAxis_SeptemberTwoThousandAndTwentyTwoDistributionAgreementMemberusgaapInvestmentTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">pstv:SeptemberTwoThousandAndTwentyTwoDistributionAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pstv:AtTheMarketOfferingProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">pstv:CanaccordGenuityLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-09-09</startDate>
            <endDate>2022-09-09</endDate>
        </period>
    </context>
    <context id="P09_09_2022To12_31_2022_AtTheMarketOfferingProgramMemberusgaapSubsidiarySaleOfStockAxis_CanaccordGenuityLLCMemberdeiLegalEntityAxis_CommonStockMemberusgaapStatementEquityComponentsAxis_SeptemberTwoThousandAndTwentyTwoDistributionAgreementMemberusgaapInvestmentTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">pstv:SeptemberTwoThousandAndTwentyTwoDistributionAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pstv:AtTheMarketOfferingProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">pstv:CanaccordGenuityLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-09-09</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="PAsOn10_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis_MaximumMembersrtRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-10-31</instant>
        </period>
    </context>
    <context id="P01_01_2024To02_26_2024_CommonStockMemberusgaapStatementEquityComponentsAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-02-26</endDate>
        </period>
    </context>
    <context id="PAsOn02_26_2024_CommonStockMemberusgaapStatementEquityComponentsAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-26</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2024_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapCashAndCashEquivalentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2024_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapCashAndCashEquivalentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2024_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_USTreasurySecuritiesMemberusgaapCashAndCashEquivalentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2024_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_USTreasurySecuritiesMemberusgaapCashAndCashEquivalentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2024_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2024_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2024_StockBasedCompensation2015EquityIncentivePlan1MemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pstv:StockBasedCompensation2015EquityIncentivePlan1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2024_StockBasedCompensation2020EquityIncentivePlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pstv:StockBasedCompensation2020EquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2024_CommonClassBMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2024_RepresentativeSeriesUWarrantMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">pstv:RepresentativeSeriesUWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2024_MaximumMembersrtRangeAxis_TermLoanMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pstv:TermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2024_CharlottesvilleMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">pstv:CharlottesvilleMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2024_SeriesUWarrantsMemberusgaapClassOfWarrantOrRightAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">pstv:SeriesUWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2024_SeriesUWarrantsMemberusgaapClassOfWarrantOrRightAxis_WarrantMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">pstv:SeriesUWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2024_TermLoanMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pstv:TermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2024_NanoTxLicensesAgreementMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">pstv:NanoTxLicensesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2024_SeriesCConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis_TwoThousandEighteenRightsOfferingMemberusgaapClassOfWarrantOrRightAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">pstv:TwoThousandEighteenRightsOfferingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pstv:SeriesCConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2024_SeriesBConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis_TwoThousandEighteenRightsOfferingMemberusgaapClassOfWarrantOrRightAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">pstv:TwoThousandEighteenRightsOfferingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pstv:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2024_PreClinicalResearchStudyObligationsMemberusgaapRecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis">pstv:PreClinicalResearchStudyObligationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2024_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="P01_01_2024To03_31_2024_GrantMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2024To03_31_2024_OptionsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">pstv:OptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2024To03_31_2024_PreferredStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2024To03_31_2024_WarrantMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2024To03_31_2024_TermLoanMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pstv:TermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2024To03_31_2024_SeriesUWarrantsMemberusgaapClassOfWarrantOrRightAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">pstv:SeriesUWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2024To03_31_2024_CommonClassAMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2024To03_31_2024_StockBasedCompensation2020EquityIncentivePlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pstv:StockBasedCompensation2020EquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2024To03_31_2024_CommonStockMemberusgaapStatementEquityComponentsAxis_LincolnParkCapitalFundLLCMemberdeiLegalEntityAxis_TwoThousandAndTwentyTwoPurchaseAgreementMemberusgaapInvestmentTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">pstv:TwoThousandAndTwentyTwoPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">pstv:LincolnParkCapitalFundLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2024To03_31_2024_BioceptAgreementMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">pstv:BioceptAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2024To03_31_2024_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2024To03_31_2024_CharlottesvilleMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">pstv:CharlottesvilleMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2024To03_31_2024_CancerPreventionAndResearchInstituteOfTexasContractMemberusgaapTypeOfArrangementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pstv:CancerPreventionAndResearchInstituteOfTexasContractMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2024To03_31_2024_MinimumMembersrtRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2024To03_31_2024_MaximumMembersrtRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2024To03_31_2024_SeriesUWarrantsMemberusgaapClassOfWarrantOrRightAxis_WarrantMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">pstv:SeriesUWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2024To03_31_2024_CancerPreventionAndResearchInstituteOfTexasContractMemberusgaapTypeOfArrangementAxis_GrantMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pstv:CancerPreventionAndResearchInstituteOfTexasContractMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2024To03_31_2024_TreasuryStockCommonMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2024To03_31_2024_MaximumMembersrtRangeAxis_TermLoanMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pstv:TermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2024To03_31_2024_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2024To03_31_2024_SeriesBConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis_TwoThousandEighteenRightsOfferingMemberusgaapClassOfWarrantOrRightAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">pstv:TwoThousandEighteenRightsOfferingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pstv:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2024To03_31_2024_SeriesCConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis_TwoThousandEighteenRightsOfferingMemberusgaapClassOfWarrantOrRightAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">pstv:TwoThousandEighteenRightsOfferingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pstv:SeriesCConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2024To03_31_2024_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2024To03_31_2024_PiramalPharmaSolutionsIncMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">pstv:PiramalPharmaSolutionsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2024To03_31_2024_BusinessContactMemberdeiEntityAddressesAddressTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:EntityAddressesAddressTypeAxis">dei:BusinessContactMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="P06_28_2023To06_28_2023_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMemberusgaapVariableRateAxis_TermLoanMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pstv:TermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-06-28</startDate>
            <endDate>2023-06-28</endDate>
        </period>
    </context>
    <context id="PAsOn06_28_2023_TermLoanMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pstv:TermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-28</instant>
        </period>
    </context>
    <context id="P08_17_2022To03_31_2024_CommonStockMemberusgaapStatementEquityComponentsAxis_LincolnParkCapitalFundLLCMemberdeiLegalEntityAxis_TwentyTwentyPurchaseAgreementMemberusgaapInvestmentTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">pstv:TwentyTwentyPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">pstv:LincolnParkCapitalFundLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-17</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="P08_18_2023To03_31_2024_CommonStockMemberusgaapStatementEquityComponentsAxis_LincolnParkCapitalFundLLCMemberdeiLegalEntityAxis_TwoThousandAndTwentyTwoPurchaseAgreementMemberusgaapInvestmentTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">pstv:TwoThousandAndTwentyTwoPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">pstv:LincolnParkCapitalFundLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-18</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="P04_20_2023To04_20_2023_MinimumMembersrtRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-20</startDate>
            <endDate>2023-04-20</endDate>
        </period>
    </context>
    <context id="P04_20_2023To04_20_2023_MaximumMembersrtRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-20</startDate>
            <endDate>2023-04-20</endDate>
        </period>
    </context>
    <context id="PAsOn05_09_2024_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-05-09</instant>
        </period>
    </context>
    <context id="PAsOn05_09_2024_May2024PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pstv:May2024PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-05-09</instant>
        </period>
    </context>
    <context id="P03_27_2020To03_28_2020_TermLoanMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pstv:TermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-27</startDate>
            <endDate>2020-03-28</endDate>
        </period>
    </context>
    <context id="P01_08_2021To01_08_2021_PiramalPharmaSolutionsIncMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">pstv:PiramalPharmaSolutionsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-08</startDate>
            <endDate>2021-01-08</endDate>
        </period>
    </context>
    <context id="PAsOn01_14_2022_AtTheMarketOfferingProgramMemberusgaapSubsidiarySaleOfStockAxis_CanaccordGenuityLLCMemberdeiLegalEntityAxis_CommonStockMemberusgaapStatementEquityComponentsAxis_JanuaryTwoThousandAndTwentyTwoDistributionAgreementMemberusgaapInvestmentTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">pstv:JanuaryTwoThousandAndTwentyTwoDistributionAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pstv:AtTheMarketOfferingProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">pstv:CanaccordGenuityLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-14</instant>
        </period>
    </context>
    <context id="P05_31_2024To05_31_2024_PershingCreditFacilityMemberusgaapCreditFacilityAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">pstv:PershingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-05-31</startDate>
            <endDate>2024-05-31</endDate>
        </period>
    </context>
    <context id="PAsOn05_31_2024_PershingCreditFacilityMemberusgaapCreditFacilityAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">pstv:PershingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-05-31</instant>
        </period>
    </context>
    <context id="P01_01_2020To09_30_2020_CommonStockMemberusgaapStatementEquityComponentsAxis_LincolnParkCapitalFundLLCMemberdeiLegalEntityAxis_TwentyTwentyPurchaseAgreementMemberusgaapInvestmentTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">pstv:TwentyTwentyPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">pstv:LincolnParkCapitalFundLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="P03_31_2022To03_31_2022_MedidataSolutionsIncMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_ServicesAgreementMemberusgaapTypeOfArrangementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">pstv:MedidataSolutionsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pstv:ServicesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-31</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="PAsOn05_05_2024_May2024PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pstv:May2024PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-05-05</instant>
        </period>
    </context>
    <context id="P05_05_2024To05_05_2024_May2024PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pstv:May2024PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-05-05</startDate>
            <endDate>2024-05-05</endDate>
        </period>
    </context>
    <context id="P05_05_2024To05_05_2024_May2024PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_SeriesAWarrantMemberusgaapClassOfWarrantOrRightAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">pstv:SeriesAWarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pstv:May2024PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-05-05</startDate>
            <endDate>2024-05-05</endDate>
        </period>
    </context>
    <context id="P05_05_2024To05_05_2024_May2024PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_SeriesBWarrantMemberusgaapClassOfWarrantOrRightAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">pstv:SeriesBWarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pstv:May2024PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-05-05</startDate>
            <endDate>2024-05-05</endDate>
        </period>
    </context>
    <context id="P05_05_2024To05_05_2024_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-05-05</startDate>
            <endDate>2024-05-05</endDate>
        </period>
    </context>
    <context id="P05_05_2024To05_05_2024_PreFundedWarrantMemberusgaapSubsidiarySaleOfStockAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pstv:PreFundedWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-05-05</startDate>
            <endDate>2024-05-05</endDate>
        </period>
    </context>
    <context id="P04_26_2024To04_26_2024_BioceptAssetPurchaseMemberusgaapAssetAcquisitionAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">pstv:BioceptAssetPurchaseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-26</startDate>
            <endDate>2024-04-26</endDate>
        </period>
    </context>
    <context id="PAsOn12_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_ConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_ConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_TreasuryStockCommonMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_ConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2023_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2023_PreferredStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2023_ConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2024_TreasuryStockCommonMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2024_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2024_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2024_ConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <unit id="Unit_USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Unit_shares">
        <measure>shares</measure>
    </unit>
    <unit id="Unit_pure">
        <measure>pure</measure>
    </unit>
    <unit id="Unit_Year">
        <measure>utr:Year</measure>
    </unit>
    <unit id="Unit_Month">
        <measure>utr:Month</measure>
    </unit>
    <unit id="Unit_USD_per_Share">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Unit_Votes">
        <measure>pstv:Votes</measure>
    </unit>
    <unit id="Unit_ReportableUnit">
        <measure>pstv:ReportableUnit</measure>
    </unit>
    <unit id="Unit_Segment">
        <measure>pstv:Segment</measure>
    </unit>
    <dei:AmendmentFlag contextRef="P01_01_2024To03_31_2024" id="ixv-20278">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey contextRef="P01_01_2024To03_31_2024" id="ixv-20279">0001095981</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="P01_01_2024To03_31_2024" id="ixv-22161">S-1</dei:DocumentType>
    <dei:EntityRegistrantName contextRef="P01_01_2024To03_31_2024" id="ixv-22162">PLUS THERAPEUTICS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="P01_01_2024To03_31_2024" id="ixv-22163">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityPrimarySicNumber contextRef="P01_01_2024To03_31_2024" id="ixv-22164">2834</dei:EntityPrimarySicNumber>
    <dei:EntityTaxIdentificationNumber contextRef="P01_01_2024To03_31_2024" id="ixv-22165">33-0827593</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="P01_01_2024To03_31_2024" id="ixv-22166">4200 Marathon Blvd.</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="P01_01_2024To03_31_2024" id="ixv-22167">Suite 200</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="P01_01_2024To03_31_2024" id="ixv-22168">Austin</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="P01_01_2024To03_31_2024" id="ixv-22169">TX</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="P01_01_2024To03_31_2024" id="ixv-22170">78756</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="P01_01_2024To03_31_2024" id="ixv-22171">737</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="P01_01_2024To03_31_2024" id="ixv-22172">255-7194</dei:LocalPhoneNumber>
    <dei:ContactPersonnelName
      contextRef="P01_01_2024To03_31_2024_BusinessContactMemberdeiEntityAddressesAddressTypeAxis"
      id="ixv-22173">Marc H. Hedrick, M.D.</dei:ContactPersonnelName>
    <dei:EntityAddressAddressLine1
      contextRef="P01_01_2024To03_31_2024_BusinessContactMemberdeiEntityAddressesAddressTypeAxis"
      id="ixv-22174">4200 Marathon Blvd.</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="P01_01_2024To03_31_2024_BusinessContactMemberdeiEntityAddressesAddressTypeAxis"
      id="ixv-22175">Suite 200</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="P01_01_2024To03_31_2024_BusinessContactMemberdeiEntityAddressesAddressTypeAxis"
      id="ixv-22176">Austin</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="P01_01_2024To03_31_2024_BusinessContactMemberdeiEntityAddressesAddressTypeAxis"
      id="ixv-22177">TX</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="P01_01_2024To03_31_2024_BusinessContactMemberdeiEntityAddressesAddressTypeAxis"
      id="ixv-22178">78756</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="P01_01_2024To03_31_2024_BusinessContactMemberdeiEntityAddressesAddressTypeAxis"
      id="ixv-22179">737</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="P01_01_2024To03_31_2024_BusinessContactMemberdeiEntityAddressesAddressTypeAxis"
      id="ixv-22180">255-7194</dei:LocalPhoneNumber>
    <dei:EntityFilerCategory contextRef="P01_01_2024To03_31_2024" id="ixv-229">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="P01_01_2024To03_31_2024" id="ixv-22181">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="P01_01_2024To03_31_2024" id="ixv-22182">false</dei:EntityEmergingGrowthCompany>
    <us-gaap:DebtInstrumentOfferingDate1 contextRef="P01_01_2023To12_31_2023" id="hidden116199096">2015-05-29</us-gaap:DebtInstrumentOfferingDate1>
    <us-gaap:DebtInstrumentOfferingDate1 contextRef="P01_01_2022To12_31_2022" id="hidden116199109">2015-05-29</us-gaap:DebtInstrumentOfferingDate1>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="PAsOn12_31_2023_MinimumMembersrtRangeAxis"
      id="hidden116200141">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1
      contextRef="P04_20_2023To04_20_2023_MinimumMembersrtRangeAxis"
      decimals="2"
      id="hidden116199108"
      unitRef="Unit_pure">0.33</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
    <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1
      contextRef="P04_20_2023To04_20_2023_MaximumMembersrtRangeAxis"
      decimals="2"
      id="hidden116199110"
      unitRef="Unit_pure">0.06</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
    <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1
      contextRef="P04_21_2023To04_21_2023"
      decimals="2"
      id="hidden116199113"
      unitRef="Unit_pure">0.06</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
    <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1
      contextRef="P04_20_2023To04_20_2023_MinimumMembersrtRangeAxis"
      decimals="2"
      id="hidden116200119"
      unitRef="Unit_pure">0.33</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
    <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1
      contextRef="P04_20_2023To04_20_2023_MaximumMembersrtRangeAxis"
      decimals="2"
      id="hidden116200122"
      unitRef="Unit_pure">0.06</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
    <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1
      contextRef="P04_21_2023To04_21_2023"
      decimals="2"
      id="hidden116200127"
      unitRef="Unit_pure">0.06</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="PAsOn03_31_2024"
      decimals="-3"
      id="ixv-22196"
      unitRef="Unit_USD">2901000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-22197"
      unitRef="Unit_USD">8554000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:ShortTermInvestments
      contextRef="PAsOn03_31_2024"
      decimals="-3"
      id="ixv-22198"
      unitRef="Unit_USD">323000</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-22199"
      unitRef="Unit_USD">0</us-gaap:ShortTermInvestments>
    <us-gaap:OtherAssetsCurrent
      contextRef="PAsOn03_31_2024"
      decimals="-3"
      id="ixv-22200"
      unitRef="Unit_USD">989000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-22201"
      unitRef="Unit_USD">1280000</us-gaap:OtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="PAsOn03_31_2024"
      decimals="-3"
      id="ixv-22202"
      unitRef="Unit_USD">4213000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-22203"
      unitRef="Unit_USD">9834000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="PAsOn03_31_2024"
      decimals="-3"
      id="ixv-22204"
      unitRef="Unit_USD">800000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-22205"
      unitRef="Unit_USD">906000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="PAsOn03_31_2024"
      decimals="-3"
      id="ixv-22206"
      unitRef="Unit_USD">171000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-22207"
      unitRef="Unit_USD">202000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:Goodwill
      contextRef="PAsOn03_31_2024"
      decimals="-3"
      id="ixv-22208"
      unitRef="Unit_USD">372000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-22209"
      unitRef="Unit_USD">372000</us-gaap:Goodwill>
    <us-gaap:OtherIntangibleAssetsNet
      contextRef="PAsOn03_31_2024"
      decimals="-3"
      id="ixv-22210"
      unitRef="Unit_USD">33000</us-gaap:OtherIntangibleAssetsNet>
    <us-gaap:OtherIntangibleAssetsNet
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-22211"
      unitRef="Unit_USD">42000</us-gaap:OtherIntangibleAssetsNet>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="PAsOn03_31_2024"
      decimals="-3"
      id="ixv-22212"
      unitRef="Unit_USD">32000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-22213"
      unitRef="Unit_USD">32000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="PAsOn03_31_2024"
      decimals="-3"
      id="ixv-22214"
      unitRef="Unit_USD">5621000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-22215"
      unitRef="Unit_USD">11388000</us-gaap:Assets>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="PAsOn03_31_2024"
      decimals="-3"
      id="ixv-22216"
      unitRef="Unit_USD">6447000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-22217"
      unitRef="Unit_USD">6631000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="PAsOn03_31_2024"
      decimals="-3"
      id="ixv-22218"
      unitRef="Unit_USD">115000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-22219"
      unitRef="Unit_USD">120000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:DeferredIncomeCurrent
      contextRef="PAsOn03_31_2024"
      decimals="-3"
      id="ixv-22220"
      unitRef="Unit_USD">247000</us-gaap:DeferredIncomeCurrent>
    <us-gaap:DeferredIncomeCurrent
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-22221"
      unitRef="Unit_USD">0</us-gaap:DeferredIncomeCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="PAsOn03_31_2024"
      decimals="-3"
      id="ixv-22222"
      unitRef="Unit_USD">3590000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-22223"
      unitRef="Unit_USD">3976000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="PAsOn03_31_2024"
      decimals="-3"
      id="ixv-22224"
      unitRef="Unit_USD">10399000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-22225"
      unitRef="Unit_USD">10727000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="PAsOn03_31_2024"
      decimals="-3"
      id="ixv-22226"
      unitRef="Unit_USD">59000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-22227"
      unitRef="Unit_USD">85000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:DeferredIncomeNoncurrent
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-22228"
      unitRef="Unit_USD">1924000</us-gaap:DeferredIncomeNoncurrent>
    <us-gaap:Liabilities
      contextRef="PAsOn03_31_2024"
      decimals="-3"
      id="ixv-22229"
      unitRef="Unit_USD">10458000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-22230"
      unitRef="Unit_USD">12736000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="PAsOn03_31_2024"
      id="ixv-22231"
      unitRef="Unit_USD"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="PAsOn12_31_2023"
      id="ixv-22232"
      unitRef="Unit_USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="PAsOn03_31_2024"
      decimals="INF"
      id="ixv-22233"
      unitRef="Unit_USD_per_Share">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="PAsOn12_31_2023"
      decimals="INF"
      id="ixv-22234"
      unitRef="Unit_USD_per_Share">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="PAsOn03_31_2024"
      decimals="INF"
      id="ixv-22235"
      unitRef="Unit_shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="PAsOn12_31_2023"
      decimals="INF"
      id="ixv-22236"
      unitRef="Unit_shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="PAsOn03_31_2024"
      decimals="INF"
      id="ixv-22237"
      unitRef="Unit_shares">1952</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="PAsOn12_31_2023"
      decimals="INF"
      id="ixv-22238"
      unitRef="Unit_shares">1952</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="PAsOn03_31_2024"
      decimals="INF"
      id="ixv-22239"
      unitRef="Unit_shares">1952</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="PAsOn12_31_2023"
      decimals="INF"
      id="ixv-22240"
      unitRef="Unit_shares">1952</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockValue
      contextRef="PAsOn03_31_2024"
      decimals="-3"
      id="ixv-22241"
      unitRef="Unit_USD">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-22242"
      unitRef="Unit_USD">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="PAsOn12_31_2023"
      decimals="INF"
      id="ixv-22243"
      unitRef="Unit_USD_per_Share">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="PAsOn03_31_2024"
      decimals="INF"
      id="ixv-22244"
      unitRef="Unit_USD_per_Share">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="PAsOn03_31_2024"
      decimals="INF"
      id="ixv-22245"
      unitRef="Unit_shares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="PAsOn12_31_2023"
      decimals="INF"
      id="ixv-22246"
      unitRef="Unit_shares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="PAsOn03_31_2024"
      decimals="INF"
      id="ixv-22247"
      unitRef="Unit_shares">4522656</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="PAsOn03_31_2024"
      decimals="INF"
      id="ixv-22248"
      unitRef="Unit_shares">4264231</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="PAsOn12_31_2023"
      decimals="INF"
      id="ixv-22249"
      unitRef="Unit_shares">4522656</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="PAsOn12_31_2023"
      decimals="INF"
      id="ixv-22250"
      unitRef="Unit_shares">4444097</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="PAsOn03_31_2024"
      decimals="-3"
      id="ixv-22251"
      unitRef="Unit_USD">5000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-22252"
      unitRef="Unit_USD">5000</us-gaap:CommonStockValue>
    <us-gaap:TreasuryStockCommonShares
      contextRef="PAsOn03_31_2024"
      decimals="INF"
      id="ixv-22253"
      unitRef="Unit_shares">258425</us-gaap:TreasuryStockCommonShares>
    <us-gaap:TreasuryStockCommonShares
      contextRef="PAsOn12_31_2023"
      decimals="INF"
      id="ixv-22254"
      unitRef="Unit_shares">78559</us-gaap:TreasuryStockCommonShares>
    <us-gaap:TreasuryStockCommonValue
      contextRef="PAsOn03_31_2024"
      decimals="-3"
      id="ixv-22255"
      unitRef="Unit_USD">500000</us-gaap:TreasuryStockCommonValue>
    <us-gaap:TreasuryStockCommonValue
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-22256"
      unitRef="Unit_USD">126000</us-gaap:TreasuryStockCommonValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="PAsOn03_31_2024"
      decimals="-3"
      id="ixv-22257"
      unitRef="Unit_USD">479420000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-22258"
      unitRef="Unit_USD">479274000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="PAsOn03_31_2024"
      decimals="-3"
      id="ixv-22259"
      unitRef="Unit_USD">-483762000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-22260"
      unitRef="Unit_USD">-480501000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn03_31_2024"
      decimals="-3"
      id="ixv-22261"
      unitRef="Unit_USD">-4837000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-22262"
      unitRef="Unit_USD">-1348000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="PAsOn03_31_2024"
      decimals="-3"
      id="ixv-22263"
      unitRef="Unit_USD">5621000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-22264"
      unitRef="Unit_USD">11388000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:Revenues
      contextRef="P01_01_2024To03_31_2024_GrantMembersrtProductOrServiceAxis"
      decimals="-3"
      id="ixv-22265"
      unitRef="Unit_USD">1677000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="P01_01_2023To03_31_2023_GrantMembersrtProductOrServiceAxis"
      decimals="-3"
      id="ixv-22266"
      unitRef="Unit_USD">506000</us-gaap:Revenues>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="P01_01_2024To03_31_2024"
      decimals="-3"
      id="ixv-22267"
      unitRef="Unit_USD">2763000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="P01_01_2023To03_31_2023"
      decimals="-3"
      id="ixv-22268"
      unitRef="Unit_USD">2983000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="P01_01_2024To03_31_2024"
      decimals="-3"
      id="ixv-22269"
      unitRef="Unit_USD">2213000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="P01_01_2023To03_31_2023"
      decimals="-3"
      id="ixv-22270"
      unitRef="Unit_USD">2245000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="P01_01_2024To03_31_2024"
      decimals="-3"
      id="ixv-22271"
      unitRef="Unit_USD">4976000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="P01_01_2023To03_31_2023"
      decimals="-3"
      id="ixv-22272"
      unitRef="Unit_USD">5228000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="P01_01_2024To03_31_2024"
      decimals="-3"
      id="ixv-22273"
      unitRef="Unit_USD">-3299000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="P01_01_2023To03_31_2023"
      decimals="-3"
      id="ixv-22274"
      unitRef="Unit_USD">-4722000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InvestmentIncomeInterest
      contextRef="P01_01_2024To03_31_2024"
      decimals="-3"
      id="ixv-22275"
      unitRef="Unit_USD">72000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="P01_01_2023To03_31_2023"
      decimals="-3"
      id="ixv-22276"
      unitRef="Unit_USD">51000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InterestExpense
      contextRef="P01_01_2024To03_31_2024"
      decimals="-3"
      id="ixv-22277"
      unitRef="Unit_USD">34000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="P01_01_2023To03_31_2023"
      decimals="-3"
      id="ixv-22278"
      unitRef="Unit_USD">134000</us-gaap:InterestExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="P01_01_2024To03_31_2024"
      decimals="-3"
      id="ixv-22279"
      unitRef="Unit_USD">38000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="P01_01_2023To03_31_2023"
      decimals="-3"
      id="ixv-22280"
      unitRef="Unit_USD">-83000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2024To03_31_2024"
      decimals="-3"
      id="ixv-22281"
      unitRef="Unit_USD">-3261000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2023To03_31_2023"
      decimals="-3"
      id="ixv-22282"
      unitRef="Unit_USD">-4805000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="P01_01_2024To03_31_2024"
      decimals="2"
      id="ixv-22283"
      unitRef="Unit_USD_per_Share">-0.75</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="P01_01_2024To03_31_2024"
      decimals="2"
      id="ixv-22284"
      unitRef="Unit_USD_per_Share">-0.75</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="P01_01_2023To03_31_2023"
      decimals="2"
      id="ixv-22285"
      unitRef="Unit_USD_per_Share">-2.07</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="P01_01_2023To03_31_2023"
      decimals="2"
      id="ixv-22286"
      unitRef="Unit_USD_per_Share">-2.07</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="P01_01_2024To03_31_2024"
      decimals="0"
      id="ixv-22287"
      unitRef="Unit_shares">4321731</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="P01_01_2024To03_31_2024"
      decimals="0"
      id="ixv-22288"
      unitRef="Unit_shares">4321731</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="P01_01_2023To03_31_2023"
      decimals="0"
      id="ixv-22289"
      unitRef="Unit_shares">2320017</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="P01_01_2023To03_31_2023"
      decimals="0"
      id="ixv-22290"
      unitRef="Unit_shares">2320017</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="PAsOn12_31_2022_ConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="0"
      id="ixv-22291"
      unitRef="Unit_shares">1952</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="PAsOn12_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      id="ixv-22292"
      unitRef="Unit_shares">2240092</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-22293"
      unitRef="Unit_USD">2000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-22294"
      unitRef="Unit_USD">473628000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-22295"
      unitRef="Unit_USD">-467185000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      id="ixv-22296"
      unitRef="Unit_USD">6445000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="P01_01_2023To03_31_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-22297"
      unitRef="Unit_USD">140000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="P01_01_2023To03_31_2023"
      decimals="-3"
      id="ixv-22298"
      unitRef="Unit_USD">140000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="P01_01_2023To03_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      id="ixv-22299"
      unitRef="Unit_shares">168164</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="P01_01_2023To03_31_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-22300"
      unitRef="Unit_USD">895000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="P01_01_2023To03_31_2023"
      decimals="-3"
      id="ixv-22301"
      unitRef="Unit_USD">895000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="P01_01_2023To03_31_2023_PreferredStockMemberusgaapStatementEquityComponentsAxis_SeriesFPreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="0"
      id="ixv-22302"
      unitRef="Unit_shares">1</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="P01_01_2023To03_31_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_SeriesFPreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="-3"
      id="ixv-22303"
      unitRef="Unit_USD">1000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="P01_01_2023To03_31_2023_SeriesFPreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="-3"
      id="ixv-22304"
      unitRef="Unit_USD">1000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2023To03_31_2023_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-22305"
      unitRef="Unit_USD">-4805000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2023To03_31_2023"
      decimals="-3"
      id="ixv-22306"
      unitRef="Unit_USD">-4805000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="PAsOn03_31_2023_PreferredStockMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      id="ixv-22307"
      unitRef="Unit_shares">1</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="PAsOn03_31_2023_ConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="0"
      id="ixv-22308"
      unitRef="Unit_shares">1952</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="PAsOn03_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      id="ixv-22309"
      unitRef="Unit_shares">2408256</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn03_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-22310"
      unitRef="Unit_USD">2000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn03_31_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-22311"
      unitRef="Unit_USD">474664000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn03_31_2023_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-22312"
      unitRef="Unit_USD">-471990000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn03_31_2023"
      decimals="-3"
      id="ixv-22313"
      unitRef="Unit_USD">2676000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="PAsOn12_31_2023_ConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="0"
      id="ixv-22314"
      unitRef="Unit_shares">1952</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="PAsOn12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      id="ixv-22315"
      unitRef="Unit_shares">4522656</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-22316"
      unitRef="Unit_USD">5000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="PAsOn12_31_2023_TreasuryStockCommonMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      id="ixv-22317"
      unitRef="Unit_shares">-78559</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2023_TreasuryStockCommonMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-22318"
      unitRef="Unit_USD">-126000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-22319"
      unitRef="Unit_USD">479274000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2023_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-22320"
      unitRef="Unit_USD">-480501000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-22321"
      unitRef="Unit_USD">-1348000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="P01_01_2024To03_31_2024_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-22322"
      unitRef="Unit_USD">146000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="P01_01_2024To03_31_2024"
      decimals="-3"
      id="ixv-22323"
      unitRef="Unit_USD">146000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="P01_01_2024To03_31_2024_TreasuryStockCommonMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      id="ixv-22324"
      unitRef="Unit_shares">179866</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="P01_01_2024To03_31_2024_TreasuryStockCommonMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-22325"
      unitRef="Unit_USD">374000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="P01_01_2024To03_31_2024"
      decimals="-3"
      id="ixv-22326"
      unitRef="Unit_USD">374000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2024To03_31_2024_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-22327"
      unitRef="Unit_USD">-3261000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2024To03_31_2024"
      decimals="-3"
      id="ixv-22328"
      unitRef="Unit_USD">-3261000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="PAsOn03_31_2024_ConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="0"
      id="ixv-22329"
      unitRef="Unit_shares">1952</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="PAsOn03_31_2024_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      id="ixv-22330"
      unitRef="Unit_shares">4522656</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn03_31_2024_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-22331"
      unitRef="Unit_USD">5000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="PAsOn03_31_2024_TreasuryStockCommonMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      id="ixv-22332"
      unitRef="Unit_shares">-258425</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn03_31_2024_TreasuryStockCommonMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-22333"
      unitRef="Unit_USD">-500000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn03_31_2024_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-22334"
      unitRef="Unit_USD">479420000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn03_31_2024_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-22335"
      unitRef="Unit_USD">-483762000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn03_31_2024"
      decimals="-3"
      id="ixv-22336"
      unitRef="Unit_USD">-4837000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2024To03_31_2024"
      decimals="-3"
      id="ixv-22337"
      unitRef="Unit_USD">-3261000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2023To03_31_2023"
      decimals="-3"
      id="ixv-22338"
      unitRef="Unit_USD">-4805000</us-gaap:NetIncomeLoss>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="P01_01_2024To03_31_2024"
      decimals="-3"
      id="ixv-22339"
      unitRef="Unit_USD">155000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="P01_01_2023To03_31_2023"
      decimals="-3"
      id="ixv-22340"
      unitRef="Unit_USD">158000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="P01_01_2024To03_31_2024"
      decimals="-3"
      id="ixv-22341"
      unitRef="Unit_USD">16000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="P01_01_2023To03_31_2023"
      decimals="-3"
      id="ixv-22342"
      unitRef="Unit_USD">66000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:ShareBasedCompensation
      contextRef="P01_01_2024To03_31_2024"
      decimals="-3"
      id="ixv-22343"
      unitRef="Unit_USD">146000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="P01_01_2023To03_31_2023"
      decimals="-3"
      id="ixv-22344"
      unitRef="Unit_USD">140000</us-gaap:ShareBasedCompensation>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="P01_01_2024To03_31_2024"
      decimals="-3"
      id="ixv-22345"
      unitRef="Unit_USD">-1000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="P01_01_2024To03_31_2024"
      decimals="-3"
      id="ixv-22346"
      unitRef="Unit_USD">31000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="P01_01_2023To03_31_2023"
      decimals="-3"
      id="ixv-22347"
      unitRef="Unit_USD">29000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:GainLossOnDispositionOfAssets
      contextRef="P01_01_2023To03_31_2023"
      decimals="-3"
      id="ixv-22348"
      unitRef="Unit_USD">-2000</us-gaap:GainLossOnDispositionOfAssets>
    <us-gaap:IncreaseDecreaseInOtherCurrentAssets
      contextRef="P01_01_2024To03_31_2024"
      decimals="-3"
      id="ixv-22349"
      unitRef="Unit_USD">-150000</us-gaap:IncreaseDecreaseInOtherCurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherCurrentAssets
      contextRef="P01_01_2023To03_31_2023"
      decimals="-3"
      id="ixv-22350"
      unitRef="Unit_USD">-2791000</us-gaap:IncreaseDecreaseInOtherCurrentAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="P01_01_2024To03_31_2024"
      decimals="-3"
      id="ixv-22351"
      unitRef="Unit_USD">-43000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="P01_01_2023To03_31_2023"
      decimals="-3"
      id="ixv-22352"
      unitRef="Unit_USD">-3639000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="P01_01_2024To03_31_2024"
      decimals="-3"
      id="ixv-22353"
      unitRef="Unit_USD">-31000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="P01_01_2023To03_31_2023"
      decimals="-3"
      id="ixv-22354"
      unitRef="Unit_USD">-29000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <pstv:IncreaseDecreaseInDeferredGrantLiability
      contextRef="P01_01_2024To03_31_2024"
      decimals="-3"
      id="ixv-22355"
      unitRef="Unit_USD">-1677000</pstv:IncreaseDecreaseInDeferredGrantLiability>
    <pstv:IncreaseDecreaseInDeferredGrantLiability
      contextRef="P01_01_2023To03_31_2023"
      decimals="-3"
      id="ixv-22356"
      unitRef="Unit_USD">-506000</pstv:IncreaseDecreaseInDeferredGrantLiability>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="P01_01_2024To03_31_2024"
      decimals="-3"
      id="ixv-22357"
      unitRef="Unit_USD">-4513000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="P01_01_2023To03_31_2023"
      decimals="-3"
      id="ixv-22358"
      unitRef="Unit_USD">-5793000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="P01_01_2024To03_31_2024"
      decimals="-3"
      id="ixv-22359"
      unitRef="Unit_USD">40000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="P01_01_2023To03_31_2023"
      decimals="-3"
      id="ixv-22360"
      unitRef="Unit_USD">97000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireShortTermInvestments
      contextRef="P01_01_2024To03_31_2024"
      decimals="-3"
      id="ixv-22361"
      unitRef="Unit_USD">324000</us-gaap:PaymentsToAcquireShortTermInvestments>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="P01_01_2024To03_31_2024"
      decimals="-3"
      id="ixv-22362"
      unitRef="Unit_USD">-364000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="P01_01_2023To03_31_2023"
      decimals="-3"
      id="ixv-22363"
      unitRef="Unit_USD">-97000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="P01_01_2024To03_31_2024"
      decimals="-3"
      id="ixv-22364"
      unitRef="Unit_USD">402000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="P01_01_2023To03_31_2023"
      decimals="-3"
      id="ixv-22365"
      unitRef="Unit_USD">402000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:PaymentsForRepurchaseOfEquity
      contextRef="P01_01_2024To03_31_2024"
      decimals="-3"
      id="ixv-22366"
      unitRef="Unit_USD">374000</us-gaap:PaymentsForRepurchaseOfEquity>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="P01_01_2023To03_31_2023"
      decimals="-3"
      id="ixv-22367"
      unitRef="Unit_USD">895000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="P01_01_2024To03_31_2024"
      decimals="-3"
      id="ixv-22368"
      unitRef="Unit_USD">-776000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="P01_01_2023To03_31_2023"
      decimals="-3"
      id="ixv-22369"
      unitRef="Unit_USD">493000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="P01_01_2024To03_31_2024"
      decimals="-3"
      id="ixv-22370"
      unitRef="Unit_USD">-5653000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="P01_01_2023To03_31_2023"
      decimals="-3"
      id="ixv-22371"
      unitRef="Unit_USD">-5397000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-22372"
      unitRef="Unit_USD">8554000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      id="ixv-22373"
      unitRef="Unit_USD">18120000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="PAsOn03_31_2024"
      decimals="-3"
      id="ixv-22374"
      unitRef="Unit_USD">2901000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="PAsOn03_31_2023"
      decimals="-3"
      id="ixv-22375"
      unitRef="Unit_USD">12723000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:InterestPaidNet
      contextRef="P01_01_2024To03_31_2024"
      decimals="-3"
      id="ixv-22376"
      unitRef="Unit_USD">23000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="P01_01_2023To03_31_2023"
      decimals="-3"
      id="ixv-22377"
      unitRef="Unit_USD">73000</us-gaap:InterestPaidNet>
    <pstv:UnpaidOfferingCosts
      contextRef="P01_01_2024To03_31_2024"
      decimals="-3"
      id="ixv-22378"
      unitRef="Unit_USD">141000</pstv:UnpaidOfferingCosts>
    <pstv:UnpaidOfferingCosts
      contextRef="P01_01_2023To03_31_2023"
      decimals="-3"
      id="ixv-22379"
      unitRef="Unit_USD">25000</pstv:UnpaidOfferingCosts>
    <us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
      contextRef="P01_01_2023To03_31_2023"
      decimals="-3"
      id="ixv-22380"
      unitRef="Unit_USD">51000</us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability>
    <us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock contextRef="P01_01_2024To03_31_2024" id="ixv-10807">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;1. Basis of Presentation and New Accounting Standards &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;The accompanying unaudited condensed financial statements for the three months ended March&#160;31, 2024 and 2023 have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information. Accordingly, they do not include all of the information and footnotes required by accounting principles generally accepted in the United States of America for annual financial statements. The condensed balance sheet at December&#160;31, 2023 has been derived from the audited financial statements at December&#160;31, 2023, but does not include all of the information and footnotes required by accounting principles generally accepted in the United States of America for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation of the financial position and results of operations of Plus Therapeutics, Inc. (the &#x201c;Company&#x201d;) have been included. Operating results for the three months ended March&#160;31, 2024 are not necessarily indicative of the results that may be expected for the year ending December&#160;31, 2024. These financial statements should be read in conjunction with the financial statements and notes therein included in the Company&#x2019;s Annual Report on Form &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;10-K&lt;/div&gt; for the year ended December&#160;31, 2023, filed with the Securities and Exchange Commission on March&#160;5, 2024. &lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Amendments to Certificate of Incorporation and Reverse Stock Split &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;At the Annual Meeting of Stockholders of the Company held on April&#160;20, 2023 (the &#x201c;Annual Meeting&#x201d;), the stockholders of the Company approved an amendment to the Company&#x2019;s Amended and Restated Certificate of Incorporation (the &#x201c;Charter&#x201d;) to implement a reverse stock split of the Company&#x2019;s then issued and outstanding common stock, par value $0.001 per share, with the ratio to be determined by the Board of Directors (the &#x201c;Board&#x201d;) of the Company, within a range of not less than &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="-sec-ix-hidden:hidden116199108;display:inline;"&gt;1-for-3&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; and not greater than &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="-sec-ix-hidden:hidden116199110;display:inline;"&gt;1-for-15&lt;/div&gt;&lt;/div&gt;.&lt;/div&gt;&lt;/div&gt; Subsequently, on April&#160;21, 2023, the Board determined to fix the ratio for the reverse stock split at &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="-sec-ix-hidden:hidden116199113;display:inline;"&gt;1-for-15&lt;/div&gt;&lt;/div&gt;,&lt;/div&gt;&lt;/div&gt; without any change to its par value (the &#x201c;Reverse Stock Split&#x201d;). &lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;On April&#160;27, 2023, following stockholder and Board approval, the Company filed a Certificate of Amendment to its Charter (the &#x201c;Amendment&#x201d;), with the Secretary of State of the State of Delaware to effectuate the Reverse Stock Split. The Amendment became effective on May 1, 2023. Upon effectiveness of the Reverse Stock Split, the number of shares of the Company&#x2019;s common stock (x)&#160;issued and outstanding decreased from approximately 37.4&#160;million shares to approximately 2.5&#160;million shares; (y)&#160;reserved for issuance upon exercise of outstanding warrants and options decreased from approximately 2.0&#160;million shares to approximately 0.1&#160;million shares, and (z)&#160;reserved but unallocated under the Company&#x2019;s current equity incentive plans decreased from approximately 3.0&#160;million shares of common stock to approximately 0.2&#160;million shares of common stock. The Company&#x2019;s common stock began trading on the Nasdaq Capital Market (&#x201c;Nasdaq&#x201d;) on a post-split basis on May&#160;1, 2023. The Company&#x2019;s 5,000,000 shares of authorized Preferred Stock were not affected by the Reverse Stock Split. No fractional shares were issued in connection with the Reverse Stock Split, and accordingly, the outstanding number of shares post Reverse Stock Split was adjusted down by approximately 1,310 (post-effect of the Reverse Stock Split) shares. Proportional adjustments for the Reverse Stock Split were made to the Company&#x2019;s outstanding stock options, warrants and equity incentive plans for the period ended March&#160;31, 2023 as presented in the condensed financial statements in this Quarterly Report on Form &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;10-Q.&lt;/div&gt; The Company&#x2019;s financial statements, and all references thereto have been retroactively adjusted to reflect the Reverse Stock Split unless specifically stated otherwise. &lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Grant Revenue Recognition &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;In applying the provisions of Accounting Standards Codification (&#x201c;ASC&#x201d;) Topic 606, Revenue from Contracts with Customers (&#x201c;ASC 606&#x201d;), the Company has determined that government grants are out of the scope of ASC &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;606 because the funding entities do not meet the definition of a &#x201c;customer&#x201d;, as defined by ASC 606, as the Company does not consider there to be a transfer of control of goods or services. With respect to each grant, the Company determines if it has a collaboration in accordance with ASC Topic 808, Collaborative Arrangements (&#x201c;ASC 808&#x201d;). For grants outside the scope of ASC 808, the Company applies International Accounting Standards No.&#160;20 (&#x201c;IAS 20&#x201d;), Accounting for Government Grants and Disclosure of Government Assistance, by analogy, and revenue is recognized when the Company incurs expenses related to the grant for the amount the Company is entitled to under the provisions of the contract. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;The Company also considers the guidance in ASC Topic 730, Research and Development, which requires an assessment, at the inception of each grant, of whether each grant agreement is a liability. If the Company is obligated to repay funds received regardless of the outcome of the related research and development activities, then the Company is required to estimate and recognize that liability. Alternatively, if the Company is not required to repay the funds, then payments received are recorded as revenue or contra-expense as the expenses are incurred. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Deferred grant liability represents grant funds received or receivable for which the allowable expenses have not yet been incurred as of the balance sheet date. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;Available-for-Sale&lt;/div&gt;&lt;/div&gt; Securities &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;The Company&#x2019;s &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;available-for-sale&lt;/div&gt;&lt;/div&gt; securities consist of U.S. government and agency securities. The Company classifies its marketable securities as &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;available-for-sale&lt;/div&gt;&lt;/div&gt; and records such assets at estimated fair value in the condensed balance sheets, with unrealized gains and losses, if any, reported as a component of other comprehensive income (loss) within the condensed statements of operations and comprehensive income/loss and as a separate component of stockholders&#x2019; equity. Realized gains and losses are calculated on the specific identification method and recorded as interest income (loss). At each balance sheet date, the Company assesses &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;available-for-sale&lt;/div&gt;&lt;/div&gt; securities in an unrealized loss position to determine whether the decline in fair value below amortized cost is a result of credit losses or other factors, whether the Company expects to recover the amortized cost of the security, the Company&#x2019;s intent to sell and if it is more likely than not that the Company will be required to sell the securities before the recovery of amortized cost. The Company records changes in allowance for expected credit loss in other income (expense). As of March&#160;31, 2024, there were no &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;available-for-sale&lt;/div&gt;&lt;/div&gt; securities in an unrealized loss position, and there has been no allowance for expected credit losses recorded during any of the periods presented. &lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Any premium arising at purchase is amortized to the earliest call date and any discount arising at purchase is accreted to maturity. Accretion of discounts are recorded in interest income in the condensed statements of operations and comprehensive income/loss. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;During the three months ended March&#160;31, 2024, the unrealized gain on the Company&#x2019;s &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;available-for-sale&lt;/div&gt;&lt;/div&gt; securities was less than $1,000, and not presented separately in the condensed statement of operations and comprehensive income/loss. &lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Recently Issued Accounting Pronouncements &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;In December 2023, the Financial Accounting Standards Board (the &#x201c;FASB&#x201d;) issued Accounting Standards Update (ASU) &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;No.&#160;2023-09&lt;/div&gt; Income Taxes (Topic 740): Improvements to Income Tax Disclosure. This ASU includes amendments that further enhance income tax disclosures, primarily through standardization and disaggregation of rate reconciliation categories and income taxes paid by jurisdiction. The ASU is effective for years beginning after December&#160;15, 2024, but early adoption is permitted. This ASU should be applied on a prospective basis, although retrospective application is permitted. Management is currently evaluating the impact of the changes required by the new standard on the Company&#x2019;s financial statements and related disclosures. &lt;/div&gt;&lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;In November 2023, the FASB issued Accounting Standard Update (ASU) &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;No.&#160;2023-07,&lt;/div&gt; Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures. The new standard is intended to improve annual and interim reportable segment disclosure requirements regardless of number of reporting units, primarily through enhanced disclosures of significant expenses. The amendment requires public entities to disclose significant segment expenses that are regularly provided to &lt;div style="display:inline;"&gt;the C&lt;/div&gt;ODM and included within each reported measure of segment profit and loss. This update is effective for fiscal years beginning after December&#160;15, 2023, and interim periods within those fiscal years starting after December&#160;15, 2024. This ASU must be applied retrospectively to all prior periods presented. Management is &lt;div style="display:inline;"&gt;currently &lt;/div&gt;evaluating the impact of the changes required by the new standard on the Company&#x2019;s financial statements and related &lt;div style="display:inline;"&gt;disclosures&lt;/div&gt;. &lt;/div&gt;</us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="P01_01_2024To03_31_2024" id="ixv-10808">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;1. Basis of Presentation and New Accounting Standards &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;The accompanying unaudited condensed financial statements for the three months ended March&#160;31, 2024 and 2023 have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information. Accordingly, they do not include all of the information and footnotes required by accounting principles generally accepted in the United States of America for annual financial statements. The condensed balance sheet at December&#160;31, 2023 has been derived from the audited financial statements at December&#160;31, 2023, but does not include all of the information and footnotes required by accounting principles generally accepted in the United States of America for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation of the financial position and results of operations of Plus Therapeutics, Inc. (the &#x201c;Company&#x201d;) have been included. Operating results for the three months ended March&#160;31, 2024 are not necessarily indicative of the results that may be expected for the year ending December&#160;31, 2024. These financial statements should be read in conjunction with the financial statements and notes therein included in the Company&#x2019;s Annual Report on Form &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;10-K&lt;/div&gt; for the year ended December&#160;31, 2023, filed with the Securities and Exchange Commission on March&#160;5, 2024. &lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <pstv:AmendmentsForCertificateofIncorporationAndReverseStockSplitPolicyTextBlock contextRef="P01_01_2024To03_31_2024" id="ixv-10814">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Amendments to Certificate of Incorporation and Reverse Stock Split &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;At the Annual Meeting of Stockholders of the Company held on April&#160;20, 2023 (the &#x201c;Annual Meeting&#x201d;), the stockholders of the Company approved an amendment to the Company&#x2019;s Amended and Restated Certificate of Incorporation (the &#x201c;Charter&#x201d;) to implement a reverse stock split of the Company&#x2019;s then issued and outstanding common stock, par value $0.001 per share, with the ratio to be determined by the Board of Directors (the &#x201c;Board&#x201d;) of the Company, within a range of not less than &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="-sec-ix-hidden:hidden116199108;display:inline;"&gt;1-for-3&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; and not greater than &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="-sec-ix-hidden:hidden116199110;display:inline;"&gt;1-for-15&lt;/div&gt;&lt;/div&gt;.&lt;/div&gt;&lt;/div&gt; Subsequently, on April&#160;21, 2023, the Board determined to fix the ratio for the reverse stock split at &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="-sec-ix-hidden:hidden116199113;display:inline;"&gt;1-for-15&lt;/div&gt;&lt;/div&gt;,&lt;/div&gt;&lt;/div&gt; without any change to its par value (the &#x201c;Reverse Stock Split&#x201d;). &lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;On April&#160;27, 2023, following stockholder and Board approval, the Company filed a Certificate of Amendment to its Charter (the &#x201c;Amendment&#x201d;), with the Secretary of State of the State of Delaware to effectuate the Reverse Stock Split. The Amendment became effective on May 1, 2023. Upon effectiveness of the Reverse Stock Split, the number of shares of the Company&#x2019;s common stock (x)&#160;issued and outstanding decreased from approximately 37.4&#160;million shares to approximately 2.5&#160;million shares; (y)&#160;reserved for issuance upon exercise of outstanding warrants and options decreased from approximately 2.0&#160;million shares to approximately 0.1&#160;million shares, and (z)&#160;reserved but unallocated under the Company&#x2019;s current equity incentive plans decreased from approximately 3.0&#160;million shares of common stock to approximately 0.2&#160;million shares of common stock. The Company&#x2019;s common stock began trading on the Nasdaq Capital Market (&#x201c;Nasdaq&#x201d;) on a post-split basis on May&#160;1, 2023. The Company&#x2019;s 5,000,000 shares of authorized Preferred Stock were not affected by the Reverse Stock Split. No fractional shares were issued in connection with the Reverse Stock Split, and accordingly, the outstanding number of shares post Reverse Stock Split was adjusted down by approximately 1,310 (post-effect of the Reverse Stock Split) shares. Proportional adjustments for the Reverse Stock Split were made to the Company&#x2019;s outstanding stock options, warrants and equity incentive plans for the period ended March&#160;31, 2023 as presented in the condensed financial statements in this Quarterly Report on Form &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;10-Q.&lt;/div&gt; The Company&#x2019;s financial statements, and all references thereto have been retroactively adjusted to reflect the Reverse Stock Split unless specifically stated otherwise. &lt;/div&gt;</pstv:AmendmentsForCertificateofIncorporationAndReverseStockSplitPolicyTextBlock>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="PAsOn04_20_2023"
      decimals="INF"
      id="ixv-22381"
      unitRef="Unit_USD_per_Share">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <pstv:ReverseStockSplitEffectiveDate contextRef="P04_27_2023To04_27_2023" id="ixv-22382">2023-05-01</pstv:ReverseStockSplitEffectiveDate>
    <us-gaap:CommonStockSharesIssued
      contextRef="PAsOn04_30_2023"
      decimals="INF"
      id="ixv-22383"
      unitRef="Unit_shares">37400000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="PAsOn05_01_2023"
      decimals="INF"
      id="ixv-22384"
      unitRef="Unit_shares">2500000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="PAsOn04_30_2023_OutstandingWarrantsAndOptionsMemberusgaapStatementEquityComponentsAxis"
      decimals="INF"
      id="ixv-22385"
      unitRef="Unit_shares">2000000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="PAsOn05_01_2023_OutstandingWarrantsAndOptionsMemberusgaapStatementEquityComponentsAxis"
      decimals="INF"
      id="ixv-22386"
      unitRef="Unit_shares">100000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="PAsOn04_30_2023_EquityIncentivePlansMemberusgaapPlanNameAxis"
      decimals="INF"
      id="ixv-22387"
      unitRef="Unit_shares">3000000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="PAsOn05_01_2023_EquityIncentivePlansMemberusgaapPlanNameAxis"
      decimals="INF"
      id="ixv-22388"
      unitRef="Unit_shares">200000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="PAsOn03_31_2024"
      decimals="INF"
      id="ixv-22389"
      unitRef="Unit_shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:StockIssuedDuringPeriodSharesStockSplits
      contextRef="P01_01_2024To03_31_2024"
      decimals="INF"
      id="ixv-22390"
      unitRef="Unit_shares">0</us-gaap:StockIssuedDuringPeriodSharesStockSplits>
    <us-gaap:StockIssuedDuringPeriodSharesReverseStockSplits
      contextRef="P01_01_2024To03_31_2024"
      decimals="INF"
      id="ixv-22391"
      unitRef="Unit_shares">1310</us-gaap:StockIssuedDuringPeriodSharesReverseStockSplits>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock contextRef="P01_01_2024To03_31_2024" id="ixv-10833">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Grant Revenue Recognition &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;In applying the provisions of Accounting Standards Codification (&#x201c;ASC&#x201d;) Topic 606, Revenue from Contracts with Customers (&#x201c;ASC 606&#x201d;), the Company has determined that government grants are out of the scope of ASC &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;606 because the funding entities do not meet the definition of a &#x201c;customer&#x201d;, as defined by ASC 606, as the Company does not consider there to be a transfer of control of goods or services. With respect to each grant, the Company determines if it has a collaboration in accordance with ASC Topic 808, Collaborative Arrangements (&#x201c;ASC 808&#x201d;). For grants outside the scope of ASC 808, the Company applies International Accounting Standards No.&#160;20 (&#x201c;IAS 20&#x201d;), Accounting for Government Grants and Disclosure of Government Assistance, by analogy, and revenue is recognized when the Company incurs expenses related to the grant for the amount the Company is entitled to under the provisions of the contract. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;The Company also considers the guidance in ASC Topic 730, Research and Development, which requires an assessment, at the inception of each grant, of whether each grant agreement is a liability. If the Company is obligated to repay funds received regardless of the outcome of the related research and development activities, then the Company is required to estimate and recognize that liability. Alternatively, if the Company is not required to repay the funds, then payments received are recorded as revenue or contra-expense as the expenses are incurred. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Deferred grant liability represents grant funds received or receivable for which the allowable expenses have not yet been incurred as of the balance sheet date. &lt;/div&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <us-gaap:AvailableForSaleSecuritiesPurchasedOptionsPricePolicy contextRef="P01_01_2024To03_31_2024" id="ixv-10861">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;Available-for-Sale&lt;/div&gt;&lt;/div&gt; Securities &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;The Company&#x2019;s &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;available-for-sale&lt;/div&gt;&lt;/div&gt; securities consist of U.S. government and agency securities. The Company classifies its marketable securities as &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;available-for-sale&lt;/div&gt;&lt;/div&gt; and records such assets at estimated fair value in the condensed balance sheets, with unrealized gains and losses, if any, reported as a component of other comprehensive income (loss) within the condensed statements of operations and comprehensive income/loss and as a separate component of stockholders&#x2019; equity. Realized gains and losses are calculated on the specific identification method and recorded as interest income (loss). At each balance sheet date, the Company assesses &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;available-for-sale&lt;/div&gt;&lt;/div&gt; securities in an unrealized loss position to determine whether the decline in fair value below amortized cost is a result of credit losses or other factors, whether the Company expects to recover the amortized cost of the security, the Company&#x2019;s intent to sell and if it is more likely than not that the Company will be required to sell the securities before the recovery of amortized cost. The Company records changes in allowance for expected credit loss in other income (expense). As of March&#160;31, 2024, there were no &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;available-for-sale&lt;/div&gt;&lt;/div&gt; securities in an unrealized loss position, and there has been no allowance for expected credit losses recorded during any of the periods presented. &lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Any premium arising at purchase is amortized to the earliest call date and any discount arising at purchase is accreted to maturity. Accretion of discounts are recorded in interest income in the condensed statements of operations and comprehensive income/loss. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;During the three months ended March&#160;31, 2024, the unrealized gain on the Company&#x2019;s &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;available-for-sale&lt;/div&gt;&lt;/div&gt; securities was less than $1,000, and not presented separately in the condensed statement of operations and comprehensive income/loss. &lt;/div&gt;</us-gaap:AvailableForSaleSecuritiesPurchasedOptionsPricePolicy>
    <us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain
      contextRef="P01_01_2024To03_31_2024_MaximumMembersrtRangeAxis"
      decimals="-3"
      id="ixv-22392"
      unitRef="Unit_USD">1000000</us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="P01_01_2024To03_31_2024" id="ixv-10880">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Recently Issued Accounting Pronouncements &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;In December 2023, the Financial Accounting Standards Board (the &#x201c;FASB&#x201d;) issued Accounting Standards Update (ASU) &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;No.&#160;2023-09&lt;/div&gt; Income Taxes (Topic 740): Improvements to Income Tax Disclosure. This ASU includes amendments that further enhance income tax disclosures, primarily through standardization and disaggregation of rate reconciliation categories and income taxes paid by jurisdiction. The ASU is effective for years beginning after December&#160;15, 2024, but early adoption is permitted. This ASU should be applied on a prospective basis, although retrospective application is permitted. Management is currently evaluating the impact of the changes required by the new standard on the Company&#x2019;s financial statements and related disclosures. &lt;/div&gt;&lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;In November 2023, the FASB issued Accounting Standard Update (ASU) &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;No.&#160;2023-07,&lt;/div&gt; Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures. The new standard is intended to improve annual and interim reportable segment disclosure requirements regardless of number of reporting units, primarily through enhanced disclosures of significant expenses. The amendment requires public entities to disclose significant segment expenses that are regularly provided to &lt;div style="display:inline;"&gt;the C&lt;/div&gt;ODM and included within each reported measure of segment profit and loss. This update is effective for fiscal years beginning after December&#160;15, 2023, and interim periods within those fiscal years starting after December&#160;15, 2024. This ASU must be applied retrospectively to all prior periods presented. Management is &lt;div style="display:inline;"&gt;currently &lt;/div&gt;evaluating the impact of the changes required by the new standard on the Company&#x2019;s financial statements and related &lt;div style="display:inline;"&gt;disclosures&lt;/div&gt;. &lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <pstv:UseOfEstimatesTextBlock contextRef="P01_01_2024To03_31_2024" id="ixv-10906">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;2. Use of Estimates &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;The preparation of financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions affecting the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of r&lt;div style="display:inline;"&gt;evenue and ex&lt;/div&gt;penses during the reporting period. The Company&#x2019;s most significant estimates and critical accounting policies involve reviewing a&lt;div style="display:inline;"&gt;ssets for&lt;/div&gt; impairment and determining the assumptions used in measuring stock-based compensation expense. &lt;/div&gt;&lt;/div&gt;</pstv:UseOfEstimatesTextBlock>
    <pstv:DisclosureOfLiquidityAndGoingConcernTextBlock contextRef="P01_01_2024To03_31_2024" id="ixv-10914">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;3. Liquidity and Going Concern &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;The Company incurred a net loss of $3.3&#160;million for the three months ended March&#160;31, 2024. The Company had an accumulated deficit of $483.8&#160;million as of March&#160;31, 2024. Additionally, the Company used net cash of $4.5&#160;million to fund its operating activities for the three months ended March&#160;31, 2024.&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt; &lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;To date, the Company&#x2019;s operating losses have been funded primarily from outside sources of invested capital from issuance of its common and preferred stocks, proceeds from its term loan and grant funding. However, the Company has had, and will continue to have, an ongoing need to raise additional cash from outside sources to fund its future clinical development programs and other operations. There can be no assurance that the Company will be able to continue to raise additional capital in the future. The Company&#x2019;s inability to raise additional cash would have a material and adverse impact on its operations and could cause the Company to default on its term loan. These factors raise substantial doubt about the Company&#x2019;s ability to continue as a going concern. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;On May&#160;9, 2024, the Company closed a private placement of securities of the Company for aggregate gross proceeds of approximately $7.25&#160;million, before deducting certain expenses payable by the Company, and excluding the proceeds, if any, from the exercise of warrants issued in the private placement. See Note 12 for further information regarding the private placement. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Nasdaq Listing Compliance &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;On March&#160;8, 2024, the Company received a letter (the &#x201c;Notice&#x201d;) from the Listing Qualifications staff of Nasdaq, notifying the Company that it no longer complied with the requirement under Nasdaq Listing Rule 5550(b)(1) to maintain a minimum of $2.5&#160;million in stockholders&#x2019; equity for continued listing on Nasdaq or the alternative requirements of having a market value of listed securities of $35&#160;million or net income from continuing operations of $500,000 in the most recently completed fiscal year or two of the last three most recently completed fiscal years (the &#x201c;Alternative Standards&#x201d;). The Notice states that the Company&#x2019;s Annual Report on Form &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;10-K&lt;/div&gt; for the fiscal year ended December&#160;31, 2023, disclosed stockholders&#x2019; equity of ($1,348,000) as of December&#160;31, 2023, and that, as of March&#160;8, 2024, the Company did not meet the Alternative Standards. &lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;On April&#160;22, 2024, the Company provided Nasdaq with its plan to achieve and sustain compliance with the stockholders&#x2019; equity requirement and requested that Nasdaq grant the Company an extension of time until September&#160;4, 2024, to provide evidence of compliance with the stockholders&#x2019; equity requirement. Nasdaq has not yet responded to the Company&#x2019;s plan, and there can be no assurance that Nasdaq will grant an extension or that the Company will be able to comply with the applicable listing standards of Nasdaq. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;The Company continues to seek additional capital from other financing alternatives and other sources in order to ensure adequate funding is available to allow the Company to continue research and product development activities at their current levels. If sufficient capital is not raised, the Company will at a minimum need to significantly reduce or curtail its research and development and other operations, and this would negatively affect its ability to achieve corporate growth goals. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Should the Company fail to raise additional cash from outside sources, it would have a material adverse impact on its operations. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;The accompanying condensed financial statements have been prepared assuming the Company will continue to operate as a going concern, which contemplates the realization of assets and settlement of liabilities in the normal course of business, and do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classifications of liabilities that may result from uncertainty related to its ability to continue as a going concern. &lt;/div&gt;&lt;/div&gt;</pstv:DisclosureOfLiquidityAndGoingConcernTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2024To03_31_2024"
      decimals="-5"
      id="ixv-22394"
      unitRef="Unit_USD">-3300000</us-gaap:NetIncomeLoss>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="PAsOn03_31_2024"
      decimals="-5"
      id="ixv-22395"
      unitRef="Unit_USD">-483800000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="P01_01_2024To03_31_2024"
      decimals="-5"
      id="ixv-22396"
      unitRef="Unit_USD">-4500000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:WarrantsAndRightsOutstanding
      contextRef="PAsOn05_09_2024_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="-4"
      id="ixv-22397"
      unitRef="Unit_USD">7250000</us-gaap:WarrantsAndRightsOutstanding>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="P03_08_2024To03_08_2024"
      decimals="-5"
      id="ixv-22398"
      unitRef="Unit_USD">2500000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <pstv:MaintainMinimumMarketValueOfListedSecurities
      contextRef="PAsOn03_08_2024"
      decimals="-6"
      id="ixv-22399"
      unitRef="Unit_USD">35000000</pstv:MaintainMinimumMarketValueOfListedSecurities>
    <us-gaap:IncomeLossFromContinuingOperations
      contextRef="P03_08_2024To03_08_2024"
      decimals="0"
      id="ixv-22400"
      unitRef="Unit_USD">500000</us-gaap:IncomeLossFromContinuingOperations>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2023"
      decimals="0"
      id="ixv-22401"
      unitRef="Unit_USD">-1348000</us-gaap:StockholdersEquity>
    <us-gaap:FairValueMeasurementInputsDisclosureTextBlock contextRef="P01_01_2024To03_31_2024" id="ixv-10951">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;4. Fair Value Measurements &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Fair value measurements are market-based measurements, not entity-specific measurements. Therefore, fair value measurements are determined based on the assumptions that market participants would use in pricing the asset or liability. The Company follows a three-level hierarchy to prioritize the inputs used in the valuation techniques to derive fair values. The basis for fair value measurements for each level within the hierarchy is described below: &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentColor; border-image: none; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 3%; vertical-align: top;text-align:left;"&gt;&#x2022;&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: top;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top;text-align:left;"&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Level&#160;1: Quoted prices in active markets for identical assets or liabilities. &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear:both;max-height:0pt;"&gt;&lt;/div&gt;&lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentColor; border-image: none; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 3%; vertical-align: top;text-align:left;"&gt;&#x2022;&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: top;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top;text-align:left;"&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Level&#160;2: Quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar instruments in markets that are not active; and model-derived valuations in which all significant inputs are observable in active markets. &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear:both;max-height:0pt;"&gt;&lt;/div&gt;&lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentColor; border-image: none; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 3%; vertical-align: top;text-align:left;"&gt;&#x2022;&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: top;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top;text-align:left;"&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Level&#160;3: Valuations derived from valuation techniques in which one or more significant inputs are unobservable in active markets. &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear:both;max-height:0pt;"&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;The Company has investments in money market accounts, which are included in cash and cash equivalents on the balance sheets. Fair value inputs for these investments are considered Level&#160;1 measurements within the fair value hierarchy since money market account fair values are known and observable through daily published floating net asset values. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;The following table summarizes the Company&#x2019;s fair value hierarchy for its financial assets measured at fair value on a recurring basis as of March&#160;31, 2024 and December&#160;31, 2023, respectively (in thousands). &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 92%; font-family: Times New Roman; font-size: 8pt; border-collapse: collapse;"&gt;
&lt;tr&gt;
&lt;td style="width: 64%;"&gt;&lt;/td&gt;
&lt;td style="width: 5%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="width: 5%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="width: 5%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="width: 5%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="14" style="vertical-align: bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Fair Value Measurements Using&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;March&#160;31, 2024&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Fair&#160;Value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&#160;1&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&#160;2&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&#160;3&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Money market&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;176&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;176&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Treasury bills and government agency bonds&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;323&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;323&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;499&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;499&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td style="height: 12pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td colspan="16" style="height: 12pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="14" style="vertical-align: bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Fair Value Measurements Using&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31, 2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Fair&#160;Value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&#160;1&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&#160;2&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&#160;3&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Money market&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;5,449&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;5,449&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FairValueMeasurementInputsDisclosureTextBlock>
    <us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock contextRef="P01_01_2024To03_31_2024" id="ixv-10992">&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;The following table summarizes the Company&#x2019;s fair value hierarchy for its financial assets measured at fair value on a recurring basis as of March&#160;31, 2024 and December&#160;31, 2023, respectively (in thousands). &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 92%; font-family: Times New Roman; font-size: 8pt; border-collapse: collapse;"&gt;
&lt;tr&gt;
&lt;td style="width: 64%;"&gt;&lt;/td&gt;
&lt;td style="width: 5%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="width: 5%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="width: 5%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="width: 5%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="14" style="vertical-align: bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Fair Value Measurements Using&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;March&#160;31, 2024&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Fair&#160;Value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&#160;1&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&#160;2&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&#160;3&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Money market&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;176&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;176&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Treasury bills and government agency bonds&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;323&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;323&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;499&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;499&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td style="height: 12pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td colspan="16" style="height: 12pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="14" style="vertical-align: bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Fair Value Measurements Using&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31, 2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Fair&#160;Value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&#160;1&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&#160;2&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&#160;3&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Money market&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;5,449&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;5,449&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="PAsOn03_31_2024_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapCashAndCashEquivalentsAxis"
      decimals="-3"
      id="ixv-22403"
      unitRef="Unit_USD">176000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="PAsOn03_31_2024_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapCashAndCashEquivalentsAxis"
      decimals="-3"
      id="ixv-22404"
      unitRef="Unit_USD">176000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="PAsOn03_31_2024_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_USTreasurySecuritiesMemberusgaapCashAndCashEquivalentsAxis"
      decimals="-3"
      id="ixv-22405"
      unitRef="Unit_USD">323000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="PAsOn03_31_2024_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_USTreasurySecuritiesMemberusgaapCashAndCashEquivalentsAxis"
      decimals="-3"
      id="ixv-22406"
      unitRef="Unit_USD">323000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="PAsOn03_31_2024_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      id="ixv-22407"
      unitRef="Unit_USD">499000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="PAsOn03_31_2024_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      id="ixv-22408"
      unitRef="Unit_USD">499000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="PAsOn12_31_2023_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapCashAndCashEquivalentsAxis"
      decimals="-3"
      id="ixv-22409"
      unitRef="Unit_USD">5449000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="PAsOn12_31_2023_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapCashAndCashEquivalentsAxis"
      decimals="-3"
      id="ixv-22410"
      unitRef="Unit_USD">5449000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:DebtDisclosureTextBlock contextRef="P01_01_2024To03_31_2024" id="ixv-11228">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;5. Term Loan Obligations &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;On May 29, 2015, the Company entered into the Loan and Security Agreement (the &#x201c;Loan and Security Agreement&#x201d;), pursuant to which Oxford Finance, LLC (&#x201c;Oxford&#x201d;) funded an aggregate principal amount of &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;$17.7&#160;million (the &#x201c;Term Loan&#x201d;), subject to the terms and conditions set forth in the Loan and Security Agreement. The Term Loan accrues interest at a floating rate of at least 8.95% per annum, comprised of a three-month LIBOR rate with a floor of 1.00% plus 7.95%. Pursuant to the Loan and Security Agreement, as amended, the Company made interest only payments through May 1, 2021, and thereafter is required to make payments of principal and accrued interest in equal monthly installments sufficient to amortize the Term Loan through June&#160;1, 2024, the maturity date. At maturity of the Term Loan, or earlier repayment in full following voluntary prepayment or upon acceleration, the Company is required to make a final payment in an aggregate amount equal to approximately $3.2&#160;million. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;From September 2017 to March 2020, the Company entered into a total of nine amendments to the Term Loan that, among other things, extended the interest only period, required repayment of $3.1&#160;million using the proceeds received from sale of the Company&#x2019;s former UK and Japan subsidiaries in April 2019, increased the final payment, increased the final payment fee upon maturity or early repayment of the Term Loan, increased the minimum liquidity covenant level to $2.0&#160;million and deferred the start date of principal repayment from May 1, 2020 to May 1, 2021 and extended the term of the Term Loan from September 1, 2021 to June 1, 2024. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;On June&#160;28, 2023, the Company and Oxford entered into a tenth amendment to the Loan and Security Agreement, and revised the interest rate of the Loan to the greater of: (1) 8.95%, or (2)&#160;the sum of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;1-month&lt;/div&gt; Secured Overnight Financing Rate and 8.05%, effective July&#160;1, 2023. &lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;The Term Loan, as amended, is collateralized by a security interest in substantially all of the Company&#x2019;s existing and subsequently acquired assets, including its intellectual property assets, subject to certain exceptions set forth in the Loan and Security Agreement, as amended. The intellectual property asset collateral will be released upon the Company achieving a certain liquidity level when the total principal outstanding under the Loan and Security Agreement is less than $3.0&#160;million. As of March&#160;31, 2024, there was $0.4&#160;million principal amount outstanding under the Term Loan, excluding the $3.2&#160;million final payment fee, and the Company was in compliance with all of the debt covenants under the Loan and Security Agreement. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;The Company&#x2019;s interest expense for the three ended March&#160;31, 2024 and 2023 was $34,000 and $0.1&#160;million, respectively. Interest expense is calculated using the effective interest method; therefore it is inclusive of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;non-cash&lt;/div&gt; amortization in the amount of $21,000 and $0.1&#160;million for the three ended March&#160;31, 2024 and 2023, respectively, related to the amortization of the debt discount, capitalized loan costs, and accretion of final payment. &lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;The Loan and Security Agreement, as amended, contains customary indemnification obligations and customary events of default, including, among other things, the Company&#x2019;s failure to fulfill certain obligations under the Term Loan, as amended, and the occurrence of a material adverse change, which is defined as a material adverse change in the Company&#x2019;s business, operations, or condition (financial or otherwise), a material impairment of the prospect of repayment of any portion of the loan. In the event of default by the Company or a declaration of material adverse change by its lender, under the Term Loan, the lender would be entitled to exercise its remedies thereunder, including the right to accelerate the debt, upon which the Company may be required to repay all amounts then outstanding under the Term Loan, which could materially harm the Company&#x2019;s financial condition. As of March&#160;31, 2024, the Company has not received any notification or indication from Oxford that it intends to invoke the material adverse change clause. See Note 12 for further information regarding the repayment of the Term Loan. &lt;/div&gt;&lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:DebtInstrumentOfferingDate1
      contextRef="P01_01_2024To03_31_2024_TermLoanMemberusgaapDebtInstrumentAxis"
      id="ixv-22411">2015-05-29</us-gaap:DebtInstrumentOfferingDate1>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="PAsOn05_29_2015_TermLoanMemberusgaapDebtInstrumentAxis"
      decimals="-5"
      id="ixv-22413"
      unitRef="Unit_USD">17700000</us-gaap:DebtInstrumentFaceAmount>
    <pstv:DebtInstrumentFloatingInterestRatePercentage
      contextRef="PAsOn05_29_2015_MinimumMembersrtRangeAxis_TermLoanMemberusgaapDebtInstrumentAxis"
      decimals="INF"
      id="ixv-22414"
      unitRef="Unit_pure">0.0895</pstv:DebtInstrumentFloatingInterestRatePercentage>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="P05_28_2015To05_29_2015_InterestRateFloorMemberusgaapDerivativeInstrumentRiskAxis_LiborMemberusgaapVariableRateAxis"
      decimals="4"
      id="ixv-22415"
      unitRef="Unit_pure">0.01</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="P05_28_2015To05_29_2015_TermLoanMemberusgaapDebtInstrumentAxis"
      decimals="4"
      id="ixv-22416"
      unitRef="Unit_pure">0.0795</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentMaturityDate
      contextRef="P05_28_2015To05_29_2015_TermLoanMemberusgaapDebtInstrumentAxis"
      id="ixv-22417">2021-05-01</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DebtInstrumentFeeAmount
      contextRef="PAsOn05_29_2015_TermLoanMemberusgaapDebtInstrumentAxis"
      decimals="-5"
      id="ixv-22418"
      unitRef="Unit_USD">3200000</us-gaap:DebtInstrumentFeeAmount>
    <us-gaap:PaymentsForLoans
      contextRef="P05_28_2015To05_29_2015_LoanAndSecurityAgreementMemberusgaapFinancialInstrumentAxis_SaleOfJapaneseSubsidiaryAndCertainAssetsMemberusgaapDisposalGroupClassificationAxis_TermLoanMemberusgaapDebtInstrumentAxis"
      decimals="-5"
      id="ixv-22419"
      unitRef="Unit_USD">3100000</us-gaap:PaymentsForLoans>
    <pstv:MinimumLiquidityCovenantAmount
      contextRef="PAsOn03_31_2024_TermLoanMemberusgaapDebtInstrumentAxis"
      decimals="-5"
      id="ixv-22420"
      unitRef="Unit_USD">2000000</pstv:MinimumLiquidityCovenantAmount>
    <pstv:DebtPrincipalRepaymentStartDate
      contextRef="P03_27_2020To03_28_2020_TermLoanMemberusgaapDebtInstrumentAxis"
      id="ixv-22421">2020-05-01</pstv:DebtPrincipalRepaymentStartDate>
    <pstv:DebtPrincipalRepaymentStartDate
      contextRef="P03_29_2020To03_29_2020_TermLoanMemberusgaapDebtInstrumentAxis"
      id="ixv-22422">2021-05-01</pstv:DebtPrincipalRepaymentStartDate>
    <us-gaap:DebtInstrumentMaturityDate
      contextRef="P03_27_2020To03_28_2020_TermLoanMemberusgaapDebtInstrumentAxis"
      id="ixv-22423">2021-09-01</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DebtInstrumentMaturityDate
      contextRef="P03_29_2020To03_29_2020_TermLoanMemberusgaapDebtInstrumentAxis"
      id="ixv-22424">2024-06-01</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="PAsOn06_28_2023_TermLoanMemberusgaapDebtInstrumentAxis"
      decimals="INF"
      id="ixv-22425"
      unitRef="Unit_pure">0.0895</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="P06_28_2023To06_28_2023_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMemberusgaapVariableRateAxis_TermLoanMemberusgaapDebtInstrumentAxis"
      decimals="4"
      id="ixv-22426"
      unitRef="Unit_pure">0.0805</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="PAsOn03_31_2024_MaximumMembersrtRangeAxis_TermLoanMemberusgaapDebtInstrumentAxis"
      decimals="-5"
      id="ixv-22427"
      unitRef="Unit_USD">3000000</us-gaap:DebtInstrumentFaceAmount>
    <pstv:LongTermDebtOutstandingThresholdAmount
      contextRef="P01_01_2024To03_31_2024_MaximumMembersrtRangeAxis_TermLoanMemberusgaapDebtInstrumentAxis"
      decimals="-5"
      id="ixv-22428"
      unitRef="Unit_USD">400000</pstv:LongTermDebtOutstandingThresholdAmount>
    <us-gaap:DebtInstrumentFeeAmount
      contextRef="PAsOn03_31_2024_TermLoanMemberusgaapDebtInstrumentAxis"
      decimals="-5"
      id="ixv-22429"
      unitRef="Unit_USD">3200000</us-gaap:DebtInstrumentFeeAmount>
    <us-gaap:DebtInstrumentCovenantCompliance
      contextRef="P01_01_2024To03_31_2024_TermLoanMemberusgaapDebtInstrumentAxis"
      id="ixv-22430">the Company was in compliance with all of the debt covenants under the Loan and Security Agreement.</us-gaap:DebtInstrumentCovenantCompliance>
    <us-gaap:InterestExpense
      contextRef="P01_01_2024To03_31_2024"
      decimals="0"
      id="ixv-22431"
      unitRef="Unit_USD">34000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="P01_01_2023To03_31_2023"
      decimals="-5"
      id="ixv-22432"
      unitRef="Unit_USD">100000</us-gaap:InterestExpense>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="P01_01_2024To03_31_2024"
      decimals="0"
      id="ixv-22433"
      unitRef="Unit_USD">21000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="P01_01_2023To03_31_2023"
      decimals="-5"
      id="ixv-22434"
      unitRef="Unit_USD">100000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:EarningsPerShareTextBlock contextRef="P01_01_2024To03_31_2024" id="ixv-11259">&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;6&lt;/div&gt;&lt;/div&gt;. &lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Loss per Share&lt;/div&gt;&lt;/div&gt; &lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Basic per share data is computed by dividing net income or loss applicable to common stockholders by the weighted average number of common shares outstanding during the period. Diluted per share data is computed by dividing net income or loss applicable to common stockholders by the weighted average number of common shares outstanding during the period increased to include, if dilutive, the number of additional common shares &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;that would have been outstanding as calculated using the treasury stock method. Potential common shares were related to outstanding but unexercised options, multiple series of convertible preferred stock, and warrants for all periods presented. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;The following were excluded from the diluted loss per share calculation for the periods presented because their effect would be anti-dilutive: &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 76%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;"&gt;
&lt;tr&gt;
&lt;td style="width: 74%;"&gt;&lt;/td&gt;
&lt;td style="width: 3%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="width: 3%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As of March&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2024&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Outstanding stock options&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;303,133&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;134,283&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Preferred stock&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;28,190&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;28,190&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Outstanding warrants&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;142,733&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;142,733&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;474,056&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;305,206&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="P01_01_2024To03_31_2024" id="ixv-11283">&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;The following were excluded from the diluted loss per share calculation for the periods presented because their effect would be anti-dilutive: &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 76%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;"&gt;
&lt;tr&gt;
&lt;td style="width: 74%;"&gt;&lt;/td&gt;
&lt;td style="width: 3%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="width: 3%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As of March&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2024&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Outstanding stock options&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;303,133&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;134,283&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Preferred stock&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;28,190&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;28,190&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Outstanding warrants&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;142,733&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;142,733&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;474,056&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;305,206&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P01_01_2024To03_31_2024_OptionsMemberusgaapStatementEquityComponentsAxis"
      decimals="INF"
      id="ixv-22435"
      unitRef="Unit_shares">303133</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P01_01_2023To03_31_2023_OptionsMemberusgaapStatementEquityComponentsAxis"
      decimals="INF"
      id="ixv-22436"
      unitRef="Unit_shares">134283</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P01_01_2024To03_31_2024_PreferredStockMemberusgaapStatementEquityComponentsAxis"
      decimals="INF"
      id="ixv-22437"
      unitRef="Unit_shares">28190</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P01_01_2023To03_31_2023_PreferredStockMemberusgaapStatementEquityComponentsAxis"
      decimals="INF"
      id="ixv-22438"
      unitRef="Unit_shares">28190</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P01_01_2024To03_31_2024_WarrantMemberusgaapStatementEquityComponentsAxis"
      decimals="INF"
      id="ixv-22439"
      unitRef="Unit_shares">142733</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P01_01_2023To03_31_2023_WarrantMemberusgaapStatementEquityComponentsAxis"
      decimals="INF"
      id="ixv-22440"
      unitRef="Unit_shares">142733</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P01_01_2024To03_31_2024"
      decimals="INF"
      id="ixv-22441"
      unitRef="Unit_shares">474056</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P01_01_2023To03_31_2023"
      decimals="INF"
      id="ixv-22442"
      unitRef="Unit_shares">305206</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:RevenueFromContractWithCustomerTextBlock contextRef="P01_01_2024To03_31_2024" id="ixv-11403">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;7. Grant Revenue &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;On September&#160;19, 2022, the Company entered into that certain CPRIT contract (&#x201c;CPRIT Contract&#x201d;), effective as of August 31, 2022, with CPRIT, pursuant to which CPRIT will provide the Company with a CPRIT grant (&#x201c;CPRIT Grant&#x201d;) over a three-year period to fund the continued development of rhenium (&lt;div style="font-size: 75%; vertical-align: top;display:inline;font-size:8.3px"&gt;186&lt;/div&gt;Re) obisbemeda for the treatment of patients with leptomeningeal metastases (&#x201c;LM&#x201d;). The CPRIT Grant is subject to customary CPRIT funding conditions, including, but not limited to, a matching fund requirement (one dollar for every two dollars awarded by CPRIT), revenue sharing obligations upon commercialization of rhenium (&lt;div style="font-size: 75%; vertical-align: top;display:inline;font-size:8.3px"&gt;186&lt;/div&gt;Re) obisbemeda based on specific dollar thresholds and tiered low single digit royalty rates until CPRIT receives the aggregate amount of 400% of the proceeds awarded under the CPRIT Grant, and certain reporting requirements. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;The CPRIT Contract will terminate on August 30, 2025, unless terminated earlier by (a)&#160;the mutual written consent of all parties to the CPRIT Contract, (b)&#160;CPRIT for an event of default by the Company, (c)&#160;CPRIT, if the funds allocated to the CPRIT Grant become legally unavailable during the term of the CPRIT Contract and CPRIT is unable to obtain additional funds for such purposes, and (d)&#160;the Company for convenience. CPRIT may require the Company to repay some or all of the disbursed CPRIT Grant proceeds (with interest not to exceed 5% annually) in the event of the early termination of the CPRIT Contract by CPRIT for an event of default by the Company or by the Company for convenience, or if the Company relocates its principal place of business outside of the state of Texas during the CPRIT Contract term or within three years after the final payment of the grant funds. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;The Company retains ownership over any intellectual property developed under the CPRIT Contract (each, a &#x201c;Project Result&#x201d;). With respect to &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;non-commercial&lt;/div&gt; use of any Project Result, the Company granted to CPRIT a nonexclusive, irrevocable, royalty-free, perpetual, worldwide license with right to sublicense any necessary additional intellectual property rights to exploit all Project Results by CPRIT, other governmental entities and agencies of the State of Texas, and private or independent institutions of higher education located in Texas, for education, research and other &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;non-commercial&lt;/div&gt; purposes. &lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;The Company recognized $1.7&#160;million and $0.5&#160;million in grant revenue from the CPRIT Contract during the three months ended March&#160;31, 2024 and 2023, respectively. &lt;/div&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerTextBlock>
    <pstv:ContractEffectiveDate
      contextRef="P09_19_2022To09_19_2022_CancerPreventionAndResearchInstituteOfTexasContractMemberusgaapTypeOfArrangementAxis"
      id="ixv-22443">2022-08-31</pstv:ContractEffectiveDate>
    <pstv:GrantFundingTerm
      contextRef="P09_19_2022To09_19_2022_CancerPreventionAndResearchInstituteOfTexasContractMemberusgaapTypeOfArrangementAxis"
      id="ixv-22444">P3Y</pstv:GrantFundingTerm>
    <pstv:CpritGrantFundingTerm
      contextRef="P01_01_2024To03_31_2024_CancerPreventionAndResearchInstituteOfTexasContractMemberusgaapTypeOfArrangementAxis"
      id="ixv-11410">The CPRIT Grant is subject to customary CPRIT funding conditions, including, but not limited to, a matching fund requirement (one dollar for every two dollars awarded by CPRIT), revenue sharing obligations upon commercialization of rhenium (186Re) obisbemeda based on specific dollar thresholds and tiered low single digit royalty rates until CPRIT receives the aggregate amount of 400% of the proceeds awarded under the CPRIT Grant, and certain reporting requirements.</pstv:CpritGrantFundingTerm>
    <pstv:PercentageOfAggregateAmountOfProceedsAwardedUnderCpritGrant
      contextRef="P09_19_2022To09_19_2022_CancerPreventionAndResearchInstituteOfTexasContractMemberusgaapTypeOfArrangementAxis"
      decimals="2"
      id="ixv-22445"
      unitRef="Unit_pure">4</pstv:PercentageOfAggregateAmountOfProceedsAwardedUnderCpritGrant>
    <pstv:ContractTerminationDate
      contextRef="P09_19_2022To09_19_2022_CancerPreventionAndResearchInstituteOfTexasContractMemberusgaapTypeOfArrangementAxis"
      id="ixv-22446">2025-08-30</pstv:ContractTerminationDate>
    <pstv:PercentageOfGrantProceedsWithInterestNotExceedAnnually
      contextRef="P09_19_2022To09_19_2022_CancerPreventionAndResearchInstituteOfTexasContractMemberusgaapTypeOfArrangementAxis"
      decimals="2"
      id="ixv-22447"
      unitRef="Unit_pure">0.05</pstv:PercentageOfGrantProceedsWithInterestNotExceedAnnually>
    <us-gaap:Revenues
      contextRef="P01_01_2024To03_31_2024_CancerPreventionAndResearchInstituteOfTexasContractMemberusgaapTypeOfArrangementAxis_GrantMembersrtProductOrServiceAxis"
      decimals="-5"
      id="ixv-22448"
      unitRef="Unit_USD">1700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="P01_01_2023To03_31_2023_CancerPreventionAndResearchInstituteOfTexasContractMemberusgaapTypeOfArrangementAxis_GrantMembersrtProductOrServiceAxis"
      decimals="-5"
      id="ixv-22449"
      unitRef="Unit_USD">500000</us-gaap:Revenues>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="P01_01_2024To03_31_2024" id="ixv-11419">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;8. Commitments and Contingencies &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Leases &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;The Company leases laboratory, office and storage facilities in San Antonio, Texas, under operating lease agreements that expire in 2025. The Company also leases certain office space in Austin, Texas under a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;month-to-month&lt;/div&gt;&lt;/div&gt; operating lease agreement and certain office space in Charlottesville, Virginia (the &#x201c;Charlottesville Lease&#x201d;). The Charlottesville Lease has a term of 12 months and the Company has the ability to renew for three additional &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;one-year&lt;/div&gt; periods. On March&#160;31, 2023, Company believed that it was reasonably &lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;certain that the Charlottesville Lease will be renewed through March&#160;31, 2026, and as a result, it remeasured the related lease liability as of March&#160;31, 2023 to be $80,000 using the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;then-in-effect&lt;/div&gt;&lt;/div&gt; discount rate of 12.76%. Effective July&#160;1, 2023, the Company added additional office lease premises in Charlottesville, which was accounted for as a separate operating lease contract with a lease liability and corresponding &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;right-of-use&lt;/div&gt;&lt;/div&gt; asset of $19,000, as a discount rate of 13.47%. &lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Piramal Master Services Agreement &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;On January 8, 2021, the Company entered into a Master Services Agreement (the &#x201c;MSA&#x201d;) with Piramal Pharma Solutions, Inc. (&#x201c;Piramal&#x201d;), for Piramal to perform certain services related to the development, manufacture, and supply of the Company&#x2019;s rhenium (&lt;div style="font-size: 75%; vertical-align: top;display:inline;font-size:8.3px"&gt;186&lt;/div&gt;Re) obisbemeda intermediate drug product. The MSA includes the transfer of analytical methods, development of microbiological methods, process transfer and optimization, intermediate drug product manufacturing, and stability studies for the Company, which has been initiated at Piramal&#x2019;s facility located in Lexington, Kentucky. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;The MSA has a term of five years and will automatically renew for successive &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;one-year&lt;/div&gt; terms unless either party notifies the other no later than six months prior to the original term or any additional terms of its intention to not renew the MSA. The Company has the right to terminate the MSA for convenience upon thirty days&#x2019; prior written notice. Either party may terminate the MSA upon an uncured material breach by the other party or upon the bankruptcy or insolvency of the other party. &lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Other commitments and contingencies &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;The Company has entered into agreements with various research organizations for &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;pre-clinical&lt;/div&gt; and clinical development studies, which have provisions for cancellation. Under the terms of these agreements, the vendors provide a variety of services including conducting research, recruiting and enrolling patients, monitoring studies and data analysis. Payments under these agreements typically include fees for services and reimbursement of expenses. The timing of payments due under these agreements is estimated based on current study progress. As of March&#160;31, 2024, the Company did not have any clinical research study obligations. &lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Legal proceedings &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;From time to time, the Company is subject to legal proceedings and claims, whether asserted or unasserted, that arise in the ordinary course of business. Due to their nature, such legal proceedings involve inherent uncertainties including, but not limited to, court rulings, negotiations between affected parties and governmental actions. Management assesses the probability of loss for such contingencies and accrues a liability and/or discloses the relevant circumstances, as appropriate. &lt;/div&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <pstv:OperatingLeasesExpiryYear contextRef="P01_01_2024To03_31_2024" id="ixv-22450">2025</pstv:OperatingLeasesExpiryYear>
    <us-gaap:LesseeOperatingLeaseOptionToExtend
      contextRef="P01_01_2024To03_31_2024_CharlottesvilleMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      id="ixv-11429">The Charlottesville Lease has a term of 12 months and the Company has the ability to renew for three additional one-year periods.</us-gaap:LesseeOperatingLeaseOptionToExtend>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="PAsOn03_31_2024_CharlottesvilleMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      id="ixv-22451">P12M</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend
      contextRef="P01_01_2024To03_31_2024_CharlottesvilleMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      id="ixv-22452">true</us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="PAsOn03_31_2024_CharlottesvilleMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      id="ixv-22453">P1Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:OperatingLeaseLiability
      contextRef="PAsOn03_31_2023_CharlottesvilleMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="0"
      id="ixv-22454"
      unitRef="Unit_USD">80000</us-gaap:OperatingLeaseLiability>
    <us-gaap:LesseeOperatingLeaseDiscountRate
      contextRef="PAsOn03_31_2023_CharlottesvilleMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="4"
      id="ixv-22455"
      unitRef="Unit_pure">0.1276</us-gaap:LesseeOperatingLeaseDiscountRate>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="PAsOn07_01_2023_CharlottesvilleMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="0"
      id="ixv-22456"
      unitRef="Unit_USD">19000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:LesseeOperatingLeaseDiscountRate
      contextRef="PAsOn07_01_2023_CharlottesvilleMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="4"
      id="ixv-22457"
      unitRef="Unit_pure">0.1347</us-gaap:LesseeOperatingLeaseDiscountRate>
    <pstv:MasterServicesAgreementDate
      contextRef="P01_08_2021To01_08_2021_PiramalPharmaSolutionsIncMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      id="ixv-22458">2021-01-08</pstv:MasterServicesAgreementDate>
    <pstv:MasterServicesAgreementTermsDescription
      contextRef="P01_01_2024To03_31_2024_PiramalPharmaSolutionsIncMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      id="ixv-11457">The MSA has a term of five years and will automatically renew for successive one-year terms unless either party notifies the other no later than six months prior to the original term or any additional terms of its intention to not renew the MSA. The Company has the right to terminate the MSA for convenience upon thirty days&#x2019; prior written notice.</pstv:MasterServicesAgreementTermsDescription>
    <pstv:MasterServicesAgreementInitialTerm
      contextRef="P01_08_2021To01_08_2021_PiramalPharmaSolutionsIncMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      id="ixv-22459">P5Y</pstv:MasterServicesAgreementInitialTerm>
    <us-gaap:ContractualObligation
      contextRef="PAsOn03_31_2024_PreClinicalResearchStudyObligationsMemberusgaapRecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis"
      decimals="-3"
      id="ixv-22460"
      unitRef="Unit_USD">0</us-gaap:ContractualObligation>
    <pstv:LicenseAgreementDisclosureTextBlock contextRef="P01_01_2024To03_31_2024" id="ixv-11469">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;9. License Agreements &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Biocept License Agreement &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;On September&#160;7, 2023, the Company entered into a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;Non-Exclusive&lt;/div&gt; License and Services Agreement (the &#x201c;Biocept Agreement&#x201d;) with Biocept, Inc (&#x201c;Biocept&#x201d;), pursuant to which Biocept granted the Company a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;non-exclusive&lt;/div&gt; license to use the Biocept proprietary cell enumeration test, CNsideTM (&#x201c;CNside&#x201d;). In exchange for the license, the Company issued to Biocept 53,381 unregistered shares, the fair value of which was $75,000. The Biocept Agreement also provides that if Biocept fully transfers the technology to the Company, a tech transfer and validation fee of $300,000 will be payable. In addition, the Company was granted an option for an exclusive worldwide license for $1,000,000 on or before December&#160;31, 2024, to process and perform cell enumeration testing for treatments for other patients including those on the Company&#x2019;s radiotherapeutic drugs. &lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;On October&#160;16, 2023, Biocept filed a voluntary petition for relief under the provisions of Chapter 7 of Title 11 of the United States Bankruptcy Code. See Note 12 for further information regarding the Company&#x2019;s acquisition of substantially all right, title and interest in CNside. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;UT Health Science Center at San Antonio (&#x201c;UTHSCSA&#x201d;) License Agreement &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;On December&#160;31, 2021, the Company entered into a Patent and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;Know-How&lt;/div&gt; License Agreement (the &#x201c;UTHSCSA License Agreement&#x201d;) with The University of Texas Health Science Center at San Antonio (&#x201c;UTHSCSA&#x201d;), pursuant to which UTHSCSA granted the Company an irrevocable, perpetual, exclusive, fully &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;paid-up&lt;/div&gt; license, with the right to sublicense and to make, develop, commercialize and otherwise exploit certain patents, &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;know-how&lt;/div&gt; and technology related to the development of biodegradable alginate microspheres (&#x201c;BAM&#x201d;) containing nanoliposomes loaded with imaging and/or therapeutic payloads. &lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;NanoTx License Agreement &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;On March&#160;29, 2020, the Company and NanoTx, Corp. (&#x201c;NanoTx&#x201d;) entered into a Patent and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;Know-How&lt;/div&gt; License Agreement, pursuant to which NanoTx granted the Company an irrevocable, perpetual, exclusive, fully &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;paid-up&lt;/div&gt; license, with the right to sublicense and to make, develop, commercialize and otherwise exploit certain patents, &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;know-how&lt;/div&gt; and technology related to the development of radiolabeled nanoliposomes. &lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;The transaction terms included an upfront payment of $0.4&#160;million in cash and $0.3&#160;million in the Company&#x2019;s voting stock. The transaction terms also included success-based milestone and royalty payments contingent on key clinical, regulatory and sales milestones, as well as the requirement to pay 15% of any &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;non-dilutive&lt;/div&gt; monetary awards or grants received from external agencies to support product development of the nanoliposome encapsulated BMEDA-chelated radioisotope, which includes grants from CPRIT. As of March&#160;31, 2024, the Company accrued $0.5&#160;million of payments due to NanoTx as a result of the CPRIT grant received (see Note 7, Grant Revenue of the condensed financial statements for additional information). &lt;/div&gt;</pstv:LicenseAgreementDisclosureTextBlock>
    <us-gaap:SharesIssued
      contextRef="PAsOn09_07_2023_BioceptAgreementMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"
      decimals="INF"
      id="ixv-22461"
      unitRef="Unit_shares">53381</us-gaap:SharesIssued>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="P01_01_2024To03_31_2024_BioceptAgreementMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"
      decimals="0"
      id="ixv-22462"
      unitRef="Unit_USD">75000</us-gaap:ResearchAndDevelopmentExpense>
    <pstv:PaymentForTechTransferAndValidationFee
      contextRef="P09_07_2023To09_07_2023_BioceptAgreementMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"
      decimals="0"
      id="ixv-22463"
      unitRef="Unit_USD">300000</pstv:PaymentForTechTransferAndValidationFee>
    <pstv:OptionForExclusiveWorldwideLicense
      contextRef="P09_07_2023To09_07_2023_BioceptAgreementMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"
      decimals="0"
      id="ixv-22464"
      unitRef="Unit_USD">1000000</pstv:OptionForExclusiveWorldwideLicense>
    <us-gaap:PaymentsForRoyalties
      contextRef="P03_29_2020To03_29_2020_NanoTxLicensesAgreementMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"
      decimals="-5"
      id="ixv-22466"
      unitRef="Unit_USD">400000</us-gaap:PaymentsForRoyalties>
    <us-gaap:CommonStockValue
      contextRef="PAsOn03_29_2020_NanoTxLicensesAgreementMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"
      decimals="-5"
      id="ixv-22467"
      unitRef="Unit_USD">300000</us-gaap:CommonStockValue>
    <pstv:PercentageOfNonDilutiveMonetaryAwardsRequiredToPay
      contextRef="P03_29_2020To03_29_2020_NanoTxLicensesAgreementMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"
      decimals="2"
      id="ixv-22468"
      unitRef="Unit_pure">0.15</pstv:PercentageOfNonDilutiveMonetaryAwardsRequiredToPay>
    <pstv:AccruedLicensePayable
      contextRef="PAsOn03_31_2024_NanoTxLicensesAgreementMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"
      decimals="-5"
      id="ixv-22469"
      unitRef="Unit_USD">500000</pstv:AccruedLicensePayable>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="P01_01_2024To03_31_2024" id="ixv-11510">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;10. Stockholders&#x2019; Equity &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Preferred Stock &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;The Company has authorized 5,000,000 shares of preferred stock, par value $0.001 per share. The Company&#x2019;s Board is authorized to designate the terms and conditions of any preferred stock the Company issues without further action by the common stockholders. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Series F Preferred Stock &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;On March&#160;3, 2023, the Company filed a certificate of designation (the &#x201c;Certificate of Designation&#x201d;) with the Secretary of State of the State of Delaware, effective as of the time of filing, designating the rights, preferences, privileges and restrictions of the Series F Preferred Stock, with the total authorization of one (1)&#160;share of Series F Preferred Stock. The Certificate of Designation provided that the share of Series F Preferred Stock would have 50,000,000 votes per share of Series F Preferred Stock and would vote together with the Company&#x2019;s common stock, as a single class exclusively with respect to any proposal to amend the Company&#x2019;s Charter to effect the Reverse Stock Split. On March&#160;3, 2023, the Company entered into a subscription and investment representation agreement with Richard J. Hawkins, chairman of the board of the Company, who is an accredited investor (the &#x201c;Series F Preferred Stock Purchaser&#x201d;), pursuant to which the Company agreed to issue and sell one (1)&#160;share of the Company&#x2019;s Series F Preferred Stock, par value $0.001 per share, to the Series F Preferred Stock Purchaser for $1,000 in cash. The sale closed on March 3, 2023. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;At the Company&#x2019;s 2023 annual meeting, the Series F Preferred Stock was voted, without action by the holder, on the proposal to approve the Reverse Stock Split in the same proportion as shares of common stock voted to approve the Reverse Stock Split. The Series F Preferred Stock otherwise had no voting rights except as otherwise required by the General Corporation Law of the State of Delaware. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;The Series F Preferred Stock was not convertible into, or exchangeable for, shares of any other class or series of stock or other securities of the Company. The Series F Preferred Stock had no rights with respect to any &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;distribution of assets of the Company, including upon a liquidation, bankruptcy, reorganization, merger, acquisition, sale, dissolution or winding up of the Company, whether voluntarily or involuntarily. The holder of the Series F Preferred Stock was not entitled to receive dividends of any kind. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;The outstanding share of Series F Preferred Stock was redeemed in whole, automatically effective upon the approval by the Company&#x2019;s stockholders of the Reverse Stock Split. Upon such redemption, the holder of the Series F Preferred Stock received consideration of $1,000 in cash. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Series B and C Preferred Stock &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;As of March&#160;31, 2024, there were 938 outstanding shares of Series C Preferred Stock that can be converted into an aggregate of 27,792 shares of common stock, and 1,014 shares of Series B Convertible Preferred Stock that can be converted into an aggregate of 398 shares of common stock. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Warrants &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;On September&#160;25, 2019, the Company completed an underwritten public offering. The Company issued 19,266 shares of its common stock, along with &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;pre-funded&lt;/div&gt; warrants to purchase 180,733 shares of its common stock and Series U Warrants to purchase 230,000 shares of its common stock. The Series U Warrants have a term of five years from the issuance date. In addition, the Company issued warrants to H.C. Wainwright&#160;&amp;amp; Co., LLC, as representatives of the underwriters, to purchase 5,000 shares of its common stock with a term of five years from the issuance date, in the form of Series U Warrants (the &#x201c;Representative Warrants&#x201d;). As of March&#160;31, 2024, there were 142,733 outstanding Series U Warrants and Representative Warrants which can be exercised into an aggregate of 142,733 shares of common stock at a weighted average exercise price of $34.10 per share. &lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Common Stock &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Lincoln Park Purchase Agreement &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;On August&#160;2, 2022, the Company entered into a purchase agreement (the &#x201c;2022 Purchase Agreement&#x201d;) and registration rights agreement pursuant to which Lincoln Park Capital Fund (&#x201c;Lincoln Park&#x201d;) committed to purchase up to $50.0&#160;million of the Company&#x2019;s common stock. Under the terms and subject to the conditions of the 2022 Purchase Agreement, the Company has the right, but not the obligation, to sell to Lincoln Park, and Lincoln Park is obligated to purchase up to $50.0&#160;million of the Company&#x2019;s common stock. Such sales of common stock by the Company are subject to certain limitations, and can occur from time to time, at the Company&#x2019;s sole discretion, over the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;36-month&lt;/div&gt; period commencing on August&#160;17, 2022, subject to the satisfaction of certain conditions. &lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;On May&#160;16, 2022, the Company received stockholder approval for purposes of the Nasdaq listing rules to permit issuances of up to 57.5&#160;million shares of the Company&#x2019;s common stock (including the issuance of more than 19.99% of the Company&#x2019;s common stock) to Lincoln Park, and it was pursuant to that approval that the Company entered into the 2022 Purchase Agreement. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Upon execution of the 2022 Purchase Agreement, the Company paid $0.1&#160;million in cash as the initial commitment fee, and issued 32,846 shares as the initial commitment shares, to Lincoln Park as consideration for its irrevocable commitment to purchase shares of the Company&#x2019;s common stock at its direction under the 2022 Purchase Agreement. The Company has agreed to pay an additional commitment fee, which it may elect to pay in cash and/or shares of its common stock, upon receipt of $25.0&#160;million aggregate gross proceeds from sales of common stock to Lincoln Park under the 2022 Purchase Agreement. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;On August&#160;17, 2022, a registration statement (the &#x201c;First Registration Statement&#x201d;) was declared effective to cover the resale of up to 633,333 shares of the Company&#x2019;s common stock comprised of (i)&#160;the 32,846 initial &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;commitment shares, and (ii)&#160;up to 600,486 that the Company has reserved for issuance and sale to Lincoln Park under the 2022 Purchase Agreement from time to time from and after the date of the prospectus. The Company sold approximately 527,166 shares under the First Registration Statement. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;On August&#160;18, 2023, a second registration statement (the &#x201c;Second Registration Statement&#x201d;) was declared effective to cover the resale of up to an additional 1,500,000 shares of the Company&#x2019;s common stock that the Company reserved for issuance and sale to Lincoln Park under the 2022 Purchase Agreement from time to time. The Company sold 150,000 shares under the Second Registration Statement. The Company cannot sell more shares than registered under the Second Registration Statement under the 2022 Purchase Agreement without registering additional shares. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Actual sales of shares of common stock to Lincoln Park under the 2022 Purchase Agreement depend on a variety of factors to be determined by the Company from time to time, including, among others, market conditions, the trading price of the common stock and determinations by the Company as to the appropriate sources of funding for the Company and its operations. The net proceeds under the 2022 Purchase Agreement to the Company depend on the frequency and prices at which the Company sells shares of its stock to Lincoln Park. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;During the period from August&#160;17, 2022 to December&#160;31, 2022, the Company issued 266,666 shares under the 2022 Purchase Agreement for net proceeds of approximately $3.2&#160;million. The Company issued 410,500 shares under the 2022 Purchase Agreement for net proceeds of approximately $1.0&#160;million from January&#160;1, 2023 to December&#160;31, 2023. The Company did not issue any common stock under the 2022 Purchase Agreement during the three months ended March&#160;31, 2024. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;At-the-market&lt;/div&gt;&lt;/div&gt; Issuances &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;On September&#160;9, 2022, the Company entered into the September 2022 Distribution Agreement with Canaccord, pursuant to which the Company could issue and sell, from time to time, shares of its common stock having an aggregate offering price of up to $5,000,000, depending on market demand, with Canaccord acting as an agent for sales. During the period from September&#160;9, 2022 to December&#160;31, 2022, the Company issued 68,758 shares of its common stock under the September 2022 Distribution Agreement for net proceeds of approximately $0.6&#160;million. From January&#160;1, 2023 through December&#160;31, 2023, the Company issued 1,819,993 shares under the September 2022 Distribution Agreement for net proceeds of approximately $4.3&#160;million. The Company has reached the capacity for sales of shares under the September 2022 Distribution Agreement and the agreement has terminated. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;The Company was obligated to pay Canaccord a commission of up to 3.0% of the gross proceeds from the sale of its common stock under the September 2022 Distribution Agreement. The Company also agreed to reimburse Canaccord for its reasonable documented &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;out-of-pocket&lt;/div&gt;&lt;/div&gt; expenses, including fees and disbursements of its counsel, in the amount of $50,000. In addition, the Company agreed to provide customary indemnification rights to Canaccord. &lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;On January&#160;14, 2022, the Company entered into the January 2022 Distribution Agreement with Canaccord, pursuant to which the Company could issue and sell, from time to time, shares of its common stock having an aggregate offering price of up to $5,000,000, with Canaccord acting as an agent for sales. The Company had no obligation to sell any of the Company&#x2019;s shares and it could instruct Canaccord not to sell any shares if the sales could not be effected at or above the price designated by the Company from time to time and the Company could at any time suspend sales pursuant to the January 2022 Distribution Agreement. During the year ended December&#160;31, 2023, the Company issued 460,151 shares under the January 2022 Distribution Agreement for net proceeds of approximately $4.8&#160;million. The January 2022 Distribution Agreement has been terminated after all available registered shares were fully utilized. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Share Repurchase Program and Treasury Stock &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;On October&#160;31, 2023, the Company announced that its Board has approved a share repurchase program (the &#x201c;Share Repurchase Program&#x201d;), with authorization to repurchase up to $500,000 of the outstanding shares of the Company&#x2019;s common stock. The Company funded repurchases under the Share Repurchase Program with available cash. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;During the year ended December&#160;31, 2023, the Company purchased 78,559 of its common stock for approximately $0.1&#160;million as treasury stock. The Company purchased 179,866 of its common shares for approximately $0.4&#160;million as treasury stock during the three months ended March&#160;31, 2024. As of March&#160;31, 2024, no amount remained authorized for repurchase. &lt;/div&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="PAsOn03_31_2024"
      decimals="INF"
      id="ixv-22470"
      unitRef="Unit_shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="PAsOn03_31_2024"
      decimals="INF"
      id="ixv-22471"
      unitRef="Unit_USD_per_Share">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="PAsOn03_03_2023_SeriesFConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      id="ixv-22472"
      unitRef="Unit_shares">1</us-gaap:PreferredStockSharesAuthorized>
    <pstv:NumberOfVotesPerShare
      contextRef="PAsOn03_03_2023_SeriesFConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      id="ixv-22473"
      unitRef="Unit_Votes">50000000</pstv:NumberOfVotesPerShare>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="P03_03_2023To03_03_2023_SeriesFConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis_SubscriptionAgreementMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="0"
      id="ixv-22474"
      unitRef="Unit_shares">1</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="PAsOn03_03_2023_SeriesFConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis_SubscriptionAgreementMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="INF"
      id="ixv-22475"
      unitRef="Unit_USD_per_Share">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="P03_03_2023To03_03_2023_SeriesFConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis_SubscriptionAgreementMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="0"
      id="ixv-22476"
      unitRef="Unit_USD">1000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:SaleOfStockTransactionDate
      contextRef="P03_03_2023To03_03_2023_SeriesFConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis_SubscriptionAgreementMemberusgaapSubsidiarySaleOfStockAxis"
      id="ixv-22477">2023-03-03</us-gaap:SaleOfStockTransactionDate>
    <us-gaap:PreferredStockVotingRights
      contextRef="P03_03_2023To03_03_2023_SeriesFConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      id="ixv-22478">no</us-gaap:PreferredStockVotingRights>
    <pstv:RightsRelatedToDistributionOfAssets
      contextRef="P03_03_2023To03_03_2023_SeriesFConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      id="ixv-22479">no</pstv:RightsRelatedToDistributionOfAssets>
    <pstv:ConsiderationPaidToPreferredStockHolders
      contextRef="P03_03_2023To03_03_2023_SeriesFConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="0"
      id="ixv-22481"
      unitRef="Unit_USD">1000</pstv:ConsiderationPaidToPreferredStockHolders>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="PAsOn03_31_2024_SeriesCConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis_TwoThousandEighteenRightsOfferingMemberusgaapClassOfWarrantOrRightAxis"
      decimals="INF"
      id="ixv-22482"
      unitRef="Unit_shares">938</us-gaap:PreferredStockSharesOutstanding>
    <pstv:NumberOfPreferredStockSharesExercised
      contextRef="P01_01_2024To03_31_2024_SeriesCConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis_TwoThousandEighteenRightsOfferingMemberusgaapClassOfWarrantOrRightAxis"
      decimals="INF"
      id="ixv-22483"
      unitRef="Unit_shares">27792</pstv:NumberOfPreferredStockSharesExercised>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="PAsOn03_31_2024_SeriesBConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis_TwoThousandEighteenRightsOfferingMemberusgaapClassOfWarrantOrRightAxis"
      decimals="INF"
      id="ixv-22484"
      unitRef="Unit_shares">1014</us-gaap:PreferredStockSharesOutstanding>
    <pstv:NumberOfPreferredStockSharesExercised
      contextRef="P01_01_2024To03_31_2024_SeriesBConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis_TwoThousandEighteenRightsOfferingMemberusgaapClassOfWarrantOrRightAxis"
      decimals="INF"
      id="ixv-22485"
      unitRef="Unit_shares">398</pstv:NumberOfPreferredStockSharesExercised>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="P01_01_2024To03_31_2024_CommonClassAMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      id="ixv-22486"
      unitRef="Unit_shares">19266</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="PAsOn03_31_2024_CommonClassBMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      id="ixv-22487"
      unitRef="Unit_shares">180733</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="P01_01_2024To03_31_2024_SeriesUWarrantsMemberusgaapClassOfWarrantOrRightAxis"
      decimals="INF"
      id="ixv-22488"
      unitRef="Unit_shares">230000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="PAsOn03_31_2024_SeriesUWarrantsMemberusgaapClassOfWarrantOrRightAxis"
      id="ixv-22489">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="PAsOn03_31_2024_RepresentativeSeriesUWarrantMemberusgaapStatementEquityComponentsAxis"
      decimals="INF"
      id="ixv-22490"
      unitRef="Unit_shares">5000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="PAsOn03_31_2024_SeriesUWarrantsMemberusgaapClassOfWarrantOrRightAxis_WarrantMemberusgaapStatementEquityComponentsAxis"
      decimals="INF"
      id="ixv-22491"
      unitRef="Unit_shares">142733</us-gaap:ClassOfWarrantOrRightOutstanding>
    <pstv:NumberOfWarrantsExercised
      contextRef="P01_01_2024To03_31_2024_SeriesUWarrantsMemberusgaapClassOfWarrantOrRightAxis_WarrantMemberusgaapStatementEquityComponentsAxis"
      decimals="INF"
      id="ixv-22492"
      unitRef="Unit_shares">142733</pstv:NumberOfWarrantsExercised>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="PAsOn03_31_2024_SeriesUWarrantsMemberusgaapClassOfWarrantOrRightAxis_WarrantMemberusgaapStatementEquityComponentsAxis"
      decimals="2"
      id="ixv-22493"
      unitRef="Unit_USD_per_Share">34.1</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <pstv:MaximumValueOfSharesToBeIssuedUnderAgreement
      contextRef="PAsOn08_02_2022_CommonStockMemberusgaapStatementEquityComponentsAxis_LincolnParkCapitalFundLLCMemberdeiLegalEntityAxis_TwoThousandAndTwentyTwoPurchaseAgreementMemberusgaapInvestmentTypeAxis"
      decimals="INF"
      id="ixv-22494"
      unitRef="Unit_USD">50000000</pstv:MaximumValueOfSharesToBeIssuedUnderAgreement>
    <pstv:MaximumValueOfSharesToBeIssuedUnderAgreement
      contextRef="PAsOn08_02_2022_CommonStockMemberusgaapStatementEquityComponentsAxis_LincolnParkCapitalFundLLCMemberdeiLegalEntityAxis_TwoThousandAndTwentyTwoPurchaseAgreementMemberusgaapInvestmentTypeAxis"
      decimals="INF"
      id="ixv-22495"
      unitRef="Unit_USD">50000000</pstv:MaximumValueOfSharesToBeIssuedUnderAgreement>
    <pstv:PeriodExercisableFromTheDateOfIssuance
      contextRef="P01_01_2024To03_31_2024_CommonStockMemberusgaapStatementEquityComponentsAxis_LincolnParkCapitalFundLLCMemberdeiLegalEntityAxis_TwoThousandAndTwentyTwoPurchaseAgreementMemberusgaapInvestmentTypeAxis"
      id="ixv-22496">P36M</pstv:PeriodExercisableFromTheDateOfIssuance>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="PAsOn05_16_2022_LincolnParkCapitalFundLLCMemberdeiLegalEntityAxis_MaximumMembersrtRangeAxis_TwoThousandAndTwentyTwoPurchaseAgreementMemberusgaapInvestmentTypeAxis"
      decimals="INF"
      id="ixv-22497"
      unitRef="Unit_shares">57500000</us-gaap:CommonStockSharesAuthorized>
    <pstv:PercentageIssuanceOfCommonStock
      contextRef="P05_16_2022To05_16_2022_CommonStockMemberusgaapStatementEquityComponentsAxis_LincolnParkCapitalFundLLCMemberdeiLegalEntityAxis_MinimumMembersrtRangeAxis_TwoThousandAndTwentyTwoPurchaseAgreementMemberusgaapInvestmentTypeAxis"
      decimals="4"
      id="ixv-22498"
      unitRef="Unit_pure">0.1999</pstv:PercentageIssuanceOfCommonStock>
    <pstv:InitialCommitmentFee
      contextRef="PAsOn08_02_2022_CommonStockMemberusgaapStatementEquityComponentsAxis_LincolnParkCapitalFundLLCMemberdeiLegalEntityAxis_TwoThousandAndTwentyTwoPurchaseAgreementMemberusgaapInvestmentTypeAxis"
      decimals="-5"
      id="ixv-22499"
      unitRef="Unit_USD">100000</pstv:InitialCommitmentFee>
    <pstv:InitialCommitmentShares
      contextRef="PAsOn08_02_2022_CommonStockMemberusgaapStatementEquityComponentsAxis_LincolnParkCapitalFundLLCMemberdeiLegalEntityAxis_TwoThousandAndTwentyTwoPurchaseAgreementMemberusgaapInvestmentTypeAxis"
      decimals="INF"
      id="ixv-22500"
      unitRef="Unit_shares">32846</pstv:InitialCommitmentShares>
    <pstv:GrossProceedsFromIssuanceOfCommonStock
      contextRef="P08_02_2022To08_02_2022_CommonStockMemberusgaapStatementEquityComponentsAxis_LincolnParkCapitalFundLLCMemberdeiLegalEntityAxis_TwoThousandAndTwentyTwoPurchaseAgreementMemberusgaapInvestmentTypeAxis"
      decimals="-5"
      id="ixv-22501"
      unitRef="Unit_USD">25000000</pstv:GrossProceedsFromIssuanceOfCommonStock>
    <pstv:NumberOfMaximumCommonSharesCanBeResale
      contextRef="PAsOn08_17_2022_CommonStockMemberusgaapStatementEquityComponentsAxis_LincolnParkCapitalFundLLCMemberdeiLegalEntityAxis_TwoThousandAndTwentyTwoPurchaseAgreementMemberusgaapInvestmentTypeAxis"
      decimals="INF"
      id="ixv-22502"
      unitRef="Unit_shares">633333</pstv:NumberOfMaximumCommonSharesCanBeResale>
    <pstv:InitialCommitmentShares
      contextRef="PAsOn07_14_2022_CommonStockMemberusgaapStatementEquityComponentsAxis_LincolnParkCapitalFundLLCMemberdeiLegalEntityAxis_TwoThousandAndTwentyTwoPurchaseAgreementMemberusgaapInvestmentTypeAxis"
      decimals="INF"
      id="ixv-22503"
      unitRef="Unit_shares">32846</pstv:InitialCommitmentShares>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="PAsOn08_17_2022_CommonStockMemberusgaapStatementEquityComponentsAxis_LincolnParkCapitalFundLLCMemberdeiLegalEntityAxis_MaximumMembersrtRangeAxis_TwoThousandAndTwentyTwoPurchaseAgreementMemberusgaapInvestmentTypeAxis"
      decimals="INF"
      id="ixv-22505"
      unitRef="Unit_shares">600486</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="P08_17_2022To03_31_2024_CommonStockMemberusgaapStatementEquityComponentsAxis_LincolnParkCapitalFundLLCMemberdeiLegalEntityAxis_TwentyTwentyPurchaseAgreementMemberusgaapInvestmentTypeAxis"
      decimals="INF"
      id="ixv-22506"
      unitRef="Unit_shares">527166</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <pstv:NumberOfMaximumCommonSharesCanBeResale
      contextRef="PAsOn08_18_2023_CommonStockMemberusgaapStatementEquityComponentsAxis_LincolnParkCapitalFundLLCMemberdeiLegalEntityAxis_MaximumMembersrtRangeAxis_TwoThousandAndTwentyTwoPurchaseAgreementMemberusgaapInvestmentTypeAxis"
      decimals="INF"
      id="ixv-22507"
      unitRef="Unit_shares">1500000</pstv:NumberOfMaximumCommonSharesCanBeResale>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="P08_18_2023To03_31_2024_CommonStockMemberusgaapStatementEquityComponentsAxis_LincolnParkCapitalFundLLCMemberdeiLegalEntityAxis_TwoThousandAndTwentyTwoPurchaseAgreementMemberusgaapInvestmentTypeAxis"
      decimals="INF"
      id="ixv-22508"
      unitRef="Unit_shares">150000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="P08_17_2022To12_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis_LincolnParkCapitalFundLLCMemberdeiLegalEntityAxis_TwoThousandAndTwentyTwoPurchaseAgreementMemberusgaapInvestmentTypeAxis"
      decimals="INF"
      id="ixv-22509"
      unitRef="Unit_shares">266666</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="P08_17_2022To12_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis_LincolnParkCapitalFundLLCMemberdeiLegalEntityAxis_TwoThousandAndTwentyTwoPurchaseAgreementMemberusgaapInvestmentTypeAxis"
      decimals="-5"
      id="ixv-22510"
      unitRef="Unit_USD">3200000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="P01_01_2023To12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis_LincolnParkCapitalFundLLCMemberdeiLegalEntityAxis_TwoThousandAndTwentyTwoPurchaseAgreementMemberusgaapInvestmentTypeAxis"
      decimals="INF"
      id="ixv-22511"
      unitRef="Unit_shares">410500</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="P01_01_2023To12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis_LincolnParkCapitalFundLLCMemberdeiLegalEntityAxis_TwoThousandAndTwentyTwoPurchaseAgreementMemberusgaapInvestmentTypeAxis"
      decimals="-5"
      id="ixv-22512"
      unitRef="Unit_USD">1000000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="P01_01_2024To03_31_2024_CommonStockMemberusgaapStatementEquityComponentsAxis_LincolnParkCapitalFundLLCMemberdeiLegalEntityAxis_TwoThousandAndTwentyTwoPurchaseAgreementMemberusgaapInvestmentTypeAxis"
      decimals="0"
      id="ixv-22513"
      unitRef="Unit_shares">0</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="P09_09_2022To09_09_2022_AtTheMarketOfferingProgramMemberusgaapSubsidiarySaleOfStockAxis_CanaccordGenuityLLCMemberdeiLegalEntityAxis_CommonStockMemberusgaapStatementEquityComponentsAxis_MaximumMembersrtRangeAxis_SeptemberTwoThousandAndTwentyTwoDistributionAgreementMemberusgaapInvestmentTypeAxis"
      decimals="0"
      id="ixv-22514"
      unitRef="Unit_USD">5000000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="P09_09_2022To12_31_2022_AtTheMarketOfferingProgramMemberusgaapSubsidiarySaleOfStockAxis_CanaccordGenuityLLCMemberdeiLegalEntityAxis_CommonStockMemberusgaapStatementEquityComponentsAxis_SeptemberTwoThousandAndTwentyTwoDistributionAgreementMemberusgaapInvestmentTypeAxis"
      decimals="INF"
      id="ixv-22515"
      unitRef="Unit_shares">68758</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="P09_09_2022To12_31_2022_AtTheMarketOfferingProgramMemberusgaapSubsidiarySaleOfStockAxis_CanaccordGenuityLLCMemberdeiLegalEntityAxis_CommonStockMemberusgaapStatementEquityComponentsAxis_SeptemberTwoThousandAndTwentyTwoDistributionAgreementMemberusgaapInvestmentTypeAxis"
      decimals="-5"
      id="ixv-22516"
      unitRef="Unit_USD">600000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="P01_01_2023To12_31_2023_AtTheMarketOfferingProgramMemberusgaapSubsidiarySaleOfStockAxis_CanaccordGenuityLLCMemberdeiLegalEntityAxis_CommonStockMemberusgaapStatementEquityComponentsAxis_SeptemberTwoThousandAndTwentyTwoDistributionAgreementMemberusgaapInvestmentTypeAxis"
      decimals="INF"
      id="ixv-22517"
      unitRef="Unit_shares">1819993</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="P01_01_2023To12_31_2023_AtTheMarketOfferingProgramMemberusgaapSubsidiarySaleOfStockAxis_CanaccordGenuityLLCMemberdeiLegalEntityAxis_CommonStockMemberusgaapStatementEquityComponentsAxis_SeptemberTwoThousandAndTwentyTwoDistributionAgreementMemberusgaapInvestmentTypeAxis"
      decimals="-5"
      id="ixv-22518"
      unitRef="Unit_USD">4300000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <pstv:PercentageOfCommissionOnGrossProceedsFromSaleOfCommonStock
      contextRef="P09_09_2022To09_09_2022_AtTheMarketOfferingProgramMemberusgaapSubsidiarySaleOfStockAxis_CanaccordGenuityLLCMemberdeiLegalEntityAxis_CommonStockMemberusgaapStatementEquityComponentsAxis_MaximumMembersrtRangeAxis_SeptemberTwoThousandAndTwentyTwoDistributionAgreementMemberusgaapInvestmentTypeAxis"
      decimals="INF"
      id="ixv-22519"
      unitRef="Unit_pure">0.03</pstv:PercentageOfCommissionOnGrossProceedsFromSaleOfCommonStock>
    <pstv:AggregateExpenseIncludingFeeAndDisbursementExpenses
      contextRef="P09_09_2022To09_09_2022_AtTheMarketOfferingProgramMemberusgaapSubsidiarySaleOfStockAxis_CanaccordGenuityLLCMemberdeiLegalEntityAxis_SeptemberTwoThousandAndTwentyTwoDistributionAgreementMemberusgaapInvestmentTypeAxis"
      decimals="0"
      id="ixv-22520"
      unitRef="Unit_USD">50000</pstv:AggregateExpenseIncludingFeeAndDisbursementExpenses>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="P01_14_2022To01_14_2022_AtTheMarketOfferingProgramMemberusgaapSubsidiarySaleOfStockAxis_CanaccordGenuityLLCMemberdeiLegalEntityAxis_CommonStockMemberusgaapStatementEquityComponentsAxis_JanuaryTwoThousandAndTwentyTwoDistributionAgreementMemberusgaapInvestmentTypeAxis_MaximumMembersrtRangeAxis"
      decimals="INF"
      id="ixv-22521"
      unitRef="Unit_USD">5000000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <pstv:CommonStockSalesAvailableForIssuance
      contextRef="PAsOn01_14_2022_AtTheMarketOfferingProgramMemberusgaapSubsidiarySaleOfStockAxis_CanaccordGenuityLLCMemberdeiLegalEntityAxis_CommonStockMemberusgaapStatementEquityComponentsAxis_JanuaryTwoThousandAndTwentyTwoDistributionAgreementMemberusgaapInvestmentTypeAxis"
      decimals="0"
      id="ixv-22522"
      unitRef="Unit_USD">0</pstv:CommonStockSalesAvailableForIssuance>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="P01_01_2023To12_31_2023_CanaccordGenuityLLCMemberdeiLegalEntityAxis_CommonStockMemberusgaapStatementEquityComponentsAxis_JanuaryTwoThousandAndTwentyTwoDistributionAgreementMemberusgaapInvestmentTypeAxis"
      decimals="INF"
      id="ixv-22523"
      unitRef="Unit_shares">460151</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="P01_01_2023To12_31_2023_CanaccordGenuityLLCMemberdeiLegalEntityAxis_CommonStockMemberusgaapStatementEquityComponentsAxis_JanuaryTwoThousandAndTwentyTwoDistributionAgreementMemberusgaapInvestmentTypeAxis"
      decimals="-5"
      id="ixv-22524"
      unitRef="Unit_USD">4800000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:StockRepurchaseProgramAuthorizedAmount1
      contextRef="PAsOn10_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis_MaximumMembersrtRangeAxis"
      decimals="INF"
      id="ixv-22526"
      unitRef="Unit_USD">500000</us-gaap:StockRepurchaseProgramAuthorizedAmount1>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="P01_01_2023To12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="INF"
      id="ixv-22527"
      unitRef="Unit_shares">78559</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:TreasuryStockValue
      contextRef="PAsOn12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-5"
      id="ixv-22528"
      unitRef="Unit_USD">100000</us-gaap:TreasuryStockValue>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="P01_01_2024To03_31_2024_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="INF"
      id="ixv-22529"
      unitRef="Unit_shares">179866</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:TreasuryStockValue
      contextRef="PAsOn03_31_2024_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-5"
      id="ixv-22530"
      unitRef="Unit_USD">400000</us-gaap:TreasuryStockValue>
    <us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1
      contextRef="PAsOn03_31_2024"
      decimals="0"
      id="ixv-22531"
      unitRef="Unit_USD">0</us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="P01_01_2024To03_31_2024" id="ixv-11622">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;11. Stock-based Compensation &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;Under the Company&#x2019;s 2015 New Employee Incentive Plan (the &#x201c;2015 Plan&#x201d;), awards may only be granted to employees who were not previously an employee or director of the Company, or following a bona fide period of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;non-employment,&lt;/div&gt; as a material inducement to entering into employment with the Company. As of March&#160;31, 2024, there were 6,024 shares of common stock remaining and available for future issuances under the 2015 Plan. &lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;The Company&#x2019;s 2020 Stock Incentive Plan (the &#x201c;2020 Plan&#x201d;), which replaced the Company&#x2019;s 2014 Equity Incentive Plan, provides for the award or sale of shares of common stock (including restricted stock), the award of stock units and stock appreciation rights, and the grant of both incentive stock options to purchase common stock to directors, officers, employees and consultants of the Company. The 2020 Plan, as amended, provides for the issuance of up to 236,667 shares of common stock, plus the number of shares available for issuance is increased to the extent that awards granted under the 2020 Plan and the Company&#x2019;s 2014 Equity Incentive Plan are forfeited or expire (except as otherwise provided in the 2020 Plan). As of March&#160;31, 2024, there were 17,582 shares remaining and available for future issuances under the 2020 Plan. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;Generally, options issued under the 2020 Plan are subject to a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;two-year&lt;/div&gt; or four-year vesting schedule with 25% of the options vesting on the one year anniversary of the grant date followed by equal monthly installment vesting, and have a contractual term of 10 years. &lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;A summary of activity for the three months ended March&#160;31, 2024 is as follows: &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 92%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;"&gt;
&lt;tr&gt;
&lt;td style="width: 55%;"&gt;&lt;/td&gt;
&lt;td style="width: 5%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="width: 5%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="width: 5%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="width: 5%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Options&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Average&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Exercise&#160;Price&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Average&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Remaining&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Contractual&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Term&lt;br/&gt; (years)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Aggregate&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Intrinsic&lt;br/&gt; Value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Balance as of December&#160;31, 2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;140,109&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;37.48&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;8.07&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Granted&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;163,025&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;2.03&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Cancelled/forfeited&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;(1&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;289,125&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Balance as of March&#160;31, 2024&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;303,133&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;17.46&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;8.94&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;7,600&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Vested and expected to vest at March&#160;31, 2024&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;278,083&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;18.64&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;8.87&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;6,800&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Exercisable at March&#160;31, 2024&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;84,908&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;50.13&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;7.37&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;500&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear:both;max-height:0pt;"&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;As of March&#160;31, 2024, the total compensation cost related to &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;non-vested&lt;/div&gt; stock options not yet recognized for all the Company&#x2019;s plans is approximately $0.8&#160;million, which is expected to be recognized as a result of vesting under service conditions over a weighted average period of 2.3 years. &lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="PAsOn03_31_2024_StockBasedCompensation2015EquityIncentivePlan1MemberusgaapPlanNameAxis"
      decimals="INF"
      id="ixv-22532"
      unitRef="Unit_shares">6024</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="P01_01_2024To03_31_2024_StockBasedCompensation2020EquityIncentivePlanMemberusgaapPlanNameAxis"
      decimals="INF"
      id="ixv-22533"
      unitRef="Unit_shares">236667</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="PAsOn03_31_2024_StockBasedCompensation2020EquityIncentivePlanMemberusgaapPlanNameAxis"
      decimals="INF"
      id="ixv-22534"
      unitRef="Unit_shares">17582</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="P01_01_2024To03_31_2024_MinimumMembersrtRangeAxis"
      id="ixv-22535">P2Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="P01_01_2024To03_31_2024_MaximumMembersrtRangeAxis"
      id="ixv-22536">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="P01_01_2024To03_31_2024"
      decimals="2"
      id="ixv-22537"
      unitRef="Unit_pure">0.25</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod contextRef="P01_01_2024To03_31_2024" id="ixv-22538">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock contextRef="P01_01_2024To03_31_2024" id="ixv-11632">&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;A summary of activity for the three months ended March&#160;31, 2024 is as follows: &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 92%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;"&gt;
&lt;tr&gt;
&lt;td style="width: 55%;"&gt;&lt;/td&gt;
&lt;td style="width: 5%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="width: 5%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="width: 5%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="width: 5%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Options&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Average&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Exercise&#160;Price&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Average&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Remaining&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Contractual&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Term&lt;br/&gt; (years)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Aggregate&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Intrinsic&lt;br/&gt; Value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Balance as of December&#160;31, 2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;140,109&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;37.48&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;8.07&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Granted&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;163,025&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;2.03&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Cancelled/forfeited&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;(1&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;289,125&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Balance as of March&#160;31, 2024&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;303,133&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;17.46&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;8.94&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;7,600&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Vested and expected to vest at March&#160;31, 2024&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;278,083&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;18.64&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;8.87&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;6,800&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Exercisable at March&#160;31, 2024&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;84,908&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;50.13&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;7.37&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;500&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="PAsOn12_31_2023"
      decimals="INF"
      id="ixv-22539"
      unitRef="Unit_shares">140109</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="PAsOn12_31_2023"
      decimals="2"
      id="ixv-22540"
      unitRef="Unit_USD_per_Share">37.48</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="P01_01_2023To12_31_2023" id="ixv-22541">P8Y25D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="P01_01_2024To03_31_2024"
      decimals="INF"
      id="ixv-22542"
      unitRef="Unit_shares">163025</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="P01_01_2024To03_31_2024"
      decimals="2"
      id="ixv-22543"
      unitRef="Unit_USD_per_Share">2.03</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="P01_01_2024To03_31_2024"
      decimals="INF"
      id="ixv-22544"
      unitRef="Unit_shares">1</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="P01_01_2024To03_31_2024"
      decimals="0"
      id="ixv-22545"
      unitRef="Unit_USD_per_Share">289125</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="PAsOn03_31_2024"
      decimals="INF"
      id="ixv-22546"
      unitRef="Unit_shares">303133</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="PAsOn03_31_2024"
      decimals="2"
      id="ixv-22547"
      unitRef="Unit_USD_per_Share">17.46</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="P01_01_2024To03_31_2024" id="ixv-22548">P8Y11M8D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="PAsOn03_31_2024"
      decimals="0"
      id="ixv-22549"
      unitRef="Unit_USD">7600</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="PAsOn03_31_2024"
      decimals="INF"
      id="ixv-22550"
      unitRef="Unit_shares">278083</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
      contextRef="PAsOn03_31_2024"
      decimals="2"
      id="ixv-22551"
      unitRef="Unit_USD_per_Share">18.64</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 contextRef="P01_01_2024To03_31_2024" id="ixv-22552">P8Y10M13D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
      contextRef="PAsOn03_31_2024"
      decimals="0"
      id="ixv-22553"
      unitRef="Unit_USD">6800</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="PAsOn03_31_2024"
      decimals="INF"
      id="ixv-22554"
      unitRef="Unit_shares">84908</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="PAsOn03_31_2024"
      decimals="2"
      id="ixv-22555"
      unitRef="Unit_USD_per_Share">50.13</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="P01_01_2024To03_31_2024" id="ixv-22556">P7Y4M13D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="PAsOn03_31_2024"
      decimals="0"
      id="ixv-22557"
      unitRef="Unit_USD">500</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="PAsOn03_31_2024"
      decimals="-5"
      id="ixv-22558"
      unitRef="Unit_USD">800000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="P01_01_2024To03_31_2024" id="ixv-22559">P2Y3M18D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:SubsequentEventsTextBlock contextRef="P01_01_2024To03_31_2024" id="ixv-11968">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;12. Subsequent Events &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Repayment of Term Loan and Use of Pershing Credit Facility &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;On May&#160;31, 2024, the Company drew $3.3&#160;million on the Pershing Credit Facility, to repay the Oxford Term Loan in full, a payment amount that totaled approximately $3.3&#160;million, which included both the balance of outstanding principal and interest and the final payment fee due. The repayment in full of the Oxford Term Loan terminated Oxford&#x2019;s security interest in the Company&#x2019;s existing and after-acquired assets, as well as all other certain restrictions and covenants under the Oxford Term Loan. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;Borrowings under the Pershing Credit Facility bear interest at the target interest rate set by the Federal Open Market Committee, subject to a floor of 5.5%, plus a spread of 1.75% and applicable fees of 0.5%, subject to a maximum interest rate of the then applicable Prime Rate as published in The Wall Street Journal plus 3.0%. Interest payments thereunder are calculated on a monthly basis and, unless paid, are added to the outstanding balance under the Pershing Credit Facility. The proceeds under the Pershing Credit Facility are available for working capital needs and other general corporate purposes. The Pershing Credit Facility includes certain covenants and restrictions, which may require the Company, on &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;an&#160;on-going&#160;basis,&lt;/div&gt; to deposit additional funds or marketable securities in order to maintain the line of credit extended by Pershing. &lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;The available credit line limit under the Pershing Credit Facility fluctuates based on the Company&#x2019;s request for extensions of credit from time to time, subject to the value of the collateralized marketable securities that the Company holds with Pershing, provided that the amount available to draw under the Pershing Credit Facility cannot exceed 91.5% of the value of the Company&#x2019;s collateralized marketable securities deposited with Pershing (the &#x201c;Collateral&#x201d;). Depending on the value of the Collateral that the Company holds with Pershing, Pershing may require the Company, on &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;an&#160;on-going&#160;basis,&lt;/div&gt; to deposit additional funds or marketable securities in order to restore the level of the Collateral to an acceptable level. The amounts borrowed under the Pershing Credit Facility are due on demand. &lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;The Pershing Credit Facility is secured by a general lien and security interest in the Company&#x2019;s Collateral held in its account with Pershing. Upon certain customary events of default, Pershing has the right, in its discretion, to liquidate, withdraw or sell all or any part of the Collateral and apply the proceeds to the amounts outstanding under the Pershing Credit Facility. The Pershing Credit Facility is also subject to certain customary terms and conditions. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;May 2024 Private Placement &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;On May&#160;5, 2024, the Company entered into a securities purchase agreement (the &#x201c;Securities Purchase Agreement&#x201d;) with certain investors, including certain of the Company&#x2019;s directors and executive officers (&#x201c;Company Insiders&#x201d;) (collectively, the &#x201c;Purchasers&#x201d;), for the sale and issuance by the Company of its securities (the &#x201c;Initial Subscription&#x201d;). On May&#160;8, 2024, the Company entered into a first amendment to the Securities Purchase Agreement (the &#x201c;Amendment&#x201d;) for the sale and issuance by the Company of additional securities to two of the Purchasers (the &#x201c;Additional Subscription&#x201d;, and together with the Initial Subscription, the &#x201c;May 2024 Private Placement&#x201d;). The Securities Purchase Agreement, as amended, provides for the sale and issuance by the Company of an aggregate of 3,591,532 shares (the &#x201c;Private Placement Shares&#x201d;) of the Company&#x2019;s common stock or, at the election of each Purchaser, &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;pre-funded&lt;/div&gt; warrants (the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#x201c;Pre-Funded&lt;/div&gt; Warrants&#x201d;), exercisable immediately at an exercise price of $0.001 per share (the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#x201c;Pre-Funded&lt;/div&gt; Warrant Shares&#x201d;), with each Private Placement Share or &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;Pre-Funded&lt;/div&gt; Warrant accompanied by (i)&#160;a Series A common warrant (&#x201c;Series A Warrants&#x201d;) to purchase one share of common stock (the &#x201c;Series A Warrant Shares&#x201d;), for an aggregate of 3,591,532 Series A Warrants, and (ii)&#160;one Series B common warrant (&#x201c;Series B Warrants&#x201d;) to purchase one share of common stock (the &#x201c;Series B Warrant Shares,&#x201d; and together with the Series A Warrant Shares, the &#x201c;Common Warrant Shares&#x201d;), for an aggregate of 3,591,532 Series B Warrants. &lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;The combined purchase price for each Private Placement Share and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;Pre-Funded&lt;/div&gt; Warrant from the Initial Subscription was $2.022, and $2.158 from the Additional Subscription, in each case together with one &lt;/div&gt;&lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;accompanying Series A Warrant and one accompanying Series B Warrant, provided, that the Company Insiders participated in the Initial Subscription at an offering price of $2.04 per Private Placement Share and accompanying Series A Warrant and Series B Warrant. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;The exercise price of each Series A Warrant and Series B Warrant from the Initial Subscription is $1.772 per share and $1.908 per share in the Additional Subscription, provided that the exercise price for the Series A Warrants and Series B Warrants issued to the Company Insiders is $1.79 per share. Subject to certain ownership limitations, the Series A Warrants will be exercisable until the five-year anniversary of issuance. Subject to certain ownership limitations, the Series B Warrants will be exercisable until the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;one-year&lt;/div&gt; anniversary of the declaration of effectiveness of a registration statement to be filed with the Securities and Exchange Commission covering the resale of the Common Warrant Shares. The &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;Pre-Funded&lt;/div&gt; Warrant will not expire until exercised in full. &lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;The May 2024 Private Offering closed on May&#160;9, 2024 (the &#x201c;May 2024 Private Placement Closing&#x201d;). The aggregate gross proceeds at the May 2024 Private Placement Closing were approximately $7.25&#160;million, before deducting certain expenses payable by the Company, and excluding the proceeds, if any, from the exercise of the Series A Warrant, the Series B Warrant, and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;Pre-Funded&lt;/div&gt; Warrant. &lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;The Company is evaluating the accounting treatment of the Series A Warrants, Series B Warrants and the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;Pre-Funded&lt;/div&gt; Warrants under the authoritative accounting guidance. &lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Biocept Asset Purchase &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;On April&#160;26, 2024, the Company acquired from Biocept, for a total cash payment of $400,000, substantially all of the right, title and interest in CNside, including (i)&#160;intellectual property, (ii)&#160;inventory and raw materials, and (iii)&#160;data, information, results and reports pertaining to the completed and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;on-going&lt;/div&gt; clinical studies involving the use of the CNside test (including, but not limited to, the FORESEE clinical study), related to the development, making, selling, and exporting or importing of CNside, after the Company&#x2019;s bid was approved by the United States Bankruptcy Court for the District of Delaware. &lt;/div&gt;</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="PAsOn05_31_2024_PershingCreditFacilityMemberusgaapCreditFacilityAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="-5"
      id="ixv-22560"
      unitRef="Unit_USD">3300000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityPeriodicPayment
      contextRef="P05_31_2024To05_31_2024_PershingCreditFacilityMemberusgaapCreditFacilityAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="-5"
      id="ixv-22561"
      unitRef="Unit_USD">3300000</us-gaap:LineOfCreditFacilityPeriodicPayment>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="PAsOn05_31_2024_PershingCreditFacilityMemberusgaapCreditFacilityAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="3"
      id="ixv-22562"
      unitRef="Unit_pure">0.055</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="P05_31_2024To05_31_2024_PershingCreditFacilityMemberusgaapCreditFacilityAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="4"
      id="ixv-22563"
      unitRef="Unit_pure">0.0175</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="PAsOn05_31_2024_PershingCreditFacilityMemberusgaapCreditFacilityAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="3"
      id="ixv-22564"
      unitRef="Unit_pure">0.005</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateDuringPeriod
      contextRef="P05_31_2024To05_31_2024_PershingCreditFacilityMemberusgaapCreditFacilityAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="3"
      id="ixv-22565"
      unitRef="Unit_pure">0.03</us-gaap:DebtInstrumentInterestRateDuringPeriod>
    <us-gaap:LineOfCreditFacilityInterestRateDuringPeriod
      contextRef="P05_31_2024To05_31_2024_PershingCreditFacilityMemberusgaapCreditFacilityAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="3"
      id="ixv-22566"
      unitRef="Unit_pure">0.915</us-gaap:LineOfCreditFacilityInterestRateDuringPeriod>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="P05_05_2024To05_05_2024_May2024PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="0"
      id="ixv-22567"
      unitRef="Unit_shares">3591532</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="PAsOn05_05_2024_May2024PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="3"
      id="ixv-22568"
      unitRef="Unit_USD_per_Share">0.001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="P05_05_2024To05_05_2024_May2024PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_SeriesAWarrantMemberusgaapClassOfWarrantOrRightAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="0"
      id="ixv-22569"
      unitRef="Unit_shares">3591532</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="P05_05_2024To05_05_2024_May2024PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_SeriesBWarrantMemberusgaapClassOfWarrantOrRightAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="0"
      id="ixv-22570"
      unitRef="Unit_shares">3591532</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <pstv:ClassOfWarrantOrRightPurchasePrice
      contextRef="P05_05_2024To05_05_2024_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="3"
      id="ixv-22571"
      unitRef="Unit_USD_per_Share">2.022</pstv:ClassOfWarrantOrRightPurchasePrice>
    <pstv:ClassOfWarrantOrRightPurchasePrice
      contextRef="P05_05_2024To05_05_2024_PreFundedWarrantMemberusgaapSubsidiarySaleOfStockAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="3"
      id="ixv-22572"
      unitRef="Unit_USD_per_Share">2.158</pstv:ClassOfWarrantOrRightPurchasePrice>
    <pstv:ClassOfWarrantOrRightOfferingPrice
      contextRef="P05_05_2024To05_05_2024_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="2"
      id="ixv-22574"
      unitRef="Unit_USD_per_Share">2.04</pstv:ClassOfWarrantOrRightOfferingPrice>
    <pstv:ClassOfWarrantOrRightExercisePriceInitialSubscription
      contextRef="PAsOn05_05_2024_May2024PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="3"
      id="ixv-22575"
      unitRef="Unit_USD_per_Share">1.772</pstv:ClassOfWarrantOrRightExercisePriceInitialSubscription>
    <pstv:ClassOfWarrantOrRightExercisePriceAdditionalSubscription
      contextRef="PAsOn05_05_2024_May2024PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="3"
      id="ixv-22576"
      unitRef="Unit_USD_per_Share">1.908</pstv:ClassOfWarrantOrRightExercisePriceAdditionalSubscription>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="PAsOn05_05_2024_May2024PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="2"
      id="ixv-22577"
      unitRef="Unit_USD_per_Share">1.79</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:WarrantsAndRightsOutstanding
      contextRef="PAsOn05_09_2024_May2024PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="-4"
      id="ixv-22578"
      unitRef="Unit_USD">7250000</us-gaap:WarrantsAndRightsOutstanding>
    <us-gaap:PaymentsToAcquireProductiveAssets
      contextRef="P04_26_2024To04_26_2024_BioceptAssetPurchaseMemberusgaapAssetAcquisitionAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="0"
      id="ixv-22579"
      unitRef="Unit_USD">400000</us-gaap:PaymentsToAcquireProductiveAssets>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-22580"
      unitRef="Unit_USD">8554000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      id="ixv-22581"
      unitRef="Unit_USD">18120000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:OtherAssetsCurrent
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-22582"
      unitRef="Unit_USD">1280000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      id="ixv-22583"
      unitRef="Unit_USD">3697000</us-gaap:OtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-22584"
      unitRef="Unit_USD">9834000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      id="ixv-22585"
      unitRef="Unit_USD">21817000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-22586"
      unitRef="Unit_USD">906000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      id="ixv-22587"
      unitRef="Unit_USD">1324000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-22588"
      unitRef="Unit_USD">202000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      id="ixv-22589"
      unitRef="Unit_USD">248000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:Goodwill
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-22590"
      unitRef="Unit_USD">372000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      id="ixv-22591"
      unitRef="Unit_USD">372000</us-gaap:Goodwill>
    <us-gaap:OtherIntangibleAssetsNet
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-22592"
      unitRef="Unit_USD">42000</us-gaap:OtherIntangibleAssetsNet>
    <us-gaap:OtherIntangibleAssetsNet
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      id="ixv-22593"
      unitRef="Unit_USD">94000</us-gaap:OtherIntangibleAssetsNet>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-22594"
      unitRef="Unit_USD">32000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      id="ixv-22595"
      unitRef="Unit_USD">12000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-22596"
      unitRef="Unit_USD">11388000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      id="ixv-22597"
      unitRef="Unit_USD">23867000</us-gaap:Assets>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-22598"
      unitRef="Unit_USD">6631000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      id="ixv-22599"
      unitRef="Unit_USD">10134000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-22600"
      unitRef="Unit_USD">120000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      id="ixv-22601"
      unitRef="Unit_USD">110000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-22602"
      unitRef="Unit_USD">3976000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      id="ixv-22603"
      unitRef="Unit_USD">1608000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-22604"
      unitRef="Unit_USD">10727000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      id="ixv-22605"
      unitRef="Unit_USD">11852000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-22606"
      unitRef="Unit_USD">85000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      id="ixv-22607"
      unitRef="Unit_USD">141000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-22608"
      unitRef="Unit_USD">0</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      id="ixv-22609"
      unitRef="Unit_USD">3786000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DeferredIncomeNoncurrent
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-22610"
      unitRef="Unit_USD">1924000</us-gaap:DeferredIncomeNoncurrent>
    <us-gaap:DeferredIncomeNoncurrent
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      id="ixv-22611"
      unitRef="Unit_USD">1643000</us-gaap:DeferredIncomeNoncurrent>
    <us-gaap:Liabilities
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-22612"
      unitRef="Unit_USD">12736000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      id="ixv-22613"
      unitRef="Unit_USD">17422000</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="PAsOn12_31_2023"
      decimals="INF"
      id="ixv-22614"
      unitRef="Unit_USD_per_Share">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="PAsOn12_31_2022"
      decimals="INF"
      id="ixv-22615"
      unitRef="Unit_USD_per_Share">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="PAsOn12_31_2023"
      decimals="INF"
      id="ixv-22616"
      unitRef="Unit_shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="PAsOn12_31_2022"
      decimals="INF"
      id="ixv-22617"
      unitRef="Unit_shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="PAsOn12_31_2023"
      decimals="INF"
      id="ixv-22618"
      unitRef="Unit_shares">1952</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="PAsOn12_31_2022"
      decimals="INF"
      id="ixv-22619"
      unitRef="Unit_shares">1952</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="PAsOn12_31_2023"
      decimals="INF"
      id="ixv-22620"
      unitRef="Unit_shares">1952</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="PAsOn12_31_2022"
      decimals="INF"
      id="ixv-22621"
      unitRef="Unit_shares">1952</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockValue
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-22622"
      unitRef="Unit_USD">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      id="ixv-22623"
      unitRef="Unit_USD">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="PAsOn12_31_2022"
      decimals="INF"
      id="ixv-22624"
      unitRef="Unit_USD_per_Share">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="PAsOn12_31_2023"
      decimals="INF"
      id="ixv-22625"
      unitRef="Unit_USD_per_Share">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="PAsOn12_31_2023"
      decimals="INF"
      id="ixv-22626"
      unitRef="Unit_shares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="PAsOn12_31_2022"
      decimals="INF"
      id="ixv-22627"
      unitRef="Unit_shares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="PAsOn12_31_2023"
      decimals="INF"
      id="ixv-22628"
      unitRef="Unit_shares">4522656</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="PAsOn12_31_2023"
      decimals="INF"
      id="ixv-22629"
      unitRef="Unit_shares">4444097</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="PAsOn12_31_2022"
      decimals="INF"
      id="ixv-22630"
      unitRef="Unit_shares">2240092</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="PAsOn12_31_2022"
      decimals="INF"
      id="ixv-22631"
      unitRef="Unit_shares">2240092</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-22632"
      unitRef="Unit_USD">5000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      id="ixv-22633"
      unitRef="Unit_USD">2000</us-gaap:CommonStockValue>
    <us-gaap:TreasuryStockCommonShares
      contextRef="PAsOn12_31_2023"
      decimals="INF"
      id="ixv-22634"
      unitRef="Unit_shares">78559</us-gaap:TreasuryStockCommonShares>
    <us-gaap:TreasuryStockCommonValue
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-22635"
      unitRef="Unit_USD">126000</us-gaap:TreasuryStockCommonValue>
    <us-gaap:TreasuryStockCommonValue
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      id="ixv-22636"
      unitRef="Unit_USD">0</us-gaap:TreasuryStockCommonValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-22637"
      unitRef="Unit_USD">479274000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      id="ixv-22638"
      unitRef="Unit_USD">473628000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-22639"
      unitRef="Unit_USD">-480501000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      id="ixv-22640"
      unitRef="Unit_USD">-467185000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-22641"
      unitRef="Unit_USD">-1348000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      id="ixv-22642"
      unitRef="Unit_USD">6445000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-22643"
      unitRef="Unit_USD">11388000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      id="ixv-22644"
      unitRef="Unit_USD">23867000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:Revenues
      contextRef="P01_01_2023To12_31_2023_GrantMembersrtProductOrServiceAxis"
      decimals="-3"
      id="ixv-22645"
      unitRef="Unit_USD">4913000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="P01_01_2022To12_31_2022_GrantMembersrtProductOrServiceAxis"
      decimals="-3"
      id="ixv-22646"
      unitRef="Unit_USD">224000</us-gaap:Revenues>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-22647"
      unitRef="Unit_USD">9690000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      id="ixv-22648"
      unitRef="Unit_USD">9698000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-22649"
      unitRef="Unit_USD">8544000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      id="ixv-22650"
      unitRef="Unit_USD">10238000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-22651"
      unitRef="Unit_USD">18234000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      id="ixv-22652"
      unitRef="Unit_USD">19936000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-22653"
      unitRef="Unit_USD">-13321000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      id="ixv-22654"
      unitRef="Unit_USD">-19712000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InvestmentIncomeInterest
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-22655"
      unitRef="Unit_USD">400000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      id="ixv-22656"
      unitRef="Unit_USD">147000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InterestExpense
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-22657"
      unitRef="Unit_USD">395000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      id="ixv-22658"
      unitRef="Unit_USD">711000</us-gaap:InterestExpense>
    <us-gaap:LiabilitiesFairValueAdjustment
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-22659"
      unitRef="Unit_USD">0</us-gaap:LiabilitiesFairValueAdjustment>
    <us-gaap:LiabilitiesFairValueAdjustment
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      id="ixv-22660"
      unitRef="Unit_USD">1000</us-gaap:LiabilitiesFairValueAdjustment>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-22661"
      unitRef="Unit_USD">5000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      id="ixv-22662"
      unitRef="Unit_USD">-563000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-22663"
      unitRef="Unit_USD">-13316000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      id="ixv-22664"
      unitRef="Unit_USD">-20275000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="P01_01_2023To12_31_2023"
      decimals="2"
      id="ixv-22665"
      unitRef="Unit_USD_per_Share">-4.24</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="P01_01_2023To12_31_2023"
      decimals="2"
      id="ixv-22666"
      unitRef="Unit_USD_per_Share">-4.24</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="P01_01_2022To12_31_2022"
      decimals="2"
      id="ixv-22667"
      unitRef="Unit_USD_per_Share">-11.58</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="P01_01_2022To12_31_2022"
      decimals="2"
      id="ixv-22668"
      unitRef="Unit_USD_per_Share">-11.58</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="P01_01_2023To12_31_2023"
      decimals="0"
      id="ixv-22669"
      unitRef="Unit_shares">3140925</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="P01_01_2023To12_31_2023"
      decimals="0"
      id="ixv-22670"
      unitRef="Unit_shares">3140925</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="P01_01_2022To12_31_2022"
      decimals="0"
      id="ixv-22671"
      unitRef="Unit_shares">1750350</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="P01_01_2022To12_31_2022"
      decimals="0"
      id="ixv-22672"
      unitRef="Unit_shares">1750350</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="PAsOn12_31_2021_ConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="0"
      id="ixv-22673"
      unitRef="Unit_shares">1952</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="PAsOn12_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      id="ixv-22674"
      unitRef="Unit_shares">1034002</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-22675"
      unitRef="Unit_USD">1000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-22676"
      unitRef="Unit_USD">457745000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-22677"
      unitRef="Unit_USD">-446910000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      id="ixv-22678"
      unitRef="Unit_USD">10836000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="P01_01_2022To12_31_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-22679"
      unitRef="Unit_USD">606000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      id="ixv-22680"
      unitRef="Unit_USD">606000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="P01_01_2022To12_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="INF"
      id="ixv-22681"
      unitRef="Unit_shares">1206090</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="P01_01_2022To12_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-22682"
      unitRef="Unit_USD">1000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="P01_01_2022To12_31_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-22683"
      unitRef="Unit_USD">15277000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      id="ixv-22684"
      unitRef="Unit_USD">15278000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2022To12_31_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-22685"
      unitRef="Unit_USD">-20275000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      id="ixv-22686"
      unitRef="Unit_USD">-20275000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="PAsOn12_31_2022_ConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="0"
      id="ixv-22687"
      unitRef="Unit_shares">1952</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="PAsOn12_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      id="ixv-22688"
      unitRef="Unit_shares">2240092</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-22689"
      unitRef="Unit_USD">2000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-22690"
      unitRef="Unit_USD">473628000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-22691"
      unitRef="Unit_USD">-467185000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      id="ixv-22692"
      unitRef="Unit_USD">6445000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="P01_01_2023To12_31_2023_PreferredStockMemberusgaapStatementEquityComponentsAxis_SeriesFPreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      id="ixv-22693"
      unitRef="Unit_shares">1</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockRedeemedOrCalledDuringPeriodShares
      contextRef="P01_01_2023To12_31_2023_PreferredStockMemberusgaapStatementEquityComponentsAxis"
      decimals="INF"
      id="ixv-22694"
      unitRef="Unit_shares">1</us-gaap:StockRedeemedOrCalledDuringPeriodShares>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="P01_01_2023To12_31_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-22695"
      unitRef="Unit_USD">569000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-22696"
      unitRef="Unit_USD">569000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="P01_01_2023To12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="INF"
      id="ixv-22697"
      unitRef="Unit_shares">2230493</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="P01_01_2023To12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-22698"
      unitRef="Unit_USD">3000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="P01_01_2023To12_31_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-22699"
      unitRef="Unit_USD">5002000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-22700"
      unitRef="Unit_USD">5005000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="P01_01_2023To12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="INF"
      id="ixv-22701"
      unitRef="Unit_shares">53381</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="P01_01_2023To12_31_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-22702"
      unitRef="Unit_USD">75000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-22703"
      unitRef="Unit_USD">75000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <pstv:FractionalAdjustmentOfCommonStock
      contextRef="P01_01_2023To12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="INF"
      id="ixv-22704"
      unitRef="Unit_shares">-1310</pstv:FractionalAdjustmentOfCommonStock>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="P01_01_2023To12_31_2023_TreasuryStockCommonMemberusgaapStatementEquityComponentsAxis"
      decimals="INF"
      id="ixv-22705"
      unitRef="Unit_shares">78559</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="P01_01_2023To12_31_2023_TreasuryStockCommonMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-22706"
      unitRef="Unit_USD">126000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-22707"
      unitRef="Unit_USD">126000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2023To12_31_2023_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-22708"
      unitRef="Unit_USD">-13316000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-22709"
      unitRef="Unit_USD">-13316000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="PAsOn12_31_2023_ConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="0"
      id="ixv-22710"
      unitRef="Unit_shares">1952</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="PAsOn12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      id="ixv-22711"
      unitRef="Unit_shares">4522656</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-22712"
      unitRef="Unit_USD">5000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="PAsOn12_31_2023_TreasuryStockCommonMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      id="ixv-22713"
      unitRef="Unit_shares">-78559</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2023_TreasuryStockCommonMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-22714"
      unitRef="Unit_USD">-126000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-22715"
      unitRef="Unit_USD">479274000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2023_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-22716"
      unitRef="Unit_USD">-480501000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-22717"
      unitRef="Unit_USD">-1348000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-22718"
      unitRef="Unit_USD">-13316000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      id="ixv-22719"
      unitRef="Unit_USD">-20275000</us-gaap:NetIncomeLoss>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-22720"
      unitRef="Unit_USD">628000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      id="ixv-22721"
      unitRef="Unit_USD">619000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-22722"
      unitRef="Unit_USD">190000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      id="ixv-22723"
      unitRef="Unit_USD">389000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <pstv:CommonStockIssuedForResearchAndDevelopment
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-22724"
      unitRef="Unit_USD">75000</pstv:CommonStockIssuedForResearchAndDevelopment>
    <pstv:CommonStockIssuedForResearchAndDevelopment
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      id="ixv-22725"
      unitRef="Unit_USD">0</pstv:CommonStockIssuedForResearchAndDevelopment>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-22726"
      unitRef="Unit_USD">0</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      id="ixv-22727"
      unitRef="Unit_USD">-1000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:GainLossOnDispositionOfAssets
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-22728"
      unitRef="Unit_USD">-2000</us-gaap:GainLossOnDispositionOfAssets>
    <us-gaap:GainLossOnDispositionOfAssets
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      id="ixv-22729"
      unitRef="Unit_USD">0</us-gaap:GainLossOnDispositionOfAssets>
    <us-gaap:ShareBasedCompensation
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-22730"
      unitRef="Unit_USD">569000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      id="ixv-22731"
      unitRef="Unit_USD">606000</us-gaap:ShareBasedCompensation>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-22732"
      unitRef="Unit_USD">117000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      id="ixv-22733"
      unitRef="Unit_USD">93000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-22734"
      unitRef="Unit_USD">-2397000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      id="ixv-22735"
      unitRef="Unit_USD">2369000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-22736"
      unitRef="Unit_USD">-3677000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      id="ixv-22737"
      unitRef="Unit_USD">6452000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-22738"
      unitRef="Unit_USD">-117000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      id="ixv-22739"
      unitRef="Unit_USD">-129000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <pstv:IncreaseDecreaseInDeferredGrantLiability
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-22740"
      unitRef="Unit_USD">281000</pstv:IncreaseDecreaseInDeferredGrantLiability>
    <pstv:IncreaseDecreaseInDeferredGrantLiability
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      id="ixv-22741"
      unitRef="Unit_USD">1643000</pstv:IncreaseDecreaseInDeferredGrantLiability>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-22742"
      unitRef="Unit_USD">-12851000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      id="ixv-22743"
      unitRef="Unit_USD">-12972000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <pstv:PaymentsToAcquirePropertyPlantAndEquipmentAndIntangibleAssets
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-22744"
      unitRef="Unit_USD">160000</pstv:PaymentsToAcquirePropertyPlantAndEquipmentAndIntangibleAssets>
    <pstv:PaymentsToAcquirePropertyPlantAndEquipmentAndIntangibleAssets
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      id="ixv-22745"
      unitRef="Unit_USD">509000</pstv:PaymentsToAcquirePropertyPlantAndEquipmentAndIntangibleAssets>
    <pstv:CashPaidForIPRDAssetAcquiredInAnAssetAcquisition
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-22746"
      unitRef="Unit_USD">0</pstv:CashPaidForIPRDAssetAcquiredInAnAssetAcquisition>
    <pstv:CashPaidForIPRDAssetAcquiredInAnAssetAcquisition
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      id="ixv-22747"
      unitRef="Unit_USD">250000</pstv:CashPaidForIPRDAssetAcquiredInAnAssetAcquisition>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-22748"
      unitRef="Unit_USD">-160000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      id="ixv-22749"
      unitRef="Unit_USD">-759000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-22750"
      unitRef="Unit_USD">1608000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      id="ixv-22751"
      unitRef="Unit_USD">1608000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-22752"
      unitRef="Unit_USD">5527000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      id="ixv-22753"
      unitRef="Unit_USD">15832000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-22754"
      unitRef="Unit_USD">348000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      id="ixv-22755"
      unitRef="Unit_USD">773000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:PaymentsForRepurchaseOfEquity
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-22756"
      unitRef="Unit_USD">126000</us-gaap:PaymentsForRepurchaseOfEquity>
    <us-gaap:PaymentsForRepurchaseOfEquity
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      id="ixv-22757"
      unitRef="Unit_USD">0</us-gaap:PaymentsForRepurchaseOfEquity>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-22758"
      unitRef="Unit_USD">3445000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      id="ixv-22759"
      unitRef="Unit_USD">13451000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-22760"
      unitRef="Unit_USD">-9566000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      id="ixv-22761"
      unitRef="Unit_USD">-280000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      id="ixv-22762"
      unitRef="Unit_USD">18120000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      id="ixv-22763"
      unitRef="Unit_USD">18400000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-22764"
      unitRef="Unit_USD">8554000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      id="ixv-22765"
      unitRef="Unit_USD">18120000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:InterestPaidNet
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-22766"
      unitRef="Unit_USD">222000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      id="ixv-22767"
      unitRef="Unit_USD">327000</us-gaap:InterestPaidNet>
    <pstv:UnpaidOfferingCosts
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-22768"
      unitRef="Unit_USD">174000</pstv:UnpaidOfferingCosts>
    <pstv:UnpaidOfferingCosts
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      id="ixv-22769"
      unitRef="Unit_USD">0</pstv:UnpaidOfferingCosts>
    <us-gaap:StockIssued1
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-22770"
      unitRef="Unit_USD">75000</us-gaap:StockIssued1>
    <us-gaap:StockIssued1
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      id="ixv-22771"
      unitRef="Unit_USD">0</us-gaap:StockIssued1>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-22772"
      unitRef="Unit_USD">71000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      id="ixv-22773"
      unitRef="Unit_USD">0</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="P01_01_2023To12_31_2023" id="ixv-14761">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;1. Organization and Operations &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;The Company &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company focused on the development, manufacture and commercialization of complex and innovative treatments for patients battling cancer and other life-threatening diseases. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Certain Risks and Uncertainties &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;The Company&#x2019;s prospects are subject to the risks and uncertainties frequently encountered by companies in the early stages of development and commercialization, especially those companies in rapidly evolving and technologically advanced industries such as the biotech/medical device field. The Company&#x2019;s future viability largely depends on its ability to complete development of new products and receive regulatory approvals for those products. No assurance can be given that the Company&#x2019;s new products will be successfully developed, regulatory approvals will be granted, or acceptance of these products will be achieved. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Going Concern &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;The Company incurred net losses of $13.3&#160;million for the year ended December&#160;31, 2023, and as of December&#160;31, 2023, the Company had an accumulated deficit of $480.5&#160;million and cash and cash equivalents of $8.6&#160;million. Additionally, the Company used net cash of $12.9&#160;million to fund its operating activities for the year ended December&#160;31, 2023. The Company&#x2019;s term loan has an outstanding principal of $0.8&#160;million principal and a $3.2&#160;million final payment fee due June 1, 2024 (Note 8). The Company expects that its research and development expenditures will increase in absolute dollars in 2024 and beyond. These factors raise substantial doubt about the Company&#x2019;s ability to continue as a going concern. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;As disclosed in more detail in Note 12, the Company has entered into various financing agreements and raised capital by issuing its common stock. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;Based on the Company&#x2019;s stockholders&#x2019; deficit of $1.3&#160;million as of December&#160;31, 2023, the Company does not meet the minimum stockholders&#x2019; equity requirement for continued listing on the Nasdaq Capital Market under Nasdaq Listing Rule 5550(b)(1). The Company expects to receive written notice from Nasdaq staff to that effect following the filing of the Annual Report on Form &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;10-K&lt;/div&gt; in which these financial statements are included. &lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;The Company continues to seek additional capital through strategic transactions and from other financing alternatives. Without additional capital, current working capital and cash generated from sales will not provide adequate funding to make debt repayments, for research, sales and marketing efforts and product development activities at their current levels. If sufficient capital is not raised, the Company will at a minimum need to significantly reduce or curtail its research and development and other operations, and this would negatively affect its ability to achieve corporate growth goals. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Should the Company fail to raise additional cash from outside sources, this would have a material adverse impact on its operations. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;The accompanying financial statements have been prepared assuming the Company will continue to operate as a going concern, which contemplates the realization of assets and settlement of liabilities in the normal course of business, and do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classifications of liabilities that may result from uncertainty related to its ability to continue as a going concern. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Amendments to Certificate of Incorporation and Reverse Stock Split &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;At the Annual Meeting of Stockholders of the Company held on April&#160;20, 2023 (the &#x201c;Annual Meeting&#x201d;), the stockholders of the Company approved an amendment to the Company&#x2019;s Amended and Restated Certificate of Incorporation to implement a reverse stock split of the Company&#x2019;s common stock, par value $0.001 per share, with the ratio to be determined by the Board of Directors (the &#x201c;Board&#x201d;) of the Company, within a range of not less than &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="-sec-ix-hidden:hidden116200119;display:inline;"&gt;1-for-3&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; and not greater than &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="-sec-ix-hidden:hidden116200122;display:inline;"&gt;1-for-15&lt;/div&gt;.&lt;/div&gt;&lt;/div&gt; Subsequently, on April&#160;21, 2023, the Board determined to fix the ratio for the reverse stock split at &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="-sec-ix-hidden:hidden116200127;display:inline;"&gt;1-for-15&lt;/div&gt;,&lt;/div&gt;&lt;/div&gt; without any change to its par value (the &#x201c;Reverse Stock Split&#x201d;). &lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;On April&#160;27, 2023, following stockholder and Board approval, the Company filed a Certificate of Amendment to its Charter (the &#x201c;Amendment&#x201d;), with the Secretary of State of the State of Delaware to effectuate the Reverse Stock Split. The Amendment became effective on May&#160;1, 2023. Upon effectiveness of the Reverse Stock Split, the number of shares of the Company&#x2019;s common stock (x)&#160;issued and outstanding decreased from approximately 37.4&#160;million shares to approximately 2.5&#160;million shares; (y)&#160;reserved for issuance upon exercise of outstanding warrants and options decreased from approximately 2.0&#160;million shares to approximately 0.1&#160;million shares, and (z)&#160;reserved but unallocated under the Company&#x2019;s current equity incentive plans decreased from approximately 3.0&#160;million common shares to approximately 0.2&#160;million common shares. The Company&#x2019;s common stock began trading on the NASDAQ Capital Market on a post-split basis on May&#160;1, 2023. The Company&#x2019;s 5,000,000 shares of authorized Preferred Stock were not affected by the Reverse Stock Split. No fractional shares were issued in connection with the Reverse Stock Split, and accordingly, the outstanding number of shares post Reverse Stock Split was adjusted down by approximately 1,310 (post-effect of Reverse Stock Split) shares. Proportional adjustments for the reverse &lt;div style="display:inline;"&gt;stock split&lt;/div&gt; were made to the Company&#x2019;s outstanding stock options, warrants and equity incentive plans for all periods presented in the financial statements in this Form &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;10-K.&lt;/div&gt; The Company&#x2019;s financial statements, and all references thereto have been retroactively adjusted to reflect the reverse split unless specifically stated otherwise. &lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2023To12_31_2023"
      decimals="-5"
      id="ixv-22774"
      unitRef="Unit_USD">-13300000</us-gaap:NetIncomeLoss>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="PAsOn12_31_2023"
      decimals="-5"
      id="ixv-22775"
      unitRef="Unit_USD">-480500000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="PAsOn12_31_2023"
      decimals="-5"
      id="ixv-22776"
      unitRef="Unit_USD">8600000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="P01_01_2023To12_31_2023"
      decimals="-5"
      id="ixv-22777"
      unitRef="Unit_USD">-12900000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <pstv:LongTermDebtOutstandingThresholdAmount
      contextRef="P01_01_2023To12_31_2023_TermLoanMemberusgaapDebtInstrumentAxis"
      decimals="-5"
      id="ixv-22778"
      unitRef="Unit_USD">800000</pstv:LongTermDebtOutstandingThresholdAmount>
    <us-gaap:DebtInstrumentFeeAmount
      contextRef="PAsOn12_31_2023_TermLoanMemberusgaapDebtInstrumentAxis"
      decimals="-5"
      id="ixv-22779"
      unitRef="Unit_USD">3200000</us-gaap:DebtInstrumentFeeAmount>
    <us-gaap:DebtInstrumentMaturityDate
      contextRef="P01_01_2023To12_31_2023_TermLoanMemberusgaapDebtInstrumentAxis"
      id="ixv-22780">2024-06-01</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2023"
      decimals="-5"
      id="ixv-22781"
      unitRef="Unit_USD">-1300000</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="PAsOn04_04_2023"
      decimals="INF"
      id="ixv-22782"
      unitRef="Unit_USD_per_Share">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesIssued
      contextRef="PAsOn04_30_2023"
      decimals="INF"
      id="ixv-22783"
      unitRef="Unit_shares">37400000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="PAsOn05_01_2023"
      decimals="INF"
      id="ixv-22784"
      unitRef="Unit_shares">2500000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="PAsOn04_30_2023_OutstandingWarrantsAndOptionsMemberusgaapStatementEquityComponentsAxis"
      decimals="INF"
      id="ixv-22785"
      unitRef="Unit_shares">2000000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="PAsOn05_01_2023_OutstandingWarrantsAndOptionsMemberusgaapStatementEquityComponentsAxis"
      decimals="INF"
      id="ixv-22786"
      unitRef="Unit_shares">100000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="PAsOn04_30_2023_EquityIncentivePlansMemberusgaapPlanNameAxis"
      decimals="INF"
      id="ixv-22787"
      unitRef="Unit_shares">3000000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="PAsOn05_01_2023_EquityIncentivePlansMemberusgaapPlanNameAxis"
      decimals="INF"
      id="ixv-22788"
      unitRef="Unit_shares">200000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="PAsOn12_31_2023"
      decimals="INF"
      id="ixv-22789"
      unitRef="Unit_shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:StockIssuedDuringPeriodSharesStockSplits
      contextRef="P01_01_2023To12_31_2023"
      decimals="INF"
      id="ixv-22790"
      unitRef="Unit_shares">0</us-gaap:StockIssuedDuringPeriodSharesStockSplits>
    <us-gaap:StockIssuedDuringPeriodSharesReverseStockSplits
      contextRef="P01_01_2023To12_31_2023"
      decimals="INF"
      id="ixv-22791"
      unitRef="Unit_shares">1310</us-gaap:StockIssuedDuringPeriodSharesReverseStockSplits>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="P01_01_2023To12_31_2023" id="ixv-14820">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;2. Summary of Significant Accounting Policies &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Use of Estimates &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;The preparation of financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions affecting the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenue and expenses during the reporting period. The most significant estimates and critical accounting policies involve reviewing assets for impairment, and determining the assumptions used in measuring share-based compensation expense. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Actual results could differ from these estimates. Management&#x2019;s estimates and assumptions are reviewed regularly, and the effects of revisions are reflected in the financial statements in the periods they are determined to be necessary. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Cash and cash equivalents &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;The Company considers all highly liquid investments with maturities of three months or less at the time of purchase to be cash equivalents. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Cash and cash equivalents include cash in readily available checking, savings accounts and money market accounts. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. The Company has not experienced any losses in such accounts and believes it is not exposed to significant risk on its cash balances due to the financial position of the depository institution in which those deposits are held. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Financial Instruments &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Financial instruments include cash equivalents, other current assets, accounts payable, accrued expenses, other liabilities and long-term debt. The carrying values of cash equivalents, other current assets, accounts payable, &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;accrued expenses and other liabilities generally approximate fair value due to the short-term nature of these instruments. Based on level 3 inputs and the borrowing rates currently available for loans with similar terms, the Company believes the fair value of the long-term debt is &lt;div style="display:inline;"&gt;materially &lt;/div&gt;consistent with its carrying value. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Property and Equipment &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Property and equipment are stated at cost, net of accumulated depreciation. Depreciation expense, which includes the amortization of capitalized leasehold improvements, is provided for on a straight-line basis over the estimated useful lives of the assets, or the life of the lease, whichever is shorter, and range from &lt;div style="-sec-ix-hidden:hidden116200141;display:inline;"&gt;three&lt;/div&gt; to five years. When assets are sold or otherwise disposed of, the cost and related accumulated depreciation are removed from the accounts and the resulting gain or loss, if any, is included in operations. Maintenance and repairs are charged to operations as incurred. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Impairment &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;The Company assesses its property and equipment for potential impairment when there is a change in circumstances that indicates carrying values of assets may not be recoverable. Such long-lived assets are deemed to be impaired when the undiscounted cash flows expected to be generated by the asset (or asset group) are less than the asset&#x2019;s carrying amount. Any required impairment loss would be measured as the amount by which the asset&#x2019;s carrying value exceeds its fair value and would be recorded as a reduction in the carrying value of the related asset and a charge to operating expense. The Company recognized no impairment losses during any of the periods presented in these financial statements. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Goodwill &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;The Company&#x2019;s goodwill represents the excess of the cost over the fair value of net assets acquired from its business combinations. The determination of the value of goodwill arising from business combinations requires extensive use of accounting estimates and judgments to allocate the purchase price to the fair value of the net tangible and intangible assets acquired. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Goodwill is not amortized; however, it is assessed for impairment using fair value measurement techniques on an annual basis or more frequently if facts and circumstance warrant such a review. Goodwill is considered to be impaired if the Company determines that the carrying value of the reporting unit exceeds its fair value. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;The Company performs its impairment test annually during the fourth quarter by comparing the Company&#x2019;s estimated fair value, calculated from the Company&#x2019;s market capitalization, to its carrying amount. The Company&#x2019;s annual evaluation for impairment of goodwill consists of one reporting unit. The Company completed its most recent annual evaluation for impairment as of December&#160;31, 2023, when the Company had stockholders&#x2019; deficit within its sole reporting unit of approximately $1.3&#160;million, and concluded that no impairment existed. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Grant Revenue Recognition &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;In applying the provisions of Accounting Standards Codification (&#x201c;ASC&#x201d;) Topic 606, Revenue from Contracts with Customers (&#x201c;ASC 606&#x201d;), the Company has determined that government grants are out of the scope of ASC 606 because the funding entities do not meet the definition of a &#x201c;customer,&#x201d; as defined by ASC 606, as there is not considered to be a transfer of control of goods or services. With respect to the grant, the Company determines if it is a collaboration arrangement in accordance with ASC Topic 808, Collaborative Arrangements (&#x201c;ASC 808&#x201d;). For grants outside the scope of ASC 808, the Company applies International Accounting Standards No.&#160;20, Accounting for Government Grants and Disclosure of Government Assistance, by analogy, and revenue is recognized when the Company incurs expenses related to the grant for the amount the Company is entitled to under the provisions of the contract. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;The Company also considers the guidance in ASC Topic 730, Research and Development (&#x201c;ASC 730&#x201d;), which requires an assessment, at the inception of the grant, of whether the agreement is a liability. If the Company is obligated to repay funds received regardless of the outcome of the related research and development activities, then the Company is required to estimate and recognize that liability. Alternatively, if the Company is not required to repay the funds, then payments received are recorded as revenue or contra-expense as the expenses are incurred. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Deferred grant liability represents grant funds received or receivable for which the allowable expenses have not yet been incurred as of the balance sheet date. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Research and Development &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;Research and development expenditures, which are charged to operations in the period incurred, include costs associated with the design, development, testing and enhancement of the Company&#x2019;s products, regulatory fees, the purchase of laboratory supplies, and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;pre-clinical&lt;/div&gt; and clinical studies as well as salaries and benefits for the Company&#x2019;s research and development employees. &lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Acquired &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;In-Process&lt;/div&gt; Research and Development (IPR&amp;amp;D) &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Acquired IPR&amp;amp;D represents the value assigned to research and development assets that have not reached technological feasibility. Upon the acquisition of IPR&amp;amp;D, the Company completes an assessment of whether the acquisition constitutes the purchase of a single asset or group of assets. The Company considers multiple factors in this assessment, including the nature of the technology acquired, the presence or absence of separate cash flows, the development process and stage of completion, quantitative significance, and the Company&#x2019;s rationale for entering into the transaction. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;The Company tests IPR&amp;amp;D assets for impairment as of December&#160;31 of each year or more frequently if indicators of impairment are present. The authoritative accounting guidance provides an optional qualitative assessment for any indicators that indefinite-lived intangible assets are impaired. If it is determined that it is more likely than not that the indefinite-lived intangible assets, including IPR&amp;amp;D, are impaired, the fair value of the indefinite-lived intangible assets is compared with the carrying amount and impairment is recorded for any excess of the carrying amount over the fair value of the indefinite-lived intangible assets. There was no impairment of the Company&#x2019;s IPR&amp;amp;D assets during 2023 or 2022. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Deferred Financing Costs and Other Debt-Related Costs &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Deferred financing costs are capitalized, recorded as an offset to debt balances and amortized to interest expense over the term of the associated debt instrument using the effective interest method. If the maturity of the debt is accelerated because of default or early debt repayment, then the amortization would be accelerated. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Income Taxes &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carry forwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income (loss) in the years in which those temporary differences are expected to be recovered or settled. Due to our history of losses, a full valuation allowance has been recognized against our deferred tax assets. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;The Company&#x2019;s policy is to recognize interest and penalties related to income tax matters in income tax expense. For the years ended December&#160;31, 2023 and 2022, the Company has not recorded any interest or penalties related to income tax matters. The Company does not foresee any material changes to unrecognized tax benefits within the next twelve months. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Share-Based Compensation &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;The Company recognizes the fair value of all share-based payment awards in our statements of operations over the requisite vesting period of each award, which approximates the period during which the employee and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;non-employee&lt;/div&gt; director is required to provide service in exchange for the award. The Company estimates the fair value of these options using the Black-Scholes option pricing model using assumptions for expected volatility, expected term, and risk-free interest rate. Expected volatility is based primarily on historical volatility and is computed using daily pricing observations for recent periods that correspond to the expected term of the options. The expected term represents the period of time that options are expected to be outstanding. Because the Company does not have historical exercise behavior, it determines the expected life assumption using the simplified method which is an average of the contractual term of the option and its vesting period. The risk-free interest rate is the interest rate for treasury instruments with maturities that approximate the expected term. &lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Segment Information &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;For the years ended December&#160;31, 2023 and 2022, the Company is managed as a single operating segment, and therefore reports its results in one operating segment. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Loss Per Share &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Basic per share data is computed by dividing net income or loss applicable to common stockholders by the weighted average number of common shares outstanding during the period. Diluted per share data is computed by dividing net income or loss applicable to common stockholders by the weighted average number of common shares outstanding during the period increased to include, if dilutive, the number of additional common shares that would have been outstanding as calculated using the treasury stock method. Potential common shares were related entirely to outstanding but unexercised options, warrants and convertible preferred stocks for all periods presented. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;The Company excluded all potentially dilutive securities from the calculation of diluted loss per share attributable to common stockholders for the years ended December&#160;31, 2023 and 2022, as their inclusion would be antidilutive. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Concentration Risk &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Although the Company&#x2019;s contracts with its vendors are not exclusive, the Company currently uses sole source providers for core materials used in its clinical trials. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Recently Issued Accounting Pronouncements &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;In June 2016, the FASB issued ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;2016-13,&lt;/div&gt; Financial Instruments&#x2014;Credit Losses (Topic 326), Measurement of Credit Losses on Financial Instruments. The standard amends the impairment model by requiring entities to use a forward-looking approach based on expected losses to estimate credit losses for most financial assets and certain other instruments that are not measured at fair value through net income. For &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;available-for-sale&lt;/div&gt;&lt;/div&gt; debt securities, entities will be required to recognize an allowance for credit losses rather than a reduction in carrying value of the asset. Entities will no longer be permitted to consider the length of time that fair value has been less than amortized cost when evaluating when credit losses should be recognized. This new guidance is effective in the first quarter of 2023 for calendar-year SEC filers that are smaller reporting companies as of the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;one-time&lt;/div&gt; determination date. Early adoption was permitted beginning in 2019. The Company adopted the new guidance as of January 1, 2023, which did not have a material impact on its financial statements and related disclosures. &lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:UseOfEstimates contextRef="P01_01_2023To12_31_2023" id="ixv-14824">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Use of Estimates &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;The preparation of financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions affecting the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenue and expenses during the reporting period. The most significant estimates and critical accounting policies involve reviewing assets for impairment, and determining the assumptions used in measuring share-based compensation expense. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Actual results could differ from these estimates. Management&#x2019;s estimates and assumptions are reviewed regularly, and the effects of revisions are reflected in the financial statements in the periods they are determined to be necessary. &lt;/div&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="P01_01_2023To12_31_2023" id="ixv-14832">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Cash and cash equivalents &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;The Company considers all highly liquid investments with maturities of three months or less at the time of purchase to be cash equivalents. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Cash and cash equivalents include cash in readily available checking, savings accounts and money market accounts. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. The Company has not experienced any losses in such accounts and believes it is not exposed to significant risk on its cash balances due to the financial position of the depository institution in which those deposits are held. &lt;/div&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="P01_01_2023To12_31_2023" id="ixv-14840">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Financial Instruments &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Financial instruments include cash equivalents, other current assets, accounts payable, accrued expenses, other liabilities and long-term debt. The carrying values of cash equivalents, other current assets, accounts payable, &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;accrued expenses and other liabilities generally approximate fair value due to the short-term nature of these instruments. Based on level 3 inputs and the borrowing rates currently available for loans with similar terms, the Company believes the fair value of the long-term debt is &lt;div style="display:inline;"&gt;materially &lt;/div&gt;consistent with its carrying value. &lt;/div&gt;&lt;/div&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="P01_01_2023To12_31_2023" id="ixv-14864">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Property and Equipment &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Property and equipment are stated at cost, net of accumulated depreciation. Depreciation expense, which includes the amortization of capitalized leasehold improvements, is provided for on a straight-line basis over the estimated useful lives of the assets, or the life of the lease, whichever is shorter, and range from &lt;div style="-sec-ix-hidden:hidden116200141;display:inline;"&gt;three&lt;/div&gt; to five years. When assets are sold or otherwise disposed of, the cost and related accumulated depreciation are removed from the accounts and the resulting gain or loss, if any, is included in operations. Maintenance and repairs are charged to operations as incurred. &lt;/div&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="PAsOn12_31_2023_MaximumMembersrtRangeAxis"
      id="ixv-22793">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentImpairment contextRef="P01_01_2023To12_31_2023" id="ixv-14871">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Impairment &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;The Company assesses its property and equipment for potential impairment when there is a change in circumstances that indicates carrying values of assets may not be recoverable. Such long-lived assets are deemed to be impaired when the undiscounted cash flows expected to be generated by the asset (or asset group) are less than the asset&#x2019;s carrying amount. Any required impairment loss would be measured as the amount by which the asset&#x2019;s carrying value exceeds its fair value and would be recorded as a reduction in the carrying value of the related asset and a charge to operating expense. The Company recognized no impairment losses during any of the periods presented in these financial statements. &lt;/div&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentImpairment>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse
      contextRef="P01_01_2022To12_31_2022"
      decimals="0"
      id="ixv-22794"
      unitRef="Unit_USD">0</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse
      contextRef="P01_01_2023To12_31_2023"
      decimals="0"
      id="ixv-22795"
      unitRef="Unit_USD">0</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock contextRef="P01_01_2023To12_31_2023" id="ixv-14877">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Goodwill &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;The Company&#x2019;s goodwill represents the excess of the cost over the fair value of net assets acquired from its business combinations. The determination of the value of goodwill arising from business combinations requires extensive use of accounting estimates and judgments to allocate the purchase price to the fair value of the net tangible and intangible assets acquired. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Goodwill is not amortized; however, it is assessed for impairment using fair value measurement techniques on an annual basis or more frequently if facts and circumstance warrant such a review. Goodwill is considered to be impaired if the Company determines that the carrying value of the reporting unit exceeds its fair value. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;The Company performs its impairment test annually during the fourth quarter by comparing the Company&#x2019;s estimated fair value, calculated from the Company&#x2019;s market capitalization, to its carrying amount. The Company&#x2019;s annual evaluation for impairment of goodwill consists of one reporting unit. The Company completed its most recent annual evaluation for impairment as of December&#160;31, 2023, when the Company had stockholders&#x2019; deficit within its sole reporting unit of approximately $1.3&#160;million, and concluded that no impairment existed. &lt;/div&gt;&lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock>
    <us-gaap:NumberOfReportingUnits
      contextRef="P01_01_2023To12_31_2023"
      decimals="INF"
      id="ixv-22796"
      unitRef="Unit_ReportableUnit">1</us-gaap:NumberOfReportingUnits>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2023"
      decimals="-5"
      id="ixv-22797"
      unitRef="Unit_USD">-1300000</us-gaap:StockholdersEquity>
    <us-gaap:AssetImpairmentCharges
      contextRef="P01_01_2023To12_31_2023"
      decimals="INF"
      id="ixv-22798"
      unitRef="Unit_USD">0</us-gaap:AssetImpairmentCharges>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock contextRef="P01_01_2023To12_31_2023" id="ixv-14887">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Grant Revenue Recognition &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;In applying the provisions of Accounting Standards Codification (&#x201c;ASC&#x201d;) Topic 606, Revenue from Contracts with Customers (&#x201c;ASC 606&#x201d;), the Company has determined that government grants are out of the scope of ASC 606 because the funding entities do not meet the definition of a &#x201c;customer,&#x201d; as defined by ASC 606, as there is not considered to be a transfer of control of goods or services. With respect to the grant, the Company determines if it is a collaboration arrangement in accordance with ASC Topic 808, Collaborative Arrangements (&#x201c;ASC 808&#x201d;). For grants outside the scope of ASC 808, the Company applies International Accounting Standards No.&#160;20, Accounting for Government Grants and Disclosure of Government Assistance, by analogy, and revenue is recognized when the Company incurs expenses related to the grant for the amount the Company is entitled to under the provisions of the contract. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;The Company also considers the guidance in ASC Topic 730, Research and Development (&#x201c;ASC 730&#x201d;), which requires an assessment, at the inception of the grant, of whether the agreement is a liability. If the Company is obligated to repay funds received regardless of the outcome of the related research and development activities, then the Company is required to estimate and recognize that liability. Alternatively, if the Company is not required to repay the funds, then payments received are recorded as revenue or contra-expense as the expenses are incurred. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Deferred grant liability represents grant funds received or receivable for which the allowable expenses have not yet been incurred as of the balance sheet date. &lt;/div&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="P01_01_2023To12_31_2023" id="ixv-14912">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Research and Development &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;Research and development expenditures, which are charged to operations in the period incurred, include costs associated with the design, development, testing and enhancement of the Company&#x2019;s products, regulatory fees, the purchase of laboratory supplies, and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;pre-clinical&lt;/div&gt; and clinical studies as well as salaries and benefits for the Company&#x2019;s research and development employees. &lt;/div&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:InProcessResearchAndDevelopmentPolicy contextRef="P01_01_2023To12_31_2023" id="ixv-14918">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Acquired &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;In-Process&lt;/div&gt; Research and Development (IPR&amp;amp;D) &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Acquired IPR&amp;amp;D represents the value assigned to research and development assets that have not reached technological feasibility. Upon the acquisition of IPR&amp;amp;D, the Company completes an assessment of whether the acquisition constitutes the purchase of a single asset or group of assets. The Company considers multiple factors in this assessment, including the nature of the technology acquired, the presence or absence of separate cash flows, the development process and stage of completion, quantitative significance, and the Company&#x2019;s rationale for entering into the transaction. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;The Company tests IPR&amp;amp;D assets for impairment as of December&#160;31 of each year or more frequently if indicators of impairment are present. The authoritative accounting guidance provides an optional qualitative assessment for any indicators that indefinite-lived intangible assets are impaired. If it is determined that it is more likely than not that the indefinite-lived intangible assets, including IPR&amp;amp;D, are impaired, the fair value of the indefinite-lived intangible assets is compared with the carrying amount and impairment is recorded for any excess of the carrying amount over the fair value of the indefinite-lived intangible assets. There was no impairment of the Company&#x2019;s IPR&amp;amp;D assets during 2023 or 2022. &lt;/div&gt;&lt;/div&gt;</us-gaap:InProcessResearchAndDevelopmentPolicy>
    <us-gaap:AssetImpairmentCharges
      contextRef="P01_01_2022To12_31_2022_InProcessResearchAndDevelopmentMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis"
      decimals="INF"
      id="ixv-22800"
      unitRef="Unit_USD">0</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges
      contextRef="P01_01_2023To12_31_2023_InProcessResearchAndDevelopmentMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis"
      decimals="INF"
      id="ixv-22801"
      unitRef="Unit_USD">0</us-gaap:AssetImpairmentCharges>
    <us-gaap:DebtPolicyTextBlock contextRef="P01_01_2023To12_31_2023" id="ixv-14926">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Deferred Financing Costs and Other Debt-Related Costs &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Deferred financing costs are capitalized, recorded as an offset to debt balances and amortized to interest expense over the term of the associated debt instrument using the effective interest method. If the maturity of the debt is accelerated because of default or early debt repayment, then the amortization would be accelerated. &lt;/div&gt;&lt;/div&gt;</us-gaap:DebtPolicyTextBlock>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="P01_01_2023To12_31_2023" id="ixv-14932">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Income Taxes &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carry forwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income (loss) in the years in which those temporary differences are expected to be recovered or settled. Due to our history of losses, a full valuation allowance has been recognized against our deferred tax assets. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;The Company&#x2019;s policy is to recognize interest and penalties related to income tax matters in income tax expense. For the years ended December&#160;31, 2023 and 2022, the Company has not recorded any interest or penalties related to income tax matters. The Company does not foresee any material changes to unrecognized tax benefits within the next twelve months. &lt;/div&gt;&lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:IncomeTaxExaminationPenaltiesAndInterestExpense
      contextRef="P01_01_2022To12_31_2022"
      decimals="INF"
      id="ixv-22802"
      unitRef="Unit_USD">0</us-gaap:IncomeTaxExaminationPenaltiesAndInterestExpense>
    <us-gaap:IncomeTaxExaminationPenaltiesAndInterestExpense
      contextRef="P01_01_2023To03_31_2023"
      decimals="INF"
      id="ixv-22803"
      unitRef="Unit_USD">0</us-gaap:IncomeTaxExaminationPenaltiesAndInterestExpense>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="P01_01_2023To12_31_2023" id="ixv-14953">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Share-Based Compensation &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;The Company recognizes the fair value of all share-based payment awards in our statements of operations over the requisite vesting period of each award, which approximates the period during which the employee and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;non-employee&lt;/div&gt; director is required to provide service in exchange for the award. The Company estimates the fair value of these options using the Black-Scholes option pricing model using assumptions for expected volatility, expected term, and risk-free interest rate. Expected volatility is based primarily on historical volatility and is computed using daily pricing observations for recent periods that correspond to the expected term of the options. The expected term represents the period of time that options are expected to be outstanding. Because the Company does not have historical exercise behavior, it determines the expected life assumption using the simplified method which is an average of the contractual term of the option and its vesting period. The risk-free interest rate is the interest rate for treasury instruments with maturities that approximate the expected term. &lt;/div&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock contextRef="P01_01_2023To12_31_2023" id="ixv-14959">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Segment Information &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;For the years ended December&#160;31, 2023 and 2022, the Company is managed as a single operating segment, and therefore reports its results in one operating segment. &lt;/div&gt;&lt;/div&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="P01_01_2022To12_31_2022"
      decimals="INF"
      id="ixv-22805"
      unitRef="Unit_Segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:NumberOfOperatingSegments
      contextRef="P01_01_2023To12_31_2023"
      decimals="INF"
      id="ixv-22806"
      unitRef="Unit_Segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="P01_01_2023To12_31_2023" id="ixv-14965">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Loss Per Share &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Basic per share data is computed by dividing net income or loss applicable to common stockholders by the weighted average number of common shares outstanding during the period. Diluted per share data is computed by dividing net income or loss applicable to common stockholders by the weighted average number of common shares outstanding during the period increased to include, if dilutive, the number of additional common shares that would have been outstanding as calculated using the treasury stock method. Potential common shares were related entirely to outstanding but unexercised options, warrants and convertible preferred stocks for all periods presented. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;The Company excluded all potentially dilutive securities from the calculation of diluted loss per share attributable to common stockholders for the years ended December&#160;31, 2023 and 2022, as their inclusion would be antidilutive. &lt;/div&gt;&lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ConcentrationRiskCreditRisk contextRef="P01_01_2023To12_31_2023" id="ixv-14973">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Concentration Risk &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Although the Company&#x2019;s contracts with its vendors are not exclusive, the Company currently uses sole source providers for core materials used in its clinical trials. &lt;/div&gt;&lt;/div&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="P01_01_2023To12_31_2023" id="ixv-14979">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Recently Issued Accounting Pronouncements &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;In June 2016, the FASB issued ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;2016-13,&lt;/div&gt; Financial Instruments&#x2014;Credit Losses (Topic 326), Measurement of Credit Losses on Financial Instruments. The standard amends the impairment model by requiring entities to use a forward-looking approach based on expected losses to estimate credit losses for most financial assets and certain other instruments that are not measured at fair value through net income. For &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;available-for-sale&lt;/div&gt;&lt;/div&gt; debt securities, entities will be required to recognize an allowance for credit losses rather than a reduction in carrying value of the asset. Entities will no longer be permitted to consider the length of time that fair value has been less than amortized cost when evaluating when credit losses should be recognized. This new guidance is effective in the first quarter of 2023 for calendar-year SEC filers that are smaller reporting companies as of the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;one-time&lt;/div&gt; determination date. Early adoption was permitted beginning in 2019. The Company adopted the new guidance as of January 1, 2023, which did not have a material impact on its financial statements and related disclosures. &lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted
      contextRef="PAsOn12_31_2023_AccountingStandardsUpdate201613MemberusgaapAdjustmentsForNewAccountingPronouncementsAxis"
      id="ixv-22807">true</us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted>
    <us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate
      contextRef="PAsOn12_31_2023_AccountingStandardsUpdate201613MemberusgaapAdjustmentsForNewAccountingPronouncementsAxis"
      id="ixv-22808">2023-01-01</us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate>
    <us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect
      contextRef="PAsOn12_31_2023_AccountingStandardsUpdate201613MemberusgaapAdjustmentsForNewAccountingPronouncementsAxis"
      id="ixv-22809">true</us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect>
    <us-gaap:FairValueMeasurementInputsDisclosureTextBlock contextRef="P01_01_2023To12_31_2023" id="ixv-14988">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;3. Fair Value Measurements &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Fair value measurements are market-based measurements, not entity-specific measurements. Therefore, fair value measurements are determined based on the assumptions that market participants would use in pricing the &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;asset or liability. The Company follows a three-level hierarchy to prioritize the inputs used in the valuation techniques to derive fair values. The basis for fair value measurements for each level within the hierarchy is described below: &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentColor; border-image: none; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 3%; vertical-align: top;text-align:left;"&gt;&#x2022;&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: top;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top;text-align:left;"&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Level&#160;1: Quoted prices in active markets for identical assets or liabilities. &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear:both;max-height:0pt;"&gt;&lt;/div&gt;&lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentColor; border-image: none; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 3%; vertical-align: top;text-align:left;"&gt;&#x2022;&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: top;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top;text-align:left;"&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Level&#160;2: Quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar instruments in markets that are not active; and model-derived valuations in which all significant inputs are observable in active markets. &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear:both;max-height:0pt;"&gt;&lt;/div&gt;&lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentColor; border-image: none; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 3%; vertical-align: top;text-align:left;"&gt;&#x2022;&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: top;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top;text-align:left;"&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Level&#160;3: Valuations derived from valuation techniques in which one or more significant inputs are unobservable in active markets. &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear:both;max-height:0pt;"&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;The Company has investments in money market accounts, which are included in cash and cash equivalents on the balance sheets. Fair value inputs for these investments are considered Level&#160;1 measurements within the fair value hierarchy since money market account fair values are known and observable through daily published floating net asset values. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;The following table summarizes the Company&#x2019;s fair value hierarchy for its financial assets measured at fair value on a recurring basis as of December&#160;31, 2023 and December&#160;31, 2022, respectively. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 92%; font-family: Times New Roman; font-size: 8pt; border-collapse: collapse;"&gt;
&lt;tr&gt;
&lt;td style="width: 56%;"&gt;&lt;/td&gt;
&lt;td style="width: 4%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="width: 4%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="width: 4%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="width: 4%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="14" style="vertical-align: bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Fair Value Measurements Using&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As of December&#160;31, 2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Fair Value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&#160;1&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&#160;2&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&#160;3&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Money market&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;5,448,990&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;5,448,990&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td style="height: 12pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td colspan="16" style="height: 12pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="14" style="vertical-align: bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Fair Value Measurements Using&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As of December&#160;31, 2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Fair Value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&#160;1&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&#160;2&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&#160;3&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Money market&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;17,573,584&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;17,573,584&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear:both;max-height:0pt;"&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Nonfinancial Assets and Liabilities &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;The Company applies fair value techniques on a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;non-recurring&lt;/div&gt; basis, if and when necessary, associated with: (1)&#160;valuing potential impairment losses related to goodwill which are accounted for pursuant to the authoritative guidance for intangibles&#x2014;goodwill and other; and (2)&#160;valuing potential impairment losses related to long-lived assets which are accounted for pursuant to the authoritative guidance for property, plant and equipment. &lt;/div&gt;</us-gaap:FairValueMeasurementInputsDisclosureTextBlock>
    <us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock contextRef="P01_01_2023To12_31_2023" id="ixv-15044">&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;The following table summarizes the Company&#x2019;s fair value hierarchy for its financial assets measured at fair value on a recurring basis as of December&#160;31, 2023 and December&#160;31, 2022, respectively. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 92%; font-family: Times New Roman; font-size: 8pt; border-collapse: collapse;"&gt;
&lt;tr&gt;
&lt;td style="width: 56%;"&gt;&lt;/td&gt;
&lt;td style="width: 4%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="width: 4%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="width: 4%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="width: 4%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="14" style="vertical-align: bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Fair Value Measurements Using&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As of December&#160;31, 2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Fair Value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&#160;1&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&#160;2&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&#160;3&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Money market&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;5,448,990&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;5,448,990&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td style="height: 12pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td colspan="16" style="height: 12pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="14" style="vertical-align: bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Fair Value Measurements Using&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As of December&#160;31, 2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Fair Value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&#160;1&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&#160;2&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&#160;3&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Money market&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;17,573,584&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;17,573,584&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="PAsOn12_31_2023_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapCashAndCashEquivalentsAxis"
      decimals="0"
      id="ixv-22811"
      unitRef="Unit_USD">5448990</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="PAsOn12_31_2023_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapCashAndCashEquivalentsAxis"
      decimals="0"
      id="ixv-22812"
      unitRef="Unit_USD">5448990</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="PAsOn12_31_2022_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapCashAndCashEquivalentsAxis"
      decimals="0"
      id="ixv-22813"
      unitRef="Unit_USD">17573584</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="PAsOn12_31_2022_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapCashAndCashEquivalentsAxis"
      decimals="0"
      id="ixv-22814"
      unitRef="Unit_USD">17573584</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:EarningsPerShareTextBlock contextRef="P01_01_2023To12_31_2023" id="ixv-15179">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;4. Loss per Share &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;The following were excluded from the diluted loss per share calculation for the periods presented because their effect would be anti-dilutive: &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 76%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;"&gt;
&lt;tr&gt;
&lt;td style="width: 74%;"&gt;&lt;/td&gt;
&lt;td style="width: 3%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="width: 3%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;For&#160;the&#160;Year&#160;Ended&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Outstanding stock options&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;140,109&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;78,334&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Preferred stock&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;28,190&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;28,190&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Outstanding warrants&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;142,733&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;142,758&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;311,032&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;249,282&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="P01_01_2023To12_31_2023" id="ixv-15183">&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;The following were excluded from the diluted loss per share calculation for the periods presented because their effect would be anti-dilutive: &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 76%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;"&gt;
&lt;tr&gt;
&lt;td style="width: 74%;"&gt;&lt;/td&gt;
&lt;td style="width: 3%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="width: 3%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;For&#160;the&#160;Year&#160;Ended&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Outstanding stock options&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;140,109&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;78,334&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Preferred stock&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;28,190&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;28,190&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Outstanding warrants&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;142,733&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;142,758&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;311,032&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;249,282&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P01_01_2023To12_31_2023_OptionsMemberusgaapStatementEquityComponentsAxis"
      decimals="INF"
      id="ixv-22815"
      unitRef="Unit_shares">140109</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P01_01_2022To12_31_2022_OptionsMemberusgaapStatementEquityComponentsAxis"
      decimals="INF"
      id="ixv-22816"
      unitRef="Unit_shares">78334</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P01_01_2023To12_31_2023_PreferredStockMemberusgaapStatementEquityComponentsAxis"
      decimals="INF"
      id="ixv-22817"
      unitRef="Unit_shares">28190</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P01_01_2022To12_31_2022_PreferredStockMemberusgaapStatementEquityComponentsAxis"
      decimals="INF"
      id="ixv-22818"
      unitRef="Unit_shares">28190</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P01_01_2023To12_31_2023_WarrantMemberusgaapStatementEquityComponentsAxis"
      decimals="INF"
      id="ixv-22819"
      unitRef="Unit_shares">142733</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P01_01_2022To12_31_2022_WarrantMemberusgaapStatementEquityComponentsAxis"
      decimals="INF"
      id="ixv-22820"
      unitRef="Unit_shares">142758</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P01_01_2023To12_31_2023"
      decimals="INF"
      id="ixv-22821"
      unitRef="Unit_shares">311032</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P01_01_2022To12_31_2022"
      decimals="INF"
      id="ixv-22822"
      unitRef="Unit_shares">249282</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:SupplementalBalanceSheetDisclosuresTextBlock contextRef="P01_01_2023To12_31_2023" id="ixv-15314">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;5. Composition of Certain Financial Statement Captions &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Other Current Assets &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;As of December&#160;31, 2023 and 2022, other current assets were comprised of the following (in thousands): &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 76%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;"&gt;
&lt;tr&gt;
&lt;td style="width: 78%;"&gt;&lt;/td&gt;
&lt;td style="width: 5%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="width: 5%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Prepaid services&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;644&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;2,999&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Prepaid insurance&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;636&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;698&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;1,280&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;3,697&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear:both;max-height:0pt;"&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Property and Equipment, net &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;As of December&#160;31, 2023 and 2022, property and equipment, net, were comprised of the following (in thousands): &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 76%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;"&gt;
&lt;tr&gt;
&lt;td style="width: 76%;"&gt;&lt;/td&gt;
&lt;td style="width: 6%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="width: 6%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Office and computer equipment&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;1,632&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;1,474&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Leasehold improvements&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;1,810&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;1,810&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;3,442&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;3,284&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Less accumulated depreciation&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;(2,536&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;(1,960&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;906&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;1,324&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear:both;max-height:0pt;"&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Depreciation expense totaled $0.6&#160;million and $0.5&#160;million for the year ended December&#160;31, 2023 and 2022, respectively. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Intangible Assets, net &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;As of December&#160;31, 2023, intangible assets included the net book value of costs incurred for software upgrades. Amortization expenses totaled $0.1&#160;million for each of the years ended December&#160;31, 2023 and 2022. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Accounts Payable and Accrued Expenses &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;As of December&#160;31, 2023 and 2022, accounts payable and accrued expenses were comprised of the following (in thousands): &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 76%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;"&gt;
&lt;tr&gt;
&lt;td style="width: 76%;"&gt;&lt;/td&gt;
&lt;td style="width: 5%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="width: 5%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Accounts payable&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;4,758&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;8,364&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Accrued payroll and bonus&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;987&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;989&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Accrued professional fees&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;128&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;147&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Accrued vacation and compensation&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;370&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;325&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Accrued R&amp;amp;D studies&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;388&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;309&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;6,631&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;10,134&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:SupplementalBalanceSheetDisclosuresTextBlock>
    <us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock contextRef="P01_01_2023To12_31_2023" id="ixv-15318">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Other Current Assets &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;As of December&#160;31, 2023 and 2022, other current assets were comprised of the following (in thousands): &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 76%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;"&gt;
&lt;tr&gt;
&lt;td style="width: 78%;"&gt;&lt;/td&gt;
&lt;td style="width: 5%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="width: 5%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Prepaid services&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;644&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;2,999&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Prepaid insurance&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;636&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;698&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;1,280&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;3,697&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock>
    <us-gaap:OtherPrepaidExpenseCurrent
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-22823"
      unitRef="Unit_USD">644000</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:OtherPrepaidExpenseCurrent
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      id="ixv-22824"
      unitRef="Unit_USD">2999000</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:PrepaidInsurance
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-22825"
      unitRef="Unit_USD">636000</us-gaap:PrepaidInsurance>
    <us-gaap:PrepaidInsurance
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      id="ixv-22826"
      unitRef="Unit_USD">698000</us-gaap:PrepaidInsurance>
    <us-gaap:OtherAssetsCurrent
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-22827"
      unitRef="Unit_USD">1280000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      id="ixv-22828"
      unitRef="Unit_USD">3697000</us-gaap:OtherAssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="P01_01_2023To12_31_2023" id="ixv-15427">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Property and Equipment, net &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;As of December&#160;31, 2023 and 2022, property and equipment, net, were comprised of the following (in thousands): &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 76%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;"&gt;
&lt;tr&gt;
&lt;td style="width: 76%;"&gt;&lt;/td&gt;
&lt;td style="width: 6%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="width: 6%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Office and computer equipment&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;1,632&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;1,474&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Leasehold improvements&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;1,810&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;1,810&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;3,442&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;3,284&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Less accumulated depreciation&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;(2,536&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;(1,960&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;906&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;1,324&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <pstv:OfficeAndComputerEquipmentGross
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-22829"
      unitRef="Unit_USD">1632000</pstv:OfficeAndComputerEquipmentGross>
    <pstv:OfficeAndComputerEquipmentGross
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      id="ixv-22830"
      unitRef="Unit_USD">1474000</pstv:OfficeAndComputerEquipmentGross>
    <us-gaap:LeaseholdImprovementsGross
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-22831"
      unitRef="Unit_USD">1810000</us-gaap:LeaseholdImprovementsGross>
    <us-gaap:LeaseholdImprovementsGross
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      id="ixv-22832"
      unitRef="Unit_USD">1810000</us-gaap:LeaseholdImprovementsGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-22833"
      unitRef="Unit_USD">3442000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      id="ixv-22834"
      unitRef="Unit_USD">3284000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-22835"
      unitRef="Unit_USD">2536000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      id="ixv-22836"
      unitRef="Unit_USD">1960000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-22837"
      unitRef="Unit_USD">906000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      id="ixv-22838"
      unitRef="Unit_USD">1324000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Depreciation
      contextRef="P01_01_2023To12_31_2023"
      decimals="-5"
      id="ixv-22839"
      unitRef="Unit_USD">600000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="P01_01_2022To12_31_2022"
      decimals="-5"
      id="ixv-22840"
      unitRef="Unit_USD">500000</us-gaap:Depreciation>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="P01_01_2022To12_31_2022"
      decimals="-5"
      id="ixv-22841"
      unitRef="Unit_USD">100000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="P01_01_2023To12_31_2023"
      decimals="-5"
      id="ixv-22842"
      unitRef="Unit_USD">100000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock contextRef="P01_01_2023To12_31_2023" id="ixv-15583">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Accounts Payable and Accrued Expenses &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;As of December&#160;31, 2023 and 2022, accounts payable and accrued expenses were comprised of the following (in thousands): &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 76%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;"&gt;
&lt;tr&gt;
&lt;td style="width: 76%;"&gt;&lt;/td&gt;
&lt;td style="width: 5%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="width: 5%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Accounts payable&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;4,758&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;8,364&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Accrued payroll and bonus&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;987&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;989&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Accrued professional fees&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;128&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;147&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Accrued vacation and compensation&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;370&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;325&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Accrued R&amp;amp;D studies&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;388&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;309&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;6,631&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;10,134&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock>
    <us-gaap:AccountsPayableCurrent
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-22843"
      unitRef="Unit_USD">4758000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      id="ixv-22844"
      unitRef="Unit_USD">8364000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedBonusesCurrent
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-22845"
      unitRef="Unit_USD">987000</us-gaap:AccruedBonusesCurrent>
    <us-gaap:AccruedBonusesCurrent
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      id="ixv-22846"
      unitRef="Unit_USD">989000</us-gaap:AccruedBonusesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-22847"
      unitRef="Unit_USD">128000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      id="ixv-22848"
      unitRef="Unit_USD">147000</us-gaap:AccruedProfessionalFeesCurrent>
    <pstv:AccruedVacationAndCompensationCurrent
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-22849"
      unitRef="Unit_USD">370000</pstv:AccruedVacationAndCompensationCurrent>
    <pstv:AccruedVacationAndCompensationCurrent
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      id="ixv-22850"
      unitRef="Unit_USD">325000</pstv:AccruedVacationAndCompensationCurrent>
    <pstv:AccruedResearchAndDevelopmentStudies
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-22851"
      unitRef="Unit_USD">388000</pstv:AccruedResearchAndDevelopmentStudies>
    <pstv:AccruedResearchAndDevelopmentStudies
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      id="ixv-22852"
      unitRef="Unit_USD">309000</pstv:AccruedResearchAndDevelopmentStudies>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-22853"
      unitRef="Unit_USD">6631000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      id="ixv-22854"
      unitRef="Unit_USD">10134000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="P01_01_2023To12_31_2023" id="ixv-15728">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;6. Commitments and Contingencies &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Leases &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;At the inception of a contractual arrangement, the Company determines whether the contract contains a lease by assessing whether there is an identified asset and whether the contract conveys the right to control the use of the &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;identified asset in exchange for consideration over a period of time. If both criteria are met, the Company calculates the associated lease liability and corresponding &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;right-of-use&lt;/div&gt;&lt;/div&gt; asset upon lease commencement using a discount rate based on the rate implicit in the lease or an incremental borrowing rate commensurate with the term of the lease. Lease renewable options are included in the estimation of lease term when it is reasonably certain that the Company will exercise such options. &lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;The Company records lease liabilities within current liabilities or long-term liabilities based upon the length of time associated with the lease payments. The Company records its operating lease &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;right-of-use&lt;/div&gt;&lt;/div&gt; assets as long-term assets. Leases with an initial term of 12 months or less are not recorded on the balance sheets. Instead, the Company recognizes lease expense for these leases on a straight-line basis over the lease term in the statements of operations. &lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;The Company leases laboratory, office and storage facilities in San Antonio, Texas, under operating lease agreements that expire in 2025. The Company also leases certain office space in Austin, Texas under a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;month-to-month&lt;/div&gt;&lt;/div&gt; operating lease agreement and certain office space in Charlottesville, Virginia (the &#x201c;Charlottesville Lease&#x201d;). The Company&#x2019;s existing operating lease agreements generally provide for periodic rent increases, and renewal and termination options. The Company&#x2019;s lease agreements do not contain any material variable lease payments, residual value guarantees or material restrictive covenants. &lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;The Charlottesville Lease has a term of 12 months and the Company has the ability to renew for three additional &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;one-year&lt;/div&gt; periods. The Charlottesville Lease is currently set to expire on March 31, 2024, and is renewable twice for twelve months each time. On March&#160;31, 2023, Company believed that it was reasonably certain that the Charlottesville Lease will be renewed through March&#160;31, 2026, and as a result, it remeasured the related lease liability as of March&#160;31, 2023 to be $80,000 using the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;then-in-effect&lt;/div&gt;&lt;/div&gt; discount rate of 12.76%. Effective July&#160;1, 2023, the Company added additional office lease premises in Charlottesville, which was accounted for as a separate operating lease contract with a lease liability and corresponding &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;right-of-use&lt;/div&gt;&lt;/div&gt; asset of $19,000, at a discount rate of 13.47%. &lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;Certain leases require the Company to pay taxes, insurance, and maintenance. Payments for the transfer of goods or services such as common area maintenance and utilities represent &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;non-lease&lt;/div&gt; components. The Company elected the package of practical expedients and therefore does not separate &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;non-lease&lt;/div&gt; components from lease components. &lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;The Company&#x2019;s operating lease liabilities and corresponding &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;right-of-use&lt;/div&gt;&lt;/div&gt; assets are included in the balance sheets. As of December&#160;31, 2023, the weighted average discount rate used to measure operating lease liabilities and the operating leases remaining term were 10.67% and 1.6 years, respectively. &lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;The table below summarizes the Company&#x2019;s operating lease costs from its statements of operations, and cash payments from its statements of cash flows. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 76%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;"&gt;
&lt;tr&gt;
&lt;td style="width: 70%;"&gt;&lt;/td&gt;
&lt;td style="width: 11%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="width: 11%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year&#160;Ended&#160;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Lease expense:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Operating lease expense&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;141&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;159&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Total lease expense&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;141&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;159&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Cash payment information:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Operating cash used for operating leases&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;141&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;159&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Total cash paid for amounts included in the measurement of lease liabilities&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;141&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;159&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear:both;max-height:0pt;"&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;Total rent expenses for each of the years ended December&#160;31, 2023 and 2022 was $0.2&#160;million, which includes leases in the table above, &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;month-to-month&lt;/div&gt;&lt;/div&gt; operating leases, and common area maintenance charges. &lt;/div&gt;&lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;The Company&#x2019;s future minimum annual lease payments under operating leases at December&#160;31, 2023 are as follows (in thousands): &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 68%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;"&gt;
&lt;tr&gt;
&lt;td style="width: 76%;"&gt;&lt;/td&gt;
&lt;td style="width: 20%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Operating&#160;Leases&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;2024&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;146&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;2025&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;60&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;2026&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;11&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Total minimum lease payments&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;217&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Less: amount representing interest&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;(12&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Present value of obligations under leases&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;205&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Less: current portion&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;(120&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Noncurrent lease obligations&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;85&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear:both;max-height:0pt;"&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Services Agreement and Sales Order with Medidata &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;On March&#160;31, 2022, the Company and Medidata Solutions, Inc. (&#x201c;Medidata&#x201d;) entered into a Sales Order (the &#x201c;Sales Order&#x201d;), pursuant to which Medidata will build a Synthetic Control Arm&lt;div style="font-size: 75%; vertical-align: top;display:inline;font-size:8.3px"&gt;&#xae;&lt;/div&gt; (&#x201c;SCA&#x201d;) platform that facilitates the use of historical clinical data to incorporate into the Company&#x2019;s Phase 2 clinical trial of rhenium (&lt;div style="font-size: 75%; vertical-align: top;display:inline;font-size:8.3px"&gt;186&lt;/div&gt;Re) obisbemeda in recurrent glioblastoma (&#x201c;GBM&#x201d;). The Sales Order is governed under the terms of a services agreement, dated November&#160;5, 2021. The Sales Order had a term of six months, and work under the Sales Order has been completed. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Piramal Master Services Agreement &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;On January 8, 2021, the Company entered into a Master Services Agreement (the &#x201c;MSA&#x201d;) with Piramal Pharma Solutions, Inc. (&#x201c;Piramal&#x201d;), for Piramal to perform certain services related to the development, manufacture, and supply of the Company&#x2019;s rhenium (&lt;div style="font-size: 75%; vertical-align: top;display:inline;font-size:8.3px"&gt;186&lt;/div&gt;Re) obisbemeda-Liposome Intermediate Drug Product. The MSA includes the transfer of analytical methods, development of microbiological methods, process transfer and optimization, intermediate drug product manufacturing, and stability studies for the Company, which has been initiated at Piramal&#x2019;s facility located in Lexington, Kentucky. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;The MSA has a term of five years and will automatically renew for successive &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;one-year&lt;/div&gt; terms unless either party notifies the other no later than six months prior to the original term or any additional terms of its intention to not renew the MSA. The Company has the right to terminate the MSA for convenience upon thirty days&#x2019; prior written notice. Either party may terminate the MSA upon an uncured material breach by the other party or upon the bankruptcy or insolvency of the other party. &lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Other Commitments and Contingencies &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;The Company has entered into agreements with various research organizations for &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;pre-clinical&lt;/div&gt; and clinical development studies, which have provisions for cancellation. Under the terms of these agreements, the vendors provide a variety of services including conducting research, recruiting and enrolling patients, monitoring studies and data analysis. Payments under these agreements typically include fees for services and reimbursement of expenses. The timing of payments due under these agreements is estimated based on current study progress. As of December&#160;31, 2023, the Company did not have any clinical research study obligations. &lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Legal proceedings &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;On December&#160;9, 2022, the Company entered into a settlement agreement (the &#x201c;Settlement Agreement&#x201d;) with Lorem Vascular, Pte. Ltd. (&#x201c;Lorem&#x201d;) to settle a prior litigation matter. Under the terms of the Settlement &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Agreement, the Company made a payment to Lorem, and Lorem moved to dismiss the lawsuit with prejudice. The Settlement Agreement released the Company from all claims made by Lorem. The parties to the Settlement Agreement recognized that it did not constitute an admission of liability, wrongdoing, or any matter of fact or law. The Settlement was conditioned on the customary terms contained in the Settlement Agreement and was approved by the Court and the case was dismissed on January&#160;17, 2023. As of December&#160;31, 2022, the Company accrued the settlement amount, as well as the accounts that the Company has confirmed to be recoverable under its insurance claims on the matter. The net amount of $1.4&#160;million that was not recoverable under the Company&#x2019;s insurance has been reflected as an expense in the statement of operations for the year ended December&#160;31, 2022. The full settlement amount was paid in January 2023. All legal costs related to the Lorem Claim were expensed as incurred. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;The Company is subject to various claims and contingencies related to legal proceedings. Due to their nature, such legal proceedings involve inherent uncertainties including, but not limited to, court rulings, negotiations between affected parties and governmental actions. Management assesses the probability of loss for such contingencies and accrues a liability and/or discloses the relevant circumstances, as appropriate. &lt;/div&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <pstv:OperatingLeasesExpiryYear contextRef="P01_01_2023To12_31_2023" id="ixv-22855">2025</pstv:OperatingLeasesExpiryYear>
    <us-gaap:LesseeOperatingLeaseOptionToExtend
      contextRef="P01_01_2023To12_31_2023_CharlottesvilleMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      id="ixv-15761">The Charlottesville Lease has a term of 12 months and the Company has the ability to renew for three additional one-year periods.</us-gaap:LesseeOperatingLeaseOptionToExtend>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="PAsOn12_31_2023_CharlottesvilleMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      id="ixv-22856">P12M</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend
      contextRef="P01_01_2023To12_31_2023_CharlottesvilleMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      id="ixv-22857">true</us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="PAsOn12_31_2023_CharlottesvilleMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      id="ixv-22858">P1Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:LeaseExpirationDate1
      contextRef="P01_01_2023To12_31_2023_CharlottesvilleMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      id="ixv-22859">2024-03-31</us-gaap:LeaseExpirationDate1>
    <us-gaap:OperatingLeaseLiability
      contextRef="PAsOn03_31_2023_CharlottesvilleMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="0"
      id="ixv-22860"
      unitRef="Unit_USD">80000</us-gaap:OperatingLeaseLiability>
    <us-gaap:LesseeOperatingLeaseDiscountRate
      contextRef="PAsOn03_31_2023_CharlottesvilleMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="4"
      id="ixv-22861"
      unitRef="Unit_pure">0.1276</us-gaap:LesseeOperatingLeaseDiscountRate>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="PAsOn07_01_2023_CharlottesvilleMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="0"
      id="ixv-22862"
      unitRef="Unit_USD">19000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:LesseeOperatingLeaseDiscountRate
      contextRef="PAsOn07_01_2023_CharlottesvilleMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="4"
      id="ixv-22863"
      unitRef="Unit_pure">0.1347</us-gaap:LesseeOperatingLeaseDiscountRate>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="PAsOn12_31_2023"
      decimals="4"
      id="ixv-22864"
      unitRef="Unit_pure">0.1067</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="PAsOn12_31_2023" id="ixv-22865">P1Y7M6D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:LeaseCostTableTextBlock contextRef="P01_01_2023To12_31_2023" id="ixv-15773">&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;The table below summarizes the Company&#x2019;s operating lease costs from its statements of operations, and cash payments from its statements of cash flows. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 76%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;"&gt;
&lt;tr&gt;
&lt;td style="width: 70%;"&gt;&lt;/td&gt;
&lt;td style="width: 11%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="width: 11%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year&#160;Ended&#160;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Lease expense:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Operating lease expense&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;141&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;159&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Total lease expense&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;141&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;159&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Cash payment information:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Operating cash used for operating leases&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;141&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;159&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Total cash paid for amounts included in the measurement of lease liabilities&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;141&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;159&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseCost
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-22866"
      unitRef="Unit_USD">141000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      id="ixv-22867"
      unitRef="Unit_USD">159000</us-gaap:OperatingLeaseCost>
    <us-gaap:LeaseCost
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-22868"
      unitRef="Unit_USD">141000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      id="ixv-22869"
      unitRef="Unit_USD">159000</us-gaap:LeaseCost>
    <us-gaap:OperatingLeasePayments
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-22870"
      unitRef="Unit_USD">141000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      id="ixv-22871"
      unitRef="Unit_USD">159000</us-gaap:OperatingLeasePayments>
    <pstv:CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-22872"
      unitRef="Unit_USD">141000</pstv:CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities>
    <pstv:CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      id="ixv-22873"
      unitRef="Unit_USD">159000</pstv:CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities>
    <us-gaap:OperatingLeaseExpense
      contextRef="P01_01_2022To12_31_2022"
      decimals="-5"
      id="ixv-22874"
      unitRef="Unit_USD">200000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="P01_01_2023To12_31_2023"
      decimals="-5"
      id="ixv-22875"
      unitRef="Unit_USD">200000</us-gaap:OperatingLeaseExpense>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock contextRef="P01_01_2023To12_31_2023" id="ixv-15969">&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;The Company&#x2019;s future minimum annual lease payments under operating leases at December&#160;31, 2023 are as follows (in thousands): &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 68%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;"&gt;
&lt;tr&gt;
&lt;td style="width: 76%;"&gt;&lt;/td&gt;
&lt;td style="width: 20%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Operating&#160;Leases&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;2024&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;146&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;2025&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;60&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;2026&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;11&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Total minimum lease payments&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;217&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Less: amount representing interest&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;(12&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Present value of obligations under leases&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;205&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Less: current portion&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;(120&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Noncurrent lease obligations&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;85&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-22877"
      unitRef="Unit_USD">146000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-22878"
      unitRef="Unit_USD">60000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-22879"
      unitRef="Unit_USD">11000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-22880"
      unitRef="Unit_USD">217000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-22881"
      unitRef="Unit_USD">12000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-22882"
      unitRef="Unit_USD">205000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-22883"
      unitRef="Unit_USD">120000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-22884"
      unitRef="Unit_USD">85000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <pstv:SalesOrderTerm
      contextRef="P03_31_2022To03_31_2022_MedidataSolutionsIncMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_ServicesAgreementMemberusgaapTypeOfArrangementAxis"
      id="ixv-22885">P6M</pstv:SalesOrderTerm>
    <pstv:MasterServicesAgreementDate
      contextRef="P01_08_2021To01_08_2021_PiramalPharmaSolutionsIncMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      id="ixv-22886">2021-01-08</pstv:MasterServicesAgreementDate>
    <pstv:MasterServicesAgreementTermsDescription
      contextRef="P01_01_2023To12_31_2023_PiramalPharmaSolutionsIncMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      id="ixv-16117">The MSA has a term of five years and will automatically renew for successive one-year terms unless either party notifies the other no later than six months prior to the original term or any additional terms of its intention to not renew the MSA. The Company has the right to terminate the MSA for convenience upon thirty days&#x2019; prior written notice.</pstv:MasterServicesAgreementTermsDescription>
    <pstv:MasterServicesAgreementInitialTerm
      contextRef="P01_08_2021To01_08_2021_PiramalPharmaSolutionsIncMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      id="ixv-22887">P5Y</pstv:MasterServicesAgreementInitialTerm>
    <us-gaap:ContractualObligation
      contextRef="PAsOn12_31_2023_PreClinicalResearchStudyObligationsMemberusgaapRecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis"
      decimals="-3"
      id="ixv-22888"
      unitRef="Unit_USD">0</us-gaap:ContractualObligation>
    <us-gaap:LitigationSettlementExpense
      contextRef="P01_01_2022To12_31_2022_LoremVascularPteLtdMembersrtLitigationCaseAxis"
      decimals="-5"
      id="ixv-22889"
      unitRef="Unit_USD">1400000</us-gaap:LitigationSettlementExpense>
    <pstv:LicenseAgreementDisclosureTextBlock contextRef="P01_01_2023To12_31_2023" id="ixv-16148">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;7. License Agreements &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Biocept License Agreement &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;On September&#160;7, 2023, the Company entered into a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;Non-Exclusive&lt;/div&gt; License and Services Agreement (the &#x201c;Biocept Agreement&#x201d;) with Biocept, Inc (&#x201c;Biocept&#x201d;), pursuant to which Biocept granted the Company a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;non-exclusive&lt;/div&gt; license to use the Biocept proprietary cell enumeration test, CNside&lt;div style="font-size: 75%; vertical-align: top;display:inline;font-size:8.3px"&gt;TM&lt;/div&gt;. In exchange for the license, the Company issued to Biocept 53,381 unregistered shares, the fair value of which was $75,000. The Biocept Agreement also provides that if Biocept fully transfers the technology to the Company, a tech transfer and validation fee of $300,000 will be payable. In addition, the Company was granted an option for an exclusive worldwide license for $1,000,000 on or before December&#160;31, 2024, to process and perform cell enumeration testing for treatments for other patients including those on the Company&#x2019;s radiotherapeutic drugs. &lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;On October&#160;16, 2023, Biocept filed a voluntary petition for relief under the provisions of Chapter 7 of Title 11 of the United States Bankruptcy Code, making the full transfer of the Biocept technology to the Company unlikely. In addition, the Biocept Agreement is subject to provisions under the Bankruptcy Code. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;UT Health Science Center at San Antonio (&#x201c;UTHSA&#x201d;) License Agreement &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;On December&#160;31, 2021, the Company entered into a Patent and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;Know-How&lt;/div&gt; License Agreement (the &#x201c;UTHSA License Agreement&#x201d;) with UTHSA, pursuant to which UTHSA granted the Company an irrevocable, perpetual, exclusive, fully &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;paid-up&lt;/div&gt; license, with the right to sublicense and to make, develop, commercialize and otherwise exploit certain patents, &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;know-how&lt;/div&gt; and technology related to the development of biodegradable alginate microspheres (BAM) containing nanoliposomes loaded with imaging and/or therapeutic payloads. &lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;Pursuant to the UTHSA License Agreement, the Company was required to make an upfront payment, which was recorded as &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;in-process&lt;/div&gt; research and development acquired in the statement of operations for the year ended December&#160;31, 2021. The upfront payment of $0.3&#160;million was paid in cash in January 2022. &lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;NanoTx License Agreement &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;On March&#160;29, 2020, the Company and NanoTx, Corp. (&#x201c;NanoTx&#x201d;) entered into a Patent and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;Know-How&lt;/div&gt; License Agreement (the &#x201c;NanoTx License Agreement&#x201d;), pursuant to which NanoTx granted the Company an irrevocable, perpetual, exclusive, fully &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;paid-up&lt;/div&gt; license, with the right to sublicense and to make, develop, commercialize and otherwise exploit certain patents, &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;know-how&lt;/div&gt; and technology related to the development of radiolabeled nanoliposomes. &lt;/div&gt;&lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;The transaction terms included an upfront payment of $0.4&#160;million in cash and $0.3&#160;million in the Company&#x2019;s voting stock. The transaction terms also included success-based milestone and royalty payments contingent on key clinical, regulatory and sales milestones, as well as the requirement to pay 15% of any &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;non-dilutive&lt;/div&gt; monetary awards or grants received from external agencies to support product development of the nanoliposome encapsulated BMEDA-chelated radioisotope, which includes grants from the Cancer Prevention&#160;&amp;amp; Research Institute of Texas (&#x201c;CPRIT&#x201d;). As of December&#160;31, 2023, the Company accrued $0.5&#160;million of payments due to NanoTx as a result of the CPRIT grant received (Note 9). &lt;/div&gt;</pstv:LicenseAgreementDisclosureTextBlock>
    <us-gaap:SharesIssued
      contextRef="PAsOn09_07_2023_BioceptAgreementMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"
      decimals="INF"
      id="ixv-22890"
      unitRef="Unit_shares">53381</us-gaap:SharesIssued>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="P10_01_2023To12_31_2023_BioceptAgreementMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"
      decimals="0"
      id="ixv-22891"
      unitRef="Unit_USD">75000</us-gaap:ResearchAndDevelopmentExpense>
    <pstv:PaymentForTechTransferAndValidationFee
      contextRef="P09_07_2023To09_07_2023_BioceptAgreementMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"
      decimals="0"
      id="ixv-22892"
      unitRef="Unit_USD">300000</pstv:PaymentForTechTransferAndValidationFee>
    <pstv:OptionForExclusiveWorldwideLicense
      contextRef="P09_07_2023To09_07_2023_BioceptAgreementMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"
      decimals="0"
      id="ixv-22893"
      unitRef="Unit_USD">1000000</pstv:OptionForExclusiveWorldwideLicense>
    <us-gaap:PaymentsForRoyalties
      contextRef="P01_01_2022To01_31_2022_UTHSALicenseAgreementMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"
      decimals="-5"
      id="ixv-22894"
      unitRef="Unit_USD">300000</us-gaap:PaymentsForRoyalties>
    <us-gaap:PaymentsForRoyalties
      contextRef="P03_29_2020To03_29_2020_NanoTxLicensesAgreementMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"
      decimals="-5"
      id="ixv-22896"
      unitRef="Unit_USD">400000</us-gaap:PaymentsForRoyalties>
    <us-gaap:CommonStockValue
      contextRef="PAsOn03_29_2020_NanoTxLicensesAgreementMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"
      decimals="-5"
      id="ixv-22897"
      unitRef="Unit_USD">300000</us-gaap:CommonStockValue>
    <pstv:PercentageOfNonDilutiveMonetaryAwardsRequiredToPay
      contextRef="P03_29_2020To03_29_2020_NanoTxLicensesAgreementMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"
      decimals="2"
      id="ixv-22898"
      unitRef="Unit_pure">0.15</pstv:PercentageOfNonDilutiveMonetaryAwardsRequiredToPay>
    <pstv:AccruedLicensePayable
      contextRef="PAsOn12_31_2023_NanoTxLicensesAgreementMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"
      decimals="-5"
      id="ixv-22899"
      unitRef="Unit_USD">500000</pstv:AccruedLicensePayable>
    <us-gaap:DebtDisclosureTextBlock contextRef="P01_01_2023To12_31_2023" id="ixv-16192">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;8. Term Loan Obligations &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;On May 29, 2015, the Company entered into the Loan and Security Agreement (the &#x201c;Loan and Security Agreement&#x201d;), pursuant to which Oxford Finance, LLC (&#x201c;Oxford&#x201d;) funded an aggregate principal amount of $17.7&#160;million (the &#x201c;Term Loan&#x201d;), subject to the terms and conditions set forth in the Loan and Security Agreement. The Term Loan accrued interest at a floating rate of at least 8.95% per annum, comprised of a three-month LIBOR rate with a floor of 1.00% plus 7.95%. Pursuant to the Loan and Security Agreement, as amended, the Company was required to make interest only payments through May 1, 2021 and thereafter it was required to make payments of principal and accrued interest in equal monthly installments sufficient to amortize the Term Loan through June&#160;1, 2024, the maturity date. At maturity of the Term Loan, or earlier repayment in full following voluntary prepayment or upon acceleration, the Company is required to make a final payment in an aggregate amount equal to approximately $3.2&#160;million. In connection with the Term Loan, on May&#160;29, 2015, the Company issued to Oxford warrants to purchase an aggregate of 188 shares of the Company&#x2019;s common stock at an exercise price of $5,175 per share. These warrants became exercisable as of November&#160;30, 2015 and will expire on May&#160;29, 2025 and, following the authoritative accounting guidance, are equity classified and their respective fair value was recorded as a discount to the debt. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;The Term Loan was collateralized by a security interest in substantially all of the Company&#x2019;s existing and subsequently acquired assets, including its intellectual property assets, subject to certain exceptions set forth in the Loan and Security Agreement, as amended. The intellectual property asset collateral would be released upon the Company achieving a certain liquidity level when the total principal outstanding under the Loan and Security Agreement is less than $3&#160;million. As of December&#160;31, 2023, there was $0.8&#160;million principal amount outstanding under the Term Loan, excluding the $3.2&#160;million final payment fee, and the Company was in compliance with all of the debt covenants under the Loan and Security Agreement. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;The Company&#x2019;s interest expense for the years ended December&#160;31, 2023 and 2022 was $0.4&#160;million and $0.7&#160;million, respectively. Interest expense is calculated using the effective interest method; therefore it is inclusive of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;non-cash&lt;/div&gt; amortization in the amount of $0.2&#160;million and $0.4&#160;million for the year ended December&#160;31, 2023 and 2022, respectively, related to the amortization of the debt discount, deferred financing costs, and accretion of final payment. &lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;The Loan and Security Agreement contains customary indemnification obligations and customary events of default, including, among other things, the Company&#x2019;s failure to fulfill certain obligations under the Term Loan, as amended, and the occurrence of a material adverse change, which is defined as a material adverse change in the Company&#x2019;s business, operations, or condition (financial or otherwise), a material impairment of the prospect of repayment of any portion of the loan. In the event of default by the Company or a declaration of material adverse change by its lender, under the Term Loan, the lender would be entitled to exercise its remedies thereunder, including the right to accelerate the debt, upon which the Company may be required to repay all amounts then outstanding under the Term Loan, which could materially harm the Company&#x2019;s financial condition. As of December&#160;31, 2023, the Company has not received any notification or indication from Oxford to invoke the material adverse change clause. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Additional information relating to the then-outstanding Term Loan as of December&#160;31, 2023 and 2022 is presented in the following table (in thousands, except interest rate): &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 100%; font-family: Times New Roman; font-size: 8pt; border-collapse: collapse;"&gt;
&lt;tr&gt;
&lt;td style="width: 53%;"&gt;&lt;/td&gt;
&lt;td style="width: 4%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="width: 4%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="width: 4%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="width: 4%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="width: 4%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="text-decoration: underline; letter-spacing: 0px; top: 0px;display:inline;"&gt;Year ended December&#160;31, 2023&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Origination Date&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Original&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Loan&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Amount&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Interest&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rate*&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Current&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Monthly&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Payment**&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Amended&lt;br/&gt; expiration&lt;br/&gt; date&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Remaining&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Principal&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(Face&#160;Value)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="-sec-ix-hidden:hidden116199096;display:inline;"&gt;May 2015&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;17,700&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;13.39&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;134&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;June 1, 2024&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;804&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear:both;max-height:0pt;"&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;"&gt;
&lt;tr&gt;
&lt;td style="width: 52%;"&gt;&lt;/td&gt;
&lt;td style="width: 4%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="width: 4%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="width: 4%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="width: 4%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="width: 4%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="text-decoration: underline; letter-spacing: 0px; top: 0px;display:inline;"&gt;Year ended December&#160;31, 2022&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Origination Date&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Original&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Loan&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Amount&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Interest&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rate*&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Monthly&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Payment**&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Amended&lt;br/&gt; expiration&lt;br/&gt; date&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Remaining&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Principal&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(Face&#160;Value)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="-sec-ix-hidden:hidden116199109;display:inline;"&gt;May 2015&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;17,700&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;8.95&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;134&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;June 1, 2024&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;2,412&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear:both;max-height:0pt;"&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentColor; border-image: none; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;text-align:left;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;*&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;text-align:left;"&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Three month LIBOR rate with a floor of 1% plus 7.95% &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear:both;max-height:0pt;"&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentColor; border-image: none; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;text-align:left;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;**&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;text-align:left;"&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Monthly payment reflects principal and interest &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:DebtInstrumentOfferingDate1
      contextRef="P01_01_2023To12_31_2023_TermLoanMemberusgaapDebtInstrumentAxis"
      id="ixv-22900">2015-05-29</us-gaap:DebtInstrumentOfferingDate1>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="PAsOn05_29_2015_TermLoanMemberusgaapDebtInstrumentAxis"
      decimals="-5"
      id="ixv-22901"
      unitRef="Unit_USD">17700000</us-gaap:DebtInstrumentFaceAmount>
    <pstv:DebtInstrumentFloatingInterestRatePercentage
      contextRef="PAsOn05_29_2015_MinimumMembersrtRangeAxis_TermLoanMemberusgaapDebtInstrumentAxis"
      decimals="INF"
      id="ixv-22902"
      unitRef="Unit_pure">0.0895</pstv:DebtInstrumentFloatingInterestRatePercentage>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="P05_28_2015To05_29_2015_InterestRateFloorMemberusgaapDerivativeInstrumentRiskAxis_LiborMemberusgaapVariableRateAxis"
      decimals="4"
      id="ixv-22903"
      unitRef="Unit_pure">0.01</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="P05_28_2015To05_29_2015_TermLoanMemberusgaapDebtInstrumentAxis"
      decimals="4"
      id="ixv-22904"
      unitRef="Unit_pure">0.0795</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentMaturityDate
      contextRef="P05_28_2015To05_29_2015_TermLoanMemberusgaapDebtInstrumentAxis"
      id="ixv-22905">2021-05-01</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DebtInstrumentFeeAmount
      contextRef="PAsOn05_29_2015_TermLoanMemberusgaapDebtInstrumentAxis"
      decimals="-5"
      id="ixv-22906"
      unitRef="Unit_USD">3200000</us-gaap:DebtInstrumentFeeAmount>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="PAsOn05_29_2015_TermLoanMemberusgaapDebtInstrumentAxis"
      decimals="INF"
      id="ixv-22907"
      unitRef="Unit_shares">188</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="PAsOn05_29_2015_TermLoanMemberusgaapDebtInstrumentAxis"
      decimals="INF"
      id="ixv-22908"
      unitRef="Unit_USD_per_Share">5175</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="PAsOn12_31_2023_MaximumMembersrtRangeAxis_TermLoanMemberusgaapDebtInstrumentAxis"
      decimals="-6"
      id="ixv-22909"
      unitRef="Unit_USD">3000000</us-gaap:DebtInstrumentFaceAmount>
    <pstv:LongTermDebtOutstandingThresholdAmount
      contextRef="P01_01_2023To12_31_2023_MaximumMembersrtRangeAxis_TermLoanMemberusgaapDebtInstrumentAxis"
      decimals="-5"
      id="ixv-22910"
      unitRef="Unit_USD">800000</pstv:LongTermDebtOutstandingThresholdAmount>
    <us-gaap:DebtInstrumentFeeAmount
      contextRef="PAsOn12_31_2023_TermLoanMemberusgaapDebtInstrumentAxis"
      decimals="-5"
      id="ixv-22911"
      unitRef="Unit_USD">3200000</us-gaap:DebtInstrumentFeeAmount>
    <us-gaap:DebtInstrumentCovenantCompliance
      contextRef="P01_01_2023To12_31_2023_TermLoanMemberusgaapDebtInstrumentAxis"
      id="ixv-22912">the Company was in compliance with all of the debt covenants under the Loan and Security Agreement.</us-gaap:DebtInstrumentCovenantCompliance>
    <us-gaap:InterestExpense
      contextRef="P01_01_2023To12_31_2023"
      decimals="-5"
      id="ixv-22913"
      unitRef="Unit_USD">400000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="P01_01_2022To12_31_2022"
      decimals="-5"
      id="ixv-22914"
      unitRef="Unit_USD">700000</us-gaap:InterestExpense>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="P01_01_2023To12_31_2023"
      decimals="-5"
      id="ixv-22915"
      unitRef="Unit_USD">200000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="P01_01_2022To12_31_2022"
      decimals="-5"
      id="ixv-22916"
      unitRef="Unit_USD">400000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:ScheduleOfDebtInstrumentsTextBlock contextRef="P01_01_2023To12_31_2023" id="ixv-16217">&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Additional information relating to the then-outstanding Term Loan as of December&#160;31, 2023 and 2022 is presented in the following table (in thousands, except interest rate): &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 100%; font-family: Times New Roman; font-size: 8pt; border-collapse: collapse;"&gt;
&lt;tr&gt;
&lt;td style="width: 53%;"&gt;&lt;/td&gt;
&lt;td style="width: 4%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="width: 4%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="width: 4%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="width: 4%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="width: 4%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="text-decoration: underline; letter-spacing: 0px; top: 0px;display:inline;"&gt;Year ended December&#160;31, 2023&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Origination Date&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Original&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Loan&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Amount&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Interest&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rate*&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Current&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Monthly&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Payment**&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Amended&lt;br/&gt; expiration&lt;br/&gt; date&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Remaining&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Principal&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(Face&#160;Value)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="-sec-ix-hidden:hidden116199096;display:inline;"&gt;May 2015&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;17,700&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;13.39&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;134&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;June 1, 2024&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;804&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear:both;max-height:0pt;"&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;"&gt;
&lt;tr&gt;
&lt;td style="width: 52%;"&gt;&lt;/td&gt;
&lt;td style="width: 4%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="width: 4%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="width: 4%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="width: 4%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="width: 4%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="text-decoration: underline; letter-spacing: 0px; top: 0px;display:inline;"&gt;Year ended December&#160;31, 2022&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Origination Date&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Original&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Loan&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Amount&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Interest&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rate*&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Monthly&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Payment**&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Amended&lt;br/&gt; expiration&lt;br/&gt; date&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Remaining&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Principal&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(Face&#160;Value)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="-sec-ix-hidden:hidden116199109;display:inline;"&gt;May 2015&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;17,700&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;8.95&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;134&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;June 1, 2024&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;2,412&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear:both;max-height:0pt;"&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentColor; border-image: none; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;text-align:left;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;*&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;text-align:left;"&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Three month LIBOR rate with a floor of 1% plus 7.95% &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear:both;max-height:0pt;"&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentColor; border-image: none; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;text-align:left;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;**&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;text-align:left;"&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Monthly payment reflects principal and interest &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfDebtInstrumentsTextBlock>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="PAsOn12_31_2023_TermLoanMemberusgaapDebtInstrumentAxis"
      decimals="-3"
      id="ixv-22918"
      unitRef="Unit_USD">17700000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="PAsOn12_31_2023_TermLoanMemberusgaapDebtInstrumentAxis"
      decimals="INF"
      id="Fact_116199642"
      unitRef="Unit_pure">0.1339</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentPeriodicPayment
      contextRef="P01_01_2023To12_31_2023_TermLoanMemberusgaapDebtInstrumentAxis"
      decimals="-3"
      id="Fact_116199643"
      unitRef="Unit_USD">134000</us-gaap:DebtInstrumentPeriodicPayment>
    <pstv:DebtInstrumentAmendedExpirationDate
      contextRef="P01_01_2023To12_31_2023_TermLoanMemberusgaapDebtInstrumentAxis"
      id="ixv-22921">2024-06-01</pstv:DebtInstrumentAmendedExpirationDate>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="PAsOn12_31_2023_TermLoanMemberusgaapDebtInstrumentAxis"
      decimals="-3"
      id="ixv-22922"
      unitRef="Unit_USD">804000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="PAsOn12_31_2022_TermLoanMemberusgaapDebtInstrumentAxis"
      decimals="-3"
      id="ixv-22923"
      unitRef="Unit_USD">17700000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="PAsOn12_31_2022_TermLoanMemberusgaapDebtInstrumentAxis"
      decimals="INF"
      id="Fact_116199647"
      unitRef="Unit_pure">0.0895</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentPeriodicPayment
      contextRef="P01_01_2022To12_31_2022_TermLoanMemberusgaapDebtInstrumentAxis"
      decimals="-3"
      id="Fact_116199648"
      unitRef="Unit_USD">134000</us-gaap:DebtInstrumentPeriodicPayment>
    <pstv:DebtInstrumentAmendedExpirationDate
      contextRef="P01_01_2022To12_31_2022_TermLoanMemberusgaapDebtInstrumentAxis"
      id="ixv-22926">2024-06-01</pstv:DebtInstrumentAmendedExpirationDate>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="PAsOn12_31_2022_TermLoanMemberusgaapDebtInstrumentAxis"
      decimals="-3"
      id="ixv-22927"
      unitRef="Unit_USD">2412000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:RevenueFromContractWithCustomerTextBlock contextRef="P01_01_2023To12_31_2023" id="ixv-16489">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;9. Grant Revenue &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;On September&#160;19, 2022, the Company entered into the CPRIT Contract, effective as of August 31, 2022, with CPRIT, pursuant to which CPRIT will provide the Company with the CPRIT Grant of up to $17.6&#160;million over a three-year period to fund the continued development of rhenium (&lt;div style="font-size: 75%; vertical-align: top;display:inline;font-size:8.3px"&gt;186&lt;/div&gt;Re) obisbemeda (previously known as &lt;div style="font-size: 75%; vertical-align: top;display:inline;font-size:8.3px"&gt;186&lt;/div&gt;RNL) for the treatment of patients with leptomeningeal metastases (&#x201c;LM&#x201d;). The CPRIT Grant is subject to customary CPRIT funding conditions, including, but not limited to, a matching fund requirement (one dollar for every two dollars awarded by CPRIT), revenue sharing obligations upon commercialization of rhenium (&lt;div style="font-size: 75%; vertical-align: top;display:inline;font-size:8.3px"&gt;186&lt;/div&gt;Re) obisbemeda based on specific dollar thresholds and tiered low single digit royalty rates until CPRIT receives the aggregate amount of 400% of the proceeds awarded under the CPRIT Grant, and certain reporting requirements. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;The CPRIT Contract will terminate on August 30, 2025, unless terminated earlier by (a)&#160;the mutual written consent of all parties to the CPRIT Contract, (b)&#160;CPRIT for an event of default by the Company, (c)&#160;CPRIT, if the funds allocated to the CPRIT Grant become legally unavailable during the term of the CPRIT Contract and CPRIT is unable to obtain additional funds for such purposes, and (d)&#160;the Company for convenience. CPRIT may require the Company to repay some or all of the disbursed CPRIT Grant proceeds (with interest not to exceed 5% annually) in the event of the early termination of the CPRIT Contract by CPRIT for an event of default by the Company or by the Company for convenience, or if the Company relocates its principal place of business outside of the state of Texas during the CPRIT Contract term or within three years after the final payment of the grant funds. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;The Company retains ownership over any intellectual property developed under the contract (each, a &#x201c;Project Result&#x201d;). With respect to &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;non-commercial&lt;/div&gt; use of any Project Result, the Company granted to CPRIT a nonexclusive, irrevocable, royalty-free, perpetual, worldwide license with right to sublicense any necessary additional intellectual property rights to exploit all Project Results by CPRIT, other governmental entities and agencies of the State of Texas, and private or independent institutions of higher education located in Texas, for education, research and other &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;non-commercial&lt;/div&gt; purposes. &lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;The Company determined that the CPRIT Contract is not in the scope of ASC 808, ASC &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;958-605,&lt;/div&gt; or ASC 606. Applying IAS 20 by analogy, the Company recognizes proceeds received under the CPRIT Contract as grant revenue on the statement of operations when related costs are incurred. &lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;During the three months ended June&#160;30, 2023, the Company identified eligible costs of approximately $637,000 and $168,000 that were incurred in the fourth quarter of 2022 and the three months ended March&#160;31, 2023, respectively, that were reimbursable under the CPRIT arrangement. The Company determined that these costs should have been recorded in these respective periods as grant revenue. The Company assessed the impact of this error on the Company&#x2019;s previously issued financial statements and determined that it was immaterial. As a result, an &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;out-of-period&lt;/div&gt;&lt;/div&gt; adjustment of approximately $637,000 has been recorded as an increase in grant revenue in the year ended December&#160;31, 2023. &lt;/div&gt;&lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;The Company recognized $4.9&#160;million and $0.2&#160;million in grant revenue from the CPRIT Contract during the year ended December&#160;31, 2023 and 2022, respectively. &lt;/div&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerTextBlock>
    <pstv:ContractEffectiveDate
      contextRef="P09_19_2022To09_19_2022_CancerPreventionAndResearchInstituteOfTexasContractMemberusgaapTypeOfArrangementAxis"
      id="ixv-22928">2022-08-31</pstv:ContractEffectiveDate>
    <pstv:MaximumGrantAmountToBeReceivedAsPerGrantContract
      contextRef="PAsOn09_19_2022_CancerPreventionAndResearchInstituteOfTexasContractMemberusgaapTypeOfArrangementAxis"
      decimals="INF"
      id="ixv-22929"
      unitRef="Unit_USD">17600000</pstv:MaximumGrantAmountToBeReceivedAsPerGrantContract>
    <pstv:GrantFundingTerm
      contextRef="P09_19_2022To09_19_2022_CancerPreventionAndResearchInstituteOfTexasContractMemberusgaapTypeOfArrangementAxis"
      id="ixv-22930">P3Y</pstv:GrantFundingTerm>
    <pstv:CpritGrantFundingTerm
      contextRef="P01_01_2023To12_31_2023_CancerPreventionAndResearchInstituteOfTexasContractMemberusgaapTypeOfArrangementAxis"
      id="ixv-16497">The CPRIT Grant is subject to customary CPRIT funding conditions, including, but not limited to, a matching fund requirement (one dollar for every two dollars awarded by CPRIT), revenue sharing obligations upon commercialization of rhenium (186Re) obisbemeda based on specific dollar thresholds and tiered low single digit royalty rates until CPRIT receives the aggregate amount of 400% of the proceeds awarded under the CPRIT Grant, and certain reporting requirements.</pstv:CpritGrantFundingTerm>
    <pstv:PercentageOfAggregateAmountOfProceedsAwardedUnderCpritGrant
      contextRef="P01_01_2023To12_31_2023_CancerPreventionAndResearchInstituteOfTexasContractMemberusgaapTypeOfArrangementAxis"
      decimals="2"
      id="ixv-22931"
      unitRef="Unit_pure">4</pstv:PercentageOfAggregateAmountOfProceedsAwardedUnderCpritGrant>
    <pstv:ContractTerminationDate
      contextRef="P09_19_2022To09_19_2022_CancerPreventionAndResearchInstituteOfTexasContractMemberusgaapTypeOfArrangementAxis"
      id="ixv-22932">2025-08-30</pstv:ContractTerminationDate>
    <pstv:PercentageOfGrantProceedsWithInterestNotExceedAnnually
      contextRef="P09_19_2022To09_19_2022_CancerPreventionAndResearchInstituteOfTexasContractMemberusgaapTypeOfArrangementAxis"
      decimals="2"
      id="ixv-22933"
      unitRef="Unit_pure">0.05</pstv:PercentageOfGrantProceedsWithInterestNotExceedAnnually>
    <pstv:ReimbursementCostsIncurred
      contextRef="P10_01_2022To12_31_2022_CancerPreventionAndResearchInstituteOfTexasContractMemberusgaapTypeOfArrangementAxis"
      decimals="0"
      id="ixv-22934"
      unitRef="Unit_USD">637000</pstv:ReimbursementCostsIncurred>
    <pstv:ReimbursementCostsIncurred
      contextRef="P01_01_2023To03_31_2023_CancerPreventionAndResearchInstituteOfTexasContractMemberusgaapTypeOfArrangementAxis"
      decimals="0"
      id="ixv-22935"
      unitRef="Unit_USD">168000</pstv:ReimbursementCostsIncurred>
    <pstv:IncreaseDecreaseInGrantRevenue
      contextRef="P01_01_2023To12_31_2023_CancerPreventionAndResearchInstituteOfTexasContractMemberusgaapTypeOfArrangementAxis"
      decimals="0"
      id="ixv-22936"
      unitRef="Unit_USD">637000</pstv:IncreaseDecreaseInGrantRevenue>
    <us-gaap:Revenues
      contextRef="P01_01_2023To12_31_2023_CancerPreventionAndResearchInstituteOfTexasContractMemberusgaapTypeOfArrangementAxis_GrantMembersrtProductOrServiceAxis"
      decimals="-5"
      id="ixv-22938"
      unitRef="Unit_USD">4900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="P01_01_2022To12_31_2022_CancerPreventionAndResearchInstituteOfTexasContractMemberusgaapTypeOfArrangementAxis_GrantMembersrtProductOrServiceAxis"
      decimals="-5"
      id="ixv-22939"
      unitRef="Unit_USD">200000</us-gaap:Revenues>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="P01_01_2023To12_31_2023" id="ixv-16524">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;10. Income Taxes &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Pursuant to the Internal Revenue Code (&#x201c;IRC&#x201d;) of 1986, as amended, specifically IRC &#xa7;382 (&#x201c;Section 382&#x201d;) and IRC &#xa7;383, the Company&#x2019;s ability to use net operating loss (&#x201c;NOLs&#x201d;) and R&amp;amp;D tax credit carry forwards (&#x201c;tax attribute carry forwards&#x201d;) to offset future taxable income is limited if the Company experiences a cumulative change in ownership of more than 50% within a three-year testing period. The Company&#x2019;s use of federal and state NOLs and research credits could be limited further by the provisions of Section&#160;382 depending upon the timing and amount of additional equity securities that the Company has issued or will issue. State NOL carryforwards may be similarly limited. If a change in ownership were to have occurred, NOL and tax credits carryforwards could be eliminated or restricted. If eliminated, the related asset would be removed from the deferred tax asset schedule with a corresponding reduction in the valuation allowance. Due to the existence of the valuation allowance, limitations created by ownership changes, if any, will not impact the Company&#x2019;s effective tax rate. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;The Company has recorded a full valuation allowance against its net deferred tax assets and due to our net losses for the years ended December&#160;31, 2023 and 2022, there was no provision or benefit for income taxes recorded. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;A reconciliation of the total income tax provision tax rate to the statutory federal income tax rates of 21% for the years ended December&#160;31, 2023 and 2022, respectively, is as follows: &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 76%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;"&gt;
&lt;tr&gt;
&lt;td style="width: 81%;"&gt;&lt;/td&gt;
&lt;td style="width: 6%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="width: 5%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Income tax expense (benefit) at federal statutory rate&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;(21.0&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;(21.0&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Change in valuation allowance&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;25.5&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;22.5&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Income tax expense (benefit) at state statutory rate&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;(0.2&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;(0.2&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Share based compensation&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;1.0&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;0.9&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;NOLs expiring and adjustments to NOL&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;(0.1&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;0.5&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Research credit&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;(5.1&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;(2.5&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Return to provision&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;(0.1&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;(0.1&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Change in state rate&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;(0.1&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;0.0&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;0.0&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear:both;max-height:0pt;"&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;The tax effects of temporary differences that give rise to significant portions of our deferred tax assets and deferred tax liabilities as of December&#160;31, 2023 and 2022 are as follows (in thousands): &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 76%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;"&gt;
&lt;tr&gt;
&lt;td style="width: 72%;"&gt;&lt;/td&gt;
&lt;td style="width: 10%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="width: 10%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Deferred tax assets:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Accrued expenses&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;269&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;262&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Share based compensation&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;99&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;107&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Net operating loss carryforwards&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;13,397&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;12,605&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Income tax credit carryforwards&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;1,630&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;956&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Property and equipment, principally due to differences in depreciation&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;154&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;89&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Intangible assets&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;3,527&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;2,073&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Other, net&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;453&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;53&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;19,529&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;16,145&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Valuation allowance&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;(19,486&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;(16,092&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Total deferred tax assets, net of allowance&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;43&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;53&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear:both;max-height:0pt;"&gt;&lt;/div&gt;&lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 76%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;"&gt;
&lt;tr&gt;
&lt;td style="width: 82%;"&gt;&lt;/td&gt;
&lt;td style="width: 5%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="width: 5%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Deferred tax liabilities:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Other&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;(43&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;(53&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Total deferred tax liability&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;(43&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;(53&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Net deferred tax assets (liability)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear:both;max-height:0pt;"&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;The Company has established a valuation allowance against its net deferred tax assets due to the uncertainty surrounding the realization of such assets. The Company periodically evaluates the recoverability of the deferred tax assets. At such time as it is determined that it is more likely than not that deferred tax assets are realizable, the valuation allowance will be reduced. The Company has recorded a full valuation allowance of $19.5&#160;million as of December&#160;31, 2023 as it does not believe it is more likely than not the net deferred tax assets will be realized. The Company increased its valuation allowance by approximately $3.4&#160;million during the year ended December&#160;31, 2023. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;At December&#160;31, 2023, the Company had federal and state tax loss carry forwards of approximately $63.2&#160;million, and $2.6&#160;million, respectively. The federal and state net operating loss carry forwards begin to expire in 2037 and 2038, if unused, respectively. The federal net operating loss carryover includes $59.8&#160;million of net operating losses generated after 2017. Federal net operating losses generated from 2018 onwards carryover indefinitely and may generally be used to offset up to 80% of future taxable income. At December&#160;31, 2023, the Company had federal tax credit carry forwards of approximately $1.9&#160;million, before reduction for uncertain tax positions. The federal credits will begin to expire in 2039, if unused. In addition, at December&#160;31, 2023, the Company had state tax credit carry forwards of approximately $0.2&#160;million, before reduction for uncertain tax positions. The state credits will begin to expire in 2043, if unused. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;The Company follows the provisions of income tax guidance which provides recognition criteria and a related measurement model for uncertain tax positions taken or expected to be taken in income tax returns. The guidance requires that a position taken or expected to be taken in a tax return be recognized in the financial statements when it is more likely than not that the position would be sustained upon examination by tax authorities. Tax positions that meet the more likely than not threshold are then measured using a probability weighted approach recognizing the largest amount of tax benefit that is greater than 50% likely of being realized upon ultimate settlement. The Company has not recognized any liability for uncertain tax positions as of December&#160;31, 2023 and 2022. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Following is a tabular reconciliation of the unrecognized tax benefits activity during the years ended December&#160;31, 2023 and 2022 (in thousands): &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 76%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;"&gt;
&lt;tr&gt;
&lt;td style="width: 82%;"&gt;&lt;/td&gt;
&lt;td style="width: 5%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="width: 5%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Unrecognized Tax Benefits &#x2013; Beginning&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;209&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;81&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Gross decreases &#x2013; tax positions in prior period&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;(16&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;(1&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Gross increase &#x2013; current-period tax positions&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;215&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;129&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Unrecognized Tax Benefits &#x2013; Ending&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;408&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;209&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear:both;max-height:0pt;"&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;The unrecognized tax benefit amounts are reflected in the determination of the Company&#x2019;s deferred tax assets. If recognized, none of these amounts would affect the Company&#x2019;s effective tax rate, since it would be offset by an equal reduction in the deferred tax asset valuation allowance. The Company does not foresee material changes to its liability for uncertain tax benefits within the next twelve months. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;The Company did not recognize interest related to unrecognized tax benefits in interest expense and penalties in operating expenses for the year ended December&#160;31, 2023. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;The Company files income tax returns with the United States and various state jurisdictions. To its knowledge, the Company is currently not under examination by the Internal Revenue Service or any other taxing authority. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;With few exceptions, the Company&#x2019;s tax years prior to 2020 are no longer open to examination by the taxing authority. While not open to examination, the tax attributes generated in tax years 2018 and forward remain subject to adjustment by the taxing authorities if utilized in tax years which are still open to examination. &lt;/div&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <pstv:CumulativeChangeInOwnership
      contextRef="PAsOn12_31_2023"
      decimals="2"
      id="ixv-22940"
      unitRef="Unit_pure">0.50</pstv:CumulativeChangeInOwnership>
    <pstv:NetOperatingLossAndResearchAndDevelopmentTaxCreditCarryForwardsToOffsetFutureTaxableIncomePeriod contextRef="P01_01_2023To12_31_2023" id="ixv-22941">P3Y</pstv:NetOperatingLossAndResearchAndDevelopmentTaxCreditCarryForwardsToOffsetFutureTaxableIncomePeriod>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="P01_01_2023To12_31_2023"
      decimals="0"
      id="ixv-22942"
      unitRef="Unit_USD">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="P01_01_2022To12_31_2022"
      decimals="0"
      id="ixv-22943"
      unitRef="Unit_USD">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="P01_01_2023To12_31_2023" id="ixv-16532">&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;A reconciliation of the total income tax provision tax rate to the statutory federal income tax rates of 21% for the years ended December&#160;31, 2023 and 2022, respectively, is as follows: &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 76%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;"&gt;
&lt;tr&gt;
&lt;td style="width: 81%;"&gt;&lt;/td&gt;
&lt;td style="width: 6%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="width: 5%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Income tax expense (benefit) at federal statutory rate&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;(21.0&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;(21.0&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Change in valuation allowance&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;25.5&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;22.5&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Income tax expense (benefit) at state statutory rate&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;(0.2&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;(0.2&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Share based compensation&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;1.0&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;0.9&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;NOLs expiring and adjustments to NOL&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;(0.1&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;0.5&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Research credit&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;(5.1&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;(2.5&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Return to provision&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;(0.1&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;(0.1&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Change in state rate&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;(0.1&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;0.0&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;0.0&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="P01_01_2023To12_31_2023"
      decimals="INF"
      id="ixv-22944"
      unitRef="Unit_pure">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="P01_01_2022To12_31_2022"
      decimals="INF"
      id="ixv-22945"
      unitRef="Unit_pure">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="P01_01_2023To12_31_2023"
      decimals="3"
      id="ixv-22946"
      unitRef="Unit_pure">0.255</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="P01_01_2022To12_31_2022"
      decimals="3"
      id="ixv-22947"
      unitRef="Unit_pure">0.225</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="P01_01_2023To12_31_2023"
      decimals="3"
      id="ixv-22948"
      unitRef="Unit_pure">-0.002</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="P01_01_2022To12_31_2022"
      decimals="3"
      id="ixv-22949"
      unitRef="Unit_pure">-0.002</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="P01_01_2023To12_31_2023"
      decimals="3"
      id="ixv-22950"
      unitRef="Unit_pure">0.01</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="P01_01_2022To12_31_2022"
      decimals="3"
      id="ixv-22951"
      unitRef="Unit_pure">0.009</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <pstv:EffectiveIncomeTaxRateReconciliationNetOperatingLossExpiration
      contextRef="P01_01_2023To12_31_2023"
      decimals="3"
      id="ixv-22952"
      unitRef="Unit_pure">-0.001</pstv:EffectiveIncomeTaxRateReconciliationNetOperatingLossExpiration>
    <pstv:EffectiveIncomeTaxRateReconciliationNetOperatingLossExpiration
      contextRef="P01_01_2022To12_31_2022"
      decimals="3"
      id="ixv-22953"
      unitRef="Unit_pure">0.005</pstv:EffectiveIncomeTaxRateReconciliationNetOperatingLossExpiration>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
      contextRef="P01_01_2023To12_31_2023"
      decimals="3"
      id="ixv-22954"
      unitRef="Unit_pure">0.051</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
      contextRef="P01_01_2022To12_31_2022"
      decimals="3"
      id="ixv-22955"
      unitRef="Unit_pure">0.025</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
    <pstv:EffectiveIncomeTaxRateReconciliationTaxReturnToProvision
      contextRef="P01_01_2023To12_31_2023"
      decimals="3"
      id="ixv-22956"
      unitRef="Unit_pure">-0.001</pstv:EffectiveIncomeTaxRateReconciliationTaxReturnToProvision>
    <pstv:EffectiveIncomeTaxRateReconciliationTaxReturnToProvision
      contextRef="P01_01_2022To12_31_2022"
      decimals="3"
      id="ixv-22957"
      unitRef="Unit_pure">-0.001</pstv:EffectiveIncomeTaxRateReconciliationTaxReturnToProvision>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxSettlementsStateAndLocal
      contextRef="P01_01_2023To12_31_2023"
      decimals="0"
      id="ixv-22958"
      unitRef="Unit_pure">0</us-gaap:EffectiveIncomeTaxRateReconciliationTaxSettlementsStateAndLocal>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxSettlementsStateAndLocal
      contextRef="P01_01_2022To12_31_2022"
      decimals="3"
      id="ixv-22959"
      unitRef="Unit_pure">-0.001</us-gaap:EffectiveIncomeTaxRateReconciliationTaxSettlementsStateAndLocal>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="P01_01_2023To12_31_2023"
      decimals="3"
      id="ixv-22960"
      unitRef="Unit_pure">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="P01_01_2022To12_31_2022"
      decimals="3"
      id="ixv-22961"
      unitRef="Unit_pure">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="P01_01_2023To12_31_2023" id="ixv-16703">&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;The tax effects of temporary differences that give rise to significant portions of our deferred tax assets and deferred tax liabilities as of December&#160;31, 2023 and 2022 are as follows (in thousands): &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 76%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;"&gt;
&lt;tr&gt;
&lt;td style="width: 72%;"&gt;&lt;/td&gt;
&lt;td style="width: 10%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="width: 10%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Deferred tax assets:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Accrued expenses&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;269&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;262&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Share based compensation&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;99&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;107&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Net operating loss carryforwards&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;13,397&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;12,605&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Income tax credit carryforwards&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;1,630&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;956&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Property and equipment, principally due to differences in depreciation&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;154&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;89&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Intangible assets&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;3,527&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;2,073&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Other, net&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;453&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;53&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;19,529&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;16,145&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Valuation allowance&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;(19,486&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;(16,092&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Total deferred tax assets, net of allowance&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;43&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;53&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear:both;max-height:0pt;"&gt;&lt;/div&gt;&lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 76%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;"&gt;
&lt;tr&gt;
&lt;td style="width: 82%;"&gt;&lt;/td&gt;
&lt;td style="width: 5%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="width: 5%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Deferred tax liabilities:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Other&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;(43&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;(53&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Total deferred tax liability&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;(43&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;(53&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Net deferred tax assets (liability)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-22962"
      unitRef="Unit_USD">269000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      id="ixv-22963"
      unitRef="Unit_USD">262000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-22964"
      unitRef="Unit_USD">99000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      id="ixv-22965"
      unitRef="Unit_USD">107000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-22966"
      unitRef="Unit_USD">13397000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      id="ixv-22967"
      unitRef="Unit_USD">12605000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwards
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-22968"
      unitRef="Unit_USD">1630000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwards
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      id="ixv-22969"
      unitRef="Unit_USD">956000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
    <us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-22970"
      unitRef="Unit_USD">154000</us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      id="ixv-22971"
      unitRef="Unit_USD">89000</us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-22972"
      unitRef="Unit_USD">3527000</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
    <us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      id="ixv-22973"
      unitRef="Unit_USD">2073000</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-22974"
      unitRef="Unit_USD">453000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      id="ixv-22975"
      unitRef="Unit_USD">53000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-22976"
      unitRef="Unit_USD">19529000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      id="ixv-22977"
      unitRef="Unit_USD">16145000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-22978"
      unitRef="Unit_USD">19486000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      id="ixv-22979"
      unitRef="Unit_USD">16092000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-22980"
      unitRef="Unit_USD">43000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      id="ixv-22981"
      unitRef="Unit_USD">53000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxLiabilitiesOther
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-22983"
      unitRef="Unit_USD">43000</us-gaap:DeferredTaxLiabilitiesOther>
    <us-gaap:DeferredTaxLiabilitiesOther
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      id="ixv-22984"
      unitRef="Unit_USD">53000</us-gaap:DeferredTaxLiabilitiesOther>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-22985"
      unitRef="Unit_USD">43000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      id="ixv-22986"
      unitRef="Unit_USD">53000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredTaxLiabilities
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-22987"
      unitRef="Unit_USD">0</us-gaap:DeferredTaxLiabilities>
    <us-gaap:DeferredTaxLiabilities
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      id="ixv-22988"
      unitRef="Unit_USD">0</us-gaap:DeferredTaxLiabilities>
    <pstv:DeferredTaxAssetsValuationAllowances
      contextRef="PAsOn12_31_2023"
      decimals="-5"
      id="ixv-22989"
      unitRef="Unit_USD">19500000</pstv:DeferredTaxAssetsValuationAllowances>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="P01_01_2023To12_31_2023"
      decimals="-5"
      id="ixv-22990"
      unitRef="Unit_USD">3400000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:OperatingLossCarryforwards
      contextRef="PAsOn12_31_2023_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis"
      decimals="-5"
      id="ixv-22991"
      unitRef="Unit_USD">63200000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="PAsOn12_31_2023_StateAndLocalJurisdictionMemberusgaapIncomeTaxAuthorityAxis"
      decimals="-5"
      id="ixv-22992"
      unitRef="Unit_USD">2600000</us-gaap:OperatingLossCarryforwards>
    <pstv:OperatingLossCarryforwardsExpirationDates1
      contextRef="P01_01_2023To12_31_2023_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis"
      id="ixv-22993">begin to expire in 2037</pstv:OperatingLossCarryforwardsExpirationDates1>
    <pstv:OperatingLossCarryforwardsExpirationDates1
      contextRef="P01_01_2023To12_31_2023_StateAndLocalJurisdictionMemberusgaapIncomeTaxAuthorityAxis"
      id="ixv-22994">2038</pstv:OperatingLossCarryforwardsExpirationDates1>
    <pstv:NetOperatingLossCarryforward
      contextRef="PAsOn12_31_2023_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis"
      decimals="-5"
      id="ixv-22995"
      unitRef="Unit_USD">59800000</pstv:NetOperatingLossCarryforward>
    <pstv:PercentageOfNetOperatingLossCarryforwardsAvailableForOffsettingAgainstFutureTaxableIncome
      contextRef="P01_01_2023To12_31_2023_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis_MaximumMembersrtRangeAxis"
      decimals="2"
      id="ixv-22996"
      unitRef="Unit_pure">0.80</pstv:PercentageOfNetOperatingLossCarryforwardsAvailableForOffsettingAgainstFutureTaxableIncome>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic
      contextRef="PAsOn12_31_2023_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis"
      decimals="-5"
      id="ixv-22997"
      unitRef="Unit_USD">1900000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic>
    <pstv:TaxCreditCarryforwardExpirationDate1
      contextRef="P01_01_2023To12_31_2023_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis"
      id="ixv-22998">begin to expire in 2039</pstv:TaxCreditCarryforwardExpirationDate1>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal
      contextRef="PAsOn12_31_2023_StateAndLocalJurisdictionMemberusgaapIncomeTaxAuthorityAxis"
      decimals="-5"
      id="ixv-22999"
      unitRef="Unit_USD">200000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal>
    <pstv:TaxCreditCarryforwardExpirationDate1
      contextRef="P01_01_2023To12_31_2023_StateAndLocalJurisdictionMemberusgaapIncomeTaxAuthorityAxis"
      id="ixv-23000">begin to expire in 2043</pstv:TaxCreditCarryforwardExpirationDate1>
    <us-gaap:LiabilityForUncertainTaxPositionsCurrent
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      id="ixv-23001"
      unitRef="Unit_USD">0</us-gaap:LiabilityForUncertainTaxPositionsCurrent>
    <us-gaap:LiabilityForUncertainTaxPositionsCurrent
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-23002"
      unitRef="Unit_USD">0</us-gaap:LiabilityForUncertainTaxPositionsCurrent>
    <us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock contextRef="P01_01_2023To12_31_2023" id="ixv-17063">&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Following is a tabular reconciliation of the unrecognized tax benefits activity during the years ended December&#160;31, 2023 and 2022 (in thousands): &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 76%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;"&gt;
&lt;tr&gt;
&lt;td style="width: 82%;"&gt;&lt;/td&gt;
&lt;td style="width: 5%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="width: 5%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Unrecognized Tax Benefits &#x2013; Beginning&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;209&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;81&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Gross decreases &#x2013; tax positions in prior period&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;(16&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;(1&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Gross increase &#x2013; current-period tax positions&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;215&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;129&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Unrecognized Tax Benefits &#x2013; Ending&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;408&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;209&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      id="ixv-23003"
      unitRef="Unit_USD">209000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      id="ixv-23004"
      unitRef="Unit_USD">81000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-23005"
      unitRef="Unit_USD">16000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      id="ixv-23006"
      unitRef="Unit_USD">1000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-23007"
      unitRef="Unit_USD">215000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      id="ixv-23008"
      unitRef="Unit_USD">129000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-23009"
      unitRef="Unit_USD">408000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      id="ixv-23010"
      unitRef="Unit_USD">209000</us-gaap:UnrecognizedTaxBenefits>
    <pstv:PeriodForMaterialChangesOfLiabilityForUncertainTaxBenefits contextRef="P01_01_2023To12_31_2023" id="ixv-23011">P12M</pstv:PeriodForMaterialChangesOfLiabilityForUncertainTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-23012"
      unitRef="Unit_USD">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense>
    <us-gaap:CompensationAndEmployeeBenefitPlansTextBlock contextRef="P01_01_2023To12_31_2023" id="ixv-17197">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;11. Employee Benefit Plan &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;The Company implemented a 401(k) retirement savings and profit sharing plan (the &#x201c;Plan&#x201d;) effective January&#160;1, 1999. During 2022, the Company commenced safe harbor matching contribution for up to 4% of eligible employee contributions. Total matching contribution under the Plan amounted to approximately $107,000 and $100,000 for the year ended December&#160;31, 2023 and 2022, respectively. &lt;/div&gt;&lt;/div&gt;</us-gaap:CompensationAndEmployeeBenefitPlansTextBlock>
    <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch
      contextRef="P01_01_2023To12_31_2023_MaximumMembersrtRangeAxis"
      decimals="INF"
      id="ixv-23014"
      unitRef="Unit_pure">0.04</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount
      contextRef="P01_01_2023To12_31_2023"
      decimals="0"
      id="ixv-23015"
      unitRef="Unit_USD">107000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount
      contextRef="P01_01_2022To12_31_2022"
      decimals="0"
      id="ixv-23016"
      unitRef="Unit_USD">100000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="P01_01_2023To12_31_2023" id="ixv-17203">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;12. Stockholders&#x2019; Equity &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Preferred Stock &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;The Company has authorized 5,000,000 shares of preferred stock, par value $0.001 per share. The Board is authorized to designate the terms and conditions of any preferred stock the Company issues without further action by the common stockholders. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Series F Preferred Stock &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;On March&#160;3, 2023, the Company filed a certificate of designation (the &#x201c;Certificate of Designation&#x201d;) with the Secretary of State of the State of Delaware, effective as of the time of filing, designating the rights, preferences, privileges and restrictions of the Series F Preferred Stock, with the total authorization of one (1)&#160;share of Series F Preferred Stock. The Certificate of Designation provided that the share of Series F Preferred Stock will have 50,000,000 votes per share of Series F Preferred Stock and will vote together with the Company&#x2019;s common stock, $0.001 par value (the &#x201c;Common Stock&#x201d;) as a single class exclusively with respect to any proposal to amend the Company&#x2019;s Charter to effect a reverse stock split of the Common Stock (the &#x201c;Reverse Stock Split&#x201d;). On March&#160;3, 2023, the Company entered into a Subscription and Investment Representation Agreement (the &#x201c;Subscription Agreement&#x201d;) with Richard J. Hawkins, Chairman of the Board, who is an accredited investor (the &#x201c;Purchaser&#x201d;), pursuant to which the Company agreed to issue and sell one (1)&#160;share of the Company&#x2019;s Series F Preferred Stock, par value $0.001 per share (the &#x201c;Preferred Stock&#x201d;), to the Purchaser for $1,000 in cash. The sale closed on March 3, 2023. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;At the Company&#x2019;s annual meeting of stockholders held on April&#160;20, 2023, the Series F Preferred Stock was voted, without action by the holder, on the proposal to approve the Reverse Stock Split in the same proportion as shares of Common Stock voted to approve the Reverse Stock Split. The Series F Preferred Stock otherwise had no voting rights except as otherwise required by the General Corporation Law of the State of Delaware. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;The Series F Preferred Stock was not convertible into, or exchangeable for, shares of any other class or series of stock or other securities of the Company. The Series F Preferred Stock had no rights with respect to any distribution of assets of the Company, including upon a liquidation, bankruptcy, reorganization, merger, acquisition, sale, dissolution or winding up of the Company, whether voluntarily or involuntarily. The holder of the Series F Preferred Stock was not entitled to receive dividends of any kind. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;The outstanding share of Series F Preferred Stock was redeemed in whole, automatically effective upon the approval by the Company&#x2019;s stockholders of a Reverse Stock Split. Upon such redemption, the holder of the Series F Preferred Stock received consideration of $1,000 in cash. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Series B and C Preferred Stock &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;As of December&#160;31, 2023, there were 938 outstanding shares of Series C Preferred Stock that can be converted into an aggregate of 27,792 shares of common stock, and 1,014 shares of Series B Convertible Preferred Stock that can be converted into an aggregate of 398 shares of common stock. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Warrants &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;On September&#160;25, 2019, the Company completed an underwritten public offering. The Company issued 19,266 shares of its common stock, along with &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;pre-funded&lt;/div&gt; warrants to purchase 180,733 shares of its common stock and Series U Warrants to purchase 230,000 shares of its common stock at $75.00 per share. The Series U Warrants have a term of five years from the issuance date. In addition, the Company issued warrants to H.C. Wainwright&#160;&amp;amp; Co., LLC, as representatives of the underwriters, to purchase 5,000 shares of its common stock at $93.75 per share with a term of 5 years from the issuance date, in the form of Series U Warrants (the &#x201c;Representative Warrants&#x201d;). &lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;As of December&#160;31, 2023, there were 142,733 outstanding Series U Warrants which can be exercised into an aggregate of 142,733 shares of common stock at the weighted average exercise price of $34.10 per share. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Common Stock &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;On August&#160;2, 2022, the Company entered into a purchase agreement (the &#x201c;2022 Purchase Agreement&#x201d;) and registration rights agreement pursuant to which Lincoln Park committed to purchase up to $50.0&#160;million of the Company&#x2019;s common stock. Under the terms and subject to the conditions of the 2022 Purchase Agreement, the Company has the right, but not the obligation, to sell to Lincoln Park, and Lincoln Park is obligated to purchase up to $50.0&#160;million of the Company&#x2019;s common stock. Such sales of common stock by the Company are subject to certain limitations, and can occur from time to time, at the Company&#x2019;s sole discretion, over the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;36-month&lt;/div&gt; period commencing on August&#160;17, 2022, subject to the satisfaction of certain conditions. Lincoln Park has no right to require the Company to sell any shares of common stock to Lincoln Park, but Lincoln Park is obligated to make purchases as the Company directs, subject to certain conditions. &lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;On May&#160;16, 2022, the Company received stockholder approval for purposes of the Nasdaq listing rules to permit issuances of up to 57.5&#160;million shares of the Company&#x2019;s common stock (including the issuance of more than 19.99% of the Company&#x2019;s common stock) to Lincoln Park, and it was pursuant to that approval that the Company entered into the 2022 Purchase Agreement. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Upon execution of the 2022 Purchase Agreement, the Company paid $125,000 in cash as the initial commitment fee, and issued 32,846 shares as the initial commitment shares, to Lincoln Park as consideration for its irrevocable commitment to purchase shares of the Company&#x2019;s common stock at its direction under the Purchase Agreement. The Company has agreed to pay an additional commitment fee, which it may elect to pay in cash and/or shares of its common stock, upon receipt of $25.0&#160;million aggregate gross proceeds from sales of common stock to Lincoln Park under the 2022 Purchase Agreement. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;On August&#160;17, 2022, a registration statement (the &#x201c;First Registration Statement&#x201d;) was declared effective to cover the resale of up to 633,333 shares of the Company&#x2019;s common stock comprised of (i)&#160;the 32,846 initial commitment shares, and (ii)&#160;up to 600,486 that the Company has reserved for issuance and sale to Lincoln Park under the 2022 Purchase Agreement from time to time from and after the date of the prospectus. The Company sold approximately 527,166 shares under the First Registration Statement. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;On August&#160;18, 2023, a second registration statement (the &#x201c;Second Registration Statement&#x201d;) was declared effective to cover the resale of up to an additional 1,500,000 shares of the Company&#x2019;s common stock that the Company reserved for issuance and sale to Lincoln Park under the 2022 Purchase Agreement from time to time. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;We sold 150,000 shares under the Second Registration Statement. The Company cannot sell more shares than registered under the Second Registration Statement under the 2022 Purchase Agreement without registering additional shares. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Actual sales of shares of common stock to Lincoln Park under the 2022 Purchase Agreement depend on a variety of factors to be determined by the Company from time to time, including, among others, market conditions, the trading price of the common stock and determinations by the Company as to the appropriate sources of funding for the Company and its operations. The net proceeds under the 2022 Purchase Agreement to the Company depend on the frequency and prices at which the Company sells shares of its stock to Lincoln Park. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;During the period from August&#160;17, 2022 to December&#160;31, 2022, the Company issued 266,666 shares under the 2022 Purchase Agreement for net proceeds of approximately $3.2&#160;million. The Company issued 410,500 shares under the 2022 Purchase Agreement for net proceeds of approximately $1.0&#160;million from January&#160;1, 2023 to December&#160;31, 2023. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;On September&#160;30, 2020, the Company entered into a purchase agreement (the &#x201c;2020 Purchase Agreement&#x201d;) and registration rights agreement pursuant to which Lincoln Park committed to purchase up to $25.0&#160;million of the Company&#x2019;s common stock. Under the terms and subject to the conditions of the 2020 Purchase Agreement, the Company had the right, but not the obligation, to sell to Lincoln Park, and Lincoln Park was obligated to purchase up to $25.0&#160;million of the Company&#x2019;s common stock. Such sales of common stock by the Company were subject to certain limitations, and could occur from time to time, at the Company&#x2019;s sole discretion, over the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;36-month&lt;/div&gt; period commencing on November&#160;6, 2020, subject to the satisfaction of certain conditions. &lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;During the year ended December&#160;31, 2022, the Company issued 377,666 shares of its common stock under the 2020 Purchase Agreement for net proceeds of approximately $7.0&#160;million. The Company no longer has any additional shares of common stock registered to sell under the 2020 Purchase Agreement and has terminated the 2020 Purchase Agreement. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;At-the-market&lt;/div&gt;&lt;/div&gt; Issuances &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;On September&#160;9, 2022, the Company entered into an Equity Distribution Agreement (the &#x201c;September 2022 Distribution Agreement&#x201d;) with Canaccord Genuity LLC (&#x201c;Canaccord&#x201d;), pursuant to which the Company could issue and sell, from time to time, shares of its common stock having an aggregate offering price of up to $5,000,000, depending on market demand, with Canaccord acting as an agent for sales. During the period from September&#160;9, 2022 to December&#160;31, 2022, the Company issued 68,758 shares of its common stock under the September 2022 Distribution Agreement for net proceeds of approximately $0.6&#160;million. From January&#160;1, 2023 through December&#160;31, 2023, the Company issued 1,819,993 shares under the September 2022 Distribution Agreement for net proceeds of approximately $4.3&#160;million. The Company has reached the capacity for sales of shares under the September 2022 Distribution Agreement and the agreement has terminated. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;The Company was obligated to pay Canaccord a commission of up to 3.0% of the gross proceeds from the sale of its common stock under the September 2022 Distribution Agreement. The Company also agreed to reimburse Canaccord for its reasonable documented &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;out-of-pocket&lt;/div&gt;&lt;/div&gt; expenses, including fees and disbursements of its counsel, in the amount of $50,000. In addition, the Company agreed to provide customary indemnification rights to Canaccord. &lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;On January&#160;14, 2022, the Company entered into an Equity Distribution Agreement (the &#x201c;January 2022 Distribution Agreement&#x201d;) with Canaccord, pursuant to which the Company could issue and sell, from time to time, shares of its common stock having an aggregate offering price of up to $5,000,000, with Canaccord acting as an agent for sales. The Company had no obligation to sell any of the Company&#x2019;s shares and it could instruct Canaccord not to sell any shares if the sales could not be effected at or above the price designated by the Company from time to time and the Company could at any time suspend sales pursuant to the January 2022 Distribution Agreement. During the year ended December&#160;31, 2022, the Company issued 460,151 shares under &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;the January 2022 Distribution Agreement for net proceeds of approximately $4.8&#160;million. The January 2022 Distribution Agreement has been terminated after all available registered shares were fully utilized. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Share Repurchase Program and Treasury Stock &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;On October&#160;31, 2023, the Company announced that its Board has approved a share repurchase program (the &#x201c;Share Repurchase Program&#x201d;), with authorization to repurchase up to $500,000 of the outstanding shares of the Company&#x2019;s common stock. The Company intends to fund any repurchases under the Share Repurchase Program with available cash. The timing and amount of any shares repurchased will be determined based on the Company&#x2019;s evaluation of market conditions and other factors, including consent of the Company&#x2019;s lender. Repurchases may be made from time to time on the open market through October&#160;31, 2024. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;During the year ended December&#160;31, 2023, the Company purchased 78,559 of its common shares for approximately $126,000 as treasury stock. During the period January&#160;1, 2024 through February&#160;26, 2024, the Company purchased 168,015 of its common shares for approximately $340,000 as treasury stock. &lt;/div&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="PAsOn12_31_2023"
      decimals="INF"
      id="ixv-23017"
      unitRef="Unit_shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="PAsOn12_31_2023"
      decimals="INF"
      id="ixv-23018"
      unitRef="Unit_USD_per_Share">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="PAsOn03_03_2023_SeriesFConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      id="ixv-23019"
      unitRef="Unit_shares">1</us-gaap:PreferredStockSharesAuthorized>
    <pstv:NumberOfVotesPerShare
      contextRef="PAsOn03_03_2023_SeriesFConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      id="ixv-23020"
      unitRef="Unit_Votes">50000000</pstv:NumberOfVotesPerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="PAsOn03_03_2023_SeriesFConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      id="ixv-23021"
      unitRef="Unit_USD_per_Share">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="P03_03_2023To03_03_2023_SeriesFConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis_SubscriptionAgreementMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="0"
      id="ixv-23022"
      unitRef="Unit_shares">1</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="PAsOn03_03_2023_SeriesFConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis_SubscriptionAgreementMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="INF"
      id="ixv-23023"
      unitRef="Unit_USD_per_Share">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="P03_03_2023To03_03_2023_SeriesFConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis_SubscriptionAgreementMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="0"
      id="ixv-23024"
      unitRef="Unit_USD">1000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:SaleOfStockTransactionDate
      contextRef="P03_03_2023To03_03_2023_SeriesFConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis_SubscriptionAgreementMemberusgaapSubsidiarySaleOfStockAxis"
      id="ixv-23025">2023-03-03</us-gaap:SaleOfStockTransactionDate>
    <us-gaap:PreferredStockVotingRights
      contextRef="P03_03_2023To03_03_2023_SeriesFConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      id="ixv-23026">no</us-gaap:PreferredStockVotingRights>
    <pstv:RightsRelatedToDistributionOfAssets
      contextRef="P03_03_2023To03_03_2023_SeriesFConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      id="ixv-23027">no</pstv:RightsRelatedToDistributionOfAssets>
    <pstv:ConsiderationPaidToPreferredStockHolders
      contextRef="P03_03_2023To03_03_2023_SeriesFConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="0"
      id="ixv-23028"
      unitRef="Unit_USD">1000</pstv:ConsiderationPaidToPreferredStockHolders>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="PAsOn12_31_2023_SeriesCConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis_TwoThousandEighteenRightsOfferingMemberusgaapClassOfWarrantOrRightAxis"
      decimals="INF"
      id="ixv-23030"
      unitRef="Unit_shares">938</us-gaap:PreferredStockSharesOutstanding>
    <pstv:NumberOfPreferredStockSharesExercised
      contextRef="P01_01_2023To12_31_2023_SeriesCConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis_TwoThousandEighteenRightsOfferingMemberusgaapClassOfWarrantOrRightAxis"
      decimals="INF"
      id="ixv-23031"
      unitRef="Unit_shares">27792</pstv:NumberOfPreferredStockSharesExercised>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="PAsOn12_31_2023_SeriesBConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis_TwoThousandEighteenRightsOfferingMemberusgaapClassOfWarrantOrRightAxis"
      decimals="INF"
      id="ixv-23032"
      unitRef="Unit_shares">1014</us-gaap:PreferredStockSharesOutstanding>
    <pstv:NumberOfPreferredStockSharesExercised
      contextRef="P01_01_2023To12_31_2023_SeriesBConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis_TwoThousandEighteenRightsOfferingMemberusgaapClassOfWarrantOrRightAxis"
      decimals="INF"
      id="ixv-23033"
      unitRef="Unit_shares">398</pstv:NumberOfPreferredStockSharesExercised>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="P01_01_2023To12_31_2023_CommonClassAMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      id="ixv-23034"
      unitRef="Unit_shares">19266</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="PAsOn12_31_2023_CommonClassBMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      id="ixv-23035"
      unitRef="Unit_shares">180733</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="P01_01_2023To12_31_2023_SeriesUWarrantsMemberusgaapClassOfWarrantOrRightAxis"
      decimals="INF"
      id="ixv-23036"
      unitRef="Unit_shares">230000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="PAsOn12_31_2023_SeriesUWarrantsMemberusgaapClassOfWarrantOrRightAxis"
      decimals="2"
      id="ixv-23037"
      unitRef="Unit_USD_per_Share">75</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="PAsOn12_31_2023_SeriesUWarrantsMemberusgaapClassOfWarrantOrRightAxis"
      id="ixv-23038">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="PAsOn12_31_2023_RepresentativeSeriesUWarrantMemberusgaapStatementEquityComponentsAxis"
      decimals="INF"
      id="ixv-23039"
      unitRef="Unit_shares">5000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="PAsOn12_31_2023_RepresentativeSeriesUWarrantMemberusgaapStatementEquityComponentsAxis"
      decimals="2"
      id="ixv-23040"
      unitRef="Unit_USD_per_Share">93.75</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="PAsOn12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis"
      id="ixv-23041">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="PAsOn12_31_2023_SeriesUWarrantsMemberusgaapClassOfWarrantOrRightAxis_WarrantMemberusgaapStatementEquityComponentsAxis"
      decimals="INF"
      id="ixv-23042"
      unitRef="Unit_shares">142733</us-gaap:ClassOfWarrantOrRightOutstanding>
    <pstv:NumberOfWarrantsExercised
      contextRef="P01_01_2023To12_31_2023_SeriesUWarrantsMemberusgaapClassOfWarrantOrRightAxis_WarrantMemberusgaapStatementEquityComponentsAxis"
      decimals="INF"
      id="ixv-23043"
      unitRef="Unit_shares">142733</pstv:NumberOfWarrantsExercised>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="PAsOn12_31_2023_SeriesUWarrantsMemberusgaapClassOfWarrantOrRightAxis_WarrantMemberusgaapStatementEquityComponentsAxis"
      decimals="2"
      id="ixv-23044"
      unitRef="Unit_USD_per_Share">34.1</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <pstv:MaximumValueOfSharesToBeIssuedUnderAgreement
      contextRef="PAsOn08_02_2022_CommonStockMemberusgaapStatementEquityComponentsAxis_LincolnParkCapitalFundLLCMemberdeiLegalEntityAxis_TwoThousandAndTwentyTwoPurchaseAgreementMemberusgaapInvestmentTypeAxis"
      decimals="INF"
      id="ixv-23045"
      unitRef="Unit_USD">50000000</pstv:MaximumValueOfSharesToBeIssuedUnderAgreement>
    <pstv:MaximumValueOfSharesToBeIssuedUnderAgreement
      contextRef="PAsOn08_02_2022_CommonStockMemberusgaapStatementEquityComponentsAxis_LincolnParkCapitalFundLLCMemberdeiLegalEntityAxis_TwoThousandAndTwentyTwoPurchaseAgreementMemberusgaapInvestmentTypeAxis"
      decimals="INF"
      id="ixv-23046"
      unitRef="Unit_USD">50000000</pstv:MaximumValueOfSharesToBeIssuedUnderAgreement>
    <pstv:PeriodExercisableFromTheDateOfIssuance
      contextRef="P01_01_2023To12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis_LincolnParkCapitalFundLLCMemberdeiLegalEntityAxis_TwoThousandAndTwentyTwoPurchaseAgreementMemberusgaapInvestmentTypeAxis"
      id="ixv-23047">P36M</pstv:PeriodExercisableFromTheDateOfIssuance>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="PAsOn05_16_2022_LincolnParkCapitalFundLLCMemberdeiLegalEntityAxis_MaximumMembersrtRangeAxis_TwoThousandAndTwentyTwoPurchaseAgreementMemberusgaapInvestmentTypeAxis"
      decimals="INF"
      id="ixv-23048"
      unitRef="Unit_shares">57500000</us-gaap:CommonStockSharesAuthorized>
    <pstv:PercentageIssuanceOfCommonStock
      contextRef="P05_16_2022To05_16_2022_CommonStockMemberusgaapStatementEquityComponentsAxis_LincolnParkCapitalFundLLCMemberdeiLegalEntityAxis_MinimumMembersrtRangeAxis_TwoThousandAndTwentyTwoPurchaseAgreementMemberusgaapInvestmentTypeAxis"
      decimals="4"
      id="ixv-23049"
      unitRef="Unit_pure">0.1999</pstv:PercentageIssuanceOfCommonStock>
    <pstv:InitialCommitmentFee
      contextRef="PAsOn08_02_2022_CommonStockMemberusgaapStatementEquityComponentsAxis_LincolnParkCapitalFundLLCMemberdeiLegalEntityAxis_TwoThousandAndTwentyTwoPurchaseAgreementMemberusgaapInvestmentTypeAxis"
      decimals="0"
      id="ixv-23050"
      unitRef="Unit_USD">125000</pstv:InitialCommitmentFee>
    <pstv:InitialCommitmentShares
      contextRef="PAsOn08_02_2022_CommonStockMemberusgaapStatementEquityComponentsAxis_LincolnParkCapitalFundLLCMemberdeiLegalEntityAxis_TwoThousandAndTwentyTwoPurchaseAgreementMemberusgaapInvestmentTypeAxis"
      decimals="INF"
      id="ixv-23051"
      unitRef="Unit_shares">32846</pstv:InitialCommitmentShares>
    <pstv:GrossProceedsFromIssuanceOfCommonStock
      contextRef="P08_02_2022To08_02_2022_CommonStockMemberusgaapStatementEquityComponentsAxis_LincolnParkCapitalFundLLCMemberdeiLegalEntityAxis_TwoThousandAndTwentyTwoPurchaseAgreementMemberusgaapInvestmentTypeAxis"
      decimals="-5"
      id="ixv-23052"
      unitRef="Unit_USD">25000000</pstv:GrossProceedsFromIssuanceOfCommonStock>
    <pstv:NumberOfMaximumCommonSharesCanBeResale
      contextRef="PAsOn08_17_2022_CommonStockMemberusgaapStatementEquityComponentsAxis_LincolnParkCapitalFundLLCMemberdeiLegalEntityAxis_TwoThousandAndTwentyTwoPurchaseAgreementMemberusgaapInvestmentTypeAxis"
      decimals="INF"
      id="ixv-23053"
      unitRef="Unit_shares">633333</pstv:NumberOfMaximumCommonSharesCanBeResale>
    <pstv:InitialCommitmentShares
      contextRef="PAsOn07_14_2022_CommonStockMemberusgaapStatementEquityComponentsAxis_LincolnParkCapitalFundLLCMemberdeiLegalEntityAxis_TwoThousandAndTwentyTwoPurchaseAgreementMemberusgaapInvestmentTypeAxis"
      decimals="INF"
      id="ixv-23054"
      unitRef="Unit_shares">32846</pstv:InitialCommitmentShares>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="PAsOn08_17_2022_CommonStockMemberusgaapStatementEquityComponentsAxis_LincolnParkCapitalFundLLCMemberdeiLegalEntityAxis_MaximumMembersrtRangeAxis_TwoThousandAndTwentyTwoPurchaseAgreementMemberusgaapInvestmentTypeAxis"
      decimals="INF"
      id="ixv-23055"
      unitRef="Unit_shares">600486</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="P08_17_2022To12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis_LincolnParkCapitalFundLLCMemberdeiLegalEntityAxis_TwentyTwentyPurchaseAgreementMemberusgaapInvestmentTypeAxis"
      decimals="0"
      id="ixv-23056"
      unitRef="Unit_shares">527166</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <pstv:NumberOfMaximumCommonSharesCanBeResale
      contextRef="PAsOn08_18_2023_CommonStockMemberusgaapStatementEquityComponentsAxis_LincolnParkCapitalFundLLCMemberdeiLegalEntityAxis_MaximumMembersrtRangeAxis_TwoThousandAndTwentyTwoPurchaseAgreementMemberusgaapInvestmentTypeAxis"
      decimals="INF"
      id="ixv-23057"
      unitRef="Unit_shares">1500000</pstv:NumberOfMaximumCommonSharesCanBeResale>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="P08_18_2023To12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis_LincolnParkCapitalFundLLCMemberdeiLegalEntityAxis_TwoThousandAndTwentyTwoPurchaseAgreementMemberusgaapInvestmentTypeAxis"
      decimals="INF"
      id="ixv-23059"
      unitRef="Unit_shares">150000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="P08_17_2022To12_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis_LincolnParkCapitalFundLLCMemberdeiLegalEntityAxis_TwoThousandAndTwentyTwoPurchaseAgreementMemberusgaapInvestmentTypeAxis"
      decimals="INF"
      id="ixv-23060"
      unitRef="Unit_shares">266666</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="P08_17_2022To12_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis_LincolnParkCapitalFundLLCMemberdeiLegalEntityAxis_TwoThousandAndTwentyTwoPurchaseAgreementMemberusgaapInvestmentTypeAxis"
      decimals="-5"
      id="ixv-23061"
      unitRef="Unit_USD">3200000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="P01_01_2023To12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis_LincolnParkCapitalFundLLCMemberdeiLegalEntityAxis_TwoThousandAndTwentyTwoPurchaseAgreementMemberusgaapInvestmentTypeAxis"
      decimals="INF"
      id="ixv-23062"
      unitRef="Unit_shares">410500</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="P01_01_2023To12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis_LincolnParkCapitalFundLLCMemberdeiLegalEntityAxis_TwoThousandAndTwentyTwoPurchaseAgreementMemberusgaapInvestmentTypeAxis"
      decimals="-5"
      id="ixv-23063"
      unitRef="Unit_USD">1000000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <pstv:MaximumValueOfSharesToBeIssuedUnderAgreement
      contextRef="PAsOn09_30_2020_CommonStockMemberusgaapStatementEquityComponentsAxis_LincolnParkCapitalFundLLCMemberdeiLegalEntityAxis_TwentyTwentyPurchaseAgreementMemberusgaapInvestmentTypeAxis"
      decimals="INF"
      id="ixv-23064"
      unitRef="Unit_USD">25000000</pstv:MaximumValueOfSharesToBeIssuedUnderAgreement>
    <pstv:MaximumValueOfSharesToBeIssuedUnderAgreement
      contextRef="PAsOn09_30_2020_CommonStockMemberusgaapStatementEquityComponentsAxis_LincolnParkCapitalFundLLCMemberdeiLegalEntityAxis_TwentyTwentyPurchaseAgreementMemberusgaapInvestmentTypeAxis"
      decimals="INF"
      id="ixv-23065"
      unitRef="Unit_USD">25000000</pstv:MaximumValueOfSharesToBeIssuedUnderAgreement>
    <pstv:PeriodExercisableFromTheDateOfIssuance
      contextRef="P01_01_2020To09_30_2020_CommonStockMemberusgaapStatementEquityComponentsAxis_LincolnParkCapitalFundLLCMemberdeiLegalEntityAxis_TwentyTwentyPurchaseAgreementMemberusgaapInvestmentTypeAxis"
      id="ixv-23066">P36M</pstv:PeriodExercisableFromTheDateOfIssuance>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="P01_01_2022To12_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis_LincolnParkCapitalFundLLCMemberdeiLegalEntityAxis_TwentyTwentyPurchaseAgreementMemberusgaapInvestmentTypeAxis"
      decimals="INF"
      id="ixv-23067"
      unitRef="Unit_USD">377666</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="P01_01_2022To12_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis_LincolnParkCapitalFundLLCMemberdeiLegalEntityAxis_TwentyTwentyPurchaseAgreementMemberusgaapInvestmentTypeAxis"
      decimals="-5"
      id="ixv-23068"
      unitRef="Unit_USD">7000000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:SharesIssued
      contextRef="PAsOn12_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis_LincolnParkCapitalFundLLCMemberdeiLegalEntityAxis_TwentyTwentyPurchaseAgreementMemberusgaapInvestmentTypeAxis"
      decimals="0"
      id="ixv-23069"
      unitRef="Unit_shares">0</us-gaap:SharesIssued>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="P09_09_2022To09_09_2022_AtTheMarketOfferingProgramMemberusgaapSubsidiarySaleOfStockAxis_CanaccordGenuityLLCMemberdeiLegalEntityAxis_CommonStockMemberusgaapStatementEquityComponentsAxis_MaximumMembersrtRangeAxis_SeptemberTwoThousandAndTwentyTwoDistributionAgreementMemberusgaapInvestmentTypeAxis"
      decimals="0"
      id="ixv-23070"
      unitRef="Unit_USD">5000000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="P09_09_2022To12_31_2022_AtTheMarketOfferingProgramMemberusgaapSubsidiarySaleOfStockAxis_CanaccordGenuityLLCMemberdeiLegalEntityAxis_CommonStockMemberusgaapStatementEquityComponentsAxis_SeptemberTwoThousandAndTwentyTwoDistributionAgreementMemberusgaapInvestmentTypeAxis"
      decimals="INF"
      id="ixv-23071"
      unitRef="Unit_shares">68758</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="P09_09_2022To12_31_2022_AtTheMarketOfferingProgramMemberusgaapSubsidiarySaleOfStockAxis_CanaccordGenuityLLCMemberdeiLegalEntityAxis_CommonStockMemberusgaapStatementEquityComponentsAxis_SeptemberTwoThousandAndTwentyTwoDistributionAgreementMemberusgaapInvestmentTypeAxis"
      decimals="-5"
      id="ixv-23072"
      unitRef="Unit_USD">600000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="P01_01_2023To12_31_2023_AtTheMarketOfferingProgramMemberusgaapSubsidiarySaleOfStockAxis_CanaccordGenuityLLCMemberdeiLegalEntityAxis_CommonStockMemberusgaapStatementEquityComponentsAxis_SeptemberTwoThousandAndTwentyTwoDistributionAgreementMemberusgaapInvestmentTypeAxis"
      decimals="INF"
      id="ixv-23073"
      unitRef="Unit_shares">1819993</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="P01_01_2023To12_31_2023_AtTheMarketOfferingProgramMemberusgaapSubsidiarySaleOfStockAxis_CanaccordGenuityLLCMemberdeiLegalEntityAxis_CommonStockMemberusgaapStatementEquityComponentsAxis_SeptemberTwoThousandAndTwentyTwoDistributionAgreementMemberusgaapInvestmentTypeAxis"
      decimals="-5"
      id="ixv-23074"
      unitRef="Unit_USD">4300000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <pstv:PercentageOfCommissionOnGrossProceedsFromSaleOfCommonStock
      contextRef="P09_09_2022To09_09_2022_AtTheMarketOfferingProgramMemberusgaapSubsidiarySaleOfStockAxis_CanaccordGenuityLLCMemberdeiLegalEntityAxis_CommonStockMemberusgaapStatementEquityComponentsAxis_MaximumMembersrtRangeAxis_SeptemberTwoThousandAndTwentyTwoDistributionAgreementMemberusgaapInvestmentTypeAxis"
      decimals="INF"
      id="ixv-23075"
      unitRef="Unit_pure">0.03</pstv:PercentageOfCommissionOnGrossProceedsFromSaleOfCommonStock>
    <pstv:AggregateExpenseIncludingFeeAndDisbursementExpenses
      contextRef="P09_09_2022To09_09_2022_AtTheMarketOfferingProgramMemberusgaapSubsidiarySaleOfStockAxis_CanaccordGenuityLLCMemberdeiLegalEntityAxis_SeptemberTwoThousandAndTwentyTwoDistributionAgreementMemberusgaapInvestmentTypeAxis"
      decimals="0"
      id="ixv-23076"
      unitRef="Unit_USD">50000</pstv:AggregateExpenseIncludingFeeAndDisbursementExpenses>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="P01_14_2022To01_14_2022_AtTheMarketOfferingProgramMemberusgaapSubsidiarySaleOfStockAxis_CanaccordGenuityLLCMemberdeiLegalEntityAxis_CommonStockMemberusgaapStatementEquityComponentsAxis_JanuaryTwoThousandAndTwentyTwoDistributionAgreementMemberusgaapInvestmentTypeAxis_MaximumMembersrtRangeAxis"
      decimals="INF"
      id="ixv-23077"
      unitRef="Unit_USD">5000000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <pstv:CommonStockSalesAvailableForIssuance
      contextRef="PAsOn01_14_2022_AtTheMarketOfferingProgramMemberusgaapSubsidiarySaleOfStockAxis_CanaccordGenuityLLCMemberdeiLegalEntityAxis_CommonStockMemberusgaapStatementEquityComponentsAxis_JanuaryTwoThousandAndTwentyTwoDistributionAgreementMemberusgaapInvestmentTypeAxis"
      decimals="0"
      id="ixv-23078"
      unitRef="Unit_USD">0</pstv:CommonStockSalesAvailableForIssuance>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="P01_01_2022To12_31_2022_CanaccordGenuityLLCMemberdeiLegalEntityAxis_CommonStockMemberusgaapStatementEquityComponentsAxis_JanuaryTwoThousandAndTwentyTwoDistributionAgreementMemberusgaapInvestmentTypeAxis"
      decimals="INF"
      id="ixv-23079"
      unitRef="Unit_shares">460151</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="P01_01_2022To12_31_2022_CanaccordGenuityLLCMemberdeiLegalEntityAxis_CommonStockMemberusgaapStatementEquityComponentsAxis_JanuaryTwoThousandAndTwentyTwoDistributionAgreementMemberusgaapInvestmentTypeAxis"
      decimals="-5"
      id="ixv-23081"
      unitRef="Unit_USD">4800000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:StockRepurchaseProgramAuthorizedAmount1
      contextRef="PAsOn10_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis_MaximumMembersrtRangeAxis"
      decimals="INF"
      id="ixv-23082"
      unitRef="Unit_USD">500000</us-gaap:StockRepurchaseProgramAuthorizedAmount1>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="P01_01_2023To12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="INF"
      id="ixv-23083"
      unitRef="Unit_shares">78559</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:TreasuryStockValue
      contextRef="PAsOn12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      id="ixv-23084"
      unitRef="Unit_USD">126000</us-gaap:TreasuryStockValue>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="P01_01_2024To02_26_2024_CommonStockMemberusgaapStatementEquityComponentsAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="INF"
      id="ixv-23085"
      unitRef="Unit_shares">168015</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:TreasuryStockValue
      contextRef="PAsOn02_26_2024_CommonStockMemberusgaapStatementEquityComponentsAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="0"
      id="ixv-23086"
      unitRef="Unit_USD">340000</us-gaap:TreasuryStockValue>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="P01_01_2023To12_31_2023" id="ixv-17318">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;13. Share-based Compensation &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;Under the Company&#x2019;s 2015 New Employee Incentive Plan (the &#x201c;2015 Plan&#x201d;), awards may only be granted to employees who were not previously an employee or director of the Company, or following a bona fide period of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;non-employment,&lt;/div&gt; as a material inducement to entering into employment with the Company. As of December&#160;31, 2023, there were 6,024 shares of common stock remaining and available for future issuances under the 2015 Plan. &lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;The Company&#x2019;s 2020 Stock Incentive Plan (the &#x201c;2020 Plan&#x201d;), which replaced the Company&#x2019;s 2014 Equity Incentive Plan, provides for the award or sale of shares of common stock (including restricted stock), the award of stock units and stock appreciation rights, and the grant of both incentive stock options to purchase common stock to directors, officers, employees and consultants of the Company. The 2020 Plan, as amended, provides for the issuance of up to 3,550,000 shares of common stock, plus the number of shares available for issuance is increased to the extent that awards granted under the 2020 Plan and the Company&#x2019;s 2014 Equity Incentive Plan are forfeited or expire (except as otherwise provided in the 2020 Plan). As of December&#160;31, 2023, there were 180,607 shares remaining and available for future issuances under the 2020 Plan. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;Generally, options issued under the 2020 Plan are subject to a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;two-year&lt;/div&gt; or four-year vesting schedule with 25% of the options vesting on the one year anniversary of the grant date followed by equal monthly installment vesting, and have a contractual term of 10 years. &lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;A summary of activity for the year ended December&#160;31, 2023 is as follows: &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 92%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;"&gt;
&lt;tr&gt;
&lt;td style="width: 58%;"&gt;&lt;/td&gt;
&lt;td style="width: 5%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="width: 5%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="width: 5%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="width: 5%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Options&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Average&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Exercise&lt;br/&gt; Price&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Average&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Remaining&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Contractual&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Term&lt;br/&gt; (years)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Aggregate&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Intrinsic&lt;br/&gt; Value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Balance as of December&#160;31, 2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;78,334&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;68.16&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;8.00&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Granted&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;68,422&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;5.00&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Cancelled/forfeited&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;(6,647&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;283.76&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Balance as of December&#160;31, 2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;140,109&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;37.48&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;8.07&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;7,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Vested and expected to vest at December&#160;31, 2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;133,810&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;38.62&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;8.02&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Exercisable at December&#160;31, 2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;72,843&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;60.17&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;7.41&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;6,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear:both;max-height:0pt;"&gt;&lt;/div&gt;&lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;The Company settles exercises of stock options with newly issued shares of its common stock. There were no stock options exercised in 2023 or 2022. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;text-indent: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;The estimated fair value of options, including the effect of estimated forfeitures, is recognized over the requisite service period, which is typically the vesting period of each option. The fair value of each option awarded during the years ended December&#160;31, 2023 and 2022 was estimated on the date of grant using the Black-Scholes-Merton option valuation model based on the following weighted-average assumptions: &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 76%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;text-indent: 0px;"&gt;
&lt;tr&gt;
&lt;td style="width: 55%;"&gt;&lt;/td&gt;
&lt;td style="width: 20%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="width: 19%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&#160;2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&#160;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Expected term&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;6.0&#160;years&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;6.0&#160;years&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Risk-free interest rate&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;4.06&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;2.83&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Expected volatility&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;127.0&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;123.4&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Dividends&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;0&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;0&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Resulting fair value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;4.47&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;7.05&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear:both;max-height:0pt;text-indent: 0px;"&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;text-indent: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;The weighted average risk-free interest rate represents the interest rate for treasury constant maturity instruments published by the Federal Reserve Board. If the term of available treasury constant maturity instruments is not equal to the expected term of an employee option, the Company uses the weighted average of the two Federal Reserve securities closest to the expected term of the employee option. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;text-indent: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;The dividend yield has been assumed to be zero as the Company (a)&#160;has never declared or paid any dividends and (b)&#160;does not currently anticipate paying any cash dividends on its outstanding shares of common stock in the foreseeable future. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;text-indent: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;The following table summarizes share-based compensation recognized during the years ended December&#160;31, 2023 and 2022 in the statement of operations: &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 76%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;text-indent: 0px;"&gt;
&lt;tr&gt;
&lt;td style="width: 82%;"&gt;&lt;/td&gt;
&lt;td style="width: 5%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="width: 5%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Research and development&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;66&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;87&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;General and administrative&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;503&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;519&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Total share-based compensation&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;569&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;606&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear:both;max-height:0pt;text-indent: 0px;"&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;text-indent: 0px;"&gt;As of December&#160;31, 2023, the total compensation cost related to &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;non-vested&lt;/div&gt; stock options and stock awards not yet recognized for all our plans is approximately $0.7&#160;million, which is expected to be recognized as a result of vesting under service conditions over a weighted average period of 1.8 years. &lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="PAsOn12_31_2023_StockBasedCompensation2015EquityIncentivePlan1MemberusgaapPlanNameAxis"
      decimals="INF"
      id="ixv-23087"
      unitRef="Unit_shares">6024</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="P01_01_2023To12_31_2023_StockBasedCompensation2020EquityIncentivePlanMemberusgaapPlanNameAxis"
      decimals="INF"
      id="ixv-23088"
      unitRef="Unit_shares">3550000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="PAsOn12_31_2023_StockBasedCompensation2020EquityIncentivePlanMemberusgaapPlanNameAxis"
      decimals="INF"
      id="ixv-23089"
      unitRef="Unit_shares">180607</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="P01_01_2023To12_31_2023_MinimumMembersrtRangeAxis"
      id="ixv-23090">P2Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="P01_01_2023To12_31_2023_MaximumMembersrtRangeAxis"
      id="ixv-23091">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="P01_01_2023To12_31_2023"
      decimals="2"
      id="ixv-23092"
      unitRef="Unit_pure">0.25</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod contextRef="P01_01_2023To12_31_2023" id="ixv-23093">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock contextRef="P01_01_2023To12_31_2023" id="ixv-17328">&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;A summary of activity for the year ended December&#160;31, 2023 is as follows: &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 92%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;"&gt;
&lt;tr&gt;
&lt;td style="width: 58%;"&gt;&lt;/td&gt;
&lt;td style="width: 5%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="width: 5%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="width: 5%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="width: 5%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Options&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Average&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Exercise&lt;br/&gt; Price&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Average&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Remaining&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Contractual&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Term&lt;br/&gt; (years)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Aggregate&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Intrinsic&lt;br/&gt; Value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Balance as of December&#160;31, 2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;78,334&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;68.16&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;8.00&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Granted&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;68,422&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;5.00&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Cancelled/forfeited&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;(6,647&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;283.76&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Balance as of December&#160;31, 2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;140,109&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;37.48&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;8.07&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;7,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Vested and expected to vest at December&#160;31, 2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;133,810&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;38.62&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;8.02&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Exercisable at December&#160;31, 2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;72,843&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;60.17&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;7.41&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;6,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="PAsOn12_31_2022"
      decimals="INF"
      id="ixv-23094"
      unitRef="Unit_shares">78334</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="PAsOn12_31_2022"
      decimals="2"
      id="ixv-23095"
      unitRef="Unit_USD_per_Share">68.16</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="P01_01_2022To12_31_2022" id="ixv-23096">P8Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="P01_01_2023To12_31_2023"
      decimals="INF"
      id="ixv-23097"
      unitRef="Unit_shares">68422</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="P01_01_2023To12_31_2023"
      decimals="2"
      id="ixv-23098"
      unitRef="Unit_USD_per_Share">5</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="P01_01_2023To12_31_2023"
      decimals="INF"
      id="ixv-23099"
      unitRef="Unit_shares">6647</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="P01_01_2023To12_31_2023"
      decimals="2"
      id="ixv-23100"
      unitRef="Unit_USD_per_Share">283.76</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="PAsOn12_31_2023"
      decimals="INF"
      id="ixv-23101"
      unitRef="Unit_shares">140109</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="PAsOn12_31_2023"
      decimals="2"
      id="ixv-23102"
      unitRef="Unit_USD_per_Share">37.48</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="P01_01_2023To12_31_2023" id="ixv-23103">P8Y25D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="PAsOn12_31_2023"
      decimals="0"
      id="ixv-23104"
      unitRef="Unit_USD">7000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="PAsOn12_31_2023"
      decimals="INF"
      id="ixv-23105"
      unitRef="Unit_shares">133810</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
      contextRef="PAsOn12_31_2023"
      decimals="2"
      id="ixv-23106"
      unitRef="Unit_USD_per_Share">38.62</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 contextRef="P01_01_2023To12_31_2023" id="ixv-23107">P8Y7D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="PAsOn12_31_2023"
      decimals="INF"
      id="ixv-23108"
      unitRef="Unit_shares">72843</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="PAsOn12_31_2023"
      decimals="2"
      id="ixv-23109"
      unitRef="Unit_USD_per_Share">60.17</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="P01_01_2023To12_31_2023" id="ixv-23110">P7Y4M28D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="PAsOn12_31_2023"
      decimals="0"
      id="ixv-23111"
      unitRef="Unit_USD">6000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="P01_01_2022To12_31_2022"
      decimals="0"
      id="ixv-23113"
      unitRef="Unit_USD">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="P01_01_2023To12_31_2023"
      decimals="0"
      id="ixv-23114"
      unitRef="Unit_USD">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="P01_01_2023To12_31_2023" id="ixv-23115">The fair value of each option awarded during the years ended December&#160;31, 2023 and 2022 was estimated on the date of grant using the Black-Scholes-Merton option valuation model based on the following weighted-average assumptions: &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 76%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;text-indent: 0px;"&gt;
&lt;tr&gt;
&lt;td style="width: 55%;"&gt;&lt;/td&gt;
&lt;td style="width: 20%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="width: 19%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&#160;2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&#160;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Expected term&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;6.0&#160;years&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;6.0&#160;years&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Risk-free interest rate&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;4.06&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;2.83&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Expected volatility&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;127.0&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;123.4&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Dividends&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;0&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;0&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Resulting fair value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;4.47&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;7.05&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="P01_01_2023To12_31_2023" id="ixv-23116">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="P01_01_2022To12_31_2022" id="ixv-23117">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="P01_01_2023To12_31_2023"
      decimals="4"
      id="ixv-23118"
      unitRef="Unit_pure">0.0406</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="P01_01_2022To12_31_2022"
      decimals="4"
      id="ixv-23119"
      unitRef="Unit_pure">0.0283</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
      contextRef="P01_01_2023To12_31_2023"
      decimals="3"
      id="ixv-23120"
      unitRef="Unit_pure">1.27</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
      contextRef="P01_01_2022To12_31_2022"
      decimals="3"
      id="ixv-23121"
      unitRef="Unit_pure">1.234</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="P01_01_2023To12_31_2023"
      decimals="2"
      id="ixv-23122"
      unitRef="Unit_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="P01_01_2022To12_31_2022"
      decimals="2"
      id="ixv-23123"
      unitRef="Unit_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="P01_01_2023To12_31_2023"
      decimals="2"
      id="ixv-23124"
      unitRef="Unit_USD_per_Share">4.47</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="P01_01_2022To12_31_2022"
      decimals="2"
      id="ixv-23125"
      unitRef="Unit_USD_per_Share">7.05</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-23126"
      unitRef="Unit_USD">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend>
    <us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock contextRef="P01_01_2023To12_31_2023" id="ixv-17755">&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;text-indent: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;The following table summarizes share-based compensation recognized during the years ended December&#160;31, 2023 and 2022 in the statement of operations: &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentColor; border-image: none; width: 76%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;text-indent: 0px;"&gt;
&lt;tr&gt;
&lt;td style="width: 82%;"&gt;&lt;/td&gt;
&lt;td style="width: 5%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="width: 5%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Research and development&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;66&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;87&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;General and administrative&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;503&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;519&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Total share-based compensation&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;569&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;text-align:right;"&gt;606&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock>
    <us-gaap:ShareBasedCompensation
      contextRef="P01_01_2023To12_31_2023_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis"
      decimals="-3"
      id="ixv-23127"
      unitRef="Unit_USD">66000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="P01_01_2022To12_31_2022_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis"
      decimals="-3"
      id="ixv-23128"
      unitRef="Unit_USD">87000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="P01_01_2023To12_31_2023_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis"
      decimals="-3"
      id="ixv-23129"
      unitRef="Unit_USD">503000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="P01_01_2022To12_31_2022_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis"
      decimals="-3"
      id="ixv-23130"
      unitRef="Unit_USD">519000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-23131"
      unitRef="Unit_USD">569000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      id="ixv-23132"
      unitRef="Unit_USD">606000</us-gaap:ShareBasedCompensation>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="PAsOn12_31_2023"
      decimals="-5"
      id="ixv-23133"
      unitRef="Unit_USD">700000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="P01_01_2023To12_31_2023" id="ixv-23134">P1Y9M18D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#Fact_116199642"
          xlink:label="Fact_116199642"
          xlink:type="locator"/>
        <link:footnote id="FN_422111" xlink:label="FN_422111" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Three month LIBOR rate with a floor of 1% plus 7.95%</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_116199642"
          xlink:to="FN_422111"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_116199643"
          xlink:label="Fact_116199643"
          xlink:type="locator"/>
        <link:footnote id="FN_422112" xlink:label="FN_422112" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Monthly payment reflects principal and interest</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_116199643"
          xlink:to="FN_422112"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_116199647"
          xlink:label="Fact_116199647"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_116199647"
          xlink:to="FN_422111"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_116199648"
          xlink:label="Fact_116199648"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_116199648"
          xlink:to="FN_422112"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
